[
	{"id":"Medical-73586ddc","source":"Medical","question":"What is the most common type of skin cancer?","answer":"Basal cell carcinoma (BCC) is the most common type of skin cancer.","question_type":"Fact Retrieval","evidence":"Basal cell carcinoma (BCC) is the most common type of skin cancer.","evidence_relations":"Basal cell carcinoma (BCC) is the most common type of skin cancer"},
	{"id":"Medical-a8bad1cf","source":"Medical","question":"From which cell type does basal cell carcinoma arise?","answer":"Basal cell carcinoma arises from basal cells in the lower part of the epidermis.","question_type":"Fact Retrieval","evidence":"Basal cell carcinoma arises from basal cells.; Basal cells are located in the lower part of the epidermis.","evidence_relations":"BCC arises from basal cells in the lower part of the epidermis"},
	{"id":"Medical-422500d5","source":"Medical","question":"Which anatomical locations are most commonly affected by basal cell carcinoma?","answer":"BCC most commonly develops in sun-exposed areas such as the face, head, and neck.","question_type":"Fact Retrieval","evidence":"BCC most commonly develops in sun-exposed areas.; Common sun-exposed areas for BCC include the face.; Common sun-exposed areas for BCC include the head.; Common sun-exposed areas for BCC include the neck.","evidence_relations":"BCC most commonly develops in sun-exposed areas such as the face, head, and neck"},
	{"id":"Medical-6d2a190d","source":"Medical","question":"What is the primary risk factor for basal cell carcinoma?","answer":"UV radiation exposure is a primary risk factor for BCC.","question_type":"Fact Retrieval","evidence":"UV radiation exposure is a primary risk factor for BCC.","evidence_relations":"UV radiation exposure is a primary risk factor for BCC"},
	{"id":"Medical-5ad931db","source":"Medical","question":"How does fair skin affect the risk of developing BCC?","answer":"Fair skin increases the risk of BCC.","question_type":"Fact Retrieval","evidence":"Fair skin increases the risk of BCC.","evidence_relations":"Fair skin, light hair, and light eye color increase the risk of BCC"},
	{"id":"Medical-6b0f8bc4","source":"Medical","question":"Does older age influence the risk of basal cell carcinoma?","answer":"Older age is associated with higher risk of BCC.","question_type":"Fact Retrieval","evidence":"Older age is associated with a higher risk of BCC.","evidence_relations":"Older age is associated with higher risk of BCC"},
	{"id":"Medical-75c9949b","source":"Medical","question":"How does family history impact the risk of basal cell carcinoma?","answer":"Family history of skin cancer increases risk of BCC.","question_type":"Fact Retrieval","evidence":"Family history of skin cancer increases the risk of BCC.","evidence_relations":"History of skin cancer or family history increases risk of BCC"},
	{"id":"Medical-ec091b24","source":"Medical","question":"Is immune suppression a risk factor for BCC?","answer":"Immune suppression is a risk factor for BCC.","question_type":"Fact Retrieval","evidence":"Immune suppression is a risk factor for BCC.","evidence_relations":"Radiation therapy and immune suppression are risk factors for BCC"},
	{"id":"Medical-8d39da2e","source":"Medical","question":"What are common symptoms of basal cell carcinoma?","answer":"BCC presents as flat, pale or yellow areas, red patches, shiny bumps, open sores, or brown/black bumps with rolled borders.","question_type":"Fact Retrieval","evidence":"BCC presents as flat, pale areas.; BCC presents as yellow areas.; BCC presents as red patches.; BCC presents as shiny bumps.; BCC presents as open sores.; BCC presents as brown bumps.; BCC presents as black bumps.; BCC presents as bumps with rolled borders.","evidence_relations":"BCC presents as flat, pale or yellow areas, red patches, shiny bumps, open sores, or brown/black bumps with rolled borders"},
	{"id":"Medical-88c0b2ba","source":"Medical","question":"Which diagnostic methods are used for BCC?","answer":"Diagnosis of BCC involves medical and family history, physical exam, skin exam, biopsy, and sometimes imaging.","question_type":"Fact Retrieval","evidence":"Diagnosis of BCC involves medical history.; Diagnosis of BCC involves family history.; Diagnosis of BCC involves a physical exam.; Diagnosis of BCC involves a skin exam.; Diagnosis of BCC involves a biopsy.; Diagnosis of BCC may involve imaging.","evidence_relations":"Diagnosis of BCC involves medical and family history, physical exam, skin exam, biopsy, and sometimes imaging"},
	{"id":"Medical-a8ee8ba1","source":"Medical","question":"What is the most common treatment for basal cell carcinoma?","answer":"Surgery is the most common treatment for BCC.","question_type":"Fact Retrieval","evidence":"Surgery is the most common treatment for basal cell carcinoma.","evidence_relations":"Surgery is the most common treatment for BCC"},
	{"id":"Medical-ec7d8801","source":"Medical","question":"When might radiation therapy be used in BCC?","answer":"Radiation therapy may be used in some cases of BCC.","question_type":"Fact Retrieval","evidence":"Radiation therapy may be used in some cases of basal cell carcinoma.","evidence_relations":"Radiation therapy or systemic therapy may be used in some cases of BCC"},
	{"id":"Medical-9797af69","source":"Medical","question":"What is recurrence in the context of BCC?","answer":"Recurrence refers to BCC returning to the original site or spreading to lymph nodes or distant sites.","question_type":"Fact Retrieval","evidence":"Recurrence refers to basal cell carcinoma returning to the original site.; Recurrence refers to basal cell carcinoma spreading to lymph nodes.; Recurrence refers to basal cell carcinoma spreading to distant sites.","evidence_relations":"Recurrence refers to BCC returning to the original site or spreading to lymph nodes or distant sites"},
	{"id":"Medical-6884d3fa","source":"Medical","question":"What does follow-up for BCC typically include?","answer":"Follow-up includes full skin exams with a doctor at least once a year.","question_type":"Fact Retrieval","evidence":"Follow-up for basal cell carcinoma includes full skin exams with a doctor.; Follow-up for basal cell carcinoma occurs at least once a year.","evidence_relations":"Follow-up includes full skin exams with a doctor at least once a year"},
	{"id":"Medical-fc6d1c33","source":"Medical","question":"Which skin cancer subtype arises from basal cells?","answer":"Basal cell carcinoma is the skin cancer subtype that arises from basal cells.","question_type":"Fact Retrieval","evidence":"Basal cell carcinoma is the skin cancer subtype that arises from basal cells.","evidence_relations":"Basal cell carcinoma (BCC) is the most common type of skin cancer"},
	{"id":"Medical-97abee55","source":"Medical","question":"What anatomical layer do basal cells belong to?","answer":"Basal cells are located in the lower part of the epidermis.","question_type":"Fact Retrieval","evidence":"Basal cells are located in the lower part of the epidermis.","evidence_relations":"BCC arises from basal cells in the lower part of the epidermis"},
	{"id":"Medical-28d1e2d7","source":"Medical","question":"Is sun exposure a risk factor for BCC?","answer":"Sun exposure is a risk factor for BCC.","question_type":"Fact Retrieval","evidence":"Sun exposure is a risk factor for basal cell carcinoma.","evidence_relations":"Sun exposure"},
	{"id":"Medical-4cf524cb","source":"Medical","question":"Do tanning beds increase the risk of BCC?","answer":"Tanning beds are a risk factor for BCC.","question_type":"Fact Retrieval","evidence":"Tanning beds are a risk factor for basal cell carcinoma.","evidence_relations":"Tanning beds are listed as a risk factor for BCC in the ontology"},
	{"id":"Medical-df1408f4","source":"Medical","question":"What hair and eye colors are associated with increased BCC risk?","answer":"Red hair, blond hair, and light eye color increase the risk of BCC.","question_type":"Fact Retrieval","evidence":"Red hair increases the risk of basal cell carcinoma.; Blond hair increases the risk of basal cell carcinoma.; Light eye color increases the risk of basal cell carcinoma.","evidence_relations":"Fair skin, light hair, and light eye color increase the risk of BCC"},
	{"id":"Medical-17ae12cd","source":"Medical","question":"Can a history of radiation therapy increase BCC risk?","answer":"Radiation therapy is a risk factor for BCC.","question_type":"Fact Retrieval","evidence":"A history of radiation therapy is a risk factor for basal cell carcinoma.","evidence_relations":"Radiation therapy and immune suppression are risk factors for BCC"},
	{"id":"Medical-965ad8a8","source":"Medical","question":"What is a common presentation of BCC on the skin?","answer":"BCC may present as a shiny bump.","question_type":"Fact Retrieval","evidence":"BCC may present as a shiny bump.","evidence_relations":"BCC presents as flat, pale or yellow areas, red patches, shiny bumps, open sores, or brown/black bumps with rolled borders"},
	{"id":"Medical-5175a85e","source":"Medical","question":"What is the role of biopsy in BCC diagnosis?","answer":"Biopsy is used as a diagnostic method for BCC.","question_type":"Fact Retrieval","evidence":"Biopsy is used as a diagnostic method for BCC.","evidence_relations":"Diagnosis of BCC involves medical and family history, physical exam, skin exam, biopsy, and sometimes imaging"},
	{"id":"Medical-5f2cb8a5","source":"Medical","question":"Which systemic therapy may be considered for BCC?","answer":"Systemic therapy may be used in some cases of BCC.","question_type":"Fact Retrieval","evidence":"Systemic therapy may be used in some cases of BCC.","evidence_relations":"Radiation therapy or systemic therapy may be used in some cases of BCC"},
	{"id":"Medical-0429f83c","source":"Medical","question":"What is included in the management of BCC recurrence?","answer":"Management of recurrence involves treatment options based on risk and recurrence.","question_type":"Fact Retrieval","evidence":"Management of BCC recurrence involves treatment options.; Treatment options for BCC recurrence are based on risk and recurrence.","evidence_relations":"Management: Treatment options based on risk and recurrence"},
	{"id":"Medical-152bec6a","source":"Medical","question":"What is the recommended frequency for full skin exams in BCC follow-up?","answer":"Full skin exams with a doctor are recommended at least once a year.","question_type":"Fact Retrieval","evidence":"Full skin exams with a doctor are recommended at least once a year.","evidence_relations":"Follow-up includes full skin exams with a doctor at least once a year"},
	{"id":"Medical-e3923e5f","source":"Medical","question":"Can BCC spread to lymph nodes?","answer":"BCC recurrence can involve spread to lymph nodes.","question_type":"Fact Retrieval","evidence":"BCC recurrence can involve spread to lymph nodes.","evidence_relations":"Recurrence refers to BCC returning to the original site or spreading to lymph nodes or distant sites"},
	{"id":"Medical-0c2f999d","source":"Medical","question":"What is a brown or glossy black bump with rolled border a symptom of?","answer":"A brown or glossy black bump with rolled border is a symptom of BCC.","question_type":"Fact Retrieval","evidence":"A brown or glossy black bump with rolled border is a symptom of BCC.","evidence_relations":"BCC presents as flat, pale or yellow areas, red patches, shiny bumps, open sores, or brown/black bumps with rolled borders"},
	{"id":"Medical-b6dc1118","source":"Medical","question":"What is the relationship between organ transplant and BCC risk?","answer":"Organ transplant is a risk factor for BCC.","question_type":"Fact Retrieval","evidence":"Organ transplant is a risk factor for BCC.","evidence_relations":"Organ transplant is listed as a risk factor for BCC in the ontology"},
	{"id":"Medical-ba2c8007","source":"Medical","question":"Is autoimmune disease associated with increased BCC risk?","answer":"Autoimmune disease is a risk factor for BCC.","question_type":"Fact Retrieval","evidence":"Autoimmune disease is a risk factor for BCC.","evidence_relations":"Autoimmune disease is listed as a risk factor for BCC in the ontology"},
	{"id":"Medical-5c30dd24","source":"Medical","question":"What is the role of imaging in BCC diagnosis?","answer":"Imaging may be used in the diagnosis of BCC.","question_type":"Fact Retrieval","evidence":"Imaging may be used in the diagnosis of BCC.","evidence_relations":"Diagnosis of BCC involves medical and family history, physical exam, skin exam, biopsy, and sometimes imaging"},
	{"id":"Medical-8622e4cc","source":"Medical","question":"Can BCC occur anywhere on the body?","answer":"BCC can occur anywhere on the body, but most commonly in sun-exposed areas.","question_type":"Fact Retrieval","evidence":"BCC can occur anywhere on the body.; BCC most commonly occurs in sun-exposed areas.","evidence_relations":"Anatomical Location: Anywhere on the body, most commonly face, head, and neck"},
	{"id":"Medical-b0b58bf2","source":"Medical","question":"What is the most common type of skin cancer?","answer":"Basal cell carcinoma (BCC) is the most common type of skin cancer.","question_type":"Fact Retrieval","evidence":"Basal cell carcinoma (BCC) is the most common type of skin cancer.","evidence_relations":"Basal cell carcinoma (BCC) is the most common type of skin cancer"},
	{"id":"Medical-90704d0a","source":"Medical","question":"From which cells does basal cell carcinoma arise?","answer":"BCC arises from basal cells in the lower part of the epidermis.","question_type":"Fact Retrieval","evidence":"BCC arises from basal cells.; BCC arises from cells in the lower part of the epidermis.","evidence_relations":"BCC arises from basal cells in the lower part of the epidermis"},
	{"id":"Medical-941c0004","source":"Medical","question":"Which anatomical locations are most commonly affected by BCC?","answer":"BCC most commonly develops in sun-exposed areas such as the face, head, and neck.","question_type":"Fact Retrieval","evidence":"BCC most commonly develops in sun-exposed areas.; Common anatomical locations affected by BCC include the face.; Common anatomical locations affected by BCC include the head.; Common anatomical locations affected by BCC include the neck.","evidence_relations":"BCC most commonly develops in sun-exposed areas such as the face, head, and neck"},
	{"id":"Medical-4bb300c3","source":"Medical","question":"What is the primary risk factor for developing basal cell carcinoma?","answer":"UV radiation exposure is a primary risk factor for BCC.","question_type":"Fact Retrieval","evidence":"UV radiation exposure is a primary risk factor for BCC.","evidence_relations":"UV radiation exposure is a primary risk factor for BCC"},
	{"id":"Medical-acec9fa2","source":"Medical","question":"How does fair skin affect the risk of basal cell carcinoma?","answer":"Fair skin increases the risk of BCC.","question_type":"Fact Retrieval","evidence":"Fair skin increases the risk of BCC.","evidence_relations":"Fair skin, light hair, and light eye color increase the risk of BCC"},
	{"id":"Medical-7c81f966","source":"Medical","question":"Does older age influence the risk of BCC?","answer":"Older age is associated with higher risk of BCC.","question_type":"Fact Retrieval","evidence":"Older age is associated with a higher risk of BCC.","evidence_relations":"Older age is associated with higher risk of BCC"},
	{"id":"Medical-f6b5155a","source":"Medical","question":"Does a family history of skin cancer affect the risk of BCC?","answer":"Family history of skin cancer increases risk of BCC.","question_type":"Fact Retrieval","evidence":"Family history of skin cancer increases the risk of BCC.","evidence_relations":"History of skin cancer or family history increases risk of BCC"},
	{"id":"Medical-4061f8c4","source":"Medical","question":"Is immune suppression a risk factor for basal cell carcinoma?","answer":"Immune suppression is a risk factor for BCC.","question_type":"Fact Retrieval","evidence":"Immune suppression is a risk factor for BCC.","evidence_relations":"Radiation therapy and immune suppression are risk factors for BCC"},
	{"id":"Medical-89de49a4","source":"Medical","question":"What are common symptoms of basal cell carcinoma?","answer":"BCC presents as flat, pale or yellow areas, red patches, shiny bumps, open sores, or brown/black bumps with rolled borders.","question_type":"Fact Retrieval","evidence":"BCC presents as flat, pale areas.; BCC presents as yellow areas.; BCC presents as red patches.; BCC presents as shiny bumps.; BCC presents as open sores.; BCC presents as brown bumps.; BCC presents as black bumps.; BCC presents as bumps with rolled borders.","evidence_relations":"BCC presents as flat, pale or yellow areas, red patches, shiny bumps, open sores, or brown/black bumps with rolled borders"},
	{"id":"Medical-624c452d","source":"Medical","question":"What diagnostic methods are used for BCC?","answer":"Diagnosis of BCC involves medical and family history, physical exam, skin exam, biopsy, and sometimes imaging.","question_type":"Fact Retrieval","evidence":"Diagnosis of BCC involves medical history.; Diagnosis of BCC involves family history.; Diagnosis of BCC involves a physical exam.; Diagnosis of BCC involves a skin exam.; Diagnosis of BCC involves a biopsy.; Diagnosis of BCC sometimes involves imaging.","evidence_relations":"Diagnosis of BCC involves medical and family history, physical exam, skin exam, biopsy, and sometimes imaging"},
	{"id":"Medical-4aab8ef7","source":"Medical","question":"What is the most common treatment for basal cell carcinoma?","answer":"Surgery is the most common treatment for BCC.","question_type":"Fact Retrieval","evidence":"Surgery is the most common treatment for BCC.","evidence_relations":"Surgery is the most common treatment for BCC"},
	{"id":"Medical-bc412bb6","source":"Medical","question":"When might radiation therapy or systemic therapy be used for BCC?","answer":"Radiation therapy or systemic therapy may be used in some cases of BCC.","question_type":"Fact Retrieval","evidence":"Radiation therapy may be used in some cases of BCC.; Systemic therapy may be used in some cases of BCC.","evidence_relations":"Radiation therapy or systemic therapy may be used in some cases of BCC"},
	{"id":"Medical-cb249d9b","source":"Medical","question":"What does recurrence mean in the context of BCC?","answer":"Recurrence refers to BCC returning to the original site or spreading to lymph nodes or distant sites.","question_type":"Fact Retrieval","evidence":"Recurrence refers to BCC returning to the original site.; Recurrence refers to BCC spreading to lymph nodes.; Recurrence refers to BCC spreading to distant sites.","evidence_relations":"Recurrence refers to BCC returning to the original site or spreading to lymph nodes or distant sites"},
	{"id":"Medical-e506aa4e","source":"Medical","question":"What is recommended for follow-up after BCC treatment?","answer":"Follow-up includes full skin exams with a doctor at least once a year.","question_type":"Fact Retrieval","evidence":"Follow-up after BCC treatment includes full skin exams.; Follow-up after BCC treatment should be done with a doctor.; Follow-up after BCC treatment is recommended at least once a year.","evidence_relations":"Follow-up includes full skin exams with a doctor at least once a year"},
	{"id":"Medical-14cee623","source":"Medical","question":"Which cell type is affected in basal cell carcinoma?","answer":"Basal cells are the cell type affected in BCC.","question_type":"Fact Retrieval","evidence":"Basal cells are the cell type affected in BCC.","evidence_relations":"Basal cells"},
	{"id":"Medical-ae28e711","source":"Medical","question":"Is sun exposure a risk factor for BCC?","answer":"Sun exposure is a risk factor for BCC.","question_type":"Fact Retrieval","evidence":"Sun exposure is a risk factor for BCC.","evidence_relations":"Sun exposure"},
	{"id":"Medical-2bef6940","source":"Medical","question":"Are tanning beds considered a risk factor for BCC?","answer":"Tanning beds are a risk factor for BCC.","question_type":"Fact Retrieval","evidence":"Tanning beds are a risk factor for BCC.","evidence_relations":"Tanning beds"},
	{"id":"Medical-0047c320","source":"Medical","question":"Does having red or blond hair increase the risk of BCC?","answer":"Red hair and blond hair increase the risk of BCC.","question_type":"Fact Retrieval","evidence":"Red hair increases the risk of BCC.; Blond hair increases the risk of BCC.","evidence_relations":"Fair skin, light hair, and light eye color increase the risk of BCC"},
	{"id":"Medical-ca377f8d","source":"Medical","question":"Is light eye color associated with increased risk of BCC?","answer":"Light eye color increases the risk of BCC.","question_type":"Fact Retrieval","evidence":"Light eye color increases the risk of BCC.","evidence_relations":"Fair skin, light hair, and light eye color increase the risk of BCC"},
	{"id":"Medical-0b2a33fc","source":"Medical","question":"Can a history of radiation therapy increase BCC risk?","answer":"Radiation therapy is a risk factor for BCC.","question_type":"Fact Retrieval","evidence":"Radiation therapy is a risk factor for BCC.","evidence_relations":"Radiation therapy and immune suppression are risk factors for BCC"},
	{"id":"Medical-de0b30b1","source":"Medical","question":"Are organ transplant recipients at higher risk for BCC?","answer":"Organ transplant is a risk factor for BCC.","question_type":"Fact Retrieval","evidence":"Organ transplant is a risk factor for BCC.","evidence_relations":"Organ transplant"},
	{"id":"Medical-4f1779a5","source":"Medical","question":"Is autoimmune disease a risk factor for BCC?","answer":"Autoimmune disease is a risk factor for BCC.","question_type":"Fact Retrieval","evidence":"Autoimmune disease is a risk factor for BCC.","evidence_relations":"Autoimmune disease"},
	{"id":"Medical-d675eecd","source":"Medical","question":"What is a flat, pale or yellow area on the skin indicative of in BCC?","answer":"A flat, pale or yellow area is a symptom of BCC.","question_type":"Fact Retrieval","evidence":"A flat, pale or yellow area is a symptom of BCC.","evidence_relations":"Flat pale or yellow area"},
	{"id":"Medical-7e4192af","source":"Medical","question":"What does a shiny bump on the skin suggest in the context of BCC?","answer":"A shiny bump is a symptom of BCC.","question_type":"Fact Retrieval","evidence":"A shiny bump is a symptom of BCC.","evidence_relations":"Shiny bump"},
	{"id":"Medical-f8b6c41e","source":"Medical","question":"What is the significance of a brown or glossy black bump with rolled border?","answer":"A brown or glossy black bump with rolled border is a symptom of BCC.","question_type":"Fact Retrieval","evidence":"A brown or glossy black bump with rolled border is a symptom of BCC.","evidence_relations":"Brown or glossy black bump with rolled border"},
	{"id":"Medical-cef34fff","source":"Medical","question":"Which exams are essential for diagnosing BCC?","answer":"Physical exam and skin exam are essential for diagnosing BCC.","question_type":"Fact Retrieval","evidence":"Physical exam is essential for diagnosing BCC.; Skin exam is essential for diagnosing BCC.","evidence_relations":"Physical exam, Skin exam"},
	{"id":"Medical-27280ca7","source":"Medical","question":"What role does biopsy play in BCC diagnosis?","answer":"Biopsy is a diagnostic method for BCC.","question_type":"Fact Retrieval","evidence":"Biopsy is a diagnostic method for BCC.","evidence_relations":"Biopsy"},
	{"id":"Medical-04249246","source":"Medical","question":"Is imaging sometimes used in the diagnosis of BCC?","answer":"Imaging may be used in the diagnosis of BCC.","question_type":"Fact Retrieval","evidence":"Imaging may be used in the diagnosis of BCC.","evidence_relations":"Diagnosis of BCC involves medical and family history, physical exam, skin exam, biopsy, and sometimes imaging"},
	{"id":"Medical-3e18a314","source":"Medical","question":"What treatments are available for BCC besides surgery?","answer":"Radiation therapy and systemic therapy are treatments for BCC besides surgery.","question_type":"Fact Retrieval","evidence":"Radiation therapy is a treatment for BCC besides surgery.; Systemic therapy is a treatment for BCC besides surgery.","evidence_relations":"Radiation therapy or systemic therapy may be used in some cases of BCC"},
	{"id":"Medical-34ad11ec","source":"Medical","question":"How is recurrence of BCC managed?","answer":"Recurrence is managed with treatment options based on risk and recurrence.","question_type":"Fact Retrieval","evidence":"Recurrence of BCC is managed with treatment options.; Treatment options for recurrence are based on risk.; Treatment options for recurrence are based on recurrence.","evidence_relations":"Management: Treatment options based on risk and recurrence"},
	{"id":"Medical-74440a6a","source":"Medical","question":"What is included in annual follow-up for BCC patients?","answer":"Annual follow-up includes a full skin exam.","question_type":"Fact Retrieval","evidence":"Annual follow-up for BCC patients includes a full skin exam.","evidence_relations":"Follow-up includes full skin exams with a doctor at least once a year"},
	{"id":"Medical-a296a86b","source":"Medical","question":"What is the primary cancer type discussed in this context?","answer":"Primary CNS lymphoma is the primary cancer type.","question_type":"Fact Retrieval","evidence":"Primary CNS lymphoma is the primary cancer type.","evidence_relations":"Primary CNS lymphoma is a rare and aggressive cancer that starts in lymphocytes within the central nervous system"},
	{"id":"Medical-f907720b","source":"Medical","question":"Which cells does primary CNS lymphoma originate from?","answer":"Primary CNS lymphoma originates from lymphocytes.","question_type":"Fact Retrieval","evidence":"Primary CNS lymphoma originates from lymphocytes.","evidence_relations":"Primary CNS lymphoma is a rare and aggressive cancer that starts in lymphocytes within the central nervous system"},
	{"id":"Medical-f80cbf85","source":"Medical","question":"What is the most common location affected by primary CNS lymphoma?","answer":"The brain is most commonly affected by primary CNS lymphoma.","question_type":"Fact Retrieval","evidence":"The brain is most commonly affected by primary CNS lymphoma.","evidence_relations":"Primary CNS lymphoma most commonly affects the brain, but can also involve the spinal cord, cerebrospinal fluid, and eyes"},
	{"id":"Medical-b3c430ef","source":"Medical","question":"Name a cancer subtype of primary CNS lymphoma that affects the eyes.","answer":"Vitreoretinal lymphoma is a subtype that affects the eyes.","question_type":"Fact Retrieval","evidence":"Vitreoretinal lymphoma is a subtype of primary CNS lymphoma.; Vitreoretinal lymphoma affects the eyes.","evidence_relations":"Vitreoretinal lymphoma is a cancer subtype of primary CNS lymphoma that affects the eyes, retina, and vitreous"},
	{"id":"Medical-304b0354","source":"Medical","question":"List three anatomical sites, other than the brain, that primary CNS lymphoma can involve.","answer":"Primary CNS lymphoma can involve the spinal cord, cerebrospinal fluid, and eyes.","question_type":"Fact Retrieval","evidence":"Primary CNS lymphoma can involve the spinal cord.; Primary CNS lymphoma can involve cerebrospinal fluid.; Primary CNS lymphoma can involve the eyes.","evidence_relations":"Primary CNS lymphoma most commonly affects the brain, but can also involve the spinal cord, cerebrospinal fluid, and eyes"},
	{"id":"Medical-bc34a6a1","source":"Medical","question":"What is a major risk factor for developing primary CNS lymphoma?","answer":"An impaired immune system is a major risk factor.","question_type":"Fact Retrieval","evidence":"An impaired immune system is a major risk factor for developing primary CNS lymphoma.","evidence_relations":"Impaired immune system is a risk factor for primary CNS lymphoma"},
	{"id":"Medical-b1a95144","source":"Medical","question":"Which viral infection is considered a risk factor for primary CNS lymphoma?","answer":"HIV infection is a risk factor for primary CNS lymphoma.","question_type":"Fact Retrieval","evidence":"HIV infection is a risk factor for primary CNS lymphoma.","evidence_relations":"Immunodeficiency disorders, HIV infection, Epstein-Barr virus, autoimmune diseases, organ transplant, and older age are risk factors for primary CNS lymphoma"},
	{"id":"Medical-473eae59","source":"Medical","question":"Name two autoimmune conditions listed as risk factors for primary CNS lymphoma.","answer":"Autoimmune disease and lupus are risk factors.","question_type":"Fact Retrieval","evidence":"Autoimmune disease is a risk factor for primary CNS lymphoma.; Lupus is a risk factor for primary CNS lymphoma.","evidence_relations":"Risk Factor includes Autoimmune disease, Lupus"},
	{"id":"Medical-1b824083","source":"Medical","question":"Which diagnostic imaging technique is considered most useful for identifying primary CNS lymphoma?","answer":"MRI with gadolinium contrast is the most useful imaging technique.","question_type":"Fact Retrieval","evidence":"MRI with gadolinium contrast is the most useful imaging technique for identifying primary CNS lymphoma.","evidence_relations":"MRI with gadolinium contrast is the most useful imaging technique for identifying primary CNS lymphoma"},
	{"id":"Medical-ba9d39eb","source":"Medical","question":"What is the standard biopsy procedure for diagnosing primary CNS lymphoma?","answer":"Stereotactic biopsy is the standard diagnostic procedure.","question_type":"Fact Retrieval","evidence":"Stereotactic biopsy is the standard diagnostic procedure for diagnosing primary CNS lymphoma.","evidence_relations":"Stereotactic biopsy is the standard diagnostic procedure for primary CNS lymphoma"},
	{"id":"Medical-e306413c","source":"Medical","question":"Which laboratory test is commonly used during the diagnosis of primary CNS lymphoma?","answer":"Complete blood count (CBC) is commonly used.","question_type":"Fact Retrieval","evidence":"Complete blood count (CBC) is commonly used during the diagnosis of primary CNS lymphoma.","evidence_relations":"Laboratory Tests include Complete blood count (CBC)"},
	{"id":"Medical-64ef6350","source":"Medical","question":"What is a typical initial clinical assessment for suspected primary CNS lymphoma?","answer":"A neurological exam is a typical initial clinical assessment.","question_type":"Fact Retrieval","evidence":"A neurological exam is a typical initial clinical assessment for suspected primary CNS lymphoma.","evidence_relations":"Primary CNS lymphoma is diagnosed using neurological exam, imaging (MRI or CT), biopsy, blood tests, eye exam, and lumbar puncture"},
	{"id":"Medical-e05d0922","source":"Medical","question":"Which procedure is performed if cancer cells are found in the cerebrospinal fluid?","answer":"Intrathecal chemotherapy may be used if cancer cells are found in the cerebrospinal fluid.","question_type":"Fact Retrieval","evidence":"Intrathecal chemotherapy may be used if cancer cells are found in the cerebrospinal fluid.","evidence_relations":"Intrathecal chemotherapy may be used if cancer cells are found in the cerebrospinal fluid"},
	{"id":"Medical-1c1492e7","source":"Medical","question":"What specialized treatment is given if the eyes are involved in primary CNS lymphoma?","answer":"Intraocular chemotherapy or radiation may be used if the eyes are involved.","question_type":"Fact Retrieval","evidence":"Intraocular chemotherapy or radiation may be used if the eyes are involved in primary CNS lymphoma.","evidence_relations":"Intraocular chemotherapy or radiation may be used if the eyes are involved"},
	{"id":"Medical-dba48e64","source":"Medical","question":"What is the main chemotherapy drug for primary CNS lymphoma?","answer":"High-dose methotrexate is the main chemotherapy drug.","question_type":"Fact Retrieval","evidence":"High-dose methotrexate is the main chemotherapy drug for primary CNS lymphoma.","evidence_relations":"High-dose methotrexate is the main chemotherapy drug used for primary CNS lymphoma"},
	{"id":"Medical-f5fc9016","source":"Medical","question":"Which immunotherapy drug is primarily used in the treatment of primary CNS lymphoma?","answer":"Rituximab is the main immunotherapy drug used.","question_type":"Fact Retrieval","evidence":"Rituximab is the main immunotherapy drug used in the treatment of primary CNS lymphoma.","evidence_relations":"Rituximab is the main immunotherapy drug used for primary CNS lymphoma"},
	{"id":"Medical-b80bf4c5","source":"Medical","question":"What is the most commonly used radiation technique for primary CNS lymphoma?","answer":"Whole-brain radiation therapy (WBRT) is the most commonly used technique.","question_type":"Fact Retrieval","evidence":"Whole-brain radiation therapy (WBRT) is the most commonly used radiation technique for primary CNS lymphoma.","evidence_relations":"Whole-brain radiation therapy (WBRT) is the most commonly used radiation technique for primary CNS lymphoma"},
	{"id":"Medical-3978515f","source":"Medical","question":"What are the two main treatment phases for primary CNS lymphoma?","answer":"Treatment is typically given in phases: induction and consolidation.","question_type":"Fact Retrieval","evidence":"Treatment for primary CNS lymphoma is typically given in phases.; The two main treatment phases for primary CNS lymphoma are induction and consolidation.","evidence_relations":"Treatment is typically given in phases: induction and consolidation"},
	{"id":"Medical-afabde7f","source":"Medical","question":"What is the purpose of supportive care in primary CNS lymphoma management?","answer":"Supportive care is provided to relieve symptoms and side effects at any stage of disease.","question_type":"Fact Retrieval","evidence":"Supportive care is provided to relieve symptoms.; Supportive care is provided to relieve side effects.; Supportive care is provided at any stage of disease.","evidence_relations":"Supportive care is provided to relieve symptoms and side effects at any stage of disease"},
	{"id":"Medical-a4081e18","source":"Medical","question":"Which performance measure is evaluated to guide treatment decisions in primary CNS lymphoma?","answer":"Performance status is evaluated to guide treatment decisions and eligibility for clinical trials.","question_type":"Fact Retrieval","evidence":"Performance status is evaluated to guide treatment decisions.; Performance status is evaluated to determine eligibility for clinical trials.","evidence_relations":"Performance status is evaluated to guide treatment decisions and eligibility for clinical trials"},
	{"id":"Medical-79a788b8","source":"Medical","question":"What is recommended for all patients with primary CNS lymphoma regarding research participation?","answer":"Clinical trial participation is recommended for all patients.","question_type":"Fact Retrieval","evidence":"Clinical trial participation is recommended for all patients with primary CNS lymphoma.","evidence_relations":"Clinical trial participation is recommended for all patients with primary CNS lymphoma"},
	{"id":"Medical-c99256ce","source":"Medical","question":"Name three neurological symptoms commonly caused by primary CNS lymphoma.","answer":"Leg weakness, confusion, and seizures are common neurological symptoms.","question_type":"Fact Retrieval","evidence":"Leg weakness is a common neurological symptom caused by primary CNS lymphoma.; Confusion is a common neurological symptom caused by primary CNS lymphoma.; Seizures are a common neurological symptom caused by primary CNS lymphoma.","evidence_relations":"Primary CNS lymphoma can cause neurological symptoms such as leg or arm weakness, coordination or movement difficulties, personality or behavior changes, depression, confusion, memory problems, incontinence, difficulty speaking or swallowing, headaches, nausea, vomiting, seizures, and vision changes"},
	{"id":"Medical-7b5a8ac6","source":"Medical","question":"Which diagnostic method is used to assess eye involvement in primary CNS lymphoma?","answer":"Eye exam is used to assess eye involvement.","question_type":"Fact Retrieval","evidence":"Eye exam is used to assess eye involvement in primary CNS lymphoma.","evidence_relations":"Primary CNS lymphoma is diagnosed using neurological exam, imaging (MRI or CT), biopsy, blood tests, eye exam, and lumbar puncture"},
	{"id":"Medical-26033837","source":"Medical","question":"What follow-up method is recommended for surveillance after treatment of primary CNS lymphoma?","answer":"Repeat MRI is recommended for follow-up surveillance.","question_type":"Fact Retrieval","evidence":"Repeat MRI is recommended for follow-up surveillance after treatment of primary CNS lymphoma.","evidence_relations":"Follow-up/Surveillance includes Repeat MRI"},
	{"id":"Medical-9f3a0a90","source":"Medical","question":"Which age group is at higher risk for primary CNS lymphoma?","answer":"Older adults are at higher risk.","question_type":"Fact Retrieval","evidence":"Older adults are at higher risk for primary CNS lymphoma.","evidence_relations":"Older age is a risk factor for primary CNS lymphoma"},
	{"id":"Medical-f619b6ea","source":"Medical","question":"What is the role of corticosteroids in the treatment of primary CNS lymphoma?","answer":"Corticosteroids are one of the treatment options for primary CNS lymphoma.","question_type":"Fact Retrieval","evidence":"Corticosteroids are one of the treatment options for primary CNS lymphoma.","evidence_relations":"Treatment options for primary CNS lymphoma include corticosteroids, chemotherapy, radiation therapy, targeted therapy, immunotherapy, stem cell rescue, and supportive care"},
	{"id":"Medical-9474c5bb","source":"Medical","question":"Which chemotherapy drugs, besides methotrexate, can be used in induction therapy for primary CNS lymphoma?","answer":"Temozolomide, vincristine, procarbazine, cytarabine, pemetrexed, pomalidomide, lenalidomide, and ibrutinib can be used.","question_type":"Fact Retrieval","evidence":"Temozolomide can be used in induction therapy for primary CNS lymphoma.; Vincristine can be used in induction therapy for primary CNS lymphoma.; Procarbazine can be used in induction therapy for primary CNS lymphoma.; Cytarabine can be used in induction therapy for primary CNS lymphoma.; Pemetrexed can be used in induction therapy for primary CNS lymphoma.; Pomalidomide can be used in induction therapy for primary CNS lymphoma.; Lenalidomide can be used in induction therapy for primary CNS lymphoma.; Ibrutinib can be used in induction therapy for primary CNS lymphoma.","evidence_relations":"Induction phase includes High-dose methotrexate, Rituximab, Temozolomide, Vincristine, Procarbazine, Cytarabine, Pemetrexed, Pomalidomide, Lenalidomide, Ibrutinib, Clinical trial"},
	{"id":"Medical-5825991f","source":"Medical","question":"Which procedure is included in laboratory tests for diagnosing primary CNS lymphoma?","answer":"Lactate dehydrogenase (LDH) testing is included in laboratory tests.","question_type":"Fact Retrieval","evidence":"Lactate dehydrogenase (LDH) testing is included in laboratory tests for diagnosing primary CNS lymphoma.","evidence_relations":"Laboratory Tests include Lactate dehydrogenase (LDH)"},
	{"id":"Medical-a4dcffa3","source":"Medical","question":"What is a potential site of relapse for primary CNS lymphoma?","answer":"Primary CNS lymphoma can relapse in the brain, spinal cord, or eyes.","question_type":"Fact Retrieval","evidence":"Primary CNS lymphoma can relapse in the brain.; Primary CNS lymphoma can relapse in the spinal cord.; Primary CNS lymphoma can relapse in the eyes.","evidence_relations":"Primary CNS lymphoma can relapse in the brain, spinal cord, or eyes"},
	{"id":"Medical-3919018c","source":"Medical","question":"How often does primary CNS lymphoma spread outside the central nervous system?","answer":"Primary CNS lymphoma rarely spreads outside the central nervous system.","question_type":"Fact Retrieval","evidence":"Primary CNS lymphoma rarely spreads outside the central nervous system.","evidence_relations":"Primary CNS lymphoma rarely spreads outside the central nervous system"},
	{"id":"Medical-d7180179","source":"Medical","question":"Which imaging technique uses gadolinium contrast for better visualization in primary CNS lymphoma?","answer":"MRI uses gadolinium contrast for better visualization.","question_type":"Fact Retrieval","evidence":"MRI uses gadolinium contrast for better visualization in primary CNS lymphoma.","evidence_relations":"MRI with gadolinium contrast is the most useful imaging technique for identifying primary CNS lymphoma"},
	{"id":"Medical-f05a2e9b","source":"Medical","question":"What supportive care interventions are recommended for patients with primary CNS lymphoma?","answer":"Symptom management, palliative care, and quality of life interventions are recommended.","question_type":"Fact Retrieval","evidence":"Symptom management is recommended for patients with primary CNS lymphoma.; Palliative care is recommended for patients with primary CNS lymphoma.; Quality of life interventions are recommended for patients with primary CNS lymphoma.","evidence_relations":"Supportive Care includes Symptom management, Palliative care, Quality of life interventions"},
	{"id":"Medical-5b1265c0","source":"Medical","question":"What is the second most common type of skin cancer?","answer":"Squamous cell skin cancer (CSCC) is the second most common type of skin cancer.","question_type":"Fact Retrieval","evidence":"Squamous cell skin cancer (CSCC) is the second most common type of skin cancer.","evidence_relations":"Squamous cell skin cancer (CSCC) is the second most common type of skin cancer"},
	{"id":"Medical-d1e50927","source":"Medical","question":"Which cancer subtype is classified as a type of nonmelanoma skin cancer?","answer":"CSCC is a type of nonmelanoma skin cancer.","question_type":"Fact Retrieval","evidence":"CSCC is a type of nonmelanoma skin cancer.","evidence_relations":"CSCC is a type of nonmelanoma skin cancer"},
	{"id":"Medical-9536f8e7","source":"Medical","question":"What are the main stages of cutaneous squamous cell carcinoma (CSCC)?","answer":"CSCC is staged as local (confined to skin), regional (spread to lymph nodes), or metastatic (distant spread).","question_type":"Fact Retrieval","evidence":"CSCC is staged as local.; CSCC is staged as regional.; CSCC is staged as metastatic.","evidence_relations":"CSCC is staged as local (confined to skin), regional (spread to lymph nodes), or metastatic (distant spread)"},
	{"id":"Medical-1f290988","source":"Medical","question":"What is a precancerous lesion that can progress to CSCC?","answer":"Actinic keratosis is a precancerous lesion that can progress to CSCC.","question_type":"Fact Retrieval","evidence":"Actinic keratosis is a precancerous lesion that can progress to CSCC.","evidence_relations":"Actinic keratosis is a precancerous lesion that can progress to CSCC"},
	{"id":"Medical-3d21bfb3","source":"Medical","question":"Which risk factors are major contributors to CSCC development?","answer":"Major risk factors for CSCC include chronic sun exposure, indoor tanning, environmental toxins, actinic keratoses, genetic syndromes, weakened immune system, and chronic wounds or scars.","question_type":"Fact Retrieval","evidence":"Chronic sun exposure is a major risk factor for CSCC.; Indoor tanning is a major risk factor for CSCC.; Environmental toxins are a major risk factor for CSCC.; Actinic keratoses are a major risk factor for CSCC.; Genetic syndromes are a major risk factor for CSCC.; A weakened immune system is a major risk factor for CSCC.; Chronic wounds or scars are a major risk factor for CSCC.","evidence_relations":"Major risk factors for CSCC include chronic sun exposure, indoor tanning, environmental toxins, actinic keratoses, genetic syndromes, weakened immune system, and chronic wounds or scars"},
	{"id":"Medical-a2555661","source":"Medical","question":"Which genetic syndromes increase the risk for CSCC?","answer":"Xeroderma pigmentosum and RDEB increase risk for CSCC.","question_type":"Fact Retrieval","evidence":"Xeroderma pigmentosum increases the risk for CSCC.; RDEB increases the risk for CSCC.","evidence_relations":"Genetic syndromes such as xeroderma pigmentosum and RDEB increase risk for CSCC"},
	{"id":"Medical-8866282b","source":"Medical","question":"What are common symptoms of CSCC?","answer":"Symptoms of CSCC include scaly patches, solid or misshapen skin lesions, and lesions in areas of chronic damage.","question_type":"Fact Retrieval","evidence":"Common symptoms of CSCC include scaly patches.; Common symptoms of CSCC include solid or misshapen skin lesions.; Common symptoms of CSCC include lesions in areas of chronic damage.","evidence_relations":"Symptoms of CSCC include scaly patches, solid or misshapen skin lesions, and lesions in areas of chronic damage"},
	{"id":"Medical-77287c53","source":"Medical","question":"Which methods are used to diagnose CSCC?","answer":"Diagnosis of CSCC involves clinical examination, skin biopsy, and imaging (CT, MRI, PET/CT) if deeper invasion or spread is suspected.","question_type":"Fact Retrieval","evidence":"Diagnosis of CSCC involves clinical examination.; Diagnosis of CSCC involves skin biopsy.; Diagnosis of CSCC involves imaging if deeper invasion or spread is suspected.; Imaging methods for diagnosing CSCC include CT, MRI, and PET/CT.","evidence_relations":"Diagnosis of CSCC involves clinical examination, skin biopsy, and imaging (CT, MRI, PET/CT) if deeper invasion or spread is suspected"},
	{"id":"Medical-d9522675","source":"Medical","question":"What biopsy types are used in the diagnosis of CSCC?","answer":"Biopsy types for diagnosis include shave biopsy, punch biopsy, and excision biopsy.","question_type":"Fact Retrieval","evidence":"Biopsy types for diagnosis of CSCC include shave biopsy.; Biopsy types for diagnosis of CSCC include punch biopsy.; Biopsy types for diagnosis of CSCC include excision biopsy.","evidence_relations":"Biopsy types for diagnosis include shave biopsy, punch biopsy, and excision biopsy"},
	{"id":"Medical-8fe8663f","source":"Medical","question":"What are the preferred treatments for low-risk local CSCC?","answer":"Low-risk local CSCC is primarily treated with surgery (C&E, standard excision, Mohs surgery/PDEMA).","question_type":"Fact Retrieval","evidence":"Low-risk local CSCC is primarily treated with surgery.; Surgical options for low-risk local CSCC include curettage and electrodessication (C&E).; Surgical options for low-risk local CSCC include standard excision.; Surgical options for low-risk local CSCC include Mohs surgery/PDEMA.","evidence_relations":"Low-risk local CSCC is primarily treated with surgery (C&E, standard excision, Mohs surgery/PDEMA)"},
	{"id":"Medical-c421a232","source":"Medical","question":"Which treatment options are considered for high-risk or very high-risk local CSCC?","answer":"High-risk or very high-risk local CSCC is treated with Mohs surgery/PDEMA or standard excision, with consideration of radiation and/or systemic therapy if surgery is not possible.","question_type":"Fact Retrieval","evidence":"High-risk or very high-risk local CSCC is treated with Mohs surgery/PDEMA.; High-risk or very high-risk local CSCC is treated with standard excision.; Consideration of radiation is made if surgery is not possible for high-risk or very high-risk local CSCC.; Consideration of systemic therapy is made if surgery is not possible for high-risk or very high-risk local CSCC.","evidence_relations":"High-risk or very high-risk local CSCC is treated with Mohs surgery/PDEMA or standard excision, with consideration of radiation and/or systemic therapy if surgery is not possible"},
	{"id":"Medical-203a2d6b","source":"Medical","question":"How is regional CSCC with lymph node involvement treated?","answer":"Regional CSCC (lymph node involvement) is treated with surgery to remove tumor and lymph nodes, often followed by radiation and sometimes systemic therapy.","question_type":"Fact Retrieval","evidence":"Regional CSCC with lymph node involvement is treated with surgery to remove the tumor.; Regional CSCC with lymph node involvement is treated with surgery to remove lymph nodes.; Treatment for regional CSCC often includes radiation.; Treatment for regional CSCC may include systemic therapy.","evidence_relations":"Regional CSCC (lymph node involvement) is treated with surgery to remove tumor and lymph nodes, often followed by radiation and sometimes systemic therapy"},
	{"id":"Medical-dc52ffce","source":"Medical","question":"What is the preferred treatment for metastatic CSCC?","answer":"Metastatic CSCC is treated with systemic therapy (immunotherapy preferred), and surgery or radiation if feasible.","question_type":"Fact Retrieval","evidence":"Metastatic CSCC is treated with systemic therapy.; Immunotherapy is the preferred systemic therapy for metastatic CSCC.; Surgery may be performed for metastatic CSCC if feasible.; Radiation may be used for metastatic CSCC if feasible.","evidence_relations":"Metastatic CSCC is treated with systemic therapy (immunotherapy preferred), and surgery or radiation if feasible"},
	{"id":"Medical-0d21d2d6","source":"Medical","question":"Which systemic therapies are used for advanced CSCC?","answer":"Systemic therapy options include platinum-based chemotherapy, EGFR inhibitors (cetuximab), and PD-1 inhibitors (cemiplimab, pembrolizumab).","question_type":"Fact Retrieval","evidence":"Systemic therapy options for advanced CSCC include platinum-based chemotherapy.; Systemic therapy options for advanced CSCC include EGFR inhibitors.; Cetuximab is an EGFR inhibitor used for advanced CSCC.; Systemic therapy options for advanced CSCC include PD-1 inhibitors.; Cemiplimab is a PD-1 inhibitor used for advanced CSCC.; Pembrolizumab is a PD-1 inhibitor used for advanced CSCC.","evidence_relations":"Systemic therapy options include platinum-based chemotherapy, EGFR inhibitors (cetuximab), and PD-1 inhibitors (cemiplimab, pembrolizumab)"},
	{"id":"Medical-bfa9a27b","source":"Medical","question":"What therapies are used for actinic keratoses and superficial CSCC?","answer":"Photodynamic therapy, cryotherapy, and topical therapies (5-fluorouracil, imiquimod, tirbanibulin) are used for actinic keratoses and superficial CSCC.","question_type":"Fact Retrieval","evidence":"Photodynamic therapy is used for actinic keratoses and superficial CSCC.; Cryotherapy is used for actinic keratoses and superficial CSCC.; Topical therapies are used for actinic keratoses and superficial CSCC.; 5-fluorouracil is a topical therapy used for actinic keratoses and superficial CSCC.; Imiquimod is a topical therapy used for actinic keratoses and superficial CSCC.; Tirbanibulin is a topical therapy used for actinic keratoses and superficial CSCC.","evidence_relations":"Photodynamic therapy, cryotherapy, and topical therapies (5-fluorouracil, imiquimod, tirbanibulin) are used for actinic keratoses and superficial CSCC"},
	{"id":"Medical-8d545fa4","source":"Medical","question":"What is the recommended follow-up strategy after CSCC treatment?","answer":"Follow-up after treatment includes regular skin and lymph node exams, with frequency based on risk and stage.","question_type":"Fact Retrieval","evidence":"Follow-up after CSCC treatment includes regular skin exams.; Follow-up after CSCC treatment includes regular lymph node exams.; The frequency of follow-up exams is based on risk and stage.","evidence_relations":"Follow-up after treatment includes regular skin and lymph node exams, with frequency based on risk and stage"},
	{"id":"Medical-6a38af6d","source":"Medical","question":"What is a key biomarker used in risk assessment for CSCC?","answer":"Perineural invasion is a key biomarker for CSCC risk assessment.","question_type":"Fact Retrieval","evidence":"Perineural invasion is a key biomarker for CSCC risk assessment.","evidence_relations":"Perineural invasion is listed as a biomarker in the ontology for CSCC"},
	{"id":"Medical-eac1c791","source":"Medical","question":"Which environmental toxins are risk factors for CSCC?","answer":"Environmental toxins such as arsenic and tobacco smoke are risk factors for CSCC.","question_type":"Fact Retrieval","evidence":"Arsenic is an environmental toxin that is a risk factor for CSCC.; Tobacco smoke is an environmental toxin that is a risk factor for CSCC.","evidence_relations":"Environmental toxins (arsenic, tobacco smoke) are listed as risk factors for CSCC"},
	{"id":"Medical-8bf3a99b","source":"Medical","question":"How is risk assessment for CSCC performed?","answer":"Risk assessment for CSCC is based on tumor location, size, border definition, recurrence, depth, perineural invasion, lymphovascular invasion, tumor grade, and patient immune status.","question_type":"Fact Retrieval","evidence":"Risk assessment for CSCC is based on tumor location.; Risk assessment for CSCC is based on tumor size.; Risk assessment for CSCC is based on border definition.; Risk assessment for CSCC is based on recurrence.; Risk assessment for CSCC is based on depth.; Risk assessment for CSCC is based on perineural invasion.; Risk assessment for CSCC is based on lymphovascular invasion.; Risk assessment for CSCC is based on tumor grade.; Risk assessment for CSCC is based on patient immune status.","evidence_relations":"Risk assessment for CSCC is based on tumor location, size, border definition, recurrence, depth, perineural invasion, lymphovascular invasion, tumor grade, and patient immune status"},
	{"id":"Medical-c8c9c0ee","source":"Medical","question":"Which imaging modalities are used for staging and surveillance in CSCC?","answer":"Imaging (CT, MRI, PET/CT) is used for staging and surveillance in regional and high-risk cases.","question_type":"Fact Retrieval","evidence":"CT is an imaging modality used for staging and surveillance in CSCC.; MRI is an imaging modality used for staging and surveillance in CSCC.; PET/CT is an imaging modality used for staging and surveillance in CSCC.; Imaging is used for staging and surveillance in regional and high-risk cases of CSCC.","evidence_relations":"Imaging is used for staging and surveillance in regional and high-risk cases"},
	{"id":"Medical-b1ab4938","source":"Medical","question":"What follow-up schedule is recommended for high-risk local CSCC after treatment?","answer":"Skin and lymph node exams every 3-6 months for 2 years, then every 6 months for 3 years, then every 6-12 months are recommended.","question_type":"Fact Retrieval","evidence":"Skin and lymph node exams are recommended every 3-6 months for 2 years after treatment for high-risk local CSCC.; Skin and lymph node exams are recommended every 6 months for 3 years after treatment for high-risk local CSCC.; Skin and lymph node exams are recommended every 6-12 months after the initial follow-up period for high-risk local CSCC.","evidence_relations":"Skin and lymph node exams every 3-6 months for 2 years, then every 6 months for 3 years, then every 6-12 months"},
	{"id":"Medical-1edadd2a","source":"Medical","question":"What are the main symptoms of CSCC in areas of chronic damage?","answer":"Lesions in areas of chronic wounds or scars are a main symptom of CSCC.","question_type":"Fact Retrieval","evidence":"Lesions in areas of chronic wounds are a main symptom of CSCC.; Lesions in areas of scars are a main symptom of CSCC.","evidence_relations":"Symptoms of CSCC include lesions in areas of chronic damage"},
	{"id":"Medical-59292b3b","source":"Medical","question":"Which topical therapies are used for actinic keratosis?","answer":"Topical therapies for actinic keratosis include 5-fluorouracil, imiquimod, calcipotriene, tirbanibulin, and diclofenac.","question_type":"Fact Retrieval","evidence":"5-fluorouracil is a topical therapy for actinic keratosis.; Imiquimod is a topical therapy for actinic keratosis.; Calcipotriene is a topical therapy for actinic keratosis.; Tirbanibulin is a topical therapy for actinic keratosis.; Diclofenac is a topical therapy for actinic keratosis.","evidence_relations":"Topical therapy (5-fluorouracil, imiquimod, calcipotriene, tirbanibulin, diclofenac) is listed for actinic keratosis"},
	{"id":"Medical-909f9360","source":"Medical","question":"What is the preferred surgical method for high-risk local CSCC?","answer":"Mohs surgery/PDEMA is the preferred surgical method for high-risk local CSCC.","question_type":"Fact Retrieval","evidence":"Mohs surgery is the preferred surgical method for high-risk local CSCC.; PDEMA is the preferred surgical method for high-risk local CSCC.","evidence_relations":"Mohs surgery/PDEMA (preferred) is listed for high-risk local CSCC"},
	{"id":"Medical-9a719269","source":"Medical","question":"Which patients are recommended to consider clinical trials in CSCC management?","answer":"Clinical trials are an option for systemic therapy, especially in advanced or refractory CSCC.","question_type":"Fact Retrieval","evidence":"Clinical trials are an option for systemic therapy in CSCC management.; Clinical trials are especially recommended for advanced CSCC.; Clinical trials are especially recommended for refractory CSCC.","evidence_relations":"Clinical trials are an option for systemic therapy, especially in advanced or refractory CSCC"},
	{"id":"Medical-f10f3bc4","source":"Medical","question":"What is the role of sentinel lymph node biopsy (SLNB) in CSCC?","answer":"Sentinel lymph node biopsy (SLNB) is used as a diagnostic method in regional CSCC.","question_type":"Fact Retrieval","evidence":"Sentinel lymph node biopsy (SLNB) is used as a diagnostic method in regional CSCC.","evidence_relations":"Lymph node biopsy (FNA, core needle biopsy) is listed as a diagnostic method for regional CSCC in the ontology"},
	{"id":"Medical-d8a3772b","source":"Medical","question":"Which immunotherapy agents are used for metastatic CSCC?","answer":"PD-1 inhibitors such as cemiplimab and pembrolizumab are used for metastatic CSCC.","question_type":"Fact Retrieval","evidence":"PD-1 inhibitors are used for metastatic CSCC.; Cemiplimab is a PD-1 inhibitor used for metastatic CSCC.; Pembrolizumab is a PD-1 inhibitor used for metastatic CSCC.","evidence_relations":"PD-1 inhibitors (cemiplimab, pembrolizumab) are listed as systemic therapy options for metastatic CSCC"},
	{"id":"Medical-2a0d5063","source":"Medical","question":"How often should skin and lymph node exams be performed for low-risk local CSCC during the first 2 years after treatment?","answer":"Skin and lymph node exams every 3-12 months for 2 years are recommended for low-risk local CSCC.","question_type":"Fact Retrieval","evidence":"Skin and lymph node exams are recommended for low-risk local CSCC.; Skin and lymph node exams should be performed every 3-12 months.; Skin and lymph node exams should be performed for 2 years.","evidence_relations":"Skin and lymph node exams every 3-12 months for 2 years for low-risk local CSCC"},
	{"id":"Medical-ff41533a","source":"Medical","question":"What is the preferred systemic therapy for metastatic CSCC?","answer":"PD-1 inhibitor is the preferred systemic therapy for metastatic CSCC.","question_type":"Fact Retrieval","evidence":"PD-1 inhibitor is the preferred systemic therapy for metastatic CSCC.","evidence_relations":"Systemic therapy (PD-1 inhibitor preferred) is listed for metastatic CSCC"},
	{"id":"Medical-c87c6baf","source":"Medical","question":"Which factors are included in clinical management risk assessment for CSCC?","answer":"Risk assessment includes tumor location and size, tumor border definition, recurrence, depth of invasion, perineural invasion, lymphovascular invasion, tumor grade, and immunosuppression.","question_type":"Fact Retrieval","evidence":"Risk assessment for CSCC includes tumor location.; Risk assessment for CSCC includes tumor size.; Risk assessment for CSCC includes tumor border definition.; Risk assessment for CSCC includes recurrence.; Risk assessment for CSCC includes depth of invasion.; Risk assessment for CSCC includes perineural invasion.; Risk assessment for CSCC includes lymphovascular invasion.; Risk assessment for CSCC includes tumor grade.; Risk assessment for CSCC includes immunosuppression.","evidence_relations":"Risk Assessment includes tumor location and size, tumor border definition, recurrence, depth of invasion, perineural invasion, lymphovascular invasion, tumor grade, immunosuppression"},
	{"id":"Medical-3e2b82f5","source":"Medical","question":"Which clinical management strategy is used for surveillance in high-risk or regional CSCC?","answer":"Surveillance involves regular skin and lymph node exams and imaging for high-risk or regional disease.","question_type":"Fact Retrieval","evidence":"Surveillance for high-risk or regional CSCC involves regular skin exams.; Surveillance for high-risk or regional CSCC involves regular lymph node exams.; Surveillance for high-risk or regional CSCC involves imaging.","evidence_relations":"Surveillance: Regular skin and lymph node exams, imaging for high-risk or regional disease"},
	{"id":"Medical-0c8340a1","source":"Medical","question":"What type of cancer is chronic myeloid leukemia (CML)?","answer":"CML is a type of blood cancer.","question_type":"Fact Retrieval","evidence":"Chronic myeloid leukemia (CML) is a type of blood cancer.","evidence_relations":"Chronic myeloid leukemia (CML) is a type of blood cancer"},
	{"id":"Medical-9b293f2c","source":"Medical","question":"What genetic alteration causes chronic myeloid leukemia?","answer":"CML is caused by the BCR::ABL1 fusion gene.","question_type":"Fact Retrieval","evidence":"CML is caused by the BCR::ABL1 fusion gene.","evidence_relations":"CML is caused by the BCR::ABL1 fusion gene"},
	{"id":"Medical-e49be454","source":"Medical","question":"Which chromosomal translocation results in the BCR::ABL1 gene?","answer":"A translocation between chromosome 9 and chromosome 22 creates the BCR::ABL1 gene.","question_type":"Fact Retrieval","evidence":"A translocation between chromosome 9 and chromosome 22 creates the BCR::ABL1 gene.","evidence_relations":"The BCR::ABL1 gene is created by a translocation between chromosome 9 and chromosome 22"},
	{"id":"Medical-c97b2e2b","source":"Medical","question":"What is the Philadelphia chromosome?","answer":"The Philadelphia chromosome (Ph) is the abnormal chromosome 22 resulting from the translocation.","question_type":"Fact Retrieval","evidence":"The Philadelphia chromosome (Ph) is an abnormal chromosome.; The Philadelphia chromosome (Ph) is chromosome 22.; The Philadelphia chromosome (Ph) results from a translocation.","evidence_relations":"The Philadelphia chromosome (Ph) is the abnormal chromosome 22 resulting from this translocation"},
	{"id":"Medical-e5676a79","source":"Medical","question":"What is required for a diagnosis of CML?","answer":"Presence of the Ph chromosome or BCR::ABL1 gene is required for CML diagnosis.","question_type":"Fact Retrieval","evidence":"Presence of the Ph chromosome is required for CML diagnosis.; Presence of the BCR::ABL1 gene is required for CML diagnosis.","evidence_relations":"Presence of the Ph chromosome or BCR::ABL1 gene is required for CML diagnosis"},
	{"id":"Medical-fad73295","source":"Medical","question":"From which cells does CML arise?","answer":"CML arises from blood stem cells producing increased myeloid progenitor cells.","question_type":"Fact Retrieval","evidence":"CML arises from blood stem cells.; CML involves the production of increased myeloid progenitor cells.","evidence_relations":"CML arises from blood stem cells producing increased myeloid progenitor cells"},
	{"id":"Medical-77457615","source":"Medical","question":"What are the two main diagnostic methods for CML?","answer":"Blood tests and bone marrow tests are used to diagnose CML.","question_type":"Fact Retrieval","evidence":"Blood tests are used to diagnose CML.; Bone marrow tests are used to diagnose CML.","evidence_relations":"Blood tests and bone marrow tests are used to diagnose CML"},
	{"id":"Medical-9fb94929","source":"Medical","question":"Which biomarker is associated with CML?","answer":"The BCR::ABL1 fusion gene is a biomarker for CML.","question_type":"Fact Retrieval","evidence":"The BCR::ABL1 fusion gene is a biomarker for CML.","evidence_relations":"Biomarker: BCR::ABL1 fusion gene"},
	{"id":"Medical-b3eac8b2","source":"Medical","question":"What is the abnormal chromosome found in most CML cases?","answer":"The Philadelphia chromosome (Ph) is the abnormal chromosome found in CML.","question_type":"Fact Retrieval","evidence":"The Philadelphia chromosome (Ph) is the abnormal chromosome found in CML.","evidence_relations":"Biomarker: Philadelphia chromosome (Ph)"},
	{"id":"Medical-72a77731","source":"Medical","question":"What is the primary treatment goal for CML?","answer":"Treatment for CML aims to inhibit BCR::ABL1 protein activity.","question_type":"Fact Retrieval","evidence":"The primary treatment goal for CML is to inhibit BCR::ABL1 protein activity.","evidence_relations":"Treatment for CML aims to inhibit BCR::ABL1 protein activity"},
	{"id":"Medical-5fe38d4e","source":"Medical","question":"Which blood cell types are increased in CML?","answer":"CML is characterized by increased white blood cells (granulocytes) and abnormal platelet counts.","question_type":"Fact Retrieval","evidence":"CML is characterized by increased white blood cells (granulocytes).; CML is characterized by abnormal platelet counts.","evidence_relations":"CML is characterized by increased white blood cells (granulocytes) and abnormal platelet counts"},
	{"id":"Medical-69537d43","source":"Medical","question":"What is blast phase CML?","answer":"Blast phase CML (BP-CML) is an advanced form of CML with increased blasts.","question_type":"Fact Retrieval","evidence":"Blast phase CML (BP-CML) is an advanced form of CML.; Blast phase CML has increased blasts.","evidence_relations":"Blast phase CML (BP-CML) is an advanced form of CML with increased blasts"},
	{"id":"Medical-6d738949","source":"Medical","question":"Which chromosomes are involved in the translocation that creates the BCR::ABL1 fusion gene?","answer":"Chromosome 9 and chromosome 22 are involved in the translocation.","question_type":"Fact Retrieval","evidence":"Chromosome 9 is involved in the translocation that creates the BCR::ABL1 fusion gene.; Chromosome 22 is involved in the translocation that creates the BCR::ABL1 fusion gene.","evidence_relations":"The BCR::ABL1 gene is created by a translocation between chromosome 9 and chromosome 22"},
	{"id":"Medical-7da67d67","source":"Medical","question":"What is the abnormality found on chromosome 22 in CML?","answer":"The Philadelphia chromosome (Ph) is the abnormality found on chromosome 22.","question_type":"Fact Retrieval","evidence":"The Philadelphia chromosome (Ph) is the abnormality found on chromosome 22 in CML.","evidence_relations":"The Philadelphia chromosome (Ph) is the abnormal chromosome 22 resulting from this translocation"},
	{"id":"Medical-3170a5f2","source":"Medical","question":"Which fusion gene is necessary for the diagnosis of CML?","answer":"The BCR::ABL1 fusion gene is necessary for the diagnosis of CML.","question_type":"Fact Retrieval","evidence":"The BCR::ABL1 fusion gene is necessary for the diagnosis of CML.","evidence_relations":"Presence of the Ph chromosome or BCR::ABL1 gene is required for CML diagnosis"},
	{"id":"Medical-dc60c354","source":"Medical","question":"Which phase of CML is considered advanced?","answer":"Blast phase CML (BP-CML) is considered advanced.","question_type":"Fact Retrieval","evidence":"Blast phase CML (BP-CML) is considered advanced.","evidence_relations":"Blast phase CML (BP-CML) is an advanced form of CML with increased blasts"},
	{"id":"Medical-62a9b979","source":"Medical","question":"Which blood cell type is produced in increased numbers in CML?","answer":"Myeloid progenitor cells are produced in increased numbers in CML.","question_type":"Fact Retrieval","evidence":"Myeloid progenitor cells are produced in increased numbers in CML.","evidence_relations":"CML arises from blood stem cells producing increased myeloid progenitor cells"},
	{"id":"Medical-57375967","source":"Medical","question":"What are the main white blood cell subtypes involved in CML?","answer":"Granulocytes, including neutrophils, eosinophils, and basophils, are involved in CML.","question_type":"Fact Retrieval","evidence":"Granulocytes are involved in CML.; Neutrophils are a subtype of granulocytes involved in CML.; Eosinophils are a subtype of granulocytes involved in CML.; Basophils are a subtype of granulocytes involved in CML.","evidence_relations":"White blood cells (WBCs): granulocytes, neutrophils, eosinophils, basophils"},
	{"id":"Medical-7044a5ef","source":"Medical","question":"Which diagnostic tests are used to detect the BCR::ABL1 fusion gene?","answer":"Blood test and bone marrow test are used to detect the BCR::ABL1 fusion gene.","question_type":"Fact Retrieval","evidence":"Blood test is used to detect the BCR::ABL1 fusion gene.; Bone marrow test is used to detect the BCR::ABL1 fusion gene.","evidence_relations":"Diagnostic Method: blood test, bone marrow test"},
	{"id":"Medical-c2ab6e9a","source":"Medical","question":"What chromosomal abnormality is characteristic of CML?","answer":"The Philadelphia chromosome (Ph) is characteristic of CML.","question_type":"Fact Retrieval","evidence":"The Philadelphia chromosome (Ph) is characteristic of CML.","evidence_relations":"Chromosomal Abnormality: Philadelphia chromosome (Ph)"},
	{"id":"Medical-61ec9250","source":"Medical","question":"Which treatment strategy targets the abnormal protein in CML?","answer":"BCR::ABL1 protein inhibition is the treatment strategy.","question_type":"Fact Retrieval","evidence":"BCR::ABL1 protein inhibition is the treatment strategy for CML.","evidence_relations":"Treatment: BCR::ABL1 protein inhibition"},
	{"id":"Medical-cbbc0e25","source":"Medical","question":"What is the result of the translocation between chromosome 9 and 22?","answer":"The result is the formation of the Philadelphia chromosome (Ph) and the BCR::ABL1 fusion gene.","question_type":"Fact Retrieval","evidence":"The translocation between chromosome 9 and 22 results in the formation of the Philadelphia chromosome (Ph).; The translocation between chromosome 9 and 22 results in the formation of the BCR::ABL1 fusion gene.","evidence_relations":"The BCR::ABL1 gene is created by a translocation between chromosome 9 and chromosome 22"},
	{"id":"Medical-5c8f25b0","source":"Medical","question":"Which phase of CML is associated with increased blasts in the blood or bone marrow?","answer":"Blast phase CML (BP-CML) is associated with increased blasts.","question_type":"Fact Retrieval","evidence":"Blast phase CML (BP-CML) is associated with increased blasts in the blood.; Blast phase CML (BP-CML) is associated with increased blasts in the bone marrow.","evidence_relations":"Blast phase CML (BP-CML) is an advanced form of CML with increased blasts"},
	{"id":"Medical-9b7aadb2","source":"Medical","question":"Which two main laboratory methods are used for CML diagnosis?","answer":"Blood test and bone marrow test are the main methods.","question_type":"Fact Retrieval","evidence":"Blood test is one of the main methods for CML diagnosis.; Bone marrow test is one of the main methods for CML diagnosis.","evidence_relations":"Blood tests and bone marrow tests are used to diagnose CML"},
	{"id":"Medical-f18cea43","source":"Medical","question":"What is the relationship between the Philadelphia chromosome and the BCR::ABL1 fusion gene?","answer":"The Philadelphia chromosome contains the BCR::ABL1 fusion gene.","question_type":"Fact Retrieval","evidence":"The Philadelphia chromosome contains the BCR::ABL1 fusion gene.","evidence_relations":"The Philadelphia chromosome (Ph) is the abnormal chromosome 22 resulting from this translocation"},
	{"id":"Medical-e2848d7f","source":"Medical","question":"Which blood cell types may show abnormal counts in CML?","answer":"White blood cells (granulocytes) and platelets (PLTs) may show abnormal counts.","question_type":"Fact Retrieval","evidence":"White blood cells may show abnormal counts in CML.; Granulocytes may show abnormal counts in CML.; Platelets may show abnormal counts in CML.","evidence_relations":"CML is characterized by increased white blood cells (granulocytes) and abnormal platelet counts"},
	{"id":"Medical-e1b6447e","source":"Medical","question":"What is the role of blood stem cells in CML?","answer":"Blood stem cells give rise to increased myeloid progenitor cells in CML.","question_type":"Fact Retrieval","evidence":"Blood stem cells give rise to increased myeloid progenitor cells in CML.","evidence_relations":"CML arises from blood stem cells producing increased myeloid progenitor cells"},
	{"id":"Medical-7db5b20d","source":"Medical","question":"Which progenitor cells are increased in blast phase CML?","answer":"Myeloid progenitor cells, lymphoid progenitor cells, and blasts are increased in blast phase CML.","question_type":"Fact Retrieval","evidence":"Myeloid progenitor cells are increased in blast phase CML.; Lymphoid progenitor cells are increased in blast phase CML.; Blasts are increased in blast phase CML.","evidence_relations":"Blast phase CML (BP-CML): Blood Cell Type: myeloid progenitor cells, lymphoid progenitor cells, blasts"},
	{"id":"Medical-ea3d4859","source":"Medical","question":"Which chromosomes are specifically mentioned as being involved in CML pathogenesis?","answer":"Chromosome 9 and chromosome 22 are involved.","question_type":"Fact Retrieval","evidence":"Chromosome 9 is involved in CML pathogenesis.; Chromosome 22 is involved in CML pathogenesis.","evidence_relations":"Chromosomal Abnormality: chromosome 9, chromosome 22"},
	{"id":"Medical-8109c3aa","source":"Medical","question":"What is the function of BCR::ABL1 protein inhibition in CML treatment?","answer":"It is the primary treatment approach for CML.","question_type":"Fact Retrieval","evidence":"BCR::ABL1 protein inhibition is the primary treatment approach for CML.","evidence_relations":"Treatment for CML aims to inhibit BCR::ABL1 protein activity"},
	{"id":"Medical-ba894e2c","source":"Medical","question":"Which two biomarkers are most relevant for CML diagnosis?","answer":"The BCR::ABL1 fusion gene and the Philadelphia chromosome (Ph) are most relevant.","question_type":"Fact Retrieval","evidence":"The BCR::ABL1 fusion gene is most relevant for CML diagnosis.; The Philadelphia chromosome is most relevant for CML diagnosis.","evidence_relations":"Biomarker: BCR::ABL1 fusion gene, Philadelphia chromosome (Ph)"},
	{"id":"Medical-622cb4e3","source":"Medical","question":"What is the most common type of lung cancer?","answer":"NSCLC is the most common type of lung cancer.","question_type":"Fact Retrieval","evidence":"NSCLC is the most common type of lung cancer.","evidence_relations":"NSCLC is the most common type of lung cancer"},
	{"id":"Medical-42f1975a","source":"Medical","question":"Which cancer subtypes are included under NSCLC?","answer":"Adenocarcinoma, squamous cell carcinoma, and large cell carcinoma are subtypes of NSCLC.","question_type":"Fact Retrieval","evidence":"Adenocarcinoma is a subtype of NSCLC.; Squamous cell carcinoma is a subtype of NSCLC.; Large cell carcinoma is a subtype of NSCLC.","evidence_relations":"Adenocarcinoma, squamous cell carcinoma, and large cell carcinoma are subtypes of NSCLC"},
	{"id":"Medical-419cadfe","source":"Medical","question":"What type of cells does adenocarcinoma often form from?","answer":"Adenocarcinoma often forms from cells that line the alveoli and make mucus.","question_type":"Fact Retrieval","evidence":"Adenocarcinoma often forms from cells that line the alveoli.; Adenocarcinoma often forms from cells that make mucus.","evidence_relations":"Adenocarcinoma often forms from cells that line the alveoli and make mucus"},
	{"id":"Medical-8be16d47","source":"Medical","question":"Which cells do squamous cell carcinoma originate from?","answer":"Squamous cell carcinoma forms from cells that line the bronchi.","question_type":"Fact Retrieval","evidence":"Squamous cell carcinoma forms from cells that line the bronchi.","evidence_relations":"Squamous cell carcinoma forms from cells that line the bronchi"},
	{"id":"Medical-9e7500a0","source":"Medical","question":"What is the origin of large cell carcinoma in NSCLC?","answer":"Large cell carcinoma forms from large cells found throughout the airways.","question_type":"Fact Retrieval","evidence":"Large cell carcinoma forms from large cells.; Large cells are found throughout the airways.","evidence_relations":"Large cell carcinoma forms from large cells found throughout the airways"},
	{"id":"Medical-a61abd42","source":"Medical","question":"How is Stage 1 NSCLC classified?","answer":"Stage 1 NSCLC is considered early stage.","question_type":"Fact Retrieval","evidence":"Stage 1 NSCLC is considered early stage.","evidence_relations":"Stage 1 NSCLC is considered early stage"},
	{"id":"Medical-74016ca7","source":"Medical","question":"What stages of NSCLC are considered locally advanced?","answer":"Stage 2 and Stage 3 NSCLC are considered locally advanced.","question_type":"Fact Retrieval","evidence":"Stage 2 NSCLC is considered locally advanced.; Stage 3 NSCLC is considered locally advanced.","evidence_relations":"Stage 2 and Stage 3 NSCLC are considered locally advanced"},
	{"id":"Medical-bffd01c2","source":"Medical","question":"What is the classification of Stage 4 NSCLC at diagnosis?","answer":"Stage 4 NSCLC is metastatic at diagnosis.","question_type":"Fact Retrieval","evidence":"Stage 4 NSCLC is metastatic at diagnosis.","evidence_relations":"Stage 4 NSCLC is metastatic at diagnosis"},
	{"id":"Medical-ef451592","source":"Medical","question":"Has early and locally advanced NSCLC spread to other organs at diagnosis?","answer":"Early and locally advanced NSCLC have not spread to the tissue lining around the lung or to other organs at diagnosis.","question_type":"Fact Retrieval","evidence":"Early NSCLC has not spread to the tissue lining around the lung at diagnosis.; Locally advanced NSCLC has not spread to other organs at diagnosis.","evidence_relations":"Early and locally advanced NSCLC have not spread to the tissue lining around the lung or to other organs at diagnosis"},
	{"id":"Medical-e1aa3f36","source":"Medical","question":"What is the primary treatment for early or locally advanced NSCLC when possible?","answer":"Surgery is a primary treatment for early or locally advanced NSCLC when possible.","question_type":"Fact Retrieval","evidence":"Surgery is a primary treatment for early NSCLC when possible.; Surgery is a primary treatment for locally advanced NSCLC when possible.","evidence_relations":"Surgery is a primary treatment for early or locally advanced NSCLC when possible"},
	{"id":"Medical-83b8a631","source":"Medical","question":"Which treatment is used for some early NSCLC cases?","answer":"Radiation therapy is used for some early NSCLC cases.","question_type":"Fact Retrieval","evidence":"Radiation therapy is used for some early NSCLC cases.","evidence_relations":"Radiation therapy is used for some early NSCLC cases"},
	{"id":"Medical-2c702150","source":"Medical","question":"What treatment is used for some locally advanced NSCLC cases?","answer":"Chemoradiation is used for some locally advanced NSCLC cases.","question_type":"Fact Retrieval","evidence":"Chemoradiation is used for some locally advanced NSCLC cases.","evidence_relations":"Chemoradiation is used for some locally advanced NSCLC cases"},
	{"id":"Medical-5bae1c96","source":"Medical","question":"What type of care extends and enhances life for people with lung cancer?","answer":"Supportive care extends and enhances life for people with lung cancer.","question_type":"Fact Retrieval","evidence":"Supportive care extends life for people with lung cancer.; Supportive care enhances life for people with lung cancer.","evidence_relations":"Supportive care extends and enhances life for people with lung cancer"},
	{"id":"Medical-a5c06d63","source":"Medical","question":"How may lung nodules be detected?","answer":"Lung nodules may be detected by imaging.","question_type":"Fact Retrieval","evidence":"Lung nodules may be detected by imaging.","evidence_relations":"Lung nodules may be detected by imaging and require further assessment to determine malignancy"},
	{"id":"Medical-4de99f79","source":"Medical","question":"What diagnostic method is used to confirm lung cancer diagnosis?","answer":"Biopsy is used to confirm lung cancer diagnosis.","question_type":"Fact Retrieval","evidence":"Biopsy is used to confirm lung cancer diagnosis.","evidence_relations":"Biopsy is used to confirm lung cancer diagnosis"},
	{"id":"Medical-ebb0af4d","source":"Medical","question":"Who is recommended to undergo lung cancer screening?","answer":"Lung cancer screening is recommended for people at high risk.","question_type":"Fact Retrieval","evidence":"Lung cancer screening is recommended for people at high risk.","evidence_relations":"Lung cancer screening is recommended for people at high risk"},
	{"id":"Medical-8217a825","source":"Medical","question":"What is the biggest risk factor for lung cancer?","answer":"Tobacco smoking is the biggest risk factor for lung cancer.","question_type":"Fact Retrieval","evidence":"Tobacco smoking is the biggest risk factor for lung cancer.","evidence_relations":"Tobacco smoking is the biggest risk factor for lung cancer"},
	{"id":"Medical-0cb322e0","source":"Medical","question":"Does exposure to second-hand smoke affect lung cancer risk?","answer":"Exposure to second-hand smoke increases lung cancer risk.","question_type":"Fact Retrieval","evidence":"Exposure to second-hand smoke increases lung cancer risk.","evidence_relations":"Exposure to second-hand smoke increases lung cancer risk"},
	{"id":"Medical-64042235","source":"Medical","question":"List environmental risk factors for lung cancer besides tobacco.","answer":"Exposure to radon, asbestos, arsenic, beryllium, cadmium, chromium, nickel, coal smoke, soot, silica, diesel fumes, and air pollution are risk factors for lung cancer.","question_type":"Fact Retrieval","evidence":"Exposure to radon is a risk factor for lung cancer.; Exposure to asbestos is a risk factor for lung cancer.; Exposure to arsenic is a risk factor for lung cancer.; Exposure to beryllium is a risk factor for lung cancer.; Exposure to cadmium is a risk factor for lung cancer.; Exposure to chromium is a risk factor for lung cancer.; Exposure to nickel is a risk factor for lung cancer.; Exposure to coal smoke is a risk factor for lung cancer.; Exposure to soot is a risk factor for lung cancer.; Exposure to silica is a risk factor for lung cancer.; Exposure to diesel fumes is a risk factor for lung cancer.; Air pollution is a risk factor for lung cancer.","evidence_relations":"Exposure to radon, asbestos, arsenic, beryllium, cadmium, chromium, nickel, coal smoke, soot, silica, diesel fumes, and air pollution are risk factors for lung cancer"},
	{"id":"Medical-b4100b78","source":"Medical","question":"What is the aim of lung cancer screening?","answer":"Lung cancer screening aims to detect cancer at an early, more treatable stage.","question_type":"Fact Retrieval","evidence":"Lung cancer screening aims to detect cancer at an early stage.; Detecting cancer at an early stage makes it more treatable.","evidence_relations":"Lung cancer screening aims to detect cancer at an early, more treatable stage"},
	{"id":"Medical-d2bac092","source":"Medical","question":"What are common symptoms of lung cancer?","answer":"Symptoms of lung cancer may include cough, chest pain, and other respiratory symptoms.","question_type":"Fact Retrieval","evidence":"Common symptoms of lung cancer may include cough.; Common symptoms of lung cancer may include chest pain.; Common symptoms of lung cancer may include other respiratory symptoms.","evidence_relations":"Symptoms of lung cancer may include cough, chest pain, and other respiratory symptoms"},
	{"id":"Medical-eab59fae","source":"Medical","question":"Are clinical trials available for lung cancer treatment and prevention?","answer":"Clinical trials are available for lung cancer treatment and prevention.","question_type":"Fact Retrieval","evidence":"Clinical trials are available for lung cancer treatment.; Clinical trials are available for lung cancer prevention.","evidence_relations":"Clinical trials are available for lung cancer treatment and prevention"},
	{"id":"Medical-61cf41ee","source":"Medical","question":"What does follow-up care after lung cancer treatment include?","answer":"Follow-up care is planned after treatment and includes surveillance for recurrence.","question_type":"Fact Retrieval","evidence":"Follow-up care is planned after lung cancer treatment.; Follow-up care includes surveillance for recurrence.","evidence_relations":"Follow-up care is planned after treatment and includes surveillance for recurrence"},
	{"id":"Medical-09d21113","source":"Medical","question":"Which imaging method is used to detect lung nodules?","answer":"Imaging is used to detect lung nodules.","question_type":"Fact Retrieval","evidence":"Imaging is used to detect lung nodules.","evidence_relations":"Lung nodules may be detected by imaging"},
	{"id":"Medical-1b7a0e02","source":"Medical","question":"How are lung nodules assessed for malignancy?","answer":"Lung nodules are assessed by biopsy and lung cancer screening.","question_type":"Fact Retrieval","evidence":"Lung nodules are assessed by biopsy.; Lung nodules are assessed by lung cancer screening.","evidence_relations":"Lung nodules may be detected by imaging and require further assessment to determine malignancy"},
	{"id":"Medical-b77be62e","source":"Medical","question":"What is the indication for lung cancer screening?","answer":"Lung cancer screening is indicated for high risk individuals.","question_type":"Fact Retrieval","evidence":"Lung cancer screening is indicated for high risk individuals.","evidence_relations":"Lung cancer screening is recommended for people at high risk"},
	{"id":"Medical-752ca0c2","source":"Medical","question":"What is the purpose of lung cancer screening?","answer":"The purpose of lung cancer screening is early detection.","question_type":"Fact Retrieval","evidence":"The purpose of lung cancer screening is early detection.","evidence_relations":"Lung cancer screening aims to detect cancer at an early, more treatable stage"},
	{"id":"Medical-4ae5ec38","source":"Medical","question":"What are the main treatments for NSCLC?","answer":"The main treatments for NSCLC are surgery, radiation therapy, chemoradiation, supportive care, and clinical trial.","question_type":"Fact Retrieval","evidence":"The main treatments for NSCLC are surgery.; The main treatments for NSCLC are radiation therapy.; The main treatments for NSCLC are chemoradiation.; The main treatments for NSCLC are supportive care.; The main treatments for NSCLC are clinical trial.","evidence_relations":"Treatment for NSCLC includes surgery, radiation therapy, chemoradiation, supportive care, and clinical trial"},
	{"id":"Medical-2f2b791e","source":"Medical","question":"Which symptoms are specifically associated with NSCLC?","answer":"Cough and chest pain are symptoms associated with NSCLC.","question_type":"Fact Retrieval","evidence":"Cough is a symptom associated with NSCLC.; Chest pain is a symptom associated with NSCLC.","evidence_relations":"Symptoms of NSCLC include cough and chest pain"},
	{"id":"Medical-563587c2","source":"Medical","question":"What are the follow-up strategies for NSCLC after treatment?","answer":"Follow-up strategies for NSCLC include follow-up care and surveillance.","question_type":"Fact Retrieval","evidence":"Follow-up strategies for NSCLC include follow-up care.; Follow-up strategies for NSCLC include surveillance.","evidence_relations":"Follow-up Strategy for NSCLC includes follow-up care and surveillance"},
	{"id":"Medical-6aaabde4","source":"Medical","question":"What is the relationship between NSCLC and lung carcinoma?","answer":"NSCLC is a type of lung carcinoma.","question_type":"Fact Retrieval","evidence":"NSCLC is a type of lung carcinoma.","evidence_relations":"NSCLC is a type of lung carcinoma"},
	{"id":"Medical-2e9466a9","source":"Medical","question":"What type of cancer is nasopharyngeal carcinoma (NPC)?","answer":"Nasopharyngeal carcinoma (NPC) is a type of head and neck cancer that affects the nasopharynx.","question_type":"Fact Retrieval","evidence":"Nasopharyngeal carcinoma (NPC) is a type of head and neck cancer.; Nasopharyngeal carcinoma (NPC) affects the nasopharynx.","evidence_relations":"Nasopharyngeal carcinoma (NPC) is a type of head and neck cancer that affects the nasopharynx"},
	{"id":"Medical-d2746bf8","source":"Medical","question":"What is the most common subtype of nasopharyngeal cancer?","answer":"Squamous cell carcinoma (SCC) is the most common subtype of nasopharyngeal cancer.","question_type":"Fact Retrieval","evidence":"Squamous cell carcinoma (SCC) is the most common subtype of nasopharyngeal cancer.","evidence_relations":"Squamous cell carcinoma (SCC) is the most common subtype of nasopharyngeal cancer"},
	{"id":"Medical-75f181e8","source":"Medical","question":"Which anatomical site is affected by nasopharyngeal carcinoma?","answer":"Nasopharyngeal carcinoma affects the nasopharynx.","question_type":"Fact Retrieval","evidence":"Nasopharyngeal carcinoma affects the nasopharynx.","evidence_relations":"Nasopharyngeal carcinoma (NPC) is a type of head and neck cancer that affects the nasopharynx"},
	{"id":"Medical-de0767ce","source":"Medical","question":"What system is used to stage nasopharyngeal carcinoma?","answer":"NPC is staged using the AJCC TNM system.","question_type":"Fact Retrieval","evidence":"Nasopharyngeal carcinoma (NPC) is staged using the AJCC TNM system.","evidence_relations":"NPC is staged using the AJCC TNM system, which includes tumor size (T), lymph node involvement (N), and distant metastasis (M)"},
	{"id":"Medical-d5c10dcf","source":"Medical","question":"Name the main numbered stages used for nasopharyngeal carcinoma.","answer":"The main numbered stages are Stage 0, Stage I, Stage II, Stage III, and Stage IV.","question_type":"Fact Retrieval","evidence":"The main numbered stages of nasopharyngeal carcinoma are Stage 0.; The main numbered stages of nasopharyngeal carcinoma are Stage I.; The main numbered stages of nasopharyngeal carcinoma are Stage II.; The main numbered stages of nasopharyngeal carcinoma are Stage III.; The main numbered stages of nasopharyngeal carcinoma are Stage IV.","evidence_relations":"Numbered Stages: [\"Stage 0\", \"Stage I\", \"Stage II\", \"Stage III\", \"Stage IV\"]"},
	{"id":"Medical-bb9550cb","source":"Medical","question":"Which virus is most commonly associated with nasopharyngeal carcinoma?","answer":"Epstein-Barr virus (EBV) is most commonly associated with NPC.","question_type":"Fact Retrieval","evidence":"The virus most commonly associated with nasopharyngeal carcinoma is Epstein-Barr virus (EBV).","evidence_relations":"Most NPCs are related to Epstein-Barr virus (EBV) infection"},
	{"id":"Medical-85c57bc9","source":"Medical","question":"List two risk factors for nasopharyngeal carcinoma.","answer":"Epstein-Barr virus (EBV) infection and tobacco use are risk factors.","question_type":"Fact Retrieval","evidence":"Epstein-Barr virus (EBV) infection is a risk factor for nasopharyngeal carcinoma.; Tobacco use is a risk factor for nasopharyngeal carcinoma.","evidence_relations":"Risk Factor: [\"Epstein-Barr virus (EBV)\", \"Tobacco use\", \"Alcohol use\", \"Geographic origin (Asia, Native America, North Africa)\"]"},
	{"id":"Medical-4196794d","source":"Medical","question":"Which geographic regions have higher rates of nasopharyngeal carcinoma?","answer":"NPC most often occurs in people from parts of Asia, Native America, and North Africa.","question_type":"Fact Retrieval","evidence":"Nasopharyngeal carcinoma most often occurs in people from parts of Asia.; Nasopharyngeal carcinoma most often occurs in Native Americans.; Nasopharyngeal carcinoma most often occurs in people from North Africa.","evidence_relations":"NPC most often occurs in people from parts of Asia, Native America, and North Africa"},
	{"id":"Medical-c5bc82ff","source":"Medical","question":"What are two common symptoms of nasopharyngeal carcinoma?","answer":"Enlarged lymph nodes and hearing loss are common symptoms.","question_type":"Fact Retrieval","evidence":"Enlarged lymph nodes are a common symptom of nasopharyngeal carcinoma.; Hearing loss is a common symptom of nasopharyngeal carcinoma.","evidence_relations":"Symptom: [\"Enlarged lymph nodes\", \"Hearing loss\", \"Symptoms may be absent until advanced stage\"]"},
	{"id":"Medical-51e5f06f","source":"Medical","question":"Which imaging methods are used for diagnosis of NPC?","answer":"CT scan, MRI, PET/CT, and ultrasound are used for diagnosis.","question_type":"Fact Retrieval","evidence":"CT scan is used for the diagnosis of nasopharyngeal carcinoma.; MRI is used for the diagnosis of nasopharyngeal carcinoma.; PET/CT is used for the diagnosis of nasopharyngeal carcinoma.; Ultrasound is used for the diagnosis of nasopharyngeal carcinoma.","evidence_relations":"Diagnosis of NPC involves medical history, physical exam, imaging (CT, MRI, PET/CT, ultrasound), and biopsy"},
	{"id":"Medical-28f101b7","source":"Medical","question":"What is the role of biopsy in diagnosing nasopharyngeal carcinoma?","answer":"Biopsy confirms diagnosis and determines cancer subtype.","question_type":"Fact Retrieval","evidence":"Biopsy confirms the diagnosis of nasopharyngeal carcinoma.; Biopsy determines the cancer subtype of nasopharyngeal carcinoma.","evidence_relations":"Biopsy confirms diagnosis and determines cancer subtype"},
	{"id":"Medical-8f64cf43","source":"Medical","question":"Which biomarker tests are recommended for nasopharyngeal carcinoma?","answer":"EBV DNA, MSI-H/dMMR, PD-L1, HPV, and tumor mutational burden are recommended biomarker tests.","question_type":"Fact Retrieval","evidence":"EBV DNA is a recommended biomarker test for nasopharyngeal carcinoma.; MSI-H/dMMR is a recommended biomarker test for nasopharyngeal carcinoma.; PD-L1 is a recommended biomarker test for nasopharyngeal carcinoma.; HPV is a recommended biomarker test for nasopharyngeal carcinoma.; Tumor mutational burden is a recommended biomarker test for nasopharyngeal carcinoma.","evidence_relations":"Biomarker testing for NPC includes EBV DNA, MSI-H/dMMR, PD-L1, HPV, and tumor mutational burden"},
	{"id":"Medical-49ff508e","source":"Medical","question":"Which performance measure is considered in NPC treatment planning?","answer":"Performance status is considered in NPC treatment planning.","question_type":"Fact Retrieval","evidence":"Performance status is considered in nasopharyngeal carcinoma treatment planning.","evidence_relations":"Performance status is considered in NPC treatment planning"},
	{"id":"Medical-debec9f1","source":"Medical","question":"What are the possible classifications of nasopharyngeal carcinoma based on extent of disease?","answer":"NPC can be classified as resectable, unresectable, locoregional, locally advanced, or metastatic.","question_type":"Fact Retrieval","evidence":"Nasopharyngeal carcinoma can be classified as resectable.; Nasopharyngeal carcinoma can be classified as unresectable.; Nasopharyngeal carcinoma can be classified as locoregional.; Nasopharyngeal carcinoma can be classified as locally advanced.; Nasopharyngeal carcinoma can be classified as metastatic.","evidence_relations":"NPC can be classified as resectable, unresectable, locoregional, locally advanced, or metastatic based on extent of disease"},
	{"id":"Medical-2f8ada62","source":"Medical","question":"Which organs are common sites for metastasis from nasopharyngeal carcinoma?","answer":"NPC commonly spreads to lymph nodes in the neck and less frequently to the lungs.","question_type":"Fact Retrieval","evidence":"Nasopharyngeal carcinoma commonly spreads to lymph nodes in the neck.; Nasopharyngeal carcinoma less frequently spreads to the lungs.","evidence_relations":"NPC commonly spreads to lymph nodes in the neck and less frequently to the lungs"},
	{"id":"Medical-b696a6b5","source":"Medical","question":"What is the purpose of EBV DNA testing in NPC?","answer":"EBV DNA testing is performed before and after treatment for NPC.","question_type":"Fact Retrieval","evidence":"EBV DNA testing is performed before treatment for nasopharyngeal carcinoma.; EBV DNA testing is performed after treatment for nasopharyngeal carcinoma.","evidence_relations":"EBV DNA testing is performed before and after treatment for NPC"},
	{"id":"Medical-fea8a757","source":"Medical","question":"Which diagnostic methods are included in the initial evaluation of NPC?","answer":"Medical history, physical exam, imaging, and biopsy are included in the initial evaluation.","question_type":"Fact Retrieval","evidence":"Medical history is included in the initial evaluation of nasopharyngeal carcinoma.; Physical exam is included in the initial evaluation of nasopharyngeal carcinoma.; Imaging is included in the initial evaluation of nasopharyngeal carcinoma.; Biopsy is included in the initial evaluation of nasopharyngeal carcinoma.","evidence_relations":"Diagnosis of NPC involves medical history, physical exam, imaging (CT, MRI, PET/CT, ultrasound), and biopsy"},
	{"id":"Medical-41723902","source":"Medical","question":"How is the cancer subtype determined in NPC?","answer":"Biopsy determines cancer subtype in NPC.","question_type":"Fact Retrieval","evidence":"Biopsy determines cancer subtype in nasopharyngeal carcinoma.","evidence_relations":"Biopsy confirms diagnosis and determines cancer subtype"},
	{"id":"Medical-558d306b","source":"Medical","question":"Which imaging tests are used for surveillance of NPC?","answer":"Imaging tests such as CT, MRI, PET/CT, and ultrasound are used for surveillance.","question_type":"Fact Retrieval","evidence":"CT is used for surveillance of nasopharyngeal carcinoma.; MRI is used for surveillance of nasopharyngeal carcinoma.; PET/CT is used for surveillance of nasopharyngeal carcinoma.; Ultrasound is used for surveillance of nasopharyngeal carcinoma.","evidence_relations":"Imaging tests such as CT, MRI, PET/CT, and ultrasound are used for staging and surveillance"},
	{"id":"Medical-806207e1","source":"Medical","question":"What are the different types of biopsy used for NPC diagnosis?","answer":"Fine-needle aspiration (FNA), fine-needle biopsy (FNB), and core needle biopsy (CNB) are used.","question_type":"Fact Retrieval","evidence":"Fine-needle aspiration (FNA) is used for nasopharyngeal carcinoma diagnosis.; Fine-needle biopsy (FNB) is used for nasopharyngeal carcinoma diagnosis.; Core needle biopsy (CNB) is used for nasopharyngeal carcinoma diagnosis.","evidence_relations":"Diagnostic Method: [\"Biopsy\", [\"Fine-needle aspiration (FNA)\", \"Fine-needle biopsy (FNB)\", \"Core needle biopsy (CNB)\"]]"},
	{"id":"Medical-0155c059","source":"Medical","question":"Which factors are considered prognostic in NPC?","answer":"EBV DNA level and performance status are prognostic factors.","question_type":"Fact Retrieval","evidence":"EBV DNA level is a prognostic factor in nasopharyngeal carcinoma.; Performance status is a prognostic factor in nasopharyngeal carcinoma.","evidence_relations":"Prognostic Factor: [\"EBV DNA level\", \"Performance status\"]"},
	{"id":"Medical-d964c7f3","source":"Medical","question":"What fertility consideration should be discussed before NPC therapy?","answer":"Fertility may be affected by NPC treatment and should be discussed before therapy.","question_type":"Fact Retrieval","evidence":"Fertility may be affected by nasopharyngeal carcinoma treatment.; Fertility should be discussed before nasopharyngeal carcinoma therapy.","evidence_relations":"Fertility may be affected by NPC treatment and should be discussed before therapy"},
	{"id":"Medical-4482bd32","source":"Medical","question":"Which assessments are recommended before starting NPC treatment?","answer":"Dental exam, nutrition assessment, and speech and swallowing assessment are recommended.","question_type":"Fact Retrieval","evidence":"Dental exam is recommended before starting nasopharyngeal carcinoma treatment.; Nutrition assessment is recommended before starting nasopharyngeal carcinoma treatment.; Speech and swallowing assessment is recommended before starting nasopharyngeal carcinoma treatment.","evidence_relations":"Diagnostic Method: [\"Dental exam\", \"Nutrition assessment\", \"Speech and swallowing assessment\"]"},
	{"id":"Medical-ecfaba9c","source":"Medical","question":"What is the impact of head and neck cancer treatment on dental health?","answer":"Dental health can be affected by head and neck cancer and its treatment.","question_type":"Fact Retrieval","evidence":"Head and neck cancer treatment can affect dental health.","evidence_relations":"Dental health can be affected by head and neck cancer and its treatment"},
	{"id":"Medical-adb77b8f","source":"Medical","question":"What is the role of imaging in NPC management?","answer":"Imaging is used for staging and surveillance of NPC.","question_type":"Fact Retrieval","evidence":"Imaging is used for staging of NPC.; Imaging is used for surveillance of NPC.","evidence_relations":"Imaging tests such as CT, MRI, PET/CT, and ultrasound are used for staging and surveillance"},
	{"id":"Medical-7409b4bb","source":"Medical","question":"What are the main components of the AJCC TNM system for NPC staging?","answer":"The AJCC TNM system includes tumor size (T), lymph node involvement (N), and distant metastasis (M).","question_type":"Fact Retrieval","evidence":"The AJCC TNM system includes tumor size (T).; The AJCC TNM system includes lymph node involvement (N).; The AJCC TNM system includes distant metastasis (M).","evidence_relations":"NPC is staged using the AJCC TNM system, which includes tumor size (T), lymph node involvement (N), and distant metastasis (M)"},
	{"id":"Medical-6b0b36c7","source":"Medical","question":"Which populations are at increased risk for NPC due to geographic origin?","answer":"People from Asia, Native America, and North Africa are at increased risk.","question_type":"Fact Retrieval","evidence":"People from Asia are at increased risk for NPC.; Native Americans are at increased risk for NPC.; People from North Africa are at increased risk for NPC.","evidence_relations":"NPC most often occurs in people from parts of Asia, Native America, and North Africa"},
	{"id":"Medical-5d011928","source":"Medical","question":"What is the significance of symptoms being absent until advanced stage in NPC?","answer":"Symptoms of NPC may be absent until advanced stage and can be similar to other conditions.","question_type":"Fact Retrieval","evidence":"Symptoms of NPC may be absent until the advanced stage.; Symptoms of NPC can be similar to other conditions.","evidence_relations":"Symptoms of NPC may be absent until advanced stage and can be similar to other conditions"},
	{"id":"Medical-07e567d4","source":"Medical","question":"Which biomarker is tested both before and after NPC treatment?","answer":"EBV DNA is tested both before and after NPC treatment.","question_type":"Fact Retrieval","evidence":"EBV DNA is tested before NPC treatment.; EBV DNA is tested after NPC treatment.","evidence_relations":"EBV DNA testing is performed before and after treatment for NPC"},
	{"id":"Medical-554369df","source":"Medical","question":"Which additional counseling is recommended for patients concerned about fertility before NPC treatment?","answer":"Fertility counseling is recommended before NPC treatment.","question_type":"Fact Retrieval","evidence":"Fertility counseling is recommended before NPC treatment.","evidence_relations":"Fertility counseling"},
	{"id":"Medical-cb2502ae","source":"Medical","question":"What is the primary cancer subtype found in the nasopharynx?","answer":"Nasopharyngeal carcinoma (NPC) is the primary cancer subtype found in the nasopharynx.","question_type":"Fact Retrieval","evidence":"Nasopharyngeal carcinoma (NPC) is the primary cancer subtype found in the nasopharynx.","evidence_relations":"Cancer Subtype: {\"Nasopharyngeal carcinoma (NPC)\"}"},
	{"id":"Medical-06ecaea9","source":"Medical","question":"Which two lifestyle factors increase the risk of head and neck cancer?","answer":"Tobacco and alcohol use are risk factors for head and neck cancer.","question_type":"Fact Retrieval","evidence":"Tobacco use is a risk factor for head and neck cancer.; Alcohol use is a risk factor for head and neck cancer.","evidence_relations":"Tobacco and alcohol use are risk factors for head and neck cancer"},
	{"id":"Medical-138aaa42","source":"Medical","question":"What type of cancer is colon cancer classified as?","answer":"Colon cancer is a type of colorectal cancer.","question_type":"Fact Retrieval","evidence":"Colon cancer is classified as a type of colorectal cancer.","evidence_relations":"Colon cancer is a type of colorectal cancer"},
	{"id":"Medical-77578361","source":"Medical","question":"What is the most common subtype of colon cancer?","answer":"Adenocarcinoma is the most common subtype of colon cancer.","question_type":"Fact Retrieval","evidence":"Adenocarcinoma is the most common subtype of colon cancer.","evidence_relations":"Adenocarcinoma is the most common subtype of colon cancer"},
	{"id":"Medical-35f3815e","source":"Medical","question":"From which type of polyp do most colon cancers originate?","answer":"Most colon cancers start in polyps, especially adenomas.","question_type":"Fact Retrieval","evidence":"Most colon cancers start in polyps.; Most colon cancers especially start in adenomas.","evidence_relations":"Most colon cancers start in polyps, especially adenomas"},
	{"id":"Medical-252d49cb","source":"Medical","question":"How does adenocarcinoma of the colon typically arise?","answer":"Adenocarcinoma arises from adenomas.","question_type":"Fact Retrieval","evidence":"Adenocarcinoma arises from adenomas.","evidence_relations":"Adenocarcinoma arises from adenomas"},
	{"id":"Medical-04a90969","source":"Medical","question":"Which types of polyps rarely become cancerous in the colon?","answer":"Hyperplastic and inflammatory polyps rarely become cancer.","question_type":"Fact Retrieval","evidence":"Hyperplastic polyps rarely become cancerous in the colon.; Inflammatory polyps rarely become cancerous in the colon.","evidence_relations":"Hyperplastic and inflammatory polyps rarely become cancer"},
	{"id":"Medical-d3fcc0fe","source":"Medical","question":"What procedure is used to remove polyps during colonoscopy?","answer":"Polypectomy removes polyps during colonoscopy.","question_type":"Fact Retrieval","evidence":"Polypectomy removes polyps during colonoscopy.","evidence_relations":"Polypectomy removes polyps during colonoscopy"},
	{"id":"Medical-640ee9ee","source":"Medical","question":"What surgery removes the cancerous part of the colon?","answer":"Colectomy is surgery to remove the cancerous part of the colon.","question_type":"Fact Retrieval","evidence":"Colectomy is surgery to remove the cancerous part of the colon.","evidence_relations":"Colectomy is surgery to remove the cancerous part of the colon"},
	{"id":"Medical-d0839ef2","source":"Medical","question":"What is the purpose of a colostomy in colon cancer treatment?","answer":"Colostomy diverts stool through an abdominal stoma if reconnection is not possible.","question_type":"Fact Retrieval","evidence":"Colostomy diverts stool through an abdominal stoma.; Colostomy is used if reconnection is not possible.","evidence_relations":"Colostomy diverts stool through an abdominal stoma if reconnection is not possible"},
	{"id":"Medical-5b005bba","source":"Medical","question":"Which system is used to stage colon cancer?","answer":"AJCC TNM system is used to stage colon cancer.","question_type":"Fact Retrieval","evidence":"AJCC TNM system is used to stage colon cancer.","evidence_relations":"AJCC TNM system is used to stage colon cancer"},
	{"id":"Medical-2360f9dd","source":"Medical","question":"What defines Stage 0 colon cancer?","answer":"Stage 0 colon cancer is carcinoma in situ.","question_type":"Fact Retrieval","evidence":"Stage 0 colon cancer is carcinoma in situ.","evidence_relations":"Stage 0 colon cancer is carcinoma in situ"},
	{"id":"Medical-25302adf","source":"Medical","question":"What characterizes Stage 1 colon cancer?","answer":"Stage 1 colon cancer invades second or third layer of colon wall, no lymph node involvement.","question_type":"Fact Retrieval","evidence":"Stage 1 colon cancer invades the second or third layer of the colon wall.; Stage 1 colon cancer has no lymph node involvement.","evidence_relations":"Stage 1 colon cancer invades second or third layer of colon wall, no lymph node involvement"},
	{"id":"Medical-c8d26f3e","source":"Medical","question":"How is Stage 2 colon cancer described?","answer":"Stage 2 colon cancer invades or passes fourth layer, no lymph node involvement.","question_type":"Fact Retrieval","evidence":"Stage 2 colon cancer invades or passes the fourth layer.; Stage 2 colon cancer has no lymph node involvement.","evidence_relations":"Stage 2 colon cancer invades or passes fourth layer, no lymph node involvement"},
	{"id":"Medical-c9408d83","source":"Medical","question":"What is the defining feature of Stage 3 colon cancer?","answer":"Stage 3 colon cancer involves spread to nearby lymph nodes or tumor deposits.","question_type":"Fact Retrieval","evidence":"Stage 3 colon cancer involves spread to nearby lymph nodes.; Stage 3 colon cancer involves tumor deposits.","evidence_relations":"Stage 3 colon cancer involves spread to nearby lymph nodes or tumor deposits"},
	{"id":"Medical-e9340ec8","source":"Medical","question":"What is characteristic of Stage 4 colon cancer?","answer":"Stage 4 colon cancer has spread to distant organs (commonly liver or lungs).","question_type":"Fact Retrieval","evidence":"Stage 4 colon cancer has spread to distant organs.; Common distant organs affected by Stage 4 colon cancer are the liver and lungs.","evidence_relations":"Stage 4 colon cancer has spread to distant organs (commonly liver or lungs)"},
	{"id":"Medical-879889ee","source":"Medical","question":"Which biomarker testing is recommended for all colon cancers?","answer":"All colon cancers should be tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H).","question_type":"Fact Retrieval","evidence":"All colon cancers should be tested for mismatch repair deficiency (dMMR).; All colon cancers should be tested for microsatellite instability-high (MSI-H).","evidence_relations":"All colon cancers should be tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H)"},
	{"id":"Medical-a77dafa9","source":"Medical","question":"Which biomarker guides immunotherapy in colon cancer?","answer":"dMMR/MSI-H is a biomarker guiding immunotherapy.","question_type":"Fact Retrieval","evidence":"dMMR/MSI-H is a biomarker that guides immunotherapy in colon cancer.","evidence_relations":"dMMR/MSI-H is a biomarker guiding immunotherapy"},
	{"id":"Medical-973bc3d0","source":"Medical","question":"How are pMMR/MSS colon cancers generally treated?","answer":"pMMR/MSS cancers are treated with chemotherapy.","question_type":"Fact Retrieval","evidence":"pMMR/MSS colon cancers are generally treated with chemotherapy.","evidence_relations":"pMMR/MSS cancers are treated with chemotherapy"},
	{"id":"Medical-0b514b7c","source":"Medical","question":"Which inherited syndromes increase the risk of colon cancer?","answer":"Lynch syndrome and familial adenomatous polyposis (FAP) are inherited syndromes increasing colon cancer risk.","question_type":"Fact Retrieval","evidence":"Lynch syndrome is an inherited syndrome that increases colon cancer risk.; Familial adenomatous polyposis (FAP) is an inherited syndrome that increases colon cancer risk.","evidence_relations":"Lynch syndrome and familial adenomatous polyposis (FAP) are inherited syndromes increasing colon cancer risk"},
	{"id":"Medical-a43ea44f","source":"Medical","question":"Is family history a risk factor for colon cancer?","answer":"Family history of colorectal cancer is a risk factor.","question_type":"Fact Retrieval","evidence":"Family history of colorectal cancer is a risk factor for colon cancer.","evidence_relations":"Family history of colorectal cancer is a risk factor"},
	{"id":"Medical-13fbbea3","source":"Medical","question":"What blood tests are recommended for initial evaluation of colon cancer?","answer":"Blood tests (CBC, chemistry profile, CEA) are recommended for initial testing.","question_type":"Fact Retrieval","evidence":"Blood tests recommended for initial evaluation of colon cancer include CBC.; Blood tests recommended for initial evaluation of colon cancer include chemistry profile.; Blood tests recommended for initial evaluation of colon cancer include CEA.","evidence_relations":"Blood tests (CBC, chemistry profile, CEA) are recommended for initial testing"},
	{"id":"Medical-1b8745a9","source":"Medical","question":"Which biomarker is used for monitoring colon cancer?","answer":"CEA is a biomarker for monitoring colon cancer.","question_type":"Fact Retrieval","evidence":"CEA is a biomarker used for monitoring colon cancer.","evidence_relations":"CEA is a biomarker for monitoring colon cancer"},
	{"id":"Medical-637bb2bd","source":"Medical","question":"What is the main imaging test for staging and surveillance of colon cancer?","answer":"CT with contrast is the main imaging test for staging and surveillance.","question_type":"Fact Retrieval","evidence":"CT with contrast is the main imaging test for staging of colon cancer.; CT with contrast is the main imaging test for surveillance of colon cancer.","evidence_relations":"CT with contrast is the main imaging test for staging and surveillance"},
	{"id":"Medical-6f2d6386","source":"Medical","question":"When is MRI used in the evaluation of colon cancer?","answer":"MRI may be used for further evaluation of liver or rectum.","question_type":"Fact Retrieval","evidence":"MRI may be used for further evaluation of the liver in colon cancer.; MRI may be used for further evaluation of the rectum in colon cancer.","evidence_relations":"MRI may be used for further evaluation of liver or rectum"},
	{"id":"Medical-80328029","source":"Medical","question":"What is the current role of ctDNA testing in colon cancer?","answer":"ctDNA testing is investigational and recommended only in clinical trials.","question_type":"Fact Retrieval","evidence":"ctDNA testing is investigational in colon cancer.; ctDNA testing is recommended only in clinical trials for colon cancer.","evidence_relations":"ctDNA testing is investigational and recommended only in clinical trials"},
	{"id":"Medical-6ff7589c","source":"Medical","question":"What adjuvant therapy is recommended after colectomy for stage 3 colon cancer?","answer":"Chemotherapy is recommended after colectomy for all stage 3 and some stage 2 colon cancers.","question_type":"Fact Retrieval","evidence":"Chemotherapy is recommended after colectomy for stage 3 colon cancer.; Chemotherapy is recommended after colectomy for some stage 2 colon cancers.","evidence_relations":"Chemotherapy is recommended after colectomy for all stage 3 and some stage 2 colon cancers"},
	{"id":"Medical-5f9dfcb6","source":"Medical","question":"What is the preferred treatment for dMMR/MSI-H colon cancers?","answer":"Immunotherapy with checkpoint inhibitors is preferred for dMMR/MSI-H cancers.","question_type":"Fact Retrieval","evidence":"Immunotherapy with checkpoint inhibitors is preferred for dMMR/MSI-H colon cancers.","evidence_relations":"Immunotherapy with checkpoint inhibitors is preferred for dMMR/MSI-H cancers"},
	{"id":"Medical-d4f3ad82","source":"Medical","question":"What are the components of surveillance after colon cancer treatment?","answer":"Surveillance after treatment includes colonoscopy, CEA testing, and CT scans.","question_type":"Fact Retrieval","evidence":"Surveillance after colon cancer treatment includes colonoscopy.; Surveillance after colon cancer treatment includes CEA testing.; Surveillance after colon cancer treatment includes CT scans.","evidence_relations":"Surveillance after treatment includes colonoscopy, CEA testing, and CT scans"},
	{"id":"Medical-a116a662","source":"Medical","question":"What fertility preservation options should be discussed with young adults before colon cancer treatment?","answer":"Young adults should be counseled about fertility risks and preservation options before treatment.","question_type":"Fact Retrieval","evidence":"Young adults should be counseled about fertility risks before colon cancer treatment.; Young adults should be counseled about fertility preservation options before colon cancer treatment.","evidence_relations":"Young adults should be counseled about fertility risks and preservation options before treatment"},
	{"id":"Medical-a438f1ad","source":"Medical","question":"Which surgical procedures are included in colon cancer treatment?","answer":"Polypectomy, colectomy, and colostomy are surgical procedures used in colon cancer treatment.","question_type":"Fact Retrieval","evidence":"Polypectomy is a surgical procedure used in colon cancer treatment.; Colectomy is a surgical procedure used in colon cancer treatment.; Colostomy is a surgical procedure used in colon cancer treatment.","evidence_relations":"Polypectomy, colectomy, and colostomy are surgical procedures used in colon cancer treatment"},
	{"id":"Medical-babf4510","source":"Medical","question":"What chemotherapy regimens are commonly used for colon cancer?","answer":"Capecitabine, 5-fluorouracil (5-FU), leucovorin, FOLFOX, and CAPEOX are chemotherapy regimens used.","question_type":"Fact Retrieval","evidence":"Capecitabine is a chemotherapy regimen used for colon cancer.; 5-fluorouracil (5-FU) is a chemotherapy regimen used for colon cancer.; Leucovorin is a chemotherapy regimen used for colon cancer.; FOLFOX is a chemotherapy regimen used for colon cancer.; CAPEOX is a chemotherapy regimen used for colon cancer.","evidence_relations":"Capecitabine, 5-fluorouracil (5-FU), Leucovorin, FOLFOX, CAPEOX"},
	{"id":"Medical-1e78dd0f","source":"Medical","question":"Which checkpoint inhibitors are used in immunotherapy for colon cancer?","answer":"Pembrolizumab (Keytruda), Nivolumab (Opdivo), and Ipilimumab (Yervoy) are checkpoint inhibitors used.","question_type":"Fact Retrieval","evidence":"Pembrolizumab (Keytruda) is a checkpoint inhibitor used in immunotherapy for colon cancer.; Nivolumab (Opdivo) is a checkpoint inhibitor used in immunotherapy for colon cancer.; Ipilimumab (Yervoy) is a checkpoint inhibitor used in immunotherapy for colon cancer.","evidence_relations":"Pembrolizumab (Keytruda), Nivolumab (Opdivo), Ipilimumab (Yervoy)"},
	{"id":"Medical-6c255c33","source":"Medical","question":"What is the primary cancer type affecting the esophagus?","answer":"Esophageal cancer is the primary type.","question_type":"Fact Retrieval","evidence":"Esophageal cancer is the primary cancer type affecting the esophagus.","evidence_relations":"Esophageal cancer starts in the inner lining of the esophagus"},
	{"id":"Medical-84c55f8a","source":"Medical","question":"Which cancer subtype originates in the squamous cells of the esophagus?","answer":"Esophageal squamous cell carcinoma originates in squamous cells.","question_type":"Fact Retrieval","evidence":"Esophageal squamous cell carcinoma originates in squamous cells.","evidence_relations":"Esophageal squamous cell carcinoma starts in squamous cells of the esophagus"},
	{"id":"Medical-34c3dd3d","source":"Medical","question":"Which cancer subtype arises from mucus-secreting cells in the esophagus?","answer":"Esophageal adenocarcinoma arises from mucus-secreting cells.","question_type":"Fact Retrieval","evidence":"Esophageal adenocarcinoma arises from mucus-secreting cells.","evidence_relations":"Esophageal adenocarcinoma starts in mucus-secreting cells of the esophagus"},
	{"id":"Medical-611ac003","source":"Medical","question":"What anatomical locations are associated with esophageal squamous cell carcinoma?","answer":"Upper, middle, and lower esophagus are associated locations.","question_type":"Fact Retrieval","evidence":"Upper esophagus is associated with esophageal squamous cell carcinoma.; Middle esophagus is associated with esophageal squamous cell carcinoma.; Lower esophagus is associated with esophageal squamous cell carcinoma.","evidence_relations":"Esophageal squamous cell carcinoma: Anatomical Location: Upper esophagus, Middle esophagus, Lower esophagus"},
	{"id":"Medical-bc1a34dd","source":"Medical","question":"Where in the esophagus does esophageal adenocarcinoma commonly occur?","answer":"It commonly occurs in the lower and middle esophagus.","question_type":"Fact Retrieval","evidence":"Esophageal adenocarcinoma commonly occurs in the lower esophagus.; Esophageal adenocarcinoma commonly occurs in the middle esophagus.","evidence_relations":"Esophageal adenocarcinoma: Anatomical Location: Lower esophagus, Middle esophagus"},
	{"id":"Medical-04e27815","source":"Medical","question":"Which anatomical sites are included for esophageal cancer in general?","answer":"Esophagus and esophagogastric junction are included.","question_type":"Fact Retrieval","evidence":"Esophagus is included as an anatomical site for esophageal cancer.; Esophagogastric junction is included as an anatomical site for esophageal cancer.","evidence_relations":"Anatomical Location: Esophagus, Esophagogastric junction"},
	{"id":"Medical-21a6662e","source":"Medical","question":"What is the definition of early-stage esophageal cancer?","answer":"Early-stage esophageal cancer is contained within the esophagus and not in lymph nodes.","question_type":"Fact Retrieval","evidence":"Early-stage esophageal cancer is contained within the esophagus.; Early-stage esophageal cancer is not in lymph nodes.","evidence_relations":"Early-stage esophageal cancer is contained within the esophagus and not in lymph nodes"},
	{"id":"Medical-552983d2","source":"Medical","question":"How is locoregional esophageal cancer defined?","answer":"Locoregional esophageal cancer has invaded the esophagus wall and/or spread to nearby lymph nodes or organs.","question_type":"Fact Retrieval","evidence":"Locoregional esophageal cancer has invaded the esophagus wall.; Locoregional esophageal cancer has spread to nearby lymph nodes.; Locoregional esophageal cancer has spread to nearby organs.","evidence_relations":"Locoregional esophageal cancer has invaded the esophagus wall and/or spread to nearby lymph nodes or organs"},
	{"id":"Medical-5179c591","source":"Medical","question":"What characterizes metastatic esophageal cancer?","answer":"Metastatic esophageal cancer has spread to distant organs such as liver, lung, bone, and brain.","question_type":"Fact Retrieval","evidence":"Metastatic esophageal cancer has spread to distant organs.; Distant organs affected by metastatic esophageal cancer include the liver.; Distant organs affected by metastatic esophageal cancer include the lung.; Distant organs affected by metastatic esophageal cancer include the bone.; Distant organs affected by metastatic esophageal cancer include the brain.","evidence_relations":"Metastatic esophageal cancer has spread to distant organs such as liver, lung, bone, and brain"},
	{"id":"Medical-4bb6d825","source":"Medical","question":"What are the common metastatic sites for esophageal cancer?","answer":"Liver, lung, bone, brain, and distant lymph nodes are common sites.","question_type":"Fact Retrieval","evidence":"Common metastatic sites for esophageal cancer include the liver.; Common metastatic sites for esophageal cancer include the lung.; Common metastatic sites for esophageal cancer include the bone.; Common metastatic sites for esophageal cancer include the brain.; Common metastatic sites for esophageal cancer include distant lymph nodes.","evidence_relations":"Metastatic: Metastatic Site: Liver, Lung, Bone, Brain, Distant lymph nodes"},
	{"id":"Medical-bb0fe530","source":"Medical","question":"What is a precancerous condition for esophageal adenocarcinoma?","answer":"Barrett esophagus is a precancerous condition.","question_type":"Fact Retrieval","evidence":"Barrett esophagus is a precancerous condition.","evidence_relations":"Barrett esophagus is a precancerous condition that increases risk for esophageal adenocarcinoma"},
	{"id":"Medical-08144fc9","source":"Medical","question":"Which risk factor increases the likelihood of developing esophageal adenocarcinoma?","answer":"Barrett esophagus increases the risk.","question_type":"Fact Retrieval","evidence":"Barrett esophagus increases the risk of developing esophageal adenocarcinoma.","evidence_relations":"Barrett esophagus is a precancerous condition that increases risk for esophageal adenocarcinoma"},
	{"id":"Medical-deee1f4b","source":"Medical","question":"What are Siewert types used for in esophageal cancer?","answer":"Siewert types are used to stage tumors at the esophagogastric junction.","question_type":"Fact Retrieval","evidence":"Siewert types are used to stage tumors.; Siewert types are used for tumors at the esophagogastric junction.","evidence_relations":"Siewert types are used to stage tumors at the esophagogastric junction"},
	{"id":"Medical-fdfcf977","source":"Medical","question":"Which diagnostic methods are involved in esophageal cancer diagnosis?","answer":"Blood tests, imaging tests, endoscopy, biopsy, biomarker testing, and genetic risk testing are used.","question_type":"Fact Retrieval","evidence":"Blood tests are used in esophageal cancer diagnosis.; Imaging tests are used in esophageal cancer diagnosis.; Endoscopy is used in esophageal cancer diagnosis.; Biopsy is used in esophageal cancer diagnosis.; Biomarker testing is used in esophageal cancer diagnosis.; Genetic risk testing is used in esophageal cancer diagnosis.","evidence_relations":"Diagnosis involves blood tests, imaging tests, endoscopy, biopsy, biomarker testing, and genetic risk testing"},
	{"id":"Medical-c06a99a5","source":"Medical","question":"What additional assessments are included in esophageal cancer diagnosis beyond imaging and biopsy?","answer":"Nutritional assessment and performance status are included.","question_type":"Fact Retrieval","evidence":"Nutritional assessment is included in esophageal cancer diagnosis.; Performance status is included in esophageal cancer diagnosis.","evidence_relations":"Diagnostic Method: Nutritional assessment, Performance status"},
	{"id":"Medical-f3a5a8a3","source":"Medical","question":"Which cancer subtypes are recognized for esophageal cancer?","answer":"Esophageal squamous cell carcinoma and esophageal adenocarcinoma are recognized subtypes.","question_type":"Fact Retrieval","evidence":"Esophageal squamous cell carcinoma is a recognized subtype of esophageal cancer.; Esophageal adenocarcinoma is a recognized subtype of esophageal cancer.","evidence_relations":"Cancer Subtype: Esophageal squamous cell carcinoma, Esophageal adenocarcinoma"},
	{"id":"Medical-db30377a","source":"Medical","question":"What anatomical layers can esophageal cancer invade?","answer":"Mucosa, submucosa, muscularis propria, and tunica adventitia can be invaded.","question_type":"Fact Retrieval","evidence":"Esophageal cancer can invade the mucosa.; Esophageal cancer can invade the submucosa.; Esophageal cancer can invade the muscularis propria.; Esophageal cancer can invade the tunica adventitia.","evidence_relations":"Entities: Mucosa, Submucosa, Muscularis propria, Tunica adventitia"},
	{"id":"Medical-5c1a382a","source":"Medical","question":"What factors are considered in treatment planning for esophageal cancer?","answer":"Cancer type, location, stage, and Siewert types (for EGJ tumors) are considered.","question_type":"Fact Retrieval","evidence":"Cancer type is considered in treatment planning for esophageal cancer.; Location is considered in treatment planning for esophageal cancer.; Stage is considered in treatment planning for esophageal cancer.; Siewert types are considered in treatment planning for esophageal cancer for EGJ tumors.","evidence_relations":"Treatment planning is based on cancer type, location, and stage"},
	{"id":"Medical-0f576b9d","source":"Medical","question":"Which genetic assessments are part of esophageal cancer diagnosis?","answer":"Biomarker testing and genetic risk testing are part of the diagnosis.","question_type":"Fact Retrieval","evidence":"Biomarker testing is part of the diagnosis for esophageal cancer.; Genetic risk testing is part of the diagnosis for esophageal cancer.","evidence_relations":"Diagnosis involves blood tests, imaging tests, endoscopy, biopsy, biomarker testing, and genetic risk testing"},
	{"id":"Medical-7d90c178","source":"Medical","question":"What is Barrett esophagus classified as in relation to esophageal cancer?","answer":"It is classified as a precancerous condition.","question_type":"Fact Retrieval","evidence":"Barrett esophagus is classified as a precancerous condition in relation to esophageal cancer.","evidence_relations":"Barrett esophagus is a precancerous condition that increases risk for esophageal adenocarcinoma"},
	{"id":"Medical-d2b6f3bf","source":"Medical","question":"Which organs are potential metastatic sites for esophageal cancer?","answer":"Liver, lung, bone, brain, and distant lymph nodes are potential metastatic sites.","question_type":"Fact Retrieval","evidence":"The liver is a potential metastatic site for esophageal cancer.; The lung is a potential metastatic site for esophageal cancer.; Bone is a potential metastatic site for esophageal cancer.; The brain is a potential metastatic site for esophageal cancer.; Distant lymph nodes are potential metastatic sites for esophageal cancer.","evidence_relations":"Metastatic: Metastatic Site: Liver, Lung, Bone, Brain, Distant lymph nodes"},
	{"id":"Medical-58a3acce","source":"Medical","question":"Which part of the esophagus is most commonly affected by esophageal adenocarcinoma?","answer":"The lower esophagus is most commonly affected.","question_type":"Fact Retrieval","evidence":"The lower esophagus is most commonly affected by esophageal adenocarcinoma.","evidence_relations":"Esophageal adenocarcinoma: Anatomical Location: Lower esophagus, Middle esophagus"},
	{"id":"Medical-5953d9c0","source":"Medical","question":"What is the anatomical location of the esophagogastric junction in esophageal cancer?","answer":"The esophagogastric junction is an anatomical location considered in esophageal cancer.","question_type":"Fact Retrieval","evidence":"The esophagogastric junction is an anatomical location considered in esophageal cancer.","evidence_relations":"Anatomical Location: Esophagus, Esophagogastric junction"},
	{"id":"Medical-6b811802","source":"Medical","question":"What are the main stages of esophageal cancer described in the ontology?","answer":"Early-stage, locoregional, and metastatic are the main stages.","question_type":"Fact Retrieval","evidence":"Early-stage is one of the main stages of esophageal cancer.; Locoregional is one of the main stages of esophageal cancer.; Metastatic is one of the main stages of esophageal cancer.","evidence_relations":"Disease Stage: Early-stage, Locoregional, Metastatic"},
	{"id":"Medical-70bd4605","source":"Medical","question":"Which subtype of esophageal cancer is associated with Barrett esophagus as a risk factor?","answer":"Esophageal adenocarcinoma is associated with Barrett esophagus.","question_type":"Fact Retrieval","evidence":"Esophageal adenocarcinoma is associated with Barrett esophagus as a risk factor.","evidence_relations":"Esophageal adenocarcinoma: Risk Factor: Barrett esophagus"},
	{"id":"Medical-430e59ee","source":"Medical","question":"What methods are used for biomarker and genetic risk assessment in esophageal cancer?","answer":"Biomarker testing and genetic risk testing are used.","question_type":"Fact Retrieval","evidence":"Biomarker testing is used for risk assessment in esophageal cancer.; Genetic risk testing is used for risk assessment in esophageal cancer.","evidence_relations":"Diagnosis involves blood tests, imaging tests, endoscopy, biopsy, biomarker testing, and genetic risk testing"},
	{"id":"Medical-2114ae1d","source":"Medical","question":"What is the initial site of origin for esophageal cancer?","answer":"It starts in the inner lining of the esophagus.","question_type":"Fact Retrieval","evidence":"Esophageal cancer starts in the inner lining of the esophagus.","evidence_relations":"Esophageal cancer starts in the inner lining of the esophagus"},
	{"id":"Medical-21c7cd3c","source":"Medical","question":"How are tumors at the esophagogastric junction staged?","answer":"They are staged using Siewert types.","question_type":"Fact Retrieval","evidence":"Tumors at the esophagogastric junction are staged using Siewert types.","evidence_relations":"Siewert types are used to stage tumors at the esophagogastric junction"},
	{"id":"Medical-9ba19145","source":"Medical","question":"Which assessments help determine performance status in esophageal cancer patients?","answer":"Performance status assessment is used.","question_type":"Fact Retrieval","evidence":"Performance status assessment is used to determine performance status in esophageal cancer patients.","evidence_relations":"Diagnostic Method: Performance status"},
	{"id":"Medical-465ca672","source":"Medical","question":"What is a key factor in planning treatment for esophageal cancer located at the esophagogastric junction?","answer":"Siewert types are a key factor for EGJ tumors.","question_type":"Fact Retrieval","evidence":"Siewert types are a key factor in planning treatment for esophageal cancer located at the esophagogastric junction.","evidence_relations":"Treatment Planning: Based on: Siewert types (for EGJ tumors)"},
	{"id":"Medical-3d1b49a8","source":"Medical","question":"What type of carcinoma starts in the mucus-secreting cells of the esophagus?","answer":"Esophageal adenocarcinoma starts in mucus-secreting cells.","question_type":"Fact Retrieval","evidence":"Esophageal adenocarcinoma starts in mucus-secreting cells.","evidence_relations":"Esophageal adenocarcinoma starts in mucus-secreting cells of the esophagus"},
	{"id":"Medical-ad0123e9","source":"Medical","question":"What is the main cancer type discussed in this dataset?","answer":"Gray zone lymphoma is the main cancer type.","question_type":"Fact Retrieval","evidence":"Gray zone lymphoma is the main cancer type discussed in this dataset.","evidence_relations":"Gray zone lymphoma is listed as a Cancer Type in the ontology."},
	{"id":"Medical-48502550","source":"Medical","question":"Which subtype of gray zone lymphoma is characterized by a large mediastinal mass?","answer":"Mediastinal gray zone lymphoma (MGZL) is characterized by a large mediastinal mass.","question_type":"Fact Retrieval","evidence":"Mediastinal gray zone lymphoma (MGZL) is characterized by a large mediastinal mass.","evidence_relations":"MGZL is characterized by a large mediastinal mass"},
	{"id":"Medical-87d7f30f","source":"Medical","question":"What are the overlapping features of gray zone lymphomas?","answer":"Gray zone lymphomas have overlapping features of primary mediastinal B-cell lymphoma (PMBL) and Hodgkin lymphoma (HL).","question_type":"Fact Retrieval","evidence":"Gray zone lymphomas have overlapping features of primary mediastinal B-cell lymphoma (PMBL).; Gray zone lymphomas have overlapping features of Hodgkin lymphoma (HL).","evidence_relations":"Gray zone lymphomas have overlapping features of primary mediastinal B-cell lymphoma (PMBL) and Hodgkin lymphoma (HL)"},
	{"id":"Medical-cf8b52e2","source":"Medical","question":"Which histopathological feature is characteristic of MGZL?","answer":"Reed-Sternberg cells are characteristic histopathological features in MGZL.","question_type":"Fact Retrieval","evidence":"Reed-Sternberg cells are characteristic histopathological features in MGZL.","evidence_relations":"Reed-Sternberg cells are characteristic histopathological features in MGZL"},
	{"id":"Medical-e875d9cd","source":"Medical","question":"What is the recommended initial treatment for MGZL?","answer":"MGZL is usually treated with chemotherapy.","question_type":"Fact Retrieval","evidence":"MGZL is usually treated with chemotherapy.","evidence_relations":"MGZL is usually treated with chemotherapy"},
	{"id":"Medical-c0ac21ce","source":"Medical","question":"Which immunotherapy agent may be added to chemotherapy for MGZL?","answer":"Rituximab may be added to chemotherapy for chemoimmunotherapy.","question_type":"Fact Retrieval","evidence":"Rituximab may be added to chemotherapy for chemoimmunotherapy.","evidence_relations":"Rituximab may be added to chemotherapy for chemoimmunotherapy"},
	{"id":"Medical-afb11f97","source":"Medical","question":"What type of radiation therapy may be used in localized MGZL?","answer":"Involved-site radiation therapy (ISRT) may be added in localized MGZL.","question_type":"Fact Retrieval","evidence":"Involved-site radiation therapy (ISRT) may be added in localized MGZL.","evidence_relations":"Involved-site radiation therapy (ISRT) may be added in localized MGZL"},
	{"id":"Medical-0cbbd549","source":"Medical","question":"What diagnostic method is required for MGZL?","answer":"Diagnosis of MGZL requires expert hematopathologist review.","question_type":"Fact Retrieval","evidence":"Diagnosis of MGZL requires expert hematopathologist review.","evidence_relations":"Diagnosis of MGZL requires expert hematopathologist review"},
	{"id":"Medical-aed3f61c","source":"Medical","question":"Which age group is most commonly affected by MGZL?","answer":"MGZL commonly affects individuals aged 20 to 40 years.","question_type":"Fact Retrieval","evidence":"MGZL commonly affects individuals aged 20 to 40 years.","evidence_relations":"MGZL commonly affects individuals aged 20 to 40 years, assigned male at birth"},
	{"id":"Medical-3c1265b5","source":"Medical","question":"Which sex assigned at birth is more commonly affected by MGZL?","answer":"MGZL commonly affects individuals assigned male at birth.","question_type":"Fact Retrieval","evidence":"MGZL commonly affects individuals assigned male at birth.","evidence_relations":"MGZL commonly affects individuals aged 20 to 40 years, assigned male at birth"},
	{"id":"Medical-368307ba","source":"Medical","question":"Which sites are typically involved in mediastinal gray zone lymphoma?","answer":"The mediastinum and lymph nodes above the collar bone (supraclavicular) are typically involved in MGZL.","question_type":"Fact Retrieval","evidence":"The mediastinum is typically involved in MGZL.; Lymph nodes above the collar bone (supraclavicular) are typically involved in MGZL.","evidence_relations":"Sites of involvement for MGZL include Mediastinum and Lymph nodes above the collar bone (supraclavicular)"},
	{"id":"Medical-30e1cf9c","source":"Medical","question":"What is a common presenting symptom of MGZL?","answer":"A large mediastinal mass is a common presenting symptom of MGZL.","question_type":"Fact Retrieval","evidence":"A large mediastinal mass is a common presenting symptom of MGZL.","evidence_relations":"MGZL is characterized by a large mediastinal mass"},
	{"id":"Medical-5dd8e62d","source":"Medical","question":"What is the relationship between gray zone lymphoma and primary mediastinal B-cell lymphoma?","answer":"Gray zone lymphomas have overlapping features with primary mediastinal B-cell lymphoma (PMBL).","question_type":"Fact Retrieval","evidence":"Gray zone lymphomas have overlapping features with primary mediastinal B-cell lymphoma (PMBL).","evidence_relations":"Gray zone lymphomas have overlapping features of primary mediastinal B-cell lymphoma (PMBL) and Hodgkin lymphoma (HL)"},
	{"id":"Medical-9086efa3","source":"Medical","question":"What is the relationship between gray zone lymphoma and Hodgkin lymphoma?","answer":"Gray zone lymphomas have overlapping features with Hodgkin lymphoma (HL).","question_type":"Fact Retrieval","evidence":"Gray zone lymphomas have overlapping features with Hodgkin lymphoma (HL).","evidence_relations":"Gray zone lymphomas have overlapping features of primary mediastinal B-cell lymphoma (PMBL) and Hodgkin lymphoma (HL)"},
	{"id":"Medical-f6793331","source":"Medical","question":"Which lymphoma subtype is diagnosed as DLBCL-NOS if extra-mediastinal disease is present?","answer":"Non-mediastinal gray zone lymphoma is diagnosed as DLBCL-NOS if extra-mediastinal disease is present.","question_type":"Fact Retrieval","evidence":"Non-mediastinal gray zone lymphoma is diagnosed as DLBCL-NOS if extra-mediastinal disease is present.","evidence_relations":"If extra-mediastinal disease: Diagnose as DLBCL-NOS"},
	{"id":"Medical-8a80ec5c","source":"Medical","question":"What is a distinguishing feature of non-mediastinal gray zone lymphomas compared to MGZL?","answer":"Non-mediastinal gray zone lymphomas occur in older persons and have higher rates of bone marrow and extranodal involvement.","question_type":"Fact Retrieval","evidence":"Non-mediastinal gray zone lymphomas occur in older persons.; Non-mediastinal gray zone lymphomas have higher rates of bone marrow involvement.; Non-mediastinal gray zone lymphomas have higher rates of extranodal involvement.","evidence_relations":"Non-mediastinal gray zone lymphomas occur in older persons and have higher rates of bone marrow and extranodal involvement"},
	{"id":"Medical-e9a8741e","source":"Medical","question":"Which sites are more commonly involved in non-mediastinal gray zone lymphomas?","answer":"Bone marrow and extranodal disease are more commonly involved in non-mediastinal gray zone lymphomas.","question_type":"Fact Retrieval","evidence":"Bone marrow disease is more commonly involved in non-mediastinal gray zone lymphomas.; Extranodal disease is more commonly involved in non-mediastinal gray zone lymphomas.","evidence_relations":"Sites of involvement for non-mediastinal gray zone lymphoma include Bone marrow involvement and Extranodal disease"},
	{"id":"Medical-c5412c78","source":"Medical","question":"What is the typical stage at diagnosis for non-mediastinal gray zone lymphomas?","answer":"Non-mediastinal gray zone lymphomas are typically diagnosed at an advanced stage.","question_type":"Fact Retrieval","evidence":"Non-mediastinal gray zone lymphomas are typically diagnosed at an advanced stage.","evidence_relations":"Stage for non-mediastinal gray zone lymphoma: Advanced-stage disease"},
	{"id":"Medical-24928f80","source":"Medical","question":"What is the role of rituximab in the treatment of MGZL?","answer":"Rituximab may be added to chemotherapy for chemoimmunotherapy in MGZL.","question_type":"Fact Retrieval","evidence":"Rituximab may be added to chemotherapy for chemoimmunotherapy in MGZL.","evidence_relations":"Rituximab may be added to chemotherapy for chemoimmunotherapy"},
	{"id":"Medical-60151004","source":"Medical","question":"Which professional is required for the diagnosis of MGZL?","answer":"Expert hematopathologist review is required for diagnosis of MGZL.","question_type":"Fact Retrieval","evidence":"An expert hematopathologist review is required for the diagnosis of MGZL.","evidence_relations":"Diagnosis of MGZL requires expert hematopathologist review"},
	{"id":"Medical-1b949b50","source":"Medical","question":"Name two related entities to gray zone lymphoma.","answer":"Primary mediastinal B-cell lymphoma (PMBL) and Hodgkin lymphoma (HL) are related entities.","question_type":"Fact Retrieval","evidence":"Primary mediastinal B-cell lymphoma (PMBL) is a related entity to gray zone lymphoma.; Hodgkin lymphoma (HL) is a related entity to gray zone lymphoma.","evidence_relations":"Related Entities: Primary mediastinal B-cell lymphoma (PMBL), Hodgkin lymphoma (HL)"},
	{"id":"Medical-f83e84a2","source":"Medical","question":"What kind of therapy may be considered for MGZL in addition to chemotherapy?","answer":"Chemoimmunotherapy and radiation therapy may be considered for MGZL in addition to chemotherapy.","question_type":"Fact Retrieval","evidence":"Chemoimmunotherapy may be considered for MGZL in addition to chemotherapy.; Radiation therapy may be considered for MGZL in addition to chemotherapy.","evidence_relations":"Treatment for MGZL includes Chemotherapy, Chemoimmunotherapy (Rituximab), and Radiation Therapy (ISRT)"},
	{"id":"Medical-e84ba674","source":"Medical","question":"Which cells are a histopathological hallmark of MGZL?","answer":"Reed-Sternberg cells are a histopathological hallmark of MGZL.","question_type":"Fact Retrieval","evidence":"Reed-Sternberg cells are a histopathological hallmark of MGZL.","evidence_relations":"Reed-Sternberg cells are characteristic histopathological features in MGZL"},
	{"id":"Medical-e7b5ec54","source":"Medical","question":"Which lymphoma is a subtype of gray zone lymphomas?","answer":"Mediastinal gray zone lymphoma (MGZL) is a subtype of gray zone lymphomas.","question_type":"Fact Retrieval","evidence":"Mediastinal gray zone lymphoma (MGZL) is a subtype of gray zone lymphomas.","evidence_relations":"Mediastinal gray zone lymphoma (MGZL) is a subtype of gray zone lymphomas"},
	{"id":"Medical-47995a35","source":"Medical","question":"What is the epidemiological profile of non-mediastinal gray zone lymphomas?","answer":"Non-mediastinal gray zone lymphomas occur in older persons.","question_type":"Fact Retrieval","evidence":"Non-mediastinal gray zone lymphomas occur in older persons.","evidence_relations":"Non-mediastinal gray zone lymphomas occur in older persons"},
	{"id":"Medical-4dcf4539","source":"Medical","question":"Which lymphoma is diagnosed if gray zone lymphoma presents with extra-mediastinal disease?","answer":"DLBCL, not otherwise specified (DLBCL-NOS) is diagnosed if there is extra-mediastinal disease.","question_type":"Fact Retrieval","evidence":"DLBCL, not otherwise specified (DLBCL-NOS) is diagnosed if gray zone lymphoma presents with extra-mediastinal disease.","evidence_relations":"If extra-mediastinal disease: Diagnose as DLBCL-NOS"},
	{"id":"Medical-efc035f3","source":"Medical","question":"What is the purpose of involved-site radiation therapy (ISRT) in MGZL?","answer":"ISRT may be added in localized MGZL.","question_type":"Fact Retrieval","evidence":"Involved-site radiation therapy (ISRT) may be added in localized MGZL.","evidence_relations":"Involved-site radiation therapy (ISRT) may be added in localized MGZL"},
	{"id":"Medical-b6d5f2ae","source":"Medical","question":"Which lymph nodes are typically involved in MGZL?","answer":"Lymph nodes above the collar bone (supraclavicular) are typically involved in MGZL.","question_type":"Fact Retrieval","evidence":"Lymph nodes above the collar bone (supraclavicular) are typically involved in MGZL.","evidence_relations":"Sites of involvement for MGZL include Lymph nodes above the collar bone (supraclavicular)"},
	{"id":"Medical-5f5a35d2","source":"Medical","question":"What is the main diagnostic method for gray zone lymphoma?","answer":"Expert hematopathologist review is the main diagnostic method.","question_type":"Fact Retrieval","evidence":"Expert hematopathologist review is the main diagnostic method for gray zone lymphoma.","evidence_relations":"Diagnostic Method for MGZL: Expert hematopathologist review"},
	{"id":"Medical-5a4056c3","source":"Medical","question":"Name two cancer types related to gray zone lymphoma.","answer":"Classical Hodgkin lymphoma (CHL) and Non-Hodgkin lymphoma are related to gray zone lymphoma.","question_type":"Fact Retrieval","evidence":"Classical Hodgkin lymphoma (CHL) is related to gray zone lymphoma.; Non-Hodgkin lymphoma is related to gray zone lymphoma.","evidence_relations":"Related Entities: Classical Hodgkin lymphoma (CHL), Non-Hodgkin lymphoma"},
	{"id":"Medical-b4916c72","source":"Medical","question":"What is the standard chemotherapy regimen for MGZL?","answer":"Chemotherapy is the standard treatment for MGZL.","question_type":"Fact Retrieval","evidence":"Chemotherapy is the standard treatment for MGZL.","evidence_relations":"MGZL is usually treated with chemotherapy"},
	{"id":"Medical-22a8c202","source":"Medical","question":"What is the most common subtype of cervical cancer?","answer":"Squamous cell carcinoma is the most common subtype.","question_type":"Fact Retrieval","evidence":"Squamous cell carcinoma is the most common subtype of cervical cancer.","evidence_relations":"Squamous cell carcinoma is the most common subtype of cervical cancer"},
	{"id":"Medical-a52a80e6","source":"Medical","question":"Which virus is most commonly associated with cervical cancer?","answer":"Human papillomavirus (HPV) is most commonly associated.","question_type":"Fact Retrieval","evidence":"Human papillomavirus (HPV) is most commonly associated with cervical cancer.","evidence_relations":"Most cervical cancers are caused by long-term infection with human papillomavirus (HPV)"},
	{"id":"Medical-5610453b","source":"Medical","question":"Which HPV types are considered high-risk for cervical cancer?","answer":"HPV16 and HPV18 are high-risk types.","question_type":"Fact Retrieval","evidence":"HPV16 is a high-risk type for cervical cancer.; HPV18 is a high-risk type for cervical cancer.","evidence_relations":"HPV16 and HPV18 are high-risk HPV types associated with cervical cancer"},
	{"id":"Medical-038b92bd","source":"Medical","question":"What screening method is used for cervical cancer?","answer":"Pap smear is used for cervical cancer screening.","question_type":"Fact Retrieval","evidence":"Pap smear is used for cervical cancer screening.","evidence_relations":"Pap smear is used for cervical cancer screening"},
	{"id":"Medical-14497bbd","source":"Medical","question":"What is the primary diagnostic method for cervical cancer?","answer":"Cervical biopsy is the primary diagnostic method.","question_type":"Fact Retrieval","evidence":"Cervical biopsy is the primary diagnostic method for cervical cancer.","evidence_relations":"Cervical biopsy is the primary diagnostic method for cervical cancer"},
	{"id":"Medical-adfde050","source":"Medical","question":"Which imaging modalities are used for staging cervical cancer?","answer":"CT scan, MRI, PET/CT, and transvaginal ultrasound are used.","question_type":"Fact Retrieval","evidence":"CT scan is used for staging cervical cancer.; MRI is used for staging cervical cancer.; PET/CT is used for staging cervical cancer.; Transvaginal ultrasound is used for staging cervical cancer.","evidence_relations":"Imaging methods such as CT, MRI, PET/CT, and transvaginal ultrasound are used for staging and assessment"},
	{"id":"Medical-29a726a3","source":"Medical","question":"What system is used to stage cervical cancer?","answer":"The FIGO system is used to stage cervical cancer.","question_type":"Fact Retrieval","evidence":"The FIGO system is used to stage cervical cancer.","evidence_relations":"The FIGO system is used to stage cervical cancer (Stages I-IV with sub-stages)"},
	{"id":"Medical-8a456673","source":"Medical","question":"What is the main treatment for early-stage cervical cancer?","answer":"Surgery is the main treatment for early-stage cervical cancer.","question_type":"Fact Retrieval","evidence":"Surgery is the main treatment for early-stage cervical cancer.","evidence_relations":"Surgery is the main treatment for early-stage cervical cancer"},
	{"id":"Medical-4262873a","source":"Medical","question":"Which surgical procedure can be both diagnostic and therapeutic for early-stage cervical cancer?","answer":"Cone biopsy can be both diagnostic and therapeutic.","question_type":"Fact Retrieval","evidence":"Cone biopsy can be both diagnostic for early-stage cervical cancer.; Cone biopsy can be therapeutic for early-stage cervical cancer.","evidence_relations":"Cone biopsy can be both diagnostic and therapeutic for early-stage cervical cancer"},
	{"id":"Medical-bb870733","source":"Medical","question":"Which fertility-sparing surgical option is available for selected early-stage cervical cancer cases?","answer":"Trachelectomy is an option for selected early-stage cases.","question_type":"Fact Retrieval","evidence":"Trachelectomy is a fertility-sparing surgical option.; Trachelectomy is available for selected early-stage cervical cancer cases.","evidence_relations":"Fertility-sparing surgery (e.g., trachelectomy) is an option for selected early-stage cases"},
	{"id":"Medical-a4c519cd","source":"Medical","question":"What is the recommended treatment for locally advanced cervical cancer?","answer":"Chemoradiation is recommended for locally advanced cervical cancer.","question_type":"Fact Retrieval","evidence":"Chemoradiation is recommended for locally advanced cervical cancer.","evidence_relations":"Chemoradiation (concurrent EBRT and platinum-based chemotherapy) is recommended for locally advanced cervical cancer"},
	{"id":"Medical-e8a07389","source":"Medical","question":"Which radiation therapies are used for local control in cervical cancer?","answer":"External beam radiation therapy (EBRT) and brachytherapy are used.","question_type":"Fact Retrieval","evidence":"External beam radiation therapy (EBRT) is used for local control in cervical cancer.; Brachytherapy is used for local control in cervical cancer.","evidence_relations":"External beam radiation therapy (EBRT) and brachytherapy are used for local control"},
	{"id":"Medical-a41f7cdf","source":"Medical","question":"Which systemic therapy options are available for cervical cancer?","answer":"Platinum-based chemotherapy, targeted therapy, and immunotherapy are options.","question_type":"Fact Retrieval","evidence":"Platinum-based chemotherapy is an option for cervical cancer.; Targeted therapy is an option for cervical cancer.; Immunotherapy is an option for cervical cancer.","evidence_relations":"Systemic therapy options include platinum-based chemotherapy, targeted therapy, and immunotherapy"},
	{"id":"Medical-e3419109","source":"Medical","question":"Which biomarker testing is recommended for recurrent or metastatic cervical cancer?","answer":"Biomarker testing for PD-L1, MSI, TMB, MMR, HER2, RET, and NTRK is recommended.","question_type":"Fact Retrieval","evidence":"Biomarker testing for PD-L1 is recommended for recurrent or metastatic cervical cancer.; Biomarker testing for MSI is recommended for recurrent or metastatic cervical cancer.; Biomarker testing for TMB is recommended for recurrent or metastatic cervical cancer.; Biomarker testing for MMR is recommended for recurrent or metastatic cervical cancer.; Biomarker testing for HER2 is recommended for recurrent or metastatic cervical cancer.; Biomarker testing for RET is recommended for recurrent or metastatic cervical cancer.; Biomarker testing for NTRK is recommended for recurrent or metastatic cervical cancer.","evidence_relations":"Biomarker testing (e.g., PD-L1, MSI, TMB, MMR, HER2, RET, NTRK) is recommended for recurrent or metastatic cervical cancer"},
	{"id":"Medical-bc97fb7b","source":"Medical","question":"What biomarker guides the use of pembrolizumab in cervical cancer?","answer":"PD-L1 positivity guides the use of pembrolizumab.","question_type":"Fact Retrieval","evidence":"PD-L1 positivity guides the use of pembrolizumab in cervical cancer.","evidence_relations":"PD-L1 positivity guides the use of immunotherapy (e.g., pembrolizumab)"},
	{"id":"Medical-5c0cc4b2","source":"Medical","question":"Which drug may be added to chemotherapy for metastatic cervical cancer?","answer":"Bevacizumab may be added to chemotherapy for metastatic cervical cancer.","question_type":"Fact Retrieval","evidence":"Bevacizumab may be added to chemotherapy for metastatic cervical cancer.","evidence_relations":"Bevacizumab may be added to chemotherapy for metastatic cervical cancer"},
	{"id":"Medical-5fb3b9ac","source":"Medical","question":"What are common symptoms of cervical cancer?","answer":"Common symptoms include watery vaginal discharge, pelvic pain, abnormal vaginal bleeding, and fatigue.","question_type":"Fact Retrieval","evidence":"Common symptoms of cervical cancer include watery vaginal discharge.; Common symptoms of cervical cancer include pelvic pain.; Common symptoms of cervical cancer include abnormal vaginal bleeding.; Common symptoms of cervical cancer include fatigue.","evidence_relations":"Cervical cancer causes symptoms such as watery vaginal discharge, pelvic pain, abnormal vaginal bleeding, and fatigue"},
	{"id":"Medical-2bbad791","source":"Medical","question":"Which factors increase the risk of cervical cancer?","answer":"HPV infection, smoking, immunosuppression, and HIV increase risk.","question_type":"Fact Retrieval","evidence":"HPV infection increases the risk of cervical cancer.; Smoking increases the risk of cervical cancer.; Immunosuppression increases the risk of cervical cancer.; HIV increases the risk of cervical cancer.","evidence_relations":"Risk factors include HPV infection, smoking, immunosuppression (e.g., HIV infection)"},
	{"id":"Medical-15dda38d","source":"Medical","question":"How does smoking affect cervical cancer risk?","answer":"Smoking increases the risk of cervical cancer.","question_type":"Fact Retrieval","evidence":"Smoking increases the risk of cervical cancer.","evidence_relations":"Smoking increases the risk of cervical cancer"},
	{"id":"Medical-788a228f","source":"Medical","question":"How does immunosuppression, such as HIV infection, affect cervical cancer risk?","answer":"Immunosuppression increases the risk of cervical cancer.","question_type":"Fact Retrieval","evidence":"Immunosuppression increases the risk of cervical cancer.","evidence_relations":"Immunosuppression (e.g., HIV infection) increases the risk of cervical cancer"},
	{"id":"Medical-bfa6e03a","source":"Medical","question":"What corresponds to a low-grade squamous intraepithelial lesion (LSIL) in cervical pathology?","answer":"LSIL corresponds to CIN 1.","question_type":"Fact Retrieval","evidence":"LSIL corresponds to CIN 1.","evidence_relations":"Low-grade squamous intraepithelial lesion (LSIL) corresponds to CIN 1"},
	{"id":"Medical-c4c487bc","source":"Medical","question":"What is considered a high-grade squamous intraepithelial lesion (HSIL)?","answer":"HSIL corresponds to CIN 2 and 3 and is considered pre-cancer.","question_type":"Fact Retrieval","evidence":"HSIL corresponds to CIN 2.; HSIL corresponds to CIN 3.; HSIL is considered pre-cancer.","evidence_relations":"High-grade squamous intraepithelial lesion (HSIL) corresponds to CIN 2 and 3 and is considered pre-cancer"},
	{"id":"Medical-c6f1ea93","source":"Medical","question":"What is the main purpose of surveillance after cervical cancer treatment?","answer":"Surveillance includes regular physical exams and imaging as indicated.","question_type":"Fact Retrieval","evidence":"Surveillance includes regular physical exams.; Surveillance includes imaging as indicated.","evidence_relations":"Surveillance after treatment includes regular physical exams and imaging as indicated"},
	{"id":"Medical-e6bc0ffc","source":"Medical","question":"What supportive care options are recommended for advanced or metastatic cervical cancer?","answer":"Supportive care and palliative care are integral for advanced or metastatic disease.","question_type":"Fact Retrieval","evidence":"Supportive care is integral for advanced cervical cancer.; Palliative care is integral for metastatic cervical cancer.","evidence_relations":"Supportive care and palliative care are integral for advanced or metastatic disease"},
	{"id":"Medical-d6b9a73e","source":"Medical","question":"What effect does smoking cessation have on treatment outcomes in cervical cancer?","answer":"Smoking cessation improves treatment outcomes.","question_type":"Fact Retrieval","evidence":"Smoking cessation improves treatment outcomes in cervical cancer.","evidence_relations":"Smoking cessation improves treatment outcomes"},
	{"id":"Medical-6397e7b3","source":"Medical","question":"Are clinical trials an option for cervical cancer patients?","answer":"Clinical trials are an option for all stages of cervical cancer.","question_type":"Fact Retrieval","evidence":"Clinical trials are an option for all stages of cervical cancer.","evidence_relations":"Clinical trials are an option for all stages of cervical cancer"},
	{"id":"Medical-4a5f5e62","source":"Medical","question":"Which rare and aggressive subtype of cervical cancer is noted in the ontology?","answer":"Neuroendocrine carcinoma of the cervix (NECC) is a rare and aggressive subtype.","question_type":"Fact Retrieval","evidence":"Neuroendocrine carcinoma of the cervix (NECC) is a rare subtype.; Neuroendocrine carcinoma of the cervix (NECC) is an aggressive subtype.","evidence_relations":"Neuroendocrine carcinoma of the cervix (NECC) is a rare and aggressive subtype"},
	{"id":"Medical-38ee28b6","source":"Medical","question":"What is the relationship between cervical dysplasia and cervical cancer?","answer":"Cervical dysplasia (CIN) can progress to cervical cancer if untreated.","question_type":"Fact Retrieval","evidence":"Cervical dysplasia (CIN) can progress to cervical cancer if untreated.","evidence_relations":"Cervical dysplasia (CIN) can progress to cervical cancer if untreated"},
	{"id":"Medical-5eeca870","source":"Medical","question":"Which physical examination methods are included in the diagnostic process for cervical cancer?","answer":"Physical exam, cystoscopy, and proctoscopy are included.","question_type":"Fact Retrieval","evidence":"Physical examination methods for cervical cancer include physical exam.; Physical examination methods for cervical cancer include cystoscopy.; Physical examination methods for cervical cancer include proctoscopy.","evidence_relations":"Other diagnostic methods include cystoscopy, proctoscopy, and physical exam"},
	{"id":"Medical-7eb90c51","source":"Medical","question":"What fertility preservation options are available for cervical cancer patients?","answer":"Options include fertility-sparing surgery, ovarian transposition, egg freezing, and surrogacy.","question_type":"Fact Retrieval","evidence":"Fertility preservation options for cervical cancer patients include fertility-sparing surgery.; Fertility preservation options for cervical cancer patients include ovarian transposition.; Fertility preservation options for cervical cancer patients include egg freezing.; Fertility preservation options for cervical cancer patients include surrogacy.","evidence_relations":"Fertility preservation options include fertility-sparing surgery, ovarian transposition, egg freezing, and surrogacy"},
	{"id":"Medical-c6e9519c","source":"Medical","question":"Which genetic alterations are relevant in cervical cancer for biomarker testing?","answer":"Relevant genetic alterations include PD-L1 positivity, MSI-H, dMMR, TMB-H, HER2 amplification, RET fusion, and NTRK fusion.","question_type":"Fact Retrieval","evidence":"Relevant genetic alterations for cervical cancer biomarker testing include PD-L1 positivity.; Relevant genetic alterations for cervical cancer biomarker testing include MSI-H.; Relevant genetic alterations for cervical cancer biomarker testing include dMMR.; Relevant genetic alterations for cervical cancer biomarker testing include TMB-H.; Relevant genetic alterations for cervical cancer biomarker testing include HER2 amplification.; Relevant genetic alterations for cervical cancer biomarker testing include RET fusion.; Relevant genetic alterations for cervical cancer biomarker testing include NTRK fusion.","evidence_relations":"Genetic alterations include PD-L1 positivity, MSI-H, dMMR, TMB-H, HER2 amplification, RET fusion, NTRK fusion"},
	{"id":"Medical-6c42674a","source":"Medical","question":"What type of cancer is Hodgkin lymphoma?","answer":"Hodgkin lymphoma is a type of lymphoma.","question_type":"Fact Retrieval","evidence":"Hodgkin lymphoma is a type of lymphoma.","evidence_relations":"Hodgkin lymphoma is a type of lymphoma"},
	{"id":"Medical-155549b0","source":"Medical","question":"What is the most common subtype of Hodgkin lymphoma?","answer":"Classic Hodgkin lymphoma (CHL) is the most common subtype.","question_type":"Fact Retrieval","evidence":"Classic Hodgkin lymphoma (CHL) is the most common subtype of Hodgkin lymphoma.","evidence_relations":"Classic Hodgkin lymphoma (CHL) is the most common subtype of Hodgkin lymphoma"},
	{"id":"Medical-56084fb4","source":"Medical","question":"Which cell type characterizes Classic Hodgkin lymphoma (CHL)?","answer":"CHL is characterized by Reed-Sternberg cells.","question_type":"Fact Retrieval","evidence":"Classic Hodgkin lymphoma (CHL) is characterized by Reed-Sternberg cells.","evidence_relations":"CHL is characterized by Reed-Sternberg cells"},
	{"id":"Medical-bc603db5","source":"Medical","question":"What is a rare subtype of Hodgkin lymphoma?","answer":"Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subtype.","question_type":"Fact Retrieval","evidence":"Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subtype of Hodgkin lymphoma.","evidence_relations":"Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subtype of Hodgkin lymphoma"},
	{"id":"Medical-d81ad4db","source":"Medical","question":"Which cell type is characteristic of NLPHL?","answer":"NLPHL is characterized by popcorn-shaped cells.","question_type":"Fact Retrieval","evidence":"Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is characterized by popcorn-shaped cells.","evidence_relations":"NLPHL is characterized by popcorn-shaped cells"},
	{"id":"Medical-41eb01ac","source":"Medical","question":"Into which disease can NLPHL transform?","answer":"NLPHL can transform into diffuse large B-cell lymphoma (DLBCL).","question_type":"Fact Retrieval","evidence":"Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) can transform into diffuse large B-cell lymphoma (DLBCL).","evidence_relations":"NLPHL can transform into diffuse large B-cell lymphoma (DLBCL)"},
	{"id":"Medical-620a1582","source":"Medical","question":"What is the primary diagnostic method for Hodgkin lymphoma?","answer":"Diagnosis of Hodgkin lymphoma is made by excisional lymph node biopsy.","question_type":"Fact Retrieval","evidence":"The primary diagnostic method for Hodgkin lymphoma is excisional lymph node biopsy.","evidence_relations":"Diagnosis of Hodgkin lymphoma is made by excisional lymph node biopsy"},
	{"id":"Medical-45b14e2d","source":"Medical","question":"Which biopsy method may be used for Hodgkin lymphoma diagnosis in some cases?","answer":"Core needle biopsy may be used for diagnosis in some cases.","question_type":"Fact Retrieval","evidence":"Core needle biopsy may be used for Hodgkin lymphoma diagnosis in some cases.","evidence_relations":"Core needle biopsy may be used for diagnosis in some cases"},
	{"id":"Medical-d3a58aef","source":"Medical","question":"Which diagnostic procedures are part of the initial workup for Hodgkin lymphoma?","answer":"Health history and physical exam are part of the diagnostic process.","question_type":"Fact Retrieval","evidence":"Health history is part of the diagnostic process for Hodgkin lymphoma.; Physical exam is part of the diagnostic process for Hodgkin lymphoma.","evidence_relations":"Health history and physical exam are part of the diagnostic process"},
	{"id":"Medical-49e5ee6e","source":"Medical","question":"What laboratory and imaging tests are used in the diagnostic workup for Hodgkin lymphoma?","answer":"Blood tests and imaging tests are used in the diagnostic workup.","question_type":"Fact Retrieval","evidence":"Blood tests are used in the diagnostic workup for Hodgkin lymphoma.; Imaging tests are used in the diagnostic workup for Hodgkin lymphoma.","evidence_relations":"Blood tests and imaging tests are used in the diagnostic workup"},
	{"id":"Medical-2b8c042d","source":"Medical","question":"Where does Hodgkin lymphoma usually start?","answer":"Hodgkin lymphoma usually starts in lymph nodes in the upper body.","question_type":"Fact Retrieval","evidence":"Hodgkin lymphoma usually starts in lymph nodes.; Hodgkin lymphoma usually starts in the upper body.","evidence_relations":"Hodgkin lymphoma usually starts in lymph nodes in the upper body"},
	{"id":"Medical-3b688fe1","source":"Medical","question":"Which age groups are most commonly diagnosed with Hodgkin lymphoma?","answer":"Most people are diagnosed between ages 15 to 30 or after age 55.","question_type":"Fact Retrieval","evidence":"Most people diagnosed with Hodgkin lymphoma are between ages 15 to 30.; Most people diagnosed with Hodgkin lymphoma are over age 55.","evidence_relations":"Most people are diagnosed between ages 15 to 30 or after age 55"},
	{"id":"Medical-140a1830","source":"Medical","question":"What are the common sites involved in Hodgkin lymphoma?","answer":"Common sites include lymph nodes in the upper body.","question_type":"Fact Retrieval","evidence":"Common sites involved in Hodgkin lymphoma include lymph nodes.; Common sites involved in Hodgkin lymphoma include lymph nodes in the upper body.","evidence_relations":"Common Sites: lymph nodes in upper body"},
	{"id":"Medical-c76d84e2","source":"Medical","question":"What are the risk factors for Hodgkin lymphoma based on age?","answer":"Risk factors include being between ages 15 to 30 or age 55.","question_type":"Fact Retrieval","evidence":"Risk factors for Hodgkin lymphoma include being between ages 15 to 30.; Risk factors for Hodgkin lymphoma include being age 55.","evidence_relations":"Risk Factor: ages 15 to 30, age 55"},
	{"id":"Medical-9b5a2b0a","source":"Medical","question":"Which two biopsy methods are listed for diagnosing CHL?","answer":"Excisional lymph node biopsy and core needle biopsy are listed for CHL diagnosis.","question_type":"Fact Retrieval","evidence":"Excisional lymph node biopsy is listed for diagnosing CHL.; Core needle biopsy is listed for diagnosing CHL.","evidence_relations":"Diagnostic Method: excisional lymph node biopsy, core needle biopsy"},
	{"id":"Medical-e39fe71c","source":"Medical","question":"What cell type is associated with Classic Hodgkin lymphoma according to the ontology?","answer":"Reed-Sternberg cells are associated with Classic Hodgkin lymphoma.","question_type":"Fact Retrieval","evidence":"Reed-Sternberg cells are associated with Classic Hodgkin lymphoma.","evidence_relations":"Cell Type: Reed-Sternberg cells"},
	{"id":"Medical-8f34d47a","source":"Medical","question":"What cell type is associated with NLPHL according to the ontology?","answer":"Popcorn-shaped cells are associated with NLPHL.","question_type":"Fact Retrieval","evidence":"Popcorn-shaped cells are associated with NLPHL.","evidence_relations":"Cell Type: popcorn-shaped cells"},
	{"id":"Medical-54f18ca7","source":"Medical","question":"Which diagnostic methods are common to both CHL and NLPHL?","answer":"Excisional lymph node biopsy, core needle biopsy, health history, physical exam, blood tests, and imaging tests are common to both.","question_type":"Fact Retrieval","evidence":"Excisional lymph node biopsy is a common diagnostic method for both CHL and NLPHL.; Core needle biopsy is a common diagnostic method for both CHL and NLPHL.; Health history is a common diagnostic method for both CHL and NLPHL.; Physical exam is a common diagnostic method for both CHL and NLPHL.; Blood tests are a common diagnostic method for both CHL and NLPHL.; Imaging tests are a common diagnostic method for both CHL and NLPHL.","evidence_relations":"Diagnostic Method: excisional lymph node biopsy, core needle biopsy, health history, physical exam, blood tests, imaging tests"},
	{"id":"Medical-e9c535e5","source":"Medical","question":"What disease transformation is noted for NLPHL?","answer":"NLPHL can transform into diffuse large B-cell lymphoma (DLBCL).","question_type":"Fact Retrieval","evidence":"NLPHL can transform into diffuse large B-cell lymphoma (DLBCL).","evidence_relations":"Disease Transformation: diffuse large B-cell lymphoma (DLBCL)"},
	{"id":"Medical-653c0da3","source":"Medical","question":"Which lymphoma subtype is most frequently associated with Reed-Sternberg cells?","answer":"Classic Hodgkin lymphoma (CHL) is most frequently associated with Reed-Sternberg cells.","question_type":"Fact Retrieval","evidence":"Classic Hodgkin lymphoma (CHL) is most frequently associated with Reed-Sternberg cells.","evidence_relations":"CHL is characterized by Reed-Sternberg cells"},
	{"id":"Medical-9d5ac399","source":"Medical","question":"What is the main cell type that distinguishes NLPHL from CHL?","answer":"Popcorn-shaped cells distinguish NLPHL from CHL.","question_type":"Fact Retrieval","evidence":"Popcorn-shaped cells distinguish NLPHL from CHL.","evidence_relations":"NLPHL is characterized by popcorn-shaped cells"},
	{"id":"Medical-cfc34fd6","source":"Medical","question":"Which cancer type does Hodgkin lymphoma belong to?","answer":"Hodgkin lymphoma belongs to the lymphoma cancer type.","question_type":"Fact Retrieval","evidence":"Hodgkin lymphoma belongs to the lymphoma cancer type.","evidence_relations":"Hodgkin lymphoma is a type of lymphoma"},
	{"id":"Medical-6e415b34","source":"Medical","question":"What physical examination is included in the diagnostic process for Hodgkin lymphoma?","answer":"Physical exam is part of the diagnostic process.","question_type":"Fact Retrieval","evidence":"Physical exam is part of the diagnostic process for Hodgkin lymphoma.","evidence_relations":"Health history and physical exam are part of the diagnostic process"},
	{"id":"Medical-d9c6b363","source":"Medical","question":"Which lymphoma subtype can transform into another lymphoma, and what is the resulting disease?","answer":"NLPHL can transform into diffuse large B-cell lymphoma (DLBCL).","question_type":"Fact Retrieval","evidence":"NLPHL can transform into diffuse large B-cell lymphoma (DLBCL).","evidence_relations":"NLPHL can transform into diffuse large B-cell lymphoma (DLBCL)"},
	{"id":"Medical-df4834b4","source":"Medical","question":"What is the significance of Reed-Sternberg cells in Hodgkin lymphoma?","answer":"Reed-Sternberg cells characterize Classic Hodgkin lymphoma (CHL).","question_type":"Fact Retrieval","evidence":"Reed-Sternberg cells characterize Classic Hodgkin lymphoma (CHL).","evidence_relations":"CHL is characterized by Reed-Sternberg cells"},
	{"id":"Medical-a208f169","source":"Medical","question":"What is the typical anatomical location where Hodgkin lymphoma begins?","answer":"Hodgkin lymphoma usually starts in lymph nodes in the upper body.","question_type":"Fact Retrieval","evidence":"Hodgkin lymphoma usually starts in lymph nodes in the upper body.","evidence_relations":"Hodgkin lymphoma usually starts in lymph nodes in the upper body"},
	{"id":"Medical-6602e33d","source":"Medical","question":"What is the diagnostic significance of excisional lymph node biopsy in Hodgkin lymphoma?","answer":"Excisional lymph node biopsy is the primary diagnostic method for Hodgkin lymphoma.","question_type":"Fact Retrieval","evidence":"Excisional lymph node biopsy is the primary diagnostic method for Hodgkin lymphoma.","evidence_relations":"Diagnosis of Hodgkin lymphoma is made by excisional lymph node biopsy"},
	{"id":"Medical-59a9ad6d","source":"Medical","question":"What are two age-related risk factors for Hodgkin lymphoma?","answer":"Ages 15 to 30 and age 55 are risk factors for Hodgkin lymphoma.","question_type":"Fact Retrieval","evidence":"Ages 15 to 30 are a risk factor for Hodgkin lymphoma.; Age 55 is a risk factor for Hodgkin lymphoma.","evidence_relations":"Risk Factor: ages 15 to 30, age 55"},
	{"id":"Medical-1b774745","source":"Medical","question":"Which subtype of Hodgkin lymphoma is rare according to the relations?","answer":"Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is rare.","question_type":"Fact Retrieval","evidence":"Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subtype.","evidence_relations":"Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subtype of Hodgkin lymphoma"},
	{"id":"Medical-3306e2b6","source":"Medical","question":"What is the role of blood tests in Hodgkin lymphoma diagnosis?","answer":"Blood tests are used in the diagnostic workup for Hodgkin lymphoma.","question_type":"Fact Retrieval","evidence":"Blood tests are used in the diagnostic workup for Hodgkin lymphoma.","evidence_relations":"Blood tests and imaging tests are used in the diagnostic workup"},
	{"id":"Medical-15c48832","source":"Medical","question":"Which imaging techniques are part of the diagnostic methods for Hodgkin lymphoma?","answer":"Imaging tests are used in the diagnostic workup for Hodgkin lymphoma.","question_type":"Fact Retrieval","evidence":"Imaging tests are used in the diagnostic workup for Hodgkin lymphoma.","evidence_relations":"Blood tests and imaging tests are used in the diagnostic workup"},
	{"id":"Medical-c8e42c69","source":"Medical","question":"What are the main cancer types associated with the gallbladder and bile ducts?","answer":"Intrahepatic bile duct cancer is a main cancer type.","question_type":"Fact Retrieval","evidence":"Intrahepatic bile duct cancer is a main cancer type associated with the gallbladder and bile ducts.","evidence_relations":"intrahepatic bile duct cancer"},
	{"id":"Medical-0e5e7e44","source":"Medical","question":"Which anatomical structures are covered by a thin, moist epithelial layer?","answer":"The gallbladder and bile ducts are covered by a thin, moist epithelial layer.","question_type":"Fact Retrieval","evidence":"The gallbladder is covered by a thin, moist epithelial layer.; The bile ducts are covered by a thin, moist epithelial layer.","evidence_relations":"The gallbladder and bile ducts are lined by a thin, moist epithelial layer"},
	{"id":"Medical-a0ee92b3","source":"Medical","question":"What is the outermost membrane covering the gallbladder and bile ducts?","answer":"Serosa is the outer membrane covering the gallbladder and bile ducts.","question_type":"Fact Retrieval","evidence":"Serosa is the outer membrane covering the gallbladder.; Serosa is the outer membrane covering the bile ducts.","evidence_relations":"Serosa is the outer membrane covering the gallbladder and bile ducts"},
	{"id":"Medical-aa283616","source":"Medical","question":"What histological layers are found in the bile duct wall?","answer":"The bile duct wall contains epithelium, lamina propria, muscularis, perimuscular fibrous tissue, and serosa.","question_type":"Fact Retrieval","evidence":"The bile duct wall contains epithelium.; The bile duct wall contains lamina propria.; The bile duct wall contains muscularis.; The bile duct wall contains perimuscular fibrous tissue.; The bile duct wall contains serosa.","evidence_relations":"bile duct has Histological Layer: epithelium, lamina propria, muscularis, perimuscular fibrous tissue, serosa"},
	{"id":"Medical-5136f646","source":"Medical","question":"Which connective tissue is located under the epithelium in the gallbladder and bile duct?","answer":"Lamina propria is the connective tissue found under the epithelium.","question_type":"Fact Retrieval","evidence":"Lamina propria is the connective tissue found under the epithelium in the gallbladder.; Lamina propria is the connective tissue found under the epithelium in the bile duct.","evidence_relations":"Lamina propria is a connective tissue found under the epithelium"},
	{"id":"Medical-7d67a49f","source":"Medical","question":"What is the function of the muscularis layer in the bile duct wall?","answer":"Muscularis is a soft tissue layer in the bile duct wall.","question_type":"Fact Retrieval","evidence":"Muscularis is a soft tissue layer in the bile duct wall.","evidence_relations":"Muscularis is a soft tissue layer in the bile duct wall"},
	{"id":"Medical-0535a6b1","source":"Medical","question":"What tissue surrounds the muscle layer in the bile duct and gallbladder?","answer":"Perimuscular fibrous tissue surrounds the muscle layer.","question_type":"Fact Retrieval","evidence":"Perimuscular fibrous tissue surrounds the muscle layer in the bile duct.; Perimuscular fibrous tissue surrounds the muscle layer in the gallbladder.","evidence_relations":"Perimuscular fibrous tissue surrounds the muscle layer"},
	{"id":"Medical-14c841bc","source":"Medical","question":"On what basis is bile duct cancer staging determined?","answer":"Bile duct cancer staging is based on tumor size and extent of spread.","question_type":"Fact Retrieval","evidence":"Bile duct cancer staging is based on tumor size.; Bile duct cancer staging is based on extent of spread.","evidence_relations":"Bile duct cancer staging is based on tumor size and extent of spread"},
	{"id":"Medical-2adbc240","source":"Medical","question":"What does the stage Tis indicate in intrahepatic bile duct cancer?","answer":"Tis (carcinoma in situ) is an intraductal tumor confined to the epithelium.","question_type":"Fact Retrieval","evidence":"Tis indicates carcinoma in situ in intrahepatic bile duct cancer.; Tis is an intraductal tumor.; Tis is confined to the epithelium.","evidence_relations":"Tis (carcinoma in situ) is an intraductal tumor confined to the epithelium"},
	{"id":"Medical-fca41ac7","source":"Medical","question":"What are the tumor characteristics of Tis stage in intrahepatic bile duct cancer?","answer":"Tis is characterized by carcinoma in situ, intraductal tumor, and confinement to the epithelium.","question_type":"Fact Retrieval","evidence":"Tis is characterized by carcinoma in situ.; Tis is characterized by an intraductal tumor.; Tis is characterized by confinement to the epithelium.","evidence_relations":"Tis: Tumor Characteristic: carcinoma in situ, intraductal tumor, confined to epithelium"},
	{"id":"Medical-ebc2ff97","source":"Medical","question":"Which structures can bile duct cancer invade as it progresses?","answer":"Cancer can invade nearby blood vessels, liver, or structures outside the liver.","question_type":"Fact Retrieval","evidence":"Bile duct cancer can invade nearby blood vessels.; Bile duct cancer can invade the liver.; Bile duct cancer can invade structures outside the liver.","evidence_relations":"Cancer can invade nearby blood vessels, liver, or structures outside the liver"},
	{"id":"Medical-da181948","source":"Medical","question":"What are the histological layers present in the gallbladder?","answer":"The gallbladder contains epithelium, lamina propria, muscularis, perimuscular fibrous tissue, and serosa.","question_type":"Fact Retrieval","evidence":"The gallbladder contains epithelium.; The gallbladder contains lamina propria.; The gallbladder contains muscularis.; The gallbladder contains perimuscular fibrous tissue.; The gallbladder contains serosa.","evidence_relations":"gallbladder has Histological Layer: epithelium, lamina propria, muscularis, perimuscular fibrous tissue, serosa"},
	{"id":"Medical-1060f44f","source":"Medical","question":"Which cancer type is classified under the anatomical structure of the bile duct?","answer":"Intrahepatic bile duct cancer is classified under the bile duct.","question_type":"Fact Retrieval","evidence":"Intrahepatic bile duct cancer is classified under the bile duct.","evidence_relations":"Cancer Type: intrahepatic bile duct cancer under bile duct"},
	{"id":"Medical-e3492f40","source":"Medical","question":"What is carcinoma in situ in the context of intrahepatic bile duct cancer?","answer":"Carcinoma in situ is an intraductal tumor confined to the epithelium.","question_type":"Fact Retrieval","evidence":"Carcinoma in situ is an intraductal tumor.; Carcinoma in situ is confined to the epithelium.","evidence_relations":"Tis (carcinoma in situ) is an intraductal tumor confined to the epithelium"},
	{"id":"Medical-5c7974c9","source":"Medical","question":"Which layer directly covers the muscularis in the gallbladder and bile duct?","answer":"Perimuscular fibrous tissue directly covers the muscularis.","question_type":"Fact Retrieval","evidence":"Perimuscular fibrous tissue directly covers the muscularis in the gallbladder.; Perimuscular fibrous tissue directly covers the muscularis in the bile duct.","evidence_relations":"Perimuscular fibrous tissue surrounds the muscle layer"},
	{"id":"Medical-d8aa135d","source":"Medical","question":"What is the primary tumor characteristic used for staging bile duct cancer?","answer":"Primary tumor size and extent of spread are used for staging.","question_type":"Fact Retrieval","evidence":"Primary tumor size is used for staging bile duct cancer.; Extent of spread is used for staging bile duct cancer.","evidence_relations":"Bile duct cancer staging is based on tumor size and extent of spread"},
	{"id":"Medical-d465de28","source":"Medical","question":"Which layer is the innermost lining of the gallbladder and bile ducts?","answer":"The epithelium is the innermost lining.","question_type":"Fact Retrieval","evidence":"The epithelium is the innermost lining of the gallbladder.; The epithelium is the innermost lining of the bile ducts.","evidence_relations":"The gallbladder and bile ducts are lined by a thin, moist epithelial layer"},
	{"id":"Medical-651ea4b6","source":"Medical","question":"What is the relationship between lamina propria and the epithelium in these cancers?","answer":"Lamina propria is a connective tissue found under the epithelium.","question_type":"Fact Retrieval","evidence":"Lamina propria is a connective tissue.; Lamina propria is found under the epithelium.","evidence_relations":"Lamina propria is a connective tissue found under the epithelium"},
	{"id":"Medical-340cdb40","source":"Medical","question":"What are examples of tumor spread in intrahepatic bile duct cancer?","answer":"Tumor can spread to blood vessels, liver, or structures outside the liver.","question_type":"Fact Retrieval","evidence":"Tumor can spread to blood vessels.; Tumor can spread to the liver.; Tumor can spread to structures outside the liver.","evidence_relations":"Cancer can invade nearby blood vessels, liver, or structures outside the liver"},
	{"id":"Medical-306b4531","source":"Medical","question":"What is an intraductal tumor in the context of cancer staging?","answer":"An intraductal tumor is a carcinoma in situ confined to the epithelium.","question_type":"Fact Retrieval","evidence":"An intraductal tumor is a carcinoma in situ.; An intraductal tumor is confined to the epithelium.","evidence_relations":"Tis (carcinoma in situ) is an intraductal tumor confined to the epithelium"},
	{"id":"Medical-d70b14a4","source":"Medical","question":"Which anatomical structures are included in the ontology for intrahepatic bile duct cancer?","answer":"Bile duct and gallbladder are included as anatomical structures.","question_type":"Fact Retrieval","evidence":"Bile duct is included as an anatomical structure for intrahepatic bile duct cancer.; Gallbladder is included as an anatomical structure for intrahepatic bile duct cancer.","evidence_relations":"Anatomical Structure: bile duct, gallbladder"},
	{"id":"Medical-47be866b","source":"Medical","question":"What is the role of the serosa in gallbladder and bile duct anatomy?","answer":"Serosa is the outer membrane covering these organs.","question_type":"Fact Retrieval","evidence":"Serosa is the outer membrane covering the gallbladder.; Serosa is the outer membrane covering the bile duct.","evidence_relations":"Serosa is the outer membrane covering the gallbladder and bile ducts"},
	{"id":"Medical-2ebac5e5","source":"Medical","question":"Which tumor characteristic involves the measurement in centimeters or millimeters?","answer":"Primary tumor size (cm or mm) is a tumor characteristic.","question_type":"Fact Retrieval","evidence":"Primary tumor size is a tumor characteristic.; Primary tumor size is measured in centimeters or millimeters.","evidence_relations":"Tumor Characteristic: primary tumor size (cm or mm)"},
	{"id":"Medical-edc4f2c6","source":"Medical","question":"What is the relationship between the muscularis and perimuscular fibrous tissue?","answer":"Perimuscular fibrous tissue surrounds the muscularis layer.","question_type":"Fact Retrieval","evidence":"Perimuscular fibrous tissue surrounds the muscularis layer.","evidence_relations":"Perimuscular fibrous tissue surrounds the muscle layer"},
	{"id":"Medical-177b0129","source":"Medical","question":"What does the term 'confined to epithelium' indicate in tumor staging?","answer":"It indicates that the tumor is limited to the epithelial layer without invasion.","question_type":"Fact Retrieval","evidence":"The term 'confined to epithelium' indicates that the tumor is limited to the epithelial layer.; The term 'confined to epithelium' indicates that the tumor has no invasion.","evidence_relations":"Tis (carcinoma in situ) is an intraductal tumor confined to the epithelium"},
	{"id":"Medical-c663d954","source":"Medical","question":"Which histological layer provides structural support under the epithelium?","answer":"Lamina propria provides structural support under the epithelium.","question_type":"Fact Retrieval","evidence":"Lamina propria provides structural support under the epithelium.","evidence_relations":"Lamina propria is a connective tissue found under the epithelium"},
	{"id":"Medical-defb6aef","source":"Medical","question":"What is the significance of the muscularis in the context of bile duct cancer?","answer":"The muscularis is a soft tissue layer that may be invaded as cancer progresses.","question_type":"Fact Retrieval","evidence":"The muscularis is a soft tissue layer.; The muscularis may be invaded as cancer progresses.","evidence_relations":"Muscularis is a soft tissue layer in the bile duct wall"},
	{"id":"Medical-16bc9e87","source":"Medical","question":"Which cancer stage is defined by a tumor that is only within the epithelial layer?","answer":"Tis (carcinoma in situ) is defined by a tumor confined to the epithelium.","question_type":"Fact Retrieval","evidence":"Tis (carcinoma in situ) is defined by a tumor confined to the epithelium.","evidence_relations":"Tis (carcinoma in situ) is an intraductal tumor confined to the epithelium"},
	{"id":"Medical-af5dbcb0","source":"Medical","question":"What anatomical layers must a tumor penetrate to reach the serosa in the bile duct?","answer":"A tumor must penetrate the epithelium, lamina propria, muscularis, and perimuscular fibrous tissue to reach the serosa.","question_type":"Fact Retrieval","evidence":"A tumor must penetrate the epithelium to reach the serosa.; A tumor must penetrate the lamina propria to reach the serosa.; A tumor must penetrate the muscularis to reach the serosa.; A tumor must penetrate the perimuscular fibrous tissue to reach the serosa.","evidence_relations":"bile duct has Histological Layer: epithelium, lamina propria, muscularis, perimuscular fibrous tissue, serosa"},
	{"id":"Medical-3539e146","source":"Medical","question":"What does spread to structures outside the liver signify in bile duct cancer?","answer":"It signifies advanced tumor invasion beyond the liver.","question_type":"Fact Retrieval","evidence":"Spread to structures outside the liver signifies advanced tumor invasion.; Spread to structures outside the liver signifies invasion beyond the liver.","evidence_relations":"Cancer can invade nearby blood vessels, liver, or structures outside the liver"},
	{"id":"Medical-e79c55d4","source":"Medical","question":"Which layer is described as a membrane in the anatomical structure of the gallbladder and bile ducts?","answer":"Serosa is described as a membrane covering the gallbladder and bile ducts.","question_type":"Fact Retrieval","evidence":"Serosa is described as a membrane.; Serosa covers the gallbladder.; Serosa covers the bile ducts.","evidence_relations":"Serosa is the outer membrane covering the gallbladder and bile ducts"},
	{"id":"Medical-e4d47909","source":"Medical","question":"What type of lymphoma is follicular lymphoma (FL)?","answer":"Follicular lymphoma (FL) is a slow-growing B-cell non-Hodgkin lymphoma.","question_type":"Fact Retrieval","evidence":"Follicular lymphoma (FL) is a slow-growing B-cell non-Hodgkin lymphoma.","evidence_relations":"Follicular lymphoma (FL) is a slow-growing B-cell non-Hodgkin lymphoma"},
	{"id":"Medical-78788ae0","source":"Medical","question":"From which cell type does follicular lymphoma (FL) develop?","answer":"FL develops from abnormal B lymphocytes.","question_type":"Fact Retrieval","evidence":"Follicular lymphoma (FL) develops from abnormal B lymphocytes.","evidence_relations":"FL develops from abnormal B lymphocytes forming clusters in lymph nodes and other tissues"},
	{"id":"Medical-c2568161","source":"Medical","question":"What are the main disease sites for follicular lymphoma (FL)?","answer":"FL affects lymph nodes, bone marrow, spleen, and extranodal sites.","question_type":"Fact Retrieval","evidence":"Follicular lymphoma (FL) affects lymph nodes.; Follicular lymphoma (FL) affects bone marrow.; Follicular lymphoma (FL) affects the spleen.; Follicular lymphoma (FL) affects extranodal sites.","evidence_relations":"Disease sites for FL include lymph node, bone marrow, spleen, and extranodal sites"},
	{"id":"Medical-49d93af8","source":"Medical","question":"How is follicular lymphoma (FL) graded?","answer":"FL is graded based on the proportion of centrocytes and centroblasts.","question_type":"Fact Retrieval","evidence":"Follicular lymphoma (FL) is graded based on the proportion of centrocytes.; Follicular lymphoma (FL) is graded based on the proportion of centroblasts.","evidence_relations":"FL is graded based on the proportion of centrocytes and centroblasts"},
	{"id":"Medical-aacc81ea","source":"Medical","question":"Which grades of FL are classified as classic FL (cFL) according to ICC?","answer":"Grades 1 and 2 FL are classified as classic FL (cFL).","question_type":"Fact Retrieval","evidence":"Grades 1 and 2 FL are classified as classic FL (cFL).","evidence_relations":"Grades 1 and 2 FL are classified as classic FL (cFL) according to ICC"},
	{"id":"Medical-7ed82690","source":"Medical","question":"How is grade 3B follicular lymphoma treated?","answer":"Grade 3B FL is treated as diffuse large B-cell lymphoma (DLBCL).","question_type":"Fact Retrieval","evidence":"Grade 3B follicular lymphoma is treated as diffuse large B-cell lymphoma.","evidence_relations":"Grade 3B FL is treated as DLBCL"},
	{"id":"Medical-13fe78ff","source":"Medical","question":"What is the typical genetic alteration found in almost all FL cases?","answer":"Almost all FL cases have a chromosome translocation or excess BCL2 protein.","question_type":"Fact Retrieval","evidence":"Almost all follicular lymphoma cases have a chromosome translocation.; Almost all follicular lymphoma cases have excess BCL2 protein.","evidence_relations":"Almost all FL cases have a chromosome translocation or excess BCL2 protein"},
	{"id":"Medical-4be4d916","source":"Medical","question":"What is the characteristic genetic alteration in uncommon FL (uFL)?","answer":"Uncommon FL (uFL) is t(14;18)-negative or has uncommon pathologic features.","question_type":"Fact Retrieval","evidence":"Uncommon follicular lymphoma is t(14;18)-negative.; Uncommon follicular lymphoma has uncommon pathologic features.","evidence_relations":"Uncommon FL (uFL) is t(14;18)-negative or has uncommon pathologic features"},
	{"id":"Medical-2e05b3f3","source":"Medical","question":"How is uncommon FL (uFL) treated?","answer":"Uncommon FL (uFL) is treated as classic FL.","question_type":"Fact Retrieval","evidence":"Uncommon follicular lymphoma is treated as classic follicular lymphoma.","evidence_relations":"Uncommon FL (uFL) is t(14;18)-negative or has uncommon pathologic features and is treated as classic FL"},
	{"id":"Medical-f3e4ed65","source":"Medical","question":"What is the typical presentation of pediatric-type follicular lymphoma (PTFL)?","answer":"PTFL usually presents with a single enlarged lymph node in the head and neck and minimal symptoms.","question_type":"Fact Retrieval","evidence":"Pediatric-type follicular lymphoma usually presents with a single enlarged lymph node.; The single enlarged lymph node in pediatric-type follicular lymphoma is located in the head and neck.; Pediatric-type follicular lymphoma usually presents with minimal symptoms.","evidence_relations":"Pediatric-type FL (PTFL) usually presents with a single enlarged lymph node in the head and neck and minimal symptoms"},
	{"id":"Medical-26ce4d1c","source":"Medical","question":"What can follicular lymphoma (FL) transform into?","answer":"FL can transform into diffuse large B-cell lymphoma (DLBCL), a more aggressive lymphoma.","question_type":"Fact Retrieval","evidence":"Follicular lymphoma can transform into diffuse large B-cell lymphoma.; Diffuse large B-cell lymphoma is a more aggressive lymphoma.","evidence_relations":"FL can transform into DLBCL, a more aggressive lymphoma"},
	{"id":"Medical-0ab293c2","source":"Medical","question":"Which diagnostic methods are used for follicular lymphoma (FL)?","answer":"Diagnosis of FL involves blood tests, bone marrow aspirate and biopsy, imaging studies, and immunophenotyping.","question_type":"Fact Retrieval","evidence":"Diagnosis of follicular lymphoma involves blood tests.; Diagnosis of follicular lymphoma involves bone marrow aspirate and biopsy.; Diagnosis of follicular lymphoma involves imaging studies.; Diagnosis of follicular lymphoma involves immunophenotyping.","evidence_relations":"Diagnosis of FL involves blood tests, bone marrow aspirate and biopsy, imaging studies, and immunophenotyping"},
	{"id":"Medical-2d90241b","source":"Medical","question":"What are common symptoms of follicular lymphoma (FL)?","answer":"Symptoms of FL include swollen lymph nodes, enlarged spleen, fever, night sweats, fatigue, and weight loss (B symptoms).","question_type":"Fact Retrieval","evidence":"Common symptoms of follicular lymphoma include swollen lymph nodes.; Common symptoms of follicular lymphoma include enlarged spleen.; Common symptoms of follicular lymphoma include fever.; Common symptoms of follicular lymphoma include night sweats.; Common symptoms of follicular lymphoma include fatigue.; Common symptoms of follicular lymphoma include weight loss.","evidence_relations":"Symptoms of FL include swollen lymph nodes, enlarged spleen, fever, night sweats, fatigue, and weight loss (B symptoms)"},
	{"id":"Medical-5730fce1","source":"Medical","question":"Do all patients with follicular lymphoma require immediate treatment?","answer":"Not all patients with FL require immediate treatment.","question_type":"Fact Retrieval","evidence":"Not all patients with follicular lymphoma require immediate treatment.","evidence_relations":"Not all patients with FL require immediate treatment"},
	{"id":"Medical-44af5ecf","source":"Medical","question":"What guides treatment decisions in follicular lymphoma (FL)?","answer":"The type of cells in FL determines the grade, which guides treatment decisions.","question_type":"Fact Retrieval","evidence":"The type of cells in follicular lymphoma determines the grade.; The grade of follicular lymphoma guides treatment decisions.","evidence_relations":"The type of cells in FL determines the grade, which guides treatment decisions"},
	{"id":"Medical-9b28edf9","source":"Medical","question":"What are the main cell types found in follicular lymphoma (FL)?","answer":"The main cell types in FL are centrocytes and centroblasts.","question_type":"Fact Retrieval","evidence":"The main cell types in follicular lymphoma are centrocytes.; The main cell types in follicular lymphoma are centroblasts.","evidence_relations":"FL is graded based on the proportion of centrocytes and centroblasts"},
	{"id":"Medical-8a166224","source":"Medical","question":"Which biomarker is commonly associated with follicular lymphoma (FL)?","answer":"BCL2 protein is a biomarker commonly associated with FL.","question_type":"Fact Retrieval","evidence":"BCL2 protein is a biomarker commonly associated with follicular lymphoma.","evidence_relations":"Biomarker: BCL2 protein"},
	{"id":"Medical-bf9805af","source":"Medical","question":"What genetic alteration is associated with FL besides t(14;18)?","answer":"Chromosome translocation is associated with FL.","question_type":"Fact Retrieval","evidence":"Chromosome translocation is associated with follicular lymphoma.","evidence_relations":"Genetic Alteration: chromosome translocation"},
	{"id":"Medical-9410dd14","source":"Medical","question":"Which FL subtype is defined by t(14;18)-negativity?","answer":"Uncommon FL (uFL) is defined by t(14;18)-negativity.","question_type":"Fact Retrieval","evidence":"Uncommon follicular lymphoma is defined by t(14;18)-negativity.","evidence_relations":"Uncommon FL (uFL) is t(14;18)-negative"},
	{"id":"Medical-2876eea3","source":"Medical","question":"What is the classification of grade 3A FL?","answer":"Grade 3A FL may be classified as classic FL or as DLBCL.","question_type":"Fact Retrieval","evidence":"Grade 3A follicular lymphoma may be classified as classic follicular lymphoma.; Grade 3A follicular lymphoma may be classified as DLBCL.","evidence_relations":"Grade 3A FL may be treated as classic FL or as diffuse large B-cell lymphoma (DLBCL)"},
	{"id":"Medical-43e5c06b","source":"Medical","question":"Which FL subtype is associated with minimal symptoms?","answer":"Pediatric-type FL (PTFL) is associated with minimal symptoms.","question_type":"Fact Retrieval","evidence":"Pediatric-type follicular lymphoma is associated with minimal symptoms.","evidence_relations":"Pediatric-type FL (PTFL) usually presents with a single enlarged lymph node in the head and neck and minimal symptoms"},
	{"id":"Medical-6a4086f1","source":"Medical","question":"What is the typical site of presentation for pediatric-type FL (PTFL)?","answer":"PTFL usually presents with a single enlarged lymph node in the head and neck region.","question_type":"Fact Retrieval","evidence":"Pediatric-type follicular lymphoma usually presents with a single enlarged lymph node.; The single enlarged lymph node in pediatric-type follicular lymphoma is located in the head and neck region.","evidence_relations":"Pediatric-type FL (PTFL) usually presents with a single enlarged lymph node in the head and neck and minimal symptoms"},
	{"id":"Medical-c79a2c52","source":"Medical","question":"What is the cell type origin of follicular lymphoma?","answer":"Follicular lymphoma originates from B lymphocytes.","question_type":"Fact Retrieval","evidence":"Follicular lymphoma originates from B lymphocytes.","evidence_relations":"Cell Type: B lymphocyte"},
	{"id":"Medical-cf21d241","source":"Medical","question":"What symptoms are collectively referred to as B symptoms in FL?","answer":"B symptoms in FL include fever, night sweats, and weight loss.","question_type":"Fact Retrieval","evidence":"B symptoms in follicular lymphoma include fever.; B symptoms in follicular lymphoma include night sweats.; B symptoms in follicular lymphoma include weight loss.","evidence_relations":"Symptoms of FL include swollen lymph nodes, enlarged spleen, fever, night sweats, fatigue, and weight loss (B symptoms)"},
	{"id":"Medical-4392ee71","source":"Medical","question":"Which diagnostic method is used to assess bone marrow involvement in FL?","answer":"Bone marrow aspirate and biopsy are used to assess bone marrow involvement in FL.","question_type":"Fact Retrieval","evidence":"Bone marrow aspirate and biopsy are used to assess bone marrow involvement in follicular lymphoma.","evidence_relations":"Diagnosis of FL involves blood tests, bone marrow aspirate and biopsy, imaging studies, and immunophenotyping"},
	{"id":"Medical-1e353d15","source":"Medical","question":"Which grades of FL are characterized by both centrocytes and centroblasts?","answer":"Grades 1, 2, and 3A FL are characterized by both centrocytes and centroblasts.","question_type":"Fact Retrieval","evidence":"Grades 1 FL are characterized by both centrocytes and centroblasts.; Grades 2 FL are characterized by both centrocytes and centroblasts.; Grades 3A FL are characterized by both centrocytes and centroblasts.","evidence_relations":"Grade 1, grade 2, and grade 3A have Cell Type: centrocyte, centroblast"},
	{"id":"Medical-fb8d613d","source":"Medical","question":"Which grade of FL is characterized only by centroblasts?","answer":"Grade 3B FL is characterized only by centroblasts.","question_type":"Fact Retrieval","evidence":"Grade 3B FL is characterized only by centroblasts.","evidence_relations":"Grade 3B: Cell Type: centroblast"},
	{"id":"Medical-08098847","source":"Medical","question":"What is the main clinical management consideration for FL?","answer":"Not all patients with FL require immediate treatment.","question_type":"Fact Retrieval","evidence":"Not all patients with FL require immediate treatment.","evidence_relations":"Not all patients with FL require immediate treatment"},
	{"id":"Medical-3fb59b05","source":"Medical","question":"What is the disease site for extranodal FL?","answer":"Extranodal FL occurs in tissues outside the lymph nodes.","question_type":"Fact Retrieval","evidence":"Extranodal FL occurs in tissues outside the lymph nodes.","evidence_relations":"FL can present as nodal or extranodal disease"},
	{"id":"Medical-cd57cf13","source":"Medical","question":"Which lymphoma subtype can FL transform into?","answer":"FL can transform into diffuse large B-cell lymphoma (DLBCL).","question_type":"Fact Retrieval","evidence":"FL can transform into diffuse large B-cell lymphoma (DLBCL).","evidence_relations":"FL can transform into DLBCL, a more aggressive lymphoma"},
	{"id":"Medical-d33f62e1","source":"Medical","question":"What is the role of immunophenotyping in FL diagnosis?","answer":"Immunophenotyping is used as a diagnostic method for FL.","question_type":"Fact Retrieval","evidence":"Immunophenotyping is used as a diagnostic method for FL.","evidence_relations":"Diagnostic Method: immunophenotyping"},
	{"id":"Medical-ffc96616","source":"Medical","question":"Which organ is commonly enlarged in FL patients?","answer":"The spleen is commonly enlarged in FL patients.","question_type":"Fact Retrieval","evidence":"The spleen is commonly enlarged in FL patients.","evidence_relations":"Symptoms of FL include swollen lymph nodes, enlarged spleen, fever, night sweats, fatigue, and weight loss (B symptoms)"},
	{"id":"Medical-665744e5","source":"Medical","question":"What is the most common type of primary liver cancer?","answer":"Hepatocellular carcinoma (HCC) is the most common type.","question_type":"Fact Retrieval","evidence":"Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer.","evidence_relations":"Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer"},
	{"id":"Medical-cc93885e","source":"Medical","question":"Which subtype of hepatocellular carcinoma occurs at a younger age?","answer":"Fibrolamellar hepatocellular carcinoma (FLHC) occurs at a younger age.","question_type":"Fact Retrieval","evidence":"Fibrolamellar hepatocellular carcinoma (FLHC) occurs at a younger age.","evidence_relations":"Fibrolamellar hepatocellular carcinoma (FLHC) is a subtype of HCC that occurs at a younger age"},
	{"id":"Medical-682c2e93","source":"Medical","question":"What is intrahepatic cholangiocarcinoma?","answer":"Intrahepatic cholangiocarcinoma is a primary liver cancer of the bile ducts.","question_type":"Fact Retrieval","evidence":"Intrahepatic cholangiocarcinoma is a primary liver cancer of the bile ducts.","evidence_relations":"Intrahepatic cholangiocarcinoma is a primary liver cancer of the bile ducts"},
	{"id":"Medical-fcc037cd","source":"Medical","question":"What defines a mixed-type liver tumor?","answer":"Mixed-type tumors contain both hepatocellular carcinoma and cholangiocarcinoma components.","question_type":"Fact Retrieval","evidence":"Mixed-type liver tumors contain hepatocellular carcinoma components.; Mixed-type liver tumors contain cholangiocarcinoma components.","evidence_relations":"Mixed-type tumors contain both hepatocellular carcinoma and cholangiocarcinoma components"},
	{"id":"Medical-3d95a5f2","source":"Medical","question":"Where does primary liver cancer originate?","answer":"Primary liver cancer originates in the liver.","question_type":"Fact Retrieval","evidence":"Primary liver cancer originates in the liver.","evidence_relations":"Primary liver cancer originates in the liver"},
	{"id":"Medical-0dfddbfc","source":"Medical","question":"What is secondary liver cancer?","answer":"Secondary liver cancer is cancer that has spread to the liver from another organ.","question_type":"Fact Retrieval","evidence":"Secondary liver cancer is cancer that has spread to the liver.; Secondary liver cancer originates from another organ.","evidence_relations":"Secondary liver cancer is cancer that has spread to the liver from another organ"},
	{"id":"Medical-4664e4cf","source":"Medical","question":"What is a major risk factor for developing liver cancer?","answer":"Cirrhosis is a major risk factor for developing liver cancer.","question_type":"Fact Retrieval","evidence":"Cirrhosis is a major risk factor for developing liver cancer.","evidence_relations":"Cirrhosis is a major risk factor for developing liver cancer"},
	{"id":"Medical-135a7719","source":"Medical","question":"How does chronic hepatitis B infection affect liver cancer risk?","answer":"Chronic hepatitis B infection increases the risk of liver cancer.","question_type":"Fact Retrieval","evidence":"Chronic hepatitis B infection increases the risk of liver cancer.","evidence_relations":"Chronic hepatitis B infection increases the risk of liver cancer"},
	{"id":"Medical-33eeb504","source":"Medical","question":"How does chronic hepatitis C infection affect liver cancer risk?","answer":"Chronic hepatitis C infection increases the risk of liver cancer.","question_type":"Fact Retrieval","evidence":"Chronic hepatitis C infection increases the risk of liver cancer.","evidence_relations":"Chronic hepatitis C infection increases the risk of liver cancer"},
	{"id":"Medical-72938445","source":"Medical","question":"Is alcohol use a risk factor for liver cancer?","answer":"Alcohol use is a risk factor for cirrhosis and liver cancer.","question_type":"Fact Retrieval","evidence":"Alcohol use is a risk factor for cirrhosis.; Alcohol use is a risk factor for liver cancer.","evidence_relations":"Alcohol use is a risk factor for cirrhosis and liver cancer"},
	{"id":"Medical-ad9d77bd","source":"Medical","question":"Does non-alcoholic fatty liver disease increase the risk of liver cancer?","answer":"Non-alcoholic fatty liver disease (NAFLD) is a risk factor for cirrhosis and liver cancer.","question_type":"Fact Retrieval","evidence":"Non-alcoholic fatty liver disease (NAFLD) is a risk factor for cirrhosis.; Non-alcoholic fatty liver disease (NAFLD) is a risk factor for liver cancer.","evidence_relations":"Non-alcoholic fatty liver disease (NAFLD) is a risk factor for cirrhosis and liver cancer"},
	{"id":"Medical-2c05b904","source":"Medical","question":"Is genetic hemochromatosis associated with liver cancer risk?","answer":"Genetic hemochromatosis is a risk factor for cirrhosis and liver cancer.","question_type":"Fact Retrieval","evidence":"Genetic hemochromatosis is a risk factor for cirrhosis.; Genetic hemochromatosis is a risk factor for liver cancer.","evidence_relations":"Genetic hemochromatosis is a risk factor for cirrhosis and liver cancer"},
	{"id":"Medical-87c96cae","source":"Medical","question":"Does alpha-1-antitrypsin deficiency increase liver cancer risk?","answer":"Alpha-1-antitrypsin deficiency is a risk factor for cirrhosis and liver cancer.","question_type":"Fact Retrieval","evidence":"Alpha-1-antitrypsin deficiency is a risk factor for cirrhosis.; Alpha-1-antitrypsin deficiency is a risk factor for liver cancer.","evidence_relations":"Alpha-1-antitrypsin deficiency is a risk factor for cirrhosis and liver cancer"},
	{"id":"Medical-d7f052f4","source":"Medical","question":"Is stage 4 primary biliary cholangitis a risk factor for liver cancer?","answer":"Stage 4 primary biliary cholangitis is a risk factor for cirrhosis and liver cancer.","question_type":"Fact Retrieval","evidence":"Stage 4 primary biliary cholangitis is a risk factor for cirrhosis.; Stage 4 primary biliary cholangitis is a risk factor for liver cancer.","evidence_relations":"Stage 4 primary biliary cholangitis is a risk factor for cirrhosis and liver cancer"},
	{"id":"Medical-b73b866c","source":"Medical","question":"Who should undergo screening for liver cancer?","answer":"Screening for liver cancer is recommended for individuals with cirrhosis or chronic hepatitis B.","question_type":"Fact Retrieval","evidence":"Screening for liver cancer is recommended for individuals with cirrhosis.; Screening for liver cancer is recommended for individuals with chronic hepatitis B.","evidence_relations":"Screening for liver cancer is recommended for individuals with cirrhosis or chronic hepatitis B"},
	{"id":"Medical-0c921721","source":"Medical","question":"What screening methods are used for liver cancer?","answer":"Liver cancer screening includes ultrasound and alpha-fetoprotein (AFP) test every 6 months.","question_type":"Fact Retrieval","evidence":"Liver cancer screening includes ultrasound.; Liver cancer screening includes alpha-fetoprotein (AFP) test.; Liver cancer screening is done every 6 months.","evidence_relations":"Liver cancer screening includes ultrasound and alpha-fetoprotein (AFP) test every 6 months"},
	{"id":"Medical-7e444f04","source":"Medical","question":"Which biomarker may indicate primary liver cancer?","answer":"Elevated alpha-fetoprotein (AFP) may indicate primary liver cancer.","question_type":"Fact Retrieval","evidence":"Elevated alpha-fetoprotein (AFP) may indicate primary liver cancer.","evidence_relations":"Elevated AFP may indicate primary liver cancer"},
	{"id":"Medical-4329a9ca","source":"Medical","question":"What tests are usually used to confirm the diagnosis of liver cancer?","answer":"Diagnosis of liver cancer is usually confirmed with imaging tests.","question_type":"Fact Retrieval","evidence":"Diagnosis of liver cancer is usually confirmed with imaging tests.","evidence_relations":"Diagnosis of liver cancer is usually confirmed with imaging tests"},
	{"id":"Medical-36b41c81","source":"Medical","question":"When may a biopsy be needed in liver cancer diagnosis?","answer":"Biopsy may be needed to confirm liver cancer.","question_type":"Fact Retrieval","evidence":"Biopsy may be needed to confirm liver cancer.","evidence_relations":"Biopsy may be needed to confirm liver cancer"},
	{"id":"Medical-73945218","source":"Medical","question":"How can liver cancer spread within the body?","answer":"Liver cancer can spread directly through the liver or to distant sites such as lung or bone.","question_type":"Fact Retrieval","evidence":"Liver cancer can spread directly through the liver.; Liver cancer can spread to distant sites such as the lung.; Liver cancer can spread to distant sites such as bone.","evidence_relations":"Liver cancer can spread directly through the liver or to distant sites such as lung or bone"},
	{"id":"Medical-f4ba3ee9","source":"Medical","question":"What are common sites of liver cancer metastasis?","answer":"Liver cancer most often metastasizes to the lung or bone.","question_type":"Fact Retrieval","evidence":"Liver cancer most often metastasizes to the lung.; Liver cancer most often metastasizes to bone.","evidence_relations":"Liver cancer most often metastasizes to the lung or bone"},
	{"id":"Medical-ff8f3b0c","source":"Medical","question":"What anatomical structure is the origin of primary liver cancer?","answer":"The liver is the origin of primary liver cancer.","question_type":"Fact Retrieval","evidence":"The liver is the origin of primary liver cancer.","evidence_relations":"Primary liver cancer originates in the liver"},
	{"id":"Medical-10ad8346","source":"Medical","question":"Which anatomical structure is affected in intrahepatic cholangiocarcinoma?","answer":"The bile ducts are affected in intrahepatic cholangiocarcinoma.","question_type":"Fact Retrieval","evidence":"The bile ducts are affected in intrahepatic cholangiocarcinoma.","evidence_relations":"Intrahepatic cholangiocarcinoma is a primary liver cancer of the bile ducts"},
	{"id":"Medical-67178f3b","source":"Medical","question":"What is the relationship between cirrhosis and liver cancer?","answer":"Cirrhosis is a major risk factor for developing liver cancer.","question_type":"Fact Retrieval","evidence":"Cirrhosis is a major risk factor for developing liver cancer.","evidence_relations":"Cirrhosis is a major risk factor for developing liver cancer"},
	{"id":"Medical-4eb4395b","source":"Medical","question":"What is the role of ultrasound in liver cancer?","answer":"Ultrasound is used as a screening method for liver cancer.","question_type":"Fact Retrieval","evidence":"Ultrasound is used as a screening method for liver cancer.","evidence_relations":"Liver cancer screening includes ultrasound and alpha-fetoprotein (AFP) test every 6 months"},
	{"id":"Medical-ce8ad4ae","source":"Medical","question":"What is the function of the alpha-fetoprotein (AFP) test in liver cancer?","answer":"The alpha-fetoprotein (AFP) test is used as a screening method and elevated levels may indicate primary liver cancer.","question_type":"Fact Retrieval","evidence":"The alpha-fetoprotein (AFP) test is used as a screening method for liver cancer.; Elevated levels of alpha-fetoprotein (AFP) may indicate primary liver cancer.","evidence_relations":"Liver cancer screening includes ultrasound and alpha-fetoprotein (AFP) test every 6 months; Elevated AFP may indicate primary liver cancer"},
	{"id":"Medical-aece5feb","source":"Medical","question":"Which genetic alteration is a risk factor for liver cancer?","answer":"Genetic hemochromatosis is a risk factor for cirrhosis and liver cancer.","question_type":"Fact Retrieval","evidence":"Genetic hemochromatosis is a risk factor for cirrhosis.; Genetic hemochromatosis is a risk factor for liver cancer.","evidence_relations":"Genetic hemochromatosis is a risk factor for cirrhosis and liver cancer"},
	{"id":"Medical-8c555476","source":"Medical","question":"What is the origin of secondary liver cancer?","answer":"Secondary liver cancer originates from other primary cancers such as colon cancer.","question_type":"Fact Retrieval","evidence":"Secondary liver cancer originates from other primary cancers.; Colon cancer can be a primary cancer that leads to secondary liver cancer.","evidence_relations":"Secondary liver cancer is cancer that has spread to the liver from another organ; Other primary cancers (e.g., colon cancer) are the origin"},
	{"id":"Medical-3c025533","source":"Medical","question":"Which diagnostic methods are listed for liver cancer in the ontology?","answer":"Imaging tests and biopsy are diagnostic methods for liver cancer.","question_type":"Fact Retrieval","evidence":"Imaging tests are diagnostic methods for liver cancer.; Biopsy is a diagnostic method for liver cancer.","evidence_relations":"Diagnosis of liver cancer is usually confirmed with imaging tests; Biopsy may be needed to confirm liver cancer"},
	{"id":"Medical-44eed7f9","source":"Medical","question":"Which liver cancer subtype is listed under hepatocellular carcinoma in the ontology?","answer":"Fibrolamellar hepatocellular carcinoma (FLHC) is a subtype of hepatocellular carcinoma.","question_type":"Fact Retrieval","evidence":"Fibrolamellar hepatocellular carcinoma (FLHC) is a subtype of hepatocellular carcinoma.","evidence_relations":"Fibrolamellar hepatocellular carcinoma (FLHC) is a subtype of HCC that occurs at a younger age"},
	{"id":"Medical-f4b744e6","source":"Medical","question":"What are the main subtypes of thyroid cancer?","answer":"Thyroid cancer is classified into papillary, follicular, oncocytic, medullary, and anaplastic subtypes.","question_type":"Fact Retrieval","evidence":"Thyroid cancer is classified into papillary subtypes.; Thyroid cancer is classified into follicular subtypes.; Thyroid cancer is classified into oncocytic subtypes.; Thyroid cancer is classified into medullary subtypes.; Thyroid cancer is classified into anaplastic subtypes.","evidence_relations":"Thyroid cancer is classified into papillary, follicular, oncocytic, medullary, and anaplastic subtypes"},
	{"id":"Medical-1517e1c3","source":"Medical","question":"Which thyroid cancer subtype is the most common?","answer":"Papillary thyroid carcinoma is the most common thyroid cancer.","question_type":"Fact Retrieval","evidence":"Papillary thyroid carcinoma is the most common thyroid cancer.","evidence_relations":"Papillary thyroid carcinoma is the most common thyroid cancer"},
	{"id":"Medical-9671d373","source":"Medical","question":"What is another name for oncocytic carcinoma?","answer":"Oncocytic carcinoma is also known as Hrthle cell carcinoma.","question_type":"Fact Retrieval","evidence":"Oncocytic carcinoma is also known as Hrthle cell carcinoma.","evidence_relations":"Oncocytic carcinoma is also known as Hrthle cell carcinoma"},
	{"id":"Medical-63709f72","source":"Medical","question":"Which thyroid cancer subtype is the rarest and most aggressive?","answer":"Anaplastic thyroid cancer is the most aggressive and rarest subtype.","question_type":"Fact Retrieval","evidence":"Anaplastic thyroid cancer is the rarest subtype of thyroid cancer.; Anaplastic thyroid cancer is the most aggressive subtype of thyroid cancer.","evidence_relations":"Anaplastic thyroid cancer is the most aggressive and rarest subtype"},
	{"id":"Medical-11483e85","source":"Medical","question":"What genetic alteration is associated with medullary thyroid cancer?","answer":"Medullary thyroid cancer is associated with RET gene fusion.","question_type":"Fact Retrieval","evidence":"Medullary thyroid cancer is associated with RET gene fusion.","evidence_relations":"Medullary thyroid cancer can be inherited and is associated with RET gene fusion"},
	{"id":"Medical-43cdd405","source":"Medical","question":"What are the main risk factors for thyroid cancer?","answer":"Radiation exposure to the head or neck, family history, and inherited syndromes increase risk.","question_type":"Fact Retrieval","evidence":"Radiation exposure to the head or neck increases the risk of thyroid cancer.; Family history increases the risk of thyroid cancer.; Inherited syndromes increase the risk of thyroid cancer.","evidence_relations":"Radiation exposure to the head or neck increases risk of thyroid cancer; Family history and inherited syndromes (FAP, Carney complex, Cowden syndrome, MEN) increase risk"},
	{"id":"Medical-1068c5b7","source":"Medical","question":"Which inherited syndromes are linked to increased thyroid cancer risk?","answer":"FAP, Carney complex, Cowden syndrome, and MEN are inherited syndromes linked to increased thyroid cancer risk.","question_type":"Fact Retrieval","evidence":"FAP is an inherited syndrome linked to increased thyroid cancer risk.; Carney complex is an inherited syndrome linked to increased thyroid cancer risk.; Cowden syndrome is an inherited syndrome linked to increased thyroid cancer risk.; MEN is an inherited syndrome linked to increased thyroid cancer risk.","evidence_relations":"Family history and inherited syndromes (FAP, Carney complex, Cowden syndrome, MEN) increase risk"},
	{"id":"Medical-e21aceef","source":"Medical","question":"What symptoms can large thyroid nodules cause?","answer":"Symptoms of large thyroid nodules include visible neck lump, neck pain, voice changes, trouble breathing, and swallowing problems.","question_type":"Fact Retrieval","evidence":"Large thyroid nodules can cause a visible neck lump.; Large thyroid nodules can cause neck pain.; Large thyroid nodules can cause voice changes.; Large thyroid nodules can cause trouble breathing.; Large thyroid nodules can cause swallowing problems.","evidence_relations":"Symptoms of large thyroid nodules include visible neck lump, neck pain, voice changes, trouble breathing, and swallowing problems"},
	{"id":"Medical-3226c376","source":"Medical","question":"Which tests are recommended for evaluating thyroid nodules?","answer":"TSH blood test and neck ultrasound are recommended for evaluation of thyroid nodules.","question_type":"Fact Retrieval","evidence":"TSH blood test is recommended for evaluating thyroid nodules.; Neck ultrasound is recommended for evaluating thyroid nodules.","evidence_relations":"TSH blood test and neck ultrasound are recommended for evaluation of thyroid nodules"},
	{"id":"Medical-420f3886","source":"Medical","question":"What procedure is used to sample suspicious thyroid nodules?","answer":"Fine-needle aspiration biopsy is used to sample suspicious thyroid nodules.","question_type":"Fact Retrieval","evidence":"Fine-needle aspiration biopsy is used to sample suspicious thyroid nodules.","evidence_relations":"Fine-needle aspiration biopsy is used to sample suspicious thyroid nodules"},
	{"id":"Medical-bedfa4d0","source":"Medical","question":"What is the main treatment for most thyroid cancers?","answer":"Surgery is the main treatment for most thyroid cancers.","question_type":"Fact Retrieval","evidence":"Surgery is the main treatment for most thyroid cancers.","evidence_relations":"Surgery is the main treatment for most thyroid cancers"},
	{"id":"Medical-06892ea0","source":"Medical","question":"When is lobectomy considered for thyroid cancer?","answer":"Lobectomy is an option for small, low-risk differentiated thyroid cancers.","question_type":"Fact Retrieval","evidence":"Lobectomy is considered for small, low-risk differentiated thyroid cancers.","evidence_relations":"Lobectomy is an option for small, low-risk differentiated thyroid cancers"},
	{"id":"Medical-219d2cb0","source":"Medical","question":"What is the recommended surgery for larger or invasive thyroid cancers?","answer":"Total thyroidectomy is recommended for larger, invasive, or high-risk cancers.","question_type":"Fact Retrieval","evidence":"Total thyroidectomy is recommended for larger thyroid cancers.; Total thyroidectomy is recommended for invasive thyroid cancers.; Total thyroidectomy is recommended for high-risk thyroid cancers.","evidence_relations":"Total thyroidectomy is recommended for larger, invasive, or high-risk cancers"},
	{"id":"Medical-d5a2a39b","source":"Medical","question":"What additional surgical procedure is performed if lymph nodes are involved in thyroid cancer?","answer":"Neck dissection is performed if lymph nodes are involved.","question_type":"Fact Retrieval","evidence":"Neck dissection is performed if lymph nodes are involved in thyroid cancer.","evidence_relations":"Neck dissection is performed if lymph nodes are involved"},
	{"id":"Medical-5a111bc2","source":"Medical","question":"What therapy is required after total thyroidectomy?","answer":"Thyroid hormone replacement therapy is required after total thyroidectomy.","question_type":"Fact Retrieval","evidence":"Thyroid hormone replacement therapy is required after total thyroidectomy.","evidence_relations":"Thyroid hormone replacement therapy is required after total thyroidectomy"},
	{"id":"Medical-2e96fdbb","source":"Medical","question":"What is the standard medication for thyroid hormone replacement?","answer":"Levothyroxine is the standard thyroid hormone replacement.","question_type":"Fact Retrieval","evidence":"Levothyroxine is the standard thyroid hormone replacement.","evidence_relations":"Levothyroxine is the standard thyroid hormone replacement"},
	{"id":"Medical-74ed1afe","source":"Medical","question":"For which thyroid cancer subtypes is RAI therapy not effective?","answer":"RAI therapy is not effective for medullary or anaplastic thyroid cancer.","question_type":"Fact Retrieval","evidence":"RAI therapy is not effective for medullary thyroid cancer.; RAI therapy is not effective for anaplastic thyroid cancer.","evidence_relations":"RAI therapy is not effective for medullary or anaplastic thyroid cancer"},
	{"id":"Medical-dffcdcf8","source":"Medical","question":"What treatment is used for anaplastic, recurrent, or metastatic thyroid cancers not amenable to surgery or RAI?","answer":"External beam radiation therapy is used for anaplastic, recurrent, or metastatic cancers not amenable to surgery or RAI.","question_type":"Fact Retrieval","evidence":"External beam radiation therapy is used for anaplastic thyroid cancers.; External beam radiation therapy is used for recurrent thyroid cancers.; External beam radiation therapy is used for metastatic thyroid cancers not amenable to surgery or RAI.","evidence_relations":"External beam radiation therapy is used for anaplastic, recurrent, or metastatic cancers not amenable to surgery or RAI"},
	{"id":"Medical-130e07e9","source":"Medical","question":"When is targeted therapy indicated in thyroid cancer?","answer":"Targeted therapy (kinase inhibitors) is used for cancers not responsive to surgery or RAI, or with metastasis.","question_type":"Fact Retrieval","evidence":"Targeted therapy is used for thyroid cancers not responsive to surgery.; Targeted therapy is used for thyroid cancers not responsive to RAI.; Targeted therapy is used for thyroid cancers with metastasis.","evidence_relations":"Targeted therapy (kinase inhibitors) is used for cancers not responsive to surgery or RAI, or with metastasis"},
	{"id":"Medical-7e564d1e","source":"Medical","question":"Which targeted therapies are used for progressive, unresectable, or metastatic thyroid cancer?","answer":"Lenvatinib, sorafenib, and cabozantinib are targeted therapies for progressive, unresectable, or metastatic thyroid cancer.","question_type":"Fact Retrieval","evidence":"Lenvatinib is a targeted therapy for progressive thyroid cancer.; Sorafenib is a targeted therapy for unresectable thyroid cancer.; Cabozantinib is a targeted therapy for metastatic thyroid cancer.","evidence_relations":"Lenvatinib, sorafenib, and cabozantinib are targeted therapies for progressive, unresectable, or metastatic thyroid cancer"},
	{"id":"Medical-dc537cd7","source":"Medical","question":"What is the role of chemotherapy in thyroid cancer?","answer":"Chemotherapy is rarely effective and mainly used for anaplastic thyroid cancer with radiation.","question_type":"Fact Retrieval","evidence":"Chemotherapy is rarely effective in thyroid cancer.; Chemotherapy is mainly used for anaplastic thyroid cancer with radiation.","evidence_relations":"Chemotherapy is rarely effective, mainly used for anaplastic thyroid cancer with radiation"},
	{"id":"Medical-af243069","source":"Medical","question":"What biomarkers are recommended for testing in recurrent, advanced, or metastatic thyroid cancers not treatable with RAI?","answer":"Biomarkers include ALK fusion, NTRK fusion, BRAF mutation, RET fusion, dMMR, MSI-H, and TMB-H.","question_type":"Fact Retrieval","evidence":"Biomarkers recommended for testing in recurrent thyroid cancers include ALK fusion.; Biomarkers recommended for testing in recurrent thyroid cancers include NTRK fusion.; Biomarkers recommended for testing in recurrent thyroid cancers include BRAF mutation.; Biomarkers recommended for testing in recurrent thyroid cancers include RET fusion.; Biomarkers recommended for testing in recurrent thyroid cancers include dMMR.; Biomarkers recommended for testing in recurrent thyroid cancers include MSI-H.; Biomarkers recommended for testing in recurrent thyroid cancers include TMB-H.","evidence_relations":"Biomarkers include ALK fusion, NTRK fusion, BRAF mutation, RET fusion, dMMR, MSI-H, TMB-H"},
	{"id":"Medical-8a22c205","source":"Medical","question":"What follow-up is recommended after total thyroidectomy?","answer":"Follow-up after total thyroidectomy includes physical exam, blood tests (TSH, Tg, Tg ab), and neck ultrasound.","question_type":"Fact Retrieval","evidence":"Follow-up after total thyroidectomy includes a physical exam.; Follow-up after total thyroidectomy includes blood tests for TSH.; Follow-up after total thyroidectomy includes blood tests for Tg.; Follow-up after total thyroidectomy includes blood tests for Tg ab.; Follow-up after total thyroidectomy includes a neck ultrasound.","evidence_relations":"Follow-up after treatment includes physical exam, blood tests (TSH, Tg, Tg ab), and neck ultrasound"},
	{"id":"Medical-0ad1bc85","source":"Medical","question":"What may rising thyroglobulin after thyroidectomy indicate?","answer":"Rising thyroglobulin after thyroidectomy may indicate recurrence.","question_type":"Fact Retrieval","evidence":"Rising thyroglobulin after thyroidectomy may indicate recurrence.","evidence_relations":"Rising thyroglobulin after thyroidectomy may indicate recurrence"},
	{"id":"Medical-cdd407be","source":"Medical","question":"To which organs does metastatic thyroid cancer most commonly spread?","answer":"Metastatic thyroid cancer most commonly spreads to lungs, liver, bones, brain, and spinal cord.","question_type":"Fact Retrieval","evidence":"Metastatic thyroid cancer most commonly spreads to the lungs.; Metastatic thyroid cancer most commonly spreads to the liver.; Metastatic thyroid cancer most commonly spreads to the bones.; Metastatic thyroid cancer most commonly spreads to the brain.; Metastatic thyroid cancer most commonly spreads to the spinal cord.","evidence_relations":"Metastatic thyroid cancer most commonly spreads to lungs, liver, bones, brain, and spinal cord"},
	{"id":"Medical-ccfe8840","source":"Medical","question":"What is an option for very-low-risk papillary thyroid cancers?","answer":"Active surveillance is an option for very-low-risk papillary thyroid cancers.","question_type":"Fact Retrieval","evidence":"Active surveillance is an option for very-low-risk papillary thyroid cancers.","evidence_relations":"Active surveillance is an option for very-low-risk papillary thyroid cancers"},
	{"id":"Medical-880faffb","source":"Medical","question":"What laboratory tests are included in the follow-up of thyroid cancer?","answer":"Laboratory tests include TSH, thyroglobulin (Tg), and anti-thyroglobulin antibodies (Tg ab).","question_type":"Fact Retrieval","evidence":"Laboratory tests include TSH.; Laboratory tests include thyroglobulin (Tg).; Laboratory tests include anti-thyroglobulin antibodies (Tg ab).","evidence_relations":"Laboratory: [\"TSH test\", \"Thyroglobulin (Tg)\", \"Anti-thyroglobulin antibodies (Tg ab)\"]"},
	{"id":"Medical-f944ae15","source":"Medical","question":"Which imaging methods are used for thyroid cancer diagnosis?","answer":"Imaging methods include ultrasound, neck ultrasound, CT scan, MRI, and whole-body RAI scan.","question_type":"Fact Retrieval","evidence":"Imaging methods include ultrasound.; Imaging methods include neck ultrasound.; Imaging methods include CT scan.; Imaging methods include MRI.; Imaging methods include whole-body RAI scan.","evidence_relations":"Imaging: [\"Ultrasound\", \"Neck ultrasound\", \"CT scan\", \"MRI\", \"Whole-body RAI scan\"]"},
	{"id":"Medical-666afa8e","source":"Medical","question":"What is the purpose of molecular tests in thyroid cancer diagnosis?","answer":"Molecular tests can help determine malignancy and need for surgery.","question_type":"Fact Retrieval","evidence":"Molecular tests can help determine malignancy.; Molecular tests can help determine the need for surgery.","evidence_relations":"Molecular tests can help determine malignancy and need for surgery"},
	{"id":"Medical-db48e1e1","source":"Medical","question":"What is the recommended treatment for localized thyroid cancer?","answer":"Treatment for localized thyroid cancer includes surgery (lobectomy or total thyroidectomy) and RAI therapy if indicated.","question_type":"Fact Retrieval","evidence":"Treatment for localized thyroid cancer includes surgery.; Surgery for localized thyroid cancer may be a lobectomy.; Surgery for localized thyroid cancer may be a total thyroidectomy.; RAI therapy may be indicated for localized thyroid cancer.","evidence_relations":"Localized: {\"Treatment\": [\"Surgery (lobectomy or total thyroidectomy)\", \"RAI therapy (if indicated)\"]}"},
	{"id":"Medical-d184bb36","source":"Medical","question":"What is the recommended treatment for regional thyroid cancer with lymph node involvement?","answer":"Treatment includes surgery with neck dissection and RAI therapy if indicated.","question_type":"Fact Retrieval","evidence":"Treatment for regional thyroid cancer with lymph node involvement includes surgery.; Surgery for regional thyroid cancer may include neck dissection.; RAI therapy may be indicated for regional thyroid cancer with lymph node involvement.","evidence_relations":"Regional (lymph node involvement): {\"Treatment\": [\"Surgery with neck dissection\", \"RAI therapy (if indicated)\"]}"},
	{"id":"Medical-4e0348b9","source":"Medical","question":"What are the treatment options for thyroid cancer with distant metastasis?","answer":"Treatment options for distant metastasis include RAI therapy (if iodine-avid), targeted therapy, external beam radiation therapy, chemotherapy (for anaplastic), and clinical trial.","question_type":"Fact Retrieval","evidence":"Treatment options for distant metastasis include RAI therapy if iodine-avid.; Treatment options for distant metastasis include targeted therapy.; Treatment options for distant metastasis include external beam radiation therapy.; Treatment options for distant metastasis include chemotherapy for anaplastic thyroid cancer.; Treatment options for distant metastasis include clinical trial.","evidence_relations":"Distant metastasis: {\"Treatment\": [\"RAI therapy (if iodine-avid)\", \"Targeted therapy\", \"External beam radiation therapy\", \"Chemotherapy (for anaplastic)\", \"Clinical trial\"]}"},
	{"id":"Medical-35f5fbd3","source":"Medical","question":"Which gene mutations are considered actionable biomarkers in thyroid cancer?","answer":"Actionable biomarkers include BRAF gene mutation, RET gene fusion, ALK gene fusion, and NTRK gene fusion.","question_type":"Fact Retrieval","evidence":"Actionable biomarkers in thyroid cancer include BRAF gene mutation.; Actionable biomarkers in thyroid cancer include RET gene fusion.; Actionable biomarkers in thyroid cancer include ALK gene fusion.; Actionable biomarkers in thyroid cancer include NTRK gene fusion.","evidence_relations":"Biomarker: [\"BRAF gene mutation\", \"RET gene fusion\", \"ALK gene fusion\", \"NTRK gene fusion\"]"},
	{"id":"Medical-f8d40959","source":"Medical","question":"What is the primary method for detecting recurrence in thyroid cancer?","answer":"Detection of recurrence is primarily by rising thyroglobulin, neck ultrasound, and imaging (CT, MRI).","question_type":"Fact Retrieval","evidence":"The primary method for detecting recurrence in thyroid cancer is rising thyroglobulin.; Neck ultrasound is a method for detecting recurrence in thyroid cancer.; Imaging methods such as CT and MRI are used to detect recurrence in thyroid cancer.","evidence_relations":"Recurrence: {\"Detection\": [\"Rising thyroglobulin\", \"Neck ultrasound\", \"Imaging (CT, MRI)\"]}"},
	{"id":"Medical-edb040bb","source":"Medical","question":"What is the origin of primary bone cancer?","answer":"Primary bone cancer originates in bone or cartilage.","question_type":"Fact Retrieval","evidence":"Primary bone cancer originates in bone.; Primary bone cancer originates in cartilage.","evidence_relations":"Primary bone cancer originates in bone or cartilage"},
	{"id":"Medical-84c13f69","source":"Medical","question":"What are secondary bone malignancies?","answer":"Secondary bone malignancies are cancers that have metastasized to bone from other organs.","question_type":"Fact Retrieval","evidence":"Secondary bone malignancies are cancers that have metastasized to bone.; Secondary bone malignancies originate from other organs.","evidence_relations":"Secondary bone malignancies are cancers that have metastasized to bone from other organs"},
	{"id":"Medical-2bd43819","source":"Medical","question":"Which cancers commonly metastasize to bone?","answer":"Breast cancer, lung cancer, and kidney cancer can metastasize to bone.","question_type":"Fact Retrieval","evidence":"Breast cancer can metastasize to bone.; Lung cancer can metastasize to bone.; Kidney cancer can metastasize to bone.","evidence_relations":"Secondary bone malignancy: Origin: [Breast cancer, Lung cancer, Kidney cancer]"},
	{"id":"Medical-6580dc7a","source":"Medical","question":"What are the main subtypes of bone sarcoma?","answer":"Bone sarcomas include osteosarcoma, Ewing sarcoma, chondrosarcoma, chordoma, and giant cell tumor of bone.","question_type":"Fact Retrieval","evidence":"Bone sarcomas include osteosarcoma.; Bone sarcomas include Ewing sarcoma.; Bone sarcomas include chondrosarcoma.; Bone sarcomas include chordoma.; Bone sarcomas include giant cell tumor of bone.","evidence_relations":"Bone sarcomas include osteosarcoma, Ewing sarcoma, chondrosarcoma, chordoma, and giant cell tumor of bone"},
	{"id":"Medical-9a0c1ed4","source":"Medical","question":"Where does osteosarcoma most commonly arise?","answer":"Osteosarcoma commonly arises in the metaphysis near growth plates.","question_type":"Fact Retrieval","evidence":"Osteosarcoma commonly arises in the metaphysis.; Osteosarcoma commonly arises near growth plates.","evidence_relations":"Osteosarcoma commonly arises in the metaphysis near growth plates"},
	{"id":"Medical-0cac50ed","source":"Medical","question":"What is the characteristic genetic alteration in Ewing sarcoma?","answer":"Ewing sarcoma is characterized by EWSR1-ETS gene fusions, most commonly EWSR1-FLI1.","question_type":"Fact Retrieval","evidence":"Ewing sarcoma is characterized by EWSR1-ETS gene fusions.; The most common gene fusion in Ewing sarcoma is EWSR1-FLI1.","evidence_relations":"Ewing sarcoma is characterized by EWSR1-ETS gene fusions, most commonly EWSR1-FLI1"},
	{"id":"Medical-122b1d5d","source":"Medical","question":"Which bone cancer subtype starts in cartilage-forming cells?","answer":"Chondrosarcoma starts in cartilage-forming cells.","question_type":"Fact Retrieval","evidence":"Chondrosarcoma starts in cartilage-forming cells.","evidence_relations":"Chondrosarcoma starts in cartilage-forming cells"},
	{"id":"Medical-54f08470","source":"Medical","question":"From which cells does chordoma arise?","answer":"Chordoma arises from notochordal cells.","question_type":"Fact Retrieval","evidence":"Chordoma arises from notochordal cells.","evidence_relations":"Chordoma arises from notochordal cells, typically in the sacrum or base of skull"},
	{"id":"Medical-eefdc433","source":"Medical","question":"What anatomic locations are typical for chordoma?","answer":"Chordoma typically arises in the sacrum or base of skull.","question_type":"Fact Retrieval","evidence":"Chordoma typically arises in the sacrum.; Chordoma typically arises at the base of the skull.","evidence_relations":"Chordoma arises from notochordal cells, typically in the sacrum or base of skull"},
	{"id":"Medical-6ded047c","source":"Medical","question":"Where does giant cell tumor of bone often occur?","answer":"Giant cell tumor of bone often occurs in the metaphysis and epiphysis.","question_type":"Fact Retrieval","evidence":"Giant cell tumor of bone often occurs in the metaphysis.; Giant cell tumor of bone often occurs in the epiphysis.","evidence_relations":"Giant cell tumor of bone often occurs in the metaphysis and epiphysis"},
	{"id":"Medical-dc9df053","source":"Medical","question":"Which imaging tests are used for bone cancer diagnosis?","answer":"Imaging tests for bone cancer include X-ray, bone scan, CT scan, MRI, and PET scan.","question_type":"Fact Retrieval","evidence":"Imaging tests for bone cancer include X-ray.; Imaging tests for bone cancer include bone scan.; Imaging tests for bone cancer include CT scan.; Imaging tests for bone cancer include MRI.; Imaging tests for bone cancer include PET scan.","evidence_relations":"Imaging tests for bone cancer include X-ray, bone scan, CT scan, MRI, and PET scan"},
	{"id":"Medical-c39b1031","source":"Medical","question":"How is the diagnosis of bone cancer confirmed?","answer":"Diagnosis of bone cancer is confirmed by core needle or surgical biopsy.","question_type":"Fact Retrieval","evidence":"Diagnosis of bone cancer is confirmed by core needle biopsy.; Diagnosis of bone cancer is confirmed by surgical biopsy.","evidence_relations":"Diagnosis of bone cancer is confirmed by core needle or surgical biopsy"},
	{"id":"Medical-38953b85","source":"Medical","question":"What blood tests are used in the evaluation of bone cancer?","answer":"Blood tests such as alkaline phosphatase, CBC, CMP, and LDH are used in evaluation.","question_type":"Fact Retrieval","evidence":"Blood tests used in the evaluation of bone cancer include alkaline phosphatase.; Blood tests used in the evaluation of bone cancer include CBC.; Blood tests used in the evaluation of bone cancer include CMP.; Blood tests used in the evaluation of bone cancer include LDH.","evidence_relations":"Blood tests such as alkaline phosphatase, CBC, CMP, and LDH are used in evaluation"},
	{"id":"Medical-0fcdee63","source":"Medical","question":"What is the purpose of genetic cancer risk testing in bone cancer?","answer":"Genetic cancer risk testing identifies germline mutations associated with increased cancer risk.","question_type":"Fact Retrieval","evidence":"Genetic cancer risk testing identifies germline mutations.; Germline mutations are associated with increased cancer risk.","evidence_relations":"Genetic cancer risk testing identifies germline mutations associated with increased cancer risk"},
	{"id":"Medical-856e9c5c","source":"Medical","question":"What does biomarker testing in bone cancer include?","answer":"Biomarker testing includes identification of gene mutations (e.g., IDH1), protein expression, and tumor mutational burden.","question_type":"Fact Retrieval","evidence":"Biomarker testing includes identification of gene mutations.; Biomarker testing includes protein expression.; Biomarker testing includes tumor mutational burden.","evidence_relations":"Biomarker testing includes identification of gene mutations (e.g., IDH1), protein expression, and tumor mutational burden"},
	{"id":"Medical-4dc9127d","source":"Medical","question":"Which mutation in chondrosarcoma can be targeted with ivosidenib?","answer":"IDH1 mutation in chondrosarcoma can be targeted with ivosidenib.","question_type":"Fact Retrieval","evidence":"IDH1 mutation in chondrosarcoma can be targeted with ivosidenib.","evidence_relations":"IDH1 mutation in chondrosarcoma can be targeted with ivosidenib"},
	{"id":"Medical-54b3e97f","source":"Medical","question":"Which status may be treated with pembrolizumab in bone cancer?","answer":"MSI-H/dMMR status may be treated with pembrolizumab.","question_type":"Fact Retrieval","evidence":"MSI-H/dMMR status may be treated with pembrolizumab.","evidence_relations":"MSI-H/dMMR status may be treated with pembrolizumab"},
	{"id":"Medical-7dd6e939","source":"Medical","question":"What treatments are available for tumor mutational burden-high (TMB-H) bone cancers?","answer":"TMB-H may be treated with pembrolizumab, nivolumab, or ipilimumab.","question_type":"Fact Retrieval","evidence":"TMB-H may be treated with pembrolizumab.; TMB-H may be treated with nivolumab.; TMB-H may be treated with ipilimumab.","evidence_relations":"Tumor mutational burden-high (TMB-H) may be treated with pembrolizumab, nivolumab, or ipilimumab"},
	{"id":"Medical-142025a5","source":"Medical","question":"What system is used for staging bone cancer?","answer":"Staging uses the TNM system: T (tumor size/location), N (lymph node involvement), M (metastasis).","question_type":"Fact Retrieval","evidence":"Staging of bone cancer uses the TNM system.; The TNM system includes T for tumor size/location.; The TNM system includes N for lymph node involvement.; The TNM system includes M for metastasis.","evidence_relations":"Staging uses the TNM system: T (tumor size/location), N (lymph node involvement), M (metastasis)"},
	{"id":"Medical-0b0c4cf9","source":"Medical","question":"How is tumor grade described in bone cancer?","answer":"Tumor grade describes histologic differentiation.","question_type":"Fact Retrieval","evidence":"Tumor grade describes histologic differentiation.","evidence_relations":"Tumor grade (G) describes histologic differentiation"},
	{"id":"Medical-8f43b36b","source":"Medical","question":"How is the stage of bone cancer determined?","answer":"Stage is determined by combining T, N, M, and G scores.","question_type":"Fact Retrieval","evidence":"Stage of bone cancer is determined by combining T scores.; Stage of bone cancer is determined by combining N scores.; Stage of bone cancer is determined by combining M scores.; Stage of bone cancer is determined by combining G scores.","evidence_relations":"Stage is determined by combining T, N, M, and G scores"},
	{"id":"Medical-712b02a6","source":"Medical","question":"Which performance status scales are used in bone cancer treatment planning?","answer":"ECOG performance status and Karnofsky Performance Status (KPS) are considered in treatment planning.","question_type":"Fact Retrieval","evidence":"ECOG performance status is used in bone cancer treatment planning.; Karnofsky Performance Status (KPS) is used in bone cancer treatment planning.","evidence_relations":"Performance status (ECOG or KPS) is considered in treatment planning"},
	{"id":"Medical-5a2979a1","source":"Medical","question":"Why should fertility preservation be discussed before bone cancer treatment?","answer":"Some treatments for bone cancer can affect fertility; fertility preservation should be discussed before treatment.","question_type":"Fact Retrieval","evidence":"Some treatments for bone cancer can affect fertility.; Fertility preservation should be discussed before bone cancer treatment.","evidence_relations":"Some treatments for bone cancer can affect fertility; fertility preservation should be discussed before treatment"},
	{"id":"Medical-7ced180c","source":"Medical","question":"What metabolic complication can bone cancer cause?","answer":"Bone cancer can cause hypercalcemia due to bone destruction.","question_type":"Fact Retrieval","evidence":"Bone cancer can cause hypercalcemia.; Hypercalcemia is due to bone destruction.","evidence_relations":"Bone cancer can cause hypercalcemia due to bone destruction"},
	{"id":"Medical-45b7e7da","source":"Medical","question":"Where can bone cancer spread?","answer":"Bone cancer can spread to lungs, other bones, or distant organs.","question_type":"Fact Retrieval","evidence":"Bone cancer can spread to the lungs.; Bone cancer can spread to other bones.; Bone cancer can spread to distant organs.","evidence_relations":"Bone cancer can spread to lungs, other bones, or distant organs"},
	{"id":"Medical-4a90fe75","source":"Medical","question":"Which gene fusions are biomarkers for Ewing sarcoma?","answer":"EWSR1-FLI1 fusion and EWSR1-ERG fusion are biomarkers for Ewing sarcoma.","question_type":"Fact Retrieval","evidence":"EWSR1-FLI1 fusion is a biomarker for Ewing sarcoma.; EWSR1-ERG fusion is a biomarker for Ewing sarcoma.","evidence_relations":"Ewing sarcoma is characterized by EWSR1-ETS gene fusions, most commonly EWSR1-FLI1"},
	{"id":"Medical-a07284fb","source":"Medical","question":"What is the role of alkaline phosphatase in bone cancer evaluation?","answer":"Alkaline phosphatase is used as a blood test in the evaluation of bone cancer.","question_type":"Fact Retrieval","evidence":"Alkaline phosphatase is used as a blood test in the evaluation of bone cancer.","evidence_relations":"Blood tests such as alkaline phosphatase, CBC, CMP, and LDH are used in evaluation"},
	{"id":"Medical-9418792b","source":"Medical","question":"Which diagnostic methods are used for bone sarcomas?","answer":"Diagnostic methods for bone sarcomas include X-ray, bone scan, CT scan, MRI, PET scan, and biopsy.","question_type":"Fact Retrieval","evidence":"X-ray is a diagnostic method for bone sarcomas.; Bone scan is a diagnostic method for bone sarcomas.; CT scan is a diagnostic method for bone sarcomas.; MRI is a diagnostic method for bone sarcomas.; PET scan is a diagnostic method for bone sarcomas.; Biopsy is a diagnostic method for bone sarcomas.","evidence_relations":"Osteosarcoma: Diagnostic Method: [X-ray, Bone scan, CT scan, MRI, PET scan, Biopsy]"},
	{"id":"Medical-6b20ca96","source":"Medical","question":"Which genetic alteration is associated with Ewing sarcoma?","answer":"Ewing sarcoma is associated with the t(11;22) translocation.","question_type":"Fact Retrieval","evidence":"Ewing sarcoma is associated with the t(11;22) translocation.","evidence_relations":"Ewing sarcoma: Genetic Alteration: [t(11;22) translocation]"},
	{"id":"Medical-7a495600","source":"Medical","question":"What are the main risk factors for bone cancer?","answer":"Family history of cancer and germline mutations are risk factors for bone cancer.","question_type":"Fact Retrieval","evidence":"Family history of cancer is a risk factor for bone cancer.; Germline mutations are a risk factor for bone cancer.","evidence_relations":"Risk Factor: [Family history of cancer, Germline mutations]"},
	{"id":"Medical-a9564c89","source":"Medical","question":"What are common symptoms of bone cancer?","answer":"Bone pain and hypercalcemia are symptoms of bone cancer.","question_type":"Fact Retrieval","evidence":"Bone pain is a symptom of bone cancer.; Hypercalcemia is a symptom of bone cancer.","evidence_relations":"Symptom: [Bone pain, Hypercalcemia]"},
	{"id":"Medical-dee2271e","source":"Medical","question":"What is the most common subtype of mouth cancer?","answer":"Squamous cell carcinoma (SCC) is the most common subtype.","question_type":"Fact Retrieval","evidence":"Squamous cell carcinoma (SCC) is the most common subtype of mouth cancer.","evidence_relations":"Squamous cell carcinoma (SCC) is the most common subtype of mouth cancer"},
	{"id":"Medical-f0c44705","source":"Medical","question":"Which cancer type does mouth cancer belong to?","answer":"Mouth cancer is a type of head and neck cancer.","question_type":"Fact Retrieval","evidence":"Mouth cancer is a type of head and neck cancer.","evidence_relations":"Mouth cancer is a type of head and neck cancer"},
	{"id":"Medical-836b4146","source":"Medical","question":"What are alternative names for mouth cancer?","answer":"Mouth cancer is also known as oral cavity cancer.","question_type":"Fact Retrieval","evidence":"Mouth cancer is also known as oral cavity cancer.","evidence_relations":"Mouth cancer: Also known as Oral cavity cancer"},
	{"id":"Medical-bb448a1f","source":"Medical","question":"Which anatomic sites can be affected by mouth cancer?","answer":"Mouth cancer can develop in the lips, gums, buccal mucosa, tongue, hard palate, alveolar ridge, floor of mouth, and retromolar trigone.","question_type":"Fact Retrieval","evidence":"Mouth cancer can develop in the lips.; Mouth cancer can develop in the gums.; Mouth cancer can develop in the buccal mucosa.; Mouth cancer can develop in the tongue.; Mouth cancer can develop in the hard palate.; Mouth cancer can develop in the alveolar ridge.; Mouth cancer can develop in the floor of mouth.; Mouth cancer can develop in the retromolar trigone.","evidence_relations":"Mouth cancer can develop in the lips, gums, buccal mucosa, tongue, hard palate, alveolar ridge, floor of mouth, and retromolar trigone"},
	{"id":"Medical-92eb2c34","source":"Medical","question":"What is the basis for cancer staging in mouth cancer?","answer":"Cancer staging is based on the TNM system, which includes tumor size and depth (T), lymph node involvement (N), and distant metastasis (M).","question_type":"Fact Retrieval","evidence":"Cancer staging in mouth cancer is based on the TNM system.; The TNM system includes tumor size and depth (T).; The TNM system includes lymph node involvement (N).; The TNM system includes distant metastasis (M).","evidence_relations":"Cancer staging is based on the TNM system, which includes tumor size and depth (T), lymph node involvement (N), and distant metastasis (M)"},
	{"id":"Medical-9a2bd385","source":"Medical","question":"What does Tis represent in the TNM classification for mouth cancer?","answer":"Tis represents carcinoma in situ.","question_type":"Fact Retrieval","evidence":"Tis represents carcinoma in situ.","evidence_relations":"Tis: Carcinoma in situ"},
	{"id":"Medical-5492a510","source":"Medical","question":"What is the definition of T1 in mouth cancer TNM classification?","answer":"T1 is a tumor 2 cm with depth of invasion (DOI) 5 mm.","question_type":"Fact Retrieval","evidence":"T1 is a tumor 2 cm.; T1 has a depth of invasion (DOI) 5 mm.","evidence_relations":"T1: Tumor 2 cm with DOI 5 mm"},
	{"id":"Medical-dbfb3406","source":"Medical","question":"How is T2 defined in mouth cancer TNM classification?","answer":"T2 is a tumor 2 cm with DOI >5 mm or 24 cm with DOI 10 mm.","question_type":"Fact Retrieval","evidence":"T2 is a tumor 2 cm with DOI >5 mm.; T2 is a tumor 24 cm with DOI 10 mm.","evidence_relations":"T2: Tumor 2 cm with DOI >5 mm or 24 cm with DOI 10 mm"},
	{"id":"Medical-97502e67","source":"Medical","question":"What characterizes a T3 tumor in mouth cancer?","answer":"T3 is a 24 cm tumor with DOI >10 mm or >4 cm tumor with DOI 10 mm.","question_type":"Fact Retrieval","evidence":"A T3 tumor in mouth cancer is 24 cm in size.; A T3 tumor in mouth cancer has a depth of invasion (DOI) greater than 10 mm.; A T3 tumor in mouth cancer can also be greater than 4 cm in size with a DOI of 10 mm or less.","evidence_relations":"T3: 24 cm with DOI >10 mm or >4 cm with DOI 10 mm"},
	{"id":"Medical-4cb0599c","source":"Medical","question":"What does T4a indicate in mouth cancer staging?","answer":"T4a indicates moderately advanced local disease.","question_type":"Fact Retrieval","evidence":"T4a indicates moderately advanced local disease in mouth cancer.","evidence_relations":"T4a: Moderately advanced local disease"},
	{"id":"Medical-2c20babc","source":"Medical","question":"What does T4b represent in the TNM classification for mouth cancer?","answer":"T4b represents very advanced local disease.","question_type":"Fact Retrieval","evidence":"T4b represents very advanced local disease in mouth cancer.","evidence_relations":"T4b: Very advanced local disease"},
	{"id":"Medical-0e684fa6","source":"Medical","question":"What is extranodal extension in the context of regional lymph nodes?","answer":"Extranodal extension is cancer spread outside the lymph node.","question_type":"Fact Retrieval","evidence":"Extranodal extension refers to cancer spread outside the lymph node.","evidence_relations":"Extranodal extension: Cancer spread outside lymph node"},
	{"id":"Medical-acda3403","source":"Medical","question":"Which imaging tests are used for diagnosis and staging of mouth cancer?","answer":"Imaging tests such as CT, MRI, PET/CT, and ultrasound are used for diagnosis and staging.","question_type":"Fact Retrieval","evidence":"Imaging tests are used for diagnosis and staging of mouth cancer.; CT is one of the imaging tests used for mouth cancer.; MRI is one of the imaging tests used for mouth cancer.; PET/CT is one of the imaging tests used for mouth cancer.; Ultrasound is one of the imaging tests used for mouth cancer.","evidence_relations":"Imaging tests such as CT, MRI, PET/CT, and ultrasound are used for diagnosis and staging"},
	{"id":"Medical-264200b9","source":"Medical","question":"What procedure is required to confirm the diagnosis of mouth cancer?","answer":"Biopsy is required to confirm diagnosis and determine histology.","question_type":"Fact Retrieval","evidence":"A biopsy is required to confirm the diagnosis of mouth cancer.; A biopsy is required to determine the histology of mouth cancer.","evidence_relations":"Biopsy is required to confirm diagnosis and determine histology"},
	{"id":"Medical-4eefc14f","source":"Medical","question":"Which diagnostic methods may be used for mouth cancer besides imaging?","answer":"Diagnostic methods include panoramic dental x-ray (Panorex), fine-needle aspiration (FNA), core needle biopsy (CNB), dental exam, speech and swallowing assessment, and nutrition assessment.","question_type":"Fact Retrieval","evidence":"Panoramic dental x-ray (Panorex) may be used as a diagnostic method for mouth cancer.; Fine-needle aspiration (FNA) may be used as a diagnostic method for mouth cancer.; Core needle biopsy (CNB) may be used as a diagnostic method for mouth cancer.; A dental exam may be used as a diagnostic method for mouth cancer.; Speech and swallowing assessment may be used as a diagnostic method for mouth cancer.; Nutrition assessment may be used as a diagnostic method for mouth cancer.","evidence_relations":"Diagnostic Method: [CT scan, MRI, PET/CT, Ultrasound, Panoramic dental x-ray (Panorex), Biopsy, Fine-needle aspiration (FNA), Core needle biopsy (CNB), Dental exam, Speech and swallowing assessment, Nutrition assessment]"},
	{"id":"Medical-6f5dcba9","source":"Medical","question":"What biomarkers may be tested in mouth cancer?","answer":"Biomarker testing may include PD-L1, MSI-H/dMMR, and tumor mutational burden (TMB).","question_type":"Fact Retrieval","evidence":"Biomarker testing in mouth cancer may include PD-L1.; Biomarker testing in mouth cancer may include MSI-H/dMMR.; Biomarker testing in mouth cancer may include tumor mutational burden (TMB).","evidence_relations":"Biomarker testing may include PD-L1, MSI-H/dMMR, and tumor mutational burden (TMB)"},
	{"id":"Medical-dde9c1e8","source":"Medical","question":"Which risk factors are associated with mouth cancer?","answer":"Tobacco use and alcohol use are risk factors for mouth cancer.","question_type":"Fact Retrieval","evidence":"Tobacco use is a risk factor for mouth cancer.; Alcohol use is a risk factor for mouth cancer.","evidence_relations":"Tobacco and alcohol use are risk factors for mouth cancer"},
	{"id":"Medical-5ec05134","source":"Medical","question":"How does smoking or vaping affect mouth cancer treatment?","answer":"Smoking or vaping negatively affects treatment outcomes and increases toxicity.","question_type":"Fact Retrieval","evidence":"Smoking negatively affects treatment outcomes for mouth cancer.; Vaping negatively affects treatment outcomes for mouth cancer.; Smoking increases toxicity in mouth cancer treatment.; Vaping increases toxicity in mouth cancer treatment.","evidence_relations":"Smoking or vaping negatively affects treatment outcomes and increases toxicity"},
	{"id":"Medical-6452b539","source":"Medical","question":"What is the role of depth of invasion (DOI) in mouth cancer?","answer":"Depth of invasion (DOI) is used to assess tumor extension in mouth cancer.","question_type":"Fact Retrieval","evidence":"Depth of invasion (DOI) is used to assess tumor extension in mouth cancer.","evidence_relations":"Depth of invasion (DOI) is used to assess tumor extension in mouth cancer"},
	{"id":"Medical-bb899a92","source":"Medical","question":"What factors are considered in treatment planning for mouth cancer?","answer":"Treatment planning is based on tumor location and stage.","question_type":"Fact Retrieval","evidence":"Treatment planning for mouth cancer is based on tumor location.; Treatment planning for mouth cancer is based on tumor stage.","evidence_relations":"Treatment planning is based on tumor location and stage"},
	{"id":"Medical-9e29cae8","source":"Medical","question":"Which clinical assessment is important for treatment selection in mouth cancer?","answer":"Performance status (ECOG) is considered in treatment selection.","question_type":"Fact Retrieval","evidence":"Performance status (ECOG) is considered in treatment selection for mouth cancer.","evidence_relations":"Performance status (ECOG) is considered in treatment selection"},
	{"id":"Medical-015910ee","source":"Medical","question":"How can cancer and its treatment impact fertility in mouth cancer patients?","answer":"Cancer and its treatment can affect fertility.","question_type":"Fact Retrieval","evidence":"Cancer can affect fertility in mouth cancer patients.; Treatment can affect fertility in mouth cancer patients.","evidence_relations":"Cancer and its treatment can affect fertility"},
	{"id":"Medical-ab04c717","source":"Medical","question":"What symptoms may indicate mouth cancer?","answer":"Symptoms may include changes in the mouth, tongue, or neck area.","question_type":"Fact Retrieval","evidence":"Symptoms of mouth cancer may include changes in the mouth.; Symptoms of mouth cancer may include changes in the tongue.; Symptoms of mouth cancer may include changes in the neck area.","evidence_relations":"Symptoms may include changes in the mouth, tongue, or neck area"},
	{"id":"Medical-69907f97","source":"Medical","question":"How is dental health affected by mouth cancer and its treatment?","answer":"Dental health is affected by head and neck cancer and its treatment.","question_type":"Fact Retrieval","evidence":"Dental health is affected by head and neck cancer.; Dental health is affected by the treatment of head and neck cancer.","evidence_relations":"Dental health is affected by head and neck cancer and its treatment"},
	{"id":"Medical-9c46dbea","source":"Medical","question":"What are the numbered stages used in mouth cancer staging?","answer":"Numbered stages used are Stage 0, Stage I, Stage II, Stage III, and Stage IV.","question_type":"Fact Retrieval","evidence":"The numbered stages used in mouth cancer staging include Stage 0.; The numbered stages used in mouth cancer staging include Stage I.; The numbered stages used in mouth cancer staging include Stage II.; The numbered stages used in mouth cancer staging include Stage III.; The numbered stages used in mouth cancer staging include Stage IV.","evidence_relations":"Numbered Stages: [Stage 0, Stage I, Stage II, Stage III, Stage IV]"},
	{"id":"Medical-f41a6eed","source":"Medical","question":"What is the purpose of a dental exam in mouth cancer management?","answer":"Dental exam is a diagnostic method used in mouth cancer.","question_type":"Fact Retrieval","evidence":"A dental exam is a diagnostic method used in mouth cancer.","evidence_relations":"Diagnostic Method: [Dental exam]"},
	{"id":"Medical-7f529715","source":"Medical","question":"Which assessments are included in the clinical evaluation of mouth cancer patients?","answer":"Speech and swallowing assessment and nutrition assessment are included in clinical evaluation.","question_type":"Fact Retrieval","evidence":"Speech and swallowing assessment is included in the clinical evaluation of mouth cancer patients.; Nutrition assessment is included in the clinical evaluation of mouth cancer patients.","evidence_relations":"Diagnostic Method: [Speech and swallowing assessment, Nutrition assessment]"},
	{"id":"Medical-25024e4e","source":"Medical","question":"What is the significance of performance status (ECOG) in mouth cancer?","answer":"Performance status (ECOG) is used as a clinical assessment in mouth cancer.","question_type":"Fact Retrieval","evidence":"Performance status (ECOG) is used as a clinical assessment in mouth cancer.","evidence_relations":"Clinical Assessment: [Performance status (ECOG)]"},
	{"id":"Medical-f598e40d","source":"Medical","question":"What fertility consideration should be addressed in mouth cancer patients?","answer":"Fertility preservation is a fertility consideration in mouth cancer.","question_type":"Fact Retrieval","evidence":"Fertility preservation is a fertility consideration in mouth cancer.","evidence_relations":"Fertility Consideration: [Fertility preservation]"},
	{"id":"Medical-f2c54ca8","source":"Medical","question":"Which genetic alterations may be evaluated in mouth cancer biomarker testing?","answer":"MSI-H/dMMR and tumor mutational burden (TMB) may be evaluated.","question_type":"Fact Retrieval","evidence":"MSI-H/dMMR may be evaluated in mouth cancer biomarker testing.; Tumor mutational burden (TMB) may be evaluated in mouth cancer biomarker testing.","evidence_relations":"Biomarker testing may include PD-L1, MSI-H/dMMR, and tumor mutational burden (TMB)"},
	{"id":"Medical-c608379f","source":"Medical","question":"What is the role of a core needle biopsy (CNB) in mouth cancer?","answer":"Core needle biopsy (CNB) is a diagnostic method for mouth cancer.","question_type":"Fact Retrieval","evidence":"Core needle biopsy (CNB) is a diagnostic method for mouth cancer.","evidence_relations":"Diagnostic Method: [Core needle biopsy (CNB)]"},
	{"id":"Medical-01f113f7","source":"Medical","question":"What is stomach cancer?","answer":"Stomach cancer is a type of cancer that arises in the stomach.","question_type":"Fact Retrieval","evidence":"Stomach cancer is a type of cancer.; Stomach cancer arises in the stomach.","evidence_relations":"Stomach cancer is a type of cancer that arises in the stomach"},
	{"id":"Medical-9dfd9d7f","source":"Medical","question":"What is the most common subtype of stomach cancer?","answer":"Most stomach cancers are adenocarcinomas.","question_type":"Fact Retrieval","evidence":"Most stomach cancers are adenocarcinomas.","evidence_relations":"Most stomach cancers are adenocarcinomas"},
	{"id":"Medical-437a1cdc","source":"Medical","question":"From which cells do adenocarcinomas of the stomach originate?","answer":"Adenocarcinomas originate from cells lining the inside of the stomach that secrete mucus.","question_type":"Fact Retrieval","evidence":"Adenocarcinomas of the stomach originate from cells lining the inside of the stomach.; These cells secrete mucus.","evidence_relations":"Adenocarcinomas originate from cells lining the inside of the stomach that secrete mucus"},
	{"id":"Medical-056be573","source":"Medical","question":"What are the two major subtypes of stomach adenocarcinoma?","answer":"The two major subtypes are intestinal type adenocarcinoma and diffuse type adenocarcinoma.","question_type":"Fact Retrieval","evidence":"The two major subtypes of stomach adenocarcinoma are intestinal type adenocarcinoma and diffuse type adenocarcinoma.","evidence_relations":"There are two major subtypes of stomach adenocarcinoma: intestinal and diffuse"},
	{"id":"Medical-79a34cfc","source":"Medical","question":"Which stomach adenocarcinoma subtype forms tube- and gland-shaped structures?","answer":"Intestinal type adenocarcinoma forms tube- and gland-shaped structures.","question_type":"Fact Retrieval","evidence":"Intestinal type adenocarcinoma forms tube- and gland-shaped structures.","evidence_relations":"Intestinal type adenocarcinoma forms tube- and gland-shaped structures"},
	{"id":"Medical-b0ebc350","source":"Medical","question":"Which subtype of stomach adenocarcinoma is more likely to have mutations treatable with targeted therapy?","answer":"Intestinal type adenocarcinoma is more likely to have mutations treatable with targeted therapy.","question_type":"Fact Retrieval","evidence":"Intestinal type adenocarcinoma is more likely to have mutations treatable with targeted therapy.","evidence_relations":"Intestinal type adenocarcinoma forms tube- and gland-shaped structures and is more likely to have mutations treatable with targeted therapy"},
	{"id":"Medical-50852ffa","source":"Medical","question":"Which subtype of stomach adenocarcinoma consists of scattered cells and is less common?","answer":"Diffuse type adenocarcinoma consists of scattered cells and is less common.","question_type":"Fact Retrieval","evidence":"Diffuse type adenocarcinoma consists of scattered cells.; Diffuse type adenocarcinoma is less common.","evidence_relations":"Diffuse type adenocarcinoma consists of scattered cells and is less common"},
	{"id":"Medical-0591c484","source":"Medical","question":"What defines early-stage stomach cancer?","answer":"Early-stage stomach cancer is confined to the mucosa and is not present in lymph nodes.","question_type":"Fact Retrieval","evidence":"Early-stage stomach cancer is confined to the mucosa.; Early-stage stomach cancer is not present in lymph nodes.","evidence_relations":"Early-stage stomach cancer is confined to the mucosa and is not present in lymph nodes"},
	{"id":"Medical-2cd3be1d","source":"Medical","question":"What characterizes locoregional or locally advanced stomach cancer?","answer":"Locoregional stomach cancer invades other layers of the stomach wall and/or regional lymph nodes or nearby organs.","question_type":"Fact Retrieval","evidence":"Locoregional stomach cancer invades other layers of the stomach wall.; Locoregional stomach cancer can invade regional lymph nodes.; Locoregional stomach cancer can invade nearby organs.","evidence_relations":"Locoregional or locally advanced stomach cancer invades other layers of the stomach wall and/or regional lymph nodes or nearby organs"},
	{"id":"Medical-5bf4dcc9","source":"Medical","question":"What is metastatic stomach cancer?","answer":"Metastatic stomach cancer has spread to distant organs such as the liver, peritoneum, or distant lymph nodes.","question_type":"Fact Retrieval","evidence":"Metastatic stomach cancer has spread to distant organs.; Metastatic stomach cancer can spread to the liver.; Metastatic stomach cancer can spread to the peritoneum.; Metastatic stomach cancer can spread to distant lymph nodes.","evidence_relations":"Metastatic stomach cancer has spread to distant organs such as the liver, peritoneum, or distant lymph nodes"},
	{"id":"Medical-5dedb4ec","source":"Medical","question":"Through which layers does stomach cancer spread outward?","answer":"Stomach cancer spreads outward through the layers of the stomach wall.","question_type":"Fact Retrieval","evidence":"Stomach cancer spreads outward through the layers of the stomach wall.","evidence_relations":"Stomach cancer spreads outward through the layers of the stomach wall"},
	{"id":"Medical-60b88999","source":"Medical","question":"Where do precancerous changes often occur before stomach cancer develops?","answer":"Precancerous changes often occur in the mucosa before cancer develops.","question_type":"Fact Retrieval","evidence":"Precancerous changes often occur in the mucosa before stomach cancer develops.","evidence_relations":"Precancerous changes often occur in the mucosa before cancer develops"},
	{"id":"Medical-442b042c","source":"Medical","question":"To which organs can stomach cancer spread?","answer":"Cancer can spread to lymph nodes, veins, arteries, and organs such as the liver, pancreas, and spleen.","question_type":"Fact Retrieval","evidence":"Stomach cancer can spread to lymph nodes.; Stomach cancer can spread to veins.; Stomach cancer can spread to arteries.; Stomach cancer can spread to the liver.; Stomach cancer can spread to the pancreas.; Stomach cancer can spread to the spleen.","evidence_relations":"Cancer can spread to lymph nodes, veins, arteries, and organs such as the liver, pancreas, and spleen"},
	{"id":"Medical-b76a0ae4","source":"Medical","question":"What diagnostic methods are used for stomach cancer?","answer":"Diagnosis involves imaging tests, endoscopy, biopsy, biomarker testing, and genetic risk testing.","question_type":"Fact Retrieval","evidence":"Diagnosis of stomach cancer involves imaging tests.; Diagnosis of stomach cancer involves endoscopy.; Diagnosis of stomach cancer involves biopsy.; Diagnosis of stomach cancer involves biomarker testing.; Diagnosis of stomach cancer involves genetic risk testing.","evidence_relations":"Diagnosis involves imaging tests, endoscopy, biopsy, biomarker testing, and genetic risk testing"},
	{"id":"Medical-d8dd3085","source":"Medical","question":"What is a risk factor for stomach cancer related to infection?","answer":"H. pylori infection is a risk factor for stomach cancer.","question_type":"Fact Retrieval","evidence":"H. pylori infection is a risk factor for stomach cancer.","evidence_relations":"H. pylori infection is a risk factor for stomach cancer"},
	{"id":"Medical-e77a80c7","source":"Medical","question":"Is family history a risk factor for stomach cancer?","answer":"Family history is a risk factor for stomach cancer.","question_type":"Fact Retrieval","evidence":"Family history is a risk factor for stomach cancer.","evidence_relations":"Family history is a risk factor for stomach cancer"},
	{"id":"Medical-5778d49d","source":"Medical","question":"What symptoms can stomach cancer cause?","answer":"Symptoms can include ulcer or mass formation in the stomach.","question_type":"Fact Retrieval","evidence":"Stomach cancer can cause ulcer formation in the stomach.; Stomach cancer can cause mass formation in the stomach.","evidence_relations":"Symptoms can include ulcer or mass formation in the stomach"},
	{"id":"Medical-b182ee0f","source":"Medical","question":"What are the anatomical locations within the stomach relevant to stomach cancer?","answer":"The anatomical locations are cardia, fundus, body, antrum, pylorus, and esophagogastric junction.","question_type":"Fact Retrieval","evidence":"The anatomical locations within the stomach relevant to stomach cancer include the cardia.; The anatomical locations within the stomach relevant to stomach cancer include the fundus.; The anatomical locations within the stomach relevant to stomach cancer include the body.; The anatomical locations within the stomach relevant to stomach cancer include the antrum.; The anatomical locations within the stomach relevant to stomach cancer include the pylorus.; The anatomical locations within the stomach relevant to stomach cancer include the esophagogastric junction.","evidence_relations":"The anatomical locations are cardia, fundus, body, antrum, pylorus, and esophagogastric junction"},
	{"id":"Medical-33e91398","source":"Medical","question":"What are the main layers of the stomach wall?","answer":"The stomach wall layers are mucosa, submucosa, muscle layer (muscularis propria), subserosa, and serosa.","question_type":"Fact Retrieval","evidence":"The main layers of the stomach wall include the mucosa.; The main layers of the stomach wall include the submucosa.; The main layers of the stomach wall include the muscle layer (muscularis propria).; The main layers of the stomach wall include the subserosa.; The main layers of the stomach wall include the serosa.","evidence_relations":"The stomach wall layers are mucosa, submucosa, muscle layer (muscularis propria), subserosa, and serosa"},
	{"id":"Medical-b59fdb33","source":"Medical","question":"Which diagnostic method is used to visually examine the stomach?","answer":"Endoscopy is used to visually examine the stomach.","question_type":"Fact Retrieval","evidence":"Endoscopy is used to visually examine the stomach.","evidence_relations":"Diagnosis involves imaging tests, endoscopy, biopsy, biomarker testing, and genetic risk testing"},
	{"id":"Medical-75f97fc6","source":"Medical","question":"Which diagnostic method involves sampling tissue for analysis in stomach cancer?","answer":"Biopsy is used to sample tissue for analysis.","question_type":"Fact Retrieval","evidence":"Biopsy is used to sample tissue for analysis.","evidence_relations":"Diagnosis involves imaging tests, endoscopy, biopsy, biomarker testing, and genetic risk testing"},
	{"id":"Medical-4a56a9a5","source":"Medical","question":"What is the local spread pattern of stomach cancer?","answer":"Local spread involves the stomach wall layers and regional lymph nodes.","question_type":"Fact Retrieval","evidence":"Local spread of stomach cancer involves the stomach wall layers.; Local spread of stomach cancer involves regional lymph nodes.","evidence_relations":"Local spread involves the stomach wall layers and regional lymph nodes"},
	{"id":"Medical-77f07857","source":"Medical","question":"What is the distant spread pattern of stomach cancer?","answer":"Distant spread involves the liver, peritoneum, distant lymph nodes, pancreas, and spleen.","question_type":"Fact Retrieval","evidence":"Distant spread of stomach cancer involves the liver.; Distant spread of stomach cancer involves the peritoneum.; Distant spread of stomach cancer involves distant lymph nodes.; Distant spread of stomach cancer involves the pancreas.; Distant spread of stomach cancer involves the spleen.","evidence_relations":"Distant spread involves the liver, peritoneum, distant lymph nodes, pancreas, and spleen"},
	{"id":"Medical-ed553dca","source":"Medical","question":"What is the role of biomarker testing in stomach cancer diagnosis?","answer":"Biomarker testing is used as part of the diagnostic process for stomach cancer.","question_type":"Fact Retrieval","evidence":"Biomarker testing is used as part of the diagnostic process for stomach cancer.","evidence_relations":"Diagnosis involves imaging tests, endoscopy, biopsy, biomarker testing, and genetic risk testing"},
	{"id":"Medical-fc8c1f25","source":"Medical","question":"What genetic risk factor is listed for stomach cancer?","answer":"Family history is listed as a genetic risk factor.","question_type":"Fact Retrieval","evidence":"Family history is listed as a genetic risk factor for stomach cancer.","evidence_relations":"Family history is a risk factor for stomach cancer"},
	{"id":"Medical-5470aded","source":"Medical","question":"Which stomach cancer subtype is less common?","answer":"Diffuse type adenocarcinoma is less common.","question_type":"Fact Retrieval","evidence":"Diffuse type adenocarcinoma is a less common subtype of stomach cancer.","evidence_relations":"Diffuse type adenocarcinoma consists of scattered cells and is less common"},
	{"id":"Medical-4c68753b","source":"Medical","question":"Which stomach wall layer is the initial site for early-stage stomach cancer?","answer":"The mucosa is the initial site for early-stage stomach cancer.","question_type":"Fact Retrieval","evidence":"The mucosa is the initial site for early-stage stomach cancer.","evidence_relations":"Early-stage stomach cancer is confined to the mucosa and is not present in lymph nodes"},
	{"id":"Medical-e18d2c7f","source":"Medical","question":"Which subtype of stomach adenocarcinoma is more likely to benefit from targeted therapy?","answer":"Intestinal type adenocarcinoma is more likely to benefit from targeted therapy.","question_type":"Fact Retrieval","evidence":"Intestinal type adenocarcinoma is more likely to benefit from targeted therapy.","evidence_relations":"Intestinal type adenocarcinoma forms tube- and gland-shaped structures and is more likely to have mutations treatable with targeted therapy"},
	{"id":"Medical-cdf0477d","source":"Medical","question":"Which organs are commonly involved in metastatic stomach cancer?","answer":"The liver, peritoneum, and distant lymph nodes are commonly involved.","question_type":"Fact Retrieval","evidence":"The liver is commonly involved in metastatic stomach cancer.; The peritoneum is commonly involved in metastatic stomach cancer.; Distant lymph nodes are commonly involved in metastatic stomach cancer.","evidence_relations":"Metastatic stomach cancer has spread to distant organs such as the liver, peritoneum, or distant lymph nodes"},
	{"id":"Medical-e542c70c","source":"Medical","question":"What are two main symptoms of stomach cancer listed in the ontology?","answer":"Ulcer and mass are two main symptoms.","question_type":"Fact Retrieval","evidence":"Ulcer is a main symptom of stomach cancer.; Mass is a main symptom of stomach cancer.","evidence_relations":"Symptoms can include ulcer or mass formation in the stomach"},
	{"id":"Medical-d3bb30e3","source":"Medical","question":"What is the significance of the mucosa in stomach cancer development?","answer":"Precancerous changes often occur in the mucosa before cancer develops.","question_type":"Fact Retrieval","evidence":"Precancerous changes often occur in the mucosa before cancer develops.","evidence_relations":"Precancerous changes often occur in the mucosa before cancer develops"},
	{"id":"Medical-56aa3e9e","source":"Medical","question":"What type of tumor is glioma?","answer":"Glioma is a type of malignant brain tumor.","question_type":"Fact Retrieval","evidence":"Glioma is a type of malignant brain tumor.","evidence_relations":"Glioma is a type of malignant brain tumor"},
	{"id":"Medical-da451391","source":"Medical","question":"From which cells do gliomas develop?","answer":"Gliomas develop from glial cells in the central nervous system.","question_type":"Fact Retrieval","evidence":"Gliomas develop from glial cells.; Gliomas develop in the central nervous system.","evidence_relations":"Gliomas develop from glial cells in the central nervous system"},
	{"id":"Medical-5724612b","source":"Medical","question":"What are the most common subtypes of glioma?","answer":"Astrocytoma, oligodendroglioma, and glioblastoma are the most common subtypes of glioma.","question_type":"Fact Retrieval","evidence":"Astrocytoma is a common subtype of glioma.; Oligodendroglioma is a common subtype of glioma.; Glioblastoma is a common subtype of glioma.","evidence_relations":"Astrocytoma, oligodendroglioma, and glioblastoma are the most common subtypes of glioma"},
	{"id":"Medical-e84e4ea0","source":"Medical","question":"Which glioma subtype is the most aggressive?","answer":"Glioblastoma is the most aggressive subtype of glioma.","question_type":"Fact Retrieval","evidence":"Glioblastoma is the most aggressive subtype of glioma.","evidence_relations":"Glioblastoma is the most aggressive subtype of glioma"},
	{"id":"Medical-9884a4b5","source":"Medical","question":"How are gliomas classified?","answer":"Gliomas are classified by histology, grade, and biomarkers.","question_type":"Fact Retrieval","evidence":"Gliomas are classified by histology.; Gliomas are classified by grade.; Gliomas are classified by biomarkers.","evidence_relations":"Gliomas are classified by histology, grade, and biomarkers"},
	{"id":"Medical-8b6ad218","source":"Medical","question":"Which grades are considered low-grade gliomas?","answer":"Grades 1 and 2 are low-grade gliomas.","question_type":"Fact Retrieval","evidence":"Grades 1 are considered low-grade gliomas.; Grades 2 are considered low-grade gliomas.","evidence_relations":"Grades 1 and 2 are low-grade gliomas; grades 3 and 4 are high-grade gliomas"},
	{"id":"Medical-a49f0182","source":"Medical","question":"Which grades are classified as high-grade gliomas?","answer":"Grades 3 and 4 are high-grade gliomas.","question_type":"Fact Retrieval","evidence":"Grades 3 are classified as high-grade gliomas.; Grades 4 are classified as high-grade gliomas.","evidence_relations":"Grades 1 and 2 are low-grade gliomas; grades 3 and 4 are high-grade gliomas"},
	{"id":"Medical-0ae25b73","source":"Medical","question":"What is the most common grade of glioblastoma?","answer":"Grade 4 gliomas are most commonly glioblastomas.","question_type":"Fact Retrieval","evidence":"Grade 4 gliomas are most commonly glioblastomas.","evidence_relations":"Grade 4 gliomas are most commonly glioblastomas"},
	{"id":"Medical-d272b033","source":"Medical","question":"What biomarker is used to classify gliomas?","answer":"IDH mutation is a biomarker used to classify gliomas.","question_type":"Fact Retrieval","evidence":"IDH mutation is a biomarker used to classify gliomas.","evidence_relations":"IDH mutation is a biomarker used to classify gliomas"},
	{"id":"Medical-90f1b2e6","source":"Medical","question":"What is the most useful imaging test for identifying glioma?","answer":"MRI is the most useful imaging test for identifying glioma.","question_type":"Fact Retrieval","evidence":"MRI is the most useful imaging test for identifying glioma.","evidence_relations":"MRI is the most useful imaging test for identifying glioma"},
	{"id":"Medical-fe7631ea","source":"Medical","question":"What procedures are required for the definitive diagnosis and molecular testing of glioma?","answer":"Biopsy is required for definitive diagnosis and molecular testing.","question_type":"Fact Retrieval","evidence":"Biopsy is required for definitive diagnosis of glioma.; Biopsy is required for molecular testing of glioma.","evidence_relations":"Biopsy is required for definitive diagnosis and molecular testing"},
	{"id":"Medical-e436ffd1","source":"Medical","question":"Which diagnostic methods are used for glioma diagnosis?","answer":"Diagnosis of glioma involves neurological exam, imaging (MRI, CT), and biopsy.","question_type":"Fact Retrieval","evidence":"Diagnosis of glioma involves a neurological exam.; Diagnosis of glioma involves imaging.; Imaging methods for glioma diagnosis include MRI.; Imaging methods for glioma diagnosis include CT.; Diagnosis of glioma involves biopsy.","evidence_relations":"Diagnosis of glioma involves neurological exam, imaging (MRI, CT), and biopsy"},
	{"id":"Medical-de960459","source":"Medical","question":"What are common symptoms of glioma?","answer":"Symptoms of glioma include headache, seizures, fatigue, nausea, vomiting, cognitive changes, weakness, personality changes, and vision problems.","question_type":"Fact Retrieval","evidence":"Common symptoms of glioma include headache.; Common symptoms of glioma include seizures.; Common symptoms of glioma include fatigue.; Common symptoms of glioma include nausea.; Common symptoms of glioma include vomiting.; Common symptoms of glioma include cognitive changes.; Common symptoms of glioma include weakness.; Common symptoms of glioma include personality changes.; Common symptoms of glioma include vision problems.","evidence_relations":"Symptoms of glioma include headache, seizures, fatigue, nausea, vomiting, cognitive changes, weakness, personality changes, and vision problems"},
	{"id":"Medical-b0d802db","source":"Medical","question":"What are the main treatment options for glioma?","answer":"Treatment options for glioma include surgery, radiation therapy, chemotherapy, and clinical trials.","question_type":"Fact Retrieval","evidence":"Treatment options for glioma include surgery.; Treatment options for glioma include radiation therapy.; Treatment options for glioma include chemotherapy.; Treatment options for glioma include clinical trials.","evidence_relations":"Treatment options for glioma include surgery, radiation therapy, chemotherapy, and clinical trials"},
	{"id":"Medical-30a29470","source":"Medical","question":"What surgical procedures may be performed for glioma?","answer":"Surgery may involve resection or biopsy.","question_type":"Fact Retrieval","evidence":"Surgery for glioma may involve resection.; Surgery for glioma may involve biopsy.","evidence_relations":"Surgery may involve resection or biopsy"},
	{"id":"Medical-7959a3b5","source":"Medical","question":"What additional therapy is required for high-grade gliomas after surgery?","answer":"High-grade gliomas require additional therapy after surgery.","question_type":"Fact Retrieval","evidence":"High-grade gliomas require additional therapy after surgery.","evidence_relations":"High-grade gliomas require additional therapy after surgery"},
	{"id":"Medical-1392e5d5","source":"Medical","question":"Are gliomas curable?","answer":"Gliomas are rarely curable but are treatable.","question_type":"Fact Retrieval","evidence":"Gliomas are rarely curable.; Gliomas are treatable.","evidence_relations":"Gliomas are rarely curable but are treatable"},
	{"id":"Medical-981edc6b","source":"Medical","question":"What is recommended for follow-up after glioma treatment?","answer":"Follow-up with periodic imaging (MRI) is recommended to monitor for recurrence.","question_type":"Fact Retrieval","evidence":"Periodic imaging (MRI) is recommended for follow-up after glioma treatment.; The purpose of follow-up imaging is to monitor for recurrence.","evidence_relations":"Follow-up with periodic imaging (MRI) is recommended to monitor for recurrence"},
	{"id":"Medical-28389677","source":"Medical","question":"What is assessed to determine treatment eligibility for glioma?","answer":"Performance status is assessed to determine treatment eligibility.","question_type":"Fact Retrieval","evidence":"Performance status is assessed to determine treatment eligibility for glioma.","evidence_relations":"Performance status is assessed to determine treatment eligibility"},
	{"id":"Medical-7b37919a","source":"Medical","question":"In which age group are gliomas more common?","answer":"Gliomas are more common in adults than children.","question_type":"Fact Retrieval","evidence":"Gliomas are more common in adults than in children.","evidence_relations":"Gliomas are more common in adults than children"},
	{"id":"Medical-ea8aac67","source":"Medical","question":"Are most gliomas hereditary?","answer":"Most gliomas are not hereditary.","question_type":"Fact Retrieval","evidence":"Most gliomas are not hereditary.","evidence_relations":"Most gliomas are not hereditary"},
	{"id":"Medical-d6bbd4d7","source":"Medical","question":"Which grades are included in low-grade gliomas according to the ontology?","answer":"Low-grade gliomas include Grade 1 and Grade 2.","question_type":"Fact Retrieval","evidence":"Low-grade gliomas include Grade 1.; Low-grade gliomas include Grade 2.","evidence_relations":"Low-grade gliomas include Grade 1 and Grade 2"},
	{"id":"Medical-885582ad","source":"Medical","question":"Which grades are included in high-grade gliomas according to the ontology?","answer":"High-grade gliomas include Grade 3 and Grade 4.","question_type":"Fact Retrieval","evidence":"High-grade gliomas include Grade 3.; High-grade gliomas include Grade 4.","evidence_relations":"High-grade gliomas include Grade 3 and Grade 4"},
	{"id":"Medical-3c7e7363","source":"Medical","question":"What performance status assessment is used in glioma diagnosis?","answer":"Performance status is assessed as part of the clinical evaluation for glioma.","question_type":"Fact Retrieval","evidence":"Performance status is assessed as part of the clinical evaluation for glioma.","evidence_relations":"Clinical evaluation for glioma includes performance status assessment"},
	{"id":"Medical-bf9e60be","source":"Medical","question":"Which imaging methods are used for glioma diagnosis according to the ontology?","answer":"MRI and CT scan are imaging methods used for glioma diagnosis.","question_type":"Fact Retrieval","evidence":"MRI is an imaging method used for glioma diagnosis.; CT scan is an imaging method used for glioma diagnosis.","evidence_relations":"Imaging for glioma diagnosis includes MRI and CT scan"},
	{"id":"Medical-aca25b7f","source":"Medical","question":"What tissue sampling methods are available for glioma diagnosis?","answer":"Tissue sampling for glioma diagnosis includes biopsy, stereotactic biopsy, open biopsy, and resection.","question_type":"Fact Retrieval","evidence":"Tissue sampling for glioma diagnosis includes biopsy.; Tissue sampling for glioma diagnosis includes stereotactic biopsy.; Tissue sampling for glioma diagnosis includes open biopsy.; Tissue sampling for glioma diagnosis includes resection.","evidence_relations":"Tissue sampling methods for glioma diagnosis include biopsy, stereotactic biopsy, open biopsy, and resection"},
	{"id":"Medical-86e59474","source":"Medical","question":"What laboratory tests are conducted for glioma diagnosis?","answer":"Laboratory testing for glioma includes molecular testing and histology.","question_type":"Fact Retrieval","evidence":"Laboratory testing for glioma includes molecular testing.; Laboratory testing for glioma includes histology.","evidence_relations":"Laboratory testing for glioma includes molecular testing and histology"},
	{"id":"Medical-2db59cde","source":"Medical","question":"What are the risk factors for glioma?","answer":"Risk factors for glioma include age (more common in adults) and non-hereditary mutation.","question_type":"Fact Retrieval","evidence":"Risk factors for glioma include age.; Glioma is more common in adults.; Risk factors for glioma include non-hereditary mutation.","evidence_relations":"Risk factors for glioma include age (more common in adults) and non-hereditary mutation"},
	{"id":"Medical-20cc11c5","source":"Medical","question":"Which biomarker is used for both astrocytoma and oligodendroglioma classification?","answer":"IDH mutation is used as a biomarker for both astrocytoma and oligodendroglioma.","question_type":"Fact Retrieval","evidence":"IDH mutation is used as a biomarker for astrocytoma.; IDH mutation is used as a biomarker for oligodendroglioma.","evidence_relations":"IDH mutation is a biomarker for astrocytoma and oligodendroglioma"},
	{"id":"Medical-228c6c0b","source":"Medical","question":"What is the prognosis for low-grade gliomas?","answer":"Low-grade gliomas have better prognosis.","question_type":"Fact Retrieval","evidence":"Low-grade gliomas have a better prognosis.","evidence_relations":"Low-grade gliomas have better prognosis"},
	{"id":"Medical-54ee540e","source":"Medical","question":"What is the prognosis for high-grade gliomas?","answer":"High-grade gliomas have poorer prognosis.","question_type":"Fact Retrieval","evidence":"High-grade gliomas have a poorer prognosis.","evidence_relations":"High-grade gliomas have poorer prognosis"},
	{"id":"Medical-198aa7f0","source":"Medical","question":"What is the purpose of follow-up MRI in glioma patients?","answer":"Follow-up MRI is used to monitor for recurrence in glioma patients.","question_type":"Fact Retrieval","evidence":"Follow-up MRI is used to monitor for recurrence in glioma patients.","evidence_relations":"Follow-up with periodic imaging (MRI) is recommended to monitor for recurrence"},
	{"id":"Medical-96567841","source":"Medical","question":"What type of cancer is AML?","answer":"AML is a type of blood cancer that starts in the stem cells of bone marrow.","question_type":"Fact Retrieval","evidence":"AML is a type of blood cancer.; AML starts in the stem cells of bone marrow.","evidence_relations":"AML is a type of blood cancer that starts in the stem cells of bone marrow"},
	{"id":"Medical-78c160d3","source":"Medical","question":"How is AML diagnosed?","answer":"AML is diagnosed by the presence of 20% myeloblasts in bone marrow or blood.","question_type":"Fact Retrieval","evidence":"AML is diagnosed by the presence of 20% myeloblasts in bone marrow.; AML is diagnosed by the presence of 20% myeloblasts in blood.","evidence_relations":"AML is diagnosed by the presence of 20% myeloblasts in bone marrow or blood"},
	{"id":"Medical-42ab49a0","source":"Medical","question":"What defines AML subtypes?","answer":"AML subtypes are defined by gene mutations or abnormal chromosomes.","question_type":"Fact Retrieval","evidence":"AML subtypes are defined by gene mutations.; AML subtypes are defined by abnormal chromosomes.","evidence_relations":"AML subtypes are defined by gene mutations or abnormal chromosomes"},
	{"id":"Medical-92941568","source":"Medical","question":"Which gene fusion characterizes Acute promyelocytic leukemia (APL)?","answer":"The PML::RARA fusion gene characterizes APL.","question_type":"Fact Retrieval","evidence":"The PML::RARA fusion gene characterizes Acute promyelocytic leukemia (APL).","evidence_relations":"Acute promyelocytic leukemia (APL) is a subtype of AML characterized by the PML::RARA fusion gene"},
	{"id":"Medical-44f40835","source":"Medical","question":"What is Blastic plasmacytoid dendritic cell neoplasm (BPDCN)?","answer":"BPDCN is an aggressive subtype of AML.","question_type":"Fact Retrieval","evidence":"Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive subtype of acute myeloid leukemia (AML).","evidence_relations":"Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive subtype of AML"},
	{"id":"Medical-4535e4eb","source":"Medical","question":"What are the main symptoms of AML?","answer":"Symptoms of AML include fatigue, infections, bleeding, and bruising.","question_type":"Fact Retrieval","evidence":"Symptoms of acute myeloid leukemia (AML) include fatigue.; Symptoms of acute myeloid leukemia (AML) include infections.; Symptoms of acute myeloid leukemia (AML) include bleeding.; Symptoms of acute myeloid leukemia (AML) include bruising.","evidence_relations":"Symptoms of AML include fatigue, infections, bleeding, and bruising"},
	{"id":"Medical-93bdac1d","source":"Medical","question":"What causes low counts of healthy blood cells in AML?","answer":"AML causes a buildup of blasts in bone marrow and blood, leading to low counts of healthy red blood cells, platelets, and white blood cells.","question_type":"Fact Retrieval","evidence":"Acute myeloid leukemia (AML) causes a buildup of blasts in bone marrow.; Acute myeloid leukemia (AML) causes a buildup of blasts in blood.; The buildup of blasts in AML leads to low counts of healthy red blood cells.; The buildup of blasts in AML leads to low counts of healthy platelets.; The buildup of blasts in AML leads to low counts of healthy white blood cells.","evidence_relations":"AML causes a buildup of blasts in bone marrow and blood, leading to low counts of healthy red blood cells, platelets, and white blood cells"},
	{"id":"Medical-98aa1f14","source":"Medical","question":"Which laboratory tests are used for AML diagnosis?","answer":"Complete blood count (CBC), comprehensive metabolic panel (CMP), lactate dehydrogenase (LDH), and blood clotting tests are used.","question_type":"Fact Retrieval","evidence":"Complete blood count (CBC) is used for AML diagnosis.; Comprehensive metabolic panel (CMP) is used for AML diagnosis.; Lactate dehydrogenase (LDH) is used for AML diagnosis.; Blood clotting tests are used for AML diagnosis.","evidence_relations":"Laboratory tests used for AML diagnosis include complete blood count (CBC), comprehensive metabolic panel (CMP), lactate dehydrogenase (LDH), and blood clotting tests"},
	{"id":"Medical-6d25f354","source":"Medical","question":"What bone marrow evaluations are performed for AML diagnosis?","answer":"Bone marrow aspirate, bone marrow biopsy, and histopathology are performed.","question_type":"Fact Retrieval","evidence":"Bone marrow aspirate is performed for AML diagnosis.; Bone marrow biopsy is performed for AML diagnosis.; Histopathology is performed for AML diagnosis.","evidence_relations":"Bone marrow evaluation for AML includes bone marrow aspirate, bone marrow biopsy, and histopathology"},
	{"id":"Medical-722f609c","source":"Medical","question":"What molecular and cytogenetic tests are used in AML workup?","answer":"Karyotype, FISH, next-generation sequencing (NGS), and PCR are used.","question_type":"Fact Retrieval","evidence":"Karyotype testing is used in AML workup.; FISH testing is used in AML workup.; Next-generation sequencing (NGS) is used in AML workup.; PCR testing is used in AML workup.","evidence_relations":"Molecular and cytogenetic testing for AML includes karyotype, FISH, next-generation sequencing (NGS), and PCR"},
	{"id":"Medical-9a67636f","source":"Medical","question":"Which imaging modalities assess extramedullary disease in AML?","answer":"CT scan, MRI, and PET/CT are used to assess extramedullary disease or complications.","question_type":"Fact Retrieval","evidence":"CT scan is used to assess extramedullary disease in AML.; MRI is used to assess extramedullary disease in AML.; PET/CT is used to assess extramedullary disease in AML.","evidence_relations":"Imaging (CT, MRI, PET/CT) is used to assess extramedullary disease or complications"},
	{"id":"Medical-b429ff37","source":"Medical","question":"What is the standard of care for AML treatment?","answer":"Chemotherapy is the standard of care for AML.","question_type":"Fact Retrieval","evidence":"Chemotherapy is the standard of care for acute myeloid leukemia (AML).","evidence_relations":"Chemotherapy is the standard of care for AML"},
	{"id":"Medical-1345f015","source":"Medical","question":"Which chemotherapy agents are commonly used in AML?","answer":"Chemotherapy regimens may include cytarabine, daunorubicin, idarubicin, and hypomethylating agents such as azacitidine and decitabine.","question_type":"Fact Retrieval","evidence":"Chemotherapy regimens for AML may include cytarabine.; Chemotherapy regimens for AML may include daunorubicin.; Chemotherapy regimens for AML may include idarubicin.; Chemotherapy regimens for AML may include hypomethylating agents such as azacitidine.; Chemotherapy regimens for AML may include hypomethylating agents such as decitabine.","evidence_relations":"Chemotherapy regimens may include antimetabolites (e.g., cytarabine), anthracyclines (e.g., daunorubicin, idarubicin), and hypomethylating agents (e.g., azacitidine, decitabine)"},
	{"id":"Medical-972209d3","source":"Medical","question":"What is the role of targeted therapy in AML?","answer":"Targeted therapies are used for AML with specific genetic alterations, such as FLT3 inhibitors for FLT3-mutated AML and gemtuzumab ozogamicin for CD33-positive AML.","question_type":"Fact Retrieval","evidence":"Targeted therapies are used for AML with specific genetic alterations.; FLT3 inhibitors are used for FLT3-mutated AML.; Gemtuzumab ozogamicin is used for CD33-positive AML.","evidence_relations":"Targeted therapies are used for AML with specific genetic alterations, such as FLT3 inhibitors for FLT3-mutated AML and gemtuzumab ozogamicin for CD33-positive AML"},
	{"id":"Medical-5cd1d09f","source":"Medical","question":"What are common genetic alterations found in AML?","answer":"Common genetic alterations in AML include FLT3-ITD, FLT3-TKD, inv(16), inv(3), t(8;21), del(5q), and PML::RARA.","question_type":"Fact Retrieval","evidence":"Common genetic alterations in AML include FLT3-ITD.; Common genetic alterations in AML include FLT3-TKD.; Common genetic alterations in AML include inv(16).; Common genetic alterations in AML include inv(3).; Common genetic alterations in AML include t(8;21).; Common genetic alterations in AML include del(5q).; Common genetic alterations in AML include PML::RARA.","evidence_relations":"Common genetic alterations in AML include FLT3-ITD, FLT3-TKD, inv(16), inv(3), t(8;21), del(5q), and PML::RARA"},
	{"id":"Medical-be0f5119","source":"Medical","question":"Which biomarker is targeted by gemtuzumab ozogamicin in AML?","answer":"CD33 is the biomarker targeted by gemtuzumab ozogamicin.","question_type":"Fact Retrieval","evidence":"CD33 is the biomarker targeted by gemtuzumab ozogamicin in AML.","evidence_relations":"Targeted therapies are used for AML with specific genetic alterations, such as gemtuzumab ozogamicin for CD33-positive AML"},
	{"id":"Medical-284507d2","source":"Medical","question":"What is the goal of AML treatment phases?","answer":"The goal of AML treatment phases is achieving remission.","question_type":"Fact Retrieval","evidence":"The goal of AML treatment phases is achieving remission.","evidence_relations":"Treatment for AML is delivered in phases with the goal of achieving remission"},
	{"id":"Medical-514e9bd7","source":"Medical","question":"When is hematopoietic cell transplant considered in AML?","answer":"Hematopoietic cell transplant is considered for eligible patients.","question_type":"Fact Retrieval","evidence":"Hematopoietic cell transplant is considered for eligible patients.","evidence_relations":"Hematopoietic cell transplant is considered for eligible patients"},
	{"id":"Medical-8ee2e2c7","source":"Medical","question":"What factors influence AML treatment selection?","answer":"Performance status and general health influence treatment selection.","question_type":"Fact Retrieval","evidence":"Performance status influences AML treatment selection.; General health influences AML treatment selection.","evidence_relations":"Performance status and general health influence treatment selection"},
	{"id":"Medical-459e0a03","source":"Medical","question":"What should be discussed before starting systemic therapy for AML regarding fertility?","answer":"Fertility preservation should be discussed before starting systemic therapy.","question_type":"Fact Retrieval","evidence":"Fertility preservation should be discussed before starting systemic therapy for AML.","evidence_relations":"Fertility preservation should be discussed before starting systemic therapy"},
	{"id":"Medical-393eabb5","source":"Medical","question":"What supportive care measures are provided in AML?","answer":"Supportive care includes transfusions, infection prevention, and management of side effects.","question_type":"Fact Retrieval","evidence":"Supportive care in AML includes transfusions.; Supportive care in AML includes infection prevention.; Supportive care in AML includes management of side effects.","evidence_relations":"Supportive care includes transfusions, infection prevention, and management of side effects"},
	{"id":"Medical-70d75840","source":"Medical","question":"What are risk factors for developing AML?","answer":"Family history of leukemia and hereditary predisposition syndromes are risk factors for AML.","question_type":"Fact Retrieval","evidence":"Family history of leukemia is a risk factor for developing AML.; Hereditary predisposition syndromes are risk factors for developing AML.","evidence_relations":"Family history of leukemia and hereditary predisposition syndromes are risk factors for AML"},
	{"id":"Medical-99a81ca9","source":"Medical","question":"Which performance status scales are used in AML?","answer":"Eastern Cooperative Oncology Group (ECOG) score and Karnofsky Performance Status (KPS) are used.","question_type":"Fact Retrieval","evidence":"Eastern Cooperative Oncology Group (ECOG) score is used in AML.; Karnofsky Performance Status (KPS) is used in AML.","evidence_relations":"Performance status in AML is assessed using Eastern Cooperative Oncology Group (ECOG) score and Karnofsky Performance Status (KPS)"},
	{"id":"Medical-5d792183","source":"Medical","question":"What is the cell of origin for AML?","answer":"AML originates from myeloid blasts and bone marrow stem cells.","question_type":"Fact Retrieval","evidence":"AML originates from myeloid blasts.; AML originates from bone marrow stem cells.","evidence_relations":"Cell of Origin for AML includes myeloid blasts and bone marrow stem cells"},
	{"id":"Medical-4811934e","source":"Medical","question":"Which tests are used for immunophenotyping in AML diagnosis?","answer":"Flow cytometry and immunophenotyping are used for immunophenotyping in AML diagnosis.","question_type":"Fact Retrieval","evidence":"Flow cytometry is used for immunophenotyping in AML diagnosis.; Immunophenotyping is used for immunophenotyping in AML diagnosis.","evidence_relations":"Flow cytometry and immunophenotyping are used for immunophenotyping in AML diagnosis"},
	{"id":"Medical-81e86b6a","source":"Medical","question":"What genetic alteration is characteristic of APL?","answer":"PML::RARA is the genetic alteration characteristic of APL.","question_type":"Fact Retrieval","evidence":"PML::RARA is the genetic alteration characteristic of APL.","evidence_relations":"Acute promyelocytic leukemia (APL) is a subtype of AML characterized by the PML::RARA fusion gene"},
	{"id":"Medical-bb057eb6","source":"Medical","question":"Which AML subtype commonly involves the skin?","answer":"Blastic plasmacytoid dendritic cell neoplasm (BPDCN) commonly involves the skin.","question_type":"Fact Retrieval","evidence":"Blastic plasmacytoid dendritic cell neoplasm (BPDCN) commonly involves the skin.","evidence_relations":"BPDCN is a subtype of AML with sites of involvement including skin"},
	{"id":"Medical-8ec806c0","source":"Medical","question":"Which agents are classified as hypomethylating agents in AML treatment?","answer":"Azacitidine (Vidaza) and decitabine (Dacogen) are hypomethylating agents used in AML.","question_type":"Fact Retrieval","evidence":"Azacitidine (Vidaza) is a hypomethylating agent used in AML.; Decitabine (Dacogen) is a hypomethylating agent used in AML.","evidence_relations":"Hypomethylating Agents for AML include azacitidine (Vidaza) and decitabine (Dacogen)"},
	{"id":"Medical-ed54bccb","source":"Medical","question":"What are the main phases of AML treatment?","answer":"The main treatment phases are induction, consolidation, and maintenance.","question_type":"Fact Retrieval","evidence":"The main treatment phases of AML are induction.; The main treatment phases of AML are consolidation.; The main treatment phases of AML are maintenance.","evidence_relations":"Treatment Phase for AML includes induction, consolidation, and maintenance"},
	{"id":"Medical-5c36e1bb","source":"Medical","question":"What is the purpose of genetic and biomarker tests in AML?","answer":"Genetic and biomarker tests are used to determine AML subtype and guide treatment.","question_type":"Fact Retrieval","evidence":"Genetic tests are used to determine AML subtype.; Biomarker tests are used to determine AML subtype.; Genetic tests are used to guide treatment in AML.; Biomarker tests are used to guide treatment in AML.","evidence_relations":"Genetic and biomarker tests are used to determine AML subtype and guide treatment"},
	{"id":"Medical-2432d7b4","source":"Medical","question":"Which prognostic factors are important in AML?","answer":"Important prognostic factors in AML are genetic alterations, performance status, age, and response to induction therapy.","question_type":"Fact Retrieval","evidence":"Genetic alterations are important prognostic factors in AML.; Performance status is an important prognostic factor in AML.; Age is an important prognostic factor in AML.; Response to induction therapy is an important prognostic factor in AML.","evidence_relations":"Prognostic Factor for AML includes genetic alterations, performance status, age, and response to induction therapy"},
	{"id":"Medical-67b8e0a9","source":"Medical","question":"What fertility preservation options are recommended in AML?","answer":"Fertility preservation counseling and referral to a reproductive specialist are recommended.","question_type":"Fact Retrieval","evidence":"Fertility preservation counseling is recommended in AML.; Referral to a reproductive specialist is recommended in AML.","evidence_relations":"Fertility Preservation in AML includes fertility preservation counseling and referral to reproductive specialist"},
	{"id":"Medical-78cecf8c","source":"Medical","question":"What is the most common type of ovarian cancer?","answer":"Ovarian cancer is most commonly an epithelial cancer arising from the ovary surface epithelium.","question_type":"Fact Retrieval","evidence":"Ovarian cancer is most commonly an epithelial cancer.; Epithelial cancer arises from the ovary surface epithelium.","evidence_relations":"Ovarian cancer is most commonly an epithelial cancer arising from the ovary surface epithelium"},
	{"id":"Medical-17badae3","source":"Medical","question":"Which subtypes are most common in epithelial ovarian cancer?","answer":"High-grade serous carcinoma and high-grade endometrioid carcinoma are the most common subtypes.","question_type":"Fact Retrieval","evidence":"High-grade serous carcinoma is a common subtype of epithelial ovarian cancer.; High-grade endometrioid carcinoma is a common subtype of epithelial ovarian cancer.","evidence_relations":"High-grade serous carcinoma and high-grade endometrioid carcinoma are the most common subtypes of epithelial ovarian cancer"},
	{"id":"Medical-1bb1f1db","source":"Medical","question":"What are some less common subtypes of ovarian cancer?","answer":"Less common ovarian cancers include low-grade serous carcinoma, low-grade endometrioid carcinoma, carcinosarcoma, clear cell carcinoma, mucinous carcinoma, borderline epithelial tumor, malignant sex-cord stromal tumors, and malignant germ cell tumors.","question_type":"Fact Retrieval","evidence":"Less common ovarian cancers include low-grade serous carcinoma.; Less common ovarian cancers include low-grade endometrioid carcinoma.; Less common ovarian cancers include carcinosarcoma.; Less common ovarian cancers include clear cell carcinoma.; Less common ovarian cancers include mucinous carcinoma.; Less common ovarian cancers include borderline epithelial tumor.; Less common ovarian cancers include malignant sex-cord stromal tumors.; Less common ovarian cancers include malignant germ cell tumors.","evidence_relations":"Less common ovarian cancers include low-grade serous carcinoma, low-grade endometrioid carcinoma, carcinosarcoma, clear cell carcinoma, mucinous carcinoma, borderline epithelial tumor, malignant sex-cord stromal tumors, and malignant germ cell tumors"},
	{"id":"Medical-ceb6a99b","source":"Medical","question":"Which cancers are managed similarly to ovarian cancer?","answer":"Primary peritoneal cancer and fallopian tube cancer are managed similarly to ovarian cancer.","question_type":"Fact Retrieval","evidence":"Primary peritoneal cancer is managed similarly to ovarian cancer.; Fallopian tube cancer is managed similarly to ovarian cancer.","evidence_relations":"Primary peritoneal cancer and fallopian tube cancer are managed similarly to ovarian cancer"},
	{"id":"Medical-c4b74b77","source":"Medical","question":"What imaging methods are used to diagnose ovarian cancer?","answer":"Diagnosis of ovarian cancer involves imaging such as ultrasound, CT, MRI, and PET.","question_type":"Fact Retrieval","evidence":"Ultrasound is used to diagnose ovarian cancer.; CT is used to diagnose ovarian cancer.; MRI is used to diagnose ovarian cancer.; PET is used to diagnose ovarian cancer.","evidence_relations":"Diagnosis of ovarian cancer involves imaging (ultrasound, CT, MRI, PET), abdominal and pelvic exam, biopsy, and blood tests including tumor markers"},
	{"id":"Medical-1a736b11","source":"Medical","question":"What are the common symptoms of ovarian cancer?","answer":"Common symptoms include bloating, pelvic or abdominal pain, trouble eating or feeling full quickly, urinary urgency or frequency, and pain during sex.","question_type":"Fact Retrieval","evidence":"Common symptoms of ovarian cancer include bloating.; Common symptoms of ovarian cancer include pelvic or abdominal pain.; Common symptoms of ovarian cancer include trouble eating or feeling full quickly.; Common symptoms of ovarian cancer include urinary urgency or frequency.; Common symptoms of ovarian cancer include pain during sex.","evidence_relations":"Common symptoms of ovarian cancer include bloating, pelvic or abdominal pain, trouble eating or feeling full quickly, urinary urgency or frequency, and pain during sex"},
	{"id":"Medical-d8149b81","source":"Medical","question":"Which hereditary syndromes are major risk factors for ovarian cancer?","answer":"BRCA1 and BRCA2 mutations and Lynch syndrome are major hereditary risk factors.","question_type":"Fact Retrieval","evidence":"BRCA1 mutations are a major hereditary risk factor for ovarian cancer.; BRCA2 mutations are a major hereditary risk factor for ovarian cancer.; Lynch syndrome is a major hereditary risk factor for ovarian cancer.","evidence_relations":"BRCA1 and BRCA2 mutations and Lynch syndrome are major hereditary risk factors for ovarian cancer"},
	{"id":"Medical-40918a31","source":"Medical","question":"Who should receive genetic testing for BRCA and other syndromes in ovarian cancer?","answer":"Genetic testing for BRCA and other hereditary syndromes is recommended for all patients with ovarian cancer.","question_type":"Fact Retrieval","evidence":"Genetic testing for BRCA and other hereditary syndromes is recommended for all patients with ovarian cancer.","evidence_relations":"Genetic testing for BRCA and other hereditary syndromes is recommended for all patients with ovarian cancer"},
	{"id":"Medical-1043deff","source":"Medical","question":"What tumor biomarker tests are performed in ovarian cancer?","answer":"Tumor biomarker testing includes BRCA mutation, HRD status, MSI, MMR, HER2 expression, TMB, BRAF V600E, FR, RET mutations, and NTRK gene fusion.","question_type":"Fact Retrieval","evidence":"Tumor biomarker testing includes BRCA mutation.; Tumor biomarker testing includes HRD status.; Tumor biomarker testing includes MSI.; Tumor biomarker testing includes MMR.; Tumor biomarker testing includes HER2 expression.; Tumor biomarker testing includes TMB.; Tumor biomarker testing includes BRAF V600E.; Tumor biomarker testing includes FR.; Tumor biomarker testing includes RET mutations.; Tumor biomarker testing includes NTRK gene fusion.","evidence_relations":"Tumor biomarker testing includes BRCA mutation, HRD status, MSI, MMR, HER2 expression, TMB, BRAF V600E, FR, RET mutations, and NTRK gene fusion"},
	{"id":"Medical-cd6393dc","source":"Medical","question":"What staging system is used for ovarian cancer?","answer":"Staging is based on the FIGO system (Stages I-IV) and requires surgical staging.","question_type":"Fact Retrieval","evidence":"Staging of ovarian cancer is based on the FIGO system.; The FIGO system has stages I-IV.; Surgical staging is required for ovarian cancer.","evidence_relations":"Staging is based on the FIGO system (Stages I-IV) and requires surgical staging"},
	{"id":"Medical-cf87aed7","source":"Medical","question":"What is the standard initial treatment for most ovarian cancers?","answer":"Surgery (hysterectomy with bilateral salpingo-oophorectomy) is the standard initial treatment for most ovarian cancers.","question_type":"Fact Retrieval","evidence":"Surgery is the standard initial treatment for most ovarian cancers.; The standard initial surgery is a hysterectomy with bilateral salpingo-oophorectomy.","evidence_relations":"Surgery (hysterectomy with bilateral salpingo-oophorectomy) is the standard initial treatment for most ovarian cancers"},
	{"id":"Medical-767b1550","source":"Medical","question":"When may fertility-sparing surgery be considered in ovarian cancer?","answer":"Fertility-sparing surgery may be considered for select early-stage cases.","question_type":"Fact Retrieval","evidence":"Fertility-sparing surgery may be considered for select early-stage cases in ovarian cancer.","evidence_relations":"Fertility-sparing surgery may be considered for select early-stage cases"},
	{"id":"Medical-ae9a09e0","source":"Medical","question":"What chemotherapy regimen is typically recommended after surgery for ovarian cancer?","answer":"Chemotherapy (typically paclitaxel and carboplatin) is recommended after surgery for most stages.","question_type":"Fact Retrieval","evidence":"Chemotherapy is typically recommended after surgery for ovarian cancer.; Paclitaxel is a chemotherapy drug recommended after surgery for ovarian cancer.; Carboplatin is a chemotherapy drug recommended after surgery for ovarian cancer.; Chemotherapy is recommended for most stages of ovarian cancer.","evidence_relations":"Chemotherapy (typically paclitaxel and carboplatin) is recommended after surgery for most stages"},
	{"id":"Medical-2ca3a0ac","source":"Medical","question":"Which drug may be added to chemotherapy in some ovarian cancer cases?","answer":"Bevacizumab may be added to chemotherapy in some cases.","question_type":"Fact Retrieval","evidence":"Bevacizumab may be added to chemotherapy in some ovarian cancer cases.","evidence_relations":"Bevacizumab may be added to chemotherapy in some cases"},
	{"id":"Medical-ba9612df","source":"Medical","question":"Which maintenance therapies are recommended for advanced or BRCA-mutated/HRD-positive ovarian cancers after initial treatment?","answer":"Maintenance therapy with PARP inhibitors (olaparib, niraparib, rucaparib) is recommended for advanced or BRCA-mutated/HRD-positive cancers after initial treatment.","question_type":"Fact Retrieval","evidence":"Maintenance therapy with PARP inhibitors is recommended for advanced ovarian cancers.; Maintenance therapy with PARP inhibitors is recommended for BRCA-mutated ovarian cancers.; Maintenance therapy with PARP inhibitors is recommended for HRD-positive ovarian cancers.; Olaparib is a PARP inhibitor recommended for maintenance therapy.; Niraparib is a PARP inhibitor recommended for maintenance therapy.; Rucaparib is a PARP inhibitor recommended for maintenance therapy.","evidence_relations":"Maintenance therapy with PARP inhibitors (olaparib, niraparib, rucaparib) is recommended for advanced or BRCA-mutated/HRD-positive cancers after initial treatment"},
	{"id":"Medical-3e80d395","source":"Medical","question":"What does surveillance after ovarian cancer treatment include?","answer":"Surveillance after treatment includes regular physical and pelvic exams, and monitoring of CA-125 or other tumor markers.","question_type":"Fact Retrieval","evidence":"Surveillance after ovarian cancer treatment includes regular physical exams.; Surveillance after ovarian cancer treatment includes pelvic exams.; Surveillance after ovarian cancer treatment includes monitoring of CA-125.; Surveillance after ovarian cancer treatment includes monitoring of other tumor markers.","evidence_relations":"Surveillance after treatment includes regular physical and pelvic exams, and monitoring of CA-125 or other tumor markers"},
	{"id":"Medical-4160eed8","source":"Medical","question":"How is recurrence of ovarian cancer managed?","answer":"Recurrence is managed based on platinum sensitivity, biomarker status, and may include surgery, chemotherapy, targeted therapy, immunotherapy, or clinical trial enrollment.","question_type":"Fact Retrieval","evidence":"Recurrence of ovarian cancer is managed based on platinum sensitivity.; Recurrence of ovarian cancer is managed based on biomarker status.; Management of recurrence may include surgery.; Management of recurrence may include chemotherapy.; Management of recurrence may include targeted therapy.; Management of recurrence may include immunotherapy.; Management of recurrence may include clinical trial enrollment.","evidence_relations":"Recurrence is managed based on platinum sensitivity, biomarker status, and may include surgery, chemotherapy, targeted therapy, immunotherapy, or clinical trial enrollment"},
	{"id":"Medical-0ce3e959","source":"Medical","question":"What are the treatment options for platinum-resistant ovarian cancer?","answer":"Platinum-resistant ovarian cancer is treated with non-platinum chemotherapy, bevacizumab, or targeted therapies such as mirvetuximab soravtansine-gynx for FR-positive tumors.","question_type":"Fact Retrieval","evidence":"Platinum-resistant ovarian cancer is treated with non-platinum chemotherapy.; Bevacizumab is a treatment option for platinum-resistant ovarian cancer.; Targeted therapies are treatment options for platinum-resistant ovarian cancer.; Mirvetuximab soravtansine-gynx is a targeted therapy for FR-positive tumors.","evidence_relations":"Platinum-resistant ovarian cancer is treated with non-platinum chemotherapy, bevacizumab, or targeted therapies such as mirvetuximab soravtansine-gynx for FR-positive tumors"},
	{"id":"Medical-7caf80a1","source":"Medical","question":"How is platinum-sensitive recurrence of ovarian cancer treated?","answer":"Platinum-sensitive recurrence is treated with platinum-based chemotherapy, possibly with bevacizumab, and may include secondary cytoreductive surgery.","question_type":"Fact Retrieval","evidence":"Platinum-sensitive recurrence of ovarian cancer is treated with platinum-based chemotherapy.; Bevacizumab may be used in the treatment of platinum-sensitive recurrence.; Secondary cytoreductive surgery may be included in the treatment of platinum-sensitive recurrence.","evidence_relations":"Platinum-sensitive recurrence is treated with platinum-based chemotherapy, possibly with bevacizumab, and may include secondary cytoreductive surgery"},
	{"id":"Medical-41491cb3","source":"Medical","question":"When are clinical trials recommended for ovarian cancer?","answer":"Clinical trials are recommended for recurrent or persistent ovarian cancer.","question_type":"Fact Retrieval","evidence":"Clinical trials are recommended for recurrent ovarian cancer.; Clinical trials are recommended for persistent ovarian cancer.","evidence_relations":"Clinical trials are recommended for recurrent or persistent ovarian cancer"},
	{"id":"Medical-fcbaf737","source":"Medical","question":"Which tumor markers are used in ovarian cancer diagnosis?","answer":"Tumor markers include CA-125, Inhibin, Beta-human chorionic gonadotropin (-hCG), Alpha-fetoprotein (AFP), Lactate dehydrogenase (LDH), Carcinoembryonic antigen (CEA), CA 19-9, and HE4.","question_type":"Fact Retrieval","evidence":"Tumor markers used in ovarian cancer diagnosis include CA-125.; Tumor markers used in ovarian cancer diagnosis include Inhibin.; Tumor markers used in ovarian cancer diagnosis include Beta-human chorionic gonadotropin (-hCG).; Tumor markers used in ovarian cancer diagnosis include Alpha-fetoprotein (AFP).; Tumor markers used in ovarian cancer diagnosis include Lactate dehydrogenase (LDH).; Tumor markers used in ovarian cancer diagnosis include Carcinoembryonic antigen (CEA).; Tumor markers used in ovarian cancer diagnosis include CA 19-9.; Tumor markers used in ovarian cancer diagnosis include HE4.","evidence_relations":"Tumor marker tests include CA-125, Inhibin, Beta-human chorionic gonadotropin (-hCG), Alpha-fetoprotein (AFP), Lactate dehydrogenase (LDH), Carcinoembryonic antigen (CEA), CA 19-9, HE4"},
	{"id":"Medical-6b4b11a7","source":"Medical","question":"Which diagnostic procedures are available for ovarian cancer?","answer":"Diagnostic methods include abdominal and pelvic exam, ultrasound, CT scan, MRI, PET scan, chest x-ray, diagnostic laparoscopy, biopsy, FNA, core biopsy, paracentesis, colonoscopy, upper endoscopy, CBC, blood chemistry profile, and liver function tests.","question_type":"Fact Retrieval","evidence":"Diagnostic methods for ovarian cancer include abdominal exams.; Diagnostic methods for ovarian cancer include pelvic exams.; Diagnostic methods for ovarian cancer include ultrasound.; Diagnostic methods for ovarian cancer include CT scan.; Diagnostic methods for ovarian cancer include MRI.; Diagnostic methods for ovarian cancer include PET scan.; Diagnostic methods for ovarian cancer include chest x-ray.; Diagnostic methods for ovarian cancer include diagnostic laparoscopy.; Diagnostic methods for ovarian cancer include biopsy.; Diagnostic methods for ovarian cancer include FNA.; Diagnostic methods for ovarian cancer include core biopsy.; Diagnostic methods for ovarian cancer include paracentesis.; Diagnostic methods for ovarian cancer include colonoscopy.; Diagnostic methods for ovarian cancer include upper endoscopy.; Diagnostic methods for ovarian cancer include CBC.; Diagnostic methods for ovarian cancer include blood chemistry profile.; Diagnostic methods for ovarian cancer include liver function tests.","evidence_relations":"Diagnostic Method includes abdominal and pelvic exam, ultrasound, CT scan, MRI, PET scan, chest x-ray, diagnostic laparoscopy, biopsy, fine-needle aspiration (FNA), core biopsy, paracentesis, colonoscopy, upper endoscopy, complete blood count (CBC), blood chemistry profile, liver function tests"},
	{"id":"Medical-476ca8b6","source":"Medical","question":"What surgical procedures are included in the treatment of ovarian cancer?","answer":"Surgical procedures include hysterectomy, bilateral salpingo-oophorectomy, unilateral salpingo-oophorectomy, debulking surgery, cytoreductive surgery, interval cytoreductive surgery, laparotomy, laparoscopy, and peritoneal washing.","question_type":"Fact Retrieval","evidence":"Surgical procedures for ovarian cancer include hysterectomy.; Surgical procedures for ovarian cancer include bilateral salpingo-oophorectomy.; Surgical procedures for ovarian cancer include unilateral salpingo-oophorectomy.; Surgical procedures for ovarian cancer include debulking surgery.; Surgical procedures for ovarian cancer include cytoreductive surgery.; Surgical procedures for ovarian cancer include interval cytoreductive surgery.; Surgical procedures for ovarian cancer include laparotomy.; Surgical procedures for ovarian cancer include laparoscopy.; Surgical procedures for ovarian cancer include peritoneal washing.","evidence_relations":"Surgical Procedure includes hysterectomy, bilateral salpingo-oophorectomy (BSO), unilateral salpingo-oophorectomy (USO), debulking surgery, cytoreductive surgery, interval cytoreductive surgery (ICS), laparotomy, laparoscopy, peritoneal washing"},
	{"id":"Medical-451efc66","source":"Medical","question":"Which chemotherapy drugs are commonly used in ovarian cancer?","answer":"Common chemotherapy drugs include paclitaxel, carboplatin, cisplatin, oxaliplatin, docetaxel, and bevacizumab.","question_type":"Fact Retrieval","evidence":"Common chemotherapy drugs for ovarian cancer include paclitaxel.; Common chemotherapy drugs for ovarian cancer include carboplatin.; Common chemotherapy drugs for ovarian cancer include cisplatin.; Common chemotherapy drugs for ovarian cancer include oxaliplatin.; Common chemotherapy drugs for ovarian cancer include docetaxel.; Common chemotherapy drugs for ovarian cancer include bevacizumab.","evidence_relations":"Chemotherapy Regimen includes paclitaxel, carboplatin, cisplatin, oxaliplatin, docetaxel, bevacizumab (Avastin)"},
	{"id":"Medical-365a0e76","source":"Medical","question":"Which maintenance therapies are available for ovarian cancer?","answer":"Maintenance therapies include olaparib, niraparib, rucaparib, bevacizumab, and mirvetuximab soravtansine-gynx.","question_type":"Fact Retrieval","evidence":"Maintenance therapies for ovarian cancer include olaparib.; Maintenance therapies for ovarian cancer include niraparib.; Maintenance therapies for ovarian cancer include rucaparib.; Maintenance therapies for ovarian cancer include bevacizumab.; Maintenance therapies for ovarian cancer include mirvetuximab soravtansine-gynx.","evidence_relations":"Maintenance Therapy includes olaparib (Lynparza), niraparib (Zejula), rucaparib (Rubraca), bevacizumab (Avastin), mirvetuximab soravtansine-gynx (Elahere)"},
	{"id":"Medical-181dd442","source":"Medical","question":"What genetic alterations are tested for in ovarian cancer?","answer":"Genetic alterations tested include BRCA1 mutation, BRCA2 mutation, HRD, MSI, MMR, HER2 expression, TMB, BRAF V600E, FR, RET mutation, and NTRK gene fusion.","question_type":"Fact Retrieval","evidence":"Genetic alterations tested for ovarian cancer include BRCA1 mutation.; Genetic alterations tested for ovarian cancer include BRCA2 mutation.; Genetic alterations tested for ovarian cancer include HRD.; Genetic alterations tested for ovarian cancer include MSI.; Genetic alterations tested for ovarian cancer include MMR.; Genetic alterations tested for ovarian cancer include HER2 expression.; Genetic alterations tested for ovarian cancer include TMB.; Genetic alterations tested for ovarian cancer include BRAF V600E.; Genetic alterations tested for ovarian cancer include FR.; Genetic alterations tested for ovarian cancer include RET mutation.; Genetic alterations tested for ovarian cancer include NTRK gene fusion.","evidence_relations":"Genetic Alteration includes BRCA1 mutation, BRCA2 mutation, homologous recombination deficiency (HRD), microsatellite instability (MSI), mismatch repair (MMR), HER2 expression, tumor mutational burden (TMB), BRAF V600E mutation, folate receptor alpha (FR), RET mutation, NTRK gene fusion"},
	{"id":"Medical-fbef0cd8","source":"Medical","question":"What are the main risk factors for ovarian cancer?","answer":"Risk factors include BRCA1 mutation, BRCA2 mutation, Lynch syndrome, and family history.","question_type":"Fact Retrieval","evidence":"Main risk factors for ovarian cancer include BRCA1 mutation.; Main risk factors for ovarian cancer include BRCA2 mutation.; Main risk factors for ovarian cancer include Lynch syndrome.; Main risk factors for ovarian cancer include family history.","evidence_relations":"Risk Factor includes BRCA1 mutation, BRCA2 mutation, Lynch syndrome, Family history"},
	{"id":"Medical-070e0d62","source":"Medical","question":"What are the stages of ovarian cancer according to the FIGO system?","answer":"The stages are Stage I (IA, IB, IC1, IC2, IC3), Stage II (IIA, IIB), Stage III (IIIA1(i), IIIA1(ii), IIIA2, IIIB, IIIC), and Stage IV (IVA, IVB).","question_type":"Fact Retrieval","evidence":"The stages of ovarian cancer according to the FIGO system include Stage I.; Stage I includes IA, IB, IC1, IC2, and IC3.; The stages of ovarian cancer according to the FIGO system include Stage II.; Stage II includes IIA and IIB.; The stages of ovarian cancer according to the FIGO system include Stage III.; Stage III includes IIIA1(i), IIIA1(ii), IIIA2, IIIB, and IIIC.; The stages of ovarian cancer according to the FIGO system include Stage IV.; Stage IV includes IVA and IVB.","evidence_relations":"Stage includes Stage I (IA, IB, IC1, IC2, IC3), Stage II (IIA, IIB), Stage III (IIIA1(i), IIIA1(ii), IIIA2, IIIB, IIIC), Stage IV (IVA, IVB)"},
	{"id":"Medical-adf818a2","source":"Medical","question":"What are common symptoms of ovarian cancer listed in the ontology?","answer":"Common symptoms include persistent bloating, pelvic pain, abdominal pain, trouble eating, feeling full quickly, urinary urgency, urinary frequency, pain during sex, fatigue, unexplained weight loss, and constipation.","question_type":"Fact Retrieval","evidence":"Common symptoms of ovarian cancer include persistent bloating.; Common symptoms of ovarian cancer include pelvic pain.; Common symptoms of ovarian cancer include abdominal pain.; Common symptoms of ovarian cancer include trouble eating.; Common symptoms of ovarian cancer include feeling full quickly.; Common symptoms of ovarian cancer include urinary urgency.; Common symptoms of ovarian cancer include urinary frequency.; Common symptoms of ovarian cancer include pain during sex.; Common symptoms of ovarian cancer include fatigue.; Common symptoms of ovarian cancer include unexplained weight loss.; Common symptoms of ovarian cancer include constipation.","evidence_relations":"Symptom includes persistent bloating, pelvic pain, abdominal pain, trouble eating, feeling full quickly, urinary urgency, urinary frequency, pain during sex, fatigue, unexplained weight loss, constipation"},
	{"id":"Medical-218c665a","source":"Medical","question":"What is the role of CA-125 in ovarian cancer management?","answer":"CA-125 is used for tumor marker monitoring in surveillance after treatment.","question_type":"Fact Retrieval","evidence":"CA-125 is used for tumor marker monitoring.; CA-125 is used in surveillance after treatment for ovarian cancer.","evidence_relations":"Surveillance after treatment includes regular physical and pelvic exams, and monitoring of CA-125 or other tumor markers"},
	{"id":"Medical-0f6078ff","source":"Medical","question":"Which therapies are considered for recurrent ovarian cancer based on platinum sensitivity?","answer":"Platinum-sensitive recurrence is treated with platinum-based chemotherapy, possibly with bevacizumab and secondary cytoreductive surgery; platinum-resistant recurrence is treated with non-platinum chemotherapy, bevacizumab, mirvetuximab soravtansine-gynx, targeted therapy, or immunotherapy.","question_type":"Fact Retrieval","evidence":"Platinum-sensitive recurrence of ovarian cancer is treated with platinum-based chemotherapy.; Platinum-sensitive recurrence may be treated with bevacizumab.; Platinum-sensitive recurrence may involve secondary cytoreductive surgery.; Platinum-resistant recurrence of ovarian cancer is treated with non-platinum chemotherapy.; Platinum-resistant recurrence may be treated with bevacizumab.; Platinum-resistant recurrence may be treated with mirvetuximab soravtansine-gynx.; Platinum-resistant recurrence may involve targeted therapy.; Platinum-resistant recurrence may involve immunotherapy.","evidence_relations":"Recurrence is managed based on platinum sensitivity, biomarker status, and may include surgery, chemotherapy, targeted therapy, immunotherapy, or clinical trial enrollment"},
	{"id":"Medical-e7671bff","source":"Medical","question":"What is the recommended management for recurrent or persistent ovarian cancer?","answer":"Clinical trial enrollment is recommended for recurrent or persistent disease.","question_type":"Fact Retrieval","evidence":"Clinical trial enrollment is recommended for recurrent ovarian cancer.; Clinical trial enrollment is recommended for persistent ovarian cancer.","evidence_relations":"Clinical trial enrollment for recurrent or persistent disease"},
	{"id":"Medical-bff939bb","source":"Medical","question":"What type of cancer is chronic lymphocytic leukemia (CLL)?","answer":"CLL is a type of blood cancer affecting B lymphocytes.","question_type":"Fact Retrieval","evidence":"Chronic lymphocytic leukemia (CLL) is a type of blood cancer.; CLL affects B lymphocytes.","evidence_relations":"Chronic lymphocytic leukemia (CLL) is a type of blood cancer affecting B lymphocytes"},
	{"id":"Medical-33f78c6c","source":"Medical","question":"What is the main difference between CLL and SLL?","answer":"SLL is the same cancer as CLL but primarily found in lymph nodes and spleen.","question_type":"Fact Retrieval","evidence":"SLL is the same cancer as CLL.; SLL is primarily found in lymph nodes.; SLL is primarily found in the spleen.","evidence_relations":"Small lymphocytic lymphoma (SLL) is the same cancer as CLL but primarily found in lymph nodes and spleen"},
	{"id":"Medical-7c7f4d0b","source":"Medical","question":"Which cells are affected in CLL?","answer":"B lymphocytes are affected in CLL.","question_type":"Fact Retrieval","evidence":"B lymphocytes are affected in CLL.","evidence_relations":"Chronic lymphocytic leukemia (CLL) is a type of blood cancer affecting B lymphocytes"},
	{"id":"Medical-bdb21d34","source":"Medical","question":"What is the primary site of SLL?","answer":"The primary site of SLL is the lymph nodes and spleen.","question_type":"Fact Retrieval","evidence":"The primary site of SLL is the lymph nodes.; The primary site of SLL is the spleen.","evidence_relations":"Small lymphocytic lymphoma (SLL) is the same cancer as CLL but primarily found in lymph nodes and spleen"},
	{"id":"Medical-150e36b6","source":"Medical","question":"How is CLL/SLL diagnosed?","answer":"CLL/SLL is diagnosed by blood test showing 5,000 monoclonal B lymphocytes per microliter.","question_type":"Fact Retrieval","evidence":"CLL/SLL is diagnosed by a blood test.; The blood test shows 5,000 monoclonal B lymphocytes per microliter.","evidence_relations":"CLL/SLL is diagnosed by blood test showing 5,000 monoclonal B lymphocytes per microliter"},
	{"id":"Medical-cdfc9ecd","source":"Medical","question":"What are common symptoms of CLL?","answer":"Symptoms of CLL include swollen glands, fatigue, night sweats, fever, recurrent infections, early satiety, and unintentional weight loss.","question_type":"Fact Retrieval","evidence":"Common symptoms of CLL include swollen glands.; Common symptoms of CLL include fatigue.; Common symptoms of CLL include night sweats.; Common symptoms of CLL include fever.; Common symptoms of CLL include recurrent infections.; Common symptoms of CLL include early satiety.; Common symptoms of CLL include unintentional weight loss.","evidence_relations":"Symptoms of CLL include swollen glands, fatigue, night sweats, fever, recurrent infections, early satiety, and unintentional weight loss"},
	{"id":"Medical-2ea1a654","source":"Medical","question":"Can CLL be asymptomatic?","answer":"CLL may be asymptomatic and discovered incidentally on routine blood testing.","question_type":"Fact Retrieval","evidence":"CLL may be asymptomatic.; CLL may be discovered incidentally on routine blood testing.","evidence_relations":"CLL may be asymptomatic and discovered incidentally on routine blood testing"},
	{"id":"Medical-4f070485","source":"Medical","question":"What are risk factors for developing CLL?","answer":"Risk factors for CLL include older age and family history of CLL.","question_type":"Fact Retrieval","evidence":"Risk factors for developing CLL include older age.; Risk factors for developing CLL include family history of CLL.","evidence_relations":"Risk factors for CLL include older age and family history of CLL"},
	{"id":"Medical-ae21e753","source":"Medical","question":"Which diagnostic methods are used to confirm CLL?","answer":"CLL is confirmed by blood test, flow cytometry, and may require lymph node or bone marrow biopsy.","question_type":"Fact Retrieval","evidence":"CLL is confirmed by a blood test.; CLL is confirmed by flow cytometry.; Confirming CLL may require a lymph node biopsy.; Confirming CLL may require a bone marrow biopsy.","evidence_relations":"CLL is confirmed by blood test, flow cytometry, and may require lymph node or bone marrow biopsy"},
	{"id":"Medical-e33e6d40","source":"Medical","question":"What surface proteins are identified in CLL cells by immunophenotyping?","answer":"Immunophenotyping identifies CLL cells by surface proteins such as CD20, CD200, and LEF1.","question_type":"Fact Retrieval","evidence":"Immunophenotyping identifies CLL cells by surface proteins.; Surface proteins identified in CLL cells include CD20.; Surface proteins identified in CLL cells include CD200.; Surface proteins identified in CLL cells include LEF1.","evidence_relations":"Immunophenotyping identifies CLL cells by surface proteins such as CD20, CD200, and LEF1"},
	{"id":"Medical-9f0ba939","source":"Medical","question":"Which biomarker tests are performed in CLL?","answer":"Biomarker testing includes FISH for 17p deletion, DNA sequencing for TP53 and IGHV mutations, and karyotype analysis.","question_type":"Fact Retrieval","evidence":"Biomarker testing for CLL includes FISH for 17p deletion.; Biomarker testing for CLL includes DNA sequencing for TP53 mutations.; Biomarker testing for CLL includes DNA sequencing for IGHV mutations.; Biomarker testing for CLL includes karyotype analysis.","evidence_relations":"Biomarker testing includes FISH for 17p deletion, DNA sequencing for TP53 and IGHV mutations, and karyotype analysis"},
	{"id":"Medical-d115e18c","source":"Medical","question":"What is the significance of beta-2 microglobulin in CLL?","answer":"Beta-2 microglobulin is a biomarker associated with CLL disease activity and prognosis.","question_type":"Fact Retrieval","evidence":"Beta-2 microglobulin is a biomarker associated with CLL disease activity.; Beta-2 microglobulin is a biomarker associated with CLL prognosis.","evidence_relations":"Beta-2 microglobulin is a biomarker associated with CLL disease activity and prognosis"},
	{"id":"Medical-99f96fdf","source":"Medical","question":"When is treatment for CLL/SLL initiated?","answer":"Treatment for CLL/SLL may not be needed immediately and is based on symptoms, blood counts, and disease progression.","question_type":"Fact Retrieval","evidence":"Treatment for CLL/SLL may not be needed immediately.; Treatment for CLL/SLL is based on symptoms.; Treatment for CLL/SLL is based on blood counts.; Treatment for CLL/SLL is based on disease progression.","evidence_relations":"Treatment for CLL/SLL may not be needed immediately and is based on symptoms, blood counts, and disease progression"},
	{"id":"Medical-e773a3cf","source":"Medical","question":"What are the treatment options for CLL/SLL?","answer":"Treatment options include oral medications, IV infusions, and combination therapies.","question_type":"Fact Retrieval","evidence":"Treatment options for CLL/SLL include oral medications.; Treatment options for CLL/SLL include IV infusions.; Treatment options for CLL/SLL include combination therapies.","evidence_relations":"Treatment options include oral medications, IV infusions, and combination therapies"},
	{"id":"Medical-37aba842","source":"Medical","question":"What is Richter transformation in CLL?","answer":"Richter transformation is a complication where CLL transforms into a more aggressive lymphoma such as DLBCL or Hodgkin lymphoma.","question_type":"Fact Retrieval","evidence":"Richter transformation is a complication of CLL.; Richter transformation involves CLL transforming into a more aggressive lymphoma.; Richter transformation can involve DLBCL.; Richter transformation can involve Hodgkin lymphoma.","evidence_relations":"Richter transformation is a complication where CLL transforms into a more aggressive lymphoma such as DLBCL or Hodgkin lymphoma"},
	{"id":"Medical-7102e82d","source":"Medical","question":"What follow-up strategies are recommended for CLL?","answer":"Follow-up strategies include watch and wait, regular monitoring, and supportive care.","question_type":"Fact Retrieval","evidence":"Follow-up strategies for CLL include watch and wait.; Follow-up strategies for CLL include regular monitoring.; Follow-up strategies for CLL include supportive care.","evidence_relations":"Follow-up strategies include watch and wait, regular monitoring, and supportive care"},
	{"id":"Medical-3eec0277","source":"Medical","question":"What imaging method is used to assess lymph node involvement in CLL?","answer":"Diagnostic CT scans may be used to assess lymph node involvement and disease extent.","question_type":"Fact Retrieval","evidence":"Diagnostic CT scans may be used to assess lymph node involvement in CLL.; Diagnostic CT scans may be used to assess disease extent in CLL.","evidence_relations":"Diagnostic CT scans may be used to assess lymph node involvement and disease extent"},
	{"id":"Medical-b31acd9a","source":"Medical","question":"What factors are considered in CLL treatment planning?","answer":"Performance status and comprehensive metabolic panel are used in treatment planning.","question_type":"Fact Retrieval","evidence":"Performance status is considered in CLL treatment planning.; Comprehensive metabolic panel is used in CLL treatment planning.","evidence_relations":"Performance status and comprehensive metabolic panel are used in treatment planning"},
	{"id":"Medical-a43be732","source":"Medical","question":"How does family history affect CLL risk?","answer":"Family history increases the risk of developing CLL.","question_type":"Fact Retrieval","evidence":"Family history increases the risk of developing CLL.","evidence_relations":"Family history increases the risk of developing CLL"},
	{"id":"Medical-3d64f92a","source":"Medical","question":"What is the treatment goal regarding minimal residual disease in CLL?","answer":"Minimal residual disease is a treatment goal indicating mostly healthy blood cells.","question_type":"Fact Retrieval","evidence":"Minimal residual disease is a treatment goal in CLL.; Minimal residual disease indicates mostly healthy blood cells.","evidence_relations":"Minimal residual disease is a treatment goal indicating mostly healthy blood cells"},
	{"id":"Medical-7bc6693e","source":"Medical","question":"What considerations are needed before starting CLL treatment in women of reproductive age?","answer":"Pregnancy testing and fertility preservation are considered before starting treatment.","question_type":"Fact Retrieval","evidence":"Pregnancy testing is considered before starting CLL treatment in women of reproductive age.; Fertility preservation is considered before starting CLL treatment in women of reproductive age.","evidence_relations":"Pregnancy testing and fertility preservation are considered before starting treatment"},
	{"id":"Medical-92b44036","source":"Medical","question":"Which genetic alterations are relevant in CLL biomarker testing?","answer":"Relevant genetic alterations include 17p deletion, TP53 mutation, and IGHV mutation.","question_type":"Fact Retrieval","evidence":"17p deletion is a relevant genetic alteration in CLL biomarker testing.; TP53 mutation is a relevant genetic alteration in CLL biomarker testing.; IGHV mutation is a relevant genetic alteration in CLL biomarker testing.","evidence_relations":"Biomarker testing includes FISH for 17p deletion, DNA sequencing for TP53 and IGHV mutations, and karyotype analysis"},
	{"id":"Medical-c9a77eee","source":"Medical","question":"What is the role of flow cytometry in CLL diagnosis?","answer":"Flow cytometry is used to confirm CLL by identifying characteristic immunophenotypes.","question_type":"Fact Retrieval","evidence":"Flow cytometry is used to confirm CLL.; Flow cytometry identifies characteristic immunophenotypes in CLL diagnosis.","evidence_relations":"CLL is confirmed by blood test, flow cytometry, and may require lymph node or bone marrow biopsy"},
	{"id":"Medical-7197a18d","source":"Medical","question":"What is the primary site of CLL?","answer":"The primary site of CLL is the blood and bone marrow.","question_type":"Fact Retrieval","evidence":"The primary site of CLL is the blood.; The primary site of CLL is the bone marrow.","evidence_relations":"The primary site of CLL is the blood and bone marrow"},
	{"id":"Medical-7d4acc17","source":"Medical","question":"Which complication of CLL involves transformation to DLBCL?","answer":"Richter transformation is a complication where CLL transforms into diffuse large B-cell lymphoma (DLBCL).","question_type":"Fact Retrieval","evidence":"Richter transformation is a complication of CLL.; Richter transformation involves the transformation of CLL into diffuse large B-cell lymphoma (DLBCL).","evidence_relations":"Richter transformation is a complication where CLL transforms into a more aggressive lymphoma such as DLBCL or Hodgkin lymphoma"},
	{"id":"Medical-9f87cac2","source":"Medical","question":"What is the purpose of a comprehensive metabolic panel in CLL management?","answer":"A comprehensive metabolic panel is used in treatment planning for CLL.","question_type":"Fact Retrieval","evidence":"A comprehensive metabolic panel is used in treatment planning for CLL.","evidence_relations":"Performance status and comprehensive metabolic panel are used in treatment planning"},
	{"id":"Medical-f7b0cf01","source":"Medical","question":"What is the function of supportive care in CLL follow-up?","answer":"Supportive care is part of follow-up strategies for CLL.","question_type":"Fact Retrieval","evidence":"Supportive care is part of follow-up strategies for CLL.","evidence_relations":"Follow-up strategies include watch and wait, regular monitoring, and supportive care"},
	{"id":"Medical-ccd3b472","source":"Medical","question":"What is the significance of complex karyotype in CLL?","answer":"Complex karyotype is a biomarker assessed in CLL.","question_type":"Fact Retrieval","evidence":"Complex karyotype is a biomarker assessed in CLL.","evidence_relations":"Biomarker testing includes FISH for 17p deletion, DNA sequencing for TP53 and IGHV mutations, and karyotype analysis"},
	{"id":"Medical-322e6d04","source":"Medical","question":"What is the role of oral medications in CLL treatment?","answer":"Oral medications are a treatment option for CLL/SLL.","question_type":"Fact Retrieval","evidence":"Oral medications are a treatment option for CLL.; Oral medications are a treatment option for SLL.","evidence_relations":"Treatment options include oral medications, IV infusions, and combination therapies"},
	{"id":"Medical-2621de32","source":"Medical","question":"Which symptoms may indicate advanced CLL?","answer":"Symptoms such as early satiety and unintentional weight loss may indicate advanced CLL.","question_type":"Fact Retrieval","evidence":"Symptoms such as early satiety may indicate advanced CLL.; Unintentional weight loss may indicate advanced CLL.","evidence_relations":"Symptoms of CLL include swollen glands, fatigue, night sweats, fever, recurrent infections, early satiety, and unintentional weight loss"},
	{"id":"Medical-1429a1d6","source":"Medical","question":"What is the most common type of throat cancer?","answer":"Squamous cell carcinoma is the most common type of throat cancer.","question_type":"Fact Retrieval","evidence":"Squamous cell carcinoma is the most common type of throat cancer.","evidence_relations":"Squamous cell carcinoma is the most common type of throat cancer"},
	{"id":"Medical-bff8d7f5","source":"Medical","question":"Which cancer type does throat cancer belong to?","answer":"Throat cancer is a type of head and neck cancer.","question_type":"Fact Retrieval","evidence":"Throat cancer is a type of head and neck cancer.","evidence_relations":"Throat cancer is a type of head and neck cancer"},
	{"id":"Medical-93c00cfb","source":"Medical","question":"What is a major risk factor for oropharyngeal squamous cell carcinoma?","answer":"HPV infection, especially HPV16, is a major risk factor.","question_type":"Fact Retrieval","evidence":"HPV infection is a major risk factor for oropharyngeal squamous cell carcinoma.; HPV16 is a specific strain of HPV that is a major risk factor.","evidence_relations":"HPV infection, especially HPV16, is a major risk factor for oropharyngeal squamous cell carcinoma"},
	{"id":"Medical-ee60087b","source":"Medical","question":"Which protein is a surrogate biomarker for HPV-mediated throat cancer?","answer":"p16 protein overexpression is a surrogate biomarker.","question_type":"Fact Retrieval","evidence":"p16 protein overexpression is a surrogate biomarker for HPV-mediated throat cancer.","evidence_relations":"p16 protein overexpression is a surrogate biomarker for HPV-mediated throat cancer"},
	{"id":"Medical-a6860279","source":"Medical","question":"What diagnostic method is required for definitive diagnosis and biomarker testing in throat cancer?","answer":"Biopsy is required for definitive diagnosis and biomarker testing.","question_type":"Fact Retrieval","evidence":"A biopsy is required for definitive diagnosis in throat cancer.; A biopsy is required for biomarker testing in throat cancer.","evidence_relations":"Biopsy is required for definitive diagnosis and biomarker testing"},
	{"id":"Medical-c5930c02","source":"Medical","question":"Which imaging studies are used for diagnosis and staging of throat cancer?","answer":"CT scan, MRI, PET/CT, and ultrasound are used for diagnosis and staging.","question_type":"Fact Retrieval","evidence":"CT scan is used for diagnosis and staging of throat cancer.; MRI is used for diagnosis and staging of throat cancer.; PET/CT is used for diagnosis and staging of throat cancer.; Ultrasound is used for diagnosis and staging of throat cancer.","evidence_relations":"Imaging studies such as CT scan, MRI, PET/CT, and ultrasound are used for diagnosis and staging"},
	{"id":"Medical-aabc078c","source":"Medical","question":"Which areas are included in the oropharynx, a common site for throat cancer?","answer":"The oropharynx includes the soft palate, tonsils, side and back walls of the throat, and base of the tongue.","question_type":"Fact Retrieval","evidence":"The oropharynx includes the soft palate.; The oropharynx includes the tonsils.; The oropharynx includes the side walls of the throat.; The oropharynx includes the back walls of the throat.; The oropharynx includes the base of the tongue.","evidence_relations":"Throat cancer commonly arises in the oropharynx, including the soft palate, tonsils, side and back walls of the throat, and base of the tongue"},
	{"id":"Medical-ff5b71cc","source":"Medical","question":"What is the recommended biomarker test for all patients with oropharyngeal cancer?","answer":"p16 (HPV) testing is recommended for all patients with oropharyngeal cancer.","question_type":"Fact Retrieval","evidence":"p16 (HPV) testing is recommended for all patients with oropharyngeal cancer.","evidence_relations":"p16 (HPV) testing is recommended for all patients with oropharyngeal cancer"},
	{"id":"Medical-20454e30","source":"Medical","question":"Which factors are considered risk factors for head and neck cancers?","answer":"Tobacco and alcohol use are risk factors.","question_type":"Fact Retrieval","evidence":"Tobacco use is a risk factor for head and neck cancers.; Alcohol use is a risk factor for head and neck cancers.","evidence_relations":"Tobacco and alcohol use are risk factors for head and neck cancers"},
	{"id":"Medical-c99a29ae","source":"Medical","question":"Which symptoms may indicate throat cancer?","answer":"Symptoms may include difficulty swallowing, sore throat, and changes in voice.","question_type":"Fact Retrieval","evidence":"Difficulty swallowing may indicate throat cancer.; Sore throat may indicate throat cancer.; Changes in voice may indicate throat cancer.","evidence_relations":"Symptoms of throat cancer may include difficulty swallowing, sore throat, and changes in voice"},
	{"id":"Medical-cea4d8ff","source":"Medical","question":"Which system is used for staging throat cancer?","answer":"Cancer staging uses the AJCC TNM system.","question_type":"Fact Retrieval","evidence":"The AJCC TNM system is used for staging throat cancer.","evidence_relations":"Cancer staging uses the AJCC TNM system, incorporating tumor size (T), lymph node involvement (N), and metastasis (M)"},
	{"id":"Medical-335d5ab4","source":"Medical","question":"What are the components of the AJCC TNM staging system?","answer":"The AJCC TNM system incorporates tumor size (T), lymph node involvement (N), and metastasis (M).","question_type":"Fact Retrieval","evidence":"The AJCC TNM system incorporates tumor size (T).; The AJCC TNM system incorporates lymph node involvement (N).; The AJCC TNM system incorporates metastasis (M).","evidence_relations":"Cancer staging uses the AJCC TNM system, incorporating tumor size (T), lymph node involvement (N), and metastasis (M)"},
	{"id":"Medical-bfc7447f","source":"Medical","question":"What are the numbered stages of throat cancer according to the ontology?","answer":"The numbered stages are Stage 0, Stage I, Stage II, Stage III, and Stage IV.","question_type":"Fact Retrieval","evidence":"The numbered stages of throat cancer include Stage 0.; The numbered stages of throat cancer include Stage I.; The numbered stages of throat cancer include Stage II.; The numbered stages of throat cancer include Stage III.; The numbered stages of throat cancer include Stage IV.","evidence_relations":"Numbered stages: [\"Stage 0\", \"Stage I\", \"Stage II\", \"Stage III\", \"Stage IV\"]"},
	{"id":"Medical-c490d37b","source":"Medical","question":"What is the definition of Tis in the AJCC TNM staging for throat cancer?","answer":"Tis is carcinoma in situ.","question_type":"Fact Retrieval","evidence":"Tis in the AJCC TNM staging for throat cancer is defined as carcinoma in situ.","evidence_relations":"Tis: Carcinoma in situ"},
	{"id":"Medical-5bf6c470","source":"Medical","question":"What tumor size corresponds to T1 in the AJCC TNM staging?","answer":"T1 is a tumor 2 cm or less.","question_type":"Fact Retrieval","evidence":"T1 in the AJCC TNM staging corresponds to a tumor 2 cm or less.","evidence_relations":"T1: Tumor 2 cm"},
	{"id":"Medical-844b00fe","source":"Medical","question":"What tumor size corresponds to T2 in the AJCC TNM staging?","answer":"T2 is a tumor greater than 2 cm and 4 cm or less.","question_type":"Fact Retrieval","evidence":"T2 in the AJCC TNM staging corresponds to a tumor greater than 2 cm and 4 cm or less.","evidence_relations":"T2: Tumor >2 cm and 4 cm"},
	{"id":"Medical-9cb7758b","source":"Medical","question":"What does T3 indicate in the AJCC TNM staging for throat cancer?","answer":"T3 is a tumor greater than 4 cm or extension to epiglottis.","question_type":"Fact Retrieval","evidence":"T3 in the AJCC TNM staging indicates a tumor greater than 4 cm.; T3 in the AJCC TNM staging indicates extension to the epiglottis.","evidence_relations":"T3: Tumor >4 cm or extension to epiglottis"},
	{"id":"Medical-c808d555","source":"Medical","question":"Which biomarker expressions may guide immunotherapy treatment decisions in throat cancer?","answer":"PD-L1 expression may guide immunotherapy treatment decisions.","question_type":"Fact Retrieval","evidence":"PD-L1 expression may guide immunotherapy treatment decisions in throat cancer.","evidence_relations":"PD-L1 expression may guide immunotherapy treatment decisions"},
	{"id":"Medical-4ba7ca1f","source":"Medical","question":"Which methods are used for tissue sampling in throat cancer diagnosis?","answer":"Fine-needle aspiration (FNA), core needle biopsy (CNB), and endoscopic biopsies are used for tissue sampling.","question_type":"Fact Retrieval","evidence":"Fine-needle aspiration (FNA) is used for tissue sampling in throat cancer diagnosis.; Core needle biopsy (CNB) is used for tissue sampling in throat cancer diagnosis.; Endoscopic biopsies are used for tissue sampling in throat cancer diagnosis.","evidence_relations":"Fine-needle aspiration (FNA), core needle biopsy (CNB), and endoscopic biopsies are used for tissue sampling"},
	{"id":"Medical-930c4439","source":"Medical","question":"Which biomarker tests are included in throat cancer biomarker testing?","answer":"Biomarker testing includes p16 (HPV), PD-L1, MSI-H/dMMR, and tumor mutational burden.","question_type":"Fact Retrieval","evidence":"Biomarker testing in throat cancer includes p16 (HPV).; Biomarker testing in throat cancer includes PD-L1.; Biomarker testing in throat cancer includes MSI-H/dMMR.; Biomarker testing in throat cancer includes tumor mutational burden.","evidence_relations":"Biomarker testing includes p16 (HPV), PD-L1, MSI-H/dMMR, and tumor mutational burden"},
	{"id":"Medical-49e7d093","source":"Medical","question":"What are the common sites of metastasis for throat cancer?","answer":"Common sites of metastasis are the lungs, liver, or spine.","question_type":"Fact Retrieval","evidence":"Common sites of metastasis for throat cancer include the lungs.; Common sites of metastasis for throat cancer include the liver.; Common sites of metastasis for throat cancer include the spine.","evidence_relations":"Cancer can spread to lymph nodes in the neck and to distant sites such as lungs, liver, or spine"},
	{"id":"Medical-43965a1c","source":"Medical","question":"What is used to determine clinical stage before treatment in throat cancer?","answer":"Clinical stage is determined before treatment using physical exam, imaging, and biopsy.","question_type":"Fact Retrieval","evidence":"Clinical stage of throat cancer is determined before treatment.; Physical exam is used to determine clinical stage before treatment in throat cancer.; Imaging is used to determine clinical stage before treatment in throat cancer.; Biopsy is used to determine clinical stage before treatment in throat cancer.","evidence_relations":"Clinical stage is determined before treatment using physical exam, imaging, and biopsy"},
	{"id":"Medical-c89d3c38","source":"Medical","question":"How is pathologic stage determined in throat cancer?","answer":"Pathologic stage is determined after surgery based on tissue examination.","question_type":"Fact Retrieval","evidence":"Pathologic stage of throat cancer is determined after surgery.; Pathologic stage is based on tissue examination.","evidence_relations":"Pathologic stage is determined after surgery based on tissue examination"},
	{"id":"Medical-d8127f85","source":"Medical","question":"Which assessment is important before treatment of throat cancer?","answer":"Dental health assessment is important before treatment.","question_type":"Fact Retrieval","evidence":"Dental health assessment is important before treatment of throat cancer.","evidence_relations":"Dental health assessment is important before treatment"},
	{"id":"Medical-26d2ebbd","source":"Medical","question":"Which performance status is considered a prognostic factor in throat cancer treatment planning?","answer":"ECOG performance status is a prognostic factor considered in treatment planning.","question_type":"Fact Retrieval","evidence":"ECOG performance status is a prognostic factor in throat cancer treatment planning.","evidence_relations":"Performance status (ECOG) is a prognostic factor considered in treatment planning"},
	{"id":"Medical-2268f7cf","source":"Medical","question":"What are the main anatomical sites in the oropharynx related to throat cancer?","answer":"The main anatomical sites are the soft palate, tonsils, base of tongue, and side and back walls of the throat.","question_type":"Fact Retrieval","evidence":"The main anatomical sites in the oropharynx related to throat cancer include the soft palate.; The main anatomical sites in the oropharynx related to throat cancer include the tonsils.; The main anatomical sites in the oropharynx related to throat cancer include the base of tongue.; The main anatomical sites in the oropharynx related to throat cancer include the side walls of the throat.; The main anatomical sites in the oropharynx related to throat cancer include the back walls of the throat.","evidence_relations":"The oropharynx includes the soft palate, tonsils, base of tongue, and side and back walls of the throat"},
	{"id":"Medical-5e15bf0c","source":"Medical","question":"Which scoping procedures are used as diagnostic methods for throat cancer?","answer":"Endoscopy, laryngoscopy, nasolaryngoscopy, esophagoscopy, bronchoscopy, and panendoscopy are used.","question_type":"Fact Retrieval","evidence":"Endoscopy is used as a diagnostic method for throat cancer.; Laryngoscopy is used as a diagnostic method for throat cancer.; Nasolaryngoscopy is used as a diagnostic method for throat cancer.; Esophagoscopy is used as a diagnostic method for throat cancer.; Bronchoscopy is used as a diagnostic method for throat cancer.; Panendoscopy is used as a diagnostic method for throat cancer.","evidence_relations":"Scoping procedures: [\"Endoscopy\", \"Laryngoscopy\", \"Nasolaryngoscopy\", \"Esophagoscopy\", \"Bronchoscopy\", \"Panendoscopy\"]"},
	{"id":"Medical-f5e27a80","source":"Medical","question":"Which genetic alterations are associated with squamous cell carcinoma of the throat?","answer":"HPV-mediated, p16-positive, and p16-negative are associated genetic alterations.","question_type":"Fact Retrieval","evidence":"HPV-mediated genetic alterations are associated with squamous cell carcinoma of the throat.; p16-positive genetic alterations are associated with squamous cell carcinoma of the throat.; p16-negative genetic alterations are associated with squamous cell carcinoma of the throat.","evidence_relations":"Genetic Alteration: [\"HPV-mediated\", \"p16-positive\", \"p16-negative\"]"},
	{"id":"Medical-75107d1d","source":"Medical","question":"What surveillance methods are used for patients after throat cancer treatment?","answer":"Surveillance includes dental health assessment, imaging follow-up, and physical exam.","question_type":"Fact Retrieval","evidence":"Surveillance methods after throat cancer treatment include dental health assessment.; Surveillance methods after throat cancer treatment include imaging follow-up.; Surveillance methods after throat cancer treatment include physical exam.","evidence_relations":"Surveillance: [\"Dental health assessment\", \"Imaging follow-up\", \"Physical exam\"]"},
	{"id":"Medical-dd68e8b3","source":"Medical","question":"What symptoms are commonly associated with throat cancer?","answer":"Difficulty swallowing, sore throat, and voice changes are common symptoms.","question_type":"Fact Retrieval","evidence":"Common symptoms associated with throat cancer include difficulty swallowing.; Common symptoms associated with throat cancer include sore throat.; Common symptoms associated with throat cancer include voice changes.","evidence_relations":"Symptoms of throat cancer may include difficulty swallowing, sore throat, and changes in voice"},
	{"id":"Medical-60bccc6c","source":"Medical","question":"What is the role of panoramic dental x-ray (Panorex) in throat cancer management?","answer":"Panoramic dental x-ray (Panorex) is used as an imaging method for dental assessment.","question_type":"Fact Retrieval","evidence":"Panoramic dental x-ray (Panorex) is used as an imaging method.; Panoramic dental x-ray (Panorex) is used for dental assessment.","evidence_relations":"Panoramic dental x-ray (Panorex) is listed under imaging for diagnostic methods and dental health assessment"},
	{"id":"Medical-fde1ce46","source":"Medical","question":"What are the main prognostic factors considered for squamous cell carcinoma of the throat?","answer":"ECOG performance status, tumor grade, and HPV/p16 status are main prognostic factors.","question_type":"Fact Retrieval","evidence":"ECOG performance status is a main prognostic factor for squamous cell carcinoma of the throat.; Tumor grade is a main prognostic factor for squamous cell carcinoma of the throat.; HPV/p16 status is a main prognostic factor for squamous cell carcinoma of the throat.","evidence_relations":"Prognostic Factor: [\"ECOG performance status\", \"Tumor grade\", \"HPV/p16 status\"]"},
	{"id":"Medical-613046c3","source":"Medical","question":"What type of lymphoma is found primarily in the skin?","answer":"Primary cutaneous lymphoma (PCL) is found in the skin.","question_type":"Fact Retrieval","evidence":"Primary cutaneous lymphoma (PCL) is found primarily in the skin.","evidence_relations":"Primary cutaneous lymphoma (PCL) is a type of non-Hodgkin lymphoma found in the skin"},
	{"id":"Medical-e60081a8","source":"Medical","question":"Which cell type is the origin of cutaneous B-cell lymphoma (CBCL)?","answer":"CBCL originates from B lymphocytes.","question_type":"Fact Retrieval","evidence":"Cutaneous B-cell lymphoma (CBCL) originates from B lymphocytes.","evidence_relations":"Cutaneous B-cell lymphoma (CBCL) starts in B cells"},
	{"id":"Medical-f8d0ca45","source":"Medical","question":"What are the main subtypes of cutaneous B-cell lymphoma?","answer":"The main subtypes are primary cutaneous marginal zone lymphoma (PCMZL), primary cutaneous follicle center lymphoma (PCFCL), and primary cutaneous diffuse large B-cell lymphoma, leg type (PC-DLBCL, leg type).","question_type":"Fact Retrieval","evidence":"The main subtypes of cutaneous B-cell lymphoma include primary cutaneous marginal zone lymphoma (PCMZL).; The main subtypes of cutaneous B-cell lymphoma include primary cutaneous follicle center lymphoma (PCFCL).; The main subtypes of cutaneous B-cell lymphoma include primary cutaneous diffuse large B-cell lymphoma, leg type (PC-DLBCL, leg type).","evidence_relations":"CBCL subtypes include primary cutaneous marginal zone lymphoma (PCMZL), primary cutaneous follicle center lymphoma (PCFCL), and primary cutaneous diffuse large B-cell lymphoma, leg type (PC-DLBCL, leg type)"},
	{"id":"Medical-d1271e37","source":"Medical","question":"What are common symptoms of cutaneous B-cell lymphoma?","answer":"Symptoms include skin nodules and papules.","question_type":"Fact Retrieval","evidence":"Common symptoms of cutaneous B-cell lymphoma include skin nodules.; Common symptoms of cutaneous B-cell lymphoma include papules.","evidence_relations":"Symptoms of CBCL include skin nodules and papules"},
	{"id":"Medical-63e12d36","source":"Medical","question":"Which diagnostic methods are used for CBCL?","answer":"Skin exam, blood test, imaging test, biopsy, and immunophenotyping are used.","question_type":"Fact Retrieval","evidence":"Skin exam is used as a diagnostic method for cutaneous B-cell lymphoma (CBCL).; Blood test is used as a diagnostic method for cutaneous B-cell lymphoma (CBCL).; Imaging test is used as a diagnostic method for cutaneous B-cell lymphoma (CBCL).; Biopsy is used as a diagnostic method for cutaneous B-cell lymphoma (CBCL).; Immunophenotyping is used as a diagnostic method for cutaneous B-cell lymphoma (CBCL).","evidence_relations":"Diagnosis of CBCL involves skin exam, blood tests, imaging tests, biopsy, and immunophenotyping"},
	{"id":"Medical-2dad02e4","source":"Medical","question":"What is the cell of origin for cutaneous T-cell lymphoma (CTCL)?","answer":"CTCL develops from abnormal T lymphocytes.","question_type":"Fact Retrieval","evidence":"Cutaneous T-cell lymphoma (CTCL) develops from abnormal T lymphocytes.","evidence_relations":"Cutaneous T-cell lymphoma (CTCL) develops from abnormal T cells"},
	{"id":"Medical-fa689991","source":"Medical","question":"Which cancer type does primary cutaneous lymphoma (PCL) belong to?","answer":"PCL is a type of non-Hodgkin lymphoma (NHL).","question_type":"Fact Retrieval","evidence":"Primary cutaneous lymphoma (PCL) is a type of non-Hodgkin lymphoma (NHL).","evidence_relations":"Primary cutaneous lymphoma (PCL) is a type of non-Hodgkin lymphoma found in the skin"},
	{"id":"Medical-d6749661","source":"Medical","question":"What type of blood cell are lymphocytes?","answer":"Lymphocytes are a type of white blood cell.","question_type":"Fact Retrieval","evidence":"Lymphocytes are a type of white blood cell.","evidence_relations":"Lymphocytes are a type of white blood cell that help fight infection"},
	{"id":"Medical-87c6269c","source":"Medical","question":"What can unregulated growth of lymphocytes lead to?","answer":"Unregulated growth of lymphocytes can develop into lymphoma.","question_type":"Fact Retrieval","evidence":"Unregulated growth of lymphocytes can develop into lymphoma.","evidence_relations":"Unregulated growth of lymphocytes can develop into lymphoma"},
	{"id":"Medical-4c260a72","source":"Medical","question":"Which test is used to assess biomarkers and genetic changes in CBCL?","answer":"Testing for CBCL includes assessment of biomarkers and genetic changes.","question_type":"Fact Retrieval","evidence":"Testing for CBCL includes assessment of biomarkers.; Testing for CBCL includes assessment of genetic changes.","evidence_relations":"Testing for CBCL includes assessment of biomarkers and genetic changes"},
	{"id":"Medical-500d2672","source":"Medical","question":"What are the typical clinical appearances of CBCL on the skin?","answer":"CBCL appears as nodules or papules under the skin.","question_type":"Fact Retrieval","evidence":"CBCL appears as nodules under the skin.; CBCL appears as papules under the skin.","evidence_relations":"CBCL appears as nodules or papules under the skin"},
	{"id":"Medical-a40a55aa","source":"Medical","question":"Which subtypes are included under cutaneous B-cell lymphoma in the ontology?","answer":"Primary cutaneous marginal zone lymphoma (PCMZL), primary cutaneous follicle center lymphoma (PCFCL), and primary cutaneous diffuse large B-cell lymphoma, leg type (PC-DLBCL, leg type) are included.","question_type":"Fact Retrieval","evidence":"Primary cutaneous marginal zone lymphoma (PCMZL) is included under cutaneous B-cell lymphoma.; Primary cutaneous follicle center lymphoma (PCFCL) is included under cutaneous B-cell lymphoma.; Primary cutaneous diffuse large B-cell lymphoma, leg type (PC-DLBCL, leg type) is included under cutaneous B-cell lymphoma.","evidence_relations":"The ontology lists PCMZL, PCFCL, and PC-DLBCL, leg type as subtypes of CBCL"},
	{"id":"Medical-8251b4f5","source":"Medical","question":"What is the growth pattern of most primary cutaneous B-cell lymphomas?","answer":"Most primary cutaneous B-cell lymphomas are indolent or slow-growing.","question_type":"Fact Retrieval","evidence":"Most primary cutaneous B-cell lymphomas are indolent.; Most primary cutaneous B-cell lymphomas are slow-growing.","evidence_relations":"Most primary cutaneous B-cell lymphomas are indolent or slow-growing"},
	{"id":"Medical-b80836d6","source":"Medical","question":"Which lymphocyte subtype gives rise to cutaneous T-cell lymphoma?","answer":"T lymphocytes give rise to cutaneous T-cell lymphoma.","question_type":"Fact Retrieval","evidence":"T lymphocytes give rise to cutaneous T-cell lymphoma.","evidence_relations":"Cutaneous T-cell lymphoma (CTCL) develops from abnormal T cells"},
	{"id":"Medical-5d17dd81","source":"Medical","question":"What is the role of lymphocytes in the body?","answer":"Lymphocytes help fight infection.","question_type":"Fact Retrieval","evidence":"Lymphocytes help fight infection.","evidence_relations":"Lymphocytes are a type of white blood cell that help fight infection"},
	{"id":"Medical-e4acadd1","source":"Medical","question":"What diagnostic method involves microscopic examination of tissue for CBCL?","answer":"Biopsy is used for microscopic examination of tissue in CBCL diagnosis.","question_type":"Fact Retrieval","evidence":"Biopsy is used for microscopic examination of tissue in CBCL diagnosis.","evidence_relations":"Diagnosis of CBCL involves skin exam, blood tests, imaging tests, biopsy, and immunophenotyping"},
	{"id":"Medical-06384900","source":"Medical","question":"Which cancer subtype starts specifically in B cells?","answer":"Cutaneous B-cell lymphoma (CBCL) starts in B cells.","question_type":"Fact Retrieval","evidence":"Cutaneous B-cell lymphoma (CBCL) starts in B cells.","evidence_relations":"Cutaneous B-cell lymphoma (CBCL) starts in B cells"},
	{"id":"Medical-fa265328","source":"Medical","question":"What are the two main cell origins for primary cutaneous lymphoma?","answer":"Primary cutaneous lymphoma develops from abnormal B or T lymphocytes.","question_type":"Fact Retrieval","evidence":"Primary cutaneous lymphoma develops from abnormal B lymphocytes.; Primary cutaneous lymphoma develops from abnormal T lymphocytes.","evidence_relations":"PCL develops from abnormal B or T lymphocytes"},
	{"id":"Medical-c7d5764f","source":"Medical","question":"What are examples of diagnostic imaging tests for CBCL?","answer":"Imaging tests are used for diagnosis of CBCL.","question_type":"Fact Retrieval","evidence":"Imaging tests are used for the diagnosis of CBCL.","evidence_relations":"Diagnosis of CBCL involves skin exam, blood tests, imaging tests, biopsy, and immunophenotyping"},
	{"id":"Medical-1295f7a6","source":"Medical","question":"Which test is used to analyze cell surface proteins in CBCL diagnosis?","answer":"Immunophenotyping is used to analyze cell surface proteins.","question_type":"Fact Retrieval","evidence":"Immunophenotyping is used to analyze cell surface proteins.","evidence_relations":"Diagnosis of CBCL involves skin exam, blood tests, imaging tests, biopsy, and immunophenotyping"},
	{"id":"Medical-6c304dfe","source":"Medical","question":"What laboratory test is commonly performed for CBCL diagnosis?","answer":"Blood test is commonly performed for CBCL diagnosis.","question_type":"Fact Retrieval","evidence":"A blood test is commonly performed for CBCL diagnosis.","evidence_relations":"Diagnosis of CBCL involves skin exam, blood tests, imaging tests, biopsy, and immunophenotyping"},
	{"id":"Medical-9b559ea7","source":"Medical","question":"What type of lymphoma is cutaneous T-cell lymphoma (CTCL)?","answer":"CTCL is a cancer subtype of primary cutaneous lymphoma derived from T lymphocytes.","question_type":"Fact Retrieval","evidence":"CTCL is a cancer subtype of primary cutaneous lymphoma.; CTCL is derived from T lymphocytes.","evidence_relations":"Cutaneous T-cell lymphoma (CTCL) develops from abnormal T cells"},
	{"id":"Medical-145d27de","source":"Medical","question":"What are the characteristic skin lesions seen in CBCL?","answer":"Nodules and papules are characteristic skin lesions in CBCL.","question_type":"Fact Retrieval","evidence":"Nodules are characteristic skin lesions in CBCL.; Papules are characteristic skin lesions in CBCL.","evidence_relations":"Symptoms of CBCL include skin nodules and papules"},
	{"id":"Medical-ed3b3141","source":"Medical","question":"Which white blood cell type can develop into lymphoma when growth is unregulated?","answer":"Lymphocytes can develop into lymphoma when growth is unregulated.","question_type":"Fact Retrieval","evidence":"Lymphocytes can develop into lymphoma when growth is unregulated.","evidence_relations":"Unregulated growth of lymphocytes can develop into lymphoma"},
	{"id":"Medical-6a57de34","source":"Medical","question":"Which diagnostic method involves examining the skin for CBCL?","answer":"Skin exam is a diagnostic method for CBCL.","question_type":"Fact Retrieval","evidence":"A skin exam is a diagnostic method for CBCL.","evidence_relations":"Diagnosis of CBCL involves skin exam, blood tests, imaging tests, biopsy, and immunophenotyping"},
	{"id":"Medical-8bfc6705","source":"Medical","question":"Which categories of biomarkers are assessed in CBCL testing?","answer":"Assessment includes both biomarkers and genetic changes.","question_type":"Fact Retrieval","evidence":"Assessment includes biomarkers.; Assessment includes genetic changes.","evidence_relations":"Testing for CBCL includes assessment of biomarkers and genetic changes"},
	{"id":"Medical-496f67b8","source":"Medical","question":"What is the relationship between primary cutaneous lymphoma and non-Hodgkin lymphoma in the ontology?","answer":"Primary cutaneous lymphoma is classified under non-Hodgkin lymphoma in the ontology.","question_type":"Fact Retrieval","evidence":"Primary cutaneous lymphoma is classified under non-Hodgkin lymphoma in the ontology.","evidence_relations":"The ontology places PCL under non-Hodgkin lymphoma (NHL)"},
	{"id":"Medical-075d923c","source":"Medical","question":"Which subtype of cutaneous lymphoma is associated with B lymphocytes in the ontology?","answer":"Cutaneous B-cell lymphoma (CBCL) is associated with B lymphocytes.","question_type":"Fact Retrieval","evidence":"Cutaneous B-cell lymphoma (CBCL) is associated with B lymphocytes.","evidence_relations":"The ontology lists CBCL under B lymphocyte as cell of origin"},
	{"id":"Medical-4c444d45","source":"Medical","question":"Which diagnostic method is used to identify genetic changes in CBCL?","answer":"Immunophenotyping is used to identify genetic changes in CBCL.","question_type":"Fact Retrieval","evidence":"Immunophenotyping is used to identify genetic changes in CBCL.","evidence_relations":"Diagnosis of CBCL involves skin exam, blood tests, imaging tests, biopsy, and immunophenotyping"},
	{"id":"Medical-ca48819b","source":"Medical","question":"What are the three named subtypes of CBCL in the ontology?","answer":"The three named subtypes are PCMZL, PCFCL, and PC-DLBCL, leg type.","question_type":"Fact Retrieval","evidence":"The three named subtypes of CBCL are PCMZL.; The three named subtypes of CBCL are PCFCL.; The three named subtypes of CBCL are PC-DLBCL, leg type.","evidence_relations":"The ontology lists PCMZL, PCFCL, and PC-DLBCL, leg type as subtypes of CBCL"},
	{"id":"Medical-76a58bea","source":"Medical","question":"What is the most common cancer diagnosed in children?","answer":"Acute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in children.","question_type":"Fact Retrieval","evidence":"Acute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in children.","evidence_relations":"ALL is the most common cancer diagnosed in children"},
	{"id":"Medical-960eb812","source":"Medical","question":"Which cell type is the origin of acute lymphoblastic leukemia (ALL)?","answer":"ALL starts in lymphocytes.","question_type":"Fact Retrieval","evidence":"Acute lymphoblastic leukemia (ALL) starts in lymphocytes.","evidence_relations":"Acute lymphoblastic leukemia (ALL) is a fast-growing blood cancer that starts in lymphocytes"},
	{"id":"Medical-1b7da7b8","source":"Medical","question":"What are the two main subtypes of ALL?","answer":"The two main subtypes of ALL are B-cell ALL (B-ALL) and T-cell ALL (T-ALL).","question_type":"Fact Retrieval","evidence":"The two main subtypes of ALL are B-cell ALL (B-ALL).; The two main subtypes of ALL are T-cell ALL (T-ALL).","evidence_relations":"ALL has two main subtypes: B-cell ALL (B-ALL) and T-cell ALL (T-ALL)"},
	{"id":"Medical-ea0a73d8","source":"Medical","question":"Which subtype of ALL is more common, B-ALL or T-ALL?","answer":"B-ALL is more common than T-ALL.","question_type":"Fact Retrieval","evidence":"B-ALL is more common than T-ALL.","evidence_relations":"B-ALL starts in B-cell lymphocytes and is more common than T-ALL"},
	{"id":"Medical-fe91b005","source":"Medical","question":"What rare subtype of B-ALL is treated differently?","answer":"Mature B-cell ALL (Burkitt leukemia) is a rare subtype and is treated differently from B-ALL.","question_type":"Fact Retrieval","evidence":"Mature B-cell ALL (Burkitt leukemia) is a rare subtype of B-ALL.; Mature B-cell ALL (Burkitt leukemia) is treated differently from B-ALL.","evidence_relations":"Mature B-cell ALL (Burkitt leukemia) is a rare subtype and is treated differently from B-ALL"},
	{"id":"Medical-a413ecf5","source":"Medical","question":"What is B-cell lymphoblastic lymphoma also called?","answer":"B-cell lymphoblastic lymphoma is also called B-LL or B-LBL.","question_type":"Fact Retrieval","evidence":"B-cell lymphoblastic lymphoma is also called B-LL.; B-cell lymphoblastic lymphoma is also called B-LBL.","evidence_relations":"B-cell lymphoblasts growing in lymph nodes is called B-cell lymphoblastic lymphoma (B-LL or B-LBL)"},
	{"id":"Medical-9ab2163c","source":"Medical","question":"What is T-cell lymphoblastic lymphoma also called?","answer":"T-cell lymphoblastic lymphoma is also called T-LL or T-LBL.","question_type":"Fact Retrieval","evidence":"T-cell lymphoblastic lymphoma is also called T-LL.; T-cell lymphoblastic lymphoma is also called T-LBL.","evidence_relations":"T-cell lymphoblasts growing in the thymus is called T-cell lymphoblastic lymphoma (T-LL or T-LBL)"},
	{"id":"Medical-a3a4e6db","source":"Medical","question":"Which diagnostic methods are used for ALL?","answer":"Blood tests, bone marrow tests, imaging tests, heart tests, and lumbar puncture are used for ALL diagnosis.","question_type":"Fact Retrieval","evidence":"Blood tests are used for ALL diagnosis.; Bone marrow tests are used for ALL diagnosis.; Imaging tests are used for ALL diagnosis.; Heart tests are used for ALL diagnosis.; Lumbar puncture is used for ALL diagnosis.","evidence_relations":"Diagnosis of ALL involves blood tests, bone marrow aspirate and biopsy, flow cytometry, immunophenotyping, genetic and biomarker testing, imaging tests, and lumbar puncture"},
	{"id":"Medical-5a825e05","source":"Medical","question":"What is the minimum percentage of lymphoblasts in bone marrow required for ALL diagnosis?","answer":"Diagnosis of ALL generally requires 20 percent or more lymphoblasts in the bone marrow.","question_type":"Fact Retrieval","evidence":"Diagnosis of ALL generally requires 20 percent or more lymphoblasts in the bone marrow.","evidence_relations":"Diagnosis of ALL generally requires 20 percent or more lymphoblasts in the bone marrow"},
	{"id":"Medical-b3af6970","source":"Medical","question":"What are the possible disease sites for ALL?","answer":"ALL can be found in bone marrow, blood, testicles, or central nervous system (CNS).","question_type":"Fact Retrieval","evidence":"ALL can be found in bone marrow.; ALL can be found in blood.; ALL can be found in testicles.; ALL can be found in the central nervous system (CNS).","evidence_relations":"ALL can be found in bone marrow, blood, testicles, or central nervous system (CNS)"},
	{"id":"Medical-53b40877","source":"Medical","question":"Which subtype of ALL can cause an enlarged thymus?","answer":"T-cell ALL (T-ALL) can cause an enlarged thymus.","question_type":"Fact Retrieval","evidence":"T-cell ALL (T-ALL) can cause an enlarged thymus.","evidence_relations":"T-ALL starts in T-cell lymphocytes and can cause an enlarged thymus"},
	{"id":"Medical-daac4d33","source":"Medical","question":"What symptom can T-ALL cause due to an enlarged thymus?","answer":"T-ALL can cause breathing problems due to an enlarged thymus.","question_type":"Fact Retrieval","evidence":"T-ALL can cause breathing problems due to an enlarged thymus.","evidence_relations":"T-ALL can cause breathing problems due to an enlarged thymus"},
	{"id":"Medical-6852591b","source":"Medical","question":"What is the initial treatment for everyone with ALL?","answer":"Everyone with ALL is treated with steroids and multiagent chemotherapy.","question_type":"Fact Retrieval","evidence":"Everyone with ALL is treated with steroids.; Everyone with ALL is treated with multiagent chemotherapy.","evidence_relations":"Everyone with ALL is treated with steroids and multiagent chemotherapy"},
	{"id":"Medical-e31f34b7","source":"Medical","question":"What are the components of ALL treatment besides chemotherapy and steroids?","answer":"Systemic therapy and supportive care are part of ALL treatment.","question_type":"Fact Retrieval","evidence":"Systemic therapy is part of ALL treatment.; Supportive care is part of ALL treatment.","evidence_relations":"Systemic therapy and supportive care are part of ALL treatment"},
	{"id":"Medical-bff01916","source":"Medical","question":"Which subtype of B-ALL requires intensive systemic therapies?","answer":"BCR::ABL1-positive B-ALL is treated with intensive systemic therapies.","question_type":"Fact Retrieval","evidence":"BCR::ABL1-positive B-ALL is treated with intensive systemic therapies.","evidence_relations":"BCR::ABL1-positive B-ALL is treated with intensive systemic therapies"},
	{"id":"Medical-b63d5b37","source":"Medical","question":"For which cases are clinical trials preferred in ALL?","answer":"Clinical trials are preferred for certain B-ALL and T-ALL cases.","question_type":"Fact Retrieval","evidence":"Clinical trials are preferred for certain B-ALL cases.; Clinical trials are preferred for certain T-ALL cases.","evidence_relations":"Clinical trials are preferred for certain B-ALL and T-ALL cases"},
	{"id":"Medical-85d1a489","source":"Medical","question":"How is infant ALL (under 12 months) treated compared to other age groups?","answer":"Infant ALL (under 12 months) is treated differently than other age groups.","question_type":"Fact Retrieval","evidence":"Infant ALL (under 12 months) is treated differently than other age groups.","evidence_relations":"Infant ALL (under 12 months) is treated differently than other age groups"},
	{"id":"Medical-84c4f293","source":"Medical","question":"What testing methods are used in ALL management for biomarkers and genetics?","answer":"Pharmacogenomic testing and biomarker/genetic testing are used in ALL management.","question_type":"Fact Retrieval","evidence":"Pharmacogenomic testing is used in ALL management.; Biomarker testing is used in ALL management.; Genetic testing is used in ALL management.","evidence_relations":"Pharmacogenomic testing and biomarker/genetic testing are used in ALL management"},
	{"id":"Medical-786c3df5","source":"Medical","question":"Which age groups are most often affected by ALL?","answer":"ALL most often affects children, adolescents, and young adults (AYAs).","question_type":"Fact Retrieval","evidence":"ALL most often affects children.; ALL most often affects adolescents.; ALL most often affects young adults (AYAs).","evidence_relations":"ALL most often affects children, adolescents, and young adults (AYAs)"},
	{"id":"Medical-ac636dac","source":"Medical","question":"Which lymphocyte subtype is the cell of origin for B-ALL?","answer":"B-ALL starts in B-cell lymphocytes.","question_type":"Fact Retrieval","evidence":"B-ALL starts in B-cell lymphocytes.","evidence_relations":"B-ALL starts in B-cell lymphocytes and is more common than T-ALL"},
	{"id":"Medical-5a7c7b88","source":"Medical","question":"Which lymphocyte subtype is the cell of origin for T-ALL?","answer":"T-ALL starts in T-cell lymphocytes.","question_type":"Fact Retrieval","evidence":"T-ALL starts in T-cell lymphocytes.","evidence_relations":"T-ALL starts in T-cell lymphocytes and can cause an enlarged thymus"},
	{"id":"Medical-1d62116d","source":"Medical","question":"What is the purpose of a lumbar puncture in ALL diagnosis?","answer":"A lumbar puncture is used as a diagnostic method for ALL.","question_type":"Fact Retrieval","evidence":"A lumbar puncture is used as a diagnostic method for ALL.","evidence_relations":"ALL is diagnosed using blood tests, bone marrow tests, imaging tests, heart tests, and lumbar puncture"},
	{"id":"Medical-5e031204","source":"Medical","question":"Name two types of testing used to identify biomarkers in ALL.","answer":"Biomarker testing and pharmacogenomic testing are used.","question_type":"Fact Retrieval","evidence":"Biomarker testing is used to identify biomarkers in ALL.; Pharmacogenomic testing is used to identify biomarkers in ALL.","evidence_relations":"Pharmacogenomic testing and biomarker/genetic testing are used in ALL management"},
	{"id":"Medical-0c88cd2e","source":"Medical","question":"What is the standard supportive care for ALL?","answer":"Supportive care is part of ALL treatment.","question_type":"Fact Retrieval","evidence":"Supportive care is part of ALL treatment.","evidence_relations":"Systemic therapy and supportive care are part of ALL treatment"},
	{"id":"Medical-4cb346cb","source":"Medical","question":"What is the main treatment protocol for both B-ALL and T-ALL?","answer":"Steroids, multiagent chemotherapy, systemic therapy, and clinical trial are main treatments.","question_type":"Fact Retrieval","evidence":"Steroids are a main treatment for both B-ALL and T-ALL.; Multiagent chemotherapy is a main treatment for both B-ALL and T-ALL.; Systemic therapy is a main treatment for both B-ALL and T-ALL.; Clinical trial is a main treatment for both B-ALL and T-ALL.","evidence_relations":"B-cell ALL (B-ALL): Treatment: [steroids, multiagent chemotherapy, systemic therapy, clinical trial]; T-cell ALL (T-ALL): Treatment: [steroids, multiagent chemotherapy, systemic therapy, clinical trial]"},
	{"id":"Medical-411895da","source":"Medical","question":"Which genetic alteration is a biomarker for B-ALL?","answer":"BCR::ABL1-positive is a biomarker for B-ALL.","question_type":"Fact Retrieval","evidence":"BCR::ABL1-positive is a biomarker for B-ALL.","evidence_relations":"BCR::ABL1-positive B-ALL is treated with intensive systemic therapies"},
	{"id":"Medical-efdf2abc","source":"Medical","question":"What cancer type is characterized by fast growth and origin in lymphocytes?","answer":"Acute lymphoblastic leukemia (ALL) is a fast-growing blood cancer that starts in lymphocytes.","question_type":"Fact Retrieval","evidence":"Acute lymphoblastic leukemia (ALL) is a fast-growing blood cancer.; ALL starts in lymphocytes.","evidence_relations":"Acute lymphoblastic leukemia (ALL) is a fast-growing blood cancer that starts in lymphocytes"},
	{"id":"Medical-8997f8d7","source":"Medical","question":"Which site is affected in B-cell lymphoblastic lymphoma?","answer":"B-cell lymphoblastic lymphoma involves lymph nodes.","question_type":"Fact Retrieval","evidence":"B-cell lymphoblastic lymphoma involves lymph nodes.","evidence_relations":"B-cell lymphoblasts growing in lymph nodes is called B-cell lymphoblastic lymphoma (B-LL or B-LBL)"},
	{"id":"Medical-45dbe22b","source":"Medical","question":"Which site is affected in T-cell lymphoblastic lymphoma?","answer":"T-cell lymphoblastic lymphoma involves the thymus.","question_type":"Fact Retrieval","evidence":"T-cell lymphoblastic lymphoma involves the thymus.","evidence_relations":"T-cell lymphoblasts growing in the thymus is called T-cell lymphoblastic lymphoma (T-LL or T-LBL)"},
	{"id":"Medical-d579b469","source":"Medical","question":"What symptom may result from T-ALL affecting the thymus?","answer":"Breathing problems may result from T-ALL affecting the thymus.","question_type":"Fact Retrieval","evidence":"Breathing problems may result from T-ALL affecting the thymus.","evidence_relations":"T-ALL can cause breathing problems due to an enlarged thymus"},
	{"id":"Medical-a685f7fb","source":"Medical","question":"Which age group requires a different treatment approach for ALL?","answer":"Infants (under 12 months) require a different treatment approach for ALL.","question_type":"Fact Retrieval","evidence":"Infants under 12 months require a different treatment approach for ALL.","evidence_relations":"Infant ALL (under 12 months) is treated differently than other age groups"},
	{"id":"Medical-e0090b36","source":"Medical","question":"What type of cancer is rectal cancer classified as?","answer":"Rectal cancer is a type of colorectal cancer.","question_type":"Fact Retrieval","evidence":"Rectal cancer is a type of colorectal cancer.","evidence_relations":"Rectal cancer is a type of colorectal cancer"},
	{"id":"Medical-2f6c215a","source":"Medical","question":"What is the most common subtype of rectal cancer?","answer":"Adenocarcinoma is the most common subtype of rectal cancer.","question_type":"Fact Retrieval","evidence":"Adenocarcinoma is the most common subtype of rectal cancer.","evidence_relations":"Adenocarcinoma is the most common subtype of rectal cancer"},
	{"id":"Medical-1b6c4690","source":"Medical","question":"From which type of polyp do most rectal cancers originate?","answer":"Most rectal cancers start in adenomatous polyps.","question_type":"Fact Retrieval","evidence":"Most rectal cancers start in adenomatous polyps.","evidence_relations":"Most rectal cancers start in adenomatous polyps"},
	{"id":"Medical-49bb5694","source":"Medical","question":"Which polyps rarely become cancerous in the rectum?","answer":"Hyperplastic and inflammatory polyps rarely turn into cancer.","question_type":"Fact Retrieval","evidence":"Hyperplastic polyps rarely turn into cancer.; Inflammatory polyps rarely turn into cancer.","evidence_relations":"Hyperplastic and inflammatory polyps rarely turn into cancer"},
	{"id":"Medical-e6a5a2c8","source":"Medical","question":"How can most polyps be removed to prevent rectal cancer?","answer":"Polypectomy during colonoscopy can remove most polyps and prevent cancer.","question_type":"Fact Retrieval","evidence":"Polypectomy during colonoscopy can remove most polyps.; Removing most polyps can prevent rectal cancer.","evidence_relations":"Polypectomy during colonoscopy can remove most polyps and prevent cancer"},
	{"id":"Medical-6b8d3af0","source":"Medical","question":"What are the recommended biomarkers to test in all rectal tumors?","answer":"All rectal tumors should be tested for dMMR or MSI-H.","question_type":"Fact Retrieval","evidence":"All rectal tumors should be tested for dMMR.; All rectal tumors should be tested for MSI-H.","evidence_relations":"All rectal tumors should be tested for dMMR or MSI-H"},
	{"id":"Medical-63846367","source":"Medical","question":"Which biomarkers are associated with rectal cancer?","answer":"Mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H) are biomarkers in rectal cancer.","question_type":"Fact Retrieval","evidence":"Mismatch repair deficiency (dMMR) is a biomarker in rectal cancer.; Microsatellite instability-high (MSI-H) is a biomarker in rectal cancer.","evidence_relations":"Mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H) are biomarkers in rectal cancer"},
	{"id":"Medical-7bd39a07","source":"Medical","question":"What genetic syndrome is a risk factor for rectal cancer?","answer":"Lynch syndrome is a genetic risk factor for rectal cancer.","question_type":"Fact Retrieval","evidence":"Lynch syndrome is a genetic risk factor for rectal cancer.","evidence_relations":"Lynch syndrome is a genetic risk factor for rectal cancer"},
	{"id":"Medical-5025010a","source":"Medical","question":"Which genetic syndrome causes multiple polyps and increases rectal cancer risk?","answer":"Familial adenomatous polyposis (FAP) is a genetic syndrome causing multiple polyps and increased rectal cancer risk.","question_type":"Fact Retrieval","evidence":"Familial adenomatous polyposis (FAP) is a genetic syndrome.; Familial adenomatous polyposis (FAP) causes multiple polyps.; Familial adenomatous polyposis (FAP) increases rectal cancer risk.","evidence_relations":"Familial adenomatous polyposis (FAP) is a genetic syndrome causing multiple polyps and increased rectal cancer risk"},
	{"id":"Medical-ebc00ba5","source":"Medical","question":"What blood test is used for monitoring rectal cancer?","answer":"Blood tests such as CEA are used for monitoring rectal cancer.","question_type":"Fact Retrieval","evidence":"Blood tests such as CEA are used for monitoring rectal cancer.","evidence_relations":"Blood tests such as CEA are used for monitoring rectal cancer"},
	{"id":"Medical-9a4b562a","source":"Medical","question":"Which imaging method is recommended for staging rectal cancer?","answer":"MRI of the pelvis is recommended for staging rectal cancer.","question_type":"Fact Retrieval","evidence":"MRI of the pelvis is recommended for staging rectal cancer.","evidence_relations":"MRI of the pelvis is recommended for staging rectal cancer"},
	{"id":"Medical-121175d0","source":"Medical","question":"What diagnostic tool can assess tumor extent and guide biopsy in rectal cancer?","answer":"Endorectal ultrasound (EUS) can assess tumor extent and guide biopsy.","question_type":"Fact Retrieval","evidence":"Endorectal ultrasound (EUS) can assess tumor extent.; Endorectal ultrasound (EUS) can guide biopsy.","evidence_relations":"Endorectal ultrasound (EUS) can assess tumor extent and guide biopsy"},
	{"id":"Medical-4418f730","source":"Medical","question":"Which scan is used to detect metastasis in rectal cancer?","answer":"CT scan of chest and abdomen is used to detect metastasis.","question_type":"Fact Retrieval","evidence":"CT scan of chest and abdomen is used to detect metastasis in rectal cancer.","evidence_relations":"CT scan of chest and abdomen is used to detect metastasis"},
	{"id":"Medical-b31188bc","source":"Medical","question":"What is the recommended treatment for T1 rectal tumors?","answer":"Endoscopic submucosal dissection (ESD) is recommended for T1 rectal tumors.","question_type":"Fact Retrieval","evidence":"Endoscopic submucosal dissection (ESD) is recommended for T1 rectal tumors.","evidence_relations":"Endoscopic submucosal dissection (ESD) is recommended for T1 rectal tumors"},
	{"id":"Medical-58b16818","source":"Medical","question":"Which surgical procedure is an option for T1 tumors at the end of the rectum?","answer":"Transanal local excision is an option for T1 tumors at the end of the rectum.","question_type":"Fact Retrieval","evidence":"Transanal local excision is an option for T1 tumors at the end of the rectum.","evidence_relations":"Transanal local excision is an option for T1 tumors at the end of the rectum"},
	{"id":"Medical-40a89900","source":"Medical","question":"What surgical treatment is recommended for T2 and some T1/T3 rectal tumors?","answer":"Transabdominal surgery is recommended for T2 and some T1/T3 tumors.","question_type":"Fact Retrieval","evidence":"Transabdominal surgery is recommended for T2 rectal tumors.; Transabdominal surgery is recommended for some T1/T3 rectal tumors.","evidence_relations":"Transabdominal surgery is recommended for T2 and some T1/T3 tumors"},
	{"id":"Medical-9fffc3b8","source":"Medical","question":"Which surgical procedure is used for tumors in the mid to upper rectum?","answer":"Low anterior resection (LAR) is used for tumors in the mid to upper rectum.","question_type":"Fact Retrieval","evidence":"Low anterior resection (LAR) is used for tumors in the mid rectum.; Low anterior resection (LAR) is used for tumors in the upper rectum.","evidence_relations":"Low anterior resection (LAR) is used for tumors in the mid to upper rectum"},
	{"id":"Medical-b73e21e2","source":"Medical","question":"What surgery is performed for tumors in the lower rectum?","answer":"Abdominoperineal resection (APR) is used for tumors in the lower rectum.","question_type":"Fact Retrieval","evidence":"Abdominoperineal resection (APR) is performed for tumors in the lower rectum.","evidence_relations":"Abdominoperineal resection (APR) is used for tumors in the lower rectum"},
	{"id":"Medical-bd4e8d31","source":"Medical","question":"What treatment is used for locally advanced rectal cancer?","answer":"Chemoradiation is used for locally advanced rectal cancer.","question_type":"Fact Retrieval","evidence":"Chemoradiation is used for locally advanced rectal cancer.","evidence_relations":"Chemoradiation is used for locally advanced rectal cancer"},
	{"id":"Medical-1537264f","source":"Medical","question":"Which chemotherapy drugs may be included in rectal cancer regimens?","answer":"Chemotherapy regimens may include oxaliplatin or irinotecan.","question_type":"Fact Retrieval","evidence":"Chemotherapy regimens for rectal cancer may include oxaliplatin.; Chemotherapy regimens for rectal cancer may include irinotecan.","evidence_relations":"Chemotherapy regimens may include oxaliplatin or irinotecan"},
	{"id":"Medical-64d6964d","source":"Medical","question":"What is the surveillance strategy after local excision or ESD for rectal cancer?","answer":"Surveillance after local excision or ESD includes regular sigmoidoscopy and imaging.","question_type":"Fact Retrieval","evidence":"Surveillance after local excision or ESD for rectal cancer includes regular sigmoidoscopy.; Surveillance after local excision or ESD for rectal cancer includes imaging.","evidence_relations":"Surveillance after local excision or ESD includes regular sigmoidoscopy and imaging"},
	{"id":"Medical-c02f01c8","source":"Medical","question":"Which procedure is recommended after surgery for surveillance of rectal cancer?","answer":"Colonoscopy is recommended after surgery for surveillance.","question_type":"Fact Retrieval","evidence":"Colonoscopy is recommended after surgery for surveillance of rectal cancer.","evidence_relations":"Colonoscopy is recommended after surgery for surveillance"},
	{"id":"Medical-3677b386","source":"Medical","question":"What are the fertility preservation options for rectal cancer patients?","answer":"Fertility preservation options include sperm banking, egg freezing, ovarian tissue banking, and ovarian transposition.","question_type":"Fact Retrieval","evidence":"Fertility preservation options for rectal cancer patients include sperm banking.; Fertility preservation options for rectal cancer patients include egg freezing.; Fertility preservation options for rectal cancer patients include ovarian tissue banking.; Fertility preservation options for rectal cancer patients include ovarian transposition.","evidence_relations":"Fertility preservation options include sperm banking, egg freezing, ovarian tissue banking, and ovarian transposition"},
	{"id":"Medical-ce8744bd","source":"Medical","question":"What symptoms may indicate rectal cancer?","answer":"Symptoms of rectal cancer may include changes in bowel habits, rectal bleeding, and abdominal pain.","question_type":"Fact Retrieval","evidence":"Symptoms of rectal cancer may include changes in bowel habits.; Symptoms of rectal cancer may include rectal bleeding.; Symptoms of rectal cancer may include abdominal pain.","evidence_relations":"Symptoms of rectal cancer may include changes in bowel habits, rectal bleeding, and abdominal pain"},
	{"id":"Medical-4aba43e4","source":"Medical","question":"What is the role of polypectomy in rectal cancer prevention?","answer":"Polypectomy during colonoscopy can remove most polyps and prevent cancer.","question_type":"Fact Retrieval","evidence":"Polypectomy during colonoscopy can remove most polyps.; Polypectomy during colonoscopy can prevent cancer.","evidence_relations":"Polypectomy during colonoscopy can remove most polyps and prevent cancer"},
	{"id":"Medical-f7e69032","source":"Medical","question":"Which genetic alterations are risk factors for rectal cancer?","answer":"Lynch syndrome and familial adenomatous polyposis (FAP) are risk factors for rectal cancer.","question_type":"Fact Retrieval","evidence":"Lynch syndrome is a risk factor for rectal cancer.; Familial adenomatous polyposis (FAP) is a risk factor for rectal cancer.","evidence_relations":"Lynch syndrome is a genetic risk factor for rectal cancer; Familial adenomatous polyposis (FAP) is a genetic syndrome causing multiple polyps and increased rectal cancer risk"},
	{"id":"Medical-4361d3ae","source":"Medical","question":"What surveillance methods are used after T1 rectal tumor resection?","answer":"Flexible sigmoidoscopy every 6 months for 5 years and imaging (EUS or MRI) every 3-6 months for 2 years, then every 6 months through year 5 are used.","question_type":"Fact Retrieval","evidence":"Flexible sigmoidoscopy is performed every 6 months for 5 years after T1 rectal tumor resection.; Imaging (EUS or MRI) is performed every 3-6 months for 2 years after T1 rectal tumor resection.; Imaging (EUS or MRI) is performed every 6 months through year 5 after T1 rectal tumor resection.","evidence_relations":"Flexible sigmoidoscopy every 6 months for 5 years; Imaging (EUS or MRI) every 3-6 months for 2 years, then every 6 months through year 5"},
	{"id":"Medical-43c23661","source":"Medical","question":"Which diagnostic methods are listed for rectal cancer?","answer":"Diagnostic methods include MRI, endorectal ultrasound (EUS), CT scan, flexible sigmoidoscopy, colonoscopy, and CEA blood test.","question_type":"Fact Retrieval","evidence":"Diagnostic methods for rectal cancer include MRI.; Diagnostic methods for rectal cancer include endorectal ultrasound (EUS).; Diagnostic methods for rectal cancer include CT scan.; Diagnostic methods for rectal cancer include flexible sigmoidoscopy.; Diagnostic methods for rectal cancer include colonoscopy.; Diagnostic methods for rectal cancer include CEA blood test.","evidence_relations":"MRI, Endorectal ultrasound (EUS), CT scan, Flexible sigmoidoscopy, Colonoscopy, CEA blood test"},
	{"id":"Medical-15f8d40a","source":"Medical","question":"Which surgical procedures are included in rectal cancer treatment?","answer":"Surgical procedures include polypectomy, transanal local excision, transabdominal surgery, low anterior resection (LAR), and abdominoperineal resection (APR).","question_type":"Fact Retrieval","evidence":"Surgical procedures for rectal cancer treatment include polypectomy.; Surgical procedures for rectal cancer treatment include transanal local excision.; Surgical procedures for rectal cancer treatment include transabdominal surgery.; Surgical procedures for rectal cancer treatment include low anterior resection (LAR).; Surgical procedures for rectal cancer treatment include abdominoperineal resection (APR).","evidence_relations":"Surgical Procedure: Polypectomy, Transanal local excision, Transabdominal surgery, Low anterior resection (LAR), Abdominoperineal resection (APR)"},
	{"id":"Medical-3a64b795","source":"Medical","question":"What are the main symptoms of rectal cancer according to the ontology?","answer":"The main symptoms are rectal bleeding, abdominal pain, and changes in bowel habits.","question_type":"Fact Retrieval","evidence":"The main symptoms of rectal cancer include rectal bleeding.; The main symptoms of rectal cancer include abdominal pain.; The main symptoms of rectal cancer include changes in bowel habits.","evidence_relations":"Symptom: Rectal bleeding, Abdominal pain, Changes in bowel habits"},
	{"id":"Medical-c17e7134","source":"Medical","question":"Which biomarkers are used for monitoring rectal cancer?","answer":"CEA blood test and ctDNA are used for monitoring rectal cancer.","question_type":"Fact Retrieval","evidence":"CEA blood test is used for monitoring rectal cancer.; ctDNA is used for monitoring rectal cancer.","evidence_relations":"Biomarker: CEA blood test, ctDNA"},
	{"id":"Medical-9a4565c5","source":"Medical","question":"What is the recommended imaging for surveillance after local excision of rectal cancer?","answer":"Imaging with EUS or MRI is recommended for surveillance after local excision.","question_type":"Fact Retrieval","evidence":"Imaging with EUS is recommended for surveillance after local excision of rectal cancer.; Imaging with MRI is recommended for surveillance after local excision of rectal cancer.","evidence_relations":"Imaging (EUS or MRI) every 3-6 months for 2 years, then every 6 months through year 5"},
	{"id":"Medical-1118823b","source":"Medical","question":"What is the most common subtype of bladder cancer?","answer":"Urothelial carcinoma is the most common subtype.","question_type":"Fact Retrieval","evidence":"Urothelial carcinoma is the most common subtype of bladder cancer.","evidence_relations":"Urothelial carcinoma is the most common subtype of bladder cancer"},
	{"id":"Medical-b7f57756","source":"Medical","question":"Which cancer subtypes are less common in bladder cancer?","answer":"Squamous cell carcinoma, adenocarcinoma, and small cell carcinoma are less common.","question_type":"Fact Retrieval","evidence":"Squamous cell carcinoma is a less common subtype of bladder cancer.; Adenocarcinoma is a less common subtype of bladder cancer.; Small cell carcinoma is a less common subtype of bladder cancer.","evidence_relations":"Squamous cell carcinoma, adenocarcinoma, and small cell carcinoma are less common subtypes of bladder cancer"},
	{"id":"Medical-535b6521","source":"Medical","question":"How is bladder cancer staged?","answer":"Bladder cancer is staged from 0 to 4 based on depth of invasion and spread.","question_type":"Fact Retrieval","evidence":"Bladder cancer is staged from 0 to 4.; Bladder cancer staging is based on depth of invasion.; Bladder cancer staging is based on spread.","evidence_relations":"Bladder cancer is staged from 0 to 4 based on depth of invasion and spread"},
	{"id":"Medical-8cd77727","source":"Medical","question":"Which stages of bladder cancer are considered nonmuscle-invasive?","answer":"Stage 0 and Stage 1 bladder cancers are nonmuscle-invasive.","question_type":"Fact Retrieval","evidence":"Stage 0 bladder cancer is nonmuscle-invasive.; Stage 1 bladder cancer is nonmuscle-invasive.","evidence_relations":"Stage 0 and Stage 1 bladder cancers are nonmuscle-invasive"},
	{"id":"Medical-cf95f911","source":"Medical","question":"Which stages of bladder cancer are muscle-invasive?","answer":"Stages 2, 3, and 4 bladder cancers are muscle-invasive.","question_type":"Fact Retrieval","evidence":"Stage 2 bladder cancer is muscle-invasive.; Stage 3 bladder cancer is muscle-invasive.; Stage 4 bladder cancer is muscle-invasive.","evidence_relations":"Stages 2, 3, and 4 bladder cancers are muscle-invasive"},
	{"id":"Medical-0dbb19e7","source":"Medical","question":"What characterizes Stage 4 bladder cancer?","answer":"Stage 4 bladder cancer is metastatic and may involve distant organs.","question_type":"Fact Retrieval","evidence":"Stage 4 bladder cancer is metastatic.; Stage 4 bladder cancer may involve distant organs.","evidence_relations":"Stage 4 bladder cancer is metastatic and may involve distant organs"},
	{"id":"Medical-0cfbdcf6","source":"Medical","question":"How is cancer grade classified in bladder cancer?","answer":"Cancer grade is classified as low grade (LG) or high grade (HG).","question_type":"Fact Retrieval","evidence":"Cancer grade in bladder cancer is classified as low grade (LG).; Cancer grade in bladder cancer is classified as high grade (HG).","evidence_relations":"Cancer grade is classified as low grade (LG) or high grade (HG)"},
	{"id":"Medical-aeb19c82","source":"Medical","question":"What is the greatest risk factor for bladder cancer?","answer":"Smoking is the greatest risk factor for bladder cancer.","question_type":"Fact Retrieval","evidence":"Smoking is the greatest risk factor for bladder cancer.","evidence_relations":"Smoking is the greatest risk factor for bladder cancer"},
	{"id":"Medical-7171cb7e","source":"Medical","question":"List other risk factors for bladder cancer besides smoking.","answer":"Other risk factors include age, family history, Lynch syndrome, and chemical exposure.","question_type":"Fact Retrieval","evidence":"Other risk factors for bladder cancer include age.; Other risk factors for bladder cancer include family history.; Other risk factors for bladder cancer include Lynch syndrome.; Other risk factors for bladder cancer include chemical exposure.","evidence_relations":"Other risk factors include age, family history, Lynch syndrome, and chemical exposure"},
	{"id":"Medical-faa1be8b","source":"Medical","question":"What is the most common symptom of bladder cancer?","answer":"Blood in urine (hematuria) is the most common symptom.","question_type":"Fact Retrieval","evidence":"Blood in urine (hematuria) is the most common symptom of bladder cancer.","evidence_relations":"Blood in urine (hematuria) is the most common symptom of bladder cancer"},
	{"id":"Medical-03cb5164","source":"Medical","question":"Name additional symptoms of bladder cancer.","answer":"Other symptoms include frequent urination, urgency, painful urination, and back pain.","question_type":"Fact Retrieval","evidence":"Other symptoms of bladder cancer include frequent urination.; Other symptoms of bladder cancer include urgency.; Other symptoms of bladder cancer include painful urination.; Other symptoms of bladder cancer include back pain.","evidence_relations":"Other symptoms include frequent urination, urgency, painful urination, and back pain"},
	{"id":"Medical-5d4c9987","source":"Medical","question":"Which diagnostic methods are used for bladder cancer?","answer":"Diagnosis of bladder cancer involves cystoscopy, urine cytology, biopsy, and imaging (CT, MRI, PET/CT, ultrasound, pyelogram, urogram).","question_type":"Fact Retrieval","evidence":"Diagnosis of bladder cancer involves cystoscopy.; Diagnosis of bladder cancer involves urine cytology.; Diagnosis of bladder cancer involves biopsy.; Diagnosis of bladder cancer involves imaging.; Imaging methods for bladder cancer diagnosis include CT.; Imaging methods for bladder cancer diagnosis include MRI.; Imaging methods for bladder cancer diagnosis include PET/CT.; Imaging methods for bladder cancer diagnosis include ultrasound.; Imaging methods for bladder cancer diagnosis include pyelogram.; Imaging methods for bladder cancer diagnosis include urogram.","evidence_relations":"Diagnosis of bladder cancer involves cystoscopy, urine cytology, biopsy, and imaging (CT, MRI, PET/CT, ultrasound, pyelogram, urogram)"},
	{"id":"Medical-a14ecb5b","source":"Medical","question":"What is the role of biomarker tests in bladder cancer?","answer":"Biomarker tests may be used for surveillance in nonmuscle-invasive bladder cancer.","question_type":"Fact Retrieval","evidence":"Biomarker tests may be used for surveillance in nonmuscle-invasive bladder cancer.","evidence_relations":"Biomarker tests may be used for surveillance in nonmuscle-invasive bladder cancer"},
	{"id":"Medical-7c3827b8","source":"Medical","question":"Which genetic alterations are associated with bladder cancer?","answer":"Mutations in CDKN2A, FGFR3, PIK3CA, and ERBB genes are associated with bladder cancer.","question_type":"Fact Retrieval","evidence":"Mutations in CDKN2A are associated with bladder cancer.; Mutations in FGFR3 are associated with bladder cancer.; Mutations in PIK3CA are associated with bladder cancer.; Mutations in ERBB genes are associated with bladder cancer.","evidence_relations":"Genetic alterations such as mutations in CDKN2A, FGFR3, PIK3CA, and ERBB genes are associated with bladder cancer"},
	{"id":"Medical-98f70f90","source":"Medical","question":"What surgical procedures are used to treat bladder cancer?","answer":"Surgery includes TURBT, radical cystectomy, and partial cystectomy.","question_type":"Fact Retrieval","evidence":"Surgery for bladder cancer includes TURBT.; Surgery for bladder cancer includes radical cystectomy.; Surgery for bladder cancer includes partial cystectomy.","evidence_relations":"Surgery is a primary treatment for bladder cancer and includes TURBT, radical cystectomy, and partial cystectomy"},
	{"id":"Medical-4d4136c1","source":"Medical","question":"What is TURBT used for in bladder cancer?","answer":"TURBT is used for tumor removal in nonmuscle-invasive bladder cancer.","question_type":"Fact Retrieval","evidence":"TURBT is used for tumor removal.; TURBT is used in nonmuscle-invasive bladder cancer.","evidence_relations":"TURBT is used for tumor removal in nonmuscle-invasive bladder cancer"},
	{"id":"Medical-87a9ce2a","source":"Medical","question":"What is the standard surgery for muscle-invasive bladder cancer?","answer":"Radical cystectomy is the standard surgery for muscle-invasive bladder cancer.","question_type":"Fact Retrieval","evidence":"Radical cystectomy is the standard surgery.; Radical cystectomy is used for muscle-invasive bladder cancer.","evidence_relations":"Radical cystectomy is the standard surgery for muscle-invasive bladder cancer"},
	{"id":"Medical-390dfa49","source":"Medical","question":"List urinary diversion procedures after bladder surgery.","answer":"Urinary diversion procedures include ileal conduit, neobladder, and continent cutaneous pouch.","question_type":"Fact Retrieval","evidence":"Urinary diversion procedures include ileal conduit.; Urinary diversion procedures include neobladder.; Urinary diversion procedures include continent cutaneous pouch.","evidence_relations":"Urinary diversion procedures include ileal conduit, neobladder, and continent cutaneous pouch"},
	{"id":"Medical-4c7b454c","source":"Medical","question":"What intravesical therapies are used for nonmuscle-invasive bladder cancer?","answer":"Intravesical therapy (BCG or chemotherapy) is used for nonmuscle-invasive bladder cancer.","question_type":"Fact Retrieval","evidence":"Intravesical therapy is used for nonmuscle-invasive bladder cancer.; Intravesical therapy includes BCG.; Intravesical therapy includes chemotherapy.","evidence_relations":"Intravesical therapy (BCG or chemotherapy) is used for nonmuscle-invasive bladder cancer"},
	{"id":"Medical-2f2a6fa6","source":"Medical","question":"What does systemic therapy for bladder cancer include?","answer":"Systemic therapy includes chemotherapy, immunotherapy (checkpoint inhibitors), and targeted therapy.","question_type":"Fact Retrieval","evidence":"Systemic therapy includes chemotherapy.; Systemic therapy includes immunotherapy.; Systemic therapy includes targeted therapy.; Immunotherapy includes checkpoint inhibitors.","evidence_relations":"Systemic therapy includes chemotherapy, immunotherapy (checkpoint inhibitors), and targeted therapy"},
	{"id":"Medical-d587c0c2","source":"Medical","question":"Which chemotherapy regimens are used for bladder cancer?","answer":"Chemotherapy regimens include cisplatin-based combinations such as ddMVAC.","question_type":"Fact Retrieval","evidence":"Chemotherapy regimens include cisplatin-based combinations.; Chemotherapy regimens include ddMVAC.","evidence_relations":"Chemotherapy regimens include cisplatin-based combinations such as ddMVAC"},
	{"id":"Medical-a605930d","source":"Medical","question":"Name immunotherapy agents used in bladder cancer treatment.","answer":"Immunotherapy agents include pembrolizumab, nivolumab, avelumab, and atezolizumab.","question_type":"Fact Retrieval","evidence":"Immunotherapy agents include pembrolizumab.; Immunotherapy agents include nivolumab.; Immunotherapy agents include avelumab.; Immunotherapy agents include atezolizumab.","evidence_relations":"Immunotherapy agents include pembrolizumab, nivolumab, avelumab, and atezolizumab"},
	{"id":"Medical-b0dbdd5a","source":"Medical","question":"Which targeted therapies are available for bladder cancer?","answer":"Targeted therapies include enfortumab vedotin-ejfv (Padcev), erdafitinib (Balversa), and sacituzumab govitecan-hziy (Trodelvy).","question_type":"Fact Retrieval","evidence":"Targeted therapies include enfortumab vedotin-ejfv (Padcev).; Targeted therapies include erdafitinib (Balversa).; Targeted therapies include sacituzumab govitecan-hziy (Trodelvy).","evidence_relations":"Targeted therapies include enfortumab vedotin-ejfv (Padcev), erdafitinib (Balversa), and sacituzumab govitecan-hziy (Trodelvy)"},
	{"id":"Medical-2349616a","source":"Medical","question":"How is radiation therapy used in bladder cancer?","answer":"Radiation therapy (EBRT) is used alone or in combination with chemotherapy (chemoradiation).","question_type":"Fact Retrieval","evidence":"Radiation therapy (EBRT) is used in bladder cancer.; Radiation therapy can be used alone.; Radiation therapy can be used in combination with chemotherapy.; The combination of radiation therapy and chemotherapy is called chemoradiation.","evidence_relations":"Radiation therapy (EBRT) is used alone or in combination with chemotherapy (chemoradiation)"},
	{"id":"Medical-01f6cee9","source":"Medical","question":"What is trimodal therapy in bladder cancer?","answer":"Trimodal therapy combines TURBT, chemotherapy, and radiation as a bladder-preserving approach.","question_type":"Fact Retrieval","evidence":"Trimodal therapy combines TURBT, chemotherapy, and radiation.; Trimodal therapy is a bladder-preserving approach.","evidence_relations":"Trimodal therapy combines TURBT, chemotherapy, and radiation as a bladder-preserving approach"},
	{"id":"Medical-f14367b4","source":"Medical","question":"Are clinical trials available for bladder cancer patients?","answer":"Clinical trials are available at all stages of bladder cancer.","question_type":"Fact Retrieval","evidence":"Clinical trials are available for bladder cancer patients.; Clinical trials are available at all stages of bladder cancer.","evidence_relations":"Clinical trials are available at all stages of bladder cancer"},
	{"id":"Medical-41a35ea5","source":"Medical","question":"Why is follow-up and surveillance important in bladder cancer?","answer":"Follow-up and surveillance are required due to high recurrence rates.","question_type":"Fact Retrieval","evidence":"Follow-up and surveillance are important in bladder cancer.; Follow-up and surveillance are required due to high recurrence rates.","evidence_relations":"Follow-up and surveillance are required due to high recurrence rates"},
	{"id":"Medical-bf15b76c","source":"Medical","question":"What does supportive care address in bladder cancer management?","answer":"Supportive care addresses symptoms and side effects of cancer and its treatment.","question_type":"Fact Retrieval","evidence":"Supportive care addresses symptoms of cancer.; Supportive care addresses side effects of cancer treatment.","evidence_relations":"Supportive care addresses symptoms and side effects of cancer and its treatment"},
	{"id":"Medical-5c1d4e51","source":"Medical","question":"What are common side effects of bladder cancer treatment?","answer":"Common side effects include bleeding, infection, sexual dysfunction, urinary incontinence, fatigue, nausea, and diarrhea.","question_type":"Fact Retrieval","evidence":"Common side effects of bladder cancer treatment include bleeding.; Common side effects of bladder cancer treatment include infection.; Common side effects of bladder cancer treatment include sexual dysfunction.; Common side effects of bladder cancer treatment include urinary incontinence.; Common side effects of bladder cancer treatment include fatigue.; Common side effects of bladder cancer treatment include nausea.; Common side effects of bladder cancer treatment include diarrhea.","evidence_relations":"Common side effects of treatment include bleeding, infection, sexual dysfunction, urinary incontinence, fatigue, nausea, and diarrhea"},
	{"id":"Medical-75349f3e","source":"Medical","question":"Which imaging modalities are used in diagnosing bladder cancer?","answer":"Imaging methods include CT scan, MRI, PET/CT, ultrasound, pyelogram, and urogram.","question_type":"Fact Retrieval","evidence":"Imaging methods used in diagnosing bladder cancer include CT scan.; Imaging methods used in diagnosing bladder cancer include MRI.; Imaging methods used in diagnosing bladder cancer include PET/CT.; Imaging methods used in diagnosing bladder cancer include ultrasound.; Imaging methods used in diagnosing bladder cancer include pyelogram.; Imaging methods used in diagnosing bladder cancer include urogram.","evidence_relations":"Diagnosis of bladder cancer involves cystoscopy, urine cytology, biopsy, and imaging (CT, MRI, PET/CT, ultrasound, pyelogram, urogram)"},
	{"id":"Medical-0a1eb649","source":"Medical","question":"Which procedures are included in follow-up and surveillance for bladder cancer?","answer":"Regular cystoscopy, urine cytology, imaging, and biomarker surveillance are included in follow-up and surveillance.","question_type":"Fact Retrieval","evidence":"Regular cystoscopy is included in follow-up and surveillance for bladder cancer.; Urine cytology is included in follow-up and surveillance for bladder cancer.; Imaging is included in follow-up and surveillance for bladder cancer.; Biomarker surveillance is included in follow-up and surveillance for bladder cancer.","evidence_relations":"Follow-up/Surveillance: [Regular cystoscopy, Urine cytology, Imaging, Biomarker surveillance]"},
	{"id":"Medical-185686b9","source":"Medical","question":"What is the most common type of kidney cancer?","answer":"Renal cell carcinoma (RCC) is the most common type.","question_type":"Fact Retrieval","evidence":"Renal cell carcinoma (RCC) is the most common type of kidney cancer.","evidence_relations":"Renal cell carcinoma (RCC) is the most common type of kidney cancer"},
	{"id":"Medical-5d6707ec","source":"Medical","question":"Which subtype is most common within renal cell carcinoma?","answer":"Clear cell RCC is the most common subtype of RCC.","question_type":"Fact Retrieval","evidence":"Clear cell RCC is the most common subtype of renal cell carcinoma.","evidence_relations":"Clear cell RCC is the most common subtype of RCC"},
	{"id":"Medical-d44eb527","source":"Medical","question":"What are the main non-clear cell subtypes of RCC?","answer":"Papillary RCC, chromophobe RCC, collecting duct RCC, and renal medullary carcinoma are the main non-clear cell RCC subtypes.","question_type":"Fact Retrieval","evidence":"Papillary RCC is a main non-clear cell subtype of RCC.; Chromophobe RCC is a main non-clear cell subtype of RCC.; Collecting duct RCC is a main non-clear cell subtype of RCC.; Renal medullary carcinoma is a main non-clear cell subtype of RCC.","evidence_relations":"Non-clear cell RCC includes papillary RCC, chromophobe RCC, collecting duct RCC, and renal medullary carcinoma"},
	{"id":"Medical-7996c42e","source":"Medical","question":"Which RCC subtype is associated with more aggressive disease due to sarcomatoid features?","answer":"Sarcomatoid features can occur in any RCC subtype and are associated with more aggressive disease.","question_type":"Fact Retrieval","evidence":"Sarcomatoid features can occur in any RCC subtype.; Sarcomatoid features are associated with more aggressive disease.","evidence_relations":"Sarcomatoid features can occur in any RCC subtype and are associated with more aggressive disease"},
	{"id":"Medical-a8f6fa76","source":"Medical","question":"Where does renal cell carcinoma originate in the kidney?","answer":"RCC starts in the cells that line the renal tubules.","question_type":"Fact Retrieval","evidence":"Renal cell carcinoma (RCC) starts in the cells that line the renal tubules.","evidence_relations":"RCC starts in the cells that line the renal tubules"},
	{"id":"Medical-37dbfdeb","source":"Medical","question":"Which kidney cancer type starts in the renal pelvis and ureter?","answer":"Urothelial carcinoma starts in the cells lining the renal pelvis and ureter.","question_type":"Fact Retrieval","evidence":"Urothelial carcinoma starts in the cells lining the renal pelvis.; Urothelial carcinoma starts in the cells lining the ureter.","evidence_relations":"Urothelial carcinoma starts in the cells lining the renal pelvis and ureter"},
	{"id":"Medical-d0e5bc04","source":"Medical","question":"Which kidney cancer type is most commonly seen in young children?","answer":"Wilms tumor usually occurs in young children and is a distinct kidney cancer type.","question_type":"Fact Retrieval","evidence":"Wilms tumor usually occurs in young children.; Wilms tumor is a distinct kidney cancer type.","evidence_relations":"Wilms tumor usually occurs in young children and is a distinct kidney cancer type"},
	{"id":"Medical-490d56f2","source":"Medical","question":"What kidney cancer type arises from the blood vessels or connective tissue?","answer":"Renal sarcoma starts in the blood vessels or connective tissue of the kidney.","question_type":"Fact Retrieval","evidence":"Renal sarcoma starts in the blood vessels of the kidney.; Renal sarcoma starts in the connective tissue of the kidney.","evidence_relations":"Renal sarcoma starts in the blood vessels or connective tissue of the kidney"},
	{"id":"Medical-10f571cf","source":"Medical","question":"Name two anatomical structures in the kidney where cancer can spread locally.","answer":"Kidney cancer can spread locally to surrounding fat and blood vessels.","question_type":"Fact Retrieval","evidence":"Kidney cancer can spread locally to surrounding fat.; Kidney cancer can spread locally to blood vessels.","evidence_relations":"Kidney cancer can spread locally to surrounding fat, blood vessels, lymph nodes, adrenal glands, and Gerotas fascia"},
	{"id":"Medical-ba155dc8","source":"Medical","question":"Which distant organs are common sites for kidney cancer metastasis?","answer":"Lungs, lymph nodes, bones, liver, and brain are common sites for metastasis.","question_type":"Fact Retrieval","evidence":"Lungs are a common site for kidney cancer metastasis.; Lymph nodes are a common site for kidney cancer metastasis.; Bones are a common site for kidney cancer metastasis.; Liver is a common site for kidney cancer metastasis.; Brain is a common site for kidney cancer metastasis.","evidence_relations":"Kidney cancer can metastasize to distant sites such as lungs, lymph nodes, bones, liver, and brain"},
	{"id":"Medical-dee6ad31","source":"Medical","question":"What diagnostic methods are used for kidney cancer?","answer":"Imaging tests, blood tests, urine tests, biopsy, biomarker testing, and genetic risk testing are used.","question_type":"Fact Retrieval","evidence":"Imaging tests are used for kidney cancer diagnosis.; Blood tests are used for kidney cancer diagnosis.; Urine tests are used for kidney cancer diagnosis.; Biopsy is used for kidney cancer diagnosis.; Biomarker testing is used for kidney cancer diagnosis.; Genetic risk testing is used for kidney cancer diagnosis.","evidence_relations":"Diagnosis of kidney cancer involves imaging tests, blood tests, urine tests, biopsy, biomarker testing, and genetic risk testing"},
	{"id":"Medical-b8dfd72f","source":"Medical","question":"Which factors determine the treatment approach for RCC?","answer":"Treatment for RCC is based on histology, tumor size, tumor location, and presence of metastasis.","question_type":"Fact Retrieval","evidence":"Treatment for RCC is based on histology.; Treatment for RCC is based on tumor size.; Treatment for RCC is based on tumor location.; Treatment for RCC is based on presence of metastasis.","evidence_relations":"Treatment for RCC is based on histology, tumor size, tumor location, and presence of metastasis"},
	{"id":"Medical-1e2c5da7","source":"Medical","question":"How are multiple tumors in one or both kidneys classified?","answer":"Multiple tumors in one or both kidneys are treated as separate primary tumors, not metastasis.","question_type":"Fact Retrieval","evidence":"Multiple tumors in one kidney are treated as separate primary tumors.; Multiple tumors in both kidneys are treated as separate primary tumors.; Multiple tumors in one or both kidneys are not considered metastasis.","evidence_relations":"Multiple tumors in one or both kidneys are treated as separate primary tumors, not metastasis"},
	{"id":"Medical-a11058f1","source":"Medical","question":"Which anatomical structure is the origin of RCC according to the ontology?","answer":"RCC originates from the renal tubules.","question_type":"Fact Retrieval","evidence":"RCC originates from the renal tubules.","evidence_relations":"RCC starts in the cells that line the renal tubules"},
	{"id":"Medical-21443bc5","source":"Medical","question":"What is the anatomical location for urothelial carcinoma in the kidney?","answer":"Urothelial carcinoma originates from the renal pelvis.","question_type":"Fact Retrieval","evidence":"Urothelial carcinoma originates from the renal pelvis.","evidence_relations":"Urothelial carcinoma starts in the cells lining the renal pelvis and ureter"},
	{"id":"Medical-e3a6570b","source":"Medical","question":"List three diagnostic tests for kidney cancer.","answer":"Imaging tests, blood tests, and urine tests are diagnostic methods.","question_type":"Fact Retrieval","evidence":"Imaging tests are a diagnostic method for kidney cancer.; Blood tests are a diagnostic method for kidney cancer.; Urine tests are a diagnostic method for kidney cancer.","evidence_relations":"Diagnosis of kidney cancer involves imaging tests, blood tests, urine tests, biopsy, biomarker testing, and genetic risk testing"},
	{"id":"Medical-5d85f130","source":"Medical","question":"Which subtype of RCC includes papillary and chromophobe RCC?","answer":"Non-clear cell RCC includes papillary RCC and chromophobe RCC.","question_type":"Fact Retrieval","evidence":"Non-clear cell RCC includes papillary RCC.; Non-clear cell RCC includes chromophobe RCC.","evidence_relations":"Non-clear cell RCC includes papillary RCC, chromophobe RCC, collecting duct RCC, and renal medullary carcinoma"},
	{"id":"Medical-a7da5e0d","source":"Medical","question":"What is a histological subtype of non-clear cell RCC?","answer":"Papillary RCC is a histological subtype of non-clear cell RCC.","question_type":"Fact Retrieval","evidence":"Papillary RCC is a histological subtype of non-clear cell RCC.","evidence_relations":"Non-clear cell RCC includes papillary RCC, chromophobe RCC, collecting duct RCC, and renal medullary carcinoma"},
	{"id":"Medical-823c7c4f","source":"Medical","question":"Which anatomical structure surrounds the kidney and can be invaded by cancer?","answer":"Gerotas fascia surrounds the kidney and can be invaded by cancer.","question_type":"Fact Retrieval","evidence":"Gerotas fascia surrounds the kidney.; Gerotas fascia can be invaded by cancer.","evidence_relations":"Kidney cancer can spread locally to surrounding fat, blood vessels, lymph nodes, adrenal glands, and Gerotas fascia"},
	{"id":"Medical-794ec19c","source":"Medical","question":"What is a potential local spread site for kidney cancer besides fat and vessels?","answer":"Adrenal glands are a potential local spread site for kidney cancer.","question_type":"Fact Retrieval","evidence":"Adrenal glands are a potential local spread site for kidney cancer.","evidence_relations":"Kidney cancer can spread locally to surrounding fat, blood vessels, lymph nodes, adrenal glands, and Gerotas fascia"},
	{"id":"Medical-1fc1a85d","source":"Medical","question":"Which diagnostic method is used to test for genetic risk in kidney cancer?","answer":"Genetic risk testing is used for diagnosis.","question_type":"Fact Retrieval","evidence":"Genetic risk testing is used for diagnosis in kidney cancer.","evidence_relations":"Diagnosis of kidney cancer involves imaging tests, blood tests, urine tests, biopsy, biomarker testing, and genetic risk testing"},
	{"id":"Medical-f0243613","source":"Medical","question":"Which RCC subtype can show sarcomatoid features?","answer":"Sarcomatoid features can occur in any RCC subtype.","question_type":"Fact Retrieval","evidence":"Sarcomatoid features can occur in any RCC subtype.","evidence_relations":"Sarcomatoid features can occur in any RCC subtype and are associated with more aggressive disease"},
	{"id":"Medical-d44fbd5d","source":"Medical","question":"Which kidney cancer subtype is described as fumarate hydratase-deficient?","answer":"Fumarate hydratase-deficient RCC is a non-clear cell RCC subtype.","question_type":"Fact Retrieval","evidence":"Fumarate hydratase-deficient RCC is a non-clear cell RCC subtype.","evidence_relations":"Fumarate hydratase-deficient RCC is listed under non-clear cell RCC in the ontology"},
	{"id":"Medical-974e88ba","source":"Medical","question":"Which cancer subtype is called nephroblastoma?","answer":"Wilms tumor is also known as nephroblastoma.","question_type":"Fact Retrieval","evidence":"Wilms tumor is also known as nephroblastoma.","evidence_relations":"Wilms tumor (nephroblastoma) is listed in the ontology"},
	{"id":"Medical-10a38986","source":"Medical","question":"Which kidney cancer arises from the connective tissue?","answer":"Renal sarcoma starts in the blood vessels or connective tissue of the kidney.","question_type":"Fact Retrieval","evidence":"Renal sarcoma starts in the blood vessels of the kidney.; Renal sarcoma starts in the connective tissue of the kidney.","evidence_relations":"Renal sarcoma starts in the blood vessels or connective tissue of the kidney"},
	{"id":"Medical-c7f55e00","source":"Medical","question":"What is the main anatomical structure involved in the origin of RCC?","answer":"The renal tubules are the main anatomical structure involved.","question_type":"Fact Retrieval","evidence":"The renal tubules are the main anatomical structure involved in the origin of RCC.","evidence_relations":"RCC starts in the cells that line the renal tubules"},
	{"id":"Medical-07accd3e","source":"Medical","question":"Which diagnostic method provides tissue for histology in kidney cancer?","answer":"Biopsy is the diagnostic method that provides tissue for histology.","question_type":"Fact Retrieval","evidence":"Biopsy is the diagnostic method that provides tissue for histology in kidney cancer.","evidence_relations":"Diagnosis of kidney cancer involves imaging tests, blood tests, urine tests, biopsy, biomarker testing, and genetic risk testing"},
	{"id":"Medical-d1937844","source":"Medical","question":"Which anatomical structure is a common site of distant metastasis from kidney cancer?","answer":"The lungs are a common site of distant metastasis.","question_type":"Fact Retrieval","evidence":"The lungs are a common site of distant metastasis from kidney cancer.","evidence_relations":"Kidney cancer can metastasize to distant sites such as lungs, lymph nodes, bones, liver, and brain"},
	{"id":"Medical-b53a2a5a","source":"Medical","question":"Which subtypes are included in non-clear cell RCC according to the ontology?","answer":"Papillary RCC, chromophobe RCC, collecting duct RCC, renal medullary carcinoma, clear cell papillary renal cell tumor, fumarate hydratase-deficient RCC, and ELOC-mutated RCC are included.","question_type":"Fact Retrieval","evidence":"Papillary RCC is included in non-clear cell RCC.; Chromophobe RCC is included in non-clear cell RCC.; Collecting duct RCC is included in non-clear cell RCC.; Renal medullary carcinoma is included in non-clear cell RCC.; Clear cell papillary renal cell tumor is included in non-clear cell RCC.; Fumarate hydratase-deficient RCC is included in non-clear cell RCC.; ELOC-mutated RCC is included in non-clear cell RCC.","evidence_relations":"Non-clear cell RCC (nccRCC) includes Papillary RCC (PRCC), Chromophobe RCC, Collecting duct RCC (cdRCC), Renal medullary carcinoma (RMC), Clear cell papillary renal cell tumor, Fumarate hydratase-deficient RCC, and ELOC-mutated RCC"},
	{"id":"Medical-ebc2f755","source":"Medical","question":"What is the relationship between tumor location and RCC treatment?","answer":"Tumor location is a treatment factor for RCC.","question_type":"Fact Retrieval","evidence":"Tumor location is a treatment factor for RCC.","evidence_relations":"Treatment for RCC is based on histology, tumor size, tumor location, and presence of metastasis"},
	{"id":"Medical-1fabcd8c","source":"Medical","question":"Which anatomical structure is part of the kidney's blood supply and can be involved in local spread?","answer":"The renal vein is part of the blood supply and can be involved in local spread.","question_type":"Fact Retrieval","evidence":"The renal vein is part of the kidney's blood supply.; The renal vein can be involved in local spread.","evidence_relations":"Local spread includes blood vessels such as the renal vein"},
	{"id":"Medical-b821991a","source":"Medical","question":"Which test is used to evaluate biomarkers in kidney cancer?","answer":"Biomarker testing is used to evaluate biomarkers.","question_type":"Fact Retrieval","evidence":"Biomarker testing is used to evaluate biomarkers in kidney cancer.","evidence_relations":"Diagnosis of kidney cancer involves imaging tests, blood tests, urine tests, biopsy, biomarker testing, and genetic risk testing"},
	{"id":"Medical-a653aa5d","source":"Medical","question":"What is the most common subtype of anal cancer?","answer":"Anal squamous cell carcinoma is the most common subtype.","question_type":"Fact Retrieval","evidence":"Anal squamous cell carcinoma is the most common subtype of anal cancer.","evidence_relations":"Anal squamous cell carcinoma is the most common subtype of anal cancer"},
	{"id":"Medical-a0d64e65","source":"Medical","question":"Which virus is the strongest risk factor for anal cancer?","answer":"HPV infection is the strongest risk factor.","question_type":"Fact Retrieval","evidence":"HPV infection is the strongest risk factor for anal cancer.","evidence_relations":"HPV infection is the strongest risk factor for anal cancer"},
	{"id":"Medical-c87340df","source":"Medical","question":"Which high-risk HPV strain is associated with anal cancer?","answer":"HPV16 is a high-risk strain associated with anal cancer.","question_type":"Fact Retrieval","evidence":"HPV16 is a high-risk strain.; HPV16 is associated with anal cancer.","evidence_relations":"HPV16 is a high-risk strain associated with anal cancer"},
	{"id":"Medical-dd224a09","source":"Medical","question":"What is the primary treatment for most non-metastatic anal cancers (stages I-III)?","answer":"Chemoradiation is the recommended primary treatment.","question_type":"Fact Retrieval","evidence":"Chemoradiation is the recommended primary treatment for most non-metastatic anal cancers.; Non-metastatic anal cancers are classified as stages I-III.","evidence_relations":"Chemoradiation is the recommended primary treatment for most non-metastatic anal cancers (stages I-III)"},
	{"id":"Medical-97813815","source":"Medical","question":"What chemotherapy regimens are recommended with radiation for anal cancer?","answer":"Mitomycin and capecitabine, mitomycin and 5-FU, or 5-FU and cisplatin are recommended.","question_type":"Fact Retrieval","evidence":"Mitomycin and capecitabine are recommended chemotherapy regimens with radiation for anal cancer.; Mitomycin and 5-FU are recommended chemotherapy regimens with radiation for anal cancer.; 5-FU and cisplatin are recommended chemotherapy regimens with radiation for anal cancer.","evidence_relations":"Recommended chemotherapy regimens with radiation include mitomycin and capecitabine, mitomycin and 5-FU, or 5-FU and cisplatin"},
	{"id":"Medical-4a5a56d2","source":"Medical","question":"Which diagnostic methods are used for the diagnosis and staging of anal cancer?","answer":"Digital rectal exam (DRE), high-resolution anoscopy (HRA), and imaging (CT, MRI, PET) are used.","question_type":"Fact Retrieval","evidence":"Digital rectal exam (DRE) is used for the diagnosis and staging of anal cancer.; High-resolution anoscopy (HRA) is used for the diagnosis and staging of anal cancer.; Imaging techniques such as CT, MRI, and PET are used for the diagnosis and staging of anal cancer.","evidence_relations":"Digital rectal exam (DRE), high-resolution anoscopy (HRA), and imaging (CT, MRI, PET) are used for diagnosis and staging"},
	{"id":"Medical-63c03e9b","source":"Medical","question":"What is the AJCC TNM stage for distant metastasis in anal cancer?","answer":"Stage IV is defined as distant metastasis.","question_type":"Fact Retrieval","evidence":"Stage IV is defined as distant metastasis in anal cancer.","evidence_relations":"Stage IV: distant metastasis"},
	{"id":"Medical-08e2b14a","source":"Medical","question":"Which surgical procedure results in a permanent colostomy for anal cancer patients?","answer":"Abdominoperineal resection (APR) results in a permanent colostomy.","question_type":"Fact Retrieval","evidence":"Abdominoperineal resection (APR) results in a permanent colostomy for anal cancer patients.","evidence_relations":"APR results in a permanent colostomy"},
	{"id":"Medical-7dfa3ebe","source":"Medical","question":"What are common symptoms of anal cancer?","answer":"Common symptoms include rectal bleeding, anal itching, pain, and a lump near the anus.","question_type":"Fact Retrieval","evidence":"Common symptoms of anal cancer include rectal bleeding.; Common symptoms of anal cancer include anal itching.; Common symptoms of anal cancer include pain.; Common symptoms of anal cancer include a lump near the anus.","evidence_relations":"Common symptoms of anal cancer include rectal bleeding, anal itching, pain, and a lump near the anus"},
	{"id":"Medical-5a8f962a","source":"Medical","question":"Which imaging techniques are used in the diagnosis of anal cancer?","answer":"CT scan, MRI, and PET scan are used for diagnosis.","question_type":"Fact Retrieval","evidence":"CT scan is used in the diagnosis of anal cancer.; MRI is used in the diagnosis of anal cancer.; PET scan is used in the diagnosis of anal cancer.","evidence_relations":"CT scan, MRI, PET scan are used for diagnosis"},
	{"id":"Medical-bb548dea","source":"Medical","question":"What is the indication for local excision in anal cancer treatment?","answer":"Local excision is an option for some early-stage, low-grade perianal cancers.","question_type":"Fact Retrieval","evidence":"Local excision is an option for some early-stage, low-grade perianal cancers.","evidence_relations":"Local excision is an option for some early-stage, low-grade perianal cancers"},
	{"id":"Medical-6b2c8ad5","source":"Medical","question":"Which immunotherapy drugs are recommended for metastatic anal cancer that progresses after chemotherapy?","answer":"Nivolumab and pembrolizumab are recommended.","question_type":"Fact Retrieval","evidence":"Nivolumab is recommended for metastatic anal cancer that progresses after chemotherapy.; Pembrolizumab is recommended for metastatic anal cancer that progresses after chemotherapy.","evidence_relations":"Immunotherapy (nivolumab, pembrolizumab) is recommended for metastatic anal cancer that progresses after chemotherapy"},
	{"id":"Medical-042aa09a","source":"Medical","question":"What is the preferred radiation technique for anal cancer?","answer":"IMRT is the preferred radiation technique.","question_type":"Fact Retrieval","evidence":"IMRT is the preferred radiation technique for anal cancer.","evidence_relations":"IMRT is the preferred radiation technique for anal cancer"},
	{"id":"Medical-0c7cb4ef","source":"Medical","question":"Which risk factor is shared by patients with a history of cervical, vulvar, or vaginal cancer or precancer?","answer":"History of cervical, vulvar, or vaginal cancer or precancer increases anal cancer risk.","question_type":"Fact Retrieval","evidence":"A history of cervical cancer increases anal cancer risk.; A history of vulvar cancer increases anal cancer risk.; A history of vaginal cancer increases anal cancer risk.; A history of precancer increases anal cancer risk.","evidence_relations":"History of cervical, vulvar, or vaginal cancer or precancer increases anal cancer risk"},
	{"id":"Medical-5fed2a2c","source":"Medical","question":"What is the recommended follow-up for complete remission after anal cancer treatment?","answer":"Follow-up includes DRE and inguinal lymph node exam every 3-6 months for 5 years, anoscopy every 6-12 months for 3 years, and imaging yearly for 3 years (stage II/III).","question_type":"Fact Retrieval","evidence":"Follow-up for complete remission after anal cancer treatment includes DRE every 3-6 months for 5 years.; Follow-up for complete remission after anal cancer treatment includes inguinal lymph node exam every 3-6 months for 5 years.; Follow-up for complete remission after anal cancer treatment includes anoscopy every 6-12 months for 3 years.; Follow-up for complete remission after anal cancer treatment includes imaging yearly for 3 years for stage II/III.","evidence_relations":"Complete remission: DRE every 3-6 months for 5 years, inguinal lymph node exam every 3-6 months for 5 years, anoscopy every 6-12 months for 3 years, imaging yearly for 3 years (stage II/III)"},
	{"id":"Medical-c68b6022","source":"Medical","question":"What is the most common site of origin for anal cancer?","answer":"Anal cancer most often starts in squamous cells lining the anal canal.","question_type":"Fact Retrieval","evidence":"Anal cancer most often starts in squamous cells.; Anal cancer most often starts in the lining of the anal canal.","evidence_relations":"Anal cancer most often starts in squamous cells lining the anal canal"},
	{"id":"Medical-facc6239","source":"Medical","question":"Which population should be tested for HIV when diagnosed with anal cancer?","answer":"HIV testing is recommended in patients with anal cancer.","question_type":"Fact Retrieval","evidence":"HIV testing is recommended in patients with anal cancer.","evidence_relations":"HIV testing is recommended in patients with anal cancer"},
	{"id":"Medical-506ba6ee","source":"Medical","question":"Which chemotherapy regimens are used for metastatic anal cancer?","answer":"Carboplatin and paclitaxel, FOLFOX, FOLFCIS, modified DCF, and 5-FU and cisplatin are used.","question_type":"Fact Retrieval","evidence":"Carboplatin and paclitaxel are used for metastatic anal cancer.; FOLFOX is used for metastatic anal cancer.; FOLFCIS is used for metastatic anal cancer.; Modified DCF is used for metastatic anal cancer.; 5-FU and cisplatin are used for metastatic anal cancer.","evidence_relations":"Metastatic anal cancer is treated with systemic chemotherapy (e.g., carboplatin and paclitaxel, FOLFOX, FOLFCIS, DCF, 5-FU and cisplatin)"},
	{"id":"Medical-63d09604","source":"Medical","question":"What precancerous lesions are associated with anal squamous cell carcinoma?","answer":"AIN, LSIL, HSIL, and Stage 0 are precancerous lesions.","question_type":"Fact Retrieval","evidence":"AIN is a precancerous lesion associated with anal squamous cell carcinoma.; LSIL is a precancerous lesion associated with anal squamous cell carcinoma.; HSIL is a precancerous lesion associated with anal squamous cell carcinoma.; Stage 0 is a precancerous lesion associated with anal squamous cell carcinoma.","evidence_relations":"Anal squamous cell carcinoma: Precancerous Lesion: [AIN, LSIL, HSIL, Stage 0]"},
	{"id":"Medical-481c27a3","source":"Medical","question":"What are the consequences of abdominoperineal resection (APR)?","answer":"APR results in a permanent colostomy.","question_type":"Fact Retrieval","evidence":"Abdominoperineal resection (APR) results in a permanent colostomy.","evidence_relations":"APR results in a permanent colostomy"},
	{"id":"Medical-beaf1678","source":"Medical","question":"What fertility preservation options should be discussed before chemoradiation for anal cancer?","answer":"Options include sperm banking, egg freezing, ovarian tissue banking, and oophoropexy.","question_type":"Fact Retrieval","evidence":"Sperm banking is a fertility preservation option before chemoradiation for anal cancer.; Egg freezing is a fertility preservation option before chemoradiation for anal cancer.; Ovarian tissue banking is a fertility preservation option before chemoradiation for anal cancer.; Oophoropexy is a fertility preservation option before chemoradiation for anal cancer.","evidence_relations":"Fertility preservation options should be discussed: sperm banking, egg freezing, ovarian tissue banking, oophoropexy"},
	{"id":"Medical-86f3ab3d","source":"Medical","question":"What is the definition of Stage I anal cancer according to the AJCC TNM system?","answer":"Stage I: tumor 2 cm, no lymph node or distant spread.","question_type":"Fact Retrieval","evidence":"Stage I anal cancer is defined as a tumor that is 2 cm or smaller.; Stage I anal cancer has no lymph node spread.; Stage I anal cancer has no distant spread.","evidence_relations":"Stage I: tumor 2 cm, no lymph node or distant spread"},
	{"id":"Medical-73b1e8c2","source":"Medical","question":"What is the indication for groin dissection in anal cancer?","answer":"Groin dissection is indicated for lymph node recurrence.","question_type":"Fact Retrieval","evidence":"Groin dissection is indicated for lymph node recurrence in anal cancer.","evidence_relations":"Groin dissection: Indication: Lymph node recurrence"},
	{"id":"Medical-f61e2128","source":"Medical","question":"What is the recommended treatment for persistent, recurrent, or locally progressive anal cancer?","answer":"Abdominoperineal resection (APR) is recommended.","question_type":"Fact Retrieval","evidence":"Abdominoperineal resection (APR) is recommended for persistent, recurrent, or locally progressive anal cancer.","evidence_relations":"Abdominoperineal resection (APR) is recommended for persistent, recurrent, or locally progressive anal cancer"},
	{"id":"Medical-912613b8","source":"Medical","question":"Which supportive care measures are provided for anal cancer patients?","answer":"Supportive care includes pelvic floor physical therapy, dietary counseling, vaginal dilator therapy, ostomy care, mental health support, and peer-to-peer support.","question_type":"Fact Retrieval","evidence":"Supportive care for anal cancer patients includes pelvic floor physical therapy.; Supportive care for anal cancer patients includes dietary counseling.; Supportive care for anal cancer patients includes vaginal dilator therapy.; Supportive care for anal cancer patients includes ostomy care.; Supportive care for anal cancer patients includes mental health support.; Supportive care for anal cancer patients includes peer-to-peer support.","evidence_relations":"Supportive Care: [Pelvic floor physical therapy, Dietary counseling, Vaginal dilator therapy, Ostomy care, Mental health support, Peer-to-peer support]"},
	{"id":"Medical-ea7aec7d","source":"Medical","question":"What are common side effects of anal cancer treatment?","answer":"Common side effects include infertility, bowel dysfunction, urinary incontinence, sexual dysfunction, hand-foot syndrome, nausea, vomiting, diarrhea, fatigue, skin irritation, mucositis, low blood cell counts, hearing loss (cisplatin), and neuropathy (oxaliplatin).","question_type":"Fact Retrieval","evidence":"Common side effects of anal cancer treatment include infertility.; Common side effects of anal cancer treatment include bowel dysfunction.; Common side effects of anal cancer treatment include urinary incontinence.; Common side effects of anal cancer treatment include sexual dysfunction.; Common side effects of anal cancer treatment include hand-foot syndrome.; Common side effects of anal cancer treatment include nausea.; Common side effects of anal cancer treatment include vomiting.; Common side effects of anal cancer treatment include diarrhea.; Common side effects of anal cancer treatment include fatigue.; Common side effects of anal cancer treatment include skin irritation.; Common side effects of anal cancer treatment include mucositis.; Common side effects of anal cancer treatment include low blood cell counts.; Common side effects of anal cancer treatment include hearing loss due to cisplatin.; Common side effects of anal cancer treatment include neuropathy due to oxaliplatin.","evidence_relations":"Side Effect: [Infertility, Bowel dysfunction, Urinary incontinence, Sexual dysfunction, Hand-foot syndrome, Nausea, Vomiting, Diarrhea, Fatigue, Skin irritation, Mucositis, Low blood cell counts, Hearing loss (cisplatin), Neuropathy (oxaliplatin)]"},
	{"id":"Medical-4c1f9dd4","source":"Medical","question":"Which patients are eligible for clinical trials in anal cancer?","answer":"All patients are encouraged to consider enrollment in clinical trials.","question_type":"Fact Retrieval","evidence":"All patients are encouraged to consider enrollment in clinical trials for anal cancer.","evidence_relations":"Clinical trials are recommended for all patients if available"},
	{"id":"Medical-f057bf07","source":"Medical","question":"What is the definition of Stage 0 anal cancer?","answer":"Stage 0 is carcinoma in situ or anal dysplasia.","question_type":"Fact Retrieval","evidence":"Stage 0 anal cancer is defined as carcinoma in situ.; Stage 0 anal cancer is defined as anal dysplasia.","evidence_relations":"Stage 0 is carcinoma in situ or anal dysplasia"},
	{"id":"Medical-8251ced4","source":"Medical","question":"What are the main anatomic locations where anal cancer can start?","answer":"Anal cancer can start in the anal canal or perianal region.","question_type":"Fact Retrieval","evidence":"Anal cancer can start in the anal canal.; Anal cancer can start in the perianal region.","evidence_relations":"Anal cancer can start in the anal canal or perianal region"},
	{"id":"Medical-dff662c1","source":"Medical","question":"Which populations are at increased risk of anal cancer due to immunosuppression?","answer":"HIV infection and immunosuppressant use increase the risk of anal cancer.","question_type":"Fact Retrieval","evidence":"HIV infection increases the risk of anal cancer.; Immunosuppressant use increases the risk of anal cancer.","evidence_relations":"HIV infection increases the risk of anal cancer; Immunosuppressant use increases the risk of anal cancer"},
	{"id":"Medical-f3817e3b","source":"Medical","question":"What is the standard method for diagnosing anal cancer after abnormal DRE or anoscopy?","answer":"Anal cancer is diagnosed by biopsy after abnormal findings on DRE or anoscopy.","question_type":"Fact Retrieval","evidence":"Anal cancer is diagnosed by biopsy after abnormal findings on DRE.; Anal cancer is diagnosed by biopsy after abnormal findings on anoscopy.","evidence_relations":"Anal cancer is diagnosed by biopsy after abnormal findings on DRE or anoscopy"},
	{"id":"Medical-23f92b9b","source":"Medical","question":"Which AJCC TNM stage involves lymph node involvement and/or invasion of nearby organs in anal cancer?","answer":"Stage III involves lymph node involvement and/or invasion of nearby organs.","question_type":"Fact Retrieval","evidence":"Stage III anal cancer involves lymph node involvement.; Stage III anal cancer involves invasion of nearby organs.","evidence_relations":"Stage III: lymph node involvement and/or invasion of nearby organs"},
	{"id":"Medical-0eed4fb2","source":"Medical","question":"What is the primary cancer type described in this context?","answer":"Acute lymphoblastic leukemia (ALL) is the primary cancer type.","question_type":"Fact Retrieval","evidence":"The primary cancer type described is acute lymphoblastic leukemia (ALL).","evidence_relations":"Acute lymphoblastic leukemia (ALL) is a fast-growing blood cancer that starts in lymphocytes"},
	{"id":"Medical-abe5fc71","source":"Medical","question":"Which cells are the origin of ALL?","answer":"ALL arises from lymphoid progenitor cells.","question_type":"Fact Retrieval","evidence":"Acute lymphoblastic leukemia (ALL) arises from lymphoid progenitor cells.","evidence_relations":"ALL arises from lymphoid progenitor cells"},
	{"id":"Medical-7904dba7","source":"Medical","question":"What are the two main subtypes of acute lymphoblastic leukemia?","answer":"The two main subtypes are B-cell ALL (B-ALL) and T-cell ALL (T-ALL).","question_type":"Fact Retrieval","evidence":"The two main subtypes of acute lymphoblastic leukemia are B-cell ALL (B-ALL) and T-cell ALL (T-ALL).","evidence_relations":"There are two main subtypes of ALL: B-cell ALL (B-ALL) and T-cell ALL (T-ALL)"},
	{"id":"Medical-e87faed8","source":"Medical","question":"Which ALL subtype is more common?","answer":"B-cell ALL (B-ALL) is more common than T-ALL.","question_type":"Fact Retrieval","evidence":"B-cell ALL (B-ALL) is more common than T-cell ALL (T-ALL).","evidence_relations":"B-ALL starts in B-cell lymphocytes and is more common than T-ALL"},
	{"id":"Medical-378948e8","source":"Medical","question":"What is the cell of origin for T-cell ALL?","answer":"T-cell ALL starts in T-cell lymphocytes.","question_type":"Fact Retrieval","evidence":"T-cell ALL starts in T-cell lymphocytes.","evidence_relations":"T-ALL starts in T-cell lymphocytes and can cause an enlarged thymus"},
	{"id":"Medical-3eede906","source":"Medical","question":"What diagnostic threshold defines ALL based on bone marrow lymphoblasts?","answer":"ALL is diagnosed when 20 percent or more lymphoblasts are present in the bone marrow.","question_type":"Fact Retrieval","evidence":"ALL is diagnosed when 20 percent or more lymphoblasts are present in the bone marrow.","evidence_relations":"ALL is diagnosed when 20 percent or more lymphoblasts are present in the bone marrow"},
	{"id":"Medical-4b10d237","source":"Medical","question":"Which diagnostic methods are used for ALL?","answer":"Diagnosis of ALL involves blood tests, bone marrow aspirate and biopsy, flow cytometry, immunophenotyping, genetic and biomarker testing, imaging tests, and lumbar puncture.","question_type":"Fact Retrieval","evidence":"Diagnosis of ALL involves blood tests.; Diagnosis of ALL involves bone marrow aspirate and biopsy.; Diagnosis of ALL involves flow cytometry.; Diagnosis of ALL involves immunophenotyping.; Diagnosis of ALL involves genetic and biomarker testing.; Diagnosis of ALL involves imaging tests.; Diagnosis of ALL involves lumbar puncture.","evidence_relations":"Diagnosis of ALL involves blood tests, bone marrow aspirate and biopsy, flow cytometry, immunophenotyping, genetic and biomarker testing, imaging tests, and lumbar puncture"},
	{"id":"Medical-b0580d86","source":"Medical","question":"What are the common sites where ALL can be found?","answer":"ALL can be found in bone marrow, blood, testicles, and central nervous system.","question_type":"Fact Retrieval","evidence":"ALL can be found in bone marrow.; ALL can be found in blood.; ALL can be found in testicles.; ALL can be found in the central nervous system.","evidence_relations":"ALL can be found in bone marrow, blood, testicles, and central nervous system"},
	{"id":"Medical-b2e840c7","source":"Medical","question":"Which ALL subtype can cause an enlarged thymus?","answer":"T-cell ALL (T-ALL) can cause an enlarged thymus.","question_type":"Fact Retrieval","evidence":"T-cell ALL (T-ALL) can cause an enlarged thymus.","evidence_relations":"T-ALL starts in T-cell lymphocytes and can cause an enlarged thymus"},
	{"id":"Medical-ce4f84f0","source":"Medical","question":"What is mature B-cell ALL also called?","answer":"Mature B-cell ALL is also called Burkitt leukemia.","question_type":"Fact Retrieval","evidence":"Mature B-cell ALL is also called Burkitt leukemia.","evidence_relations":"Mature B-cell ALL (Burkitt leukemia) is a rare subtype and is treated differently from B-ALL"},
	{"id":"Medical-ea9eb2d8","source":"Medical","question":"What is the main difference in treatment for mature B-cell ALL compared to B-ALL?","answer":"Mature B-cell ALL (Burkitt leukemia) is treated differently from B-ALL.","question_type":"Fact Retrieval","evidence":"Mature B-cell ALL is also known as Burkitt leukemia.; Mature B-cell ALL is treated differently from B-ALL.","evidence_relations":"Mature B-cell ALL (Burkitt leukemia) is a rare subtype and is treated differently from B-ALL"},
	{"id":"Medical-b58d9012","source":"Medical","question":"What is B-cell lymphoblastic lymphoma (B-LL/B-LBL)?","answer":"B-cell lymphoblastic lymphoma occurs when B-cell lymphoblasts grow mostly in lymph nodes.","question_type":"Fact Retrieval","evidence":"B-cell lymphoblastic lymphoma occurs when B-cell lymphoblasts grow.; B-cell lymphoblasts primarily grow in lymph nodes.","evidence_relations":"B-cell lymphoblastic lymphoma (B-LL/B-LBL) occurs when B-cell lymphoblasts grow mostly in lymph nodes"},
	{"id":"Medical-925c6318","source":"Medical","question":"Where do T-cell lymphoblastic lymphomas (T-LL/T-LBL) primarily grow?","answer":"T-cell lymphoblastic lymphomas grow mostly in the thymus.","question_type":"Fact Retrieval","evidence":"T-cell lymphoblastic lymphomas primarily grow in the thymus.","evidence_relations":"T-cell lymphoblastic lymphoma (T-LL/T-LBL) occurs when T-cell lymphoblasts grow mostly in the thymus"},
	{"id":"Medical-1b8db6c8","source":"Medical","question":"What are the main treatment modalities for ALL?","answer":"Everyone with ALL is treated with steroids and multiagent chemotherapy.","question_type":"Fact Retrieval","evidence":"Everyone with ALL is treated with steroids.; Everyone with ALL is treated with multiagent chemotherapy.","evidence_relations":"Everyone with ALL is treated with steroids and multiagent chemotherapy"},
	{"id":"Medical-da8083a2","source":"Medical","question":"When may targeted therapy be used in ALL?","answer":"Targeted therapy may be used based on genetic alterations.","question_type":"Fact Retrieval","evidence":"Targeted therapy may be used in ALL.; Targeted therapy may be used based on genetic alterations.","evidence_relations":"Targeted therapy may be used based on genetic alterations"},
	{"id":"Medical-99cee2d0","source":"Medical","question":"Which ALL subtype is treated with therapies targeting the BCR::ABL protein?","answer":"BCR::ABL1-positive B-ALL is treated with therapies targeting the BCR::ABL protein.","question_type":"Fact Retrieval","evidence":"BCR::ABL1-positive B-ALL is treated with therapies targeting the BCR::ABL protein.","evidence_relations":"BCR::ABL1-positive B-ALL is treated with therapies targeting the BCR::ABL protein"},
	{"id":"Medical-dfc549c9","source":"Medical","question":"What is the preferred treatment approach for certain subtypes such as BCR::ABL1-negative or BCR::ABL1-like B-ALL?","answer":"Clinical trials are preferred for certain subtypes such as BCR::ABL1-negative or BCR::ABL1-like B-ALL.","question_type":"Fact Retrieval","evidence":"Clinical trials are preferred for certain subtypes of ALL.; Certain subtypes include BCR::ABL1-negative or BCR::ABL1-like B-ALL.","evidence_relations":"Clinical trials are preferred for certain subtypes such as BCR::ABL1-negative or BCR::ABL1-like B-ALL"},
	{"id":"Medical-0b9d8142","source":"Medical","question":"What are the treatment options for T-ALL?","answer":"T-ALL treatment options include chemotherapy and clinical trials.","question_type":"Fact Retrieval","evidence":"T-ALL treatment options include chemotherapy.; T-ALL treatment options include clinical trials.","evidence_relations":"T-ALL treatment options include chemotherapy and clinical trials"},
	{"id":"Medical-3c195424","source":"Medical","question":"What are common symptoms of ALL?","answer":"Symptoms of ALL may include anemia, infections, bleeding, enlarged lymph nodes, and organ involvement.","question_type":"Fact Retrieval","evidence":"Symptoms of ALL may include anemia.; Symptoms of ALL may include infections.; Symptoms of ALL may include bleeding.; Symptoms of ALL may include enlarged lymph nodes.; Symptoms of ALL may include organ involvement.","evidence_relations":"Symptoms of ALL may include anemia, infections, bleeding, enlarged lymph nodes, and organ involvement"},
	{"id":"Medical-06ecb1df","source":"Medical","question":"What are some risk factors for developing ALL?","answer":"Risk factors for ALL include certain genetic syndromes and family history.","question_type":"Fact Retrieval","evidence":"Risk factors for developing ALL include certain genetic syndromes.; Risk factors for developing ALL include family history.","evidence_relations":"Risk factors for ALL include certain genetic syndromes and family history"},
	{"id":"Medical-fcfc4ee8","source":"Medical","question":"Which patient populations are most commonly affected by ALL?","answer":"ALL is more common in children but also occurs in adolescents and young adults (AYAs) and adults.","question_type":"Fact Retrieval","evidence":"ALL is more common in children.; ALL also occurs in adolescents and young adults (AYAs).; ALL occurs in adults.","evidence_relations":"ALL is more common in children but also occurs in adolescents and young adults (AYAs) and adults"},
	{"id":"Medical-ae39f048","source":"Medical","question":"Which biomarker is associated with B-cell ALL?","answer":"BCR::ABL1 is a biomarker associated with B-cell ALL.","question_type":"Fact Retrieval","evidence":"BCR::ABL1 is a biomarker associated with B-cell ALL.","evidence_relations":"B-cell ALL (B-ALL): Biomarker: [BCR::ABL1, Other gene or chromosome changes]"},
	{"id":"Medical-612b302a","source":"Medical","question":"What supportive care should be considered before ALL treatment?","answer":"Fertility preservation should be considered before treatment.","question_type":"Fact Retrieval","evidence":"Fertility preservation should be considered before ALL treatment.","evidence_relations":"Fertility preservation should be considered before treatment"},
	{"id":"Medical-5496bd62","source":"Medical","question":"What is included in follow-up for ALL patients?","answer":"Follow-up includes regular blood tests and surveillance for relapse.","question_type":"Fact Retrieval","evidence":"Follow-up for ALL patients includes regular blood tests.; Follow-up for ALL patients includes surveillance for relapse.","evidence_relations":"Follow-up includes regular blood tests and surveillance for relapse"},
	{"id":"Medical-c3fbbeb8","source":"Medical","question":"What laboratory method is essential for immunophenotyping in ALL diagnosis?","answer":"Flow cytometry is essential for immunophenotyping in ALL diagnosis.","question_type":"Fact Retrieval","evidence":"Flow cytometry is essential for immunophenotyping in ALL diagnosis.","evidence_relations":"Diagnosis of ALL involves flow cytometry, immunophenotyping"},
	{"id":"Medical-58758b1e","source":"Medical","question":"What genetic alteration is targeted in BCR::ABL1-positive B-ALL?","answer":"BCR::ABL1 fusion is the genetic alteration targeted in BCR::ABL1-positive B-ALL.","question_type":"Fact Retrieval","evidence":"BCR::ABL1 fusion is the genetic alteration targeted in BCR::ABL1-positive B-ALL.","evidence_relations":"Genetic Alteration: [BCR::ABL1 fusion, Other gene or chromosome changes]"},
	{"id":"Medical-30093110","source":"Medical","question":"Which organs may show involvement in ALL besides bone marrow?","answer":"ALL may involve blood, lymph nodes, thymus, testicles, and central nervous system.","question_type":"Fact Retrieval","evidence":"ALL may involve blood.; ALL may involve lymph nodes.; ALL may involve thymus.; ALL may involve testicles.; ALL may involve central nervous system.","evidence_relations":"ALL can be found in bone marrow, blood, testicles, and central nervous system"},
	{"id":"Medical-ad34fb71","source":"Medical","question":"What is the initial cell type affected in ALL?","answer":"Lymphoblasts are the initial cell type affected in ALL.","question_type":"Fact Retrieval","evidence":"Lymphoblasts are the initial cell type affected in ALL.","evidence_relations":"ALL is diagnosed when 20 percent or more lymphoblasts are present in the bone marrow"},
	{"id":"Medical-a06b41f4","source":"Medical","question":"Which subtype of ALL is associated with an enlarged thymus?","answer":"T-cell ALL (T-ALL) is associated with an enlarged thymus.","question_type":"Fact Retrieval","evidence":"T-cell ALL (T-ALL) is associated with an enlarged thymus.","evidence_relations":"T-ALL starts in T-cell lymphocytes and can cause an enlarged thymus"},
	{"id":"Medical-277e2774","source":"Medical","question":"What is the role of steroids in ALL treatment?","answer":"Steroids are part of the standard multiagent chemotherapy for ALL.","question_type":"Fact Retrieval","evidence":"Steroids are part of the standard multiagent chemotherapy for ALL.","evidence_relations":"Everyone with ALL is treated with steroids and multiagent chemotherapy"},
	{"id":"Medical-76a07999","source":"Medical","question":"Which diagnostic procedure is used to examine the central nervous system in ALL?","answer":"Lumbar puncture is used to examine the central nervous system in ALL.","question_type":"Fact Retrieval","evidence":"Lumbar puncture is used to examine the central nervous system.; Lumbar puncture is used in ALL.","evidence_relations":"Diagnosis of ALL involves lumbar puncture"},
	{"id":"Medical-4505fae9","source":"Medical","question":"What is the most common subtype of pancreatic cancer?","answer":"Pancreatic ductal adenocarcinoma (PDAC) is the most common subtype.","question_type":"Fact Retrieval","evidence":"Pancreatic ductal adenocarcinoma (PDAC) is the most common subtype of pancreatic cancer.","evidence_relations":"Pancreatic ductal adenocarcinoma (PDAC) is the most common subtype of pancreatic cancer"},
	{"id":"Medical-146a909f","source":"Medical","question":"Which subtype of pancreatic cancer is less common?","answer":"Pancreatic neuroendocrine tumor is a less common subtype.","question_type":"Fact Retrieval","evidence":"Pancreatic neuroendocrine tumor is a less common subtype of pancreatic cancer.","evidence_relations":"Pancreatic neuroendocrine tumor is a less common subtype of pancreatic cancer"},
	{"id":"Medical-ce9c83a7","source":"Medical","question":"What is Stage 0 pancreatic cancer?","answer":"Stage 0 pancreatic cancer is confined to the innermost layer of the duct wall.","question_type":"Fact Retrieval","evidence":"Stage 0 pancreatic cancer is confined to the innermost layer of the duct wall.","evidence_relations":"Stage 0 pancreatic cancer is confined to the innermost layer of the duct wall"},
	{"id":"Medical-f27ac6b8","source":"Medical","question":"What characterizes Stage I pancreatic cancer?","answer":"Stage I pancreatic cancer is a tumor 4 cm or smaller and has not spread outside the pancreas.","question_type":"Fact Retrieval","evidence":"Stage I pancreatic cancer is characterized by a tumor 4 cm or smaller.; Stage I pancreatic cancer has not spread outside the pancreas.","evidence_relations":"Stage I pancreatic cancer is a tumor 4 cm or smaller and has not spread outside the pancreas"},
	{"id":"Medical-69adc0f1","source":"Medical","question":"How is Stage II pancreatic cancer defined?","answer":"Stage II pancreatic cancer is a tumor larger than 4 cm or has spread to 1-3 nearby lymph nodes.","question_type":"Fact Retrieval","evidence":"Stage II pancreatic cancer is defined by a tumor larger than 4 cm.; Stage II pancreatic cancer may have spread to 1-3 nearby lymph nodes.","evidence_relations":"Stage II pancreatic cancer is a tumor larger than 4 cm or has spread to 1-3 nearby lymph nodes"},
	{"id":"Medical-edd74751","source":"Medical","question":"What defines Stage III pancreatic cancer?","answer":"Stage III pancreatic cancer has grown to nearby major arteries or spread to 4 or more lymph nodes.","question_type":"Fact Retrieval","evidence":"Stage III pancreatic cancer has grown to nearby major arteries.; Stage III pancreatic cancer may have spread to 4 or more lymph nodes.","evidence_relations":"Stage III pancreatic cancer has grown to nearby major arteries or spread to 4 or more lymph nodes"},
	{"id":"Medical-484cdbd7","source":"Medical","question":"What is Stage IV pancreatic cancer?","answer":"Stage IV pancreatic cancer has spread to distant organs such as liver, lungs, or abdominal lining.","question_type":"Fact Retrieval","evidence":"Stage IV pancreatic cancer has spread to distant organs.; Distant organs affected by Stage IV pancreatic cancer include the liver, lungs, or abdominal lining.","evidence_relations":"Stage IV pancreatic cancer has spread to distant organs such as liver, lungs, or abdominal lining"},
	{"id":"Medical-12c14164","source":"Medical","question":"What is another name for Stage IV pancreatic cancer?","answer":"Stage IV pancreatic cancer is also known as metastatic cancer.","question_type":"Fact Retrieval","evidence":"Stage IV pancreatic cancer is also known as metastatic cancer.","evidence_relations":"Stage IV pancreatic cancer is metastatic cancer"},
	{"id":"Medical-0c8447e4","source":"Medical","question":"List three risk factors for pancreatic cancer.","answer":"Risk factors include smoking, heavy alcohol use, and unhealthy diet.","question_type":"Fact Retrieval","evidence":"Risk factors for pancreatic cancer include smoking.; Risk factors for pancreatic cancer include heavy alcohol use.; Risk factors for pancreatic cancer include unhealthy diet.","evidence_relations":"Risk factors for pancreatic cancer include smoking, heavy alcohol use, unhealthy diet, exposure to pesticides, diabetes, chronic pancreatitis, and family history of certain cancers"},
	{"id":"Medical-62915cf3","source":"Medical","question":"Which hereditary syndromes increase the risk of pancreatic cancer?","answer":"HBOC, Peutz-Jeghers syndrome, Lynch syndrome, Li-Fraumeni syndrome, FAMMM syndrome, and hereditary pancreatitis increase risk.","question_type":"Fact Retrieval","evidence":"HBOC increases the risk of pancreatic cancer.; Peutz-Jeghers syndrome increases the risk of pancreatic cancer.; Lynch syndrome increases the risk of pancreatic cancer.; Li-Fraumeni syndrome increases the risk of pancreatic cancer.; FAMMM syndrome increases the risk of pancreatic cancer.; Hereditary pancreatitis increases the risk of pancreatic cancer.","evidence_relations":"Hereditary syndromes such as HBOC, Peutz-Jeghers syndrome, Lynch syndrome, Li-Fraumeni syndrome, FAMMM syndrome, and hereditary pancreatitis increase risk of pancreatic cancer"},
	{"id":"Medical-5d1e33ba","source":"Medical","question":"What diagnostic methods are used for pancreatic cancer?","answer":"Diagnostic methods include imaging, endoscopic tests, biopsy, blood tests, genetic tests, and biomarker tests.","question_type":"Fact Retrieval","evidence":"Imaging is a diagnostic method for pancreatic cancer.; Endoscopic tests are a diagnostic method for pancreatic cancer.; Biopsy is a diagnostic method for pancreatic cancer.; Blood tests are a diagnostic method for pancreatic cancer.; Genetic tests are a diagnostic method for pancreatic cancer.; Biomarker tests are a diagnostic method for pancreatic cancer.","evidence_relations":"Diagnostic methods for pancreatic cancer include imaging, endoscopic tests, biopsy, blood tests, genetic tests, and biomarker tests"},
	{"id":"Medical-bbe2b0d9","source":"Medical","question":"What is the role of imaging in pancreatic cancer diagnosis?","answer":"Imaging is used for staging and determining surgical eligibility in pancreatic cancer.","question_type":"Fact Retrieval","evidence":"Imaging is used for staging in pancreatic cancer.; Imaging is used for determining surgical eligibility in pancreatic cancer.","evidence_relations":"Imaging is used for staging and determining surgical eligibility in pancreatic cancer"},
	{"id":"Medical-294e8af8","source":"Medical","question":"Which test can detect inherited mutations linked to hereditary pancreatic cancer?","answer":"Genetic tests can detect inherited mutations linked to hereditary pancreatic cancer.","question_type":"Fact Retrieval","evidence":"Genetic tests can detect inherited mutations linked to hereditary pancreatic cancer.","evidence_relations":"Genetic tests can detect inherited mutations linked to hereditary pancreatic cancer"},
	{"id":"Medical-73631aaa","source":"Medical","question":"What symptom may indicate pancreatic cancer?","answer":"Jaundice (yellowed skin or eyes) may indicate pancreatic cancer.","question_type":"Fact Retrieval","evidence":"Jaundice may indicate pancreatic cancer.; Jaundice is characterized by yellowed skin or eyes.","evidence_relations":"Symptoms of pancreatic cancer may include jaundice (yellowed skin or eyes)"},
	{"id":"Medical-3785154c","source":"Medical","question":"What treatment is an option for some patients with stage I, II, or III pancreatic cancer?","answer":"Surgery is a treatment option for some patients with stage I, II, or III pancreatic cancer.","question_type":"Fact Retrieval","evidence":"Surgery is a treatment option for some patients with stage I pancreatic cancer.; Surgery is a treatment option for some patients with stage II pancreatic cancer.; Surgery is a treatment option for some patients with stage III pancreatic cancer.","evidence_relations":"Surgery is a treatment option for some patients with stage I, II, or III pancreatic cancer"},
	{"id":"Medical-f5dd3419","source":"Medical","question":"What is the main purpose of drug treatment in pancreatic cancer?","answer":"Drug treatment is most often used to control growth and reduce symptoms in pancreatic cancer.","question_type":"Fact Retrieval","evidence":"Drug treatment is most often used to control growth in pancreatic cancer.; Drug treatment is most often used to reduce symptoms in pancreatic cancer.","evidence_relations":"Drug treatment is most often used to control growth and reduce symptoms in pancreatic cancer"},
	{"id":"Medical-ba2d6fae","source":"Medical","question":"Are clinical trials available for pancreatic cancer patients?","answer":"Yes, clinical trials are available for pancreatic cancer patients.","question_type":"Fact Retrieval","evidence":"Clinical trials are available for pancreatic cancer patients.","evidence_relations":"Clinical trials are available for pancreatic cancer patients"},
	{"id":"Medical-227447b0","source":"Medical","question":"Why is a multidisciplinary care team important in pancreatic cancer?","answer":"A multidisciplinary care team is essential for diagnosis and treatment planning in pancreatic cancer.","question_type":"Fact Retrieval","evidence":"A multidisciplinary care team is essential for diagnosis in pancreatic cancer.; A multidisciplinary care team is essential for treatment planning in pancreatic cancer.","evidence_relations":"A multidisciplinary care team is essential for diagnosis and treatment planning in pancreatic cancer"},
	{"id":"Medical-e947f2af","source":"Medical","question":"What is the role of supportive care in pancreatic cancer management?","answer":"Supportive care is an important part of pancreatic cancer management.","question_type":"Fact Retrieval","evidence":"Supportive care is an important part of pancreatic cancer management.","evidence_relations":"Supportive care is an important part of pancreatic cancer management"},
	{"id":"Medical-83d2a1a9","source":"Medical","question":"Which cancer type starts in the pancreas?","answer":"Pancreatic cancer is a type of cancer that starts in the pancreas.","question_type":"Fact Retrieval","evidence":"Pancreatic cancer is a type of cancer.; Pancreatic cancer starts in the pancreas.","evidence_relations":"Pancreatic cancer is a type of cancer that starts in the pancreas"},
	{"id":"Medical-e354dbd2","source":"Medical","question":"Which care team member specializes in imaging for diagnosis?","answer":"A diagnostic radiologist specializes in imaging for diagnosis.","question_type":"Fact Retrieval","evidence":"A diagnostic radiologist specializes in imaging.; A diagnostic radiologist specializes in diagnosis.","evidence_relations":"Diagnostic radiologist is listed as a Care Team Role in the ontology"},
	{"id":"Medical-79a126e8","source":"Medical","question":"Who on the care team provides genetic counseling for pancreatic cancer?","answer":"A genetic counselor provides genetic counseling for pancreatic cancer.","question_type":"Fact Retrieval","evidence":"A genetic counselor provides genetic counseling.; A genetic counselor provides genetic counseling for pancreatic cancer.","evidence_relations":"Genetic counselor is listed as a Care Team Role in the ontology"},
	{"id":"Medical-c6d4a32e","source":"Medical","question":"Which care team member is responsible for performing biopsies?","answer":"A pathologist is responsible for performing biopsies.","question_type":"Fact Retrieval","evidence":"A pathologist is responsible for performing biopsies.","evidence_relations":"Pathologist is listed as a Care Team Role in the ontology"},
	{"id":"Medical-a8dea23c","source":"Medical","question":"Which care team professional manages drug treatments for pancreatic cancer?","answer":"A medical oncologist manages drug treatments for pancreatic cancer.","question_type":"Fact Retrieval","evidence":"A medical oncologist manages drug treatments.; A medical oncologist manages drug treatments for pancreatic cancer.","evidence_relations":"Medical oncologist is listed as a Care Team Role in the ontology"},
	{"id":"Medical-5a1326ab","source":"Medical","question":"What is a common genetic syndrome associated with increased pancreatic cancer risk?","answer":"Hereditary breast-ovarian cancer syndrome (HBOC) is associated with increased pancreatic cancer risk.","question_type":"Fact Retrieval","evidence":"Hereditary breast-ovarian cancer syndrome (HBOC) is associated with increased pancreatic cancer risk.","evidence_relations":"Hereditary breast-ovarian cancer syndrome, HBOC, is listed under Genetic Syndrome increasing risk of pancreatic cancer"},
	{"id":"Medical-dfabcfaf","source":"Medical","question":"What is the definition of metastatic pancreatic cancer?","answer":"Metastatic pancreatic cancer is pancreatic cancer that has spread to distant organs.","question_type":"Fact Retrieval","evidence":"Metastatic pancreatic cancer is pancreatic cancer.; Metastatic pancreatic cancer has spread to distant organs.","evidence_relations":"Stage IV pancreatic cancer has spread to distant organs such as liver, lungs, or abdominal lining"},
	{"id":"Medical-a79c7070","source":"Medical","question":"Which diagnostic method is used to obtain tissue samples in pancreatic cancer?","answer":"Biopsy is used to obtain tissue samples in pancreatic cancer.","question_type":"Fact Retrieval","evidence":"Biopsy is used to obtain tissue samples.; Biopsy is used to obtain tissue samples in pancreatic cancer.","evidence_relations":"Biopsy is listed as a Diagnostic Method for pancreatic cancer"},
	{"id":"Medical-34cfff2d","source":"Medical","question":"Name a blood-based diagnostic method for pancreatic cancer.","answer":"Blood test is a blood-based diagnostic method for pancreatic cancer.","question_type":"Fact Retrieval","evidence":"Blood test is a blood-based diagnostic method.; Blood test is a diagnostic method for pancreatic cancer.","evidence_relations":"Blood test is listed as a Diagnostic Method for pancreatic cancer"},
	{"id":"Medical-11267008","source":"Medical","question":"Which lifestyle factor is a risk factor for pancreatic cancer?","answer":"Smoking is a lifestyle risk factor for pancreatic cancer.","question_type":"Fact Retrieval","evidence":"Smoking is a lifestyle risk factor.; Smoking is a risk factor for pancreatic cancer.","evidence_relations":"Risk factors for pancreatic cancer include smoking"},
	{"id":"Medical-05ba3aaa","source":"Medical","question":"What is the role of a registered dietitian in pancreatic cancer care?","answer":"A registered dietitian is part of the care team for pancreatic cancer.","question_type":"Fact Retrieval","evidence":"A registered dietitian is part of the care team for pancreatic cancer.","evidence_relations":"Registered dietitian is listed as a Care Team Role in the ontology"},
	{"id":"Medical-33142c97","source":"Medical","question":"Which syndrome is characterized by increased risk of both melanoma and pancreatic cancer?","answer":"Familial malignant melanoma syndrome (FAMMM syndrome) is associated with increased risk of both.","question_type":"Fact Retrieval","evidence":"Familial malignant melanoma syndrome is associated with increased risk of melanoma.; Familial malignant melanoma syndrome is associated with increased risk of pancreatic cancer.","evidence_relations":"Familial malignant melanoma syndrome, FAMMM syndrome, is listed under Genetic Syndrome increasing risk of pancreatic cancer"},
	{"id":"Medical-3b1e4517","source":"Medical","question":"What supportive care options are included in pancreatic cancer management?","answer":"Supportive care options include symptom management and palliative care.","question_type":"Fact Retrieval","evidence":"Supportive care options for pancreatic cancer include symptom management.; Supportive care options for pancreatic cancer include palliative care.","evidence_relations":"Supportive Care includes symptom management and palliative care in the ontology"},
	{"id":"Medical-f7ffe25a","source":"Medical","question":"What is the primary cancer type discussed in this dataset?","answer":"Prostate cancer is the primary cancer type.","question_type":"Fact Retrieval","evidence":"Prostate cancer is the primary cancer type discussed in this dataset.","evidence_relations":"Prostate cancer is a disease where cells in the prostate gland grow out of control"},
	{"id":"Medical-9fbd09c4","source":"Medical","question":"Which subtype of prostate cancer is confined to the prostate gland?","answer":"Localized prostate cancer is confined to the prostate.","question_type":"Fact Retrieval","evidence":"Localized prostate cancer is confined to the prostate gland.","evidence_relations":"Localized prostate cancer is early-stage and confined to the prostate"},
	{"id":"Medical-83e047ca","source":"Medical","question":"What stage is regional prostate cancer classified as?","answer":"Regional prostate cancer is classified as advanced-stage.","question_type":"Fact Retrieval","evidence":"Regional prostate cancer is classified as advanced-stage.","evidence_relations":"Regional prostate cancer has spread to nearby lymph nodes"},
	{"id":"Medical-e8796bdf","source":"Medical","question":"Which organs can metastatic prostate cancer spread to?","answer":"Metastatic prostate cancer can spread to bones, liver, or lungs.","question_type":"Fact Retrieval","evidence":"Metastatic prostate cancer can spread to bones.; Metastatic prostate cancer can spread to the liver.; Metastatic prostate cancer can spread to the lungs.","evidence_relations":"Metastatic prostate cancer has spread to distant organs such as bones, liver, or lungs"},
	{"id":"Medical-85da0dd2","source":"Medical","question":"What blood test is commonly used for prostate cancer screening?","answer":"The PSA test is commonly used for screening.","question_type":"Fact Retrieval","evidence":"The PSA test is commonly used for prostate cancer screening.","evidence_relations":"PSA test and digital rectal exam are used for screening and diagnosis"},
	{"id":"Medical-90da4658","source":"Medical","question":"What procedure is required to confirm a prostate cancer diagnosis?","answer":"A biopsy is required to confirm the diagnosis.","question_type":"Fact Retrieval","evidence":"A biopsy is required to confirm a prostate cancer diagnosis.","evidence_relations":"Biopsy is required to confirm prostate cancer diagnosis"},
	{"id":"Medical-3c98e480","source":"Medical","question":"Which imaging modalities are used to assess the extent of prostate cancer?","answer":"MRI, CT, PET, ultrasound, and bone scan are used to assess extent of disease.","question_type":"Fact Retrieval","evidence":"MRI is used to assess the extent of prostate cancer.; CT is used to assess the extent of prostate cancer.; PET is used to assess the extent of prostate cancer.; Ultrasound is used to assess the extent of prostate cancer.; Bone scan is used to assess the extent of prostate cancer.","evidence_relations":"MRI, CT, PET, ultrasound, and bone scan are imaging methods used to assess extent of disease"},
	{"id":"Medical-53fae064","source":"Medical","question":"Which genetic mutation increases the risk of prostate cancer?","answer":"BRCA2 mutation increases risk of prostate cancer.","question_type":"Fact Retrieval","evidence":"BRCA2 mutation increases the risk of prostate cancer.","evidence_relations":"BRCA2 mutation increases risk of prostate cancer"},
	{"id":"Medical-c6d69844","source":"Medical","question":"For which patients is germline genetic testing recommended in prostate cancer?","answer":"Germline genetic testing is recommended for patients with high-risk, very-high-risk, regional, or metastatic prostate cancer.","question_type":"Fact Retrieval","evidence":"Germline genetic testing is recommended for patients with high-risk prostate cancer.; Germline genetic testing is recommended for patients with very-high-risk prostate cancer.; Germline genetic testing is recommended for patients with regional prostate cancer.; Germline genetic testing is recommended for patients with metastatic prostate cancer.","evidence_relations":"Germline genetic testing is recommended for patients with high-risk, very-high-risk, regional, or metastatic prostate cancer"},
	{"id":"Medical-78a954b5","source":"Medical","question":"What is the role of molecular biomarker testing in prostate cancer?","answer":"Molecular biomarker testing helps assess risk and guide treatment decisions.","question_type":"Fact Retrieval","evidence":"Molecular biomarker testing helps assess risk in prostate cancer.; Molecular biomarker testing helps guide treatment decisions in prostate cancer.","evidence_relations":"Molecular biomarker testing helps assess risk and guide treatment decisions"},
	{"id":"Medical-ae01850d","source":"Medical","question":"Which grading systems are used to estimate prostate cancer aggressiveness?","answer":"Grade Group and Gleason score are used to estimate aggressiveness.","question_type":"Fact Retrieval","evidence":"Grade Group is used to estimate prostate cancer aggressiveness.; Gleason score is used to estimate prostate cancer aggressiveness.","evidence_relations":"Grade Group and Gleason score are used to estimate cancer aggressiveness"},
	{"id":"Medical-7960f915","source":"Medical","question":"How are risk groups utilized in prostate cancer management?","answer":"Risk groups guide prognosis and treatment.","question_type":"Fact Retrieval","evidence":"Risk groups guide prognosis in prostate cancer.; Risk groups guide treatment in prostate cancer.","evidence_relations":"Risk groups (very low, low, intermediate, high, very high) guide prognosis and treatment"},
	{"id":"Medical-f2fb665d","source":"Medical","question":"What are the main treatment options for prostate cancer?","answer":"Hormone therapy, surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy, and radiopharmaceuticals are treatment options.","question_type":"Fact Retrieval","evidence":"Hormone therapy is a treatment option for prostate cancer.; Surgery is a treatment option for prostate cancer.; Radiation therapy is a treatment option for prostate cancer.; Chemotherapy is a treatment option for prostate cancer.; Immunotherapy is a treatment option for prostate cancer.; Targeted therapy is a treatment option for prostate cancer.; Radiopharmaceuticals are a treatment option for prostate cancer.","evidence_relations":"Hormone therapy, surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy, and radiopharmaceuticals are treatment options"},
	{"id":"Medical-c9348a2d","source":"Medical","question":"What is the mainstay of advanced prostate cancer treatment?","answer":"Androgen deprivation therapy (ADT) is a mainstay of advanced prostate cancer treatment.","question_type":"Fact Retrieval","evidence":"Androgen deprivation therapy (ADT) is a mainstay of advanced prostate cancer treatment.","evidence_relations":"Androgen deprivation therapy (ADT) is a mainstay of advanced prostate cancer treatment"},
	{"id":"Medical-b1056b54","source":"Medical","question":"Which management strategy is recommended for low-risk, early-stage prostate cancer?","answer":"Active surveillance is a management option for low-risk, early-stage prostate cancer.","question_type":"Fact Retrieval","evidence":"Active surveillance is a management option for low-risk prostate cancer.; Active surveillance is a management option for early-stage prostate cancer.","evidence_relations":"Active surveillance is a management option for low-risk, early-stage prostate cancer"},
	{"id":"Medical-261cef1d","source":"Medical","question":"What symptoms are associated with advanced prostate cancer?","answer":"Symptoms of advanced prostate cancer include blood in urine or semen, bone pain, weight loss, and urinary symptoms.","question_type":"Fact Retrieval","evidence":"Symptoms of advanced prostate cancer include blood in urine.; Symptoms of advanced prostate cancer include blood in semen.; Symptoms of advanced prostate cancer include bone pain.; Symptoms of advanced prostate cancer include weight loss.; Symptoms of advanced prostate cancer include urinary symptoms.","evidence_relations":"Symptoms of advanced prostate cancer include blood in urine or semen, bone pain, weight loss, and urinary symptoms"},
	{"id":"Medical-4eaa05dd","source":"Medical","question":"What are the risk factors for developing prostate cancer?","answer":"Age, family history, race, genetic mutations, diet, obesity, and smoking are risk factors.","question_type":"Fact Retrieval","evidence":"Age is a risk factor for developing prostate cancer.; Family history is a risk factor for developing prostate cancer.; Race is a risk factor for developing prostate cancer.; Genetic mutations are a risk factor for developing prostate cancer.; Diet is a risk factor for developing prostate cancer.; Obesity is a risk factor for developing prostate cancer.; Smoking is a risk factor for developing prostate cancer.","evidence_relations":"Age, family history, race, genetic mutations, diet, obesity, and smoking are risk factors for prostate cancer"},
	{"id":"Medical-e22e810e","source":"Medical","question":"What is included in follow-up for prostate cancer patients?","answer":"Follow-up includes regular PSA testing, imaging, and biopsies as needed.","question_type":"Fact Retrieval","evidence":"Follow-up for prostate cancer patients includes regular PSA testing.; Follow-up for prostate cancer patients includes imaging.; Follow-up for prostate cancer patients includes biopsies as needed.","evidence_relations":"Follow-up includes regular PSA testing, imaging, and biopsies as needed"},
	{"id":"Medical-34a94dcc","source":"Medical","question":"Which diagnostic methods are used for localized prostate cancer?","answer":"PSA test, digital rectal exam, biopsy, MRI, and ultrasound are used for localized prostate cancer.","question_type":"Fact Retrieval","evidence":"The PSA test is used for localized prostate cancer.; A digital rectal exam is used for localized prostate cancer.; A biopsy is used for localized prostate cancer.; MRI is used for localized prostate cancer.; Ultrasound is used for localized prostate cancer.","evidence_relations":"Localized prostate cancer: Diagnostic Method: PSA test, Digital rectal exam, Biopsy, MRI, Ultrasound"},
	{"id":"Medical-ff590b8b","source":"Medical","question":"Which treatments are available for metastatic prostate cancer?","answer":"Metastatic prostate cancer treatments include ADT, LHRH agonist/antagonist, chemotherapy, immunotherapy, targeted therapy, radiation therapy, and radiopharmaceuticals.","question_type":"Fact Retrieval","evidence":"ADT is a treatment for metastatic prostate cancer.; LHRH agonist/antagonist is a treatment for metastatic prostate cancer.; Chemotherapy is a treatment for metastatic prostate cancer.; Immunotherapy is a treatment for metastatic prostate cancer.; Targeted therapy is a treatment for metastatic prostate cancer.; Radiation therapy is a treatment for metastatic prostate cancer.; Radiopharmaceuticals are a treatment for metastatic prostate cancer.","evidence_relations":"Metastatic prostate cancer: Treatment: Androgen deprivation therapy (ADT), LHRH agonist, LHRH antagonist, Leuprolide, Goserelin, Triptorelin, Degarelix, Relugolix, Bicalutamide, Flutamide, Nilutamide, Orchiectomy, Chemotherapy, Immunotherapy, Targeted therapy, Radiation therapy, Radiopharmaceuticals"},
	{"id":"Medical-f9135c63","source":"Medical","question":"Which genetic alterations are associated with metastatic prostate cancer?","answer":"BRCA1, BRCA2, ATM, CHEK2, MLH1, MSH2, MSH6, PALB2, PMS2, and FANCA are associated with metastatic prostate cancer.","question_type":"Fact Retrieval","evidence":"BRCA1 is associated with metastatic prostate cancer.; BRCA2 is associated with metastatic prostate cancer.; ATM is associated with metastatic prostate cancer.; CHEK2 is associated with metastatic prostate cancer.; MLH1 is associated with metastatic prostate cancer.; MSH2 is associated with metastatic prostate cancer.; MSH6 is associated with metastatic prostate cancer.; PALB2 is associated with metastatic prostate cancer.; PMS2 is associated with metastatic prostate cancer.; FANCA is associated with metastatic prostate cancer.","evidence_relations":"Metastatic prostate cancer: Genetic Alteration: BRCA1, BRCA2, ATM, CHEK2, MLH1, MSH2, MSH6, PALB2, PMS2, FANCA"},
	{"id":"Medical-1ad52a4e","source":"Medical","question":"What are common urinary symptoms of prostate cancer?","answer":"Common urinary symptoms include frequent urination, weak urine stream, and trouble urinating.","question_type":"Fact Retrieval","evidence":"Frequent urination is a common urinary symptom of prostate cancer.; A weak urine stream is a common urinary symptom of prostate cancer.; Trouble urinating is a common urinary symptom of prostate cancer.","evidence_relations":"Symptom: Frequent urination, Weak urine stream, Trouble urinating"},
	{"id":"Medical-677867c1","source":"Medical","question":"Which blood and urine biomarker tests are used in prostate cancer diagnosis?","answer":"4Kscore, PHI, IsoPSA, ExoDx, miR Sentinel, MPS, PCA3, and SelectMDx are used for biomarker testing.","question_type":"Fact Retrieval","evidence":"4Kscore is used for biomarker testing in prostate cancer diagnosis.; PHI is used for biomarker testing in prostate cancer diagnosis.; IsoPSA is used for biomarker testing in prostate cancer diagnosis.; ExoDx is used for biomarker testing in prostate cancer diagnosis.; miR Sentinel is used for biomarker testing in prostate cancer diagnosis.; MPS is used for biomarker testing in prostate cancer diagnosis.; PCA3 is used for biomarker testing in prostate cancer diagnosis.; SelectMDx is used for biomarker testing in prostate cancer diagnosis.","evidence_relations":"Blood and urine biomarker tests (4Kscore, PHI, IsoPSA, ExoDx, miR Sentinel, MPS, PCA3, SelectMDx)"},
	{"id":"Medical-babba8f2","source":"Medical","question":"What is the recommended follow-up strategy for patients on active surveillance?","answer":"Repeat biopsy and regular PSA testing are recommended for active surveillance.","question_type":"Fact Retrieval","evidence":"Repeat biopsy is recommended for patients on active surveillance.; Regular PSA testing is recommended for patients on active surveillance.","evidence_relations":"Follow-up Strategy: Repeat biopsy for active surveillance, Regular PSA testing"},
	{"id":"Medical-a45d778d","source":"Medical","question":"Which risk group classification guides prognosis and treatment decisions?","answer":"Very low, low, intermediate, high, and very high risk groups guide prognosis and treatment.","question_type":"Fact Retrieval","evidence":"Very low risk group guides prognosis and treatment decisions.; Low risk group guides prognosis and treatment decisions.; Intermediate risk group guides prognosis and treatment decisions.; High risk group guides prognosis and treatment decisions.; Very high risk group guides prognosis and treatment decisions.","evidence_relations":"Risk groups (very low, low, intermediate, high, very high) guide prognosis and treatment"},
	{"id":"Medical-da107a1e","source":"Medical","question":"Which imaging test is specifically used to detect bone metastases in prostate cancer?","answer":"Bone scan is used to detect bone metastases.","question_type":"Fact Retrieval","evidence":"A bone scan is used to detect bone metastases in prostate cancer.","evidence_relations":"Bone scan are imaging methods used to assess extent of disease"},
	{"id":"Medical-a0e852ec","source":"Medical","question":"Which treatment is a surgical option for advanced prostate cancer?","answer":"Orchiectomy is a surgical option for advanced prostate cancer.","question_type":"Fact Retrieval","evidence":"Orchiectomy is a surgical option for advanced prostate cancer.","evidence_relations":"Metastatic prostate cancer: Treatment: Orchiectomy"},
	{"id":"Medical-8a3d6beb","source":"Medical","question":"What is a common symptom of prostate cancer that affects sexual function?","answer":"Erectile dysfunction is a common symptom affecting sexual function.","question_type":"Fact Retrieval","evidence":"Erectile dysfunction is a common symptom of prostate cancer.; Erectile dysfunction affects sexual function.","evidence_relations":"Symptom: Erectile dysfunction"},
	{"id":"Medical-bbe1e6e4","source":"Medical","question":"Which demographic factor increases prostate cancer risk?","answer":"Black race increases the risk of prostate cancer.","question_type":"Fact Retrieval","evidence":"Black race increases the risk of prostate cancer.","evidence_relations":"Risk Factor: Black race"},
	{"id":"Medical-4ae3b829","source":"Medical","question":"What is the purpose of the Gleason score in prostate cancer?","answer":"The Gleason score estimates cancer aggressiveness.","question_type":"Fact Retrieval","evidence":"The Gleason score estimates cancer aggressiveness.","evidence_relations":"Grade Group and Gleason score are used to estimate cancer aggressiveness"},
	{"id":"Medical-fec61a48","source":"Medical","question":"Which dietary habits are considered risk factors for prostate cancer?","answer":"High-fat diet and low fruit and vegetable intake are risk factors.","question_type":"Fact Retrieval","evidence":"A high-fat diet is a risk factor for prostate cancer.; Low fruit and vegetable intake is a risk factor for prostate cancer.","evidence_relations":"Risk Factor: High-fat diet, Low fruit and vegetable intake"},
	{"id":"Medical-2eb79e75","source":"Medical","question":"What is the main hormonal therapy for advanced prostate cancer?","answer":"Androgen deprivation therapy (ADT) is the main hormonal therapy.","question_type":"Fact Retrieval","evidence":"Androgen deprivation therapy (ADT) is the main hormonal therapy for advanced prostate cancer.","evidence_relations":"Androgen deprivation therapy (ADT) is a mainstay of advanced prostate cancer treatment"},
	{"id":"Medical-338ef222","source":"Medical","question":"What is the most common type of adrenal gland tumor?","answer":"Adenoma is the most common type of adrenal gland tumor.","question_type":"Fact Retrieval","evidence":"Adenoma is the most common type of adrenal gland tumor.","evidence_relations":"Adenoma is the most common type of adrenal gland tumor and can be functioning or nonfunctioning"},
	{"id":"Medical-29777a9b","source":"Medical","question":"Which adrenal tumor arises from the adrenal cortex and is malignant?","answer":"Adrenocortical carcinoma (ACC) is a rare malignant tumor of the adrenal cortex.","question_type":"Fact Retrieval","evidence":"Adrenocortical carcinoma (ACC) is a rare malignant tumor of the adrenal cortex.","evidence_relations":"Adrenocortical carcinoma (ACC) is a rare malignant tumor of the adrenal cortex"},
	{"id":"Medical-bfb768d9","source":"Medical","question":"What hormone is produced in excess by aldosteronoma?","answer":"Aldosteronoma produces excess aldosterone.","question_type":"Fact Retrieval","evidence":"Aldosteronoma produces excess aldosterone.","evidence_relations":"Aldosteronoma produces excess aldosterone"},
	{"id":"Medical-d909a766","source":"Medical","question":"Which adrenal tumor is associated with Cushing syndrome?","answer":"Adenoma producing excess cortisol causes Cushing syndrome.","question_type":"Fact Retrieval","evidence":"Adenoma producing excess cortisol causes Cushing syndrome.","evidence_relations":"Adenoma producing excess cortisol causes Cushing syndrome"},
	{"id":"Medical-f3697acd","source":"Medical","question":"What are the two main types of adrenal tumors based on malignancy?","answer":"Adrenal tumors can be benign or malignant.","question_type":"Fact Retrieval","evidence":"Adrenal tumors can be benign.; Adrenal tumors can be malignant.","evidence_relations":"Adrenal tumors can be benign or malignant"},
	{"id":"Medical-72b24739","source":"Medical","question":"Do benign adrenal tumors metastasize?","answer":"Benign adrenal tumors do not metastasize.","question_type":"Fact Retrieval","evidence":"Benign adrenal tumors do not metastasize.","evidence_relations":"Benign adrenal tumors do not metastasize"},
	{"id":"Medical-7c516e03","source":"Medical","question":"What is the main population affected by neuroblastoma?","answer":"Neuroblastoma is a rare malignant adrenal tumor affecting mainly children under 5.","question_type":"Fact Retrieval","evidence":"Neuroblastoma is a rare malignant adrenal tumor.; Neuroblastoma mainly affects children under 5.","evidence_relations":"Neuroblastoma is a rare malignant adrenal tumor affecting mainly children under 5"},
	{"id":"Medical-a4b7873b","source":"Medical","question":"Which adrenal tumor is often associated with high blood pressure and headaches?","answer":"Pheochromocytoma arises from the adrenal medulla and is often associated with high blood pressure, headache, rapid heartbeat, and sweating.","question_type":"Fact Retrieval","evidence":"Pheochromocytoma arises from the adrenal medulla.; Pheochromocytoma is often associated with high blood pressure.; Pheochromocytoma is often associated with headache.; Pheochromocytoma is often associated with rapid heartbeat.; Pheochromocytoma is often associated with sweating.","evidence_relations":"Pheochromocytoma arises from the adrenal medulla and is often associated with high blood pressure, headache, rapid heartbeat, and sweating"},
	{"id":"Medical-1bae3e94","source":"Medical","question":"What are the common imaging tests used to diagnose adrenal tumors?","answer":"Imaging tests for adrenal tumors include CT scan, MRI scan, PET scan, FDG-PET/CT, and SSTR-PET/CT.","question_type":"Fact Retrieval","evidence":"Common imaging tests for adrenal tumors include CT scan.; Common imaging tests for adrenal tumors include MRI scan.; Common imaging tests for adrenal tumors include PET scan.; Common imaging tests for adrenal tumors include FDG-PET/CT.; Common imaging tests for adrenal tumors include SSTR-PET/CT.","evidence_relations":"Imaging tests for adrenal tumors include CT scan, MRI scan, PET scan, FDG-PET/CT, and SSTR-PET/CT"},
	{"id":"Medical-133462dd","source":"Medical","question":"Which diagnostic methods are used to detect hormone secretion by adrenal tumors?","answer":"Blood and biochemical tests are used to detect hormone secretion by adrenal tumors.","question_type":"Fact Retrieval","evidence":"Blood tests are used to detect hormone secretion by adrenal tumors.; Biochemical tests are used to detect hormone secretion by adrenal tumors.","evidence_relations":"Blood and biochemical tests are used to detect hormone secretion by adrenal tumors"},
	{"id":"Medical-4cfb5a3a","source":"Medical","question":"Which genetic tests may be performed to identify hereditary risk factors for adrenal tumors?","answer":"Genetic testing may be performed to identify hereditary risk factors.","question_type":"Fact Retrieval","evidence":"Genetic testing may be performed to identify hereditary risk factors for adrenal tumors.","evidence_relations":"Genetic testing may be performed to identify hereditary risk factors"},
	{"id":"Medical-c76c4ce3","source":"Medical","question":"What is the function of functional adrenal tumors?","answer":"Functional adrenal tumors may produce excess hormones.","question_type":"Fact Retrieval","evidence":"Functional adrenal tumors may produce excess hormones.","evidence_relations":"Functional adrenal tumors may produce excess hormones"},
	{"id":"Medical-10fa6b86","source":"Medical","question":"Which hereditary syndromes are risk factors for adrenocortical carcinoma?","answer":"Risk factors for adrenocortical carcinoma include Beckwith-Wiedemann syndrome, Carney complex, Familial adenomatous polyposis (FAP), Hereditary paraganglioma-pheochromocytoma (PGL/PCC) syndrome, Li-Fraumeni syndrome, Lynch syndrome, Multiple endocrine neoplasia type 1 (MEN 1), Multiple endocrine neoplasia type 2 (MEN 2), Neurofibromatosis type 1 (NF1), and Von Hippel-Lindau syndrome (VHL).","question_type":"Fact Retrieval","evidence":"Risk factors for adrenocortical carcinoma include Beckwith-Wiedemann syndrome.; Risk factors for adrenocortical carcinoma include Carney complex.; Risk factors for adrenocortical carcinoma include Familial adenomatous polyposis (FAP).; Risk factors for adrenocortical carcinoma include Hereditary paraganglioma-pheochromocytoma (PGL/PCC) syndrome.; Risk factors for adrenocortical carcinoma include Li-Fraumeni syndrome.; Risk factors for adrenocortical carcinoma include Lynch syndrome.; Risk factors for adrenocortical carcinoma include Multiple endocrine neoplasia type 1 (MEN 1).; Risk factors for adrenocortical carcinoma include Multiple endocrine neoplasia type 2 (MEN 2).; Risk factors for adrenocortical carcinoma include Neurofibromatosis type 1 (NF1).; Risk factors for adrenocortical carcinoma include Von Hippel-Lindau syndrome (VHL).","evidence_relations":"Risk Factor for Adrenocortical Carcinoma (ACC) includes Beckwith-Wiedemann syndrome, Carney complex, Familial adenomatous polyposis (FAP), Hereditary paraganglioma-pheochromocytoma (PGL/PCC) syndrome, Li-Fraumeni syndrome, Lynch syndrome, Multiple endocrine neoplasia type 1 (MEN 1), Multiple endocrine neoplasia type 2 (MEN 2), Neurofibromatosis type 1 (NF1), Von Hippel-Lindau syndrome (VHL)"},
	{"id":"Medical-189210ec","source":"Medical","question":"Which adrenal tumor originates from the adrenal medulla?","answer":"Pheochromocytoma originates from the adrenal medulla.","question_type":"Fact Retrieval","evidence":"Pheochromocytoma originates from the adrenal medulla.","evidence_relations":"Origin of Pheochromocytoma is Adrenal medulla"},
	{"id":"Medical-df3d2ccc","source":"Medical","question":"What are common symptoms of adrenocortical carcinoma?","answer":"Symptoms of adrenocortical carcinoma include weight gain, muscle weakness, pink or purple stretch marks, excess facial hair, hair loss on the head, irregular periods, enlarged breast tissue, shrinking testicles, nausea, vomiting, abdominal bloating, back pain, fever, loss of appetite, and loss of weight without trying.","question_type":"Fact Retrieval","evidence":"Common symptoms of adrenocortical carcinoma include weight gain.; Common symptoms of adrenocortical carcinoma include muscle weakness.; Common symptoms of adrenocortical carcinoma include pink or purple stretch marks.; Common symptoms of adrenocortical carcinoma include excess facial hair.; Common symptoms of adrenocortical carcinoma include hair loss on the head.; Common symptoms of adrenocortical carcinoma include irregular periods.; Common symptoms of adrenocortical carcinoma include enlarged breast tissue.; Common symptoms of adrenocortical carcinoma include shrinking testicles.; Common symptoms of adrenocortical carcinoma include nausea.; Common symptoms of adrenocortical carcinoma include vomiting.; Common symptoms of adrenocortical carcinoma include abdominal bloating.; Common symptoms of adrenocortical carcinoma include back pain.; Common symptoms of adrenocortical carcinoma include fever.; Common symptoms of adrenocortical carcinoma include loss of appetite.; Common symptoms of adrenocortical carcinoma include loss of weight without trying.","evidence_relations":"Symptom of Adrenocortical Carcinoma (ACC) includes weight gain, muscle weakness, pink or purple stretch marks, excess facial hair, hair loss on the head, irregular periods, enlarged breast tissue, shrinking testicles, nausea, vomiting, abdominal bloating, back pain, fever, loss of appetite, and loss of weight without trying"},
	{"id":"Medical-f14c7935","source":"Medical","question":"Which symptoms are commonly associated with pheochromocytoma?","answer":"Symptoms of pheochromocytoma include high blood pressure, headache, rapid heartbeat, and sweating.","question_type":"Fact Retrieval","evidence":"Symptoms of pheochromocytoma include high blood pressure.; Symptoms of pheochromocytoma include headache.; Symptoms of pheochromocytoma include rapid heartbeat.; Symptoms of pheochromocytoma include sweating.","evidence_relations":"Symptom of Pheochromocytoma includes high blood pressure, headache, rapid heartbeat, and sweating"},
	{"id":"Medical-32b97819","source":"Medical","question":"What is the main population at risk for adrenocortical carcinoma?","answer":"Adrenocortical carcinoma can occur at any age but is most likely in children under 5 and adults in their 40s and 50s.","question_type":"Fact Retrieval","evidence":"Adrenocortical carcinoma can occur at any age.; Adrenocortical carcinoma is most likely in children under 5.; Adrenocortical carcinoma is most likely in adults in their 40s and 50s.","evidence_relations":"Adrenocortical carcinoma can occur at any age but is most likely in children under 5 and adults in their 40s and 50s"},
	{"id":"Medical-c78a374e","source":"Medical","question":"Which adrenal tumor may metastasize to bones?","answer":"Neuroblastoma may metastasize to bones.","question_type":"Fact Retrieval","evidence":"Neuroblastoma may metastasize to bones.","evidence_relations":"Spread of Neuroblastoma: May metastasize to bones"},
	{"id":"Medical-bfcfdc70","source":"Medical","question":"Which imaging methods are included in the diagnosis of adrenocortical carcinoma?","answer":"Diagnostic methods for adrenocortical carcinoma include CT scan, MRI scan, PET scan, FDG-PET/CT, SSTR-PET/CT, blood test, biochemical test, genetic test, and biopsy.","question_type":"Fact Retrieval","evidence":"Diagnostic methods for adrenocortical carcinoma include CT scan.; Diagnostic methods for adrenocortical carcinoma include MRI scan.; Diagnostic methods for adrenocortical carcinoma include PET scan.; Diagnostic methods for adrenocortical carcinoma include FDG-PET/CT.; Diagnostic methods for adrenocortical carcinoma include SSTR-PET/CT.; Diagnostic methods for adrenocortical carcinoma include blood test.; Diagnostic methods for adrenocortical carcinoma include biochemical test.; Diagnostic methods for adrenocortical carcinoma include genetic test.; Diagnostic methods for adrenocortical carcinoma include biopsy.","evidence_relations":"Diagnostic Method of Adrenocortical Carcinoma (ACC) includes CT scan, MRI scan, PET scan, FDG-PET/CT, SSTR-PET/CT, blood test, biochemical test, genetic test, and biopsy"},
	{"id":"Medical-3b36f388","source":"Medical","question":"What is the role of biopsy in adrenal tumor diagnosis?","answer":"Biopsy may be used for diagnosis.","question_type":"Fact Retrieval","evidence":"Biopsy may be used for diagnosis of adrenal tumors.","evidence_relations":"Biopsy may be used for diagnosis"},
	{"id":"Medical-dfca353c","source":"Medical","question":"What percentage of adrenal cancer patients have symptoms due to hormone excess?","answer":"Half of adrenal cancer patients have symptoms due to hormone excess.","question_type":"Fact Retrieval","evidence":"Half of adrenal cancer patients have symptoms due to hormone excess.","evidence_relations":"Half of adrenal cancer patients have symptoms due to hormone excess"},
	{"id":"Medical-7f86e4c5","source":"Medical","question":"What are the two functional categories of adenoma in the adrenal gland?","answer":"Adenoma can be functioning or nonfunctioning.","question_type":"Fact Retrieval","evidence":"Adenoma can be functioning.; Adenoma can be nonfunctioning.","evidence_relations":"Adenoma is the most common type of adrenal gland tumor and can be functioning or nonfunctioning"},
	{"id":"Medical-539448fd","source":"Medical","question":"What is the biomarker for aldosteronoma?","answer":"Aldosterone is the biomarker for aldosteronoma.","question_type":"Fact Retrieval","evidence":"Aldosterone is the biomarker for aldosteronoma.","evidence_relations":"Biomarker of Aldosteronoma: Aldosterone"},
	{"id":"Medical-77bf9d25","source":"Medical","question":"What is the biomarker for cortisol-producing adenoma?","answer":"Cortisol is the biomarker for cortisol-producing adenoma.","question_type":"Fact Retrieval","evidence":"Cortisol is the biomarker for cortisol-producing adenoma.","evidence_relations":"Biomarker of Cortisol-producing Adenoma: Cortisol"},
	{"id":"Medical-efe7f41a","source":"Medical","question":"Which syndrome is associated with excess cortisol production by adrenal adenoma?","answer":"Cushing syndrome is associated with cortisol-producing adenoma.","question_type":"Fact Retrieval","evidence":"Cushing syndrome is associated with cortisol-producing adenoma.","evidence_relations":"Associated Syndrome of Cortisol-producing Adenoma: Cushing syndrome"},
	{"id":"Medical-bc1d5800","source":"Medical","question":"Which tests are used to identify hereditary risk factors for adrenal tumors?","answer":"Genetic test is used to identify hereditary risk factors for adrenal tumors.","question_type":"Fact Retrieval","evidence":"A genetic test is used to identify hereditary risk factors for adrenal tumors.","evidence_relations":"Genetic testing may be performed to identify hereditary risk factors"},
	{"id":"Medical-b79e4ca7","source":"Medical","question":"How are adrenal tumors often discovered?","answer":"Adrenal tumors are often found incidentally on imaging tests such as CT or MRI.","question_type":"Fact Retrieval","evidence":"Adrenal tumors are often found incidentally.; Adrenal tumors are found on imaging tests.; Imaging tests include CT scans.; Imaging tests include MRI scans.","evidence_relations":"Adrenal tumors are often found incidentally on imaging tests such as CT or MRI"},
	{"id":"Medical-e171b56c","source":"Medical","question":"Which diagnostic methods are used for pheochromocytoma?","answer":"Diagnostic methods for pheochromocytoma include CT scan, MRI scan, and biochemical test.","question_type":"Fact Retrieval","evidence":"Diagnostic methods for pheochromocytoma include CT scan.; Diagnostic methods for pheochromocytoma include MRI scan.; Diagnostic methods for pheochromocytoma include biochemical test.","evidence_relations":"Diagnostic Method of Pheochromocytoma includes CT scan, MRI scan, Biochemical test"},
	{"id":"Medical-28728520","source":"Medical","question":"Which diagnostic methods are used for neuroblastoma?","answer":"Diagnostic methods for neuroblastoma include imaging tests and biochemical test.","question_type":"Fact Retrieval","evidence":"Diagnostic methods for neuroblastoma include imaging tests.; Diagnostic methods for neuroblastoma include biochemical test.","evidence_relations":"Diagnostic Method of Neuroblastoma includes Imaging tests, Biochemical test"},
	{"id":"Medical-2085b009","source":"Medical","question":"What are some risk factors for adrenal tumors in general?","answer":"Certain hereditary syndromes and family history increase the risk of adrenal tumors.","question_type":"Fact Retrieval","evidence":"Certain hereditary syndromes increase the risk of adrenal tumors.; Family history increases the risk of adrenal tumors.","evidence_relations":"Risk Factor for Adrenal Tumor includes Hereditary syndromes, Family history"},
	{"id":"Medical-ccecf24d","source":"Medical","question":"What is the most common type of invasive breast cancer?","answer":"Invasive ductal carcinoma is the most common type.","question_type":"Fact Retrieval","evidence":"Invasive ductal carcinoma is the most common type of invasive breast cancer.","evidence_relations":"Invasive ductal carcinoma is the most common type of invasive breast cancer"},
	{"id":"Medical-328ec8f3","source":"Medical","question":"Which breast cancer subtype is noninvasive and found in the ducts?","answer":"Ductal carcinoma in situ (DCIS) is a noninvasive breast cancer found in the ducts.","question_type":"Fact Retrieval","evidence":"Ductal carcinoma in situ (DCIS) is a noninvasive breast cancer.; Ductal carcinoma in situ (DCIS) is found in the ducts.","evidence_relations":"Ductal carcinoma in situ (DCIS) is a noninvasive breast cancer found in the ducts"},
	{"id":"Medical-57129a04","source":"Medical","question":"What subtype of breast cancer is characterized by cancer cells blocking lymph vessels in the skin?","answer":"Inflammatory breast cancer (IBC) is characterized by cancer cells blocking lymph vessels in the skin.","question_type":"Fact Retrieval","evidence":"Inflammatory breast cancer (IBC) is characterized by cancer cells blocking lymph vessels.; Inflammatory breast cancer (IBC) affects the skin.","evidence_relations":"Inflammatory breast cancer (IBC) is a rare, aggressive subtype characterized by cancer cells blocking lymph vessels in the skin"},
	{"id":"Medical-bfc5a235","source":"Medical","question":"What is the definition of metastatic breast cancer (MBC)?","answer":"Metastatic breast cancer (MBC) is breast cancer that has spread to distant organs.","question_type":"Fact Retrieval","evidence":"Metastatic breast cancer (MBC) is breast cancer that has spread.; Metastatic breast cancer (MBC) spreads to distant organs.","evidence_relations":"Metastatic breast cancer (MBC) is breast cancer that has spread to distant organs"},
	{"id":"Medical-b7bc98cd","source":"Medical","question":"Which system is used for staging breast cancer?","answer":"The TNM system (Tumor, Node, Metastasis) is used for breast cancer staging.","question_type":"Fact Retrieval","evidence":"The TNM system is used for staging breast cancer.; TNM stands for Tumor, Node, Metastasis.","evidence_relations":"Breast cancer staging uses the TNM system (Tumor, Node, Metastasis)"},
	{"id":"Medical-b8694972","source":"Medical","question":"What stage is assigned to noninvasive ductal carcinoma in situ (DCIS)?","answer":"Stage 0 is assigned to noninvasive DCIS.","question_type":"Fact Retrieval","evidence":"Stage 0 is assigned to noninvasive ductal carcinoma in situ (DCIS).","evidence_relations":"Stage 0 breast cancer is noninvasive (DCIS)"},
	{"id":"Medical-8df61619","source":"Medical","question":"Which stages of breast cancer are considered invasive?","answer":"Stages I-III are invasive breast cancer.","question_type":"Fact Retrieval","evidence":"Stages I-III are considered invasive breast cancer.","evidence_relations":"Stages I-III are invasive breast cancer"},
	{"id":"Medical-30486792","source":"Medical","question":"What stage is metastatic breast cancer classified as?","answer":"Stage IV is metastatic breast cancer.","question_type":"Fact Retrieval","evidence":"Stage IV is classified as metastatic breast cancer.","evidence_relations":"Stage IV is metastatic breast cancer"},
	{"id":"Medical-a3f601d8","source":"Medical","question":"What does tumor grade describe in breast cancer?","answer":"Grade describes how abnormal the tumor cells look under a microscope.","question_type":"Fact Retrieval","evidence":"Tumor grade describes how abnormal the tumor cells look under a microscope.","evidence_relations":"Grade describes how abnormal the tumor cells look under a microscope"},
	{"id":"Medical-d47d0c68","source":"Medical","question":"Which biomarkers are key for breast cancer?","answer":"Hormone receptor status (ER, PR) and HER2 status are key biomarkers.","question_type":"Fact Retrieval","evidence":"Hormone receptor status (ER, PR) is a key biomarker for breast cancer.; HER2 status is a key biomarker for breast cancer.","evidence_relations":"Hormone receptor status (ER, PR) and HER2 status are key biomarkers for breast cancer"},
	{"id":"Medical-b71386f7","source":"Medical","question":"What genetic mutations increase the risk of breast cancer?","answer":"BRCA1 and BRCA2 mutations increase the risk.","question_type":"Fact Retrieval","evidence":"BRCA1 mutations increase the risk of breast cancer.; BRCA2 mutations increase the risk of breast cancer.","evidence_relations":"BRCA1 and BRCA2 mutations increase the risk of breast cancer"},
	{"id":"Medical-3e184ed2","source":"Medical","question":"Which mutation can be targeted with specific therapies in breast cancer?","answer":"PIK3CA mutation can be targeted with specific therapies.","question_type":"Fact Retrieval","evidence":"PIK3CA mutation can be targeted with specific therapies in breast cancer.","evidence_relations":"PIK3CA mutation can be targeted with specific therapies"},
	{"id":"Medical-dd137889","source":"Medical","question":"Which biomarker status may influence immunotherapy options in breast cancer?","answer":"MSI-H/dMMR status may influence immunotherapy options.","question_type":"Fact Retrieval","evidence":"MSI-H/dMMR status may influence immunotherapy options in breast cancer.","evidence_relations":"MSI-H/dMMR status may influence immunotherapy options"},
	{"id":"Medical-03388322","source":"Medical","question":"Which biomarker may guide immunotherapy use in breast cancer?","answer":"PD-L1 expression may guide immunotherapy use.","question_type":"Fact Retrieval","evidence":"PD-L1 expression may guide immunotherapy use in breast cancer.","evidence_relations":"PD-L1 expression may guide immunotherapy use"},
	{"id":"Medical-c1a69780","source":"Medical","question":"What diagnostic methods are used to diagnose breast cancer?","answer":"Diagnosis involves imaging (mammogram, ultrasound, MRI, CT, PET), biopsy, and blood tests.","question_type":"Fact Retrieval","evidence":"Diagnosis of breast cancer involves imaging.; Imaging methods include mammogram, ultrasound, MRI, CT, and PET.; Diagnosis of breast cancer involves biopsy.; Diagnosis of breast cancer involves blood tests.","evidence_relations":"Diagnosis involves imaging (mammogram, ultrasound, MRI, CT, PET), biopsy, and blood tests"},
	{"id":"Medical-08b4a3c0","source":"Medical","question":"What is the purpose of screening mammograms?","answer":"Screening mammograms are used for early detection in asymptomatic individuals.","question_type":"Fact Retrieval","evidence":"Screening mammograms are used for early detection.; Screening mammograms are used in asymptomatic individuals.","evidence_relations":"Screening mammograms are used for early detection in asymptomatic individuals"},
	{"id":"Medical-4e8dec79","source":"Medical","question":"When are diagnostic mammograms used?","answer":"Diagnostic mammograms are used for individuals with symptoms or abnormal screening results.","question_type":"Fact Retrieval","evidence":"Diagnostic mammograms are used for individuals with symptoms.; Diagnostic mammograms are used for individuals with abnormal screening results.","evidence_relations":"Diagnostic mammograms are used for individuals with symptoms or abnormal screening results"},
	{"id":"Medical-bf6e0650","source":"Medical","question":"What procedure is required for definitive diagnosis and biomarker testing in breast cancer?","answer":"Biopsy is required for definitive diagnosis and biomarker testing.","question_type":"Fact Retrieval","evidence":"A biopsy is required for definitive diagnosis.; A biopsy is required for biomarker testing in breast cancer.","evidence_relations":"Biopsy is required for definitive diagnosis and biomarker testing"},
	{"id":"Medical-1560f6ac","source":"Medical","question":"How is lymph node involvement assessed in breast cancer?","answer":"Sentinel lymph node biopsy is used to assess lymph node involvement.","question_type":"Fact Retrieval","evidence":"Sentinel lymph node biopsy is used to assess lymph node involvement in breast cancer.","evidence_relations":"Sentinel lymph node biopsy is used to assess lymph node involvement"},
	{"id":"Medical-eece107d","source":"Medical","question":"What are the main treatment options for breast cancer?","answer":"Treatment options include surgery, radiation therapy, chemotherapy, endocrine therapy, HER2-targeted therapy, immunotherapy, and targeted inhibitors.","question_type":"Fact Retrieval","evidence":"Treatment options for breast cancer include surgery.; Treatment options for breast cancer include radiation therapy.; Treatment options for breast cancer include chemotherapy.; Treatment options for breast cancer include endocrine therapy.; Treatment options for breast cancer include HER2-targeted therapy.; Treatment options for breast cancer include immunotherapy.; Treatment options for breast cancer include targeted inhibitors.","evidence_relations":"Treatment options include surgery (mastectomy, lumpectomy), radiation therapy, chemotherapy, endocrine therapy, HER2-targeted therapy, immunotherapy, and targeted inhibitors"},
	{"id":"Medical-8280c389","source":"Medical","question":"For which types of breast cancer is systemic therapy used?","answer":"Systemic therapy is used for invasive and metastatic breast cancer.","question_type":"Fact Retrieval","evidence":"Systemic therapy is used for invasive breast cancer.; Systemic therapy is used for metastatic breast cancer.","evidence_relations":"Systemic therapy is used for invasive and metastatic breast cancer"},
	{"id":"Medical-6c8055a7","source":"Medical","question":"Which therapy is used for hormone receptor-positive breast cancer?","answer":"Endocrine therapy is used for hormone receptor-positive breast cancer.","question_type":"Fact Retrieval","evidence":"Endocrine therapy is used for hormone receptor-positive breast cancer.","evidence_relations":"Endocrine therapy is used for hormone receptor-positive breast cancer"},
	{"id":"Medical-6fa265bc","source":"Medical","question":"What therapy is used for HER2-positive breast cancer?","answer":"HER2-targeted therapy is used for HER2-positive breast cancer.","question_type":"Fact Retrieval","evidence":"HER2-targeted therapy is used for HER2-positive breast cancer.","evidence_relations":"HER2-targeted therapy is used for HER2-positive breast cancer"},
	{"id":"Medical-6f086f1b","source":"Medical","question":"Which therapy is used for BRCA-mutated, HER2-negative breast cancer?","answer":"PARP inhibitors are used for BRCA-mutated, HER2-negative breast cancer.","question_type":"Fact Retrieval","evidence":"PARP inhibitors are used for BRCA-mutated, HER2-negative breast cancer.","evidence_relations":"PARP inhibitors are used for BRCA-mutated, HER2-negative breast cancer"},
	{"id":"Medical-85ed509e","source":"Medical","question":"Which inhibitors are used for hormone receptor-positive, HER2-negative breast cancer?","answer":"CDK4/6 inhibitors are used for hormone receptor-positive, HER2-negative breast cancer.","question_type":"Fact Retrieval","evidence":"CDK4/6 inhibitors are used for hormone receptor-positive, HER2-negative breast cancer.","evidence_relations":"CDK4/6 inhibitors are used for hormone receptor-positive, HER2-negative breast cancer"},
	{"id":"Medical-ff5afce7","source":"Medical","question":"Which inhibitors are used for PIK3CA-mutated, hormone receptor-positive, HER2-negative breast cancer?","answer":"PIK3CA inhibitors are used for PIK3CA-mutated, hormone receptor-positive, HER2-negative breast cancer.","question_type":"Fact Retrieval","evidence":"PIK3CA inhibitors are used for PIK3CA-mutated breast cancer.; PIK3CA inhibitors are used for hormone receptor-positive breast cancer.; PIK3CA inhibitors are used for HER2-negative breast cancer.","evidence_relations":"PIK3CA inhibitors are used for PIK3CA-mutated, hormone receptor-positive, HER2-negative breast cancer"},
	{"id":"Medical-869c8d57","source":"Medical","question":"What are common symptoms of breast cancer?","answer":"Common symptoms include breast lump, pain, nipple discharge, skin changes, redness, swelling, and peau dorange.","question_type":"Fact Retrieval","evidence":"Common symptoms of breast cancer include breast lump.; Common symptoms of breast cancer include pain.; Common symptoms of breast cancer include nipple discharge.; Common symptoms of breast cancer include skin changes.; Common symptoms of breast cancer include redness.; Common symptoms of breast cancer include swelling.; Common symptoms of breast cancer include peau dorange.","evidence_relations":"Common symptoms include breast lump, pain, nipple discharge, skin changes, redness, swelling, and peau dorange"},
	{"id":"Medical-69eae99e","source":"Medical","question":"What are risk factors for breast cancer?","answer":"Risk factors include family history, BRCA mutations, and being assigned female at birth.","question_type":"Fact Retrieval","evidence":"Risk factors for breast cancer include family history.; Risk factors for breast cancer include BRCA mutations.; Risk factors for breast cancer include being assigned female at birth.","evidence_relations":"Risk factors include family history, BRCA mutations, and being assigned female at birth"},
	{"id":"Medical-329de573","source":"Medical","question":"What should be discussed before starting breast cancer treatment regarding reproductive health?","answer":"Fertility preservation should be discussed before starting treatment.","question_type":"Fact Retrieval","evidence":"Fertility preservation should be discussed before starting breast cancer treatment.","evidence_relations":"Fertility preservation should be discussed before starting treatment"},
	{"id":"Medical-e79a7e61","source":"Medical","question":"What patient factor is considered in treatment planning for breast cancer?","answer":"Performance status is considered in treatment planning.","question_type":"Fact Retrieval","evidence":"Performance status is considered in treatment planning for breast cancer.","evidence_relations":"Performance status is considered in treatment planning"},
	{"id":"Medical-883feb97","source":"Medical","question":"What does follow-up for breast cancer include?","answer":"Follow-up includes imaging, physical exams, and monitoring for recurrence.","question_type":"Fact Retrieval","evidence":"Follow-up for breast cancer includes imaging.; Follow-up for breast cancer includes physical exams.; Follow-up for breast cancer includes monitoring for recurrence.","evidence_relations":"Follow-up includes imaging, physical exams, and monitoring for recurrence"},
	{"id":"Medical-53f6f364","source":"Medical","question":"Which breast cancer subtype commonly presents with redness, swelling, and peau dorange?","answer":"Inflammatory breast cancer (IBC) commonly presents with redness, swelling, and peau dorange.","question_type":"Fact Retrieval","evidence":"Inflammatory breast cancer (IBC) commonly presents with redness.; Inflammatory breast cancer (IBC) commonly presents with swelling.; Inflammatory breast cancer (IBC) commonly presents with peau dorange.","evidence_relations":"Inflammatory breast cancer (IBC): Symptom: Redness, Swelling, Peau dorange"},
	{"id":"Medical-6598f21c","source":"Medical","question":"What is the main symptom of metastatic breast cancer involving bones?","answer":"Bone pain is a main symptom of metastatic breast cancer involving bones.","question_type":"Fact Retrieval","evidence":"Bone pain is a main symptom of metastatic breast cancer involving bones.","evidence_relations":"Metastatic breast cancer (MBC): Symptom: Bone pain"},
	{"id":"Medical-604c9d44","source":"Medical","question":"Why is a patient with fair skin and a history of organ transplant at particularly high risk for developing basal cell carcinoma?","answer":"Because both fair skin and immune suppression from organ transplant are independent risk factors for BCC.","question_type":"Complex Reasoning","evidence":"Fair skin is an independent risk factor for basal cell carcinoma (BCC).; Immune suppression from organ transplant is an independent risk factor for basal cell carcinoma (BCC).","evidence_relations":"Fair skin, light hair, and light eye color increase the risk of BCC; Immune suppression is a risk factor for BCC; Basal cell carcinoma risk factors include fair skin and organ transplant"},
	{"id":"Medical-df366063","source":"Medical","question":"If a patient presents with a shiny bump on the face and has a history of tanning bed use, what diagnostic steps should be taken to evaluate for basal cell carcinoma?","answer":"A medical and family history, physical and skin exam, and biopsy should be performed.","question_type":"Complex Reasoning","evidence":"A medical and family history should be performed to evaluate for basal cell carcinoma.; A physical and skin exam should be performed to evaluate for basal cell carcinoma.; A biopsy should be performed to evaluate for basal cell carcinoma.","evidence_relations":"BCC presents as shiny bumps; BCC most commonly develops in sun-exposed areas such as the face; Tanning beds are a risk factor for BCC; Diagnosis of BCC involves medical and family history, physical exam, skin exam, biopsy"},
	{"id":"Medical-0a90f1f2","source":"Medical","question":"How does the management of recurrent basal cell carcinoma differ from initial treatment, and what factors influence this?","answer":"Management of recurrence depends on risk and recurrence site, with treatment options tailored accordingly.","question_type":"Complex Reasoning","evidence":"Management of recurrent basal cell carcinoma depends on risk.; Management of recurrent basal cell carcinoma depends on the recurrence site.; Treatment options for recurrent basal cell carcinoma are tailored accordingly.","evidence_relations":"Recurrence refers to BCC returning to the original site or spreading to lymph nodes or distant sites; Management of recurrence involves treatment options based on risk and recurrence; Surgery is the most common treatment for BCC"},
	{"id":"Medical-831bb1e6","source":"Medical","question":"Which combination of risk factors should prompt earlier and more frequent skin exams for BCC?","answer":"A combination of older age, fair skin, and family history of skin cancer should prompt more frequent skin exams.","question_type":"Complex Reasoning","evidence":"Older age is a risk factor for basal cell carcinoma.; Fair skin is a risk factor for basal cell carcinoma.; Family history of skin cancer is a risk factor for basal cell carcinoma.; A combination of these risk factors should prompt more frequent skin exams.","evidence_relations":"Older age is associated with higher risk of BCC; Fair skin and family history of skin cancer increase risk of BCC; Follow-up includes full skin exams with a doctor at least once a year"},
	{"id":"Medical-01e3a9ea","source":"Medical","question":"Why might a patient with a shiny bump and a history of radiation therapy require both imaging and biopsy for diagnosis?","answer":"Because radiation therapy is a risk factor for BCC and shiny bumps are a symptom, so both imaging and biopsy help confirm diagnosis.","question_type":"Complex Reasoning","evidence":"A shiny bump can be a symptom of basal cell carcinoma.; A history of radiation therapy is a risk factor for basal cell carcinoma.; Imaging is needed to help confirm the diagnosis of basal cell carcinoma.; A biopsy is needed to help confirm the diagnosis of basal cell carcinoma.","evidence_relations":"Radiation therapy is a risk factor for BCC; BCC presents as shiny bumps; Diagnosis of BCC involves biopsy and sometimes imaging"},
	{"id":"Medical-c69c2732","source":"Medical","question":"What follow-up strategy is recommended for a patient treated for BCC on the neck, and why?","answer":"Annual full skin exams are recommended to monitor for recurrence or new lesions.","question_type":"Complex Reasoning","evidence":"Annual full skin exams are recommended for patients treated for basal cell carcinoma.; The purpose of annual full skin exams is to monitor for recurrence.; The purpose of annual full skin exams is to monitor for new lesions.","evidence_relations":"BCC most commonly develops in sun-exposed areas such as the neck; Recurrence refers to BCC returning to the original site; Follow-up includes full skin exams with a doctor at least once a year"},
	{"id":"Medical-f034d77d","source":"Medical","question":"How does UV radiation contribute to both the development and recurrence of basal cell carcinoma?","answer":"UV radiation is a primary risk factor for BCC and continued exposure increases recurrence risk.","question_type":"Complex Reasoning","evidence":"UV radiation is a primary risk factor for basal cell carcinoma.; Continued exposure to UV radiation increases the risk of recurrence of basal cell carcinoma.","evidence_relations":"UV radiation exposure is a primary risk factor for BCC; Recurrence refers to BCC returning to the original site or spreading; Basal cell carcinoma risk factors include UV radiation"},
	{"id":"Medical-1eab8fa2","source":"Medical","question":"Why should a patient with a family history of skin cancer and light eye color be particularly vigilant about skin changes?","answer":"Because both family history and light eye color are risk factors for BCC, increasing overall risk.","question_type":"Complex Reasoning","evidence":"A family history of skin cancer is a risk factor for basal cell carcinoma.; Light eye color is a risk factor for basal cell carcinoma.; These risk factors increase the overall risk of basal cell carcinoma.","evidence_relations":"Family history increases risk of BCC; Light eye color increases the risk of BCC; Basal cell carcinoma risk factors include family history and light eye color"},
	{"id":"Medical-14016ce3","source":"Medical","question":"What is the rationale for recommending surgery as the most common treatment for BCC lesions on sun-exposed areas?","answer":"Because BCC most commonly develops on sun-exposed areas and surgery is the most effective treatment.","question_type":"Complex Reasoning","evidence":"Basal cell carcinoma most commonly develops on sun-exposed areas.; Surgery is the most effective treatment for basal cell carcinoma lesions.","evidence_relations":"BCC most commonly develops in sun-exposed areas such as the face, head, and neck; Surgery is the most common treatment for BCC"},
	{"id":"Medical-5e530443","source":"Medical","question":"Which symptoms and risk factors together would most strongly indicate the need for biopsy to rule out BCC?","answer":"A flat pale area on sun-exposed skin in a fair-skinned patient with a history of sun exposure strongly indicates the need for biopsy.","question_type":"Complex Reasoning","evidence":"A flat pale area on sun-exposed skin is a symptom that may indicate basal cell carcinoma.; Fair-skinned patients with a history of sun exposure are at higher risk for basal cell carcinoma.; This combination of symptoms and risk factors strongly indicates the need for biopsy.","evidence_relations":"BCC presents as flat, pale or yellow areas; BCC most commonly develops in sun-exposed areas; Fair skin and sun exposure are risk factors for BCC; Diagnosis of BCC involves biopsy"},
	{"id":"Medical-c8dd3e29","source":"Medical","question":"How do immune suppression and prior radiation therapy interact to affect BCC risk and management?","answer":"Both are risk factors that increase BCC risk and may necessitate more aggressive management.","question_type":"Complex Reasoning","evidence":"Immune suppression is a risk factor that increases basal cell carcinoma risk.; Prior radiation therapy is a risk factor that increases basal cell carcinoma risk.; Both factors may necessitate more aggressive management of basal cell carcinoma.","evidence_relations":"Radiation therapy and immune suppression are risk factors for BCC; Management of recurrence involves treatment options based on risk and recurrence"},
	{"id":"Medical-a9a52704","source":"Medical","question":"What combination of anatomical location and cell type defines basal cell carcinoma?","answer":"BCC arises from basal cells in the lower part of the epidermis, often in sun-exposed locations.","question_type":"Complex Reasoning","evidence":"Basal cell carcinoma arises from basal cells.; Basal cells are located in the lower part of the epidermis.; Basal cell carcinoma often occurs in sun-exposed locations.","evidence_relations":"BCC arises from basal cells in the lower part of the epidermis; BCC most commonly develops in sun-exposed areas such as the face, head, and neck; Basal cell carcinoma cell type is basal cells"},
	{"id":"Medical-346b12e8","source":"Medical","question":"Why is annual follow-up with full skin exams critical for patients with a history of BCC?","answer":"Because recurrence can occur at the original site or spread, so annual full skin exams help detect new or returning lesions.","question_type":"Complex Reasoning","evidence":"Annual follow-up with full skin exams is critical for patients with a history of BCC.; Recurrence of BCC can occur at the original site.; BCC can spread to other areas.; Annual full skin exams help detect new lesions.; Annual full skin exams help detect returning lesions.","evidence_relations":"Recurrence refers to BCC returning to the original site or spreading to lymph nodes or distant sites; Follow-up includes full skin exams with a doctor at least once a year"},
	{"id":"Medical-8ff5dd5a","source":"Medical","question":"Why might systemic therapy be considered for a patient with BCC that has spread to distant sites?","answer":"Because systemic therapy is a treatment option for BCC that has recurred or spread to distant sites.","question_type":"Complex Reasoning","evidence":"Systemic therapy may be considered for patients with BCC that has spread to distant sites.; Systemic therapy is a treatment option for BCC.; Systemic therapy is used for BCC that has recurred.","evidence_relations":"Recurrence refers to BCC spreading to distant sites; Systemic therapy may be used in some cases of BCC"},
	{"id":"Medical-322bb52d","source":"Medical","question":"How do medical and family history contribute to the diagnostic process for BCC in a patient with a suspicious skin lesion?","answer":"Both are part of the diagnostic workup to assess risk and guide further testing like biopsy.","question_type":"Complex Reasoning","evidence":"Medical history contributes to the diagnostic process for BCC.; Family history contributes to the diagnostic process for BCC.; Medical and family history are part of the diagnostic workup.; The diagnostic workup assesses risk for BCC.; The diagnostic workup guides further testing like biopsy.","evidence_relations":"Diagnosis of BCC involves medical and family history, physical exam, skin exam, biopsy; History of skin cancer or family history increases risk of BCC"},
	{"id":"Medical-35fee661","source":"Medical","question":"Which diagnostic procedures would be prioritized for a patient with primary CNS lymphoma presenting with blurry vision and suspected eye involvement?","answer":"Eye exam, slit lamp, and vitrectomy would be prioritized for suspected eye involvement.","question_type":"Complex Reasoning","evidence":"Eye exam is prioritized for a patient with primary CNS lymphoma and suspected eye involvement.; Slit lamp examination is prioritized for suspected eye involvement.; Vitrectomy is prioritized for suspected eye involvement.","evidence_relations":"Primary CNS lymphoma most commonly affects the brain, but can also involve the spinal cord, cerebrospinal fluid, and eyes; Primary CNS lymphoma can cause neurological symptoms such as vision changes; Diagnostic Method for Primary CNS lymphoma includes Eye exam, Slit lamp, and Vitrectomy"},
	{"id":"Medical-f473bcb0","source":"Medical","question":"What is the main chemotherapy agent used during the induction phase of primary CNS lymphoma treatment and which diagnostic procedure confirms the diagnosis?","answer":"High-dose methotrexate is the main chemotherapy agent, and stereotactic biopsy is the standard diagnostic procedure.","question_type":"Complex Reasoning","evidence":"High-dose methotrexate is the main chemotherapy agent used during the induction phase of primary CNS lymphoma treatment.; Stereotactic biopsy is the standard diagnostic procedure for primary CNS lymphoma.","evidence_relations":"High-dose methotrexate is the main chemotherapy drug used for primary CNS lymphoma; Stereotactic biopsy is the standard diagnostic procedure for primary CNS lymphoma; Treatment is typically given in phases: induction and consolidation"},
	{"id":"Medical-f3af6f24","source":"Medical","question":"For a patient with primary CNS lymphoma and cerebrospinal fluid involvement, which specialized treatment is indicated and how is the involvement detected?","answer":"Intrathecal chemotherapy is indicated, with CSF involvement detected by lumbar puncture.","question_type":"Complex Reasoning","evidence":"Intrathecal chemotherapy is indicated for a patient with primary CNS lymphoma and cerebrospinal fluid involvement.; CSF involvement is detected by lumbar puncture.","evidence_relations":"Intrathecal chemotherapy may be used if cancer cells are found in the cerebrospinal fluid; Primary CNS lymphoma is diagnosed using lumbar puncture; Disease Location for Primary CNS lymphoma includes Cerebrospinal fluid (CSF)"},
	{"id":"Medical-ade4b34a","source":"Medical","question":"If a patient with primary CNS lymphoma presents with memory problems and confusion, what imaging modality is most useful and why?","answer":"MRI with gadolinium contrast is most useful because it best identifies CNS lesions causing these symptoms.","question_type":"Complex Reasoning","evidence":"MRI with gadolinium contrast is the most useful imaging modality for a patient with primary CNS lymphoma presenting with memory problems and confusion.; MRI with gadolinium contrast best identifies CNS lesions causing memory problems and confusion.","evidence_relations":"MRI with gadolinium contrast is the most useful imaging technique for identifying primary CNS lymphoma; Primary CNS lymphoma can cause neurological symptoms such as memory problems and confusion; Diagnostic Method for Primary CNS lymphoma includes MRI and Gadolinium contrast"},
	{"id":"Medical-ade95016","source":"Medical","question":"Which risk factors should be considered for an older adult with a history of organ transplant who develops primary CNS lymphoma?","answer":"Older age and organ transplant are both risk factors for primary CNS lymphoma.","question_type":"Complex Reasoning","evidence":"Older age is a risk factor for primary CNS lymphoma.; Organ transplant is a risk factor for primary CNS lymphoma.","evidence_relations":"Immunodeficiency disorders, organ transplant, and older age are risk factors for primary CNS lymphoma; Risk Factor for Primary CNS lymphoma includes Older adult and Organ transplant"},
	{"id":"Medical-8435c9f6","source":"Medical","question":"How would the treatment approach change for a primary CNS lymphoma patient with both brain and eye involvement?","answer":"The patient would receive standard CNS-directed therapy plus intraocular chemotherapy or radiation for eye involvement.","question_type":"Complex Reasoning","evidence":"The treatment approach for a primary CNS lymphoma patient with both brain and eye involvement would change.; The patient would receive standard CNS-directed therapy.; The patient would receive intraocular chemotherapy or radiation for eye involvement.","evidence_relations":"Primary CNS lymphoma most commonly affects the brain, but can also involve the eyes; Intraocular chemotherapy or radiation may be used if the eyes are involved; Treatment options for primary CNS lymphoma include chemotherapy and radiation therapy"},
	{"id":"Medical-23e6b6df","source":"Medical","question":"What are the two main phases of primary CNS lymphoma treatment, and which therapies are typically administered in each?","answer":"Induction phase uses high-dose methotrexate and rituximab, while consolidation phase uses whole-brain radiation therapy or stem cell rescue.","question_type":"Complex Reasoning","evidence":"The two main phases of primary CNS lymphoma treatment are induction phase and consolidation phase.; The induction phase uses high-dose methotrexate and rituximab.; The consolidation phase uses whole-brain radiation therapy or stem cell rescue.","evidence_relations":"Treatment is typically given in phases: induction and consolidation; High-dose methotrexate is the main chemotherapy drug used for primary CNS lymphoma; Rituximab is the main immunotherapy drug used for primary CNS lymphoma; Whole-brain radiation therapy (WBRT) is the most commonly used radiation technique for primary CNS lymphoma; Consolidation phase includes whole-brain radiation therapy (WBRT) and stem cell rescue"},
	{"id":"Medical-4744dfa7","source":"Medical","question":"Which performance evaluation is necessary before determining eligibility for clinical trials in primary CNS lymphoma patients and why?","answer":"Performance status evaluation is necessary to guide treatment decisions and clinical trial eligibility.","question_type":"Complex Reasoning","evidence":"Performance status evaluation is necessary before determining eligibility for clinical trials in primary CNS lymphoma patients.; Performance status evaluation guides treatment decisions.; Performance status evaluation guides clinical trial eligibility.","evidence_relations":"Performance status is evaluated to guide treatment decisions and eligibility for clinical trials; Diagnostic Method for Primary CNS lymphoma includes Performance status evaluation"},
	{"id":"Medical-59ea36ca","source":"Medical","question":"What follow-up procedures are recommended after achieving remission in primary CNS lymphoma?","answer":"Repeat MRI, eye exam, blood tests, and performance status assessment are recommended for surveillance.","question_type":"Complex Reasoning","evidence":"Repeat MRI is recommended after achieving remission in primary CNS lymphoma.; Eye exam is recommended after achieving remission in primary CNS lymphoma.; Blood tests are recommended after achieving remission in primary CNS lymphoma.; Performance status assessment is recommended after achieving remission in primary CNS lymphoma.","evidence_relations":"Follow-up/Surveillance for Primary CNS lymphoma includes Repeat MRI, Eye exam, Blood tests, Performance status assessment; Remission is a stage after treatment in primary CNS lymphoma"},
	{"id":"Medical-4124f00f","source":"Medical","question":"If a patient with primary CNS lymphoma relapses in the spinal cord, which diagnostic and treatment strategies should be considered?","answer":"Imaging (MRI), lumbar puncture, and possible intrathecal chemotherapy should be considered for spinal cord relapse.","question_type":"Complex Reasoning","evidence":"Imaging (MRI) should be considered for spinal cord relapse in primary CNS lymphoma.; Lumbar puncture should be considered for spinal cord relapse in primary CNS lymphoma.; Possible intrathecal chemotherapy should be considered for spinal cord relapse in primary CNS lymphoma.","evidence_relations":"Primary CNS lymphoma can relapse in the brain, spinal cord, or eyes; MRI with gadolinium contrast is the most useful imaging technique for identifying primary CNS lymphoma; Intrathecal chemotherapy may be used if cancer cells are found in the cerebrospinal fluid; Lumbar puncture is a diagnostic method for Primary CNS lymphoma"},
	{"id":"Medical-ed26b623","source":"Medical","question":"Which laboratory tests are essential for initial workup of primary CNS lymphoma, particularly in patients with suspected immunodeficiency?","answer":"Blood tests including CBC, CMP, LDH, and HIV blood test are essential for initial workup.","question_type":"Complex Reasoning","evidence":"Blood tests including CBC are essential for initial workup of primary CNS lymphoma.; Blood tests including CMP are essential for initial workup of primary CNS lymphoma.; Blood tests including LDH are essential for initial workup of primary CNS lymphoma.; HIV blood test is essential for initial workup of primary CNS lymphoma.","evidence_relations":"Primary CNS lymphoma is diagnosed using blood tests; Laboratory Tests for Primary CNS lymphoma include Complete blood count (CBC), Comprehensive metabolic panel (CMP), Lactate dehydrogenase (LDH), HIV blood test"},
	{"id":"Medical-fbc9e7ec","source":"Medical","question":"What supportive care measures are recommended at any stage for primary CNS lymphoma patients experiencing severe side effects from treatment?","answer":"Symptom management, palliative care, and quality of life interventions are recommended at any disease stage.","question_type":"Complex Reasoning","evidence":"Symptom management is recommended for primary CNS lymphoma patients experiencing severe side effects from treatment.; Palliative care is recommended for primary CNS lymphoma patients experiencing severe side effects from treatment.; Quality of life interventions are recommended for primary CNS lymphoma patients experiencing severe side effects from treatment.","evidence_relations":"Supportive care is provided to relieve symptoms and side effects at any stage of disease; Supportive Care for Primary CNS lymphoma includes Symptom management, Palliative care, Quality of life interventions"},
	{"id":"Medical-9a34e14c","source":"Medical","question":"In a patient with primary CNS lymphoma and concurrent HIV infection, why is additional laboratory testing necessary?","answer":"HIV blood test is needed because immunodeficiency is a risk factor for primary CNS lymphoma and may influence management.","question_type":"Complex Reasoning","evidence":"HIV blood test is needed for patients with primary CNS lymphoma and concurrent HIV infection.; Immunodeficiency is a risk factor for primary CNS lymphoma.; Immunodeficiency may influence management of primary CNS lymphoma.","evidence_relations":"Immunodeficiency disorders, HIV infection, and Epstein-Barr virus are risk factors for primary CNS lymphoma; Laboratory Tests for Primary CNS lymphoma include HIV blood test"},
	{"id":"Medical-bfe2b31f","source":"Medical","question":"Which imaging and biopsy methods are used together to confirm a diagnosis of primary CNS lymphoma localized to the brain?","answer":"MRI with gadolinium contrast and stereotactic biopsy are used together for diagnosis.","question_type":"Complex Reasoning","evidence":"MRI with gadolinium contrast is used to confirm a diagnosis of primary CNS lymphoma localized to the brain.; Stereotactic biopsy is used to confirm a diagnosis of primary CNS lymphoma localized to the brain.","evidence_relations":"MRI with gadolinium contrast is the most useful imaging technique for identifying primary CNS lymphoma; Stereotactic biopsy is the standard diagnostic procedure for primary CNS lymphoma; Disease Location for Primary CNS lymphoma includes Brain"},
	{"id":"Medical-b6fbf092","source":"Medical","question":"Why is clinical trial participation recommended for all primary CNS lymphoma patients regardless of treatment phase?","answer":"Because clinical trial participation is recommended for all patients and can be part of both induction and consolidation phases.","question_type":"Complex Reasoning","evidence":"Clinical trial participation is recommended for all primary CNS lymphoma patients.; Clinical trial participation can be part of the induction phase for primary CNS lymphoma patients.; Clinical trial participation can be part of the consolidation phase for primary CNS lymphoma patients.","evidence_relations":"Clinical trial participation is recommended for all patients with primary CNS lymphoma; Treatment is typically given in phases: induction and consolidation; Clinical trial is listed as an option in both induction and consolidation phases"},
	{"id":"Medical-55898188","source":"Medical","question":"Which diagnostic procedures are necessary for a patient with suspected regional CSCC presenting with lymph node involvement?","answer":"Lymph node exam, imaging (CT, PET/CT), and lymph node biopsy are required for regional CSCC with lymph node involvement.","question_type":"Complex Reasoning","evidence":"Lymph node exam is necessary for a patient with suspected regional CSCC presenting with lymph node involvement.; Imaging (CT, PET/CT) is necessary for a patient with suspected regional CSCC presenting with lymph node involvement.; Lymph node biopsy is necessary for a patient with suspected regional CSCC presenting with lymph node involvement.","evidence_relations":"Regional CSCC (lymph node involvement) is treated with surgery to remove tumor and lymph nodes, often followed by radiation and sometimes systemic therapy; Regional CSCC: Diagnostic Method: Lymph node exam, Imaging (CT, PET/CT), Lymph node biopsy (FNA, core needle biopsy)"},
	{"id":"Medical-8b99b755","source":"Medical","question":"How does the management of high-risk local CSCC differ from low-risk local CSCC in terms of treatment and follow-up?","answer":"High-risk local CSCC is treated with Mohs surgery or standard excision and may require radiation or systemic therapy, with more frequent follow-up exams than low-risk cases.","question_type":"Complex Reasoning","evidence":"High-risk local CSCC is treated with Mohs surgery.; High-risk local CSCC is treated with standard excision.; High-risk local CSCC may require radiation therapy.; High-risk local CSCC may require systemic therapy.; High-risk local CSCC requires more frequent follow-up exams than low-risk cases.","evidence_relations":"High-risk or very high-risk local CSCC is treated with Mohs surgery/PDEMA or standard excision, with consideration of radiation and/or systemic therapy if surgery is not possible; Low-risk local CSCC is primarily treated with surgery (C&E, standard excision, Mohs surgery/PDEMA); High-risk: Follow-up Strategy: Skin and lymph node exams every 3-6 months for 2 years, then every 6 months for 3 years, then every 6-12 months; Low-risk: Follow-up Strategy: Skin and lymph node exams every 3-12 months for 2 years, then every 6-12 months for 3 years, then annually"},
	{"id":"Medical-e0f29bbd","source":"Medical","question":"What are the preferred systemic therapy options for metastatic CSCC, and when might surgery or radiation be considered?","answer":"Preferred systemic therapies for metastatic CSCC are PD-1 inhibitors, with surgery or radiation considered if feasible.","question_type":"Complex Reasoning","evidence":"Preferred systemic therapies for metastatic CSCC are PD-1 inhibitors.; Surgery or radiation may be considered if feasible.","evidence_relations":"Metastatic CSCC is treated with systemic therapy (immunotherapy preferred), and surgery or radiation if feasible; Systemic therapy options include platinum-based chemotherapy, EGFR inhibitors (cetuximab), and PD-1 inhibitors (cemiplimab, pembrolizumab); Metastatic CSCC: Treatment: Systemic therapy (PD-1 inhibitor preferred), Surgery or radiation if feasible"},
	{"id":"Medical-55f0c0e2","source":"Medical","question":"Why is actinic keratosis considered a risk factor for CSCC, and how is it managed to prevent progression?","answer":"Actinic keratosis is a precancerous lesion that can progress to CSCC and is managed with photodynamic therapy, cryotherapy, or topical treatments.","question_type":"Complex Reasoning","evidence":"Actinic keratosis is a precancerous lesion.; Actinic keratosis can progress to CSCC.; Actinic keratosis is managed with photodynamic therapy.; Actinic keratosis is managed with cryotherapy.; Actinic keratosis is managed with topical treatments.","evidence_relations":"Actinic keratosis is a precancerous lesion that can progress to CSCC; Photodynamic therapy, cryotherapy, and topical therapies (5-fluorouracil, imiquimod, tirbanibulin) are used for actinic keratoses and superficial CSCC"},
	{"id":"Medical-8407a0ab","source":"Medical","question":"Which patient characteristics would prompt the use of imaging during the diagnostic workup of CSCC?","answer":"Imaging is used if deeper invasion or spread is suspected, especially in high-risk, regional, or metastatic CSCC cases.","question_type":"Complex Reasoning","evidence":"Imaging is used if deeper invasion is suspected.; Imaging is used if spread is suspected.; Imaging is especially used in high-risk CSCC cases.; Imaging is especially used in regional CSCC cases.; Imaging is especially used in metastatic CSCC cases.","evidence_relations":"Diagnosis of CSCC involves clinical examination, skin biopsy, and imaging (CT, MRI, PET/CT) if deeper invasion or spread is suspected; Imaging is used for staging and surveillance in regional and high-risk cases"},
	{"id":"Medical-7b4429ac","source":"Medical","question":"What findings on risk assessment would classify a local CSCC as high-risk, and how does this affect treatment choices?","answer":"Features such as perineural invasion, lymphovascular invasion, or high tumor grade classify local CSCC as high-risk, requiring Mohs surgery or systemic therapy if surgery/radiation is not possible.","question_type":"Complex Reasoning","evidence":"Perineural invasion classifies local CSCC as high-risk.; Lymphovascular invasion classifies local CSCC as high-risk.; High tumor grade classifies local CSCC as high-risk.; High-risk local CSCC requires Mohs surgery.; High-risk local CSCC may require systemic therapy if surgery or radiation is not possible.","evidence_relations":"Risk assessment for CSCC is based on tumor location, size, border definition, recurrence, depth, perineural invasion, lymphovascular invasion, tumor grade, and patient immune status; High-risk or very high-risk local CSCC is treated with Mohs surgery/PDEMA or standard excision, with consideration of radiation and/or systemic therapy if surgery is not possible"},
	{"id":"Medical-6d12f4ff","source":"Medical","question":"How does immunosuppression influence both the risk and clinical management of CSCC?","answer":"Immunosuppression increases CSCC risk and is a factor in risk assessment, requiring intensified surveillance and potentially altered treatment.","question_type":"Complex Reasoning","evidence":"Immunosuppression increases CSCC risk.; Immunosuppression is a factor in risk assessment for CSCC.; Immunosuppression requires intensified surveillance for CSCC.; Immunosuppression may require altered treatment for CSCC.","evidence_relations":"Major risk factors for CSCC include weakened immune system; Risk assessment for CSCC is based on patient immune status; Clinical Management: Risk Assessment: Immunosuppression"},
	{"id":"Medical-baed6d13","source":"Medical","question":"For a patient with CSCC arising in a chronic wound, what two risk factors are present and how does this affect staging and management?","answer":"Both chronic wounds and scars are risk factors, increasing the likelihood of high-risk CSCC, which may require advanced staging and aggressive treatment.","question_type":"Complex Reasoning","evidence":"Chronic wounds are a risk factor for high-risk CSCC.; Scars are a risk factor for high-risk CSCC.; Chronic wounds and scars increase the likelihood of high-risk CSCC.; High-risk CSCC may require advanced staging.; High-risk CSCC may require aggressive treatment.","evidence_relations":"Major risk factors for CSCC include chronic wounds or scars; CSCC is staged as local (confined to skin), regional (spread to lymph nodes), or metastatic (distant spread); High-risk or very high-risk local CSCC is treated with Mohs surgery/PDEMA or standard excision, with consideration of radiation and/or systemic therapy if surgery is not possible"},
	{"id":"Medical-eb7624ca","source":"Medical","question":"What is the recommended follow-up strategy after treatment for regional CSCC compared to local low-risk CSCC?","answer":"Regional CSCC requires more frequent skin and lymph node exams than local low-risk CSCC, especially in the first two years.","question_type":"Complex Reasoning","evidence":"Regional CSCC requires more frequent skin exams than local low-risk CSCC.; Regional CSCC requires more frequent lymph node exams than local low-risk CSCC.; More frequent exams are especially needed in the first two years after treatment.","evidence_relations":"Regional CSCC: Follow-up Strategy: Skin and lymph node exams every 2-3 months for 1 year, every 2-4 months for year 2, every 4-6 months for 3 years, then every 6-12 months; Low-risk: Follow-up Strategy: Skin and lymph node exams every 3-12 months for 2 years, then every 6-12 months for 3 years, then annually"},
	{"id":"Medical-0a6379ff","source":"Medical","question":"Which genetic syndromes are associated with increased CSCC risk and what is their implication for surveillance?","answer":"Xeroderma pigmentosum and RDEB increase CSCC risk, necessitating regular skin and lymph node exams for surveillance.","question_type":"Complex Reasoning","evidence":"Xeroderma pigmentosum is associated with increased CSCC risk.; RDEB is associated with increased CSCC risk.; Xeroderma pigmentosum necessitates regular skin exams for surveillance.; RDEB necessitates regular skin exams for surveillance.; Xeroderma pigmentosum necessitates regular lymph node exams for surveillance.; RDEB necessitates regular lymph node exams for surveillance.","evidence_relations":"Genetic syndromes such as xeroderma pigmentosum and RDEB increase risk for CSCC; Clinical Management: Surveillance: Regular skin and lymph node exams"},
	{"id":"Medical-462ecc23","source":"Medical","question":"How are PD-1 inhibitors used in the treatment of CSCC and at which stage are they preferred?","answer":"PD-1 inhibitors are systemic therapy options preferred for metastatic CSCC, but may also be used for high-risk or regional disease if other treatments are not possible.","question_type":"Complex Reasoning","evidence":"PD-1 inhibitors are systemic therapy options for CSCC.; PD-1 inhibitors are preferred for metastatic CSCC.; PD-1 inhibitors may also be used for high-risk disease.; PD-1 inhibitors may also be used for regional disease if other treatments are not possible.","evidence_relations":"Systemic therapy options include platinum-based chemotherapy, EGFR inhibitors (cetuximab), and PD-1 inhibitors (cemiplimab, pembrolizumab); Metastatic CSCC is treated with systemic therapy (immunotherapy preferred), and surgery or radiation if feasible; High-risk or very high-risk local CSCC is treated with Mohs surgery/PDEMA or standard excision, with consideration of radiation and/or systemic therapy if surgery is not possible"},
	{"id":"Medical-2782702e","source":"Medical","question":"What symptoms would prompt a clinician to perform a skin biopsy for suspected CSCC?","answer":"Scaly patches, solid or misshapen lesions, or lesions in areas of chronic damage would prompt a skin biopsy.","question_type":"Complex Reasoning","evidence":"Scaly patches would prompt a skin biopsy for suspected CSCC.; Solid or misshapen lesions would prompt a skin biopsy for suspected CSCC.; Lesions in areas of chronic damage would prompt a skin biopsy for suspected CSCC.","evidence_relations":"Symptoms of CSCC include scaly patches, solid or misshapen skin lesions, and lesions in areas of chronic damage; Diagnosis of CSCC involves clinical examination, skin biopsy, and imaging (CT, MRI, PET/CT) if deeper invasion or spread is suspected"},
	{"id":"Medical-f978cb28","source":"Medical","question":"What is the role of clinical trials in the management of advanced or refractory CSCC?","answer":"Clinical trials are an option for systemic therapy, especially in advanced or refractory CSCC cases.","question_type":"Complex Reasoning","evidence":"Clinical trials are an option for systemic therapy.; Clinical trials are especially relevant in advanced CSCC cases.; Clinical trials are especially relevant in refractory CSCC cases.","evidence_relations":"Clinical trials are an option for systemic therapy, especially in advanced or refractory CSCC; Metastatic CSCC: Treatment: Clinical trial"},
	{"id":"Medical-4f5a8531","source":"Medical","question":"Why might a patient with actinic keratosis require ongoing dermatologic surveillance even after lesion treatment?","answer":"Because actinic keratosis can progress to CSCC and regular skin exams are recommended for surveillance.","question_type":"Complex Reasoning","evidence":"Actinic keratosis can progress to CSCC.; Regular skin exams are recommended for surveillance after lesion treatment.","evidence_relations":"Actinic keratosis is a precancerous lesion that can progress to CSCC; Clinical Management: Surveillance: Regular skin and lymph node exams"},
	{"id":"Medical-db5aa2e3","source":"Medical","question":"What distinguishes Mohs surgery from other surgical options in the treatment of high-risk local CSCC?","answer":"Mohs surgery is preferred for high-risk local CSCC due to its tissue-sparing and margin-assessing technique.","question_type":"Complex Reasoning","evidence":"Mohs surgery is preferred for high-risk local CSCC.; Mohs surgery uses a tissue-sparing technique.; Mohs surgery uses a margin-assessing technique.","evidence_relations":"High-risk or very high-risk local CSCC is treated with Mohs surgery/PDEMA or standard excision, with consideration of radiation and/or systemic therapy if surgery is not possible; High-risk: Treatment: Mohs surgery/PDEMA (preferred)"},
	{"id":"Medical-193a4b7f","source":"Medical","question":"What chromosomal abnormality must be present for a diagnosis of chronic myeloid leukemia (CML)?","answer":"The Philadelphia chromosome (Ph), resulting from a translocation between chromosome 9 and chromosome 22, must be present.","question_type":"Complex Reasoning","evidence":"The Philadelphia chromosome must be present for a diagnosis of CML.; The Philadelphia chromosome results from a translocation between chromosome 9 and chromosome 22.","evidence_relations":"Presence of the Ph chromosome or BCR::ABL1 gene is required for CML diagnosis; The Philadelphia chromosome (Ph) is the abnormal chromosome 22 resulting from this translocation; The BCR::ABL1 gene is created by a translocation between chromosome 9 and chromosome 22"},
	{"id":"Medical-e9ac42f1","source":"Medical","question":"How does the BCR::ABL1 fusion gene relate to both the diagnosis and treatment of CML?","answer":"The BCR::ABL1 fusion gene is required for diagnosis and is also the target of CML treatment.","question_type":"Complex Reasoning","evidence":"The BCR::ABL1 fusion gene is required for the diagnosis of CML.; The BCR::ABL1 fusion gene is the target of CML treatment.","evidence_relations":"Presence of the Ph chromosome or BCR::ABL1 gene is required for CML diagnosis; CML is caused by the BCR::ABL1 fusion gene; Treatment for CML aims to inhibit BCR::ABL1 protein activity"},
	{"id":"Medical-78897235","source":"Medical","question":"Which two diagnostic methods are used to confirm CML by detecting its key biomarkers?","answer":"Blood tests and bone marrow tests are used to detect the BCR::ABL1 fusion gene or Philadelphia chromosome.","question_type":"Complex Reasoning","evidence":"Blood tests are used to confirm CML by detecting key biomarkers.; Bone marrow tests are used to confirm CML by detecting key biomarkers.; Blood tests can detect the BCR::ABL1 fusion gene.; Blood tests can detect the Philadelphia chromosome.","evidence_relations":"Blood tests and bone marrow tests are used to diagnose CML; Presence of the Ph chromosome or BCR::ABL1 gene is required for CML diagnosis; Biomarker includes BCR::ABL1 fusion gene and Philadelphia chromosome (Ph)"},
	{"id":"Medical-33494794","source":"Medical","question":"What cellular changes would you expect to find in a patient with CML, and which test would confirm these findings?","answer":"Increased white blood cells (granulocytes) and abnormal platelet counts, confirmed by blood tests.","question_type":"Complex Reasoning","evidence":"Increased white blood cells (granulocytes) are expected in a patient with CML.; Abnormal platelet counts are expected in a patient with CML.; Blood tests can confirm the findings of increased white blood cells and abnormal platelet counts.","evidence_relations":"CML is characterized by increased white blood cells (granulocytes) and abnormal platelet counts; Blood tests and bone marrow tests are used to diagnose CML"},
	{"id":"Medical-a7826934","source":"Medical","question":"Explain the relationship between the Philadelphia chromosome, BCR::ABL1 fusion gene, and the origin of CML.","answer":"The Philadelphia chromosome results from a translocation that creates the BCR::ABL1 fusion gene, which causes CML.","question_type":"Complex Reasoning","evidence":"The Philadelphia chromosome results from a translocation.; The translocation creates the BCR::ABL1 fusion gene.; The BCR::ABL1 fusion gene causes CML.","evidence_relations":"The Philadelphia chromosome (Ph) is the abnormal chromosome 22 resulting from this translocation; The BCR::ABL1 gene is created by a translocation between chromosome 9 and chromosome 22; CML is caused by the BCR::ABL1 fusion gene"},
	{"id":"Medical-50bafb57","source":"Medical","question":"Which blood cell types are abnormally increased in CML and what underlying cellular process causes this?","answer":"Granulocytes (a type of white blood cell) are increased due to overproduction by myeloid progenitor cells.","question_type":"Complex Reasoning","evidence":"Granulocytes are abnormally increased in CML.; Granulocytes are a type of white blood cell.; Granulocytes are increased due to overproduction by myeloid progenitor cells.","evidence_relations":"CML is characterized by increased white blood cells (granulocytes); CML arises from blood stem cells producing increased myeloid progenitor cells"},
	{"id":"Medical-24373ebe","source":"Medical","question":"How does the disease phase of CML affect the types of blood cells present?","answer":"Blast phase CML is characterized by increased blasts and progenitor cells, while chronic phase has increased mature granulocytes.","question_type":"Complex Reasoning","evidence":"Blast phase CML is characterized by increased blasts.; Blast phase CML is characterized by increased progenitor cells.; Chronic phase CML has increased mature granulocytes.","evidence_relations":"Blast phase CML (BP-CML) is an advanced form of CML with increased blasts; Blast phase CML (BP-CML) includes myeloid progenitor cells, lymphoid progenitor cells, and blasts; CML is characterized by increased white blood cells (granulocytes)"},
	{"id":"Medical-9528082d","source":"Medical","question":"Why is detecting either the Philadelphia chromosome or BCR::ABL1 gene sufficient for diagnosing CML?","answer":"Because both result from the same chromosomal translocation specific to CML and serve as key biomarkers.","question_type":"Complex Reasoning","evidence":"Detecting the Philadelphia chromosome is sufficient for diagnosing CML.; Detecting the BCR::ABL1 gene is sufficient for diagnosing CML.; Both the Philadelphia chromosome and BCR::ABL1 gene result from the same chromosomal translocation specific to CML.; The Philadelphia chromosome and BCR::ABL1 gene serve as key biomarkers for CML.","evidence_relations":"Presence of the Ph chromosome or BCR::ABL1 gene is required for CML diagnosis; The BCR::ABL1 gene is created by a translocation between chromosome 9 and chromosome 22; The Philadelphia chromosome (Ph) is the abnormal chromosome 22 resulting from this translocation"},
	{"id":"Medical-8b16a7bd","source":"Medical","question":"What is the rationale for targeting BCR::ABL1 protein activity in CML treatment?","answer":"Since CML is caused by the BCR::ABL1 fusion gene, inhibiting its protein product addresses the underlying cause.","question_type":"Complex Reasoning","evidence":"CML is caused by the BCR::ABL1 fusion gene.; Targeting BCR::ABL1 protein activity addresses the underlying cause of CML.","evidence_relations":"CML is caused by the BCR::ABL1 fusion gene; Treatment for CML aims to inhibit BCR::ABL1 protein activity"},
	{"id":"Medical-4fe06961","source":"Medical","question":"What is the sequence of genetic and chromosomal events leading to CML?","answer":"A translocation between chromosome 9 and 22 creates the Philadelphia chromosome, which produces the BCR::ABL1 fusion gene that causes CML.","question_type":"Complex Reasoning","evidence":"A translocation between chromosome 9 and 22 creates the Philadelphia chromosome.; The Philadelphia chromosome produces the BCR::ABL1 fusion gene.; The BCR::ABL1 fusion gene causes CML.","evidence_relations":"The BCR::ABL1 gene is created by a translocation between chromosome 9 and chromosome 22; The Philadelphia chromosome (Ph) is the abnormal chromosome 22 resulting from this translocation; CML is caused by the BCR::ABL1 fusion gene"},
	{"id":"Medical-41b1601a","source":"Medical","question":"Which two main biomarkers are tested to confirm a diagnosis of CML, and how are they related?","answer":"BCR::ABL1 fusion gene and Philadelphia chromosome are tested, both resulting from the same chromosomal translocation.","question_type":"Complex Reasoning","evidence":"The BCR::ABL1 fusion gene is tested to confirm a diagnosis of CML.; The Philadelphia chromosome is tested to confirm a diagnosis of CML.; Both the BCR::ABL1 fusion gene and Philadelphia chromosome result from the same chromosomal translocation.","evidence_relations":"Presence of the Ph chromosome or BCR::ABL1 gene is required for CML diagnosis; The Philadelphia chromosome (Ph) is the abnormal chromosome 22 resulting from this translocation; Biomarker includes BCR::ABL1 fusion gene and Philadelphia chromosome (Ph)"},
	{"id":"Medical-38fe5331","source":"Medical","question":"How does the detection of increased blasts in blood or bone marrow influence the classification of CML phase?","answer":"Increased blasts indicate progression to blast phase CML (BP-CML), an advanced disease stage.","question_type":"Complex Reasoning","evidence":"Increased blasts in blood or bone marrow indicate progression to blast phase CML.; Blast phase CML (BP-CML) is an advanced disease stage.","evidence_relations":"Blast phase CML (BP-CML) is an advanced form of CML with increased blasts; Blast phase CML (BP-CML) includes myeloid progenitor cells, lymphoid progenitor cells, and blasts"},
	{"id":"Medical-4987de7f","source":"Medical","question":"What are the cellular and molecular hallmarks required to definitively diagnose CML?","answer":"Increased granulocytes and presence of either the Philadelphia chromosome or BCR::ABL1 fusion gene are required.","question_type":"Complex Reasoning","evidence":"Increased granulocytes are required to definitively diagnose CML.; The presence of the Philadelphia chromosome is required to definitively diagnose CML.; The presence of the BCR::ABL1 fusion gene is required to definitively diagnose CML.","evidence_relations":"CML is characterized by increased white blood cells (granulocytes); Presence of the Ph chromosome or BCR::ABL1 gene is required for CML diagnosis"},
	{"id":"Medical-c2ead218","source":"Medical","question":"Which abnormal blood counts and genetic findings together support a diagnosis of CML?","answer":"Increased white blood cells and abnormal platelet counts, along with the Philadelphia chromosome or BCR::ABL1 gene, support CML diagnosis.","question_type":"Complex Reasoning","evidence":"Increased white blood cells support a diagnosis of CML.; Abnormal platelet counts support a diagnosis of CML.; The Philadelphia chromosome supports a diagnosis of CML.; The BCR::ABL1 gene supports a diagnosis of CML.","evidence_relations":"CML is characterized by increased white blood cells (granulocytes) and abnormal platelet counts; Presence of the Ph chromosome or BCR::ABL1 gene is required for CML diagnosis"},
	{"id":"Medical-4d01de98","source":"Medical","question":"How do blood stem cells contribute to the abnormal blood cell profile observed in CML?","answer":"Blood stem cells in CML produce increased myeloid progenitor cells, leading to elevated granulocytes.","question_type":"Complex Reasoning","evidence":"Blood stem cells in CML produce increased myeloid progenitor cells.; Increased myeloid progenitor cells lead to elevated granulocytes.","evidence_relations":"CML arises from blood stem cells producing increased myeloid progenitor cells; CML is characterized by increased white blood cells (granulocytes)"},
	{"id":"Medical-34a9155d","source":"Medical","question":"Why is a lung nodule detected by imaging not sufficient for a lung cancer diagnosis?","answer":"Because biopsy is required to confirm the malignancy of a lung nodule detected by imaging.","question_type":"Complex Reasoning","evidence":"A lung nodule detected by imaging is not sufficient for a lung cancer diagnosis.; A biopsy is required to confirm the malignancy of a lung nodule detected by imaging.","evidence_relations":"Lung nodules may be detected by imaging and require further assessment to determine malignancy; Biopsy is used to confirm lung cancer diagnosis"},
	{"id":"Medical-b7e4be0e","source":"Medical","question":"What combination of risk factors and diagnostic methods would justify recommending lung cancer screening?","answer":"Individuals with high-risk factors such as tobacco smoking should undergo lung cancer screening using imaging.","question_type":"Complex Reasoning","evidence":"Individuals with high-risk factors such as tobacco smoking should undergo lung cancer screening.; Lung cancer screening should use imaging.","evidence_relations":"Tobacco smoking is the biggest risk factor for lung cancer; Lung cancer screening is recommended for people at high risk; Screening: lung cancer screening is indicated for high risk individuals"},
	{"id":"Medical-96bb3762","source":"Medical","question":"How does the treatment approach differ between Stage 1 and Stage 2 NSCLC?","answer":"Stage 1 NSCLC is treated with surgery and possibly radiation therapy, while Stage 2 NSCLC may require surgery and chemoradiation.","question_type":"Complex Reasoning","evidence":"Stage 1 NSCLC is treated with surgery.; Stage 1 NSCLC may be treated with radiation therapy.; Stage 2 NSCLC may require surgery.; Stage 2 NSCLC may require chemoradiation.","evidence_relations":"Stage 1 NSCLC is considered early stage; Surgery is a primary treatment for early or locally advanced NSCLC when possible; Radiation therapy is used for some early NSCLC cases; Stage 2 and Stage 3 NSCLC are considered locally advanced; Chemoradiation is used for some locally advanced NSCLC cases"},
	{"id":"Medical-7ea7ec68","source":"Medical","question":"Why would a patient with a history of exposure to asbestos and a persistent cough be prioritized for lung cancer screening?","answer":"Because asbestos exposure is a risk factor and persistent cough is a symptom, both increasing the need for early detection via screening.","question_type":"Complex Reasoning","evidence":"Asbestos exposure is a risk factor for lung cancer.; A persistent cough is a symptom of lung cancer.; Both asbestos exposure and persistent cough increase the need for early detection via screening.","evidence_relations":"Exposure to asbestos is a risk factor for lung cancer; Symptoms of lung cancer may include cough; Lung cancer screening is recommended for people at high risk"},
	{"id":"Medical-e7d1cd1c","source":"Medical","question":"How does the subtype of NSCLC influence the origin of the cancer cells?","answer":"Adenocarcinoma forms from alveolar mucus-producing cells, while squamous cell carcinoma originates from bronchial lining cells.","question_type":"Complex Reasoning","evidence":"Adenocarcinoma forms from alveolar mucus-producing cells.; Squamous cell carcinoma originates from bronchial lining cells.","evidence_relations":"Adenocarcinoma often forms from cells that line the alveoli and make mucus; Squamous cell carcinoma forms from cells that line the bronchi"},
	{"id":"Medical-c7c59020","source":"Medical","question":"What is the rationale for using both imaging and biopsy in the assessment of a lung nodule?","answer":"Imaging detects the lung nodule, but biopsy is necessary to determine if it is cancerous.","question_type":"Complex Reasoning","evidence":"Imaging detects the lung nodule.; A biopsy is necessary to determine if the lung nodule is cancerous.","evidence_relations":"Lung nodules may be detected by imaging and require further assessment to determine malignancy; Biopsy is used to confirm lung cancer diagnosis"},
	{"id":"Medical-ee49f3e8","source":"Medical","question":"Why is surgery not typically a treatment option for Stage 4 NSCLC?","answer":"Because Stage 4 NSCLC is metastatic at diagnosis, making local treatments like surgery ineffective.","question_type":"Complex Reasoning","evidence":"Stage 4 NSCLC is metastatic at diagnosis.; Local treatments like surgery are ineffective for Stage 4 NSCLC.","evidence_relations":"Stage 4 NSCLC is metastatic at diagnosis; Surgery is a primary treatment for early or locally advanced NSCLC when possible"},
	{"id":"Medical-b77d8e3d","source":"Medical","question":"How do follow-up strategies change after initial treatment for NSCLC?","answer":"After initial treatment, follow-up care and surveillance are implemented to monitor for recurrence.","question_type":"Complex Reasoning","evidence":"After initial treatment for NSCLC, follow-up care is implemented.; Surveillance is implemented to monitor for recurrence after initial treatment for NSCLC.","evidence_relations":"Follow-up care is planned after treatment and includes surveillance for recurrence; Follow-up Strategy for NSCLC includes follow-up care and surveillance"},
	{"id":"Medical-6fb8996b","source":"Medical","question":"What factors would lead to recommending a clinical trial for a lung cancer patient?","answer":"Patients with lung cancer may be eligible for clinical trials as part of their treatment or prevention options.","question_type":"Complex Reasoning","evidence":"Patients with lung cancer may be eligible for clinical trials.; Clinical trials can be part of treatment options for lung cancer patients.; Clinical trials can be part of prevention options for lung cancer patients.","evidence_relations":"Clinical trials are available for lung cancer treatment and prevention; NSCLC treatment options include clinical trial"},
	{"id":"Medical-edc3c6eb","source":"Medical","question":"Why is lung cancer screening particularly important for individuals exposed to air pollution and diesel fumes?","answer":"Because both air pollution and diesel fumes are established risk factors for lung cancer, necessitating early detection strategies.","question_type":"Complex Reasoning","evidence":"Air pollution is an established risk factor for lung cancer.; Diesel fumes are an established risk factor for lung cancer.; Both air pollution and diesel fumes necessitate early detection strategies for lung cancer.","evidence_relations":"Exposure to diesel fumes and air pollution are risk factors for lung cancer; Lung cancer screening is recommended for people at high risk"},
	{"id":"Medical-f3048835","source":"Medical","question":"What are the main differences in treatment between early and locally advanced NSCLC?","answer":"Early NSCLC is mainly treated with surgery and sometimes radiation, while locally advanced NSCLC may also require chemoradiation.","question_type":"Complex Reasoning","evidence":"Early NSCLC is mainly treated with surgery.; Early NSCLC may sometimes be treated with radiation.; Locally advanced NSCLC may require chemoradiation.","evidence_relations":"Surgery is a primary treatment for early or locally advanced NSCLC when possible; Radiation therapy is used for some early NSCLC cases; Chemoradiation is used for some locally advanced NSCLC cases"},
	{"id":"Medical-f79d978d","source":"Medical","question":"How does the presence of a lung nodule on imaging affect the diagnostic workflow for lung cancer?","answer":"A lung nodule detected by imaging prompts further assessment, including biopsy, to confirm or exclude cancer.","question_type":"Complex Reasoning","evidence":"A lung nodule detected by imaging prompts further assessment.; Further assessment of a lung nodule includes a biopsy.; A biopsy is performed to confirm or exclude cancer in the presence of a lung nodule.","evidence_relations":"Lung nodules may be detected by imaging and require further assessment to determine malignancy; Biopsy is used to confirm lung cancer diagnosis"},
	{"id":"Medical-47504b64","source":"Medical","question":"Why is supportive care considered a treatment option for all stages of lung cancer?","answer":"Supportive care improves quality of life for people with lung cancer regardless of stage.","question_type":"Complex Reasoning","evidence":"Supportive care improves quality of life for people with lung cancer.; Supportive care is considered a treatment option for all stages of lung cancer.","evidence_relations":"Supportive care extends and enhances life for people with lung cancer; NSCLC treatment options include supportive care"},
	{"id":"Medical-328006b7","source":"Medical","question":"What combination of exposure and symptom would most strongly suggest the need for diagnostic evaluation for lung cancer?","answer":"A history of tobacco smoking combined with chest pain should prompt diagnostic evaluation for lung cancer.","question_type":"Complex Reasoning","evidence":"A history of tobacco smoking should prompt diagnostic evaluation for lung cancer.; Chest pain should prompt diagnostic evaluation for lung cancer.; The combination of tobacco smoking and chest pain suggests the need for diagnostic evaluation for lung cancer.","evidence_relations":"Tobacco smoking is the biggest risk factor for lung cancer; Symptoms of lung cancer may include chest pain; Biopsy is used to confirm lung cancer diagnosis"},
	{"id":"Medical-659d7c0a","source":"Medical","question":"How do the purposes of lung cancer screening and follow-up care differ?","answer":"Screening aims for early detection in high-risk individuals, while follow-up care monitors for recurrence after treatment.","question_type":"Complex Reasoning","evidence":"Screening aims for early detection in high-risk individuals.; Follow-up care monitors for recurrence after treatment.; The purposes of lung cancer screening and follow-up care differ.","evidence_relations":"Lung cancer screening aims to detect cancer at an early, more treatable stage; Follow-up care is planned after treatment and includes surveillance for recurrence"},
	{"id":"Medical-689b17ad","source":"Medical","question":"Which biomarker should be tested both before and after treatment in nasopharyngeal carcinoma patients, and why is this monitoring important?","answer":"EBV DNA should be tested before and after treatment because its level serves as a prognostic factor and is used for surveillance.","question_type":"Complex Reasoning","evidence":"EBV DNA should be tested before treatment in nasopharyngeal carcinoma patients.; EBV DNA should be tested after treatment in nasopharyngeal carcinoma patients.; The level of EBV DNA serves as a prognostic factor.; The level of EBV DNA is used for surveillance.","evidence_relations":"EBV DNA testing is performed before and after treatment for NPC; Biomarker testing for NPC includes EBV DNA; EBV DNA level is a prognostic factor; Surveillance for NPC includes EBV DNA testing"},
	{"id":"Medical-a7e62dce","source":"Medical","question":"What combination of diagnostic methods is necessary to both confirm nasopharyngeal carcinoma and determine its subtype?","answer":"Biopsy is required to confirm NPC and to determine its cancer subtype.","question_type":"Complex Reasoning","evidence":"A biopsy is required to confirm nasopharyngeal carcinoma.; A biopsy is required to determine the subtype of nasopharyngeal carcinoma.","evidence_relations":"Biopsy confirms diagnosis and determines cancer subtype; Diagnosis of NPC involves medical history, physical exam, imaging (CT, MRI, PET/CT, ultrasound), and biopsy"},
	{"id":"Medical-80912696","source":"Medical","question":"Why should fertility counseling be considered for patients undergoing treatment for nasopharyngeal carcinoma?","answer":"Fertility counseling should be considered because NPC treatment can affect fertility.","question_type":"Complex Reasoning","evidence":"Fertility counseling should be considered for patients undergoing treatment for nasopharyngeal carcinoma.; Nasopharyngeal carcinoma treatment can affect fertility.","evidence_relations":"Fertility may be affected by NPC treatment and should be discussed before therapy; Fertility counseling is part of the diagnostic and planning process for NPC; Fertility counseling and impact of treatment on fertility are listed under Fertility Consideration in the ontology"},
	{"id":"Medical-aa1b8dbb","source":"Medical","question":"How does a patient's performance status influence nasopharyngeal carcinoma treatment planning?","answer":"Performance status is assessed and considered in NPC treatment planning as a prognostic factor.","question_type":"Complex Reasoning","evidence":"Performance status is assessed in nasopharyngeal carcinoma treatment planning.; Performance status is considered in nasopharyngeal carcinoma treatment planning.; Performance status is a prognostic factor in nasopharyngeal carcinoma treatment planning.","evidence_relations":"Performance status is considered in NPC treatment planning; Performance status evaluation is a diagnostic method for NPC; Performance status is a prognostic factor for NPC"},
	{"id":"Medical-d256aef2","source":"Medical","question":"If a patient with nasopharyngeal carcinoma presents with enlarged lymph nodes, what does this indicate about possible disease spread and staging?","answer":"Enlarged lymph nodes suggest lymph node metastasis, which is included in the TNM staging system for NPC.","question_type":"Complex Reasoning","evidence":"Enlarged lymph nodes suggest lymph node metastasis.; Lymph node metastasis is included in the TNM staging system for nasopharyngeal carcinoma.","evidence_relations":"Symptoms of NPC include enlarged lymph nodes; NPC commonly spreads to lymph nodes in the neck; NPC is staged using the AJCC TNM system, which includes lymph node involvement (N)"},
	{"id":"Medical-c09d2bcb","source":"Medical","question":"Which populations are at increased risk for nasopharyngeal carcinoma and what risk factors contribute to this increased incidence?","answer":"People from Asia, Native America, and North Africa are at increased risk due to geographic origin and EBV infection.","question_type":"Complex Reasoning","evidence":"People from Asia are at increased risk for nasopharyngeal carcinoma.; Native Americans are at increased risk for nasopharyngeal carcinoma.; People from North Africa are at increased risk for nasopharyngeal carcinoma.; Geographic origin contributes to the increased incidence of nasopharyngeal carcinoma.; EBV infection contributes to the increased incidence of nasopharyngeal carcinoma.","evidence_relations":"NPC most often occurs in people from parts of Asia, Native America, and North Africa; Most NPCs are related to Epstein-Barr virus (EBV) infection; Geographic origin and EBV are risk factors for NPC"},
	{"id":"Medical-5fdb115b","source":"Medical","question":"What imaging modalities are used for both staging and surveillance of nasopharyngeal carcinoma?","answer":"CT scan, MRI, PET/CT, and ultrasound are used for both staging and surveillance of NPC.","question_type":"Complex Reasoning","evidence":"CT scan is used for both staging and surveillance of nasopharyngeal carcinoma.; MRI is used for both staging and surveillance of nasopharyngeal carcinoma.; PET/CT is used for both staging and surveillance of nasopharyngeal carcinoma.; Ultrasound is used for both staging and surveillance of nasopharyngeal carcinoma.","evidence_relations":"Imaging tests such as CT, MRI, PET/CT, and ultrasound are used for staging and surveillance; Diagnosis of NPC involves imaging (CT, MRI, PET/CT, ultrasound)"},
	{"id":"Medical-9231a873","source":"Medical","question":"Which cancer subtype is most commonly found in the nasopharynx and how is it classified within the cancer ontology?","answer":"Squamous cell carcinoma (SCC) is the most common subtype of nasopharyngeal cancer, classified under nasopharyngeal carcinoma (NPC) in the ontology.","question_type":"Complex Reasoning","evidence":"Squamous cell carcinoma (SCC) is the most common subtype of nasopharyngeal cancer.; SCC is classified under nasopharyngeal carcinoma (NPC) in the cancer ontology.","evidence_relations":"Squamous cell carcinoma (SCC) is the most common subtype of nasopharyngeal cancer; Squamous cell carcinoma (SCC) is a subtype of NPC in the ontology"},
	{"id":"Medical-ad0cc053","source":"Medical","question":"If a nasopharyngeal carcinoma patient has both high EBV DNA levels and poor performance status, what does this indicate about their prognosis?","answer":"High EBV DNA levels and poor performance status are both poor prognostic factors in NPC.","question_type":"Complex Reasoning","evidence":"High EBV DNA levels are a poor prognostic factor in nasopharyngeal carcinoma (NPC).; Poor performance status is a poor prognostic factor in nasopharyngeal carcinoma (NPC).","evidence_relations":"EBV DNA level is a prognostic factor; Performance status is a prognostic factor; Biomarker testing for NPC includes EBV DNA"},
	{"id":"Medical-5a6b98a7","source":"Medical","question":"Why might symptoms of nasopharyngeal carcinoma be absent until advanced stages, and how does this affect the diagnostic process?","answer":"Symptoms may be absent until advanced stage, making imaging and biopsy essential for early diagnosis.","question_type":"Complex Reasoning","evidence":"Symptoms of nasopharyngeal carcinoma may be absent until advanced stages.; The absence of symptoms until advanced stages makes imaging essential for early diagnosis.; The absence of symptoms until advanced stages makes biopsy essential for early diagnosis.","evidence_relations":"Symptoms of NPC may be absent until advanced stage and can be similar to other conditions; Diagnosis of NPC involves imaging (CT, MRI, PET/CT, ultrasound) and biopsy"},
	{"id":"Medical-1c53b384","source":"Medical","question":"What combination of risk factors should prompt clinicians to consider nasopharyngeal carcinoma in a differential diagnosis?","answer":"Epstein-Barr virus infection, tobacco use, alcohol use, and geographic origin (Asia, Native America, North Africa) should prompt consideration of NPC.","question_type":"Complex Reasoning","evidence":"Epstein-Barr virus infection should prompt consideration of nasopharyngeal carcinoma (NPC).; Tobacco use should prompt consideration of nasopharyngeal carcinoma (NPC).; Alcohol use should prompt consideration of nasopharyngeal carcinoma (NPC).; Geographic origin (Asia, Native America, North Africa) should prompt consideration of nasopharyngeal carcinoma (NPC).","evidence_relations":"Risk factors for NPC include Epstein-Barr virus (EBV), tobacco use, alcohol use, and geographic origin (Asia, Native America, North Africa); NPC most often occurs in people from parts of Asia, Native America, and North Africa"},
	{"id":"Medical-0e2be889","source":"Medical","question":"How does the AJCC TNM system contribute to the staging of nasopharyngeal carcinoma, and what aspects does it assess?","answer":"The AJCC TNM system stages NPC by assessing tumor size (T), lymph node involvement (N), and distant metastasis (M).","question_type":"Complex Reasoning","evidence":"The AJCC TNM system stages nasopharyngeal carcinoma (NPC).; The AJCC TNM system assesses tumor size (T) in NPC.; The AJCC TNM system assesses lymph node involvement (N) in NPC.; The AJCC TNM system assesses distant metastasis (M) in NPC.","evidence_relations":"NPC is staged using the AJCC TNM system, which includes tumor size (T), lymph node involvement (N), and distant metastasis (M); Stage in the ontology includes AJCC TNM system"},
	{"id":"Medical-ff2105ab","source":"Medical","question":"Why is dental health assessment important in the management of nasopharyngeal carcinoma?","answer":"Dental health can be affected by head and neck cancer and its treatment, so dental exams are part of NPC management.","question_type":"Complex Reasoning","evidence":"Dental health can be affected by head and neck cancer.; Dental health can be affected by the treatment of head and neck cancer.; Dental exams are part of the management of nasopharyngeal carcinoma (NPC).","evidence_relations":"Dental health can be affected by head and neck cancer and its treatment; Dental exam is a diagnostic method for NPC"},
	{"id":"Medical-6a90b47e","source":"Medical","question":"What methods are used to assess both nutritional status and speech/swallowing function in nasopharyngeal carcinoma patients?","answer":"Nutrition assessment and speech and swallowing assessment are used in NPC patients.","question_type":"Complex Reasoning","evidence":"Nutrition assessment is used in nasopharyngeal carcinoma (NPC) patients.; Speech and swallowing assessment is used in nasopharyngeal carcinoma (NPC) patients.","evidence_relations":"Nutrition assessment and speech and swallowing assessment are diagnostic methods for NPC; Diagnostic Method in the ontology includes nutrition assessment and speech and swallowing assessment"},
	{"id":"Medical-0d237b40","source":"Medical","question":"Which metastatic sites are most common in nasopharyngeal carcinoma and how is this reflected in the ontology?","answer":"Lymph node and lung are the most common metastatic sites for NPC, as indicated in the ontology.","question_type":"Complex Reasoning","evidence":"Lymph node is a common metastatic site for nasopharyngeal carcinoma (NPC).; Lung is a common metastatic site for nasopharyngeal carcinoma (NPC).; The ontology indicates lymph node and lung as common metastatic sites for NPC.","evidence_relations":"NPC commonly spreads to lymph nodes in the neck and less frequently to the lungs; Metastasis in the ontology for NPC includes lymph node and lung"},
	{"id":"Medical-cfab4b2d","source":"Medical","question":"Why is immunotherapy with checkpoint inhibitors recommended for some colon cancer patients but not others?","answer":"Immunotherapy with checkpoint inhibitors is recommended for dMMR/MSI-H colon cancers but not for pMMR/MSS cancers, which are treated with chemotherapy.","question_type":"Complex Reasoning","evidence":"Immunotherapy with checkpoint inhibitors is recommended for dMMR/MSI-H colon cancers.; Immunotherapy with checkpoint inhibitors is not recommended for pMMR/MSS colon cancers.; pMMR/MSS colon cancers are treated with chemotherapy.","evidence_relations":"dMMR/MSI-H is a biomarker guiding immunotherapy; Immunotherapy with checkpoint inhibitors is preferred for dMMR/MSI-H cancers; pMMR/MSS cancers are treated with chemotherapy"},
	{"id":"Medical-b2da7aee","source":"Medical","question":"What are the recommended surveillance strategies after treatment for colon cancer and which biomarkers are involved?","answer":"Surveillance includes colonoscopy, CEA testing, and CT scans, with CEA serving as a biomarker for monitoring.","question_type":"Complex Reasoning","evidence":"Surveillance after treatment for colon cancer includes colonoscopy.; Surveillance after treatment for colon cancer includes CEA testing.; Surveillance after treatment for colon cancer includes CT scans.; CEA serves as a biomarker for monitoring after treatment for colon cancer.","evidence_relations":"Surveillance after treatment includes colonoscopy, CEA testing, and CT scans; CEA is a biomarker for monitoring colon cancer"},
	{"id":"Medical-7b422282","source":"Medical","question":"How does the presence of Lynch syndrome affect colon cancer risk and management?","answer":"Lynch syndrome increases colon cancer risk and requires testing for mismatch repair deficiency (dMMR) or MSI-H, which guides immunotherapy decisions.","question_type":"Complex Reasoning","evidence":"Lynch syndrome increases colon cancer risk.; Lynch syndrome requires testing for mismatch repair deficiency (dMMR) or MSI-H.; Testing for dMMR or MSI-H guides immunotherapy decisions.","evidence_relations":"Lynch syndrome and familial adenomatous polyposis (FAP) are inherited syndromes increasing colon cancer risk; All colon cancers should be tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H); dMMR/MSI-H is a biomarker guiding immunotherapy"},
	{"id":"Medical-fc13ecfe","source":"Medical","question":"What is the rationale for recommending chemotherapy after colectomy in stage 3 colon cancer but not always in stage 2?","answer":"Chemotherapy is recommended after colectomy for all stage 3 colon cancers due to lymph node involvement, while only some stage 2 cases receive it as they lack lymph node spread.","question_type":"Complex Reasoning","evidence":"Chemotherapy is recommended after colectomy for all stage 3 colon cancers.; Stage 3 colon cancers have lymph node involvement.; Only some stage 2 colon cancer cases receive chemotherapy.; Some stage 2 colon cancer cases lack lymph node spread.","evidence_relations":"Stage 3 colon cancer involves spread to nearby lymph nodes or tumor deposits; Chemotherapy is recommended after colectomy for all stage 3 and some stage 2 colon cancers"},
	{"id":"Medical-3447851a","source":"Medical","question":"Why should young adults with colon cancer be counseled about fertility preservation before treatment?","answer":"Young adults should be counseled because treatments like chemotherapy and surgery can impair fertility, and options such as sperm banking, egg freezing, or ovarian tissue banking are available.","question_type":"Complex Reasoning","evidence":"Young adults with colon cancer should be counseled about fertility preservation.; Treatments like chemotherapy and surgery can impair fertility.; Options for fertility preservation include sperm banking, egg freezing, and ovarian tissue banking.","evidence_relations":"Young adults should be counseled about fertility risks and preservation options before treatment; Fertility Preservation includes sperm banking, egg freezing, and ovarian tissue banking"},
	{"id":"Medical-97022167","source":"Medical","question":"How does the origin of colon cancer from adenomas influence early detection and prevention strategies?","answer":"Since most colon cancers start in adenomas, early detection and removal of polyps via colonoscopy and polypectomy are crucial for prevention.","question_type":"Complex Reasoning","evidence":"Most colon cancers start in adenomas.; Early detection and removal of polyps are crucial for prevention.; Colonoscopy and polypectomy are methods for early detection and removal of polyps.","evidence_relations":"Most colon cancers start in polyps, especially adenomas; Polypectomy removes polyps during colonoscopy"},
	{"id":"Medical-781a9787","source":"Medical","question":"What diagnostic tests are used for both initial evaluation and staging of colon cancer, and what unique information does each provide?","answer":"Blood tests (CBC, chemistry profile, CEA) are used for initial evaluation, while CT with contrast is the main imaging test for staging and surveillance; CEA is also a biomarker for monitoring.","question_type":"Complex Reasoning","evidence":"Blood tests like CBC, chemistry profile, and CEA are used for initial evaluation of colon cancer.; CT with contrast is the main imaging test for staging and surveillance of colon cancer.; CEA is a biomarker for monitoring colon cancer.","evidence_relations":"Blood tests (CBC, chemistry profile, CEA) are recommended for initial testing; CT with contrast is the main imaging test for staging and surveillance; CEA is a biomarker for monitoring colon cancer"},
	{"id":"Medical-104b2f70","source":"Medical","question":"For a patient with a first-degree relative with colorectal cancer, what risk factors and inherited syndromes should be considered?","answer":"A first-degree relative is a risk factor, and inherited syndromes like Lynch syndrome and FAP should be evaluated for increased colon cancer risk.","question_type":"Complex Reasoning","evidence":"A first-degree relative with colorectal cancer is a risk factor.; Inherited syndromes like Lynch syndrome and FAP should be evaluated for increased colon cancer risk.","evidence_relations":"Family history of colorectal cancer is a risk factor; Risk Factor includes inherited syndromes such as Lynch syndrome and FAP"},
	{"id":"Medical-e1ede6d6","source":"Medical","question":"What distinguishes stage 4 colon cancer from earlier stages in terms of spread and treatment approach?","answer":"Stage 4 colon cancer has spread to distant organs like the liver or lungs, requiring different treatment strategies compared to localized or regional disease.","question_type":"Complex Reasoning","evidence":"Stage 4 colon cancer has spread to distant organs like the liver or lungs.; Stage 4 colon cancer requires different treatment strategies compared to localized or regional disease.","evidence_relations":"Stage 4 colon cancer has spread to distant organs (commonly liver or lungs); AJCC TNM system is used to stage colon cancer"},
	{"id":"Medical-e8957bed","source":"Medical","question":"Why is ctDNA testing not routinely used in colon cancer management outside clinical trials?","answer":"ctDNA testing is considered investigational and recommended only in clinical trials, not in standard management.","question_type":"Complex Reasoning","evidence":"ctDNA testing is considered investigational.; ctDNA testing is recommended only in clinical trials.; ctDNA testing is not used in standard management of colon cancer.","evidence_relations":"ctDNA testing is investigational and recommended only in clinical trials; ctDNA is listed as a biomarker but not part of routine diagnostic or surveillance methods"},
	{"id":"Medical-38fc968c","source":"Medical","question":"Which surgical procedures may be required for colon cancer patients and under what circumstances is a colostomy necessary?","answer":"Colectomy removes the cancerous colon segment, and colostomy is needed if bowel reconnection is not possible, diverting stool through a stoma.","question_type":"Complex Reasoning","evidence":"Colectomy removes the cancerous segment of the colon.; A colostomy is needed if bowel reconnection is not possible.; A colostomy diverts stool through a stoma.","evidence_relations":"Colectomy is surgery to remove the cancerous part of the colon; Colostomy diverts stool through an abdominal stoma if reconnection is not possible"},
	{"id":"Medical-00ef7b5d","source":"Medical","question":"How are dMMR/MSI-H and pMMR/MSS statuses determined and how do they influence therapy choices?","answer":"All colon cancers should be tested for dMMR/MSI-H or pMMR/MSS, with dMMR/MSI-H guiding immunotherapy and pMMR/MSS leading to chemotherapy.","question_type":"Complex Reasoning","evidence":"All colon cancers should be tested for dMMR/MSI-H or pMMR/MSS.; dMMR/MSI-H status guides immunotherapy.; pMMR/MSS status leads to chemotherapy.","evidence_relations":"All colon cancers should be tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H); dMMR/MSI-H is a biomarker guiding immunotherapy; pMMR/MSS cancers are treated with chemotherapy"},
	{"id":"Medical-ebfc4679","source":"Medical","question":"What is the relationship between adenocarcinoma, adenomas, and the development of colon cancer?","answer":"Adenocarcinoma, the most common colon cancer subtype, arises from adenomas that can become invasive cancer over many years.","question_type":"Complex Reasoning","evidence":"Adenocarcinoma is the most common subtype of colon cancer.; Adenocarcinoma arises from adenomas.; Adenomas can become invasive cancer over many years.","evidence_relations":"Adenocarcinoma is the most common subtype of colon cancer; Adenocarcinoma arises from adenomas; Adenomas can become invasive colon cancer over many years"},
	{"id":"Medical-f27c64c0","source":"Medical","question":"What steps are involved in the diagnostic workup for a patient suspected of colon cancer based on symptoms?","answer":"Diagnostic workup includes colonoscopy (with possible polypectomy), blood tests (CBC, chemistry profile, CEA), and CT with contrast for staging.","question_type":"Complex Reasoning","evidence":"The diagnostic workup for suspected colon cancer includes colonoscopy.; Colonoscopy may include a polypectomy.; The diagnostic workup includes blood tests.; The blood tests include CBC, chemistry profile, and CEA.; The diagnostic workup includes CT with contrast for staging.","evidence_relations":"Colonoscopy and polypectomy are diagnostic methods; Blood tests (CBC, chemistry profile, CEA) are recommended for initial testing; CT with contrast is the main imaging test for staging and surveillance"},
	{"id":"Medical-5b17d14f","source":"Medical","question":"Why are hyperplastic and inflammatory polyps less concerning than adenomas in colon cancer prevention?","answer":"Hyperplastic and inflammatory polyps rarely become cancer, while adenomas can develop into invasive colon cancer.","question_type":"Complex Reasoning","evidence":"Hyperplastic polyps rarely become cancer.; Inflammatory polyps rarely become cancer.; Adenomas can develop into invasive colon cancer.","evidence_relations":"Hyperplastic and inflammatory polyps rarely become cancer; Adenomas can become invasive colon cancer over many years"},
	{"id":"Medical-bea3adf4","source":"Medical","question":"How does the presence of Barrett esophagus influence both risk and diagnostic approach for esophageal adenocarcinoma?","answer":"Barrett esophagus increases risk for esophageal adenocarcinoma and necessitates biomarker and genetic risk testing during diagnosis.","question_type":"Complex Reasoning","evidence":"Barrett esophagus increases the risk for esophageal adenocarcinoma.; Barrett esophagus necessitates biomarker testing during diagnosis.; Barrett esophagus necessitates genetic risk testing during diagnosis.","evidence_relations":"Barrett esophagus is a precancerous condition that increases risk for esophageal adenocarcinoma; Diagnosis involves blood tests, imaging tests, endoscopy, biopsy, biomarker testing, and genetic risk testing; Esophageal adenocarcinoma has risk factor Barrett esophagus"},
	{"id":"Medical-99dd217e","source":"Medical","question":"What distinguishes early-stage esophageal cancer from locoregional and metastatic disease in terms of anatomical spread and diagnostic requirements?","answer":"Early-stage is limited to the esophagus without lymph node involvement, while locoregional and metastatic involve spread to nodes or distant organs, requiring imaging and biopsy for staging.","question_type":"Complex Reasoning","evidence":"Early-stage esophageal cancer is limited to the esophagus.; Early-stage esophageal cancer does not involve lymph nodes.; Locoregional disease involves spread to lymph nodes.; Metastatic disease involves spread to distant organs.; Locoregional and metastatic disease require imaging for staging.; Locoregional and metastatic disease require biopsy for staging.","evidence_relations":"Early-stage esophageal cancer is contained within the esophagus and not in lymph nodes; Locoregional esophageal cancer has invaded the esophagus wall and/or spread to nearby lymph nodes or organs; Metastatic esophageal cancer has spread to distant organs such as liver, lung, bone, and brain; Diagnosis involves blood tests, imaging tests, endoscopy, biopsy, biomarker testing, and genetic risk testing"},
	{"id":"Medical-166bcaa7","source":"Medical","question":"Why is Siewert type classification particularly important in the staging and treatment planning of tumors at the esophagogastric junction?","answer":"Siewert types determine staging and guide treatment planning for esophagogastric junction tumors.","question_type":"Complex Reasoning","evidence":"Siewert types determine staging for esophagogastric junction tumors.; Siewert types guide treatment planning for esophagogastric junction tumors.","evidence_relations":"Siewert types are used to stage tumors at the esophagogastric junction; Treatment planning is based on cancer type, location, and stage; Siewert types (for EGJ tumors) are included in treatment planning"},
	{"id":"Medical-48cb097c","source":"Medical","question":"Which anatomical locations are most associated with esophageal squamous cell carcinoma and esophageal adenocarcinoma, and how does this affect treatment planning?","answer":"Squamous cell carcinoma often occurs in the upper/middle esophagus, adenocarcinoma in the lower/middle, and treatment planning considers these locations.","question_type":"Complex Reasoning","evidence":"Esophageal squamous cell carcinoma often occurs in the upper esophagus.; Esophageal squamous cell carcinoma often occurs in the middle esophagus.; Esophageal adenocarcinoma often occurs in the lower esophagus.; Esophageal adenocarcinoma often occurs in the middle esophagus.; Treatment planning considers the anatomical locations of the tumors.","evidence_relations":"Esophageal squamous cell carcinoma starts in squamous cells of the esophagus; Esophageal adenocarcinoma starts in mucus-secreting cells of the esophagus; Esophageal squamous cell carcinoma: Anatomical Location: Upper esophagus, Middle esophagus, Lower esophagus; Esophageal adenocarcinoma: Anatomical Location: Lower esophagus, Middle esophagus; Treatment planning is based on cancer type, location, and stage"},
	{"id":"Medical-a88065af","source":"Medical","question":"If a patient with esophageal cancer presents with liver and bone metastases, what is their disease stage and which diagnostic methods are necessary?","answer":"The patient has metastatic disease and requires imaging tests and biopsy for confirmation.","question_type":"Complex Reasoning","evidence":"The patient has metastatic disease.; The patient requires imaging tests for confirmation.; The patient requires biopsy for confirmation.","evidence_relations":"Metastatic esophageal cancer has spread to distant organs such as liver, lung, bone, and brain; Diagnosis involves blood tests, imaging tests, endoscopy, biopsy, biomarker testing, and genetic risk testing; Metastatic: Spread to distant organs, including liver and bone"},
	{"id":"Medical-c41cab28","source":"Medical","question":"How does the identification of Barrett esophagus change the risk profile and surveillance strategy for esophageal cancer?","answer":"Barrett esophagus increases adenocarcinoma risk, so surveillance includes biomarker and genetic risk testing.","question_type":"Complex Reasoning","evidence":"The identification of Barrett esophagus increases adenocarcinoma risk.; Surveillance for esophageal cancer includes biomarker testing.; Surveillance for esophageal cancer includes genetic risk testing.","evidence_relations":"Barrett esophagus is a precancerous condition that increases risk for esophageal adenocarcinoma; Diagnosis involves blood tests, imaging tests, endoscopy, biopsy, biomarker testing, and genetic risk testing; Barrett esophagus is a risk factor for esophageal adenocarcinoma"},
	{"id":"Medical-f00f6356","source":"Medical","question":"What combination of factors must be considered in treatment planning for a locoregional esophageal adenocarcinoma at the lower esophagus?","answer":"Treatment planning requires cancer type (adenocarcinoma), location (lower esophagus), and stage (locoregional).","question_type":"Complex Reasoning","evidence":"Treatment planning for locoregional esophageal adenocarcinoma requires cancer type.; Treatment planning for locoregional esophageal adenocarcinoma requires location.; Treatment planning for locoregional esophageal adenocarcinoma requires stage.","evidence_relations":"Treatment planning is based on cancer type, location, and stage; Esophageal adenocarcinoma: Anatomical Location: Lower esophagus, Middle esophagus; Locoregional esophageal cancer has invaded the esophagus wall and/or spread to nearby lymph nodes or organs"},
	{"id":"Medical-c22fc609","source":"Medical","question":"Why must both performance status and nutritional assessment be included in the diagnostic workup for esophageal cancer?","answer":"Both are required to assess patient suitability for treatment and are listed as diagnostic methods.","question_type":"Complex Reasoning","evidence":"Performance status must be included in the diagnostic workup for esophageal cancer.; Nutritional assessment must be included in the diagnostic workup for esophageal cancer.; Both performance status and nutritional assessment are required to assess patient suitability for treatment.; Performance status and nutritional assessment are listed as diagnostic methods.","evidence_relations":"Diagnosis involves blood tests, imaging tests, endoscopy, biopsy, biomarker testing, and genetic risk testing; Nutritional assessment and performance status are diagnostic methods for esophageal cancer"},
	{"id":"Medical-e7ebb96c","source":"Medical","question":"Which diagnostic methods are necessary for confirming both the subtype and stage of esophageal cancer?","answer":"Imaging tests, endoscopy, and biopsy are required to determine both subtype and stage.","question_type":"Complex Reasoning","evidence":"Imaging tests are necessary for confirming the subtype and stage of esophageal cancer.; Endoscopy is necessary for confirming the subtype and stage of esophageal cancer.; Biopsy is necessary for confirming the subtype and stage of esophageal cancer.","evidence_relations":"Diagnosis involves blood tests, imaging tests, endoscopy, biopsy, biomarker testing, and genetic risk testing; Treatment planning is based on cancer type, location, and stage"},
	{"id":"Medical-c7bf38df","source":"Medical","question":"If a tumor is located at the esophagogastric junction, which classification system and factors are used for staging and treatment planning?","answer":"The Siewert classification and factors such as cancer type, location, and stage are used.","question_type":"Complex Reasoning","evidence":"The Siewert classification is used for staging and treatment planning of tumors at the esophagogastric junction.; Factors such as cancer type are used for staging and treatment planning.; Factors such as cancer location are used for staging and treatment planning.; Factors such as cancer stage are used for staging and treatment planning.","evidence_relations":"Siewert types are used to stage tumors at the esophagogastric junction; Treatment planning is based on cancer type, location, and stage; Siewert types (for EGJ tumors) are included in treatment planning"},
	{"id":"Medical-833304f8","source":"Medical","question":"How does the anatomical location of a tumor help distinguish between esophageal squamous cell carcinoma and adenocarcinoma?","answer":"Squamous cell carcinoma is more common in the upper/middle esophagus, while adenocarcinoma is more common in the lower/middle esophagus.","question_type":"Complex Reasoning","evidence":"Esophageal squamous cell carcinoma is more common in the upper esophagus.; Esophageal squamous cell carcinoma is more common in the middle esophagus.; Esophageal adenocarcinoma is more common in the lower esophagus.; Esophageal adenocarcinoma is more common in the middle esophagus.","evidence_relations":"Esophageal squamous cell carcinoma: Anatomical Location: Upper esophagus, Middle esophagus, Lower esophagus; Esophageal adenocarcinoma: Anatomical Location: Lower esophagus, Middle esophagus"},
	{"id":"Medical-efd5b238","source":"Medical","question":"What is the significance of identifying the disease stage in esophageal cancer for determining metastatic sites?","answer":"Disease stage determines if metastasis to organs like liver, lung, bone, and brain has occurred.","question_type":"Complex Reasoning","evidence":"Identifying the disease stage in esophageal cancer is significant for determining metastatic sites.; Disease stage determines if metastasis to the liver has occurred.; Disease stage determines if metastasis to the lung has occurred.; Disease stage determines if metastasis to the bone has occurred.; Disease stage determines if metastasis to the brain has occurred.","evidence_relations":"Disease Stage: Metastatic: Spread to distant organs, including liver, lung, bone, brain, and distant lymph nodes; Metastatic esophageal cancer has spread to distant organs such as liver, lung, bone, and brain"},
	{"id":"Medical-52ca0ffb","source":"Medical","question":"Why are both biomarker testing and genetic risk testing included in the diagnostic process for esophageal cancer?","answer":"Both are needed to identify molecular and inherited factors influencing cancer risk and treatment.","question_type":"Complex Reasoning","evidence":"Biomarker testing is included in the diagnostic process for esophageal cancer.; Genetic risk testing is included in the diagnostic process for esophageal cancer.; Biomarker testing is needed to identify molecular factors influencing cancer risk.; Genetic risk testing is needed to identify inherited factors influencing cancer risk.; Both tests influence treatment decisions.","evidence_relations":"Diagnosis involves blood tests, imaging tests, endoscopy, biopsy, biomarker testing, and genetic risk testing; Biomarker testing and genetic risk testing are diagnostic methods for esophageal cancer"},
	{"id":"Medical-16a39fa8","source":"Medical","question":"What role do anatomical layers of the esophagus play in distinguishing early-stage from locoregional esophageal cancer?","answer":"Early-stage is confined to the esophagus, while locoregional involves invasion through esophageal layers and nearby structures.","question_type":"Complex Reasoning","evidence":"Anatomical layers of the esophagus help distinguish early-stage from locoregional esophageal cancer.; Early-stage esophageal cancer is confined to the esophagus.; Locoregional esophageal cancer involves invasion through esophageal layers.; Locoregional esophageal cancer involves invasion into nearby structures.","evidence_relations":"Early-stage esophageal cancer is contained within the esophagus and not in lymph nodes; Locoregional esophageal cancer has invaded the esophagus wall and/or spread to nearby lymph nodes or organs"},
	{"id":"Medical-a5d38351","source":"Medical","question":"How does the presence of distant metastasis affect treatment planning for esophageal cancer?","answer":"Distant metastasis classifies the cancer as metastatic, which alters treatment planning based on stage.","question_type":"Complex Reasoning","evidence":"The presence of distant metastasis affects treatment planning for esophageal cancer.; Distant metastasis classifies the cancer as metastatic.; The classification of cancer as metastatic alters treatment planning based on stage.","evidence_relations":"Metastatic esophageal cancer has spread to distant organs such as liver, lung, bone, and brain; Treatment planning is based on cancer type, location, and stage"},
	{"id":"Medical-f57e3ab2","source":"Medical","question":"What combination of clinical and pathological features would support a diagnosis of mediastinal gray zone lymphoma (MGZL) in a young male patient?","answer":"A large mediastinal mass, Reed-Sternberg cells, and an age of 20-40 years assigned male at birth support MGZL diagnosis.","question_type":"Complex Reasoning","evidence":"A large mediastinal mass supports a diagnosis of mediastinal gray zone lymphoma (MGZL).; Reed-Sternberg cells support a diagnosis of mediastinal gray zone lymphoma (MGZL).; An age of 20-40 years assigned male at birth supports a diagnosis of mediastinal gray zone lymphoma (MGZL).","evidence_relations":"MGZL is characterized by a large mediastinal mass; Reed-Sternberg cells are characteristic histopathological features in MGZL; MGZL commonly affects individuals aged 20 to 40 years, assigned male at birth"},
	{"id":"Medical-7b682af7","source":"Medical","question":"Which additional therapy may be used alongside chemotherapy for localized MGZL, and under what circumstance?","answer":"Involved-site radiation therapy (ISRT) may be added to chemotherapy in localized MGZL.","question_type":"Complex Reasoning","evidence":"Involved-site radiation therapy (ISRT) may be used alongside chemotherapy for localized MGZL.; ISRT is added to chemotherapy under the circumstance of localized MGZL.","evidence_relations":"Involved-site radiation therapy (ISRT) may be added in localized MGZL; MGZL is usually treated with chemotherapy"},
	{"id":"Medical-def9b488","source":"Medical","question":"Why is expert hematopathologist review crucial in diagnosing MGZL?","answer":"Because diagnosis of MGZL requires expert hematopathologist review due to its overlapping features with PMBL and HL.","question_type":"Complex Reasoning","evidence":"Expert hematopathologist review is crucial in diagnosing MGZL.; The diagnosis of MGZL requires expert hematopathologist review.; MGZL has overlapping features with PMBL.; MGZL has overlapping features with HL.","evidence_relations":"Diagnosis of MGZL requires expert hematopathologist review; Gray zone lymphomas have overlapping features of primary mediastinal B-cell lymphoma (PMBL) and Hodgkin lymphoma (HL)"},
	{"id":"Medical-950b879f","source":"Medical","question":"How does the typical site of involvement differ between mediastinal and non-mediastinal gray zone lymphomas?","answer":"Mediastinal gray zone lymphomas involve the mediastinum and supraclavicular lymph nodes, while non-mediastinal types involve bone marrow and extranodal sites.","question_type":"Complex Reasoning","evidence":"Mediastinal gray zone lymphomas involve the mediastinum.; Mediastinal gray zone lymphomas involve supraclavicular lymph nodes.; Non-mediastinal gray zone lymphomas involve bone marrow.; Non-mediastinal gray zone lymphomas involve extranodal sites.","evidence_relations":"Sites of involvement for MGZL include mediastinum and lymph nodes above the collar bone (supraclavicular); Non-mediastinal gray zone lymphomas occur in older persons and have higher rates of bone marrow and extranodal involvement"},
	{"id":"Medical-35afeb4b","source":"Medical","question":"What treatment modification is made for MGZL patients to enhance chemoimmunotherapy?","answer":"Rituximab may be added to chemotherapy for chemoimmunotherapy in MGZL patients.","question_type":"Complex Reasoning","evidence":"Rituximab may be added to chemotherapy for MGZL patients.; The addition of rituximab enhances chemoimmunotherapy in MGZL patients.","evidence_relations":"Rituximab may be added to chemotherapy for chemoimmunotherapy; MGZL is usually treated with chemotherapy"},
	{"id":"Medical-b9f39886","source":"Medical","question":"What factors distinguish non-mediastinal gray zone lymphomas from mediastinal gray zone lymphomas?","answer":"Non-mediastinal gray zone lymphomas occur in older persons and have more bone marrow and extranodal involvement, unlike mediastinal types seen in younger males.","question_type":"Complex Reasoning","evidence":"Non-mediastinal gray zone lymphomas occur in older persons.; Non-mediastinal gray zone lymphomas have more bone marrow involvement.; Non-mediastinal gray zone lymphomas have more extranodal involvement.; Mediastinal gray zone lymphomas are seen in younger males.","evidence_relations":"Non-mediastinal gray zone lymphomas occur in older persons and have higher rates of bone marrow and extranodal involvement; MGZL commonly affects individuals aged 20 to 40 years, assigned male at birth"},
	{"id":"Medical-6d56985a","source":"Medical","question":"How does the diagnosis of gray zone lymphoma change if there is extra-mediastinal disease?","answer":"If extra-mediastinal disease is present, the diagnosis changes to DLBCL, not otherwise specified (DLBCL-NOS).","question_type":"Complex Reasoning","evidence":"If extra-mediastinal disease is present, the diagnosis changes.; The diagnosis changes to DLBCL, not otherwise specified (DLBCL-NOS) if extra-mediastinal disease is present.","evidence_relations":"If extra-mediastinal disease: Diagnose as DLBCL-NOS; Non-mediastinal gray zone lymphomas occur in older persons and have higher rates of bone marrow and extranodal involvement"},
	{"id":"Medical-f9e22272","source":"Medical","question":"Which two related lymphomas share overlapping features with gray zone lymphomas, complicating diagnosis?","answer":"Primary mediastinal B-cell lymphoma (PMBL) and Hodgkin lymphoma (HL) share overlapping features with gray zone lymphomas.","question_type":"Complex Reasoning","evidence":"Primary mediastinal B-cell lymphoma (PMBL) shares overlapping features with gray zone lymphomas.; Hodgkin lymphoma (HL) shares overlapping features with gray zone lymphomas.","evidence_relations":"Gray zone lymphomas have overlapping features of primary mediastinal B-cell lymphoma (PMBL) and Hodgkin lymphoma (HL); Related Entities for gray zone lymphoma include Primary mediastinal B-cell lymphoma (PMBL) and Hodgkin lymphoma (HL)"},
	{"id":"Medical-efd1af00","source":"Medical","question":"What evidence supports the use of chemoimmunotherapy instead of chemotherapy alone in MGZL?","answer":"Chemoimmunotherapy is supported because rituximab may be added to chemotherapy for MGZL treatment.","question_type":"Complex Reasoning","evidence":"Chemoimmunotherapy is supported for MGZL treatment.; Rituximab may be added to chemotherapy for MGZL treatment.","evidence_relations":"Rituximab may be added to chemotherapy for chemoimmunotherapy; MGZL is usually treated with chemotherapy"},
	{"id":"Medical-dc695a12","source":"Medical","question":"What histopathological finding is essential for diagnosing MGZL, and how is it confirmed?","answer":"Reed-Sternberg cells are essential and diagnosis is confirmed by expert hematopathologist review.","question_type":"Complex Reasoning","evidence":"Reed-Sternberg cells are essential for diagnosing MGZL.; Diagnosis of MGZL is confirmed by expert hematopathologist review.","evidence_relations":"Reed-Sternberg cells are characteristic histopathological features in MGZL; Diagnosis of MGZL requires expert hematopathologist review"},
	{"id":"Medical-34a70628","source":"Medical","question":"Which population is most at risk for developing mediastinal gray zone lymphoma based on epidemiology?","answer":"Individuals aged 20 to 40 years assigned male at birth are most at risk for MGZL.","question_type":"Complex Reasoning","evidence":"Individuals aged 20 to 40 years assigned male at birth are most at risk for MGZL.","evidence_relations":"MGZL commonly affects individuals aged 20 to 40 years, assigned male at birth; Epidemiology of MGZL includes Age 20-40 years and Assigned male at birth"},
	{"id":"Medical-5e3016f9","source":"Medical","question":"What combination of features would indicate a diagnosis of non-mediastinal gray zone lymphoma rather than MGZL?","answer":"Older age, bone marrow or extranodal involvement, and absence of mediastinal mass indicate non-mediastinal gray zone lymphoma.","question_type":"Complex Reasoning","evidence":"Older age indicates non-mediastinal gray zone lymphoma.; Bone marrow involvement indicates non-mediastinal gray zone lymphoma.; Extranodal involvement indicates non-mediastinal gray zone lymphoma.; Absence of mediastinal mass indicates non-mediastinal gray zone lymphoma.","evidence_relations":"Non-mediastinal gray zone lymphomas occur in older persons and have higher rates of bone marrow and extranodal involvement; MGZL is characterized by a large mediastinal mass"},
	{"id":"Medical-e0c754c6","source":"Medical","question":"How does the histopathology of MGZL relate to its clinical presentation?","answer":"MGZL presents with a large mediastinal mass and Reed-Sternberg cells as histopathological features.","question_type":"Complex Reasoning","evidence":"MGZL presents with a large mediastinal mass.; MGZL has Reed-Sternberg cells as histopathological features.","evidence_relations":"MGZL is characterized by a large mediastinal mass; Reed-Sternberg cells are characteristic histopathological features in MGZL"},
	{"id":"Medical-6ac9b753","source":"Medical","question":"What diagnostic methods are required for confirming MGZL and why?","answer":"Expert hematopathologist review is required because of the overlapping features with other lymphomas.","question_type":"Complex Reasoning","evidence":"Expert hematopathologist review is required to confirm MGZL.; MGZL has overlapping features with other lymphomas.","evidence_relations":"Diagnosis of MGZL requires expert hematopathologist review; Gray zone lymphomas have overlapping features of primary mediastinal B-cell lymphoma (PMBL) and Hodgkin lymphoma (HL)"},
	{"id":"Medical-23080670","source":"Medical","question":"If a patient presents with a large mediastinal mass and is assigned male at birth aged 25, what additional diagnostic step is necessary?","answer":"Expert hematopathologist review is necessary to confirm MGZL diagnosis.","question_type":"Complex Reasoning","evidence":"A patient with a large mediastinal mass and assigned male at birth aged 25 requires expert hematopathologist review.; Expert hematopathologist review is necessary to confirm MGZL diagnosis.","evidence_relations":"MGZL is characterized by a large mediastinal mass; MGZL commonly affects individuals aged 20 to 40 years, assigned male at birth; Diagnosis of MGZL requires expert hematopathologist review"},
	{"id":"Medical-bd7c7e1a","source":"Medical","question":"Which patients with recurrent or metastatic cervical cancer are eligible for immunotherapy, and what biomarker guides this decision?","answer":"Patients with recurrent or metastatic cervical cancer who are PD-L1 positive are eligible for immunotherapy such as pembrolizumab.","question_type":"Complex Reasoning","evidence":"Patients with recurrent or metastatic cervical cancer who are PD-L1 positive are eligible for immunotherapy.; Pembrolizumab is an example of immunotherapy for eligible patients.","evidence_relations":"Biomarker testing (e.g., PD-L1, MSI, TMB, MMR, HER2, RET, NTRK) is recommended for recurrent or metastatic cervical cancer; PD-L1 positivity guides the use of immunotherapy (e.g., pembrolizumab); PD-L1 is a biomarker for cervical cancer according to the ontology"},
	{"id":"Medical-92ed141f","source":"Medical","question":"How does the approach to fertility preservation differ between early-stage cervical cancer patients and those with advanced disease?","answer":"Early-stage patients may undergo fertility-sparing surgery or ovarian transposition, while these options are not available for advanced disease.","question_type":"Complex Reasoning","evidence":"Early-stage cervical cancer patients may undergo fertility-sparing surgery.; Early-stage cervical cancer patients may undergo ovarian transposition.; Fertility-sparing surgery and ovarian transposition are not available for advanced disease.","evidence_relations":"Fertility-sparing surgery (e.g., trachelectomy) is an option for selected early-stage cases; Ovarian transposition is listed under fertility preservation in the ontology; Surgery is the main treatment for early-stage cervical cancer; Fertility preservation is not mentioned as an option for advanced stages in the ontology"},
	{"id":"Medical-6428d1f1","source":"Medical","question":"Why is chemoradiation the standard of care for locally advanced cervical cancer rather than surgery?","answer":"Because chemoradiation is recommended for locally advanced cervical cancer, while surgery is the main treatment for early-stage disease.","question_type":"Complex Reasoning","evidence":"Chemoradiation is the standard of care for locally advanced cervical cancer.; Surgery is the main treatment for early-stage cervical cancer.","evidence_relations":"Chemoradiation (concurrent EBRT and platinum-based chemotherapy) is recommended for locally advanced cervical cancer; Surgery is the main treatment for early-stage cervical cancer; Chemoradiation is included under systemic therapy and radiation therapy in the ontology"},
	{"id":"Medical-04e9f25b","source":"Medical","question":"Which imaging modalities are used both for staging and surveillance in cervical cancer management?","answer":"CT scan, MRI, PET/CT, and transvaginal ultrasound are used for staging and can be used for surveillance imaging as indicated.","question_type":"Complex Reasoning","evidence":"CT scan is used for staging and surveillance in cervical cancer management.; MRI is used for staging and surveillance in cervical cancer management.; PET/CT is used for staging and surveillance in cervical cancer management.; Transvaginal ultrasound is used for staging and can be used for surveillance imaging.","evidence_relations":"Imaging methods such as CT, MRI, PET/CT, and transvaginal ultrasound are used for staging and assessment; Surveillance after treatment includes regular physical exams and imaging as indicated; CT scan, MRI, PET/CT, and transvaginal ultrasound are listed as imaging diagnostic methods in the ontology"},
	{"id":"Medical-213bbcca","source":"Medical","question":"What are the main histological subtypes of cervical cancer and how do their frequencies compare?","answer":"Squamous cell carcinoma is the most common, while adenocarcinoma, adenosquamous carcinoma, and NECC are less common or rare.","question_type":"Complex Reasoning","evidence":"Squamous cell carcinoma is the most common histological subtype of cervical cancer.; Adenocarcinoma is less common than squamous cell carcinoma.; Adenosquamous carcinoma is less common than squamous cell carcinoma.; NECC is rare compared to squamous cell carcinoma.","evidence_relations":"Squamous cell carcinoma is the most common subtype of cervical cancer; Adenocarcinoma and adenosquamous carcinoma are less common subtypes; Neuroendocrine carcinoma of the cervix (NECC) is a rare and aggressive subtype; The ontology lists these as subtypes under cervical cancer"},
	{"id":"Medical-e0a5fcc5","source":"Medical","question":"How is high-grade squamous intraepithelial lesion (HSIL) related to cervical cancer progression and diagnosis?","answer":"HSIL corresponds to CIN 2 and 3, is considered pre-cancer, and may be identified by biopsy as part of cervical cancer diagnosis.","question_type":"Complex Reasoning","evidence":"High-grade squamous intraepithelial lesion (HSIL) corresponds to CIN 2 and 3.; HSIL is considered pre-cancer.; HSIL may be identified by biopsy as part of cervical cancer diagnosis.","evidence_relations":"High-grade squamous intraepithelial lesion (HSIL) corresponds to CIN 2 and 3 and is considered pre-cancer; Cervical biopsy is the primary diagnostic method for cervical cancer; Biopsy is listed as a diagnostic method for cervical cancer in the ontology"},
	{"id":"Medical-423d4257","source":"Medical","question":"Which risk factors are shared by cervical cancer and its precursor lesions, and how do they contribute to disease development?","answer":"HPV infection, smoking, and immunosuppression are risk factors for both cervical cancer and cervical dysplasia, contributing to disease progression.","question_type":"Complex Reasoning","evidence":"HPV infection is a risk factor for both cervical cancer and cervical dysplasia.; Smoking is a risk factor for both cervical cancer and cervical dysplasia.; Immunosuppression is a risk factor for both cervical cancer and cervical dysplasia.; These risk factors contribute to disease progression.","evidence_relations":"Most cervical cancers are caused by long-term infection with human papillomavirus (HPV); Smoking increases the risk of cervical cancer; Immunosuppression (e.g., HIV infection) increases the risk of cervical cancer; Cervical dysplasia (CIN) can progress to cervical cancer if untreated; HPV infection, smoking, and immunosuppression are listed as risk factors for cervical cancer in the ontology"},
	{"id":"Medical-68ea8206","source":"Medical","question":"What is the relationship between Pap smear screening and the detection of cervical dysplasia and cancer?","answer":"Pap smear is used for cervical cancer screening and can detect cervical dysplasia, which may progress to cancer if untreated.","question_type":"Complex Reasoning","evidence":"Pap smear is used for cervical cancer screening.; Pap smear can detect cervical dysplasia.; Cervical dysplasia may progress to cancer if untreated.","evidence_relations":"Pap smear is used for cervical cancer screening; Cervical dysplasia (CIN) can progress to cervical cancer if untreated; Pap smear is listed as a screening diagnostic method for cervical cancer in the ontology"},
	{"id":"Medical-e2ac8ec4","source":"Medical","question":"How does the addition of bevacizumab to chemotherapy alter the management of metastatic cervical cancer?","answer":"Bevacizumab may be added to chemotherapy to improve outcomes in metastatic cervical cancer.","question_type":"Complex Reasoning","evidence":"Bevacizumab may be added to chemotherapy.; The addition of bevacizumab aims to improve outcomes in metastatic cervical cancer.","evidence_relations":"Bevacizumab may be added to chemotherapy for metastatic cervical cancer; Systemic therapy options include platinum-based chemotherapy, targeted therapy, and immunotherapy; Bevacizumab is listed as a systemic therapy for cervical cancer in the ontology"},
	{"id":"Medical-413d4c7e","source":"Medical","question":"What are the main symptoms prompting diagnostic evaluation for cervical cancer, and which diagnostic methods confirm the diagnosis?","answer":"Symptoms like watery vaginal discharge, pelvic pain, and abnormal vaginal bleeding prompt evaluation, confirmed by cervical biopsy.","question_type":"Complex Reasoning","evidence":"Symptoms prompting diagnostic evaluation for cervical cancer include watery vaginal discharge.; Symptoms prompting diagnostic evaluation for cervical cancer include pelvic pain.; Symptoms prompting diagnostic evaluation for cervical cancer include abnormal vaginal bleeding.; Cervical biopsy confirms the diagnosis of cervical cancer.","evidence_relations":"Watery vaginal discharge, pelvic pain, and abnormal vaginal bleeding are symptoms of cervical cancer; Cervical biopsy is the primary diagnostic method for cervical cancer; These symptoms and diagnostic methods are listed for cervical cancer in the ontology"},
	{"id":"Medical-f63520dd","source":"Medical","question":"What is the role of supportive and palliative care in advanced or metastatic cervical cancer management?","answer":"Supportive and palliative care are integral for advanced or metastatic cervical cancer to manage symptoms and improve quality of life.","question_type":"Complex Reasoning","evidence":"Supportive care is integral for advanced cervical cancer management.; Palliative care is integral for advanced cervical cancer management.; Supportive and palliative care help manage symptoms.; Supportive and palliative care improve quality of life.","evidence_relations":"Supportive care and palliative care are integral for advanced or metastatic disease; Supportive care and palliative care are listed as treatments for cervical cancer in the ontology"},
	{"id":"Medical-8307a348","source":"Medical","question":"Which surgical procedures are available for early-stage cervical cancer, and how do they relate to fertility preservation?","answer":"Cone biopsy and trachelectomy are surgical options for early-stage disease, with trachelectomy serving as a fertility-sparing procedure.","question_type":"Complex Reasoning","evidence":"Cone biopsy is a surgical option for early-stage cervical cancer.; Trachelectomy is a surgical option for early-stage cervical cancer.; Trachelectomy serves as a fertility-sparing procedure.","evidence_relations":"Cone biopsy can be both diagnostic and therapeutic for early-stage cervical cancer; Fertility-sparing surgery (e.g., trachelectomy) is an option for selected early-stage cases; Cone biopsy and trachelectomy are listed as surgical procedures for cervical cancer in the ontology"},
	{"id":"Medical-86e095c3","source":"Medical","question":"How does smoking status influence both the risk and treatment outcomes of cervical cancer?","answer":"Smoking increases the risk of cervical cancer, and smoking cessation improves treatment outcomes.","question_type":"Complex Reasoning","evidence":"Smoking increases the risk of cervical cancer.; Smoking cessation improves treatment outcomes for cervical cancer.","evidence_relations":"Smoking increases the risk of cervical cancer; Smoking cessation improves treatment outcomes; Smoking is listed as a risk factor for cervical cancer in the ontology"},
	{"id":"Medical-02d254bc","source":"Medical","question":"For which stages of cervical cancer is surgery the primary treatment, and when is chemoradiation preferred?","answer":"Surgery is primary for early-stage cervical cancer, while chemoradiation is preferred for locally advanced stages.","question_type":"Complex Reasoning","evidence":"Surgery is the primary treatment for early-stage cervical cancer.; Chemoradiation is preferred for locally advanced stages of cervical cancer.","evidence_relations":"Surgery is the main treatment for early-stage cervical cancer; Chemoradiation (concurrent EBRT and platinum-based chemotherapy) is recommended for locally advanced cervical cancer; The ontology lists surgical procedures and chemoradiation as treatments for cervical cancer by stage"},
	{"id":"Medical-83eb6b6b","source":"Medical","question":"What follow-up methods are recommended after cervical cancer treatment, and how do they help in surveillance?","answer":"Regular physical exams, imaging as indicated, Pap testing, and blood tests are recommended for surveillance after treatment.","question_type":"Complex Reasoning","evidence":"Regular physical exams are recommended for surveillance after cervical cancer treatment.; Imaging as indicated is recommended for surveillance after cervical cancer treatment.; Pap testing is recommended for surveillance after cervical cancer treatment.; Blood tests are recommended for surveillance after cervical cancer treatment.","evidence_relations":"Surveillance after treatment includes regular physical exams and imaging as indicated; Follow-up in the ontology includes physical exam, imaging, Pap testing, and blood tests"},
	{"id":"Medical-df78005a","source":"Medical","question":"How can you distinguish between classic Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma based on cell morphology?","answer":"Classic Hodgkin lymphoma has Reed-Sternberg cells, while nodular lymphocyte-predominant Hodgkin lymphoma has popcorn-shaped cells.","question_type":"Complex Reasoning","evidence":"Classic Hodgkin lymphoma has Reed-Sternberg cells.; Nodular lymphocyte-predominant Hodgkin lymphoma has popcorn-shaped cells.","evidence_relations":"CHL is characterized by Reed-Sternberg cells; NLPHL is characterized by popcorn-shaped cells"},
	{"id":"Medical-f8e45373","source":"Medical","question":"Which subtype of Hodgkin lymphoma is most likely to transform into diffuse large B-cell lymphoma, and how is this subtype identified?","answer":"Nodular lymphocyte-predominant Hodgkin lymphoma can transform into diffuse large B-cell lymphoma and is identified by popcorn-shaped cells.","question_type":"Complex Reasoning","evidence":"Nodular lymphocyte-predominant Hodgkin lymphoma can transform into diffuse large B-cell lymphoma.; Nodular lymphocyte-predominant Hodgkin lymphoma is identified by popcorn-shaped cells.","evidence_relations":"NLPHL is characterized by popcorn-shaped cells; NLPHL can transform into diffuse large B-cell lymphoma (DLBCL)"},
	{"id":"Medical-b503f3f3","source":"Medical","question":"What combination of diagnostic methods is typically used to confirm Hodgkin lymphoma and assess its extent?","answer":"Excisional lymph node biopsy, blood tests, and imaging tests are used together for diagnosis and staging.","question_type":"Complex Reasoning","evidence":"Excisional lymph node biopsy is used to confirm Hodgkin lymphoma.; Blood tests are used to confirm Hodgkin lymphoma.; Imaging tests are used to confirm Hodgkin lymphoma.; These methods are used together for diagnosis and staging.","evidence_relations":"Diagnosis of Hodgkin lymphoma is made by excisional lymph node biopsy; Blood tests and imaging tests are used in the diagnostic workup"},
	{"id":"Medical-705f9e89","source":"Medical","question":"If a patient aged 25 presents with swollen lymph nodes in the upper body, what cancer type should be highly suspected and why?","answer":"Hodgkin lymphoma should be suspected because it usually starts in upper body lymph nodes and is common between ages 15 to 30.","question_type":"Complex Reasoning","evidence":"Hodgkin lymphoma should be suspected in a patient aged 25 with swollen lymph nodes in the upper body.; Hodgkin lymphoma usually starts in upper body lymph nodes.; Hodgkin lymphoma is common between ages 15 to 30.","evidence_relations":"Hodgkin lymphoma usually starts in lymph nodes in the upper body; Most people are diagnosed between ages 15 to 30 or after age 55"},
	{"id":"Medical-8779d729","source":"Medical","question":"What are the main differences in cell type and disease progression risk between classic Hodgkin lymphoma and NLPHL?","answer":"Classic Hodgkin lymphoma has Reed-Sternberg cells and is the most common subtype, while NLPHL has popcorn-shaped cells and can transform into DLBCL.","question_type":"Complex Reasoning","evidence":"Classic Hodgkin lymphoma has Reed-Sternberg cells.; Classic Hodgkin lymphoma is the most common subtype.; Nodular lymphocyte-predominant Hodgkin lymphoma has popcorn-shaped cells.; Nodular lymphocyte-predominant Hodgkin lymphoma can transform into diffuse large B-cell lymphoma.","evidence_relations":"Classic Hodgkin lymphoma (CHL) is the most common subtype of Hodgkin lymphoma; CHL is characterized by Reed-Sternberg cells; NLPHL is characterized by popcorn-shaped cells; NLPHL can transform into diffuse large B-cell lymphoma (DLBCL)"},
	{"id":"Medical-f7300f3c","source":"Medical","question":"Which diagnostic methods are shared between classic Hodgkin lymphoma and NLPHL, and what does this suggest about their diagnostic process?","answer":"Both use excisional lymph node biopsy, core needle biopsy, health history, physical exam, blood tests, and imaging tests, indicating a similar diagnostic process.","question_type":"Complex Reasoning","evidence":"Both classic Hodgkin lymphoma and NLPHL use excisional lymph node biopsy.; Both classic Hodgkin lymphoma and NLPHL use core needle biopsy.; Both classic Hodgkin lymphoma and NLPHL use health history in diagnosis.; Both classic Hodgkin lymphoma and NLPHL use physical exams in diagnosis.; Both classic Hodgkin lymphoma and NLPHL use blood tests in diagnosis.; Both classic Hodgkin lymphoma and NLPHL use imaging tests in diagnosis.; This suggests a similar diagnostic process for both types.","evidence_relations":"Classic Hodgkin lymphoma (CHL): Diagnostic Method: excisional lymph node biopsy, core needle biopsy, health history, physical exam, blood tests, imaging tests; Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL): Diagnostic Method: excisional lymph node biopsy, core needle biopsy, health history, physical exam, blood tests, imaging tests"},
	{"id":"Medical-c31057de","source":"Medical","question":"What evidence supports the use of both health history and physical exam in the diagnostic workup for Hodgkin lymphoma?","answer":"Health history and physical exam are part of the diagnostic process for Hodgkin lymphoma and are included in the diagnostic methods for both CHL and NLPHL.","question_type":"Complex Reasoning","evidence":"Health history is part of the diagnostic process for Hodgkin lymphoma.; Physical exam is part of the diagnostic process for Hodgkin lymphoma.; Health history and physical exam are included in the diagnostic methods for both classic Hodgkin lymphoma and NLPHL.","evidence_relations":"Health history and physical exam are part of the diagnostic process; Classic Hodgkin lymphoma (CHL): Diagnostic Method: health history, physical exam; Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL): Diagnostic Method: health history, physical exam"},
	{"id":"Medical-45173331","source":"Medical","question":"How does the age of onset relate to the risk factors for Hodgkin lymphoma according to the ontology?","answer":"Ages 15 to 30 and after age 55 are risk factors for Hodgkin lymphoma, matching the typical age of diagnosis.","question_type":"Complex Reasoning","evidence":"Ages 15 to 30 are risk factors for Hodgkin lymphoma.; Ages over 55 are risk factors for Hodgkin lymphoma.; These ages match the typical age of diagnosis for Hodgkin lymphoma.","evidence_relations":"Most people are diagnosed between ages 15 to 30 or after age 55; Risk Factor: ages 15 to 30, age 55"},
	{"id":"Medical-1930c305","source":"Medical","question":"What features distinguish Hodgkin lymphoma from other lymphomas based on the ontology and relations provided?","answer":"Hodgkin lymphoma is defined by its subtypes (CHL and NLPHL), characteristic cell types (Reed-Sternberg or popcorn-shaped cells), and typical onset in upper body lymph nodes.","question_type":"Complex Reasoning","evidence":"Hodgkin lymphoma is defined by its subtypes, which are classic Hodgkin lymphoma and NLPHL.; Hodgkin lymphoma is characterized by Reed-Sternberg cells or popcorn-shaped cells.; Hodgkin lymphoma typically has an onset in upper body lymph nodes.","evidence_relations":"Hodgkin lymphoma is a type of lymphoma; Classic Hodgkin lymphoma (CHL) is the most common subtype of Hodgkin lymphoma; NLPHL is a rare subtype of Hodgkin lymphoma; CHL is characterized by Reed-Sternberg cells; NLPHL is characterized by popcorn-shaped cells; Hodgkin lymphoma usually starts in lymph nodes in the upper body"},
	{"id":"Medical-9d34bcac","source":"Medical","question":"Which subtype of Hodgkin lymphoma is less common, and what unique risk does it carry compared to the common subtype?","answer":"Nodular lymphocyte-predominant Hodgkin lymphoma is less common and can transform into diffuse large B-cell lymphoma, unlike the classic subtype.","question_type":"Complex Reasoning","evidence":"Nodular lymphocyte-predominant Hodgkin lymphoma is less common than classic Hodgkin lymphoma.; Nodular lymphocyte-predominant Hodgkin lymphoma can transform into diffuse large B-cell lymphoma.; Classic Hodgkin lymphoma does not carry the same risk of transformation.","evidence_relations":"Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subtype of Hodgkin lymphoma; NLPHL can transform into diffuse large B-cell lymphoma (DLBCL)"},
	{"id":"Medical-68694b91","source":"Medical","question":"Why might a core needle biopsy be chosen over an excisional lymph node biopsy in Hodgkin lymphoma diagnosis?","answer":"Core needle biopsy may be used in some cases as an alternative to excisional lymph node biopsy for diagnosis.","question_type":"Complex Reasoning","evidence":"Core needle biopsy may be used as an alternative to excisional lymph node biopsy.; Core needle biopsy can be chosen in some cases for Hodgkin lymphoma diagnosis.","evidence_relations":"Diagnosis of Hodgkin lymphoma is made by excisional lymph node biopsy; Core needle biopsy may be used for diagnosis in some cases"},
	{"id":"Medical-9bc8aaa1","source":"Medical","question":"What findings from both the patient's age and the location of lymph node involvement would increase suspicion for Hodgkin lymphoma?","answer":"A patient aged 15-30 or over 55 with lymph node involvement in the upper body increases suspicion for Hodgkin lymphoma.","question_type":"Complex Reasoning","evidence":"A patient aged 15-30 with lymph node involvement in the upper body increases suspicion for Hodgkin lymphoma.; A patient over 55 with lymph node involvement in the upper body increases suspicion for Hodgkin lymphoma.","evidence_relations":"Most people are diagnosed between ages 15 to 30 or after age 55; Hodgkin lymphoma usually starts in lymph nodes in the upper body"},
	{"id":"Medical-b2a64d4a","source":"Medical","question":"Which cell type is diagnostic for the most common subtype of Hodgkin lymphoma, and how is this subtype classified in the ontology?","answer":"Reed-Sternberg cells are diagnostic for classic Hodgkin lymphoma, which is the most common subtype of Hodgkin lymphoma.","question_type":"Complex Reasoning","evidence":"Reed-Sternberg cells are diagnostic for classic Hodgkin lymphoma.; Classic Hodgkin lymphoma is the most common subtype of Hodgkin lymphoma.","evidence_relations":"Classic Hodgkin lymphoma (CHL) is the most common subtype of Hodgkin lymphoma; CHL is characterized by Reed-Sternberg cells"},
	{"id":"Medical-4b359d87","source":"Medical","question":"If a patient's lymph node biopsy reveals popcorn-shaped cells, what is the diagnosis and what is a potential complication?","answer":"The diagnosis is nodular lymphocyte-predominant Hodgkin lymphoma, which can transform into diffuse large B-cell lymphoma.","question_type":"Complex Reasoning","evidence":"The diagnosis is nodular lymphocyte-predominant Hodgkin lymphoma.; Nodular lymphocyte-predominant Hodgkin lymphoma can transform into diffuse large B-cell lymphoma.","evidence_relations":"NLPHL is characterized by popcorn-shaped cells; NLPHL can transform into diffuse large B-cell lymphoma (DLBCL)"},
	{"id":"Medical-5459ea22","source":"Medical","question":"Why is a tumor classified as Tis (carcinoma in situ) in intrahepatic bile duct cancer only found in the epithelium and not in deeper layers?","answer":"Because Tis tumors are intraductal and confined to the epithelium, not invading lamina propria or deeper layers.","question_type":"Complex Reasoning","evidence":"Tis tumors are intraductal.; Tis tumors are confined to the epithelium.; Tis tumors do not invade lamina propria or deeper layers.","evidence_relations":"Tis (carcinoma in situ) is an intraductal tumor confined to the epithelium; The gallbladder and bile ducts are lined by a thin, moist epithelial layer; Intrahepatic bile duct cancer Tis tumors are described as carcinoma in situ and confined to epithelium"},
	{"id":"Medical-f25adcc2","source":"Medical","question":"If a primary tumor in intrahepatic bile duct cancer is found in the perimuscular fibrous tissue, why can it not be staged as Tis?","answer":"Because Tis is defined as a tumor confined to the epithelium, and perimuscular fibrous tissue is a deeper layer.","question_type":"Complex Reasoning","evidence":"Tis is defined as a tumor confined to the epithelium.; Perimuscular fibrous tissue is a deeper layer.","evidence_relations":"Tis (carcinoma in situ) is an intraductal tumor confined to the epithelium; Perimuscular fibrous tissue surrounds the muscle layer; The bile duct wall consists of epithelium, lamina propria, muscularis, perimuscular fibrous tissue, and serosa"},
	{"id":"Medical-904e0a11","source":"Medical","question":"How does the anatomical structure of the bile duct relate to the spread of cancer to the liver?","answer":"The bile duct is composed of several layers, and cancer can invade through these layers into the liver.","question_type":"Complex Reasoning","evidence":"The bile duct is composed of several layers.; Cancer can invade through the layers of the bile duct into the liver.","evidence_relations":"The bile duct wall consists of epithelium, lamina propria, muscularis, perimuscular fibrous tissue, and serosa; Cancer can invade nearby blood vessels, liver, or structures outside the liver"},
	{"id":"Medical-3c536762","source":"Medical","question":"Why is tumor size and extent of spread important in staging bile duct cancer?","answer":"Because bile duct cancer staging is based on tumor size and how far it has spread beyond the original location.","question_type":"Complex Reasoning","evidence":"Bile duct cancer staging is based on tumor size.; Bile duct cancer staging is based on how far the tumor has spread beyond the original location.","evidence_relations":"Bile duct cancer staging is based on tumor size and extent of spread; Tumor Characteristic includes primary tumor size (cm or mm) and spread to blood vessels, liver, or structures outside the liver"},
	{"id":"Medical-aacc98ed","source":"Medical","question":"What histological layers must a tumor penetrate to reach the serosa from the epithelium in the bile duct?","answer":"A tumor must penetrate the lamina propria, muscularis, and perimuscular fibrous tissue to reach the serosa from the epithelium.","question_type":"Complex Reasoning","evidence":"A tumor must penetrate the lamina propria to reach the serosa from the epithelium.; A tumor must penetrate the muscularis to reach the serosa from the epithelium.; A tumor must penetrate the perimuscular fibrous tissue to reach the serosa from the epithelium.","evidence_relations":"The bile duct wall consists of epithelium, lamina propria, muscularis, perimuscular fibrous tissue, and serosa; Lamina propria is a connective tissue found under the epithelium; Muscularis is a soft tissue layer in the bile duct wall; Perimuscular fibrous tissue surrounds the muscle layer"},
	{"id":"Medical-7bf81d77","source":"Medical","question":"Why does carcinoma in situ not involve spread to blood vessels or the liver?","answer":"Because carcinoma in situ is by definition confined to the epithelium and does not invade deeper tissues or structures.","question_type":"Complex Reasoning","evidence":"Carcinoma in situ is confined to the epithelium.; Carcinoma in situ does not invade deeper tissues or structures.","evidence_relations":"Tis (carcinoma in situ) is an intraductal tumor confined to the epithelium; Tumor Characteristic includes spread to blood vessels and liver for advanced stages"},
	{"id":"Medical-6e39cbe0","source":"Medical","question":"Which anatomical layer acts as a barrier before cancer reaches the outer membrane (serosa) of the gallbladder?","answer":"The perimuscular fibrous tissue acts as a barrier before the serosa.","question_type":"Complex Reasoning","evidence":"The perimuscular fibrous tissue acts as a barrier before the serosa.","evidence_relations":"Perimuscular fibrous tissue surrounds the muscle layer; Serosa is the outer membrane covering the gallbladder and bile ducts; The gallbladder wall consists of epithelium, lamina propria, muscularis, perimuscular fibrous tissue, and serosa"},
	{"id":"Medical-41284331","source":"Medical","question":"If a tumor is described as intraductal and confined to the epithelium, what stage and tumor characteristic does it correspond to in intrahepatic bile duct cancer?","answer":"It corresponds to Tis stage and carcinoma in situ tumor characteristic.","question_type":"Complex Reasoning","evidence":"A tumor described as intraductal and confined to the epithelium corresponds to Tis stage.; A tumor described as intraductal and confined to the epithelium corresponds to carcinoma in situ tumor characteristic.","evidence_relations":"Tis (carcinoma in situ) is an intraductal tumor confined to the epithelium; Intrahepatic bile duct cancer Tis tumors are described as carcinoma in situ and confined to epithelium"},
	{"id":"Medical-f078c897","source":"Medical","question":"Why is the lamina propria not included in the definition of carcinoma in situ for intrahepatic bile duct cancer?","answer":"Because carcinoma in situ is restricted to the epithelium, and the lamina propria is a connective tissue beneath it.","question_type":"Complex Reasoning","evidence":"Carcinoma in situ is restricted to the epithelium.; The lamina propria is a connective tissue beneath the epithelium.; The lamina propria is not included in the definition of carcinoma in situ.","evidence_relations":"Tis (carcinoma in situ) is an intraductal tumor confined to the epithelium; Lamina propria is a connective tissue found under the epithelium"},
	{"id":"Medical-7c1c087a","source":"Medical","question":"How does the presence of serosa impact the potential for cancer to spread outside the gallbladder or bile duct?","answer":"The serosa acts as the last anatomical barrier before cancer can spread to structures outside the organ.","question_type":"Complex Reasoning","evidence":"The serosa acts as the last anatomical barrier.; The serosa prevents cancer from spreading to structures outside the organ.","evidence_relations":"Serosa is the outer membrane covering the gallbladder and bile ducts; Cancer can invade nearby blood vessels, liver, or structures outside the liver"},
	{"id":"Medical-787b9c0b","source":"Medical","question":"If a tumor in the bile duct is only found in the muscularis layer, how does this affect its staging compared to a tumor confined to the epithelium?","answer":"A tumor in the muscularis is a more advanced stage than one confined to the epithelium (Tis).","question_type":"Complex Reasoning","evidence":"A tumor in the muscularis layer is a more advanced stage than one confined to the epithelium.; A tumor confined to the epithelium is classified as Tis.","evidence_relations":"Tis (carcinoma in situ) is an intraductal tumor confined to the epithelium; Muscularis is a soft tissue layer in the bile duct wall; The bile duct wall consists of epithelium, lamina propria, muscularis, perimuscular fibrous tissue, and serosa"},
	{"id":"Medical-a0c1c9cd","source":"Medical","question":"Why is the anatomical knowledge of layers like lamina propria and muscularis important for understanding tumor invasion in bile duct cancer?","answer":"Because the depth of tumor invasion into these layers determines the cancer stage and treatment approach.","question_type":"Complex Reasoning","evidence":"The depth of tumor invasion into anatomical layers determines the cancer stage.; The depth of tumor invasion into anatomical layers affects the treatment approach.","evidence_relations":"Bile duct cancer staging is based on tumor size and extent of spread; The bile duct wall consists of epithelium, lamina propria, muscularis, perimuscular fibrous tissue, and serosa"},
	{"id":"Medical-c5b8734d","source":"Medical","question":"What distinguishes carcinoma in situ from invasive bile duct cancer based on histological layers?","answer":"Carcinoma in situ is confined to the epithelium, while invasive cancer penetrates deeper layers such as lamina propria and beyond.","question_type":"Complex Reasoning","evidence":"Carcinoma in situ is confined to the epithelium.; Invasive bile duct cancer penetrates deeper layers such as lamina propria and beyond.","evidence_relations":"Tis (carcinoma in situ) is an intraductal tumor confined to the epithelium; The bile duct wall consists of epithelium, lamina propria, muscularis, perimuscular fibrous tissue, and serosa"},
	{"id":"Medical-56f4cb0b","source":"Medical","question":"How does the involvement of blood vessels or liver affect the classification of bile duct cancer compared to a tumor confined to the epithelium?","answer":"Involvement of blood vessels or liver indicates a higher stage than a tumor confined to the epithelium (Tis).","question_type":"Complex Reasoning","evidence":"Involvement of blood vessels or liver indicates a higher stage of bile duct cancer.; A tumor confined to the epithelium is classified as Tis.","evidence_relations":"Tumor Characteristic includes spread to blood vessels and liver; Tis (carcinoma in situ) is an intraductal tumor confined to the epithelium"},
	{"id":"Medical-7f3beb74","source":"Medical","question":"If a tumor spreads through all histological layers of the bile duct, which anatomical structures could it potentially invade next?","answer":"It could invade nearby blood vessels, the liver, or structures outside the liver.","question_type":"Complex Reasoning","evidence":"A tumor that spreads through all histological layers of the bile duct could invade nearby blood vessels.; A tumor that spreads could invade the liver.; A tumor that spreads could invade structures outside the liver.","evidence_relations":"The bile duct wall consists of epithelium, lamina propria, muscularis, perimuscular fibrous tissue, and serosa; Cancer can invade nearby blood vessels, liver, or structures outside the liver"},
	{"id":"Medical-2d14639d","source":"Medical","question":"How does the grade of follicular lymphoma influence its classification and treatment approach?","answer":"Grades 1 and 2 are classified as classic FL and treated accordingly, while grade 3B is classified and treated as DLBCL.","question_type":"Complex Reasoning","evidence":"Grades 1 and 2 of follicular lymphoma are classified as classic FL.; Grades 1 and 2 of follicular lymphoma are treated accordingly.; Grade 3B of follicular lymphoma is classified and treated as DLBCL.","evidence_relations":"Grades 1 and 2 FL are classified as classic FL (cFL) according to ICC; Grade 3B FL is treated as DLBCL; The type of cells in FL determines the grade, which guides treatment decisions"},
	{"id":"Medical-1e1b5f1d","source":"Medical","question":"What diagnostic procedures are necessary to confirm follicular lymphoma and why are multiple methods required?","answer":"Diagnosis requires blood tests, bone marrow aspirate and biopsy, imaging studies, and immunophenotyping to fully characterize the disease.","question_type":"Complex Reasoning","evidence":"Diagnosis of follicular lymphoma requires blood tests.; Diagnosis requires a bone marrow aspirate and biopsy.; Diagnosis requires imaging studies.; Diagnosis requires immunophenotyping to fully characterize the disease.","evidence_relations":"Diagnosis of FL involves blood tests, bone marrow aspirate and biopsy, imaging studies, and immunophenotyping; Follicular lymphoma (FL) is a slow-growing B-cell non-Hodgkin lymphoma; FL develops from abnormal B lymphocytes forming clusters in lymph nodes and other tissues"},
	{"id":"Medical-a660735d","source":"Medical","question":"Why might a patient with pediatric-type follicular lymphoma present differently from an adult with classic FL?","answer":"PTFL usually presents with a single enlarged lymph node and minimal symptoms, unlike classic FL which may have widespread lymphadenopathy and B symptoms.","question_type":"Complex Reasoning","evidence":"Pediatric-type follicular lymphoma usually presents with a single enlarged lymph node.; Pediatric-type follicular lymphoma usually presents with minimal symptoms.; Classic follicular lymphoma may have widespread lymphadenopathy.; Classic follicular lymphoma may have B symptoms.","evidence_relations":"Pediatric-type FL (PTFL) usually presents with a single enlarged lymph node in the head and neck and minimal symptoms; Symptoms of FL include swollen lymph nodes, enlarged spleen, fever, night sweats, fatigue, and weight loss (B symptoms); classic FL (cFL) is the classification for most adult FL"},
	{"id":"Medical-4a4eaab8","source":"Medical","question":"How does the presence or absence of the t(14;18) translocation affect the classification of follicular lymphoma?","answer":"FL cases lacking t(14;18) or with uncommon pathologic features are classified as uncommon FL (uFL) but are treated as classic FL.","question_type":"Complex Reasoning","evidence":"FL cases lacking t(14;18) are classified as uncommon FL (uFL).; FL cases with uncommon pathologic features are classified as uncommon FL (uFL).; Uncommon FL (uFL) is treated as classic FL.","evidence_relations":"Uncommon FL (uFL) is t(14;18)-negative or has uncommon pathologic features and is treated as classic FL; Almost all FL cases have a chromosome translocation or excess BCL2 protein; Genetic Alteration of uncommon FL (uFL) is t(14;18)-negative"},
	{"id":"Medical-37f18801","source":"Medical","question":"What features distinguish grade 3A from grade 3B follicular lymphoma in terms of treatment?","answer":"Grade 3A FL may be treated as classic FL or as DLBCL, while grade 3B FL is always treated as DLBCL.","question_type":"Complex Reasoning","evidence":"Grade 3A FL may be treated as classic FL.; Grade 3A FL may be treated as DLBCL.; Grade 3B FL is always treated as DLBCL.","evidence_relations":"Grade 3A FL may be treated as classic FL or as diffuse large B-cell lymphoma (DLBCL); Grade 3B FL is treated as DLBCL; Grade 3A and 3B differ in classification and management"},
	{"id":"Medical-d7e8bc97","source":"Medical","question":"Which symptoms would raise suspicion for advanced follicular lymphoma involving multiple disease sites?","answer":"Swollen lymph nodes, enlarged spleen, fever, night sweats, fatigue, and weight loss suggest advanced FL involving lymph nodes, spleen, and possibly bone marrow.","question_type":"Complex Reasoning","evidence":"Swollen lymph nodes suggest advanced follicular lymphoma.; Enlarged spleen suggests advanced follicular lymphoma.; Fever suggests advanced follicular lymphoma.; Night sweats suggest advanced follicular lymphoma.; Fatigue suggests advanced follicular lymphoma.; Weight loss suggests advanced follicular lymphoma.; Advanced follicular lymphoma may involve lymph nodes, spleen, and possibly bone marrow.","evidence_relations":"Symptoms of FL include swollen lymph nodes, enlarged spleen, fever, night sweats, fatigue, and weight loss (B symptoms); FL can present as nodal or extranodal disease; Disease Site of FL includes lymph node, bone marrow, spleen, extranodal sites"},
	{"id":"Medical-6a5c89f3","source":"Medical","question":"Why do not all patients with follicular lymphoma require immediate treatment upon diagnosis?","answer":"Because clinical management guidelines state not all patients require immediate treatment and treatment decisions are guided by grade and cell type.","question_type":"Complex Reasoning","evidence":"Not all patients with follicular lymphoma require immediate treatment upon diagnosis.; Clinical management guidelines state that treatment decisions are guided by grade.; Clinical management guidelines state that treatment decisions are guided by cell type.","evidence_relations":"Not all patients with FL require immediate treatment; Treatment decisions are guided by grade and cell type; Follicular lymphoma (FL) is a slow-growing B-cell non-Hodgkin lymphoma"},
	{"id":"Medical-c76b58b2","source":"Medical","question":"How is the transformation of follicular lymphoma into a more aggressive disease identified and classified?","answer":"Transformation is identified by the development of DLBCL from FL, which is classified as transformed FL.","question_type":"Complex Reasoning","evidence":"Transformation of follicular lymphoma is identified by the development of DLBCL from FL.; Transformed FL is classified as transformed FL.","evidence_relations":"FL can transform into DLBCL, a more aggressive lymphoma; transformed FL: Transformation is to diffuse large B-cell lymphoma (DLBCL); DLBCL is a distinct classification in the ontology"},
	{"id":"Medical-fb234ffb","source":"Medical","question":"What is the significance of BCL2 protein in the diagnosis or classification of follicular lymphoma?","answer":"BCL2 protein is a biomarker found in almost all FL cases, often due to chromosome translocation, and helps confirm the diagnosis.","question_type":"Complex Reasoning","evidence":"BCL2 protein is a biomarker found in almost all follicular lymphoma cases.; BCL2 protein is often due to chromosome translocation.; BCL2 protein helps confirm the diagnosis of follicular lymphoma.","evidence_relations":"Almost all FL cases have a chromosome translocation or excess BCL2 protein; Biomarker of FL is BCL2 protein; Genetic Alteration of FL includes chromosome translocation, t(14;18)"},
	{"id":"Medical-0030eab4","source":"Medical","question":"What combination of cell types is used to determine the grade of follicular lymphoma and how does this affect management?","answer":"The proportion of centrocytes and centroblasts determines the grade, which guides treatment decisions.","question_type":"Complex Reasoning","evidence":"The proportion of centrocytes determines the grade of follicular lymphoma.; The proportion of centroblasts determines the grade of follicular lymphoma.; The grade of follicular lymphoma guides treatment decisions.","evidence_relations":"FL is graded based on the proportion of centrocytes and centroblasts; The type of cells in FL determines the grade, which guides treatment decisions; Grade 1 and 2 FL have both centrocytes and centroblasts, while grade 3B has only centroblasts"},
	{"id":"Medical-f9bc1472","source":"Medical","question":"If a patient presents with a single enlarged lymph node in the head and neck and minimal symptoms, which FL subtype is most likely, and what is its typical genetic status?","answer":"Pediatric-type FL (PTFL) is most likely, typically lacking the t(14;18) translocation.","question_type":"Complex Reasoning","evidence":"Pediatric-type FL (PTFL) is most likely if a patient presents with a single enlarged lymph node in the head and neck.; Pediatric-type FL (PTFL) typically lacks the t(14;18) translocation.","evidence_relations":"Pediatric-type FL (PTFL) usually presents with a single enlarged lymph node in the head and neck and minimal symptoms; Genetic Alteration of uncommon FL (uFL) is t(14;18)-negative; PTFL is a distinct cancer subtype in the ontology"},
	{"id":"Medical-3aa8a2c6","source":"Medical","question":"How does the site of disease involvement influence the presentation of follicular lymphoma symptoms?","answer":"Involvement of lymph nodes, spleen, and bone marrow leads to symptoms such as swollen lymph nodes, enlarged spleen, and B symptoms.","question_type":"Complex Reasoning","evidence":"Involvement of lymph nodes leads to symptoms of follicular lymphoma.; Involvement of the spleen leads to symptoms of follicular lymphoma.; Involvement of bone marrow leads to symptoms of follicular lymphoma.; Symptoms of follicular lymphoma include swollen lymph nodes, enlarged spleen, and B symptoms.","evidence_relations":"Disease Site of FL includes lymph node, bone marrow, spleen, extranodal sites; Symptoms of FL include swollen lymph nodes, enlarged spleen, fever, night sweats, fatigue, and weight loss (B symptoms)"},
	{"id":"Medical-96508468","source":"Medical","question":"Why are both immunophenotyping and biopsy necessary in the diagnostic workup of follicular lymphoma?","answer":"Both are required to identify cell type and confirm the diagnosis, as FL arises from abnormal B lymphocytes and is graded based on cell proportions.","question_type":"Complex Reasoning","evidence":"Both immunophenotyping and biopsy are necessary in the diagnostic workup of follicular lymphoma.; Immunophenotyping is required to identify cell type.; Biopsy is required to confirm the diagnosis.; Follicular lymphoma arises from abnormal B lymphocytes.; Follicular lymphoma is graded based on cell proportions.","evidence_relations":"Diagnosis of FL involves blood tests, bone marrow aspirate and biopsy, imaging studies, and immunophenotyping; FL develops from abnormal B lymphocytes forming clusters in lymph nodes and other tissues; FL is graded based on the proportion of centrocytes and centroblasts"},
	{"id":"Medical-98bb0bbc","source":"Medical","question":"How does the classification of uncommon FL (uFL) differ from classic FL (cFL), and how does this affect treatment?","answer":"Uncommon FL is t(14;18)-negative or has unusual features, but is treated as classic FL.","question_type":"Complex Reasoning","evidence":"Uncommon FL is t(14;18)-negative.; Uncommon FL has unusual features.; Uncommon FL is treated as classic FL.","evidence_relations":"Uncommon FL (uFL) is t(14;18)-negative or has uncommon pathologic features and is treated as classic FL; classic FL (cFL) is the standard classification for most FL"},
	{"id":"Medical-5581adb2","source":"Medical","question":"What combination of symptoms and diagnostic findings would suggest follicular lymphoma with bone marrow involvement?","answer":"Symptoms like fatigue and weight loss, combined with abnormal findings on bone marrow aspirate and biopsy, suggest FL with bone marrow involvement.","question_type":"Complex Reasoning","evidence":"Symptoms like fatigue suggest follicular lymphoma with bone marrow involvement.; Symptoms like weight loss suggest follicular lymphoma with bone marrow involvement.; Abnormal findings on bone marrow aspirate suggest follicular lymphoma with bone marrow involvement.; Abnormal findings on bone marrow biopsy suggest follicular lymphoma with bone marrow involvement.","evidence_relations":"Diagnosis of FL involves blood tests, bone marrow aspirate and biopsy, imaging studies, and immunophenotyping; Symptoms of FL include fatigue and weight loss (B symptoms); Disease Site of FL includes bone marrow"},
	{"id":"Medical-31580ac0","source":"Medical","question":"Which liver cancer subtype is most likely to be found in younger patients, and what are the main risk factors for its parent cancer type?","answer":"Fibrolamellar hepatocellular carcinoma (FLHC) is found in younger patients, and its parent type, HCC, is mainly associated with cirrhosis, hepatitis B, and hepatitis C.","question_type":"Complex Reasoning","evidence":"Fibrolamellar hepatocellular carcinoma (FLHC) is found in younger patients.; The parent type of FLHC is hepatocellular carcinoma (HCC).; Cirrhosis is a main risk factor for HCC.; Hepatitis B is a main risk factor for HCC.; Hepatitis C is a main risk factor for HCC.","evidence_relations":"Fibrolamellar hepatocellular carcinoma (FLHC) is a subtype of HCC that occurs at a younger age; Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer; Cirrhosis is a major risk factor for developing liver cancer; Chronic hepatitis B infection increases the risk of liver cancer; Chronic hepatitis C infection increases the risk of liver cancer"},
	{"id":"Medical-cfc21569","source":"Medical","question":"Why is liver cancer screening with ultrasound and AFP test recommended every 6 months for some individuals?","answer":"Because individuals with cirrhosis or chronic hepatitis B are at increased risk for liver cancer, and regular screening with ultrasound and AFP can detect cancer early.","question_type":"Complex Reasoning","evidence":"Liver cancer screening with ultrasound is recommended every 6 months for some individuals.; Liver cancer screening with AFP test is recommended every 6 months for some individuals.; Individuals with cirrhosis are at increased risk for liver cancer.; Individuals with chronic hepatitis B are at increased risk for liver cancer.; Regular screening can detect liver cancer early.","evidence_relations":"Screening for liver cancer is recommended for individuals with cirrhosis or chronic hepatitis B; Liver cancer screening includes ultrasound and alpha-fetoprotein (AFP) test every 6 months"},
	{"id":"Medical-443e3d36","source":"Medical","question":"If a patient with chronic hepatitis C and cirrhosis develops elevated AFP, which cancer type and diagnostic methods should be considered?","answer":"Primary liver cancer should be considered, and diagnosis should be confirmed with imaging tests and possibly biopsy.","question_type":"Complex Reasoning","evidence":"Primary liver cancer should be considered if a patient has chronic hepatitis C and cirrhosis with elevated AFP.; Diagnosis of primary liver cancer should be confirmed with imaging tests.; Diagnosis of primary liver cancer may require a biopsy.","evidence_relations":"Chronic hepatitis C infection increases the risk of liver cancer; Cirrhosis is a major risk factor for developing liver cancer; Elevated AFP may indicate primary liver cancer; Diagnosis of liver cancer is usually confirmed with imaging tests; Biopsy may be needed to confirm liver cancer"},
	{"id":"Medical-e9ef7d6f","source":"Medical","question":"What distinguishes secondary liver cancer from primary liver cancer in terms of origin and anatomical structure involved?","answer":"Primary liver cancer originates in the liver, while secondary liver cancer spreads to the liver from other organs.","question_type":"Complex Reasoning","evidence":"Primary liver cancer originates in the liver.; Secondary liver cancer spreads to the liver from other organs.","evidence_relations":"Primary liver cancer originates in the liver; Secondary liver cancer is cancer that has spread to the liver from another organ; Secondary liver cancer: Origin: Other primary cancers (e.g., colon cancer)"},
	{"id":"Medical-c2af5dd7","source":"Medical","question":"Which two risk factors for liver cancer are also major causes of cirrhosis, further increasing cancer risk?","answer":"Alcohol use and non-alcoholic fatty liver disease (NAFLD) are both risk factors for cirrhosis and liver cancer.","question_type":"Complex Reasoning","evidence":"Alcohol use is a risk factor for liver cancer.; Alcohol use is a major cause of cirrhosis.; Non-alcoholic fatty liver disease (NAFLD) is a risk factor for liver cancer.; Non-alcoholic fatty liver disease (NAFLD) is a major cause of cirrhosis.","evidence_relations":"Alcohol use is a risk factor for cirrhosis and liver cancer; Non-alcoholic fatty liver disease (NAFLD) is a risk factor for cirrhosis and liver cancer"},
	{"id":"Medical-83ff7511","source":"Medical","question":"If liver cancer is found to have both hepatocellular and cholangiocarcinoma components, what is the tumor called and what does this imply about its classification?","answer":"Such a tumor is called a mixed-type tumor, implying it contains both HCC and cholangiocarcinoma features.","question_type":"Complex Reasoning","evidence":"A tumor with both hepatocellular and cholangiocarcinoma components is called a mixed-type tumor.; A mixed-type tumor contains both HCC and cholangiocarcinoma features.","evidence_relations":"Mixed-type tumors contain both hepatocellular carcinoma and cholangiocarcinoma components; Cancer Subtype: Mixed-type tumor contains both HCC and cholangiocarcinoma"},
	{"id":"Medical-5a2c0504","source":"Medical","question":"Which anatomical sites are most commonly affected by metastasis from primary liver cancer, and how is this supported by the ontology?","answer":"The lung and bone are the most common metastasis sites for primary liver cancer.","question_type":"Complex Reasoning","evidence":"The lung is a common site for metastasis from primary liver cancer.; Bone is a common site for metastasis from primary liver cancer.","evidence_relations":"Liver cancer most often metastasizes to the lung or bone; Metastasis Site: Primary liver cancer commonly spreads to lung and bone"},
	{"id":"Medical-38a8b852","source":"Medical","question":"Why might a patient with genetic hemochromatosis require regular liver cancer screening, and which methods are used?","answer":"Because genetic hemochromatosis is a risk factor for cirrhosis and liver cancer, screening with ultrasound and AFP test is recommended.","question_type":"Complex Reasoning","evidence":"Genetic hemochromatosis is a risk factor for cirrhosis.; Genetic hemochromatosis is a risk factor for liver cancer.; Screening with ultrasound is recommended for patients with genetic hemochromatosis.; Screening with AFP test is recommended for patients with genetic hemochromatosis.","evidence_relations":"Genetic hemochromatosis is a risk factor for cirrhosis and liver cancer; Screening for liver cancer is recommended for individuals with cirrhosis or chronic hepatitis B; Liver cancer screening includes ultrasound and alpha-fetoprotein (AFP) test every 6 months"},
	{"id":"Medical-0b5acb42","source":"Medical","question":"What is the relationship between alpha-1-antitrypsin deficiency, cirrhosis, and liver cancer risk?","answer":"Alpha-1-antitrypsin deficiency increases the risk of cirrhosis, which in turn increases the risk of liver cancer.","question_type":"Complex Reasoning","evidence":"Alpha-1-antitrypsin deficiency increases the risk of cirrhosis.; Cirrhosis increases the risk of liver cancer.","evidence_relations":"Alpha-1-antitrypsin deficiency is a risk factor for cirrhosis and liver cancer; Cirrhosis is a major risk factor for developing liver cancer"},
	{"id":"Medical-535c413f","source":"Medical","question":"Which diagnostic steps should be taken if a screening ultrasound and AFP test suggest liver cancer in a patient with hepatitis B?","answer":"Imaging tests should be performed to confirm diagnosis, and a biopsy may be needed.","question_type":"Complex Reasoning","evidence":"Imaging tests should be performed to confirm diagnosis.; A biopsy may be needed.","evidence_relations":"Screening for liver cancer is recommended for individuals with cirrhosis or chronic hepatitis B; Liver cancer screening includes ultrasound and alpha-fetoprotein (AFP) test every 6 months; Diagnosis of liver cancer is usually confirmed with imaging tests; Biopsy may be needed to confirm liver cancer"},
	{"id":"Medical-c6a7964c","source":"Medical","question":"How do risk factors for primary liver cancer differ from those for secondary liver cancer according to the ontology?","answer":"Primary liver cancer risk factors include cirrhosis, hepatitis B, hepatitis C, and others, while secondary liver cancer originates from cancers in other organs.","question_type":"Complex Reasoning","evidence":"Primary liver cancer risk factors include cirrhosis.; Primary liver cancer risk factors include hepatitis B.; Primary liver cancer risk factors include hepatitis C.; Secondary liver cancer originates from cancers in other organs.","evidence_relations":"Risk Factor: Primary liver cancer is associated with cirrhosis, hepatitis B virus (HBV), hepatitis C virus (HCV), alcohol use, non-alcoholic fatty liver disease (NAFLD), genetic hemochromatosis, alpha-1-antitrypsin deficiency, and stage 4 primary biliary cholangitis; Secondary liver cancer: Origin: Other primary cancers (e.g., colon cancer)"},
	{"id":"Medical-803f66d8","source":"Medical","question":"Why is elevated alpha-fetoprotein (AFP) particularly significant in the context of primary liver cancer screening and diagnosis?","answer":"Because elevated AFP may indicate primary liver cancer and is used as a biomarker in screening and diagnostic protocols.","question_type":"Complex Reasoning","evidence":"Elevated alpha-fetoprotein (AFP) may indicate primary liver cancer.; Elevated AFP is used as a biomarker in screening protocols.; Elevated AFP is used as a biomarker in diagnostic protocols.","evidence_relations":"Elevated AFP may indicate primary liver cancer; Liver cancer screening includes ultrasound and alpha-fetoprotein (AFP) test every 6 months; Biomarker: Alpha-fetoprotein (AFP) is used for primary liver cancer"},
	{"id":"Medical-819d9c6c","source":"Medical","question":"What distinguishes intrahepatic cholangiocarcinoma from other primary liver cancer subtypes in terms of anatomical origin?","answer":"Intrahepatic cholangiocarcinoma arises from the bile ducts within the liver, unlike HCC or mixed-type tumors.","question_type":"Complex Reasoning","evidence":"Intrahepatic cholangiocarcinoma arises from the bile ducts within the liver.; HCC is a different subtype of primary liver cancer.; Mixed-type tumors are different from intrahepatic cholangiocarcinoma.","evidence_relations":"Intrahepatic cholangiocarcinoma is a primary liver cancer of the bile ducts; Anatomical Structure: Bile ducts are a part of the liver"},
	{"id":"Medical-ac781c3a","source":"Medical","question":"If a patient with stage 4 primary biliary cholangitis develops liver cancer, what is the likely sequence of risk events?","answer":"Stage 4 primary biliary cholangitis increases risk of cirrhosis, which then raises the risk for liver cancer.","question_type":"Complex Reasoning","evidence":"Stage 4 primary biliary cholangitis increases the risk of cirrhosis.; Cirrhosis raises the risk for liver cancer.","evidence_relations":"Stage 4 primary biliary cholangitis is a risk factor for cirrhosis and liver cancer; Cirrhosis is a major risk factor for developing liver cancer"},
	{"id":"Medical-0955a900","source":"Medical","question":"How does the presence of both hepatitis B and alcohol use affect liver cancer risk, and what does the ontology indicate about their combined effect?","answer":"Both hepatitis B and alcohol use independently increase the risk of liver cancer, and their presence together further elevates the risk.","question_type":"Complex Reasoning","evidence":"Hepatitis B independently increases the risk of liver cancer.; Alcohol use independently increases the risk of liver cancer.; The presence of both hepatitis B and alcohol use further elevates the risk of liver cancer.","evidence_relations":"Chronic hepatitis B infection increases the risk of liver cancer; Alcohol use is a risk factor for cirrhosis and liver cancer; Risk Factor: Primary liver cancer is associated with hepatitis B virus (HBV) and alcohol use"},
	{"id":"Medical-18be1c24","source":"Medical","question":"Which diagnostic and biomarker tests are indicated for a patient with a visible neck lump suspected to be papillary thyroid carcinoma?","answer":"TSH test, neck ultrasound, fine-needle aspiration, pathology review, molecular tests, and biomarker analysis for BRAF, NTRK, and ALK gene mutations are indicated.","question_type":"Complex Reasoning","evidence":"TSH test is indicated for a patient with a visible neck lump suspected to be papillary thyroid carcinoma.; Neck ultrasound is indicated for a patient with a visible neck lump suspected to be papillary thyroid carcinoma.; Fine-needle aspiration is indicated for a patient with a visible neck lump suspected to be papillary thyroid carcinoma.; Pathology review is indicated for a patient with a visible neck lump suspected to be papillary thyroid carcinoma.; Molecular tests are indicated for a patient with a visible neck lump suspected to be papillary thyroid carcinoma.; Biomarker analysis for BRAF, NTRK, and ALK gene mutations is indicated for a patient with a visible neck lump suspected to be papillary thyroid carcinoma.","evidence_relations":"Symptoms of large thyroid nodules include visible neck lump; Papillary thyroid carcinoma Diagnostic Method: TSH test, Ultrasound, Fine-needle aspiration, Pathology review, Molecular tests; Papillary thyroid carcinoma Biomarker: BRAF gene mutation, NTRK gene fusion, ALK gene fusion"},
	{"id":"Medical-09eac393","source":"Medical","question":"Why is radioactive iodine therapy not used for medullary thyroid cancer after total thyroidectomy, and what alternative therapies are recommended?","answer":"RAI therapy is ineffective for medullary thyroid cancer, so targeted therapy and thyroid hormone replacement are recommended alternatives.","question_type":"Complex Reasoning","evidence":"Radioactive iodine (RAI) therapy is ineffective for medullary thyroid cancer.; Targeted therapy is recommended for medullary thyroid cancer.; Thyroid hormone replacement is recommended for medullary thyroid cancer.","evidence_relations":"RAI therapy is not effective for medullary or anaplastic thyroid cancer; Medullary thyroid cancer Treatment: Total thyroidectomy, Neck dissection, Targeted therapy (if advanced/metastatic), Thyroid hormone replacement therapy"},
	{"id":"Medical-3f8a738d","source":"Medical","question":"If a patient with a history of head and neck radiation presents with a neck lump and trouble swallowing, what diagnostic steps should be taken to evaluate for thyroid cancer?","answer":"TSH test, neck ultrasound, and fine-needle aspiration biopsy should be performed to evaluate for thyroid cancer.","question_type":"Complex Reasoning","evidence":"TSH test should be performed to evaluate for thyroid cancer.; Neck ultrasound should be performed to evaluate for thyroid cancer.; Fine-needle aspiration biopsy should be performed to evaluate for thyroid cancer.","evidence_relations":"Radiation exposure to the head or neck increases risk of thyroid cancer; Symptoms of large thyroid nodules include visible neck lump, problems swallowing; TSH blood test and neck ultrasound are recommended for evaluation of thyroid nodules; Fine-needle aspiration biopsy is used to sample suspicious thyroid nodules"},
	{"id":"Medical-03451b65","source":"Medical","question":"What is the recommended management for a small, noninvasive papillary thyroid carcinoma found to be less than 1 cm with no lymph node involvement?","answer":"Active surveillance or lobectomy are recommended management options.","question_type":"Complex Reasoning","evidence":"Active surveillance is a recommended management option for small, noninvasive papillary thyroid carcinoma.; Lobectomy is a recommended management option for small, noninvasive papillary thyroid carcinoma.","evidence_relations":"Active surveillance is an option for very-low-risk papillary thyroid cancers; Lobectomy is an option for small, low-risk differentiated thyroid cancers; Papillary thyroid carcinoma Treatment: Active surveillance (for very-low-risk, small tumors), Lobectomy (for small, noninvasive tumors 1-4 cm, no spread)"},
	{"id":"Medical-f4972c91","source":"Medical","question":"Which treatments are used for metastatic differentiated thyroid cancer that is iodine-avid and which are considered if the disease is not iodine-avid?","answer":"RAI therapy is used for iodine-avid disease, while targeted therapy and external beam radiation therapy are used if the disease is not iodine-avid.","question_type":"Complex Reasoning","evidence":"RAI therapy is used for iodine-avid metastatic differentiated thyroid cancer.; Targeted therapy is used for metastatic differentiated thyroid cancer that is not iodine-avid.; External beam radiation therapy is used for metastatic differentiated thyroid cancer that is not iodine-avid.","evidence_relations":"RAI therapy is used after total thyroidectomy for differentiated thyroid cancers that take up iodine; Targeted therapy (kinase inhibitors) is used for cancers not responsive to surgery or RAI, or with metastasis; Stage Distant metastasis Treatment: RAI therapy (if iodine-avid), Targeted therapy, External beam radiation therapy"},
	{"id":"Medical-a0cd1d28","source":"Medical","question":"Which genetic alteration is most associated with inherited medullary thyroid cancer and what implication does this have for family members?","answer":"RET gene fusion is most associated, indicating the need for family genetic screening for inherited syndromes.","question_type":"Complex Reasoning","evidence":"RET gene fusion is most associated with inherited medullary thyroid cancer.; Family genetic screening for inherited syndromes is indicated due to RET gene fusion.","evidence_relations":"Medullary thyroid cancer can be inherited and is associated with RET gene fusion; Medullary thyroid cancer Risk Factor: Inherited syndromes (MEN, RET mutation)"},
	{"id":"Medical-2f70ddcb","source":"Medical","question":"What follow-up tests are recommended after total thyroidectomy for thyroid cancer, and how can recurrence be detected?","answer":"Physical exam, TSH, thyroglobulin, anti-thyroglobulin antibodies blood tests, and neck ultrasound are recommended; recurrence may be detected by rising thyroglobulin or imaging.","question_type":"Complex Reasoning","evidence":"Physical exam is a recommended follow-up test after total thyroidectomy for thyroid cancer.; TSH blood test is a recommended follow-up test after total thyroidectomy for thyroid cancer.; Thyroglobulin blood test is a recommended follow-up test after total thyroidectomy for thyroid cancer.; Anti-thyroglobulin antibodies blood test is a recommended follow-up test after total thyroidectomy for thyroid cancer.; Neck ultrasound is a recommended follow-up test after total thyroidectomy for thyroid cancer.; Recurrence of thyroid cancer may be detected by rising thyroglobulin levels.; Recurrence of thyroid cancer may be detected by imaging.","evidence_relations":"Follow-up after treatment includes physical exam, blood tests (TSH, Tg, Tg ab), and neck ultrasound; Rising thyroglobulin after thyroidectomy may indicate recurrence; Recurrence Detection: Rising thyroglobulin, Neck ultrasound, Imaging (CT, MRI)"},
	{"id":"Medical-6e99ce81","source":"Medical","question":"For a patient with anaplastic thyroid cancer and distant metastasis, which combination of therapies is most likely to be recommended?","answer":"External beam radiation therapy, chemotherapy, and possibly targeted therapy are most likely recommended.","question_type":"Complex Reasoning","evidence":"External beam radiation therapy is likely recommended for a patient with anaplastic thyroid cancer and distant metastasis.; Chemotherapy is likely recommended for a patient with anaplastic thyroid cancer and distant metastasis.; Possibly targeted therapy is likely recommended for a patient with anaplastic thyroid cancer and distant metastasis.","evidence_relations":"Anaplastic thyroid cancer is the most aggressive and rarest subtype; Anaplastic thyroid cancer Treatment: External beam radiation therapy, Chemotherapy (with radiation), Surgery (if possible), Targeted therapy (if indicated); Stage Distant metastasis Treatment: External beam radiation therapy, Chemotherapy (for anaplastic), Targeted therapy"},
	{"id":"Medical-b94e5d8e","source":"Medical","question":"If a thyroid cancer patient develops brain and bone metastases, which treatment options should be considered?","answer":"External beam radiation therapy, targeted therapy, and clinical trial participation should be considered.","question_type":"Complex Reasoning","evidence":"External beam radiation therapy should be considered for a thyroid cancer patient with brain and bone metastases.; Targeted therapy should be considered for a thyroid cancer patient with brain and bone metastases.; Clinical trial participation should be considered for a thyroid cancer patient with brain and bone metastases.","evidence_relations":"Metastatic thyroid cancer most commonly spreads to lungs, liver, bones, brain, and spinal cord; Metastasis Treatment: External beam radiation therapy, Targeted therapy, Clinical trial"},
	{"id":"Medical-32fce5f0","source":"Medical","question":"What are the standard hormone replacement options after total thyroidectomy and why are they necessary?","answer":"Levothyroxine, Levoxyl, or Synthroid are necessary to replace lost thyroid hormone after total thyroidectomy.","question_type":"Complex Reasoning","evidence":"Levothyroxine is a standard hormone replacement option after total thyroidectomy.; Levoxyl is a standard hormone replacement option after total thyroidectomy.; Synthroid is a standard hormone replacement option after total thyroidectomy.; Hormone replacement is necessary after total thyroidectomy to replace lost thyroid hormone.","evidence_relations":"Thyroid hormone replacement therapy is required after total thyroidectomy; Thyroid hormone replacement therapy: Levothyroxine, Levoxyl, Synthroid"},
	{"id":"Medical-e1deaedc","source":"Medical","question":"Which molecular biomarkers should be tested in recurrent or advanced thyroid cancers not treatable with RAI therapy, and why?","answer":"ALK fusion, NTRK fusion, BRAF mutation, RET fusion, dMMR, MSI-H, and TMB-H should be tested to guide targeted therapy.","question_type":"Complex Reasoning","evidence":"ALK fusion should be tested in recurrent or advanced thyroid cancers not treatable with RAI therapy.; NTRK fusion should be tested in recurrent or advanced thyroid cancers not treatable with RAI therapy.; BRAF mutation should be tested in recurrent or advanced thyroid cancers not treatable with RAI therapy.; RET fusion should be tested in recurrent or advanced thyroid cancers not treatable with RAI therapy.; dMMR should be tested in recurrent or advanced thyroid cancers not treatable with RAI therapy.; MSI-H should be tested in recurrent or advanced thyroid cancers not treatable with RAI therapy.; TMB-H should be tested in recurrent or advanced thyroid cancers not treatable with RAI therapy.; Testing molecular biomarkers guides targeted therapy in recurrent or advanced thyroid cancers.","evidence_relations":"Biomarker testing is recommended for recurrent, advanced, or metastatic cancers not treatable with RAI; Biomarkers include ALK fusion, NTRK fusion, BRAF mutation, RET fusion, dMMR, MSI-H, TMB-H"},
	{"id":"Medical-ee644399","source":"Medical","question":"Why is lobectomy preferred over total thyroidectomy for some small, low-risk differentiated thyroid cancers?","answer":"Lobectomy is preferred because it is sufficient for small, noninvasive tumors and avoids the need for lifelong thyroid hormone replacement.","question_type":"Complex Reasoning","evidence":"Lobectomy is preferred over total thyroidectomy for some small, low-risk differentiated thyroid cancers.; Lobectomy is sufficient for small, noninvasive tumors.; Lobectomy avoids the need for lifelong thyroid hormone replacement.","evidence_relations":"Lobectomy is an option for small, low-risk differentiated thyroid cancers; Total thyroidectomy is recommended for larger, invasive, or high-risk cancers; Thyroid hormone replacement therapy is required after total thyroidectomy"},
	{"id":"Medical-072545c5","source":"Medical","question":"What is the role of molecular tests in the management of thyroid nodules and how do they impact surgical decisions?","answer":"Molecular tests help determine malignancy and the need for surgery in patients with suspicious thyroid nodules.","question_type":"Complex Reasoning","evidence":"Molecular tests help determine malignancy in thyroid nodules.; Molecular tests help determine the need for surgery in patients with suspicious thyroid nodules.","evidence_relations":"Molecular tests can help determine malignancy and need for surgery; Fine-needle aspiration biopsy is used to sample suspicious thyroid nodules"},
	{"id":"Medical-0e57f27f","source":"Medical","question":"When should a clinical trial be considered for a thyroid cancer patient, and what disease characteristics warrant this recommendation?","answer":"Clinical trials are recommended for patients with advanced or metastatic thyroid cancer, especially when standard treatments are ineffective.","question_type":"Complex Reasoning","evidence":"Clinical trials are recommended for patients with advanced thyroid cancer.; Clinical trials are recommended for patients with metastatic thyroid cancer.; Clinical trials are recommended when standard treatments are ineffective.","evidence_relations":"Clinical trials are recommended for patients with advanced or metastatic thyroid cancer; Metastasis Treatment: Clinical trial"},
	{"id":"Medical-c58fae3b","source":"Medical","question":"Which targeted therapies are approved for progressive, unresectable, or metastatic thyroid cancer, and what is their main indication?","answer":"Lenvatinib, sorafenib, and cabozantinib are approved for progressive, unresectable, or metastatic thyroid cancer not responsive to surgery or RAI.","question_type":"Complex Reasoning","evidence":"Lenvatinib is approved for progressive thyroid cancer.; Sorafenib is approved for progressive thyroid cancer.; Cabozantinib is approved for progressive thyroid cancer.; These therapies are approved for unresectable thyroid cancer.; These therapies are approved for metastatic thyroid cancer.; These therapies are not responsive to surgery or RAI.","evidence_relations":"Lenvatinib, sorafenib, and cabozantinib are targeted therapies for progressive, unresectable, or metastatic thyroid cancer; Targeted therapy (kinase inhibitors) is used for cancers not responsive to surgery or RAI, or with metastasis"},
	{"id":"Medical-66e7fe35","source":"Medical","question":"Which diagnostic methods are necessary to confirm a case of Ewing sarcoma, and which biomarker supports the diagnosis?","answer":"Diagnosis of Ewing sarcoma requires imaging tests and biopsy, with EWSR1-FLI1 fusion serving as a supporting biomarker.","question_type":"Complex Reasoning","evidence":"Diagnosis of Ewing sarcoma requires imaging tests.; Diagnosis of Ewing sarcoma requires a biopsy.; EWSR1-FLI1 fusion serves as a supporting biomarker for Ewing sarcoma.","evidence_relations":"Ewing sarcoma is characterized by EWSR1-ETS gene fusions, most commonly EWSR1-FLI1; Imaging tests for bone cancer include X-ray, bone scan, CT scan, MRI, and PET scan; Diagnosis of bone cancer is confirmed by core needle or surgical biopsy; Ewing sarcoma: Diagnostic Method: [\"X-ray\", \"Bone scan\", \"CT scan\", \"MRI\", \"PET scan\", \"Biopsy\"]"},
	{"id":"Medical-47b62614","source":"Medical","question":"What is the appropriate targeted therapy for a patient with chondrosarcoma harboring an IDH1 mutation, and how is this mutation identified?","answer":"Ivosidenib is the targeted therapy for chondrosarcoma with IDH1 mutation, which is identified through biomarker testing.","question_type":"Complex Reasoning","evidence":"Ivosidenib is the targeted therapy for chondrosarcoma with IDH1 mutation.; IDH1 mutation is identified through biomarker testing.","evidence_relations":"IDH1 mutation in chondrosarcoma can be targeted with ivosidenib; Biomarker testing includes identification of gene mutations (e.g., IDH1); Chondrosarcoma: Treatment: [\"Ivosidenib (for IDH1 mutation)\"]"},
	{"id":"Medical-06055fa9","source":"Medical","question":"How does the TNM system integrate with tumor grade to determine the stage of primary bone cancer?","answer":"The stage of primary bone cancer is determined by combining TNM scores and tumor grade.","question_type":"Complex Reasoning","evidence":"The stage of primary bone cancer is determined by TNM scores.; The stage of primary bone cancer is determined by tumor grade.","evidence_relations":"Staging uses the TNM system: T (tumor size/location), N (lymph node involvement), M (metastasis); Tumor grade (G) describes histologic differentiation; Stage is determined by combining T, N, M, and G scores"},
	{"id":"Medical-81c95a46","source":"Medical","question":"Which anatomic locations are most commonly associated with osteosarcoma and giant cell tumor of bone, and what do these locations have in common?","answer":"Osteosarcoma commonly arises in the metaphysis near growth plates, and giant cell tumor of bone often occurs in the metaphysis and epiphysis; both involve the metaphysis.","question_type":"Complex Reasoning","evidence":"Osteosarcoma commonly arises in the metaphysis near growth plates.; Giant cell tumor of bone often occurs in the metaphysis.; Giant cell tumor of bone often occurs in the epiphysis.; Both osteosarcoma and giant cell tumor of bone involve the metaphysis.","evidence_relations":"Osteosarcoma commonly arises in the metaphysis near growth plates; Giant cell tumor of bone often occurs in the metaphysis and epiphysis; Osteosarcoma: Anatomic Location: [\"Metaphysis\", \"Near growth plates\"]; Giant cell tumor of bone (GCTB): Anatomic Location: [\"Metaphysis\", \"Epiphysis\"]"},
	{"id":"Medical-fe7f2575","source":"Medical","question":"What two performance status scales are considered when planning treatment for primary bone cancer?","answer":"ECOG performance status and Karnofsky Performance Status (KPS) are considered in treatment planning.","question_type":"Complex Reasoning","evidence":"ECOG performance status is considered in treatment planning for primary bone cancer.; Karnofsky Performance Status (KPS) is considered in treatment planning for primary bone cancer.","evidence_relations":"Performance status (ECOG or KPS) is considered in treatment planning; Performance Status: [\"ECOG performance status\", \"Karnofsky Performance Status (KPS)\"]"},
	{"id":"Medical-ce635798","source":"Medical","question":"Which genetic alterations are characteristic of Ewing sarcoma, and by which diagnostic methods can these be detected?","answer":"Ewing sarcoma is characterized by EWSR1-FLI1 and EWSR1-ERG fusions, detectable via biomarker testing such as PCR or next-generation sequencing.","question_type":"Complex Reasoning","evidence":"Ewing sarcoma is characterized by EWSR1-FLI1 fusion.; Ewing sarcoma is characterized by EWSR1-ERG fusion.; These fusions can be detected via biomarker testing.; These fusions can be detected via PCR.; These fusions can be detected via next-generation sequencing.","evidence_relations":"Ewing sarcoma is characterized by EWSR1-ETS gene fusions, most commonly EWSR1-FLI1; Biomarker testing includes identification of gene mutations (e.g., IDH1), protein expression, and tumor mutational burden; Next-generation sequencing (NGS); Polymerase chain reaction (PCR); Ewing sarcoma: Biomarker: [\"EWSR1-FLI1 fusion\", \"EWSR1-ERG fusion\"]"},
	{"id":"Medical-b2b43c1e","source":"Medical","question":"Which bone sarcoma subtype is most likely to originate from cartilage-forming cells, and what biomarker is relevant for its targeted therapy?","answer":"Chondrosarcoma originates from cartilage-forming cells and the IDH1 mutation is relevant for targeted therapy.","question_type":"Complex Reasoning","evidence":"Chondrosarcoma originates from cartilage-forming cells.; The IDH1 mutation is relevant for targeted therapy of chondrosarcoma.","evidence_relations":"Chondrosarcoma starts in cartilage-forming cells; IDH1 mutation in chondrosarcoma can be targeted with ivosidenib; Chondrosarcoma: Biomarker: [\"IDH1 mutation\"]"},
	{"id":"Medical-e6db1c4b","source":"Medical","question":"Which imaging modalities and biopsy types are recommended for the diagnosis of osteosarcoma?","answer":"Diagnosis of osteosarcoma involves X-ray, bone scan, CT scan, MRI, PET scan, and either core needle or surgical biopsy.","question_type":"Complex Reasoning","evidence":"Diagnosis of osteosarcoma involves X-ray.; Diagnosis of osteosarcoma involves bone scan.; Diagnosis of osteosarcoma involves CT scan.; Diagnosis of osteosarcoma involves MRI.; Diagnosis of osteosarcoma involves PET scan.; Diagnosis of osteosarcoma involves core needle biopsy.; Diagnosis of osteosarcoma involves surgical biopsy.","evidence_relations":"Osteosarcoma: Diagnostic Method: [\"X-ray\", \"Bone scan\", \"CT scan\", \"MRI\", \"PET scan\", \"Biopsy\"]; Diagnosis of bone cancer is confirmed by core needle or surgical biopsy"},
	{"id":"Medical-14d39f0c","source":"Medical","question":"What are the common symptoms and metabolic complications associated with bone cancer, and what causes the metabolic complication?","answer":"Bone pain and hypercalcemia are common symptoms, with hypercalcemia caused by bone destruction.","question_type":"Complex Reasoning","evidence":"Common symptoms of bone cancer include bone pain.; Common symptoms of bone cancer include hypercalcemia.; Hypercalcemia is caused by bone destruction.","evidence_relations":"Bone cancer can cause hypercalcemia due to bone destruction; Symptom: [\"Bone pain\", \"Hypercalcemia\"]"},
	{"id":"Medical-bce86fcf","source":"Medical","question":"How are germline mutations relevant to bone cancer risk, and what testing modality is used to identify them?","answer":"Germline mutations are risk factors for bone cancer and can be identified by genetic cancer risk testing.","question_type":"Complex Reasoning","evidence":"Germline mutations are risk factors for bone cancer.; Germline mutations can be identified by genetic cancer risk testing.","evidence_relations":"Genetic cancer risk testing identifies germline mutations associated with increased cancer risk; Risk Factor: [\"Family history of cancer\", \"Germline mutations\"]"},
	{"id":"Medical-a6155d9a","source":"Medical","question":"Which systemic therapies may be considered for bone sarcoma patients with MSI-H, dMMR, or TMB-H, and what is the biomarker testing relevance?","answer":"Pembrolizumab, nivolumab, or ipilimumab may be used for bone sarcoma patients with MSI-H, dMMR, or TMB-H identified by biomarker testing.","question_type":"Complex Reasoning","evidence":"Pembrolizumab may be used for bone sarcoma patients with MSI-H, dMMR, or TMB-H.; Nivolumab may be used for bone sarcoma patients with MSI-H, dMMR, or TMB-H.; Ipilimumab may be used for bone sarcoma patients with MSI-H, dMMR, or TMB-H.; Biomarker testing is used to identify patients with MSI-H, dMMR, or TMB-H.","evidence_relations":"MSI-H/dMMR status may be treated with pembrolizumab; Tumor mutational burden-high (TMB-H) may be treated with pembrolizumab, nivolumab, or ipilimumab; Biomarker testing includes identification of gene mutations (e.g., IDH1), protein expression, and tumor mutational burden"},
	{"id":"Medical-9b3c8ac0","source":"Medical","question":"Why should fertility preservation be discussed before starting treatment for bone cancer in young patients?","answer":"Some treatments for bone cancer can affect fertility, so fertility preservation should be discussed prior to treatment.","question_type":"Complex Reasoning","evidence":"Some treatments for bone cancer can affect fertility.; Fertility preservation should be discussed prior to treatment for bone cancer.","evidence_relations":"Some treatments for bone cancer can affect fertility; fertility preservation should be discussed before treatment; Fertility Consideration: [\"Fertility preservation\"]"},
	{"id":"Medical-4aed3e10","source":"Medical","question":"Which blood tests are included in the evaluation of bone cancer, and what is their collective purpose?","answer":"Alkaline phosphatase, CBC, CMP, and LDH are used to evaluate bone cancer as part of blood tests.","question_type":"Complex Reasoning","evidence":"Alkaline phosphatase is included in the evaluation of bone cancer.; CBC is included in the evaluation of bone cancer.; CMP is included in the evaluation of bone cancer.; LDH is included in the evaluation of bone cancer.; These blood tests are used to evaluate bone cancer.","evidence_relations":"Blood tests such as alkaline phosphatase, CBC, CMP, and LDH are used in evaluation; Blood tests: [\"Alkaline phosphatase\", \"CBC\", \"Comprehensive metabolic panel (CMP)\", \"Lactate dehydrogenase (LDH)\"]"},
	{"id":"Medical-641dcaf5","source":"Medical","question":"What distinguishes primary bone cancer from secondary bone malignancy in terms of origin and common cancer types?","answer":"Primary bone cancer originates in bone or cartilage and includes sarcomas, while secondary bone malignancies are metastases from other organs such as breast, lung, or kidney.","question_type":"Complex Reasoning","evidence":"Primary bone cancer originates in bone or cartilage.; Primary bone cancer includes sarcomas.; Secondary bone malignancies are metastases from other organs.; Common organs for secondary bone malignancies include breast, lung, or kidney.","evidence_relations":"Primary bone cancer originates in bone or cartilage; Most primary bone cancers are sarcomas; Secondary bone malignancies are cancers that have metastasized to bone from other organs; Secondary bone malignancy: Origin: [\"Breast cancer\", \"Lung cancer\", \"Kidney cancer\"]"},
	{"id":"Medical-333a4a3b","source":"Medical","question":"Which bone sarcoma subtype is most likely to arise in the diaphysis or flat bones, and what genetic alteration is characteristic of this subtype?","answer":"Ewing sarcoma most commonly arises in the diaphysis or flat bones and is characterized by the t(11;22) translocation.","question_type":"Complex Reasoning","evidence":"Ewing sarcoma most commonly arises in the diaphysis or flat bones.; Ewing sarcoma is characterized by the t(11;22) translocation.","evidence_relations":"Ewing sarcoma: Anatomic Location: [\"Diaphysis\", \"Flat bones (pelvis, scapula)\"]; Ewing sarcoma is characterized by EWSR1-ETS gene fusions, most commonly EWSR1-FLI1; Ewing sarcoma: Genetic Alteration: [\"t(11;22) translocation\"]"},
	{"id":"Medical-54cc91bf","source":"Medical","question":"Which diagnostic methods are needed to both confirm squamous cell carcinoma (SCC) in the mouth and assess its anatomical extent?","answer":"Biopsy is required to confirm SCC diagnosis and imaging tests like CT, MRI, PET/CT, and ultrasound are used to assess anatomical extent.","question_type":"Complex Reasoning","evidence":"A biopsy is required to confirm the diagnosis of squamous cell carcinoma (SCC) in the mouth.; Imaging tests like CT are used to assess the anatomical extent of SCC.; Imaging tests like MRI are used to assess the anatomical extent of SCC.; Imaging tests like PET/CT are used to assess the anatomical extent of SCC.; Imaging tests like ultrasound are used to assess the anatomical extent of SCC.","evidence_relations":"Biopsy is required to confirm diagnosis and determine histology; Imaging tests such as CT, MRI, PET/CT, and ultrasound are used for diagnosis and staging"},
	{"id":"Medical-ee09c8e9","source":"Medical","question":"Why is performance status (ECOG) considered in treatment selection for mouth cancer?","answer":"Performance status (ECOG) is used to guide treatment selection based on the patient's ability to tolerate therapy.","question_type":"Complex Reasoning","evidence":"Performance status (ECOG) is used to guide treatment selection for mouth cancer.; Performance status (ECOG) is based on the patient's ability to tolerate therapy.","evidence_relations":"Performance status (ECOG) is considered in treatment selection; Clinical Assessment includes Performance status (ECOG) in the ontology for squamous cell carcinoma (SCC) of the mouth"},
	{"id":"Medical-27c72004","source":"Medical","question":"How do tobacco and alcohol use impact both the risk and outcomes of mouth cancer treatment?","answer":"Tobacco and alcohol use increase the risk of mouth cancer and negatively affect treatment outcomes by increasing toxicity.","question_type":"Complex Reasoning","evidence":"Tobacco use increases the risk of mouth cancer.; Alcohol use increases the risk of mouth cancer.; Tobacco use negatively affects treatment outcomes for mouth cancer.; Alcohol use negatively affects treatment outcomes for mouth cancer.; Tobacco and alcohol use increase toxicity in mouth cancer treatment.","evidence_relations":"Tobacco and alcohol use are risk factors for mouth cancer; Smoking or vaping negatively affects treatment outcomes and increases toxicity"},
	{"id":"Medical-fe83d01e","source":"Medical","question":"What two assessments are necessary for comprehensive care due to the effects of mouth cancer and its treatment on dental health and swallowing?","answer":"Dental exam and speech and swallowing assessment are necessary for comprehensive care.","question_type":"Complex Reasoning","evidence":"A dental exam is necessary for comprehensive care due to mouth cancer.; A speech and swallowing assessment is necessary for comprehensive care due to mouth cancer.","evidence_relations":"Dental health is affected by head and neck cancer and its treatment; Dental exam and speech and swallowing assessment are listed as diagnostic methods in the ontology"},
	{"id":"Medical-69bd1f37","source":"Medical","question":"Which biomarkers should be tested in a patient with SCC of the tongue to inform treatment options?","answer":"PD-L1, MSI-H/dMMR, and tumor mutational burden (TMB) should be tested.","question_type":"Complex Reasoning","evidence":"PD-L1 should be tested in a patient with SCC of the tongue.; MSI-H/dMMR should be tested in a patient with SCC of the tongue.; Tumor mutational burden (TMB) should be tested in a patient with SCC of the tongue.","evidence_relations":"Biomarker testing may include PD-L1, MSI-H/dMMR, and tumor mutational burden (TMB); Biomarker includes PD-L1, MSI-H/dMMR, and TMB for SCC in the ontology"},
	{"id":"Medical-70db1204","source":"Medical","question":"How is the stage of mouth cancer determined using both tumor characteristics and lymph node involvement?","answer":"Stage is determined by the TNM system, which includes tumor size and depth, lymph node involvement, and distant metastasis.","question_type":"Complex Reasoning","evidence":"The stage of mouth cancer is determined by the TNM system.; The TNM system includes tumor size.; The TNM system includes tumor depth.; The TNM system includes lymph node involvement.; The TNM system includes distant metastasis.","evidence_relations":"Cancer staging is based on the TNM system, which includes tumor size and depth (T), lymph node involvement (N), and distant metastasis (M); TNM Classification includes T, N, and M parameters in the ontology for mouth cancer"},
	{"id":"Medical-b016ff7a","source":"Medical","question":"Why is depth of invasion (DOI) important in the TNM staging of mouth cancer?","answer":"DOI is used to assess tumor extension and is a criterion in T classification for staging.","question_type":"Complex Reasoning","evidence":"Depth of invasion (DOI) is used to assess tumor extension.; Depth of invasion (DOI) is a criterion in T classification for staging.","evidence_relations":"Depth of invasion (DOI) is used to assess tumor extension in mouth cancer; TNM Classification uses DOI in the definitions for T1, T2, and T3 in the ontology"},
	{"id":"Medical-7dd235f1","source":"Medical","question":"What is the significance of extranodal extension in regional lymph nodes for mouth cancer staging?","answer":"Extranodal extension indicates cancer spread outside the lymph node and affects staging and prognosis.","question_type":"Complex Reasoning","evidence":"Extranodal extension indicates cancer spread outside the lymph node.; Extranodal extension affects staging of mouth cancer.; Extranodal extension affects prognosis of mouth cancer.","evidence_relations":"Regional lymph node involvement includes extranodal extension; Extranodal extension is defined as cancer spread outside lymph node in the ontology"},
	{"id":"Medical-5adcec8a","source":"Medical","question":"How do symptoms guide the use of imaging and biopsy in the diagnostic process for mouth cancer?","answer":"Symptoms such as changes in the mouth, tongue, or neck area prompt the use of imaging and biopsy for diagnosis.","question_type":"Complex Reasoning","evidence":"Symptoms such as changes in the mouth prompt the use of imaging for diagnosis.; Symptoms such as changes in the tongue prompt the use of imaging for diagnosis.; Symptoms such as changes in the neck area prompt the use of imaging for diagnosis.; Symptoms prompt the use of biopsy for diagnosis.","evidence_relations":"Symptoms may include changes in the mouth, tongue, or neck area; Imaging tests such as CT, MRI, PET/CT, and ultrasound are used for diagnosis and staging; Biopsy is required to confirm diagnosis and determine histology"},
	{"id":"Medical-25d1d605","source":"Medical","question":"Why should fertility preservation be discussed with certain mouth cancer patients before treatment?","answer":"Cancer and its treatment can affect fertility, so fertility preservation should be considered before therapy.","question_type":"Complex Reasoning","evidence":"Cancer can affect fertility.; Treatment for cancer can affect fertility.; Fertility preservation should be discussed with certain mouth cancer patients before treatment.","evidence_relations":"Cancer and its treatment can affect fertility; Fertility preservation is included under Fertility Consideration in the ontology for SCC"},
	{"id":"Medical-2cc4ff58","source":"Medical","question":"For a patient with a tumor in the retromolar trigone, which cancer subtype and anatomic site categories are relevant for diagnosis and staging?","answer":"The relevant cancer subtype is squamous cell carcinoma (SCC) and the anatomic site is the retromolar trigone.","question_type":"Complex Reasoning","evidence":"The relevant cancer subtype for a tumor in the retromolar trigone is squamous cell carcinoma (SCC).; The relevant anatomic site for a tumor in the retromolar trigone is the retromolar trigone.","evidence_relations":"Squamous cell carcinoma (SCC) is the most common subtype of mouth cancer; Mouth cancer can develop in the retromolar trigone; Anatomic Site includes retromolar trigone for SCC in the ontology"},
	{"id":"Medical-48843076","source":"Medical","question":"How does the location and stage of a mouth tumor influence treatment planning?","answer":"Treatment planning is based on both tumor location and stage.","question_type":"Complex Reasoning","evidence":"Treatment planning is based on tumor location.; Treatment planning is based on tumor stage.","evidence_relations":"Treatment planning is based on tumor location and stage; Stage and anatomic site are both specified under SCC in the ontology"},
	{"id":"Medical-aa9a54c8","source":"Medical","question":"Which diagnostic methods would be used to assess both lymph node involvement and distant metastasis in mouth cancer?","answer":"Imaging tests such as CT, MRI, PET/CT, and ultrasound are used to assess lymph node involvement and distant metastasis.","question_type":"Complex Reasoning","evidence":"Imaging tests such as CT are used to assess lymph node involvement.; Imaging tests such as MRI are used to assess lymph node involvement.; Imaging tests such as PET/CT are used to assess lymph node involvement.; Imaging tests such as ultrasound are used to assess lymph node involvement.; Imaging tests are used to assess distant metastasis.","evidence_relations":"Imaging tests such as CT, MRI, PET/CT, and ultrasound are used for diagnosis and staging; Cancer staging is based on the TNM system, which includes lymph node involvement and distant metastasis"},
	{"id":"Medical-ec4712e3","source":"Medical","question":"Why is a panoramic dental x-ray (Panorex) included in diagnostic evaluation for mouth cancer?","answer":"A Panorex is used to assess dental health, which is affected by mouth cancer and its treatment.","question_type":"Complex Reasoning","evidence":"A panoramic dental x-ray (Panorex) is used to assess dental health.; Dental health is affected by mouth cancer.; Dental health is affected by the treatment of mouth cancer.","evidence_relations":"Dental health is affected by head and neck cancer and its treatment; Panoramic dental x-ray (Panorex) is listed as a diagnostic method in the ontology for SCC"},
	{"id":"Medical-299b8b83","source":"Medical","question":"How do risk factors and performance status together influence mouth cancer management?","answer":"Risk factors like tobacco and alcohol use increase risk and affect outcomes, while performance status helps guide treatment selection.","question_type":"Complex Reasoning","evidence":"Risk factors like tobacco use increase the risk of mouth cancer.; Risk factors like alcohol use increase the risk of mouth cancer.; Risk factors affect outcomes of mouth cancer management.; Performance status helps guide treatment selection for mouth cancer.","evidence_relations":"Tobacco and alcohol use are risk factors for mouth cancer; Performance status (ECOG) is considered in treatment selection"},
	{"id":"Medical-2350fb33","source":"Medical","question":"What diagnostic methods should be employed to confirm a suspected case of metastatic stomach cancer with a family history of the disease?","answer":"Imaging tests, endoscopy, biopsy, biomarker testing, and genetic risk testing should be used.","question_type":"Complex Reasoning","evidence":"Imaging tests should be used to confirm a suspected case of metastatic stomach cancer.; Endoscopy should be used to confirm a suspected case of metastatic stomach cancer.; Biopsy should be used to confirm a suspected case of metastatic stomach cancer.; Biomarker testing should be used to confirm a suspected case of metastatic stomach cancer.; Genetic risk testing should be used to confirm a suspected case of metastatic stomach cancer.","evidence_relations":"Diagnosis involves imaging tests, endoscopy, biopsy, biomarker testing, and genetic risk testing; Metastatic stomach cancer has spread to distant organs such as the liver, peritoneum, or distant lymph nodes; Family history is a risk factor for stomach cancer"},
	{"id":"Medical-984c0f56","source":"Medical","question":"How does the spread of early-stage versus locoregional stomach cancer differ in terms of stomach wall invasion and lymph node involvement?","answer":"Early-stage is confined to mucosa without lymph node involvement, while locoregional invades deeper layers and/or regional lymph nodes.","question_type":"Complex Reasoning","evidence":"Early-stage stomach cancer is confined to the mucosa.; Early-stage stomach cancer does not involve lymph nodes.; Locoregional stomach cancer invades deeper layers of the stomach wall.; Locoregional stomach cancer may involve regional lymph nodes.","evidence_relations":"Early-stage stomach cancer is confined to the mucosa and is not present in lymph nodes; Locoregional or locally advanced stomach cancer invades other layers of the stomach wall and/or regional lymph nodes or nearby organs; Early-stage stomach cancer: Confined to mucosa, not in lymph nodes (ontology rewritten); Locoregional stomach cancer: Invades other layers and/or regional lymph nodes or nearby organs (ontology rewritten)"},
	{"id":"Medical-01abc791","source":"Medical","question":"Why is intestinal type adenocarcinoma more likely to benefit from targeted therapy compared to diffuse type?","answer":"Because intestinal type more often has mutations treatable with targeted therapy, while diffuse type is less common and lacks these features.","question_type":"Complex Reasoning","evidence":"Intestinal type adenocarcinoma is more likely to benefit from targeted therapy.; Intestinal type adenocarcinoma often has mutations that are treatable with targeted therapy.; Diffuse type adenocarcinoma is less common.; Diffuse type adenocarcinoma lacks mutations that are treatable with targeted therapy.","evidence_relations":"Intestinal type adenocarcinoma forms tube- and gland-shaped structures and is more likely to have mutations treatable with targeted therapy; Diffuse type adenocarcinoma consists of scattered cells and is less common; There are two major subtypes of stomach adenocarcinoma: intestinal and diffuse"},
	{"id":"Medical-7faeddee","source":"Medical","question":"If a patient presents with an ulcer and mass in the stomach, what cancer subtype is most likely and what is the cell of origin?","answer":"Adenocarcinoma, originating from mucus-secreting cells lining the stomach.","question_type":"Complex Reasoning","evidence":"Adenocarcinoma is the most likely cancer subtype if a patient presents with an ulcer and mass in the stomach.; Adenocarcinoma originates from mucus-secreting cells lining the stomach.","evidence_relations":"Most stomach cancers are adenocarcinomas; Adenocarcinomas originate from cells lining the inside of the stomach that secrete mucus; Symptoms can include ulcer or mass formation in the stomach"},
	{"id":"Medical-ef429fbb","source":"Medical","question":"Which risk factors should be investigated in a patient with a suspected stomach mass and a positive genetic risk test?","answer":"H. pylori infection and family history should be investigated.","question_type":"Complex Reasoning","evidence":"H. pylori infection should be investigated in a patient with a suspected stomach mass.; Family history should be investigated in a patient with a suspected stomach mass.","evidence_relations":"H. pylori infection is a risk factor for stomach cancer; Family history is a risk factor for stomach cancer; Genetic risk testing is a diagnostic method for stomach cancer (ontology rewritten); Symptoms can include ulcer or mass formation in the stomach"},
	{"id":"Medical-370cff35","source":"Medical","question":"How does stomach cancer typically progress from a precancerous state to metastatic disease?","answer":"It begins with mucosal changes, spreads outward through stomach wall layers, and eventually reaches distant organs like the liver.","question_type":"Complex Reasoning","evidence":"Stomach cancer typically progresses from a precancerous state to metastatic disease.; Stomach cancer begins with mucosal changes.; Stomach cancer spreads outward through stomach wall layers.; Stomach cancer eventually reaches distant organs like the liver.","evidence_relations":"Precancerous changes often occur in the mucosa before cancer develops; Stomach cancer spreads outward through the layers of the stomach wall; Metastatic stomach cancer has spread to distant organs such as the liver, peritoneum, or distant lymph nodes"},
	{"id":"Medical-3e87c7a1","source":"Medical","question":"What anatomical locations are at risk for distant metastasis from stomach cancer and what is the typical spread pattern?","answer":"The liver, peritoneum, distant lymph nodes, pancreas, and spleen are at risk due to distant spread.","question_type":"Complex Reasoning","evidence":"The liver is at risk for distant metastasis from stomach cancer.; The peritoneum is at risk for distant metastasis from stomach cancer.; Distant lymph nodes are at risk for distant metastasis from stomach cancer.; The pancreas is at risk for distant metastasis from stomach cancer.; The spleen is at risk for distant metastasis from stomach cancer.; Stomach cancer typically spreads to distant organs.","evidence_relations":"Metastatic stomach cancer has spread to distant organs such as the liver, peritoneum, or distant lymph nodes; Cancer can spread to lymph nodes, veins, arteries, and organs such as the liver, pancreas, and spleen; Distant spread pattern includes liver, peritoneum, distant lymph nodes, pancreas, and spleen (ontology rewritten)"},
	{"id":"Medical-84ec68f0","source":"Medical","question":"Why is it important to perform both biomarker and genetic risk testing in the diagnosis of stomach cancer?","answer":"Because diagnosis requires comprehensive assessment, including identification of treatable mutations and genetic risk factors.","question_type":"Complex Reasoning","evidence":"It is important to perform biomarker testing in the diagnosis of stomach cancer.; It is important to perform genetic risk testing in the diagnosis of stomach cancer.; Diagnosis of stomach cancer requires comprehensive assessment.; Diagnosis of stomach cancer includes identification of treatable mutations.; Diagnosis of stomach cancer includes identification of genetic risk factors.","evidence_relations":"Diagnosis involves imaging tests, endoscopy, biopsy, biomarker testing, and genetic risk testing; Intestinal type adenocarcinoma is more likely to have mutations treatable with targeted therapy; Family history is a risk factor for stomach cancer"},
	{"id":"Medical-2157ec85","source":"Medical","question":"What features distinguish diffuse type adenocarcinoma from intestinal type in stomach cancer pathology?","answer":"Diffuse type consists of scattered cells and is less common, while intestinal type forms tube- and gland-shaped structures.","question_type":"Complex Reasoning","evidence":"Diffuse type adenocarcinoma consists of scattered cells.; Diffuse type adenocarcinoma is less common than intestinal type.; Intestinal type adenocarcinoma forms tube-shaped structures.; Intestinal type adenocarcinoma forms gland-shaped structures.","evidence_relations":"Intestinal type adenocarcinoma forms tube- and gland-shaped structures and is more likely to have mutations treatable with targeted therapy; Diffuse type adenocarcinoma consists of scattered cells and is less common; There are two major subtypes of stomach adenocarcinoma: intestinal and diffuse"},
	{"id":"Medical-56e2a338","source":"Medical","question":"If a stomach cancer is found to be confined to the mucosa and there is no lymph node involvement, what is the stage and which stomach wall layer is affected?","answer":"It is early-stage stomach cancer, affecting only the mucosa.","question_type":"Complex Reasoning","evidence":"The cancer is classified as early-stage stomach cancer.; The cancer is confined to the mucosa.; There is no lymph node involvement.","evidence_relations":"Early-stage stomach cancer is confined to the mucosa and is not present in lymph nodes; Early-stage stomach cancer: Confined to mucosa, not in lymph nodes (ontology rewritten); Mucosa is the innermost layer of the stomach wall (ontology rewritten)"},
	{"id":"Medical-33af9785","source":"Medical","question":"What is the relationship between H. pylori infection, precancerous mucosal changes, and stomach cancer development?","answer":"H. pylori infection is a risk factor that can lead to precancerous mucosal changes, which may progress to stomach cancer.","question_type":"Complex Reasoning","evidence":"H. pylori infection is a risk factor for stomach cancer.; H. pylori infection can lead to precancerous mucosal changes.; Precancerous mucosal changes may progress to stomach cancer.","evidence_relations":"H. pylori infection is a risk factor for stomach cancer; Precancerous changes often occur in the mucosa before cancer develops; Stomach cancer is a type of cancer that arises in the stomach"},
	{"id":"Medical-7fba506d","source":"Medical","question":"How does the anatomical location within the stomach influence the potential spread of cancer to nearby organs?","answer":"Tumors in any stomach region can invade adjacent organs such as the pancreas and spleen through local and distant spread.","question_type":"Complex Reasoning","evidence":"Tumors in any stomach region can invade adjacent organs.; Adjacent organs include the pancreas.; Adjacent organs include the spleen.; Cancer can spread through local and distant mechanisms.","evidence_relations":"Anatomical Location includes cardia, fundus, body, antrum, pylorus, and esophagogastric junction (ontology rewritten); Locoregional or locally advanced stomach cancer invades other layers of the stomach wall and/or regional lymph nodes or nearby organs; Cancer can spread to lymph nodes, veins, arteries, and organs such as the liver, pancreas, and spleen"},
	{"id":"Medical-032223d5","source":"Medical","question":"Why might a patient with a stomach mass and positive family history undergo genetic risk testing in addition to biopsy?","answer":"Because family history is a genetic risk factor and diagnosis requires both tissue confirmation and risk assessment.","question_type":"Complex Reasoning","evidence":"A patient with a stomach mass and positive family history may undergo genetic risk testing.; Family history is a genetic risk factor.; Diagnosis requires tissue confirmation.; Diagnosis requires risk assessment.","evidence_relations":"Family history is a risk factor for stomach cancer; Diagnosis involves imaging tests, endoscopy, biopsy, biomarker testing, and genetic risk testing; Genetic risk testing is a diagnostic method for stomach cancer (ontology rewritten)"},
	{"id":"Medical-d42f24b5","source":"Medical","question":"What is the sequence of diagnostic steps for a patient presenting with symptoms of ulcer or mass suspected to be stomach cancer?","answer":"Imaging tests, endoscopy, and biopsy are performed, followed by biomarker and genetic risk testing.","question_type":"Complex Reasoning","evidence":"The sequence of diagnostic steps includes imaging tests.; The sequence of diagnostic steps includes endoscopy.; The sequence of diagnostic steps includes biopsy.; Biomarker testing is performed after the initial diagnostic steps.; Genetic risk testing is performed after the initial diagnostic steps.","evidence_relations":"Symptoms can include ulcer or mass formation in the stomach; Diagnosis involves imaging tests, endoscopy, biopsy, biomarker testing, and genetic risk testing; Biopsy is a diagnostic method for stomach cancer (ontology rewritten)"},
	{"id":"Medical-c4772f49","source":"Medical","question":"How do the submucosa and muscle layer relate to the progression from early-stage to locoregional stomach cancer?","answer":"Progression from early-stage to locoregional involves invasion beyond the mucosa into the submucosa and muscle layer.","question_type":"Complex Reasoning","evidence":"Progression from early-stage stomach cancer involves invasion beyond the mucosa.; Invasion beyond the mucosa includes the submucosa.; Invasion beyond the mucosa includes the muscle layer.","evidence_relations":"Early-stage stomach cancer is confined to the mucosa and is not present in lymph nodes; Locoregional or locally advanced stomach cancer invades other layers of the stomach wall and/or regional lymph nodes or nearby organs; Stomach Wall Layer includes mucosa, submucosa, muscle layer, subserosa, and serosa (ontology rewritten)"},
	{"id":"Medical-cb781b83","source":"Medical","question":"What sequence of diagnostic steps is required to confirm a glioma diagnosis and classify its grade and biomarker status?","answer":"A neurological exam, imaging with MRI, and a biopsy for histology and molecular testing are required.","question_type":"Complex Reasoning","evidence":"A neurological exam is required to confirm a glioma diagnosis.; Imaging with MRI is required to confirm a glioma diagnosis.; A biopsy for histology is required to confirm a glioma diagnosis.; Molecular testing is required to classify glioma grade and biomarker status.","evidence_relations":"Diagnosis of glioma involves neurological exam, imaging (MRI, CT), and biopsy; MRI is the most useful imaging test for identifying glioma; Biopsy is required for definitive diagnosis and molecular testing; Gliomas are classified by histology, grade, and biomarkers"},
	{"id":"Medical-6cb18929","source":"Medical","question":"Which glioma subtype is always considered high-grade and what diagnostic and treatment steps are typically involved?","answer":"Glioblastoma is always high-grade (Grade 4) and requires MRI, biopsy, and additional therapy after surgery.","question_type":"Complex Reasoning","evidence":"Glioblastoma is always considered high-grade.; Glioblastoma is classified as Grade 4.; MRI is required for glioblastoma diagnosis.; A biopsy is required for glioblastoma diagnosis.; Additional therapy is required after surgery for glioblastoma.","evidence_relations":"Glioblastoma is the most aggressive subtype of glioma; Grade 4 gliomas are most commonly glioblastomas; MRI is the most useful imaging test for identifying glioma; Biopsy is required for definitive diagnosis and molecular testing; High-grade gliomas require additional therapy after surgery"},
	{"id":"Medical-569780c4","source":"Medical","question":"How is IDH mutation status relevant for classifying both astrocytoma and oligodendroglioma, and what procedure is necessary to determine this status?","answer":"IDH mutation is a biomarker used to classify both astrocytoma and oligodendroglioma, and biopsy is necessary to determine this status.","question_type":"Complex Reasoning","evidence":"IDH mutation status is relevant for classifying astrocytoma.; IDH mutation status is relevant for classifying oligodendroglioma.; A biopsy is necessary to determine IDH mutation status.","evidence_relations":"IDH mutation is a biomarker used to classify gliomas; Astrocytoma and oligodendroglioma have IDH mutation as a biomarker; Biopsy is required for definitive diagnosis and molecular testing"},
	{"id":"Medical-32b9ef93","source":"Medical","question":"If a patient presents with seizures and cognitive changes, what diagnostic methods should be prioritized and why?","answer":"A neurological exam and MRI should be prioritized because these symptoms are common in glioma and MRI is the best imaging test.","question_type":"Complex Reasoning","evidence":"A neurological exam should be prioritized for patients with seizures and cognitive changes.; An MRI should be prioritized for patients with seizures and cognitive changes.; Seizures and cognitive changes are common symptoms in glioma.; MRI is the best imaging test for glioma.","evidence_relations":"Symptoms of glioma include headache, seizures, fatigue, nausea, vomiting, cognitive changes, weakness, personality changes, and vision problems; Diagnosis of glioma involves neurological exam, imaging (MRI, CT), and biopsy; MRI is the most useful imaging test for identifying glioma"},
	{"id":"Medical-6f0e62e5","source":"Medical","question":"Why is follow-up with periodic MRI imaging recommended after treatment for glioma?","answer":"Follow-up MRI is recommended to monitor for recurrence after glioma treatment.","question_type":"Complex Reasoning","evidence":"Follow-up MRI is recommended after treatment for glioma.; Follow-up MRI is used to monitor for recurrence after glioma treatment.","evidence_relations":"Follow-up with periodic imaging (MRI) is recommended to monitor for recurrence; Treatment options for glioma include surgery, radiation therapy, chemotherapy, and clinical trials"},
	{"id":"Medical-732c4e13","source":"Medical","question":"How does performance status influence treatment eligibility for glioma patients, and how is it assessed?","answer":"Performance status is assessed clinically and determines eligibility for glioma treatments.","question_type":"Complex Reasoning","evidence":"Performance status is assessed clinically.; Performance status determines eligibility for glioma treatments.","evidence_relations":"Performance status is assessed to determine treatment eligibility; Clinical Evaluation includes performance status and neurological exam"},
	{"id":"Medical-889e2c6a","source":"Medical","question":"What factors contribute to a poorer prognosis in glioma patients, and how are these factors determined?","answer":"High-grade glioma and glioblastoma contribute to poorer prognosis, determined by histology and grade from biopsy.","question_type":"Complex Reasoning","evidence":"High-grade glioma contributes to poorer prognosis in glioma patients.; Glioblastoma contributes to poorer prognosis in glioma patients.; Prognosis factors are determined by histology and grade from biopsy.","evidence_relations":"High-grade gliomas have poorer prognosis; Glioblastoma is the most aggressive subtype of glioma; Gliomas are classified by histology, grade, and biomarkers; Biopsy is required for definitive diagnosis and molecular testing"},
	{"id":"Medical-68c30458","source":"Medical","question":"What is the rationale for recommending molecular testing after a biopsy in glioma diagnosis?","answer":"Molecular testing after biopsy is recommended to determine biomarker status and guide classification and treatment.","question_type":"Complex Reasoning","evidence":"Molecular testing is recommended after biopsy in glioma diagnosis.; Molecular testing determines biomarker status.; Molecular testing guides classification and treatment of glioma.","evidence_relations":"Biopsy is required for definitive diagnosis and molecular testing; Gliomas are classified by histology, grade, and biomarkers; IDH mutation is a biomarker used to classify gliomas"},
	{"id":"Medical-3a5fb7b0","source":"Medical","question":"Why are high-grade gliomas treated differently than low-grade gliomas following surgery?","answer":"High-grade gliomas require additional therapy after surgery due to their aggressive nature, unlike low-grade gliomas.","question_type":"Complex Reasoning","evidence":"High-grade gliomas require additional therapy after surgery.; Low-grade gliomas do not require additional therapy after surgery.; High-grade gliomas are more aggressive than low-grade gliomas.","evidence_relations":"High-grade gliomas require additional therapy after surgery; Grades 1 and 2 are low-grade gliomas; grades 3 and 4 are high-grade gliomas; Glioblastoma is the most aggressive subtype of glioma"},
	{"id":"Medical-4191d4b2","source":"Medical","question":"Which two diagnostic methods are essential for both initial detection and definitive classification of glioma?","answer":"MRI is essential for initial detection and biopsy for definitive classification of glioma.","question_type":"Complex Reasoning","evidence":"MRI is essential for the initial detection of glioma.; Biopsy is essential for the definitive classification of glioma.","evidence_relations":"MRI is the most useful imaging test for identifying glioma; Biopsy is required for definitive diagnosis and molecular testing"},
	{"id":"Medical-43a4d872","source":"Medical","question":"What symptoms in an adult patient should prompt evaluation for glioma using imaging and neurological examination?","answer":"Symptoms like headache, seizures, and cognitive changes in adults should prompt MRI and neurological exam for glioma.","question_type":"Complex Reasoning","evidence":"Symptoms like headache should prompt evaluation for glioma.; Symptoms like seizures should prompt evaluation for glioma.; Symptoms like cognitive changes should prompt evaluation for glioma.; MRI and neurological exam should be used for glioma evaluation.","evidence_relations":"Gliomas are more common in adults than children; Symptoms of glioma include headache, seizures, fatigue, nausea, vomiting, cognitive changes, weakness, personality changes, and vision problems; Diagnosis of glioma involves neurological exam, imaging (MRI, CT), and biopsy"},
	{"id":"Medical-9386f24f","source":"Medical","question":"How do grade and biomarker status together affect the classification of astrocytoma and oligodendroglioma?","answer":"Grade and IDH mutation status are both required to classify astrocytoma and oligodendroglioma.","question_type":"Complex Reasoning","evidence":"Grade is required to classify astrocytoma.; IDH mutation status is required to classify astrocytoma.; Grade is required to classify oligodendroglioma.; IDH mutation status is required to classify oligodendroglioma.","evidence_relations":"Astrocytoma and oligodendroglioma have IDH mutation as a biomarker; Gliomas are classified by histology, grade, and biomarkers; Astrocytoma: Grade 1, 2, 3, 4; Oligodendroglioma: Grade 2, 3"},
	{"id":"Medical-91742d51","source":"Medical","question":"Why is glioblastoma associated with the worst prognosis among glioma subtypes?","answer":"Glioblastoma is the most aggressive subtype and is always high-grade, leading to a poor prognosis.","question_type":"Complex Reasoning","evidence":"Glioblastoma is associated with the worst prognosis among glioma subtypes.; Glioblastoma is the most aggressive subtype of glioma.; Glioblastoma is always high-grade.","evidence_relations":"Glioblastoma is the most aggressive subtype of glioma; Grade 4 gliomas are most commonly glioblastomas; High-grade gliomas have poorer prognosis"},
	{"id":"Medical-c6b862bd","source":"Medical","question":"What are the key risk factors for developing glioma, and how are these determined from the ontology?","answer":"Key risk factors are age (more common in adults) and non-hereditary mutation, as indicated by the ontology.","question_type":"Complex Reasoning","evidence":"Key risk factors for developing glioma include age.; Glioma is more common in adults.; Non-hereditary mutation is a key risk factor for glioma.; The ontology indicates the key risk factors for glioma.","evidence_relations":"Gliomas are more common in adults than children; Most gliomas are not hereditary; Risk Factor includes age (more common in adults) and non-hereditary mutation"},
	{"id":"Medical-39012a36","source":"Medical","question":"Which treatments may be considered for a glioma patient after surgical resection and how is this decision guided?","answer":"Radiation therapy, chemotherapy, or clinical trials may be considered after surgery, guided by grade and performance status.","question_type":"Complex Reasoning","evidence":"Radiation therapy may be considered for a glioma patient after surgical resection.; Chemotherapy may be considered for a glioma patient after surgical resection.; Clinical trials may be considered for a glioma patient after surgical resection.; The decision for treatment is guided by the grade of the glioma.; The decision for treatment is guided by the performance status of the patient.","evidence_relations":"Treatment options for glioma include surgery, radiation therapy, chemotherapy, and clinical trials; High-grade gliomas require additional therapy after surgery; Performance status is assessed to determine treatment eligibility"},
	{"id":"Medical-ca3e2437","source":"Medical","question":"Which diagnostic procedures are necessary to both confirm an AML diagnosis and determine the specific subtype?","answer":"Bone marrow aspirate and biopsy, flow cytometry, immunophenotyping, and molecular/cytogenetic testing are required.","question_type":"Complex Reasoning","evidence":"Bone marrow aspirate and biopsy are necessary to confirm an AML diagnosis.; Flow cytometry is necessary to confirm an AML diagnosis.; Immunophenotyping is necessary to confirm an AML diagnosis.; Molecular/cytogenetic testing is necessary to confirm an AML diagnosis.; These procedures are required to determine the specific subtype of AML.","evidence_relations":"AML is diagnosed by the presence of 20% myeloblasts in bone marrow or blood; Diagnosis of AML involves blood tests, bone marrow aspirate and biopsy, flow cytometry, immunophenotyping, cytogenetic and molecular testing, and imaging studies; Genetic and biomarker tests are used to determine AML subtype and guide treatment"},
	{"id":"Medical-ec84ae56","source":"Medical","question":"Why would a patient with FLT3-ITD mutated AML receive a targeted therapy in addition to chemotherapy?","answer":"FLT3 inhibitors are used as targeted therapy for FLT3-mutated AML, which is treated alongside standard chemotherapy.","question_type":"Complex Reasoning","evidence":"FLT3 inhibitors are used as targeted therapy for FLT3-mutated AML.; FLT3-ITD mutated AML may receive targeted therapy in addition to chemotherapy.; FLT3-mutated AML is treated alongside standard chemotherapy.","evidence_relations":"Targeted therapies are used for AML with specific genetic alterations, such as FLT3 inhibitors for FLT3-mutated AML; Chemotherapy is the standard of care for AML; Common genetic alterations in AML include FLT3-ITD"},
	{"id":"Medical-890965f6","source":"Medical","question":"What laboratory findings and symptoms together would strongly suggest a diagnosis of AML?","answer":"The presence of 20% myeloblasts in bone marrow or blood along with symptoms such as fatigue, infections, bleeding, and bruising suggest AML.","question_type":"Complex Reasoning","evidence":"The presence of 20% myeloblasts in bone marrow or blood suggests AML.; Symptoms such as fatigue suggest AML.; Symptoms such as infections suggest AML.; Symptoms such as bleeding suggest AML.; Symptoms such as bruising suggest AML.","evidence_relations":"AML is diagnosed by the presence of 20% myeloblasts in bone marrow or blood; Symptoms of AML include fatigue, infections, bleeding, and bruising"},
	{"id":"Medical-2a61ebd2","source":"Medical","question":"How does the identification of the PML::RARA fusion gene influence both the classification and treatment of AML?","answer":"Detection of PML::RARA classifies the AML as acute promyelocytic leukemia (APL), which is treated with chemotherapy and targeted therapy.","question_type":"Complex Reasoning","evidence":"Detection of the PML::RARA fusion gene classifies the AML as acute promyelocytic leukemia (APL).; Acute promyelocytic leukemia (APL) is treated with chemotherapy.; Acute promyelocytic leukemia (APL) is treated with targeted therapy.","evidence_relations":"Acute promyelocytic leukemia (APL) is a subtype of AML characterized by the PML::RARA fusion gene; AML subtypes are defined by gene mutations or abnormal chromosomes; Acute promyelocytic leukemia (APL) is a subtype of AML characterized by the PML::RARA fusion gene; Acute promyelocytic leukemia (APL) is treated with chemotherapy and targeted therapy"},
	{"id":"Medical-0a8d750c","source":"Medical","question":"What are the key factors influencing the selection of treatment in AML patients?","answer":"Genetic alterations, performance status, and general health are key factors influencing treatment selection.","question_type":"Complex Reasoning","evidence":"Genetic alterations are key factors influencing treatment selection in AML patients.; Performance status is a key factor influencing treatment selection in AML patients.; General health is a key factor influencing treatment selection in AML patients.","evidence_relations":"Genetic and biomarker tests are used to determine AML subtype and guide treatment; Performance status and general health influence treatment selection; Prognostic Factor includes genetic alterations and performance status"},
	{"id":"Medical-f6a94128","source":"Medical","question":"Which tests are essential to perform before starting systemic therapy in a young AML patient concerned about fertility?","answer":"Fertility preservation counseling and referral to a reproductive specialist should be done before therapy.","question_type":"Complex Reasoning","evidence":"Fertility preservation counseling should be done before starting systemic therapy in a young AML patient.; Referral to a reproductive specialist should be done before starting systemic therapy in a young AML patient.","evidence_relations":"Fertility preservation should be discussed before starting systemic therapy; Fertility Preservation includes fertility preservation counseling and referral to reproductive specialist"},
	{"id":"Medical-4e39d9d5","source":"Medical","question":"What steps are necessary to diagnose and fully characterize an AML case with suspected extramedullary involvement?","answer":"Diagnosis requires blood tests, bone marrow evaluation, flow cytometry, molecular/cytogenetic testing, and imaging (CT, MRI, PET/CT) for extramedullary disease.","question_type":"Complex Reasoning","evidence":"Diagnosis of AML with suspected extramedullary involvement requires blood tests.; Diagnosis of AML with suspected extramedullary involvement requires bone marrow evaluation.; Diagnosis of AML with suspected extramedullary involvement requires flow cytometry.; Diagnosis of AML with suspected extramedullary involvement requires molecular/cytogenetic testing.; Imaging (CT, MRI, PET/CT) is required for extramedullary disease.","evidence_relations":"Diagnosis of AML involves blood tests, bone marrow aspirate and biopsy, flow cytometry, immunophenotyping, cytogenetic and molecular testing, and imaging studies; Imaging (CT, MRI, PET/CT) is used to assess extramedullary disease or complications; Diagnostic Method includes Imaging: CT scan, MRI, PET/CT"},
	{"id":"Medical-57f0c93d","source":"Medical","question":"Which combination of therapies may be considered for an AML patient with CD33-positive blasts and why?","answer":"Chemotherapy plus gemtuzumab ozogamicin (GO), a targeted therapy for CD33-positive AML, may be used.","question_type":"Complex Reasoning","evidence":"Chemotherapy may be considered for an AML patient with CD33-positive blasts.; Gemtuzumab ozogamicin (GO) is a targeted therapy for CD33-positive AML.; Chemotherapy plus gemtuzumab ozogamicin (GO) may be used for an AML patient with CD33-positive blasts.","evidence_relations":"Targeted therapies are used for AML with specific genetic alterations, such as gemtuzumab ozogamicin for CD33-positive AML; Chemotherapy is the standard of care for AML; Biomarker includes CD33"},
	{"id":"Medical-ddde0e24","source":"Medical","question":"For which AML patients is hematopoietic cell transplant considered and what factors influence this decision?","answer":"Hematopoietic cell transplant is considered for eligible patients based on performance status, genetic alterations, and response to induction therapy.","question_type":"Complex Reasoning","evidence":"Hematopoietic cell transplant is considered for eligible patients.; The decision for hematopoietic cell transplant is based on performance status.; The decision for hematopoietic cell transplant is based on genetic alterations.; The decision for hematopoietic cell transplant is based on response to induction therapy.","evidence_relations":"Hematopoietic cell transplant is considered for eligible patients; Prognostic Factor includes genetic alterations, performance status, and response to induction therapy"},
	{"id":"Medical-c57bf64d","source":"Medical","question":"How does family history affect AML risk assessment, and what additional steps should be taken in such cases?","answer":"Family history increases AML risk due to hereditary predisposition, so genetic counseling and testing may be indicated.","question_type":"Complex Reasoning","evidence":"Family history increases AML risk.; Family history increases AML risk due to hereditary predisposition.; Genetic counseling may be indicated for patients with a family history of AML.; Genetic testing may be indicated for patients with a family history of AML.","evidence_relations":"Family history of leukemia and hereditary predisposition syndromes are risk factors for AML; Risk Factor includes family history of leukemia and leukemia predisposition syndrome"},
	{"id":"Medical-640a315c","source":"Medical","question":"Which supportive care interventions are necessary for an AML patient presenting with severe anemia and infection risk?","answer":"Transfusions and infection prevention measures are necessary supportive care interventions.","question_type":"Complex Reasoning","evidence":"Transfusions are necessary supportive care interventions for AML patients.; Infection prevention measures are necessary supportive care interventions for AML patients.","evidence_relations":"Supportive care includes transfusions, infection prevention, and management of side effects; AML causes a buildup of blasts in bone marrow and blood, leading to low counts of healthy red blood cells, platelets, and white blood cells"},
	{"id":"Medical-669af50b","source":"Medical","question":"How does performance status impact the treatment plan for an AML patient?","answer":"Performance status influences the selection and intensity of AML treatment.","question_type":"Complex Reasoning","evidence":"Performance status impacts the treatment plan for an AML patient.; Performance status influences the selection of AML treatment.; Performance status influences the intensity of AML treatment.","evidence_relations":"Performance status and general health influence treatment selection; Performance Status includes Eastern Cooperative Oncology Group (ECOG) score and Karnofsky Performance Status (KPS)"},
	{"id":"Medical-1ab31cd8","source":"Medical","question":"What combination of findings would support a diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN)?","answer":"BPDCN diagnosis is supported by its aggressive nature, involvement of blood, bone marrow, lymph nodes, and skin, and its classification as an AML subtype.","question_type":"Complex Reasoning","evidence":"The aggressive nature of BPDCN supports its diagnosis.; Involvement of blood supports the diagnosis of BPDCN.; Involvement of bone marrow supports the diagnosis of BPDCN.; Involvement of lymph nodes supports the diagnosis of BPDCN.; Involvement of skin supports the diagnosis of BPDCN.; BPDCN is classified as an AML subtype.","evidence_relations":"Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive subtype of AML; Sites of Involvement for BPDCN include blood, bone marrow, lymph nodes, skin; AML subtypes are defined by gene mutations or abnormal chromosomes"},
	{"id":"Medical-575e6d7f","source":"Medical","question":"Which phases make up the standard treatment course for AML and what is their primary goal?","answer":"Induction, consolidation, and maintenance phases make up AML treatment, aiming for remission.","question_type":"Complex Reasoning","evidence":"The standard treatment course for AML includes induction phases.; The standard treatment course for AML includes consolidation phases.; The standard treatment course for AML includes maintenance phases.; The primary goal of AML treatment is to achieve remission.","evidence_relations":"Treatment for AML is delivered in phases with the goal of achieving remission; Treatment Phase includes induction, consolidation, and maintenance"},
	{"id":"Medical-ee302181","source":"Medical","question":"Why is it important to perform both flow cytometry and molecular testing in newly diagnosed AML?","answer":"Both tests are essential to identify cell surface markers and genetic alterations for accurate classification and treatment guidance.","question_type":"Complex Reasoning","evidence":"Flow cytometry is essential in newly diagnosed AML.; Molecular testing is essential in newly diagnosed AML.; Flow cytometry identifies cell surface markers in AML.; Molecular testing identifies genetic alterations in AML.; Both tests provide accurate classification and treatment guidance for AML.","evidence_relations":"Diagnosis of AML involves blood tests, bone marrow aspirate and biopsy, flow cytometry, immunophenotyping, cytogenetic and molecular testing, and imaging studies; Genetic and biomarker tests are used to determine AML subtype and guide treatment"},
	{"id":"Medical-54a3a465","source":"Medical","question":"Which maintenance therapies are recommended for a patient with advanced ovarian cancer who is BRCA-mutated after initial treatment?","answer":"PARP inhibitors such as olaparib, niraparib, or rucaparib are recommended as maintenance therapy for advanced or BRCA-mutated ovarian cancer after initial treatment.","question_type":"Complex Reasoning","evidence":"PARP inhibitors are recommended as maintenance therapy for advanced ovarian cancer.; Olaparib is a recommended PARP inhibitor for advanced or BRCA-mutated ovarian cancer.; Niraparib is a recommended PARP inhibitor for advanced or BRCA-mutated ovarian cancer.; Rucaparib is a recommended PARP inhibitor for advanced or BRCA-mutated ovarian cancer.; Maintenance therapy is recommended after initial treatment for advanced or BRCA-mutated ovarian cancer.","evidence_relations":"Maintenance therapy with PARP inhibitors (olaparib, niraparib, rucaparib) is recommended for advanced or BRCA-mutated/HRD-positive cancers after initial treatment; BRCA1 and BRCA2 mutations are major hereditary risk factors for ovarian cancer; Olaparib (Lynparza), Niraparib (Zejula), and Rucaparib (Rubraca) are listed as maintenance therapy options in the ontology"},
	{"id":"Medical-8f1032c7","source":"Medical","question":"What diagnostic steps should be taken for a woman presenting with persistent bloating and pelvic pain suggestive of ovarian cancer?","answer":"Imaging such as ultrasound or CT, abdominal and pelvic exam, biopsy, and tumor marker blood tests should be performed.","question_type":"Complex Reasoning","evidence":"Imaging such as ultrasound should be performed for a woman with persistent bloating and pelvic pain.; CT imaging should be performed for a woman with persistent bloating and pelvic pain.; An abdominal and pelvic exam should be performed for a woman with persistent bloating and pelvic pain.; A biopsy should be performed for a woman with persistent bloating and pelvic pain.; Tumor marker blood tests should be performed for a woman with persistent bloating and pelvic pain.","evidence_relations":"Diagnosis of ovarian cancer involves imaging (ultrasound, CT, MRI, PET), abdominal and pelvic exam, biopsy, and blood tests including tumor markers; Common symptoms of ovarian cancer include bloating and pelvic or abdominal pain; The ontology lists 'persistent bloating' and 'pelvic pain' as symptoms and includes diagnostic methods such as imaging, biopsy, and tumor marker tests"},
	{"id":"Medical-ffffe4b8","source":"Medical","question":"How is platinum-resistant ovarian cancer managed differently from platinum-sensitive recurrence?","answer":"Platinum-resistant disease is treated with non-platinum chemotherapy, bevacizumab, or targeted therapies, while platinum-sensitive recurrence is treated with platinum-based chemotherapy, possibly with bevacizumab and secondary cytoreductive surgery.","question_type":"Complex Reasoning","evidence":"Platinum-resistant ovarian cancer is treated with non-platinum chemotherapy.; Platinum-resistant ovarian cancer is treated with bevacizumab.; Platinum-resistant ovarian cancer is treated with targeted therapies.; Platinum-sensitive recurrence is treated with platinum-based chemotherapy.; Platinum-sensitive recurrence may be treated with bevacizumab.; Platinum-sensitive recurrence may involve secondary cytoreductive surgery.","evidence_relations":"Platinum-resistant ovarian cancer is treated with non-platinum chemotherapy, bevacizumab, or targeted therapies such as mirvetuximab soravtansine-gynx for FR-positive tumors; Platinum-sensitive recurrence is treated with platinum-based chemotherapy, possibly with bevacizumab, and may include secondary cytoreductive surgery; The ontology specifies different treatment regimens for platinum-sensitive and platinum-resistant recurrence"},
	{"id":"Medical-2521e4dd","source":"Medical","question":"Why is genetic testing for BRCA mutations recommended for all ovarian cancer patients?","answer":"Because BRCA mutations are major hereditary risk factors and influence eligibility for targeted therapies such as PARP inhibitors.","question_type":"Complex Reasoning","evidence":"BRCA mutations are major hereditary risk factors.; BRCA mutations influence eligibility for targeted therapies.; Targeted therapies include PARP inhibitors.","evidence_relations":"Genetic testing for BRCA and other hereditary syndromes is recommended for all patients with ovarian cancer; BRCA1 and BRCA2 mutations are major hereditary risk factors for ovarian cancer; Maintenance therapy with PARP inhibitors is recommended for advanced or BRCA-mutated/HRD-positive cancers after initial treatment"},
	{"id":"Medical-884a8392","source":"Medical","question":"Which cancers are managed similarly to ovarian cancer and why might their management overlap?","answer":"Primary peritoneal cancer and fallopian tube cancer are managed similarly to ovarian cancer due to shared origin and treatment protocols.","question_type":"Complex Reasoning","evidence":"Primary peritoneal cancer is managed similarly to ovarian cancer.; Fallopian tube cancer is managed similarly to ovarian cancer.; Primary peritoneal cancer and fallopian tube cancer share an origin.; Primary peritoneal cancer and fallopian tube cancer have similar treatment protocols.","evidence_relations":"Primary peritoneal cancer and fallopian tube cancer are managed similarly to ovarian cancer; The ontology lists primary peritoneal cancer and fallopian tube cancer as related cancers under ovarian cancer"},
	{"id":"Medical-e851fe04","source":"Medical","question":"What factors determine the use of fertility-sparing surgery in ovarian cancer patients?","answer":"Fertility-sparing surgery is considered for select early-stage cases, depending on stage and patient fertility desires.","question_type":"Complex Reasoning","evidence":"Fertility-sparing surgery is considered for select early-stage cases.; The use of fertility-sparing surgery depends on the stage of cancer.; The use of fertility-sparing surgery depends on patient fertility desires.","evidence_relations":"Fertility-sparing surgery may be considered for select early-stage cases; Staging is based on the FIGO system (Stages I-IV) and requires surgical staging; The ontology lists surgical procedures and stages relevant to ovarian cancer"},
	{"id":"Medical-6e8f1b95","source":"Medical","question":"Which tumor markers should be monitored during surveillance after ovarian cancer treatment?","answer":"CA-125 or other tumor markers such as HE4, CEA, and CA 19-9 should be monitored during surveillance.","question_type":"Complex Reasoning","evidence":"CA-125 should be monitored during surveillance after ovarian cancer treatment.; HE4 should be monitored during surveillance after ovarian cancer treatment.; CEA should be monitored during surveillance after ovarian cancer treatment.; CA 19-9 should be monitored during surveillance after ovarian cancer treatment.","evidence_relations":"Surveillance after treatment includes regular physical and pelvic exams, and monitoring of CA-125 or other tumor markers; The ontology lists CA-125, HE4, CEA, and CA 19-9 as tumor markers for ovarian cancer"},
	{"id":"Medical-18fc35e5","source":"Medical","question":"What are the recommended initial treatments for most stages of epithelial ovarian cancer?","answer":"Surgery (hysterectomy with bilateral salpingo-oophorectomy) followed by chemotherapy (typically paclitaxel and carboplatin) is recommended.","question_type":"Complex Reasoning","evidence":"Surgery is recommended for most stages of epithelial ovarian cancer.; Hysterectomy with bilateral salpingo-oophorectomy is a recommended surgical procedure.; Chemotherapy is recommended after surgery for epithelial ovarian cancer.; Paclitaxel and carboplatin are typically used in chemotherapy for epithelial ovarian cancer.","evidence_relations":"Surgery (hysterectomy with bilateral salpingo-oophorectomy) is the standard initial treatment for most ovarian cancers; Chemotherapy (typically paclitaxel and carboplatin) is recommended after surgery for most stages; Epithelial ovarian cancer is the most common type of ovarian cancer"},
	{"id":"Medical-eb042e58","source":"Medical","question":"Which biomarkers are tested to determine eligibility for targeted therapies in ovarian cancer?","answer":"BRCA mutation, HRD status, MSI, MMR, HER2 expression, TMB, BRAF V600E, FR, RET mutations, and NTRK gene fusion are tested.","question_type":"Complex Reasoning","evidence":"BRCA mutation is tested to determine eligibility for targeted therapies in ovarian cancer.; HRD status is tested to determine eligibility for targeted therapies in ovarian cancer.; MSI is tested to determine eligibility for targeted therapies in ovarian cancer.; MMR is tested to determine eligibility for targeted therapies in ovarian cancer.; HER2 expression is tested to determine eligibility for targeted therapies in ovarian cancer.; TMB is tested to determine eligibility for targeted therapies in ovarian cancer.; BRAF V600E is tested to determine eligibility for targeted therapies in ovarian cancer.; FR is tested to determine eligibility for targeted therapies in ovarian cancer.; RET mutations are tested to determine eligibility for targeted therapies in ovarian cancer.; NTRK gene fusion is tested to determine eligibility for targeted therapies in ovarian cancer.","evidence_relations":"Tumor biomarker testing includes BRCA mutation, HRD status, MSI, MMR, HER2 expression, TMB, BRAF V600E, FR, RET mutations, and NTRK gene fusion; The ontology lists these as genetic alterations or biomarkers for ovarian cancer"},
	{"id":"Medical-6bed629f","source":"Medical","question":"How does the management of recurrent ovarian cancer differ based on platinum sensitivity?","answer":"Platinum-sensitive recurrence is managed with platinum-based chemotherapy and possibly surgery, while platinum-resistant recurrence uses non-platinum chemotherapy or targeted agents.","question_type":"Complex Reasoning","evidence":"Platinum-sensitive recurrence is managed with platinum-based chemotherapy.; Platinum-sensitive recurrence may involve surgery.; Platinum-resistant recurrence is managed with non-platinum chemotherapy.; Platinum-resistant recurrence may involve targeted agents.","evidence_relations":"Recurrence is managed based on platinum sensitivity, biomarker status, and may include surgery, chemotherapy, targeted therapy, immunotherapy, or clinical trial enrollment; Platinum-sensitive recurrence is treated with platinum-based chemotherapy, possibly with bevacizumab, and may include secondary cytoreductive surgery; Platinum-resistant ovarian cancer is treated with non-platinum chemotherapy, bevacizumab, or targeted therapies"},
	{"id":"Medical-0be2176d","source":"Medical","question":"Why might a patient with FR-positive platinum-resistant ovarian cancer be treated with mirvetuximab soravtansine-gynx?","answer":"Mirvetuximab soravtansine-gynx is a targeted therapy specifically indicated for FR-positive platinum-resistant ovarian cancer.","question_type":"Complex Reasoning","evidence":"Mirvetuximab soravtansine-gynx is a targeted therapy.; Mirvetuximab soravtansine-gynx is indicated for FR-positive platinum-resistant ovarian cancer.","evidence_relations":"Platinum-resistant ovarian cancer is treated with non-platinum chemotherapy, bevacizumab, or targeted therapies such as mirvetuximab soravtansine-gynx for FR-positive tumors; Folate receptor alpha (FR) is listed as a genetic alteration/biomarker in the ontology"},
	{"id":"Medical-45847608","source":"Medical","question":"Which hereditary syndromes increase the risk for ovarian cancer and how does this affect patient management?","answer":"BRCA1, BRCA2 mutations, and Lynch syndrome increase risk and prompt genetic testing and consideration of targeted therapies.","question_type":"Complex Reasoning","evidence":"BRCA1 mutations increase the risk for ovarian cancer.; BRCA2 mutations increase the risk for ovarian cancer.; Lynch syndrome increases the risk for ovarian cancer.; BRCA1, BRCA2 mutations, and Lynch syndrome prompt genetic testing.; BRCA1, BRCA2 mutations, and Lynch syndrome prompt consideration of targeted therapies.","evidence_relations":"BRCA1 and BRCA2 mutations and Lynch syndrome are major hereditary risk factors for ovarian cancer; Genetic testing for BRCA and other hereditary syndromes is recommended for all patients with ovarian cancer; Maintenance therapy with PARP inhibitors is recommended for advanced or BRCA-mutated/HRD-positive cancers after initial treatment"},
	{"id":"Medical-4e5d3831","source":"Medical","question":"What role does imaging play in the diagnosis and surveillance of ovarian cancer?","answer":"Imaging is used for initial diagnosis (ultrasound, CT, MRI, PET) and for surveillance as indicated after treatment.","question_type":"Complex Reasoning","evidence":"Imaging is used for the initial diagnosis of ovarian cancer.; Ultrasound is used for the initial diagnosis of ovarian cancer.; CT is used for the initial diagnosis of ovarian cancer.; MRI is used for the initial diagnosis of ovarian cancer.; PET is used for the initial diagnosis of ovarian cancer.; Imaging is used for surveillance after treatment as indicated.","evidence_relations":"Diagnosis of ovarian cancer involves imaging (ultrasound, CT, MRI, PET); Surveillance after treatment includes regular physical and pelvic exams, and monitoring of CA-125 or other tumor markers, and imaging as indicated; The ontology lists imaging modalities under diagnostic methods and surveillance"},
	{"id":"Medical-d7765001","source":"Medical","question":"Which symptoms should prompt evaluation for possible ovarian cancer using tumor markers and imaging?","answer":"Symptoms such as persistent bloating, pelvic pain, trouble eating, and urinary urgency should prompt evaluation with tumor markers and imaging.","question_type":"Complex Reasoning","evidence":"Persistent bloating should prompt evaluation for possible ovarian cancer.; Pelvic pain should prompt evaluation for possible ovarian cancer.; Trouble eating should prompt evaluation for possible ovarian cancer.; Urinary urgency should prompt evaluation for possible ovarian cancer.","evidence_relations":"Common symptoms of ovarian cancer include bloating, pelvic or abdominal pain, trouble eating or feeling full quickly, urinary urgency or frequency, and pain during sex; Diagnosis of ovarian cancer involves imaging (ultrasound, CT, MRI, PET), abdominal and pelvic exam, biopsy, and blood tests including tumor markers"},
	{"id":"Medical-e2bcebf4","source":"Medical","question":"When is enrollment in a clinical trial particularly recommended for ovarian cancer patients?","answer":"Clinical trial enrollment is recommended for recurrent or persistent ovarian cancer.","question_type":"Complex Reasoning","evidence":"Clinical trial enrollment is recommended for recurrent ovarian cancer.; Clinical trial enrollment is recommended for persistent ovarian cancer.","evidence_relations":"Clinical trials are recommended for recurrent or persistent ovarian cancer; The ontology lists clinical trial enrollment for recurrent or persistent disease"},
	{"id":"Medical-22b8a5ee","source":"Medical","question":"How is small lymphocytic lymphoma (SLL) differentiated from chronic lymphocytic leukemia (CLL) in terms of primary site and diagnostic approach?","answer":"SLL primarily affects lymph nodes and spleen, while CLL affects blood and bone marrow, and both require blood tests and biopsies for diagnosis.","question_type":"Complex Reasoning","evidence":"Small lymphocytic lymphoma (SLL) primarily affects lymph nodes.; Small lymphocytic lymphoma (SLL) primarily affects the spleen.; Chronic lymphocytic leukemia (CLL) primarily affects blood.; Chronic lymphocytic leukemia (CLL) primarily affects bone marrow.; Both SLL and CLL require blood tests for diagnosis.; Both SLL and CLL require biopsies for diagnosis.","evidence_relations":"Small lymphocytic lymphoma (SLL) is the same cancer as CLL but primarily found in lymph nodes and spleen; Chronic lymphocytic leukemia (CLL) is a type of blood cancer affecting B lymphocytes; CLL/SLL is diagnosed by blood test showing 5,000 monoclonal B lymphocytes per microliter; CLL is confirmed by blood test, flow cytometry, and may require lymph node or bone marrow biopsy; In the ontology, SLL is listed under CLL as a subtype with primary sites of lymph nodes and spleen, while CLL's primary sites are blood and bone marrow"},
	{"id":"Medical-eab49131","source":"Medical","question":"Which diagnostic tests are necessary to confirm CLL and detect prognostic biomarkers, and why are multiple methods needed?","answer":"Blood test, flow cytometry, FISH, DNA sequencing, and karyotype are all needed to confirm CLL and identify prognostic biomarkers.","question_type":"Complex Reasoning","evidence":"A blood test is necessary to confirm CLL.; Flow cytometry is necessary to confirm CLL.; FISH is necessary to confirm CLL.; DNA sequencing is necessary to confirm CLL.; Karyotype is necessary to confirm CLL.; Multiple methods are needed to identify prognostic biomarkers.","evidence_relations":"CLL is confirmed by blood test, flow cytometry, and may require lymph node or bone marrow biopsy; Immunophenotyping identifies CLL cells by surface proteins such as CD20, CD200, and LEF1; Biomarker testing includes FISH for 17p deletion, DNA sequencing for TP53 and IGHV mutations, and karyotype analysis; In the ontology, diagnostic methods for CLL include blood test, flow cytometry, FISH, DNA sequencing, and karyotype"},
	{"id":"Medical-223def84","source":"Medical","question":"What factors determine whether a newly diagnosed CLL patient should begin treatment immediately or undergo watchful waiting?","answer":"Treatment is based on symptoms, blood counts, and disease progression, so asymptomatic or stable patients may be managed with watch and wait.","question_type":"Complex Reasoning","evidence":"Treatment for newly diagnosed CLL patients is based on symptoms.; Treatment for newly diagnosed CLL patients is based on blood counts.; Treatment for newly diagnosed CLL patients is based on disease progression.; Asymptomatic patients may be managed with watchful waiting.; Stable patients may be managed with watchful waiting.","evidence_relations":"Treatment for CLL/SLL may not be needed immediately and is based on symptoms, blood counts, and disease progression; Follow-up strategies include watch and wait, regular monitoring, and supportive care; CLL may be asymptomatic and discovered incidentally on routine blood testing"},
	{"id":"Medical-48e987ed","source":"Medical","question":"How do risk factors and symptoms together contribute to the early detection of CLL?","answer":"Older age and family history increase risk, and the presence of symptoms like swollen glands or incidental findings on blood tests aid early detection.","question_type":"Complex Reasoning","evidence":"Older age increases the risk of CLL.; Family history increases the risk of CLL.; Symptoms like swollen glands aid in early detection of CLL.; Incidental findings on blood tests aid in early detection of CLL.","evidence_relations":"Risk factors for CLL include older age and family history of CLL; Symptoms of CLL include swollen glands, fatigue, night sweats, fever, recurrent infections, early satiety, and unintentional weight loss; CLL may be asymptomatic and discovered incidentally on routine blood testing"},
	{"id":"Medical-c92bbd26","source":"Medical","question":"Why is immunophenotyping by flow cytometry essential in the diagnosis of CLL?","answer":"It identifies CLL cells by their surface proteins (CD20, CD200, LEF1), confirming the diagnosis after initial blood tests.","question_type":"Complex Reasoning","evidence":"Immunophenotyping by flow cytometry identifies CLL cells.; Immunophenotyping by flow cytometry identifies CLL cells by their surface proteins.; Surface proteins CD20, CD200, and LEF1 are used to confirm the diagnosis of CLL.; Immunophenotyping is done after initial blood tests.","evidence_relations":"CLL is confirmed by blood test, flow cytometry, and may require lymph node or bone marrow biopsy; Immunophenotyping identifies CLL cells by surface proteins such as CD20, CD200, and LEF1; In the ontology, flow cytometry with immunophenotype markers is a diagnostic method for CLL"},
	{"id":"Medical-2ebcf55d","source":"Medical","question":"What is the clinical significance of detecting a 17p deletion or TP53 mutation in CLL patients?","answer":"Detection of 17p deletion or TP53 mutation indicates poorer prognosis and guides treatment selection.","question_type":"Complex Reasoning","evidence":"Detection of 17p deletion indicates poorer prognosis in CLL patients.; Detection of TP53 mutation indicates poorer prognosis in CLL patients.; Detection of 17p deletion guides treatment selection in CLL patients.; Detection of TP53 mutation guides treatment selection in CLL patients.","evidence_relations":"Biomarker testing includes FISH for 17p deletion, DNA sequencing for TP53 and IGHV mutations, and karyotype analysis; Beta-2 microglobulin is a biomarker associated with CLL disease activity and prognosis; In the ontology, 17p deletion and TP53 mutation are listed as biomarkers for CLL"},
	{"id":"Medical-a7fb4f11","source":"Medical","question":"How does the management plan for CLL change if a patient develops Richter transformation?","answer":"Richter transformation requires a shift to therapies targeting aggressive lymphomas such as DLBCL or Hodgkin lymphoma.","question_type":"Complex Reasoning","evidence":"Richter transformation requires a shift to therapies targeting aggressive lymphomas.; Therapies targeting DLBCL are required for Richter transformation.; Therapies targeting Hodgkin lymphoma are required for Richter transformation.","evidence_relations":"Richter transformation is a complication where CLL transforms into a more aggressive lymphoma such as DLBCL or Hodgkin lymphoma; In the ontology, Richter transformation is a complication of CLL with subtypes DLBCL and Hodgkin lymphoma"},
	{"id":"Medical-ce7076ea","source":"Medical","question":"Why is a comprehensive metabolic panel and assessment of performance status important before starting CLL treatment?","answer":"These assessments help guide treatment planning and ensure patient suitability for specific therapies.","question_type":"Complex Reasoning","evidence":"A comprehensive metabolic panel is important before starting CLL treatment.; Assessment of performance status is important before starting CLL treatment.; These assessments help guide treatment planning.; These assessments ensure patient suitability for specific therapies.","evidence_relations":"Performance status and comprehensive metabolic panel are used in treatment planning; In the ontology, performance status and comprehensive metabolic panel are listed under clinical management and diagnostic methods for CLL"},
	{"id":"Medical-6108fa72","source":"Medical","question":"What follow-up strategies are recommended for CLL patients not requiring immediate therapy, and what is their purpose?","answer":"Watch and wait, regular monitoring, and supportive care are used to track disease progression and manage symptoms.","question_type":"Complex Reasoning","evidence":"Watch and wait is a follow-up strategy for CLL patients not requiring immediate therapy.; Regular monitoring is a follow-up strategy for CLL patients not requiring immediate therapy.; Supportive care is a follow-up strategy for CLL patients not requiring immediate therapy.; The purpose of these strategies is to track disease progression.; The purpose of these strategies is to manage symptoms.","evidence_relations":"Follow-up strategies include watch and wait, regular monitoring, and supportive care; Treatment for CLL/SLL may not be needed immediately and is based on symptoms, blood counts, and disease progression"},
	{"id":"Medical-56131016","source":"Medical","question":"How do family history and older age together influence the risk and screening approach for CLL?","answer":"Both increase CLL risk, so older individuals with a family history may warrant closer monitoring for early detection.","question_type":"Complex Reasoning","evidence":"Family history increases the risk of CLL.; Older age increases the risk of CLL.; Older individuals with a family history of CLL may warrant closer monitoring.; Closer monitoring is recommended for early detection of CLL.","evidence_relations":"Risk factors for CLL include older age and family history of CLL; Family history increases the risk of developing CLL"},
	{"id":"Medical-1e7500e4","source":"Medical","question":"What combination of tests would be used to assess both disease burden and prognosis in CLL?","answer":"CBC, beta-2 microglobulin, biomarker testing (FISH, DNA sequencing, karyotype), and diagnostic CT scan assess disease burden and prognosis.","question_type":"Complex Reasoning","evidence":"CBC is used to assess disease burden in CLL.; Beta-2 microglobulin is used to assess prognosis in CLL.; Biomarker testing, including FISH, DNA sequencing, and karyotype, is used to assess disease burden in CLL.; A diagnostic CT scan is used to assess prognosis in CLL.","evidence_relations":"CLL is confirmed by blood test, flow cytometry, and may require lymph node or bone marrow biopsy; Biomarker testing includes FISH for 17p deletion, DNA sequencing for TP53 and IGHV mutations, and karyotype analysis; Beta-2 microglobulin is a biomarker associated with CLL disease activity and prognosis; Diagnostic CT scans may be used to assess lymph node involvement and disease extent"},
	{"id":"Medical-29a8ae2e","source":"Medical","question":"Why might a pregnancy test and fertility preservation be considered in the management of CLL?","answer":"They are considered before starting treatment to address potential impacts of therapy on fertility and pregnancy.","question_type":"Complex Reasoning","evidence":"A pregnancy test may be considered in the management of CLL.; Fertility preservation may be considered in the management of CLL.; These considerations are made before starting treatment.; The purpose is to address potential impacts of therapy on fertility and pregnancy.","evidence_relations":"Pregnancy testing and fertility preservation are considered before starting treatment; In the ontology, pregnancy test and fertility preservation are listed under clinical management for CLL"},
	{"id":"Medical-3776fc3d","source":"Medical","question":"How does achieving minimal residual disease status affect the prognosis and management of CLL?","answer":"Minimal residual disease indicates mostly healthy blood cells and is a treatment goal associated with better prognosis.","question_type":"Complex Reasoning","evidence":"Achieving minimal residual disease status indicates mostly healthy blood cells.; Minimal residual disease status is a treatment goal in CLL.; Achieving minimal residual disease status is associated with better prognosis.","evidence_relations":"Minimal residual disease is a treatment goal indicating mostly healthy blood cells; In the ontology, minimal residual disease is listed as a disease stage for CLL"},
	{"id":"Medical-836e7db0","source":"Medical","question":"Which symptoms, when present together, would most strongly suggest CLL as a diagnosis requiring further blood and immunophenotyping tests?","answer":"Swollen glands, fatigue, and recurrent infections together should prompt CLL workup with blood test and flow cytometry.","question_type":"Complex Reasoning","evidence":"Swollen glands, fatigue, and recurrent infections together suggest CLL as a diagnosis.; These symptoms should prompt a CLL workup.; A blood test is required for the CLL workup.; Flow cytometry is required for the CLL workup.","evidence_relations":"Symptoms of CLL include swollen glands, fatigue, night sweats, fever, recurrent infections, early satiety, and unintentional weight loss; CLL is confirmed by blood test, flow cytometry, and may require lymph node or bone marrow biopsy"},
	{"id":"Medical-1852bc75","source":"Medical","question":"What is the rationale for using both oral medications and IV infusions in the treatment of CLL?","answer":"Combination therapy using oral and IV drugs may be required for optimal disease control based on disease progression and patient factors.","question_type":"Complex Reasoning","evidence":"Combination therapy using oral medications and IV infusions may be required for CLL treatment.; Optimal disease control may require both oral and IV drugs.; The need for combination therapy is based on disease progression.; The need for combination therapy is based on patient factors.","evidence_relations":"Treatment options include oral medications, IV infusions, and combination therapies; Treatment for CLL/SLL may not be needed immediately and is based on symptoms, blood counts, and disease progression"},
	{"id":"Medical-8ac49b5b","source":"Medical","question":"Which biomarker must be tested in all patients diagnosed with oropharyngeal cancer, and what is its clinical significance?","answer":"p16 (HPV) testing must be performed in all oropharyngeal cancer patients as it serves as a surrogate biomarker for HPV-mediated disease.","question_type":"Complex Reasoning","evidence":"p16 (HPV) testing must be performed in all oropharyngeal cancer patients.; p16 (HPV) serves as a surrogate biomarker for HPV-mediated disease.","evidence_relations":"p16 (HPV) testing is recommended for all patients with oropharyngeal cancer; p16 protein overexpression is a surrogate biomarker for HPV-mediated throat cancer"},
	{"id":"Medical-cf2fbd21","source":"Medical","question":"How do risk factors for oropharyngeal squamous cell carcinoma differ from those for head and neck cancers in general?","answer":"HPV infection, especially HPV16, is a major risk factor for oropharyngeal squamous cell carcinoma, while tobacco and alcohol use are risk factors for head and neck cancers in general.","question_type":"Complex Reasoning","evidence":"HPV infection, especially HPV16, is a major risk factor for oropharyngeal squamous cell carcinoma.; Tobacco use is a risk factor for head and neck cancers in general.; Alcohol use is a risk factor for head and neck cancers in general.","evidence_relations":"HPV infection, especially HPV16, is a major risk factor for oropharyngeal squamous cell carcinoma; Tobacco and alcohol use are risk factors for head and neck cancers"},
	{"id":"Medical-30e7caf0","source":"Medical","question":"Which diagnostic methods are required to confirm throat cancer and determine its biomarkers?","answer":"Imaging studies and biopsy are required for diagnosis, and biopsy enables biomarker testing.","question_type":"Complex Reasoning","evidence":"Imaging studies are required to confirm throat cancer.; A biopsy is required to confirm throat cancer.; A biopsy enables biomarker testing.","evidence_relations":"Imaging studies such as CT scan, MRI, PET/CT, and ultrasound are used for diagnosis and staging; Biopsy is required for definitive diagnosis and biomarker testing"},
	{"id":"Medical-ab708cf8","source":"Medical","question":"What anatomical sites are included under oropharyngeal cancer, and how does this relate to the diagnosis of throat cancer?","answer":"Oropharyngeal cancer includes the soft palate, tonsils, base of tongue, and side and back walls of the throat, which are common sites where throat cancer arises.","question_type":"Complex Reasoning","evidence":"Oropharyngeal cancer includes the soft palate.; Oropharyngeal cancer includes the tonsils.; Oropharyngeal cancer includes the base of tongue.; Oropharyngeal cancer includes the side walls of the throat.; Oropharyngeal cancer includes the back walls of the throat.; Throat cancer commonly arises in the oropharyngeal sites.","evidence_relations":"Oropharyngeal cancer is a subtype of throat cancer; Throat cancer commonly arises in the oropharynx, including the soft palate, tonsils, side and back walls of the throat, and base of the tongue"},
	{"id":"Medical-321f2f6d","source":"Medical","question":"What staging system is used for throat cancer, and which parameters does it incorporate?","answer":"The AJCC TNM system is used, incorporating tumor size (T), lymph node involvement (N), and metastasis (M).","question_type":"Complex Reasoning","evidence":"The AJCC TNM system is used for throat cancer staging.; The AJCC TNM system incorporates tumor size (T).; The AJCC TNM system incorporates lymph node involvement (N).; The AJCC TNM system incorporates metastasis (M).","evidence_relations":"Cancer staging uses the AJCC TNM system, incorporating tumor size (T), lymph node involvement (N), and metastasis (M); AJCC TNM staging includes Tis, T1, T2, T3, T4a, and T4b for tumor classification"},
	{"id":"Medical-95bdfdba","source":"Medical","question":"Which symptoms should prompt consideration of throat cancer and subsequent diagnostic evaluation?","answer":"Difficulty swallowing, sore throat, and voice changes should prompt evaluation for throat cancer.","question_type":"Complex Reasoning","evidence":"Difficulty swallowing should prompt evaluation for throat cancer.; A sore throat should prompt evaluation for throat cancer.; Voice changes should prompt evaluation for throat cancer.","evidence_relations":"Symptoms of throat cancer may include difficulty swallowing, sore throat, and changes in voice; Imaging studies such as CT scan, MRI, PET/CT, and ultrasound are used for diagnosis and staging"},
	{"id":"Medical-1892185a","source":"Medical","question":"What is the role of p16 protein in distinguishing subtypes of squamous cell carcinoma in the oropharynx?","answer":"p16 protein overexpression identifies HPV-mediated squamous cell carcinoma in the oropharynx.","question_type":"Complex Reasoning","evidence":"p16 protein overexpression identifies HPV-mediated squamous cell carcinoma.; p16 protein is used to distinguish subtypes of squamous cell carcinoma in the oropharynx.","evidence_relations":"p16 protein overexpression is a surrogate biomarker for HPV-mediated throat cancer; Squamous cell carcinoma is the most common type of throat cancer"},
	{"id":"Medical-ade34649","source":"Medical","question":"Which diagnostic procedures are used for tissue sampling in throat cancer, and why are they important?","answer":"Fine-needle aspiration, core needle biopsy, and endoscopic biopsies are used to obtain tissue for definitive diagnosis and biomarker testing.","question_type":"Complex Reasoning","evidence":"Fine-needle aspiration is used for tissue sampling in throat cancer.; Core needle biopsy is used for tissue sampling in throat cancer.; Endoscopic biopsies are used for tissue sampling in throat cancer.; Tissue sampling is important for definitive diagnosis.; Tissue sampling is important for biomarker testing.","evidence_relations":"Fine-needle aspiration (FNA), core needle biopsy (CNB), and endoscopic biopsies are used for tissue sampling; Biopsy is required for definitive diagnosis and biomarker testing"},
	{"id":"Medical-cd4d3dd1","source":"Medical","question":"What factors are considered prognostic in treatment planning for throat cancer?","answer":"ECOG performance status and HPV/p16 status are prognostic factors in treatment planning.","question_type":"Complex Reasoning","evidence":"ECOG performance status is a prognostic factor in treatment planning for throat cancer.; HPV/p16 status is a prognostic factor in treatment planning for throat cancer.","evidence_relations":"Performance status (ECOG) is a prognostic factor considered in treatment planning; HPV/p16 status is a prognostic factor for throat cancer"},
	{"id":"Medical-6624a28a","source":"Medical","question":"How is clinical stage of throat cancer determined prior to treatment?","answer":"Clinical stage is determined by physical exam, imaging, and biopsy before treatment.","question_type":"Complex Reasoning","evidence":"Clinical stage of throat cancer is determined by physical exam.; Clinical stage of throat cancer is determined by imaging.; Clinical stage of throat cancer is determined by biopsy.; Clinical stage is determined before treatment.","evidence_relations":"Clinical stage is determined before treatment using physical exam, imaging, and biopsy; Imaging studies such as CT scan, MRI, PET/CT, and ultrasound are used for diagnosis and staging"},
	{"id":"Medical-60acb9ee","source":"Medical","question":"Which patients with throat cancer should undergo dental health assessment and why?","answer":"All patients should have dental health assessment before treatment as dental health impacts treatment planning and outcomes.","question_type":"Complex Reasoning","evidence":"All patients with throat cancer should undergo dental health assessment.; Dental health assessment impacts treatment planning for throat cancer.; Dental health assessment impacts outcomes for throat cancer.","evidence_relations":"Dental health assessment is important before treatment; Surveillance includes dental health assessment"},
	{"id":"Medical-ac502742","source":"Medical","question":"How can PD-L1 expression influence the treatment of throat cancer?","answer":"PD-L1 expression may guide immunotherapy treatment decisions in throat cancer.","question_type":"Complex Reasoning","evidence":"PD-L1 expression may guide immunotherapy treatment decisions in throat cancer.","evidence_relations":"PD-L1 expression may guide immunotherapy treatment decisions; Biomarker testing includes PD-L1"},
	{"id":"Medical-6e4da4de","source":"Medical","question":"What are the main routes of metastasis in throat cancer and which distant sites are commonly involved?","answer":"Throat cancer can spread to lymph nodes in the neck and to distant sites such as lungs, liver, or spine.","question_type":"Complex Reasoning","evidence":"Throat cancer can spread to lymph nodes in the neck.; Throat cancer can spread to distant sites such as the lungs.; Throat cancer can spread to distant sites such as the liver.; Throat cancer can spread to distant sites such as the spine.","evidence_relations":"Cancer can spread to lymph nodes in the neck and to distant sites such as lungs, liver, or spine; Metastasis includes lungs, liver, and spine"},
	{"id":"Medical-b6f1658b","source":"Medical","question":"What is the relationship between HPV status and the recommended biomarker testing in oropharyngeal cancer?","answer":"HPV status is assessed by p16 (HPV) testing, which is recommended for all oropharyngeal cancer patients.","question_type":"Complex Reasoning","evidence":"HPV status is assessed by p16 (HPV) testing.; p16 (HPV) testing is recommended for all oropharyngeal cancer patients.","evidence_relations":"p16 (HPV) testing is recommended for all patients with oropharyngeal cancer; p16 protein overexpression is a surrogate biomarker for HPV-mediated throat cancer"},
	{"id":"Medical-a0a1a141","source":"Medical","question":"Which imaging modalities are used for both diagnosis and staging of throat cancer, and what is their role?","answer":"CT scan, MRI, PET/CT, and ultrasound are used for both diagnosis and staging to assess tumor extent and spread.","question_type":"Complex Reasoning","evidence":"CT scan is used for both diagnosis and staging of throat cancer.; MRI is used for both diagnosis and staging of throat cancer.; PET/CT is used for both diagnosis and staging of throat cancer.; Ultrasound is used for both diagnosis and staging of throat cancer.; These imaging modalities assess tumor extent and spread.","evidence_relations":"Imaging studies such as CT scan, MRI, PET/CT, and ultrasound are used for diagnosis and staging; Cancer staging uses the AJCC TNM system, incorporating tumor size (T), lymph node involvement (N), and metastasis (M)"},
	{"id":"Medical-6e3e48fa","source":"Medical","question":"Which diagnostic procedures are essential for confirming a case of cutaneous B-cell lymphoma presenting with skin nodules?","answer":"Skin exam, blood tests, imaging tests, biopsy, and immunophenotyping are essential for confirming CBCL with nodules.","question_type":"Complex Reasoning","evidence":"Skin exam is essential for confirming cutaneous B-cell lymphoma with skin nodules.; Blood tests are essential for confirming cutaneous B-cell lymphoma with skin nodules.; Imaging tests are essential for confirming cutaneous B-cell lymphoma with skin nodules.; Biopsy is essential for confirming cutaneous B-cell lymphoma with skin nodules.; Immunophenotyping is essential for confirming cutaneous B-cell lymphoma with skin nodules.","evidence_relations":"Diagnosis of CBCL involves skin exam, blood tests, imaging tests, biopsy, and immunophenotyping; Symptoms of CBCL include skin nodules and papules"},
	{"id":"Medical-2529e505","source":"Medical","question":"What distinguishes cutaneous B-cell lymphoma from cutaneous T-cell lymphoma in terms of cell of origin and cancer subtype?","answer":"CBCL originates from B lymphocytes and includes subtypes like PCMZL, PCFCL, and PC-DLBCL leg type, while CTCL originates from T lymphocytes.","question_type":"Complex Reasoning","evidence":"Cutaneous B-cell lymphoma originates from B lymphocytes.; Cutaneous B-cell lymphoma includes subtypes like PCMZL, PCFCL, and PC-DLBCL leg type.; Cutaneous T-cell lymphoma originates from T lymphocytes.","evidence_relations":"Cutaneous B-cell lymphoma (CBCL) starts in B cells; CBCL subtypes include primary cutaneous marginal zone lymphoma (PCMZL), primary cutaneous follicle center lymphoma (PCFCL), and primary cutaneous diffuse large B-cell lymphoma, leg type (PC-DLBCL, leg type); Cutaneous T-cell lymphoma (CTCL) develops from abnormal T cells"},
	{"id":"Medical-68e55e0e","source":"Medical","question":"If a patient has papules under the skin and is diagnosed with a lymphoma subtype originating from B lymphocytes, which subtypes should be considered?","answer":"Primary cutaneous marginal zone lymphoma, primary cutaneous follicle center lymphoma, and primary cutaneous diffuse large B-cell lymphoma, leg type should be considered.","question_type":"Complex Reasoning","evidence":"Primary cutaneous marginal zone lymphoma should be considered.; Primary cutaneous follicle center lymphoma should be considered.; Primary cutaneous diffuse large B-cell lymphoma, leg type should be considered.","evidence_relations":"CBCL subtypes include primary cutaneous marginal zone lymphoma (PCMZL), primary cutaneous follicle center lymphoma (PCFCL), and primary cutaneous diffuse large B-cell lymphoma, leg type (PC-DLBCL, leg type); CBCL appears as nodules or papules under the skin; CBCL starts in B cells"},
	{"id":"Medical-8d55a40b","source":"Medical","question":"Which cancer type is characterized by the development of abnormal lymphocytes in the skin and can originate from either B or T cells?","answer":"Primary cutaneous lymphoma (PCL) is characterized by abnormal lymphocytes in the skin and can originate from B or T cells.","question_type":"Complex Reasoning","evidence":"Primary cutaneous lymphoma is characterized by abnormal lymphocytes in the skin.; Primary cutaneous lymphoma can originate from B cells.; Primary cutaneous lymphoma can originate from T cells.","evidence_relations":"Primary cutaneous lymphoma (PCL) is a type of non-Hodgkin lymphoma found in the skin; PCL develops from abnormal B or T lymphocytes"},
	{"id":"Medical-8233f77f","source":"Medical","question":"What laboratory and tissue-based tests are required to assess both biomarkers and genetic alterations in cutaneous B-cell lymphoma?","answer":"Biopsy and immunophenotyping are required to assess biomarkers and genetic changes in CBCL.","question_type":"Complex Reasoning","evidence":"Biopsy is required to assess biomarkers in cutaneous B-cell lymphoma.; Immunophenotyping is required to assess biomarkers in cutaneous B-cell lymphoma.; Biopsy is required to assess genetic changes in cutaneous B-cell lymphoma.; Immunophenotyping is required to assess genetic changes in cutaneous B-cell lymphoma.","evidence_relations":"Diagnosis of CBCL involves skin exam, blood tests, imaging tests, biopsy, and immunophenotyping; Testing for CBCL includes assessment of biomarkers and genetic changes"},
	{"id":"Medical-bc622c63","source":"Medical","question":"How does the unregulated growth of lymphocytes relate to the development of cutaneous B-cell lymphoma?","answer":"Unregulated growth of B lymphocytes can develop into CBCL, a subtype of primary cutaneous lymphoma.","question_type":"Complex Reasoning","evidence":"Unregulated growth of B lymphocytes can develop into cutaneous B-cell lymphoma.; Cutaneous B-cell lymphoma is a subtype of primary cutaneous lymphoma.","evidence_relations":"Unregulated growth of lymphocytes can develop into lymphoma; CBCL starts in B cells; Primary cutaneous lymphoma (PCL) is a type of non-Hodgkin lymphoma found in the skin"},
	{"id":"Medical-de3d6946","source":"Medical","question":"Which diagnostic methods would be most informative for differentiating between cutaneous B-cell and T-cell lymphomas?","answer":"Immunophenotyping and biopsy are most informative for differentiating CBCL from CTCL.","question_type":"Complex Reasoning","evidence":"Immunophenotyping is informative for differentiating cutaneous B-cell lymphoma from cutaneous T-cell lymphoma.; Biopsy is informative for differentiating cutaneous B-cell lymphoma from cutaneous T-cell lymphoma.","evidence_relations":"Diagnosis of CBCL involves skin exam, blood tests, imaging tests, biopsy, and immunophenotyping; Testing for CBCL includes assessment of biomarkers and genetic changes; Cutaneous B-cell lymphoma (CBCL) starts in B cells; Cutaneous T-cell lymphoma (CTCL) develops from abnormal T cells"},
	{"id":"Medical-5f54bb84","source":"Medical","question":"What symptoms and diagnostic findings would prompt a clinician to test for biomarkers and genetic changes in a suspected case of CBCL?","answer":"The presence of skin nodules or papules and findings from biopsy or immunophenotyping would prompt biomarker and genetic testing in suspected CBCL.","question_type":"Complex Reasoning","evidence":"The presence of skin nodules or papules would prompt testing for biomarkers in suspected cutaneous B-cell lymphoma.; Findings from biopsy would prompt testing for biomarkers in suspected cutaneous B-cell lymphoma.; Findings from immunophenotyping would prompt testing for biomarkers in suspected cutaneous B-cell lymphoma.","evidence_relations":"CBCL appears as nodules or papules under the skin; Diagnosis of CBCL involves skin exam, blood tests, imaging tests, biopsy, and immunophenotyping; Testing for CBCL includes assessment of biomarkers and genetic changes"},
	{"id":"Medical-618ab93c","source":"Medical","question":"If a patient is diagnosed with a slow-growing primary cutaneous lymphoma of B-cell origin, which subtypes are likely?","answer":"Primary cutaneous marginal zone lymphoma and primary cutaneous follicle center lymphoma are likely, as most CBCLs are indolent.","question_type":"Complex Reasoning","evidence":"Primary cutaneous marginal zone lymphoma is a likely subtype of slow-growing primary cutaneous lymphoma of B-cell origin.; Primary cutaneous follicle center lymphoma is a likely subtype of slow-growing primary cutaneous lymphoma of B-cell origin.; Most cutaneous B-cell lymphomas (CBCLs) are indolent.","evidence_relations":"Most primary cutaneous B-cell lymphomas are indolent or slow-growing; CBCL subtypes include primary cutaneous marginal zone lymphoma (PCMZL), primary cutaneous follicle center lymphoma (PCFCL), and primary cutaneous diffuse large B-cell lymphoma, leg type (PC-DLBCL, leg type); CBCL starts in B cells"},
	{"id":"Medical-bb678310","source":"Medical","question":"What is the hierarchical relationship between non-Hodgkin lymphoma, primary cutaneous lymphoma, and cutaneous B-cell lymphoma?","answer":"Cutaneous B-cell lymphoma is a subtype of primary cutaneous lymphoma, which is a form of non-Hodgkin lymphoma.","question_type":"Complex Reasoning","evidence":"Cutaneous B-cell lymphoma is a subtype of primary cutaneous lymphoma.; Primary cutaneous lymphoma is a form of non-Hodgkin lymphoma.","evidence_relations":"Primary cutaneous lymphoma (PCL) is a type of non-Hodgkin lymphoma found in the skin; Cutaneous B-cell lymphoma (CBCL) starts in B cells; CBCL is a subtype of primary cutaneous lymphoma according to the ontology"},
	{"id":"Medical-58981bbb","source":"Medical","question":"What combination of cell type and clinical presentation would suggest a diagnosis of cutaneous B-cell lymphoma rather than T-cell lymphoma?","answer":"A neoplasm originating from B lymphocytes presenting as nodules or papules under the skin suggests cutaneous B-cell lymphoma.","question_type":"Complex Reasoning","evidence":"A neoplasm originating from B lymphocytes suggests cutaneous B-cell lymphoma.; Nodules or papules under the skin suggest cutaneous B-cell lymphoma.","evidence_relations":"CBCL starts in B cells; CBCL appears as nodules or papules under the skin; Cutaneous T-cell lymphoma (CTCL) develops from abnormal T cells"},
	{"id":"Medical-63b4b70c","source":"Medical","question":"Which subtypes of cutaneous B-cell lymphoma should be considered when a biopsy confirms B-cell origin in a patient with skin papules?","answer":"Primary cutaneous marginal zone lymphoma, primary cutaneous follicle center lymphoma, and primary cutaneous diffuse large B-cell lymphoma, leg type should be considered.","question_type":"Complex Reasoning","evidence":"Primary cutaneous marginal zone lymphoma should be considered when a biopsy confirms B-cell origin in a patient with skin papules.; Primary cutaneous follicle center lymphoma should be considered when a biopsy confirms B-cell origin in a patient with skin papules.; Primary cutaneous diffuse large B-cell lymphoma, leg type should be considered when a biopsy confirms B-cell origin in a patient with skin papules.","evidence_relations":"CBCL subtypes include primary cutaneous marginal zone lymphoma (PCMZL), primary cutaneous follicle center lymphoma (PCFCL), and primary cutaneous diffuse large B-cell lymphoma, leg type (PC-DLBCL, leg type); CBCL starts in B cells; CBCL appears as nodules or papules under the skin"},
	{"id":"Medical-d163acf5","source":"Medical","question":"How does the function of lymphocytes as white blood cells relate to the pathogenesis of cutaneous B-cell lymphoma?","answer":"Lymphocytes are white blood cells that help fight infection, and their unregulated growth can lead to cutaneous B-cell lymphoma.","question_type":"Complex Reasoning","evidence":"Lymphocytes are white blood cells.; Lymphocytes help fight infection.; Unregulated growth of lymphocytes can lead to cutaneous B-cell lymphoma.","evidence_relations":"Lymphocytes are a type of white blood cell that help fight infection; Unregulated growth of lymphocytes can develop into lymphoma; CBCL starts in B cells"},
	{"id":"Medical-2a24f6a2","source":"Medical","question":"Which methods are used to confirm both the presence and subtype of cutaneous B-cell lymphoma in a patient with skin lesions?","answer":"Biopsy and immunophenotyping are used to confirm both the presence and subtype of CBCL.","question_type":"Complex Reasoning","evidence":"Biopsy is used to confirm the presence and subtype of cutaneous B-cell lymphoma.; Immunophenotyping is used to confirm the presence and subtype of cutaneous B-cell lymphoma.","evidence_relations":"Diagnosis of CBCL involves skin exam, blood tests, imaging tests, biopsy, and immunophenotyping; CBCL subtypes include primary cutaneous marginal zone lymphoma (PCMZL), primary cutaneous follicle center lymphoma (PCFCL), and primary cutaneous diffuse large B-cell lymphoma, leg type (PC-DLBCL, leg type)"},
	{"id":"Medical-417cbcfd","source":"Medical","question":"What is the connection between the assessment of biomarkers/genetic changes and the selection of diagnostic methods in CBCL?","answer":"Assessment of biomarkers and genetic changes in CBCL requires diagnostic methods like biopsy and immunophenotyping.","question_type":"Complex Reasoning","evidence":"Assessment of biomarkers in CBCL requires diagnostic methods.; Assessment of genetic changes in CBCL requires diagnostic methods.; Biopsy is a diagnostic method used in CBCL.; Immunophenotyping is a diagnostic method used in CBCL.","evidence_relations":"Testing for CBCL includes assessment of biomarkers and genetic changes; Diagnosis of CBCL involves skin exam, blood tests, imaging tests, biopsy, and immunophenotyping"},
	{"id":"Medical-6a1c421a","source":"Medical","question":"What diagnostic procedures are essential for confirming ALL in children and why are multiple tests necessary?","answer":"Blood tests, bone marrow tests, imaging tests, heart tests, lumbar puncture, biomarker testing, and pharmacogenomic testing are all necessary because diagnosis requires both identifying lymphoblasts and assessing disease extent and subtype.","question_type":"Complex Reasoning","evidence":"Blood tests are necessary for confirming ALL in children.; Bone marrow tests are necessary for confirming ALL in children.; Imaging tests are necessary for confirming ALL in children.; Heart tests are necessary for confirming ALL in children.; Lumbar puncture is necessary for confirming ALL in children.; Biomarker testing is necessary for confirming ALL in children.; Pharmacogenomic testing is necessary for confirming ALL in children.; Diagnosis of ALL requires identifying lymphoblasts.; Diagnosis of ALL requires assessing disease extent and subtype.","evidence_relations":"ALL is diagnosed using blood tests, bone marrow tests, imaging tests, heart tests, and lumbar puncture; Diagnosis of ALL generally requires 20 percent or more lymphoblasts in the bone marrow; Pharmacogenomic testing and biomarker/genetic testing are used in ALL management; Acute lymphoblastic leukemia (ALL) is a fast-growing blood cancer that starts in lymphocytes"},
	{"id":"Medical-4777cfbb","source":"Medical","question":"Why would a child with an enlarged thymus and breathing problems be evaluated for T-cell ALL rather than B-cell ALL?","answer":"Because T-cell ALL can cause an enlarged thymus leading to breathing problems, whereas these symptoms are not associated with B-cell ALL.","question_type":"Complex Reasoning","evidence":"A child with an enlarged thymus and breathing problems may be evaluated for T-cell ALL.; T-cell ALL can cause an enlarged thymus.; T-cell ALL can lead to breathing problems.; Breathing problems are not associated with B-cell ALL.","evidence_relations":"T-ALL starts in T-cell lymphocytes and can cause an enlarged thymus; T-ALL can cause breathing problems due to an enlarged thymus; B-ALL starts in B-cell lymphocytes and is more common than T-ALL"},
	{"id":"Medical-88e1fb4a","source":"Medical","question":"How does the treatment approach differ for mature B-cell ALL (Burkitt leukemia) compared to other B-cell ALL subtypes in children?","answer":"Mature B-cell ALL (Burkitt leukemia) is treated differently from B-ALL, requiring a distinct therapeutic protocol.","question_type":"Complex Reasoning","evidence":"Mature B-cell ALL (Burkitt leukemia) is treated differently from other B-cell ALL subtypes.; Mature B-cell ALL (Burkitt leukemia) requires a distinct therapeutic protocol.","evidence_relations":"Mature B-cell ALL (Burkitt leukemia) is a rare subtype and is treated differently from B-ALL; B-cell ALL (B-ALL) starts in B-cell lymphocytes and is more common than T-ALL; B-cell ALL (B-ALL) has a variant called Mature B-cell ALL (Burkitt leukemia)"},
	{"id":"Medical-2ca88e8f","source":"Medical","question":"What factors determine the specific treatment regimen for a pediatric ALL patient?","answer":"Treatment for ALL depends on subtype, age at diagnosis, and other factors such as biomarkers and genetic alterations.","question_type":"Complex Reasoning","evidence":"Treatment for pediatric ALL depends on subtype.; Treatment for pediatric ALL depends on age at diagnosis.; Treatment for pediatric ALL depends on biomarkers.; Treatment for pediatric ALL depends on genetic alterations.","evidence_relations":"Treatment for ALL depends on subtype, age at diagnosis, and other factors; Everyone with ALL is treated with steroids and multiagent chemotherapy; BCR::ABL1-positive B-ALL is treated with intensive systemic therapies"},
	{"id":"Medical-213847bd","source":"Medical","question":"Why is clinical trial enrollment especially considered for certain B-ALL and T-ALL cases in children?","answer":"Clinical trials are preferred for certain B-ALL and T-ALL cases to provide access to novel therapies and tailored treatment approaches.","question_type":"Complex Reasoning","evidence":"Clinical trials are preferred for certain B-ALL cases in children.; Clinical trials are preferred for certain T-ALL cases in children.; Clinical trials provide access to novel therapies.; Clinical trials provide tailored treatment approaches.","evidence_relations":"Clinical trials are preferred for certain B-ALL and T-ALL cases; B-cell ALL (B-ALL) and T-cell ALL (T-ALL) are subtypes of ALL; ALL treatment includes clinical trial as an option"},
	{"id":"Medical-1a56336a","source":"Medical","question":"What distinguishes B-cell lymphoblastic lymphoma (B-LL, B-LBL) from B-cell ALL in terms of disease site?","answer":"B-cell lymphoblastic lymphoma is characterized by B-cell lymphoblasts growing in lymph nodes, whereas B-cell ALL primarily involves bone marrow and blood.","question_type":"Complex Reasoning","evidence":"B-cell lymphoblastic lymphoma is characterized by B-cell lymphoblasts growing in lymph nodes.; B-cell ALL primarily involves bone marrow.; B-cell ALL primarily involves blood.","evidence_relations":"B-cell lymphoblasts growing in lymph nodes is called B-cell lymphoblastic lymphoma (B-LL or B-LBL); Acute lymphoblastic leukemia (ALL) can be found in bone marrow, blood, testicles, or central nervous system (CNS); B-cell ALL (B-ALL) starts in B-cell lymphocytes"},
	{"id":"Medical-a4ac550d","source":"Medical","question":"What is the rationale for using both steroids and multiagent chemotherapy in the treatment of all pediatric ALL patients?","answer":"All patients receive steroids and multiagent chemotherapy to target lymphoblasts and maximize treatment efficacy regardless of subtype.","question_type":"Complex Reasoning","evidence":"All pediatric ALL patients receive steroids.; All pediatric ALL patients receive multiagent chemotherapy.; Steroids and multiagent chemotherapy target lymphoblasts.; Steroids and multiagent chemotherapy maximize treatment efficacy.","evidence_relations":"Everyone with ALL is treated with steroids and multiagent chemotherapy; Acute lymphoblastic leukemia (ALL) is a fast-growing blood cancer that starts in lymphocytes; B-cell ALL (B-ALL) and T-cell ALL (T-ALL) both list steroids and multiagent chemotherapy as treatment"},
	{"id":"Medical-4d6219bc","source":"Medical","question":"Why is pharmacogenomic and biomarker testing important in the management of pediatric ALL?","answer":"Pharmacogenomic and biomarker testing guide treatment decisions and help tailor therapies for optimal outcomes.","question_type":"Complex Reasoning","evidence":"Pharmacogenomic testing is important in the management of pediatric ALL.; Biomarker testing is important in the management of pediatric ALL.; Pharmacogenomic and biomarker testing guide treatment decisions.; Pharmacogenomic and biomarker testing help tailor therapies for optimal outcomes.","evidence_relations":"Pharmacogenomic testing and biomarker/genetic testing are used in ALL management; BCR::ABL1-positive B-ALL is treated with intensive systemic therapies; Diagnostic Method for ALL includes biomarker testing and pharmacogenomic testing"},
	{"id":"Medical-ef073c61","source":"Medical","question":"What age group is most commonly affected by ALL and how does this influence diagnostic and treatment strategies?","answer":"Children, adolescents, and young adults are most often affected, requiring age-specific diagnostic and treatment approaches.","question_type":"Complex Reasoning","evidence":"Children are most commonly affected by ALL.; Adolescents are most commonly affected by ALL.; Young adults are most commonly affected by ALL.; The age group affected by ALL influences diagnostic strategies.; The age group affected by ALL influences treatment strategies.","evidence_relations":"ALL is the most common cancer diagnosed in children; ALL most often affects children, adolescents, and young adults (AYAs); Treatment for ALL depends on subtype, age at diagnosis, and other factors"},
	{"id":"Medical-99964376","source":"Medical","question":"Why would a lumbar puncture be performed in the diagnostic workup of a child with ALL?","answer":"A lumbar puncture is performed to assess central nervous system (CNS) involvement, a potential disease site in ALL.","question_type":"Complex Reasoning","evidence":"A lumbar puncture is performed in the diagnostic workup of a child with ALL.; A lumbar puncture assesses central nervous system involvement.; Central nervous system involvement is a potential disease site in ALL.","evidence_relations":"ALL is diagnosed using blood tests, bone marrow tests, imaging tests, heart tests, and lumbar puncture; ALL can be found in bone marrow, blood, testicles, or central nervous system (CNS); Lumbar puncture is listed as a diagnostic method for ALL"},
	{"id":"Medical-cdce534a","source":"Medical","question":"In what situation would a pediatric ALL patient receive supportive care in addition to systemic therapy?","answer":"Supportive care is given alongside systemic therapy to manage side effects and complications during ALL treatment.","question_type":"Complex Reasoning","evidence":"Supportive care is given alongside systemic therapy for pediatric ALL patients.; Supportive care manages side effects during ALL treatment.; Supportive care manages complications during ALL treatment.","evidence_relations":"Systemic therapy and supportive care are part of ALL treatment; Treatment for ALL includes systemic therapy and supportive care; Everyone with ALL is treated with steroids and multiagent chemotherapy"},
	{"id":"Medical-1f7241a3","source":"Medical","question":"How does the presence of BCR::ABL1-positive status in B-ALL affect treatment choice in children?","answer":"BCR::ABL1-positive B-ALL requires intensive systemic therapies compared to other B-ALL cases.","question_type":"Complex Reasoning","evidence":"BCR::ABL1-positive B-ALL requires intensive systemic therapies.; BCR::ABL1-positive B-ALL is different from other B-ALL cases in treatment choice.","evidence_relations":"BCR::ABL1-positive B-ALL is treated with intensive systemic therapies; B-cell ALL (B-ALL) has a biomarker called BCR::ABL1-positive; Treatment for ALL depends on subtype, age at diagnosis, and other factors"},
	{"id":"Medical-d186c439","source":"Medical","question":"What distinguishes T-cell lymphoblastic lymphoma (T-LL, T-LBL) from T-cell ALL in terms of disease location?","answer":"T-cell lymphoblastic lymphoma involves T-cell lymphoblasts growing in the thymus, while T-cell ALL primarily involves bone marrow and blood.","question_type":"Complex Reasoning","evidence":"T-cell lymphoblastic lymphoma involves T-cell lymphoblasts growing in the thymus.; T-cell ALL primarily involves bone marrow.; T-cell ALL primarily involves blood.","evidence_relations":"T-cell lymphoblasts growing in the thymus is called T-cell lymphoblastic lymphoma (T-LL or T-LBL); Acute lymphoblastic leukemia (ALL) can be found in bone marrow, blood, testicles, or central nervous system (CNS); T-cell ALL (T-ALL) starts in T-cell lymphocytes"},
	{"id":"Medical-222ee61b","source":"Medical","question":"Why is the diagnostic threshold of 20 percent or more lymphoblasts in bone marrow important for ALL diagnosis?","answer":"It ensures that the diagnosis of ALL is based on a significant proportion of malignant lymphoblasts in the bone marrow.","question_type":"Complex Reasoning","evidence":"The diagnostic threshold of 20 percent or more lymphoblasts in bone marrow is important for ALL diagnosis.; This threshold ensures that the diagnosis of ALL is based on a significant proportion of malignant lymphoblasts.","evidence_relations":"Diagnosis of ALL generally requires 20 percent or more lymphoblasts in the bone marrow; Acute lymphoblastic leukemia (ALL) is a fast-growing blood cancer that starts in lymphocytes; Bone marrow test is a diagnostic method for ALL"},
	{"id":"Medical-c650bba8","source":"Medical","question":"How does the treatment of infant ALL differ from that of older children or adolescents?","answer":"Infant ALL (under 12 months) is treated differently than other age groups, with specialized protocols.","question_type":"Complex Reasoning","evidence":"Infant ALL is treated differently than older children or adolescents.; Infant ALL refers to patients under 12 months of age.; Specialized protocols are used for treating infant ALL.","evidence_relations":"Infant ALL (under 12 months) is treated differently than other age groups; Treatment for ALL depends on subtype, age at diagnosis, and other factors; Age Group for ALL includes infant, child, adolescent, and young adult (AYA)"},
	{"id":"Medical-50fe4cfa","source":"Medical","question":"Why should all rectal tumors be tested for mismatch repair deficiency or microsatellite instability-high, especially in patients with Lynch syndrome?","answer":"Because dMMR/MSI-H are biomarkers for rectal cancer and Lynch syndrome is a genetic risk factor, making testing essential for management.","question_type":"Complex Reasoning","evidence":"All rectal tumors should be tested for mismatch repair deficiency or microsatellite instability-high.; dMMR/MSI-H are biomarkers for rectal cancer.; Lynch syndrome is a genetic risk factor for rectal cancer.; Testing for dMMR/MSI-H is essential for management in patients with Lynch syndrome.","evidence_relations":"All rectal tumors should be tested for dMMR or MSI-H; Mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H) are biomarkers in rectal cancer; Lynch syndrome is a genetic risk factor for rectal cancer"},
	{"id":"Medical-ac73c113","source":"Medical","question":"What combination of diagnostic tools is recommended for staging and detecting metastasis in rectal cancer?","answer":"MRI of the pelvis and CT scan of chest and abdomen are recommended for staging and detecting metastasis.","question_type":"Complex Reasoning","evidence":"MRI of the pelvis is recommended for staging and detecting metastasis in rectal cancer.; CT scan of the chest and abdomen is recommended for staging and detecting metastasis in rectal cancer.","evidence_relations":"MRI of the pelvis is recommended for staging rectal cancer; CT scan of chest and abdomen is used to detect metastasis; Rectal cancer diagnostic methods include MRI and CT scan"},
	{"id":"Medical-f7ce6257","source":"Medical","question":"How does the treatment approach differ between T1 and T2 rectal tumors according to surgical recommendations?","answer":"T1 tumors are treated with local excision or endoscopic methods, while T2 tumors require transabdominal surgery.","question_type":"Complex Reasoning","evidence":"T1 rectal tumors are treated with local excision or endoscopic methods.; T2 rectal tumors require transabdominal surgery.","evidence_relations":"Endoscopic submucosal dissection (ESD) is recommended for T1 rectal tumors; Transanal local excision is an option for T1 tumors at the end of the rectum; Transabdominal surgery is recommended for T2 and some T1/T3 tumors"},
	{"id":"Medical-136a5739","source":"Medical","question":"Which two polyp types are unlikely to progress to rectal cancer, and how does this contrast with adenomas?","answer":"Hyperplastic and inflammatory polyps rarely turn into cancer, while adenomas can become invasive rectal cancer over many years.","question_type":"Complex Reasoning","evidence":"Hyperplastic polyps rarely turn into rectal cancer.; Inflammatory polyps rarely turn into rectal cancer.; Adenomas can become invasive rectal cancer over many years.","evidence_relations":"Hyperplastic and inflammatory polyps rarely turn into cancer; Adenomas can become invasive rectal cancer over many years"},
	{"id":"Medical-aaefb0f2","source":"Medical","question":"What surveillance strategies are recommended after local excision or ESD for T1 rectal cancer?","answer":"Regular flexible sigmoidoscopy every 6 months and imaging (EUS or MRI) every 3-6 months are recommended for up to 5 years.","question_type":"Complex Reasoning","evidence":"Regular flexible sigmoidoscopy every 6 months is recommended after local excision or ESD for T1 rectal cancer.; Imaging (EUS or MRI) every 3-6 months is recommended for up to 5 years after local excision or ESD for T1 rectal cancer.","evidence_relations":"Surveillance after local excision or ESD includes regular sigmoidoscopy and imaging; Flexible sigmoidoscopy every 6 months for 5 years is recommended for T1 rectal tumors; Imaging (EUS or MRI) every 3-6 months for 2 years, then every 6 months through year 5 is part of surveillance for T1 tumors"},
	{"id":"Medical-a5435dbc","source":"Medical","question":"Why is colonoscopy recommended after rectal cancer surgery, and what risk factor may increase its importance?","answer":"Colonoscopy is recommended for surveillance after surgery, especially important in patients with familial adenomatous polyposis (FAP) due to high polyp risk.","question_type":"Complex Reasoning","evidence":"Colonoscopy is recommended for surveillance after rectal cancer surgery.; Colonoscopy is especially important in patients with familial adenomatous polyposis (FAP).; Patients with FAP have a high risk of polyps.","evidence_relations":"Colonoscopy is recommended after surgery for surveillance; Familial adenomatous polyposis (FAP) is a genetic syndrome causing multiple polyps and increased rectal cancer risk"},
	{"id":"Medical-e8163237","source":"Medical","question":"Which surgical procedures are specifically used for tumors in different parts of the rectum?","answer":"Low anterior resection (LAR) is used for mid to upper rectum tumors, while abdominoperineal resection (APR) is used for lower rectum tumors.","question_type":"Complex Reasoning","evidence":"Low anterior resection (LAR) is used for mid to upper rectum tumors.; Abdominoperineal resection (APR) is used for lower rectum tumors.","evidence_relations":"Low anterior resection (LAR) is used for tumors in the mid to upper rectum; Abdominoperineal resection (APR) is used for tumors in the lower rectum"},
	{"id":"Medical-af6105a0","source":"Medical","question":"What are the recommended fertility preservation options for rectal cancer patients, and why might these be important?","answer":"Sperm banking, egg freezing, ovarian tissue banking, and ovarian transposition are recommended, important due to risks of premature ovarian insufficiency from treatment.","question_type":"Complex Reasoning","evidence":"Sperm banking is a recommended fertility preservation option for rectal cancer patients.; Egg freezing is a recommended fertility preservation option for rectal cancer patients.; Ovarian tissue banking is a recommended fertility preservation option for rectal cancer patients.; Ovarian transposition is a recommended fertility preservation option for rectal cancer patients.; Fertility preservation options are important due to risks of premature ovarian insufficiency from treatment.","evidence_relations":"Fertility preservation options include sperm banking, egg freezing, ovarian tissue banking, and ovarian transposition; Premature ovarian insufficiency (POI) is a risk after some cancer treatments"},
	{"id":"Medical-c58dca0f","source":"Medical","question":"Which chemotherapy agents may be included in rectal cancer treatment regimens and for what stage are they typically used?","answer":"Oxaliplatin and irinotecan may be included in chemotherapy regimens, typically used for locally advanced rectal cancer.","question_type":"Complex Reasoning","evidence":"Oxaliplatin may be included in chemotherapy regimens for rectal cancer.; Irinotecan may be included in chemotherapy regimens for rectal cancer.; Oxaliplatin and irinotecan are typically used for locally advanced rectal cancer.","evidence_relations":"Chemotherapy regimens may include oxaliplatin or irinotecan; Chemoradiation is used for locally advanced rectal cancer"},
	{"id":"Medical-f5089b0a","source":"Medical","question":"What symptoms, if present together, should prompt diagnostic testing for rectal cancer using imaging and endoscopic methods?","answer":"Changes in bowel habits, rectal bleeding, and abdominal pain should prompt MRI, EUS, and colonoscopy for diagnosis.","question_type":"Complex Reasoning","evidence":"Changes in bowel habits should prompt diagnostic testing for rectal cancer.; Rectal bleeding should prompt diagnostic testing for rectal cancer.; Abdominal pain should prompt diagnostic testing for rectal cancer.; MRI is recommended for diagnosing rectal cancer.; EUS is recommended for diagnosing rectal cancer.; Colonoscopy is recommended for diagnosing rectal cancer.","evidence_relations":"Symptoms of rectal cancer may include changes in bowel habits, rectal bleeding, and abdominal pain; MRI of the pelvis is recommended for staging rectal cancer; Endorectal ultrasound (EUS) can assess tumor extent and guide biopsy; Colonoscopy is a diagnostic method for rectal cancer"},
	{"id":"Medical-a73aa030","source":"Medical","question":"Why is polypectomy during colonoscopy considered a preventive strategy for rectal cancer?","answer":"Because most rectal cancers start in adenomatous polyps and polypectomy can remove these polyps to prevent cancer.","question_type":"Complex Reasoning","evidence":"Most rectal cancers start in adenomatous polyps.; Polypectomy during colonoscopy can remove adenomatous polyps.; Polypectomy is considered a preventive strategy for rectal cancer.","evidence_relations":"Most rectal cancers start in adenomatous polyps; Polypectomy during colonoscopy can remove most polyps and prevent cancer"},
	{"id":"Medical-fad3190e","source":"Medical","question":"For a patient with a history of FAP, what combination of surveillance and diagnostic methods is most critical?","answer":"Regular colonoscopy and polypectomy are critical due to the high risk of multiple polyps and rectal cancer.","question_type":"Complex Reasoning","evidence":"Regular colonoscopy is critical for patients with a history of FAP.; Polypectomy is critical for patients with a history of FAP.; Patients with a history of FAP have a high risk of multiple polyps.; Patients with a history of FAP have a high risk of rectal cancer.","evidence_relations":"Familial adenomatous polyposis (FAP) is a genetic syndrome causing multiple polyps and increased rectal cancer risk; Colonoscopy is recommended after surgery for surveillance; Polypectomy during colonoscopy can remove most polyps and prevent cancer"},
	{"id":"Medical-2e2c9c8e","source":"Medical","question":"If a rectal cancer patient has dMMR or MSI-H, what does this indicate regarding their tumor, and what testing is required?","answer":"It indicates a biomarker status relevant for management, and all rectal tumors should be tested for dMMR or MSI-H.","question_type":"Complex Reasoning","evidence":"dMMR or MSI-H indicates a biomarker status relevant for management of rectal cancer.; All rectal tumors should be tested for dMMR.; All rectal tumors should be tested for MSI-H.","evidence_relations":"Mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H) are biomarkers in rectal cancer; All rectal tumors should be tested for dMMR or MSI-H"},
	{"id":"Medical-9675683c","source":"Medical","question":"What methods are used to monitor rectal cancer after initial treatment and what biomarker is involved?","answer":"Blood tests such as CEA and imaging are used for monitoring after treatment.","question_type":"Complex Reasoning","evidence":"Blood tests such as CEA are used for monitoring rectal cancer after treatment.; Imaging is used for monitoring rectal cancer after treatment.","evidence_relations":"Blood tests such as CEA are used for monitoring rectal cancer; Surveillance after local excision or ESD includes regular sigmoidoscopy and imaging"},
	{"id":"Medical-26ced7a1","source":"Medical","question":"How are endoscopic and surgical options distinguished for early-stage rectal tumors?","answer":"Endoscopic methods like ESD and EMR are used for T1 tumors, while transabdominal surgery is used for T2 and some T1/T3 tumors.","question_type":"Complex Reasoning","evidence":"Endoscopic methods like ESD are used for T1 tumors.; Endoscopic methods like EMR are used for T1 tumors.; Transabdominal surgery is used for T2 tumors.; Transabdominal surgery is used for some T1/T3 tumors.","evidence_relations":"Endoscopic submucosal dissection (ESD) is recommended for T1 rectal tumors; Transabdominal surgery is recommended for T2 and some T1/T3 tumors"},
	{"id":"Medical-a6968a78","source":"Medical","question":"Which diagnostic methods are recommended for a patient presenting with hematuria and frequent urination suspected of having bladder cancer?","answer":"Cystoscopy, urine cytology, biopsy, and imaging such as CT scan or MRI are recommended diagnostic methods.","question_type":"Complex Reasoning","evidence":"Cystoscopy is a recommended diagnostic method for suspected bladder cancer.; Urine cytology is a recommended diagnostic method for suspected bladder cancer.; Biopsy is a recommended diagnostic method for suspected bladder cancer.; Imaging such as CT scan is a recommended diagnostic method for suspected bladder cancer.; Imaging such as MRI is a recommended diagnostic method for suspected bladder cancer.","evidence_relations":"Blood in urine (hematuria) is the most common symptom of bladder cancer; Other symptoms include frequent urination; Diagnosis of bladder cancer involves cystoscopy, urine cytology, biopsy, and imaging (CT, MRI, PET/CT, ultrasound, pyelogram, urogram)"},
	{"id":"Medical-91c35427","source":"Medical","question":"What is the standard surgical procedure for muscle-invasive bladder cancer, and what urinary diversion options may follow?","answer":"Radical cystectomy is the standard surgery for muscle-invasive bladder cancer, followed by urinary diversion procedures such as ileal conduit, neobladder, or continent cutaneous pouch.","question_type":"Complex Reasoning","evidence":"Radical cystectomy is the standard surgery for muscle-invasive bladder cancer.; Urinary diversion procedures may follow radical cystectomy.; Ileal conduit is a urinary diversion option after radical cystectomy.; Neobladder is a urinary diversion option after radical cystectomy.; Continent cutaneous pouch is a urinary diversion option after radical cystectomy.","evidence_relations":"Radical cystectomy is the standard surgery for muscle-invasive bladder cancer; Urinary diversion procedures include ileal conduit, neobladder, and continent cutaneous pouch; Stages 2, 3, and 4 bladder cancers are muscle-invasive"},
	{"id":"Medical-da2b7d6f","source":"Medical","question":"Which treatments are used for nonmuscle-invasive bladder cancer and what surgical procedure is typically involved?","answer":"TURBT and intravesical therapy (BCG or chemotherapy) are used for nonmuscle-invasive bladder cancer.","question_type":"Complex Reasoning","evidence":"TURBT is used for nonmuscle-invasive bladder cancer.; Intravesical therapy is used for nonmuscle-invasive bladder cancer.; BCG is a type of intravesical therapy for nonmuscle-invasive bladder cancer.; Chemotherapy is a type of intravesical therapy for nonmuscle-invasive bladder cancer.","evidence_relations":"Stage 0 and Stage 1 bladder cancers are nonmuscle-invasive; TURBT is used for tumor removal in nonmuscle-invasive bladder cancer; Intravesical therapy (BCG or chemotherapy) is used for nonmuscle-invasive bladder cancer"},
	{"id":"Medical-27edd702","source":"Medical","question":"What systemic therapies are available for bladder cancer patients with advanced or metastatic disease?","answer":"Systemic therapies include chemotherapy (cisplatin-based regimens), immunotherapy (checkpoint inhibitors), and targeted therapies.","question_type":"Complex Reasoning","evidence":"Systemic therapies for advanced or metastatic bladder cancer include chemotherapy.; Cisplatin-based regimens are a type of chemotherapy for bladder cancer.; Systemic therapies for advanced or metastatic bladder cancer include immunotherapy.; Checkpoint inhibitors are a type of immunotherapy for bladder cancer.; Systemic therapies for advanced or metastatic bladder cancer include targeted therapies.","evidence_relations":"Systemic therapy includes chemotherapy, immunotherapy (checkpoint inhibitors), and targeted therapy; Chemotherapy regimens include cisplatin-based combinations such as ddMVAC; Immunotherapy agents include pembrolizumab, nivolumab, avelumab, and atezolizumab; Targeted therapies include enfortumab vedotin-ejfv (Padcev), erdafitinib (Balversa), and sacituzumab govitecan-hziy (Trodelvy); Stage 4 bladder cancer is metastatic and may involve distant organs"},
	{"id":"Medical-ac86bfad","source":"Medical","question":"How does the treatment approach differ between muscle-invasive and nonmuscle-invasive bladder cancer?","answer":"Muscle-invasive bladder cancer is treated with radical cystectomy and may require urinary diversion, while nonmuscle-invasive bladder cancer is treated with TURBT and intravesical therapy.","question_type":"Complex Reasoning","evidence":"Muscle-invasive bladder cancer is treated with radical cystectomy.; Muscle-invasive bladder cancer may require urinary diversion.; Non-muscle-invasive bladder cancer is treated with TURBT.; Non-muscle-invasive bladder cancer is treated with intravesical therapy.","evidence_relations":"Stages 2, 3, and 4 bladder cancers are muscle-invasive; Radical cystectomy is the standard surgery for muscle-invasive bladder cancer; Stage 0 and Stage 1 bladder cancers are nonmuscle-invasive; TURBT is used for tumor removal in nonmuscle-invasive bladder cancer; Intravesical therapy (BCG or chemotherapy) is used for nonmuscle-invasive bladder cancer"},
	{"id":"Medical-d1c9cdcd","source":"Medical","question":"What are the common genetic alterations associated with bladder cancer, and how might these influence targeted therapy options?","answer":"Genetic alterations such as FGFR3, CDKN2A, PIK3CA, and ERBB mutations are associated with bladder cancer and may be targeted by therapies like erdafitinib and enfortumab vedotin-ejfv.","question_type":"Complex Reasoning","evidence":"Genetic alterations associated with bladder cancer include FGFR3.; Genetic alterations associated with bladder cancer include CDKN2A.; Genetic alterations associated with bladder cancer include PIK3CA.; Genetic alterations associated with bladder cancer include ERBB mutations.; Therapies like erdafitinib may target genetic alterations in bladder cancer.; Therapies like enfortumab vedotin-ejfv may target genetic alterations in bladder cancer.","evidence_relations":"Genetic alterations such as mutations in CDKN2A, FGFR3, PIK3CA, and ERBB genes are associated with bladder cancer; Targeted therapies include enfortumab vedotin-ejfv (Padcev), erdafitinib (Balversa), and sacituzumab govitecan-hziy (Trodelvy); FGFR3 mutation is a genetic alteration linked to bladder cancer"},
	{"id":"Medical-0bd26353","source":"Medical","question":"What are the main components of trimodal therapy for bladder cancer and in which clinical context is it used?","answer":"Trimodal therapy combines TURBT, chemotherapy, and radiation as a bladder-preserving approach for muscle-invasive bladder cancer.","question_type":"Complex Reasoning","evidence":"Trimodal therapy combines TURBT.; Trimodal therapy combines chemotherapy.; Trimodal therapy combines radiation.; Trimodal therapy is used as a bladder-preserving approach for muscle-invasive bladder cancer.","evidence_relations":"Trimodal therapy combines TURBT, chemotherapy, and radiation as a bladder-preserving approach; Radical cystectomy is the standard surgery for muscle-invasive bladder cancer; Trimodal therapy is an alternative to radical cystectomy for bladder preservation"},
	{"id":"Medical-025c325c","source":"Medical","question":"Which symptoms and risk factors would prompt early diagnostic evaluation for bladder cancer?","answer":"Blood in urine, frequent urination, and risk factors like smoking and chemical exposure should prompt early diagnostic evaluation.","question_type":"Complex Reasoning","evidence":"Blood in urine should prompt early diagnostic evaluation for bladder cancer.; Frequent urination should prompt early diagnostic evaluation for bladder cancer.; Smoking is a risk factor that should prompt early diagnostic evaluation for bladder cancer.; Chemical exposure is a risk factor that should prompt early diagnostic evaluation for bladder cancer.","evidence_relations":"Blood in urine (hematuria) is the most common symptom of bladder cancer; Other symptoms include frequent urination; Smoking is the greatest risk factor for bladder cancer; Other risk factors include chemical exposure"},
	{"id":"Medical-79d13dd8","source":"Medical","question":"What follow-up and surveillance methods are recommended after initial treatment of nonmuscle-invasive bladder cancer?","answer":"Regular cystoscopy, urine cytology, imaging, and biomarker surveillance are recommended for follow-up after nonmuscle-invasive bladder cancer treatment.","question_type":"Complex Reasoning","evidence":"Regular cystoscopy is recommended for follow-up after non-muscle-invasive bladder cancer treatment.; Urine cytology is recommended for follow-up after non-muscle-invasive bladder cancer treatment.; Imaging is recommended for follow-up after non-muscle-invasive bladder cancer treatment.; Biomarker surveillance is recommended for follow-up after non-muscle-invasive bladder cancer treatment.","evidence_relations":"Follow-up and surveillance are required due to high recurrence rates; Biomarker tests may be used for surveillance in nonmuscle-invasive bladder cancer; Follow-up/Surveillance includes regular cystoscopy, urine cytology, imaging, and biomarker surveillance"},
	{"id":"Medical-a0699e9e","source":"Medical","question":"Which side effects might a patient experience after radical cystectomy and urinary diversion for bladder cancer?","answer":"Patients may experience urinary incontinence, sexual dysfunction, infection, and fatigue after radical cystectomy and urinary diversion.","question_type":"Complex Reasoning","evidence":"Patients may experience urinary incontinence after radical cystectomy and urinary diversion.; Patients may experience sexual dysfunction after radical cystectomy and urinary diversion.; Patients may experience infection after radical cystectomy and urinary diversion.; Patients may experience fatigue after radical cystectomy and urinary diversion.","evidence_relations":"Radical cystectomy is the standard surgery for muscle-invasive bladder cancer; Urinary diversion procedures include ileal conduit, neobladder, and continent cutaneous pouch; Common side effects of treatment include urinary incontinence, sexual dysfunction, infection, and fatigue"},
	{"id":"Medical-a7a91e43","source":"Medical","question":"For a patient with high-grade, muscle-invasive urothelial carcinoma, what are the standard treatment options?","answer":"Radical cystectomy, systemic chemotherapy, and possibly chemoradiation or trimodal therapy are standard options.","question_type":"Complex Reasoning","evidence":"Standard treatment options for high-grade, muscle-invasive urothelial carcinoma include radical cystectomy.; Standard treatment options for high-grade, muscle-invasive urothelial carcinoma include systemic chemotherapy.; Standard treatment options for high-grade, muscle-invasive urothelial carcinoma may include chemoradiation.; Standard treatment options for high-grade, muscle-invasive urothelial carcinoma may include trimodal therapy.","evidence_relations":"Cancer grade is classified as low grade (LG) or high grade (HG); Radical cystectomy is the standard surgery for muscle-invasive bladder cancer; Systemic therapy includes chemotherapy; Radiation therapy (EBRT) is used alone or in combination with chemotherapy (chemoradiation); Trimodal therapy combines TURBT, chemotherapy, and radiation as a bladder-preserving approach"},
	{"id":"Medical-b200a90c","source":"Medical","question":"Which bladder cancer subtypes are less common and how does this affect the overall classification of the disease?","answer":"Squamous cell carcinoma, adenocarcinoma, and small cell carcinoma are less common subtypes, with urothelial carcinoma being the most common.","question_type":"Complex Reasoning","evidence":"Squamous cell carcinoma is a less common subtype of bladder cancer.; Adenocarcinoma is a less common subtype of bladder cancer.; Small cell carcinoma is a less common subtype of bladder cancer.; Urothelial carcinoma is the most common subtype of bladder cancer.","evidence_relations":"Urothelial carcinoma is the most common subtype of bladder cancer; Squamous cell carcinoma, adenocarcinoma, and small cell carcinoma are less common subtypes of bladder cancer"},
	{"id":"Medical-2a5688d0","source":"Medical","question":"What are the main imaging modalities used in the diagnosis and surveillance of bladder cancer?","answer":"CT scan, MRI, PET/CT, ultrasound, pyelogram, and urogram are main imaging modalities used.","question_type":"Complex Reasoning","evidence":"CT scan is a main imaging modality used in the diagnosis of bladder cancer.; MRI is a main imaging modality used in the diagnosis of bladder cancer.; PET/CT is a main imaging modality used in the diagnosis of bladder cancer.; Ultrasound is a main imaging modality used in the diagnosis of bladder cancer.; Pyelogram is a main imaging modality used in the diagnosis of bladder cancer.; Urogram is a main imaging modality used in the diagnosis of bladder cancer.","evidence_relations":"Diagnosis of bladder cancer involves imaging (CT, MRI, PET/CT, ultrasound, pyelogram, urogram); Follow-up/Surveillance includes imaging"},
	{"id":"Medical-e54f3250","source":"Medical","question":"What are the roles of immunotherapy agents in systemic therapy for advanced bladder cancer?","answer":"Immunotherapy agents like pembrolizumab, nivolumab, avelumab, and atezolizumab are used as systemic therapy for advanced bladder cancer.","question_type":"Complex Reasoning","evidence":"Immunotherapy agents are used as systemic therapy for advanced bladder cancer.; Pembrolizumab is an immunotherapy agent for advanced bladder cancer.; Nivolumab is an immunotherapy agent for advanced bladder cancer.; Avelumab is an immunotherapy agent for advanced bladder cancer.; Atezolizumab is an immunotherapy agent for advanced bladder cancer.","evidence_relations":"Systemic therapy includes immunotherapy (checkpoint inhibitors); Immunotherapy agents include pembrolizumab, nivolumab, avelumab, and atezolizumab; Stage 4 bladder cancer is metastatic and may involve distant organs"},
	{"id":"Medical-18263083","source":"Medical","question":"Which risk factors should be considered when assessing a patient's likelihood of developing bladder cancer?","answer":"Smoking, secondhand smoke, age, family history, Lynch syndrome, and chemical exposure should be considered.","question_type":"Complex Reasoning","evidence":"Smoking is a risk factor for developing bladder cancer.; Secondhand smoke is a risk factor for developing bladder cancer.; Age is a risk factor for developing bladder cancer.; Family history is a risk factor for developing bladder cancer.; Lynch syndrome is a risk factor for developing bladder cancer.; Chemical exposure is a risk factor for developing bladder cancer.","evidence_relations":"Smoking is the greatest risk factor for bladder cancer; Other risk factors include age, family history, Lynch syndrome, and chemical exposure"},
	{"id":"Medical-648df362","source":"Medical","question":"What distinguishes Wilms tumor from other kidney cancer subtypes in terms of patient population and classification?","answer":"Wilms tumor is a distinct kidney cancer type that usually occurs in young children, unlike other subtypes.","question_type":"Complex Reasoning","evidence":"Wilms tumor is a distinct type of kidney cancer.; Wilms tumor usually occurs in young children.; Wilms tumor is different from other kidney cancer subtypes.","evidence_relations":"Wilms tumor usually occurs in young children and is a distinct kidney cancer type; Wilms tumor (nephroblastoma) is listed as a separate subtype under Cancer Type: Kidney cancer in the ontology"},
	{"id":"Medical-97e7a1d0","source":"Medical","question":"If a kidney tumor is found to have sarcomatoid features, what does this indicate regarding its subtype and disease aggressiveness?","answer":"Sarcomatoid features can occur in any RCC subtype and are associated with more aggressive disease.","question_type":"Complex Reasoning","evidence":"Sarcomatoid features can occur in any subtype of renal cell carcinoma (RCC).; Sarcomatoid features are associated with more aggressive disease.","evidence_relations":"Sarcomatoid features can occur in any RCC subtype and are associated with more aggressive disease; Sarcomatoid RCC (sRCC) is included under Histology for RCC in the ontology"},
	{"id":"Medical-a56d528c","source":"Medical","question":"How does the origin of RCC differ from that of urothelial carcinoma within the kidney?","answer":"RCC starts in the cells lining the renal tubules, while urothelial carcinoma starts in the cells lining the renal pelvis and ureter.","question_type":"Complex Reasoning","evidence":"RCC starts in the cells lining the renal tubules.; Urothelial carcinoma starts in the cells lining the renal pelvis and ureter.","evidence_relations":"RCC starts in the cells that line the renal tubules; Urothelial carcinoma starts in the cells lining the renal pelvis and ureter"},
	{"id":"Medical-99713759","source":"Medical","question":"Which diagnostic methods are recommended for confirming a diagnosis of kidney cancer, and what is their basis in the classification system?","answer":"Imaging tests, blood tests, urine tests, biopsy, biomarker testing, and genetic risk testing are all recommended diagnostic methods for kidney cancer.","question_type":"Complex Reasoning","evidence":"Imaging tests are recommended for confirming a diagnosis of kidney cancer.; Blood tests are recommended for confirming a diagnosis of kidney cancer.; Urine tests are recommended for confirming a diagnosis of kidney cancer.; Biopsy is recommended for confirming a diagnosis of kidney cancer.; Biomarker testing is recommended for confirming a diagnosis of kidney cancer.; Genetic risk testing is recommended for confirming a diagnosis of kidney cancer.","evidence_relations":"Diagnosis of kidney cancer involves imaging tests, blood tests, urine tests, biopsy, biomarker testing, and genetic risk testing; Diagnostic Method includes imaging tests, blood tests, urine tests, biopsy, biomarker testing, and genetic risk testing for Kidney cancer in the ontology"},
	{"id":"Medical-daeae948","source":"Medical","question":"What are the most common and less common subtypes of RCC, and how are they organized?","answer":"Clear cell RCC is the most common subtype, while non-clear cell RCC includes papillary, chromophobe, collecting duct RCC, and renal medullary carcinoma.","question_type":"Complex Reasoning","evidence":"Clear cell RCC is the most common subtype of RCC.; Non-clear cell RCC includes several subtypes.; Papillary RCC is a subtype of non-clear cell RCC.; Chromophobe RCC is a subtype of non-clear cell RCC.; Collecting duct RCC is a subtype of non-clear cell RCC.; Renal medullary carcinoma is a subtype of non-clear cell RCC.","evidence_relations":"Clear cell RCC is the most common subtype of RCC; Non-clear cell RCC includes papillary RCC, chromophobe RCC, collecting duct RCC, and renal medullary carcinoma; Clear cell RCC (ccRCC) and Non-clear cell RCC (nccRCC) with its subtypes are listed under Histology for RCC in the ontology"},
	{"id":"Medical-d2458aa7","source":"Medical","question":"If a patient has multiple tumors in both kidneys, how should these be classified and why?","answer":"They should be treated as separate primary tumors, not metastasis.","question_type":"Complex Reasoning","evidence":"Multiple tumors in both kidneys should be treated as separate primary tumors.; Multiple tumors in both kidneys should not be classified as metastasis.","evidence_relations":"Multiple tumors in one or both kidneys are treated as separate primary tumors, not metastasis; The ontology distinguishes between local spread/metastasis and primary tumors in classification"},
	{"id":"Medical-ed5085d7","source":"Medical","question":"Which anatomical structures are at risk for local spread of kidney cancer, and how are they categorized?","answer":"Surrounding fat, blood vessels, lymph nodes, adrenal glands, and Gerotas fascia are at risk for local spread.","question_type":"Complex Reasoning","evidence":"Surrounding fat is at risk for local spread of kidney cancer.; Blood vessels are at risk for local spread of kidney cancer.; Lymph nodes are at risk for local spread of kidney cancer.; Adrenal glands are at risk for local spread of kidney cancer.; Gerotas fascia is at risk for local spread of kidney cancer.","evidence_relations":"Kidney cancer can spread locally to surrounding fat, blood vessels, lymph nodes, adrenal glands, and Gerotas fascia; Stage in the ontology lists local spread to surrounding fat, blood vessels, lymph nodes, adrenal glands, and Gerotas fascia"},
	{"id":"Medical-74b73ed7","source":"Medical","question":"What distant organs are common sites of kidney cancer metastasis, and how is this reflected in the classification?","answer":"Lungs, lymph nodes, bones, liver, and brain are common distant metastatic sites.","question_type":"Complex Reasoning","evidence":"Lungs are common sites of kidney cancer metastasis.; Lymph nodes are common sites of kidney cancer metastasis.; Bones are common sites of kidney cancer metastasis.; Liver is a common site of kidney cancer metastasis.; Brain is a common site of kidney cancer metastasis.","evidence_relations":"Kidney cancer can metastasize to distant sites such as lungs, lymph nodes, bones, liver, and brain; Stage in the ontology includes metastasis to lungs, lymph nodes, bones, liver, and brain"},
	{"id":"Medical-bb361e83","source":"Medical","question":"How does the presence of sarcomatoid features influence treatment considerations for RCC?","answer":"Sarcomatoid features indicate more aggressive disease, which is a treatment factor for RCC.","question_type":"Complex Reasoning","evidence":"Sarcomatoid features indicate more aggressive disease.; Sarcomatoid features are a treatment factor for RCC.","evidence_relations":"Sarcomatoid features can occur in any RCC subtype and are associated with more aggressive disease; Treatment for RCC is based on histology, tumor size, tumor location, and presence of metastasis; Histology, including sarcomatoid RCC, is listed as a treatment factor in the ontology"},
	{"id":"Medical-6b3f89bd","source":"Medical","question":"Which RCC subtypes are considered non-clear cell RCC, and how are they grouped in the classification?","answer":"Papillary RCC, chromophobe RCC, collecting duct RCC, renal medullary carcinoma, clear cell papillary renal cell tumor, fumarate hydratase-deficient RCC, and ELOC-mutated RCC are all non-clear cell RCC subtypes.","question_type":"Complex Reasoning","evidence":"Papillary RCC is a non-clear cell RCC subtype.; Chromophobe RCC is a non-clear cell RCC subtype.; Collecting duct RCC is a non-clear cell RCC subtype.; Renal medullary carcinoma is a non-clear cell RCC subtype.; Clear cell papillary renal cell tumor is a non-clear cell RCC subtype.; Fumarate hydratase-deficient RCC is a non-clear cell RCC subtype.; ELOC-mutated RCC is a non-clear cell RCC subtype.","evidence_relations":"Non-clear cell RCC includes papillary RCC, chromophobe RCC, collecting duct RCC, and renal medullary carcinoma; Non-clear cell RCC (nccRCC) in the ontology includes Papillary RCC, Chromophobe RCC, Collecting duct RCC, Renal medullary carcinoma, Clear cell papillary renal cell tumor, Fumarate hydratase-deficient RCC, and ELOC-mutated RCC"},
	{"id":"Medical-a5f2e7a9","source":"Medical","question":"What are the key factors that determine the treatment approach for RCC according to the classification system?","answer":"Histology, tumor size, tumor location, and presence of metastasis are key treatment factors for RCC.","question_type":"Complex Reasoning","evidence":"Histology is a key treatment factor for RCC.; Tumor size is a key treatment factor for RCC.; Tumor location is a key treatment factor for RCC.; Presence of metastasis is a key treatment factor for RCC.","evidence_relations":"Treatment for RCC is based on histology, tumor size, tumor location, and presence of metastasis; Treatment Factor in the ontology lists histology, tumor size, tumor location, and presence of metastasis"},
	{"id":"Medical-4ff142d9","source":"Medical","question":"How does the starting location of renal cell carcinoma compare to that of renal sarcoma within the kidney?","answer":"RCC starts in the renal tubules, while renal sarcoma starts in the blood vessels or connective tissue of the kidney.","question_type":"Complex Reasoning","evidence":"RCC starts in the renal tubules.; Renal sarcoma starts in the blood vessels or connective tissue of the kidney.","evidence_relations":"RCC starts in the cells that line the renal tubules; Renal sarcoma starts in the blood vessels or connective tissue of the kidney"},
	{"id":"Medical-5504201a","source":"Medical","question":"If a kidney tumor is found in the renal pelvis, which cancer subtype is most likely and why?","answer":"Urothelial carcinoma is most likely since it starts in the cells lining the renal pelvis.","question_type":"Complex Reasoning","evidence":"Urothelial carcinoma is most likely if a kidney tumor is found in the renal pelvis.; Urothelial carcinoma starts in the cells lining the renal pelvis.","evidence_relations":"Urothelial carcinoma starts in the cells lining the renal pelvis and ureter; Renal pelvis is listed under Anatomical Structure for Kidney cancer in the ontology"},
	{"id":"Medical-6d335c18","source":"Medical","question":"What histological subtypes are found under RCC and how are they organized in the classification?","answer":"Clear cell RCC, non-clear cell RCC (with papillary, chromophobe, collecting duct, renal medullary carcinoma, clear cell papillary, fumarate hydratase-deficient, ELOC-mutated), and sarcomatoid RCC are all histological subtypes under RCC.","question_type":"Complex Reasoning","evidence":"Clear cell RCC is a histological subtype under RCC.; Non-clear cell RCC is a histological subtype under RCC.; Papillary RCC is a subtype of non-clear cell RCC.; Chromophobe RCC is a subtype of non-clear cell RCC.; Collecting duct RCC is a subtype of non-clear cell RCC.; Renal medullary carcinoma is a subtype of non-clear cell RCC.; Clear cell papillary is a subtype of non-clear cell RCC.; Fumarate hydratase-deficient RCC is a subtype of non-clear cell RCC.; ELOC-mutated RCC is a subtype of non-clear cell RCC.; Sarcomatoid RCC is a histological subtype under RCC.","evidence_relations":"Clear cell RCC is the most common subtype of RCC; Non-clear cell RCC includes papillary RCC, chromophobe RCC, collecting duct RCC, and renal medullary carcinoma; Histology for RCC in the ontology lists clear cell RCC, non-clear cell RCC (with its subtypes), and sarcomatoid RCC"},
	{"id":"Medical-b272ce63","source":"Medical","question":"Which anatomical structures are directly involved in the spread of kidney cancer and how are these structures classified?","answer":"Renal vein, renal artery, Gerotas fascia, adrenal gland, and lymph nodes are anatomical structures involved in local spread or metastasis of kidney cancer.","question_type":"Complex Reasoning","evidence":"Renal vein is involved in the spread of kidney cancer.; Renal artery is involved in the spread of kidney cancer.; Gerotas fascia is involved in the spread of kidney cancer.; Adrenal gland is involved in the spread of kidney cancer.; Lymph nodes are involved in the spread of kidney cancer.","evidence_relations":"Kidney cancer can spread locally to surrounding fat, blood vessels, lymph nodes, adrenal glands, and Gerotas fascia; Anatomical Structure in the ontology includes renal vein, renal artery, Gerotas fascia, adrenal gland, and lymph nodes"},
	{"id":"Medical-32861246","source":"Medical","question":"Which combination of diagnostic methods is necessary to confirm and stage anal cancer after a patient presents with rectal bleeding and an anal lump?","answer":"Digital rectal exam (DRE), anoscopy or high-resolution anoscopy (HRA), biopsy, and imaging (CT, MRI, PET) are necessary to confirm and stage anal cancer.","question_type":"Complex Reasoning","evidence":"Digital rectal exam (DRE) is necessary to confirm and stage anal cancer.; Anoscopy or high-resolution anoscopy (HRA) is necessary to confirm and stage anal cancer.; Biopsy is necessary to confirm and stage anal cancer.; Imaging (CT, MRI, PET) is necessary to confirm and stage anal cancer.","evidence_relations":"Anal cancer is diagnosed by biopsy after abnormal findings on DRE or anoscopy; Digital rectal exam (DRE), high-resolution anoscopy (HRA), and imaging (CT, MRI, PET) are used for diagnosis and staging; Common symptoms of anal cancer include rectal bleeding, anal itching, pain, and a lump near the anus"},
	{"id":"Medical-219da1ba","source":"Medical","question":"Why should fertility preservation be discussed before chemoradiation in a young patient with Stage II anal cancer?","answer":"Because chemoradiation can cause infertility and Stage II anal cancer is treated with chemoradiation, so fertility preservation options should be considered.","question_type":"Complex Reasoning","evidence":"Fertility preservation should be discussed before chemoradiation in a young patient with Stage II anal cancer.; Chemoradiation can cause infertility.; Stage II anal cancer is treated with chemoradiation.; Fertility preservation options should be considered.","evidence_relations":"Chemoradiation is the recommended primary treatment for most non-metastatic anal cancers (stages I-III); Radiation and chemotherapy can cause infertility; fertility preservation options should be discussed; Fertility Preservation includes sperm banking, egg freezing, ovarian tissue banking, and oophoropexy"},
	{"id":"Medical-ec0be6f4","source":"Medical","question":"How is the treatment approach different for a patient with Stage III anal cancer compared to one with Stage IV disease?","answer":"Stage III is treated with chemoradiation while Stage IV requires systemic chemotherapy and possibly immunotherapy.","question_type":"Complex Reasoning","evidence":"Stage III anal cancer is treated with chemoradiation.; Stage IV anal cancer requires systemic chemotherapy.; Stage IV anal cancer may require immunotherapy.","evidence_relations":"Chemoradiation is the recommended primary treatment for most non-metastatic anal cancers (stages I-III); Metastatic anal cancer is treated with systemic chemotherapy (e.g., carboplatin and paclitaxel, FOLFOX, FOLFCIS, DCF, 5-FU and cisplatin); Immunotherapy (nivolumab, pembrolizumab) is recommended for metastatic anal cancer that progresses after chemotherapy"},
	{"id":"Medical-3964e4de","source":"Medical","question":"What factors would indicate that a patient with anal cancer should undergo HIV testing as part of their diagnostic workup?","answer":"Because HIV infection increases anal cancer risk and HIV testing is recommended in patients with anal cancer.","question_type":"Complex Reasoning","evidence":"HIV infection increases anal cancer risk.; HIV testing is recommended in patients with anal cancer.","evidence_relations":"HIV infection increases the risk of anal cancer; HIV testing is recommended in patients with anal cancer"},
	{"id":"Medical-441c763b","source":"Medical","question":"Which treatment is indicated for a patient with persistent or recurrent anal cancer after initial chemoradiation, and what is a major consequence of this intervention?","answer":"Abdominoperineal resection (APR) is indicated, resulting in a permanent colostomy.","question_type":"Complex Reasoning","evidence":"Abdominoperineal resection (APR) is indicated for persistent or recurrent anal cancer after initial chemoradiation.; Abdominoperineal resection (APR) results in a permanent colostomy.","evidence_relations":"Abdominoperineal resection (APR) is recommended for persistent, recurrent, or locally progressive anal cancer; APR results in a permanent colostomy"},
	{"id":"Medical-9626892c","source":"Medical","question":"If a patient with a history of cervical cancer presents with anal pain and is found to have HSIL on biopsy, what does this indicate about their risk and disease status?","answer":"They have an increased risk for anal cancer and HSIL represents a precancerous lesion (Stage 0).","question_type":"Complex Reasoning","evidence":"A patient with a history of cervical cancer and anal pain has an increased risk for anal cancer.; HSIL represents a precancerous lesion (Stage 0).","evidence_relations":"History of cervical, vulvar, or vaginal cancer or precancer increases anal cancer risk; HSIL (high-grade squamous intraepithelial lesion) is a precancerous lesion for anal cancer; Stage 0 is carcinoma in situ or anal dysplasia"},
	{"id":"Medical-402f416c","source":"Medical","question":"Which chemotherapy regimens are recommended as part of chemoradiation for a patient with Stage II anal squamous cell carcinoma?","answer":"Mitomycin and capecitabine, mitomycin and 5-FU, or 5-FU and cisplatin are recommended regimens.","question_type":"Complex Reasoning","evidence":"Mitomycin and capecitabine are recommended chemotherapy regimens for Stage II anal squamous cell carcinoma.; Mitomycin and 5-FU are recommended chemotherapy regimens for Stage II anal squamous cell carcinoma.; 5-FU and cisplatin are recommended chemotherapy regimens for Stage II anal squamous cell carcinoma.","evidence_relations":"Chemoradiation is the recommended primary treatment for most non-metastatic anal cancers (stages I-III); Recommended chemotherapy regimens with radiation include mitomycin and capecitabine, mitomycin and 5-FU, or 5-FU and cisplatin; Anal squamous cell carcinoma is the most common subtype of anal cancer"},
	{"id":"Medical-59890a0c","source":"Medical","question":"What is the preferred radiation technique for treating non-metastatic anal cancer and which stages does this include?","answer":"IMRT is the preferred technique for stages I-III anal cancer.","question_type":"Complex Reasoning","evidence":"IMRT is the preferred radiation technique for treating non-metastatic anal cancer.; Stages I-III anal cancer are included in the preferred radiation technique.","evidence_relations":"IMRT is the preferred radiation technique for anal cancer; Chemoradiation is the recommended primary treatment for most non-metastatic anal cancers (stages I-III)"},
	{"id":"Medical-fd4cca6e","source":"Medical","question":"When is local excision considered as a treatment option in anal cancer, and what are the tumor characteristics that support this choice?","answer":"Local excision is considered for early-stage, low-grade perianal cancers.","question_type":"Complex Reasoning","evidence":"Local excision is considered for early-stage perianal cancers.; Local excision is considered for low-grade perianal cancers.","evidence_relations":"Local excision is an option for some early-stage, low-grade perianal cancers; Anal cancer can start in the anal canal or perianal region"},
	{"id":"Medical-9499de40","source":"Medical","question":"Which biomarkers are most closely associated with the development of anal squamous cell carcinoma, and what is the most common risk factor?","answer":"HPV and HPV16 are closely associated biomarkers, with HPV infection being the strongest risk factor.","question_type":"Complex Reasoning","evidence":"HPV is closely associated with the development of anal squamous cell carcinoma.; HPV16 is closely associated with the development of anal squamous cell carcinoma.; HPV infection is the strongest risk factor for anal squamous cell carcinoma.","evidence_relations":"HPV infection is the strongest risk factor for anal cancer; HPV16 is a high-risk strain associated with anal cancer; Anal squamous cell carcinoma is the most common subtype of anal cancer; HPV and HPV16 are listed as biomarkers for anal cancer"},
	{"id":"Medical-bcfc4592","source":"Medical","question":"What surveillance methods are recommended after complete remission of Stage III anal cancer, and how does the frequency of these methods vary?","answer":"DRE and inguinal lymph node exams every 3-6 months for 5 years, anoscopy every 6-12 months for 3 years, and imaging yearly for 3 years are recommended.","question_type":"Complex Reasoning","evidence":"DRE and inguinal lymph node exams are recommended every 3-6 months for 5 years after complete remission of Stage III anal cancer.; Anoscopy is recommended every 6-12 months for 3 years after complete remission of Stage III anal cancer.; Imaging is recommended yearly for 3 years after complete remission of Stage III anal cancer.","evidence_relations":"Surveillance after treatment includes DRE, lymph node exams, anoscopy, and imaging; Complete remission: DRE every 3-6 months for 5 years, inguinal lymph node exam every 3-6 months for 5 years, anoscopy every 6-12 months for 3 years, imaging yearly for 3 years (stage II/III)"},
	{"id":"Medical-fd151825","source":"Medical","question":"Which patients with anal cancer should be encouraged to enroll in clinical trials, and what phases might these trials include?","answer":"All patients with anal cancer should be encouraged to consider clinical trial enrollment, which may include phases I-IV.","question_type":"Complex Reasoning","evidence":"All patients with anal cancer should be encouraged to consider clinical trial enrollment.; Clinical trials may include phases I-IV.","evidence_relations":"Clinical trials are recommended for all patients if available; Clinical Trial: Eligibility: All patients encouraged to consider enrollment; Clinical Trial: Phases: Phase I, Phase II, Phase III, Phase IV"},
	{"id":"Medical-27281f31","source":"Medical","question":"If a patient develops lymph node recurrence after initial treatment for anal cancer, what are the recommended interventions?","answer":"Groin dissection, chemotherapy, and radiation (if not previously given) are recommended for lymph node recurrence.","question_type":"Complex Reasoning","evidence":"Groin dissection is recommended for lymph node recurrence after initial treatment for anal cancer.; Chemotherapy is recommended for lymph node recurrence after initial treatment for anal cancer.; Radiation is recommended for lymph node recurrence if not previously given after initial treatment for anal cancer.","evidence_relations":"Lymph node recurrence: Groin dissection, chemotherapy, radiation (if not previously given); Groin dissection: Indication: Lymph node recurrence"},
	{"id":"Medical-95283550","source":"Medical","question":"Which metastatic anal cancer patients are eligible for immunotherapy, and which drugs are recommended in this setting?","answer":"Patients with metastatic anal cancer that progresses after chemotherapy are eligible for immunotherapy with nivolumab or pembrolizumab.","question_type":"Complex Reasoning","evidence":"Patients with metastatic anal cancer that progresses after chemotherapy are eligible for immunotherapy.; Nivolumab is a recommended drug for immunotherapy in metastatic anal cancer.; Pembrolizumab is a recommended drug for immunotherapy in metastatic anal cancer.","evidence_relations":"Immunotherapy (nivolumab, pembrolizumab) is recommended for metastatic anal cancer that progresses after chemotherapy; Metastatic (Stage IV): Immunotherapy: Nivolumab, Pembrolizumab"},
	{"id":"Medical-fdd40f83","source":"Medical","question":"What symptoms would most likely prompt a physician to perform a digital rectal exam and anoscopy for suspected anal cancer?","answer":"Rectal bleeding, anal itching, anal pain, and an anal lump would prompt these exams.","question_type":"Complex Reasoning","evidence":"Rectal bleeding would prompt a physician to perform a digital rectal exam and anoscopy for suspected anal cancer.; Anal itching would prompt a physician to perform a digital rectal exam and anoscopy for suspected anal cancer.; Anal pain would prompt a physician to perform a digital rectal exam and anoscopy for suspected anal cancer.; An anal lump would prompt a physician to perform a digital rectal exam and anoscopy for suspected anal cancer.","evidence_relations":"Common symptoms of anal cancer include rectal bleeding, anal itching, pain, and a lump near the anus; Anal cancer is diagnosed by biopsy after abnormal findings on DRE or anoscopy"},
	{"id":"Medical-3d54d9e7","source":"Medical","question":"Which diagnostic methods are necessary to confirm a diagnosis of ALL and why must both bone marrow and blood tests be used?","answer":"Both bone marrow and blood tests are necessary because ALL is diagnosed when lymphoblasts are present in the bone marrow and can also be detected in the blood.","question_type":"Complex Reasoning","evidence":"Both bone marrow and blood tests are necessary to confirm a diagnosis of ALL.; ALL is diagnosed when lymphoblasts are present in the bone marrow.; Lymphoblasts can also be detected in the blood.","evidence_relations":"ALL is diagnosed when 20 percent or more lymphoblasts are present in the bone marrow; Diagnosis of ALL involves blood tests, bone marrow aspirate and biopsy, flow cytometry, immunophenotyping, genetic and biomarker testing, imaging tests, and lumbar puncture"},
	{"id":"Medical-a3c6c911","source":"Medical","question":"How does the presence of BCR::ABL1 in B-ALL influence both the prognosis and the treatment approach?","answer":"BCR::ABL1 in B-ALL defines a prognostic subgroup and requires therapies targeting the BCR::ABL protein.","question_type":"Complex Reasoning","evidence":"BCR::ABL1 in B-ALL defines a prognostic subgroup.; BCR::ABL1 in B-ALL requires therapies targeting the BCR::ABL protein.","evidence_relations":"BCR::ABL1-positive B-ALL is treated with therapies targeting the BCR::ABL protein; B-cell ALL (B-ALL) has prognostic groups including BCR::ABL1-positive B-ALL; B-cell ALL (B-ALL) has biomarkers such as BCR::ABL1"},
	{"id":"Medical-64f219fe","source":"Medical","question":"Why is fertility preservation considered before ALL treatment, and which treatment modalities make this necessary?","answer":"Fertility preservation is considered before ALL treatment because steroids and multiagent chemotherapy may affect fertility.","question_type":"Complex Reasoning","evidence":"Fertility preservation is considered before ALL treatment.; Steroids may affect fertility.; Multiagent chemotherapy may affect fertility.","evidence_relations":"Everyone with ALL is treated with steroids and multiagent chemotherapy; Fertility preservation should be considered before treatment; Treatment for ALL depends on subtype, age at diagnosis, and other factors"},
	{"id":"Medical-99cbd976","source":"Medical","question":"What distinguishes mature B-cell ALL (Burkitt leukemia) from typical B-ALL in terms of classification and treatment?","answer":"Mature B-cell ALL (Burkitt leukemia) is a rare subtype of B-ALL and is treated differently than typical B-ALL.","question_type":"Complex Reasoning","evidence":"Mature B-cell ALL (Burkitt leukemia) is a rare subtype of B-ALL.; Mature B-cell ALL (Burkitt leukemia) is treated differently than typical B-ALL.","evidence_relations":"Mature B-cell ALL (Burkitt leukemia) is a rare subtype and is treated differently from B-ALL; B-cell ALL (B-ALL) has subtypes including Mature B-cell ALL (Burkitt leukemia)"},
	{"id":"Medical-e1ef9e9b","source":"Medical","question":"If a patient presents with enlarged lymph nodes and the diagnosis is B-cell lymphoblastic lymphoma, what does this indicate about the disease site and cell of origin?","answer":"It indicates that B-cell lymphoblasts are primarily growing in lymph nodes and originate from lymphoid progenitor cells.","question_type":"Complex Reasoning","evidence":"B-cell lymphoblasts are primarily growing in lymph nodes.; B-cell lymphoblasts originate from lymphoid progenitor cells.","evidence_relations":"B-cell lymphoblastic lymphoma (B-LL/B-LBL) occurs when B-cell lymphoblasts grow mostly in lymph nodes; ALL arises from lymphoid progenitor cells"},
	{"id":"Medical-1024ca84","source":"Medical","question":"How does the treatment strategy for T-ALL differ from BCR::ABL1-positive B-ALL, and what evidence supports this distinction?","answer":"T-ALL is treated with chemotherapy and clinical trials, while BCR::ABL1-positive B-ALL is treated with therapies targeting the BCR::ABL protein.","question_type":"Complex Reasoning","evidence":"T-ALL is treated with chemotherapy and clinical trials.; BCR::ABL1-positive B-ALL is treated with therapies targeting the BCR::ABL protein.","evidence_relations":"T-ALL treatment options include chemotherapy and clinical trials; BCR::ABL1-positive B-ALL is treated with therapies targeting the BCR::ABL protein"},
	{"id":"Medical-40446029","source":"Medical","question":"Why are clinical trials particularly preferred for BCR::ABL1-negative or BCR::ABL1-like B-ALL subtypes?","answer":"Because these subtypes may have poorer prognosis or lack targeted therapies, making clinical trials a preferred option.","question_type":"Complex Reasoning","evidence":"Clinical trials are preferred for BCR::ABL1-negative B-ALL subtypes.; Clinical trials are preferred for BCR::ABL1-like B-ALL subtypes.; BCR::ABL1-negative or BCR::ABL1-like B-ALL subtypes may have poorer prognosis.; BCR::ABL1-negative or BCR::ABL1-like B-ALL subtypes may lack targeted therapies.","evidence_relations":"Clinical trials are preferred for certain subtypes such as BCR::ABL1-negative or BCR::ABL1-like B-ALL; B-cell ALL (B-ALL) has prognostic groups including BCR::ABL1-negative and BCR::ABL1-like B-ALL"},
	{"id":"Medical-2b2dd1fb","source":"Medical","question":"What combination of symptoms and diagnostic methods would most likely lead to an ALL diagnosis involving the central nervous system?","answer":"Symptoms like organ involvement combined with lumbar puncture and imaging tests would indicate CNS involvement in ALL.","question_type":"Complex Reasoning","evidence":"Symptoms like organ involvement would indicate CNS involvement in ALL.; A lumbar puncture would indicate CNS involvement in ALL.; Imaging tests would indicate CNS involvement in ALL.","evidence_relations":"ALL can be found in bone marrow, blood, testicles, and central nervous system; Symptoms of ALL may include organ involvement; Diagnosis of ALL involves imaging tests and lumbar puncture"},
	{"id":"Medical-04fc1c61","source":"Medical","question":"How does the age of a patient influence the management of ALL, and which patient populations are most commonly affected?","answer":"Age influences treatment choices, and ALL is most common in children but also affects adolescents, young adults, and adults.","question_type":"Complex Reasoning","evidence":"Age influences treatment choices for ALL.; ALL is most common in children.; ALL also affects adolescents.; ALL affects young adults.; ALL affects adults.","evidence_relations":"Treatment for ALL depends on subtype, age at diagnosis, and other factors; ALL is more common in children but also occurs in adolescents and young adults (AYAs) and adults"},
	{"id":"Medical-594504cc","source":"Medical","question":"What genetic and biomarker testing is necessary for ALL patients and how does it impact therapy selection?","answer":"ALL patients require genetic and biomarker testing to identify alterations like BCR::ABL1, which guide targeted therapy selection.","question_type":"Complex Reasoning","evidence":"ALL patients require genetic testing.; ALL patients require biomarker testing.; Genetic and biomarker testing identifies alterations like BCR::ABL1.; BCR::ABL1 alterations guide targeted therapy selection.","evidence_relations":"Diagnosis of ALL involves genetic and biomarker testing; Targeted therapy may be used based on genetic alterations; BCR::ABL1-positive B-ALL is treated with therapies targeting the BCR::ABL protein"},
	{"id":"Medical-3d9e3424","source":"Medical","question":"In what situations is a lumbar puncture indicated during the diagnosis of ALL, and what does its use suggest about disease spread?","answer":"A lumbar puncture is indicated to assess CNS involvement, suggesting possible spread of ALL to the central nervous system.","question_type":"Complex Reasoning","evidence":"A lumbar puncture is indicated to assess CNS involvement.; A lumbar puncture suggests possible spread of ALL to the central nervous system.","evidence_relations":"Diagnosis of ALL involves lumbar puncture; ALL can be found in bone marrow, blood, testicles, and central nervous system"},
	{"id":"Medical-141fd876","source":"Medical","question":"Why are both flow cytometry and immunophenotyping required in the diagnostic process for ALL?","answer":"Both are required to accurately identify the lineage and subtype of ALL cells by analyzing their surface markers.","question_type":"Complex Reasoning","evidence":"Flow cytometry is required in the diagnostic process for ALL.; Immunophenotyping is required in the diagnostic process for ALL.; Both methods analyze surface markers of ALL cells.; Both methods help accurately identify the lineage and subtype of ALL cells.","evidence_relations":"Diagnosis of ALL involves flow cytometry and immunophenotyping; There are two main subtypes of ALL: B-cell ALL (B-ALL) and T-cell ALL (T-ALL)"},
	{"id":"Medical-5422875d","source":"Medical","question":"What risk factors should be evaluated in a patient suspected of having ALL and why are these important?","answer":"Genetic syndromes and family history should be evaluated as they increase the risk of developing ALL.","question_type":"Complex Reasoning","evidence":"Genetic syndromes should be evaluated in patients suspected of having ALL.; Family history should be evaluated in patients suspected of having ALL.; Genetic syndromes increase the risk of developing ALL.; Family history increases the risk of developing ALL.","evidence_relations":"Risk factors for ALL include certain genetic syndromes and family history; ALL is a fast-growing blood cancer that starts in lymphocytes"},
	{"id":"Medical-82f4c628","source":"Medical","question":"How does the disease site differ between B-cell lymphoblastic lymphoma and T-cell lymphoblastic lymphoma, and what does this imply for clinical presentation?","answer":"B-cell lymphoblastic lymphoma mainly affects lymph nodes, while T-cell lymphoblastic lymphoma primarily involves the thymus, affecting clinical symptoms.","question_type":"Complex Reasoning","evidence":"B-cell lymphoblastic lymphoma mainly affects lymph nodes.; T-cell lymphoblastic lymphoma primarily involves the thymus.; The disease site affects clinical symptoms.","evidence_relations":"B-cell lymphoblastic lymphoma (B-LL/B-LBL) occurs when B-cell lymphoblasts grow mostly in lymph nodes; T-cell lymphoblastic lymphoma (T-LL/T-LBL) occurs when T-cell lymphoblasts grow mostly in the thymus"},
	{"id":"Medical-2148e062","source":"Medical","question":"What is the purpose of surveillance for relapse in ALL patients and which follow-up methods are used?","answer":"Surveillance for relapse aims to detect disease return using regular blood tests and clinical monitoring.","question_type":"Complex Reasoning","evidence":"Surveillance for relapse aims to detect disease return.; Regular blood tests are used for surveillance in ALL patients.; Clinical monitoring is used for surveillance in ALL patients.","evidence_relations":"Follow-up includes regular blood tests and surveillance for relapse; ALL is a fast-growing blood cancer that starts in lymphocytes"},
	{"id":"Medical-2be4d7f3","source":"Medical","question":"Which stages of pancreatic ductal adenocarcinoma are eligible for surgery, and what is the criterion for eligibility at Stage III?","answer":"Stages I, II, and selected cases of Stage III pancreatic ductal adenocarcinoma are eligible for surgery, with eligibility at Stage III depending on tumor spread to major arteries or lymph nodes.","question_type":"Complex Reasoning","evidence":"Stages I and II pancreatic ductal adenocarcinoma are eligible for surgery.; Selected cases of Stage III pancreatic ductal adenocarcinoma are eligible for surgery.; Eligibility at Stage III depends on tumor spread to major arteries.; Eligibility at Stage III depends on tumor spread to lymph nodes.","evidence_relations":"Surgery is a treatment option for some patients with stage I, II, or III pancreatic cancer; Stage III pancreatic cancer has grown to nearby major arteries or spread to 4 or more lymph nodes; Surgery: Stage I, Stage II, Stage III (selected cases) (ontology, rewritten: Surgery is a treatment for Stage I, Stage II, and selected Stage III pancreatic ductal adenocarcinoma)"},
	{"id":"Medical-3a5671fc","source":"Medical","question":"What diagnostic methods are used to detect hereditary pancreatic cancer risk, and which genetic syndromes are relevant?","answer":"Genetic tests are used to detect hereditary pancreatic cancer risk, especially in patients with syndromes like HBOC, Peutz-Jeghers, Lynch, Li-Fraumeni, FAMMM, and hereditary pancreatitis.","question_type":"Complex Reasoning","evidence":"Genetic tests are used to detect hereditary pancreatic cancer risk.; Patients with HBOC syndrome are relevant for hereditary pancreatic cancer risk.; Patients with Peutz-Jeghers syndrome are relevant for hereditary pancreatic cancer risk.; Patients with Lynch syndrome are relevant for hereditary pancreatic cancer risk.; Patients with Li-Fraumeni syndrome are relevant for hereditary pancreatic cancer risk.; Patients with FAMMM syndrome are relevant for hereditary pancreatic cancer risk.; Patients with hereditary pancreatitis are relevant for hereditary pancreatic cancer risk.","evidence_relations":"Genetic tests can detect inherited mutations linked to hereditary pancreatic cancer; Hereditary syndromes such as HBOC, Peutz-Jeghers syndrome, Lynch syndrome, Li-Fraumeni syndrome, FAMMM syndrome, and hereditary pancreatitis increase risk of pancreatic cancer; Genetic test is a diagnostic method for pancreatic ductal adenocarcinoma (ontology, rewritten: Genetic tests are among the diagnostic methods for pancreatic ductal adenocarcinoma); Genetic Syndrome: Hereditary breast-ovarian cancer syndrome, HBOC, Peutz-Jeghers syndrome, Lynch syndrome, Li-Fraumeni syndrome, Familial malignant melanoma syndrome, FAMMM syndrome, Hereditary pancreatitis (ontology, rewritten: These genetic syndromes are risk factors for pancreatic ductal adenocarcinoma)"},
	{"id":"Medical-42d7ac7c","source":"Medical","question":"If a patient presents with jaundice and has a family history of breast cancer, which diagnostic tests and risk factors should be considered?","answer":"Imaging, endoscopic tests, biopsy, blood tests, genetic tests, and biomarker tests should be considered, and family history of breast cancer is a risk factor for pancreatic ductal adenocarcinoma.","question_type":"Complex Reasoning","evidence":"Imaging tests should be considered for a patient with jaundice and a family history of breast cancer.; Endoscopic tests should be considered for a patient with jaundice and a family history of breast cancer.; Biopsy should be considered for a patient with jaundice and a family history of breast cancer.; Blood tests should be considered for a patient with jaundice and a family history of breast cancer.; Genetic tests should be considered for a patient with jaundice and a family history of breast cancer.; Biomarker tests should be considered for a patient with jaundice and a family history of breast cancer.; Family history of breast cancer is a risk factor for pancreatic ductal adenocarcinoma.","evidence_relations":"Symptoms of pancreatic cancer may include jaundice (yellowed skin or eyes); Family history of breast cancer is a risk factor for pancreatic cancer; Diagnostic methods for pancreatic cancer include imaging, endoscopic tests, biopsy, blood tests, genetic tests, and biomarker tests; Risk Factor: Family history of breast cancer (ontology, rewritten: Family history of breast cancer is a risk factor for pancreatic ductal adenocarcinoma)"},
	{"id":"Medical-4f7fc60b","source":"Medical","question":"How is Stage IV pancreatic cancer defined, and what is its alternative name?","answer":"Stage IV pancreatic cancer is defined by distant metastasis to organs like liver, lungs, or abdominal lining, and is also known as metastatic pancreatic cancer.","question_type":"Complex Reasoning","evidence":"Stage IV pancreatic cancer is defined by distant metastasis.; Distant metastasis in Stage IV pancreatic cancer can occur to the liver.; Distant metastasis in Stage IV pancreatic cancer can occur to the lungs.; Distant metastasis in Stage IV pancreatic cancer can occur to the abdominal lining.; Stage IV pancreatic cancer is also known as metastatic pancreatic cancer.","evidence_relations":"Stage IV pancreatic cancer has spread to distant organs such as liver, lungs, or abdominal lining; Stage IV pancreatic cancer is metastatic cancer; Stage IV: Distant metastasis (liver, lungs, abdominal lining), Also known as: Metastatic pancreatic cancer (ontology, rewritten: Stage IV pancreatic ductal adenocarcinoma is also called metastatic pancreatic cancer and involves distant metastasis)"},
	{"id":"Medical-f2800f11","source":"Medical","question":"Which care team roles are necessary for comprehensive diagnosis and treatment planning in pancreatic cancer?","answer":"A multidisciplinary care team including diagnostic radiologist, interventional radiologist, pathologist, gastroenterologist, medical oncologist, surgical oncologist, radiation oncologist, geriatrician, registered dietitian, genetic counselor, palliative care provider, and mental health provider is necessary.","question_type":"Complex Reasoning","evidence":"A multidisciplinary care team is necessary for comprehensive diagnosis and treatment planning in pancreatic cancer.; The care team includes a diagnostic radiologist.; The care team includes an interventional radiologist.; The care team includes a pathologist.; The care team includes a gastroenterologist.; The care team includes a medical oncologist.; The care team includes a surgical oncologist.; The care team includes a radiation oncologist.; The care team includes a geriatrician.; The care team includes a registered dietitian.; The care team includes a genetic counselor.; The care team includes a palliative care provider.; The care team includes a mental health provider.","evidence_relations":"A multidisciplinary care team is essential for diagnosis and treatment planning in pancreatic cancer; Care Team Role: Diagnostic radiologist, Interventional radiologist, Pathologist, Gastroenterologist, Medical oncologist, Surgical oncologist, Radiation oncologist, Geriatrician, Registered dietitian, Genetic counselor, Palliative care provider, Mental health provider (ontology, rewritten: These roles are part of the multidisciplinary care team for pancreatic cancer)"},
	{"id":"Medical-833eac1d","source":"Medical","question":"Which risk factors and genetic syndromes should prompt genetic testing in a patient with pancreatic cancer?","answer":"Risk factors like family history of pancreatic, breast, ovarian, colorectal cancer, or melanoma, and genetic syndromes such as HBOC, Peutz-Jeghers, Lynch, Li-Fraumeni, FAMMM, and hereditary pancreatitis should prompt genetic testing.","question_type":"Complex Reasoning","evidence":"Family history of pancreatic cancer is a risk factor for genetic testing.; Family history of breast cancer is a risk factor for genetic testing.; Family history of ovarian cancer is a risk factor for genetic testing.; Family history of colorectal cancer is a risk factor for genetic testing.; Family history of melanoma is a risk factor for genetic testing.; Genetic syndromes that should prompt genetic testing include HBOC.; Genetic syndromes that should prompt genetic testing include Peutz-Jeghers.; Genetic syndromes that should prompt genetic testing include Lynch syndrome.; Genetic syndromes that should prompt genetic testing include Li-Fraumeni syndrome.; Genetic syndromes that should prompt genetic testing include FAMMM.; Genetic syndromes that should prompt genetic testing include hereditary pancreatitis.","evidence_relations":"Risk factors for pancreatic cancer include family history of certain cancers; Hereditary syndromes such as HBOC, Peutz-Jeghers syndrome, Lynch syndrome, Li-Fraumeni syndrome, FAMMM syndrome, and hereditary pancreatitis increase risk of pancreatic cancer; Genetic test is a diagnostic method for pancreatic ductal adenocarcinoma (ontology, rewritten: Genetic testing is used to diagnose hereditary pancreatic cancer risk)"},
	{"id":"Medical-25c17c3d","source":"Medical","question":"What treatments are recommended for advanced or metastatic pancreatic ductal adenocarcinoma?","answer":"Drug treatment, clinical trials, and supportive care are recommended for advanced or metastatic pancreatic ductal adenocarcinoma.","question_type":"Complex Reasoning","evidence":"Drug treatment is recommended for advanced or metastatic pancreatic ductal adenocarcinoma.; Clinical trials are recommended for advanced or metastatic pancreatic ductal adenocarcinoma.; Supportive care is recommended for advanced or metastatic pancreatic ductal adenocarcinoma.","evidence_relations":"Drug treatment is most often used to control growth and reduce symptoms in pancreatic cancer; Stage IV pancreatic cancer is metastatic cancer; Drug treatment: All stages, especially advanced; Clinical trial: All stages; Supportive care: All stages (ontology, rewritten: Drug treatment, clinical trials, and supportive care are recommended for all stages, especially advanced pancreatic ductal adenocarcinoma)"},
	{"id":"Medical-17015c75","source":"Medical","question":"Which subtypes of pancreatic cancer are described, and which is most common?","answer":"Pancreatic ductal adenocarcinoma is the most common subtype, while pancreatic neuroendocrine tumor is less common.","question_type":"Complex Reasoning","evidence":"Pancreatic ductal adenocarcinoma is the most common subtype of pancreatic cancer.; Pancreatic neuroendocrine tumor is a less common subtype of pancreatic cancer.","evidence_relations":"Pancreatic ductal adenocarcinoma (PDAC) is the most common subtype of pancreatic cancer; Pancreatic neuroendocrine tumor is a less common subtype of pancreatic cancer; Cancer Subtype: Pancreatic ductal adenocarcinoma, Pancreatic neuroendocrine tumor (ontology, rewritten: The main subtypes of pancreatic cancer are pancreatic ductal adenocarcinoma and pancreatic neuroendocrine tumor)"},
	{"id":"Medical-fa092b30","source":"Medical","question":"What is the significance of imaging in the management of pancreatic cancer, and for which purposes is it used?","answer":"Imaging is used for staging, determining surgical eligibility, and as a diagnostic method in pancreatic cancer.","question_type":"Complex Reasoning","evidence":"Imaging is used for staging in pancreatic cancer.; Imaging is used to determine surgical eligibility in pancreatic cancer.; Imaging is used as a diagnostic method in pancreatic cancer.","evidence_relations":"Imaging is used for staging and determining surgical eligibility in pancreatic cancer; Diagnostic methods for pancreatic cancer include imaging; Imaging is a diagnostic method for pancreatic ductal adenocarcinoma (ontology, rewritten: Imaging is used to diagnose and stage pancreatic ductal adenocarcinoma and assess surgical eligibility)"},
	{"id":"Medical-c218fffa","source":"Medical","question":"Which supportive care approaches are important for pancreatic cancer management, and what symptoms might require them?","answer":"Supportive care including symptom management and palliative care is important, particularly for symptoms like jaundice.","question_type":"Complex Reasoning","evidence":"Supportive care is important for pancreatic cancer management.; Symptom management is a part of supportive care for pancreatic cancer.; Palliative care is a part of supportive care for pancreatic cancer.; Jaundice is a symptom that might require supportive care.","evidence_relations":"Supportive care is an important part of pancreatic cancer management; Symptoms of pancreatic cancer may include jaundice (yellowed skin or eyes); Supportive Care: Symptom management, Palliative care (ontology, rewritten: Symptom management and palliative care are supportive care approaches for pancreatic cancer)"},
	{"id":"Medical-056e1e60","source":"Medical","question":"If a patient with pancreatic ductal adenocarcinoma has chronic pancreatitis and a family history of melanoma, what are their risk factors and what additional testing should be considered?","answer":"Chronic pancreatitis and family history of melanoma are risk factors, and genetic testing should be considered to assess for hereditary syndromes.","question_type":"Complex Reasoning","evidence":"Chronic pancreatitis is a risk factor for a patient with pancreatic ductal adenocarcinoma.; Family history of melanoma is a risk factor for a patient with pancreatic ductal adenocarcinoma.; Genetic testing should be considered to assess for hereditary syndromes in this patient.","evidence_relations":"Risk factors for pancreatic cancer include chronic pancreatitis and family history of melanoma; Genetic tests can detect inherited mutations linked to hereditary pancreatic cancer; Risk Factor: Chronic pancreatitis, Family history of melanoma (ontology, rewritten: Chronic pancreatitis and family history of melanoma are risk factors for pancreatic ductal adenocarcinoma)"},
	{"id":"Medical-bb794987","source":"Medical","question":"What are the primary symptoms and diagnostic methods associated with pancreatic ductal adenocarcinoma?","answer":"Jaundice is a primary symptom, and diagnostic methods include imaging, endoscopic test, biopsy, blood test, genetic test, and biomarker test.","question_type":"Complex Reasoning","evidence":"Jaundice is a primary symptom of pancreatic ductal adenocarcinoma.; Imaging is a diagnostic method for pancreatic ductal adenocarcinoma.; Endoscopic tests are a diagnostic method for pancreatic ductal adenocarcinoma.; Biopsy is a diagnostic method for pancreatic ductal adenocarcinoma.; Blood tests are a diagnostic method for pancreatic ductal adenocarcinoma.; Genetic tests are a diagnostic method for pancreatic ductal adenocarcinoma.; Biomarker tests are a diagnostic method for pancreatic ductal adenocarcinoma.","evidence_relations":"Symptoms of pancreatic cancer may include jaundice (yellowed skin or eyes); Diagnostic methods for pancreatic cancer include imaging, endoscopic tests, biopsy, blood tests, genetic tests, and biomarker tests; Symptom: Jaundice; Diagnostic Method: Imaging, Endoscopic test, Biopsy, Blood test, Genetic test, Biomarker test (ontology, rewritten: Jaundice is a symptom and these are the diagnostic methods for pancreatic ductal adenocarcinoma)"},
	{"id":"Medical-aba4e30c","source":"Medical","question":"Which stages of pancreatic ductal adenocarcinoma may involve lymph node spread, and how does this affect staging?","answer":"Stage II involves spread to 1-3 lymph nodes, while Stage III involves spread to 4 or more lymph nodes.","question_type":"Complex Reasoning","evidence":"Stage II pancreatic ductal adenocarcinoma may involve spread to 1-3 lymph nodes.; Stage III pancreatic ductal adenocarcinoma may involve spread to 4 or more lymph nodes.","evidence_relations":"Stage II pancreatic cancer is a tumor larger than 4 cm or has spread to 1-3 nearby lymph nodes; Stage III pancreatic cancer has grown to nearby major arteries or spread to 4 or more lymph nodes; Stage: Stage II: Tumor >4 cm or spread to 1-3 lymph nodes; Stage III: Spread to major arteries or 4 lymph nodes (ontology, rewritten: Stage II involves 1-3 lymph nodes; Stage III involves 4 or more lymph nodes)"},
	{"id":"Medical-0103d518","source":"Medical","question":"How are hereditary breast-ovarian cancer syndrome and HBOC related to pancreatic ductal adenocarcinoma risk?","answer":"Both hereditary breast-ovarian cancer syndrome and HBOC are genetic syndromes that increase the risk of pancreatic ductal adenocarcinoma.","question_type":"Complex Reasoning","evidence":"Hereditary breast-ovarian cancer syndrome is a genetic syndrome.; HBOC is a genetic syndrome.; Both hereditary breast-ovarian cancer syndrome and HBOC increase the risk of pancreatic ductal adenocarcinoma.","evidence_relations":"Hereditary syndromes such as HBOC and hereditary breast-ovarian cancer syndrome increase risk of pancreatic cancer; Genetic Syndrome: Hereditary breast-ovarian cancer syndrome, HBOC (ontology, rewritten: Both hereditary breast-ovarian cancer syndrome and HBOC are risk factors for pancreatic ductal adenocarcinoma)"},
	{"id":"Medical-ad078f77","source":"Medical","question":"Which treatments are available to all patients with pancreatic ductal adenocarcinoma, regardless of stage?","answer":"Drug treatment, clinical trials, and supportive care are available to all patients with pancreatic ductal adenocarcinoma, regardless of stage.","question_type":"Complex Reasoning","evidence":"Drug treatment is available to all patients with pancreatic ductal adenocarcinoma.; Clinical trials are available to all patients with pancreatic ductal adenocarcinoma.; Supportive care is available to all patients with pancreatic ductal adenocarcinoma.; These treatments are available regardless of stage.","evidence_relations":"Drug treatment is most often used to control growth and reduce symptoms in pancreatic cancer; Clinical trials are available for pancreatic cancer patients; Drug treatment: All stages, especially advanced; Clinical trial: All stages; Supportive care: All stages (ontology, rewritten: Drug treatment, clinical trials, and supportive care are available to all stages of pancreatic ductal adenocarcinoma)"},
	{"id":"Medical-b914d234","source":"Medical","question":"Which diagnostic procedures and biomarkers are required to confirm and assess the aggressiveness of localized prostate cancer?","answer":"PSA test, digital rectal exam, and biopsy are used for diagnosis, while Gleason score and Grade Group estimate aggressiveness.","question_type":"Complex Reasoning","evidence":"PSA test is used for the diagnosis of localized prostate cancer.; Digital rectal exam is used for the diagnosis of localized prostate cancer.; Biopsy is used for the diagnosis of localized prostate cancer.; Gleason score is used to estimate the aggressiveness of localized prostate cancer.; Grade Group is used to estimate the aggressiveness of localized prostate cancer.","evidence_relations":"PSA test and digital rectal exam are used for screening and diagnosis; Biopsy is required to confirm prostate cancer diagnosis; Gleason score and Grade Group are used to estimate cancer aggressiveness; Localized prostate cancer uses PSA test, digital rectal exam, biopsy, MRI, and ultrasound as diagnostic methods and PSA, Gleason score, and Grade Group as biomarkers"},
	{"id":"Medical-b3fece20","source":"Medical","question":"Why should germline genetic testing be considered for a patient with metastatic prostate cancer?","answer":"Because metastatic prostate cancer is high-risk and may involve genetic mutations like BRCA2, which increase risk and influence treatment.","question_type":"Complex Reasoning","evidence":"Germline genetic testing should be considered for a patient with metastatic prostate cancer.; Metastatic prostate cancer is high-risk.; Metastatic prostate cancer may involve genetic mutations.; BRCA2 is a genetic mutation that increases risk in metastatic prostate cancer.; Genetic mutations can influence treatment for metastatic prostate cancer.","evidence_relations":"Germline genetic testing is recommended for patients with high-risk, very-high-risk, regional, or metastatic prostate cancer; BRCA2 mutation increases risk of prostate cancer; Metastatic prostate cancer includes genetic alterations such as BRCA2"},
	{"id":"Medical-0093e2ec","source":"Medical","question":"What combination of symptoms and imaging findings would indicate metastatic prostate cancer?","answer":"Bone pain and unexplained weight loss with positive findings on bone scan or PET scan indicate metastatic prostate cancer.","question_type":"Complex Reasoning","evidence":"Bone pain can indicate metastatic prostate cancer.; Unexplained weight loss can indicate metastatic prostate cancer.; Positive findings on a bone scan can indicate metastatic prostate cancer.; Positive findings on a PET scan can indicate metastatic prostate cancer.","evidence_relations":"Symptoms of advanced prostate cancer include bone pain, weight loss; Metastatic prostate cancer has spread to distant organs such as bones; Bone scan and PET scan are imaging methods used to assess extent of disease"},
	{"id":"Medical-65f00413","source":"Medical","question":"How does the treatment strategy differ between localized low-risk and metastatic prostate cancer?","answer":"Localized low-risk prostate cancer may be managed with active surveillance, while metastatic disease requires androgen deprivation therapy and other systemic treatments.","question_type":"Complex Reasoning","evidence":"Localized low-risk prostate cancer may be managed with active surveillance.; Metastatic prostate cancer requires androgen deprivation therapy.; Metastatic prostate cancer requires other systemic treatments.","evidence_relations":"Active surveillance is a management option for low-risk, early-stage prostate cancer; Androgen deprivation therapy (ADT) is a mainstay of advanced prostate cancer treatment; Metastatic prostate cancer treatment includes ADT, chemotherapy, immunotherapy, and more"},
	{"id":"Medical-cfdb85ba","source":"Medical","question":"Which risk factors and genetic alterations should be evaluated in a patient with a family history of prostate cancer?","answer":"Age, family history, and genetic mutations such as BRCA1, BRCA2, ATM, CHEK2, MLH1, MSH2, MSH6, PALB2, and PMS2 should be evaluated.","question_type":"Complex Reasoning","evidence":"Age should be evaluated in a patient with a family history of prostate cancer.; Family history should be evaluated in a patient with a family history of prostate cancer.; Genetic mutations should be evaluated in a patient with a family history of prostate cancer.; BRCA1 is a genetic mutation that should be evaluated.; BRCA2 is a genetic mutation that should be evaluated.; ATM is a genetic mutation that should be evaluated.; CHEK2 is a genetic mutation that should be evaluated.; MLH1 is a genetic mutation that should be evaluated.; MSH2 is a genetic mutation that should be evaluated.; MSH6 is a genetic mutation that should be evaluated.; PALB2 is a genetic mutation that should be evaluated.; PMS2 is a genetic mutation that should be evaluated.","evidence_relations":"Age, family history, and genetic mutations are risk factors for prostate cancer; BRCA2 mutation increases risk of prostate cancer; Genetic Alteration category includes BRCA1, BRCA2, ATM, CHEK2, MLH1, MSH2, MSH6, PALB2, PMS2"},
	{"id":"Medical-727f425f","source":"Medical","question":"What follow-up strategies are recommended for a patient on active surveillance for localized prostate cancer?","answer":"Regular PSA testing, repeat biopsy, and imaging as indicated are recommended for active surveillance.","question_type":"Complex Reasoning","evidence":"Regular PSA testing is recommended for a patient on active surveillance for localized prostate cancer.; Repeat biopsy is recommended for a patient on active surveillance for localized prostate cancer.; Imaging as indicated is recommended for a patient on active surveillance for localized prostate cancer.","evidence_relations":"Follow-up includes regular PSA testing, imaging, and biopsies as needed; Localized prostate cancer follow-up strategy includes regular PSA testing, repeat biopsy, and imaging as indicated; Active surveillance is a management option for low-risk, early-stage prostate cancer"},
	{"id":"Medical-9b9b7f4a","source":"Medical","question":"Which diagnostic and molecular tests are used to guide treatment decisions in high-risk localized prostate cancer?","answer":"PSA test, biopsy, MRI, and molecular biomarker testing are used to guide treatment decisions.","question_type":"Complex Reasoning","evidence":"PSA test is used to guide treatment decisions in high-risk localized prostate cancer.; Biopsy is used to guide treatment decisions in high-risk localized prostate cancer.; MRI is used to guide treatment decisions in high-risk localized prostate cancer.; Molecular biomarker testing is used to guide treatment decisions in high-risk localized prostate cancer.","evidence_relations":"Molecular biomarker testing helps assess risk and guide treatment decisions; Localized prostate cancer diagnostic methods include PSA test, biopsy, and MRI; High-risk group guides prognosis and treatment"},
	{"id":"Medical-72cfd9c6","source":"Medical","question":"What symptoms and risk factors would prompt early screening for prostate cancer?","answer":"Urinary symptoms and risk factors such as age, family history, and Black race would prompt early screening.","question_type":"Complex Reasoning","evidence":"Urinary symptoms would prompt early screening for prostate cancer.; Risk factors such as age would prompt early screening for prostate cancer.; Family history would prompt early screening for prostate cancer.; Black race would prompt early screening for prostate cancer.","evidence_relations":"Symptoms of prostate cancer include urinary symptoms; Age, family history, and Black race are risk factors for prostate cancer; PSA test and digital rectal exam are used for screening"},
	{"id":"Medical-e9900b5c","source":"Medical","question":"Why is androgen deprivation therapy a key component in the management of metastatic prostate cancer?","answer":"Because ADT is a mainstay for advanced disease and is included among treatments for metastatic prostate cancer.","question_type":"Complex Reasoning","evidence":"Androgen deprivation therapy (ADT) is a mainstay for advanced prostate cancer.; ADT is included among treatments for metastatic prostate cancer.","evidence_relations":"Androgen deprivation therapy (ADT) is a mainstay of advanced prostate cancer treatment; Metastatic prostate cancer treatment includes ADT"},
	{"id":"Medical-3bea99a2","source":"Medical","question":"Which imaging modalities are necessary to fully stage a patient with suspected regional prostate cancer spread?","answer":"MRI, CT scan, and PSMA-PET are necessary to assess regional spread in prostate cancer.","question_type":"Complex Reasoning","evidence":"MRI is necessary to assess regional spread in prostate cancer.; CT scan is necessary to assess regional spread in prostate cancer.; PSMA-PET is necessary to assess regional spread in prostate cancer.","evidence_relations":"Regional prostate cancer has spread to nearby lymph nodes; MRI, CT, PET, ultrasound, and bone scan are imaging methods used to assess extent of disease; Regional prostate cancer diagnostic methods include MRI, CT scan, and PSMA-PET"},
	{"id":"Medical-0125ebb1","source":"Medical","question":"How do Gleason score and Grade Group contribute to the management of prostate cancer?","answer":"They estimate cancer aggressiveness and help assign risk groups that guide prognosis and treatment decisions.","question_type":"Complex Reasoning","evidence":"Gleason score estimates cancer aggressiveness.; Grade Group estimates cancer aggressiveness.; Gleason score and Grade Group help assign risk groups.; Risk groups guide prognosis in prostate cancer.; Risk groups guide treatment decisions in prostate cancer.","evidence_relations":"Gleason score and Grade Group are used to estimate cancer aggressiveness; Risk groups (very low, low, intermediate, high, very high) guide prognosis and treatment; Biomarkers for prostate cancer include Gleason score and Grade Group"},
	{"id":"Medical-33e5776d","source":"Medical","question":"Which patients with prostate cancer should receive molecular biomarker testing as part of their follow-up?","answer":"Patients with high-risk, very-high-risk, regional, or metastatic prostate cancer should receive molecular biomarker testing.","question_type":"Complex Reasoning","evidence":"Patients with high-risk prostate cancer should receive molecular biomarker testing.; Patients with very-high-risk prostate cancer should receive molecular biomarker testing.; Patients with regional prostate cancer should receive molecular biomarker testing.; Patients with metastatic prostate cancer should receive molecular biomarker testing.","evidence_relations":"Germline genetic testing is recommended for patients with high-risk, very-high-risk, regional, or metastatic prostate cancer; Molecular biomarker testing helps assess risk and guide treatment decisions; Follow-up strategy includes molecular biomarker testing"},
	{"id":"Medical-b0ec1abf","source":"Medical","question":"What is the rationale for using both PSA testing and imaging in the follow-up of advanced prostate cancer?","answer":"Because PSA monitoring detects biochemical recurrence, while imaging assesses disease progression or metastasis.","question_type":"Complex Reasoning","evidence":"PSA monitoring detects biochemical recurrence in advanced prostate cancer.; Imaging assesses disease progression in advanced prostate cancer.; Imaging assesses metastasis in advanced prostate cancer.","evidence_relations":"Follow-up includes regular PSA testing, imaging, and biopsies as needed; Advanced prostate cancer follow-up strategy includes PSA monitoring and imaging; Imaging methods include MRI, CT, PET, bone scan, and PSMA-PET"},
	{"id":"Medical-5c6a1008","source":"Medical","question":"Which combination of therapies might be considered for a patient with metastatic prostate cancer and a BRCA2 mutation?","answer":"Androgen deprivation therapy, chemotherapy, and targeted therapy may be considered for metastatic prostate cancer with BRCA2 mutation.","question_type":"Complex Reasoning","evidence":"Androgen deprivation therapy may be considered for metastatic prostate cancer with BRCA2 mutation.; Chemotherapy may be considered for metastatic prostate cancer with BRCA2 mutation.; Targeted therapy may be considered for metastatic prostate cancer with BRCA2 mutation.","evidence_relations":"Metastatic prostate cancer treatment includes ADT, chemotherapy, targeted therapy; BRCA2 mutation increases risk of prostate cancer; Metastatic prostate cancer includes BRCA2 as a genetic alteration"},
	{"id":"Medical-2e171c34","source":"Medical","question":"How do risk group classification and molecular biomarker testing together influence treatment selection in prostate cancer?","answer":"Risk group classification guides prognosis and initial management, while molecular biomarker testing refines risk assessment and guides therapy choices.","question_type":"Complex Reasoning","evidence":"Risk group classification guides prognosis in prostate cancer.; Risk group classification guides initial management in prostate cancer.; Molecular biomarker testing refines risk assessment in prostate cancer.; Molecular biomarker testing guides therapy choices in prostate cancer.","evidence_relations":"Risk groups (very low, low, intermediate, high, very high) guide prognosis and treatment; Molecular biomarker testing helps assess risk and guide treatment decisions; Biomarkers include molecular biomarker tests and are linked to risk group assignment"},
	{"id":"Medical-a9db9ed9","source":"Medical","question":"If a child under 5 presents with an adrenal mass and bone metastases, what is the most likely diagnosis and which diagnostic methods should be prioritized?","answer":"Neuroblastoma is most likely, and imaging tests plus biochemical tests should be prioritized.","question_type":"Complex Reasoning","evidence":"Neuroblastoma is the most likely diagnosis for a child under 5 with an adrenal mass and bone metastases.; Imaging tests should be prioritized for diagnosis.; Biochemical tests should be prioritized for diagnosis.","evidence_relations":"Neuroblastoma is a rare malignant adrenal tumor affecting mainly children under 5; Neuroblastoma may metastasize to bones; Neuroblastoma diagnostic methods include imaging tests and biochemical test"},
	{"id":"Medical-015f2cf7","source":"Medical","question":"How would you distinguish between a functional adenoma and a pheochromocytoma in a patient with an adrenal mass and high blood pressure?","answer":"A pheochromocytoma arises from the adrenal medulla and causes high blood pressure, while functional adenoma does not typically present with high blood pressure.","question_type":"Complex Reasoning","evidence":"A pheochromocytoma arises from the adrenal medulla.; A pheochromocytoma causes high blood pressure.; A functional adenoma does not typically present with high blood pressure.","evidence_relations":"Pheochromocytoma arises from the adrenal medulla and is often associated with high blood pressure; Adenoma is the most common type of adrenal gland tumor and can be functioning or nonfunctioning; Functional adenoma subtypes are aldosteronoma and cortisol-producing adenoma"},
	{"id":"Medical-1a7ab06f","source":"Medical","question":"What combination of symptoms and test results would suggest an aldosteronoma rather than a cortisol-producing adenoma?","answer":"Excess aldosterone on biochemical testing without Cushing syndrome symptoms suggests aldosteronoma.","question_type":"Complex Reasoning","evidence":"Excess aldosterone on biochemical testing suggests aldosteronoma.; The absence of Cushing syndrome symptoms suggests aldosteronoma.; Cortisol-producing adenoma typically presents with Cushing syndrome symptoms.","evidence_relations":"Aldosteronoma produces excess aldosterone; Adenoma producing excess cortisol causes Cushing syndrome; Cortisol-producing adenoma is associated with Cushing syndrome"},
	{"id":"Medical-5456c556","source":"Medical","question":"Which hereditary syndromes should be considered risk factors if a patient is diagnosed with adrenocortical carcinoma (ACC)?","answer":"Beckwith-Wiedemann syndrome, Carney complex, FAP, PGL/PCC syndrome, Li-Fraumeni syndrome, Lynch syndrome, MEN 1, MEN 2, NF1, and VHL should be considered as risk factors for ACC.","question_type":"Complex Reasoning","evidence":"Beckwith-Wiedemann syndrome is a risk factor for adrenocortical carcinoma (ACC).; Carney complex is a risk factor for adrenocortical carcinoma (ACC).; FAP is a risk factor for adrenocortical carcinoma (ACC).; PGL/PCC syndrome is a risk factor for adrenocortical carcinoma (ACC).; Li-Fraumeni syndrome is a risk factor for adrenocortical carcinoma (ACC).; Lynch syndrome is a risk factor for adrenocortical carcinoma (ACC).; MEN 1 is a risk factor for adrenocortical carcinoma (ACC).; MEN 2 is a risk factor for adrenocortical carcinoma (ACC).; NF1 is a risk factor for adrenocortical carcinoma (ACC).; VHL is a risk factor for adrenocortical carcinoma (ACC).","evidence_relations":"Certain hereditary syndromes increase the risk of adrenal tumors; Adrenocortical carcinoma (ACC) risk factors include Beckwith-Wiedemann syndrome, Carney complex, Familial adenomatous polyposis (FAP), Hereditary paraganglioma-pheochromocytoma (PGL/PCC) syndrome, Li-Fraumeni syndrome, Lynch syndrome, Multiple endocrine neoplasia type 1 (MEN 1), Multiple endocrine neoplasia type 2 (MEN 2), Neurofibromatosis type 1 (NF1), and Von Hippel-Lindau syndrome (VHL)"},
	{"id":"Medical-d3dfaf75","source":"Medical","question":"If a patient presents with rapid heartbeat, headache, and sweating, which adrenal tumor is most likely and what is its origin?","answer":"Pheochromocytoma is most likely, and it originates from the adrenal medulla.","question_type":"Complex Reasoning","evidence":"Pheochromocytoma is the most likely adrenal tumor in this case.; Pheochromocytoma originates from the adrenal medulla.","evidence_relations":"Pheochromocytoma arises from the adrenal medulla and is often associated with high blood pressure, headache, rapid heartbeat, and sweating; Pheochromocytoma origin is adrenal medulla"},
	{"id":"Medical-e3da3cd7","source":"Medical","question":"Which diagnostic methods are common to both adrenocortical carcinoma (ACC) and pheochromocytoma, and which are unique to ACC?","answer":"CT scan, MRI scan, and biochemical test are common to both; PET scan, FDG-PET/CT, SSTR-PET/CT, blood test, genetic test, and biopsy are unique to ACC.","question_type":"Complex Reasoning","evidence":"CT scan is a common diagnostic method for both adrenocortical carcinoma (ACC) and pheochromocytoma.; MRI scan is a common diagnostic method for both adrenocortical carcinoma (ACC) and pheochromocytoma.; Biochemical test is a common diagnostic method for both adrenocortical carcinoma (ACC) and pheochromocytoma.; PET scan is a diagnostic method unique to adrenocortical carcinoma (ACC).; FDG-PET/CT is a diagnostic method unique to adrenocortical carcinoma (ACC).; SSTR-PET/CT is a diagnostic method unique to adrenocortical carcinoma (ACC).; Blood test is a diagnostic method unique to adrenocortical carcinoma (ACC).; Genetic test is a diagnostic method unique to adrenocortical carcinoma (ACC).; Biopsy is a diagnostic method unique to adrenocortical carcinoma (ACC).","evidence_relations":"Adrenocortical carcinoma (ACC) diagnostic methods include CT scan, MRI scan, PET scan, FDG-PET/CT, SSTR-PET/CT, blood test, biochemical test, genetic test, and biopsy; Pheochromocytoma diagnostic methods include CT scan, MRI scan, and biochemical test"},
	{"id":"Medical-9db4f113","source":"Medical","question":"What evidence would indicate that an adrenal tumor is benign and unlikely to metastasize?","answer":"If the tumor is a benign adrenal tumor, such as an adenoma, it does not metastasize.","question_type":"Complex Reasoning","evidence":"A benign adrenal tumor is an adenoma.; A benign adrenal tumor does not metastasize.","evidence_relations":"Adrenal tumors can be benign or malignant; Benign adrenal tumors do not metastasize; Adenoma is the most common type of adrenal gland tumor"},
	{"id":"Medical-395b9708","source":"Medical","question":"Which symptoms and hormone findings would suggest a cortisol-producing adenoma causing Cushing syndrome?","answer":"Symptoms such as weight gain, muscle weakness, and pink or purple stretch marks with excess cortisol on testing suggest a cortisol-producing adenoma causing Cushing syndrome.","question_type":"Complex Reasoning","evidence":"Symptoms of weight gain suggest a cortisol-producing adenoma causing Cushing syndrome.; Symptoms of muscle weakness suggest a cortisol-producing adenoma causing Cushing syndrome.; Pink or purple stretch marks suggest a cortisol-producing adenoma causing Cushing syndrome.; Excess cortisol on testing suggests a cortisol-producing adenoma causing Cushing syndrome.","evidence_relations":"Adenoma producing excess cortisol causes Cushing syndrome; Cortisol-producing adenoma is associated with Cushing syndrome; Adrenocortical carcinoma (ACC) symptoms include weight gain, muscle weakness, and pink or purple stretch marks"},
	{"id":"Medical-7718481e","source":"Medical","question":"If imaging and biochemical tests reveal an adrenal mass with excess aldosterone, what is the most probable diagnosis?","answer":"Aldosteronoma is the most probable diagnosis.","question_type":"Complex Reasoning","evidence":"Aldosteronoma is the most probable diagnosis if there is an adrenal mass with excess aldosterone.","evidence_relations":"Aldosteronoma produces excess aldosterone; Imaging tests for adrenal tumors include CT scan, MRI scan, PET scan, FDG-PET/CT, and SSTR-PET/CT; Blood and biochemical tests are used to detect hormone secretion by adrenal tumors"},
	{"id":"Medical-8e0c15db","source":"Medical","question":"What combination of findings would indicate the need for genetic testing in a patient with an adrenal tumor?","answer":"If there is a family history or features of hereditary syndromes in a patient with an adrenal tumor, genetic testing should be performed.","question_type":"Complex Reasoning","evidence":"A family history of hereditary syndromes indicates the need for genetic testing in a patient with an adrenal tumor.; Features of hereditary syndromes indicate the need for genetic testing in a patient with an adrenal tumor.","evidence_relations":"Certain hereditary syndromes increase the risk of adrenal tumors; Genetic testing may be performed to identify hereditary risk factors; Risk factors for adrenal tumor include hereditary syndromes and family history"},
	{"id":"Medical-6e464eb2","source":"Medical","question":"In a patient with symptoms of hormone excess and an adrenal mass found incidentally on CT, what further tests are indicated to determine tumor type?","answer":"Biochemical tests to assess hormone secretion and further imaging such as MRI or PET scan are indicated.","question_type":"Complex Reasoning","evidence":"Biochemical tests are indicated to assess hormone secretion in a patient with an adrenal mass.; Further imaging such as MRI is indicated to determine tumor type in a patient with an adrenal mass.; Further imaging such as PET scan is indicated to determine tumor type in a patient with an adrenal mass.","evidence_relations":"Half of adrenal cancer patients have symptoms due to hormone excess; Adrenal tumors are often found incidentally on imaging tests such as CT or MRI; Blood and biochemical tests are used to detect hormone secretion by adrenal tumors; Imaging tests for adrenal tumors include CT scan, MRI scan, PET scan, FDG-PET/CT, and SSTR-PET/CT"},
	{"id":"Medical-15b033b6","source":"Medical","question":"How does the origin of ACC differ from that of pheochromocytoma, and how does this affect their typical symptoms?","answer":"ACC arises from the adrenal cortex and can cause a range of hormone-related symptoms, while pheochromocytoma arises from the adrenal medulla and typically causes high blood pressure, headache, rapid heartbeat, and sweating.","question_type":"Complex Reasoning","evidence":"Adrenocortical carcinoma (ACC) arises from the adrenal cortex.; Adrenocortical carcinoma (ACC) can cause a range of hormone-related symptoms.; Pheochromocytoma arises from the adrenal medulla.; Pheochromocytoma typically causes high blood pressure.; Pheochromocytoma typically causes headache.; Pheochromocytoma typically causes rapid heartbeat.; Pheochromocytoma typically causes sweating.","evidence_relations":"Adrenocortical carcinoma (ACC) is a rare malignant tumor of the adrenal cortex; Pheochromocytoma arises from the adrenal medulla and is often associated with high blood pressure, headache, rapid heartbeat, and sweating"},
	{"id":"Medical-5e710a7f","source":"Medical","question":"Which adrenal tumor is most commonly associated with children under 5, and what is a key difference in its spread compared to benign tumors?","answer":"Neuroblastoma is most common in children under 5 and may metastasize to bones, unlike benign tumors which do not metastasize.","question_type":"Complex Reasoning","evidence":"Neuroblastoma is the most common adrenal tumor in children under 5.; Neuroblastoma may metastasize to bones.; Benign tumors do not metastasize.","evidence_relations":"Neuroblastoma is a rare malignant adrenal tumor affecting mainly children under 5; Neuroblastoma may metastasize to bones; Benign adrenal tumors do not metastasize"},
	{"id":"Medical-c0103315","source":"Medical","question":"What differentiates a functional from a nonfunctioning adrenal adenoma, and how does this impact patient symptoms?","answer":"Functional adenomas secrete excess hormones and cause symptoms, while nonfunctioning adenomas do not secrete hormones and are usually asymptomatic.","question_type":"Complex Reasoning","evidence":"Functional adrenal adenomas secrete excess hormones.; Functional adrenal adenomas cause symptoms.; Nonfunctioning adrenal adenomas do not secrete hormones.; Nonfunctioning adrenal adenomas are usually asymptomatic.","evidence_relations":"Adenoma is the most common type of adrenal gland tumor and can be functioning or nonfunctioning; Functional adrenal tumors may produce excess hormones"},
	{"id":"Medical-2045d4e4","source":"Medical","question":"Which diagnostic approach is shared among all adrenal tumor types and why is it important?","answer":"CT scan and MRI scan are shared diagnostic methods among all adrenal tumor types because they are essential for detecting and characterizing adrenal masses.","question_type":"Complex Reasoning","evidence":"CT scan is a shared diagnostic method among all adrenal tumor types.; MRI scan is a shared diagnostic method among all adrenal tumor types.; CT scan and MRI scan are essential for detecting adrenal masses.; CT scan and MRI scan are essential for characterizing adrenal masses.","evidence_relations":"Imaging tests for adrenal tumors include CT scan, MRI scan, PET scan, FDG-PET/CT, and SSTR-PET/CT; Adrenocortical carcinoma (ACC) diagnostic methods include CT scan and MRI scan; Pheochromocytoma diagnostic methods include CT scan and MRI scan"},
	{"id":"Medical-ef8fe744","source":"Medical","question":"Which diagnostic tests are necessary to confirm and further characterize invasive ductal carcinoma presenting with a breast lump?","answer":"Mammogram, ultrasound, MRI, biopsy, and blood tests are necessary to confirm and characterize invasive ductal carcinoma with a breast lump.","question_type":"Complex Reasoning","evidence":"Mammogram is necessary to confirm invasive ductal carcinoma.; Ultrasound is necessary to confirm invasive ductal carcinoma.; MRI is necessary to confirm invasive ductal carcinoma.; Biopsy is necessary to confirm invasive ductal carcinoma.; Blood tests are necessary to confirm invasive ductal carcinoma.","evidence_relations":"Invasive ductal carcinoma is the most common type of invasive breast cancer; Diagnosis involves imaging (mammogram, ultrasound, MRI, CT, PET), biopsy, and blood tests; Invasive ductal carcinoma uses mammogram, ultrasound, MRI, biopsy, and blood tests as diagnostic methods"},
	{"id":"Medical-8ff4d088","source":"Medical","question":"What treatment options are specifically recommended for hormone receptor-positive, HER2-negative, PIK3CA-mutated metastatic breast cancer?","answer":"Endocrine therapy, CDK4/6 inhibitors, and PIK3CA inhibitors are recommended for hormone receptor-positive, HER2-negative, PIK3CA-mutated metastatic breast cancer.","question_type":"Complex Reasoning","evidence":"Endocrine therapy is recommended for hormone receptor-positive, HER2-negative, PIK3CA-mutated metastatic breast cancer.; CDK4/6 inhibitors are recommended for hormone receptor-positive, HER2-negative, PIK3CA-mutated metastatic breast cancer.; PIK3CA inhibitors are recommended for hormone receptor-positive, HER2-negative, PIK3CA-mutated metastatic breast cancer.","evidence_relations":"CDK4/6 inhibitors are used for hormone receptor-positive, HER2-negative breast cancer; PIK3CA inhibitors are used for PIK3CA-mutated, hormone receptor-positive, HER2-negative breast cancer; Metastatic breast cancer (MBC) is breast cancer that has spread to distant organs"},
	{"id":"Medical-020cc551","source":"Medical","question":"How does the presence of a BRCA1 mutation influence both risk assessment and treatment in HER2-negative breast cancer?","answer":"BRCA1 mutation increases breast cancer risk and enables the use of PARP inhibitors for HER2-negative disease.","question_type":"Complex Reasoning","evidence":"BRCA1 mutation increases breast cancer risk.; BRCA1 mutation enables the use of PARP inhibitors for HER2-negative breast cancer.","evidence_relations":"BRCA1 and BRCA2 mutations increase the risk of breast cancer; PARP inhibitors are used for BRCA-mutated, HER2-negative breast cancer"},
	{"id":"Medical-1c34ae24","source":"Medical","question":"What is the clinical significance of PD-L1 expression in the management of metastatic breast cancer?","answer":"PD-L1 expression may guide immunotherapy use in metastatic breast cancer.","question_type":"Complex Reasoning","evidence":"PD-L1 expression may guide immunotherapy use in metastatic breast cancer.","evidence_relations":"PD-L1 expression may guide immunotherapy use; Metastatic breast cancer (MBC) is breast cancer that has spread to distant organs; Immunotherapy is a treatment option for metastatic breast cancer"},
	{"id":"Medical-e99acf57","source":"Medical","question":"For a patient presenting with redness, swelling, and peau dorange of the breast, what subtype and stage of breast cancer should be suspected and which diagnostic methods are indicated?","answer":"Inflammatory breast cancer (IBC), typically stage III or IV, should be suspected and diagnosis should include physical exam, medical photographs, imaging, and biopsy.","question_type":"Complex Reasoning","evidence":"Inflammatory breast cancer (IBC) should be suspected for a patient with redness, swelling, and peau dorange of the breast.; Inflammatory breast cancer is typically stage III or IV.; Diagnosis of inflammatory breast cancer should include a physical exam.; Diagnosis of inflammatory breast cancer should include medical photographs.; Diagnosis of inflammatory breast cancer should include imaging.; Diagnosis of inflammatory breast cancer should include biopsy.","evidence_relations":"Inflammatory breast cancer (IBC) is a rare, aggressive subtype characterized by cancer cells blocking lymph vessels in the skin; IBC symptoms include redness, swelling, and peau dorange; IBC is diagnosed with physical exam, medical photographs, mammogram, ultrasound, MRI, CT scan, PET scan, biopsy, skin biopsy, and sentinel lymph node biopsy"},
	{"id":"Medical-a13a1285","source":"Medical","question":"What are the distinguishing features between Stage 0 and Stage IV breast cancer in terms of pathology and clinical management?","answer":"Stage 0 is noninvasive (DCIS) and managed with surgery and radiation, while Stage IV is metastatic and managed with systemic therapy.","question_type":"Complex Reasoning","evidence":"Stage 0 breast cancer is noninvasive (DCIS).; Stage 0 breast cancer is managed with surgery.; Stage 0 breast cancer is managed with radiation.; Stage IV breast cancer is metastatic.; Stage IV breast cancer is managed with systemic therapy.","evidence_relations":"Stage 0 breast cancer is noninvasive (DCIS); Stages I-III are invasive breast cancer; Stage IV is metastatic breast cancer; Treatment options include surgery and radiation for DCIS, and systemic therapy for metastatic breast cancer"},
	{"id":"Medical-647b438f","source":"Medical","question":"Which biomarkers must be tested to guide targeted therapy decisions in invasive ductal carcinoma, and why?","answer":"Estrogen receptor, progesterone receptor, HER2, BRCA1/2, PIK3CA, MSI-H/dMMR, and PD-L1 must be tested to guide targeted therapy in invasive ductal carcinoma.","question_type":"Complex Reasoning","evidence":"Estrogen receptor must be tested to guide targeted therapy in invasive ductal carcinoma.; Progesterone receptor must be tested to guide targeted therapy in invasive ductal carcinoma.; HER2 must be tested to guide targeted therapy in invasive ductal carcinoma.; BRCA1/2 must be tested to guide targeted therapy in invasive ductal carcinoma.; PIK3CA must be tested to guide targeted therapy in invasive ductal carcinoma.; MSI-H/dMMR must be tested to guide targeted therapy in invasive ductal carcinoma.; PD-L1 must be tested to guide targeted therapy in invasive ductal carcinoma.","evidence_relations":"Hormone receptor status (ER, PR) and HER2 status are key biomarkers for breast cancer; PIK3CA mutation can be targeted with specific therapies; MSI-H/dMMR status may influence immunotherapy options; PD-L1 expression may guide immunotherapy use; Invasive ductal carcinoma biomarkers include ER, PR, HER2, BRCA1 mutation, BRCA2 mutation, PIK3CA mutation, MSI-H, dMMR, and PD-L1"},
	{"id":"Medical-6bd5b75d","source":"Medical","question":"What is the rationale for performing a sentinel lymph node biopsy in invasive breast cancer and not in DCIS?","answer":"Sentinel lymph node biopsy is performed in invasive breast cancer to assess lymph node involvement, which is not required in noninvasive DCIS.","question_type":"Complex Reasoning","evidence":"Sentinel lymph node biopsy is performed in invasive breast cancer.; Sentinel lymph node biopsy assesses lymph node involvement.; Sentinel lymph node biopsy is not required in noninvasive DCIS.","evidence_relations":"Sentinel lymph node biopsy is used to assess lymph node involvement; Invasive ductal carcinoma diagnostic methods include sentinel lymph node biopsy; DCIS is noninvasive and does not require sentinel lymph node biopsy"},
	{"id":"Medical-8488f954","source":"Medical","question":"How does performance status influence the treatment plan for a patient with metastatic breast cancer?","answer":"Performance status is considered in treatment planning for metastatic breast cancer to tailor therapy to the patient's functional capacity.","question_type":"Complex Reasoning","evidence":"Performance status is considered in treatment planning for metastatic breast cancer.; Performance status helps tailor therapy to the patient's functional capacity.","evidence_relations":"Performance status is considered in treatment planning; Metastatic breast cancer (MBC) is breast cancer that has spread to distant organs; Clinical management includes performance status assessment"},
	{"id":"Medical-f5688b0c","source":"Medical","question":"What are the necessary follow-up procedures after completing primary treatment for breast cancer to monitor for recurrence?","answer":"Follow-up includes imaging, physical exams, and monitoring for recurrence after primary breast cancer treatment.","question_type":"Complex Reasoning","evidence":"Follow-up after primary breast cancer treatment includes imaging.; Follow-up after primary breast cancer treatment includes physical exams.; Follow-up after primary breast cancer treatment includes monitoring for recurrence.","evidence_relations":"Follow-up includes imaging, physical exams, and monitoring for recurrence; Follow-up/Surveillance for breast cancer includes these components"},
	{"id":"Medical-1eda4787","source":"Medical","question":"Which patients with breast cancer should receive fertility preservation counseling before treatment, and why?","answer":"All patients of reproductive potential should receive fertility preservation counseling before starting breast cancer treatment.","question_type":"Complex Reasoning","evidence":"All patients of reproductive potential should receive fertility preservation counseling before starting breast cancer treatment.","evidence_relations":"Fertility preservation should be discussed before starting treatment; Clinical management includes fertility preservation counseling"},
	{"id":"Medical-24f2e8ea","source":"Medical","question":"How does the presence of HER2 positivity alter the systemic therapy options for invasive breast cancer?","answer":"HER2 positivity adds HER2-targeted therapy to the systemic treatment options for invasive breast cancer.","question_type":"Complex Reasoning","evidence":"HER2 positivity adds HER2-targeted therapy to the systemic treatment options for invasive breast cancer.","evidence_relations":"HER2-targeted therapy is used for HER2-positive breast cancer; Treatment options for invasive ductal carcinoma include HER2-targeted therapy"},
	{"id":"Medical-d1a87cb4","source":"Medical","question":"What combination of clinical findings and diagnostic results would indicate metastatic breast cancer (Stage IV)?","answer":"Symptoms like bone pain or neurological symptoms plus imaging or biopsy showing distant spread indicate metastatic breast cancer (Stage IV).","question_type":"Complex Reasoning","evidence":"Symptoms like bone pain or neurological symptoms indicate metastatic breast cancer (Stage IV).; Imaging or biopsy showing distant spread indicates metastatic breast cancer (Stage IV).","evidence_relations":"Metastatic breast cancer (MBC) is breast cancer that has spread to distant organs; MBC symptoms include bone pain, shortness of breath, liver dysfunction, neurological symptoms; MBC diagnostic methods include imaging tests and biopsy"},
	{"id":"Medical-311d66d6","source":"Medical","question":"Which risk factors should be evaluated in a patient with a new breast lump to assess their likelihood of breast cancer?","answer":"Family history, BRCA1/2 mutations, and assigned female at birth should be evaluated as risk factors for breast cancer.","question_type":"Complex Reasoning","evidence":"Family history should be evaluated as a risk factor for breast cancer.; BRCA1/2 mutations should be evaluated as a risk factor for breast cancer.; Assigned female at birth should be evaluated as a risk factor for breast cancer.","evidence_relations":"Risk factors include family history, BRCA mutations, and being assigned female at birth; Breast lump is a common symptom of breast cancer"},
	{"id":"Medical-ac117ebf","source":"Medical","question":"Why is a biopsy essential in both the diagnosis and management planning for breast cancer?","answer":"Biopsy is essential for definitive diagnosis and biomarker testing, which guides treatment planning in breast cancer.","question_type":"Complex Reasoning","evidence":"A biopsy is essential for definitive diagnosis in breast cancer.; A biopsy is essential for biomarker testing in breast cancer.; Biomarker testing guides treatment planning in breast cancer.","evidence_relations":"Biopsy is required for definitive diagnosis and biomarker testing; Diagnosis involves imaging (mammogram, ultrasound, MRI, CT, PET), biopsy, and blood tests"},
	{"id":"Medical-5fd3c02d","source":"Medical","question":"What are the main risk factors associated with the development of basal cell carcinoma?","answer":"The main risk factors associated with the development of basal cell carcinoma include exposure to ultraviolet (UV) radiation from the sun or tanning beds, which can damage the DNA in skin cells. Individuals with fair skin, red or blond hair, and light eye color are at higher risk because they have less melanin to protect against UV rays. Additional risk factors include older age, as cumulative sun exposure increases over time, a personal or family history of skin cancer, previous radiation therapy (especially at a young age), and conditions that suppress the immune system, such as organ transplantation or autoimmune diseases. These factors all contribute to an increased likelihood of developing basal cell carcinoma.","question_type":"Contextual Summarize","evidence":"Basal cell carcinoma risk is increased by UV radiation.; Basal cell carcinoma risk is increased by sun exposure.; Basal cell carcinoma risk is increased by tanning beds.; Basal cell carcinoma risk is increased by having fair skin.; Basal cell carcinoma risk is increased by having light hair and eye color.; Basal cell carcinoma risk is increased by older age.; Basal cell carcinoma risk is increased by prior or family history of skin cancer.; Basal cell carcinoma risk is increased by radiation therapy.; Basal cell carcinoma risk is increased by immune suppression.; Basal cell carcinoma risk is increased by organ transplant.; Basal cell carcinoma risk is increased by autoimmune disease.","evidence_relations":"UV radiation exposure is a primary risk factor for BCC; Fair skin, light hair, and light eye color increase the risk of BCC; Older age is associated with higher risk of BCC; History of skin cancer or family history increases risk of BCC; Radiation therapy and immune suppression are risk factors for BCC; Basal cell carcinoma has risk factors including tanning beds, organ transplant, and autoimmune disease; Risk factors listed in the ontology for BCC include UV radiation, sun exposure, tanning beds, fair skin, red hair, blond hair, light eye color, older age, history of skin cancer, family history of skin cancer, radiation therapy, immune suppression, organ transplant, and autoimmune disease"},
	{"id":"Medical-b8b22d33","source":"Medical","question":"Which anatomical locations and cell types are most commonly involved in basal cell carcinoma?","answer":"Basal cell carcinoma arises from basal cells in the lower part of the epidermis and most commonly develops in sun-exposed areas such as the face, head, and neck, but can occur anywhere on the body.","question_type":"Contextual Summarize","evidence":"Basal cell carcinoma arises from basal cells in the lower part of the epidermis.; Basal cell carcinoma most commonly develops in sun-exposed areas such as the face.; Basal cell carcinoma most commonly develops in sun-exposed areas such as the head.; Basal cell carcinoma most commonly develops in sun-exposed areas such as the neck.; Basal cell carcinoma can occur anywhere on the body.","evidence_relations":"BCC arises from basal cells in the lower part of the epidermis; BCC most commonly develops in sun-exposed areas such as the face, head, and neck; Basal cell carcinoma is a subtype of skin cancer affecting basal cells; Anatomical locations for BCC include face, head, neck, arms, legs, trunk, and anywhere on the body; Cell type for BCC is basal cells as listed in the ontology"},
	{"id":"Medical-9c85110b","source":"Medical","question":"What are the typical symptoms and presentations of basal cell carcinoma?","answer":"Basal cell carcinoma (BCC) typically presents as skin lesions that may appear as flat, pale or yellow areas resembling a scar, red patches that might be itchy, small pink or red shiny bumps that can have blue, brown, or black areas, open sores that do not heal and may bleed or recur, or brown or glossy black bumps with rolled borders, especially in individuals with darker skin. These lesions most commonly develop on sun-exposed areas such as the face, head, and neck, but can occur anywhere on the body. It is important to monitor for any new, changing, bleeding, or unusual skin growths, as early detection improves the likelihood of successful treatment.","question_type":"Contextual Summarize","evidence":"Basal cell carcinoma typically presents as flat pale or yellow areas.; Basal cell carcinoma typically presents as red patches.; Basal cell carcinoma typically presents as shiny bumps.; Basal cell carcinoma typically presents as open sores.; Basal cell carcinoma typically presents as brown or glossy black bumps with rolled borders.; Basal cell carcinoma often appears as skin lesions.","evidence_relations":"BCC presents as flat, pale or yellow areas, red patches, shiny bumps, open sores, or brown/black bumps with rolled borders; Basal cell carcinoma symptoms include flat pale or yellow area; Symptoms also include red patch, shiny bump, open sore, and brown or glossy black bump with rolled border; Skin lesion is a symptom of BCC; The ontology lists these symptoms under BCC: flat pale or yellow area, red patch, shiny bump, open sore, brown or glossy black bump with rolled border, and skin lesion"},
	{"id":"Medical-fcf87025","source":"Medical","question":"Which diagnostic methods are used to confirm basal cell carcinoma and what does the process involve?","answer":"Diagnosis of basal cell carcinoma involves a thorough process that includes taking a detailed medical and family history, performing a physical examination and a focused skin exam to assess any suspicious lesions, and confirming the diagnosis with a biopsy, where a sample of the lesion is removed and examined under a microscope. In some cases, imaging studies may be used to determine the extent of the disease, especially if there is concern for deeper tissue involvement or spread. These diagnostic steps are essential for accurate diagnosis and to guide appropriate treatment planning.","question_type":"Contextual Summarize","evidence":"Diagnosis of basal cell carcinoma involves a combination of medical history and family history.; Diagnosis of basal cell carcinoma involves physical exams.; Diagnosis of basal cell carcinoma involves skin exams.; Diagnosis of basal cell carcinoma involves biopsy.; Diagnosis of basal cell carcinoma sometimes involves imaging.; The process confirms the presence and extent of the disease.","evidence_relations":"Diagnosis of BCC involves medical and family history, physical exam, skin exam, biopsy, and sometimes imaging; Diagnostic methods for BCC include medical history, family history, physical exam, skin exam, biopsy, and imaging; Biopsy is a diagnostic method used in BCC; Imaging may be used in the diagnostic process for BCC; The ontology lists all of these diagnostic methods under BCC"},
	{"id":"Medical-6baf8bff","source":"Medical","question":"What are the standard treatment options for basal cell carcinoma?","answer":"The standard treatment options for basal cell carcinoma (BCC) primarily include surgery, which is the most common and effective approach for removing the cancer. Surgical techniques may involve standard excision or Mohs micrographic surgery, especially for high-risk or recurrent cases. In situations where surgery is not feasible or if the cancer is not completely removed, radiation therapy may be considered as an alternative or adjunct treatment. Systemic therapy, such as platinum-based chemotherapy or immunotherapy with immune checkpoint inhibitors, may be used in advanced cases, when radiation is not suitable, or when the cancer has spread. The choice of treatment depends on factors such as tumor size, location, risk of recurrence, and patient health.","question_type":"Contextual Summarize","evidence":"Surgery is the most common treatment for basal cell carcinoma.; Radiation therapy is used in selected cases for basal cell carcinoma.; Systemic therapy is used in selected cases for basal cell carcinoma.","evidence_relations":"Surgery is the most common treatment for BCC; Radiation therapy or systemic therapy may be used in some cases of BCC; Treatment options for BCC include surgery, radiation therapy, and systemic therapy; The ontology lists treatment for BCC as surgery, radiation therapy, and systemic therapy; Radiation therapy (as treatment) and systemic therapy are included as entities for BCC"},
	{"id":"Medical-643b2b9d","source":"Medical","question":"What constitutes recurrence in basal cell carcinoma and how is it managed?","answer":"Recurrence in basal cell carcinoma refers to the cancer returning to the original site or spreading to lymph nodes or distant sites, with management involving treatment options based on risk and recurrence.","question_type":"Contextual Summarize","evidence":"Recurrence in basal cell carcinoma refers to the cancer returning to the original site.; Recurrence in basal cell carcinoma can involve spreading to lymph nodes.; Recurrence in basal cell carcinoma can involve spreading to distant sites.; Management of recurrence involves treatment options based on risk.; Management of recurrence involves treatment options based on recurrence.","evidence_relations":"Recurrence refers to BCC returning to the original site or spreading to lymph nodes or distant sites; Recurrence in BCC can include spread to lymph nodes; Recurrence in BCC can include spread to distant sites; Recurrence management involves treatment options based on risk and recurrence; The ontology defines recurrence for BCC as return to original site, spread to lymph nodes, or distant sites, and management by treatment options based on risk"},
	{"id":"Medical-25f8ca5e","source":"Medical","question":"What follow-up practices are recommended after treatment for basal cell carcinoma?","answer":"Follow-up after basal cell carcinoma includes a full skin exam with a doctor at least once a year to monitor for recurrence or new lesions.","question_type":"Contextual Summarize","evidence":"Follow-up after basal cell carcinoma includes a full skin exam with a doctor.; Follow-up should occur at least once a year.; The purpose of follow-up is to monitor for recurrence.; The purpose of follow-up is to monitor for new lesions.","evidence_relations":"Follow-up includes full skin exams with a doctor at least once a year; Full skin exam is a follow-up method for BCC; Annual follow-up is recommended for BCC; The ontology lists follow-up for BCC as full skin exam and annual follow-up; Follow-up is important to detect recurrence or new skin cancers"},
	{"id":"Medical-d961b796","source":"Medical","question":"How does a patients medical and family history contribute to the diagnosis and risk assessment of basal cell carcinoma?","answer":"A patient's medical and family history play a crucial role in both the diagnosis and risk assessment of basal cell carcinoma (BCC). A detailed medical history helps identify previous health issues, treatments, and exposures that may increase the risk of BCC, such as a personal history of skin cancer or significant sun exposure. Family history is also important, as having close relatives with skin cancer can indicate a genetic predisposition to BCC. Collecting this information allows clinicians to identify individuals at higher risk, guide diagnostic evaluation, and inform decisions about surveillance and prevention strategies.","question_type":"Contextual Summarize","evidence":"A patient's medical history is used to assess risk for basal cell carcinoma.; A patient's family history is used to assess risk for basal cell carcinoma.; Medical and family history are part of the diagnostic process.; Medical and family history help identify individuals at higher risk.","evidence_relations":"Diagnosis of BCC involves medical and family history; History of skin cancer or family history increases risk of BCC; Medical history is a diagnostic method for BCC; Family history is a diagnostic method for BCC; The ontology lists medical history and family history as both risk factors and diagnostic methods for BCC"},
	{"id":"Medical-915df475","source":"Medical","question":"What are the connections between risk factors, symptoms, and anatomical location in basal cell carcinoma?","answer":"Basal cell carcinoma most often affects sun-exposed areas such as the face, head, and neck, with risk factors including UV radiation and fair skin, and typically presents with symptoms like flat pale or yellow areas, red patches, shiny bumps, open sores, or brown/black bumps with rolled borders.","question_type":"Contextual Summarize","evidence":"Basal cell carcinoma most often affects sun-exposed areas.; Common sun-exposed areas include the face, head, and neck.; Risk factors for basal cell carcinoma include UV radiation.; Risk factors for basal cell carcinoma include fair skin.; Basal cell carcinoma typically presents with flat pale or yellow areas.; Basal cell carcinoma typically presents with red patches.; Basal cell carcinoma typically presents with shiny bumps.; Basal cell carcinoma typically presents with open sores.; Basal cell carcinoma typically presents with brown or black bumps with rolled borders.","evidence_relations":"BCC most commonly develops in sun-exposed areas such as the face, head, and neck; UV radiation exposure is a primary risk factor for BCC; Fair skin, light hair, and light eye color increase the risk of BCC; BCC presents as flat, pale or yellow areas, red patches, shiny bumps, open sores, or brown/black bumps with rolled borders; Anatomical locations for BCC include face, head, neck, arms, legs, trunk, and anywhere on the body"},
	{"id":"Medical-e0e8fd6d","source":"Medical","question":"What are the major risk factors and disease locations associated with primary CNS lymphoma?","answer":"Primary CNS lymphoma is a rare and aggressive cancer that most often affects the brain, but can also involve the spinal cord, cerebrospinal fluid (CSF), and eyes. Major risk factors include conditions that impair the immune system, such as immunodeficiency disorders, HIV infection, and organ transplantation (which requires immunosuppressive therapy). Additional risk factors are infection with Epstein-Barr virus, autoimmune diseases like lupus, and older age, as the majority of cases occur in individuals in their 60s or 70s.","question_type":"Contextual Summarize","evidence":"Primary CNS lymphoma most commonly affects the brain.; Primary CNS lymphoma most commonly affects the spinal cord.; Primary CNS lymphoma most commonly affects cerebrospinal fluid.; Primary CNS lymphoma most commonly affects the eyes.; Risk factors for primary CNS lymphoma include immunodeficiency disorders.; Risk factors for primary CNS lymphoma include HIV infection.; Risk factors for primary CNS lymphoma include Epstein-Barr virus.; Risk factors for primary CNS lymphoma include autoimmune diseases such as lupus.; Risk factors for primary CNS lymphoma include organ transplant.; Risk factors for primary CNS lymphoma include older age.","evidence_relations":"Primary CNS lymphoma most commonly affects the brain, but can also involve the spinal cord, cerebrospinal fluid, and eyes; Impaired immune system is a risk factor for primary CNS lymphoma; Immunodeficiency disorders, HIV infection, Epstein-Barr virus, autoimmune diseases, organ transplant, and older age are risk factors for primary CNS lymphoma; Disease Location for Primary CNS lymphoma includes: Brain, Spinal cord, Cerebrospinal fluid (CSF), Eyes; Risk Factor for Primary CNS lymphoma includes: Immunodeficiency disorder, HIV, Epstein-Barr virus, Autoimmune disease, Lupus, Organ transplant, Older adult"},
	{"id":"Medical-d7012112","source":"Medical","question":"Which diagnostic methods are used to identify primary CNS lymphoma and what are their specific roles?","answer":"The diagnosis of primary CNS lymphoma involves a combination of clinical evaluation and specialized diagnostic tests. A neurological exam is performed to assess neurological function and identify deficits. Imaging studies, particularly MRI of the brain with gadolinium contrast, are the most useful for detecting lesions characteristic of primary CNS lymphoma; CT scans may be used if MRI is unavailable. If imaging suggests lymphoma, a stereotactic biopsy is the standard and most definitive diagnostic procedure, allowing for precise sampling of tumor tissue for pathological confirmation. Additional diagnostic methods include blood tests (such as HIV testing, as immunosuppression is a risk factor), a thorough eye examination to detect ocular involvement, and lumbar puncture to analyze cerebrospinal fluid for malignant cells. Each method plays a specific role: imaging identifies and localizes lesions, biopsy confirms the diagnosis and guides treatment, and ancillary tests assess disease extent and associated risk factors.","question_type":"Contextual Summarize","evidence":"Diagnosis of primary CNS lymphoma involves a neurological exam.; Diagnosis of primary CNS lymphoma involves imaging with MRI.; MRI is especially useful with gadolinium contrast.; Diagnosis of primary CNS lymphoma involves CT imaging.; Diagnosis of primary CNS lymphoma involves stereotactic biopsy.; Diagnosis of primary CNS lymphoma involves blood tests.; Diagnosis of primary CNS lymphoma involves an eye exam.; Diagnosis of primary CNS lymphoma involves a lumbar puncture.; MRI with gadolinium is the most useful imaging method.; Stereotactic biopsy is the standard procedure for diagnosis.","evidence_relations":"Primary CNS lymphoma is diagnosed using neurological exam, imaging (MRI or CT), biopsy, blood tests, eye exam, and lumbar puncture; Stereotactic biopsy is the standard diagnostic procedure for primary CNS lymphoma; MRI with gadolinium contrast is the most useful imaging technique for identifying primary CNS lymphoma; Diagnostic Method for Primary CNS lymphoma includes: Neurological exam, Performance status evaluation, MRI, Gadolinium contrast, CT scan, PET scan, Stereotactic biopsy, Vitrectomy, Blood tests, Eye exam, Lumbar puncture; Imaging (MRI or CT) and biopsy are key diagnostic methods for primary CNS lymphoma"},
	{"id":"Medical-6bb8a85b","source":"Medical","question":"What are the common neurological and systemic symptoms observed in patients with primary CNS lymphoma?","answer":"Patients with primary CNS lymphoma may experience neurological symptoms such as leg or arm weakness, coordination and movement difficulties, personality or behavior changes, depression, confusion, memory problems, incontinence, difficulty speaking or swallowing, headaches, nausea, vomiting, seizures, and vision changes.","question_type":"Contextual Summarize","evidence":"Patients with primary CNS lymphoma may experience leg or arm weakness.; Patients with primary CNS lymphoma may experience coordination difficulties.; Patients with primary CNS lymphoma may experience movement difficulties.; Patients with primary CNS lymphoma may experience personality changes.; Patients with primary CNS lymphoma may experience behavior changes.; Patients with primary CNS lymphoma may experience depression.; Patients with primary CNS lymphoma may experience confusion.; Patients with primary CNS lymphoma may experience memory problems.; Patients with primary CNS lymphoma may experience incontinence.; Patients with primary CNS lymphoma may experience difficulty speaking.; Patients with primary CNS lymphoma may experience difficulty swallowing.; Patients with primary CNS lymphoma may experience headaches.; Patients with primary CNS lymphoma may experience nausea.; Patients with primary CNS lymphoma may experience vomiting.; Patients with primary CNS lymphoma may experience seizures.; Patients with primary CNS lymphoma may experience vision changes.","evidence_relations":"Primary CNS lymphoma can cause neurological symptoms such as leg or arm weakness, coordination or movement difficulties, personality or behavior changes, depression, confusion, memory problems, incontinence, difficulty speaking or swallowing, headaches, nausea, vomiting, seizures, and vision changes; Symptom for Primary CNS lymphoma includes: Leg weakness, Arm weakness, Coordination difficulties, Movement difficulties, Personality changes, Behavior changes, Depression, Confusion, Memory problems, Incontinence, Difficulty speaking, Difficulty swallowing, Headaches, Nausea, Vomiting, Seizures, Blurry vision, Double vision; Blurry vision and double vision are among the symptoms listed for Primary CNS lymphoma; Primary CNS lymphoma presents with both neurological and systemic symptoms; Symptoms such as headaches, seizures, and memory problems are associated with Primary CNS lymphoma"},
	{"id":"Medical-0a87d395","source":"Medical","question":"What are the main treatment modalities and phases for primary CNS lymphoma, and which drugs are commonly used?","answer":"The main treatment modalities for primary CNS lymphoma include corticosteroids to reduce inflammation and symptoms, high-dose methotrexate-based chemotherapy as the cornerstone of therapy, whole-brain radiation therapy (WBRT) particularly for patients who cannot tolerate chemotherapy or as consolidation, targeted therapies that attack specific cancer cell mechanisms, immunotherapy with rituximab (the primary immunotherapy agent), autologous stem cell rescue following high-dose chemotherapy, and supportive care to manage symptoms and side effects. Treatment is typically structured in two main phases: induction, which aims to eliminate as many lymphoma cells as possible, and consolidation, which seeks to eradicate any remaining disease and prevent relapse. Multidisciplinary care and consideration of clinical trials are also important aspects of management.","question_type":"Contextual Summarize","evidence":"Treatment for primary CNS lymphoma includes corticosteroids.; Treatment for primary CNS lymphoma includes chemotherapy.; High-dose methotrexate is a notable chemotherapy drug for primary CNS lymphoma.; Treatment for primary CNS lymphoma includes radiation therapy.; Whole-brain radiation therapy is particularly used for primary CNS lymphoma.; Treatment for primary CNS lymphoma includes targeted therapy.; Treatment for primary CNS lymphoma includes immunotherapy.; Rituximab is a main drug used in immunotherapy for primary CNS lymphoma.; Treatment for primary CNS lymphoma includes stem cell rescue.; Treatment for primary CNS lymphoma includes supportive care.; Treatment is typically administered in induction phases.; Treatment is typically administered in consolidation phases.","evidence_relations":"Treatment options for primary CNS lymphoma include corticosteroids, chemotherapy, radiation therapy, targeted therapy, immunotherapy, stem cell rescue, and supportive care; High-dose methotrexate is the main chemotherapy drug used for primary CNS lymphoma; Rituximab is the main immunotherapy drug used for primary CNS lymphoma; Whole-brain radiation therapy (WBRT) is the most commonly used radiation technique for primary CNS lymphoma; Treatment is typically given in phases: induction and consolidation"},
	{"id":"Medical-23285edf","source":"Medical","question":"How is treatment tailored for primary CNS lymphoma involving the cerebrospinal fluid or eyes?","answer":"For primary CNS lymphoma with cerebrospinal fluid involvement, intrathecal chemotherapy may be used, while intraocular chemotherapy or radiation therapy is considered if the eyes are affected.","question_type":"Contextual Summarize","evidence":"Intrathecal chemotherapy may be used for primary CNS lymphoma with cerebrospinal fluid involvement.; Intraocular chemotherapy is considered if the eyes are affected in primary CNS lymphoma.; Radiation therapy is considered if the eyes are affected in primary CNS lymphoma.","evidence_relations":"Intrathecal chemotherapy may be used if cancer cells are found in the cerebrospinal fluid; Intraocular chemotherapy or radiation may be used if the eyes are involved; Specialized Treatments for Primary CNS lymphoma include: Intrathecal chemotherapy for CSF involvement, Intraocular chemotherapy for eye involvement, Radiation therapy for ocular involvement; Disease Location for Primary CNS lymphoma includes: Cerebrospinal fluid (CSF), Eyes; Treatment for Primary CNS lymphoma is adapted based on disease location, including CSF and ocular involvement"},
	{"id":"Medical-a1adaecd","source":"Medical","question":"What is the role of supportive care and follow-up in the management of primary CNS lymphoma?","answer":"Supportive care in the management of primary CNS lymphoma is aimed at relieving symptoms, managing side effects of cancer and its treatments, and maintaining or improving quality of life at any stage of the disease. This includes interventions such as pain management, nutritional support, psychological counseling, rehabilitation therapies, and palliative care. Supportive care is provided alongside active cancer treatments and may be the primary focus for patients with significant comorbidities or reduced ability to perform daily activities. Follow-up care is essential for monitoring disease status and treatment effects, and typically includes repeat MRI scans to assess for recurrence or progression, comprehensive eye examinations to detect ocular involvement, blood tests to monitor for treatment-related complications, and regular assessment of performance status to guide ongoing management and eligibility for further therapies or clinical trials. Multidisciplinary care teams coordinate these efforts to ensure holistic patient support.","question_type":"Contextual Summarize","evidence":"Supportive care in primary CNS lymphoma focuses on symptom management.; Supportive care in primary CNS lymphoma focuses on quality of life.; Follow-up for primary CNS lymphoma involves repeat MRI.; Follow-up for primary CNS lymphoma involves eye exams.; Follow-up for primary CNS lymphoma involves blood tests.; Follow-up for primary CNS lymphoma involves performance status assessment.","evidence_relations":"Supportive care is provided to relieve symptoms and side effects at any stage of disease; Supportive Care for Primary CNS lymphoma includes: Symptom management, Palliative care, Quality of life interventions; Follow-up/Surveillance for Primary CNS lymphoma includes: Repeat MRI, Eye exam, Blood tests, Performance status assessment; Performance status is evaluated to guide treatment decisions and eligibility for clinical trials; Follow-up procedures include imaging, laboratory tests, and clinical assessments"},
	{"id":"Medical-ead123bc","source":"Medical","question":"What are the recommendations regarding clinical trial participation and how does performance status influence treatment for primary CNS lymphoma?","answer":"Participation in clinical trials is recommended for all patients with primary CNS lymphoma, as these studies provide access to new and potentially more effective treatment options that are being evaluated for safety and efficacy. Clinical trials are considered a key component of both induction and consolidation phases of treatment. Performance status, which measures a patient's ability to carry out daily activities, is routinely assessed to help determine the most appropriate treatment approach and to establish eligibility for clinical trials. Patients with better performance status are more likely to tolerate intensive therapies and meet the inclusion criteria for clinical studies, while those with reduced performance status may require modified treatment plans or supportive care. Thus, performance status plays a critical role in guiding individualized treatment decisions and access to investigational therapies.","question_type":"Contextual Summarize","evidence":"Clinical trial participation is recommended for all patients with primary CNS lymphoma.; Performance status is assessed to guide treatment decisions for primary CNS lymphoma.; Performance status is assessed to determine eligibility for clinical trials in primary CNS lymphoma.","evidence_relations":"Clinical trial participation is recommended for all patients with primary CNS lymphoma; Performance status is evaluated to guide treatment decisions and eligibility for clinical trials; Clinical trial is listed as a treatment modality and in both induction and consolidation phases; Performance status evaluation is included as a diagnostic method and part of follow-up/surveillance; Performance status assessment is a key component in the management of primary CNS lymphoma"},
	{"id":"Medical-ce5815bf","source":"Medical","question":"How does primary CNS lymphoma typically progress and where is relapse most likely to occur?","answer":"Primary central nervous system (CNS) lymphoma is a rare and aggressive cancer that originates within the CNS, most commonly in the brain, but it can also involve the spinal cord, cerebrospinal fluid, and eyes. The disease typically remains confined to the CNS and rarely spreads to other parts of the body. Relapse most often occurs within the CNS compartments, specifically in the brain, spinal cord, or eyes. Surveillance after treatment focuses on monitoring these areas for signs of recurrence, as relapse outside the CNS is uncommon.","question_type":"Contextual Summarize","evidence":"Primary CNS lymphoma rarely spreads outside the central nervous system.; Primary CNS lymphoma can relapse in the brain.; Primary CNS lymphoma can relapse in the spinal cord.; Primary CNS lymphoma can relapse in the eyes.","evidence_relations":"Primary CNS lymphoma rarely spreads outside the central nervous system; Primary CNS lymphoma can relapse in the brain, spinal cord, or eyes; Disease Location for Primary CNS lymphoma includes: Brain, Spinal cord, Eyes; Relapse is noted to occur in central nervous system compartments; Follow-up/Surveillance includes monitoring for relapse in brain, spinal cord, or eyes"},
	{"id":"Medical-17444c2c","source":"Medical","question":"What are the major risk factors and genetic syndromes associated with cutaneous squamous cell carcinoma (CSCC)?","answer":"Major risk factors for cutaneous squamous cell carcinoma (CSCC) include chronic sun exposure, especially in fair-skinned individuals, and the use of indoor tanning devices. Additional risk factors are exposure to environmental toxins such as arsenic and tobacco smoke, the presence of actinic keratoses (precancerous skin lesions caused by sun damage), immunosuppression (such as in organ transplant recipients), and chronic wounds or scars (including nonhealing ulcers and burns, known as Marjolins ulcer). Certain genetic syndromes, notably xeroderma pigmentosum (a condition with defective DNA repair leading to increased sensitivity to UV light) and recessive dystrophic epidermolysis bullosa (RDEB, a rare inherited disorder causing fragile skin), significantly increase the risk of developing CSCC.","question_type":"Contextual Summarize","evidence":"Major risk factors for cutaneous squamous cell carcinoma (CSCC) include chronic sun exposure.; Indoor tanning is a major risk factor for CSCC.; Environmental toxins are a major risk factor for CSCC.; Actinic keratoses are a major risk factor for CSCC.; Genetic syndromes such as xeroderma pigmentosum are associated with CSCC.; Genetic syndromes such as RDEB are associated with CSCC.; Immunosuppression is a major risk factor for CSCC.; Chronic wounds or scars are a major risk factor for CSCC.","evidence_relations":"Major risk factors for CSCC include chronic sun exposure, indoor tanning, environmental toxins, actinic keratoses, genetic syndromes, weakened immune system, and chronic wounds or scars; CSCC most commonly arises in sun-exposed areas, especially in fair-skinned individuals; Actinic keratosis is a precancerous lesion that can progress to CSCC; Genetic syndromes such as xeroderma pigmentosum and RDEB increase risk for CSCC; Risk Factor in CSCC ontology includes chronic sun exposure, indoor tanning, actinic keratosis, genetic syndromes (xeroderma pigmentosum, RDEB), immunosuppression, chronic wounds or scars, and environmental toxins (arsenic, tobacco smoke)"},
	{"id":"Medical-9e04431e","source":"Medical","question":"Which diagnostic methods are used for CSCC at different stages, and how do they differ between local, regional, and metastatic disease?","answer":"CSCC diagnosis involves clinical examination and skin biopsy for local disease, with imaging (CT, MRI, PET/CT) used when deeper invasion or spread is suspected; regional CSCC requires lymph node exams and biopsies, while metastatic CSCC relies on advanced imaging techniques.","question_type":"Contextual Summarize","evidence":"CSCC diagnosis involves clinical examination for local disease.; CSCC diagnosis involves skin biopsy for local disease.; Imaging techniques such as CT, MRI, and PET/CT are used when deeper invasion or spread is suspected in CSCC.; Regional CSCC requires lymph node exams.; Regional CSCC requires lymph node biopsies.; Metastatic CSCC relies on advanced imaging techniques.","evidence_relations":"Diagnosis of CSCC involves clinical examination, skin biopsy, and imaging (CT, MRI, PET/CT) if deeper invasion or spread is suspected; Biopsy types for diagnosis include shave biopsy, punch biopsy, and excision biopsy; Imaging is used for staging and surveillance in regional and high-risk cases; Regional CSCC (lymph node involvement) is treated with surgery to remove tumor and lymph nodes, often followed by radiation and sometimes systemic therapy; Metastatic CSCC is treated with systemic therapy (immunotherapy preferred), and surgery or radiation if feasible; Regional CSCC Diagnostic Method: Lymph node exam, Imaging (CT, PET/CT), Lymph node biopsy (FNA, core needle biopsy); Metastatic CSCC Diagnostic Method: Imaging (CT, PET/CT, MRI)"},
	{"id":"Medical-0170eecb","source":"Medical","question":"What are the main symptoms and typical clinical presentations of cutaneous squamous cell carcinoma?","answer":"Cutaneous squamous cell carcinoma (CSCC) most commonly presents as scaly patches or plaques, solid or misshapen skin lesions, and lesions that may develop in areas of chronic wounds or scars. These lesions often arise in sun-exposed areas, particularly in fair-skinned individuals, and may appear as persistent, rough, or thickened areas of skin. CSCC can also develop in sites of chronic skin damage, such as old scars or ulcers. Early recognition of these typical clinical presentations is important for prompt diagnosis and management.","question_type":"Contextual Summarize","evidence":"CSCC typically presents as scaly patches.; CSCC typically presents as solid or misshapen skin lesions.; CSCC lesions can develop in areas of chronic wounds or scars.","evidence_relations":"Symptoms of CSCC include scaly patches, solid or misshapen skin lesions, and lesions in areas of chronic damage; CSCC most commonly arises in sun-exposed areas, especially in fair-skinned individuals; Lesions in chronic wounds or scars are a symptom of CSCC; Symptom in CSCC ontology includes scaly patches, solid or misshapen lesions, and lesions in chronic wounds or scars; Actinic keratosis is a precancerous lesion that can progress to CSCC"},
	{"id":"Medical-79b30aaa","source":"Medical","question":"How is risk assessment performed for CSCC, and what factors are considered in determining risk level?","answer":"Risk assessment for cutaneous squamous cell carcinoma (CSCC) involves evaluating several clinical and pathological factors to determine whether the cancer is low-, high-, or very high-risk. Key factors considered include the tumor's location (with tumors on the head, neck, hands, feet, shins, or genitalia being higher risk), size (tumors over 2 cm on the trunk, arms, or legs, or any size on high-risk locations, and any tumor over 4 cm in any location are considered higher risk), border definition (ill-defined or uneven borders increase risk), history of recurrence (recurrent tumors are high risk), depth of invasion (deeper tumors have higher risk of recurrence), perineural and lymphovascular invasion (spread into nerves or blood/lymph vessels is associated with higher risk), tumor grade (higher grade indicates more aggressive behavior), and patient immune status (immunosuppressed patients are at increased risk). The overall risk category is determined by the highest risk factor present, and this stratification guides treatment decisions and prognosis.","question_type":"Contextual Summarize","evidence":"Risk assessment for CSCC is based on tumor location.; Risk assessment for CSCC is based on tumor size.; Risk assessment for CSCC is based on border definition.; Risk assessment for CSCC is based on recurrence.; Risk assessment for CSCC is based on depth of invasion.; Risk assessment for CSCC is based on perineural invasion.; Risk assessment for CSCC is based on lymphovascular invasion.; Risk assessment for CSCC is based on tumor grade.; Risk assessment for CSCC is based on patient immune status.","evidence_relations":"Risk assessment for CSCC is based on tumor location, size, border definition, recurrence, depth, perineural invasion, lymphovascular invasion, tumor grade, and patient immune status; Clinical Management Risk Assessment includes tumor location and size, tumor border definition, recurrence, depth of invasion, perineural invasion, lymphovascular invasion, tumor grade, immunosuppression; Perineural invasion, lymphovascular invasion, and tumor grade are considered biomarkers in CSCC; Risk Factor in CSCC ontology includes immunosuppression; CSCC is staged as local (confined to skin), regional (spread to lymph nodes), or metastatic (distant spread)"},
	{"id":"Medical-76e69cd5","source":"Medical","question":"What are the recommended treatment strategies for local CSCC based on risk stratification?","answer":"Low-risk local CSCC is mainly treated with surgical methods such as C&E, standard excision, or Mohs surgery/PDEMA, while high-risk and very high-risk cases may require Mohs surgery/PDEMA (preferred), standard excision, radiation if surgery is not possible, or systemic therapy if neither surgery nor radiation is feasible.","question_type":"Contextual Summarize","evidence":"Low-risk local CSCC is mainly treated with surgical methods.; Surgical methods for low-risk local CSCC include curettage and electrodessication (C&E).; Surgical methods for low-risk local CSCC include standard excision.; Surgical methods for low-risk local CSCC include Mohs surgery/PDEMA.; High-risk and very high-risk local CSCC may require Mohs surgery/PDEMA.; High-risk and very high-risk local CSCC may require standard excision.; High-risk and very high-risk local CSCC may require radiation if surgery is not possible.; High-risk and very high-risk local CSCC may require systemic therapy if neither surgery nor radiation is feasible.","evidence_relations":"Low-risk local CSCC is primarily treated with surgery (C&E, standard excision, Mohs surgery/PDEMA); High-risk or very high-risk local CSCC is treated with Mohs surgery/PDEMA or standard excision, with consideration of radiation and/or systemic therapy if surgery is not possible; Local CSCC Risk Assessment: Low-risk, High-risk, Very high-risk; Low-risk Treatment: Curettage and electrodesiccation (C&E), Shave excision, Standard surgical excision, Mohs surgery/PDEMA, Radiation therapy (if not surgical candidate); High-risk/Very high-risk Treatment: Mohs surgery/PDEMA (preferred), Standard surgical excision, Radiation therapy (if not surgical candidate), Systemic therapy (if surgery/radiation not possible)"},
	{"id":"Medical-ff793656","source":"Medical","question":"How are regional and metastatic CSCC managed, and what systemic therapies are available?","answer":"Regional CSCC is managed with surgery, often followed by radiation and sometimes systemic therapy, while metastatic CSCC is primarily treated with systemic therapypreferably PD-1 inhibitorswith surgery or radiation considered if feasible; available systemic therapies include platinum-based chemotherapy, EGFR inhibitors, and PD-1 inhibitors.","question_type":"Contextual Summarize","evidence":"Regional CSCC is managed with surgery.; Regional CSCC is often followed by radiation.; Regional CSCC may require systemic therapy.; Metastatic CSCC is primarily treated with systemic therapy.; PD-1 inhibitors are preferred for treating metastatic CSCC.; Surgery or radiation may be considered for metastatic CSCC if feasible.; Available systemic therapies for metastatic CSCC include platinum-based chemotherapy.; Available systemic therapies for metastatic CSCC include EGFR inhibitors.; Available systemic therapies for metastatic CSCC include PD-1 inhibitors.","evidence_relations":"Regional CSCC (lymph node involvement) is treated with surgery to remove tumor and lymph nodes, often followed by radiation and sometimes systemic therapy; Metastatic CSCC is treated with systemic therapy (immunotherapy preferred), and surgery or radiation if feasible; Systemic therapy options include platinum-based chemotherapy, EGFR inhibitors (cetuximab), and PD-1 inhibitors (cemiplimab, pembrolizumab); Regional CSCC Treatment: Surgery (tumor and lymph node excision), Radiation therapy (adjuvant), Systemic therapy (platinum-based chemotherapy, EGFR inhibitor, PD-1 inhibitor), Clinical trial; Metastatic CSCC Treatment: Systemic therapy (PD-1 inhibitor preferred), Surgery or radiation if feasible, Clinical trial, Platinum-based chemotherapy, EGFR inhibitor"},
	{"id":"Medical-62d1fdf9","source":"Medical","question":"What are the follow-up strategies after CSCC treatment, and how are they tailored by risk and stage?","answer":"Follow-up after CSCC treatment involves regular, comprehensive skin and lymph node examinations, with the frequency and duration of monitoring tailored to the patient's risk category and disease stage. For low-risk local CSCC, exams are recommended every 3 to 12 months for the first 2 years, then every 6 to 12 months for the next 3 years, and annually thereafter. High-risk or very high-risk local CSCC requires more frequent examsevery 3 to 6 months for 2 years, then every 6 months for 3 years, and then every 6 to 12 months. Regional CSCC (with lymph node involvement) follow-up includes exams every 2 to 3 months for the first year, every 2 to 4 months in the second year, every 4 to 6 months for the next 3 years, and then every 6 to 12 months. For metastatic CSCC, follow-up is individualized based on the extent of disease and response to treatment. These follow-up visits are essential for early detection of recurrence or new skin cancers, and may include a full-body skin exam and assessment of regional lymph nodes.","question_type":"Contextual Summarize","evidence":"Follow-up after CSCC treatment consists of regular skin exams.; Follow-up after CSCC treatment consists of regular lymph node exams.; The frequency of follow-up exams is determined by risk and stage.; Low-risk local cases require less frequent monitoring.; High-risk cases require more intensive surveillance schedules.; Regional cases require more intensive surveillance schedules.; Metastatic cases require more intensive surveillance schedules.","evidence_relations":"Follow-up after treatment includes regular skin and lymph node exams, with frequency based on risk and stage; Low-risk local CSCC follow-up: Skin and lymph node exams every 3-12 months for 2 years, then every 6-12 months for 3 years, then annually; High-risk/Very high-risk local CSCC follow-up: Skin and lymph node exams every 3-6 months for 2 years, then every 6 months for 3 years, then every 6-12 months; Regional CSCC follow-up: Skin and lymph node exams every 2-3 months for 1 year, every 2-4 months for year 2, every 4-6 months for 3 years, then every 6-12 months; Metastatic CSCC follow-up: Individualized based on disease extent and response"},
	{"id":"Medical-fd3d70cc","source":"Medical","question":"Which therapies are used to treat actinic keratosis and superficial CSCC, and what are their main types?","answer":"Therapies used to treat actinic keratosis and superficial cutaneous squamous cell carcinoma (CSCC) include photodynamic therapy, cryotherapy, and various topical therapies. Photodynamic therapy involves applying a light-sensitive drug to the skin, which is then activated by exposure to specific wavelengths of light to destroy abnormal cells. Cryotherapy uses extreme cold, typically liquid nitrogen, to freeze and destroy precancerous and cancerous cells. Topical therapies are medications applied directly to the skin and include 5-fluorouracil (a topical chemotherapy), imiquimod (an immune response modifier), calcipotriene (a vitamin D analog that activates the skins immune system), tirbanibulin (a microtubule inhibitor that targets rapidly dividing cells), and diclofenac (a nonsteroidal anti-inflammatory drug). These treatments are considered superficial therapies, as they primarily affect the top layer of the skin and are suitable for early or superficial lesions.","question_type":"Contextual Summarize","evidence":"Actinic keratosis is treated with photodynamic therapy.; Actinic keratosis is treated with cryotherapy.; Actinic keratosis is treated with topical therapies.; Topical therapies for actinic keratosis include 5-fluorouracil.; Topical therapies for actinic keratosis include imiquimod.; Topical therapies for actinic keratosis include calcipotriene.; Topical therapies for actinic keratosis include tirbanibulin.; Topical therapies for actinic keratosis include diclofenac.; Superficial CSCC is treated with photodynamic therapy.; Superficial CSCC is treated with cryotherapy.; Superficial CSCC is treated with topical therapies.","evidence_relations":"Photodynamic therapy, cryotherapy, and topical therapies (5-fluorouracil, imiquimod, tirbanibulin) are used for actinic keratoses and superficial CSCC; Precancerous Lesion: Actinic keratosis Treatment: Photodynamic therapy, Cryotherapy, Topical therapy (5-fluorouracil, imiquimod, calcipotriene, tirbanibulin, diclofenac); Actinic keratosis is a precancerous lesion that can progress to CSCC; Topical therapy includes 5-fluorouracil, imiquimod, calcipotriene, tirbanibulin, diclofenac; Cryotherapy and photodynamic therapy are local treatment options for actinic keratosis and superficial CSCC"},
	{"id":"Medical-1b9a995e","source":"Medical","question":"What is the hierarchical classification of CSCC within the broader context of skin cancers?","answer":"CSCC, also known as cutaneous squamous cell carcinoma, is a subtype of nonmelanoma skin cancer and is the second most common type of skin cancer after basal cell carcinoma.","question_type":"Contextual Summarize","evidence":"CSCC is also known as cutaneous squamous cell carcinoma.; CSCC is a subtype of nonmelanoma skin cancer.; CSCC is the second most common type of skin cancer.; Basal cell carcinoma is the most common type of skin cancer.","evidence_relations":"Squamous cell skin cancer (CSCC) is the second most common type of skin cancer; CSCC is a type of nonmelanoma skin cancer; Nonmelanoma skin cancer includes subtypes such as cutaneous squamous cell carcinoma (CSCC); Basal cell carcinoma and melanoma are other types of skin cancer; Cancer Type ontology: Nonmelanoma skin cancer > Cutaneous squamous cell carcinoma (CSCC)"},
	{"id":"Medical-7544e6ca","source":"Medical","question":"Which biomarkers are considered in CSCC, and how do they relate to prognosis and risk assessment?","answer":"In cutaneous squamous cell carcinoma (CSCC), key biomarkers considered for prognosis and risk assessment include perineural invasion, lymphovascular invasion, and tumor grade. The presence of perineural invasion (tumor cells found around or within nerves) and lymphovascular invasion (tumor cells within lymphatic or blood vessels) are high-risk features that are associated with an increased likelihood of recurrence and poorer prognosis. Tumor grade, which reflects how abnormal the cancer cells appear and how quickly the tumor is likely to grow and spread, also plays a significant role in determining risk. These biomarkers are used alongside other clinical factors to guide risk stratification and inform management decisions, such as the need for more aggressive treatment or closer follow-up.","question_type":"Contextual Summarize","evidence":"Perineural invasion is a key biomarker in CSCC.; Lymphovascular invasion is a key biomarker in CSCC.; Tumor grade is a key biomarker in CSCC.; The presence of key biomarkers is associated with higher risk in CSCC.; The presence of key biomarkers is associated with worse prognosis in CSCC.; Key biomarkers influence risk assessment in CSCC.; Key biomarkers influence management decisions in CSCC.","evidence_relations":"Risk assessment for CSCC is based on tumor location, size, border definition, recurrence, depth, perineural invasion, lymphovascular invasion, tumor grade, and patient immune status; Biomarker in CSCC ontology includes perineural invasion, lymphovascular invasion, tumor grade; Perineural invasion, lymphovascular invasion, and tumor grade are considered biomarkers in CSCC; High-risk features in CSCC include perineural invasion and lymphovascular invasion; Tumor grade is a factor in risk assessment and prognosis for CSCC"},
	{"id":"Medical-aae429f4","source":"Medical","question":"What are the key genetic and chromosomal abnormalities involved in the diagnosis of chronic myeloid leukemia (CML)?","answer":"CML diagnosis relies on the presence of the BCR::ABL1 fusion gene and the Philadelphia chromosome, which results from a translocation between chromosome 9 and chromosome 22.","question_type":"Contextual Summarize","evidence":"CML diagnosis relies on the presence of the BCR::ABL1 fusion gene.; CML diagnosis relies on the presence of the Philadelphia chromosome.; The Philadelphia chromosome results from a translocation between chromosome 9 and chromosome 22.","evidence_relations":"CML is caused by the BCR::ABL1 fusion gene; The BCR::ABL1 gene is created by a translocation between chromosome 9 and chromosome 22; The Philadelphia chromosome (Ph) is the abnormal chromosome 22 resulting from this translocation; Presence of the Ph chromosome or BCR::ABL1 gene is required for CML diagnosis; CML includes biomarkers: BCR::ABL1 fusion gene, Philadelphia chromosome (Ph)"},
	{"id":"Medical-d21811b0","source":"Medical","question":"Which diagnostic methods and biomarkers are essential for identifying CML, and what blood cell abnormalities are commonly observed?","answer":"Chronic myeloid leukemia (CML) is diagnosed through a combination of blood tests and bone marrow tests. Essential diagnostic biomarkers include the detection of the BCR::ABL1 fusion gene and the Philadelphia (Ph) chromosome, both of which are required for a definitive diagnosis of CML. These genetic abnormalities are not found in normal blood cells and are specific to CML. Blood cell abnormalities commonly observed in CML include a marked increase in white blood cells (particularly granulocytes) and abnormal platelet counts, which may be elevated or decreased. These findings reflect the uncontrolled proliferation of myeloid progenitor cells due to the activity of the BCR::ABL1 protein.","question_type":"Contextual Summarize","evidence":"CML is diagnosed using blood tests.; CML is diagnosed using bone marrow tests.; The detection of the BCR::ABL1 fusion gene is a key biomarker for CML.; The detection of the Philadelphia chromosome is a key biomarker for CML.; CML is characterized by increased white blood cells.; CML is characterized by abnormal platelet counts.","evidence_relations":"Blood tests and bone marrow tests are used to diagnose CML; Presence of the Ph chromosome or BCR::ABL1 gene is required for CML diagnosis; CML includes biomarkers: BCR::ABL1 fusion gene, Philadelphia chromosome (Ph); CML is characterized by increased white blood cells (granulocytes) and abnormal platelet counts; CML arises from blood stem cells producing increased myeloid progenitor cells"},
	{"id":"Medical-61d081d5","source":"Medical","question":"How does the BCR::ABL1 fusion gene contribute to the pathogenesis and treatment strategy of CML?","answer":"The BCR::ABL1 fusion gene drives CML development through abnormal chromosomal translocation, and treatment is focused on inhibiting the BCR::ABL1 protein activity.","question_type":"Contextual Summarize","evidence":"The BCR::ABL1 fusion gene drives CML development.; CML development is caused by abnormal chromosomal translocation.; Treatment for CML is focused on inhibiting the BCR::ABL1 protein activity.","evidence_relations":"CML is caused by the BCR::ABL1 fusion gene; The BCR::ABL1 gene is created by a translocation between chromosome 9 and chromosome 22; Treatment for CML aims to inhibit BCR::ABL1 protein activity; CML includes treatment: BCR::ABL1 protein inhibition; CML includes genetic alteration: BCR::ABL1 fusion gene"},
	{"id":"Medical-2952a7a6","source":"Medical","question":"What are the main phases of CML and how do they differ in terms of blood cell involvement?","answer":"Chronic myeloid leukemia (CML) progresses through distinct phases: the chronic phase and the blast phase (BP-CML). In the chronic phase, there is an overproduction of mature and maturing myeloid cells, particularly granulocytes, in the blood and bone marrow, often accompanied by abnormal counts of platelets and sometimes red blood cells. The blast phase represents an advanced stage of CML, characterized by a marked increase in immature cells called blasts, which can be of myeloid or lymphoid lineage. This phase involves a significant accumulation of these immature progenitor cells, leading to more aggressive disease and symptoms, and the specific lineage of blasts (myeloid or lymphoid) can influence treatment decisions.","question_type":"Contextual Summarize","evidence":"CML includes a chronic phase.; CML includes a blast phase.; The blast phase is marked by increased blasts.; The blast phase involves myeloid progenitor cells.; The blast phase involves lymphoid progenitor cells.","evidence_relations":"Blast phase CML (BP-CML) is an advanced form of CML with increased blasts; CML arises from blood stem cells producing increased myeloid progenitor cells; CML includes disease phases: Chronic phase, Blast phase CML (BP-CML); Blast phase CML (BP-CML) includes blood cell types: myeloid progenitor cells, lymphoid progenitor cells, blasts; CML includes blood cell types: White blood cells (WBCs), Red blood cells (RBCs), Platelets (PLTs)"},
	{"id":"Medical-0a7d95fc","source":"Medical","question":"Which blood cell types are affected in CML, and what lineage changes are observed in the disease?","answer":"CML primarily affects white blood cells, especially granulocytes, and can also involve abnormal counts of red blood cells and platelets due to increased myeloid progenitor cell production.","question_type":"Contextual Summarize","evidence":"CML primarily affects white blood cells.; Granulocytes are especially affected in CML.; CML can involve abnormal counts of red blood cells.; CML can involve abnormal counts of platelets.; Increased myeloid progenitor cell production is observed in CML.","evidence_relations":"CML is characterized by increased white blood cells (granulocytes) and abnormal platelet counts; CML arises from blood stem cells producing increased myeloid progenitor cells; CML includes blood cell types: White blood cells (WBCs), Red blood cells (RBCs), Platelets (PLTs); White blood cells (WBCs) include granulocytes, neutrophils, eosinophils, basophils; CML includes blood cell type: myeloid progenitor cells"},
	{"id":"Medical-f8dc595c","source":"Medical","question":"What is the relationship between chromosomal abnormalities and biomarkers in the diagnosis of CML?","answer":"The Philadelphia chromosome, resulting from a translocation between chromosomes 9 and 22, and the BCR::ABL1 fusion gene are interrelated chromosomal abnormalities and biomarkers essential for CML diagnosis.","question_type":"Contextual Summarize","evidence":"The Philadelphia chromosome is a chromosomal abnormality in CML.; The Philadelphia chromosome results from a translocation between chromosomes 9 and 22.; The BCR::ABL1 fusion gene is a biomarker essential for CML diagnosis.; The BCR::ABL1 fusion gene is a chromosomal abnormality in CML.; The Philadelphia chromosome and BCR::ABL1 fusion gene are interrelated.","evidence_relations":"The BCR::ABL1 gene is created by a translocation between chromosome 9 and chromosome 22; The Philadelphia chromosome (Ph) is the abnormal chromosome 22 resulting from this translocation; Presence of the Ph chromosome or BCR::ABL1 gene is required for CML diagnosis; CML includes biomarkers: BCR::ABL1 fusion gene, Philadelphia chromosome (Ph); CML includes chromosomal abnormality: Philadelphia chromosome (Ph), chromosome 9, chromosome 22"},
	{"id":"Medical-48edb564","source":"Medical","question":"How are blood and bone marrow tests utilized in the context of CML diagnosis and monitoring?","answer":"Blood and bone marrow tests play a critical role in both the diagnosis and ongoing monitoring of chronic myeloid leukemia (CML). These tests are used to detect the presence of the BCR::ABL1 fusion gene or the Philadelphia chromosome, which are required for a definitive diagnosis of CML. In addition to identifying these specific genetic abnormalities, blood tests can reveal characteristic changes such as increased white blood cell counts (particularly granulocytes) and abnormal platelet counts. Bone marrow tests may be performed to further assess the extent of disease and to provide samples for more detailed genetic analysis, including karyotyping and molecular testing. These diagnostic findings guide treatment decisions and are also used to monitor response to therapy and disease progression over time.","question_type":"Contextual Summarize","evidence":"Blood tests are essential for diagnosing CML.; Bone marrow tests are essential for diagnosing CML.; Blood tests can detect the BCR::ABL1 fusion gene.; Bone marrow tests can detect the BCR::ABL1 fusion gene.; Blood tests can detect the Philadelphia chromosome.; Bone marrow tests can detect the Philadelphia chromosome.; Blood tests assess blood cell abnormalities.; Blood tests can show increased granulocytes.; Blood tests can show abnormal platelet counts.","evidence_relations":"Blood tests and bone marrow tests are used to diagnose CML; Presence of the Ph chromosome or BCR::ABL1 gene is required for CML diagnosis; CML includes diagnostic method: blood test, bone marrow test; CML is characterized by increased white blood cells (granulocytes) and abnormal platelet counts; CML includes biomarkers: BCR::ABL1 fusion gene, Philadelphia chromosome (Ph)"},
	{"id":"Medical-b55db5c0","source":"Medical","question":"Which molecular and cytogenetic features are central to the classification and targeted treatment of CML?","answer":"The central molecular and cytogenetic features for the classification and targeted treatment of chronic myeloid leukemia (CML) are the presence of the BCR::ABL1 fusion gene and the Philadelphia chromosome (Ph), which results from a translocation between chromosomes 9 and 22. The BCR::ABL1 gene produces an abnormal protein that drives uncontrolled cell growth, and its detection is essential for diagnosing CML. Targeted therapies, such as tyrosine kinase inhibitors, are specifically designed to inhibit the activity of the BCR::ABL1 protein, making these molecular and cytogenetic markers critical for both classification and treatment decisions in CML.","question_type":"Contextual Summarize","evidence":"CML classification is based on the detection of the BCR::ABL1 fusion gene.; CML classification is based on the detection of the Philadelphia chromosome.; Targeted treatment for CML aims to inhibit BCR::ABL1 protein activity.","evidence_relations":"CML is caused by the BCR::ABL1 fusion gene; The Philadelphia chromosome (Ph) is the abnormal chromosome 22 resulting from this translocation; Treatment for CML aims to inhibit BCR::ABL1 protein activity; CML includes biomarkers: BCR::ABL1 fusion gene, Philadelphia chromosome (Ph); CML includes treatment: BCR::ABL1 protein inhibition"},
	{"id":"Medical-024ef7a1","source":"Medical","question":"What are the main subtypes of NSCLC and how do their cellular origins differ?","answer":"The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, each arising from different lung cell types including mucus-producing alveolar cells, bronchial lining cells, and large cells throughout the airways.","question_type":"Contextual Summarize","evidence":"The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.; Adenocarcinoma arises from mucus-producing alveolar cells.; Squamous cell carcinoma arises from bronchial lining cells.; Large cell carcinoma arises from large cells throughout the airways.","evidence_relations":"Adenocarcinoma, squamous cell carcinoma, and large cell carcinoma are subtypes of NSCLC; Adenocarcinoma often forms from cells that line the alveoli and make mucus; Squamous cell carcinoma forms from cells that line the bronchi; Large cell carcinoma forms from large cells found throughout the airways; NSCLC is a type of lung carcinoma; NSCLC includes subtypes: adenocarcinoma, squamous cell carcinoma, large cell carcinoma; Adenocarcinoma, squamous cell carcinoma, and large cell carcinoma are classified under NSCLC in the ontology"},
	{"id":"Medical-c0c6b4fb","source":"Medical","question":"What are the stages of NSCLC and how do their characteristics and treatments differ?","answer":"Non-small cell lung cancer (NSCLC) is classified into four main stages based on the extent of disease spread. Stage 1 is considered early-stage NSCLC, where the cancer is confined to the lung and is typically treated with surgery to remove the tumor, and in some cases, radiation therapy if surgery is not possible. Stages 2 and 3 are referred to as locally advanced NSCLC, where the cancer has grown into nearby lung tissue or lymph nodes but has not spread to distant organs. Treatment for these stages often involves a combination of surgery and chemoradiation (chemotherapy plus radiation therapy), depending on the tumor's location and the patient's overall health. Stage 4 NSCLC is metastatic, meaning the cancer has spread to distant organs or tissues at the time of diagnosis. Treatment for stage 4 is generally focused on systemic therapies such as chemotherapy, targeted therapy, or immunotherapy, rather than surgery.","question_type":"Contextual Summarize","evidence":"NSCLC is staged from 1 to 4.; Stage 1 NSCLC is early disease.; Stage 1 NSCLC is treated primarily with surgery or radiation.; Stages 2 and 3 NSCLC are locally advanced.; Stages 2 and 3 NSCLC are treated with surgery and chemoradiation.; Stage 4 NSCLC represents metastatic disease.","evidence_relations":"Stage 1 NSCLC is considered early stage; Stage 2 and Stage 3 NSCLC are considered locally advanced; Stage 4 NSCLC is metastatic at diagnosis; Surgery is a primary treatment for early or locally advanced NSCLC when possible; Radiation therapy is used for some early NSCLC cases; Chemoradiation is used for some locally advanced NSCLC cases; Stage 1: Treatment includes surgery and radiation therapy; Stage 2 and 3: Treatment includes surgery and chemoradiation; Stage 4: Described as metastatic NSCLC in the ontology"},
	{"id":"Medical-3cd90d08","source":"Medical","question":"Which diagnostic methods are used to detect and confirm NSCLC, and how are lung nodules evaluated?","answer":"NSCLC diagnosis involves imaging, biopsy, lung nodule assessment, and lung cancer screening, with lung nodules detected by imaging and further assessed by biopsy or screening to determine malignancy.","question_type":"Contextual Summarize","evidence":"NSCLC diagnosis involves imaging.; NSCLC diagnosis involves biopsy.; NSCLC diagnosis involves lung nodule assessment.; NSCLC diagnosis involves lung cancer screening.; Lung nodules are detected by imaging.; Lung nodules are assessed by biopsy or screening to determine malignancy.","evidence_relations":"Imaging and biopsy are used as diagnostic methods for NSCLC; Lung nodules may be detected by imaging and require further assessment to determine malignancy; Biopsy is used to confirm lung cancer diagnosis; Lung cancer screening is recommended for people at high risk; Lung nodule: Detected by imaging, assessed by biopsy and lung cancer screening; NSCLC: Diagnostic Method includes imaging, biopsy, lung nodule assessment, and lung cancer screening"},
	{"id":"Medical-024819a8","source":"Medical","question":"What are the most significant risk factors for NSCLC according to current biomedical knowledge?","answer":"Major risk factors for NSCLC include tobacco smoking, exposure to second-hand smoke, radon, asbestos, arsenic, various metals, coal smoke, soot, silica, diesel fumes, and air pollution.","question_type":"Contextual Summarize","evidence":"Major risk factors for NSCLC include tobacco smoking.; Major risk factors for NSCLC include exposure to second-hand smoke.; Major risk factors for NSCLC include radon.; Major risk factors for NSCLC include asbestos.; Major risk factors for NSCLC include arsenic.; Major risk factors for NSCLC include various metals.; Major risk factors for NSCLC include coal smoke.; Major risk factors for NSCLC include soot.; Major risk factors for NSCLC include silica.; Major risk factors for NSCLC include diesel fumes.; Major risk factors for NSCLC include air pollution.","evidence_relations":"Tobacco smoking is the biggest risk factor for lung cancer; Exposure to second-hand smoke increases lung cancer risk; Exposure to radon, asbestos, arsenic, beryllium, cadmium, chromium, nickel, coal smoke, soot, silica, diesel fumes, and air pollution are risk factors for lung cancer; NSCLC: Risk Factor includes tobacco smoking, second-hand smoke, radon, asbestos, arsenic, beryllium, cadmium, chromium, nickel, coal smoke, soot, silica, diesel fumes, air pollution; Lung cancer risk factors are explicitly listed in the ontology under NSCLC"},
	{"id":"Medical-3cc76c04","source":"Medical","question":"What symptoms are commonly associated with NSCLC and how are they described?","answer":"Non-small cell lung cancer (NSCLC) commonly presents with respiratory symptoms, most notably a persistent cough and chest pain. Other associated symptoms can include shortness of breath, wheezing, and hemoptysis (coughing up blood). These symptoms arise due to the tumor's effects on the airways and lung tissue. As with other forms of lung cancer, symptoms may vary depending on the tumor's location and extent of disease.","question_type":"Contextual Summarize","evidence":"NSCLC commonly presents with respiratory symptoms.; Common respiratory symptoms of NSCLC include cough.; Common respiratory symptoms of NSCLC include chest pain.; NSCLC may include other related symptoms as part of lung cancer.","evidence_relations":"Symptoms of lung cancer may include cough, chest pain, and other respiratory symptoms; NSCLC: Symptom includes cough and chest pain; Cough and chest pain are listed as symptoms in the ontology for NSCLC; NSCLC is the most common type of lung cancer; Lung cancer symptoms are described as respiratory in nature"},
	{"id":"Medical-df2fbbd7","source":"Medical","question":"What are the primary treatment options for NSCLC at various stages, including supportive and investigational approaches?","answer":"The primary treatment options for non-small cell lung cancer (NSCLC) vary depending on the stage of the disease. For early-stage NSCLC (stage 1), surgery is often the preferred treatment to remove the tumor, provided the patient is a suitable candidate. In some cases where surgery is not possible, radiation therapy may be used as an alternative. For locally advanced NSCLC (stages 2 and 3), treatment may involve a combination of surgery, radiation therapy, and chemoradiation (the use of chemotherapy and radiation together) to improve outcomes. Supportive care is an important component at all stages, aiming to relieve symptoms and improve quality of life, and has been shown to extend and enhance life for people with lung cancer. Additionally, participation in clinical trials is encouraged, as these offer access to investigational therapies and new approaches to treatment. The choice of treatment is individualized based on the patient's overall health, cancer stage, and preferences, and is best determined in collaboration with a multidisciplinary care team.","question_type":"Contextual Summarize","evidence":"Treatment options for NSCLC include surgery.; Treatment options for NSCLC include radiation therapy.; Treatment options for NSCLC include chemoradiation.; Treatment options for NSCLC depend on the stage.; Supportive care is a treatment option for NSCLC.; Participation in clinical trials is a treatment option for NSCLC.","evidence_relations":"Surgery is a primary treatment for early or locally advanced NSCLC when possible; Radiation therapy is used for some early NSCLC cases; Chemoradiation is used for some locally advanced NSCLC cases; Supportive care extends and enhances life for people with lung cancer; Clinical trials are available for lung cancer treatment and prevention; NSCLC: Treatment includes surgery, radiation therapy, chemoradiation, supportive care, clinical trial"},
	{"id":"Medical-2fcaf5ff","source":"Medical","question":"How is lung cancer screening utilized for NSCLC, and who is recommended to undergo screening?","answer":"Lung cancer screening is primarily utilized to detect non-small cell lung cancer (NSCLC) at an early, more treatable stage, often before symptoms develop. Screening is not recommended for everyone, but is specifically advised for individuals at high risk for lung cancer, based on factors such as age, smoking history, and other risk factors. The screening process typically involves imaging studies, such as low-dose computed tomography (CT) scans, to identify lung nodules or other abnormalities. Early detection through screening increases the likelihood of successful treatment. Individuals should discuss their risk factors and eligibility for lung cancer screening with their healthcare provider to determine if screening is appropriate for them.","question_type":"Contextual Summarize","evidence":"Lung cancer screening is recommended for high-risk individuals.; Lung cancer screening aims to detect NSCLC at an early stage.; Lung cancer screening uses imaging.; Lung cancer screening involves assessment of lung nodules.","evidence_relations":"Lung cancer screening is recommended for people at high risk; Lung cancer screening aims to detect cancer at an early, more treatable stage; Lung nodule: Detected by imaging, assessed by lung cancer screening; Screening: Indication is high risk individuals, purpose is early detection; NSCLC: Diagnostic Method includes lung cancer screening"},
	{"id":"Medical-bbb1e0c6","source":"Medical","question":"What strategies are recommended for follow-up and surveillance after NSCLC treatment?","answer":"After treatment for non-small cell lung cancer (NSCLC), follow-up care and surveillance are essential to monitor for cancer recurrence and address ongoing health needs. Recommended strategies include regular physical examinations, assessment for new or worsening symptoms, and periodic imaging studies as indicated. The frequency and type of follow-up may vary based on individual risk factors and the stage of cancer at diagnosis. Surveillance aims to detect recurrence early and to manage any late effects of treatment, and may also include consideration of clinical trial participation during the follow-up phase.","question_type":"Contextual Summarize","evidence":"Follow-up care is planned after NSCLC treatment.; Surveillance is planned after NSCLC treatment.; Follow-up care monitors for recurrence.; Surveillance manages ongoing health needs.","evidence_relations":"Follow-up care is planned after treatment and includes surveillance for recurrence; NSCLC: Follow-up Strategy includes follow-up care and surveillance; Follow-up care is included in the ontology under NSCLC; Surveillance is part of post-treatment strategy for NSCLC; Clinical trials may also be available in the follow-up phase"},
	{"id":"Medical-31427bc6","source":"Medical","question":"How does the progression from early to advanced stages of NSCLC affect treatment approaches?","answer":"Early and locally advanced NSCLC, which have not spread beyond the lung, are often treated with surgery and radiation or chemoradiation, while metastatic (Stage 4) NSCLC has different management strategies.","question_type":"Contextual Summarize","evidence":"Early and locally advanced NSCLC have not spread beyond the lung.; Early and locally advanced NSCLC are often treated with surgery.; Early and locally advanced NSCLC are often treated with radiation.; Early and locally advanced NSCLC are often treated with chemoradiation.; Metastatic (Stage 4) NSCLC has different management strategies.","evidence_relations":"Early and locally advanced NSCLC have not spread to the tissue lining around the lung or to other organs at diagnosis; Surgery is a primary treatment for early or locally advanced NSCLC when possible; Radiation therapy is used for some early NSCLC cases; Chemoradiation is used for some locally advanced NSCLC cases; Stage 4 NSCLC is metastatic at diagnosis; Stage 1: Treatment includes surgery and radiation therapy; Stage 2 and 3: Treatment includes surgery and chemoradiation"},
	{"id":"Medical-0c1ef334","source":"Medical","question":"What is the role of lung nodules in the detection and diagnosis of NSCLC?","answer":"Lung nodules play a critical role in the detection and diagnosis of non-small cell lung cancer (NSCLC). These small masses of tissue in the lungs are often first identified through imaging studies such as chest X-rays or CT scans. While most lung nodules are benign and may result from infections, scar tissue, or other non-cancerous conditions, some can be malignant and indicative of NSCLC. To determine the nature of a lung nodule, a multidisciplinary teamincluding pulmonologists, thoracic radiologists, and thoracic surgeonswill assess the patient's risk factors, review imaging findings, and may recommend additional imaging or a biopsy. Biopsy of the nodule is essential to confirm malignancy and establish a definitive diagnosis of NSCLC. Early detection and accurate diagnosis of malignant lung nodules are crucial for timely treatment planning and improved outcomes.","question_type":"Contextual Summarize","evidence":"Lung nodules are detected by imaging.; Lung nodules are assessed by biopsy.; Lung nodules are assessed by lung cancer screening.; Lung nodules are evaluated to determine if they are malignant.; Malignant lung nodules may indicate NSCLC.","evidence_relations":"Lung nodules may be detected by imaging and require further assessment to determine malignancy; Lung nodule: Detected by imaging; Lung nodule: Assessed by biopsy and lung cancer screening; Biopsy is used to confirm lung cancer diagnosis; Imaging is a diagnostic method for NSCLC"},
	{"id":"Medical-611836a0","source":"Medical","question":"What are the major diagnostic methods and biomarkers used in nasopharyngeal carcinoma (NPC)?","answer":"Diagnosis of NPC involves medical history, physical exam, imaging modalities such as CT, MRI, PET/CT, and ultrasound, as well as biopsy, with biomarker testing including EBV DNA, MSI-H/dMMR, PD-L1, HPV, and tumor mutational burden.","question_type":"Contextual Summarize","evidence":"Diagnosis of NPC involves medical history.; Diagnosis of NPC involves a physical exam.; Diagnosis of NPC involves imaging modalities.; Imaging modalities for NPC include CT.; Imaging modalities for NPC include MRI.; Imaging modalities for NPC include PET/CT.; Imaging modalities for NPC include ultrasound.; Diagnosis of NPC involves biopsy.; Biomarker testing for NPC includes EBV DNA.; Biomarker testing for NPC includes MSI-H/dMMR.; Biomarker testing for NPC includes PD-L1.; Biomarker testing for NPC includes HPV.; Biomarker testing for NPC includes tumor mutational burden.","evidence_relations":"Diagnosis of NPC involves medical history, physical exam, imaging (CT, MRI, PET/CT, ultrasound), and biopsy; Biomarker testing for NPC includes EBV DNA, MSI-H/dMMR, PD-L1, HPV, and tumor mutational burden; Imaging tests such as CT, MRI, PET/CT, and ultrasound are used for staging and surveillance; Biopsy confirms diagnosis and determines cancer subtype; EBV DNA testing is performed before and after treatment for NPC; NPC Diagnostic Method includes: Medical history, Physical exam, Imaging, Biopsy; NPC Biomarker includes: EBV DNA, MSI-H/dMMR, PD-L1, HPV, Tumor mutational burden (TMB)"},
	{"id":"Medical-e168b4d3","source":"Medical","question":"Which risk factors and geographic regions are most associated with nasopharyngeal carcinoma (NPC)?","answer":"Nasopharyngeal carcinoma (NPC) is most commonly associated with infection by the Epstein-Barr virus (EBV), which is a major risk factor for the development of this cancer. Additional risk factors include tobacco use and alcohol consumption, which are known to increase the risk of head and neck cancers, including NPC. Geographically, NPC occurs more frequently in individuals from certain regions, particularly parts of Asia (such as southern China), Native American populations, and North Africa. These populations have a higher incidence of NPC compared to other regions, likely due to a combination of genetic, environmental, and viral factors.","question_type":"Contextual Summarize","evidence":"NPC is most often associated with Epstein-Barr virus infection.; NPC is associated with tobacco use.; NPC is associated with alcohol use.; NPC occurs more frequently in people from Asia.; NPC occurs more frequently in Native Americans.; NPC occurs more frequently in people from North Africa.","evidence_relations":"Most NPCs are related to Epstein-Barr virus (EBV) infection; Tobacco and alcohol use are risk factors for head and neck cancer; NPC most often occurs in people from parts of Asia, Native America, and North Africa; Risk Factor includes: Epstein-Barr virus (EBV), Tobacco use, Alcohol use, Geographic origin (Asia, Native America, North Africa); Nasopharyngeal carcinoma (NPC) is a type of head and neck cancer that affects the nasopharynx"},
	{"id":"Medical-9f34bb0a","source":"Medical","question":"How is nasopharyngeal carcinoma (NPC) staged and what are the key classification systems used?","answer":"NPC is staged using the AJCC TNM system, which evaluates tumor size, lymph node involvement, and distant metastasis, and is also classified into numbered stages (0IV) and categories such as resectable, unresectable, locoregional, locally advanced, or metastatic.","question_type":"Contextual Summarize","evidence":"NPC is staged using the AJCC TNM system.; The AJCC TNM system evaluates tumor size.; The AJCC TNM system evaluates lymph node involvement.; The AJCC TNM system evaluates distant metastasis.; NPC is classified into numbered stages from 0 to IV.; NPC is classified into categories such as resectable.; NPC is classified into categories such as unresectable.; NPC is classified into categories such as locoregional.; NPC is classified into categories such as locally advanced.; NPC is classified into categories such as metastatic.","evidence_relations":"NPC is staged using the AJCC TNM system, which includes tumor size (T), lymph node involvement (N), and distant metastasis (M); NPC can be classified as resectable, unresectable, locoregional, locally advanced, or metastatic based on extent of disease; AJCC TNM system includes T0, Tis, T1, T2; Numbered Stages include: Stage 0, Stage I, Stage II, Stage III, Stage IV; Classification includes: Resectable, Unresectable, Locoregional, Locally advanced, Metastatic"},
	{"id":"Medical-69e0dbc6","source":"Medical","question":"What are the most common symptoms and metastatic sites of nasopharyngeal carcinoma (NPC)?","answer":"Nasopharyngeal carcinoma (NPC) most commonly presents with symptoms such as enlarged lymph nodes in the neck and hearing loss. However, symptoms may be absent or nonspecific until the disease reaches an advanced stage, making early detection challenging. Other possible symptoms can include nasal congestion, nosebleeds, or symptoms similar to other less serious conditions. The most common sites of metastasis for NPC are the lymph nodes in the neck, while distant metastasis occurs less frequently, most often involving the lungs.","question_type":"Contextual Summarize","evidence":"NPC often presents with enlarged lymph nodes.; NPC often presents with hearing loss.; Symptoms of NPC may be absent until advanced stages.; NPC commonly metastasizes to neck lymph nodes.; NPC less frequently metastasizes to the lungs.","evidence_relations":"Symptoms of NPC may be absent until advanced stage and can be similar to other conditions; NPC commonly spreads to lymph nodes in the neck and less frequently to the lungs; Symptom includes: Enlarged lymph nodes, Hearing loss, Symptoms may be absent until advanced stage; Metastasis includes: Lymph node, Lung; Nasopharyngeal carcinoma (NPC) is a type of head and neck cancer that affects the nasopharynx"},
	{"id":"Medical-6c6ace8b","source":"Medical","question":"How is treatment for nasopharyngeal carcinoma (NPC) planned and what factors are considered?","answer":"NPC treatment planning is based on results from imaging, biopsy, and biomarker testing, with consideration of performance status and potential impact on fertility.","question_type":"Contextual Summarize","evidence":"NPC treatment planning is based on imaging results.; NPC treatment planning is based on biopsy results.; NPC treatment planning is based on biomarker testing results.; Performance status is considered in NPC treatment planning.; Potential impact on fertility is considered in NPC treatment planning.","evidence_relations":"Treatment planning for NPC is based on test results including imaging, biopsy, and biomarker testing; Performance status is considered in NPC treatment planning; Fertility may be affected by NPC treatment and should be discussed before therapy; Diagnostic Method includes: Imaging, Biopsy, Biomarker testing; Fertility counseling is part of diagnostic and treatment considerations"},
	{"id":"Medical-7b4b0aa6","source":"Medical","question":"Which biomarkers are used for surveillance and prognosis in nasopharyngeal carcinoma (NPC)?","answer":"EBV DNA levels are used both for surveillance and as a prognostic factor in NPC, with additional biomarker testing for MSI-H/dMMR, PD-L1, HPV, and tumor mutational burden.","question_type":"Contextual Summarize","evidence":"EBV DNA levels are used for surveillance in NPC.; EBV DNA levels are used as a prognostic factor in NPC.; Additional biomarker testing for NPC includes MSI-H/dMMR.; Additional biomarker testing for NPC includes PD-L1.; Additional biomarker testing for NPC includes HPV.; Additional biomarker testing for NPC includes tumor mutational burden.","evidence_relations":"EBV DNA testing is performed before and after treatment for NPC; Biomarker testing for NPC includes EBV DNA, MSI-H/dMMR, PD-L1, HPV, and tumor mutational burden; Surveillance includes: Imaging tests, EBV DNA testing; Prognostic Factor includes: EBV DNA level; NPC Biomarker includes: EBV DNA, MSI-H/dMMR, PD-L1, HPV, Tumor mutational burden (TMB)"},
	{"id":"Medical-9712745d","source":"Medical","question":"What are the main cancer subtypes and anatomical sites involved in nasopharyngeal carcinoma (NPC)?","answer":"Nasopharyngeal carcinoma (NPC) is a type of head and neck cancer that specifically arises in the nasopharynx, which is the upper part of the throat located behind the nose and above the back of the mouth. The most common histological subtype of NPC is squamous cell carcinoma, which originates from the thin, flat cells lining the mucous membranes of the nasopharynx. While the nasopharynx is the primary anatomical site involved, NPC can also spread to nearby tissues and lymph nodes in the neck.","question_type":"Contextual Summarize","evidence":"NPC is a subtype of head and neck cancer.; NPC arises in the nasopharynx.; Squamous cell carcinoma is the most common histological subtype of NPC.","evidence_relations":"Nasopharyngeal carcinoma (NPC) is a type of head and neck cancer that affects the nasopharynx; Squamous cell carcinoma (SCC) is the most common subtype of nasopharyngeal cancer; Anatomical Site includes: Pharynx, Nasopharynx; Cancer Subtype includes: Nasopharyngeal carcinoma (NPC), Squamous cell carcinoma (SCC); Head and neck cancer includes anatomical sites such as the nasopharynx"},
	{"id":"Medical-0ae62420","source":"Medical","question":"What assessments and counseling are recommended for patients with nasopharyngeal carcinoma (NPC) prior to treatment?","answer":"Before starting treatment, patients with nasopharyngeal carcinoma (NPC) should receive comprehensive assessments and counseling, including dental evaluation (as head and neck cancer and its treatment can affect oral health), nutrition assessment (to ensure adequate and sustained nutrition), and speech and swallowing assessment (to evaluate and address potential difficulties that may arise from the tumor or its treatment). Additionally, performance status evaluation is important to determine the patient's general fitness and ability to perform daily activities, which can influence treatment planning. Fertility counseling is also recommended, as treatments such as chemotherapy and radiation can impact fertility; patients interested in future fertility should be referred to a specialist to discuss preservation options. Other assessments that may be considered include eye exams, endocrine (hormone) tests, and hearing tests, depending on individual risk factors and planned therapies.","question_type":"Contextual Summarize","evidence":"Patients with NPC should undergo dental assessments.; Patients with NPC should undergo nutrition assessments.; Patients with NPC should undergo speech and swallowing assessments.; Patients with NPC should receive fertility counseling.; Patients with NPC should have performance status evaluated before treatment.","evidence_relations":"Dental health can be affected by head and neck cancer and its treatment; Nutrition assessment and speech and swallowing assessment are part of diagnostic methods; Performance status evaluation is included in diagnostic methods; Fertility counseling is recommended before therapy; Diagnostic Method includes: Dental exam, Nutrition assessment, Speech and swallowing assessment, Performance status evaluation, Fertility counseling"},
	{"id":"Medical-35e77a1a","source":"Medical","question":"How does performance status influence the management and prognosis of nasopharyngeal carcinoma (NPC)?","answer":"Performance status is a critical factor in the management and prognosis of nasopharyngeal carcinoma (NPC). It is routinely evaluated as part of the diagnostic process and helps determine a patient's general level of fitness and ability to perform daily self-care tasks. This assessment influences treatment planning by guiding the selection and intensity of therapies that a patient can safely tolerate. Additionally, performance status serves as an important prognostic factor, as patients with better performance status generally have improved treatment outcomes and survival rates. Alongside other factors such as tumor stage and EBV DNA levels, performance status is used to predict prognosis and tailor individualized treatment strategies for NPC.","question_type":"Contextual Summarize","evidence":"Performance status is a key consideration in nasopharyngeal carcinoma treatment planning.; Performance status serves as a prognostic factor in nasopharyngeal carcinoma.; Performance status influences management decisions in nasopharyngeal carcinoma.; Performance status influences expected outcomes in nasopharyngeal carcinoma.","evidence_relations":"Performance status is considered in NPC treatment planning; Prognostic Factor includes: Performance status; Performance status evaluation is part of diagnostic methods; Treatment planning for NPC is based on test results including imaging, biopsy, and biomarker testing, and performance status; NPC Prognostic Factor includes: EBV DNA level, Performance status"},
	{"id":"Medical-97ddb491","source":"Medical","question":"What are the main diagnostic methods and surveillance strategies for colon cancer?","answer":"Colon cancer diagnosis relies on colonoscopy with polypectomy, blood tests including CBC, CMP, and CEA, as well as imaging with CT scan and MRI, while post-treatment surveillance includes colonoscopy, CEA testing, CT scans, and physical exams.","question_type":"Contextual Summarize","evidence":"Colon cancer diagnosis relies on colonoscopy with polypectomy.; Blood tests including CBC, CMP, and CEA are used for colon cancer diagnosis.; Imaging with CT scan and MRI is used for colon cancer diagnosis.; Post-treatment surveillance for colon cancer includes colonoscopy.; Post-treatment surveillance for colon cancer includes CEA testing.; Post-treatment surveillance for colon cancer includes CT scans.; Post-treatment surveillance for colon cancer includes physical exams.","evidence_relations":"Colonoscopy with polypectomy is a diagnostic method for colon cancer; Blood tests (CBC, chemistry profile, CEA) are recommended for initial testing; CT with contrast is the main imaging test for staging and surveillance; MRI may be used for further evaluation of liver or rectum; Surveillance after treatment includes colonoscopy, CEA testing, and CT scans; Physical exam is included in surveillance strategies; ctDNA testing is investigational and recommended only in clinical trials"},
	{"id":"Medical-fe85502c","source":"Medical","question":"How do genetic alterations and inherited syndromes influence colon cancer risk and management?","answer":"Genetic alterations, particularly mutations in mismatch repair (MMR) genes, and inherited syndromes such as Lynch syndrome and familial adenomatous polyposis (FAP), significantly increase the risk of developing colon cancer. Lynch syndrome, caused by inherited mutations in MMR genes, predisposes individuals to colon, endometrial, and ovarian cancers, while FAP leads to the formation of hundreds to thousands of polyps in the colon and rectum, often resulting in cancer by age 50. Because of these risks, all colon cancers should be tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H), which are important biomarkers that can guide treatment decisions, including the use of immunotherapy. If dMMR/MSI-H is detected, further testing for inherited syndromes like Lynch syndrome is recommended, and referral to a genetic counselor may be appropriate for genetic testing and family risk assessment.","question_type":"Contextual Summarize","evidence":"Genetic alterations such as MMR gene mutations increase colon cancer risk.; Inherited syndromes like Lynch syndrome increase colon cancer risk.; Inherited syndromes like FAP increase colon cancer risk.; Biomarker testing for dMMR/MSI-H is necessary to guide immunotherapy decisions.","evidence_relations":"Lynch syndrome and familial adenomatous polyposis (FAP) are inherited syndromes increasing colon cancer risk; First-degree relative with colorectal cancer is a risk factor; All colon cancers should be tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H); MMR gene mutations are a genetic alteration in colon cancer; dMMR/MSI-H is a biomarker guiding immunotherapy; Inherited syndromes include Lynch syndrome and FAP; Attenuated FAP is a subtype of FAP"},
	{"id":"Medical-8644244f","source":"Medical","question":"What are the stages of colon cancer and their key characteristics according to the AJCC TNM system?","answer":"According to the AJCC TNM system, colon cancer is staged as follows: Stage 0 (carcinoma in situ) involves abnormal cells confined to the innermost mucosal layer of the colon wall. Stage 1 is characterized by cancer invading the second or third layer of the colon wall (submucosa or muscularis propria) without lymph node involvement. Stage 2 cancer has grown into or beyond the fourth layer (serosa or adventitia) but still shows no spread to lymph nodes or distant sites. Stage 3 indicates the cancer has spread to nearby lymph nodes or there are tumor deposits in the fat surrounding the colon, but not to distant organs. Stage 4 is defined by metastasis to distant organs, most commonly the liver or lungs. The TNM system uses tumor depth (T), lymph node involvement (N), and presence of metastasis (M) to assign these stages.","question_type":"Contextual Summarize","evidence":"Colon cancer stages progress from carcinoma in situ (Stage 0).; Stage 1 of colon cancer involves invasion of the colon wall without lymph node involvement.; Stage 2 of colon cancer involves invasion of the colon wall without lymph node involvement.; Stage 3 of colon cancer involves spread to nearby lymph nodes or tumor deposits.; Stage 4 of colon cancer involves distant organ metastasis.; Common sites for distant organ metastasis in colon cancer are the liver and lungs.","evidence_relations":"AJCC TNM system is used to stage colon cancer; Stage 0 colon cancer is carcinoma in situ; Stage 1 colon cancer invades second or third layer of colon wall, no lymph node involvement; Stage 2 colon cancer invades or passes fourth layer, no lymph node involvement; Stage 3 colon cancer involves spread to nearby lymph nodes or tumor deposits; Stage 4 colon cancer has spread to distant organs (commonly liver or lungs); Stage descriptions are provided in the ontology"},
	{"id":"Medical-c2a36052","source":"Medical","question":"How do biomarkers influence treatment selection in colon cancer?","answer":"Biomarker testing for dMMR/MSI-H guides the use of immunotherapy with checkpoint inhibitors, while pMMR/MSS cancers are treated with chemotherapy and CEA is used for disease monitoring.","question_type":"Contextual Summarize","evidence":"Biomarker testing for dMMR/MSI-H guides the use of immunotherapy with checkpoint inhibitors.; pMMR/MSS cancers are treated with chemotherapy.; CEA is used for disease monitoring in colon cancer.","evidence_relations":"All colon cancers should be tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H); dMMR/MSI-H is a biomarker guiding immunotherapy; Immunotherapy with checkpoint inhibitors is preferred for dMMR/MSI-H cancers; pMMR/MSS cancers are treated with chemotherapy; CEA is a biomarker for monitoring colon cancer; Biomarker ontology includes dMMR, MSI-H, pMMR, MSS, CEA, and ctDNA"},
	{"id":"Medical-8cb461ed","source":"Medical","question":"What are the main types of surgical and non-surgical treatments available for colon cancer?","answer":"The main types of treatments for colon cancer include both surgical and non-surgical approaches. Surgical treatments involve procedures such as polypectomy, which removes polyps during colonoscopy and is often sufficient for early-stage or malignant polyps; colectomy, which is the surgical removal of the cancerous portion of the colon and is standard for non-metastatic colon cancer; and colostomy, which diverts stool through an abdominal stoma if reconnection of the colon is not possible. Non-surgical treatments include chemotherapy, which is typically recommended after colectomy for all stage 3 and some stage 2 colon cancers, and is administered in cycles to target cancer cells throughout the body. Immunotherapy with checkpoint inhibitors, such as pembrolizumab or nivolumab (with or without ipilimumab), is preferred for patients whose tumors have mismatch repair deficiency (dMMR) or high microsatellite instability (MSI-H). In certain cases, radiation therapy may also be used, particularly for unresectable cancers. Treatment selection is guided by tumor stage, biomarker status, and individual patient factors.","question_type":"Contextual Summarize","evidence":"Colon cancer treatments include surgical procedures such as polypectomy.; Colon cancer treatments include surgical procedures such as colectomy.; Colon cancer treatments include surgical procedures such as colostomy.; Colon cancer treatments include chemotherapy regimens.; Colon cancer treatments include immunotherapy with checkpoint inhibitors for biomarker-selected patients.","evidence_relations":"Polypectomy removes polyps during colonoscopy; Colectomy is surgery to remove the cancerous part of the colon; Colostomy diverts stool through an abdominal stoma if reconnection is not possible; Chemotherapy is recommended after colectomy for all stage 3 and some stage 2 colon cancers; Immunotherapy with checkpoint inhibitors is preferred for dMMR/MSI-H cancers; Treatment ontology includes surgical procedures, chemotherapy, and immunotherapy"},
	{"id":"Medical-60b3092a","source":"Medical","question":"What are the origins and most common subtypes of colon cancer?","answer":"Most colon cancers originate from adenomas, with adenocarcinoma being the most common subtype, while hyperplastic and inflammatory polyps rarely progress to cancer.","question_type":"Contextual Summarize","evidence":"Most colon cancers originate from adenomas.; Adenocarcinoma is the most common subtype of colon cancer.; Hyperplastic polyps rarely progress to cancer.; Inflammatory polyps rarely progress to cancer.","evidence_relations":"Most colon cancers start in polyps, especially adenomas; Adenocarcinoma is the most common subtype of colon cancer; Adenomas can become invasive colon cancer over many years; Adenocarcinoma arises from adenomas; Hyperplastic and inflammatory polyps rarely become cancer; Origin ontology lists adenoma, hyperplastic polyp, and inflammatory polyp"},
	{"id":"Medical-83b86188","source":"Medical","question":"What risk factors and inherited conditions are associated with increased colon cancer risk?","answer":"Risk factors for colon cancer include having a first-degree relative (such as a parent, sibling, or child) with colorectal cancer, which increases an individual's risk compared to the general population. Inherited cancer syndromes are also significant risk factors, particularly Lynch syndrome (caused by inherited mutations in mismatch repair genes) and familial adenomatous polyposis (FAP), including its attenuated form. Lynch syndrome is associated with a high risk of developing colon, endometrial, and ovarian cancers, while FAP leads to the development of numerous polyps in the colon and rectum, which can progress to invasive colon cancer, often by age 50 in classic FAP. Attenuated FAP presents with fewer polyps and typically develops later in life. Identification of these inherited conditions may involve genetic counseling and testing for gene mutations.","question_type":"Contextual Summarize","evidence":"Risk factors for colon cancer include having a first-degree relative with colorectal cancer.; Inherited syndromes such as Lynch syndrome are associated with increased colon cancer risk.; Inherited syndromes such as FAP are associated with increased colon cancer risk.; The attenuated form of FAP is associated with increased colon cancer risk.","evidence_relations":"Family history of colorectal cancer is a risk factor; First-degree relative with colorectal cancer is a risk factor; Lynch syndrome and familial adenomatous polyposis (FAP) are inherited syndromes increasing colon cancer risk; Inherited syndromes include Lynch syndrome, FAP, and attenuated FAP; Risk factor ontology includes first-degree relative and inherited syndromes"},
	{"id":"Medical-01f95b27","source":"Medical","question":"What are the recommended fertility preservation options for young adults undergoing colon cancer treatment?","answer":"Young adults should be counseled about fertility risks and offered options such as sperm banking, egg freezing, and ovarian tissue banking before colon cancer treatment.","question_type":"Contextual Summarize","evidence":"Young adults should be counseled about fertility risks before colon cancer treatment.; Young adults should be offered sperm banking as a fertility preservation option.; Young adults should be offered egg freezing as a fertility preservation option.; Young adults should be offered ovarian tissue banking as a fertility preservation option.","evidence_relations":"Young adults should be counseled about fertility risks and preservation options before treatment; Fertility Preservation ontology includes sperm banking, egg freezing, and ovarian tissue banking; Fertility preservation is recommended prior to treatment; Ovarian tissue banking is listed as a method for fertility preservation; Sperm banking and egg freezing are available options"},
	{"id":"Medical-67b7cadd","source":"Medical","question":"How is chemotherapy utilized in the management of colon cancer across different stages?","answer":"Chemotherapy is utilized in the management of colon cancer based on the stage of disease. For stage 1 colon cancer, chemotherapy is not recommended after colectomy. In stage 2, chemotherapy is generally not recommended after surgery for most dMMR/MSI-H cancers, but may be considered for some high-risk cases, particularly in pMMR/MSS cancers with features suggesting a higher risk of recurrence. In these cases, regimens such as capecitabine, 5-fluorouracil (5-FU) with leucovorin, FOLFOX, or CAPEOX may be used, with the duration and choice of regimen depending on risk factors. For all stage 3 colon cancers, which involve spread to nearby lymph nodes or tumor deposits, chemotherapy is recommended after colectomy, with preferred regimens including CAPEOX and FOLFOX, and other options such as capecitabine and 5-FU. Chemotherapy is typically administered in cycles over 3 to 6 months. In stage 4 disease, where the cancer has spread to distant organs, chemotherapy (sometimes combined with immunotherapy for certain molecular subtypes) may be given before or after surgery, or as the primary treatment if surgery is not feasible. Chemotherapy is usually given intravenously and works systemically to target cancer cells throughout the body.","question_type":"Contextual Summarize","evidence":"Chemotherapy is recommended after colectomy for all stage 3 colon cancers.; Chemotherapy is recommended after colectomy for some stage 2 colon cancers.; Chemotherapy regimens for colon cancer include capecitabine.; Chemotherapy regimens for colon cancer include 5-fluorouracil.; Chemotherapy regimens for colon cancer include leucovorin.; Chemotherapy regimens for colon cancer include FOLFOX.; Chemotherapy regimens for colon cancer include CAPEOX.","evidence_relations":"Chemotherapy is recommended after colectomy for all stage 3 and some stage 2 colon cancers; Chemotherapy regimens include capecitabine, 5-fluorouracil (5-FU), leucovorin, FOLFOX, and CAPEOX; Colectomy is surgery to remove the cancerous part of the colon; Stage 3 colon cancer involves spread to nearby lymph nodes or tumor deposits; Stage 2 colon cancer invades or passes fourth layer, no lymph node involvement; Chemotherapy is a treatment modality listed in the ontology"},
	{"id":"Medical-18b6cbc6","source":"Medical","question":"What are the main cancer subtypes of esophageal cancer and their typical anatomical locations?","answer":"The primary subtypes of esophageal cancer are esophageal squamous cell carcinoma, which occurs in the upper, middle, and lower esophagus, and esophageal adenocarcinoma, which typically arises in the lower and middle esophagus.","question_type":"Contextual Summarize","evidence":"The primary subtypes of esophageal cancer are esophageal squamous cell carcinoma and esophageal adenocarcinoma.; Esophageal squamous cell carcinoma occurs in the upper esophagus.; Esophageal squamous cell carcinoma occurs in the middle esophagus.; Esophageal squamous cell carcinoma occurs in the lower esophagus.; Esophageal adenocarcinoma typically arises in the lower esophagus.; Esophageal adenocarcinoma typically arises in the middle esophagus.","evidence_relations":"Esophageal squamous cell carcinoma starts in squamous cells of the esophagus; Esophageal adenocarcinoma starts in mucus-secreting cells of the esophagus; Esophageal squamous cell carcinoma: Anatomical Location: Upper esophagus, Middle esophagus, Lower esophagus; Esophageal adenocarcinoma: Anatomical Location: Lower esophagus, Middle esophagus; Cancer Subtype: Esophageal squamous cell carcinoma and Esophageal adenocarcinoma are both subtypes of esophageal cancer"},
	{"id":"Medical-296c7595","source":"Medical","question":"How are the stages of esophageal cancer defined and what are their distinguishing features?","answer":"The stages of esophageal cancer are defined based on how far the cancer has spread. Early-stage esophageal cancer is confined to the inside of the esophagus and has not spread to lymph nodes; the tumor is often small and limited to the mucosa or submucosa. Locoregional (or locally advanced) esophageal cancer has invaded deeper layers of the esophagus wall and/or has spread to nearby lymph nodes or adjacent organs in direct contact with the esophagus. Metastatic esophageal cancer has spread to distant organs, most commonly the liver, distant lymph nodes, lung, bone, and brain. These stages help guide treatment decisions and prognosis.","question_type":"Contextual Summarize","evidence":"Esophageal cancer stages include early-stage.; Early-stage esophageal cancer is confined to the esophagus.; Early-stage esophageal cancer is not in lymph nodes.; Esophageal cancer stages include locoregional.; Locoregional esophageal cancer invades the esophagus wall.; Locoregional esophageal cancer may involve nearby lymph nodes or organs.; Esophageal cancer stages include metastatic.; Metastatic esophageal cancer spreads to distant organs.","evidence_relations":"Early-stage esophageal cancer is contained within the esophagus and not in lymph nodes; Locoregional esophageal cancer has invaded the esophagus wall and/or spread to nearby lymph nodes or organs; Metastatic esophageal cancer has spread to distant organs such as liver, lung, bone, and brain; Disease Stage: Early-stage: Definition: Contained within esophagus, not in lymph nodes; Disease Stage: Metastatic: Definition: Spread to distant organs, Metastatic Site: Liver, Lung, Bone, Brain, Distant lymph nodes"},
	{"id":"Medical-e8019816","source":"Medical","question":"What diagnostic methods are commonly used for esophageal cancer and what aspects of the disease do they assess?","answer":"Diagnosis of esophageal cancer involves blood tests, imaging tests, endoscopy, biopsy, biomarker testing, genetic risk testing, nutritional assessment, and evaluation of performance status, each contributing to the assessment of disease presence, subtype, risk, and patient condition.","question_type":"Contextual Summarize","evidence":"Diagnosis of esophageal cancer involves blood tests.; Diagnosis of esophageal cancer involves imaging tests.; Diagnosis of esophageal cancer involves endoscopy.; Diagnosis of esophageal cancer involves biopsy.; Diagnosis of esophageal cancer involves biomarker testing.; Diagnosis of esophageal cancer involves genetic risk testing.; Diagnosis of esophageal cancer involves nutritional assessment.; Diagnosis of esophageal cancer involves evaluation of performance status.; These diagnostic methods assess disease presence, subtype, risk, and patient condition.","evidence_relations":"Diagnosis involves blood tests, imaging tests, endoscopy, biopsy, biomarker testing, and genetic risk testing; Diagnostic Method: Blood tests, Imaging tests, Endoscopy, Biopsy, Biomarker testing, Genetic risk testing, Nutritional assessment, Performance status; Biopsy is a diagnostic method for esophageal cancer; Endoscopy is a diagnostic method for esophageal cancer; Nutritional assessment and performance status are included as diagnostic methods in the ontology"},
	{"id":"Medical-733f63f7","source":"Medical","question":"How does Barrett esophagus relate to esophageal adenocarcinoma in terms of risk and classification?","answer":"Barrett esophagus is classified as a precancerous condition in which the normal squamous cells lining the lower esophagus are replaced with abnormal, intestinal-type cells due to chronic reflux. This cellular change significantly increases the risk of developing esophageal adenocarcinoma. In clinical and oncological classification systems, Barrett esophagus is recognized as a key risk factor and precursor lesion for esophageal adenocarcinoma, highlighting its importance in both risk assessment and early detection strategies for this type of cancer.","question_type":"Contextual Summarize","evidence":"Barrett esophagus is classified as a precancerous condition.; Barrett esophagus is a recognized risk factor for esophageal adenocarcinoma.; Barrett esophagus increases the likelihood of developing esophageal adenocarcinoma.","evidence_relations":"Barrett esophagus is a precancerous condition that increases risk for esophageal adenocarcinoma; Precancerous Condition: Barrett esophagus; Esophageal adenocarcinoma: Risk Factor: Barrett esophagus; Barrett esophagus is included as a risk factor in the ontology for esophageal adenocarcinoma; Barrett esophagus is listed as a precancerous condition in the ontology for esophageal cancer"},
	{"id":"Medical-2ab4a26d","source":"Medical","question":"What factors are considered in treatment planning for esophageal cancer according to the knowledge base?","answer":"Treatment planning for esophageal cancer takes into account several critical factors, including the histological type of cancer (such as adenocarcinoma or squamous cell carcinoma), the anatomical location of the tumor within the esophagus or at the esophagogastric junction, the stage of the disease (extent of tumor spread), and, specifically for tumors at the esophagogastric junction, the Siewert classification, which describes the tumor's position relative to the esophagus and stomach. These factors guide decisions regarding the most appropriate therapeutic approach and staging.","question_type":"Contextual Summarize","evidence":"Treatment planning for esophageal cancer is based on cancer type.; Treatment planning for esophageal cancer is based on anatomical location.; Treatment planning for esophageal cancer is based on disease stage.; Treatment planning for esophageal cancer considers Siewert types for tumors at the esophagogastric junction.","evidence_relations":"Treatment planning is based on cancer type, location, and stage; Siewert types are used to stage tumors at the esophagogastric junction; Treatment Planning: Based on: Cancer type, Location, Stage, Siewert types (for EGJ tumors); Anatomical Location: Esophagus, Esophagogastric junction; The ontology lists Siewert types as relevant for tumors at the esophagogastric junction in treatment planning"},
	{"id":"Medical-78a99b6b","source":"Medical","question":"Which metastatic sites are commonly involved in advanced esophageal cancer?","answer":"Metastatic esophageal cancer commonly spreads to distant organs including the liver, lung, bone, brain, and distant lymph nodes.","question_type":"Contextual Summarize","evidence":"Metastatic esophageal cancer commonly spreads to the liver.; Metastatic esophageal cancer commonly spreads to the lung.; Metastatic esophageal cancer commonly spreads to bone.; Metastatic esophageal cancer commonly spreads to the brain.; Metastatic esophageal cancer commonly spreads to distant lymph nodes.","evidence_relations":"Metastatic esophageal cancer has spread to distant organs such as liver, lung, bone, and brain; Disease Stage: Metastatic: Metastatic Site: Liver, Lung, Bone, Brain, Distant lymph nodes; Metastatic sites listed in the ontology include liver, lung, bone, brain, and distant lymph nodes; Metastatic esophageal cancer involves distant organs; The ontology specifies metastatic sites for esophageal cancer"},
	{"id":"Medical-d6d07c2c","source":"Medical","question":"What is the significance of Siewert types in the management of esophageal cancer?","answer":"Siewert types classify tumors located at the esophagogastric junction (EGJ) based on their anatomical position relative to the esophagus and stomach. This classification is essential for accurate staging and guides treatment planning for esophageal cancers involving the EGJ, as management strategies may differ depending on the Siewert type and the tumor's precise location.","question_type":"Contextual Summarize","evidence":"Siewert types are used to stage tumors at the esophagogastric junction.; Siewert types are an important factor in treatment planning for esophageal cancer.","evidence_relations":"Siewert types are used to stage tumors at the esophagogastric junction; Treatment Planning: Based on: Siewert types (for EGJ tumors); Anatomical Location: Esophagogastric junction; Siewert types are referenced in the ontology for staging and treatment planning; Siewert types are specifically mentioned for tumors at the esophagogastric junction"},
	{"id":"Medical-d90aa96f","source":"Medical","question":"How do anatomical locations differ between esophageal squamous cell carcinoma and esophageal adenocarcinoma?","answer":"Esophageal squamous cell carcinoma (ESCC) most commonly arises in the upper and middle portions of the esophagus but can also occur in the lower esophagus. In contrast, esophageal adenocarcinoma (EAC) is primarily found in the lower esophagus, particularly near the esophagogastric (gastroesophageal) junction, but may also occur in the middle esophagus. These differences in anatomical location reflect the distinct cell types from which each cancer originates: ESCC develops from the squamous cells lining the esophagus, while EAC arises from mucus-secreting glandular cells, often in the setting of Barrett esophagus.","question_type":"Contextual Summarize","evidence":"Esophageal squamous cell carcinoma can occur in the upper esophagus.; Esophageal squamous cell carcinoma can occur in the middle esophagus.; Esophageal squamous cell carcinoma can occur in the lower esophagus.; Esophageal adenocarcinoma is primarily found in the lower esophagus.; Esophageal adenocarcinoma is primarily found in the middle esophagus.","evidence_relations":"Esophageal squamous cell carcinoma: Anatomical Location: Upper esophagus, Middle esophagus, Lower esophagus; Esophageal adenocarcinoma: Anatomical Location: Lower esophagus, Middle esophagus; Esophageal squamous cell carcinoma starts in squamous cells of the esophagus; Esophageal adenocarcinoma starts in mucus-secreting cells of the esophagus; Ontology distinguishes anatomical locations for both subtypes"},
	{"id":"Medical-b7a4ed28","source":"Medical","question":"What are the key clinical, pathological, and epidemiological features of mediastinal gray zone lymphoma (MGZL)?","answer":"MGZL is characterized by a large mediastinal mass, the presence of Reed-Sternberg cells, predominantly affects individuals aged 20 to 40 years assigned male at birth, and requires expert hematopathologist review for diagnosis.","question_type":"Contextual Summarize","evidence":"Mediastinal gray zone lymphoma (MGZL) is characterized by a large mediastinal mass.; MGZL has the presence of Reed-Sternberg cells.; MGZL predominantly affects individuals aged 20 to 40 years assigned male at birth.; MGZL requires expert hematopathologist review for diagnosis.","evidence_relations":"MGZL is characterized by a large mediastinal mass; Reed-Sternberg cells are characteristic histopathological features in MGZL; MGZL commonly affects individuals aged 20 to 40 years, assigned male at birth; Diagnosis of MGZL requires expert hematopathologist review; Mediastinal gray zone lymphoma (MGZL) is a subtype of gray zone lymphomas; MGZL involves the mediastinum and lymph nodes above the collar bone (supraclavicular); MGZL has overlapping features of primary mediastinal B-cell lymphoma (PMBL) and Hodgkin lymphoma (HL)"},
	{"id":"Medical-b5a3c96e","source":"Medical","question":"How do the sites of involvement and epidemiology differ between mediastinal and non-mediastinal gray zone lymphomas?","answer":"Mediastinal gray zone lymphoma primarily involves the mediastinum and supraclavicular lymph nodes in younger males, while non-mediastinal gray zone lymphomas occur in older persons and are associated with bone marrow and extranodal involvement.","question_type":"Contextual Summarize","evidence":"Mediastinal gray zone lymphoma primarily involves the mediastinum.; Mediastinal gray zone lymphoma primarily involves supraclavicular lymph nodes.; Mediastinal gray zone lymphoma primarily affects younger males.; Non-mediastinal gray zone lymphomas occur in older persons.; Non-mediastinal gray zone lymphomas are associated with bone marrow involvement.; Non-mediastinal gray zone lymphomas are associated with extranodal involvement.","evidence_relations":"MGZL commonly affects individuals aged 20 to 40 years, assigned male at birth; MGZL is characterized by a large mediastinal mass; Non-mediastinal gray zone lymphomas occur in older persons and have higher rates of bone marrow and extranodal involvement; Sites of involvement for MGZL include mediastinum and lymph nodes above the collar bone (supraclavicular); Sites of involvement for non-mediastinal gray zone lymphoma include bone marrow involvement and extranodal disease; Non-mediastinal gray zone lymphoma is associated with advanced-stage disease"},
	{"id":"Medical-bcf1ff5a","source":"Medical","question":"What are the main treatment options for mediastinal gray zone lymphoma (MGZL) and their indications?","answer":"The main treatment options for mediastinal gray zone lymphoma (MGZL) include chemotherapy as the primary approach. If the tumor cells express appropriate markers, rituximab may be added to chemotherapy to form chemoimmunotherapy. Involved-site radiation therapy (ISRT) can be considered for patients with localized disease. The choice of treatment depends on disease extent and individual patient factors, and management is best conducted at specialized cancer centers due to the complexity and rarity of MGZL.","question_type":"Contextual Summarize","evidence":"Mediastinal gray zone lymphoma (MGZL) is usually treated with chemotherapy.; Rituximab is added for chemoimmunotherapy in the treatment of MGZL.; Involved-site radiation therapy (ISRT) may be used in localized disease of MGZL.","evidence_relations":"MGZL is usually treated with chemotherapy; Rituximab may be added to chemotherapy for chemoimmunotherapy; Involved-site radiation therapy (ISRT) may be added in localized MGZL; Treatment options for MGZL include chemotherapy, chemoimmunotherapy (with rituximab), and radiation therapy (ISRT); Radiation therapy is specifically indicated for localized MGZL"},
	{"id":"Medical-b1ec8b7e","source":"Medical","question":"What diagnostic methods and histopathological features are essential for identifying mediastinal gray zone lymphoma (MGZL)?","answer":"The diagnosis of mediastinal gray zone lymphoma (MGZL) requires expert hematopathologist review due to its overlapping features with other lymphomas. Essential diagnostic methods include thorough histopathological examination of a biopsy from the mediastinal mass. Key histopathological features are the presence of a large mediastinal mass and identification of Reed-Sternberg cells, which are large, abnormal lymphocytes that may contain more than one nucleus and resemble those seen in Hodgkin lymphoma. The tumor cells in MGZL can vary in size and appearance, further necessitating specialized pathological assessment to distinguish MGZL from related entities such as primary mediastinal large B-cell lymphoma (PMBL) and classical Hodgkin lymphoma (CHL).","question_type":"Contextual Summarize","evidence":"Diagnosis of mediastinal gray zone lymphoma (MGZL) requires expert hematopathologist review.; Diagnosis of MGZL is based on identifying a large mediastinal mass.; Reed-Sternberg cells are key histopathological features for identifying MGZL.","evidence_relations":"Diagnosis of MGZL requires expert hematopathologist review; MGZL is characterized by a large mediastinal mass; Reed-Sternberg cells are characteristic histopathological features in MGZL; Diagnostic Method for MGZL includes expert hematopathologist review; Histopathology of MGZL includes large mediastinal mass and Reed-Sternberg cells"},
	{"id":"Medical-f24f442f","source":"Medical","question":"How are gray zone lymphomas related to other lymphoma subtypes, and what are their overlapping features?","answer":"Gray zone lymphomas, including MGZL, have overlapping features of primary mediastinal B-cell lymphoma (PMBL) and Hodgkin lymphoma (HL), and may also share characteristics with classical Hodgkin lymphoma (CHL) and non-Hodgkin lymphoma.","question_type":"Contextual Summarize","evidence":"Gray zone lymphomas include mediastinal gray zone lymphoma (MGZL).; Gray zone lymphomas have overlapping features with primary mediastinal B-cell lymphoma (PMBL).; Gray zone lymphomas have overlapping features with Hodgkin lymphoma (HL).; Gray zone lymphomas may share characteristics with classical Hodgkin lymphoma (CHL).; Gray zone lymphomas may share characteristics with non-Hodgkin lymphoma.","evidence_relations":"Gray zone lymphomas have overlapping features of primary mediastinal B-cell lymphoma (PMBL) and Hodgkin lymphoma (HL); Mediastinal gray zone lymphoma (MGZL) is a subtype of gray zone lymphomas; Gray zone lymphoma is related to primary mediastinal B-cell lymphoma (PMBL), Hodgkin lymphoma (HL), classical Hodgkin lymphoma (CHL), and non-Hodgkin lymphoma; MGZL has overlapping pathological features with PMBL and HL; Related entities for gray zone lymphoma include PMBL, HL, CHL, and non-Hodgkin lymphoma"},
	{"id":"Medical-e14162c2","source":"Medical","question":"What criteria distinguish extra-mediastinal gray zone lymphoma from DLBCL, not otherwise specified (DLBCL-NOS)?","answer":"Extra-mediastinal gray zone lymphoma is distinguished from DLBCL, not otherwise specified (DLBCL-NOS), based on the site of disease involvement. When gray zone lymphoma presents outside the mediastinumsuch as with bone marrow or extranodal involvement, and in cases of advanced-stage diseaseit is classified and diagnosed as DLBCL-NOS. This distinction is important because non-mediastinal gray zone lymphomas tend to occur in older individuals and are more likely to involve bone marrow and extranodal sites compared to mediastinal gray zone lymphomas. According to current guidelines, any gray zone lymphoma with extra-mediastinal disease should be diagnosed as DLBCL-NOS.","question_type":"Contextual Summarize","evidence":"Extra-mediastinal gray zone lymphoma is diagnosed as DLBCL-NOS when presenting with disease outside the mediastinum.; Extra-mediastinal gray zone lymphoma is particularly diagnosed as DLBCL-NOS in cases with bone marrow involvement.; Extra-mediastinal gray zone lymphoma is particularly diagnosed as DLBCL-NOS in cases with extranodal involvement.; Extra-mediastinal gray zone lymphoma is particularly diagnosed as DLBCL-NOS in cases of advanced-stage disease.","evidence_relations":"Non-mediastinal gray zone lymphomas occur in older persons and have higher rates of bone marrow and extranodal involvement; Sites of involvement for non-mediastinal gray zone lymphoma include bone marrow involvement and extranodal disease; Non-mediastinal gray zone lymphoma is associated with advanced-stage disease; If extra-mediastinal disease: Diagnose as DLBCL-NOS; Extra-mediastinal disease in gray zone lymphoma leads to diagnosis of DLBCL-NOS"},
	{"id":"Medical-46ec9d7b","source":"Medical","question":"What are the major risk factors and high-risk HPV types associated with cervical cancer?","answer":"Cervical cancer is strongly linked to persistent infection with high-risk HPV types such as HPV16 and HPV18, with additional risk factors including smoking, immunosuppression (e.g., HIV), high parity, oral contraceptive use, early sexual activity, multiple sexual partners, a history of sexually transmitted infection, and autoimmune diseases.","question_type":"Contextual Summarize","evidence":"Cervical cancer is strongly linked to persistent infection with high-risk HPV types.; High-risk HPV types associated with cervical cancer include HPV16 and HPV18.; Additional risk factors for cervical cancer include smoking.; Additional risk factors for cervical cancer include immunosuppression, such as HIV.; Additional risk factors for cervical cancer include high parity.; Additional risk factors for cervical cancer include oral contraceptive use.; Additional risk factors for cervical cancer include early sexual activity.; Additional risk factors for cervical cancer include multiple sexual partners.; Additional risk factors for cervical cancer include a history of sexually transmitted infection.; Additional risk factors for cervical cancer include autoimmune diseases.","evidence_relations":"Most cervical cancers are caused by long-term infection with human papillomavirus (HPV); HPV16 and HPV18 are high-risk HPV types associated with cervical cancer; Smoking increases the risk of cervical cancer; Immunosuppression (e.g., HIV infection) increases the risk of cervical cancer; Risk Factor includes: HPV infection, HPV16, HPV18, Smoking, Immunosuppression, HIV, High parity, Oral contraceptive use, Early sexual activity, Multiple sexual partners, History of sexually transmitted infection, Autoimmune diseases"},
	{"id":"Medical-1565017b","source":"Medical","question":"What are the primary screening and diagnostic methods used for cervical cancer detection and staging?","answer":"Cervical cancer screening is performed with Pap smear, diagnosis is confirmed by cervical biopsy or cone biopsy, and staging and assessment utilize imaging modalities such as CT scan, MRI, PET/CT, and transvaginal ultrasound.","question_type":"Contextual Summarize","evidence":"Cervical cancer screening is performed with a Pap smear.; Cervical cancer diagnosis is confirmed by cervical biopsy.; Cervical cancer diagnosis can also be confirmed by cone biopsy.; Staging and assessment of cervical cancer utilize imaging modalities.; Imaging modalities for cervical cancer staging include CT scan.; Imaging modalities for cervical cancer staging include MRI.; Imaging modalities for cervical cancer staging include PET/CT.; Imaging modalities for cervical cancer staging include transvaginal ultrasound.","evidence_relations":"Pap smear is used for cervical cancer screening; Cervical biopsy is the primary diagnostic method for cervical cancer; Cone biopsy can be both diagnostic and therapeutic for early-stage cervical cancer; Imaging methods such as CT, MRI, PET/CT, and transvaginal ultrasound are used for staging and assessment; Diagnostic Method includes: Screening (Pap smear), Biopsy (Cervical biopsy, Cone biopsy), Imaging (CT scan, MRI, PET/CT, Transvaginal ultrasound)"},
	{"id":"Medical-51a4d6d2","source":"Medical","question":"What are the main histological subtypes of cervical cancer and their relative prevalence?","answer":"The main histological subtypes of cervical cancer are squamous cell carcinoma, which is the most common and typically arises from the ectocervix; adenocarcinoma, which accounts for about 20% of cases and originates from the glandular cells of the endocervical canal; adenosquamous carcinoma, a less common mixed tumor containing both squamous and glandular components; and neuroendocrine carcinoma of the cervix (NECC), which is a rare and aggressive subtype. Squamous cell carcinoma is the predominant form, followed by adenocarcinoma, with adenosquamous and neuroendocrine carcinomas being less frequent.","question_type":"Contextual Summarize","evidence":"The main histological subtype of cervical cancer is squamous cell carcinoma.; Squamous cell carcinoma is the most common subtype of cervical cancer.; Other histological subtypes of cervical cancer include adenocarcinoma.; Other histological subtypes of cervical cancer include adenosquamous carcinoma.; Neuroendocrine carcinoma of the cervix (NECC) is a rare and aggressive subtype of cervical cancer.","evidence_relations":"Squamous cell carcinoma is the most common subtype of cervical cancer; Adenocarcinoma and adenosquamous carcinoma are less common subtypes; Neuroendocrine carcinoma of the cervix (NECC) is a rare and aggressive subtype; Cancer Subtype includes: Squamous cell carcinoma, Adenocarcinoma, Adenosquamous carcinoma, Neuroendocrine carcinoma of the cervix (NECC); Cervical cancer is a common cancer of the female reproductive system"},
	{"id":"Medical-f9a73f1e","source":"Medical","question":"How is cervical cancer staged and what are the main treatment modalities at different stages?","answer":"Cervical cancer is staged using the FIGO system (Stages I-IV with sub-stages); early-stage disease is mainly treated with surgery (including fertility-sparing options), while locally advanced stages are managed with chemoradiation, and metastatic or recurrent disease may require systemic therapy including chemotherapy, targeted therapy, or immunotherapy.","question_type":"Contextual Summarize","evidence":"Cervical cancer is staged using the FIGO system.; The FIGO system includes Stages I-IV with sub-stages.; Early-stage cervical cancer is mainly treated with surgery.; Fertility-sparing options are available for early-stage cervical cancer treatment.; Locally advanced stages of cervical cancer are managed with chemoradiation.; Metastatic or recurrent cervical cancer may require systemic therapy.; Systemic therapy for cervical cancer may include chemotherapy.; Systemic therapy for cervical cancer may include targeted therapy.; Systemic therapy for cervical cancer may include immunotherapy.","evidence_relations":"The FIGO system is used to stage cervical cancer (Stages I-IV with sub-stages); Surgery is the main treatment for early-stage cervical cancer; Fertility-sparing surgery (e.g., trachelectomy) is an option for selected early-stage cases; Chemoradiation (concurrent EBRT and platinum-based chemotherapy) is recommended for locally advanced cervical cancer; Systemic therapy options include platinum-based chemotherapy, targeted therapy, and immunotherapy"},
	{"id":"Medical-b08051d8","source":"Medical","question":"Which biomarkers and genetic alterations are relevant for guiding therapy in recurrent or metastatic cervical cancer?","answer":"In recurrent or metastatic cervical cancer, comprehensive biomarker testing is recommended to guide therapy decisions. Key biomarkers and genetic alterations include PD-L1 expression, microsatellite instability (MSI), mismatch repair deficiency (MMR), tumor mutational burden (TMB), HER2 amplification, RET gene fusion, and NTRK gene fusion. PD-L1 positivity is particularly important, as it guides the use of immunotherapy agents such as pembrolizumab. Other alterations, such as MSI-high, dMMR, TMB-high, HER2 amplification, RET, and NTRK fusions, may inform eligibility for targeted therapies or clinical trials. Testing is typically performed on tumor tissue or, if not available, on blood samples. The results help determine the most appropriate systemic therapy, including immunotherapy or targeted agents, for patients with recurrent or metastatic disease.","question_type":"Contextual Summarize","evidence":"In recurrent or metastatic cervical cancer, biomarker testing is recommended.; Relevant biomarkers for guiding therapy in recurrent or metastatic cervical cancer include PD-L1.; Relevant biomarkers for guiding therapy in recurrent or metastatic cervical cancer include MSI.; Relevant biomarkers for guiding therapy in recurrent or metastatic cervical cancer include MMR.; Relevant biomarkers for guiding therapy in recurrent or metastatic cervical cancer include TMB.; Relevant biomarkers for guiding therapy in recurrent or metastatic cervical cancer include HER2.; Relevant biomarkers for guiding therapy in recurrent or metastatic cervical cancer include RET.; Relevant biomarkers for guiding therapy in recurrent or metastatic cervical cancer include NTRK.; PD-L1 positivity guides immunotherapy in recurrent or metastatic cervical cancer.; Other genetic alterations may inform targeted therapy in recurrent or metastatic cervical cancer.","evidence_relations":"Biomarker testing (e.g., PD-L1, MSI, TMB, MMR, HER2, RET, NTRK) is recommended for recurrent or metastatic cervical cancer; PD-L1 positivity guides the use of immunotherapy (e.g., pembrolizumab); Biomarker includes: PD-L1, MSI, MMR, TMB, HER2, RET, NTRK; Genetic Alteration includes: PD-L1 positivity, MSI-H, dMMR, TMB-H, HER2 amplification, RET fusion, NTRK fusion; Pembrolizumab is used as immunotherapy guided by PD-L1 status"},
	{"id":"Medical-5df1a831","source":"Medical","question":"What are the key symptoms of cervical cancer and how do they inform clinical suspicion?","answer":"Cervical cancer commonly presents with symptoms such as watery vaginal discharge, pelvic pain, abnormal vaginal bleeding, and fatigue, which should prompt clinical suspicion and further diagnostic evaluation.","question_type":"Contextual Summarize","evidence":"Cervical cancer commonly presents with watery vaginal discharge.; Cervical cancer commonly presents with pelvic pain.; Cervical cancer commonly presents with abnormal vaginal bleeding.; Cervical cancer commonly presents with fatigue.; Symptoms of cervical cancer should prompt clinical suspicion.; Symptoms of cervical cancer should lead to further diagnostic evaluation.","evidence_relations":"Cervical cancer is a common cancer of the female reproductive system; Symptom includes: Watery vaginal discharge, Pelvic pain, Abnormal vaginal bleeding, Fatigue; Cervical cancer presents with watery vaginal discharge; Cervical cancer presents with pelvic pain and abnormal vaginal bleeding; Fatigue is a symptom of cervical cancer"},
	{"id":"Medical-5779b132","source":"Medical","question":"What fertility preservation options are available for patients with early-stage cervical cancer?","answer":"For patients with early-stage cervical cancer who wish to preserve fertility, several options are available. Fertility-sparing surgery, such as trachelectomy or cone biopsy, may be considered for cancers confined to the cervix (typically stage 1) and in the absence of certain risk factors. These procedures aim to remove the cancer while preserving the uterus and ovaries, allowing for the possibility of future natural pregnancy. Ovarian transposition (oophoropexy) can be performed to move the ovaries out of the radiation field if pelvic radiation is planned, helping to preserve ovarian function. Additionally, egg (oocyte) freezing prior to treatment is an option for those at risk of losing fertility due to surgery or radiation. Surrogacy may also be considered for patients who are unable to carry a pregnancy after treatment. Consultation with a reproductive endocrinologist is recommended to discuss the most appropriate fertility preservation strategies based on individual circumstances and cancer stage.","question_type":"Contextual Summarize","evidence":"Fertility preservation options for patients with early-stage cervical cancer can include fertility-sparing surgery.; Trachelectomy is a type of fertility-sparing surgery for early-stage cervical cancer.; Ovarian transposition is a fertility preservation option for early-stage cervical cancer patients.; Egg freezing is a fertility preservation option for early-stage cervical cancer patients.; Surrogacy is a fertility preservation option for early-stage cervical cancer patients.","evidence_relations":"Fertility-sparing surgery (e.g., trachelectomy) is an option for selected early-stage cases; Fertility Preservation includes: Fertility-sparing surgery, Ovarian transposition, Egg freezing, Surrogacy; Trachelectomy is a fertility-sparing surgical procedure; Ovarian transposition and egg freezing are fertility preservation options; Surrogacy is included among fertility preservation strategies for cervical cancer patients"},
	{"id":"Medical-dfb56ae9","source":"Medical","question":"How is surveillance and follow-up managed after cervical cancer treatment?","answer":"Surveillance after cervical cancer treatment involves regular physical exams, imaging as indicated, Pap testing, and blood tests to monitor for recurrence or complications.","question_type":"Contextual Summarize","evidence":"Surveillance after cervical cancer treatment involves regular physical exams.; Surveillance after cervical cancer treatment may include imaging as indicated.; Pap testing is part of the surveillance after cervical cancer treatment.; Blood tests are used in surveillance after cervical cancer treatment to monitor for recurrence or complications.","evidence_relations":"Surveillance after treatment includes regular physical exams and imaging as indicated; Follow-up includes: Physical exam, Imaging as indicated, Pap testing, Blood tests; Pap testing is part of post-treatment surveillance; Physical exam and blood tests are used in follow-up; Imaging as indicated is recommended for surveillance"},
	{"id":"Medical-37ade7a5","source":"Medical","question":"What are the main components of supportive and palliative care in advanced or metastatic cervical cancer?","answer":"The main components of supportive and palliative care in advanced or metastatic cervical cancer include comprehensive symptom management (such as relief of pain, nausea, and other distressing symptoms), emotional and psychological support, spiritual care, and assistance with advance care planning. Supportive care also involves access to hospice services, pain specialists, and multidisciplinary teams that may include social workers, nutritionists, and rehabilitation specialists. The primary goals are to improve quality of life, address the side effects of cancer and its treatments, and provide support for both patients and their families, whether care is given alongside active cancer treatment or as the main focus when disease-directed therapies are no longer effective.","question_type":"Contextual Summarize","evidence":"Supportive care is integral for patients with advanced or metastatic cervical cancer.; Palliative care is integral for patients with advanced or metastatic cervical cancer.; The aim of supportive care is to manage symptoms in advanced or metastatic cervical cancer.; The aim of palliative care is to improve quality of life in advanced or metastatic cervical cancer.; Comprehensive support is provided alongside or in place of disease-directed therapies in advanced or metastatic cervical cancer.","evidence_relations":"Supportive care and palliative care are integral for advanced or metastatic disease; Supportive Care includes: Supportive care, Palliative care; Palliative care is recommended for advanced cervical cancer; Supportive care is part of the treatment options in cervical cancer; Supportive and palliative care focus on symptom management and quality of life"},
	{"id":"Medical-0a9237ce","source":"Medical","question":"Which therapeutic options are available for metastatic cervical cancer, including the role of clinical trials?","answer":"Therapeutic options for metastatic cervical cancer include systemic therapies such as platinum-based chemotherapy (e.g., cisplatin or carboplatin, often combined with paclitaxel or topotecan), targeted therapy (such as bevacizumab, which may be added to chemotherapy regimens), and immunotherapy. The use of immunotherapy, particularly immune checkpoint inhibitors like pembrolizumab, is guided by biomarker testing (e.g., PD-L1 positivity, TMB-H, or MSI-H/dMMR status). For patients whose tumors lack these biomarkers, other immunotherapies (such as tisotumab vedotin-tftv or cemiplimab) may be considered. Supportive and palliative care are important components of management to improve quality of life. Clinical trials are recommended as an option at all stages of metastatic cervical cancer, offering access to novel therapies and combinations. Treatment selection is individualized based on prior therapies, biomarker status, and patient factors.","question_type":"Contextual Summarize","evidence":"Metastatic cervical cancer may be treated with systemic therapies.; Platinum-based chemotherapy is a treatment option for metastatic cervical cancer.; Targeted therapy is a treatment option for metastatic cervical cancer.; Immunotherapy guided by biomarkers is a treatment option for metastatic cervical cancer.; Bevacizumab is a treatment option for metastatic cervical cancer.; Clinical trials are an option for treating metastatic cervical cancer at all stages.","evidence_relations":"Systemic therapy options include platinum-based chemotherapy, targeted therapy, and immunotherapy; Bevacizumab may be added to chemotherapy for metastatic cervical cancer; Clinical trials are an option for all stages of cervical cancer; Systemic Therapy includes: Chemoradiation, Cisplatin, Carboplatin, Paclitaxel, Topotecan, Bevacizumab, Pembrolizumab, Tisotumab vedotin-tftv, Cemiplimab; Biomarker testing (e.g., PD-L1) guides the use of immunotherapy (e.g., pembrolizumab)"},
	{"id":"Medical-50c09918","source":"Medical","question":"What are the main diagnostic methods used for Hodgkin lymphoma and its subtypes?","answer":"Hodgkin lymphoma and its subtypes are diagnosed through excisional lymph node biopsy, core needle biopsy, health history, physical exam, blood tests, and imaging tests.","question_type":"Contextual Summarize","evidence":"Hodgkin lymphoma is diagnosed through excisional lymph node biopsy.; Hodgkin lymphoma is diagnosed through core needle biopsy.; Health history is used in the diagnosis of Hodgkin lymphoma.; A physical exam is part of the diagnostic process for Hodgkin lymphoma.; Blood tests are used to diagnose Hodgkin lymphoma.; Imaging tests are used to diagnose Hodgkin lymphoma.","evidence_relations":"Diagnosis of Hodgkin lymphoma is made by excisional lymph node biopsy; Core needle biopsy may be used for diagnosis in some cases; Health history and physical exam are part of the diagnostic process; Blood tests and imaging tests are used in the diagnostic workup; Classic Hodgkin lymphoma (CHL) and Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) both use excisional lymph node biopsy, core needle biopsy, health history, physical exam, blood tests, and imaging tests as diagnostic methods"},
	{"id":"Medical-62476085","source":"Medical","question":"How are the subtypes of Hodgkin lymphoma characterized in terms of cell type?","answer":"The subtypes of Hodgkin lymphoma are characterized by distinct abnormal cell types. Classic Hodgkin lymphoma (CHL), the most common subtype, is defined by the presence of large, abnormal lymphocytes known as Reed-Sternberg cells, which often have more than one nucleus. In contrast, nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subtype characterized by 'popcorn-shaped' cells, also called lymphocytic and histiocytic (L&H) cells. These unique cellular features help distinguish between the subtypes during diagnosis.","question_type":"Contextual Summarize","evidence":"Classic Hodgkin lymphoma (CHL) is characterized by Reed-Sternberg cells.; Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is characterized by popcorn-shaped cells.","evidence_relations":"Classic Hodgkin lymphoma (CHL) is the most common subtype of Hodgkin lymphoma; CHL is characterized by Reed-Sternberg cells; Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subtype of Hodgkin lymphoma; NLPHL is characterized by popcorn-shaped cells; CHL and NLPHL are both subtypes of Hodgkin lymphoma, each defined by distinct cell types: Reed-Sternberg cells for CHL and popcorn-shaped cells for NLPHL"},
	{"id":"Medical-5cb17774","source":"Medical","question":"What are the common sites and age-related risk factors associated with Hodgkin lymphoma?","answer":"Hodgkin lymphoma commonly starts in lymph nodes in the upper body and is most often diagnosed in people aged 15 to 30 or after age 55.","question_type":"Contextual Summarize","evidence":"Hodgkin lymphoma commonly starts in lymph nodes in the upper body.; Hodgkin lymphoma is most often diagnosed in people aged 15 to 30.; Hodgkin lymphoma is also diagnosed in people after age 55.","evidence_relations":"Hodgkin lymphoma usually starts in lymph nodes in the upper body; Most people are diagnosed between ages 15 to 30 or after age 55; Common Sites for Hodgkin lymphoma include lymph nodes in upper body; Risk Factor for Hodgkin lymphoma includes ages 15 to 30; Risk Factor for Hodgkin lymphoma includes age 55"},
	{"id":"Medical-1d7e42b7","source":"Medical","question":"How does nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) differ from classic Hodgkin lymphoma (CHL) in terms of rarity and disease transformation?","answer":"Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subtype of Hodgkin lymphoma characterized by slow growth and the presence of distinctive 'popcorn-shaped' cells. NLPHL can, in some cases, transform into more aggressive forms of lymphoma, most notably diffuse large B-cell lymphoma (DLBCL). In contrast, classic Hodgkin lymphoma (CHL) is the most common subtype of Hodgkin lymphoma, recognized by the presence of Reed-Sternberg cells, and is not typically associated with transformation into DLBCL or other aggressive lymphomas.","question_type":"Contextual Summarize","evidence":"Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subtype of Hodgkin lymphoma.; NLPHL can transform into diffuse large B-cell lymphoma (DLBCL).; Classic Hodgkin lymphoma (CHL) is the most common subtype of Hodgkin lymphoma.; Classic Hodgkin lymphoma (CHL) is not associated with transformation into DLBCL.","evidence_relations":"Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subtype of Hodgkin lymphoma; Classic Hodgkin lymphoma (CHL) is the most common subtype of Hodgkin lymphoma; NLPHL can transform into diffuse large B-cell lymphoma (DLBCL); Disease Transformation for NLPHL includes diffuse large B-cell lymphoma (DLBCL); CHL is not noted to undergo disease transformation in the provided data"},
	{"id":"Medical-0b161de9","source":"Medical","question":"What are the hierarchical relationships among lymphoma, Hodgkin lymphoma, and its subtypes according to the ontology?","answer":"Hodgkin lymphoma is a type of lymphoma, which includes classic Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) as subtypes.","question_type":"Contextual Summarize","evidence":"Hodgkin lymphoma is a type of lymphoma.; Classic Hodgkin lymphoma (CHL) is a subtype of Hodgkin lymphoma.; Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a subtype of Hodgkin lymphoma.","evidence_relations":"Hodgkin lymphoma is a type of lymphoma; Classic Hodgkin lymphoma (CHL) is the most common subtype of Hodgkin lymphoma; Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subtype of Hodgkin lymphoma; Lymphoma includes Hodgkin lymphoma as a cancer type in the ontology; Hodgkin lymphoma includes subtypes: Classic Hodgkin lymphoma (CHL) and Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)"},
	{"id":"Medical-0dd275c6","source":"Medical","question":"Which diagnostic steps are shared between classic Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)?","answer":"Both CHL and NLPHL utilize excisional lymph node biopsy, core needle biopsy, health history, physical exam, blood tests, and imaging tests in their diagnostic process.","question_type":"Contextual Summarize","evidence":"Both classic Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) utilize excisional lymph node biopsy.; Both CHL and NLPHL utilize core needle biopsy in their diagnostic process.; Health history is shared in the diagnostic steps of both CHL and NLPHL.; A physical exam is shared in the diagnostic steps of both CHL and NLPHL.; Blood tests are shared in the diagnostic steps of both CHL and NLPHL.; Imaging tests are shared in the diagnostic steps of both CHL and NLPHL.","evidence_relations":"Diagnosis of Hodgkin lymphoma is made by excisional lymph node biopsy; Core needle biopsy may be used for diagnosis in some cases; Health history and physical exam are part of the diagnostic process; Blood tests and imaging tests are used in the diagnostic workup; CHL and NLPHL share the same diagnostic methods according to the ontology: excisional lymph node biopsy, core needle biopsy, health history, physical exam, blood tests, and imaging tests"},
	{"id":"Medical-3c38602c","source":"Medical","question":"What is the significance of cell type identification in diagnosing Hodgkin lymphoma subtypes?","answer":"Cell type identification is crucial in diagnosing Hodgkin lymphoma subtypes because the presence of Reed-Sternberg cells is characteristic of classic Hodgkin lymphoma (CHL), whereas the identification of popcorn-shaped cells is indicative of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Recognizing these distinct cell types under the microscope allows clinicians to accurately differentiate between CHL and NLPHL, which is essential for determining the appropriate treatment and prognosis.","question_type":"Contextual Summarize","evidence":"Identifying Reed-Sternberg cells indicates classical Hodgkin lymphoma (CHL).; Finding popcorn-shaped cells points to nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL).; Identifying cell types helps distinguish between Hodgkin lymphoma subtypes.","evidence_relations":"CHL is characterized by Reed-Sternberg cells; NLPHL is characterized by popcorn-shaped cells; Classic Hodgkin lymphoma (CHL) and Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) are defined by unique cell types; Cell Type for CHL: Reed-Sternberg cells; Cell Type for NLPHL: popcorn-shaped cells"},
	{"id":"Medical-5ba676fd","source":"Medical","question":"What are the main histological layers of the gallbladder and bile ducts, and how are they organized anatomically?","answer":"The gallbladder and bile ducts are organized anatomically into five main histological layers, arranged from the innermost to the outermost as follows: (1) the epithelium, which is a thin, moist layer of cells lining the lumen; (2) the lamina propria, a connective tissue layer located just beneath the epithelium; (3) the muscularis, a layer of smooth muscle tissue; (4) the perimuscular fibrous tissue, which is connective tissue surrounding the muscle layer; and (5) the serosa, an outer membrane also known as the serous membrane or visceral peritoneum, which covers the external surface of the gallbladder and bile ducts.","question_type":"Contextual Summarize","evidence":"The gallbladder and bile ducts are composed of five main histological layers.; The five histological layers are epithelium, lamina propria, muscularis, perimuscular fibrous tissue, and serosa.; The histological layers are arranged from inner to outer.","evidence_relations":"The gallbladder and bile ducts are lined by a thin, moist epithelial layer; Lamina propria is a connective tissue found under the epithelium; Muscularis is a soft tissue layer in the bile duct wall; Perimuscular fibrous tissue surrounds the muscle layer; Serosa is the outer membrane covering the gallbladder and bile ducts; bile duct: Histological Layer: epithelium, lamina propria, muscularis, perimuscular fibrous tissue, serosa; gallbladder: Histological Layer: epithelium, lamina propria, muscularis, perimuscular fibrous tissue, serosa"},
	{"id":"Medical-20eb3bc8","source":"Medical","question":"How is bile duct cancer staging determined and what tumor characteristics are considered?","answer":"Bile duct cancer staging is determined by evaluating several tumor characteristics, including the size of the primary tumor (measured in centimeters or millimeters) and the extent of its spread. This assessment considers whether the tumor has invaded nearby blood vessels, the liver, or structures outside the liver. These factors help define the stage of the cancer, which is essential for guiding treatment decisions and predicting prognosis.","question_type":"Contextual Summarize","evidence":"Bile duct cancer staging is determined by assessing the primary tumor size.; The extent of tumor spread is considered in bile duct cancer staging.; Invasion into blood vessels is a factor in staging bile duct cancer.; Invasion into the liver is a factor in staging bile duct cancer.; Invasion into structures outside the liver is a factor in staging bile duct cancer.","evidence_relations":"Bile duct cancer staging is based on tumor size and extent of spread; Cancer can invade nearby blood vessels, liver, or structures outside the liver; primary tumor size (cm or mm) is a tumor characteristic; spread to blood vessels is a tumor characteristic; spread to liver is a tumor characteristic; spread to structures outside the liver is a tumor characteristic"},
	{"id":"Medical-3b99f5cd","source":"Medical","question":"What defines the Tis (carcinoma in situ) stage in intrahepatic bile duct cancer?","answer":"Tis (carcinoma in situ) in intrahepatic bile duct cancer is defined as an intraductal tumor that is confined to the epithelial layer and has not invaded deeper tissues.","question_type":"Contextual Summarize","evidence":"Tis (carcinoma in situ) in intrahepatic bile duct cancer is defined as an intraductal tumor.; The intraductal tumor in Tis is confined to the epithelial layer.; The tumor in Tis has not invaded deeper tissues.","evidence_relations":"Tis (carcinoma in situ) is an intraductal tumor confined to the epithelium; intrahepatic bile duct cancer: Stage: Tis: Tumor Characteristic: carcinoma in situ; intrahepatic bile duct cancer: Stage: Tis: Tumor Characteristic: intraductal tumor; intrahepatic bile duct cancer: Stage: Tis: Tumor Characteristic: confined to epithelium; epithelium is the innermost histological layer of the bile duct and gallbladder"},
	{"id":"Medical-ec4330ad","source":"Medical","question":"Which anatomical structures are at risk of invasion by bile duct cancer, and how does this affect staging?","answer":"Bile duct cancer can invade anatomical structures such as nearby blood vessels, the liver, and other structures outside the liver. The extent of this invasion is a critical factor in staging the disease, as tumor spread to these areas indicates more advanced stages and can significantly impact prognosis and treatment decisions.","question_type":"Contextual Summarize","evidence":"Bile duct cancer can invade nearby blood vessels.; Bile duct cancer can invade the liver.; Bile duct cancer can invade structures outside the liver.; Invasions by bile duct cancer are key factors in determining the stage of the disease.","evidence_relations":"Cancer can invade nearby blood vessels, liver, or structures outside the liver; Bile duct cancer staging is based on tumor size and extent of spread; spread to blood vessels is a tumor characteristic; spread to liver is a tumor characteristic; spread to structures outside the liver is a tumor characteristic"},
	{"id":"Medical-a8a154f8","source":"Medical","question":"What are the shared histological layers between the gallbladder and bile duct, and what is their functional significance?","answer":"Both the gallbladder and bile duct share the histological layers of epithelium, lamina propria, muscularis, perimuscular fibrous tissue, and serosa. The epithelial layer provides a protective, moist lining for the lumen, facilitating the passage of bile. The lamina propria, a connective tissue layer beneath the epithelium, supports the epithelium and contains blood vessels and immune cells. The muscularis layer enables contraction and movement of bile. The perimuscular fibrous tissue surrounds the muscle, providing additional support and flexibility. The serosa, or outer membrane, covers and protects the organ, reducing friction with surrounding structures. Together, these layers maintain structural integrity, compartmentalize the organ, and support their roles in bile storage, transport, and release.","question_type":"Contextual Summarize","evidence":"The gallbladder and bile duct share the histological layers of epithelium, lamina propria, muscularis, perimuscular fibrous tissue, and serosa.; The shared histological layers provide structural integrity.; The shared histological layers provide compartmentalization.","evidence_relations":"bile duct: Histological Layer: epithelium, lamina propria, muscularis, perimuscular fibrous tissue, serosa; gallbladder: Histological Layer: epithelium, lamina propria, muscularis, perimuscular fibrous tissue, serosa; The gallbladder and bile ducts are lined by a thin, moist epithelial layer; Lamina propria is a connective tissue found under the epithelium; Serosa is the outer membrane covering the gallbladder and bile ducts"},
	{"id":"Medical-f04a4100","source":"Medical","question":"How does the anatomical layering of the bile duct relate to the progression of cancer invasion?","answer":"The anatomical layering of the bile duct plays a critical role in the progression of cancer invasion. Tumors typically originate in the epithelial lining and, as they advance, can invade sequentially through the lamina propria (a connective tissue layer), the muscularis (muscle layer), and the perimuscular fibrous tissue, eventually reaching the serosa, which is the outermost membrane. As cancer penetrates deeper layers, it gains access to blood vessels, lymphatics, and adjacent organs, increasing the risk of local extension and distant metastasis. The depth of invasion into these layers is an important factor in staging, prognosis, and treatment planning for bile duct cancers.","question_type":"Contextual Summarize","evidence":"Cancer progression in the bile duct is influenced by its anatomical layers.; Tumors in the bile duct start in the epithelium.; Tumors can invade through the lamina propria.; Tumors can invade through the muscularis.; Tumors can invade through the perimuscular fibrous tissue.; Tumors can reach the serosa.","evidence_relations":"The gallbladder and bile ducts are lined by a thin, moist epithelial layer; Lamina propria is a connective tissue found under the epithelium; Muscularis is a soft tissue layer in the bile duct wall; Perimuscular fibrous tissue surrounds the muscle layer; Serosa is the outer membrane covering the gallbladder and bile ducts; Cancer can invade nearby blood vessels, liver, or structures outside the liver"},
	{"id":"Medical-f38ec745","source":"Medical","question":"What are the key diagnostic methods and common symptoms associated with follicular lymphoma (FL)?","answer":"Follicular lymphoma is diagnosed using blood tests, bone marrow aspirate and biopsy, imaging studies, and immunophenotyping, and it commonly presents with symptoms such as swollen lymph nodes, enlarged spleen, fever, night sweats, fatigue, and weight loss.","question_type":"Contextual Summarize","evidence":"Follicular lymphoma is diagnosed using blood tests.; Follicular lymphoma is diagnosed using bone marrow aspirate and biopsy.; Follicular lymphoma is diagnosed using imaging studies.; Follicular lymphoma is diagnosed using immunophenotyping.; Common symptoms of follicular lymphoma include swollen lymph nodes.; Common symptoms of follicular lymphoma include enlarged spleen.; Common symptoms of follicular lymphoma include fever.; Common symptoms of follicular lymphoma include night sweats.; Common symptoms of follicular lymphoma include fatigue.; Common symptoms of follicular lymphoma include weight loss.","evidence_relations":"Diagnosis of FL involves blood tests, bone marrow aspirate and biopsy, imaging studies, and immunophenotyping; Symptoms of FL include swollen lymph nodes, enlarged spleen, fever, night sweats, fatigue, and weight loss (B symptoms); FL can present as nodal or extranodal disease; FL develops from abnormal B lymphocytes forming clusters in lymph nodes and other tissues; Symptom ontology for FL includes swollen lymph nodes, enlarged spleen, fever, night sweats, fatigue, weight loss, and B symptoms"},
	{"id":"Medical-0bc96001","source":"Medical","question":"How is follicular lymphoma (FL) classified by grade and what are the clinical implications of each grade?","answer":"Follicular lymphoma (FL) is graded according to the proportion of two types of cells: centrocytes (small cells) and centroblasts (large cells). Grades 1 and 2, which contain mostly centrocytes with fewer centroblasts, are classified as classic FL (cFL) and are typically managed as indolent lymphomas. Grade 3A FL has an increased number of centroblasts but still includes centrocytes; it may be treated as either classic FL or as diffuse large B-cell lymphoma (DLBCL), depending on institutional protocols and specific pathological findings. Grade 3B FL consists almost entirely of centroblasts and is treated as DLBCL, reflecting its more aggressive clinical behavior. The grade of FL is important because it guides treatment decisions and helps predict disease behavior.","question_type":"Contextual Summarize","evidence":"Follicular lymphoma (FL) is graded based on the proportion of centrocytes and centroblasts.; Grades 1 and 2 are classified as classic FL.; Grade 3A may be treated as classic FL or diffuse large B-cell lymphoma (DLBCL).; Grade 3B is treated as DLBCL.; The grade of FL guides treatment decisions.","evidence_relations":"FL is graded based on the proportion of centrocytes and centroblasts; Grades 1 and 2 FL are classified as classic FL (cFL) according to ICC; Grade 3A FL may be treated as classic FL or as diffuse large B-cell lymphoma (DLBCL); Grade 3B FL is treated as DLBCL; The type of cells in FL determines the grade, which guides treatment decisions"},
	{"id":"Medical-d1ead1ea","source":"Medical","question":"What are the main genetic alterations and biomarkers found in follicular lymphoma (FL), and how do they differ in uncommon FL (uFL)?","answer":"The main genetic alteration in most cases of follicular lymphoma (FL) is a chromosome translocation, specifically t(14;18), which leads to overexpression of the BCL2 protein. BCL2 protein overexpression is a key biomarker in classic FL. In contrast, uncommon FL (uFL) is characterized by the absence of the t(14;18) translocation (t(14;18)-negative) or by other uncommon pathological features. Despite these differences in genetic alterations and biomarkers, uncommon FL is generally managed in the same way as classic FL.","question_type":"Contextual Summarize","evidence":"Most follicular lymphoma cases have a chromosome translocation.; Most follicular lymphoma cases have excess BCL2 protein.; Uncommon follicular lymphoma (uFL) is t(14;18)-negative.; Uncommon follicular lymphoma may have uncommon pathologic features.; Uncommon follicular lymphoma is still treated as classic FL.","evidence_relations":"Almost all FL cases have a chromosome translocation or excess BCL2 protein; Uncommon FL (uFL) is t(14;18)-negative or has uncommon pathologic features and is treated as classic FL; FL includes biomarkers: BCL2 protein; FL includes genetic alterations: chromosome translocation, t(14;18); Uncommon FL (uFL) has the genetic alteration t(14;18)-negative"},
	{"id":"Medical-cd32265c","source":"Medical","question":"How does the presentation and clinical course of pediatric-type follicular lymphoma (PTFL) differ from classic FL?","answer":"Pediatric-type follicular lymphoma (PTFL) typically presents with a single enlarged lymph node, most often in the head and neck region, and is usually associated with minimal or no symptoms. In contrast, classic follicular lymphoma (FL) often involves multiple lymph node sites and may present with systemic symptoms such as fever, night sweats, fatigue, and weight loss (known as B symptoms). Classic FL can also involve extranodal sites, such as the spleen or bone marrow, and tends to have a more indolent but widespread clinical course compared to the localized and less symptomatic presentation of PTFL.","question_type":"Contextual Summarize","evidence":"Pediatric-type follicular lymphoma usually presents with a single enlarged lymph node in the head and neck.; Pediatric-type follicular lymphoma usually has minimal symptoms.; Classic follicular lymphoma can involve multiple sites.; Classic follicular lymphoma can have more systemic symptoms.","evidence_relations":"Pediatric-type FL (PTFL) usually presents with a single enlarged lymph node in the head and neck and minimal symptoms; FL can present as nodal or extranodal disease; FL develops from abnormal B lymphocytes forming clusters in lymph nodes and other tissues; Symptoms of FL include swollen lymph nodes, enlarged spleen, fever, night sweats, fatigue, and weight loss (B symptoms); PTFL is a cancer subtype under FL with unique presentation"},
	{"id":"Medical-363f6824","source":"Medical","question":"In what ways can follicular lymphoma (FL) progress or transform, and what are the implications for disease management?","answer":"Follicular lymphoma (FL) can progress by transforming into diffuse large B-cell lymphoma (DLBCL), which is a more aggressive and rapidly growing form of lymphoma. This transformation can occur before, during, or after treatment and is associated with a poorer prognosis and the need for more intensive therapy. Additionally, FL is graded based on the types of cells present: grade 3B FL, which contains only large centroblasts, is rare and is treated as DLBCL due to its aggressive behavior. Grade 3A FL may be managed as either classic FL or as DLBCL, depending on clinical features. The potential for transformation and the specific grade of FL significantly influence disease management strategies and expected outcomes.","question_type":"Contextual Summarize","evidence":"Follicular lymphoma can transform into diffuse large B-cell lymphoma.; Diffuse large B-cell lymphoma is a more aggressive lymphoma.; Grade 3B follicular lymphoma is treated as diffuse large B-cell lymphoma.; The transformation of follicular lymphoma affects treatment strategies.; The transformation of follicular lymphoma affects prognosis.","evidence_relations":"FL can transform into DLBCL, a more aggressive lymphoma; Grade 3B FL is treated as DLBCL; Grade 3A FL may be treated as classic FL or as DLBCL; Transformed FL is a cancer subtype with transformation to DLBCL; The type of cells in FL determines the grade, which guides treatment decisions"},
	{"id":"Medical-da6253bc","source":"Medical","question":"What are the typical disease sites and cell types involved in follicular lymphoma (FL)?","answer":"FL typically involves B lymphocytes and affects lymph nodes, bone marrow, spleen, and sometimes extranodal sites, with the cell types centrocytes and centroblasts determining the grade.","question_type":"Contextual Summarize","evidence":"Follicular lymphoma typically involves B lymphocytes.; Follicular lymphoma affects lymph nodes.; Follicular lymphoma affects bone marrow.; Follicular lymphoma affects the spleen.; Follicular lymphoma can affect extranodal sites.; Centrocytes and centroblasts are cell types involved in follicular lymphoma.; The cell types centrocytes and centroblasts determine the grade of follicular lymphoma.","evidence_relations":"FL develops from abnormal B lymphocytes forming clusters in lymph nodes and other tissues; Disease site ontology for FL includes lymph node, bone marrow, spleen, and extranodal sites; Cell type ontology for FL includes B lymphocyte, centrocyte, and centroblast; FL is graded based on the proportion of centrocytes and centroblasts; FL can present as nodal or extranodal disease"},
	{"id":"Medical-61c0e9bc","source":"Medical","question":"How are treatment decisions and clinical management determined for follicular lymphoma (FL)?","answer":"Treatment decisions and clinical management for follicular lymphoma (FL) are primarily determined by the grade and cell type of the lymphoma. Accurate diagnosis involves a combination of blood tests, biopsies, immunophenotyping, and imaging studies to assess the extent and characteristics of the disease. Not all patients with FL require immediate treatment; some may be managed with observation, especially if they are asymptomatic and have a low tumor burden. The grade of FL, which is based on the proportion of centroblasts (large B cells) present, guides therapy: grades 1, 2, and 3A are often treated as classic FL, while grade 3B is managed as diffuse large B-cell lymphoma (DLBCL) due to its more aggressive nature. Uncommon FL (uFL), which may lack the typical t(14;18) translocation or have unusual pathological features, is generally treated in the same way as classic FL. In addition, transformed FL, where the disease evolves into a more aggressive lymphoma such as DLBCL, requires a different treatment approach. Thus, individualized management is based on disease grade, cell type, clinical presentation, and the presence or absence of symptoms.","question_type":"Contextual Summarize","evidence":"Treatment decisions in follicular lymphoma are guided by grade.; Treatment decisions in follicular lymphoma are guided by cell type.; Not all patients with follicular lymphoma require immediate treatment.; Some subtypes of follicular lymphoma are treated as classic follicular lymphoma.","evidence_relations":"Treatment decisions are guided by grade and cell type; Not all patients with FL require immediate treatment; Uncommon FL (uFL) is t(14;18)-negative or has uncommon pathologic features and is treated as classic FL; Grade 3A FL may be treated as classic FL or as diffuse large B-cell lymphoma (DLBCL); Grade 3B FL is treated as DLBCL"},
	{"id":"Medical-bc92c071","source":"Medical","question":"What are the major subtypes of primary liver cancer and their distinguishing features?","answer":"Primary liver cancer includes hepatocellular carcinoma (HCC), fibrolamellar hepatocellular carcinoma (a subtype of HCC occurring at a younger age), intrahepatic cholangiocarcinoma (arising from bile ducts), and mixed-type tumors containing both HCC and cholangiocarcinoma components.","question_type":"Contextual Summarize","evidence":"Primary liver cancer includes hepatocellular carcinoma.; Primary liver cancer includes fibrolamellar hepatocellular carcinoma.; Fibrolamellar hepatocellular carcinoma occurs at a younger age.; Primary liver cancer includes intrahepatic cholangiocarcinoma.; Intrahepatic cholangiocarcinoma arises from bile ducts.; Primary liver cancer can include mixed-type tumors.; Mixed-type tumors contain both hepatocellular carcinoma and cholangiocarcinoma components.","evidence_relations":"Primary liver cancer originates in the liver; Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer; Fibrolamellar hepatocellular carcinoma (FLHC) is a subtype of HCC that occurs at a younger age; Intrahepatic cholangiocarcinoma is a primary liver cancer of the bile ducts; Mixed-type tumors contain both hepatocellular carcinoma and cholangiocarcinoma components"},
	{"id":"Medical-8897e674","source":"Medical","question":"Which risk factors are associated with the development of primary liver cancer?","answer":"Cirrhosis, chronic hepatitis B and C infections, alcohol use, non-alcoholic fatty liver disease, genetic hemochromatosis, alpha-1-antitrypsin deficiency, and stage 4 primary biliary cholangitis are all significant risk factors for primary liver cancer.","question_type":"Contextual Summarize","evidence":"Cirrhosis is a significant risk factor for primary liver cancer.; Chronic hepatitis B infection is a significant risk factor for primary liver cancer.; Chronic hepatitis C infection is a significant risk factor for primary liver cancer.; Alcohol use is a significant risk factor for primary liver cancer.; Non-alcoholic fatty liver disease is a significant risk factor for primary liver cancer.; Genetic hemochromatosis is a significant risk factor for primary liver cancer.; Alpha-1-antitrypsin deficiency is a significant risk factor for primary liver cancer.; Stage 4 primary biliary cholangitis is a significant risk factor for primary liver cancer.","evidence_relations":"Cirrhosis is a major risk factor for developing liver cancer; Chronic hepatitis B infection increases the risk of liver cancer; Chronic hepatitis C infection increases the risk of liver cancer; Alcohol use is a risk factor for cirrhosis and liver cancer; Non-alcoholic fatty liver disease (NAFLD) is a risk factor for cirrhosis and liver cancer; Genetic hemochromatosis is a risk factor for cirrhosis and liver cancer; Alpha-1-antitrypsin deficiency is a risk factor for cirrhosis and liver cancer; Stage 4 primary biliary cholangitis is a risk factor for cirrhosis and liver cancer"},
	{"id":"Medical-6e7c77a8","source":"Medical","question":"What screening methods and criteria are recommended for liver cancer detection?","answer":"Liver cancer screening is recommended for individuals at increased risk, particularly those with cirrhosis or chronic hepatitis B infection. The standard screening methods include an abdominal ultrasound and a blood test for alpha-fetoprotein (AFP), both performed every 6 months. The ultrasound uses sound waves to create images of the liver to detect any abnormal growths, while the AFP test measures a protein that can be elevated in liver cancer. If the ultrasound identifies nodules 10 mm or larger, or if AFP levels are elevated, further diagnostic testing is warranted. For smaller nodules or negative findings, repeat screening is advised at regular intervals. The goal of this screening protocol is to detect liver cancer at an early, more treatable stage in high-risk individuals.","question_type":"Contextual Summarize","evidence":"Screening for liver cancer is recommended for individuals with cirrhosis.; Screening for liver cancer is recommended for individuals with chronic hepatitis B.; Liver cancer screening typically includes ultrasound tests.; Liver cancer screening typically includes alpha-fetoprotein tests.; Liver cancer screening is typically done every 6 months.","evidence_relations":"Screening for liver cancer is recommended for individuals with cirrhosis or chronic hepatitis B; Liver cancer screening includes ultrasound and alpha-fetoprotein (AFP) test every 6 months; Ultrasound is a screening method for primary liver cancer; Alpha-fetoprotein (AFP) test is a screening method for primary liver cancer; Cirrhosis and chronic hepatitis B are risk factors that determine screening eligibility"},
	{"id":"Medical-0fd3dcfd","source":"Medical","question":"Which diagnostic methods and biomarkers are used to confirm liver cancer?","answer":"Diagnosis of liver cancer is usually confirmed with imaging tests and may require biopsy, while elevated alpha-fetoprotein (AFP) serves as a biomarker that may indicate primary liver cancer.","question_type":"Contextual Summarize","evidence":"Diagnosis of liver cancer is usually confirmed with imaging tests.; Diagnosis of liver cancer may require a biopsy.; Elevated alpha-fetoprotein serves as a biomarker for liver cancer.; Elevated alpha-fetoprotein may indicate primary liver cancer.","evidence_relations":"Diagnosis of liver cancer is usually confirmed with imaging tests; Biopsy may be needed to confirm liver cancer; Elevated AFP may indicate primary liver cancer; Imaging tests are a diagnostic method for primary liver cancer; Alpha-fetoprotein (AFP) is a biomarker for primary liver cancer"},
	{"id":"Medical-c39fbc42","source":"Medical","question":"What are the common sites of metastasis for primary liver cancer and how does it spread?","answer":"Primary liver cancer can spread locally by invading surrounding liver tissue and can also metastasize to distant organs. The most common sites of distant metastasis are the lungs and bones. The cancer spreads through blood vessels and the lymphatic system, although spread to nearby lymph nodes is less common. Understanding these patterns of spread is important for staging and treatment planning.","question_type":"Contextual Summarize","evidence":"Primary liver cancer can spread directly through the liver.; Primary liver cancer most often metastasizes to the lung.; Primary liver cancer most often metastasizes to bone.","evidence_relations":"Liver cancer can spread directly through the liver or to distant sites such as lung or bone; Liver cancer most often metastasizes to the lung or bone; Primary liver cancer includes metastasis sites: lung and bone; Lung and bone are anatomical structures listed as metastasis sites in the ontology; Primary liver cancer originates in the liver but can spread to other organs"},
	{"id":"Medical-5161f780","source":"Medical","question":"What distinguishes primary from secondary liver cancer?","answer":"Primary liver cancer originates in the liver, while secondary liver cancer is cancer that has spread to the liver from another organ.","question_type":"Contextual Summarize","evidence":"Primary liver cancer originates in the liver.; Secondary liver cancer is cancer that has spread to the liver from another organ.","evidence_relations":"Primary liver cancer originates in the liver; Secondary liver cancer is cancer that has spread to the liver from another organ; Primary liver cancer is listed as a cancer type in the ontology; Secondary liver cancer has its origin in other primary cancers (e.g., colon cancer); The ontology distinguishes primary and secondary liver cancer based on origin"},
	{"id":"Medical-2a12c6b8","source":"Medical","question":"How are cirrhosis and its causes linked to liver cancer risk and screening?","answer":"Cirrhosis is a major risk factor for developing liver cancer, particularly hepatocellular carcinoma. It results from long-term liver damage and scarring, which can be caused by chronic hepatitis B or C infection, excessive alcohol use, non-alcoholic fatty liver disease (NAFLD), genetic hemochromatosis, alpha-1-antitrypsin deficiency, and stage 4 primary biliary cholangitis. Because individuals with cirrhosis have a significantly increased risk of liver cancer, they are recommended to undergo regular liver cancer screening. Screening typically includes an abdominal ultrasound and an alpha-fetoprotein (AFP) blood test every 6 months, aiming to detect liver cancer at an early, more treatable stage.","question_type":"Contextual Summarize","evidence":"Cirrhosis is a major risk factor for liver cancer.; Cirrhosis can be caused by hepatitis B.; Cirrhosis can be caused by hepatitis C.; Cirrhosis can be caused by alcohol use.; Cirrhosis can be caused by NAFLD.; Cirrhosis can be caused by genetic hemochromatosis.; Cirrhosis can be caused by alpha-1-antitrypsin deficiency.; Cirrhosis can be caused by stage 4 primary biliary cholangitis.; Cirrhosis determines eligibility for liver cancer screening.","evidence_relations":"Cirrhosis is a major risk factor for developing liver cancer; Alcohol use is a risk factor for cirrhosis and liver cancer; Non-alcoholic fatty liver disease (NAFLD) is a risk factor for cirrhosis and liver cancer; Genetic hemochromatosis is a risk factor for cirrhosis and liver cancer; Alpha-1-antitrypsin deficiency is a risk factor for cirrhosis and liver cancer; Stage 4 primary biliary cholangitis is a risk factor for cirrhosis and liver cancer; Screening for liver cancer is recommended for individuals with cirrhosis"},
	{"id":"Medical-4357e2e4","source":"Medical","question":"What are the main diagnostic methods used for evaluating thyroid nodules and confirming thyroid cancer?","answer":"The main diagnostic methods for evaluating thyroid nodules and confirming thyroid cancer include several steps. First, a thyroid-stimulating hormone (TSH) blood test is performed to assess thyroid function and determine if the nodule is producing thyroid hormone, as nodules that produce hormone are rarely cancerous. Next, a neck ultrasound is used to visualize the size, shape, and characteristics of the nodule and to identify any suspicious lymph nodes. If the ultrasound findings are concerning, a fine-needle aspiration (FNA) biopsy is performed to obtain tissue samples from the nodule. These samples are then reviewed by a pathologist to determine if cancer is present and to identify the specific type of thyroid cancer. In certain cases, especially when the diagnosis is unclear, molecular tests may be used on the biopsy sample to help determine the likelihood of malignancy and guide the need for surgery. Additional imaging, such as CT or MRI, may be recommended if there are suspicious lymph nodes or to further evaluate the extent of disease.","question_type":"Contextual Summarize","evidence":"TSH blood tests are used to evaluate thyroid nodules.; Neck ultrasound is used to evaluate thyroid nodules.; Fine-needle aspiration biopsy is used to confirm thyroid cancer.; Pathology review is used to confirm thyroid cancer.; Molecular tests are used to confirm thyroid cancer.","evidence_relations":"TSH blood test and neck ultrasound are recommended for evaluation of thyroid nodules; Fine-needle aspiration biopsy is used to sample suspicious thyroid nodules; Pathology review determines cancer type and guides treatment; Molecular tests can help determine malignancy and need for surgery; Diagnostic Method includes TSH test, ultrasound, fine-needle aspiration, pathology review, and molecular tests"},
	{"id":"Medical-3dea6ece","source":"Medical","question":"Which risk factors are associated with the development of thyroid cancer?","answer":"Risk factors for thyroid cancer include radiation exposure to the head or neck, family history, and inherited syndromes such as FAP, Carney complex, Cowden syndrome, and MEN.","question_type":"Contextual Summarize","evidence":"Risk factors for thyroid cancer include radiation exposure to the head or neck.; Risk factors for thyroid cancer include family history.; Risk factors for thyroid cancer include inherited syndromes.; Inherited syndromes associated with thyroid cancer include FAP.; Inherited syndromes associated with thyroid cancer include Carney complex.; Inherited syndromes associated with thyroid cancer include Cowden syndrome.; Inherited syndromes associated with thyroid cancer include MEN.","evidence_relations":"Radiation exposure to the head or neck increases risk of thyroid cancer; Family history and inherited syndromes (FAP, Carney complex, Cowden syndrome, MEN) increase risk; Risk Factor includes radiation exposure, family history of thyroid cancer, and inherited syndromes (FAP, Carney complex, Cowden syndrome/PTEN hamartoma tumor syndrome, MEN); Medullary thyroid cancer can be inherited and is associated with RET gene fusion; Risk Factor for papillary, follicular, and oncocytic carcinomas includes radiation exposure, family history, and inherited syndromes"},
	{"id":"Medical-06ba718a","source":"Medical","question":"What are the typical symptoms and signs of thyroid cancer, especially when nodules are large?","answer":"Typical symptoms and signs of thyroid cancer, particularly when nodules are large, include a visible lump in the neck, neck pain, changes in voice (such as hoarseness), difficulty breathing, and problems swallowing. These symptoms occur because large nodules can compress or invade nearby structures in the neck, such as the trachea, esophagus, or nerves controlling the vocal cords. While most thyroid nodules are benign and asymptomatic, the presence of these symptomsespecially in the context of a growing or firm neck massshould prompt evaluation for possible thyroid cancer.","question_type":"Contextual Summarize","evidence":"Typical symptoms of thyroid cancer include a visible neck lump.; Typical symptoms of thyroid cancer include neck pain.; Typical symptoms of thyroid cancer include voice changes.; Typical symptoms of thyroid cancer include trouble breathing.; Typical symptoms of thyroid cancer include problems swallowing.","evidence_relations":"Symptoms of large thyroid nodules include visible neck lump, neck pain, voice changes, trouble breathing, and swallowing problems; Symptom includes visible neck lump, neck pain, voice changes, trouble breathing, and problems swallowing; Papillary thyroid carcinoma symptom list includes visible neck lump, neck pain, voice changes, trouble breathing, and problems swallowing; Thyroid nodules are often benign but can be the origin of thyroid cancer; Symptom is a core concept associated with thyroid cancer"},
	{"id":"Medical-c01491e4","source":"Medical","question":"How are differentiated thyroid cancers (papillary, follicular, oncocytic) treated based on tumor size and spread?","answer":"Treatment of differentiated thyroid cancers (including papillary, follicular, and oncocytic types) is based on tumor size, extent, and spread. For small, low-risk tumors confined to one lobe of the thyroid, a lobectomy (removal of the affected lobe and isthmus) may be sufficient, and may reduce the need for lifelong thyroid hormone replacement. Total thyroidectomy (removal of the entire thyroid gland) is recommended for larger tumors (typically greater than 4 cm), tumors that have invaded beyond the thyroid, or when there is evidence of spread to both lobes. If lymph nodes in the neck are involved, a neck dissection is performed to remove affected nodes. After total thyroidectomy, radioactive iodine (RAI) therapy may be used to destroy any remaining thyroid tissue or microscopic cancer cells, particularly in cases with higher risk features. Lifelong thyroid hormone replacement therapy is required after total thyroidectomy, and may be needed after lobectomy in some cases. The treatment plan is individualized based on tumor characteristics and patient factors.","question_type":"Contextual Summarize","evidence":"Differentiated thyroid cancers are treated with lobectomy for small, confined tumors.; Differentiated thyroid cancers are treated with total thyroidectomy for larger or invasive tumors.; Neck dissection is performed if lymph nodes are involved.; Radioactive iodine therapy may be used post-thyroidectomy if indicated.","evidence_relations":"Papillary, follicular, and oncocytic carcinomas are differentiated thyroid cancers; Lobectomy is an option for small, low-risk differentiated thyroid cancers; Total thyroidectomy is recommended for larger, invasive, or high-risk cancers; Neck dissection is performed if lymph nodes are involved; RAI therapy is used after total thyroidectomy for differentiated thyroid cancers that take up iodine"},
	{"id":"Medical-64c2bdbe","source":"Medical","question":"Which biomarkers and genetic alterations are relevant for thyroid cancer diagnosis and therapy selection?","answer":"Relevant biomarkers and genetic alterations for thyroid cancer diagnosis and therapy selection include BRAF gene mutations (commonly found in papillary and anaplastic thyroid carcinomas), RET gene fusions (notably associated with medullary thyroid cancer), ALK gene fusions, and NTRK gene fusions. Additional molecular features such as mismatch repair deficiency (dMMR), microsatellite instability-high (MSI-H), and tumor mutational burden-high (TMB-H) are also important, as their presence may guide the use of targeted therapies or immunotherapy, particularly in recurrent, advanced, or metastatic thyroid cancers that are not amenable to radioactive iodine (RAI) therapy. Biomarker testing is typically performed on tumor tissue or blood samples and may be done individually or as part of next-generation sequencing panels.","question_type":"Contextual Summarize","evidence":"Relevant biomarkers in thyroid cancer include BRAF gene mutation.; Relevant biomarkers in thyroid cancer include RET gene fusion.; Relevant biomarkers in thyroid cancer include ALK gene fusion.; Relevant biomarkers in thyroid cancer include NTRK gene fusion.; Relevant biomarkers in thyroid cancer include mismatch repair deficiency (dMMR).; Relevant biomarkers in thyroid cancer include microsatellite instability-high (MSI-H).; Relevant biomarkers in thyroid cancer include tumor mutational burden-high (TMB-H).","evidence_relations":"Biomarker testing is recommended for recurrent, advanced, or metastatic cancers not treatable with RAI; Biomarkers include ALK fusion, NTRK fusion, BRAF mutation, RET fusion, dMMR, MSI-H, TMB-H; Papillary thyroid carcinoma biomarkers include BRAF gene mutation, NTRK gene fusion, ALK gene fusion; Medullary thyroid cancer is associated with RET gene fusion; Anaplastic thyroid cancer biomarkers include BRAF gene mutation and other actionable mutations"},
	{"id":"Medical-d76e4df9","source":"Medical","question":"What are the main treatment modalities for advanced, metastatic, or RAI-refractory thyroid cancer?","answer":"Advanced, metastatic, or RAI-refractory thyroid cancer is treated with targeted therapy (kinase inhibitors such as lenvatinib, sorafenib, cabozantinib), external beam radiation therapy, chemotherapy (mainly for anaplastic subtype), and participation in clinical trials.","question_type":"Contextual Summarize","evidence":"Advanced thyroid cancer is treated with targeted therapy.; Kinase inhibitors such as lenvatinib are used in targeted therapy.; Kinase inhibitors such as sorafenib are used in targeted therapy.; Kinase inhibitors such as cabozantinib are used in targeted therapy.; External beam radiation therapy is used for advanced thyroid cancer.; Chemotherapy is mainly used for the anaplastic subtype of thyroid cancer.; Participation in clinical trials is an option for advanced thyroid cancer treatment.","evidence_relations":"Targeted therapy (kinase inhibitors) is used for cancers not responsive to surgery or RAI, or with metastasis; Lenvatinib, sorafenib, and cabozantinib are targeted therapies for progressive, unresectable, or metastatic thyroid cancer; External beam radiation therapy is used for anaplastic, recurrent, or metastatic cancers not amenable to surgery or RAI; Chemotherapy is rarely effective, mainly used for anaplastic thyroid cancer with radiation; Clinical trials are recommended for patients with advanced or metastatic thyroid cancer"},
	{"id":"Medical-0fe6af86","source":"Medical","question":"What follow-up and surveillance strategies are recommended after thyroid cancer treatment?","answer":"Recommended follow-up and surveillance after thyroid cancer treatment depend on the type of surgery and risk of recurrence. After total thyroidectomy, short-term follow-up includes a physical exam, blood tests (thyroid-stimulating hormone [TSH], thyroglobulin [Tg], and anti-thyroglobulin antibodies [Tg ab]), and a neck ultrasound 612 months postoperatively. If radioactive iodine (RAI) therapy was given, a whole-body RAI scan may be performed, especially in high-risk patients or those with abnormal test results. For patients who have undergone lobectomy, follow-up consists of a physical exam, TSH blood test, and neck ultrasound 612 months after surgery; Tg testing is not useful in this setting. Long-term surveillance for all patients with no evidence of disease includes periodic physical exams, blood tests (TSH, and for total thyroidectomy, Tg and Tg ab), and periodic neck ultrasound. If there is suspicion of recurrence, additional laboratory tests, TSH-stimulated testing, or imaging such as CT or MRI may be indicated. Surveillance is continued long-term, as recurrence can occur years after initial treatment.","question_type":"Contextual Summarize","evidence":"Post-treatment follow-up for thyroid cancer includes periodic physical exams.; Post-treatment follow-up for thyroid cancer includes blood tests for TSH.; Post-treatment follow-up for thyroid cancer includes blood tests for thyroglobulin.; Post-treatment follow-up for thyroid cancer includes blood tests for anti-thyroglobulin antibodies.; Post-treatment follow-up for thyroid cancer includes neck ultrasound.; Post-treatment follow-up for thyroid cancer includes whole-body RAI scan if indicated.; Surveillance for thyroid cancer continues long-term.","evidence_relations":"Follow-up after treatment includes physical exam, blood tests (TSH, Tg, Tg ab), and neck ultrasound; After total thyroidectomy: physical exam, TSH, Tg, Tg ab blood tests, neck ultrasound (6-12 months post-op), whole-body RAI scan (if RAI given); After lobectomy: physical exam, TSH blood test, neck ultrasound (6-12 months post-op); Surveillance: Long-term: periodic physical exams, blood tests, neck ultrasound; Rising thyroglobulin after thyroidectomy may indicate recurrence"},
	{"id":"Medical-6c832349","source":"Medical","question":"How is recurrence of thyroid cancer detected and managed?","answer":"Recurrence of thyroid cancer is detected through a combination of rising thyroglobulin (Tg) levels (after total thyroidectomy), neck ultrasound, and additional imaging studies such as CT or MRI if recurrence is suspected. Anti-thyroglobulin antibody levels may also be monitored, as they can interfere with Tg measurement. Management of recurrent thyroid cancer depends on the location and extent of disease. If the recurrence is localized and resectable, surgery is the preferred treatment. For cancers that are iodine-avid, radioactive iodine (RAI) therapy may be used. If the cancer is not amenable to surgery or does not take up iodine, external beam radiation therapy or targeted therapies (such as lenvatinib, sorafenib, or cabozantinib) may be considered, especially for progressive or metastatic disease. Biomarker testing may guide the use of targeted or immunotherapies in certain cases. Enrollment in clinical trials is also recommended if standard therapies are not effective or available.","question_type":"Contextual Summarize","evidence":"Recurrence of thyroid cancer is detected by rising thyroglobulin levels.; Recurrence of thyroid cancer is detected by neck ultrasound.; Recurrence of thyroid cancer is detected by imaging.; Recurrence of thyroid cancer is managed with surgery.; Recurrence of thyroid cancer is managed with radioactive iodine therapy if iodine-avid.; Recurrence of thyroid cancer is managed with external beam radiation therapy.; Recurrence of thyroid cancer is managed with targeted therapy.; Recurrence of thyroid cancer may be managed by enrolling in clinical trials.","evidence_relations":"Rising thyroglobulin after thyroidectomy may indicate recurrence; Neck ultrasound is used in follow-up and recurrence detection; Imaging (CT, MRI) is used for recurrence detection; Recurrence treatment includes surgery (if resectable), RAI therapy (if iodine-avid), external beam radiation therapy, targeted therapy, and clinical trial; Detection of recurrence includes rising thyroglobulin, neck ultrasound, and imaging (CT, MRI)"},
	{"id":"Medical-0dc6b940","source":"Medical","question":"What are the common sites of metastasis for thyroid cancer and the available treatment options?","answer":"Thyroid cancer most commonly metastasizes to the lungs, liver, bones, brain, and spinal cord. Treatment options for metastatic thyroid cancer include radioactive iodine (RAI) therapy for tumors that are iodine-avid, targeted therapies such as kinase inhibitors for cancers that do not respond to RAI or are progressing, and external beam radiation therapy for metastatic sites that cannot be surgically removed or are not amenable to RAI. Clinical trials may also be considered to access investigational treatments. The choice of therapy depends on the cancer type, extent of metastasis, and whether the tumor retains the ability to take up iodine.","question_type":"Contextual Summarize","evidence":"Thyroid cancer most commonly metastasizes to the lungs.; Thyroid cancer most commonly metastasizes to the liver.; Thyroid cancer most commonly metastasizes to the bones.; Thyroid cancer most commonly metastasizes to the brain.; Thyroid cancer most commonly metastasizes to the spinal cord.; Treatment options for metastatic thyroid cancer include radioactive iodine therapy if iodine-avid.; Treatment options for metastatic thyroid cancer include targeted therapy.; Treatment options for metastatic thyroid cancer include external beam radiation therapy.; Treatment options for metastatic thyroid cancer include clinical trials.","evidence_relations":"Metastatic thyroid cancer most commonly spreads to lungs, liver, bones, brain, and spinal cord; Metastasis: Sites include lungs, liver, bones, brain, spinal cord; Metastasis treatment includes RAI therapy (if iodine-avid), targeted therapy, external beam radiation therapy, and clinical trial; Targeted therapy (kinase inhibitors) is used for cancers with metastasis; External beam radiation therapy is used for metastatic cancers not amenable to surgery or RAI"},
	{"id":"Medical-31dd8ffb","source":"Medical","question":"What are the main diagnostic methods used for primary bone cancer and what types of tests are included in the diagnostic process?","answer":"The main diagnostic methods for primary bone cancer include a combination of imaging testssuch as X-ray, bone scan, CT scan, MRI, and PET scanto evaluate the location and extent of the tumor. Diagnosis is confirmed by a biopsy, which may be performed as a core needle biopsy or a surgical biopsy, ideally at a specialized center. Additional tests in the diagnostic process include blood tests (such as alkaline phosphatase, complete blood count, comprehensive metabolic panel, and lactate dehydrogenase), bone marrow tests (aspirate and biopsy), genetic cancer risk testing to identify germline mutations, and biomarker testing to detect gene mutations (e.g., IDH1), protein expression, and tumor mutational burden. These tests help guide treatment planning and assess prognosis.","question_type":"Contextual Summarize","evidence":"Primary bone cancer is diagnosed using imaging tests.; Imaging tests for primary bone cancer include X-ray.; Imaging tests for primary bone cancer include bone scan.; Imaging tests for primary bone cancer include CT scan.; Imaging tests for primary bone cancer include MRI.; Imaging tests for primary bone cancer include PET scan.; A biopsy is used in the diagnosis of primary bone cancer.; Blood tests are included in the diagnostic process for primary bone cancer.; Bone marrow tests are included in the diagnostic process for primary bone cancer.; Genetic cancer risk testing is part of the diagnostic process for primary bone cancer.; Biomarker testing is included in the diagnostic process for primary bone cancer.","evidence_relations":"Diagnosis of bone cancer is confirmed by core needle or surgical biopsy; Imaging tests for bone cancer include X-ray, bone scan, CT scan, MRI, and PET scan; Blood tests such as alkaline phosphatase, CBC, CMP, and LDH are used in evaluation; Genetic cancer risk testing identifies germline mutations associated with increased cancer risk; Biomarker testing includes identification of gene mutations (e.g., IDH1), protein expression, and tumor mutational burden; Biopsy includes core needle biopsy and surgical biopsy; Bone marrow tests include bone marrow aspirate and bone marrow biopsy"},
	{"id":"Medical-8d17a0a2","source":"Medical","question":"Which subtypes of bone sarcoma are recognized and what are their characteristic anatomic locations?","answer":"Recognized subtypes of bone sarcoma include osteosarcoma, which most commonly arises in the metaphysis of long bones near growth plates; Ewing sarcoma, typically found in the diaphysis of long bones and in flat bones such as the pelvis and scapula; chondrosarcoma, which originates from cartilage-forming cells and can occur in various bones; chordoma, which develops from notochordal cells and is usually located in the sacrum or at the base of the skull; and giant cell tumor of bone, which often involves the metaphysis and extends into the epiphysis near joint surfaces.","question_type":"Contextual Summarize","evidence":"Recognized bone sarcoma subtypes include osteosarcoma.; Osteosarcoma is typically located in the metaphysis near growth plates.; Recognized bone sarcoma subtypes include Ewing sarcoma.; Ewing sarcoma is typically located in the diaphysis and flat bones.; Recognized bone sarcoma subtypes include chondrosarcoma.; Chondrosarcoma arises from cartilage-forming cells.; Recognized bone sarcoma subtypes include chordoma.; Chordoma is typically located in the sacrum or base of the skull.; Recognized bone sarcoma subtypes include giant cell tumor of bone.; Giant cell tumor of bone is typically located in the metaphysis and epiphysis.","evidence_relations":"Bone sarcomas include osteosarcoma, Ewing sarcoma, chondrosarcoma, chordoma, and giant cell tumor of bone; Osteosarcoma commonly arises in the metaphysis near growth plates; Ewing sarcoma is characterized by EWSR1-ETS gene fusions, most commonly EWSR1-FLI1; Chondrosarcoma starts in cartilage-forming cells; Chordoma arises from notochordal cells, typically in the sacrum or base of skull; Giant cell tumor of bone often occurs in the metaphysis and epiphysis; Ewing sarcoma anatomic location: diaphysis, flat bones (pelvis, scapula)"},
	{"id":"Medical-0002d2de","source":"Medical","question":"How are bone cancers staged and what factors are considered in determining the stage?","answer":"Bone cancers are staged using the TNM system, which considers tumor size/location (T), lymph node involvement (N), metastasis (M), and tumor grade (G), with the final stage determined by combining these scores.","question_type":"Contextual Summarize","evidence":"Bone cancers are staged using the TNM system.; The TNM system considers tumor size and location (T).; The TNM system considers lymph node involvement (N).; The TNM system considers metastasis (M).; The TNM system considers tumor grade (G).; The final stage of bone cancer is determined by combining TNM scores.","evidence_relations":"Staging uses the TNM system: T (tumor size/location), N (lymph node involvement), M (metastasis); Tumor grade (G) describes histologic differentiation; Stage is determined by combining T, N, M, and G scores; Numbered stages include Stage I, Stage II, Stage III, and Stage IV; TNM staging includes T1-T4, N0-N1, M0-M1; Tumor grade includes G1, G2, G3, GX"},
	{"id":"Medical-6da13b57","source":"Medical","question":"What are the key biomarkers and genetic alterations in bone cancer, and how do they inform targeted therapy?","answer":"Key biomarkers and genetic alterations in bone cancer include EWSR1-FLI1 and EWSR1-ERG fusions in Ewing sarcoma, IDH1 mutation in chondrosarcoma (targeted by ivosidenib), and MSI-H/dMMR or TMB-H status (treated with pembrolizumab, nivolumab, or ipilimumab).","question_type":"Contextual Summarize","evidence":"Key biomarkers in bone cancer include EWSR1-FLI1 fusions.; EWSR1-FLI1 fusions are associated with Ewing sarcoma.; Key biomarkers in bone cancer include EWSR1-ERG fusions.; IDH1 mutation is a key alteration in chondrosarcoma.; IDH1 mutation can be targeted by ivosidenib.; MSI-H/dMMR or TMB-H status are key alterations in bone cancer.; MSI-H/dMMR or TMB-H status can be treated with pembrolizumab.; MSI-H/dMMR or TMB-H status can be treated with nivolumab.; MSI-H/dMMR or TMB-H status can be treated with ipilimumab.","evidence_relations":"Ewing sarcoma is characterized by EWSR1-ETS gene fusions, most commonly EWSR1-FLI1; IDH1 mutation in chondrosarcoma can be targeted with ivosidenib; MSI-H/dMMR status may be treated with pembrolizumab; Tumor mutational burden-high (TMB-H) may be treated with pembrolizumab, nivolumab, or ipilimumab; Biomarker testing includes identification of gene mutations (e.g., IDH1), protein expression, and tumor mutational burden; Genetic Alteration includes EWSR1-FLI1 fusion, EWSR1-ERG fusion, IDH1 mutation, MSI-H, dMMR, TMB-H"},
	{"id":"Medical-3e66af03","source":"Medical","question":"What are the main risk factors and symptoms associated with primary bone cancer?","answer":"Primary bone cancer risk factors include a family history of cancer and the presence of germline mutations, which can be identified through genetic cancer risk testing. Common symptoms associated with primary bone cancer are persistent bone pain and hypercalcemia, which occurs as a result of bone destruction by the tumor. Additional evaluation may include a thorough medical and family history, physical examination, and diagnostic testing to confirm the diagnosis and guide treatment.","question_type":"Contextual Summarize","evidence":"Primary bone cancer risk factors include family history of cancer.; Primary bone cancer risk factors include germline mutations.; Common symptoms of primary bone cancer include bone pain.; Common symptoms of primary bone cancer include hypercalcemia.; Hypercalcemia results from bone destruction.","evidence_relations":"Risk Factor includes Family history of cancer, Germline mutations; Genetic cancer risk testing identifies germline mutations associated with increased cancer risk; Bone cancer can cause hypercalcemia due to bone destruction; Symptom includes Bone pain, Hypercalcemia; Primary bone cancer originates in bone or cartilage"},
	{"id":"Medical-5f6b723d","source":"Medical","question":"How does performance status influence treatment planning in bone cancer patients?","answer":"Performance status, evaluated using scales such as the Eastern Cooperative Oncology Group (ECOG) or Karnofsky Performance Status (KPS), is a key factor in treatment planning for bone cancer patients. These scales assess a patient's general level of fitness and ability to perform daily activities, which helps guide the selection and intensity of treatment options. A lower performance status may limit the suitability of aggressive therapies, while a higher performance status may allow for more intensive treatment approaches. Incorporating performance status into treatment planning ensures that therapy is tailored to the patient's overall health and functional capacity.","question_type":"Contextual Summarize","evidence":"Performance status is assessed by ECOG or Karnofsky Performance Status (KPS).; Performance status is an important consideration in treatment planning for bone cancer patients.","evidence_relations":"Performance status (ECOG or KPS) is considered in treatment planning; Performance Status includes ECOG performance status, Karnofsky Performance Status (KPS); ECOG and KPS are used to assess patient functional status; Treatment planning for bone cancer incorporates performance status; ECOG and KPS are performance status scales included in the ontology"},
	{"id":"Medical-d72543ef","source":"Medical","question":"What fertility considerations should be addressed prior to initiating bone cancer treatment?","answer":"Because some treatments for bone cancer can affect fertility, fertility preservation should be discussed with patients before starting therapy.","question_type":"Contextual Summarize","evidence":"Some treatments for bone cancer can affect fertility.; Fertility preservation should be discussed with patients before starting therapy.","evidence_relations":"Some treatments for bone cancer can affect fertility; fertility preservation should be discussed before treatment; Fertility Consideration includes Fertility preservation; Fertility preservation is a consideration prior to therapy; Certain treatments may impact reproductive potential; Fertility preservation is included in the ontology as a consideration for bone cancer patients"},
	{"id":"Medical-ee0d07fe","source":"Medical","question":"How do primary and secondary bone cancers differ in origin and classification?","answer":"Primary bone cancer arises from bone or cartilage, most commonly as sarcomas, whereas secondary bone malignancies are cancers that have metastasized to bone from other organs such as breast, lung, or kidney.","question_type":"Contextual Summarize","evidence":"Primary bone cancer arises from bone or cartilage.; Primary bone cancer is most commonly classified as sarcomas.; Secondary bone malignancies are cancers that have metastasized to bone.; Secondary bone malignancies can originate from other organs such as breast, lung, or kidney.","evidence_relations":"Primary bone cancer originates in bone or cartilage; Most primary bone cancers are sarcomas; Secondary bone malignancies are cancers that have metastasized to bone from other organs; Secondary bone malignancy origin includes breast cancer, lung cancer, kidney cancer; Bone sarcomas include osteosarcoma, Ewing sarcoma, chondrosarcoma, chordoma, and giant cell tumor of bone"},
	{"id":"Medical-880d8f25","source":"Medical","question":"What is the role of biomarker and genetic testing in the evaluation and management of bone cancer?","answer":"Biomarker and genetic testing play a crucial role in the evaluation and management of bone cancer. Biomarker testing involves analyzing tumor samples for specific gene mutations (such as IDH1), protein expression levels, and tumor mutational burden (TMB). These findings can help identify patients who may benefit from targeted therapies, such as ivosidenib for IDH1-mutated chondrosarcoma or immune checkpoint inhibitors like pembrolizumab for tumors with high microsatellite instability (MSI-H), deficient mismatch repair (dMMR), or high TMB. Genetic cancer risk testing, typically performed on blood or saliva, identifies inherited (germline) mutations that may increase the risk of bone cancer and other malignancies, informing both patient management and family counseling. Together, these tests assist in risk assessment, guide personalized treatment decisions, and may influence prognosis.","question_type":"Contextual Summarize","evidence":"Biomarker and genetic testing in bone cancer involve identifying gene mutations.; Biomarker and genetic testing in bone cancer involve identifying protein expression.; Biomarker and genetic testing in bone cancer involve identifying tumor mutational burden.; Biomarker and genetic testing aid in risk assessment for bone cancer.; Biomarker and genetic testing guide targeted therapy options for bone cancer.","evidence_relations":"Biomarker testing includes identification of gene mutations (e.g., IDH1), protein expression, and tumor mutational burden; Genetic cancer risk testing identifies germline mutations associated with increased cancer risk; IDH1 mutation in chondrosarcoma can be targeted with ivosidenib; MSI-H/dMMR status may be treated with pembrolizumab; Tumor mutational burden-high (TMB-H) may be treated with pembrolizumab, nivolumab, or ipilimumab"},
	{"id":"Medical-2a43b505","source":"Medical","question":"What are the main diagnostic methods and clinical assessments used for mouth cancer?","answer":"The main diagnostic methods and clinical assessments for mouth cancer include a combination of imaging studies, tissue sampling, and functional evaluations. Imaging tests such as computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography/computed tomography (PET/CT), ultrasound, and panoramic dental x-ray (Panorex) are used to assess the extent of the tumor, involvement of surrounding structures, and possible lymph node or distant metastases. A biopsy is essential to confirm the diagnosis and determine the histological subtype of the cancer; this may involve techniques such as fine-needle aspiration (FNA), core needle biopsy (CNB), or surgical biopsy, sometimes guided by imaging. Clinical assessments include a thorough dental examination, evaluation of speech and swallowing function, nutritional assessment, and assessment of performance status using tools such as the ECOG scale. In some cases, biomarker testing or molecular profiling may be performed, particularly in advanced disease, to help guide treatment decisions.","question_type":"Contextual Summarize","evidence":"Mouth cancer diagnosis relies on imaging tests.; Imaging tests for mouth cancer include CT.; Imaging tests for mouth cancer include MRI.; Imaging tests for mouth cancer include PET/CT.; Imaging tests for mouth cancer include ultrasound.; Imaging tests for mouth cancer include Panorex.; A biopsy is used in the diagnosis of mouth cancer.; Clinical assessments for mouth cancer include dental exam.; Clinical assessments for mouth cancer include speech and swallowing assessment.; Clinical assessments for mouth cancer include nutrition assessment.; Clinical assessments for mouth cancer include evaluation of performance status (ECOG).","evidence_relations":"Imaging tests such as CT, MRI, PET/CT, and ultrasound are used for diagnosis and staging; Biopsy is required to confirm diagnosis and determine histology; Panoramic dental x-ray (Panorex) is listed as a diagnostic method for mouth cancer; Clinical assessments include dental exam, speech and swallowing assessment, and nutrition assessment; Performance status (ECOG) is considered in treatment selection"},
	{"id":"Medical-181fe114","source":"Medical","question":"How is mouth cancer staged and what criteria are used in the TNM classification?","answer":"Mouth cancer staging is based on the TNM system, which evaluates tumor size and depth (T), lymph node involvement (N), and distant metastasis (M), with depth of invasion (DOI) specifically used to assess tumor extension.","question_type":"Contextual Summarize","evidence":"Mouth cancer staging is based on the TNM system.; The TNM system evaluates tumor size and depth.; The TNM system evaluates lymph node involvement.; The TNM system evaluates distant metastasis.; Depth of invasion (DOI) is used to assess tumor extension.","evidence_relations":"Cancer staging is based on the TNM system, which includes tumor size and depth (T), lymph node involvement (N), and distant metastasis (M); Depth of invasion (DOI) is used to assess tumor extension in mouth cancer; TNM staging is listed as part of the ontology for mouth cancer; The TNM classification includes Tis, T1, T2, T3, T4a, and T4b categories; Regional lymph node and extranodal extension are specified in the TNM system"},
	{"id":"Medical-251615ea","source":"Medical","question":"Which anatomic sites are commonly affected by squamous cell carcinoma (SCC) of the mouth?","answer":"Squamous cell carcinoma (SCC) of the mouth commonly affects the lips, gums, buccal mucosa, tongue (front two-thirds), hard palate, alveolar ridge, floor of mouth, and retromolar trigone.","question_type":"Contextual Summarize","evidence":"Squamous cell carcinoma (SCC) of the mouth commonly affects the lips.; SCC of the mouth commonly affects the gums.; SCC of the mouth commonly affects the buccal mucosa.; SCC of the mouth commonly affects the front two-thirds of the tongue.; SCC of the mouth commonly affects the hard palate.; SCC of the mouth commonly affects the alveolar ridge.; SCC of the mouth commonly affects the floor of mouth.; SCC of the mouth commonly affects the retromolar trigone.","evidence_relations":"Squamous cell carcinoma (SCC) is the most common subtype of mouth cancer; Mouth cancer can develop in the lips, gums, buccal mucosa, tongue, hard palate, alveolar ridge, floor of mouth, and retromolar trigone; SCC's anatomic sites include: Lips (mucosal lip), Gums (gingiva), Buccal mucosa, Tongue (front two-thirds), Hard palate, Alveolar ridge, Floor of mouth, Retromolar trigone; The ontology lists these sites under SCC of mouth cancer; Oral cavity cancer is another term for mouth cancer, encompassing these sites"},
	{"id":"Medical-1e74344c","source":"Medical","question":"What biomarkers are tested in mouth cancer and how might they inform management?","answer":"Biomarker testing in mouth cancer may include assessment of PD-L1 expression, microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR), and tumor mutational burden (TMB). These biomarkers can provide important information for prognosis and may influence treatment planning. For example, PD-L1 expression can help determine eligibility for certain immunotherapies, while MSI-H/dMMR status and TMB may identify patients who could benefit from targeted or immune-based therapies. Although molecular testing has a more limited role in mouth cancer compared to some other cancers, these biomarkers are increasingly considered in advanced or metastatic cases to help guide personalized treatment decisions.","question_type":"Contextual Summarize","evidence":"Biomarker testing in mouth cancer may include PD-L1.; Biomarker testing in mouth cancer may include MSI-H/dMMR.; Biomarker testing in mouth cancer may include tumor mutational burden (TMB).; Biomarker testing can provide information relevant to prognosis.; Biomarker testing can provide information relevant to treatment planning.","evidence_relations":"Biomarker testing may include PD-L1, MSI-H/dMMR, and tumor mutational burden (TMB); Biomarker is a core concept for mouth cancer in the ontology; PD-L1, MSI-H/dMMR, and TMB are listed as biomarkers under SCC of mouth cancer; Biomarker testing is included in the management of mouth cancer; Biomarker results may influence treatment decisions"},
	{"id":"Medical-69c5e22f","source":"Medical","question":"What are the major risk factors for developing mouth cancer and their impact on outcomes?","answer":"Major risk factors for developing mouth cancer include tobacco use (such as smoking cigarettes or using smokeless tobacco), alcohol use, smoking, and vaping. These factors significantly increase the likelihood of developing mouth cancer. Continued use of tobacco products or vaping during and after diagnosis not only raises the risk of developing mouth cancer but also negatively impacts treatment outcomes by increasing treatment toxicity and reducing the effectiveness of therapy. Therefore, cessation of smoking and vaping is strongly recommended to improve prognosis and reduce complications.","question_type":"Contextual Summarize","evidence":"Tobacco use is a major risk factor for mouth cancer.; Alcohol use is a major risk factor for mouth cancer.; Smoking is a major risk factor for mouth cancer.; Vaping is a major risk factor for mouth cancer.; Continued smoking negatively affects treatment outcomes.; Continued vaping negatively affects treatment outcomes.; Continued smoking increases toxicity.","evidence_relations":"Tobacco and alcohol use are risk factors for mouth cancer; Smoking or vaping negatively affects treatment outcomes and increases toxicity; Risk factors for mouth cancer include tobacco use, alcohol use, smoking, and vaping; These risk factors are listed in the ontology for SCC of mouth cancer; Alcohol and tobacco are repeatedly cited as important contributors to mouth cancer risk"},
	{"id":"Medical-61a5ec94","source":"Medical","question":"How is treatment for mouth cancer determined and what factors are considered in planning?","answer":"Treatment for mouth cancer is determined by several key factors, including the location of the tumor within the oral cavity, the stage of the cancer (which reflects the size of the tumor, involvement of nearby lymph nodes, and presence of metastasis), and the patient's overall performance status, often assessed using the ECOG scale. Additional considerations may include results from imaging studies, biopsy findings, and, in some cases, molecular or biomarker testing of the tumor. These factors help guide the selection of the most appropriate therapy, which may involve surgery, radiation, chemotherapy, or targeted therapies. The goal is to tailor treatment to the individual patient's disease characteristics and overall health to optimize outcomes.","question_type":"Contextual Summarize","evidence":"Treatment planning for mouth cancer is based on tumor location.; Treatment planning for mouth cancer is based on tumor stage.; Performance status (ECOG) is considered in treatment planning.","evidence_relations":"Treatment planning is based on tumor location and stage; Performance status (ECOG) is considered in treatment selection; Stage and anatomic site are included in the ontology as determinants for treatment; Mouth cancer management includes assessment of performance status; Tumor location is a key factor in the treatment decision process"},
	{"id":"Medical-088c7ad0","source":"Medical","question":"What are the common symptoms and additional health considerations for patients with mouth cancer?","answer":"Common symptoms of mouth cancer include changes in the mouth, tongue, or neck area, such as persistent sores, lumps, or patches in the oral cavity, difficulty chewing or swallowing, and unexplained bleeding. Additional health considerations for patients with mouth cancer include the impact of both the cancer and its treatment on dental health, which may affect the jaw, teeth, and gums, making regular dental exams and care important. Furthermore, cancer and its treatment can affect fertility, so fertility preservation should be discussed as part of the management plan.","question_type":"Contextual Summarize","evidence":"Symptoms of mouth cancer may include changes in the mouth.; Symptoms of mouth cancer may include changes in the tongue.; Symptoms of mouth cancer may include changes in the neck area.; Both the cancer and its treatment can impact dental health.; Both the cancer and its treatment can impact fertility.","evidence_relations":"Symptoms may include changes in the mouth, tongue, or neck area; Dental health is affected by head and neck cancer and its treatment; Cancer and its treatment can affect fertility; Fertility preservation is listed as a consideration in the ontology; Dental exam is included in the clinical assessment for mouth cancer"},
	{"id":"Medical-b17a5c65","source":"Medical","question":"What fertility considerations are relevant for patients with mouth cancer?","answer":"Cancer and its treatment can affect fertility, so fertility preservation is an important consideration in the management of mouth cancer.","question_type":"Contextual Summarize","evidence":"Cancer and its treatment can affect fertility.; Fertility preservation is an important consideration in the management of mouth cancer.","evidence_relations":"Cancer and its treatment can affect fertility; Fertility preservation is included as a consideration in the ontology; Fertility Consideration is a core concept for mouth cancer; Fertility preservation is listed as an option for patients; Mouth cancer management includes assessment of fertility impact"},
	{"id":"Medical-c9e77dca","source":"Medical","question":"What is the relationship between mouth cancer, its subtypes, and head and neck cancer?","answer":"Mouth cancer, also known as oral cavity cancer, is a subtype of head and neck cancer, with squamous cell carcinoma (SCC) being the most common form.","question_type":"Contextual Summarize","evidence":"Mouth cancer is also known as oral cavity cancer.; Mouth cancer is a subtype of head and neck cancer.; Squamous cell carcinoma (SCC) is the most common form of mouth cancer.","evidence_relations":"Mouth cancer is a type of head and neck cancer; Oral cavity cancer is another term for mouth cancer; Squamous cell carcinoma (SCC) is the most common subtype of mouth cancer; The ontology lists mouth cancer under head and neck cancer; Mouth cancer is further classified into subtypes such as SCC"},
	{"id":"Medical-eb6686a0","source":"Medical","question":"What are the main diagnostic methods and risk factors for stomach cancer?","answer":"The main diagnostic methods for stomach cancer include imaging tests (such as CT scans), endoscopy procedures to directly visualize the stomach lining, biopsy to obtain tissue samples for pathological examination, biomarker testing to identify specific molecular features of the tumor, and genetic risk testing to assess inherited predispositions. Key risk factors for developing stomach cancer are infection with Helicobacter pylori (H. pylori) and a family history of stomach cancer.","question_type":"Contextual Summarize","evidence":"Stomach cancer is diagnosed using imaging tests.; Stomach cancer is diagnosed using endoscopy.; Stomach cancer is diagnosed using biopsy.; Stomach cancer is diagnosed using biomarker testing.; Stomach cancer is diagnosed using genetic risk testing.; Risk factors for stomach cancer include H. pylori infection.; Risk factors for stomach cancer include family history.","evidence_relations":"Diagnosis involves imaging tests, endoscopy, biopsy, biomarker testing, and genetic risk testing; H. pylori infection is a risk factor for stomach cancer; Family history is a risk factor for stomach cancer; Stomach cancer includes diagnostic methods: imaging tests, endoscopy, biopsy, biomarker testing, genetic risk testing; Stomach cancer includes risk factors: H. pylori infection, family history"},
	{"id":"Medical-4641d74e","source":"Medical","question":"How are the stages of stomach cancer defined and what patterns of spread are associated with each stage?","answer":"Early-stage stomach cancer is confined to the mucosa and not present in lymph nodes, locoregional stomach cancer invades other stomach wall layers and/or regional lymph nodes or nearby organs, while metastatic stomach cancer spreads to distant organs such as the liver, peritoneum, and distant lymph nodes.","question_type":"Contextual Summarize","evidence":"Early-stage stomach cancer is confined to the mucosa.; Early-stage stomach cancer is not present in lymph nodes.; Locoregional stomach cancer invades other stomach wall layers.; Locoregional stomach cancer invades regional lymph nodes.; Locoregional stomach cancer invades nearby organs.; Metastatic stomach cancer spreads to distant organs.; Metastatic stomach cancer spreads to the liver.; Metastatic stomach cancer spreads to the peritoneum.; Metastatic stomach cancer spreads to distant lymph nodes.","evidence_relations":"Early-stage stomach cancer is confined to the mucosa and is not present in lymph nodes; Locoregional or locally advanced stomach cancer invades other layers of the stomach wall and/or regional lymph nodes or nearby organs; Metastatic stomach cancer has spread to distant organs such as the liver, peritoneum, or distant lymph nodes; Cancer can spread to lymph nodes, veins, arteries, and organs such as the liver, pancreas, and spleen; Spread Pattern: Local includes stomach wall layers and regional lymph nodes; Distant includes liver, peritoneum, distant lymph nodes, pancreas, and spleen"},
	{"id":"Medical-9e6a8495","source":"Medical","question":"What are the major subtypes of stomach adenocarcinoma and how do they differ in cellular structure and clinical features?","answer":"The two major subtypes of stomach adenocarcinoma are the intestinal type and the diffuse type. The intestinal type is characterized by cells that adhere to each other and form tube- and gland-shaped structures, and it is more likely to harbor mutations that can be targeted with specific therapies. In contrast, the diffuse type is less common and is composed of cells that do not stick together, appearing scattered over a wide area, which makes it more difficult to detect on the surface. These differences in cellular structure also influence clinical features and treatment approaches.","question_type":"Contextual Summarize","evidence":"Stomach adenocarcinoma consists of intestinal and diffuse subtypes.; The intestinal subtype forms tube- and gland-shaped structures.; The intestinal subtype is more likely to have mutations treatable with targeted therapy.; The diffuse subtype consists of scattered cells.; The diffuse subtype is less common than the intestinal subtype.","evidence_relations":"There are two major subtypes of stomach adenocarcinoma: intestinal and diffuse; Intestinal type adenocarcinoma forms tube- and gland-shaped structures and is more likely to have mutations treatable with targeted therapy; Diffuse type adenocarcinoma consists of scattered cells and is less common; Adenocarcinomas originate from cells lining the inside of the stomach that secrete mucus; Adenocarcinoma has subtypes: Intestinal type adenocarcinoma, Diffuse type adenocarcinoma"},
	{"id":"Medical-6f917f07","source":"Medical","question":"What are the anatomical locations and wall layers relevant to stomach cancer development and progression?","answer":"Stomach cancer can develop in anatomical locations such as the cardia, fundus, body, antrum, pylorus, and esophagogastric junction, and progresses outward through the stomach wall layers: mucosa, submucosa, muscle layer (muscularis propria), subserosa, and serosa.","question_type":"Contextual Summarize","evidence":"Stomach cancer can develop in the cardia.; Stomach cancer can develop in the fundus.; Stomach cancer can develop in the body.; Stomach cancer can develop in the antrum.; Stomach cancer can develop in the pylorus.; Stomach cancer can develop in the esophagogastric junction.; Stomach cancer progresses outward through the mucosa.; Stomach cancer progresses outward through the submucosa.; Stomach cancer progresses outward through the muscle layer (muscularis propria).; Stomach cancer progresses outward through the subserosa.; Stomach cancer progresses outward through the serosa.","evidence_relations":"Anatomical Location: Cardia, Fundus, Body, Antrum, Pylorus, Esophagogastric junction; Stomach Wall Layer: Mucosa, Submucosa, Muscle layer (muscularis propria), Subserosa, Serosa; Stomach cancer spreads outward through the layers of the stomach wall; Precancerous changes often occur in the mucosa before cancer develops; Stomach cancer develops in various anatomical locations and progresses through defined wall layers"},
	{"id":"Medical-6b047fee","source":"Medical","question":"What are the key symptoms and physical manifestations of stomach cancer?","answer":"Key symptoms and physical manifestations of stomach cancer include the formation of ulcers or masses within the stomach. These lesions may cause additional symptoms such as abdominal discomfort, pain, or bleeding, depending on their size and location. As the cancer progresses, it can also lead to more generalized symptoms related to tumor growth and possible spread to nearby lymph nodes or organs.","question_type":"Contextual Summarize","evidence":"Stomach cancer can present with ulcer formation in the stomach.; Stomach cancer can present with mass formation in the stomach.","evidence_relations":"Symptoms can include ulcer or mass formation in the stomach; Symptom: Ulcer, Mass; Stomach cancer is associated with the formation of ulcers and masses; Ulcer and mass are listed as symptoms of stomach cancer in the ontology; Ulcer and mass are physical manifestations of stomach cancer"},
	{"id":"Medical-a9f73379","source":"Medical","question":"How does stomach cancer typically spread within and beyond the stomach?","answer":"Stomach cancer spreads locally through the stomach wall layers and regional lymph nodes, and distantly to organs such as the liver, peritoneum, distant lymph nodes, pancreas, and spleen.","question_type":"Contextual Summarize","evidence":"Stomach cancer spreads locally through the stomach wall layers.; Stomach cancer spreads to regional lymph nodes.; Stomach cancer spreads distantly to the liver.; Stomach cancer spreads distantly to the peritoneum.; Stomach cancer spreads distantly to distant lymph nodes.; Stomach cancer spreads distantly to the pancreas.; Stomach cancer spreads distantly to the spleen.","evidence_relations":"Stomach cancer spreads outward through the layers of the stomach wall; Spread Pattern: Local includes stomach wall layers and regional lymph nodes; Spread Pattern: Distant includes liver, peritoneum, distant lymph nodes, pancreas, and spleen; Cancer can spread to lymph nodes, veins, arteries, and organs such as the liver, pancreas, and spleen; Metastatic stomach cancer has spread to distant organs such as the liver, peritoneum, or distant lymph nodes"},
	{"id":"Medical-77d91ba8","source":"Medical","question":"Which risk factors and genetic predispositions are associated with stomach cancer development?","answer":"Risk factors for developing stomach cancer include infection with Helicobacter pylori (H. pylori), which is a significant contributor to gastric carcinogenesis, and a family history of stomach cancer, indicating a possible inherited genetic predisposition. Genetic risk testing may be used to identify individuals with inherited susceptibility to stomach cancer. Assessment of family history and genetic factors is important in evaluating overall risk.","question_type":"Contextual Summarize","evidence":"H. pylori infection is a risk factor for stomach cancer.; Family history is a risk factor for stomach cancer.; Genetic risk testing is used to identify inherited predispositions to stomach cancer.","evidence_relations":"H. pylori infection is a risk factor for stomach cancer; Family history is a risk factor for stomach cancer; Genetic Risk Factor: Family history; Risk Factor: H. pylori infection, Family history; Diagnosis involves genetic risk testing"},
	{"id":"Medical-e1db913e","source":"Medical","question":"What sequence of pathological changes leads to the development of stomach cancer?","answer":"Stomach cancer typically develops through a sequence of pathological changes that begin with precancerous alterations in the innermost layer of the stomach wall, known as the mucosa. These early changes often go undetected because they rarely cause symptoms. Over time, these precancerous changes can progress to cancer, most commonly adenocarcinomas, which originate from the mucus-secreting cells lining the inside of the stomach. As the cancer develops, it starts in the mucosa and can grow outward through the other layers of the stomach wall, potentially invading nearby lymph nodes and, in advanced stages, spreading to distant organs such as the liver, peritoneum, and distant lymph nodes.","question_type":"Contextual Summarize","evidence":"Stomach cancer often develops after precancerous changes occur in the mucosa.; Adenocarcinomas originate from mucus-secreting cells lining the stomach.","evidence_relations":"Precancerous changes often occur in the mucosa before cancer develops; Adenocarcinomas originate from cells lining the inside of the stomach that secrete mucus; Early-stage stomach cancer is confined to the mucosa; Stomach Wall Layer: Mucosa is the innermost layer; Stomach cancer arises in the stomach"},
	{"id":"Medical-05f3bf13","source":"Medical","question":"What are the main subtypes of glioma and how are they classified by grade and biomarkers?","answer":"The main subtypes of glioma are astrocytoma, oligodendroglioma, and glioblastoma. Gliomas are classified based on histology (the microscopic appearance of the tumor cells), tumor grade, and molecular biomarkers. Tumor grade reflects how abnormal the cells appear and how quickly the tumor is likely to grow: grades 1 and 2 are considered low-grade gliomas, while grades 3 and 4 are high-grade, with grade 4 (glioblastoma) being the most aggressive. Biomarkers, such as mutations in the IDH gene, are also used to further classify gliomas and guide treatment decisions. For example, an astrocytoma with an IDH mutation would be classified as an 'astrocytoma, IDH-mutant,' and the grade would indicate its growth rate and prognosis.","question_type":"Contextual Summarize","evidence":"The main subtypes of glioma are astrocytoma, oligodendroglioma, and glioblastoma.; Gliomas are classified by histology.; Gliomas are classified by grade.; Grades 1 and 2 are considered low-grade gliomas.; Grades 3 and 4 are considered high-grade gliomas.; Gliomas are classified by biomarkers such as IDH mutation.","evidence_relations":"Astrocytoma, oligodendroglioma, and glioblastoma are the most common subtypes of glioma; Gliomas are classified by histology, grade, and biomarkers; Grades 1 and 2 are low-grade gliomas; grades 3 and 4 are high-grade gliomas; IDH mutation is a biomarker used to classify gliomas; Astrocytoma and oligodendroglioma both include IDH mutation as a biomarker in the ontology"},
	{"id":"Medical-2148aacc","source":"Medical","question":"What diagnostic methods are used to identify and classify gliomas?","answer":"The diagnosis and classification of gliomas involve several steps. Initially, a neurological examination is performed to assess symptoms and neurological function. Imaging studies, particularly MRI (the most useful imaging modality), and sometimes CT scans, are used to identify the presence, location, and characteristics of the brain tumor. Definitive diagnosis requires tissue sampling through biopsy, which may be performed as a stereotactic biopsy, open biopsy, or during surgical resection. The tissue sample is analyzed by a neuropathologist using histology (microscopic examination of cell type), grading (assessment of how abnormal and aggressive the tumor cells are), and molecular testing for biomarkers (such as genetic mutations). These three factorshistology, grade, and biomarkersare combined to fully classify the glioma and guide treatment planning.","question_type":"Contextual Summarize","evidence":"Glioma diagnosis involves a neurological exam.; Glioma diagnosis involves imaging such as MRI and CT scan.; Tissue sampling through biopsy is used for glioma diagnosis.; MRI is the most useful imaging test for glioma diagnosis.; Biopsy is required for definitive diagnosis and molecular testing of gliomas.","evidence_relations":"Diagnosis of glioma involves neurological exam, imaging (MRI, CT), and biopsy; MRI is the most useful imaging test for identifying glioma; Biopsy is required for definitive diagnosis and molecular testing; Clinical Evaluation includes neurological exam and performance status; Imaging includes MRI and CT scan; tissue sampling includes biopsy, stereotactic biopsy, open biopsy, and resection"},
	{"id":"Medical-5905da7e","source":"Medical","question":"What are the typical symptoms experienced by patients with glioma?","answer":"Glioma commonly presents with symptoms such as headache, seizures, fatigue, nausea, vomiting, cognitive changes, memory loss, speech difficulties, muscle weakness, balance problems, personality changes, and vision problems.","question_type":"Contextual Summarize","evidence":"Glioma commonly presents with headache.; Glioma commonly presents with seizures.; Glioma commonly presents with fatigue.; Glioma commonly presents with nausea.; Glioma commonly presents with vomiting.; Glioma commonly presents with cognitive changes.; Glioma commonly presents with memory loss.; Glioma commonly presents with speech difficulties.; Glioma commonly presents with muscle weakness.; Glioma commonly presents with balance problems.; Glioma commonly presents with personality changes.; Glioma commonly presents with vision problems.","evidence_relations":"Symptoms of glioma include headache, seizures, fatigue, nausea, vomiting, cognitive changes, weakness, personality changes, and vision problems; Symptom list in ontology includes memory loss, speech difficulties, muscle weakness, balance problems, personality changes, and vision problems; Headache is a symptom of glioma; Seizure is a symptom of glioma; Cognitive changes and personality changes are symptoms of glioma"},
	{"id":"Medical-74be0fed","source":"Medical","question":"What are the standard treatment options for glioma and how does grade influence therapy?","answer":"Standard treatment options for glioma include surgery (either resection or biopsy), radiation therapy, chemotherapy, and participation in clinical trials. The choice of therapy is strongly influenced by the tumor grade. Low-grade gliomas (grades 1 and 2) may be managed with surgery alone if complete resection is possible, but additional therapy may be considered if the tumor recurs or cannot be fully removed. High-grade gliomas (grades 3 and 4), which are more aggressive and rapidly growing, require additional therapy after surgery, typically involving radiation and chemotherapy to help control tumor growth and prolong survival. Biomarker testing may also guide treatment decisions in some cases. While gliomas are rarely curable, these treatments can slow tumor progression, reduce symptoms, and extend life.","question_type":"Contextual Summarize","evidence":"Standard treatment options for glioma include surgery.; Standard treatment options for glioma include radiation therapy.; Standard treatment options for glioma include chemotherapy.; Standard treatment options for glioma include clinical trials.; High-grade gliomas require additional therapy after surgery.","evidence_relations":"Treatment options for glioma include surgery, radiation therapy, chemotherapy, and clinical trials; Surgery may involve resection or biopsy; High-grade gliomas require additional therapy after surgery; Treatment ontology includes surgery, radiation therapy, chemotherapy, and clinical trial; Gliomas are rarely curable but are treatable"},
	{"id":"Medical-1991db28","source":"Medical","question":"How is follow-up care managed in patients with glioma?","answer":"Follow-up care for glioma patients involves periodic imaging, especially follow-up MRI, to monitor for recurrence after initial treatment.","question_type":"Contextual Summarize","evidence":"Follow-up care for glioma patients involves periodic imaging.; Follow-up MRI is especially important for glioma patients.; Periodic imaging is used to monitor for recurrence after initial treatment.","evidence_relations":"Follow-up with periodic imaging (MRI) is recommended to monitor for recurrence; Follow-up MRI is included in the follow-up ontology; Periodic imaging is part of follow-up care for glioma; MRI is the most useful imaging test for identifying glioma; Gliomas are rarely curable but are treatable, necessitating ongoing monitoring"},
	{"id":"Medical-f3cb62dc","source":"Medical","question":"What are the key risk factors and demographic patterns associated with glioma?","answer":"Gliomas are the most common type of malignant brain tumor in adults and are significantly more prevalent in adults than in children. The majority of gliomas are not hereditary; instead, they typically arise from non-hereditary (sporadic) mutations that cause glial cells in the central nervous system to grow uncontrollably. Age is a notable risk factor, as gliomas occur more frequently with increasing age. While a family history of cancer is routinely assessed, most gliomas do not have a strong hereditary component. Overall, the key risk factors and demographic patterns for glioma include older age and the presence of non-hereditary genetic mutations, with the disease being much more common in adults than in children.","question_type":"Contextual Summarize","evidence":"Gliomas are more common in adults than in children.; Most gliomas are not hereditary.; Non-hereditary mutations are a notable risk factor for glioma.; Age is a notable risk factor for glioma.","evidence_relations":"Gliomas are more common in adults than children; Most gliomas are not hereditary; Risk Factor ontology includes age (more common in adults) and non-hereditary mutation; Gliomas develop from glial cells in the central nervous system; Gliomas are a type of malignant brain tumor"},
	{"id":"Medical-8171339b","source":"Medical","question":"How does performance status affect treatment decisions in glioma patients?","answer":"Performance status is assessed in glioma patients to determine eligibility for specific treatments and is part of the clinical evaluation during diagnosis and management.","question_type":"Contextual Summarize","evidence":"Performance status is assessed in glioma patients.; Performance status helps determine eligibility for specific treatments.; Performance status is part of the clinical evaluation during diagnosis and management of glioma.","evidence_relations":"Performance status is assessed to determine treatment eligibility; Clinical Evaluation in the ontology includes performance status; Diagnosis of glioma involves neurological exam and performance status; Performance status is an entity listed for glioma management; Treatment options are influenced by the patient's performance status"},
	{"id":"Medical-c1c8e6d9","source":"Medical","question":"What is the relationship between glioma grade and prognosis?","answer":"Low-grade gliomas (grades 1 and 2) have a better prognosis, while high-grade gliomas (grades 3 and 4), especially glioblastoma, are associated with poorer outcomes.","question_type":"Contextual Summarize","evidence":"Low-grade gliomas are classified as grades 1 and 2.; Low-grade gliomas have a better prognosis.; High-grade gliomas are classified as grades 3 and 4.; High-grade gliomas, especially glioblastoma, are associated with poorer outcomes.","evidence_relations":"Grades 1 and 2 are low-grade gliomas; grades 3 and 4 are high-grade gliomas; Low-grade gliomas have better prognosis; High-grade gliomas have poorer prognosis; Glioblastoma is the most aggressive subtype of glioma; Grade 4 gliomas are most commonly glioblastomas"},
	{"id":"Medical-a7769409","source":"Medical","question":"Which genetic alterations and biomarkers are important in the classification and management of gliomas?","answer":"Important genetic alterations and biomarkers in the classification and management of gliomas include mutations in the IDH gene, which are used to distinguish subtypes such as astrocytoma IDH-mutant and oligodendroglioma IDH-mutant. Molecular testing for these biomarkers, typically performed on biopsy samples, helps determine the exact tumor type, predict disease course, and guide treatment decisions. Biomarker testing can also identify other genetic changes that may influence prognosis and eligibility for targeted therapies.","question_type":"Contextual Summarize","evidence":"IDH mutation is a key genetic alteration in gliomas.; IDH mutation is a key biomarker used in the classification of astrocytoma.; IDH mutation is a key biomarker used in the classification of oligodendroglioma.; IDH mutation influences diagnosis and management strategies for gliomas.","evidence_relations":"IDH mutation is a biomarker used to classify gliomas; Astrocytoma and oligodendroglioma both include IDH mutation as a biomarker in the ontology; IDH mutation is listed as a genetic alteration in glioma ontology; Biopsy is required for definitive diagnosis and molecular testing; Laboratory Testing in the ontology includes molecular testing and histology"},
	{"id":"Medical-25f9adbb","source":"Medical","question":"What are the main diagnostic methods and laboratory tests used to diagnose AML?","answer":"The main diagnostic methods and laboratory tests used to diagnose acute myeloid leukemia (AML) include a combination of blood tests, bone marrow evaluation, specialized laboratory analyses, and imaging studies. Initial laboratory tests typically include a complete blood count (CBC) with differential to assess for abnormal white blood cells, anemia, and thrombocytopenia, as well as a comprehensive metabolic panel (CMP), lactate dehydrogenase (LDH), uric acid, and blood clotting tests to evaluate organ function and metabolic status. Definitive diagnosis requires a bone marrow aspirate and biopsy, which are examined for the presence of 20% myeloblasts, although diagnosis can sometimes be made with fewer blasts if specific genetic abnormalities are present. Flow cytometry and immunophenotyping are performed on blood or bone marrow samples to characterize the immunologic profile of the leukemic cells. Molecular and cytogenetic testingincluding karyotyping, fluorescence in situ hybridization (FISH), next-generation sequencing (NGS), and polymerase chain reaction (PCR)are used to identify chromosomal abnormalities and gene mutations that inform prognosis and guide therapy. Imaging studies such as CT, MRI, and PET/CT may be used to assess for extramedullary disease or complications, and additional tests like lumbar puncture or heart function assessment may be performed based on clinical indications.","question_type":"Contextual Summarize","evidence":"AML diagnosis involves laboratory tests such as CBC.; AML diagnosis involves laboratory tests such as CMP.; AML diagnosis involves laboratory tests such as LDH.; AML diagnosis involves blood clotting tests.; AML diagnosis involves bone marrow aspirate and biopsy.; AML diagnosis involves flow cytometry and immunophenotyping.; AML diagnosis involves molecular and cytogenetic testing.; AML diagnosis involves imaging studies like CT.; AML diagnosis involves imaging studies like MRI.; AML diagnosis involves imaging studies like PET/CT.","evidence_relations":"AML is diagnosed by the presence of 20% myeloblasts in bone marrow or blood; Diagnosis of AML involves blood tests, bone marrow aspirate and biopsy, flow cytometry, immunophenotyping, cytogenetic and molecular testing, and imaging studies; Laboratory Tests include complete blood count (CBC), comprehensive metabolic panel (CMP), lactate dehydrogenase (LDH), and blood clotting tests; Bone Marrow Evaluation includes bone marrow aspirate, bone marrow biopsy, and histopathology; Imaging (CT, MRI, PET/CT) is used to assess extramedullary disease or complications; Flow Cytometry: flow cytometry, immunophenotyping; Molecular and Cytogenetic Testing: karyotype, FISH, next-generation sequencing (NGS), PCR"},
	{"id":"Medical-0d99173e","source":"Medical","question":"Which genetic alterations and biomarkers are commonly associated with AML and how do they influence treatment?","answer":"Common genetic alterations and biomarkers in AML include FLT3-ITD, FLT3-TKD, inv(16), inv(3), t(8;21), del(5q), PML::RARA, and CD33; these guide the use of targeted therapies such as FLT3 inhibitors for FLT3-mutated AML and gemtuzumab ozogamicin for CD33-positive AML.","question_type":"Contextual Summarize","evidence":"Common genetic alterations in AML include FLT3-ITD.; Common genetic alterations in AML include FLT3-TKD.; Common genetic alterations in AML include inv(16).; Common genetic alterations in AML include inv(3).; Common genetic alterations in AML include t(8;21).; Common genetic alterations in AML include del(5q).; Common genetic alterations in AML include PML::RARA.; Common genetic alterations in AML include CD33.; These genetic alterations guide the use of targeted therapies in AML.","evidence_relations":"Common genetic alterations in AML include FLT3-ITD, FLT3-TKD, inv(16), inv(3), t(8;21), del(5q), and PML::RARA; Genetic and biomarker tests are used to determine AML subtype and guide treatment; Targeted therapies are used for AML with specific genetic alterations, such as FLT3 inhibitors for FLT3-mutated AML and gemtuzumab ozogamicin for CD33-positive AML; Biomarker: CD33, PML::RARA, FLT3-ITD, FLT3-TKD, inv(16), inv(3), t(8;21), del(5q), RUNX1::RUNX1T1; Genetic Alteration: FLT3-ITD, FLT3-TKD, inv(16), inv(3), t(8;21), del(5q), PML::RARA, RUNX1::RUNX1T1"},
	{"id":"Medical-18c0b2dd","source":"Medical","question":"What are the main treatment modalities and phases for AML, and how are they selected?","answer":"The main treatment modalities for acute myeloid leukemia (AML) include chemotherapy (such as antimetabolites like cytarabine and anthracyclines like daunorubicin or idarubicin), hypomethylating agents (e.g., azacitidine, decitabine), targeted therapies, and hematopoietic cell transplant. Treatment is typically delivered in distinct phases: induction (to achieve remission), consolidation (to eliminate residual disease), and sometimes maintenance. The selection of specific treatments and regimens is guided by genetic and biomarker testing to determine the AML subtype, as well as by the patient's performance status, general health, and personal preferences. A multidisciplinary care team uses results from blood tests, bone marrow biopsy, and imaging studies to tailor the treatment plan to each individual.","question_type":"Contextual Summarize","evidence":"AML treatment consists of chemotherapy.; AML treatment consists of hypomethylating agents.; AML treatment consists of targeted therapy.; AML treatment consists of hematopoietic cell transplant.; AML treatment is delivered in induction phases.; AML treatment is delivered in consolidation phases.; AML treatment is delivered in maintenance phases.; Treatment selection is influenced by genetic alterations.; Treatment selection is influenced by performance status.; Treatment selection is influenced by general health.","evidence_relations":"Chemotherapy is the standard of care for AML; Chemotherapy regimens may include antimetabolites (e.g., cytarabine), anthracyclines (e.g., daunorubicin, idarubicin), and hypomethylating agents (e.g., azacitidine, decitabine); Treatment for AML is delivered in phases with the goal of achieving remission; Hematopoietic cell transplant is considered for eligible patients; Performance status and general health influence treatment selection; Treatment Phase: induction, consolidation, maintenance; Genetic and biomarker tests are used to determine AML subtype and guide treatment"},
	{"id":"Medical-27277239","source":"Medical","question":"How are AML subtypes defined and what are key features of notable subtypes?","answer":"AML subtypes are defined by gene mutations or abnormal chromosomes, with notable subtypes such as APL characterized by the PML::RARA fusion gene and BPDCN involving blood, bone marrow, lymph nodes, and skin.","question_type":"Contextual Summarize","evidence":"AML subtypes are defined by gene mutations.; AML subtypes are defined by abnormal chromosomes.; Notable subtypes of AML include APL.; APL is characterized by the PML::RARA fusion gene.; Notable subtypes of AML include BPDCN.; BPDCN involves blood, bone marrow, lymph nodes, and skin.","evidence_relations":"AML subtypes are defined by gene mutations or abnormal chromosomes; Acute promyelocytic leukemia (APL) is a subtype of AML characterized by the PML::RARA fusion gene; Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive subtype of AML; Acute promyelocytic leukemia (APL): Genetic Alteration: PML::RARA; Blastic plasmacytoid dendritic cell neoplasm (BPDCN): Sites of Involvement: blood, bone marrow, lymph nodes, skin"},
	{"id":"Medical-192138ad","source":"Medical","question":"What are the typical symptoms and risk factors associated with AML?","answer":"Typical symptoms of acute myeloid leukemia (AML) include fatigue, frequent infections, easy bleeding, and bruising. These symptoms result from the accumulation of immature myeloid blasts in the bone marrow and blood, which leads to decreased production of healthy red blood cells, platelets, and white blood cells. In addition to these symptoms, patients may also experience pallor, shortness of breath, and other signs related to low blood cell counts. Risk factors for AML include a family history of leukemia and hereditary predisposition syndromes, which increase the likelihood of developing the disease.","question_type":"Contextual Summarize","evidence":"Typical symptoms of AML include fatigue.; Typical symptoms of AML include infections.; Typical symptoms of AML include bleeding.; Typical symptoms of AML include bruising.; Risk factors for AML include family history of leukemia.; Risk factors for AML include hereditary predisposition syndromes.","evidence_relations":"Symptoms of AML include fatigue, infections, bleeding, and bruising; AML causes a buildup of blasts in bone marrow and blood, leading to low counts of healthy red blood cells, platelets, and white blood cells; Symptom: fatigue, infections, bleeding, bruising; Risk Factor: family history of leukemia, leukemia predisposition syndrome; Family history of leukemia and hereditary predisposition syndromes are risk factors for AML"},
	{"id":"Medical-7099cc9f","source":"Medical","question":"What supportive care measures are important during AML treatment and why?","answer":"Supportive care during AML treatment is crucial and includes blood transfusions to manage anemia and low platelet counts, infection prevention strategies such as antibiotics and protective isolation due to increased infection risk from low white blood cell counts, and management of treatment-related side effects. These measures are essential because both the disease and its treatments, such as chemotherapy, can cause significant reductions in healthy blood cells, leading to complications like severe infections, bleeding, and fatigue. Effective supportive care helps improve patient outcomes and quality of life during intensive AML therapy.","question_type":"Contextual Summarize","evidence":"Supportive care for AML includes transfusions.; Supportive care for AML includes infection prevention.; Supportive care for AML includes side effect management.; Supportive care is essential due to low blood cell counts.; Supportive care is essential due to treatment-related complications.","evidence_relations":"Supportive care includes transfusions, infection prevention, and management of side effects; AML causes a buildup of blasts in bone marrow and blood, leading to low counts of healthy red blood cells, platelets, and white blood cells; Chemotherapy is the standard of care for AML; Supportive Care: transfusions, infection prevention, side effect management; Symptoms of AML include infections, bleeding, and bruising"},
	{"id":"Medical-dcbc35dd","source":"Medical","question":"Which factors are considered prognostic in AML and how do they impact treatment decisions?","answer":"Prognostic factors in AML include genetic alterations, performance status, age, and response to induction therapy, all of which influence treatment selection and expected outcomes.","question_type":"Contextual Summarize","evidence":"Prognostic factors in AML include genetic alterations.; Prognostic factors in AML include performance status.; Prognostic factors in AML include age.; Prognostic factors in AML include response to induction therapy.; Prognostic factors influence treatment selection.; Prognostic factors influence expected outcomes.","evidence_relations":"Prognostic Factor: genetic alterations, performance status, age, response to induction therapy; Performance status and general health influence treatment selection; Genetic and biomarker tests are used to determine AML subtype and guide treatment; Treatment for AML is delivered in phases with the goal of achieving remission; Performance Status: Eastern Cooperative Oncology Group (ECOG) score, Karnofsky Performance Status (KPS)"},
	{"id":"Medical-7d2a19f6","source":"Medical","question":"What considerations are recommended regarding fertility for patients with AML before treatment?","answer":"Before starting treatment for AML, it is important to discuss the potential impact of chemotherapy and other therapies on fertility, as these treatments can cause temporary or permanent infertility. Patients who may want to have children in the future should be referred to a fertility or reproductive specialist to discuss preservation options, such as sperm banking or egg/embryo freezing, prior to initiating therapy. The risk of fertility impairment depends on factors such as age, treatment type, dose, and duration. Additionally, patients should be counseled on the need for effective contraception during and after treatment, as cancer therapies can harm a developing fetus. Early discussion with the care team ensures that patients are informed about their options and can make decisions that align with their future family planning goals.","question_type":"Contextual Summarize","evidence":"Fertility preservation should be discussed before starting systemic therapy for AML.; Options for fertility preservation include counseling.; Options for fertility preservation include referral to a reproductive specialist.","evidence_relations":"Fertility preservation should be discussed before starting systemic therapy; Fertility Preservation: fertility preservation counseling, referral to reproductive specialist; Chemotherapy is the standard of care for AML; Treatment for AML is delivered in phases with the goal of achieving remission; General health and performance status influence treatment selection"},
	{"id":"Medical-3276a6de","source":"Medical","question":"How is performance status assessed in AML and why is it important?","answer":"Performance status in acute myeloid leukemia (AML) is assessed using standardized tools such as the Eastern Cooperative Oncology Group (ECOG) score or the Karnofsky Performance Status (KPS). These assessments evaluate a patient's general health and ability to perform daily activities. Performance status is a critical factor in AML because it influences treatment selectionpatients with better performance status are more likely to tolerate intensive chemotherapy, while those with poorer status may require less aggressive approaches. Additionally, performance status is an important prognostic factor, as it is associated with overall outcomes and survival in AML.","question_type":"Contextual Summarize","evidence":"Performance status in AML is assessed using the ECOG score.; Performance status in AML is assessed using the Karnofsky Performance Status.; Performance status is important because it guides treatment selection.; Performance status is important because it guides prognosis.","evidence_relations":"Performance status and general health influence treatment selection; Performance Status: Eastern Cooperative Oncology Group (ECOG) score, Karnofsky Performance Status (KPS); Prognostic Factor: genetic alterations, performance status, age, response to induction therapy; Treatment for AML is delivered in phases with the goal of achieving remission; Chemotherapy is the standard of care for AML"},
	{"id":"Medical-03a82e56","source":"Medical","question":"What are the main subtypes of ovarian cancer and how are related cancers managed?","answer":"Ovarian cancer consists primarily of epithelial and non-epithelial subtypes, with high-grade serous and high-grade endometrioid carcinomas being most common, and related cancers such as primary peritoneal and fallopian tube cancer are managed similarly to ovarian cancer.","question_type":"Contextual Summarize","evidence":"Ovarian cancer consists primarily of epithelial subtypes.; Ovarian cancer consists primarily of non-epithelial subtypes.; High-grade serous carcinoma is a common subtype of ovarian cancer.; High-grade endometrioid carcinoma is a common subtype of ovarian cancer.; Primary peritoneal cancer is managed similarly to ovarian cancer.; Fallopian tube cancer is managed similarly to ovarian cancer.","evidence_relations":"Ovarian cancer is most commonly an epithelial cancer arising from the ovary surface epithelium; High-grade serous carcinoma and high-grade endometrioid carcinoma are the most common subtypes of epithelial ovarian cancer; Less common ovarian cancers include low-grade serous carcinoma, low-grade endometrioid carcinoma, carcinosarcoma, clear cell carcinoma, mucinous carcinoma, borderline epithelial tumor, malignant sex-cord stromal tumors, and malignant germ cell tumors; Primary peritoneal cancer and fallopian tube cancer are managed similarly to ovarian cancer; Epithelial ovarian cancer includes common subtypes: High-grade serous carcinoma (HGSC), High-grade endometrioid carcinoma; and less common subtypes: Low-grade serous carcinoma, Low-grade endometrioid carcinoma, Carcinosarcoma, Clear cell carcinoma, Mucinous carcinoma, Borderline epithelial tumor"},
	{"id":"Medical-8e6563e6","source":"Medical","question":"What diagnostic methods and biomarkers are used in the evaluation of ovarian cancer?","answer":"The evaluation of ovarian cancer utilizes a combination of diagnostic methods and biomarker assessments. Diagnostic methods include physical examination (abdominal and pelvic exam), imaging studies such as ultrasound (including transvaginal ultrasound), CT scan, MRI, PET scan, and chest x-ray to assess the extent of disease and possible metastasis. Diagnostic laparoscopy may be performed to evaluate disease spread in the abdomen. Definitive diagnosis requires a biopsy, which is often performed during initial surgery or, if surgery is not immediately possible, via fine-needle aspiration (FNA), core biopsy, or paracentesis. Blood tests are also important and include complete blood count (CBC), blood chemistry profile, liver function tests, and tumor marker tests. Key tumor markers for ovarian cancer include CA-125 and HE4, as well as others such as inhibin, beta-human chorionic gonadotropin (-hCG), alpha-fetoprotein (AFP), lactate dehydrogenase (LDH), carcinoembryonic antigen (CEA), and CA 19-9, which may be elevated in less common ovarian cancers. Biomarker and genetic testing are recommended for all patients and include assessment for BRCA1 and BRCA2 mutations (both germline and somatic), homologous recombination deficiency (HRD) status, microsatellite instability (MSI), mismatch repair (MMR) deficiency, HER2 expression, tumor mutational burden (TMB), BRAF V600E mutation, folate receptor alpha (FR) expression, RET mutations, and NTRK gene fusions. These biomarkers help guide treatment decisions and eligibility for targeted therapies or clinical trials.","question_type":"Contextual Summarize","evidence":"Diagnosis of ovarian cancer involves imaging modalities such as ultrasound.; Diagnosis of ovarian cancer involves imaging modalities such as CT.; Diagnosis of ovarian cancer involves imaging modalities such as MRI.; Diagnosis of ovarian cancer involves imaging modalities such as PET.; Diagnosis of ovarian cancer involves physical examination.; Diagnosis of ovarian cancer involves biopsy.; Diagnosis of ovarian cancer involves blood tests for tumor markers.; CA-125 is a tumor marker used in the diagnosis of ovarian cancer.; HE4 is a tumor marker used in the diagnosis of ovarian cancer.; Genetic alterations like BRCA mutations are evaluated in ovarian cancer diagnosis.; HRD status is evaluated in ovarian cancer diagnosis.","evidence_relations":"Diagnosis of ovarian cancer involves imaging (ultrasound, CT, MRI, PET), abdominal and pelvic exam, biopsy, and blood tests including tumor markers; Tumor biomarker testing includes BRCA mutation, HRD status, MSI, MMR, HER2 expression, TMB, BRAF V600E, FR, RET mutations, and NTRK gene fusion; Diagnostic Method includes: Abdominal and pelvic exam, Ultrasound, Transvaginal ultrasound, CT scan, MRI, PET scan, Chest x-ray, Diagnostic laparoscopy, Biopsy, Fine-needle aspiration (FNA), Core biopsy, Paracentesis, Colonoscopy, Upper endoscopy, Complete blood count (CBC), Blood chemistry profile, Liver function tests, Tumor marker tests; Biomarker: Tumor Markers include CA-125, Inhibin, Beta-human chorionic gonadotropin (-hCG), Alpha-fetoprotein (AFP), Lactate dehydrogenase (LDH), Carcinoembryonic antigen (CEA), CA 19-9, HE4; Genetic testing for BRCA and other hereditary syndromes is recommended for all patients with ovarian cancer"},
	{"id":"Medical-a3c885aa","source":"Medical","question":"Which hereditary and genetic risk factors are associated with ovarian cancer?","answer":"Ovarian cancer risk is significantly increased by hereditary factors such as BRCA1 and BRCA2 mutations and Lynch syndrome, and genetic testing for these and other hereditary syndromes is recommended for all patients.","question_type":"Contextual Summarize","evidence":"Ovarian cancer risk is significantly increased by BRCA1 mutations.; Ovarian cancer risk is significantly increased by BRCA2 mutations.; Ovarian cancer risk is significantly increased by Lynch syndrome.; Genetic testing for hereditary syndromes is recommended for all patients.","evidence_relations":"BRCA1 and BRCA2 mutations and Lynch syndrome are major hereditary risk factors for ovarian cancer; Genetic testing for BRCA and other hereditary syndromes is recommended for all patients with ovarian cancer; Risk Factor includes: BRCA1 mutation, BRCA2 mutation, Lynch syndrome, Family history; Biomarker: Genetic Alteration includes BRCA1 mutation, BRCA2 mutation, Homologous recombination deficiency (HRD), Microsatellite instability (MSI), Mismatch repair (MMR); Ovarian cancer includes risk factors such as family history and hereditary syndromes"},
	{"id":"Medical-14de13d0","source":"Medical","question":"What are the standard initial treatments and surgical procedures for ovarian cancer?","answer":"The standard initial treatment for most ovarian cancers involves surgery, most commonly a hysterectomy (removal of the uterus) with bilateral salpingo-oophorectomy (removal of both ovaries and fallopian tubes). This procedure is often accompanied by additional surgical steps such as debulking or cytoreductive surgery to remove as much of the tumor as possible, and may include removal of nearby organs if the cancer has spread. Surgical staging, based on the FIGO system, is performed to determine the extent of disease. In select early-stage cases where fertility preservation is desired and the cancer has not spread beyond the ovaries, fertility-sparing surgery (such as unilateral salpingo-oophorectomy) may be considered. Surgery is typically followed by chemotherapy, most often with paclitaxel and carboplatin, for most stages of ovarian cancer.","question_type":"Contextual Summarize","evidence":"The standard initial treatment for most ovarian cancers is surgery.; Surgery typically involves hysterectomy with bilateral salpingo-oophorectomy.; Chemotherapy often follows surgery for ovarian cancer.; Fertility-sparing surgery may be considered for select early-stage cases.","evidence_relations":"Surgery (hysterectomy with bilateral salpingo-oophorectomy) is the standard initial treatment for most ovarian cancers; Fertility-sparing surgery may be considered for select early-stage cases; Chemotherapy (typically paclitaxel and carboplatin) is recommended after surgery for most stages; Surgical Procedure includes: Hysterectomy, Bilateral salpingo-oophorectomy (BSO), Unilateral salpingo-oophorectomy (USO), Debulking surgery, Cytoreductive surgery, Interval cytoreductive surgery (ICS), Laparotomy, Laparoscopy, Peritoneal washing; Staging is based on the FIGO system (Stages I-IV) and requires surgical staging"},
	{"id":"Medical-fb67edf6","source":"Medical","question":"What chemotherapy regimens and maintenance therapies are commonly used in ovarian cancer treatment?","answer":"Chemotherapy for ovarian cancer typically consists of a combination of paclitaxel and carboplatin, administered in cycles following surgery for most stages of the disease. In some cases, bevacizumab (a targeted therapy that inhibits blood vessel growth to the tumor) may be added to the chemotherapy regimen. For patients with advanced ovarian cancer or those whose tumors are BRCA-mutated or homologous recombination deficiency (HRD)-positive, maintenance therapy with PARP inhibitors such as olaparib, niraparib, or rucaparib is recommended after initial treatment to reduce the risk of recurrence or delay disease progression. Maintenance therapy with bevacizumab alone or in combination with a PARP inhibitor may also be considered, depending on the patient's BRCA status and prior treatments.","question_type":"Contextual Summarize","evidence":"Ovarian cancer is commonly treated with chemotherapy regimens such as paclitaxel.; Ovarian cancer is commonly treated with chemotherapy regimens such as carboplatin.; Bevacizumab is sometimes added to chemotherapy regimens for ovarian cancer.; Maintenance therapy with PARP inhibitors is recommended for advanced cases.; Olaparib is a PARP inhibitor used in maintenance therapy for ovarian cancer.; Niraparib is a PARP inhibitor used in maintenance therapy for ovarian cancer.; Rucaparib is a PARP inhibitor used in maintenance therapy for ovarian cancer.; Maintenance therapy is recommended for BRCA-mutated or HRD-positive cases.","evidence_relations":"Chemotherapy (typically paclitaxel and carboplatin) is recommended after surgery for most stages; Bevacizumab may be added to chemotherapy in some cases; Maintenance therapy with PARP inhibitors (olaparib, niraparib, rucaparib) is recommended for advanced or BRCA-mutated/HRD-positive cancers after initial treatment; Chemotherapy Regimen includes: Paclitaxel, Carboplatin, Cisplatin, Oxaliplatin, Docetaxel, Bevacizumab (Avastin); Maintenance Therapy includes: Olaparib (Lynparza), Niraparib (Zejula), Rucaparib (Rubraca), Bevacizumab (Avastin), Mirvetuximab soravtansine-gynx (Elahere)"},
	{"id":"Medical-28687496","source":"Medical","question":"How is recurrence of ovarian cancer managed based on platinum sensitivity and biomarker status?","answer":"Recurrence in ovarian cancer is managed by assessing platinum sensitivity and biomarker status, with platinum-sensitive cases receiving platinum-based chemotherapy and possibly surgery, while platinum-resistant cases are treated with non-platinum chemotherapy, bevacizumab, targeted therapies, or immunotherapy.","question_type":"Contextual Summarize","evidence":"Recurrence in ovarian cancer is managed by assessing platinum sensitivity.; Recurrence in ovarian cancer is managed by assessing biomarker status.; Platinum-sensitive cases receive platinum-based chemotherapy.; Platinum-sensitive cases may undergo surgery.; Platinum-resistant cases are treated with non-platinum chemotherapy.; Platinum-resistant cases may be treated with bevacizumab.; Platinum-resistant cases may be treated with targeted therapies.; Platinum-resistant cases may be treated with immunotherapy.","evidence_relations":"Recurrence is managed based on platinum sensitivity, biomarker status, and may include surgery, chemotherapy, targeted therapy, immunotherapy, or clinical trial enrollment; Platinum-resistant ovarian cancer is treated with non-platinum chemotherapy, bevacizumab, or targeted therapies such as mirvetuximab soravtansine-gynx for FR-positive tumors; Platinum-sensitive recurrence is treated with platinum-based chemotherapy, possibly with bevacizumab, and may include secondary cytoreductive surgery; Recurrence: Platinum-sensitive includes: Platinum-based chemotherapy, Bevacizumab, Secondary cytoreductive surgery, Maintenance therapy with PARP inhibitor; Recurrence: Platinum-resistant includes: Non-platinum chemotherapy, Bevacizumab, Mirvetuximab soravtansine-gynx (Elahere), Targeted therapy, Immunotherapy"},
	{"id":"Medical-9601f6f1","source":"Medical","question":"What symptoms are commonly associated with ovarian cancer and how are they categorized?","answer":"Common symptoms of ovarian cancer include persistent bloating, pelvic or abdominal pain or pressure, trouble eating or feeling full quickly, urinary urgency or frequency, pain during sex, fatigue, unexplained weight loss, and constipation. These symptoms are often categorized as gastrointestinal (such as bloating, trouble eating, feeling full quickly, and constipation), genitourinary (urinary urgency or frequency), gynecologic (pain during sex), and constitutional (fatigue, unexplained weight loss). Symptoms are more likely to be related to ovarian cancer if they are new (less than one year in duration), occur more than 12 days per month, and become more severe over time.","question_type":"Contextual Summarize","evidence":"Common symptoms of ovarian cancer include persistent bloating.; Common symptoms of ovarian cancer include pelvic or abdominal pain.; Common symptoms of ovarian cancer include trouble eating or feeling full quickly.; Common symptoms of ovarian cancer include urinary urgency or frequency.; Common symptoms of ovarian cancer include pain during sex.; Common symptoms of ovarian cancer include fatigue.; Common symptoms of ovarian cancer include unexplained weight loss.; Common symptoms of ovarian cancer include constipation.","evidence_relations":"Common symptoms of ovarian cancer include bloating, pelvic or abdominal pain, trouble eating or feeling full quickly, urinary urgency or frequency, and pain during sex; Symptom: Persistent bloating, Pelvic pain, Abdominal pain, Trouble eating, Feeling full quickly, Urinary urgency, Urinary frequency, Pain during sex, Fatigue, Unexplained weight loss, Constipation; Ovarian cancer includes symptoms such as persistent bloating, pelvic pain, abdominal pain, and trouble eating; Ovarian cancer symptoms include urinary urgency, urinary frequency, and pain during sex; Fatigue, unexplained weight loss, and constipation are also symptoms of ovarian cancer"},
	{"id":"Medical-19aa2257","source":"Medical","question":"What surveillance strategies are recommended after initial treatment for ovarian cancer?","answer":"Recommended surveillance strategies after initial treatment for ovarian cancer include regular physical and pelvic examinations, typically every 2 to 4 months for the first 2 years, every 3 to 6 months for the next 3 years, and annually after 5 years. Monitoring of CA-125 or other tumor markers is advised if these markers were elevated at diagnosis. Imaging studies such as ultrasound, CT, or MRI may be performed if symptoms develop or if there is clinical suspicion of recurrence. Surveillance is individualized based on patient risk factors and symptoms, and ongoing communication with the oncology care team is essential.","question_type":"Contextual Summarize","evidence":"Post-treatment surveillance for ovarian cancer includes regular physical examinations.; Post-treatment surveillance for ovarian cancer includes regular pelvic examinations.; Post-treatment surveillance for ovarian cancer includes monitoring of CA-125 or other tumor markers.; Post-treatment surveillance for ovarian cancer includes imaging as indicated.","evidence_relations":"Surveillance after treatment includes regular physical and pelvic exams, and monitoring of CA-125 or other tumor markers; Surveillance: Physical and pelvic exams, CA-125 or tumor marker monitoring, Imaging as indicated; Tumor marker tests are part of surveillance after ovarian cancer treatment; Imaging modalities such as ultrasound, CT, and MRI may be used during surveillance as indicated; CA-125 is a commonly monitored tumor marker in ovarian cancer surveillance"},
	{"id":"Medical-ee34cda2","source":"Medical","question":"How are clinical trials integrated into the management of recurrent or persistent ovarian cancer?","answer":"Clinical trial enrollment is recommended as a management option for patients with recurrent or persistent ovarian cancer, especially when standard therapies are insufficient.","question_type":"Contextual Summarize","evidence":"Clinical trial enrollment is recommended for patients with recurrent ovarian cancer.; Clinical trial enrollment is recommended for patients with persistent ovarian cancer.; Clinical trial enrollment is especially recommended when standard therapies are insufficient.","evidence_relations":"Recurrence is managed based on platinum sensitivity, biomarker status, and may include surgery, chemotherapy, targeted therapy, immunotherapy, or clinical trial enrollment; Clinical trials are recommended for recurrent or persistent ovarian cancer; Clinical Trial: Clinical trial enrollment for recurrent or persistent disease; Ovarian cancer management includes clinical trial participation for certain patients; Clinical trial enrollment is considered for patients with recurrent or persistent ovarian cancer"},
	{"id":"Medical-fc7727b2","source":"Medical","question":"What are the main diagnostic methods and biomarkers used in the diagnosis and management of CLL?","answer":"The main diagnostic methods and biomarkers used in the diagnosis and management of chronic lymphocytic leukemia (CLL) include several laboratory and imaging tests. Diagnosis typically begins with a complete blood count (CBC) with differential, which often reveals elevated white blood cell counts and may show low red blood cell or platelet counts. Flow cytometry is used for immunophenotyping to identify CLL cells by their characteristic surface proteins, such as CD20, CD200, and LEF1. Additional tests may include lymph node or bone marrow biopsies if further tissue characterization is needed. Biomarker testing is essential for prognosis and treatment planning: fluorescence in situ hybridization (FISH) detects chromosomal abnormalities such as 17p deletion; DNA sequencing identifies mutations in the TP53 and IGHV genes; and karyotype analysis assesses for complex chromosomal changes. Measurement of beta-2 microglobulin in the blood serves as a biomarker for disease activity and prognosis. Imaging studies, such as diagnostic CT scans, may be used to evaluate lymph node involvement and disease extent prior to treatment. These diagnostic and biomarker assessments guide both the initial diagnosis and ongoing management of CLL.","question_type":"Contextual Summarize","evidence":"CLL is diagnosed using blood tests including complete blood count.; CLL is diagnosed using flow cytometry for immunophenotyping.; CLL is diagnosed using biopsies.; CLL is diagnosed using FISH for 17p deletion.; CLL is diagnosed using DNA sequencing for TP53 and IGHV mutations.; CLL is diagnosed using karyotype analysis.; CLL is managed by measuring beta-2 microglobulin.","evidence_relations":"CLL/SLL is diagnosed by blood test showing 5,000 monoclonal B lymphocytes per microliter; CLL is confirmed by blood test, flow cytometry, and may require lymph node or bone marrow biopsy; Immunophenotyping identifies CLL cells by surface proteins such as CD20, CD200, and LEF1; Biomarker testing includes FISH for 17p deletion, DNA sequencing for TP53 and IGHV mutations, and karyotype analysis; Beta-2 microglobulin is a biomarker associated with CLL disease activity and prognosis"},
	{"id":"Medical-403bb394","source":"Medical","question":"What symptoms and risk factors are commonly associated with CLL?","answer":"Common symptoms of CLL include swollen glands, fatigue, night sweats, fever, recurrent infections, early satiety, and unintentional weight loss, while risk factors include older age and a family history of CLL.","question_type":"Contextual Summarize","evidence":"Common symptoms of CLL include swollen glands.; Common symptoms of CLL include fatigue.; Common symptoms of CLL include night sweats.; Common symptoms of CLL include fever.; Common symptoms of CLL include recurrent infections.; Common symptoms of CLL include early satiety.; Common symptoms of CLL include unintentional weight loss.; Risk factors for CLL include older age.; Risk factors for CLL include a family history of CLL.","evidence_relations":"Symptoms of CLL include swollen glands, fatigue, night sweats, fever, recurrent infections, early satiety, and unintentional weight loss; CLL may be asymptomatic and discovered incidentally on routine blood testing; Risk factors for CLL include older age and family history of CLL; Family history increases the risk of developing CLL; Older age is a risk factor for CLL"},
	{"id":"Medical-b9f1cbe3","source":"Medical","question":"How do clinical management and follow-up strategies guide the care of CLL patients?","answer":"Clinical management of CLL (chronic lymphocytic leukemia) begins with a thorough assessment of the patient's medical history, including review of B symptoms (such as unexplained fevers, night sweats, and weight loss), family history, and a physical examination focusing on lymph nodes, spleen, and liver. Laboratory testsincluding complete blood count (CBC) with differential, comprehensive metabolic panel, flow cytometry, and relevant biomarkersare used to guide treatment planning. Before initiating therapy, pregnancy testing and consideration of fertility preservation are important, as cancer treatments can affect fertility. Follow-up strategies for CLL often involve a 'watch and wait' approach, where treatment is deferred until there are symptoms, changes in blood counts, or evidence of disease progression. During this period, patients undergo regular monitoring with clinical assessments and laboratory tests. Supportive care is also a key component, addressing symptoms and maintaining quality of life. The overall approach is individualized, with ongoing evaluation to determine if and when active treatment is needed.","question_type":"Contextual Summarize","evidence":"CLL management involves assessing performance status.; CLL management includes conducting pregnancy testing.; CLL management considers fertility preservation.; Follow-up strategies for CLL include watch and wait.; Follow-up strategies for CLL include regular monitoring.; Follow-up strategies for CLL include supportive care.","evidence_relations":"Performance status and comprehensive metabolic panel are used in treatment planning; Pregnancy testing and fertility preservation are considered before starting treatment; Follow-up strategies include watch and wait, regular monitoring, and supportive care; Treatment for CLL/SLL may not be needed immediately and is based on symptoms, blood counts, and disease progression; Supportive care is part of the follow-up strategy for CLL"},
	{"id":"Medical-0d661e08","source":"Medical","question":"What are the primary treatment options for CLL and when are they initiated?","answer":"Treatment options for CLL include oral medications, IV infusions, combination therapies, watch and wait, and supportive care, with initiation based on symptoms, blood counts, and disease progression.","question_type":"Contextual Summarize","evidence":"Treatment options for CLL include oral medications.; Treatment options for CLL include IV infusions.; Treatment options for CLL include combination therapies.; Treatment options for CLL include watch and wait.; Treatment options for CLL include supportive care.; Treatment for CLL is initiated based on symptoms.; Treatment for CLL is initiated based on blood counts.; Treatment for CLL is initiated based on disease progression.","evidence_relations":"Treatment for CLL/SLL may not be needed immediately and is based on symptoms, blood counts, and disease progression; Treatment options include oral medications, IV infusions, and combination therapies; Watch and wait is a treatment approach for CLL; Supportive care is included as a treatment for CLL; Clinical management strategies inform when to initiate treatment"},
	{"id":"Medical-2c03807c","source":"Medical","question":"What complications can arise from CLL and what are their characteristics?","answer":"A major complication of chronic lymphocytic leukemia (CLL) is Richter transformation, in which CLL transforms into a more aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL) or, less frequently, Hodgkin lymphoma. This transformation is characterized by a sudden worsening of symptoms, including rapidly enlarging lymph nodes, new or worsening B symptoms (such as fevers, drenching night sweats, and unexplained weight loss), and a more aggressive clinical course. In addition to Richter transformation, CLL can also lead to complications such as increased risk of infections due to impaired immune function, anemia, and low platelet counts as abnormal B cells crowd out healthy blood cells.","question_type":"Contextual Summarize","evidence":"A major complication of CLL is Richter transformation.; Richter transformation involves CLL transforming into a more aggressive lymphoma.; Richter transformation can result in diffuse large B-cell lymphoma (DLBCL).; Richter transformation can result in Hodgkin lymphoma.","evidence_relations":"Richter transformation is a complication where CLL transforms into a more aggressive lymphoma such as DLBCL or Hodgkin lymphoma; Complication: Richter transformation includes diffuse large B-cell lymphoma (DLBCL) and Hodgkin lymphoma; CLL can progress to more aggressive lymphomas as a complication; Richter transformation is a known risk during CLL disease course; DLBCL and Hodgkin lymphoma are aggressive lymphomas associated with Richter transformation"},
	{"id":"Medical-d33066da","source":"Medical","question":"How are biomarkers and genetic alterations integrated into the prognosis and treatment planning for CLL?","answer":"Biomarkers and genetic alterations such as 17p deletion, TP53 mutation, IGHV mutation, complex karyotype, and beta-2 microglobulin are assessed through FISH, DNA sequencing, and karyotype analysis to guide prognosis and inform treatment planning in CLL.","question_type":"Contextual Summarize","evidence":"Biomarkers and genetic alterations are assessed in CLL.; 17p deletion is a genetic alteration assessed in CLL.; TP53 mutation is a genetic alteration assessed in CLL.; IGHV mutation is a genetic alteration assessed in CLL.; Complex karyotype is a genetic alteration assessed in CLL.; Beta-2 microglobulin is a biomarker assessed in CLL.; FISH is used to assess biomarkers and genetic alterations in CLL.; DNA sequencing is used to assess biomarkers and genetic alterations in CLL.; Karyotype analysis is used to assess biomarkers and genetic alterations in CLL.; Biomarkers and genetic alterations guide prognosis in CLL.; Biomarkers and genetic alterations inform treatment planning in CLL.","evidence_relations":"Biomarker testing includes FISH for 17p deletion, DNA sequencing for TP53 and IGHV mutations, and karyotype analysis; Beta-2 microglobulin is a biomarker associated with CLL disease activity and prognosis; Immunophenotyping identifies CLL cells by surface proteins such as CD20, CD200, and LEF1; Complex karyotype is a genetic alteration evaluated in CLL; Performance status and comprehensive metabolic panel are used in treatment planning"},
	{"id":"Medical-0895dc9d","source":"Medical","question":"What distinguishes CLL from its subtype SLL in terms of primary site and presentation?","answer":"Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are considered the same disease, but they are distinguished by their primary sites of involvement and clinical presentation. CLL primarily affects the blood and bone marrow, with abnormal B lymphocytes circulating in the bloodstream and accumulating in the marrow. In contrast, SLL involves the same malignant B cells but is mainly found in the lymph nodes and spleen, with minimal involvement of the blood (fewer than 5,000 cancerous cells per microliter). Both conditions can cause lymph node or spleen enlargement, but CLL is typically diagnosed through blood tests, while SLL is often identified by lymph node biopsy. Despite these differences in presentation, the underlying cancer cells are the same, and treatment approaches are similar for both CLL and SLL.","question_type":"Contextual Summarize","evidence":"CLL primarily affects the blood.; CLL primarily affects the bone marrow.; The subtype SLL involves the same cancer as CLL.; SLL is mainly found in lymph nodes.; SLL is mainly found in the spleen.","evidence_relations":"Chronic lymphocytic leukemia (CLL) is a type of blood cancer affecting B lymphocytes; Small lymphocytic lymphoma (SLL) is the same cancer as CLL but primarily found in lymph nodes and spleen; CLL: Primary Site includes blood and bone marrow; SLL: Primary Site includes lymph nodes and spleen; CLL and SLL are classified under the same disease spectrum"},
	{"id":"Medical-aa179e3f","source":"Medical","question":"What is the role of minimal residual disease in the management of CLL?","answer":"Minimal residual disease in CLL represents a treatment goal indicating mostly healthy blood cells and is used to assess disease status after therapy.","question_type":"Contextual Summarize","evidence":"Minimal residual disease in CLL represents a treatment goal.; Minimal residual disease indicates mostly healthy blood cells.; Minimal residual disease is used to assess disease status after therapy.","evidence_relations":"Minimal residual disease is a treatment goal indicating mostly healthy blood cells; Disease Stage: Minimal residual disease is recognized in the CLL ontology; Assessment of minimal residual disease is part of CLL management; Minimal residual disease reflects response to treatment in CLL; CLL clinical management includes monitoring for minimal residual disease"},
	{"id":"Medical-d94fa48e","source":"Medical","question":"Which laboratory and imaging studies are commonly employed to assess CLL at diagnosis and during follow-up?","answer":"Assessment of chronic lymphocytic leukemia (CLL) at diagnosis and during follow-up commonly involves several laboratory and imaging studies. A complete blood count (CBC) with differential is used to evaluate white blood cell, red blood cell, and platelet counts, which are often abnormal in CLL. Flow cytometry is performed to confirm the presence of monoclonal B lymphocytes and to characterize their immunophenotype. A comprehensive metabolic panel assesses kidney and liver function, which is important for treatment planning. Beta-2 microglobulin testing serves as a biomarker for disease activity and prognosis. Diagnostic CT scans of the chest, abdomen, and pelvis may be used to assess lymph node involvement and the extent of disease. Additional tests, such as biomarker studies (e.g., FISH for chromosomal abnormalities, DNA sequencing for gene mutations), may also be performed to guide treatment decisions.","question_type":"Contextual Summarize","evidence":"Common studies for CLL include complete blood count.; Common studies for CLL include flow cytometry.; Common studies for CLL include comprehensive metabolic panel.; Common studies for CLL include beta-2 microglobulin testing.; Common studies for CLL include diagnostic CT scans.; These studies evaluate disease status and extent.","evidence_relations":"CLL/SLL is diagnosed by blood test showing 5,000 monoclonal B lymphocytes per microliter; CLL is confirmed by blood test, flow cytometry, and may require lymph node or bone marrow biopsy; Comprehensive metabolic panel is used in treatment planning; Beta-2 microglobulin is a biomarker associated with CLL disease activity and prognosis; Diagnostic CT scans may be used to assess lymph node involvement and disease extent"},
	{"id":"Medical-18e51427","source":"Medical","question":"What are the key risk factors and biomarkers associated with oropharyngeal squamous cell carcinoma?","answer":"Oropharyngeal squamous cell carcinoma is strongly associated with HPV infection, especially HPV16, and tobacco and alcohol use are additional risk factors; key biomarkers include p16 protein overexpression, PD-L1, MSI-H/dMMR, and high tumor mutational burden.","question_type":"Contextual Summarize","evidence":"Oropharyngeal squamous cell carcinoma is strongly associated with HPV infection.; HPV16 is a specific type of HPV associated with oropharyngeal squamous cell carcinoma.; Tobacco use is a risk factor for oropharyngeal squamous cell carcinoma.; Alcohol use is a risk factor for oropharyngeal squamous cell carcinoma.; Key biomarkers for oropharyngeal squamous cell carcinoma include p16 protein overexpression.; PD-L1 is a key biomarker for oropharyngeal squamous cell carcinoma.; MSI-H/dMMR is a key biomarker for oropharyngeal squamous cell carcinoma.; High tumor mutational burden is a key biomarker for oropharyngeal squamous cell carcinoma.","evidence_relations":"HPV infection, especially HPV16, is a major risk factor for oropharyngeal squamous cell carcinoma; Tobacco and alcohol use are risk factors for head and neck cancers; p16 protein overexpression is a surrogate biomarker for HPV-mediated throat cancer; Biomarker testing includes p16 (HPV), PD-L1, MSI-H/dMMR, and tumor mutational burden; Squamous cell carcinoma (SCC) includes biomarkers: p16 protein, HPV, HPV16, HPV18, PD-L1, MSI-H, dMMR, Tumor mutational burden-high (TMB-H)"},
	{"id":"Medical-bf479234","source":"Medical","question":"Which anatomic sites are most commonly involved in throat cancer and what are the main symptoms?","answer":"Throat cancer commonly arises in the oropharynx, including the soft palate, tonsils, side and back walls of the throat, and base of the tongue, and typically presents with symptoms such as difficulty swallowing, sore throat, and changes in voice.","question_type":"Contextual Summarize","evidence":"Throat cancer commonly arises in the oropharynx.; The soft palate is a common site involved in throat cancer.; The tonsils are a common site involved in throat cancer.; The side walls of the throat are a common site involved in throat cancer.; The back walls of the throat are a common site involved in throat cancer.; The base of the tongue is a common site involved in throat cancer.; Common symptoms of throat cancer include difficulty swallowing.; Common symptoms of throat cancer include sore throat.; Common symptoms of throat cancer include changes in voice.","evidence_relations":"Throat cancer commonly arises in the oropharynx, including the soft palate, tonsils, side and back walls of the throat, and base of the tongue; Oropharynx includes soft palate, tonsils, base of tongue, side and back walls of throat; Symptoms of throat cancer may include difficulty swallowing, sore throat, and changes in voice; Squamous cell carcinoma (SCC) includes symptoms: Difficulty swallowing, Sore throat, Voice changes; Oropharyngeal cancer is a subtype of throat cancer"},
	{"id":"Medical-67d6c501","source":"Medical","question":"What diagnostic methods and procedures are used to evaluate and stage throat cancer?","answer":"Evaluation and staging of throat cancer involve a comprehensive approach that includes taking a detailed medical history and performing physical and dental examinations to assess symptoms and identify any visible or palpable abnormalities. Imaging studies such as CT scan, MRI, PET/CT, and ultrasound are used to determine the size and extent of the tumor, involvement of lymph nodes, and possible distant metastases. Scoping procedures, including endoscopy, laryngoscopy, nasolaryngoscopy, esophagoscopy, bronchoscopy, and panendoscopy, allow direct visualization of the tumor and surrounding structures. Tissue sampling through biopsysuch as fine-needle aspiration (FNA), core needle biopsy (CNB), or endoscopic biopsyis required for definitive diagnosis and may also be used for biomarker testing, including HPV (p16) status. Staging is performed using the AJCC TNM system, which evaluates tumor size (T), lymph node involvement (N), and distant metastasis (M), and may be further refined after surgical removal of the tumor and lymph nodes.","question_type":"Contextual Summarize","evidence":"Evaluation of throat cancer involves medical history.; Evaluation of throat cancer involves physical exams.; Evaluation of throat cancer involves dental exams.; Imaging studies for throat cancer include CT scan.; Imaging studies for throat cancer include MRI.; Imaging studies for throat cancer include PET/CT.; Imaging studies for throat cancer include ultrasound.; Scoping procedures for throat cancer include endoscopy.; Scoping procedures for throat cancer include laryngoscopy.; Tissue sampling for throat cancer includes biopsy.; Tissue sampling methods include fine-needle aspiration.; Tissue sampling methods include core needle biopsy.","evidence_relations":"Imaging studies such as CT scan, MRI, PET/CT, and ultrasound are used for diagnosis and staging; Biopsy is required for definitive diagnosis and biomarker testing; Fine-needle aspiration (FNA), core needle biopsy (CNB), and endoscopic biopsies are used for tissue sampling; Cancer staging uses the AJCC TNM system, incorporating tumor size (T), lymph node involvement (N), and metastasis (M); Diagnostic Method includes: Medical history, Physical exam, Dental exam, Imaging (CT scan, MRI, PET/CT, Ultrasound, Panoramic dental x-ray), Scoping procedures (Endoscopy, Laryngoscopy, Nasolaryngoscopy, Esophagoscopy, Bronchoscopy, Panendoscopy), Biopsy (FNA, CNB, Endoscopic biopsy), Biomarker testing"},
	{"id":"Medical-aa279376","source":"Medical","question":"How is HPV status assessed and what is its clinical significance in oropharyngeal cancer?","answer":"HPV status in oropharyngeal cancer is assessed primarily through p16 (HPV) testing, which is recommended for all patients diagnosed with this cancer type. Overexpression of the p16 protein, detected by immunohistochemistry on tumor biopsy samples, serves as a surrogate biomarker for HPV-mediated disease, particularly for HPV16. Determining HPV status is clinically significant because HPV-positive oropharyngeal cancers generally have a better prognosis and may influence staging and treatment planning. Accurate assessment of HPV status helps guide therapeutic decisions and provides important prognostic information.","question_type":"Contextual Summarize","evidence":"HPV status in oropharyngeal cancer is assessed using p16 testing.; p16 testing is recommended for all patients with oropharyngeal cancer.; p16 protein overexpression serves as a surrogate biomarker for HPV-mediated disease.; HPV status influences prognosis in oropharyngeal cancer.; HPV status influences treatment planning in oropharyngeal cancer.","evidence_relations":"p16 protein overexpression is a surrogate biomarker for HPV-mediated throat cancer; p16 (HPV) testing is recommended for all patients with oropharyngeal cancer; Biomarker testing includes p16 (HPV); HPV infection, especially HPV16, is a major risk factor for oropharyngeal squamous cell carcinoma; Squamous cell carcinoma (SCC) includes genetic alterations: HPV-mediated, p16-positive, p16-negative"},
	{"id":"Medical-a3c71579","source":"Medical","question":"What staging systems and factors are used to determine the extent and prognosis of throat cancer?","answer":"Throat cancer staging is based on the AJCC TNM system, which evaluates tumor size, lymph node involvement, and metastasis, and incorporates both clinical and pathologic stages; prognosis is further informed by factors such as ECOG performance status and HPV/p16 status.","question_type":"Contextual Summarize","evidence":"Throat cancer staging is based on the AJCC TNM system.; The AJCC TNM system evaluates tumor size.; The AJCC TNM system evaluates lymph node involvement.; The AJCC TNM system evaluates metastasis.; Throat cancer staging incorporates both clinical and pathologic stages.; Prognosis for throat cancer is informed by ECOG performance status.; Prognosis for throat cancer is informed by HPV/p16 status.","evidence_relations":"Cancer staging uses the AJCC TNM system, incorporating tumor size (T), lymph node involvement (N), and metastasis (M); Clinical stage is determined before treatment using physical exam, imaging, and biopsy; Pathologic stage is determined after surgery based on tissue examination; Performance status (ECOG) is a prognostic factor considered in treatment planning; Prognostic Factor includes: ECOG performance status, Tumor grade, HPV/p16 status"},
	{"id":"Medical-6809b810","source":"Medical","question":"What are the main types and subtypes of throat cancer and how are they classified within head and neck cancers?","answer":"Throat cancer is classified within the broader category of head and neck cancers, which include malignancies arising in various regions such as the mouth (oral cavity), oropharynx, nasopharynx, larynx, and hypopharynx. The main types of throat cancer are based on the anatomic site within the pharynx: nasopharyngeal, oropharyngeal, and hypopharyngeal cancers. Oropharyngeal cancer is a key subtype of throat cancer, involving areas such as the soft palate, tonsils, side and back walls of the throat, and base of the tongue. The most common histologic type of throat cancer is squamous cell carcinoma (SCC), which arises from the thin, flat squamous cells lining the mucous membranes of the pharynx. SCC is the predominant type across head and neck cancers, including those of the throat. Classification is therefore based on both the anatomic location (e.g., oropharynx) and the histologic type (most commonly SCC).","question_type":"Contextual Summarize","evidence":"Throat cancer is classified as a subtype of head and neck cancer.; Oropharyngeal cancer is a further subtype of throat cancer.; Squamous cell carcinoma is the most common type of throat cancer.; Squamous cell carcinoma often arises in the oropharynx.","evidence_relations":"Throat cancer is a type of head and neck cancer; Oropharyngeal cancer is a subtype of throat cancer; Squamous cell carcinoma is the most common type of throat cancer; Oropharynx is a key anatomic site for throat cancer; Head and neck cancer includes subtypes: Throat cancer, Oropharyngeal cancer, Squamous cell carcinoma (SCC)"},
	{"id":"Medical-3cf18099","source":"Medical","question":"Which biomarkers are tested in throat cancer and how do they influence treatment decisions?","answer":"Biomarker testing in throat cancer includes p16 (HPV), PD-L1, MSI-H/dMMR, and tumor mutational burden; PD-L1 expression may guide immunotherapy, while p16 status is particularly relevant for HPV-mediated disease.","question_type":"Contextual Summarize","evidence":"Biomarker testing in throat cancer includes p16 testing.; Biomarker testing in throat cancer includes PD-L1 testing.; Biomarker testing in throat cancer includes MSI-H/dMMR testing.; Biomarker testing in throat cancer includes tumor mutational burden testing.; PD-L1 expression may guide immunotherapy in throat cancer.; p16 status is particularly relevant for HPV-mediated disease in throat cancer.","evidence_relations":"Biomarker testing includes p16 (HPV), PD-L1, MSI-H/dMMR, and tumor mutational burden; PD-L1 expression may guide immunotherapy treatment decisions; p16 (HPV) testing is recommended for all patients with oropharyngeal cancer; Squamous cell carcinoma (SCC) includes biomarkers: p16 protein, HPV, HPV16, HPV18, PD-L1, MSI-H, dMMR, Tumor mutational burden-high (TMB-H); p16 protein overexpression is a surrogate biomarker for HPV-mediated throat cancer"},
	{"id":"Medical-c2dcacec","source":"Medical","question":"How is tissue sampling performed for diagnosis and biomarker analysis in throat cancer?","answer":"Tissue sampling for diagnosis and biomarker analysis in throat cancer is typically performed using biopsy techniques such as fine-needle aspiration (FNA), core needle biopsy (CNB), and endoscopic biopsy. These procedures obtain tissue or fluid samples from the tumor or lymph nodes, which are then examined by a pathologist to confirm the presence and subtype of cancer. The collected tissue is also used for biomarker testing, including analysis for p16 (HPV status), PD-L1 expression, microsatellite instability (MSI-H/dMMR), and tumor mutational burden. These biomarkers can help guide prognosis and inform targeted therapy decisions. In some cases, imaging guidance (such as ultrasound or CT) may be used to assist with biopsy, especially for lymph nodes or metastatic sites.","question_type":"Contextual Summarize","evidence":"Tissue sampling for throat cancer diagnosis is performed using biopsy techniques.; Biopsy techniques include fine-needle aspiration.; Biopsy techniques include core needle biopsy.; Biopsy techniques include endoscopic biopsy.; Tissue sampling provides material for definitive diagnosis.; Tissue sampling provides material for biomarker testing.","evidence_relations":"Biopsy is required for definitive diagnosis and biomarker testing; Fine-needle aspiration (FNA), core needle biopsy (CNB), and endoscopic biopsies are used for tissue sampling; Diagnostic Method includes: Biopsy, Fine-needle aspiration (FNA), Core needle biopsy (CNB), Endoscopic biopsy; Biomarker testing includes p16 (HPV), PD-L1, MSI-H/dMMR, and tumor mutational burden; Squamous cell carcinoma (SCC) includes diagnostic methods: Biopsy, FNA, CNB, Endoscopic biopsy, Biomarker testing"},
	{"id":"Medical-f657d12f","source":"Medical","question":"What surveillance strategies are recommended for patients with throat cancer after initial treatment?","answer":"Surveillance for throat cancer patients includes regular dental health assessment, imaging follow-up, and physical examinations to monitor for recurrence and manage complications.","question_type":"Contextual Summarize","evidence":"Surveillance for throat cancer patients includes regular dental health assessment.; Surveillance for throat cancer patients includes imaging follow-up.; Surveillance for throat cancer patients includes physical examinations.; Surveillance for throat cancer patients is conducted to monitor for recurrence.; Surveillance for throat cancer patients is conducted to manage complications.","evidence_relations":"Dental health assessment is important before treatment; Surveillance includes: Dental health assessment, Imaging follow-up, Physical exam; Squamous cell carcinoma (SCC) includes surveillance: Dental health assessment, Imaging follow-up, Physical exam; Imaging studies such as CT scan, MRI, PET/CT, and ultrasound are used for diagnosis and staging; Panoramic dental x-ray (Panorex) is included in diagnostic and surveillance imaging"},
	{"id":"Medical-ee0525ef","source":"Medical","question":"What are the main diagnostic methods and symptoms associated with cutaneous B-cell lymphoma (CBCL)?","answer":"Cutaneous B-cell lymphoma (CBCL) is primarily diagnosed through a combination of clinical and laboratory methods, including a thorough skin examination, blood tests (such as complete blood count and metabolic panels), imaging studies, biopsy of skin lesions, and immunophenotyping to characterize the type of lymphocytes involved. CBCL typically presents with skin symptoms such as nodules or papules, which are lumps or small, pimple-like lesions under the skin. Accurate diagnosis is essential for treatment planning, and additional tests may be performed to assess the extent of disease and guide therapy.","question_type":"Contextual Summarize","evidence":"CBCL is primarily diagnosed using a skin exam.; CBCL is primarily diagnosed using blood tests.; CBCL is primarily diagnosed using imaging tests.; CBCL is primarily diagnosed using biopsy.; CBCL is primarily diagnosed using immunophenotyping.; CBCL typically presents as nodules under the skin.; CBCL typically presents as papules under the skin.","evidence_relations":"Diagnosis of CBCL involves skin exam, blood tests, imaging tests, biopsy, and immunophenotyping; Symptoms of CBCL include skin nodules and papules; CBCL appears as nodules or papules under the skin; Cutaneous B-cell lymphoma (CBCL) is a subtype of primary cutaneous lymphoma (PCL); CBCL includes symptoms: nodule, papule; CBCL includes diagnostic methods: skin exam, blood test, imaging test, biopsy, immunophenotyping"},
	{"id":"Medical-2cb951c9","source":"Medical","question":"Which subtypes are classified under cutaneous B-cell lymphoma (CBCL), and what is their cell of origin?","answer":"CBCL subtypes include primary cutaneous marginal zone lymphoma (PCMZL), primary cutaneous follicle center lymphoma (PCFCL), and primary cutaneous diffuse large B-cell lymphoma, leg type (PC-DLBCL, leg type), all of which originate from B lymphocytes.","question_type":"Contextual Summarize","evidence":"CBCL subtypes include primary cutaneous marginal zone lymphoma (PCMZL).; CBCL subtypes include primary cutaneous follicle center lymphoma (PCFCL).; CBCL subtypes include primary cutaneous diffuse large B-cell lymphoma, leg type (PC-DLBCL, leg type).; All CBCL subtypes originate from B lymphocytes.","evidence_relations":"CBCL subtypes include primary cutaneous marginal zone lymphoma (PCMZL), primary cutaneous follicle center lymphoma (PCFCL), and primary cutaneous diffuse large B-cell lymphoma, leg type (PC-DLBCL, leg type); Cutaneous B-cell lymphoma (CBCL) starts in B cells; CBCL is a cancer subtype under B lymphocyte cell of origin; Primary cutaneous lymphoma (PCL) develops from abnormal B or T lymphocytes; CBCL includes subtypes: PCMZL, PCFCL, PC-DLBCL, leg type"},
	{"id":"Medical-84f32cc1","source":"Medical","question":"How does cutaneous B-cell lymphoma (CBCL) relate to non-Hodgkin lymphoma and primary cutaneous lymphoma in terms of classification and origin?","answer":"CBCL is a subtype of primary cutaneous lymphoma, which itself is a type of non-Hodgkin lymphoma originating from abnormal B lymphocytes.","question_type":"Contextual Summarize","evidence":"CBCL is a subtype of primary cutaneous lymphoma.; Primary cutaneous lymphoma is a type of non-Hodgkin lymphoma.; CBCL originates from abnormal B lymphocytes.","evidence_relations":"Primary cutaneous lymphoma (PCL) is a type of non-Hodgkin lymphoma found in the skin; Cutaneous B-cell lymphoma (CBCL) is a subtype of primary cutaneous lymphoma (PCL); CBCL starts in B cells; PCL develops from abnormal B or T lymphocytes; CBCL is classified under B lymphocyte cell of origin in the ontology"},
	{"id":"Medical-1edecc97","source":"Medical","question":"What are the typical features and growth patterns of primary cutaneous B-cell lymphomas?","answer":"Primary cutaneous B-cell lymphomas (CBCLs) typically present as indolent or slow-growing lesions on the skin, most often appearing as nodules or papules that may resemble small pimples. These lymphomas develop from abnormal B lymphocytes and are a subtype of primary cutaneous lymphoma. The most common types include primary cutaneous marginal zone lymphoma, primary cutaneous follicle center lymphoma, and primary cutaneous diffuse large B-cell lymphoma, leg type. CBCLs are generally characterized by their slow progression and localized skin involvement.","question_type":"Contextual Summarize","evidence":"Most primary cutaneous B-cell lymphomas are indolent or slow-growing.; Primary cutaneous B-cell lymphomas commonly present as skin nodules.; Primary cutaneous B-cell lymphomas commonly present as papules.","evidence_relations":"Most primary cutaneous B-cell lymphomas are indolent or slow-growing; Symptoms of CBCL include skin nodules and papules; CBCL appears as nodules or papules under the skin; CBCL is a subtype of primary cutaneous lymphoma (PCL); CBCL includes symptoms: nodule, papule"},
	{"id":"Medical-f23b49f6","source":"Medical","question":"What are the key components assessed during the diagnosis of cutaneous B-cell lymphoma (CBCL)?","answer":"The diagnosis of CBCL involves clinical evaluation through skin exam, laboratory analysis with blood tests, imaging studies, tissue assessment by biopsy, and cellular characterization using immunophenotyping.","question_type":"Contextual Summarize","evidence":"The diagnosis of CBCL involves clinical evaluation through skin exam.; The diagnosis of CBCL involves laboratory analysis with blood tests.; The diagnosis of CBCL involves imaging studies.; The diagnosis of CBCL involves tissue assessment by biopsy.; The diagnosis of CBCL involves cellular characterization using immunophenotyping.","evidence_relations":"Diagnosis of CBCL involves skin exam, blood tests, imaging tests, biopsy, and immunophenotyping; CBCL includes diagnostic methods: skin exam, blood test, imaging test, biopsy, immunophenotyping; Testing for CBCL includes assessment of biomarkers and genetic changes; CBCL is a subtype of primary cutaneous lymphoma (PCL); CBCL is classified under B lymphocyte cell of origin"},
	{"id":"Medical-29e992c3","source":"Medical","question":"Which biomarkers and genetic alterations are evaluated in cutaneous B-cell lymphoma (CBCL), and how are they assessed?","answer":"In cutaneous B-cell lymphoma (CBCL), the evaluation of biomarkers and genetic alterations is an important part of the diagnostic process. These assessments are typically performed using immunophenotyping, which analyzes the specific proteins expressed on the surface of lymphoma cells to determine their B-cell origin and subtype. Additional laboratory tests may be used to detect genetic changes associated with CBCL. The results from these tests help confirm the diagnosis, classify the lymphoma, and guide treatment planning.","question_type":"Contextual Summarize","evidence":"CBCL diagnosis involves assessment of biomarkers.; CBCL diagnosis involves assessment of genetic changes.; Biomarkers and genetic changes in CBCL are typically evaluated through immunophenotyping.; Biomarkers and genetic changes in CBCL are typically evaluated through related laboratory tests.","evidence_relations":"Testing for CBCL includes assessment of biomarkers and genetic changes; Diagnosis of CBCL involves immunophenotyping; CBCL includes biomarkers: biomarker, genetic change; CBCL is a subtype of primary cutaneous lymphoma (PCL); Immunophenotyping is a diagnostic method used in CBCL"},
	{"id":"Medical-aec58243","source":"Medical","question":"What is the relationship between lymphocytes and the development of cutaneous B-cell lymphoma (CBCL)?","answer":"Cutaneous B-cell lymphoma (CBCL) develops from abnormal B lymphocytes, a type of white blood cell responsible for producing antibodies to fight infections. In CBCL, these B cells undergo unregulated growth and proliferation, which can result in the formation of lymphoma within the skin. This abnormal growth leads to the development of nodules or papules under the skin, characteristic of CBCL. The disease is classified as a type of non-Hodgkin lymphoma that originates specifically from B lymphocytes, distinguishing it from cutaneous T-cell lymphomas, which arise from T lymphocytes.","question_type":"Contextual Summarize","evidence":"CBCL develops from abnormal B lymphocytes.; B lymphocytes are a type of white blood cell.; Unregulated growth of B lymphocytes can lead to lymphoma.","evidence_relations":"PCL develops from abnormal B or T lymphocytes; Cutaneous B-cell lymphoma (CBCL) starts in B cells; Lymphocytes are a type of white blood cell that help fight infection; Unregulated growth of lymphocytes can develop into lymphoma; CBCL is classified under B lymphocyte cell of origin"},
	{"id":"Medical-56575021","source":"Medical","question":"What are the main diagnostic methods and criteria for diagnosing acute lymphoblastic leukemia (ALL) in children?","answer":"ALL in children is diagnosed using blood tests, bone marrow tests, imaging tests, heart tests, and lumbar puncture, with diagnosis generally requiring 20 percent or more lymphoblasts in the bone marrow.","question_type":"Contextual Summarize","evidence":"ALL in children is diagnosed using blood tests.; ALL in children is diagnosed using bone marrow tests.; ALL in children is diagnosed using imaging tests.; ALL in children is diagnosed using heart tests.; ALL in children is diagnosed using lumbar puncture.; Diagnosis of ALL generally requires 20 percent or more lymphoblasts in the bone marrow.","evidence_relations":"ALL is diagnosed using blood tests, bone marrow tests, imaging tests, heart tests, and lumbar puncture; Diagnosis of ALL generally requires 20 percent or more lymphoblasts in the bone marrow; Diagnostic Method for ALL includes blood test, bone marrow test, imaging test, heart test, lumbar puncture, biomarker testing, and pharmacogenomic testing; ALL is a fast-growing blood cancer that starts in lymphocytes; Bone marrow and blood are disease sites for ALL"},
	{"id":"Medical-209dcb5d","source":"Medical","question":"How are the main subtypes of ALL in children characterized and what are their distinguishing features?","answer":"The main subtypes of acute lymphoblastic leukemia (ALL) in children are B-cell ALL (B-ALL) and T-cell ALL (T-ALL). B-ALL originates from B-cell lymphocytes and is the more common subtype. In some cases, B-cell lymphoblasts primarily grow in the lymph nodes rather than the bone marrow, a condition known as B-cell lymphoblastic lymphoma (B-LL or B-LBL). T-ALL arises from T-cell lymphocytes and is less common. A distinguishing feature of T-ALL is its tendency to cause enlargement of the thymus, which can lead to breathing difficulties due to pressure on the windpipe and blood vessels. When T-cell lymphoblasts predominantly grow in the thymus, this is referred to as T-cell lymphoblastic lymphoma (T-LL or T-LBL). The subtypes are further characterized by the type and maturity of the lymphocyte involved, as well as specific genetic or chromosomal changes within the leukemia cells.","question_type":"Contextual Summarize","evidence":"The main subtypes of ALL in children are B-cell ALL (B-ALL).; B-cell ALL starts in B-cell lymphocytes.; B-cell ALL is more common than T-cell ALL.; The main subtypes of ALL in children are T-cell ALL (T-ALL).; T-cell ALL starts in T-cell lymphocytes.; T-cell ALL can cause an enlarged thymus.; T-cell ALL can cause breathing problems.","evidence_relations":"ALL has two main subtypes: B-cell ALL (B-ALL) and T-cell ALL (T-ALL); B-ALL starts in B-cell lymphocytes and is more common than T-ALL; T-ALL starts in T-cell lymphocytes and can cause an enlarged thymus; T-ALL can cause breathing problems due to an enlarged thymus; B-cell lymphoblasts growing in lymph nodes is called B-cell lymphoblastic lymphoma (B-LL or B-LBL)"},
	{"id":"Medical-7a915f7f","source":"Medical","question":"What are the common treatment approaches for childhood ALL and how do they vary by subtype or special cases?","answer":"Treatment for childhood ALL typically includes steroids, multiagent chemotherapy, systemic therapy, and supportive care, with clinical trials preferred for certain B-ALL and T-ALL cases, and different regimens used for mature B-cell ALL and infant ALL.","question_type":"Contextual Summarize","evidence":"Treatment for childhood ALL typically includes steroids.; Treatment for childhood ALL typically includes multiagent chemotherapy.; Treatment for childhood ALL typically includes systemic therapy.; Treatment for childhood ALL typically includes supportive care.; Clinical trials are preferred for certain B-ALL cases.; Clinical trials are preferred for certain T-ALL cases.; Different regimens are used for mature B-cell ALL.; Different regimens are used for infant ALL.","evidence_relations":"Treatment for ALL depends on subtype, age at diagnosis, and other factors; Everyone with ALL is treated with steroids and multiagent chemotherapy; Systemic therapy and supportive care are part of ALL treatment; Clinical trials are preferred for certain B-ALL and T-ALL cases; Infant ALL (under 12 months) is treated differently than other age groups"},
	{"id":"Medical-d7a42746","source":"Medical","question":"Which biomarkers and genetic alterations are important in the management of B-cell ALL in children?","answer":"Important biomarkers and genetic alterations in the management of B-cell acute lymphoblastic leukemia (ALL) in children include BCR::ABL1-positive, BCR::ABL1-negative, and BCR::ABL1-like subtypes. BCR::ABL1-positive B-ALL is characterized by the presence of the BCR::ABL1 gene fusion, which leads to the production of the BCR::ABL protein and typically requires intensive combination systemic therapies targeting this abnormality. BCR::ABL1-negative and BCR::ABL1-like B-ALL represent other molecular subtypes, with BCR::ABL1-like cases sharing similar gene expression profiles to BCR::ABL1-positive but lacking the actual fusion gene. Accurate biomarker and genetic testing, including pharmacogenomic testing, is essential for diagnosis, risk stratification, and guiding individualized treatment decisions in pediatric B-cell ALL.","question_type":"Contextual Summarize","evidence":"BCR::ABL1-positive is a key biomarker in B-cell ALL.; BCR::ABL1-negative is a key biomarker in B-cell ALL.; BCR::ABL1-like is a key biomarker in B-cell ALL.; BCR::ABL1-positive cases receive intensive systemic therapies.; Biomarker and genetic testing guide management in B-cell ALL.","evidence_relations":"BCR::ABL1-positive B-ALL is treated with intensive systemic therapies; Biomarker for B-cell ALL includes BCR::ABL1-positive, BCR::ABL1-negative, and BCR::ABL1-like; Pharmacogenomic testing and biomarker/genetic testing are used in ALL management; B-cell ALL (B-ALL) is a subtype of ALL; Treatment for B-ALL includes systemic therapy and clinical trial"},
	{"id":"Medical-b2f0a4f3","source":"Medical","question":"What are the typical disease sites and symptoms associated with ALL in children?","answer":"In children, acute lymphoblastic leukemia (ALL) commonly involves the bone marrow and blood, but can also affect other sites such as the testicles and central nervous system (CNS). Disease sites may include lymph nodes and, in the case of T-cell ALL, the thymus. T-cell ALL can cause an enlarged thymus, which may lead to breathing difficulties due to compression of the windpipe and nearby blood vessels. Additionally, when lymphoblasts primarily grow in lymph nodes or the thymus, the disease may present as lymphoblastic lymphoma. Symptoms can vary depending on the sites involved, but may include fatigue, easy bruising or bleeding, infections, bone pain, and, in T-ALL, respiratory symptoms related to a mediastinal mass.","question_type":"Contextual Summarize","evidence":"ALL in children can be found in the bone marrow.; ALL in children can be found in the blood.; ALL in children can be found in the testicles.; ALL in children can be found in the central nervous system.; T-cell ALL specifically causes an enlarged thymus.; T-cell ALL specifically causes breathing problems.","evidence_relations":"ALL can be found in bone marrow, blood, testicles, or central nervous system (CNS); Disease Site for ALL includes bone marrow, blood, lymph nodes, thymus, testicles, and CNS; T-ALL starts in T-cell lymphocytes and can cause an enlarged thymus; T-ALL can cause breathing problems due to an enlarged thymus; B-cell lymphoblasts growing in lymph nodes is called B-cell lymphoblastic lymphoma (B-LL or B-LBL)"},
	{"id":"Medical-cbbe92d1","source":"Medical","question":"How does the age group at diagnosis influence the management and treatment of ALL in children?","answer":"The age group at diagnosis significantly influences the management and treatment of acute lymphoblastic leukemia (ALL) in children. Infants (under 12 months) are treated differently from older children, adolescents, and young adults due to differences in disease biology and response to therapy. Treatment protocols are tailored based on age, with infants often requiring specialized regimens. Additionally, ALL is most commonly diagnosed in children, adolescents, and young adults, and treatment decisions also consider the specific subtype of ALL and other individual factors. Participation in clinical trials is often recommended for certain subtypes and age groups to optimize outcomes.","question_type":"Contextual Summarize","evidence":"Management and treatment of ALL in children are influenced by age.; Infants under 12 months receive different treatments for ALL.; ALL most commonly affects children.; ALL most commonly affects adolescents.; ALL most commonly affects young adults.","evidence_relations":"Treatment for ALL depends on subtype, age at diagnosis, and other factors; Infant ALL (under 12 months) is treated differently than other age groups; ALL most often affects children, adolescents, and young adults (AYAs); Age Group for ALL includes infant, child, adolescent, and young adult (AYA); Clinical trials are preferred for certain B-ALL and T-ALL cases"},
	{"id":"Medical-30f4f09d","source":"Medical","question":"What role do supportive care and systemic therapy play in the treatment of ALL in children?","answer":"Supportive care and systemic therapy are integral to ALL treatment in children, provided alongside steroids and multiagent chemotherapy to address both disease and treatment-related needs.","question_type":"Contextual Summarize","evidence":"Supportive care is integral to ALL treatment in children.; Systemic therapy is integral to ALL treatment in children.; Supportive care is provided alongside steroids.; Supportive care is provided alongside multiagent chemotherapy.; Supportive care addresses both disease and treatment-related needs.","evidence_relations":"Systemic therapy and supportive care are part of ALL treatment; Everyone with ALL is treated with steroids and multiagent chemotherapy; Treatment for ALL includes steroids, multiagent chemotherapy, systemic therapy, supportive care, and clinical trial; Supportive care is listed as a treatment option in the ALL ontology; Clinical trials are preferred for certain B-ALL and T-ALL cases"},
	{"id":"Medical-3c58f2c2","source":"Medical","question":"What are the key differences in presentation and management between B-cell ALL and T-cell ALL in children?","answer":"B-cell acute lymphoblastic leukemia (B-ALL) is more common in children and is characterized by the presence of B-cell biomarkers, such as BCR::ABL1-positive, BCR::ABL1-negative, and BCR::ABL1-like subtypes. B-ALL typically presents with symptoms related to bone marrow failure, such as anemia, infections, and bleeding. In contrast, T-cell ALL (T-ALL) arises from T-cell lymphocytes and often presents with a mediastinal (thymic) mass, which can cause an enlarged thymus and lead to breathing difficulties due to compression of the windpipe and blood vessels. Both B-ALL and T-ALL are managed with similar treatment strategies, including steroids, multiagent chemotherapy, systemic therapy, and participation in clinical trials. However, the initial presentation and potential complications, such as airway compromise in T-ALL, may influence specific management considerations.","question_type":"Contextual Summarize","evidence":"B-cell ALL is more common than T-cell ALL.; B-cell ALL is defined by B-cell biomarkers.; T-cell ALL often presents with an enlarged thymus.; T-cell ALL often presents with breathing problems.; Both B-cell ALL and T-cell ALL are managed using steroids.; Both B-cell ALL and T-cell ALL are managed using multiagent chemotherapy.; Both B-cell ALL and T-cell ALL are managed using systemic therapy.; Both B-cell ALL and T-cell ALL may involve clinical trials.","evidence_relations":"B-ALL starts in B-cell lymphocytes and is more common than T-ALL; T-ALL starts in T-cell lymphocytes and can cause an enlarged thymus; T-ALL can cause breathing problems due to an enlarged thymus; Biomarker for B-cell ALL includes BCR::ABL1-positive, BCR::ABL1-negative, and BCR::ABL1-like; Treatment for B-ALL and T-ALL includes steroids, multiagent chemotherapy, systemic therapy, and clinical trial"},
	{"id":"Medical-5ac7f21f","source":"Medical","question":"What are the main diagnostic methods and surveillance strategies used in rectal cancer management?","answer":"Rectal cancer is diagnosed using MRI, endorectal ultrasound (EUS), CT scan, flexible sigmoidoscopy, colonoscopy, and CEA blood tests, while surveillance after treatment includes regular flexible sigmoidoscopy, imaging (EUS or MRI), and colonoscopy.","question_type":"Contextual Summarize","evidence":"Rectal cancer is diagnosed using MRI.; Rectal cancer is diagnosed using endorectal ultrasound (EUS).; Rectal cancer is diagnosed using CT scan.; Rectal cancer is diagnosed using flexible sigmoidoscopy.; Rectal cancer is diagnosed using colonoscopy.; Rectal cancer is diagnosed using CEA blood tests.; Surveillance after treatment includes regular flexible sigmoidoscopy.; Surveillance after treatment includes imaging such as EUS or MRI.; Surveillance after treatment includes colonoscopy.","evidence_relations":"MRI of the pelvis is recommended for staging rectal cancer; Endorectal ultrasound (EUS) can assess tumor extent and guide biopsy; CT scan of chest and abdomen is used to detect metastasis; Colonoscopy is recommended after surgery for surveillance; Surveillance after local excision or ESD includes regular sigmoidoscopy and imaging; Diagnostic Method includes: MRI, Endorectal ultrasound (EUS), CT scan, Flexible sigmoidoscopy, Colonoscopy, CEA blood test, ctDNA; Surveillance Strategy includes: Flexible sigmoidoscopy, Imaging (EUS or MRI), Colonoscopy"},
	{"id":"Medical-b3d60550","source":"Medical","question":"Which polyp types are associated with rectal cancer, and how does polypectomy impact cancer prevention?","answer":"Adenomas are the main type of polyp associated with rectal cancer, as they can gradually develop into invasive rectal cancer (adenocarcinoma) over many years. In contrast, hyperplastic and inflammatory polyps are much less likely to become cancerous. Most rectal cancers begin in adenomatous polyps. Polypectomy, which is the removal of polyps during colonoscopy, is an effective preventive measure because it eliminates precancerous polyps before they can progress to cancer. This procedure not only reduces the risk of rectal cancer development but also allows for histological examination to ensure that cancer has not already started to form within the polyp.","question_type":"Contextual Summarize","evidence":"Adenomas are the primary polyp type associated with rectal cancer.; Adenomas can become invasive rectal cancer over many years.; Hyperplastic polyps rarely turn into cancer.; Inflammatory polyps rarely turn into cancer.; Polypectomy during colonoscopy can remove most polyps.; Polypectomy can prevent cancer development.","evidence_relations":"Most rectal cancers start in adenomatous polyps; Adenomas can become invasive rectal cancer over many years; Hyperplastic and inflammatory polyps rarely turn into cancer; Polypectomy during colonoscopy can remove most polyps and prevent cancer; Polyp Type includes: Adenoma, Hyperplastic polyp, Inflammatory polyp"},
	{"id":"Medical-0e7e9c94","source":"Medical","question":"What are the common genetic and biomarker features of rectal cancer and their implications for diagnosis?","answer":"Rectal cancer is characterized by biomarkers such as mismatch repair deficiency (dMMR) and microsatellite instability-high (MSI-H), with all tumors recommended for dMMR or MSI-H testing, and genetic risk factors including Lynch syndrome and familial adenomatous polyposis (FAP).","question_type":"Contextual Summarize","evidence":"Rectal cancer is characterized by mismatch repair deficiency (dMMR).; Rectal cancer is characterized by microsatellite instability-high (MSI-H).; All tumors are recommended for dMMR testing.; All tumors are recommended for MSI-H testing.; Genetic risk factors for rectal cancer include Lynch syndrome.; Genetic risk factors for rectal cancer include familial adenomatous polyposis (FAP).","evidence_relations":"Mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H) are biomarkers in rectal cancer; All rectal tumors should be tested for dMMR or MSI-H; Lynch syndrome is a genetic risk factor for rectal cancer; Familial adenomatous polyposis (FAP) is a genetic syndrome causing multiple polyps and increased rectal cancer risk; Biomarker includes: Mismatch repair deficiency (dMMR), Microsatellite instability-high (MSI-H), Microsatellite stable (MSS), Mismatch repair proficient (pMMR), CEA blood test, ctDNA"},
	{"id":"Medical-09c3281f","source":"Medical","question":"How are treatment strategies for rectal cancer determined by tumor stage?","answer":"Treatment for rectal cancer is stage-dependent: T1 tumors are managed with endoscopic and transanal procedures, T2 and T3 tumors require transabdominal surgery, and locally advanced cases are treated with chemoradiation and chemotherapy regimens including oxaliplatin or irinotecan.","question_type":"Contextual Summarize","evidence":"Treatment for rectal cancer is stage-dependent.; T1 tumors are managed with endoscopic procedures.; T1 tumors are managed with transanal procedures.; T2 tumors require transabdominal surgery.; T3 tumors require transabdominal surgery.; Locally advanced cases are treated with chemoradiation.; Locally advanced cases are treated with chemotherapy regimens including oxaliplatin.; Locally advanced cases are treated with chemotherapy regimens including irinotecan.","evidence_relations":"Endoscopic submucosal dissection (ESD) is recommended for T1 rectal tumors; Transanal local excision is an option for T1 tumors at the end of the rectum; Transabdominal surgery is recommended for T2 and some T1/T3 tumors; Chemoradiation is used for locally advanced rectal cancer; Chemotherapy regimens may include oxaliplatin or irinotecan"},
	{"id":"Medical-80578893","source":"Medical","question":"What are the primary surgical procedures used in rectal cancer, and how do they relate to tumor location and stage?","answer":"The primary surgical procedures for rectal cancer are selected based on both the tumor's stage and its location within the rectum. For very early-stage cancers or polyps, a polypectomy performed during colonoscopy may be sufficient. T1 tumors, especially those located at the distal end of the rectum, can often be managed with transanal local excision or endoscopic submucosal dissection. For tumors that have invaded the muscle layer (T2) or some T1/T3 tumors, transabdominal surgery is recommended. The specific type of transabdominal surgery depends on tumor location: low anterior resection (LAR) is typically used for tumors in the mid to upper rectum, allowing for removal of the tumor and part of the colon with the possibility of reconnecting the bowel. For tumors in the lower rectum, especially those involving the anus or nearby muscle, abdominoperineal resection (APR) is performed, which involves removal of the rectum and anus and results in a permanent colostomy. The choice of procedure is guided by the goal of complete tumor removal while preserving as much normal bowel function as possible.","question_type":"Contextual Summarize","evidence":"Surgical procedures for rectal cancer include polypectomy.; Transanal local excision is used for early-stage or distal tumors.; Transabdominal surgery is used for more advanced stages of rectal cancer.; Low anterior resection (LAR) is used for mid to upper rectal tumors.; Abdominoperineal resection (APR) is used for lower rectal tumors.","evidence_relations":"Polypectomy during colonoscopy can remove most polyps and prevent cancer; Transanal local excision is an option for T1 tumors at the end of the rectum; Transabdominal surgery is recommended for T2 and some T1/T3 tumors; Low anterior resection (LAR) is used for tumors in the mid to upper rectum; Abdominoperineal resection (APR) is used for tumors in the lower rectum"},
	{"id":"Medical-dbdb19b5","source":"Medical","question":"Which risk factors and genetic syndromes are linked to rectal cancer, and what is their significance?","answer":"Lynch syndrome and familial adenomatous polyposis (FAP) are significant genetic risk factors for rectal cancer, with FAP causing multiple polyps and increased cancer risk, highlighting the importance of genetic assessment in at-risk individuals.","question_type":"Contextual Summarize","evidence":"Lynch syndrome is a significant genetic risk factor for rectal cancer.; Familial adenomatous polyposis (FAP) is a significant genetic risk factor for rectal cancer.; FAP causes multiple polyps.; FAP increases the risk of cancer.; Genetic assessment is important for at-risk individuals.","evidence_relations":"Lynch syndrome is a genetic risk factor for rectal cancer; Familial adenomatous polyposis (FAP) is a genetic syndrome causing multiple polyps and increased rectal cancer risk; Risk Factor includes: Lynch syndrome, Familial adenomatous polyposis (FAP); Genetic Alteration includes: Lynch syndrome, Familial adenomatous polyposis (FAP); Adenomas can become invasive rectal cancer over many years"},
	{"id":"Medical-89593bb0","source":"Medical","question":"What symptoms are commonly observed in patients with rectal cancer?","answer":"Common symptoms observed in patients with rectal cancer include changes in bowel habits (such as diarrhea, constipation, or narrowing of the stool), rectal bleeding (which may appear as blood in the stool or on toilet paper), and abdominal pain. Additional symptoms can include a feeling of incomplete evacuation after a bowel movement, unexplained weight loss, and fatigue. These symptoms may be subtle in early stages and can be mistaken for benign conditions, so persistent or worsening symptoms should prompt further medical evaluation.","question_type":"Contextual Summarize","evidence":"Rectal cancer commonly presents with changes in bowel habits.; Rectal cancer commonly presents with rectal bleeding.; Rectal cancer commonly presents with abdominal pain.","evidence_relations":"Symptoms of rectal cancer may include changes in bowel habits, rectal bleeding, and abdominal pain; Symptom includes: Rectal bleeding, Abdominal pain, Changes in bowel habits; Rectal bleeding is a symptom of rectal cancer; Abdominal pain is a symptom of rectal cancer; Changes in bowel habits are a symptom of rectal cancer"},
	{"id":"Medical-904ab164","source":"Medical","question":"What fertility preservation options are available to patients undergoing rectal cancer treatment?","answer":"Fertility preservation options for rectal cancer patients include sperm banking, egg freezing, ovarian tissue banking, and ovarian transposition, which can be considered prior to treatment.","question_type":"Contextual Summarize","evidence":"Fertility preservation options for rectal cancer patients include sperm banking.; Fertility preservation options for rectal cancer patients include egg freezing.; Fertility preservation options for rectal cancer patients include ovarian tissue banking.; Fertility preservation options for rectal cancer patients include ovarian transposition.; Fertility preservation options can be considered prior to treatment.","evidence_relations":"Fertility preservation options include sperm banking, egg freezing, ovarian tissue banking, and ovarian transposition; Fertility Preservation includes: Sperm banking, Egg freezing, Ovarian tissue banking, Ovarian transposition; Ovarian transposition is a fertility preservation option; Egg freezing is a fertility preservation option; Sperm banking is a fertility preservation option"},
	{"id":"Medical-ef0f9988","source":"Medical","question":"How is surveillance structured following local excision or endoscopic submucosal dissection in rectal cancer?","answer":"Surveillance following local excision or endoscopic submucosal dissection (ESD) for rectal cancer is structured to monitor for recurrence over at least 5 years. This includes flexible sigmoidoscopy approximately every 6 months, with the first examination possibly as early as 3 months after the procedure. Imaging with endorectal ultrasound (EUS) or pelvic MRI with contrast is recommended every 3 to 6 months for the first 2 years, then every 6 months through year 5. Additionally, a colonoscopy is advised 1 year after surgery, with subsequent colonoscopies at 3 years and then every 5 years if results remain normal.","question_type":"Contextual Summarize","evidence":"Surveillance after local excision for rectal cancer involves regular flexible sigmoidoscopy every 6 months for 5 years.; Surveillance after local excision for rectal cancer involves imaging with EUS or MRI every 3-6 months for 2 years.; Surveillance after local excision for rectal cancer involves imaging every 6 months through year 5.","evidence_relations":"Surveillance after local excision or ESD includes regular sigmoidoscopy and imaging; Flexible sigmoidoscopy every 6 months for 5 years is part of the surveillance strategy for T1 tumors; Imaging (EUS or MRI) every 3-6 months for 2 years, then every 6 months through year 5 is part of the surveillance strategy for T1 tumors; Surveillance Strategy includes: Flexible sigmoidoscopy, Imaging (EUS or MRI), Colonoscopy; Flexible sigmoidoscopy is recommended for surveillance"},
	{"id":"Medical-6b88dffb","source":"Medical","question":"What are the main subtypes, stages, and grades of bladder cancer, and how are they classified?","answer":"Bladder cancer is classified by subtype, stage, and grade. The main subtypes include urothelial carcinoma (the most common), squamous cell carcinoma, adenocarcinoma, and small cell carcinoma. Urothelial carcinoma can also have rare variants such as glandular, micropapillary, plasmacytoid, sarcomatoid, nested, lymphoepithelioma-like, and microcystic/tubular subtypes. Staging ranges from 0 to 4 and is based on the depth of invasion and spread: Stage 0 (non-invasive, limited to the inner lining), Stage 1 (invades connective tissue but not muscle), Stage 2 (invades muscle layer), Stage 3 (extends through the bladder wall into surrounding tissue or lymph nodes), and Stage 4 (spread to distant organs or lymph nodes). Some stages have subgroups, such as 0a (papillary) and 0is (carcinoma in situ), and 3A/3B or 4A/4B, depending on the extent of local or distant spread. Grading assesses how aggressive the cancer is, with low grade (LG) indicating slow-growing tumors and high grade (HG) indicating fast-growing, more aggressive tumors. Grade is determined by how abnormal the cancer cells appear compared to normal cells.","question_type":"Contextual Summarize","evidence":"Bladder cancer is classified into subtypes.; The most common subtype of bladder cancer is urothelial carcinoma.; Other subtypes of bladder cancer include squamous cell carcinoma, adenocarcinoma, and small cell carcinoma.; Bladder cancer is staged from 0 to 4 based on invasion and spread.; Bladder cancer grades are designated as low grade (LG) or high grade (HG).","evidence_relations":"Bladder cancer is a disease of the inner lining of the bladder; Urothelial carcinoma is the most common subtype of bladder cancer; Squamous cell carcinoma, adenocarcinoma, and small cell carcinoma are less common subtypes of bladder cancer; Bladder cancer is staged from 0 to 4 based on depth of invasion and spread; Cancer grade is classified as low grade (LG) or high grade (HG)"},
	{"id":"Medical-a3a6eab2","source":"Medical","question":"What are the primary risk factors and genetic alterations associated with bladder cancer?","answer":"The primary risk factors for bladder cancer include smoking (the most significant risk, accounting for about half of all cases), exposure to secondhand smoke, increasing age, family history of bladder cancer, inherited conditions such as Lynch syndrome, and exposure to certain chemicals used in industries like dyes, rubber, leather, printing, textiles, and paint. Genetic alterations associated with bladder cancer include mutations in the CDKN2A, FGFR3, PIK3CA, and ERBB genes. While most genetic mutations in bladder cancer are acquired rather than inherited, individuals with a family history or inherited mutations may have an increased risk and could benefit from genetic counseling and testing.","question_type":"Contextual Summarize","evidence":"Smoking is the greatest risk factor for bladder cancer.; Additional risk factors for bladder cancer include age.; Family history is a risk factor for bladder cancer.; Lynch syndrome is a risk factor for bladder cancer.; Chemical exposure is a risk factor for bladder cancer.; Genetic alterations associated with bladder cancer include CDKN2A, FGFR3, PIK3CA, and ERBB mutations.","evidence_relations":"Smoking is the greatest risk factor for bladder cancer; Other risk factors include age, family history, Lynch syndrome, and chemical exposure; Genetic alterations such as mutations in CDKN2A, FGFR3, PIK3CA, and ERBB genes are associated with bladder cancer; Risk Factor: [\"Smoking\", \"Secondhand smoke\", \"Age\", \"Family history\", \"Lynch syndrome\", \"Chemical exposure\"]; Genetic Alteration: [\"CDKN2A mutation\", \"FGFR3 mutation\", \"PIK3CA mutation\", \"ERBB mutation\"]"},
	{"id":"Medical-5d754d6e","source":"Medical","question":"What symptoms and diagnostic methods are commonly associated with bladder cancer?","answer":"Bladder cancer commonly presents with blood in urine (hematuria), frequent urination, urgency, painful urination, and back pain, and is diagnosed using cystoscopy, urine cytology, biopsy, and imaging techniques such as CT, MRI, PET/CT, ultrasound, pyelogram, and urogram.","question_type":"Contextual Summarize","evidence":"Bladder cancer commonly presents with blood in urine (hematuria).; Bladder cancer commonly presents with frequent urination.; Bladder cancer commonly presents with urgency.; Bladder cancer commonly presents with painful urination.; Bladder cancer commonly presents with back pain.; Bladder cancer is diagnosed using cystoscopy.; Bladder cancer is diagnosed using urine cytology.; Bladder cancer is diagnosed using biopsy.; Bladder cancer is diagnosed using imaging techniques such as CT, MRI, PET/CT, ultrasound, pyelogram, and urogram.","evidence_relations":"Blood in urine (hematuria) is the most common symptom of bladder cancer; Other symptoms include frequent urination, urgency, painful urination, and back pain; Diagnosis of bladder cancer involves cystoscopy, urine cytology, biopsy, and imaging (CT, MRI, PET/CT, ultrasound, pyelogram, urogram); Symptom: [\"Blood in urine\", \"Hematuria\", \"Frequent urination\", \"Urgency\", \"Painful urination\", \"Back pain\"]; Diagnostic Method: {\"Cystoscopy\": {}, \"Urine cytology\": {}, \"Biopsy\": {}, \"Imaging\": {\"CT scan\": {}, \"MRI\": {}, \"PET/CT\": {}, \"Ultrasound\": {}, \"Pyelogram\": {}, \"Urogram\": {}}}"},
	{"id":"Medical-4937721e","source":"Medical","question":"How are nonmuscle-invasive and muscle-invasive bladder cancers defined and treated?","answer":"Nonmuscle-invasive bladder cancers (Stage 0 and 1) are defined as tumors that have not invaded the muscle layer of the bladder wall; they are confined to the inner lining or connective tissue. These are typically treated with transurethral resection of bladder tumor (TURBT) to remove the tumor, often followed by intravesical therapy (such as BCG or chemotherapy) to reduce the risk of recurrence. Muscle-invasive bladder cancers (Stages 2, 3, and 4) are defined by tumor invasion into the muscle layer of the bladder wall or beyond. Treatment for muscle-invasive disease usually involves radical cystectomy (surgical removal of the bladder), and may also include systemic therapies (such as chemotherapy or immunotherapy) and/or radiation therapy, depending on the extent of disease and patient factors.","question_type":"Contextual Summarize","evidence":"Nonmuscle-invasive bladder cancers are classified as Stage 0 and 1.; Nonmuscle-invasive bladder cancers are treated with TURBT and intravesical therapy.; Muscle-invasive bladder cancers are classified as Stages 2, 3, and 4.; Muscle-invasive bladder cancers typically require radical cystectomy.; Additional treatment options for muscle-invasive bladder cancers include systemic therapy and radiation.","evidence_relations":"Stage 0 and Stage 1 bladder cancers are nonmuscle-invasive; Stages 2, 3, and 4 bladder cancers are muscle-invasive; TURBT is used for tumor removal in nonmuscle-invasive bladder cancer; Radical cystectomy is the standard surgery for muscle-invasive bladder cancer; Intravesical therapy (BCG or chemotherapy) is used for nonmuscle-invasive bladder cancer"},
	{"id":"Medical-01692d91","source":"Medical","question":"What systemic therapies are available for bladder cancer and what agents are commonly used?","answer":"Systemic therapies for bladder cancer include chemotherapy, immunotherapy, and targeted therapies. Chemotherapy is commonly administered as cisplatin-based regimens, such as dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC). Chemotherapy is typically given intravenously in cycles and may be used before or after surgery, or as the main treatment for metastatic disease. Immunotherapy involves checkpoint inhibitors, which help the immune system recognize and attack cancer cells; commonly used agents include pembrolizumab (Keytruda), nivolumab (Opdivo), avelumab (Bavencio), and atezolizumab (Tecentriq). Targeted therapies are used for patients with specific genetic mutations or markers and include enfortumab vedotin-ejfv (Padcev), which targets Nectin-4, erdafitinib (Balversa) for FGFR3 mutations, and sacituzumab govitecan-hziy (Trodelvy). The choice of systemic therapy depends on factors such as cancer stage, overall health, and kidney function.","question_type":"Contextual Summarize","evidence":"Systemic therapy for bladder cancer includes chemotherapy.; Cisplatin-based regimens like ddMVAC are used in chemotherapy for bladder cancer.; Immunotherapy for bladder cancer includes checkpoint inhibitors.; Common checkpoint inhibitors for bladder cancer include pembrolizumab, nivolumab, avelumab, and atezolizumab.; Targeted therapies for bladder cancer include enfortumab vedotin-ejfv, erdafitinib, and sacituzumab govitecan-hziy.","evidence_relations":"Systemic therapy includes chemotherapy, immunotherapy (checkpoint inhibitors), and targeted therapy; Chemotherapy regimens include cisplatin-based combinations such as ddMVAC; Immunotherapy agents include pembrolizumab, nivolumab, avelumab, and atezolizumab; Targeted therapies include enfortumab vedotin-ejfv (Padcev), erdafitinib (Balversa), and sacituzumab govitecan-hziy (Trodelvy); Systemic Therapy: {\"Chemotherapy\": [\"Cisplatin\", \"Methotrexate\", \"Vinblastine\", \"Doxorubicin\", \"ddMVAC\"], \"Immunotherapy\": [\"Pembrolizumab (Keytruda)\", \"Nivolumab (Opdivo)\", \"Avelumab (Bavencio)\", \"Atezolizumab (Tecentriq)\"], \"Targeted Therapy\": [\"Enfortumab vedotin-ejfv (Padcev)\", \"Erdafitinib (Balversa)\", \"Sacituzumab govitecan-hziy (Trodelvy)\"]}"},
	{"id":"Medical-766a9a4c","source":"Medical","question":"What are the main surgical procedures and urinary diversion options used in bladder cancer treatment?","answer":"Bladder cancer surgery includes TURBT, radical cystectomy, partial cystectomy, and urinary diversion procedures such as ileal conduit, neobladder, and continent cutaneous pouch (Indiana pouch).","question_type":"Contextual Summarize","evidence":"Bladder cancer surgery includes TURBT.; Bladder cancer surgery includes radical cystectomy.; Bladder cancer surgery includes partial cystectomy.; Urinary diversion procedures include ileal conduit.; Urinary diversion procedures include neobladder.; Urinary diversion procedures include continent cutaneous pouch (Indiana pouch).","evidence_relations":"Surgery is a primary treatment for bladder cancer and includes TURBT, radical cystectomy, and partial cystectomy; TURBT is used for tumor removal in nonmuscle-invasive bladder cancer; Radical cystectomy is the standard surgery for muscle-invasive bladder cancer; Urinary diversion procedures include ileal conduit, neobladder, and continent cutaneous pouch; Surgical Procedure: {\"TURBT\": {}, \"Radical cystectomy\": {}, \"Partial cystectomy\": {}, \"Urinary Diversion\": [\"Ileal conduit\", \"Neobladder\", \"Continent cutaneous pouch (Indiana pouch)\"]}"},
	{"id":"Medical-ab49732b","source":"Medical","question":"Which therapies are used as bladder-preserving approaches in bladder cancer, and what do they involve?","answer":"Bladder-preserving approaches in bladder cancer include trimodal therapy and radiation-based treatments. Trimodal therapy consists of three components: transurethral resection of bladder tumor (TURBT) to remove all visible cancer, followed by external beam radiation therapy (EBRT) and concurrent chemotherapy (chemoradiation). This approach aims to eradicate the tumor while preserving the bladder, and is considered for select patients as an alternative to radical cystectomy. Radiation therapy (EBRT) can also be used alone or in combination with chemotherapy (chemoradiation) to enhance treatment effectiveness. The choice of therapy depends on tumor characteristics and patient factors, and these approaches are designed to maintain bladder function while achieving cancer control.","question_type":"Contextual Summarize","evidence":"Bladder-preserving approaches include trimodal therapy.; Trimodal therapy combines TURBT, chemotherapy, and radiation.; Bladder-preserving approaches include radiation therapy (EBRT) alone.; Bladder-preserving approaches include radiation therapy (EBRT) with chemotherapy (chemoradiation).","evidence_relations":"Trimodal therapy combines TURBT, chemotherapy, and radiation as a bladder-preserving approach; Radiation therapy (EBRT) is used alone or in combination with chemotherapy (chemoradiation); Treatment: {\"Trimodal therapy\": {}, \"Radiation Therapy\": [\"External beam radiation therapy (EBRT)\", \"Chemoradiation\"]}; TURBT is used for tumor removal in nonmuscle-invasive bladder cancer; Chemotherapy regimens include cisplatin-based combinations such as ddMVAC"},
	{"id":"Medical-f67e9cbf","source":"Medical","question":"How is follow-up and surveillance conducted in bladder cancer patients and why is it important?","answer":"Follow-up and surveillance in bladder cancer involve regular cystoscopy, urine cytology, imaging, and biomarker tests, which are essential due to the high recurrence rates of the disease.","question_type":"Contextual Summarize","evidence":"Follow-up and surveillance in bladder cancer involve regular cystoscopy.; Follow-up and surveillance in bladder cancer involve urine cytology.; Follow-up and surveillance in bladder cancer involve imaging.; Follow-up and surveillance in bladder cancer involve biomarker tests.; Follow-up and surveillance are essential due to high recurrence rates of bladder cancer.","evidence_relations":"Follow-up and surveillance are required due to high recurrence rates; Follow-up/Surveillance: [\"Regular cystoscopy\", \"Urine cytology\", \"Imaging\", \"Biomarker surveillance\"]; Diagnosis of bladder cancer involves cystoscopy, urine cytology, biopsy, and imaging (CT, MRI, PET/CT, ultrasound, pyelogram, urogram); Biomarker tests may be used for surveillance in nonmuscle-invasive bladder cancer; Bladder cancer has a high recurrence rate necessitating ongoing surveillance"},
	{"id":"Medical-5b662312","source":"Medical","question":"What are the most common side effects and symptoms experienced by bladder cancer patients, both from the disease and its treatments?","answer":"Bladder cancer patients most commonly experience symptoms such as blood in the urine (hematuria), which is often the first and most noticeable sign. Other frequent symptoms include increased frequency of urination, urgency to urinate, painful urination (dysuria), and back pain. In addition to these disease-related symptoms, treatments for bladder cancerincluding surgery, intravesical therapy, chemotherapy, and immunotherapycan cause a range of side effects. Common treatment-related side effects include bleeding, blood clots, kidney problems, infection, sexual dysfunction (which may involve decreased desire or difficulty with sexual activity), urinary incontinence (trouble controlling urine flow), fatigue, nausea, vomiting, diarrhea, constipation, fever, and, in some cases, swelling or inflammation of the bladder lining. The type and severity of side effects can vary depending on the specific treatment and individual patient factors.","question_type":"Contextual Summarize","evidence":"Bladder cancer patients commonly experience hematuria.; Bladder cancer patients commonly experience frequent urination.; Bladder cancer patients commonly experience urgency.; Bladder cancer patients commonly experience painful urination.; Bladder cancer patients commonly experience back pain.; Treatments for bladder cancer often cause side effects like bleeding.; Treatments for bladder cancer often cause side effects like infection.; Treatments for bladder cancer often cause side effects like sexual dysfunction.; Treatments for bladder cancer often cause side effects like urinary incontinence.; Treatments for bladder cancer often cause side effects like fatigue.; Treatments for bladder cancer often cause side effects like nausea.; Treatments for bladder cancer often cause side effects like diarrhea.","evidence_relations":"Blood in urine (hematuria) is the most common symptom of bladder cancer; Other symptoms include frequent urination, urgency, painful urination, and back pain; Common side effects of treatment include bleeding, infection, sexual dysfunction, urinary incontinence, fatigue, nausea, and diarrhea; Symptom: [\"Blood in urine\", \"Hematuria\", \"Frequent urination\", \"Urgency\", \"Painful urination\", \"Back pain\"]; Side Effect: [\"Bleeding\", \"Blood clots\", \"Kidney problems\", \"Infection\", \"Sexual dysfunction\", \"Urinary incontinence\", \"Fatigue\", \"Nausea\", \"Vomiting\", \"Diarrhea\", \"Constipation\", \"Fever\"]"},
	{"id":"Medical-8c9d1ae8","source":"Medical","question":"What roles do clinical trials and supportive care play in the management of bladder cancer?","answer":"Clinical trials are available at all stages of bladder cancer, offering access to new treatments, while supportive care addresses symptoms and side effects from both the cancer and its treatments.","question_type":"Contextual Summarize","evidence":"Clinical trials are available at all stages of bladder cancer.; Clinical trials offer access to new treatments for bladder cancer.; Supportive care addresses symptoms from bladder cancer.; Supportive care addresses side effects from bladder cancer treatments.","evidence_relations":"Clinical trials are available at all stages of bladder cancer; Supportive care addresses symptoms and side effects of cancer and its treatment; Treatment: {\"Clinical trial\": {}, \"Supportive care\": {}}; Common side effects of treatment include bleeding, infection, sexual dysfunction, urinary incontinence, fatigue, nausea, and diarrhea; Supportive care is included as a treatment modality in the ontology for bladder cancer"},
	{"id":"Medical-a4897c00","source":"Medical","question":"What are the major subtypes of kidney cancer and how are they histologically classified?","answer":"The major subtypes of kidney cancer include renal cell carcinoma (RCC), urothelial carcinoma, Wilms tumor, and renal sarcoma. RCC is the most common type, accounting for about 90% of kidney cancers, and arises from the cells lining the renal tubules. Histologically, RCC is classified into clear cell RCC (the most common subtype, characterized by pale or clear cells under the microscope), and non-clear cell RCC, which includes papillary RCC (with finger-like projections), chromophobe RCC (with larger, pale cells), collecting duct RCC, renal medullary carcinoma, clear cell papillary renal cell tumor, fumarate hydratase-deficient RCC, and ELOC-mutated RCC. Sarcomatoid features can develop in any RCC subtype and are associated with more aggressive disease. Urothelial carcinoma originates from the lining of the renal pelvis and ureter, Wilms tumor (nephroblastoma) typically occurs in children, and renal sarcoma arises from the kidney's connective tissues or blood vessels. Histological classification is essential for diagnosis and treatment planning.","question_type":"Contextual Summarize","evidence":"Kidney cancer includes subtypes such as renal cell carcinoma (RCC).; Kidney cancer includes subtypes such as urothelial carcinoma.; Kidney cancer includes subtypes such as Wilms tumor.; Kidney cancer includes subtypes such as renal sarcoma.; RCC is further classified by histology into clear cell RCC.; RCC is further classified by histology into non-clear cell RCC.; Non-clear cell RCC includes papillary RCC.; Non-clear cell RCC includes chromophobe RCC.; Non-clear cell RCC includes collecting duct RCC.; Non-clear cell RCC includes renal medullary carcinoma.; Non-clear cell RCC includes clear cell papillary renal cell tumor.; Non-clear cell RCC includes fumarate hydratase-deficient RCC.; Non-clear cell RCC includes ELOC-mutated RCC.; RCC can also be classified as sarcomatoid RCC.","evidence_relations":"Renal cell carcinoma (RCC) is the most common type of kidney cancer; Clear cell RCC is the most common subtype of RCC; Non-clear cell RCC includes papillary RCC, chromophobe RCC, collecting duct RCC, and renal medullary carcinoma; Wilms tumor usually occurs in young children and is a distinct kidney cancer type; Renal sarcoma starts in the blood vessels or connective tissue of the kidney; RCC starts in the cells that line the renal tubules; Sarcomatoid features can occur in any RCC subtype and are associated with more aggressive disease"},
	{"id":"Medical-ad636be8","source":"Medical","question":"Which anatomical structures are involved in the origin and local spread of kidney cancer?","answer":"Kidney cancer originates in structures such as the renal tubules and renal pelvis and can locally spread to surrounding fat, blood vessels, lymph nodes, adrenal glands, and Gerotas fascia.","question_type":"Contextual Summarize","evidence":"Kidney cancer originates in the renal tubules.; Kidney cancer originates in the renal pelvis.; Kidney cancer can locally spread to surrounding fat.; Kidney cancer can locally spread to blood vessels.; Kidney cancer can locally spread to lymph nodes.; Kidney cancer can locally spread to adrenal glands.; Kidney cancer can locally spread to Gerotas fascia.","evidence_relations":"RCC starts in the cells that line the renal tubules; Urothelial carcinoma starts in the cells lining the renal pelvis and ureter; Kidney cancer can spread locally to surrounding fat, blood vessels, lymph nodes, adrenal glands, and Gerotas fascia; Anatomical Structure includes: Renal tubules, Renal pelvis, Renal vein, Renal artery, Gerotas fascia, Adrenal gland; Stage: Local spread includes: Surrounding fat, Blood vessels, Lymph nodes, Adrenal glands, Gerotas fascia"},
	{"id":"Medical-1f8fc3b0","source":"Medical","question":"What diagnostic methods are used to identify kidney cancer and its subtypes?","answer":"Diagnosis of kidney cancer and its subtypes involves a combination of imaging tests (such as CT, MRI, renal ultrasound, and pyelogram) to visualize the kidneys and detect tumors, as well as blood and urine tests to assess kidney function and look for markers of disease. A biopsy may be performed to obtain tissue for histological examination, which helps determine the specific subtype of renal cell carcinoma (RCC), such as clear cell RCC (the most common subtype), papillary RCC, chromophobe RCC, collecting duct RCC, or renal medullary carcinoma. Additional diagnostic methods include biomarker testing and genetic risk testing, which can provide further information about the tumor's characteristics and guide treatment decisions.","question_type":"Contextual Summarize","evidence":"Diagnosis of kidney cancer involves imaging tests.; Diagnosis of kidney cancer involves blood tests.; Diagnosis of kidney cancer involves urine tests.; Diagnosis of kidney cancer involves biopsy.; Diagnosis of kidney cancer involves biomarker testing.; Diagnosis of kidney cancer involves genetic risk testing.","evidence_relations":"Diagnosis of kidney cancer involves imaging tests, blood tests, urine tests, biopsy, biomarker testing, and genetic risk testing; Diagnostic Method includes: Imaging tests, Blood tests, Urine tests, Biopsy, Biomarker testing, Genetic risk testing; Clear cell RCC is the most common subtype of RCC; Non-clear cell RCC includes papillary RCC, chromophobe RCC, collecting duct RCC, and renal medullary carcinoma; Renal cell carcinoma (RCC) is the most common type of kidney cancer"},
	{"id":"Medical-b87987f5","source":"Medical","question":"How does kidney cancer metastasize and what are the common distant sites of spread?","answer":"Kidney cancer, most commonly renal cell carcinoma (RCC), can metastasize by spreading cancer cells through the blood or lymphatic system to distant sites in the body. The most common sites of distant metastasis are the lungs, lymph nodes, bones, liver, and brain. In addition to distant spread, kidney cancer can also invade nearby tissues such as surrounding fat, blood vessels, adrenal glands, and Gerotas fascia. The process of metastasis significantly impacts prognosis and treatment options.","question_type":"Contextual Summarize","evidence":"Kidney cancer can metastasize to the lungs.; Kidney cancer can metastasize to lymph nodes.; Kidney cancer can metastasize to bones.; Kidney cancer can metastasize to the liver.; Kidney cancer can metastasize to the brain.","evidence_relations":"Kidney cancer can metastasize to distant sites such as lungs, lymph nodes, bones, liver, and brain; Stage: Metastasis includes: Lungs, Lymph nodes, Bones, Liver, Brain; Kidney cancer can spread locally to surrounding fat, blood vessels, lymph nodes, adrenal glands, and Gerotas fascia; Renal cell carcinoma (RCC) is the most common type of kidney cancer; RCC starts in the cells that line the renal tubules"},
	{"id":"Medical-0ab278c6","source":"Medical","question":"What factors influence treatment decisions for renal cell carcinoma (RCC)?","answer":"Treatment decisions for renal cell carcinoma (RCC) are influenced by several key factors, including the histology (subtype) of the tumor, its size, and its location within the kidney. The presence or absence of metastasis (spread of cancer to other parts of the body) is also critical in determining the appropriate treatment approach. Additional considerations may include whether the tumor exhibits aggressive features, such as sarcomatoid differentiation, and the results of diagnostic tests such as imaging and biopsy. These factors help guide the selection of surgical, medical, or other therapeutic options tailored to the individual patient's disease characteristics.","question_type":"Contextual Summarize","evidence":"Treatment for renal cell carcinoma (RCC) is determined by histology.; Treatment for renal cell carcinoma (RCC) is determined by tumor size.; Treatment for renal cell carcinoma (RCC) is determined by tumor location.; Treatment for renal cell carcinoma (RCC) is determined by the presence of metastasis.","evidence_relations":"Treatment for RCC is based on histology, tumor size, tumor location, and presence of metastasis; Treatment Factor includes: Histology, Tumor size, Tumor location, Presence of metastasis; Renal cell carcinoma (RCC) is the most common type of kidney cancer; Clear cell RCC is the most common subtype of RCC; Sarcomatoid features can occur in any RCC subtype and are associated with more aggressive disease"},
	{"id":"Medical-4019aff7","source":"Medical","question":"What distinguishes Wilms tumor from other kidney cancer types?","answer":"Wilms tumor is a distinct type of kidney cancer that usually occurs in young children, unlike other subtypes such as RCC, urothelial carcinoma, and renal sarcoma.","question_type":"Contextual Summarize","evidence":"Wilms tumor is a distinct type of kidney cancer.; Wilms tumor usually occurs in young children.; Other subtypes of kidney cancer include RCC, urothelial carcinoma, and renal sarcoma.","evidence_relations":"Wilms tumor usually occurs in young children and is a distinct kidney cancer type; Wilms tumor (nephroblastoma) is listed as a Cancer Subtype under Kidney cancer; Renal cell carcinoma (RCC) is the most common type of kidney cancer; Urothelial carcinoma starts in the cells lining the renal pelvis and ureter; Renal sarcoma starts in the blood vessels or connective tissue of the kidney"},
	{"id":"Medical-fd2c6b79","source":"Medical","question":"How are multiple tumors in the kidneys classified in relation to metastasis?","answer":"Multiple tumors in one or both kidneys are treated as separate primary tumors and not considered metastasis.","question_type":"Contextual Summarize","evidence":"Multiple tumors in one or both kidneys are treated as separate primary tumors.; Multiple tumors in one or both kidneys are not considered metastasis.","evidence_relations":"Multiple tumors in one or both kidneys are treated as separate primary tumors, not metastasis; Kidney cancer can metastasize to distant sites such as lungs, lymph nodes, bones, liver, and brain; Stage: Metastasis includes: Lungs, Lymph nodes, Bones, Liver, Brain; Renal cell carcinoma (RCC) is the most common type of kidney cancer; Clear cell RCC is the most common subtype of RCC"},
	{"id":"Medical-8fc62c51","source":"Medical","question":"What are the key histological features and subtypes of non-clear cell RCC?","answer":"Non-clear cell renal cell carcinoma (nccRCC) includes several distinct subtypes, each with unique histological features. These subtypes are: papillary RCC (characterized by finger-like projections of tumor cells), chromophobe RCC (with pale, larger cells that appear different from clear cells), collecting duct RCC (arising from the collecting ducts or tubules), renal medullary carcinoma (typically associated with sickle cell trait or disease), clear cell papillary renal cell tumor, fumarate hydratase-deficient RCC, and ELOC-mutated RCC. Accurate histological classification is important for determining prognosis and guiding treatment.","question_type":"Contextual Summarize","evidence":"Non-clear cell RCC comprises several subtypes.; Subtypes of non-clear cell RCC include papillary RCC.; Subtypes of non-clear cell RCC include chromophobe RCC.; Subtypes of non-clear cell RCC include collecting duct RCC.; Subtypes of non-clear cell RCC include renal medullary carcinoma.; Subtypes of non-clear cell RCC include clear cell papillary renal cell tumor.; Subtypes of non-clear cell RCC include fumarate hydratase-deficient RCC.; Subtypes of non-clear cell RCC include ELOC-mutated RCC.","evidence_relations":"Non-clear cell RCC includes papillary RCC, chromophobe RCC, collecting duct RCC, and renal medullary carcinoma; Non-clear cell RCC (nccRCC) includes: Papillary RCC (PRCC), Chromophobe RCC, Collecting duct RCC (cdRCC), Renal medullary carcinoma (RMC), Clear cell papillary renal cell tumor, Fumarate hydratase-deficient RCC, ELOC-mutated RCC; Clear cell RCC is the most common subtype of RCC; Renal cell carcinoma (RCC) is the most common type of kidney cancer; Sarcomatoid features can occur in any RCC subtype and are associated with more aggressive disease"},
	{"id":"Medical-4a723f3f","source":"Medical","question":"What are the origins and histological diversity of renal cell carcinoma?","answer":"Renal cell carcinoma (RCC) originates from the epithelial cells lining the renal tubules, which are responsible for filtering blood and forming urine in the kidneys. RCC is the most common type of kidney cancer and exhibits significant histological diversity. The main subtypes include clear cell RCC, which is the most prevalent and characterized by pale or clear-appearing cells under the microscope; non-clear cell RCC, which encompasses papillary RCC (with finger-like projections), chromophobe RCC (with larger, pale cells), collecting duct RCC, and renal medullary carcinoma; and tumors with sarcomatoid features, which can arise from any RCC subtype and are associated with more aggressive disease behavior. Accurate identification of the histological subtype is important for prognosis and treatment planning.","question_type":"Contextual Summarize","evidence":"Renal cell carcinoma originates from cells lining the renal tubules.; Renal cell carcinoma displays histological diversity.; Histological subtypes of renal cell carcinoma include clear cell.; Histological subtypes of renal cell carcinoma include non-clear cell.; Histological subtypes of renal cell carcinoma include sarcomatoid.","evidence_relations":"RCC starts in the cells that line the renal tubules; Clear cell RCC is the most common subtype of RCC; Non-clear cell RCC includes papillary RCC, chromophobe RCC, collecting duct RCC, and renal medullary carcinoma; Sarcomatoid features can occur in any RCC subtype and are associated with more aggressive disease; Renal cell carcinoma (RCC) is the most common type of kidney cancer"},
	{"id":"Medical-84c1024b","source":"Medical","question":"What are the main risk factors and biomarkers associated with anal cancer?","answer":"Anal cancer is strongly linked to risk factors such as HPV infection (especially HPV16), HIV infection, immunosuppressant use, smoking, and a history of gynecologic cancers or precancers, with HPV and HPV16 also serving as key biomarkers.","question_type":"Contextual Summarize","evidence":"Anal cancer is strongly linked to HPV infection, especially HPV16.; Anal cancer is strongly linked to HIV infection.; Anal cancer is strongly linked to immunosuppressant use.; Anal cancer is strongly linked to smoking.; Anal cancer is strongly linked to a history of gynecologic cancers or precancers.; HPV serves as a key biomarker for anal cancer.; HPV16 serves as a key biomarker for anal cancer.","evidence_relations":"HPV infection is the strongest risk factor for anal cancer; HIV infection increases the risk of anal cancer; Immunosuppressant use increases the risk of anal cancer; Smoking is a risk factor for anal cancer; History of cervical, vulvar, or vaginal cancer or precancer increases anal cancer risk; HPV16 is a high-risk strain associated with anal cancer; Biomarker: HPV, HPV16"},
	{"id":"Medical-6baff610","source":"Medical","question":"Which diagnostic methods are used for the detection and staging of anal cancer?","answer":"Anal cancer diagnosis and staging utilize digital rectal exam (DRE), high-resolution anoscopy (HRA), anoscopy, biopsy, and imaging modalities such as CT, MRI, and PET scans, with HIV testing also recommended for patients.","question_type":"Contextual Summarize","evidence":"Anal cancer diagnosis and staging utilize digital rectal exam (DRE).; Anal cancer diagnosis and staging utilize high-resolution anoscopy (HRA).; Anal cancer diagnosis and staging utilize anoscopy.; Anal cancer diagnosis and staging utilize biopsy.; Anal cancer diagnosis and staging utilize imaging modalities such as CT.; Anal cancer diagnosis and staging utilize imaging modalities such as MRI.; Anal cancer diagnosis and staging utilize imaging modalities such as PET scans.; HIV testing is recommended for patients with anal cancer.","evidence_relations":"Anal cancer is diagnosed by biopsy after abnormal findings on DRE or anoscopy; Digital rectal exam (DRE), high-resolution anoscopy (HRA), and imaging (CT, MRI, PET) are used for diagnosis and staging; HIV testing is recommended in patients with anal cancer; Diagnostic Method: Digital rectal exam (DRE), High-resolution anoscopy (HRA), Anoscopy, Biopsy, CT scan, MRI, PET scan, HIV testing; Staging uses the AJCC TNM system"},
	{"id":"Medical-b6606867","source":"Medical","question":"What are the primary symptoms of anal cancer and its most common subtype?","answer":"The primary symptoms of anal cancer, especially its most common subtype, anal squamous cell carcinoma, include rectal bleeding (which may be seen in the stool, on toilet paper, or in the toilet bowl), anal itching, pain in the anal area, and the presence of a lump or mass near the anus. These symptoms can sometimes be mistaken for benign conditions such as hemorrhoids, but persistent or unexplained symptoms should prompt evaluation by a healthcare professional.","question_type":"Contextual Summarize","evidence":"The main symptoms of anal cancer include rectal bleeding.; The main symptoms of anal cancer include anal itching.; The main symptoms of anal cancer include anal pain.; The main symptoms of anal cancer include a lump near the anus.; Anal squamous cell carcinoma is the most prevalent subtype of anal cancer.","evidence_relations":"Anal squamous cell carcinoma is the most common subtype of anal cancer; Anal cancer most often starts in squamous cells lining the anal canal; Common symptoms of anal cancer include rectal bleeding, anal itching, pain, and a lump near the anus; Symptom: Rectal bleeding, Anal itching, Anal pain, Anal lump; Anal cancer can start in the anal canal or perianal region"},
	{"id":"Medical-420f5e71","source":"Medical","question":"How is anal cancer staged, and what do the different stages represent?","answer":"Anal cancer is staged using the American Joint Committee on Cancer (AJCC) TNM system, which assesses tumor size (T), lymph node involvement (N), and distant metastasis (M). Stage 0 (carcinoma in situ or anal dysplasia) refers to abnormal cells confined to the surface layer, also called high-grade anal intraepithelial neoplasia (AIN) or high-grade squamous intraepithelial lesions (HSIL). Stage I is defined by a tumor 2 cm or smaller (T1) with no spread to lymph nodes (N0) or distant sites (M0). Stage II is divided into IIA (tumor >2 cm but 5 cm, T2) and IIB (tumor >5 cm, T3), both without lymph node or distant spread. Stage III is subdivided: IIIA involves tumors 5 cm with spread to nearby lymph nodes (N1), IIIB involves invasion into adjacent organs (such as the vagina, urethra, or bladder) without lymph node involvement, and IIIC includes larger tumors or those invading nearby organs with lymph node involvement. Stage IV indicates distant metastasis, meaning the cancer has spread beyond the pelvis to organs such as the liver or lungs. Accurate staging guides treatment decisions and prognosis.","question_type":"Contextual Summarize","evidence":"Anal cancer is staged using the AJCC TNM system.; Stage 0 represents carcinoma in situ or anal dysplasia.; Stage I is for tumors that are 2 cm or smaller without spread.; Stage II is for tumors larger than 2 cm without spread.; Stage III indicates lymph node involvement or local invasion.; Stage IV represents distant metastasis.","evidence_relations":"Staging uses the AJCC TNM system; Stage 0 is carcinoma in situ or anal dysplasia; Stage I: tumor 2 cm, no lymph node or distant spread; Stage II: tumor >2 cm, no lymph node or distant spread; Stage III: lymph node involvement and/or invasion of nearby organs; Stage IV: distant metastasis"},
	{"id":"Medical-2def53f0","source":"Medical","question":"What are the standard treatment approaches for non-metastatic and metastatic anal cancer?","answer":"Non-metastatic anal cancers (Stages I-III) are primarily treated with chemoradiation using IMRT or EBRT and regimens such as mitomycin with capecitabine or 5-FU, while metastatic (Stage IV) disease is managed with systemic chemotherapy, immunotherapy, and palliative radiation.","question_type":"Contextual Summarize","evidence":"Non-metastatic anal cancers (Stages I-III) are primarily treated with chemoradiation.; Chemoradiation for non-metastatic anal cancers may use IMRT or EBRT.; Regimens for non-metastatic anal cancers may include mitomycin with capecitabine or 5-FU.; Metastatic anal cancer (Stage IV) is managed with systemic chemotherapy.; Metastatic anal cancer (Stage IV) is managed with immunotherapy.; Metastatic anal cancer (Stage IV) is managed with palliative radiation.","evidence_relations":"Chemoradiation is the recommended primary treatment for most non-metastatic anal cancers (stages I-III); IMRT is the preferred radiation technique for anal cancer; Recommended chemotherapy regimens with radiation include mitomycin and capecitabine, mitomycin and 5-FU, or 5-FU and cisplatin; Metastatic anal cancer is treated with systemic chemotherapy (e.g., carboplatin and paclitaxel, FOLFOX, FOLFCIS, DCF, 5-FU and cisplatin); Immunotherapy (nivolumab, pembrolizumab) is recommended for metastatic anal cancer that progresses after chemotherapy"},
	{"id":"Medical-6746d569","source":"Medical","question":"What surgical procedures are used in the management of anal cancer and under what circumstances are they indicated?","answer":"Surgical procedures used in the management of anal cancer include local excision, abdominoperineal resection (APR), and groin (inguinal lymph node) dissection. Local excision is reserved for select early-stage, low-grade perianal cancers where the tumor is small and well-defined. Abdominoperineal resection (APR) is indicated for cases of anal cancer that are persistent, recurrent, or locally progressive after initial treatment, or when the cancer returns to the anal area. APR is a radical surgery that involves removal of the anus, rectum, and surrounding tissues, resulting in the need for a permanent colostomy, as there is no longer a natural route for stool to exit the body. Groin dissection is performed when there is recurrence of cancer in the inguinal lymph nodes. In some cases, muscle flap reconstruction may be required to aid healing after APR, especially if prior radiation therapy has compromised tissue in the perineal area.","question_type":"Contextual Summarize","evidence":"Local excision is reserved for select early-stage, low-grade perianal cancers.; Abdominoperineal resection (APR) is indicated for persistent anal cancer.; Abdominoperineal resection (APR) is indicated for recurrent anal cancer.; Abdominoperineal resection (APR) is indicated for locally progressive anal cancer.; Abdominoperineal resection (APR) results in a permanent colostomy.; Groin dissection is performed for lymph node recurrence.","evidence_relations":"Local excision is an option for some early-stage, low-grade perianal cancers; Abdominoperineal resection (APR) is recommended for persistent, recurrent, or locally progressive anal cancer; APR results in a permanent colostomy; Groin dissection: Indication: Lymph node recurrence; Surgical Procedure: Abdominoperineal resection (APR), Groin dissection"},
	{"id":"Medical-bc903265","source":"Medical","question":"What follow-up and surveillance strategies are recommended after treatment for anal cancer?","answer":"Post-treatment surveillance for anal cancer includes regular digital rectal exams, inguinal lymph node exams, anoscopy, and imaging over several years, with more frequent intervals in the first five years and annual imaging for higher stages.","question_type":"Contextual Summarize","evidence":"Post-treatment surveillance for anal cancer includes regular digital rectal exams.; Post-treatment surveillance for anal cancer includes inguinal lymph node exams.; Post-treatment surveillance for anal cancer includes anoscopy.; Post-treatment surveillance for anal cancer includes imaging over several years.; Surveillance for anal cancer has more frequent intervals in the first five years.; Annual imaging is recommended for higher stages of anal cancer.","evidence_relations":"Surveillance after treatment includes DRE, lymph node exams, anoscopy, and imaging; Complete remission: DRE: Every 3-6 months for 5 years; Complete remission: Inguinal lymph node exam: Every 3-6 months for 5 years; Complete remission: Anoscopy: Every 6-12 months for 3 years; Complete remission: Imaging: Yearly for 3 years (stage II/III)"},
	{"id":"Medical-172b14e6","source":"Medical","question":"What are the main side effects of anal cancer treatments and what fertility preservation options are available?","answer":"Anal cancer treatments, particularly radiation therapy and chemotherapy, can lead to a range of side effects. These include infertility (due to damage to the ovaries or sperm), bowel dysfunction (such as diarrhea and incontinence), urinary dysfunction (including frequent urination or incontinence), and sexual dysfunction. Additional systemic side effects may include hand-foot syndrome, nausea, vomiting, fatigue, skin irritation, mucositis, low blood cell counts, hearing loss (with cisplatin), and neuropathy (with oxaliplatin). To address the risk of infertility, several fertility preservation options are available and should be discussed prior to treatment. These options include sperm banking (semen cryopreservation), egg freezing (oocyte cryopreservation), ovarian tissue banking, and oophoropexy (surgical repositioning of the ovaries to minimize radiation exposure).","question_type":"Contextual Summarize","evidence":"Anal cancer treatments can cause side effects such as infertility.; Anal cancer treatments can cause bowel dysfunction.; Anal cancer treatments can cause urinary dysfunction.; Anal cancer treatments can cause sexual dysfunction.; Anal cancer treatments can cause various systemic symptoms.; Fertility preservation options include sperm banking.; Fertility preservation options include egg freezing.; Fertility preservation options include ovarian tissue banking.; Fertility preservation options include oophoropexy.","evidence_relations":"Radiation and chemotherapy can cause infertility; fertility preservation options should be discussed; Side Effect: Infertility, Bowel dysfunction, Urinary incontinence, Sexual dysfunction, Hand-foot syndrome, Nausea, Vomiting, Diarrhea, Fatigue, Skin irritation, Mucositis, Low blood cell counts, Hearing loss (cisplatin), Neuropathy (oxaliplatin); Fertility Preservation: Sperm banking, Egg freezing, Ovarian tissue banking, Oophoropexy; Supportive Care: Pelvic floor physical therapy, Dietary counseling, Vaginal dilator therapy, Ostomy care, Mental health support, Peer-to-peer support; Radiation and chemotherapy can cause infertility"},
	{"id":"Medical-ee24dc0c","source":"Medical","question":"How are recurrences of anal cancer managed depending on the site of recurrence?","answer":"Local recurrence of anal cancer is typically managed with abdominoperineal resection (APR), lymph node recurrence with groin dissection, chemotherapy, or additional radiation, and distant recurrence with systemic chemotherapy or immunotherapy.","question_type":"Contextual Summarize","evidence":"Local recurrence of anal cancer is typically managed with abdominoperineal resection (APR).; Lymph node recurrence of anal cancer is managed with groin dissection.; Lymph node recurrence of anal cancer may also be managed with chemotherapy.; Lymph node recurrence of anal cancer may also be managed with additional radiation.; Distant recurrence of anal cancer is managed with systemic chemotherapy.; Distant recurrence of anal cancer may also be managed with immunotherapy.","evidence_relations":"Recurrence: Local: APR; Recurrence: Lymph node: Groin dissection, Chemotherapy, Radiation (if not previously given); Recurrence: Distant: Systemic chemotherapy, immunotherapy; Abdominoperineal resection (APR) is recommended for persistent, recurrent, or locally progressive anal cancer; Groin dissection: Indication: Lymph node recurrence"},
	{"id":"Medical-2a88c6c4","source":"Medical","question":"What are the main diagnostic methods and common sites of involvement for acute lymphoblastic leukemia (ALL)?","answer":"ALL is diagnosed using blood tests, bone marrow aspirate and biopsy, flow cytometry, immunophenotyping, genetic and biomarker testing, imaging tests, and lumbar puncture, and it commonly involves the bone marrow, blood, lymph nodes, thymus, testicles, and central nervous system.","question_type":"Contextual Summarize","evidence":"Acute lymphoblastic leukemia (ALL) is diagnosed using blood tests.; ALL is diagnosed using bone marrow aspirate and biopsy.; ALL is diagnosed using flow cytometry.; ALL is diagnosed using immunophenotyping.; ALL is diagnosed using genetic and biomarker testing.; ALL is diagnosed using imaging tests.; ALL is diagnosed using lumbar puncture.; ALL commonly involves the bone marrow.; ALL commonly involves the blood.; ALL commonly involves the lymph nodes.; ALL commonly involves the thymus.; ALL commonly involves the testicles.; ALL commonly involves the central nervous system.","evidence_relations":"Diagnosis of ALL involves blood tests, bone marrow aspirate and biopsy, flow cytometry, immunophenotyping, genetic and biomarker testing, imaging tests, and lumbar puncture; ALL can be found in bone marrow, blood, testicles, and central nervous system; ALL includes Disease Site: bone marrow, blood, lymph nodes, thymus, testicles, central nervous system (CNS); ALL is diagnosed when 20 percent or more lymphoblasts are present in the bone marrow; Diagnostic Method for ALL includes blood tests, bone marrow aspirate, bone marrow biopsy, flow cytometry, immunophenotyping, genetic testing, biomarker testing, imaging tests, lumbar puncture"},
	{"id":"Medical-831734ba","source":"Medical","question":"How are the subtypes of ALL classified and what are their distinguishing features?","answer":"The subtypes of acute lymphoblastic leukemia (ALL) are primarily classified based on the type of lymphocyte from which the leukemia originates and the maturity of the cells. The two main subtypes are B-cell ALL (B-ALL), which starts in B-cell lymphocytes and is more common, and T-cell ALL (T-ALL), which arises from T-cell lymphocytes. B-ALL is characterized by the proliferation of immature B lymphoblasts, while T-ALL involves immature T lymphoblasts and can cause an enlarged thymus, sometimes leading to breathing difficulties. Rare subtypes include mature B-cell ALL (also known as Burkitt leukemia), which is closely related to Burkitt lymphoma and is treated differently from typical B-ALL. Additionally, when lymphoblasts primarily grow in lymph nodes or the thymus rather than the bone marrow, the disease is referred to as lymphoblastic lymphoma (B-cell lymphoblastic lymphoma or T-cell lymphoblastic lymphoma, respectively). Classification also considers immunophenotype and specific genetic or chromosomal changes within the leukemia cells.","question_type":"Contextual Summarize","evidence":"ALL is classified into B-cell ALL and T-cell ALL.; B-cell ALL starts in B-cell lymphocytes.; B-cell ALL is more common than T-cell ALL.; T-cell ALL arises from T-cell lymphocytes.; T-cell ALL may cause an enlarged thymus.; Mature B-cell ALL is also known as Burkitt leukemia.; Lymphoblastic lymphomas are notable subtypes of ALL.; Mature B-cell ALL and lymphoblastic lymphomas have specific sites of growth.","evidence_relations":"There are two main subtypes of ALL: B-cell ALL (B-ALL) and T-cell ALL (T-ALL); B-ALL starts in B-cell lymphocytes and is more common than T-ALL; T-ALL starts in T-cell lymphocytes and can cause an enlarged thymus; Mature B-cell ALL (Burkitt leukemia) is a rare subtype and is treated differently from B-ALL; B-cell lymphoblastic lymphoma (B-LL/B-LBL) occurs when B-cell lymphoblasts grow mostly in lymph nodes; T-cell lymphoblastic lymphoma (T-LL/T-LBL) occurs when T-cell lymphoblasts grow mostly in the thymus"},
	{"id":"Medical-5c82be50","source":"Medical","question":"What are the standard treatment approaches for ALL and how do they vary by subtype or prognostic group?","answer":"Standard treatment approaches for acute lymphoblastic leukemia (ALL) typically involve the use of steroids and multiagent chemotherapy for all patients. The specific treatment plan is further tailored based on the ALL subtype and prognostic group. For BCR::ABL1-positive B-ALL, therapy includes agents that specifically target the BCR::ABL protein, often as part of an intensive combination of systemic therapies. For BCR::ABL1-negative or BCR::ABL1-like B-ALL, participation in clinical trials is preferred, as these subtypes may benefit from novel or investigational therapies. T-cell ALL (T-ALL) is less common and is generally treated with chemotherapy, with clinical trials also being an option. Additionally, treatment strategies may vary depending on patient age (such as infants under 12 months) and other individual factors. Overall, the choice of therapy is influenced by genetic and biomarker testing, which helps guide the use of targeted therapies and enrollment in clinical trials for specific subgroups.","question_type":"Contextual Summarize","evidence":"Treatment for ALL generally includes steroids.; Treatment for ALL generally includes multiagent chemotherapy.; Targeted therapy is considered for specific subtypes of ALL.; Clinical trials may be considered for specific subtypes of ALL.; BCR::ABL1-positive B-ALL is treated with chemotherapy.; BCR::ABL1-negative B-ALL is treated with chemotherapy.; T-ALL is treated with chemotherapy.; T-ALL treatment may involve clinical trials.","evidence_relations":"Everyone with ALL is treated with steroids and multiagent chemotherapy; Targeted therapy may be used based on genetic alterations; Clinical trials are preferred for certain subtypes such as BCR::ABL1-negative or BCR::ABL1-like B-ALL; BCR::ABL1-positive B-ALL is treated with therapies targeting the BCR::ABL protein; T-ALL treatment options include chemotherapy and clinical trials; Treatment for ALL depends on subtype, age at diagnosis, and other factors"},
	{"id":"Medical-1b4960b5","source":"Medical","question":"Which biomarkers and genetic alterations are important in the management of B-cell ALL?","answer":"B-cell ALL management is guided by biomarkers and genetic alterations such as BCR::ABL1 and other gene or chromosome changes, which influence prognosis and the use of targeted therapies.","question_type":"Contextual Summarize","evidence":"B-cell ALL management is guided by biomarkers.; B-cell ALL management is guided by genetic alterations.; BCR::ABL1 is an important biomarker in B-cell ALL management.; Other gene or chromosome changes influence B-cell ALL management.; Biomarkers and genetic alterations influence prognosis in B-cell ALL.","evidence_relations":"BCR::ABL1-positive B-ALL is treated with therapies targeting the BCR::ABL protein; BCR::ABL1 is a biomarker for B-cell ALL; Other gene or chromosome changes are biomarkers in B-cell ALL; Genetic Alteration in ALL includes BCR::ABL1 fusion and other gene or chromosome changes; Targeted therapy may be used based on genetic alterations"},
	{"id":"Medical-34be9c71","source":"Medical","question":"What are the common symptoms and risk factors associated with ALL?","answer":"Acute lymphoblastic leukemia (ALL) commonly presents with symptoms such as anemia (due to decreased red blood cell production), increased susceptibility to infections (from low white blood cell counts), bleeding or easy bruising (from low platelet counts), enlarged lymph nodes, and organ involvement such as hepatosplenomegaly. In some cases, T-cell ALL can cause an enlarged thymus, which may lead to breathing difficulties. Risk factors for ALL include certain genetic syndromes and a family history of the disease.","question_type":"Contextual Summarize","evidence":"ALL commonly presents with symptoms such as anemia.; ALL commonly presents with infections.; ALL commonly presents with bleeding.; ALL commonly presents with enlarged lymph nodes.; ALL commonly presents with organ involvement.; Risk factors for ALL include certain genetic syndromes.; Risk factors for ALL include family history.","evidence_relations":"Symptoms of ALL may include anemia, infections, bleeding, enlarged lymph nodes, and organ involvement; Risk factors for ALL include certain genetic syndromes and family history; Symptom ontology for ALL includes anemia, infections, bleeding, enlarged lymph nodes, organ involvement; Risk Factor ontology for ALL includes genetic syndromes and family history; ALL is a fast-growing blood cancer that starts in lymphocytes"},
	{"id":"Medical-1587857f","source":"Medical","question":"Which patient populations are most commonly affected by ALL and what supportive care considerations are important?","answer":"Acute lymphoblastic leukemia (ALL) most commonly affects children, but it also occurs in adolescents, young adults (AYAs), and adults. Supportive care considerations are important for all patient populations and include fertility preservation prior to starting treatment, as therapies may impact future fertility. Additional supportive care may involve managing side effects, providing emotional and psychosocial support, and addressing quality of life issues throughout the course of treatment.","question_type":"Contextual Summarize","evidence":"ALL most often affects children.; ALL also occurs in adolescents.; ALL also occurs in young adults.; ALL also occurs in adults.; Supportive care such as fertility preservation should be considered before treatment.","evidence_relations":"ALL is more common in children but also occurs in adolescents and young adults (AYAs) and adults; Patient Population for ALL includes children, adolescents and young adults (AYAs), and adults; Fertility preservation should be considered before treatment; Supportive Care for ALL includes fertility preservation; Treatment for ALL depends on subtype, age at diagnosis, and other factors"},
	{"id":"Medical-1acacc3d","source":"Medical","question":"What are the key steps involved in the follow-up and surveillance of ALL patients after initial treatment?","answer":"The key steps involved in the follow-up and surveillance of ALL (acute lymphoblastic leukemia) patients after initial treatment include regular blood tests to monitor for signs of relapse and assess overall blood counts. Surveillance also involves clinical evaluations to detect early symptoms or physical findings suggestive of recurrence. Imaging studies are generally reserved for cases where there are new or worsening symptoms or other findings that raise suspicion for relapse or disease spread. The frequency and type of follow-up may be adjusted based on individual risk factors and time since treatment completion, with more frequent visits in the first few years and less frequent visits thereafter. The overall goal is early detection of relapse and management of any late effects of therapy.","question_type":"Contextual Summarize","evidence":"Follow-up for ALL patients includes regular blood tests.; Follow-up for ALL patients includes surveillance for relapse.; Surveillance is conducted to monitor disease status after initial treatment.","evidence_relations":"Follow-up includes regular blood tests and surveillance for relapse; Follow-up/Surveillance ontology for ALL includes regular blood tests and surveillance for relapse; Diagnosis of ALL involves blood tests; ALL is diagnosed when 20 percent or more lymphoblasts are present in the bone marrow; ALL can be found in bone marrow, blood, testicles, and central nervous system"},
	{"id":"Medical-d2ff311e","source":"Medical","question":"How do the sites of disease involvement differ between B-cell and T-cell lymphoblastic lymphoma?","answer":"B-cell lymphoblastic lymphoma primarily involves lymph nodes, while T-cell lymphoblastic lymphoma mainly affects the thymus.","question_type":"Contextual Summarize","evidence":"B-cell lymphoblastic lymphoma primarily involves lymph nodes.; T-cell lymphoblastic lymphoma mainly affects the thymus.","evidence_relations":"B-cell lymphoblastic lymphoma (B-LL/B-LBL) occurs when B-cell lymphoblasts grow mostly in lymph nodes; T-cell lymphoblastic lymphoma (T-LL/T-LBL) occurs when T-cell lymphoblasts grow mostly in the thymus; Disease Site ontology for ALL includes lymph nodes and thymus; B-cell ALL (B-ALL) includes the subtype B-cell lymphoblastic lymphoma (B-LL, B-LBL); T-cell ALL (T-ALL) includes the subtype T-cell lymphoblastic lymphoma (T-LL, T-LBL)"},
	{"id":"Medical-00bf955d","source":"Medical","question":"What is the role of clinical trials in the treatment of specific ALL subtypes?","answer":"Clinical trials play a significant role in the treatment of specific acute lymphoblastic leukemia (ALL) subtypes. For BCR::ABL1-negative or BCR::ABL1-like B-cell ALL (B-ALL), clinical trials are the preferred treatment approach, as they offer access to novel therapies and investigational treatments that may improve outcomes. Clinical trials are also an important option for patients with T-cell ALL (T-ALL), alongside standard chemotherapy regimens. Participation in clinical trials allows patients to benefit from the latest advances in therapy and may be particularly important for subtypes with limited standard treatment options.","question_type":"Contextual Summarize","evidence":"Clinical trials are preferred for certain ALL subtypes.; BCR::ABL1-negative B-ALL is one of the ALL subtypes for which clinical trials are preferred.; BCR::ABL1-like B-ALL is another ALL subtype for which clinical trials are preferred.; Clinical trials are an option for T-ALL.; Clinical trials provide access to novel therapies.","evidence_relations":"Clinical trials are preferred for certain subtypes such as BCR::ABL1-negative or BCR::ABL1-like B-ALL; T-ALL treatment options include chemotherapy and clinical trials; Treatment for ALL depends on subtype, age at diagnosis, and other factors; B-cell ALL (B-ALL) includes the prognostic groups BCR::ABL1-negative B-ALL, BCR::ABL1-like B-ALL, and BCR::ABL1-positive B-ALL; Treatment Modality ontology for ALL includes clinical trial"},
	{"id":"Medical-4094ccc8","source":"Medical","question":"What are the main diagnostic methods and symptoms associated with pancreatic ductal adenocarcinoma (PDAC)?","answer":"Pancreatic ductal adenocarcinoma is primarily diagnosed using imaging, endoscopic tests, biopsy, blood tests, genetic tests, and biomarker tests, with jaundice being a notable symptom.","question_type":"Contextual Summarize","evidence":"Pancreatic ductal adenocarcinoma is primarily diagnosed using imaging.; Endoscopic tests are used to diagnose pancreatic ductal adenocarcinoma.; Biopsy is a diagnostic method for pancreatic ductal adenocarcinoma.; Blood tests are used in the diagnosis of pancreatic ductal adenocarcinoma.; Genetic tests are part of the diagnostic methods for pancreatic ductal adenocarcinoma.; Biomarker tests are used to diagnose pancreatic ductal adenocarcinoma.; Jaundice is a notable symptom of pancreatic ductal adenocarcinoma.","evidence_relations":"Diagnostic methods for pancreatic cancer include imaging, endoscopic tests, biopsy, blood tests, genetic tests, and biomarker tests; Pancreatic ductal adenocarcinoma (PDAC) is the most common subtype of pancreatic cancer; Symptoms of pancreatic cancer may include jaundice (yellowed skin or eyes); Imaging is used for staging and determining surgical eligibility in pancreatic cancer; Pancreatic ductal adenocarcinoma includes diagnostic methods: Imaging, Endoscopic test, Biopsy, Blood test, Genetic test, Biomarker test; Pancreatic ductal adenocarcinoma includes symptom: Jaundice"},
	{"id":"Medical-30340b89","source":"Medical","question":"Which risk factors and hereditary syndromes are associated with increased risk of pancreatic cancer?","answer":"Risk factors for pancreatic cancer include smoking, heavy alcohol use, unhealthy diet, exposure to pesticides, diabetes, chronic pancreatitis, and a family history of certain cancers, while hereditary syndromes such as HBOC, Peutz-Jeghers syndrome, Lynch syndrome, Li-Fraumeni syndrome, FAMMM syndrome, and hereditary pancreatitis also increase risk.","question_type":"Contextual Summarize","evidence":"Risk factors for pancreatic cancer include smoking.; Heavy alcohol use is a risk factor for pancreatic cancer.; An unhealthy diet is a risk factor for pancreatic cancer.; Exposure to pesticides is a risk factor for pancreatic cancer.; Diabetes is a risk factor for pancreatic cancer.; Chronic pancreatitis is a risk factor for pancreatic cancer.; A family history of certain cancers increases the risk of pancreatic cancer.; Hereditary syndromes increase the risk of pancreatic cancer.; HBOC is a hereditary syndrome associated with increased risk of pancreatic cancer.; Peutz-Jeghers syndrome is a hereditary syndrome associated with increased risk of pancreatic cancer.; Lynch syndrome is a hereditary syndrome associated with increased risk of pancreatic cancer.; Li-Fraumeni syndrome is a hereditary syndrome associated with increased risk of pancreatic cancer.; FAMMM syndrome is a hereditary syndrome associated with increased risk of pancreatic cancer.; Hereditary pancreatitis is a hereditary syndrome associated with increased risk of pancreatic cancer.","evidence_relations":"Risk factors for pancreatic cancer include smoking, heavy alcohol use, unhealthy diet, exposure to pesticides, diabetes, chronic pancreatitis, and family history of certain cancers; Hereditary syndromes such as HBOC, Peutz-Jeghers syndrome, Lynch syndrome, Li-Fraumeni syndrome, FAMMM syndrome, and hereditary pancreatitis increase risk of pancreatic cancer; Pancreatic ductal adenocarcinoma includes risk factors: Smoking, Heavy alcohol use, Unhealthy diet, Pesticides, Diabetes, Chronic pancreatitis, Family history of pancreatic cancer, Family history of breast cancer, Family history of ovarian cancer, Family history of colorectal cancer, Family history of melanoma; Pancreatic ductal adenocarcinoma includes genetic syndromes: Hereditary breast-ovarian cancer syndrome, HBOC, Peutz-Jeghers syndrome, Lynch syndrome, Li-Fraumeni syndrome, Familial malignant melanoma syndrome, FAMMM syndrome, Hereditary pancreatitis; Genetic tests can detect inherited mutations linked to hereditary pancreatic cancer"},
	{"id":"Medical-adb2e872","source":"Medical","question":"How are the stages of pancreatic ductal adenocarcinoma defined and what is the significance of Stage IV disease?","answer":"The stages of pancreatic ductal adenocarcinoma (PDAC) are defined based on the size of the tumor and the extent of its spread. Stage 0 is limited to the innermost layer of the duct wall. Stage I consists of a tumor 4 centimeters or smaller that has not spread outside the pancreas. Stage II involves a tumor larger than 4 centimeters or cancer that has spread to 1 to 3 nearby lymph nodes. Stage III is characterized by tumor growth into nearby major arteries or spread to 4 or more lymph nodes. Stage IV, also known as metastatic pancreatic cancer, is defined by the spread of cancer to distant organs such as the liver, lungs, or abdominal lining. The significance of Stage IV disease is that it represents advanced cancer with distant metastasis, which greatly impacts treatment options and prognosis.","question_type":"Contextual Summarize","evidence":"The stages of pancreatic ductal adenocarcinoma range from Stage 0 to Stage IV.; Stage 0 is confined to the duct wall.; Stage IV is characterized by distant metastasis.; Distant metastasis in Stage IV can occur to organs such as the liver.; Distant metastasis in Stage IV can occur to the lungs.; Distant metastasis in Stage IV can occur to the abdominal lining.; Stage IV is also known as metastatic pancreatic cancer.","evidence_relations":"Stage 0 pancreatic cancer is confined to the innermost layer of the duct wall; Stage I pancreatic cancer is a tumor 4 cm or smaller and has not spread outside the pancreas; Stage II pancreatic cancer is a tumor larger than 4 cm or has spread to 1-3 nearby lymph nodes; Stage III pancreatic cancer has grown to nearby major arteries or spread to 4 or more lymph nodes; Stage IV pancreatic cancer has spread to distant organs such as liver, lungs, or abdominal lining; Stage IV pancreatic cancer is metastatic cancer; Pancreatic ductal adenocarcinoma includes stages: Stage 0, Stage I, Stage II, Stage III, Stage IV"},
	{"id":"Medical-91bd2db8","source":"Medical","question":"What are the primary treatment options for pancreatic ductal adenocarcinoma at different stages?","answer":"The primary treatment options for pancreatic ductal adenocarcinoma vary by stage. For select patients with Stage I, II, or III disease, surgery to remove the tumor may be possible and is considered when the cancer is localized and resectable. Drug treatment, including chemotherapy and targeted therapies, is used across all stages, particularly to control tumor growth and manage symptoms in advanced or metastatic cases (Stage IV). Clinical trials are available at all stages and may offer access to new or investigational therapies. Supportive care, including symptom management and palliative care, is an essential component of treatment at every stage to improve quality of life.","question_type":"Contextual Summarize","evidence":"Surgery is a treatment option for select patients with Stage I pancreatic ductal adenocarcinoma.; Surgery is a treatment option for select patients with Stage II pancreatic ductal adenocarcinoma.; Surgery is a treatment option for select patients with Stage III pancreatic ductal adenocarcinoma.; Drug treatment is available for all stages of pancreatic ductal adenocarcinoma.; Drug treatment is especially important for advanced cases of pancreatic ductal adenocarcinoma.; Clinical trials are a treatment option for pancreatic ductal adenocarcinoma.; Supportive care is provided across all stages of pancreatic ductal adenocarcinoma.","evidence_relations":"Surgery is a treatment option for some patients with stage I, II, or III pancreatic cancer; Drug treatment is most often used to control growth and reduce symptoms in pancreatic cancer; Clinical trials are available for pancreatic cancer patients; Supportive care is an important part of pancreatic cancer management; Pancreatic ductal adenocarcinoma includes treatments: Surgery (Stage I, II, III), Drug treatment (all stages), Clinical trial (all stages), Supportive care (all stages)"},
	{"id":"Medical-39074ccf","source":"Medical","question":"Who are the key members of the multidisciplinary care team involved in pancreatic cancer management?","answer":"The multidisciplinary care team for pancreatic cancer includes diagnostic and interventional radiologists, pathologists, gastroenterologists, medical, surgical, and radiation oncologists, geriatricians, registered dietitians, genetic counselors, palliative care providers, and mental health providers.","question_type":"Contextual Summarize","evidence":"The multidisciplinary care team for pancreatic cancer includes diagnostic radiologists.; The multidisciplinary care team for pancreatic cancer includes interventional radiologists.; The multidisciplinary care team for pancreatic cancer includes pathologists.; The multidisciplinary care team for pancreatic cancer includes gastroenterologists.; The multidisciplinary care team for pancreatic cancer includes medical oncologists.; The multidisciplinary care team for pancreatic cancer includes surgical oncologists.; The multidisciplinary care team for pancreatic cancer includes radiation oncologists.; The multidisciplinary care team for pancreatic cancer includes geriatricians.; The multidisciplinary care team for pancreatic cancer includes registered dietitians.; The multidisciplinary care team for pancreatic cancer includes genetic counselors.; The multidisciplinary care team for pancreatic cancer includes palliative care providers.; The multidisciplinary care team for pancreatic cancer includes mental health providers.","evidence_relations":"A multidisciplinary care team is essential for diagnosis and treatment planning in pancreatic cancer; Care Team Role includes: Diagnostic radiologist, Interventional radiologist, Pathologist, Gastroenterologist, Medical oncologist, Surgical oncologist, Radiation oncologist, Geriatrician, Registered dietitian, Genetic counselor, Palliative care provider, Mental health provider; Pancreatic cancer includes care team roles: Diagnostic radiologist, Interventional radiologist, Pathologist, Gastroenterologist, Medical oncologist, Surgical oncologist, Radiation oncologist, Geriatrician, Registered dietitian, Genetic counselor, Palliative care provider, Mental health provider; Supportive care is an important part of pancreatic cancer management; Supportive Care includes: Symptom management, Palliative care"},
	{"id":"Medical-3ad15fef","source":"Medical","question":"What is the role and scope of supportive care in pancreatic cancer management?","answer":"Supportive care in pancreatic cancer plays a critical role throughout all stages of the disease and is aimed at relieving symptoms, managing side effects of cancer and its treatments, and improving quality of life. This includes palliative care measures such as pain control, nutritional support, management of digestive issues, and addressing psychological and social needs. Supportive care is not limited to end-of-life care but is integrated alongside active cancer treatments to help patients maintain daily functioning and comfort. A multidisciplinary care team is essential to provide comprehensive supportive care, ensuring that patients' physical, emotional, and practical needs are addressed as part of their overall management plan.","question_type":"Contextual Summarize","evidence":"Supportive care in pancreatic cancer focuses on symptom management.; Supportive care in pancreatic cancer includes palliative care.; Supportive care is considered an important component of pancreatic cancer management.; Supportive care is important at all stages of pancreatic cancer.","evidence_relations":"Supportive care is an important part of pancreatic cancer management; Supportive Care includes: Symptom management, Palliative care; Pancreatic ductal adenocarcinoma includes supportive care at all stages; Drug treatment is most often used to control growth and reduce symptoms in pancreatic cancer; A multidisciplinary care team is essential for diagnosis and treatment planning in pancreatic cancer"},
	{"id":"Medical-9351c8ee","source":"Medical","question":"How do genetic testing and biomarker tests contribute to the diagnosis and risk assessment of pancreatic cancer?","answer":"Genetic tests and biomarker tests are used in the diagnosis of pancreatic cancer to detect inherited mutations associated with hereditary risk and to identify disease-specific biomarkers.","question_type":"Contextual Summarize","evidence":"Genetic tests are used in the diagnosis of pancreatic cancer.; Genetic tests detect inherited mutations associated with hereditary risk.; Biomarker tests are used in the diagnosis of pancreatic cancer.; Biomarker tests identify disease-specific biomarkers.","evidence_relations":"Genetic tests can detect inherited mutations linked to hereditary pancreatic cancer; Diagnostic methods for pancreatic cancer include imaging, endoscopic tests, biopsy, blood tests, genetic tests, and biomarker tests; Pancreatic ductal adenocarcinoma includes diagnostic methods: Genetic test, Biomarker test; Hereditary syndromes such as HBOC, Peutz-Jeghers syndrome, Lynch syndrome, Li-Fraumeni syndrome, FAMMM syndrome, and hereditary pancreatitis increase risk of pancreatic cancer; Risk factors for pancreatic cancer include family history of certain cancers"},
	{"id":"Medical-8f9d5dde","source":"Medical","question":"What are the main diagnostic methods and biomarkers used for prostate cancer across its stages?","answer":"The main diagnostic methods for prostate cancer include prostate-specific antigen (PSA) testing and digital rectal examination (DRE) for initial screening and assessment. If these tests suggest the possibility of cancer, a prostate biopsy is performed to confirm the diagnosis. Imaging modalities such as MRI, CT scan, PET scan (including PSMA-PET), bone scan, and ultrasound are used to evaluate the extent of disease, guide biopsy procedures, and assess for metastasis, particularly in higher-risk or advanced stages. Biomarkers play a crucial role throughout all stages: PSA is used for screening and monitoring; biopsy samples are evaluated for Gleason score and Grade Group to assess tumor aggressiveness; and molecular biomarker tests (such as 4Kscore, PHI, IsoPSA in blood, and ExoDx, miR Sentinel, MPS, PCA3, SelectMDx in urine) provide additional information on cancer risk and prognosis. Molecular biomarker testing of tumor tissue can further stratify risk and guide management decisions, especially in localized, regional, or metastatic disease.","question_type":"Contextual Summarize","evidence":"Prostate cancer diagnosis commonly involves PSA testing.; Digital rectal exam is a method used to diagnose prostate cancer.; Biopsy is a common diagnostic method for prostate cancer.; Imaging modalities such as MRI are used in prostate cancer diagnosis.; CT scans are used in the diagnosis of prostate cancer.; PET scans are used in the diagnosis of prostate cancer.; Bone scans are used in the diagnosis of prostate cancer.; Ultrasound is used in the diagnosis of prostate cancer.; Biomarkers used for prostate cancer include PSA.; Gleason score is a biomarker used for prostate cancer.; Grade Group is a biomarker used for prostate cancer.; Molecular biomarker tests are used throughout all stages of prostate cancer.","evidence_relations":"PSA test and digital rectal exam are used for screening and diagnosis; Biopsy is required to confirm prostate cancer diagnosis; MRI, CT, PET, ultrasound, and bone scan are imaging methods used to assess extent of disease; Biomarker: PSA, Gleason score, Grade Group, Molecular biomarker tests; Diagnostic Method: PSA test, Digital rectal exam, Biopsy, MRI, CT scan, PET scan, Bone scan, Ultrasound, PSMA-PET, Blood and urine biomarker tests (4Kscore, PHI, IsoPSA, ExoDx, miR Sentinel, MPS, PCA3, SelectMDx)"},
	{"id":"Medical-e75b6871","source":"Medical","question":"How do risk groups and genetic alterations influence prognosis and management in prostate cancer?","answer":"Risk groups (very low to very high) and genetic alterations such as BRCA1, BRCA2, and others inform prognosis and guide treatment and genetic testing decisions in prostate cancer.","question_type":"Contextual Summarize","evidence":"Risk groups for prostate cancer range from very low to very high.; Genetic alterations such as BRCA1 and BRCA2 influence prognosis in prostate cancer.; Risk groups and genetic alterations guide treatment decisions in prostate cancer.; Risk groups and genetic alterations inform genetic testing decisions in prostate cancer.","evidence_relations":"Risk groups (very low, low, intermediate, high, very high) guide prognosis and treatment; BRCA2 mutation increases risk of prostate cancer; Genetic Alteration: BRCA1, BRCA2, ATM, CHEK2, MLH1, MSH2, MSH6, PALB2, PMS2, FANCA; Germline genetic testing is recommended for patients with high-risk, very-high-risk, regional, or metastatic prostate cancer; Molecular biomarker testing helps assess risk and guide treatment decisions"},
	{"id":"Medical-46639f91","source":"Medical","question":"What are the primary treatment options for localized, regional, and metastatic prostate cancer?","answer":"Treatment options for localized prostate cancer include active surveillance, surgery, radiation therapy, and hormone therapy, while regional and metastatic disease are managed with combinations of hormone therapy, surgery, radiation, chemotherapy, targeted therapy, immunotherapy, and radiopharmaceuticals.","question_type":"Contextual Summarize","evidence":"Treatment options for localized prostate cancer include active surveillance.; Treatment options for localized prostate cancer include surgery.; Treatment options for localized prostate cancer include radiation therapy.; Treatment options for localized prostate cancer include hormone therapy.; Regional and metastatic prostate cancer are managed with combinations of hormone therapy.; Regional and metastatic prostate cancer are managed with surgery.; Regional and metastatic prostate cancer are managed with radiation.; Regional and metastatic prostate cancer are managed with chemotherapy.; Regional and metastatic prostate cancer are managed with targeted therapy.; Regional and metastatic prostate cancer are managed with immunotherapy.; Regional and metastatic prostate cancer are managed with radiopharmaceuticals.","evidence_relations":"Localized prostate cancer: Treatment: Active surveillance, Surgery, Radiation therapy, Hormone therapy; Regional prostate cancer: Treatment: Hormone therapy, Radiation therapy, Surgery, Chemotherapy, Targeted therapy; Metastatic prostate cancer: Treatment: Androgen deprivation therapy (ADT), LHRH agonist, LHRH antagonist, Leuprolide, Goserelin, Triptorelin, Degarelix, Relugolix, Bicalutamide, Flutamide, Nilutamide, Orchiectomy, Chemotherapy, Immunotherapy, Targeted therapy, Radiation therapy, Radiopharmaceuticals; Hormone therapy, surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy, and radiopharmaceuticals are treatment options; Androgen deprivation therapy (ADT) is a mainstay of advanced prostate cancer treatment"},
	{"id":"Medical-436b2db6","source":"Medical","question":"Which symptoms are associated with advanced and metastatic prostate cancer?","answer":"Symptoms associated with advanced and metastatic prostate cancer include bone pain (particularly in the hips and back), blood in the urine or semen, unexplained weight loss, and a range of urinary symptoms such as frequent urination (especially at night), weak or intermittent urine stream, difficulty urinating or straining to urinate, trouble holding in urine, and a sensation of incomplete bladder emptying. Burning or pain while urinating, dull pain in the groin or pelvis, and erectile dysfunction or painful ejaculation may also occur. These symptoms result from the cancer spreading beyond the prostate gland to other areas such as bones and nearby tissues.","question_type":"Contextual Summarize","evidence":"Advanced prostate cancer commonly presents with bone pain.; Advanced prostate cancer can present with blood in urine or semen.; Advanced prostate cancer may cause unexplained weight loss.; Advanced prostate cancer can cause hip and back pain.; Advanced prostate cancer may present with various urinary symptoms.","evidence_relations":"Symptoms of advanced prostate cancer include blood in urine or semen, bone pain, weight loss, and urinary symptoms; Metastatic prostate cancer: Symptom: Bone pain, Hip pain, Back pain, Unexplained weight loss, Blood in urine, Blood in semen, Urinary symptoms; Bone pain, hip pain, and back pain are symptoms of metastatic prostate cancer; Blood in urine and blood in semen are symptoms of advanced prostate cancer; Unexplained weight loss and urinary symptoms occur in advanced stages"},
	{"id":"Medical-0fec5b62","source":"Medical","question":"What are the main risk factors for developing prostate cancer?","answer":"The main risk factors for prostate cancer include age, family history, Black race, genetic mutations such as BRCA1/2 and others, obesity, smoking, and dietary habits like high-fat diet and low fruit and vegetable intake.","question_type":"Contextual Summarize","evidence":"The main risk factors for prostate cancer include age.; Family history is a risk factor for prostate cancer.; Black race is a risk factor for prostate cancer.; Genetic mutations such as BRCA1 and BRCA2 are risk factors for prostate cancer.; Obesity is a risk factor for prostate cancer.; Smoking is a risk factor for prostate cancer.; Dietary habits like a high-fat diet are risk factors for prostate cancer.; Low fruit and vegetable intake is a risk factor for prostate cancer.","evidence_relations":"Age, family history, race, genetic mutations, diet, obesity, and smoking are risk factors for prostate cancer; Risk Factor: Age, Family history, Black race, Genetic mutations (BRCA1, BRCA2, ATM, CHEK2, MLH1, MSH2, MSH6, PALB2, PMS2), Obesity, Smoking, High-fat diet, Low fruit and vegetable intake; BRCA2 mutation increases risk of prostate cancer; Obesity and smoking are risk factors for prostate cancer; High-fat diet and low fruit and vegetable intake are risk factors"},
	{"id":"Medical-7b29a89d","source":"Medical","question":"How is follow-up managed after prostate cancer diagnosis and treatment?","answer":"Follow-up after prostate cancer diagnosis and treatment involves regular monitoring of prostate-specific antigen (PSA) levels to detect recurrence or progression, as well as imaging studies such as MRI, CT, PET, ultrasound, or bone scans when indicated by symptoms or risk factors. Repeat prostate biopsies may be performed, particularly for patients on active surveillance, and molecular biomarker testing or nomogram-based risk assessments may be used to further guide management. The specific follow-up strategy is tailored to the patient's risk group and disease stage, and may also include assessment of symptoms and quality of life.","question_type":"Contextual Summarize","evidence":"Follow-up for prostate cancer includes regular PSA testing.; Imaging is part of follow-up for prostate cancer as indicated.; Repeat biopsies may be part of follow-up for prostate cancer.; Molecular biomarker testing may be part of follow-up for prostate cancer.; Follow-up strategies are tailored to risk group and disease stage.","evidence_relations":"Follow-up includes regular PSA testing, imaging, and biopsies as needed; Localized prostate cancer: Follow-up Strategy: Regular PSA testing, Repeat biopsy, Imaging as indicated; Regional prostate cancer: Follow-up Strategy: PSA monitoring, Imaging, Biopsy as needed; Metastatic prostate cancer: Follow-up Strategy: PSA monitoring, Imaging, Biopsy as indicated; Follow-up Strategy: Regular PSA testing, Imaging as indicated, Repeat biopsy for active surveillance, Molecular biomarker testing, Nomogram-based risk assessment"},
	{"id":"Medical-502e8349","source":"Medical","question":"What is the role of molecular biomarker and genetic testing in prostate cancer management?","answer":"Molecular biomarker and genetic testing play a critical role in prostate cancer management by helping to assess the risk of disease progression and guide individualized treatment decisions. Molecular biomarker testing, performed on biopsy samples, evaluates the molecular characteristics of the tumor to determine whether the cancer is lower or higher risk, which can influence whether immediate treatment is necessary or if active surveillance is appropriate. Genetic testing, particularly germline testing for mutations in genes such as BRCA1, BRCA2, ATM, CHEK2, MLH1, MSH2, MSH6, PALB2, PMS2, and FANCA, is recommended for patients with high-risk, very-high-risk, regional, or metastatic prostate cancer, as well as those with a relevant family history. Identifying these mutations can inform prognosis, eligibility for targeted therapies, and the need for genetic counseling for patients and their families.","question_type":"Contextual Summarize","evidence":"Molecular biomarker testing is used to assess risk in prostate cancer.; Genetic testing guides treatment decisions in prostate cancer.; Molecular biomarker and genetic testing are recommended for high-risk prostate cancer.; Molecular biomarker and genetic testing are recommended for regional prostate cancer.; Molecular biomarker and genetic testing are recommended for metastatic prostate cancer.","evidence_relations":"Molecular biomarker testing helps assess risk and guide treatment decisions; Germline genetic testing is recommended for patients with high-risk, very-high-risk, regional, or metastatic prostate cancer; Biomarker: Molecular biomarker tests; Genetic Alteration: BRCA1, BRCA2, ATM, CHEK2, MLH1, MSH2, MSH6, PALB2, PMS2, FANCA; Follow-up Strategy: Molecular biomarker testing"},
	{"id":"Medical-66093871","source":"Medical","question":"Which urinary and sexual symptoms can present in prostate cancer patients?","answer":"Prostate cancer can cause urinary symptoms such as frequent urination, weak urine stream, trouble urinating, and sexual symptoms like erectile dysfunction and painful ejaculation.","question_type":"Contextual Summarize","evidence":"Prostate cancer can cause urinary symptoms such as frequent urination.; Prostate cancer can cause a weak urine stream.; Prostate cancer can cause trouble urinating.; Prostate cancer can cause sexual symptoms like erectile dysfunction.; Prostate cancer can cause painful ejaculation.","evidence_relations":"Symptom: Blood in urine, Blood in semen, Burning or pain while urinating, Unexplained weight loss, Bone pain, Hip pain, Back pain, Frequent urination, Weak urine stream, Trouble urinating, Trouble holding in urine, Feeling of incomplete bladder emptying, Dull pain in groin or pelvis, Erectile dysfunction, Painful ejaculation; Symptoms of advanced prostate cancer include blood in urine or semen, bone pain, weight loss, and urinary symptoms; Localized prostate cancer: Symptom: Often asymptomatic, Blood in urine, Blood in semen, Urinary symptoms, Erectile dysfunction; Urinary symptoms are common in localized, regional, and metastatic prostate cancer; Erectile dysfunction and painful ejaculation are sexual symptoms associated with prostate cancer"},
	{"id":"Medical-e4cfdc32","source":"Medical","question":"How does the staging of prostate cancer affect diagnostic and imaging strategies?","answer":"Staging determines the extent of diagnostic and imaging evaluation, with localized disease using PSA, digital rectal exam, biopsy, MRI, and ultrasound, while regional and metastatic stages require additional imaging such as CT, PET, bone scan, and PSMA-PET.","question_type":"Contextual Summarize","evidence":"Staging determines the extent of diagnostic evaluation in prostate cancer.; Localized prostate cancer uses PSA for diagnostic evaluation.; Localized prostate cancer uses digital rectal exam for diagnostic evaluation.; Localized prostate cancer uses biopsy for diagnostic evaluation.; Localized prostate cancer uses MRI for diagnostic evaluation.; Localized prostate cancer uses ultrasound for diagnostic evaluation.; Regional and metastatic prostate cancer require additional imaging such as CT.; Regional and metastatic prostate cancer require additional imaging such as PET.; Regional and metastatic prostate cancer require additional imaging such as bone scan.; Regional and metastatic prostate cancer require additional imaging such as PSMA-PET.","evidence_relations":"Localized prostate cancer: Diagnostic Method: PSA test, Digital rectal exam, Biopsy, MRI, Ultrasound; Regional prostate cancer: Diagnostic Method: PSA test, Digital rectal exam, Biopsy, MRI, CT scan, PSMA-PET; Metastatic prostate cancer: Diagnostic Method: PSA test, Biopsy, MRI, CT scan, PET scan, Bone scan, PSMA-PET; MRI, CT, PET, ultrasound, and bone scan are imaging methods used to assess extent of disease; PSA test and digital rectal exam are used for screening and diagnosis"},
	{"id":"Medical-c84d2076","source":"Medical","question":"What are the main types of adrenal tumors and how do they differ in terms of malignancy and function?","answer":"The main types of adrenal tumors are classified as benign or malignant. Benign adrenal tumors, such as adrenocortical adenomas, do not metastasize and are often discovered incidentally during imaging for unrelated reasons. These adenomas can be either functioning (producing excess hormones such as aldosterone or cortisol, leading to conditions like Cushing syndrome or primary aldosteronism) or nonfunctioning (not producing hormones and often asymptomatic). Malignant adrenal tumors include adrenocortical carcinoma (ACC), pheochromocytoma, and neuroblastoma. ACC is a rare cancer of the adrenal cortex that can be functioning or nonfunctioning and has the potential to metastasize. Pheochromocytomas arise from the adrenal medulla, may produce excess catecholamines (causing symptoms like high blood pressure, headache, rapid heartbeat, and sweating), and while most are benign, some can be malignant. Neuroblastoma is a rare, malignant tumor primarily affecting children under 5 years old and can spread to other parts of the body, including bones. Functional tumors, whether benign or malignant, may cause symptoms due to hormone overproduction, while nonfunctioning tumors may remain asymptomatic unless they grow large enough to cause local effects.","question_type":"Contextual Summarize","evidence":"Adrenal tumors can be benign or malignant.; Benign adrenal tumors like adenomas are often non-metastasizing.; Benign adrenal tumors can be functional or nonfunctioning.; Malignant adrenal tumors include adrenocortical carcinoma.; Malignant adrenal tumors include pheochromocytoma.; Malignant adrenal tumors include neuroblastoma.; Malignant adrenal tumors may produce hormones.; Malignant adrenal tumors have potential for metastasis.","evidence_relations":"Adrenal tumors can be benign or malignant; Benign adrenal tumors do not metastasize; Adenoma is the most common type of adrenal gland tumor and can be functioning or nonfunctioning; Adrenocortical carcinoma (ACC) is a rare malignant tumor of the adrenal cortex; Neuroblastoma is a rare malignant adrenal tumor affecting mainly children under 5; Functional adrenal tumors may produce excess hormones; Malignant adrenal tumors include Adrenocortical Carcinoma (ACC), Pheochromocytoma, and Neuroblastoma"},
	{"id":"Medical-eeadd54a","source":"Medical","question":"What are the key symptoms and hormone-related syndromes associated with adrenocortical carcinoma and functional adrenal tumors?","answer":"Adrenocortical carcinoma (ACC) can present with a range of symptoms, including weight gain, muscle weakness, pink or purple stretch marks on the skin, and various hormonal changes such as excess facial hair, hair loss on the head, irregular periods, enlarged breast tissue, and shrinking testicles. Additional symptoms may include nausea, vomiting, abdominal bloating, back pain, fever, loss of appetite, and unintentional weight loss. Functional adrenal tumors may produce excess hormones, leading to specific hormone-related syndromes: for example, cortisol-producing adenomas can cause Cushing syndrome, characterized by features such as central obesity, muscle weakness, and skin changes, while aldosteronomas produce excess aldosterone, resulting in symptoms related to hypertension and electrolyte imbalance. About half of patients with adrenal cancer experience symptoms due to hormone excess.","question_type":"Contextual Summarize","evidence":"Adrenocortical carcinoma may cause weight gain.; Adrenocortical carcinoma may cause muscle weakness.; Adrenocortical carcinoma may cause stretch marks.; Adrenocortical carcinoma may cause hormonal changes.; Adrenocortical carcinoma may cause loss of appetite.; Functional adrenal tumors can lead to hormone excess syndromes.; Cushing syndrome can result from cortisol-producing adenomas.; Excess aldosterone can result from aldosteronoma.","evidence_relations":"Symptoms of adrenal cancer include weight gain, muscle weakness, stretch marks, hormonal changes, nausea, vomiting, abdominal bloating, back pain, fever, loss of appetite, and unintentional weight loss; Half of adrenal cancer patients have symptoms due to hormone excess; Adenoma producing excess cortisol causes Cushing syndrome; Aldosteronoma produces excess aldosterone; Adrenocortical carcinoma (ACC) is a rare malignant tumor of the adrenal cortex; Adrenocortical Carcinoma (ACC) symptoms include weight gain, muscle weakness, pink or purple stretch marks, and hormonal changes"},
	{"id":"Medical-081395a7","source":"Medical","question":"Which diagnostic methods are commonly used to evaluate adrenal tumors and what is their purpose?","answer":"Adrenal tumors are commonly evaluated using imaging tests such as CT scan, MRI scan, PET scan, FDG-PET/CT, and SSTR-PET/CT, as well as blood and biochemical tests to detect hormone secretion, with genetic testing and biopsy also used for diagnosis.","question_type":"Contextual Summarize","evidence":"Adrenal tumors are commonly evaluated using imaging tests.; Common imaging tests for adrenal tumors include CT scan, MRI scan, PET scan, FDG-PET/CT, and SSTR-PET/CT.; Blood and biochemical tests are used to detect hormone secretion in adrenal tumors.; Genetic testing is used for the diagnosis of adrenal tumors.; Biopsy is also used for the diagnosis of adrenal tumors.","evidence_relations":"Adrenal tumors are often found incidentally on imaging tests such as CT or MRI; Imaging tests for adrenal tumors include CT scan, MRI scan, PET scan, FDG-PET/CT, and SSTR-PET/CT; Blood and biochemical tests are used to detect hormone secretion by adrenal tumors; Genetic testing may be performed to identify hereditary risk factors; Biopsy may be used for diagnosis; Diagnostic methods for Adrenocortical Carcinoma (ACC) include CT scan, MRI scan, PET scan, FDG-PET/CT, SSTR-PET/CT, blood test, biochemical test, genetic test, and biopsy"},
	{"id":"Medical-af1875a1","source":"Medical","question":"What hereditary syndromes are recognized as risk factors for adrenocortical carcinoma?","answer":"Adrenocortical carcinoma risk is increased by hereditary syndromes such as Beckwith-Wiedemann syndrome, Carney complex, FAP, PGL/PCC syndrome, Li-Fraumeni syndrome, Lynch syndrome, MEN 1, MEN 2, NF1, and Von Hippel-Lindau syndrome.","question_type":"Contextual Summarize","evidence":"Adrenocortical carcinoma risk is increased by hereditary syndromes.; Recognized hereditary syndromes that increase risk include Beckwith-Wiedemann syndrome.; Carney complex is a hereditary syndrome that increases the risk of adrenocortical carcinoma.; Familial adenomatous polyposis (FAP) is a hereditary syndrome that increases the risk of adrenocortical carcinoma.; PGL/PCC syndrome is a hereditary syndrome that increases the risk of adrenocortical carcinoma.; Li-Fraumeni syndrome is a hereditary syndrome that increases the risk of adrenocortical carcinoma.; Lynch syndrome is a hereditary syndrome that increases the risk of adrenocortical carcinoma.; Multiple endocrine neoplasia type 1 (MEN 1) is a hereditary syndrome that increases the risk of adrenocortical carcinoma.; Multiple endocrine neoplasia type 2 (MEN 2) is a hereditary syndrome that increases the risk of adrenocortical carcinoma.; Neurofibromatosis type 1 (NF1) is a hereditary syndrome that increases the risk of adrenocortical carcinoma.; Von Hippel-Lindau syndrome is a hereditary syndrome that increases the risk of adrenocortical carcinoma.","evidence_relations":"Certain hereditary syndromes increase the risk of adrenal tumors; Risk factors for Adrenocortical Carcinoma (ACC) include Beckwith-Wiedemann syndrome, Carney complex, Familial adenomatous polyposis (FAP), Hereditary paraganglioma-pheochromocytoma (PGL/PCC) syndrome, Li-Fraumeni syndrome, Lynch syndrome, Multiple endocrine neoplasia type 1 (MEN 1), Multiple endocrine neoplasia type 2 (MEN 2), Neurofibromatosis type 1 (NF1), and Von Hippel-Lindau syndrome (VHL); Adrenocortical carcinoma can occur at any age but is most likely in children under 5 and adults in their 40s and 50s; Genetic testing may be performed to identify hereditary risk factors; Risk factors for adrenal tumors include hereditary syndromes and family history"},
	{"id":"Medical-b2552c99","source":"Medical","question":"How do the symptoms and diagnostic approaches differ between pheochromocytoma and adrenocortical carcinoma?","answer":"Pheochromocytoma, which arises from the adrenal medulla, typically presents with symptoms related to excess catecholamine production, such as high blood pressure, headache, rapid heartbeat (tachycardia), and sweating. Diagnosis of pheochromocytoma involves imaging studies like CT or MRI scans, as well as biochemical tests to detect elevated catecholamines or their metabolites. In contrast, adrenocortical carcinoma (ACC) originates from the adrenal cortex and can present with a broader spectrum of symptoms, including weight gain, muscle weakness, pink or purple stretch marks, and various hormonal changes such as excess facial hair, hair loss on the head, irregular periods, enlarged breast tissue, and shrinking testicles. ACC may also cause nonspecific symptoms like nausea, vomiting, abdominal bloating, back pain, fever, loss of appetite, and unintentional weight loss. Diagnostic approaches for ACC are more extensive and may include CT scan, MRI, PET scans (such as FDG-PET/CT or SSTR-PET/CT), blood and biochemical tests to assess hormone levels, genetic testing for hereditary syndromes, and biopsy to confirm malignancy.","question_type":"Contextual Summarize","evidence":"Pheochromocytoma typically presents with high blood pressure.; Pheochromocytoma typically presents with headache.; Pheochromocytoma typically presents with rapid heartbeat.; Pheochromocytoma typically presents with sweating.; Pheochromocytoma is diagnosed using CT scan.; Pheochromocytoma is diagnosed using MRI scan.; Pheochromocytoma is diagnosed using biochemical tests.; Adrenocortical carcinoma presents with a broader range of symptoms.; Adrenocortical carcinoma is diagnosed with a wider array of imaging tests.; Adrenocortical carcinoma is diagnosed with blood tests.; Adrenocortical carcinoma is diagnosed with genetic tests.; Adrenocortical carcinoma is diagnosed with biopsy tests.","evidence_relations":"Pheochromocytoma arises from the adrenal medulla and is often associated with high blood pressure, headache, rapid heartbeat, and sweating; Pheochromocytoma diagnostic methods include CT scan, MRI scan, and biochemical test; Symptoms of adrenocortical carcinoma include weight gain, muscle weakness, stretch marks, hormonal changes, and loss of appetite; Diagnostic methods for Adrenocortical Carcinoma (ACC) include CT scan, MRI scan, PET scan, FDG-PET/CT, SSTR-PET/CT, blood test, biochemical test, genetic test, and biopsy; Adrenocortical carcinoma (ACC) is a rare malignant tumor of the adrenal cortex"},
	{"id":"Medical-226ee2f8","source":"Medical","question":"What populations are most affected by neuroblastoma and what are its diagnostic features?","answer":"Neuroblastoma is a rare malignant tumor that primarily affects children under 5 years old. It often arises in the adrenal glands and has the potential to metastasize to other parts of the body, including the bones. Diagnostic features of neuroblastoma include the use of imaging tests, such as CT or MRI scans, to identify the tumor and assess its spread, as well as biochemical tests to detect tumor markers or hormone levels associated with the disease.","question_type":"Contextual Summarize","evidence":"Neuroblastoma primarily affects children under 5 years old.; Neuroblastoma may metastasize to bones.; Neuroblastoma is diagnosed using imaging tests.; Neuroblastoma is diagnosed using biochemical tests.","evidence_relations":"Neuroblastoma is a rare malignant adrenal tumor affecting mainly children under 5; Neuroblastoma may metastasize to bones; Neuroblastoma diagnostic methods include imaging tests and biochemical test; Malignant adrenal tumors include neuroblastoma; Imaging tests are used in the diagnosis of adrenal tumors"},
	{"id":"Medical-32153300","source":"Medical","question":"What are the functional categories of adrenal adenomas and their associated hormone excess syndromes or biomarkers?","answer":"Adrenal adenomas can be functional, such as aldosteronoma producing excess aldosterone or cortisol-producing adenoma causing Cushing syndrome, or nonfunctioning, with their respective biomarkers being aldosterone and cortisol.","question_type":"Contextual Summarize","evidence":"Adrenal adenomas can be functional.; Functional adrenal adenomas include aldosteronoma, which produces excess aldosterone.; Functional adrenal adenomas include cortisol-producing adenoma, which causes Cushing syndrome.; Adrenal adenomas can also be nonfunctioning.; The respective biomarkers for adrenal adenomas include aldosterone and cortisol.","evidence_relations":"Adenoma is the most common type of adrenal gland tumor and can be functioning or nonfunctioning; Functional adrenal tumors may produce excess hormones; Aldosteronoma produces excess aldosterone; Adenoma producing excess cortisol causes Cushing syndrome; Aldosteronoma biomarker is aldosterone; cortisol-producing adenoma biomarker is cortisol"},
	{"id":"Medical-704ecbec","source":"Medical","question":"Which symptoms are commonly observed in patients with adrenal cancer and what is their origin?","answer":"Patients with adrenal cancer commonly experience symptoms that arise either from excess hormone production by the tumor or from the tumor's local growth. Symptoms due to hormone excess include weight gain, muscle weakness, and pink or purple stretch marks on the skin, as well as hormonal changes such as excess facial hair, hair loss on the head, irregular periods, enlarged breast tissue, and shrinking testicles. Other symptoms, such as nausea, vomiting, abdominal bloating, back pain, fever, loss of appetite, and unintentional weight loss, may result from the tumor pressing on nearby organs or from systemic effects of the cancer.","question_type":"Contextual Summarize","evidence":"Patients with adrenal cancer commonly experience weight gain.; Patients with adrenal cancer commonly experience muscle weakness.; Patients with adrenal cancer commonly experience stretch marks.; Patients with adrenal cancer commonly experience hormonal changes.; Patients with adrenal cancer commonly experience nausea.; Patients with adrenal cancer commonly experience vomiting.; Patients with adrenal cancer commonly experience abdominal bloating.; Patients with adrenal cancer commonly experience back pain.; Patients with adrenal cancer commonly experience fever.; Patients with adrenal cancer commonly experience loss of appetite.; Patients with adrenal cancer commonly experience unintentional weight loss.; Symptoms of adrenal cancer originate from hormone excess or tumor growth.","evidence_relations":"Symptoms of adrenal cancer include weight gain, muscle weakness, stretch marks, hormonal changes, nausea, vomiting, abdominal bloating, back pain, fever, loss of appetite, and unintentional weight loss; Half of adrenal cancer patients have symptoms due to hormone excess; Adrenocortical carcinoma (ACC) is a rare malignant tumor of the adrenal cortex; Adrenocortical Carcinoma (ACC) symptoms include weight gain, muscle weakness, pink or purple stretch marks, and hormonal changes; Functional adrenal tumors may produce excess hormones"},
	{"id":"Medical-97625b74","source":"Medical","question":"What are the main diagnostic methods and common symptoms across major subtypes of breast cancer?","answer":"Breast cancer diagnosis commonly involves mammogram, ultrasound, MRI, CT scan, PET scan, biopsy, sentinel lymph node biopsy, blood tests, and physical exam, while symptoms include breast lump, pain, nipple discharge, skin changes, redness, swelling, peau dorange, and, in advanced cases, systemic symptoms such as bone pain or shortness of breath.","question_type":"Contextual Summarize","evidence":"Breast cancer diagnosis commonly involves mammogram.; Breast cancer diagnosis commonly involves ultrasound.; Breast cancer diagnosis commonly involves MRI.; Breast cancer diagnosis commonly involves CT scan.; Breast cancer diagnosis commonly involves PET scan.; Breast cancer diagnosis commonly involves biopsy.; Breast cancer diagnosis commonly involves sentinel lymph node biopsy.; Breast cancer diagnosis commonly involves blood tests.; Breast cancer diagnosis commonly involves physical exam.; Common symptoms of breast cancer include breast lump.; Common symptoms of breast cancer include pain.; Common symptoms of breast cancer include nipple discharge.; Common symptoms of breast cancer include skin changes.; Common symptoms of breast cancer include redness.; Common symptoms of breast cancer include swelling.; Common symptoms of breast cancer include peau dorange.; In advanced cases of breast cancer, systemic symptoms may include bone pain.; In advanced cases of breast cancer, systemic symptoms may include shortness of breath.","evidence_relations":"Diagnosis involves imaging (mammogram, ultrasound, MRI, CT, PET), biopsy, and blood tests; Sentinel lymph node biopsy is used to assess lymph node involvement; Common symptoms include breast lump, pain, nipple discharge, skin changes, redness, swelling, and peau dorange; Metastatic breast cancer (MBC) symptoms include bone pain, shortness of breath, liver dysfunction, and neurological symptoms; Inflammatory breast cancer (IBC) presents with redness, swelling, warmth, peau dorange, skin thickening, edema, and erythema; Invasive ductal carcinoma symptoms include breast lump, breast pain, nipple discharge, skin thickening, redness, swelling, and peau dorange; Diagnostic methods listed in the ontology include mammogram, ultrasound, MRI, CT scan, PET scan, biopsy, sentinel lymph node biopsy, blood tests, and physical exam"},
	{"id":"Medical-25d7185d","source":"Medical","question":"How are breast cancer subtypes defined and what are their distinguishing clinical and pathological features?","answer":"Breast cancer subtypes are defined based on their site of origin, degree of invasiveness, and clinical and pathological features. Ductal carcinoma in situ (DCIS) is a noninvasive cancer confined to the milk ducts and classified as stage 0. Invasive ductal carcinoma, the most common type, originates in the ducts and invades surrounding breast tissue. Lobular carcinoma starts in the lobules (milk-producing glands) and can also be invasive. Inflammatory breast cancer (IBC) is a rare and aggressive subtype characterized by cancer cells blocking lymph vessels in the skin, leading to symptoms such as redness, swelling, warmth, peau dorange (dimpled skin), and rapid progression; it is typically diagnosed at stage III or IV. Metastatic breast cancer (MBC) refers to cancer that has spread beyond the breast to distant organs (stage IV). Staging incorporates tumor size, lymph node involvement, and presence of metastasis, and is essential for prognosis and treatment planning. Each subtype has unique clinical presentations, pathological findings, and implications for management.","question_type":"Contextual Summarize","evidence":"Breast cancer subtypes include ductal carcinoma in situ (DCIS).; Breast cancer subtypes include invasive ductal carcinoma.; Breast cancer subtypes include lobular carcinoma.; Breast cancer subtypes include inflammatory breast cancer (IBC).; Breast cancer subtypes include metastatic breast cancer (MBC).; Breast cancer subtypes are defined by site of origin.; Breast cancer subtypes are defined by invasiveness.; Breast cancer subtypes are defined by stage.; Breast cancer subtypes are defined by unique symptoms.; Breast cancer subtypes are defined by specific diagnostic considerations.; Breast cancer subtypes are defined by specific treatment considerations.","evidence_relations":"Ductal carcinoma in situ (DCIS) is a noninvasive breast cancer found in the ducts; Invasive ductal carcinoma is the most common type of invasive breast cancer; Lobular carcinoma starts in the lobules of the breast; Inflammatory breast cancer (IBC) is a rare, aggressive subtype characterized by cancer cells blocking lymph vessels in the skin; Metastatic breast cancer (MBC) is breast cancer that has spread to distant organs; Stage 0 breast cancer is noninvasive (DCIS); Stages I-III are invasive breast cancer; Stage IV is metastatic breast cancer"},
	{"id":"Medical-47ffef04","source":"Medical","question":"What are the key biomarkers and genetic alterations relevant to breast cancer diagnosis and targeted therapy?","answer":"Key biomarkers and genetic alterations in breast cancer include hormone receptor status (estrogen and progesterone receptors), HER2 status, BRCA1/2 mutations, PIK3CA mutation, MSI-H/dMMR status, and PD-L1 expression, which guide both diagnosis and the selection of targeted therapies.","question_type":"Contextual Summarize","evidence":"Key biomarkers in breast cancer include hormone receptor status.; Hormone receptor status includes estrogen receptors.; Hormone receptor status includes progesterone receptors.; Key biomarkers in breast cancer include HER2 status.; Key genetic alterations in breast cancer include BRCA1 mutations.; Key genetic alterations in breast cancer include BRCA2 mutations.; Key genetic alterations in breast cancer include PIK3CA mutation.; Key genetic alterations in breast cancer include MSI-H/dMMR status.; Key genetic alterations in breast cancer include PD-L1 expression.; These biomarkers and genetic alterations guide breast cancer diagnosis.; These biomarkers and genetic alterations guide the selection of targeted therapies.","evidence_relations":"Hormone receptor status (ER, PR) and HER2 status are key biomarkers for breast cancer; BRCA1 and BRCA2 mutations increase the risk of breast cancer; PIK3CA mutation can be targeted with specific therapies; MSI-H/dMMR status may influence immunotherapy options; PD-L1 expression may guide immunotherapy use; Biomarker ontology includes Estrogen receptor (ER), Progesterone receptor (PR), HER2, BRCA1 mutation, BRCA2 mutation, PIK3CA mutation, MSI-H, dMMR, and PD-L1; Biopsy is required for definitive diagnosis and biomarker testing"},
	{"id":"Medical-edced729","source":"Medical","question":"How does the stage of breast cancer influence treatment options and management strategies?","answer":"The stage of breast cancer significantly influences treatment options and management strategies. Stage 0 (ductal carcinoma in situ, DCIS) is noninvasive and typically managed with surgery (such as lumpectomy or mastectomy) and may include radiation therapy to reduce recurrence risk. Stages I-III represent invasive breast cancer, where the tumor has spread beyond the ducts or lobules and may involve regional lymph nodes. Treatment for these stages is multimodal and may include surgery, radiation therapy, chemotherapy, endocrine therapy for hormone receptor-positive tumors, HER2-targeted therapy for HER2-positive cancers, and immunotherapy in select cases. Stage IV (metastatic) breast cancer indicates that the disease has spread to distant organs. Management at this stage focuses on systemic therapies such as chemotherapy, endocrine therapy, HER2-targeted agents, and other targeted therapies, with an emphasis on controlling disease progression, alleviating symptoms, and improving quality of life through palliative interventions. Staging is determined using the TNM system and guides both prognosis and individualized treatment planning.","question_type":"Contextual Summarize","evidence":"Breast cancer stage determines treatment approaches.; Stage 0 (DCIS) is managed with surgery and radiation.; Stages I-III (invasive) involve surgery.; Stages I-III (invasive) involve radiation.; Stages I-III (invasive) involve chemotherapy.; Stages I-III (invasive) involve endocrine therapy.; Stages I-III (invasive) involve HER2-targeted therapy.; Stages I-III (invasive) involve immunotherapy.; Stage IV (metastatic) emphasizes systemic therapies.; Stage IV (metastatic) emphasizes targeted agents.; Stage IV (metastatic) emphasizes palliative interventions.","evidence_relations":"Stage 0 breast cancer is noninvasive (DCIS); Stages I-III are invasive breast cancer; Stage IV is metastatic breast cancer; Treatment options include surgery (mastectomy, lumpectomy), radiation therapy, chemotherapy, endocrine therapy, HER2-targeted therapy, immunotherapy, and targeted inhibitors; Systemic therapy is used for invasive and metastatic breast cancer; Endocrine therapy is used for hormone receptor-positive breast cancer; HER2-targeted therapy is used for HER2-positive breast cancer"},
	{"id":"Medical-5562c2ca","source":"Medical","question":"Which treatments are matched to specific breast cancer biomarkers or genetic alterations?","answer":"Specific breast cancer treatments are matched to particular biomarkers or genetic alterations identified through biomarker testing. Endocrine therapy is indicated for hormone receptor-positive breast cancer, targeting tumors that express estrogen or progesterone receptors. HER2-targeted therapies are used for HER2-positive breast cancers, which overexpress the HER2 protein. PARP inhibitors are prescribed for patients with BRCA1 or BRCA2 mutations who have HER2-negative breast cancer. CDK4/6 inhibitors are used in hormone receptor-positive, HER2-negative breast cancers to inhibit cell cycle progression. PIK3CA inhibitors are specifically used for PIK3CA-mutated, hormone receptor-positive, HER2-negative breast cancer. These targeted therapies are selected based on the results of molecular and genetic testing, allowing for personalized treatment approaches.","question_type":"Contextual Summarize","evidence":"Endocrine therapy is used for hormone receptor-positive breast cancer.; HER2-targeted therapy is used for HER2-positive breast cancer cases.; PARP inhibitors are used for BRCA-mutated, HER2-negative breast cancers.; CDK4/6 inhibitors are used for hormone receptor-positive, HER2-negative tumors.; PIK3CA inhibitors are used for PIK3CA-mutated, hormone receptor-positive, HER2-negative breast cancer.","evidence_relations":"Endocrine therapy is used for hormone receptor-positive breast cancer; HER2-targeted therapy is used for HER2-positive breast cancer; PARP inhibitors are used for BRCA-mutated, HER2-negative breast cancer; CDK4/6 inhibitors are used for hormone receptor-positive, HER2-negative breast cancer; PIK3CA inhibitors are used for PIK3CA-mutated, hormone receptor-positive, HER2-negative breast cancer; Biomarker ontology includes hormone receptor, HER2, BRCA1 mutation, BRCA2 mutation, PIK3CA mutation"},
	{"id":"Medical-0cba5d0a","source":"Medical","question":"What are the main risk factors and considerations for breast cancer prevention and patient counseling?","answer":"The main risk factors for breast cancer include a family history of breast cancer, the presence of BRCA1 or BRCA2 gene mutations, and being assigned female at birth. These genetic and familial factors significantly increase an individual's risk of developing breast cancer. In patient counseling prior to treatment, it is important to address considerations such as fertility preservation, as some treatments may impact reproductive potential, and to assess the patient's performance status, which can influence treatment planning and outcomes. Comprehensive counseling should also include discussions about genetic counseling and testing for those at risk for hereditary breast cancer, as well as the potential impact of treatment on sexual health and quality of life.","question_type":"Contextual Summarize","evidence":"Major risk factors for breast cancer include family history.; Major risk factors for breast cancer include BRCA1/2 mutations.; Major risk factors for breast cancer include being assigned female at birth.; Fertility preservation is an important consideration in patient counseling before treatment.; Performance status is an important consideration in patient counseling before treatment.","evidence_relations":"Risk factors include family history, BRCA mutations, and being assigned female at birth; BRCA1 and BRCA2 mutations increase the risk of breast cancer; Fertility preservation should be discussed before starting treatment; Performance status is considered in treatment planning; Risk Factor ontology includes family history, BRCA1 mutation, BRCA2 mutation, assigned female at birth"},
	{"id":"Medical-d72d7cb9","source":"Medical","question":"How is follow-up and surveillance conducted for breast cancer patients after initial treatment?","answer":"Follow-up for breast cancer patients includes regular imaging, physical examinations, and monitoring for recurrence to ensure early detection of relapse or new disease.","question_type":"Contextual Summarize","evidence":"Follow-up for breast cancer patients includes regular imaging.; Follow-up for breast cancer patients includes physical examinations.; Follow-up for breast cancer patients includes monitoring for recurrence.; Follow-up for breast cancer patients aims to ensure early detection of relapse or new disease.","evidence_relations":"Follow-up includes imaging, physical exams, and monitoring for recurrence; Follow-up/Surveillance ontology includes imaging, physical exams, and monitoring for recurrence; Imaging methods include mammogram, ultrasound, MRI, CT scan, and PET scan; Physical exams are part of ongoing surveillance; Monitoring for recurrence is a component of follow-up care"},
	{"id":"Medical-97d64c1f","source":"Medical","question":"What is the clinical significance of tumor grade in breast cancer, and how is it assessed?","answer":"The clinical significance of tumor grade in breast cancer lies in its ability to reflect how abnormal the tumor cells appear under a microscope (histology), which provides important information about how quickly the tumor is likely to grow and spread. Tumor grade is assessed by a pathologist and is categorized as GX (grade cannot be assessed), G1 (well differentiated), G2 (moderately differentiated), or G3 (poorly differentiated). Higher-grade tumors (G3) tend to be more aggressive and have a worse prognosis compared to lower-grade tumors (G1). Tumor grade is distinct from cancer stage and is a key factor in prognosis and treatment planning, helping guide decisions about the most appropriate management strategies for each patient.","question_type":"Contextual Summarize","evidence":"Tumor grade in breast cancer is described as GX, G1, G2, or G3.; Tumor grade reflects how abnormal the tumor cells appear microscopically.; Tumor grade helps predict disease aggressiveness.; Tumor grade helps guide management of breast cancer.","evidence_relations":"Grade describes how abnormal the tumor cells look under a microscope; Grade ontology includes GX, G1, G2, G3; Tumor grade is used in breast cancer assessment; Grade is distinct from stage and provides information about tumor differentiation; Pathological assessment of grade informs prognosis and treatment planning"},
	{"id":"Medical-4dc06fbd","source":"Medical","question":"What are the most common therapies used in the systemic treatment of breast cancer, and when are they indicated?","answer":"Systemic therapies for breast cancer include chemotherapy, endocrine therapy, HER2-targeted therapy, immunotherapy, and targeted inhibitors, which are indicated for invasive and metastatic disease based on biomarker status.","question_type":"Contextual Summarize","evidence":"Systemic therapies for breast cancer include chemotherapy.; Systemic therapies for breast cancer include endocrine therapy.; Systemic therapies for breast cancer include HER2-targeted therapy.; Systemic therapies for breast cancer include immunotherapy.; Systemic therapies for breast cancer include targeted inhibitors.; Systemic therapies are indicated for invasive and metastatic breast cancer based on biomarker status.","evidence_relations":"Systemic therapy is used for invasive and metastatic breast cancer; Treatment options include chemotherapy, endocrine therapy, HER2-targeted therapy, immunotherapy, and targeted inhibitors; Endocrine therapy is used for hormone receptor-positive breast cancer; HER2-targeted therapy is used for HER2-positive breast cancer; Immunotherapy is used based on PD-L1 expression and MSI-H/dMMR status"},
	{"id":"Medical-19f19b9b","source":"Medical","question":"How are imaging and biopsy utilized throughout the continuum of breast cancer care, from screening to diagnosis and surveillance?","answer":"Imaging and biopsy play critical roles throughout the continuum of breast cancer care. Imaging modalities such as mammography, ultrasound, MRI, CT, and PET are used at various stages: screening mammograms are performed regularly in asymptomatic individuals for early detection; diagnostic mammograms and other imaging are used to further evaluate symptoms or abnormal screening results; and advanced imaging helps with staging and surveillance for recurrence. Biopsy is essential for obtaining a definitive diagnosis and allows for biomarker testing, including assessment of hormone receptors (estrogen and progesterone) and HER2 status, which guide treatment decisions. Both imaging and biopsy are integral at every stage, from initial screening and diagnosis to ongoing monitoring and follow-up care.","question_type":"Contextual Summarize","evidence":"Imaging is used for screening breast cancer.; Imaging is used for diagnosing breast cancer.; Imaging is used for staging breast cancer.; Imaging is used for surveillance of breast cancer.; Biopsy is required for definitive diagnosis of breast cancer.; Biopsy is required for biomarker testing in breast cancer.; Both imaging and biopsy are essential across all stages of breast cancer care.","evidence_relations":"Screening mammograms are used for early detection in asymptomatic individuals; Diagnostic mammograms are used for individuals with symptoms or abnormal screening results; Diagnosis involves imaging (mammogram, ultrasound, MRI, CT, PET), biopsy, and blood tests; Biopsy is required for definitive diagnosis and biomarker testing; Follow-up includes imaging, physical exams, and monitoring for recurrence"},
	{"id":"Medical-fe3240a4","source":"Medical","question":"Imagine you are a dermatology attending receiving a new patient referral for a suspicious lesion on the face. Write a consult note summarizing the key risk factors, diagnostic steps, and initial management plan for suspected basal cell carcinoma, referencing current clinical practice guidelines.","answer":"Consult Note:\n\nA new patient was referred for evaluation of a suspicious lesion on the left cheek. Key risk factors for basal cell carcinoma (BCC) in this patient include significant cumulative sun exposure, fair skin phenotype, and a personal history of skin cancer. On physical examination, the lesion is located on a sun-exposed area of the face and appears as a shiny, pearly papule with rolled borders, consistent with classic BCC morphology.\n\nDiagnostic steps will follow current clinical practice guidelines and include: (1) a comprehensive skin examination to assess for additional lesions, (2) a detailed medical and family history to identify further risk factors or hereditary syndromes, and (3) a skin biopsy of the lesion to establish a definitive diagnosis. Imaging studies may be considered if there is clinical suspicion for perineural invasion or deep tissue involvement.\n\nIf the diagnosis of BCC is confirmed, the initial management plan will prioritize surgical excision, which is the standard first-line treatment. The patient will be counseled regarding the risk of recurrence and the importance of ongoing surveillance, including annual full skin examinations, as recommended by current guidelines. Additional education will be provided on sun protection and self-skin examination to reduce future risk.","question_type":"Creative Generation","evidence":"The patient presents with a suspicious lesion on the left cheek.; Key risk factors for basal cell carcinoma include significant sun exposure.; Key risk factors for basal cell carcinoma include fair skin.; Key risk factors for basal cell carcinoma include a personal history of skin cancer.; The lesion appears as a shiny, pearly bump with rolled borders.; The diagnostic plan includes a thorough skin exam.; The diagnostic plan includes a detailed medical and family history.; The diagnostic plan includes performing a skin biopsy to confirm basal cell carcinoma.; Imaging may be considered if there is suspicion of deep tissue involvement.; Surgical excision is proposed as the first-line treatment if basal cell carcinoma is confirmed.; The patient will be counseled on recurrence risk.; The patient will be advised on the importance of annual full skin exams for follow-up.","evidence_relations":"BCC most commonly develops in sun-exposed areas such as the face, head, and neck; Fair skin, light hair, and light eye color increase the risk of BCC; History of skin cancer or family history increases risk of BCC; Diagnosis of BCC involves medical and family history, physical exam, skin exam, biopsy, and sometimes imaging; Surgery is the most common treatment for BCC; Follow-up includes full skin exams with a doctor at least once a year"},
	{"id":"Medical-8f5233d5","source":"Medical","question":"You are a general practitioner drafting a discharge summary for a patient treated for basal cell carcinoma on the scalp. Transform the clinical facts into a formal discharge summary, ensuring inclusion of risk factors, clinical presentation, diagnostic workup, treatment, and follow-up recommendations.","answer":"Discharge Summary:\n\nDiagnosis: Basal cell carcinoma (BCC) of the scalp\n\nSummary: The patient presented with a shiny bump with rolled borders on the scalp, a sun-exposed area. Risk factors include prolonged UV radiation exposure, fair skin, and older age. Diagnostic evaluation included a physical and skin exam, as well as a skin biopsy confirming BCC. The patient underwent surgical excision of the lesion. No evidence of recurrence or metastasis was found. The patient is advised to attend full skin exams at least annually for follow-up and to practice sun protection to reduce recurrence risk.","question_type":"Creative Generation","evidence":"The patient was diagnosed with basal cell carcinoma of the scalp.; The patient presented with a shiny bump with rolled borders on the scalp.; The lesion is located in a sun-exposed area.; Risk factors for basal cell carcinoma include prolonged UV radiation exposure.; Risk factors for basal cell carcinoma include fair skin.; Risk factors for basal cell carcinoma include older age.; Diagnostic evaluation included a physical and skin exam.; Diagnostic evaluation included a skin biopsy confirming basal cell carcinoma.; The patient underwent surgical excision of the lesion.; No evidence of recurrence or metastasis was found.; The patient is advised to attend full skin exams at least annually for follow-up.; The patient is advised to practice sun protection to reduce recurrence risk.","evidence_relations":"BCC most commonly develops in sun-exposed areas such as the face, head, and neck; Older age is associated with higher risk of BCC; Fair skin, light hair, and light eye color increase the risk of BCC; Diagnosis of BCC involves medical and family history, physical exam, skin exam, biopsy, and sometimes imaging; Surgery is the most common treatment for BCC; Follow-up includes full skin exams with a doctor at least once a year"},
	{"id":"Medical-c9c108e1","source":"Medical","question":"Assume the role of a patient who has just been diagnosed with basal cell carcinoma. Write a letter to your family explaining what the diagnosis means, the likely causes, the treatment you will receive, and what you will need to do to monitor your health going forward, using evidence from the clinical guideline.","answer":"Dear Family,\n\nI wanted to let you know that I have been diagnosed with basal cell carcinoma (BCC), which is the most common type of skin cancer. BCC arises from basal cells in the lower part of the skins outer layer (epidermis) and most often develops in areas that have been exposed to the sun, such as the face, head, and neck. The main risk factors for BCC include fair skin, frequent or intense sun (UV) exposure, a personal or family history of skin cancer, and factors like previous radiation therapy or immune suppression. My diagnosis was made after a thorough skin examination and a biopsy of the suspicious area. The standard and most effective treatment is surgery to remove the cancerous tissue, and my care team will guide me through this process. After treatment, I will need to have regular full skin exams with my doctor at least once a year to monitor for any recurrence or new skin cancers. Moving forward, I will be vigilant about sun protectionusing sunscreen, wearing protective clothing, and avoiding tanning bedsto help reduce my risk. I am also encouraged to stay organized with my medical records and communicate openly with my care team. Please know that BCC is highly treatable, especially when detected early, and I am taking all recommended steps to ensure the best possible outcome.","question_type":"Creative Generation","evidence":"The patient has been diagnosed with basal cell carcinoma.; Basal cell carcinoma is the most common type of skin cancer.; Basal cell carcinoma develops from basal cells in the lower part of the skins outer layer.; Basal cell carcinoma usually occurs in areas exposed to the sun, like the face or scalp.; Risk factors for basal cell carcinoma include fair skin.; Risk factors for basal cell carcinoma include significant sun or UV exposure.; Risk factors for basal cell carcinoma include family history.; The diagnosis was made after a skin exam and biopsy.; Surgery is the standard treatment for basal cell carcinoma.; The patient will need regular full skin exams at least once a year to monitor for recurrence.; The patient plans to be extra careful about sun protection.","evidence_relations":"Basal cell carcinoma (BCC) is the most common type of skin cancer; BCC arises from basal cells in the lower part of the epidermis; BCC most commonly develops in sun-exposed areas such as the face, head, and neck; UV radiation exposure is a primary risk factor for BCC; Diagnosis of BCC involves medical and family history, physical exam, skin exam, biopsy, and sometimes imaging; Surgery is the most common treatment for BCC; Follow-up includes full skin exams with a doctor at least once a year"},
	{"id":"Medical-bf68d23e","source":"Medical","question":"Rewrite the following scenario into a public health advisory: There has been an increase in basal cell carcinoma diagnoses in your community, particularly among older adults with fair skin. Use the clinical guideline to construct an evidence-based advisory focused on prevention, early detection, and high-risk groups.","answer":"Public Health Advisory: Increased Basal Cell Carcinoma Cases in Our Community\n\nWe are observing a rise in basal cell carcinoma (BCC), the most common type of skin cancer, especially among older adults with fair skin and light-colored eyes or hair. BCC typically develops in sun-exposed areas such as the face, head, and neck, and risk increases with UV radiation exposure. Individuals with a personal or family history of skin cancer, those who have undergone radiation therapy, or those with immune suppression are at higher risk. We urge the community to practice sun protection, avoid tanning beds, and seek medical evaluation for new or changing skin lesions. Annual full skin exams with your healthcare provider are recommended for early detection and improved outcomes.","question_type":"Creative Generation","evidence":"There has been an increase in basal cell carcinoma diagnoses in the community.; The increase is particularly among older adults with fair skin.; Basal cell carcinoma is the most common type of skin cancer.; Basal cell carcinoma typically develops in sun-exposed areas such as the face, head, and neck.; The risk of basal cell carcinoma increases with UV radiation exposure.; Individuals with a personal or family history of skin cancer are at higher risk.; Individuals who have undergone radiation therapy are at higher risk for basal cell carcinoma.; Individuals with immune suppression are at higher risk for basal cell carcinoma.; The community is urged to practice sun protection.; The community is urged to avoid tanning beds.; The community is urged to seek medical evaluation for new or changing skin lesions.; Annual full skin exams with a healthcare provider are recommended for early detection.","evidence_relations":"Basal cell carcinoma (BCC) is the most common type of skin cancer; BCC most commonly develops in sun-exposed areas such as the face, head, and neck; Fair skin, light hair, and light eye color increase the risk of BCC; Older age is associated with higher risk of BCC; History of skin cancer or family history increases risk of BCC; Radiation therapy and immune suppression are risk factors for BCC; Follow-up includes full skin exams with a doctor at least once a year"},
	{"id":"Medical-fd1b07be","source":"Medical","question":"You are a dermatology intern preparing a referral letter to oncology for a patient with recurrent basal cell carcinoma that has spread to lymph nodes. Summarize the clinical findings, risk factors, diagnostic confirmation, and rationale for referral, referencing the guideline.","answer":"Referral Letter to Oncology:\n\nDear Colleague,\n\nI am referring a patient with a history of basal cell carcinoma (BCC) who now presents with a recurrence at the original site and clinical evidence of regional lymph node involvement. Clinical findings include a recurrent lesion at the prior excision site and palpable lymphadenopathy. The patient possesses several risk factors for BCC, including fair skin, significant ultraviolet (UV) exposure, and a prior personal history of skin cancer. Diagnostic confirmation was achieved through a combination of thorough medical and family history, physical and skin examination, a confirmatory biopsy of the recurrent lesion, and imaging studies to assess the extent of lymph node involvement. According to NCCN guidelines, recurrence and regional spread of BCC represent a higher-risk scenario that may require multimodal management. The rationale for referral is to evaluate the need for systemic therapy or radiation, as these options are recommended for cases where surgical management alone may be insufficient. Further staging and treatment planning are requested in accordance with current evidence-based guidelines.","question_type":"Creative Generation","evidence":"The patient has a history of basal cell carcinoma (BCC).; The patient presents with recurrence at the original site.; The patient has evidence of spread to regional lymph nodes.; The patient has multiple risk factors, including fair skin.; The patient has significant UV exposure.; The patient has a prior history of skin cancer.; The current diagnosis was established via physical and skin examination.; A confirmatory biopsy was performed.; Imaging studies were conducted.; The referral is for expertise regarding systemic therapy or radiation options.; The referral seeks advice on further staging and treatment recommendations.","evidence_relations":"Recurrence refers to BCC returning to the original site or spreading to lymph nodes or distant sites; Fair skin, light hair, and light eye color increase the risk of BCC; History of skin cancer or family history increases risk of BCC; Diagnosis of BCC involves medical and family history, physical exam, skin exam, biopsy, and sometimes imaging; Radiation therapy or systemic therapy may be used in some cases of BCC; Treatment options based on risk and recurrence"},
	{"id":"Medical-ea29b9d8","source":"Medical","question":"Imagine you are a neuro-oncology fellow. Write a detailed initial diagnostic workup and staging plan for a 62-year-old patient presenting with progressive leg weakness, memory problems, and blurry vision, suspected of having primary CNS lymphoma. Your plan should outline all relevant assessments and justify their use.","answer":"For a 62-year-old patient presenting with progressive leg weakness, memory problems, and blurry vision, the initial diagnostic workup for suspected primary CNS lymphoma should include:\n\n1. Neurological examination to assess the extent of neurological deficits and establish a clinical baseline.\n2. MRI of the brain with gadolinium contrast as the most sensitive imaging modality to identify CNS lesions characteristic of lymphoma.\n3. Eye examination using slit lamp and potentially vitrectomy if ocular involvement is suspected, given the blurry vision.\n4. Stereotactic biopsy of the brain lesion to obtain histopathologic confirmation, as this is the standard diagnostic procedure.\n5. Laboratory assessments including complete blood count, comprehensive metabolic panel, lactate dehydrogenase (LDH) levels, and HIV and hepatitis B testing to evaluate for risk factors and baseline organ function.\n6. Lumbar puncture to analyze cerebrospinal fluid for malignant cells, especially given the possibility of CSF involvement in primary CNS lymphoma.\n7. Performance status evaluation to guide further diagnostic and treatment decisions.\nThis comprehensive approach ensures accurate diagnosis, detection of disease extent (including possible eye and CSF involvement), and risk factor assessment to inform treatment planning.","question_type":"Creative Generation","evidence":"The patient is 62 years old.; The patient presents with progressive leg weakness.; The patient has memory problems.; The patient experiences blurry vision.; The initial diagnostic workup includes a neurological examination.; The neurological examination assesses the extent of neurological deficits.; An MRI of the brain with gadolinium contrast is included in the workup.; MRI is the most sensitive imaging modality for identifying CNS lesions.; An eye examination using a slit lamp is part of the workup.; Vitrectomy may be performed if ocular involvement is suspected.; A stereotactic biopsy of the brain lesion is necessary for histopathologic confirmation.; Laboratory assessments include complete blood count and comprehensive metabolic panel.; Lactate dehydrogenase (LDH) levels are assessed.; HIV and hepatitis B testing are included in the laboratory assessments.; A lumbar puncture is performed to analyze cerebrospinal fluid for malignant cells.; Performance status evaluation is conducted to guide further decisions.","evidence_relations":"Primary CNS lymphoma is diagnosed using neurological exam, imaging (MRI or CT), biopsy, blood tests, eye exam, and lumbar puncture.; MRI with gadolinium contrast is the most useful imaging technique for identifying primary CNS lymphoma.; Stereotactic biopsy is the standard diagnostic procedure for primary CNS lymphoma.; Eye exam and vitrectomy may be used if the eyes are involved.; Laboratory tests include complete blood count (CBC), comprehensive metabolic panel (CMP), lactate dehydrogenase (LDH), HIV blood test, and hepatitis B testing.; Lumbar puncture is used to assess for cerebrospinal fluid involvement.; Performance status is evaluated to guide treatment decisions and eligibility for clinical trials."},
	{"id":"Medical-c2658ea4","source":"Medical","question":"As a hematologist, develop a comprehensive induction and consolidation treatment plan for a newly diagnosed immunocompetent adult with primary CNS lymphoma confined to the brain. The plan should detail drug regimens, rationale, and supportive care measures.","answer":"For an immunocompetent adult with newly diagnosed primary CNS lymphoma confined to the brain, a comprehensive treatment plan includes both induction and consolidation phases, with careful attention to supportive care and multidisciplinary management:\n\nInduction Phase:\n- Initiate high-dose methotrexate-based chemotherapy, which is the cornerstone of induction therapy for primary CNS lymphoma due to its ability to penetrate the blood-brain barrier and effectively target lymphoma cells in the CNS.\n- Add rituximab, a monoclonal antibody targeting CD20, to enhance treatment response, as it is the primary immunotherapy agent used in this setting.\n- Additional agents such as temozolomide or vincristine may be incorporated into the regimen based on established protocols and individual patient tolerance.\n- Corticosteroids (e.g., dexamethasone) should be used as needed to reduce cerebral edema and alleviate neurological symptoms, but should be tapered as soon as feasible to avoid masking disease activity.\n\nConsolidation Phase:\n- After achieving remission or maximal response to induction therapy, proceed to consolidation. The most commonly used approach is whole-brain radiation therapy (WBRT), which aims to eradicate residual disease and reduce the risk of relapse.\n- Alternatively, for selected patients with good performance status, high-dose chemotherapy followed by autologous hematopoietic stem cell rescue may be considered, particularly to minimize long-term neurotoxicity associated with WBRT.\n\nSupportive Care and Monitoring:\n- Throughout all phases, provide comprehensive supportive care to manage treatment-related side effects, prevent infections, and address neurological and cognitive symptoms. This includes regular monitoring of renal function (due to high-dose methotrexate), hydration, leucovorin rescue, and management of cytopenias.\n- Engage a multidisciplinary teamincluding neurology, oncology, nursing, pharmacy, and supportive servicesto optimize patient outcomes and quality of life.\n- Assess performance status regularly to guide treatment intensity and eligibility for clinical trials, which should be considered for all patients given the rarity and complexity of primary CNS lymphoma.\n\nThis approach is consistent with current guidelines and evidence, aiming to maximize disease control while minimizing toxicity and preserving neurological function.","question_type":"Creative Generation","evidence":"The patient is an immunocompetent adult.; The patient has newly diagnosed primary CNS lymphoma confined to the brain.; The treatment plan consists of an induction phase.; The induction phase includes high-dose methotrexate-based chemotherapy.; Rituximab is combined with chemotherapy to enhance response.; Temozolomide or vincristine may be added based on protocol and patient tolerance.; Supportive corticosteroids may be used to reduce cerebral edema.; The consolidation phase follows the induction phase.; Consolidation includes whole-brain radiation therapy (WBRT).; High-dose chemotherapy followed by hematopoietic stem cell rescue may be considered.; Supportive care is provided throughout treatment.; A multidisciplinary team is involved in supportive care.; Performance status is monitored regularly.","evidence_relations":"Treatment options for primary CNS lymphoma include corticosteroids, chemotherapy, radiation therapy, targeted therapy, immunotherapy, stem cell rescue, and supportive care.; High-dose methotrexate is the main chemotherapy drug used for primary CNS lymphoma.; Rituximab is the main immunotherapy drug used for primary CNS lymphoma.; Treatment is typically given in phases: induction and consolidation.; Whole-brain radiation therapy (WBRT) is the most commonly used radiation technique for primary CNS lymphoma.; Supportive care is provided to relieve symptoms and side effects at any stage of disease.; Performance status is evaluated to guide treatment decisions and eligibility for clinical trials."},
	{"id":"Medical-e6da7d3c","source":"Medical","question":"Rewrite the core recommendations for the diagnosis and management of primary CNS lymphoma into a formal referral letter from a general neurologist to a neuro-oncologist, ensuring all key clinical, diagnostic, and management considerations are included.","answer":"Dear Neuro-Oncology Colleague,\n\nI am referring a 58-year-old patient with recent onset progressive arm weakness, confusion, and double vision. MRI with gadolinium contrast revealed a solitary enhancing lesion in the right frontal lobe. The patient has no known history of immunodeficiency but is an older adult. Given these findings, primary CNS lymphoma is strongly suspected.\n\nTo confirm the diagnosis, I recommend proceeding with stereotactic biopsy, as this is the standard diagnostic procedure. Additional workup should include comprehensive laboratory tests (CBC, CMP, LDH, HIV, and hepatitis B), lumbar puncture to assess for cerebrospinal fluid involvement, and detailed eye examination due to reported visual symptoms. Performance status assessment is essential to guide both treatment planning and clinical trial eligibility.\n\nFor management, high-dose methotrexate-based chemotherapy, with consideration for rituximab, should be initiated as induction therapy, followed by consolidation with whole-brain radiation therapy or high-dose chemotherapy with stem cell rescue as appropriate. Supportive care should be provided throughout. I recommend considering clinical trial enrollment if available.\n\nThank you for your expert evaluation and management.","question_type":"Creative Generation","evidence":"The patient is 58 years old.; The patient has recent onset progressive arm weakness.; The patient experiences confusion.; The patient has double vision.; MRI with gadolinium contrast revealed a solitary enhancing lesion in the right frontal lobe.; The patient has no known history of immunodeficiency.; Primary CNS lymphoma is strongly suspected.; A stereotactic biopsy is recommended to confirm the diagnosis.; Comprehensive laboratory tests are recommended, including CBC, CMP, LDH, HIV, and hepatitis B.; A lumbar puncture is recommended to assess for cerebrospinal fluid involvement.; A detailed eye examination is necessary due to reported visual symptoms.; Performance status assessment is essential for treatment planning.; High-dose methotrexate-based chemotherapy should be initiated as induction therapy.; Rituximab should be considered for induction therapy.; Consolidation may involve whole-brain radiation therapy or high-dose chemotherapy with stem cell rescue.; Supportive care should be provided throughout treatment.; Clinical trial enrollment should be considered if available.","evidence_relations":"Primary CNS lymphoma is diagnosed using neurological exam, imaging (MRI or CT), biopsy, blood tests, eye exam, and lumbar puncture.; MRI with gadolinium contrast is the most useful imaging technique for identifying primary CNS lymphoma.; Stereotactic biopsy is the standard diagnostic procedure for primary CNS lymphoma.; Laboratory tests include complete blood count (CBC), comprehensive metabolic panel (CMP), lactate dehydrogenase (LDH), HIV blood test, and hepatitis B testing.; Lumbar puncture is used to assess for cerebrospinal fluid involvement.; Performance status is evaluated to guide treatment decisions and eligibility for clinical trials.; High-dose methotrexate is the main chemotherapy drug used for primary CNS lymphoma.; Whole-brain radiation therapy (WBRT) is the most commonly used radiation technique for primary CNS lymphoma.; Clinical trial participation is recommended for all patients with primary CNS lymphoma."},
	{"id":"Medical-96352a3c","source":"Medical","question":"Transform the main points of the guideline into a discharge summary for a patient with primary CNS lymphoma who has completed induction chemotherapy and is entering the consolidation phase.","answer":"Discharge Summary\n\nDiagnosis: Primary Central Nervous System Lymphoma (PCNSL)\n\nSummary of Hospital Course: The patient presented with headaches, nausea, and coordination difficulties. MRI with gadolinium contrast revealed multifocal enhancing lesions in the brain, and stereotactic biopsy confirmed the diagnosis of PCNSL. Laboratory evaluation included complete blood count (CBC), comprehensive metabolic panel (CMP), lactate dehydrogenase (LDH), and HIV testing. Ophthalmologic examination and lumbar puncture were performed, with no evidence of ocular or cerebrospinal fluid (CSF) involvement. The patient's performance status was monitored throughout the hospital course.\n\nTreatment: The patient completed induction chemotherapy consisting of high-dose methotrexate and rituximab, in accordance with current guidelines. Corticosteroids were administered for symptom management. The patient tolerated induction therapy well, with noted improvement in neurological symptoms and no significant complications.\n\nPlan: The patient will now transition to the consolidation phase of treatment, which will include whole-brain radiation therapy (WBRT) as recommended by guidelines. Supportive care measures will continue to address ongoing symptoms and potential side effects of therapy, including counseling, nutritional support, and physical therapy as needed. The patient is encouraged to consider participation in clinical trials, as this is recommended for all patients with PCNSL. Ongoing follow-up will include regular neurological assessments, repeat MRI imaging, blood tests, and performance status evaluations to monitor for disease response and treatment-related effects. Multidisciplinary care will be maintained to optimize quality of life and address any emerging needs.","question_type":"Creative Generation","evidence":"The patient has primary central nervous system lymphoma (PCNSL).; The patient presented with headaches, nausea, and coordination difficulties.; MRI with gadolinium contrast demonstrated multifocal enhancing lesions in the brain.; Stereotactic biopsy confirmed the diagnosis of PCNSL.; Laboratory evaluation included CBC, CMP, LDH, and HIV testing.; An eye examination showed no evidence of ocular involvement.; A lumbar puncture showed no evidence of cerebrospinal fluid involvement.; Performance status was assessed throughout the hospital course.; The patient completed induction chemotherapy with high-dose methotrexate and rituximab.; Corticosteroids were used for symptom management.; The patient tolerated therapy well.; The patient showed improvement in neurological symptoms.; The patient will transition to consolidation therapy with whole-brain radiation therapy (WBRT).; Supportive care will continue to address ongoing symptoms.; The patient is encouraged to consider clinical trial participation.; Regular follow-up will include repeat MRI, blood tests, and performance status assessments.","evidence_relations":"Primary CNS lymphoma is diagnosed using neurological exam, imaging (MRI or CT), biopsy, blood tests, eye exam, and lumbar puncture.; MRI with gadolinium contrast is the most useful imaging technique for identifying primary CNS lymphoma.; Stereotactic biopsy is the standard diagnostic procedure for primary CNS lymphoma.; Treatment is typically given in phases: induction and consolidation.; High-dose methotrexate is the main chemotherapy drug used for primary CNS lymphoma.; Rituximab is the main immunotherapy drug used for primary CNS lymphoma.; Whole-brain radiation therapy (WBRT) is the most commonly used radiation technique for primary CNS lymphoma.; Supportive care is provided to relieve symptoms and side effects at any stage of disease.; Follow-up/Surveillance: Repeat MRI, eye exam, blood tests, performance status assessment.; Clinical trial participation is recommended for all patients with primary CNS lymphoma."},
	{"id":"Medical-3396b459","source":"Medical","question":"Write a public health advisory summarizing risk factors, key symptoms, and the importance of early specialist referral for primary CNS lymphoma, using evidence from the guideline.","answer":"Public Health Advisory: Primary Central Nervous System Lymphoma (PCNSL)\n\nPrimary CNS lymphoma is a rare but aggressive cancer that originates from lymphocytes within the central nervous system, most commonly affecting the brain but also the spinal cord, cerebrospinal fluid, and eyes. Individuals at increased risk include those with impaired immune systems, such as patients with immunodeficiency disorders, HIV infection, Epstein-Barr virus, autoimmune diseases, organ transplants, and older adults.\n\nKey symptoms to watch for include leg or arm weakness, difficulties with coordination or movement, changes in personality or behavior, memory problems, headaches, nausea, vomiting, seizures, and vision changes such as blurry or double vision. Early and accurate diagnosis is critical for improving outcomes. Diagnostic evaluation includes neurological examination, MRI with gadolinium contrast, stereotactic biopsy, laboratory tests, eye examination, and lumbar puncture.\n\nPrompt referral to a neuro-oncology specialist is essential for timely diagnosis and initiation of evidence-based therapy, which typically involves high-dose methotrexate-based chemotherapy and possible whole-brain radiation therapy. Participation in clinical trials and supportive care are also recommended. Early detection and specialist management can significantly impact patient prognosis.","question_type":"Creative Generation","evidence":"Primary CNS lymphoma is a rare but aggressive cancer.; Primary CNS lymphoma originates from lymphocytes within the central nervous system.; It most commonly affects the brain.; Primary CNS lymphoma can also affect the spinal cord, cerebrospinal fluid, and eyes.; Individuals at increased risk include those with impaired immune systems.; Risk factors include immunodeficiency disorders, HIV infection, and Epstein-Barr virus.; Autoimmune diseases and organ transplants are also risk factors.; Older adults are at increased risk for primary CNS lymphoma.; Key symptoms include leg or arm weakness.; Other symptoms include difficulties with coordination or movement.; Changes in personality or behavior can occur.; Memory problems are a symptom of primary CNS lymphoma.; Headaches, nausea, vomiting, seizures, and vision changes are also symptoms.; Early and accurate diagnosis is critical for improving outcomes.; Diagnostic evaluation includes neurological examination and MRI with gadolinium contrast.; Stereotactic biopsy is part of the diagnostic evaluation.; Laboratory tests, eye examination, and lumbar puncture are included in the evaluation.; Prompt referral to a neuro-oncology specialist is essential for timely diagnosis.; Evidence-based therapy typically involves high-dose methotrexate-based chemotherapy.; Whole-brain radiation therapy may also be part of the treatment.; Participation in clinical trials and supportive care are recommended.","evidence_relations":"Primary CNS lymphoma is a rare and aggressive cancer that starts in lymphocytes within the central nervous system.; Primary CNS lymphoma most commonly affects the brain, but can also involve the spinal cord, cerebrospinal fluid, and eyes.; Impaired immune system is a risk factor for primary CNS lymphoma.; Immunodeficiency disorders, HIV infection, Epstein-Barr virus, autoimmune diseases, organ transplant, and older age are risk factors for primary CNS lymphoma.; Primary CNS lymphoma can cause neurological symptoms such as leg or arm weakness, coordination or movement difficulties, personality or behavior changes, depression, confusion, memory problems, incontinence, difficulty speaking or swallowing, headaches, nausea, vomiting, seizures, and vision changes.; Primary CNS lymphoma is diagnosed using neurological exam, imaging (MRI or CT), biopsy, blood tests, eye exam, and lumbar puncture.; MRI with gadolinium contrast is the most useful imaging technique for identifying primary CNS lymphoma.; Stereotactic biopsy is the standard diagnostic procedure for primary CNS lymphoma.; High-dose methotrexate is the main chemotherapy drug used for primary CNS lymphoma.; Clinical trial participation is recommended for all patients with primary CNS lymphoma."},
	{"id":"Medical-beb1f30e","source":"Medical","question":"Imagine you are a dermatology attending preparing a referral letter for a patient with a newly diagnosed high-risk cutaneous squamous cell carcinoma (CSCC) on the scalp. Summarize the case, risk assessment, diagnostic findings, and recommend next steps, incorporating relevant guideline recommendations.","answer":"Dear Colleague,\n\nI am referring a 68-year-old fair-skinned male recently diagnosed with high-risk cutaneous squamous cell carcinoma (CSCC) of the scalp. The patient has a history of chronic sun exposure and presented with a 2.5 cm solid, irregular lesion on an area of chronic scarring. Clinical examination and excision biopsy confirmed invasive CSCC with perineural invasion and poorly defined borders. Imaging (CT) did not reveal nodal or distant metastasis. Risk assessment classified the tumor as high-risk due to its size, location (scalp), perineural invasion, and history of recurrence. \n\nGuidelines recommend Mohs surgery/PDEMA as the preferred treatment for high-risk local CSCC, with consideration of adjuvant radiation therapy if surgical margins are inadequate or perineural invasion is extensive. Regular skin and lymph node exams every 3-6 months for the first 2 years are advised for surveillance. Please see attached pathology and imaging reports for further details.\n\nSincerely,\nDermatology Attending","question_type":"Creative Generation","evidence":"The patient is a 68-year-old fair-skinned male.; The patient has been diagnosed with high-risk cutaneous squamous cell carcinoma (CSCC) of the scalp.; The patient has a history of chronic sun exposure.; The patient presented with a 2.5 cm solid, irregular lesion on an area of chronic scarring.; Clinical examination confirmed invasive CSCC with perineural invasion.; The tumor has poorly defined borders.; Imaging (CT) did not reveal nodal or distant metastasis.; Risk assessment classified the tumor as high-risk due to its size and location.; Mohs surgery/PDEMA is the preferred treatment for high-risk local CSCC.; Adjuvant radiation therapy may be considered if surgical margins are inadequate.; Regular skin and lymph node exams every 3-6 months for the first 2 years are advised.","evidence_relations":"High-risk or very high-risk local CSCC is treated with Mohs surgery/PDEMA or standard excision, with consideration of radiation and/or systemic therapy if surgery is not possible.; Risk assessment for CSCC is based on tumor location, size, border definition, recurrence, depth, perineural invasion, lymphovascular invasion, tumor grade, and patient immune status.; CSCC most commonly arises in sun-exposed areas, especially in fair-skinned individuals.; Diagnosis of CSCC involves clinical examination, skin biopsy, and imaging (CT, MRI, PET/CT) if deeper invasion or spread is suspected.; Follow-up after treatment includes regular skin and lymph node exams, with frequency based on risk and stage."},
	{"id":"Medical-9e9cc51b","source":"Medical","question":"You are an oncology nurse tasked with drafting a patient-friendly discharge summary for a person with regional CSCC (lymph node involvement) who has completed surgery and adjuvant radiation. Use the guideline to summarize their diagnosis, treatment, risk factors, and follow-up plan.","answer":"Discharge Summary for Regional Cutaneous Squamous Cell Carcinoma (CSCC)\n\nDiagnosis: You have been diagnosed with cutaneous squamous cell carcinoma (CSCC) that had spread to a nearby lymph node, which is known as regional CSCC. Major risk factors for this type of skin cancer include chronic sun exposure and a weakened immune system.\n\nTreatment: Your treatment included surgery to remove both the skin tumor and the affected lymph node(s). After surgery, you received radiation therapy to the area to help lower the risk of the cancer coming back. Imaging tests after treatment did not show any further spread of the cancer.\n\nRisk Factors: The main risk factors for CSCC are long-term sun exposure, a weakened immune system, and a history of chronic wounds or scarring. These factors can increase the chance of developing skin cancer or having it return.\n\nFollow-up Plan: Regular follow-up is important to monitor for any signs of recurrence. You will have skin and lymph node checks every 23 months during the first year after treatment, then every 24 months in the second year, and less frequently in the following years. Imaging may be used as part of your ongoing surveillance. Please continue to protect your skin from the sun and promptly report any new or changing skin lesions to your care team.\n\nThank you for your cooperation and commitment to your follow-up care.","question_type":"Creative Generation","evidence":"The patient has regional cutaneous squamous cell carcinoma (CSCC) with lymph node involvement.; Major risk factors include chronic sun exposure and a weakened immune system.; The patient underwent surgery to remove the skin tumor and the affected lymph node.; The patient received radiation therapy to reduce the risk of recurrence.; No evidence of further spread was found on imaging.; Follow-up will include skin and lymph node checks every 23 months in the first year.; Follow-up will include checks every 24 months in the second year.; Follow-up will be less frequent after the second year.; Imaging will be used for ongoing surveillance.; The patient is advised to continue sun protection.; The patient should report any new skin changes promptly.","evidence_relations":"Regional CSCC (lymph node involvement) is treated with surgery to remove tumor and lymph nodes, often followed by radiation and sometimes systemic therapy.; Major risk factors for CSCC include chronic sun exposure, indoor tanning, environmental toxins, actinic keratoses, genetic syndromes, weakened immune system, and chronic wounds or scars.; Follow-up after treatment includes regular skin and lymph node exams, with frequency based on risk and stage.; Imaging is used for staging and surveillance in regional and high-risk cases.; Skin and lymph node exams every 2-3 months for 1 year, every 2-4 months for year 2, every 4-6 months for 3 years, then every 6-12 months."},
	{"id":"Medical-970792d6","source":"Medical","question":"Assume the role of a medical intern on the dermatology service. You are asked to write a SOAP progress note for a patient with actinic keratosis and a history of immunosuppression, referencing both diagnosis and management per guidelines.","answer":"SOAP Note\n\nSubjective: Patient reports several rough, scaly patches on sun-exposed areas of the face and forearms. Denies pain or bleeding. Notable history includes chronic immunosuppression following organ transplantation, which increases the risk for skin malignancies.\n\nObjective: Physical examination reveals multiple erythematous, scaly papules on the left cheek and dorsal hands, consistent with actinic keratoses. No palpable lymphadenopathy is present. Skin biopsy confirms the diagnosis of actinic keratosis. No evidence of invasive disease at this time.\n\nAssessment: Actinic keratosis in a patient with chronic immunosuppression. Immunosuppressed individuals are at significantly increased risk for progression of actinic keratosis to cutaneous squamous cell carcinoma (CSCC), as well as for developing additional lesions.\n\nPlan: Initiate cryotherapy for discrete, visible lesions and prescribe topical 5-fluorouracil for field treatment of affected areas, in accordance with current guidelines. Provide education on strict photoprotection, including use of broad-spectrum sunscreen, protective clothing, and avoidance of peak sun exposure. Emphasize the importance of regular self-skin examinations and schedule dermatologic follow-up every 36 months for comprehensive skin and lymph node exams, given the elevated risk of progression to CSCC. Advise prompt evaluation of any new, changing, or symptomatic lesions.","question_type":"Creative Generation","evidence":"The patient has actinic keratosis.; The patient has a history of immunosuppression due to organ transplant.; The patient reports several rough, scaly patches on sun-exposed areas of the face and forearms.; The patient reports no pain or bleeding.; The examination reveals multiple erythematous, scaly papules on the left cheek and dorsal hands.; There is no palpable lymphadenopathy.; A biopsy confirms the diagnosis of actinic keratosis.; The assessment indicates an increased risk for progression to cutaneous squamous cell carcinoma (CSCC).; Cryotherapy will be initiated for visible lesions.; Topical 5-fluorouracil will be used for field treatment.; The patient will be educated on strict photoprotection.; Regular skin exams will be scheduled every 36 months due to increased risk.; The patient will be monitored for any new or changing lesions.","evidence_relations":"Actinic keratosis is a precancerous lesion that can progress to CSCC.; Photodynamic therapy, cryotherapy, and topical therapies (5-fluorouracil, imiquimod, tirbanibulin) are used for actinic keratoses and superficial CSCC.; Major risk factors for CSCC include chronic sun exposure, actinic keratosis, genetic syndromes, weakened immune system, and chronic wounds or scars.; Follow-up after treatment includes regular skin and lymph node exams, with frequency based on risk and stage.; Immunosuppression is a risk factor for both actinic keratosis and progression to CSCC."},
	{"id":"Medical-5b2de94d","source":"Medical","question":"You are a public health official drafting an advisory for primary care providers about prevention, early detection, and high-risk populations for cutaneous squamous cell carcinoma (CSCC). Use guideline facts to inform your advisory.","answer":"Public Health Advisory: Prevention and Early Detection of Cutaneous Squamous Cell Carcinoma (CSCC)\n\nPrimary care providers should be vigilant for CSCC, the second most common skin cancer, particularly in fair-skinned individuals and those with extensive sun exposure. High-risk populations include patients with chronic sun exposure, indoor tanning history, actinic keratosis, genetic syndromes (e.g., xeroderma pigmentosum, RDEB), immunosuppression, and chronic wounds or scars. \n\nEarly detection relies on clinical examination for scaly patches or misshapen skin lesions, especially in sun-exposed or chronically damaged areas. Biopsy is essential for suspicious lesions. Encourage sun protection and routine skin exams, especially for high-risk patients. Prompt referral for dermatologic evaluation is recommended for new, persistent, or changing lesions.\n","question_type":"Creative Generation","evidence":"CSCC is the second most common skin cancer.; Primary care providers should be vigilant for CSCC.; Fair-skinned individuals are at higher risk for CSCC.; Individuals with extensive sun exposure are at higher risk for CSCC.; High-risk populations include patients with chronic sun exposure.; Indoor tanning history is a risk factor for CSCC.; Actinic keratosis is a precursor to CSCC.; Genetic syndromes such as xeroderma pigmentosum increase risk for CSCC.; Immunosuppression is a risk factor for CSCC.; Chronic wounds or scars are associated with increased risk for CSCC.; Early detection relies on clinical examination for scaly patches or misshapen skin lesions.; Biopsy is essential for suspicious lesions.; Sun protection and routine skin exams are encouraged for high-risk patients.; Prompt referral for dermatologic evaluation is recommended for new, persistent, or changing lesions.","evidence_relations":"Squamous cell skin cancer (CSCC) is the second most common type of skin cancer.; CSCC most commonly arises in sun-exposed areas, especially in fair-skinned individuals.; Major risk factors for CSCC include chronic sun exposure, indoor tanning, environmental toxins, actinic keratoses, genetic syndromes, weakened immune system, and chronic wounds or scars.; Symptoms of CSCC include scaly patches, solid or misshapen skin lesions, and lesions in areas of chronic damage.; Diagnosis of CSCC involves clinical examination, skin biopsy, and imaging (CT, MRI, PET/CT) if deeper invasion or spread is suspected."},
	{"id":"Medical-22918f14","source":"Medical","question":"Imagine you are a hematology fellow receiving a new referral for a patient with suspected chronic myeloid leukemia (CML). Draft a detailed diagnostic workup plan, including key laboratory and molecular studies, and explain how you would confirm the diagnosis and characterize the disease phase.","answer":"For a patient with suspected chronic myeloid leukemia (CML), the diagnostic workup should be comprehensive and systematic. I would begin with a detailed medical history and physical examination, including assessment for symptoms such as fatigue, weight loss, night sweats, and splenomegaly. Laboratory evaluation would start with a complete blood count (CBC) with differential to identify leukocytosis, particularly increased granulocytes, and to assess platelet and red blood cell levels. A peripheral blood smear would be performed to evaluate the spectrum of granulocyte maturation and to detect any abnormal or immature cells. Bone marrow aspiration and biopsy would be considered to assess cellularity, myeloid proliferation, and the percentage of blasts, which is critical for distinguishing between chronic, accelerated, and blast phases of CML. Cytogenetic analysis (karyotyping) would be performed to detect the Philadelphia chromosome (Ph), resulting from the t(9;22)(q34;q11) translocation. Fluorescence in situ hybridization (FISH) or reverse transcriptase polymerase chain reaction (RT-PCR) would be used to confirm the presence of the BCR::ABL1 fusion gene, which is required for a definitive diagnosis. The disease phase is characterized by the proportion of blasts in blood or marrow: chronic phase (<10% blasts), accelerated phase (1019% blasts), or blast phase (20% blasts). This integrated approach confirms the diagnosis, distinguishes CML from other myeloproliferative neoplasms, and guides subsequent management.","question_type":"Creative Generation","evidence":"The diagnostic workup for suspected chronic myeloid leukemia (CML) begins with a complete blood count (CBC).; The CBC assesses for increased white blood cell (WBC) counts, particularly granulocytes.; The CBC evaluates platelet (PLT) and red blood cell (RBC) levels.; A peripheral blood smear is ordered to characterize granulocyte lineage.; The peripheral blood smear helps identify abnormal cells.; A bone marrow aspiration and biopsy are requested to assess myeloid progenitor cell proliferation.; The bone marrow evaluation looks for any increase in blasts.; An increase in blasts could indicate blast phase CML (BP-CML).; Cytogenetic analysis is performed to detect the presence of the Philadelphia chromosome (Ph).; The Philadelphia chromosome is the abnormal chromosome 22 resulting from the translocation between chromosomes 9 and 22.; Molecular testing for the BCR::ABL1 fusion gene is conducted.; The presence of the BCR::ABL1 fusion gene is required for a definitive diagnosis of CML.; The combination of clinical, morphologic, cytogenetic, and molecular findings confirms CML.; The findings help differentiate CML from other myeloproliferative neoplasms.; The findings determine if the disease is in chronic or blast phase.","evidence_relations":"CML is characterized by increased white blood cells (granulocytes) and abnormal platelet counts.; Blood tests and bone marrow tests are used to diagnose CML.; CML arises from blood stem cells producing increased myeloid progenitor cells.; Presence of the Ph chromosome or BCR::ABL1 gene is required for CML diagnosis.; The BCR::ABL1 gene is created by a translocation between chromosome 9 and chromosome 22.; Blast phase CML (BP-CML) is an advanced form of CML with increased blasts."},
	{"id":"Medical-c5176f5c","source":"Medical","question":"You are an oncologist preparing a treatment initiation summary for a patient newly diagnosed with chronic phase CML. Summarize the pathogenesis, diagnostic criteria, and first-line therapeutic strategy, referencing relevant biomarkers and molecular targets.","answer":"Chronic myeloid leukemia (CML) is a blood cancer caused by the BCR::ABL1 fusion gene, which arises from a translocation between chromosomes 9 and 22, forming the Philadelphia chromosome (Ph). Diagnosis is established by detecting either the Ph chromosome or the BCR::ABL1 fusion gene, typically via cytogenetic and molecular testing of blood or bone marrow samples. The disease originates in blood stem cells, leading to excessive production of myeloid progenitor cells and increased granulocyte (white blood cell) counts, often accompanied by abnormal platelet levels. The primary therapeutic approach targets the BCR::ABL1 protein, whose abnormal tyrosine kinase activity drives disease progression. Initiation of treatment with a BCR::ABL1 protein inhibitor is recommended as first-line therapy for chronic phase CML, with ongoing monitoring of molecular response.","question_type":"Creative Generation","evidence":"Chronic myeloid leukemia (CML) is caused by the BCR::ABL1 fusion gene.; The BCR::ABL1 fusion gene arises from a translocation between chromosomes 9 and 22.; The translocation forms the Philadelphia chromosome (Ph).; Diagnosis of CML is established by detecting the Ph chromosome or the BCR::ABL1 fusion gene.; Detection is typically done via cytogenetic and molecular testing of blood or bone marrow samples.; CML originates in blood stem cells.; CML leads to excessive production of myeloid progenitor cells.; CML is associated with increased granulocyte (white blood cell) counts.; CML is often accompanied by abnormal platelet levels.; The primary therapeutic approach targets the BCR::ABL1 protein.; The BCR::ABL1 protein has abnormal tyrosine kinase activity.; The abnormal tyrosine kinase activity drives disease progression.; Initiation of treatment with a BCR::ABL1 protein inhibitor is recommended as first-line therapy for chronic phase CML.; Ongoing monitoring of molecular response is necessary.","evidence_relations":"Chronic myeloid leukemia (CML) is a type of blood cancer.; CML is caused by the BCR::ABL1 fusion gene.; The BCR::ABL1 gene is created by a translocation between chromosome 9 and chromosome 22.; The Philadelphia chromosome (Ph) is the abnormal chromosome 22 resulting from this translocation.; Presence of the Ph chromosome or BCR::ABL1 gene is required for CML diagnosis.; CML arises from blood stem cells producing increased myeloid progenitor cells.; Treatment for CML aims to inhibit BCR::ABL1 protein activity."},
	{"id":"Medical-3aed2370","source":"Medical","question":"Transform the core clinical facts about chronic myeloid leukemia (CML) into a structured discharge summary for a patient completing diagnostic evaluation and beginning therapy.","answer":"**Discharge Summary**\n\nDiagnosis: Chronic Myeloid Leukemia (CML)\n\nSummary of Hospital Course:\nThe patient underwent evaluation for persistent leukocytosis and abnormal platelet counts identified on routine laboratory testing. Further assessment included blood and bone marrow analyses, which demonstrated marked proliferation of granulocytes and myeloid progenitor cells. Cytogenetic testing revealed the presence of the Philadelphia chromosome (Ph), resulting from a translocation between chromosomes 9 and 22. Molecular studies confirmed the BCR::ABL1 fusion gene, establishing the diagnosis of CML. The disease is currently classified as being in the chronic phase, with no evidence of accelerated or blast phase transformation.\n\nKey Diagnostic Findings:\n- Hematology: Elevated white blood cell count (predominantly granulocytes) and abnormal platelet counts\n- Bone Marrow: Hypercellularity with increased myeloid progenitor cells\n- Cytogenetics: Philadelphia chromosome (t(9;22)(q34;q11)) detected\n- Molecular: BCR::ABL1 fusion gene present\n\nManagement Plan:\n- Initiate BCR::ABL1 tyrosine kinase inhibitor therapy as first-line treatment\n- Arrange for regular monitoring of complete blood counts and molecular response (BCR::ABL1 transcript levels)\n- Provide education on disease process, treatment expectations, and the importance of adherence and follow-up\n- Encourage the patient to maintain organized medical records and communicate any new symptoms promptly\n- Recommend ongoing support from family, caregivers, and the healthcare team\n\nThe patient and family have been counseled regarding the diagnosis, treatment plan, and the need for close follow-up with the hematology/oncology team.","question_type":"Creative Generation","evidence":"The diagnosis is chronic myeloid leukemia (CML).; The patient was evaluated for elevated white blood cell counts.; The patient had abnormal platelet counts.; Blood analyses revealed increased granulocytes.; Bone marrow analyses revealed increased myeloid progenitor cells.; Cytogenetic studies confirmed the presence of the Philadelphia chromosome (Ph).; The Philadelphia chromosome results from a translocation between chromosome 9 and 22.; Molecular studies confirmed the presence of the BCR::ABL1 fusion gene.; The findings fulfill diagnostic criteria for CML.; The disease is currently in the chronic phase.; Initiation of BCR::ABL1 protein inhibitor therapy is planned.; Ongoing monitoring of blood counts and molecular response will occur.","evidence_relations":"CML is characterized by increased white blood cells (granulocytes) and abnormal platelet counts.; CML arises from blood stem cells producing increased myeloid progenitor cells.; Blood tests and bone marrow tests are used to diagnose CML.; The BCR::ABL1 gene is created by a translocation between chromosome 9 and chromosome 22.; Presence of the Ph chromosome or BCR::ABL1 gene is required for CML diagnosis.; Treatment for CML aims to inhibit BCR::ABL1 protein activity."},
	{"id":"Medical-fbacfb98","source":"Medical","question":"Reframe the guideline information into a referral note addressed to a specialist, clearly stating the clinical suspicion, supporting laboratory findings, and rationale for specialist input.","answer":"Dear Hematology Specialist,\n\nI am referring a patient with clinical and laboratory findings suggestive of chronic myeloid leukemia (CML). The patient presents with persistent leukocytosis, notably increased granulocytes, and abnormal platelet counts identified on routine blood tests. Bone marrow evaluation demonstrated hypercellularity with expansion of myeloid progenitor cells. Cytogenetic analysis revealed the Philadelphia chromosome (Ph), resulting from a translocation between chromosomes 9 and 22. Molecular studies confirmed the presence of the BCR::ABL1 fusion gene. Given these findings, CML is strongly suspected and I am seeking your expertise for confirmation of diagnosis, disease phase classification, and initiation of targeted therapy.","question_type":"Creative Generation","evidence":"The patient is being referred for suspected chronic myeloid leukemia (CML).; The patient presents with persistent leukocytosis.; The patient has notably increased granulocytes.; The patient has abnormal platelet counts identified on routine blood tests.; Bone marrow evaluation demonstrated hypercellularity.; The hypercellularity indicates expansion of myeloid progenitor cells.; Cytogenetic analysis revealed the Philadelphia chromosome (Ph).; The Philadelphia chromosome results from a translocation between chromosomes 9 and 22.; Molecular studies confirmed the presence of the BCR::ABL1 fusion gene.; CML is strongly suspected based on these findings.; The referral seeks confirmation of diagnosis.; The referral seeks disease phase classification.; The referral seeks initiation of targeted therapy.","evidence_relations":"CML is characterized by increased white blood cells (granulocytes) and abnormal platelet counts.; CML arises from blood stem cells producing increased myeloid progenitor cells.; Blood tests and bone marrow tests are used to diagnose CML.; The BCR::ABL1 gene is created by a translocation between chromosome 9 and chromosome 22.; The Philadelphia chromosome (Ph) is the abnormal chromosome 22 resulting from this translocation.; Presence of the Ph chromosome or BCR::ABL1 gene is required for CML diagnosis."},
	{"id":"Medical-70301a25","source":"Medical","question":"You are a public health officer tasked with writing an educational advisory on the importance of genetic and molecular testing in diagnosing chronic myeloid leukemia (CML). Summarize the key genetic mechanisms, diagnostic requirements, and implications for treatment.","answer":"**Public Health Advisory: The Role of Genetic and Molecular Testing in CML Diagnosis**\n\nChronic myeloid leukemia (CML) is a blood cancer defined by a specific genetic alteration: the BCR::ABL1 fusion gene, formed by a translocation between chromosomes 9 and 22, leading to the formation of the Philadelphia chromosome (Ph). Accurate diagnosis requires laboratory confirmation of either the Ph chromosome or the BCR::ABL1 fusion gene through cytogenetic and molecular testing of blood or bone marrow samples. These tests distinguish CML from other blood disorders and are critical for selecting appropriate therapy. Targeted treatments that inhibit the BCR::ABL1 protein have dramatically improved outcomes. Public health initiatives should ensure access to advanced molecular diagnostics for all suspected CML patients.","question_type":"Creative Generation","evidence":"Chronic myeloid leukemia (CML) is defined by the BCR::ABL1 fusion gene.; The BCR::ABL1 fusion gene is formed by a translocation between chromosomes 9 and 22.; The translocation leads to the formation of the Philadelphia chromosome (Ph).; Accurate diagnosis of CML requires laboratory confirmation of the Ph chromosome or the BCR::ABL1 fusion gene.; Laboratory confirmation is done through cytogenetic and molecular testing of blood or bone marrow samples.; These tests distinguish CML from other blood disorders.; The tests are critical for selecting appropriate therapy.; Targeted treatments that inhibit the BCR::ABL1 protein have improved outcomes.; Public health initiatives should ensure access to advanced molecular diagnostics for suspected CML patients.","evidence_relations":"CML is caused by the BCR::ABL1 fusion gene.; The BCR::ABL1 gene is created by a translocation between chromosome 9 and chromosome 22.; The Philadelphia chromosome (Ph) is the abnormal chromosome 22 resulting from this translocation.; Presence of the Ph chromosome or BCR::ABL1 gene is required for CML diagnosis.; Blood tests and bone marrow tests are used to diagnose CML.; Treatment for CML aims to inhibit BCR::ABL1 protein activity."},
	{"id":"Medical-0f84be73","source":"Medical","question":"As a pulmonologist, you are seeing a 62-year-old patient with a 40 pack-year smoking history who presents with a persistent cough. Imaging has revealed a solitary lung nodule. Using the clinical practice guidelines provided, draft a detailed diagnostic and initial management plan, including risk assessment, confirmatory steps, and early treatment considerations.","answer":"This 62-year-old patient with a 40 pack-year smoking history and a persistent cough is at high risk for lung cancer, as tobacco use is the most significant risk factor. The discovery of a solitary lung nodule on imaging requires a structured diagnostic approach. First, a comprehensive risk assessment should be performed, considering the patient's age, smoking history, and nodule characteristics. Multidisciplinary evaluation by a pulmonologist, thoracic radiologist, and thoracic surgeon is recommended. Further imaging, such as a high-resolution CT scan, may be obtained to better characterize the nodule and assess for additional lesions or lymphadenopathy. If the nodule is suspicious for malignancy, a tissue diagnosis via biopsy (e.g., CT-guided, bronchoscopic, or surgical) is essential to confirm cancer and determine the histologic subtype, most commonly non-small cell lung cancer (NSCLC). Staging investigations, including PET-CT and brain imaging if indicated, should be performed to assess for local or distant spread. For early-stage NSCLC, surgical resection is the preferred treatment, with radiation therapy as an alternative for patients who are not surgical candidates. In cases of locally advanced disease, a combination of chemotherapy and radiation, and possibly surgery, may be considered. Throughout the process, supportive care should address symptoms such as cough and chest pain, and a plan for post-treatment surveillance should be established to monitor for recurrence.","question_type":"Creative Generation","evidence":"The patient has a significant tobacco smoking history.; The patient is at high risk for lung cancer.; A solitary lung nodule was detected on imaging.; A biopsy is recommended to confirm malignancy.; The biopsy is essential for diagnosis.; If the biopsy confirms non-small cell lung cancer (NSCLC), the subtype will be determined.; The likely subtypes of NSCLC include adenocarcinoma, squamous cell carcinoma, or large cell carcinoma.; The disease will be staged after biopsy confirmation.; For early-stage (Stage 1) NSCLC, surgery is the primary treatment.; Radiation therapy may be an option in some cases for early-stage NSCLC.; If the disease is locally advanced (Stage 2 or 3), chemoradiation and possibly surgery would be considered.; Supportive care should be integrated to address symptoms such as cough and chest pain.; Follow-up care with surveillance will be planned after initial treatment.","evidence_relations":"Tobacco smoking is the biggest risk factor for lung cancer.; Lung nodules may be detected by imaging and require further assessment to determine malignancy.; Biopsy is used to confirm lung cancer diagnosis.; NSCLC is the most common type of lung cancer.; Surgery is a primary treatment for early or locally advanced NSCLC when possible.; Radiation therapy is used for some early NSCLC cases.; Chemoradiation is used for some locally advanced NSCLC cases.; Symptoms of lung cancer may include cough, chest pain, and other respiratory symptoms.; Follow-up care is planned after treatment and includes surveillance for recurrence."},
	{"id":"Medical-6e3f025e","source":"Medical","question":"You are a medical intern tasked with writing a referral note for a patient with suspected Stage 2 NSCLC based on the guideline. Your note should summarize the diagnostic findings, risk factors, and recommend further specialist evaluation and treatment options.","answer":"Referral Note:\n\nThe patient is a 58-year-old individual with a significant 30 pack-year history of tobacco use, presenting with persistent cough and chest pain. Diagnostic imaging identified a lung nodule, and subsequent biopsy confirmed the diagnosis of non-small cell lung cancer (NSCLC). Staging workup suggests likely Stage 2 disease, characterized by local extension of the tumor without evidence of distant metastasis. Notable risk factors include chronic tobacco exposure and possible occupational exposure to asbestos, both of which are established contributors to lung cancer risk.\n\nGiven the diagnosis and staging, referral to a thoracic oncology specialist is recommended for comprehensive evaluation and definitive management planning. According to current guidelines, treatment options for Stage 2 NSCLC include surgical resection when feasible, and/or chemoradiation, depending on the patient's overall health status and tumor characteristics. Multidisciplinary discussion is advised to tailor the treatment approach. Supportive care should be initiated to address symptoms and optimize quality of life, and a structured follow-up plan for surveillance of recurrence or progression should be established.","question_type":"Creative Generation","evidence":"The patient is a 58-year-old with a 30 pack-year smoking history.; The patient presents with persistent cough and chest pain.; Imaging revealed a lung nodule.; A biopsy confirmed non-small cell lung cancer (NSCLC).; The NSCLC is likely Stage 2 based on local extension without distant spread.; Major risk factors include tobacco use.; Possible occupational exposure to asbestos is also a risk factor.; A thoracic oncology evaluation is recommended for definitive staging and management.; Treatment options include surgery and/or chemoradiation.; Supportive care for symptom management should be discussed.; Follow-up surveillance should be planned.","evidence_relations":"Stage 2 and Stage 3 NSCLC are considered locally advanced.; Biopsy is used to confirm lung cancer diagnosis.; Imaging is used to detect lung nodules.; Tobacco smoking is the biggest risk factor for lung cancer.; Exposure to asbestos increases lung cancer risk.; Surgery is a primary treatment for early or locally advanced NSCLC when possible.; Chemoradiation is used for some locally advanced NSCLC cases.; Symptoms of lung cancer may include cough, chest pain, and other respiratory symptoms.; Follow-up care is planned after treatment and includes surveillance for recurrence."},
	{"id":"Medical-8c4b4b2f","source":"Medical","question":"Rewrite the clinical practice guideline content into a patient-friendly discharge summary for a person who has undergone surgery for Stage 1 NSCLC. The summary should explain the diagnosis, risk factors, treatment performed, and follow-up plan.","answer":"Discharge Summary:\n\nDiagnosis: Early-stage non-small cell lung cancer (NSCLC), specifically Stage 1, was confirmed after your recent surgery. This cancer type most often develops in people with risk factors like tobacco smoking and exposure to substances such as asbestos or air pollution. You underwent successful surgical removal of the tumor, which is the standard treatment for early NSCLC. No evidence of spread was found at this stage. Moving forward, you will have regular follow-up visits and imaging to monitor for recurrence. Please report any new symptoms such as cough or chest pain promptly.","question_type":"Creative Generation","evidence":"The diagnosis is early-stage non-small cell lung cancer (NSCLC), specifically Stage 1.; The diagnosis was confirmed after recent surgery.; Early-stage NSCLC most often develops in people with risk factors like tobacco smoking.; Exposure to substances such as asbestos or air pollution is also a risk factor.; The patient underwent successful surgical removal of the tumor.; Surgical removal is the standard treatment for early NSCLC.; No evidence of spread was found at this stage.; Regular follow-up visits and imaging will be conducted to monitor for recurrence.; The patient should report any new symptoms such as cough or chest pain promptly.","evidence_relations":"Stage 1 NSCLC is considered early stage.; Surgery is a primary treatment for early or locally advanced NSCLC when possible.; NSCLC is the most common type of lung cancer.; Tobacco smoking is the biggest risk factor for lung cancer.; Exposure to asbestos and air pollution are risk factors for lung cancer.; Follow-up care is planned after treatment and includes surveillance for recurrence.; Symptoms of lung cancer may include cough, chest pain, and other respiratory symptoms."},
	{"id":"Medical-d5964ccf","source":"Medical","question":"As a public health officer, draft a community health advisory on lung cancer prevention and early detection, integrating key guideline facts on risk factors, screening, and symptom awareness.","answer":"Community Health Advisory: Preventing and Detecting Lung Cancer Early\n\nLung cancer is a leading cause of cancer-related deaths, with non-small cell lung cancer (NSCLC) being the most common type. The primary risk factor for lung cancer is tobacco smoking, but exposure to secondhand smoke, radon, asbestos, air pollution, and certain occupational hazards (such as diesel fumes) also increase risk. While anyone can develop lung cancer, individuals with a history of heavy smoking or significant exposure to these risk factors are at higher risk and should discuss lung cancer screening with their healthcare provider. Screening, such as low-dose CT scans, is recommended for those at high risk and can detect lung cancer at an early, more treatable stageoften before symptoms appear. Early symptoms may include a persistent cough, chest pain, shortness of breath, or unexplained weight loss. Quitting smoking and minimizing exposure to harmful substances are the most effective ways to reduce your risk. Regular checkups, updating your healthcare provider on your family and exposure history, and being aware of new or persistent respiratory symptoms are important for early detection. Participation in clinical trials and supportive care services may also improve outcomes for those diagnosed with lung cancer.","question_type":"Creative Generation","evidence":"Lung cancer is a leading cause of cancer-related deaths.; The most common type of lung cancer is non-small cell lung cancer (NSCLC).; NSCLC is strongly linked to tobacco smoking.; Exposure to substances like radon, asbestos, and air pollution is also a risk factor for lung cancer.; Individuals with a history of heavy smoking should ask their healthcare provider about lung cancer screening.; Lung cancer screening can detect cancer at an early, more treatable stage.; Warning signs of lung cancer include persistent cough and chest pain.; Quitting smoking significantly lowers the risk of lung cancer.; Reducing exposure to harmful substances also lowers the risk.; Regular follow-up and participation in clinical trials may improve outcomes.","evidence_relations":"NSCLC is the most common type of lung cancer.; Tobacco smoking is the biggest risk factor for lung cancer.; Exposure to radon, asbestos, and air pollution are risk factors for lung cancer.; Lung cancer screening is recommended for people at high risk.; Lung cancer screening aims to detect cancer at an early, more treatable stage.; Symptoms of lung cancer may include cough, chest pain, and other respiratory symptoms.; Clinical trials are available for lung cancer treatment and prevention.; Supportive care extends and enhances life for people with lung cancer."},
	{"id":"Medical-0ec610fa","source":"Medical","question":"Format the key elements of NSCLC diagnosis and management from the guideline into a SOAP (Subjective, Objective, Assessment, Plan) note for a new oncology consultation.","answer":"SOAP Note:\n\nSubjective: Patient reports persistent cough and intermittent chest pain. History includes current tobacco smoking and prior exposure to diesel fumes.\n\nObjective: Imaging revealed a lung nodule; biopsy confirmed NSCLC. No evidence of distant spread on staging.\n\nAssessment: Newly diagnosed NSCLC, likely early or locally advanced stage. Significant risk factors include tobacco use and occupational exposure.\n\nPlan: Refer for surgical evaluation (if early stage), consider chemoradiation for locally advanced disease. Initiate supportive care for symptom management. Enroll in follow-up care and surveillance after primary treatment. Discuss potential clinical trial participation.","question_type":"Creative Generation","evidence":"The patient reports persistent cough and intermittent chest pain.; The patient has a history of current tobacco smoking.; The patient has prior exposure to diesel fumes.; Imaging revealed a lung nodule.; A biopsy confirmed non-small cell lung cancer (NSCLC).; There is no evidence of distant spread on staging.; The assessment indicates newly diagnosed NSCLC, likely early or locally advanced stage.; Significant risk factors include tobacco use and occupational exposure.; A referral for surgical evaluation is planned if the disease is early stage.; Chemoradiation will be considered for locally advanced disease.; Supportive care for symptom management will be initiated.; Follow-up care and surveillance after primary treatment will be enrolled.; Potential clinical trial participation will be discussed.","evidence_relations":"Symptoms of lung cancer may include cough, chest pain, and other respiratory symptoms.; Lung nodules may be detected by imaging and require further assessment to determine malignancy.; Biopsy is used to confirm lung cancer diagnosis.; NSCLC is the most common type of lung cancer.; Surgery is a primary treatment for early or locally advanced NSCLC when possible.; Chemoradiation is used for some locally advanced NSCLC cases.; Tobacco smoking and exposure to diesel fumes are risk factors for lung cancer.; Follow-up care is planned after treatment and includes surveillance for recurrence.; Clinical trials are available for lung cancer treatment and prevention.; Supportive care extends and enhances life for people with lung cancer."},
	{"id":"Medical-65be7ca5","source":"Medical","question":"Imagine you are a head and neck cancer specialist preparing a referral letter for a 45-year-old male from Southeast Asia with suspected nasopharyngeal carcinoma (NPC). Summarize the relevant risk factors, preliminary findings, required diagnostic workup, and initial management considerations to the oncology team.","answer":"Dear Oncology Team,\n\nI am referring a 45-year-old male of Southeast Asian origin with clinical suspicion of nasopharyngeal carcinoma (NPC). Relevant risk factors include his geographic background, as NPC is more prevalent in individuals from Southeast Asia, and a history of tobacco and alcohol use, both of which are established risk factors for head and neck cancers. Epstein-Barr virus (EBV) infection is a major etiologic factor in NPC, and should be considered in this case.\n\nPreliminary findings include the presence of a neck mass, intermittent hearing loss, and an enlarged cervical lymph node on examination. These symptoms are consistent with NPC, which often presents with lymphadenopathy and may cause hearing loss due to Eustachian tube dysfunction. Early-stage NPC can be asymptomatic, so these findings warrant prompt investigation.\n\nThe recommended diagnostic workup includes:\n- Comprehensive medical history and physical examination, with attention to risk factors and family history.\n- Imaging studies: Contrast-enhanced CT or MRI of the head and neck to assess the primary tumor and nodal involvement, and PET/CT to evaluate for distant metastases.\n- Biopsy: Histopathological confirmation via biopsy of the nasopharyngeal lesion and/or fine-needle aspiration (FNA), fine-needle biopsy (FNB), or core needle biopsy (CNB) of the cervical lymph node.\n- Biomarker testing: Assessment for EBV DNA, PD-L1, and MSI-H/dMMR status, as these may inform prognosis and therapeutic options.\n\nInitial management considerations include evaluation of performance status to guide treatment planning, and discussion of fertility preservation options prior to initiation of therapy, as treatment may impact fertility. Dental and nutritional assessments are also advised due to the potential effects of head and neck cancer treatment on oral health and nutritional status. Please proceed with the recommended workup and multidisciplinary evaluation.","question_type":"Creative Generation","evidence":"The patient is a 45-year-old male of Southeast Asian origin.; The patient has a clinical suspicion of nasopharyngeal carcinoma (NPC).; The patient presents with a neck mass.; The patient experiences intermittent hearing loss.; The patient has a history of tobacco use.; The patient has a history of alcohol use.; NPC is more prevalent in individuals from Asia.; EBV infection is a major etiologic factor for NPC.; An examination reveals an enlarged cervical lymph node.; A thorough diagnostic workup is recommended.; Imaging studies including CT/MRI and PET/CT should be performed.; A biopsy of the nasopharyngeal lesion is necessary for histopathological confirmation.; Biomarker testing for EBV DNA, PD-L1, and MSI-H/dMMR should be conducted.; Performance status should be evaluated.; Fertility preservation options should be discussed prior to therapy.; Dental and nutritional assessments are advised due to potential treatment impacts.","evidence_relations":"NPC most often occurs in people from parts of Asia, Native America, and North Africa.; Most NPCs are related to Epstein-Barr virus (EBV) infection.; Tobacco and alcohol use are risk factors for head and neck cancer.; Symptoms of NPC may be absent until advanced stage and can be similar to other conditions; common symptoms include enlarged lymph nodes and hearing loss.; Diagnosis of NPC involves medical history, physical exam, imaging (CT, MRI, PET/CT, ultrasound), and biopsy.; Biomarker testing for NPC includes EBV DNA, MSI-H/dMMR, PD-L1, HPV, and tumor mutational burden.; Performance status is considered in NPC treatment planning.; Fertility may be affected by NPC treatment and should be discussed before therapy.; Dental health can be affected by head and neck cancer and its treatment."},
	{"id":"Medical-700264e4","source":"Medical","question":"Rewrite the key recommendations for NPC diagnosis and surveillance as a structured clinical protocol for a multidisciplinary tumor board. Include essential steps for staging, biomarker evaluation, and follow-up planning.","answer":"**Nasopharyngeal Carcinoma (NPC): Multidisciplinary Clinical Protocol**\n\n1. Initial Assessment:\n   - Obtain a comprehensive medical history, including geographic origin (notably Asia, Native America, North Africa), family history, and risk factors such as tobacco and alcohol use, and potential EBV exposure.\n   - Document all current symptoms, including neck mass, hearing loss, nasal obstruction, or other head and neck complaints, recognizing that early NPC may be asymptomatic.\n\n2. Physical Examination:\n   - Perform a thorough head and neck examination, including nasopharyngeal fiberoptic endoscopy and assessment for cervical lymphadenopathy.\n\n3. Diagnostic Workup:\n   - Imaging: Order contrast-enhanced CT and/or MRI of the head and neck to assess the primary tumor and regional lymph nodes. PET/CT should be considered to evaluate for distant metastases. Ultrasound may be used to guide lymph node biopsy.\n   - Biopsy: Obtain tissue diagnosis via biopsy of the nasopharyngeal lesion and/or fine-needle aspiration (FNA), fine-needle biopsy (FNB), or core needle biopsy (CNB) of suspicious lymph nodes. If metastases are suspected, biopsy of metastatic sites should be performed as appropriate.\n\n4. Biomarker Evaluation:\n   - At diagnosis, perform biomarker testing for EBV DNA (plasma or tumor), MSI-H/dMMR, PD-L1, HPV, and tumor mutational burden, as these may inform prognosis and therapeutic decision-making.\n\n5. Staging:\n   - Utilize the AJCC TNM system to classify tumor size (T), nodal involvement (N), and distant metastasis (M).\n   - Categorize disease as resectable, unresectable, locoregional, locally advanced, or metastatic based on imaging and clinical findings.\n\n6. Multidisciplinary Review and Initial Management Planning:\n   - Present the case at a multidisciplinary tumor board to review diagnostic findings and determine optimal management.\n   - Assess performance status to guide treatment selection.\n   - Conduct dental and nutritional evaluations prior to therapy due to the potential impact of treatment on oral health and nutrition.\n   - Discuss fertility preservation options with the patient before initiating therapy, as treatment may affect fertility.\n\n7. Surveillance and Follow-up Planning:\n   - Develop a surveillance plan including periodic physical examinations and imaging (CT, MRI, or PET/CT) as clinically indicated, particularly in the first 5 years post-treatment.\n   - Schedule serial EBV DNA testing for early detection of recurrence.\n   - Adjust follow-up intervals based on individual risk of recurrence and patient-specific factors.\n\nThis protocol ensures a comprehensive, evidence-based approach to the diagnosis, staging, biomarker evaluation, and surveillance of NPC, facilitating coordinated multidisciplinary care.","question_type":"Creative Generation","evidence":"The protocol is for nasopharyngeal carcinoma (NPC).; Initial assessment should include a comprehensive medical history.; Attention should be given to geographic origin, notably Asia, Native America, and North Africa.; Risk factors for NPC include tobacco use, alcohol use, and EBV exposure.; Symptom evaluation should assess for enlarged lymph nodes and hearing loss.; Early NPC may be asymptomatic.; A physical examination and imaging studies should be performed for diagnostic workup.; Imaging studies include CT, MRI, PET/CT, and ultrasound.; Histopathologic confirmation requires a biopsy of the nasopharyngeal lesion or lymph node.; Biomarker testing should include EBV DNA, MSI-H/dMMR, PD-L1, HPV, and tumor mutational burden.; Staging should utilize the AJCC TNM system.; The tumor should be classified based on size, nodal involvement, and distant metastasis.; A multidisciplinary review should assess performance status and dental and nutritional health.; Fertility preservation should be discussed when appropriate.; Surveillance should include periodic imaging and serial EBV DNA testing post-treatment.","evidence_relations":"NPC most often occurs in people from parts of Asia, Native America, and North Africa.; Tobacco and alcohol use are risk factors for head and neck cancer.; Symptoms of NPC may be absent until advanced stage and can be similar to other conditions.; Diagnosis of NPC involves medical history, physical exam, imaging (CT, MRI, PET/CT, ultrasound), and biopsy.; Biomarker testing for NPC includes EBV DNA, MSI-H/dMMR, PD-L1, HPV, and tumor mutational burden.; NPC is staged using the AJCC TNM system, which includes tumor size (T), lymph node involvement (N), and distant metastasis (M).; NPC can be classified as resectable, unresectable, locoregional, locally advanced, or metastatic based on extent of disease.; Performance status is considered in NPC treatment planning.; Imaging tests such as CT, MRI, PET/CT, and ultrasound are used for staging and surveillance.; EBV DNA testing is performed before and after treatment for NPC."},
	{"id":"Medical-cc919ee4","source":"Medical","question":"As a patient education nurse, draft a public health announcement informing high-risk communities about nasopharyngeal carcinoma (NPC). Emphasize risk factors, warning signs, and the importance of early medical evaluation.","answer":"**Public Health Announcement: Protect Yourself Against Nasopharyngeal Carcinoma (NPC)**\n\nNasopharyngeal carcinoma (NPC) is a type of cancer that develops in the nasopharynx, the area behind the nose and above the back of the throat. Certain communitiesincluding people of Asian, Native American, and North African descentare at higher risk, especially if they have been exposed to the Epstein-Barr virus (EBV). Additional risk factors include the use of tobacco and alcohol, which can further increase the likelihood of developing NPC.\n\nNPC often does not cause symptoms until it has reached an advanced stage. However, early warning signs may include a painless lump in the neck (enlarged lymph node), hearing loss, or a feeling of fullness in the ear. Other possible symptoms can be nasal congestion, nosebleeds, or persistent sore throat. Because these symptoms can be mistaken for other common conditions, it is important for individuals with risk factors to be vigilant.\n\nEarly detection greatly improves treatment outcomes. If you notice any of these warning signs or have risk factors for NPC, seek prompt medical evaluation. Diagnosis typically involves a thorough medical history, physical examination, imaging tests (such as CT or MRI scans), and a biopsy of any suspicious tissue. Your healthcare provider may also recommend EBV DNA testing and other assessments as part of the diagnostic process.\n\nTalk to your healthcare provider about your risk factors, the importance of regular checkups, and ways to reduce your risk. Early medical evaluation can make a significant difference in outcomes for nasopharyngeal carcinoma.","question_type":"Creative Generation","evidence":"Nasopharyngeal carcinoma (NPC) affects the area behind the nose and above the back of the throat.; People from Asia, Native America, and North Africa are at higher risk for NPC.; Exposure to the Epstein-Barr virus (EBV) increases the risk of NPC.; Use of tobacco and alcohol can also increase the risk of NPC.; NPC may not cause symptoms until it is advanced.; Warning signs of NPC include lumps in the neck and hearing loss.; Early detection of NPC is important.; Individuals with symptoms or risk factors should seek medical evaluation promptly.; Diagnosis of NPC involves a physical exam, imaging tests, and a biopsy.; Patients should talk to their healthcare provider about reducing risk and the importance of regular checkups.","evidence_relations":"Nasopharyngeal carcinoma (NPC) is a type of head and neck cancer that affects the nasopharynx.; NPC most often occurs in people from parts of Asia, Native America, and North Africa.; Most NPCs are related to Epstein-Barr virus (EBV) infection.; Tobacco and alcohol use are risk factors for head and neck cancer.; Symptoms of NPC may be absent until advanced stage and can be similar to other conditions.; Symptom: Enlarged lymph nodes, hearing loss.; Diagnosis of NPC involves medical history, physical exam, imaging (CT, MRI, PET/CT, ultrasound), and biopsy."},
	{"id":"Medical-d96c57fa","source":"Medical","question":"You are a medical intern tasked with writing a SOAP (Subjective, Objective, Assessment, Plan) note for a patient newly diagnosed with Stage II nasopharyngeal carcinoma. Incorporate relevant history, exam findings, diagnostic results, and initial management steps.","answer":"**S:** 38-year-old male of North African descent presents with a painless neck mass and occasional hearing loss. Reports no other significant symptoms. Past history notable for moderate tobacco and alcohol use.\n\n**O:** Physical exam reveals a 2-cm firm, non-tender lymph node in the left cervical chain. No oral or pharyngeal lesions visible. Imaging with CT and MRI shows a nasopharyngeal mass with ipsilateral lymphadenopathy. Biopsy confirms squamous cell carcinoma. EBV DNA detected in plasma. Performance status is ECOG 1. Dental and nutritional evaluations completed.\n\n**A:** Stage II nasopharyngeal carcinoma (NPC), squamous cell carcinoma subtype, EBV-associated, with cervical lymph node involvement. Risk factors include geographic origin and substance use. Good performance status.\n\n**P:** Multidisciplinary tumor board discussion. Begin definitive therapy per guidelines. Counsel patient regarding potential effects on fertility and oral health. Schedule baseline and surveillance EBV DNA testing. Continue nutritional and speech/swallowing support as indicated.","question_type":"Creative Generation","evidence":"The patient is a 38-year-old male of North African descent.; The patient presents with a painless neck mass.; The patient reports occasional hearing loss.; The patient has no other significant symptoms.; The patient's past history includes moderate tobacco use.; The patient's past history includes alcohol use.; Physical examination reveals a 2-cm firm, non-tender lymph node in the left cervical chain.; No oral or pharyngeal lesions are visible on examination.; Imaging with CT and MRI shows a nasopharyngeal mass with ipsilateral lymphadenopathy.; A biopsy confirms squamous cell carcinoma.; EBV DNA is detected in the patient's plasma.; The patient's performance status is ECOG 1.; Dental and nutritional evaluations have been completed.; The diagnosis is Stage II nasopharyngeal carcinoma (NPC).; The subtype of NPC is squamous cell carcinoma.; The NPC is EBV-associated with cervical lymph node involvement.; The patient has a good performance status.; A multidisciplinary tumor board discussion is planned.; Definitive therapy will begin per guidelines.; The patient will be counseled regarding potential effects on fertility and oral health.; Baseline and surveillance EBV DNA testing will be scheduled.; Nutritional and speech/swallowing support will continue as indicated.","evidence_relations":"NPC most often occurs in people from parts of Asia, Native America, and North Africa.; Tobacco and alcohol use are risk factors for head and neck cancer.; Symptoms of NPC may be absent until advanced stage and can be similar to other conditions; common symptoms include enlarged lymph nodes and hearing loss.; Diagnosis of NPC involves medical history, physical exam, imaging (CT, MRI, PET/CT, ultrasound), and biopsy.; Biomarker testing for NPC includes EBV DNA.; NPC is staged using the AJCC TNM system, which includes tumor size (T), lymph node involvement (N), and distant metastasis (M).; Performance status is considered in NPC treatment planning.; Dental health can be affected by head and neck cancer and its treatment.; Fertility may be affected by NPC treatment and should be discussed before therapy.; Nutrition assessment and speech and swallowing assessment are recommended in diagnostic method."},
	{"id":"Medical-caab7a58","source":"Medical","question":"You are a radiation oncologist preparing an initial case summary for a patient with locally advanced, unresectable nasopharyngeal carcinoma (NPC). Summarize the diagnostic findings, relevant biomarkers, staging, and multidisciplinary considerations for the tumor board.","answer":"The patient is a 52-year-old male who presents with a large nasopharyngeal mass and multiple enlarged cervical lymph nodes. Diagnostic imaging with MRI and PET/CT reveals extensive locoregional disease involving the nasopharynx and regional lymph nodes, but no evidence of distant metastasis. Histopathological examination of the biopsy confirms squamous cell carcinoma, the most common subtype of nasopharyngeal carcinoma (NPC). Biomarker analysis demonstrates elevated Epstein-Barr virus (EBV) DNA levels and positive PD-L1 expression, both of which are relevant for prognosis and potential therapeutic options. According to the American Joint Committee on Cancer (AJCC) TNM staging system, the tumor is classified as locally advanced and unresectable. The patient's performance status is ECOG 2, which is an important consideration for treatment planning. Pre-treatment assessments, including dental and nutritional evaluations, have been completed to address potential complications from therapy. The patient has also received counseling regarding the possible impact of treatment on fertility. For optimal management, multidisciplinary input is recommended, including medical oncology for systemic therapy, speech and swallowing therapy for functional support, and comprehensive supportive care.","question_type":"Creative Generation","evidence":"The patient is a 52-year-old male.; The patient presents with a large nasopharyngeal mass.; The patient has multiple enlarged cervical lymph nodes.; Imaging with MRI and PET/CT demonstrates extensive locoregional disease.; There is no distant metastasis observed.; A biopsy confirms the squamous cell carcinoma subtype of NPC.; Biomarker analysis reveals elevated EBV DNA levels.; Biomarker analysis shows positive PD-L1 expression.; Staging per AJCC TNM system classifies the tumor as locally advanced and unresectable.; The patient's performance status is ECOG 2.; Pre-treatment dental and nutritional assessments have been completed.; The patient has been counseled about potential fertility impacts of therapy.; Multidisciplinary input from medical oncology, speech/swallowing therapy, and supportive care is recommended.","evidence_relations":"Squamous cell carcinoma (SCC) is the most common subtype of nasopharyngeal cancer.; Diagnosis of NPC involves medical history, physical exam, imaging (CT, MRI, PET/CT, ultrasound), and biopsy.; Biomarker testing for NPC includes EBV DNA, MSI-H/dMMR, PD-L1, HPV, and tumor mutational burden.; NPC is staged using the AJCC TNM system, which includes tumor size (T), lymph node involvement (N), and distant metastasis (M).; NPC can be classified as resectable, unresectable, locoregional, locally advanced, or metastatic based on extent of disease.; Performance status is considered in NPC treatment planning.; Dental health can be affected by head and neck cancer and its treatment.; Fertility may be affected by NPC treatment and should be discussed before therapy.; Nutrition assessment and speech and swallowing assessment are recommended in diagnostic method."},
	{"id":"Medical-048eef0e","source":"Medical","question":"You are a colorectal surgeon receiving a referral for a 45-year-old patient newly diagnosed with Stage 3 colon adenocarcinoma. Based on the clinical practice guideline, draft a surgical and perioperative management plan, including diagnostic confirmation, surgical intervention, adjuvant therapy, biomarker testing, and postoperative surveillance.","answer":"Upon referral of the patient with Stage 3 colon adenocarcinoma, I would first confirm the diagnosis and staging with a colonoscopy and biopsy, supplemented by CT scan with contrast to assess for nodal involvement and distant metastases. Preoperative blood tests, including CBC, chemistry profile, and CEA, would be obtained for baseline assessment. All colon cancers should undergo testing for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H) to guide postoperative therapy. The primary surgical approach would be a colectomy to remove the cancerous segment of the colon, with en bloc resection of adjacent lymph nodes. Intraoperatively, if primary anastomosis is not possible, a colostomy may be required. After recovery, adjuvant chemotherapytypically FOLFOX or CAPEOXshould be initiated. Postoperative surveillance will include regular colonoscopy, CEA testing, and CT scans. The patient should also be counseled on genetic risk factors and offered referral to genetic counseling if appropriate.","question_type":"Creative Generation","evidence":"The patient is 45 years old.; The patient has been newly diagnosed with Stage 3 colon adenocarcinoma.; The diagnosis and staging will be confirmed with a colonoscopy and biopsy.; A CT scan with contrast will be used to assess for nodal involvement and distant metastases.; Preoperative blood tests will include CBC, chemistry profile, and CEA.; All colon cancers should undergo testing for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H).; Testing for dMMR or MSI-H will guide postoperative therapy.; The primary surgical approach will be a colectomy to remove the cancerous segment of the colon.; En bloc resection of adjacent lymph nodes will be performed.; If primary anastomosis is not possible, a colostomy may be required.; Adjuvant chemotherapy, typically FOLFOX or CAPEOX, should be initiated after recovery.; Postoperative surveillance will include regular colonoscopy, CEA testing, and CT scans.; The patient should be counseled on genetic risk factors.; Referral to genetic counseling should be offered if appropriate.","evidence_relations":"Stage 3 colon cancer involves spread to nearby lymph nodes or tumor deposits.; Colonoscopy is the recommended diagnostic method for colon cancer, with polypectomy performed for removal of polyps.; CT with contrast is the main imaging test for staging and surveillance.; All colon cancers should be tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H).; Colectomy is surgery to remove the cancerous part of the colon.; Colostomy diverts stool through an abdominal stoma if reconnection is not possible.; Chemotherapy is recommended after colectomy for all stage 3 and some stage 2 colon cancers.; Surveillance after treatment includes colonoscopy, CEA testing, and CT scans.; Blood tests (CBC, chemistry profile, CEA) are recommended for initial testing."},
	{"id":"Medical-80b6ffc1","source":"Medical","question":"Rewrite the clinical management of a young adult with newly diagnosed colon cancer into a formal discharge summary, ensuring inclusion of diagnostic workup, staging, biomarker assessment, surgical and adjuvant treatment, and fertility preservation counseling as per guidelines.","answer":"Discharge Summary:\n\nPatient: [Name Redacted]\nAge: 32\nDiagnosis: Stage 2 colon adenocarcinoma\n\nHospital Course:\nThe patient presented with rectal bleeding and was diagnosed with colon adenocarcinoma following colonoscopy and biopsy. CT scan with contrast confirmed stage 2 disease with no lymph node or distant organ involvement. Baseline laboratory evaluation included CBC, chemistry profile, and CEA. Tumor tissue was tested for mismatch repair deficiency (dMMR) and found to be dMMR/MSI-H. The patient underwent segmental colectomy with primary anastomosis. Given dMMR/MSI-H status, adjuvant immunotherapy with a checkpoint inhibitor was recommended over standard chemotherapy. The patient received counseling regarding the risk of infertility associated with treatment and was offered sperm banking prior to therapy. Discharge instructions included scheduling for follow-up colonoscopy, CEA testing, and CT imaging as part of surveillance.","question_type":"Creative Generation","evidence":"The patient is 32 years old.; The patient has been diagnosed with Stage 2 colon adenocarcinoma.; The patient presented with rectal bleeding.; The diagnosis of colon adenocarcinoma was made following colonoscopy and biopsy.; A CT scan with contrast confirmed stage 2 disease.; There is no lymph node or distant organ involvement.; Baseline laboratory evaluation included CBC, chemistry profile, and CEA.; Tumor tissue was tested for mismatch repair deficiency (dMMR).; The tumor was found to be dMMR/MSI-H.; The patient underwent segmental colectomy with primary anastomosis.; Adjuvant immunotherapy with a checkpoint inhibitor was recommended due to dMMR/MSI-H status.; The patient received counseling regarding the risk of infertility associated with treatment.; The patient was offered sperm banking prior to therapy.; Discharge instructions included scheduling for follow-up colonoscopy, CEA testing, and CT imaging as part of surveillance.","evidence_relations":"Colonoscopy is the recommended diagnostic method for colon cancer.; Stage 2 colon cancer invades or passes fourth layer, no lymph node involvement.; CT with contrast is the main imaging test for staging and surveillance.; Blood tests (CBC, chemistry profile, CEA) are recommended for initial testing.; All colon cancers should be tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H).; Immunotherapy with checkpoint inhibitors is preferred for dMMR/MSI-H cancers.; Colectomy is surgery to remove the cancerous part of the colon.; Young adults should be counseled about fertility risks and preservation options before treatment.; Surveillance after treatment includes colonoscopy, CEA testing, and CT scans."},
	{"id":"Medical-cf4e8f59","source":"Medical","question":"Imagine you are a genetic counselor receiving a patient with a new diagnosis of colon adenocarcinoma and a family history of colorectal cancer. Draft a counseling summary addressing inherited syndromes, genetic testing recommendations, implications for at-risk relatives, and surveillance strategies.","answer":"As a genetic counselor, I would inform the patient that a family history of colorectal cancer increases the likelihood of inherited cancer syndromes, most commonly Lynch syndrome and familial adenomatous polyposis (FAP). I would recommend genetic testing for germline mutations in mismatch repair (MMR) genes associated with Lynch syndrome, as well as APC gene testing if FAP is suspected, in accordance with current guidelines. Identifying an inherited syndrome is important not only for the patient's management but also for at-risk relatives, who should be offered predictive genetic testing and, if positive, appropriate surveillance. For individuals with Lynch syndrome, earlier and more frequent colonoscopic surveillance is recommended to detect new or recurrent cancers at an early stage. I would discuss the implications of a positive genetic test, including the risk of other associated cancers, and provide information on the clinical features, risks, and recommended management strategies for both Lynch syndrome and FAP. Additionally, I would coordinate referrals for genetic testing, facilitate communication with family members regarding their potential risk, and outline surveillance strategies tailored to the specific syndrome identified.","question_type":"Creative Generation","evidence":"A family history of colorectal cancer increases the risk of inherited cancer syndromes.; Inherited cancer syndromes include Lynch syndrome and familial adenomatous polyposis (FAP).; Genetic testing for mismatch repair gene mutations associated with Lynch syndrome is recommended.; Genetic testing for APC gene mutations is recommended if FAP is suspected.; Identification of an inherited syndrome has implications for the patient and at-risk relatives.; At-risk relatives should be offered predictive testing.; At-risk relatives should be offered appropriate surveillance.; Regular colonoscopy at earlier and more frequent intervals is advised for patients with Lynch syndrome.; Information on the signs, risks, and management of Lynch syndrome and FAP will be provided.; Referrals for genetic testing and surveillance will be coordinated as per guidelines.","evidence_relations":"Lynch syndrome and familial adenomatous polyposis (FAP) are inherited syndromes increasing colon cancer risk.; Family history of colorectal cancer is a risk factor.; All colon cancers should be tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H).; MMR gene mutations are genetic alterations associated with inherited syndromes.; First-degree relative with colorectal cancer is a recognized risk factor.; Surveillance after treatment includes colonoscopy.; Inherited syndromes include Lynch syndrome and FAP."},
	{"id":"Medical-ec48f89d","source":"Medical","question":"Transform the following clinical recommendations into a public health advisory for primary care providers: Highlight the importance of early detection, risk stratification, and guideline-based management of colon cancer.","answer":"Public Health Advisory for Primary Care Providers: Early Detection and Management of Colon Cancer\n\nColon cancer is a leading cause of cancer-related morbidity and mortality. Early detection through colonoscopy and removal of precancerous polyps (adenomas) significantly reduces cancer risk. Providers should identify individuals with risk factors, such as a family history of colorectal cancer or inherited syndromes (Lynch syndrome, FAP), and refer them for genetic counseling and earlier surveillance. All patients diagnosed with colon cancer should have their tumors tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H), as these biomarkers guide therapy. Post-treatment, ongoing surveillance with colonoscopy, CEA testing, and CT scans is essential to detect recurrence. Discuss fertility preservation options with young adults prior to initiating therapy.","question_type":"Creative Generation","evidence":"Colon cancer is a leading cause of cancer-related morbidity and mortality.; Early detection through colonoscopy significantly reduces cancer risk.; Removal of precancerous polyps (adenomas) is important for cancer prevention.; Providers should identify individuals with risk factors for colon cancer.; Risk factors include a family history of colorectal cancer and inherited syndromes.; Individuals with risk factors should be referred for genetic counseling.; Individuals with risk factors should be referred for earlier surveillance.; All patients diagnosed with colon cancer should have their tumors tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H).; Testing for dMMR or MSI-H guides therapy.; Ongoing surveillance with colonoscopy, CEA testing, and CT scans is essential post-treatment.; Fertility preservation options should be discussed with young adults prior to initiating therapy.","evidence_relations":"Most colon cancers start in polyps, especially adenomas.; Polypectomy removes polyps during colonoscopy.; Family history of colorectal cancer is a risk factor.; Lynch syndrome and familial adenomatous polyposis (FAP) are inherited syndromes increasing colon cancer risk.; All colon cancers should be tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H).; Surveillance after treatment includes colonoscopy, CEA testing, and CT scans.; Young adults should be counseled about fertility risks and preservation options before treatment."},
	{"id":"Medical-5b2ade97","source":"Medical","question":"You are a medical oncologist asked to summarize the evidence-based first-line treatment options for metastatic (Stage 4) colon cancer, including biomarker-driven therapy, surgical considerations, and palliative care integration.","answer":"The first-line treatment of metastatic (Stage 4) colon cancer begins with confirmation of distant metastases using contrast-enhanced CT imaging. All patients should have their tumors tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H), as these biomarkers guide therapy selection. For patients with dMMR/MSI-H tumors, immunotherapy with checkpoint inhibitors such as pembrolizumab or nivolumab (with or without ipilimumab) is preferred due to superior efficacy. For patients with proficient mismatch repair (pMMR) or microsatellite stable (MSS) tumors, standard first-line systemic chemotherapy regimens include FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin) or CAPEOX (capecitabine and oxaliplatin). Surgical resection of the primary tumor or metastatic lesions may be considered in select patients with limited, resectable disease, particularly if it may improve survival or alleviate symptoms. Early integration of palliative care is recommended to manage symptoms, support quality of life, and address psychosocial needs. Ongoing surveillance with imaging and carcinoembryonic antigen (CEA) testing is essential to monitor treatment response and detect disease progression.","question_type":"Creative Generation","evidence":"For Stage 4 (metastatic) colon cancer, distant metastases must be confirmed with contrast-enhanced CT imaging.; All tumors must be tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H).; Immunotherapy with checkpoint inhibitors is preferred for dMMR/MSI-H cancers.; Examples of checkpoint inhibitors include pembrolizumab and nivolumab.; Systemic chemotherapy regimens such as FOLFOX or CAPEOX are recommended for pMMR/MSS tumors.; Surgical resection of the primary tumor or metastases may be considered for select patients.; Palliative care should be integrated early to address symptoms.; Palliative care aims to improve quality of life.; Surveillance with imaging and CEA testing is essential for monitoring treatment response.","evidence_relations":"Stage 4 colon cancer has spread to distant organs (commonly liver or lungs).; CT with contrast is the main imaging test for staging and surveillance.; All colon cancers should be tested for mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H).; Immunotherapy with checkpoint inhibitors is preferred for dMMR/MSI-H cancers.; pMMR/MSS cancers are treated with chemotherapy.; FOLFOX and CAPEOX are recommended chemotherapy regimens.; Colectomy is surgery to remove the cancerous part of the colon.; Surveillance after treatment includes colonoscopy, CEA testing, and CT scans."},
	{"id":"Medical-9d9b1ed1","source":"Medical","question":"Imagine you are a gastroenterologist evaluating a patient newly diagnosed with esophageal cancer. Write a comprehensive case summary that includes cancer subtype differentiation, staging considerations, diagnostic workup, and initial factors for treatment planning, referencing the relevant clinical practice guidelines.","answer":"The patient presents with a new diagnosis of esophageal cancer. A comprehensive case summary begins with differentiation of the histological subtype: esophageal squamous cell carcinoma, which arises from the squamous cells lining the upper and middle esophagus, and esophageal adenocarcinoma, which originates from mucus-secreting cells typically in the lower esophagus and is often associated with Barrett esophagus. Accurate subtype identification is essential for guiding management. Staging is a critical next step and is based on the extent of tumor invasion (T), involvement of regional lymph nodes (N), and presence of distant metastases (M), following established staging systems such as the AJCC. Early-stage disease is confined to the esophagus without lymph node involvement; locoregional disease involves invasion into the esophageal wall and/or spread to regional lymph nodes or adjacent organs; metastatic disease is defined by distant spread, commonly to the liver, lungs, bone, or brain. The diagnostic workup should include a thorough medical history, blood tests, imaging studies (CT, PET scans), and endoscopic evaluation with biopsy for histopathological confirmation. Biomarker and genetic risk testing are recommended to identify potential therapeutic targets. For tumors at the esophagogastric junction, the Siewert classification is used to further refine staging and inform treatment strategy. Initial treatment planning should consider cancer subtype, anatomical location, and stage, as well as the patient's nutritional status and performance status, in accordance with current clinical practice guidelines. Multidisciplinary input is essential to optimize outcomes and tailor therapy to individual patient needs.","question_type":"Creative Generation","evidence":"The patient has a new diagnosis of esophageal cancer.; The first step is to determine the histological subtype of the cancer.; Esophageal squamous cell carcinoma originates from the squamous cells of the upper and middle esophagus.; Esophageal adenocarcinoma arises from the mucus-secreting cells in the lower esophagus.; Barrett esophagus is often associated with esophageal adenocarcinoma.; Staging is crucial for esophageal cancer.; Early-stage disease is confined to the esophagus without lymph node involvement.; Locoregional disease involves invasion of the esophageal wall and/or spread to regional lymph nodes or adjacent organs.; Metastatic disease is defined by distant spread to organs such as the liver, lung, bone, or brain.; The diagnostic workup includes blood tests.; Imaging studies such as CT or PET scans are part of the diagnostic workup.; Endoscopic evaluation with biopsy is necessary for histopathological confirmation.; Biomarker testing is included in the diagnostic workup.; Assessment of genetic risk factors is part of the diagnostic workup.; Siewert classification assists in staging tumors at the esophagogastric junction.; Treatment planning is based on cancer type, anatomical location, and stage.; The patient's nutritional status and performance are considered in treatment planning.","evidence_relations":"Esophageal squamous cell carcinoma starts in squamous cells of the esophagus.; Esophageal adenocarcinoma starts in mucus-secreting cells of the esophagus.; Barrett esophagus is a precancerous condition that increases risk for esophageal adenocarcinoma.; Early-stage esophageal cancer is contained within the esophagus and not in lymph nodes.; Diagnosis involves blood tests, imaging tests, endoscopy, biopsy, biomarker testing, and genetic risk testing.; Siewert types are used to stage tumors at the esophagogastric junction.; Treatment planning is based on cancer type, location, and stage."},
	{"id":"Medical-09c35fc8","source":"Medical","question":"You are a medical oncologist preparing a multidisciplinary treatment plan for a patient diagnosed with locoregional esophageal adenocarcinoma at the esophagogastric junction. Detail your diagnostic confirmation steps, staging process, and key considerations for therapy selection, using the guideline.","answer":"For this case of locoregional esophageal adenocarcinoma at the esophagogastric junction, I would initiate comprehensive diagnostic confirmation with endoscopic biopsy to determine histology, supported by blood tests and imaging studies to assess extent of disease. The Siewert classification will be applied for precise staging at the esophagogastric junction. The staging process distinguishes locoregional disease, where the tumor has invaded the esophageal wall and/or spread to regional lymph nodes or nearby organs, from early-stage or metastatic disease. Biomarker and genetic risk testing will be included to identify potential therapeutic targets. Nutritional assessment and evaluation of performance status are essential components of the pre-treatment workup. The treatment plan will be tailored based on cancer type (adenocarcinoma), anatomical location (esophagogastric junction), and locoregional stage, in accordance with current multidisciplinary guidelines.","question_type":"Creative Generation","evidence":"The patient has locoregional esophageal adenocarcinoma at the esophagogastric junction.; Comprehensive diagnostic confirmation begins with an endoscopic biopsy to determine histology.; Blood tests and imaging studies are used to assess the extent of the disease.; Siewert classification is applied for precise staging at the esophagogastric junction.; The staging process distinguishes locoregional disease from early-stage or metastatic disease.; Locoregional disease involves tumor invasion of the esophageal wall and/or spread to regional lymph nodes or nearby organs.; Biomarker and genetic risk testing are included to identify potential therapeutic targets.; Nutritional assessment is essential in the pre-treatment workup.; Evaluation of performance status is an important component of the pre-treatment workup.; The treatment plan is tailored based on cancer type, anatomical location, and locoregional stage.","evidence_relations":"Esophageal adenocarcinoma starts in mucus-secreting cells of the esophagus.; Locoregional esophageal cancer has invaded the esophagus wall and/or spread to nearby lymph nodes or organs.; Siewert types are used to stage tumors at the esophagogastric junction.; Diagnosis involves blood tests, imaging tests, endoscopy, biopsy, biomarker testing, and genetic risk testing.; Treatment planning is based on cancer type, location, and stage.; Nutritional assessment and performance status are part of the diagnostic method."},
	{"id":"Medical-bc7d17ab","source":"Medical","question":"Transform the clinical facts into a formal discharge summary for a patient with metastatic esophageal squamous cell carcinoma, referencing relevant staging, diagnostic, and treatment planning considerations from the guideline.","answer":"**Discharge Summary**\n\nDiagnosis: Metastatic esophageal squamous cell carcinoma\n\nHospital Course: The patient was admitted for evaluation and management of esophageal cancer. The diagnostic workup included comprehensive blood tests, cross-sectional imaging with CT and PET scans, endoscopic examination, and tissue biopsy. Pathology confirmed squamous cell carcinoma originating in the middle esophagus, which is a typical anatomical site for this histologic subtype. Staging investigations demonstrated metastatic disease with involvement of the liver and lung, consistent with advanced (stage IV) esophageal cancer. Biomarker and genetic risk testing were performed to guide potential targeted therapies and further inform prognosis. Multidisciplinary tumor board review was conducted, and treatment planning considered the cancer type, anatomical location, extent of metastatic spread, and the patient's performance status. Given the metastatic stage, palliative systemic therapy was recommended as per current guidelines. Nutritional assessment was performed due to the patient's risk of dysphagia and weight loss, and supportive care measures were initiated. The patient was discharged in stable condition with a coordinated follow-up plan for oncology evaluation, ongoing supportive care, and symptom management.","question_type":"Creative Generation","evidence":"The patient has metastatic esophageal squamous cell carcinoma.; The patient was admitted for evaluation and management of esophageal cancer.; The diagnostic workup included blood tests.; Imaging studies such as CT and PET scans were part of the diagnostic workup.; Endoscopic examination and biopsy confirmed squamous cell carcinoma of the esophagus.; Staging revealed metastatic disease with involvement of the liver and lung.; Biomarker and genetic risk testing were performed.; The tumor originated in the middle esophagus.; Multidisciplinary discussions recommended palliative systemic therapy.; Palliative therapy is based on the metastatic stage, primary tumor type, and patient performance status.; A nutritional assessment was conducted due to the risk of dysphagia and weight loss.; The patient was discharged with a follow-up plan for oncology and supportive care.","evidence_relations":"Esophageal squamous cell carcinoma starts in squamous cells of the esophagus.; Metastatic esophageal cancer has spread to distant organs such as liver, lung, bone, and brain.; Diagnosis involves blood tests, imaging tests, endoscopy, biopsy, biomarker testing, and genetic risk testing.; Treatment planning is based on cancer type, location, and stage.; Nutritional assessment and performance status are part of the diagnostic method.; Anatomical location for squamous cell carcinoma includes the middle esophagus."},
	{"id":"Medical-9b2a1d38","source":"Medical","question":"As a primary care physician, draft a referral note to an oncology center for a patient with Barrett esophagus and new-onset dysphagia, incorporating risk stratification and diagnostic recommendations from the guidelines.","answer":"**Referral Note**\n\nPatient: [Name Redacted]\nDOB: [Redacted]\n\nReason for Referral: Barrett esophagus with new-onset dysphagia\n\nSummary: The patient has a history of Barrett esophagus, a recognized precancerous condition for esophageal adenocarcinoma. He now presents with progressive dysphagia. Given the increased risk of malignant transformation, prompt evaluation for possible esophageal cancer is warranted. I recommend a comprehensive diagnostic workup including endoscopy with biopsy, imaging studies, blood tests, biomarker testing, and genetic risk assessment. Please consider staging and Siewert classification if a lesion is identified at the esophagogastric junction. Nutritional assessment should be performed due to risk of malnutrition. Thank you for your evaluation and management.","question_type":"Creative Generation","evidence":"The patient has Barrett esophagus and new-onset dysphagia.; Barrett esophagus is a recognized precancerous condition for esophageal adenocarcinoma.; The patient presents with progressive dysphagia.; Prompt evaluation for possible esophageal cancer is warranted due to increased risk of malignant transformation.; A comprehensive diagnostic workup is recommended.; The diagnostic workup should include endoscopy with biopsy.; Imaging studies and blood tests are part of the diagnostic recommendations.; Biomarker testing and genetic risk assessment should be included.; Staging and Siewert classification should be considered if a lesion is identified at the esophagogastric junction.; Nutritional assessment should be performed due to the risk of malnutrition.","evidence_relations":"Barrett esophagus is a precancerous condition that increases risk for esophageal adenocarcinoma.; Diagnosis involves blood tests, imaging tests, endoscopy, biopsy, biomarker testing, and genetic risk testing.; Siewert types are used to stage tumors at the esophagogastric junction.; Treatment planning is based on cancer type, location, and stage.; Nutritional assessment is part of the diagnostic method."},
	{"id":"Medical-45390bd2","source":"Medical","question":"Rewrite the core clinical recommendations into a public health advisory aimed at increasing awareness of esophageal cancer risk factors, early detection, and diagnostic pathways.","answer":"**Public Health Advisory: Esophageal Cancer Awareness and Early Detection**\n\nEsophageal cancer arises from the inner lining of the esophagus and may develop as either squamous cell carcinoma or adenocarcinoma. Risk factors include the presence of Barrett esophagus, a precancerous condition that increases the likelihood of adenocarcinoma. Early-stage esophageal cancer is often asymptomatic and confined to the esophagus, while advanced stages may involve spread to lymph nodes or distant organs such as the liver, lungs, bones, and brain. Early detection is critical and involves blood tests, imaging, endoscopy, biopsy, and assessment of biomarkers and genetic risk. If symptoms such as persistent difficulty swallowing occur, prompt medical evaluation is advised. Comprehensive treatment planning requires accurate cancer type, location, and stage determination. Public awareness and timely screening can improve outcomes for those at risk.","question_type":"Creative Generation","evidence":"Esophageal cancer arises from the inner lining of the esophagus.; Esophageal cancer may develop as either squamous cell carcinoma or adenocarcinoma.; Risk factors for esophageal cancer include Barrett esophagus.; Barrett esophagus increases the likelihood of adenocarcinoma.; Early-stage esophageal cancer is often asymptomatic and confined to the esophagus.; Advanced stages of esophageal cancer may involve spread to lymph nodes or distant organs.; Distant organs affected may include the liver, lungs, bones, and brain.; Early detection of esophageal cancer is critical.; Early detection involves blood tests, imaging, endoscopy, biopsy, and assessment of biomarkers and genetic risk.; Symptoms such as persistent difficulty swallowing should prompt medical evaluation.; Comprehensive treatment planning requires accurate determination of cancer type, location, and stage.; Public awareness and timely screening can improve outcomes for those at risk.","evidence_relations":"Esophageal cancer starts in the inner lining of the esophagus.; Barrett esophagus is a precancerous condition that increases risk for esophageal adenocarcinoma.; Early-stage esophageal cancer is contained within the esophagus and not in lymph nodes.; Metastatic esophageal cancer has spread to distant organs such as liver, lung, bone, and brain.; Diagnosis involves blood tests, imaging tests, endoscopy, biopsy, biomarker testing, and genetic risk testing.; Treatment planning is based on cancer type, location, and stage."},
	{"id":"Medical-dca8ac49","source":"Medical","question":"Imagine you are a hematopathologist receiving a referral for a 32-year-old male with a large mediastinal mass and supraclavicular lymphadenopathy. Based on the provided clinical practice guideline, write a diagnostic summary that outlines the differential diagnosis, key histopathological features, and the necessary steps to confirm mediastinal gray zone lymphoma (MGZL).","answer":"Diagnostic Summary:\n\nThis 32-year-old male presents with a large mediastinal mass and supraclavicular lymphadenopathy. The differential diagnosis includes mediastinal gray zone lymphoma (MGZL), primary mediastinal B-cell lymphoma (PMBL), and classical Hodgkin lymphoma (CHL), as these entities share overlapping clinical and histopathological features. MGZL is characterized by large tumor cells that may vary in size and often resemble Reed-Sternberg cellslarge, abnormal lymphocytes that may contain more than one nucleus. Key histopathological features to assess include the presence and morphology of Reed-Sternberg-like cells, the overall cellular architecture, and features intermediate between PMBL and CHL. To confirm MGZL, a thorough histological evaluation by an expert hematopathologist is essential, supported by immunophenotyping with a comprehensive panel of markers to identify characteristics of both PMBL and CHL. Accurate diagnosis is critical, as MGZL is distinct from other mediastinal lymphomas and requires tailored management. The diagnostic process should also exclude extra-mediastinal disease, which would favor a diagnosis of diffuse large B-cell lymphoma, not otherwise specified (DLBCL-NOS). The final diagnosis will inform treatment planning, which typically involves chemotherapy, with the addition of rituximab if tumor cells express CD20, and consideration of involved-site radiation therapy (ISRT) for localized disease.","question_type":"Creative Generation","evidence":"The patient is a 32-year-old male with a large mediastinal mass and supraclavicular lymphadenopathy.; The differential diagnosis includes mediastinal gray zone lymphoma (MGZL).; Other differential diagnoses include primary mediastinal B-cell lymphoma (PMBL) and classical Hodgkin lymphoma (CHL).; The differential diagnoses are based on overlapping clinical and histopathological features.; Histological evaluation is essential for diagnosis.; Reed-Sternberg cells are important in the histological evaluation.; Diagnosis of MGZL requires an expert hematopathologist review.; Immunophenotyping and a comprehensive panel of markers should be employed.; The final diagnosis will guide appropriate therapy.; Therapy may include chemotherapy with or without rituximab.","evidence_relations":"MGZL is characterized by a large mediastinal mass.; MGZL commonly affects individuals aged 20 to 40 years, assigned male at birth.; Gray zone lymphomas have overlapping features of primary mediastinal B-cell lymphoma (PMBL) and Hodgkin lymphoma (HL).; Reed-Sternberg cells are characteristic histopathological features in MGZL.; Diagnosis of MGZL requires expert hematopathologist review."},
	{"id":"Medical-e89fa155","source":"Medical","question":"You are an oncology fellow tasked with constructing an initial treatment plan for a patient newly diagnosed with localized mediastinal gray zone lymphoma (MGZL). Integrate the guidelines recommendations regarding therapeutic modalities and patient characteristics.","answer":"Initial Treatment Plan:\n\nFor this patient with newly diagnosed, localized mediastinal gray zone lymphoma (MGZL), the recommended initial treatment is systemic chemotherapy, which serves as the cornerstone of therapy. If the tumor cells express CD20, rituximab may be added to the chemotherapy regimen to form chemoimmunotherapy, as this approach has been associated with improved outcomes in similar lymphomas. Given the localized presentation, involved-site radiation therapy (ISRT) should be considered following systemic therapy to enhance local disease control. This treatment strategy is supported by the patient's age (commonly 2040 years) and the presence of a large mediastinal mass, which are characteristic features of MGZL. Management should involve a multidisciplinary team, including medical and radiation oncology, and regular assessment of treatment response. Referral to a cancer center with expertise in gray zone lymphomas and consideration of clinical trial enrollment may also be appropriate.","question_type":"Creative Generation","evidence":"The patient has newly diagnosed, localized mediastinal gray zone lymphoma (MGZL).; Chemotherapy is recommended as the foundation of treatment.; Rituximab may be added to create a chemoimmunotherapy regimen.; The addition of rituximab is based on current evidence for improved outcomes.; Involved-site radiation therapy (ISRT) should be considered as an adjunct to systemic therapy.; The patient's age is within the typical 2040 year range.; Mediastinal involvement supports the treatment approach.; Multidisciplinary collaboration with radiation oncology is crucial.; Regular assessment of treatment response is important.","evidence_relations":"MGZL is usually treated with chemotherapy.; Rituximab may be added to chemotherapy for chemoimmunotherapy.; Involved-site radiation therapy (ISRT) may be added in localized MGZL.; MGZL commonly affects individuals aged 20 to 40 years, assigned male at birth.; MGZL is characterized by a large mediastinal mass."},
	{"id":"Medical-de2ed9e3","source":"Medical","question":"Transform the core clinical and pathological features of mediastinal gray zone lymphoma (MGZL) into a formal referral letter from a primary care physician to a hematology specialist.","answer":"Referral Letter:\n\nDear Hematology Specialist,\n\nI am referring a 28-year-old male who presents with a rapidly enlarging mediastinal mass and supraclavicular lymphadenopathy. Imaging studies confirm a bulky mediastinal tumor. Histopathological examination has revealed the presence of Reed-Sternberg cells. Given the overlap of features between primary mediastinal B-cell lymphoma (PMBL) and Hodgkin lymphoma (HL), I am seeking your expert evaluation for possible mediastinal gray zone lymphoma (MGZL). I recommend expert hematopathologist review to establish a definitive diagnosis and guide management, including consideration of chemoimmunotherapy and potential involved-site radiation therapy.\n\nSincerely,\n[Referring Physician]","question_type":"Creative Generation","evidence":"The patient is a 28-year-old male with a rapidly enlarging mediastinal mass and supraclavicular lymphadenopathy.; Imaging studies confirm a bulky mediastinal tumor.; Histopathological examination revealed the presence of Reed-Sternberg cells.; There is an overlap of features between primary mediastinal B-cell lymphoma (PMBL) and Hodgkin lymphoma (HL).; An expert evaluation is sought for possible mediastinal gray zone lymphoma (MGZL).; Expert hematopathologist review is recommended to establish a definitive diagnosis.; Management may include consideration of chemoimmunotherapy.; Involved-site radiation therapy may also be considered.","evidence_relations":"MGZL is characterized by a large mediastinal mass.; Lymph nodes above the collar bone (supraclavicular) may be involved.; Reed-Sternberg cells are characteristic histopathological features in MGZL.; Gray zone lymphomas have overlapping features of primary mediastinal B-cell lymphoma (PMBL) and Hodgkin lymphoma (HL).; Diagnosis of MGZL requires expert hematopathologist review."},
	{"id":"Medical-6956692c","source":"Medical","question":"Rewrite the main findings and recommendations regarding non-mediastinal gray zone lymphoma into a discharge summary for a 68-year-old patient diagnosed with this entity, highlighting clinical presentation, diagnostic process, and treatment considerations.","answer":"Discharge Summary:\n\nPatient: [Name], 68-year-old\nDiagnosis: Non-mediastinal gray zone lymphoma\n\nClinical Presentation:\nThe patient, a 68-year-old, presented with generalized lymphadenopathy and evidence of both bone marrow and extranodal involvement, consistent with advanced-stage disease. Notably, there was no mediastinal mass identified, which distinguishes this presentation from mediastinal gray zone lymphoma.\n\nDiagnostic Process:\nDiagnosis was established through histopathological and immunophenotypic evaluation, which revealed features characteristic of gray zone lymphoma. The absence of mediastinal involvement, combined with advanced-stage findings such as bone marrow and extranodal disease, supported the diagnosis of non-mediastinal gray zone lymphoma. According to current guidelines, cases with extra-mediastinal disease are classified and managed as diffuse large B-cell lymphoma, not otherwise specified (DLBCL-NOS).\n\nTreatment Considerations:\nNon-mediastinal gray zone lymphomas predominantly affect older adults and are associated with a higher incidence of bone marrow and extranodal involvement compared to mediastinal cases. These lymphomas often present at an advanced stage. The recommended management aligns with treatment protocols for DLBCL-NOS, which typically involve systemic chemotherapy. The patient will be referred for systemic chemotherapy as per DLBCL-NOS protocols. Ongoing follow-up will focus on monitoring response in both marrow and extranodal sites. Consideration of supportive care and advance care planning is also recommended, given the advanced stage of disease.","question_type":"Creative Generation","evidence":"The patient is a 68-year-old diagnosed with non-mediastinal gray zone lymphoma.; The patient presented with generalized lymphadenopathy.; There is evidence of bone marrow and extranodal involvement.; No mediastinal mass was observed in the patient.; Histopathological and immunophenotypic studies demonstrated features consistent with gray zone lymphoma.; The absence of mediastinal disease led to the diagnosis of non-mediastinal gray zone lymphoma.; Non-mediastinal gray zone lymphomas are more common in older adults.; Non-mediastinal gray zone lymphomas tend to present at advanced stages.; Management typically follows protocols for diffuse large B-cell lymphoma, not otherwise specified (DLBCL-NOS).; The patient will be referred for systemic chemotherapy as per DLBCL-NOS protocols.; Follow-up will include monitoring for marrow and extranodal disease response.","evidence_relations":"Non-mediastinal gray zone lymphomas occur in older persons and have higher rates of bone marrow and extranodal involvement.; Sites of involvement include bone marrow involvement and extranodal disease.; Non-mediastinal gray zone lymphomas often present as advanced-stage disease.; If extra-mediastinal disease: Diagnose as DLBCL-NOS.; Treatment protocols for advanced-stage or extra-mediastinal disease align with those for DLBCL-NOS."},
	{"id":"Medical-27b6e451","source":"Medical","question":"You are drafting a public health information sheet for primary care providers on the recognition and referral of patients with suspected mediastinal gray zone lymphoma (MGZL). Summarize the key clinical features, diagnostic approach, and referral recommendations using evidence from the guideline.","answer":"Information Sheet: Recognizing and Referring Mediastinal Gray Zone Lymphoma (MGZL)\n\nKey Clinical Features:\n- MGZL typically presents as a large mediastinal mass, often with supraclavicular lymph node involvement.\n- Most affected individuals are aged 2040 years and assigned male at birth.\n\nDiagnostic Approach:\n- Histopathological assessment is critical, with Reed-Sternberg cells often observed.\n- MGZL shares overlapping features with both primary mediastinal B-cell lymphoma (PMBL) and Hodgkin lymphoma (HL), making diagnosis challenging.\n- An expert hematopathologist review is required for accurate classification.\n\nReferral Recommendations:\n- Refer patients with unexplained mediastinal masses, especially in young males, for specialist hematology evaluation.\n- Ensure tissue samples are reviewed by a hematopathology expert to guide appropriate therapy, including consideration of chemoimmunotherapy and involved-site radiation therapy in localized cases.","question_type":"Creative Generation","evidence":"Mediastinal gray zone lymphoma (MGZL) typically presents as a large mediastinal mass.; MGZL often involves supraclavicular lymph node involvement.; Most affected individuals are aged 2040 years.; Most affected individuals are assigned male at birth.; Histopathological assessment is critical for diagnosis.; Reed-Sternberg cells are often observed in MGZL.; MGZL shares overlapping features with primary mediastinal B-cell lymphoma (PMBL) and Hodgkin lymphoma (HL).; An expert hematopathologist review is required for accurate classification.; Patients with unexplained mediastinal masses should be referred for specialist hematology evaluation.; Tissue samples should be reviewed by a hematopathology expert to guide appropriate therapy.","evidence_relations":"MGZL is characterized by a large mediastinal mass.; MGZL commonly affects individuals aged 20 to 40 years, assigned male at birth.; Lymph nodes above the collar bone (supraclavicular) may be involved.; Reed-Sternberg cells are characteristic histopathological features in MGZL.; Diagnosis of MGZL requires expert hematopathologist review."},
	{"id":"Medical-1bd20d18","source":"Medical","question":"Imagine you are a gynecologic oncologist receiving a referral for a 32-year-old woman with a recent diagnosis of stage IB1 squamous cell carcinoma of the cervix. The patient wishes to preserve fertility. Draft a detailed treatment plan, including diagnostic confirmation, staging, treatment options, and fertility preservation strategies, referencing the latest clinical practice guidelines.","answer":"As a gynecologic oncologist, my initial approach would involve confirming the diagnosis of stage IB1 squamous cell carcinoma of the cervix through cervical biopsy and reviewing the pathology. Comprehensive staging should be performed using the FIGO system, with pelvic MRI and/or CT scan to evaluate the extent of local disease and assess for lymph node involvement. Baseline laboratory studies, including a complete blood count and assessment of organ function, should also be obtained. Given the patient's strong desire for fertility preservation and the early stage of her disease, I would discuss fertility-sparing surgical options in detail, specifically radical trachelectomy with pelvic lymph node dissection or sentinel lymph node biopsy, as recommended by current clinical guidelines. Referral to a fertility specialist prior to treatment initiation is advised to discuss fertility preservation strategies and reproductive planning. Ovarian transposition may be considered to preserve ovarian function if adjuvant pelvic radiation is anticipated. The treatment plan should be developed in a multidisciplinary setting, involving reproductive endocrinology as appropriate. Regular surveillance with physical examinations and imaging will be essential post-treatment. Supportive care, psychosocial support, and discussion of clinical trial opportunities should be integrated throughout the care process.","question_type":"Creative Generation","evidence":"The initial step is to confirm the diagnosis of stage IB1 squamous cell carcinoma with a cervical biopsy.; Complete staging is ensured using the FIGO system.; Pelvic MRI and/or CT scan are used to assess local and nodal involvement.; Fertility-sparing surgery is an option for the patient.; Radical trachelectomy with pelvic lymph node dissection or sentinel lymph node biopsy is discussed.; Ovarian transposition may be considered to preserve ovarian function if adjuvant therapy is needed.; Regular follow-up with physical exams and imaging is essential for surveillance.; Supportive care is provided throughout the process.; The option of clinical trial participation is discussed.","evidence_relations":"Cervical biopsy is the primary diagnostic method for cervical cancer.; The FIGO system is used to stage cervical cancer (Stages I-IV with sub-stages).; Imaging methods such as CT, MRI, PET/CT, and transvaginal ultrasound are used for staging and assessment.; Fertility-sparing surgery (e.g., trachelectomy) is an option for selected early-stage cases.; Ovarian transposition is a fertility preservation strategy.; Surveillance after treatment includes regular physical exams and imaging as indicated.; Clinical trials are an option for all stages of cervical cancer."},
	{"id":"Medical-47ec9e64","source":"Medical","question":"As a medical intern in the oncology ward, write a referral letter to a radiation oncologist for a patient with newly diagnosed FIGO stage IIB cervical cancer. Your note should summarize the diagnostic findings, risk factors, and rationale for the recommended treatment approach.","answer":"Dear Radiation Oncology Team,\n\nI am referring Ms. J, a 45-year-old woman recently diagnosed with FIGO stage IIB squamous cell carcinoma of the cervix. Her diagnosis was established via cervical biopsy following symptoms of abnormal vaginal bleeding and pelvic pain. Imaging with pelvic MRI and PET/CT confirmed parametrial invasion without distant metastasis. Notable risk factors include a history of smoking and chronic immunosuppression due to HIV infection. Given the locally advanced disease, concurrent chemoradiation with external beam radiation therapy (EBRT) and cisplatin-based chemotherapy is recommended as per current guidelines. Please assess for initiation of chemoradiation and consider brachytherapy for local control. Thank you for your expert evaluation.","question_type":"Creative Generation","evidence":"Ms. J is a 45-year-old woman diagnosed with FIGO stage IIB squamous cell carcinoma of the cervix.; Her diagnosis was established via cervical biopsy.; She presented with symptoms of abnormal vaginal bleeding and pelvic pain.; Imaging with pelvic MRI and PET/CT confirmed parametrial invasion without distant metastasis.; Notable risk factors include a history of smoking and chronic immunosuppression due to HIV infection.; Concurrent chemoradiation with external beam radiation therapy (EBRT) and cisplatin-based chemotherapy is recommended.","evidence_relations":"Cervical biopsy is the primary diagnostic method for cervical cancer.; The FIGO system is used to stage cervical cancer (Stages I-IV with sub-stages).; Imaging methods such as CT, MRI, PET/CT, and transvaginal ultrasound are used for staging and assessment.; Smoking increases the risk of cervical cancer.; Immunosuppression (e.g., HIV infection) increases the risk of cervical cancer.; Chemoradiation (concurrent EBRT and platinum-based chemotherapy) is recommended for locally advanced cervical cancer.; External beam radiation therapy (EBRT) and brachytherapy are used for local control."},
	{"id":"Medical-a4a83818","source":"Medical","question":"Transform the guideline information into a comprehensive discharge summary for a patient with stage IIIB adenocarcinoma of the cervix who has completed chemoradiation. Include the diagnosis, staging, treatments provided, biomarkers tested, and follow-up recommendations.","answer":"Discharge Summary:\n\nDiagnosis: Stage IIIB adenocarcinoma of the cervix, confirmed by cervical biopsy.\n\nStaging: Pelvic MRI and PET/CT indicated parametrial extension and involvement of the pelvic sidewall, consistent with FIGO IIIB disease.\n\nTreatment: The patient completed concurrent chemoradiation, consisting of external beam radiation therapy (EBRT), brachytherapy, and weekly cisplatin. Biomarker testing for PD-L1, MSI, and TMB was performed to inform potential future systemic therapy options.\n\nFollow-up: The patient will undergo regular physical examinations and imaging as indicated for surveillance. Supportive care and palliative care resources have been discussed. Smoking cessation is strongly encouraged to improve long-term outcomes. Participation in clinical trials will be considered if recurrent or metastatic disease develops.","question_type":"Creative Generation","evidence":"The diagnosis is stage IIIB adenocarcinoma of the cervix, confirmed by cervical biopsy.; Staging indicated parametrial extension and involvement of the pelvic sidewall.; The staging is consistent with FIGO IIIB disease.; The patient completed concurrent chemoradiation.; The treatment consisted of external beam radiation therapy (EBRT), brachytherapy, and weekly cisplatin.; Biomarker testing for PD-L1, MSI, and TMB was performed.; Regular physical examinations and imaging are recommended for follow-up.; Supportive care and palliative care resources have been discussed.; Smoking cessation is strongly encouraged to improve long-term outcomes.; Participation in clinical trials will be considered if recurrent or metastatic disease develops.","evidence_relations":"Adenocarcinoma and adenosquamous carcinoma are less common subtypes.; The FIGO system is used to stage cervical cancer (Stages I-IV with sub-stages).; Imaging methods such as CT, MRI, PET/CT, and transvaginal ultrasound are used for staging and assessment.; Chemoradiation (concurrent EBRT and platinum-based chemotherapy) is recommended for locally advanced cervical cancer.; External beam radiation therapy (EBRT) and brachytherapy are used for local control.; Biomarker testing (e.g., PD-L1, MSI, TMB, MMR, HER2, RET, NTRK) is recommended for recurrent or metastatic cervical cancer.; Surveillance after treatment includes regular physical exams and imaging as indicated.; Supportive care and palliative care are integral for advanced or metastatic disease.; Smoking cessation improves treatment outcomes.; Clinical trials are an option for all stages of cervical cancer."},
	{"id":"Medical-e0a374bb","source":"Medical","question":"You are a public health officer tasked with creating an evidence-based public health advisory to reduce cervical cancer incidence in your community. Incorporate screening, prevention, risk factor modification, and follow-up recommendations from the clinical practice guideline.","answer":"**Public Health Advisory: Preventing Cervical Cancer in Our Community**\n\nCervical cancer is a preventable disease that remains a significant threat to women's health. The majority of cases are caused by persistent infection with high-risk human papillomavirus (HPV) types, especially HPV16 and HPV18. To reduce the incidence of cervical cancer, we recommend the following evidence-based strategies:\n\n**Screening:**\n- Regular cervical cancer screening with Pap smears (cytology) is essential for early detection of precancerous changes (cervical dysplasia) and cancer. Early identification allows for timely treatment and can prevent progression to invasive cancer.\n- All eligible individuals should participate in recommended screening programs based on age and risk factors.\n\n**Prevention:**\n- HPV vaccination is highly effective in preventing infection with the most common high-risk HPV types and is recommended for eligible individuals.\n- Safe sexual practices can reduce the risk of HPV transmission.\n\n**Risk Factor Modification:**\n- Smoking significantly increases the risk of cervical cancer. We strongly encourage tobacco cessation and offer resources for quitting.\n- Immunosuppression, including HIV infection, also increases risk. Individuals with immunosuppression should adhere to recommended screening intervals and seek regular medical care.\n- Maintaining a healthy lifestyle, including a balanced diet and regular exercise, may contribute to overall cancer risk reduction.\n\n**Follow-up Recommendations:**\n- Individuals with abnormal screening results or a history of cervical dysplasia or cancer should receive appropriate follow-up, including physical examinations and imaging as indicated.\n- Ongoing surveillance is important for early detection of recurrence or new disease.\n\n**Additional Resources:**\n- Participation in clinical trials may provide access to new prevention and treatment options.\n- Community education and outreach are vital to increase awareness and participation in prevention and screening programs.\n\nBy following these guidelines, we can work together to reduce the burden of cervical cancer in our community.","question_type":"Creative Generation","evidence":"Cervical cancer is a significant threat to women's health.; Most cases are caused by persistent infection with high-risk human papillomavirus (HPV) types.; Regular screening with Pap smears is essential for early detection and prevention of cervical cancer.; Cervical dysplasia can be treated to prevent progression to cancer.; Risk factors for cervical cancer include smoking and immunosuppression, including HIV infection.; Eligible individuals are urged to participate in screening programs.; Tobacco use should be avoided.; Follow-up after abnormal screening or treatment should include physical exams and imaging as appropriate.; Clinical trials are available and may offer additional options for prevention and care.","evidence_relations":"Most cervical cancers are caused by long-term infection with human papillomavirus (HPV).; HPV16 and HPV18 are high-risk HPV types associated with cervical cancer.; Pap smear is used for cervical cancer screening.; Cervical dysplasia (CIN) can progress to cervical cancer if untreated.; Smoking increases the risk of cervical cancer.; Immunosuppression (e.g., HIV infection) increases the risk of cervical cancer.; Surveillance after treatment includes regular physical exams and imaging as indicated.; Clinical trials are an option for all stages of cervical cancer."},
	{"id":"Medical-11abd566","source":"Medical","question":"Reformat the following clinical scenario into a structured SOAP note: A 55-year-old woman presents with abnormal vaginal bleeding and fatigue. Imaging and biopsy confirm stage IVA neuroendocrine carcinoma of the cervix. She has a history of smoking and multiple sexual partners. Document the relevant findings, assessment, and plan based on guideline recommendations.","answer":"SOAP Note:\n\nSubjective: 55-year-old female presents with abnormal vaginal bleeding and fatigue. Past medical history significant for chronic tobacco use and multiple sexual partners.\n\nObjective: On examination, watery vaginal discharge and pelvic pain noted. Imaging (CT and MRI) reveals local invasion into adjacent pelvic organs, consistent with FIGO stage IVA. Cervical biopsy confirms neuroendocrine carcinoma of the cervix.\n\nAssessment: Advanced (stage IVA) neuroendocrine carcinoma of the cervix with poor prognostic features (aggressive histology, high-risk behaviors).\n\nPlan:\n- Initiate systemic therapy, including platinum-based chemotherapy and consider targeted or immunotherapy based on biomarker testing (PD-L1, MSI, MMR, TMB, HER2, RET, NTRK).\n- Consider external beam radiation therapy (EBRT) and/or brachytherapy for local control as appropriate.\n- Engage palliative care for symptom management and supportive care.\n- Counsel on smoking cessation to improve treatment outcomes.\n- Offer clinical trial enrollment if eligible.","question_type":"Creative Generation","evidence":"The patient is a 55-year-old woman presenting with abnormal vaginal bleeding and fatigue.; Her past medical history includes chronic tobacco use and multiple sexual partners.; On examination, watery vaginal discharge and pelvic pain were noted.; Imaging (CT and MRI) reveals local invasion into adjacent pelvic organs.; The findings are consistent with FIGO stage IVA.; Cervical biopsy confirms neuroendocrine carcinoma of the cervix.; The assessment indicates advanced (stage IVA) neuroendocrine carcinoma of the cervix with poor prognostic features.; The plan includes initiating systemic therapy with platinum-based chemotherapy.; Targeted or immunotherapy may be considered based on biomarker testing.; External beam radiation therapy (EBRT) and/or brachytherapy may be considered for local control.; Palliative care will be engaged for symptom management and supportive care.; Counseling on smoking cessation is recommended to improve treatment outcomes.; Clinical trial enrollment will be offered if eligible.","evidence_relations":"Abnormal vaginal bleeding and fatigue are symptoms associated with cervical cancer.; Imaging methods such as CT, MRI, PET/CT, and transvaginal ultrasound are used for staging and assessment.; Neuroendocrine carcinoma of the cervix (NECC) is a rare and aggressive subtype.; The FIGO system is used to stage cervical cancer (Stages I-IV with sub-stages).; Systemic therapy options include platinum-based chemotherapy, targeted therapy, and immunotherapy.; Biomarker testing (e.g., PD-L1, MSI, TMB, MMR, HER2, RET, NTRK) is recommended for recurrent or metastatic cervical cancer.; Supportive care and palliative care are integral for advanced or metastatic disease.; Smoking increases the risk of cervical cancer.; Smoking cessation improves treatment outcomes.; Clinical trials are an option for all stages of cervical cancer."},
	{"id":"Medical-c8a65fec","source":"Medical","question":"You are a hematology fellow evaluating a 28-year-old patient who presents with painless cervical lymphadenopathy. Based on the clinical practice guideline for Hodgkin lymphoma, compose a detailed diagnostic summary outlining the steps and rationale for confirming the diagnosis and differentiating between classic Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL).","answer":"The diagnostic evaluation of a 28-year-old presenting with painless cervical lymphadenopathy should begin with a comprehensive health history and physical examination, with particular attention to the distribution and characteristics of lymphadenopathy and the presence of systemic 'B' symptoms (fever, night sweats, weight loss). Initial laboratory studies, including complete blood count and other relevant blood tests, help assess for cytopenias or organ involvement. Imaging studies, such as CT or PET/CT scans, are performed to determine the extent of lymph node involvement and to guide biopsy. The definitive diagnosis of Hodgkin lymphoma requires a tissue sample, with excisional lymph node biopsy being the gold standard, as it provides sufficient tissue architecture for accurate histopathological assessment; a core needle biopsy may be considered if excisional biopsy is not feasible. Histopathological examination is essential to differentiate between classic Hodgkin lymphoma (CHL), which is characterized by the presence of Reed-Sternberg cells, and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), which is identified by 'popcorn-shaped' lymphocyte-predominant (LP) cells. This distinction is critical, as NLPHL has a different clinical course and can transform into diffuse large B-cell lymphoma, affecting prognosis and management. Accurate subtyping based on histology and immunophenotyping informs treatment decisions and long-term follow-up strategies.","question_type":"Creative Generation","evidence":"The initial diagnostic approach begins with a thorough health history and physical examination.; The focus is on lymph node regions and systemic symptoms.; Laboratory assessment with blood tests and imaging studies is necessary to evaluate the extent of disease.; A tissue sample is required for definitive diagnosis.; Excisional lymph node biopsy is the gold standard for diagnosis.; Core needle biopsy may be considered if excisional biopsy is not feasible.; Histopathological analysis is crucial to distinguish between classic Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma.; Classic Hodgkin lymphoma is characterized by Reed-Sternberg cells.; Nodular lymphocyte-predominant Hodgkin lymphoma is characterized by popcorn-shaped cells.; Accurate subtyping guides prognosis and treatment planning.","evidence_relations":"Most people are diagnosed between ages 15 to 30 or after age 55.; Diagnosis of Hodgkin lymphoma is made by excisional lymph node biopsy.; Core needle biopsy may be used for diagnosis in some cases.; Health history and physical exam are part of the diagnostic process.; Blood tests and imaging tests are used in the diagnostic workup.; Classic Hodgkin lymphoma (CHL) is characterized by Reed-Sternberg cells.; Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is characterized by popcorn-shaped cells.; NLPHL can transform into diffuse large B-cell lymphoma (DLBCL)."},
	{"id":"Medical-5d99d529","source":"Medical","question":"Rewrite the guideline facts into a formal referral letter from a primary care physician to a hematologist, summarizing the clinical suspicion of Hodgkin lymphoma and requesting specialist evaluation.","answer":"Dear Hematology Colleague,\n\nI am referring a 32-year-old patient with persistent, painless lymphadenopathy in the cervical and supraclavicular regions. The patient falls within the typical age range for Hodgkin lymphoma onset and has no significant past medical history. Initial workup included health history, physical examination, blood tests, and imaging, all of which indicate lymph node involvement predominantly in the upper body. Given these findings, I am concerned about possible Hodgkin lymphoma. I request your expertise for further diagnostic evaluation, including consideration of excisional lymph node biopsy to confirm the diagnosis and distinguish between classic Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), as subtyping will guide subsequent management.","question_type":"Creative Generation","evidence":"The patient is a 32-year-old with persistent, painless lymphadenopathy in the cervical and supraclavicular regions.; The patient falls within the typical age range for Hodgkin lymphoma onset.; The patient has no significant past medical history.; Initial workup included health history, physical examination, blood tests, and imaging.; The findings indicate lymph node involvement predominantly in the upper body.; There is concern about possible Hodgkin lymphoma.; Further diagnostic evaluation is requested, including excisional lymph node biopsy.; The biopsy will confirm the diagnosis and distinguish between classic Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma.","evidence_relations":"Hodgkin lymphoma usually starts in lymph nodes in the upper body.; Most people are diagnosed between ages 15 to 30 or after age 55.; Health history and physical exam are part of the diagnostic process.; Blood tests and imaging tests are used in the diagnostic workup.; Diagnosis of Hodgkin lymphoma is made by excisional lymph node biopsy.; Classic Hodgkin lymphoma (CHL) is the most common subtype of Hodgkin lymphoma.; Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subtype of Hodgkin lymphoma."},
	{"id":"Medical-29982b18","source":"Medical","question":"As a patient recently diagnosed with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), write a progress note for your oncology visit, summarizing what you have learned about your disease, the diagnostic process, and potential risks.","answer":"Progress Note:\nDuring my oncology visit today, I reviewed my recent diagnosis of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), a rare subtype of Hodgkin lymphoma. I learned that NLPHL is characterized by the presence of distinctive 'popcorn-shaped' cells seen on lymph node biopsy. My diagnostic process included a detailed health history, physical examination, blood tests, and imaging studies, which led to an excisional lymph node biopsy that confirmed the diagnosis. My oncologist explained that NLPHL is less common than classic Hodgkin lymphoma and has unique clinical and pathological features. Importantly, I was informed that NLPHL carries a risk of transformation into a more aggressive lymphoma, specifically diffuse large B-cell lymphoma (DLBCL), which may impact future management and follow-up. Understanding the nature of my disease, the steps taken to diagnose it, and the potential risks involved will help me participate actively in decisions about my treatment and ongoing care.","question_type":"Creative Generation","evidence":"The patient has been diagnosed with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL).; NLPHL is a rare subtype of Hodgkin lymphoma.; It is identified by the presence of popcorn-shaped cells in the lymph node biopsy.; The diagnosis was confirmed after an excisional lymph node biopsy.; Initial blood tests, imaging, and physical examination were performed prior to the biopsy.; NLPHL is less common than classic Hodgkin lymphoma.; NLPHL has unique features and can sometimes transform into diffuse large B-cell lymphoma (DLBCL).","evidence_relations":"Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subtype of Hodgkin lymphoma.; NLPHL is characterized by popcorn-shaped cells.; Diagnosis of Hodgkin lymphoma is made by excisional lymph node biopsy.; Health history and physical exam are part of the diagnostic process.; Blood tests and imaging tests are used in the diagnostic workup.; NLPHL can transform into diffuse large B-cell lymphoma (DLBCL)."},
	{"id":"Medical-80542737","source":"Medical","question":"Transform the key points into a structured discharge summary for an adult patient hospitalized for initial workup and diagnosis of Hodgkin lymphoma.","answer":"Discharge Summary:\n\nDiagnosis: Classic Hodgkin lymphoma (CHL)\n\nPatient: 24-year-old adult\n\nReason for Admission: Initial workup and diagnosis of persistent supraclavicular lymphadenopathy.\n\nHospital Course:\n- The patient presented with persistent, painless swelling in the supraclavicular lymph nodes. \n- A comprehensive evaluation was performed, including a detailed health history, physical examination, blood tests, and imaging studies, which demonstrated lymph node involvement in the upper body, consistent with the typical presentation of Hodgkin lymphoma.\n- Excisional lymph node biopsy was performed, and histopathology revealed the presence of Reed-Sternberg cells, confirming the diagnosis of classic Hodgkin lymphoma, the most common subtype of this disease.\n- The patient was informed about the diagnosis, the typical age distribution of Hodgkin lymphoma (most commonly diagnosed between ages 15 to 30 or after age 55), and the importance of understanding test results and maintaining organized medical records.\n- Counseling was provided regarding the need for a support system during diagnosis and treatment, and the importance of ongoing hematologic and oncologic follow-up for treatment planning.\n\nDischarge Plan:\n- The patient was advised to keep copies of all test results and pathology reports, and to maintain communication with the care team.\n- Follow-up with hematology/oncology was arranged for further staging and initiation of treatment planning based on the diagnostic findings.\n- The patient was encouraged to enlist support from family or friends and to utilize available resources, such as online patient portals, for tracking appointments and test results.","question_type":"Creative Generation","evidence":"The diagnosis is classic Hodgkin lymphoma (CHL).; The patient is aged 24.; The patient was admitted for evaluation of persistent supraclavicular lymphadenopathy.; Workup included detailed health history, physical examination, blood tests, and imaging studies.; The workup indicated lymph node involvement in the upper body.; Definitive diagnosis was established via excisional lymph node biopsy.; The biopsy revealed Reed-Sternberg cells, confirming classic Hodgkin lymphoma.; The patient was counseled on the nature of the disease and its typical age distribution.; Ongoing hematologic follow-up is important for treatment planning.","evidence_relations":"Classic Hodgkin lymphoma (CHL) is the most common subtype of Hodgkin lymphoma.; CHL is characterized by Reed-Sternberg cells.; Diagnosis of Hodgkin lymphoma is made by excisional lymph node biopsy.; Health history and physical exam are part of the diagnostic process.; Blood tests and imaging tests are used in the diagnostic workup.; Hodgkin lymphoma usually starts in lymph nodes in the upper body.; Most people are diagnosed between ages 15 to 30 or after age 55."},
	{"id":"Medical-44f9a6ad","source":"Medical","question":"You are a hepatobiliary surgeon receiving a pathology report for a patient with a suspected intrahepatic bile duct tumor. Based on the provided clinical practice guideline, synthesize a case summary detailing the anatomical structures involved, tumor staging, and potential implications for surgical management.","answer":"The patient presents with a primary intrahepatic bile duct tumor. Histopathological analysis reveals the tumor is confined to the epithelial layer, consistent with a carcinoma in situ (Tis). The bile duct wall is composed of multiple histological layers: epithelium, lamina propria, muscularis, perimuscular fibrous tissue, and serosa. The current staging, Tis, indicates the neoplasm remains intraductal without invasion into the lamina propria, muscularis, or surrounding tissue. There is no evidence of spread to nearby blood vessels, liver parenchyma, or structures outside the liver. This early stage may be amenable to local excision with preservation of adjacent tissues, but careful assessment of the serosal boundary is necessary to exclude occult invasion.","question_type":"Creative Generation","evidence":"The patient presents with a primary intrahepatic bile duct tumor.; Histopathological analysis reveals the tumor is confined to the epithelial layer.; The tumor is consistent with a carcinoma in situ (Tis).; The bile duct wall is composed of multiple histological layers.; The histological layers include epithelium, lamina propria, muscularis, perimuscular fibrous tissue, and serosa.; The current staging is Tis, indicating the neoplasm remains intraductal.; There is no invasion into the lamina propria, muscularis, or surrounding tissue.; There is no evidence of spread to nearby blood vessels, liver parenchyma, or structures outside the liver.; This early stage may be amenable to local excision with preservation of adjacent tissues.; Careful assessment of the serosal boundary is necessary to exclude occult invasion.","evidence_relations":"The gallbladder and bile ducts are lined by a thin, moist epithelial layer.; Lamina propria is a connective tissue found under the epithelium.; Muscularis is a soft tissue layer in the bile duct wall.; Tis (carcinoma in situ) is an intraductal tumor confined to the epithelium.; Cancer can invade nearby blood vessels, liver, or structures outside the liver."},
	{"id":"Medical-e122bd14","source":"Medical","question":"Rewrite the facts about intrahepatic bile duct cancer staging and tumor characteristics into a formal discharge summary for a patient who underwent evaluation for a biliary mass.","answer":"Discharge Summary:\n\nDiagnosis: Intrahepatic bile duct carcinoma in situ (Tis)\n\nHospital Course: The patient was admitted for evaluation of a biliary mass. Imaging and histopathological examination confirmed an intraductal tumor limited to the epithelial layer of the bile duct, without invasion into the lamina propria, muscularis, or perimuscular fibrous tissue. No extension to the serosa or adjacent liver tissue was identified. There was no radiological or intraoperative evidence of tumor spread to blood vessels or structures outside the liver. The tumor is staged as Tis, carcinoma in situ, based on these findings.\n\nPlan: Outpatient follow-up with hepatobiliary surgery and oncology for consideration of localized excision and surveillance.","question_type":"Creative Generation","evidence":"The diagnosis is intrahepatic bile duct carcinoma in situ (Tis).; The patient was admitted for evaluation of a biliary mass.; Imaging confirmed an intraductal tumor limited to the epithelial layer of the bile duct.; The tumor did not invade the lamina propria, muscularis, or perimuscular fibrous tissue.; No extension to the serosa or adjacent liver tissue was identified.; There was no evidence of tumor spread to blood vessels or structures outside the liver.; The tumor is staged as Tis, carcinoma in situ.; The plan includes outpatient follow-up with hepatobiliary surgery and oncology.","evidence_relations":"Bile duct cancer staging is based on tumor size and extent of spread.; Tis (carcinoma in situ) is an intraductal tumor confined to the epithelium.; The gallbladder and bile ducts are lined by a thin, moist epithelial layer.; Lamina propria is a connective tissue found under the epithelium.; Cancer can invade nearby blood vessels, liver, or structures outside the liver."},
	{"id":"Medical-d8403485","source":"Medical","question":"As a medical intern, draft a referral letter to a specialized oncology center for a patient with a newly diagnosed primary intrahepatic bile duct tumor. Ensure your letter summarizes relevant anatomical, pathological, and staging details for multidisciplinary evaluation.","answer":"Dear Oncology Colleagues,\n\nI am referring a patient with a newly diagnosed primary intrahepatic bile duct tumor for multidisciplinary evaluation. The tumor has been identified as an intraductal neoplasm confined to the epithelial layer of the bile duct, with no evidence of invasion into the underlying lamina propria, muscularis, perimuscular fibrous tissue, or serosa. Imaging and histopathological assessment confirm that there is no extension into the adjacent liver parenchyma, blood vessels, or extrahepatic structures. Based on these findings, the tumor is staged as Tis (carcinoma in situ), representing a non-invasive, early-stage lesion. The bile duct wall anatomy, including the epithelium, lamina propria, muscularis, perimuscular fibrous tissue, and serosa, has been carefully evaluated to exclude deeper invasion. There is no radiological or intraoperative evidence of metastatic spread. Given the early stage and localized nature of the disease, I am seeking your expertise for further oncological assessment, discussion of potential localized surgical excision, and recommendations for ongoing management and surveillance.","question_type":"Creative Generation","evidence":"The patient has a newly diagnosed primary intrahepatic bile duct tumor.; Pathology reports describe an intraductal neoplasm confined to the epithelial layer.; The tumor is consistent with carcinoma in situ (Tis).; There is no evidence of invasion into deeper layers of the bile duct.; There is no extension to the surrounding liver, blood vessels, or extrahepatic structures.; Tumor staging is Tis, indicating early disease.; The referral is for multidisciplinary evaluation and management planning.","evidence_relations":"Intrahepatic bile duct cancer: Stage Tis is defined as a carcinoma in situ, an intraductal tumor confined to the epithelium.; The bile duct wall consists of epithelium, lamina propria, muscularis, perimuscular fibrous tissue, and serosa.; Bile duct cancer staging is based on tumor size and extent of spread.; Cancer can invade nearby blood vessels, liver, or structures outside the liver.; Primary tumor size (cm or mm), spread to blood vessels, spread to liver, and spread to structures outside the liver are key tumor characteristics."},
	{"id":"Medical-67cf9d75","source":"Medical","question":"Transform the clinical guideline information into a SOAP (Subjective, Objective, Assessment, Plan) note summarizing the initial evaluation of a patient with suspected bile duct cancer.","answer":"SOAP Note:\n\nSubjective: Patient presents with right upper quadrant discomfort and mild jaundice. No prior history of liver disease.\n\nObjective: Imaging reveals a mass within the intrahepatic bile duct. Biopsy demonstrates an intraductal neoplasm limited to the epithelial layer. No invasion of the lamina propria, muscularis, or perimuscular fibrous tissue observed. No evidence of spread to blood vessels, liver parenchyma, or structures outside the liver.\n\nAssessment: Intrahepatic bile duct carcinoma in situ (Tis), confined to the epithelial layer, without local extension or metastasis.\n\nPlan: Refer to hepatobiliary surgery for consideration of local excision. Schedule further imaging to confirm absence of serosal or vascular involvement. Initiate multidisciplinary tumor board review.","question_type":"Creative Generation","evidence":"The patient presents with right upper quadrant discomfort.; The patient has mild jaundice.; The patient has no prior history of liver disease.; Imaging reveals a mass within the intrahepatic bile duct.; Biopsy demonstrates an intraductal neoplasm limited to the epithelial layer.; There is no invasion of the lamina propria, muscularis, or perimuscular fibrous tissue.; There is no evidence of spread to blood vessels, liver parenchyma, or structures outside the liver.; The assessment is intrahepatic bile duct carcinoma in situ (Tis).; The plan includes referral to hepatobiliary surgery for local excision.","evidence_relations":"Tis (carcinoma in situ) is an intraductal tumor confined to the epithelium.; The gallbladder and bile ducts are lined by a thin, moist epithelial layer.; Lamina propria is a connective tissue found under the epithelium.; Cancer can invade nearby blood vessels, liver, or structures outside the liver.; Bile duct cancer staging is based on tumor size and extent of spread."},
	{"id":"Medical-f847846c","source":"Medical","question":"You are a hematology fellow evaluating a 56-year-old patient with generalized lymphadenopathy, mild fatigue, and no B symptoms. Laboratory and imaging studies suggest follicular lymphoma. Please synthesize a diagnostic workup plan and discuss how you would determine the grade and guide subsequent management based on the clinical practice guideline.","answer":"The diagnostic workup for a 56-year-old patient with generalized lymphadenopathy, mild fatigue, and no B symptoms, with laboratory and imaging findings suggestive of follicular lymphoma (FL), should begin with a thorough medical and family history, including assessment for B symptoms (fever, night sweats, weight loss) and risk factors. A comprehensive physical examination should evaluate lymph node regions, spleen, and liver for enlargement. Laboratory studies should include a complete blood count with differential, comprehensive metabolic panel, and beta-2 microglobulin. The definitive diagnosis requires an excisional lymph node biopsy for histopathological evaluation, including immunophenotyping to confirm B-cell lineage and to assess for characteristic markers such as BCL2 overexpression or t(14;18) translocation. Bone marrow aspiration and biopsy are performed to determine marrow involvement. Imaging studies, such as CT or PET-CT, are used to assess the extent of nodal and extranodal disease. The pathologist will grade FL based on the proportion of centrocytes and centroblasts: grades 1 and 2 are considered classic FL, grade 3A is intermediate, and grade 3B is managed as diffuse large B-cell lymphoma (DLBCL). This grading is essential for guiding management decisions. In patients without B symptoms and with low tumor burden, observation may be appropriate, as not all require immediate therapy. The results of these assessments will inform individualized treatment planning according to clinical practice guidelines.","question_type":"Creative Generation","evidence":"The patient is 56 years old.; The patient has generalized lymphadenopathy.; The patient has mild fatigue.; The patient has no B symptoms.; The diagnosis of follicular lymphoma (FL) will be confirmed using blood tests, imaging studies, and histopathological evaluation.; A lymph node biopsy will be obtained.; Immunophenotyping will identify B-cell lineage markers.; Bone marrow aspiration and biopsy are necessary to assess marrow involvement.; Imaging will determine the extent of nodal and extranodal disease.; The pathologist will evaluate the lymph node specimen for the proportion of centrocytes and centroblasts.; The FL grade will influence management decisions.","evidence_relations":"Diagnosis of FL involves blood tests, bone marrow aspirate and biopsy, imaging studies, and immunophenotyping.; FL is graded based on the proportion of centrocytes and centroblasts.; Grades 1 and 2 FL are classified as classic FL (cFL) according to ICC.; Grade 3B FL is treated as DLBCL.; Almost all FL cases have a chromosome translocation or excess BCL2 protein.; Not all patients with FL require immediate treatment.; The type of cells in FL determines the grade, which guides treatment decisions."},
	{"id":"Medical-cabc388f","source":"Medical","question":"Imagine you are a pathologist preparing a diagnostic summary for a lymph node biopsy suspected of follicular lymphoma. Write a pathology report that includes grading, cell type identification, and recommendations for further clinical management based on the guidelines.","answer":"Pathology Report:\n\nSpecimen: Excisional biopsy, left cervical lymph node\n\nMicroscopic Description: The lymph node architecture is completely effaced by closely packed neoplastic follicles. These follicles are composed predominantly of small cleaved lymphocytes (centrocytes) with occasional larger non-cleaved cells (centroblasts). The average number of centroblasts per high-power field is consistent with Grade 2 follicular lymphoma, according to established grading criteria. No areas of diffuse large B-cell lymphoma (DLBCL) are identified.\n\nImmunophenotyping: The neoplastic cells express B-cell markers and show strong BCL2 protein expression. Cytogenetic analysis demonstrates the presence of the t(14;18) translocation, which is characteristic of classic follicular lymphoma.\n\nDiagnosis: Follicular lymphoma, Grade 2 (classic FL), BCL2-positive, t(14;18)-positive\n\nRecommendations: The findings are diagnostic of classic follicular lymphoma, Grade 2. It is recommended to correlate with clinical findings to determine the need for immediate therapy, as not all patients with follicular lymphoma require treatment at diagnosis. Further clinical management should include comprehensive staging with bone marrow biopsy and appropriate imaging studies to assess the extent of disease. Multidisciplinary discussion is advised to guide individualized treatment planning based on current guidelines.","question_type":"Creative Generation","evidence":"The specimen is an excisional biopsy of the left cervical lymph node.; The architecture is effaced by neoplastic follicles.; The neoplastic follicles are composed predominantly of small cleaved lymphocytes (centrocytes).; There are occasional larger non-cleaved cells (centroblasts).; The number of centroblasts per high-power field is consistent with Grade 2 follicular lymphoma (classic FL).; Immunophenotyping reveals a B-cell phenotype with strong BCL2 protein expression.; Cytogenetic analysis demonstrates t(14;18) translocation.; No areas of diffuse large B-cell lymphoma are identified.; The diagnosis is follicular lymphoma, Grade 2 (classic FL), BCL2-positive, t(14;18)-positive.; Clinical correlation is recommended to determine the need for immediate treatment.","evidence_relations":"FL is graded based on the proportion of centrocytes and centroblasts.; Grades 1 and 2 FL are classified as classic FL (cFL) according to ICC.; Almost all FL cases have a chromosome translocation or excess BCL2 protein.; Diagnosis of FL involves blood tests, bone marrow aspirate and biopsy, imaging studies, and immunophenotyping.; The type of cells in FL determines the grade, which guides treatment decisions.; Not all patients with FL require immediate treatment."},
	{"id":"Medical-165e8fae","source":"Medical","question":"Rewrite the clinical facts into a comprehensive discharge summary for a patient with pediatric-type follicular lymphoma (PTFL) after excisional biopsy and observation, integrating all relevant diagnostic, pathologic, and management details per the guidelines.","answer":"Discharge Summary\n\nPatient Name: [Redacted]\nMRN: [Redacted]\nAdmission Date: [Date]\nDischarge Date: [Date]\n\nDiagnosis: Pediatric-type follicular lymphoma (PTFL), localized, head and neck\n\nSummary of Hospital Stay: The patient presented with a single enlarged lymph node in the cervical region and minimal symptoms. Excisional lymph node biopsy was performed, and pathology confirmed pediatric-type follicular lymphoma, characterized by follicular proliferation with minimal centroblast presence and absence of t(14;18) translocation. No evidence of bone marrow or extranodal involvement was identified on imaging and marrow studies. The patient did not exhibit B symptoms (fever, night sweats, weight loss) or systemic signs. Given the localized disease and minimal symptoms, no immediate therapy was initiated; the patient will be followed closely with periodic clinical and radiologic assessment.\n\nPlan: Outpatient follow-up in hematology/oncology clinic. No adjuvant therapy required at this time. Education regarding symptom monitoring provided.","question_type":"Creative Generation","evidence":"The diagnosis is pediatric-type follicular lymphoma (PTFL), localized, in the head and neck.; The patient presented with a single enlarged lymph node in the cervical region.; The patient had minimal symptoms.; An excisional lymph node biopsy was performed.; Pathology confirmed pediatric-type follicular lymphoma.; The lymphoma is characterized by follicular proliferation with minimal centroblast presence.; There is an absence of t(14;18) translocation.; No evidence of bone marrow or extranodal involvement was identified.; The patient did not exhibit B symptoms.; No immediate therapy was initiated due to localized disease and minimal symptoms.","evidence_relations":"Pediatric-type FL (PTFL) usually presents with a single enlarged lymph node in the head and neck and minimal symptoms.; Uncommon FL (uFL) is t(14;18)-negative or has uncommon pathologic features and is treated as classic FL.; Diagnosis of FL involves blood tests, bone marrow aspirate and biopsy, imaging studies, and immunophenotyping.; Symptoms of FL include swollen lymph nodes, enlarged spleen, fever, night sweats, fatigue, and weight loss (B symptoms).; Not all patients with FL require immediate treatment.; The type of cells in FL determines the grade, which guides treatment decisions."},
	{"id":"Medical-f9d1c48a","source":"Medical","question":"You are a primary care physician writing a referral letter to hematology-oncology for a 64-year-old with persistent, painless lymphadenopathy and recent onset of night sweats and fatigue. Summarize the clinical findings, initial workup, and rationale for specialist referral using evidence from the guideline.","answer":"Dear Hematology-Oncology Colleagues,\n\nI am referring a 64-year-old patient who presents with a two-month history of persistent, painless lymphadenopathy involving both cervical and axillary regions. The patient has recently developed night sweats and fatigue, but denies fever or significant weight loss. On physical examination, there are multiple enlarged, non-tender lymph nodes. Initial laboratory evaluation reveals mild anemia. These findings, particularly the presence of B symptoms (night sweats and fatigue) and generalized lymphadenopathy, raise suspicion for non-Hodgkin lymphoma, with follicular lymphoma being a leading consideration based on the clinical presentation and guideline evidence.\n\nThe initial workup has included a thorough physical examination and basic laboratory studies. To establish a definitive diagnosis and guide management, I recommend further evaluation with excisional lymph node biopsy, bone marrow aspiration and biopsy, imaging studies (such as CT or PET scans), and immunophenotyping. These investigations are necessary to confirm the diagnosis, determine the histologic grade, and assess the extent of disease, as treatment decisions in follicular lymphoma are based on cell type and grade. Early specialist involvement is important for optimal diagnostic accuracy and to initiate appropriate management. Thank you for your expert assessment and care.","question_type":"Creative Generation","evidence":"The patient is 64 years old.; The patient has persistent, painless lymphadenopathy.; The lymphadenopathy involves cervical and axillary regions.; The patient reports recent onset of night sweats and fatigue.; The patient denies fever or significant weight loss.; Physical examination reveals multiple enlarged, non-tender lymph nodes.; Initial laboratory studies show mild anemia.; Non-Hodgkin lymphoma, specifically follicular lymphoma, is suspected.; Further evaluation is recommended, including excisional lymph node biopsy.; Bone marrow aspiration, imaging studies, and immunophenotyping are needed to confirm diagnosis and determine grade.","evidence_relations":"Follicular lymphoma (FL) is a slow-growing B-cell non-Hodgkin lymphoma.; FL develops from abnormal B lymphocytes forming clusters in lymph nodes and other tissues.; Symptoms of FL include swollen lymph nodes, enlarged spleen, fever, night sweats, fatigue, and weight loss (B symptoms).; Diagnosis of FL involves blood tests, bone marrow aspirate and biopsy, imaging studies, and immunophenotyping.; The type of cells in FL determines the grade, which guides treatment decisions.; Not all patients with FL require immediate treatment."},
	{"id":"Medical-2352775b","source":"Medical","question":"Transform the clinical guideline into a public health advisory for primary care providers, highlighting key features of follicular lymphoma, its diagnosis, and referral triggers.","answer":"**Public Health Advisory: Recognizing and Managing Follicular Lymphoma (FL) in Primary Care**\n\nFollicular lymphoma (FL) is a slow-growing B-cell non-Hodgkin lymphoma that may present as painless lymphadenopathy in nodal or extranodal sites. Classic symptoms include swollen lymph nodes, enlarged spleen, fatigue, night sweats, and weight loss (B symptoms). FL is graded based on the proportion of centrocytes and centroblasts, influencing management decisions. Diagnosis requires a combination of blood tests, bone marrow aspirate and biopsy, imaging, and immunophenotyping. Most cases exhibit BCL2 protein overexpression or t(14;18) translocation. Not all patients require immediate treatment; however, patients with B symptoms, rapidly enlarging nodes, or cytopenias should be referred promptly to hematology-oncology for further evaluation. Early diagnosis and appropriate grading are essential for optimal outcomes.","question_type":"Creative Generation","evidence":"Follicular lymphoma (FL) is a slow-growing B-cell non-Hodgkin lymphoma.; FL may present as painless lymphadenopathy in nodal or extranodal sites.; Classic symptoms of FL include swollen lymph nodes, enlarged spleen, fatigue, night sweats, and weight loss.; FL is graded based on the proportion of centrocytes and centroblasts.; Diagnosis requires blood tests, bone marrow aspirate and biopsy, imaging, and immunophenotyping.; Most cases exhibit BCL2 protein overexpression or t(14;18) translocation.; Not all patients require immediate treatment.; Patients with B symptoms, rapidly enlarging nodes, or cytopenias should be referred promptly to hematology-oncology.","evidence_relations":"Follicular lymphoma (FL) is a slow-growing B-cell non-Hodgkin lymphoma.; FL can present as nodal or extranodal disease.; Symptoms of FL include swollen lymph nodes, enlarged spleen, fever, night sweats, fatigue, and weight loss (B symptoms).; Diagnosis of FL involves blood tests, bone marrow aspirate and biopsy, imaging studies, and immunophenotyping.; FL is graded based on the proportion of centrocytes and centroblasts.; Almost all FL cases have a chromosome translocation or excess BCL2 protein.; Not all patients with FL require immediate treatment."},
	{"id":"Medical-8df9d4bc","source":"Medical","question":"You are a hepatology specialist preparing a comprehensive case summary for a multidisciplinary tumor board review. The patient is a 48-year-old with cirrhosis and chronic hepatitis B, recently found to have a liver mass on surveillance ultrasound. Summarize the likely diagnosis, relevant risk factors, recommended diagnostic steps, and potential for metastatic disease, referencing the clinical practice guidelines.","answer":"This 48-year-old patient with cirrhosis and chronic hepatitis B is at significantly increased risk for primary liver cancer, most commonly hepatocellular carcinoma (HCC), as both cirrhosis and chronic HBV infection are well-established risk factors. Surveillance ultrasound has identified a liver mass, which is highly suspicious for HCC in this clinical context. According to clinical practice guidelines, the recommended diagnostic steps include further characterization of the lesion with contrast-enhanced imaging, such as MRI or CT, to assess for radiologic features typical of HCC. Measurement of serum alpha-fetoprotein (AFP) is also advised, as elevated or rising AFP levels may support the diagnosis, though not all HCCs are AFP-secreting. If imaging findings are inconclusive, a liver biopsy may be necessary to establish a definitive diagnosis. Given the propensity of HCC to metastasize, particularly to the lungs and bones, a comprehensive staging workup should be performed to evaluate for extrahepatic spread. This will guide treatment planning and multidisciplinary management.","question_type":"Creative Generation","evidence":"The patient is 48 years old.; The patient has cirrhosis and chronic hepatitis B.; A liver mass was found on surveillance ultrasound.; The patient is at high risk for primary liver cancer, specifically hepatocellular carcinoma (HCC).; Cirrhosis and hepatitis B are established risk factors for HCC.; The liver mass raises suspicion for HCC.; The recommended diagnostic approach includes imaging tests such as contrast-enhanced MRI or CT.; Assessment of alpha-fetoprotein (AFP) levels is necessary.; Elevated AFP may support the diagnosis of HCC.; Biopsy may be considered if imaging is inconclusive.","evidence_relations":"Cirrhosis is a major risk factor for developing liver cancer.; Chronic hepatitis B infection increases the risk of liver cancer.; Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer.; Screening for liver cancer is recommended for individuals with cirrhosis or chronic hepatitis B.; Liver cancer most often metastasizes to the lung or bone."},
	{"id":"Medical-f24b3922","source":"Medical","question":"Imagine you are a primary care physician writing a referral note to a hepatologist for a patient with chronic hepatitis C, abnormal liver enzymes, and a recent ultrasound showing a suspicious liver lesion. Draft a detailed referral letter that includes risk factors, screening rationale, and next diagnostic steps.","answer":"Dear Hepatology Colleague,\n\nI am referring a 55-year-old male with a history of chronic hepatitis C and persistently elevated liver enzymes. He has additional metabolic risk factors, including obesity and features suggestive of non-alcoholic fatty liver disease. Surveillance ultrasound revealed a 2.5 cm hypoechoic lesion in the right hepatic lobe. Given his background of chronic hepatitis C and possible NAFLD, he is at increased risk for primary liver cancer, particularly hepatocellular carcinoma. I have ordered an alpha-fetoprotein (AFP) test and would appreciate your assessment for further imaging (MRI/CT) and management. Biopsy may be needed if imaging is inconclusive.\n\nThank you for your expert evaluation.","question_type":"Creative Generation","evidence":"The patient is a 55-year-old male.; The patient has a history of chronic hepatitis C.; The patient has persistently elevated liver enzymes.; The patient has additional metabolic risk factors, including obesity.; The patient has features suggestive of non-alcoholic fatty liver disease.; Surveillance ultrasound revealed a 2.5 cm hypoechoic lesion in the right hepatic lobe.; The patient is at increased risk for primary liver cancer, particularly hepatocellular carcinoma.; An alpha-fetoprotein (AFP) test has been ordered.; Further imaging (MRI/CT) and management are needed.; Biopsy may be needed if imaging is inconclusive.","evidence_relations":"Chronic hepatitis C infection increases the risk of liver cancer.; Non-alcoholic fatty liver disease (NAFLD) is a risk factor for cirrhosis and liver cancer.; Screening for liver cancer is recommended for individuals with cirrhosis or chronic hepatitis B.; Liver cancer screening includes ultrasound and alpha-fetoprotein (AFP) test every 6 months.; Diagnosis of liver cancer is usually confirmed with imaging tests."},
	{"id":"Medical-4dcd1884","source":"Medical","question":"You are a radiology resident tasked with drafting a structured imaging report for a patient with a history of genetic hemochromatosis and new liver mass detected on surveillance. Incorporate relevant risk factors, differential diagnoses, and recommended next steps based on the guidelines.","answer":"Imaging Report:\n\nPatient: 60-year-old male with a history of genetic hemochromatosis, currently undergoing routine liver cancer surveillance. Recent ultrasound has identified a 3 cm mass in the right hepatic lobe. Relevant risk factors for primary liver malignancy in this patient include genetic hemochromatosis, which predisposes to iron overload, and possible underlying cirrhosis, both of which significantly increase the risk for hepatocellular carcinoma (HCC).\n\nDifferential diagnoses for the detected liver mass include:\n- Hepatocellular carcinoma (HCC), which is the most common primary liver cancer and the leading consideration given the patient's risk profile.\n- Intrahepatic cholangiocarcinoma, a primary malignancy of the bile ducts.\n- Mixed-type tumors (combined HCC-cholangiocarcinoma).\n\nRecommended next steps, in accordance with current guidelines, include further characterization of the lesion with contrast-enhanced MRI or CT to assess for features typical of HCC (such as arterial phase hyperenhancement and washout in the portal venous or delayed phase). Assessment of serum alpha-fetoprotein (AFP) levels is also advised as an adjunct marker. If imaging findings are indeterminate or non-diagnostic, a biopsy should be considered to obtain histopathological confirmation. Multidisciplinary discussion is recommended to guide further management.","question_type":"Creative Generation","evidence":"The patient is a 60-year-old male.; The patient has a history of genetic hemochromatosis.; The patient is undergoing routine liver cancer surveillance.; A recent ultrasound identified a 3 cm mass in the right hepatic lobe.; The patient's risk factors include genetic hemochromatosis.; The patient may have underlying cirrhosis.; Differential diagnoses include hepatocellular carcinoma.; Differential diagnoses include intrahepatic cholangiocarcinoma.; Differential diagnoses include mixed-type tumors.; Further evaluation with contrast-enhanced MRI or CT is recommended.; Assessment of alpha-fetoprotein (AFP) levels is recommended.; A biopsy should be considered if imaging findings are indeterminate.","evidence_relations":"Genetic hemochromatosis is a risk factor for cirrhosis and liver cancer.; Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer.; Intrahepatic cholangiocarcinoma is a primary liver cancer of the bile ducts.; Diagnosis of liver cancer is usually confirmed with imaging tests.; Biopsy may be needed to confirm liver cancer."},
	{"id":"Medical-ec347ef8","source":"Medical","question":"Rewrite the core recommendations from the liver cancer guideline as a public health advisory targeted at patients with cirrhosis or chronic hepatitis B. Ensure to include screening frequency, methods, and rationale using evidence from the guideline.","answer":"**Public Health Advisory: Liver Cancer Screening for At-Risk Individuals**\n\nIf you have cirrhosis or chronic hepatitis B, you are at increased risk for developing liver cancer. Early detection improves treatment options and outcomes. We strongly recommend that all individuals with cirrhosis or chronic hepatitis B undergo liver cancer screening with ultrasound and alpha-fetoprotein (AFP) blood tests every 6 months. These tests can identify liver cancer at a stage when it is more treatable. Please speak with your healthcare provider about arranging regular screening.","question_type":"Creative Generation","evidence":"Individuals with cirrhosis or chronic hepatitis B are at increased risk for developing liver cancer.; Early detection improves treatment options and outcomes.; All individuals with cirrhosis or chronic hepatitis B should undergo liver cancer screening.; Liver cancer screening should include ultrasound and alpha-fetoprotein (AFP) blood tests.; Screening should occur every 6 months.; These tests can identify liver cancer at a more treatable stage.; Patients should speak with their healthcare provider about arranging regular screening.","evidence_relations":"Cirrhosis is a major risk factor for developing liver cancer.; Chronic hepatitis B infection increases the risk of liver cancer.; Screening for liver cancer is recommended for individuals with cirrhosis or chronic hepatitis B.; Liver cancer screening includes ultrasound and alpha-fetoprotein (AFP) test every 6 months.; Early-stage detection of liver cancer improves treatment options and outcomes."},
	{"id":"Medical-c780f053","source":"Medical","question":"You are a medical intern asked to write a discharge summary for a patient diagnosed with intrahepatic cholangiocarcinoma following workup for a liver mass. Summarize the diagnosis, underlying risk factors, diagnostic process, and sites of potential metastasis as per the guideline.","answer":"Discharge Summary:\n\nDiagnosis: Intrahepatic cholangiocarcinoma, confirmed following imaging and biopsy of a liver mass. The patient has a history of cirrhosis and primary biliary cholangitis, both recognized risk factors for liver cancer. Diagnosis was established through imaging tests, including ultrasound and MRI, with confirmation via biopsy. The patient has been counseled regarding the risk of metastatic spread, particularly to the lung and bone, and will undergo further staging. Follow-up with oncology and hepatology is arranged.","question_type":"Creative Generation","evidence":"The patient has been diagnosed with intrahepatic cholangiocarcinoma.; The diagnosis was confirmed following imaging and biopsy of a liver mass.; The patient has a history of cirrhosis.; The patient has a history of primary biliary cholangitis.; Cirrhosis and primary biliary cholangitis are recognized risk factors for liver cancer.; The diagnosis was established through imaging tests, including ultrasound and MRI.; The diagnosis was confirmed via biopsy.; The patient has been counseled regarding the risk of metastatic spread.; Potential sites of metastasis include the lung and bone.; The patient will undergo further staging.; Follow-up with oncology and hepatology has been arranged.","evidence_relations":"Intrahepatic cholangiocarcinoma is a primary liver cancer of the bile ducts.; Stage 4 primary biliary cholangitis is a risk factor for cirrhosis and liver cancer.; Cirrhosis is a major risk factor for developing liver cancer.; Diagnosis of liver cancer is usually confirmed with imaging tests.; Liver cancer most often metastasizes to the lung or bone."},
	{"id":"Medical-4cab379f","source":"Medical","question":"You are an endocrinologist evaluating a 45-year-old patient with a newly discovered 2.5 cm thyroid nodule. Construct a stepwise diagnostic and initial management plan, referencing appropriate risk stratification, diagnostic modalities, and treatment recommendations from the guideline.","answer":"The stepwise diagnostic and initial management plan for a 45-year-old patient with a newly discovered 2.5 cm thyroid nodule begins with a comprehensive clinical evaluation, including a detailed history to assess for risk factors such as prior head or neck radiation exposure and family history of thyroid cancer or related hereditary syndromes (e.g., familial adenomatous polyposis, Cowden syndrome, MEN). The initial laboratory test should be a thyroid-stimulating hormone (TSH) blood test to determine thyroid function and whether the nodule is hyperfunctioning, as hyperfunctioning nodules are rarely malignant. A high-resolution neck ultrasound is then performed to assess the nodules size, echogenicity, margins, presence of microcalcifications, and any suspicious cervical lymphadenopathy. For nodules 1 cm with suspicious features, or any nodule 2 cm, fine-needle aspiration (FNA) biopsy is indicated to obtain cytological material for diagnosis. If the FNA result is malignant or indeterminate, molecular testing for mutations (such as BRAF, RET, or NTRK fusions) may be considered to further stratify malignancy risk and guide management. If the nodule is confirmed as a differentiated thyroid carcinoma (e.g., papillary or follicular) and is localized without evidence of extrathyroidal extension or lymph node involvement, lobectomy is an appropriate initial surgical approach. However, if there are high-risk features (such as extrathyroidal extension, aggressive histology, or lymph node metastases), total thyroidectomy with possible central or lateral neck dissection is recommended. Ongoing management should be tailored based on final pathology and risk stratification.","question_type":"Creative Generation","evidence":"The patient is a 45-year-old with a newly discovered 2.5 cm thyroid nodule.; A thorough clinical evaluation is the first step in the diagnostic process.; Risk factors such as prior radiation exposure or family history of thyroid cancer should be assessed.; A TSH blood test should be ordered.; A neck ultrasound should be performed to characterize the nodule.; The ultrasound should assess the nodules size, echogenicity, margins, and lymph node involvement.; A fine-needle aspiration (FNA) biopsy should be performed to obtain cytological material.; If the FNA indicates malignancy or is indeterminate, molecular testing may be performed.; Molecular testing may assess for mutations such as BRAF, RET, and NTRK fusions.; If the lesion is confirmed as papillary or follicular thyroid carcinoma, lobectomy may be considered.; If there are high-risk features or lymph node involvement, total thyroidectomy with possible neck dissection may be recommended.","evidence_relations":"TSH blood test and neck ultrasound are recommended for evaluation of thyroid nodules.; Fine-needle aspiration biopsy is used to sample suspicious thyroid nodules.; Pathology review determines cancer type and guides treatment.; Molecular tests can help determine malignancy and need for surgery.; Lobectomy is an option for small, low-risk differentiated thyroid cancers.; Total thyroidectomy is recommended for larger, invasive, or high-risk cancers.; Neck dissection is performed if lymph nodes are involved.; Radiation exposure to the head or neck increases risk of thyroid cancer.; Family history and inherited syndromes (FAP, Carney complex, Cowden syndrome, MEN) increase risk."},
	{"id":"Medical-32eaeeb1","source":"Medical","question":"Rewrite the evidence-based management of recurrent differentiated thyroid cancer into a formal referral letter from a primary care physician to a tertiary oncology center.","answer":"Dear Oncology Colleague,\n\nI am referring a 58-year-old female with a history of papillary thyroid carcinoma, status post total thyroidectomy and radioactive iodine therapy. She now presents with rising serum thyroglobulin levels and a suspicious cervical lymph node on recent neck ultrasound. Given these findings suggest recurrent disease, I request your expertise for further evaluation and management. \n\nRelevant investigations include physical exam, TSH, Tg, Tg ab blood tests, and neck ultrasound. Imaging with CT or MRI may be warranted for further assessment. According to current guidelines, management options for recurrent, resectable disease include surgical excision. For iodine-avid recurrence, additional RAI therapy may be considered. For unresectable or non-RAI-avid recurrence, external beam radiation therapy or targeted therapy (e.g., lenvatinib, sorafenib, cabozantinib) may be indicated. Biomarker testing for actionable mutations (e.g., BRAF, ALK, NTRK, RET) is recommended in these cases. \n\nThank you for your attention to this complex case.\n\nSincerely,\n[Referring Physician]","question_type":"Creative Generation","evidence":"The patient is a 58-year-old female.; The patient has a history of papillary thyroid carcinoma.; The patient underwent total thyroidectomy and radioactive iodine therapy.; The patient presents with rising serum thyroglobulin levels.; The patient has a suspicious cervical lymph node on recent neck ultrasound.; These findings suggest recurrent disease.; Relevant investigations include physical exam, TSH, Tg, Tg ab blood tests, and neck ultrasound.; Imaging with CT or MRI may be warranted for further assessment.; Management options for recurrent, resectable disease include surgical excision.; For iodine-avid recurrence, additional RAI therapy may be considered.; For unresectable or non-RAI-avid recurrence, external beam radiation therapy or targeted therapy may be indicated.; Biomarker testing for actionable mutations is recommended.","evidence_relations":"Follow-up after treatment includes physical exam, blood tests (TSH, Tg, Tg ab), and neck ultrasound.; Rising thyroglobulin after thyroidectomy may indicate recurrence.; Recurrence detection: Rising thyroglobulin, neck ultrasound, imaging (CT, MRI).; Surgery (if resectable), RAI therapy (if iodine-avid), external beam radiation therapy, targeted therapy, and clinical trial are treatment options for recurrence.; Biomarker testing is recommended for recurrent, advanced, or metastatic cancers not treatable with RAI.; Biomarkers include ALK fusion, NTRK fusion, BRAF mutation, RET fusion, dMMR, MSI-H, TMB-H.; Lenvatinib, sorafenib, and cabozantinib are targeted therapies for progressive, unresectable, or metastatic thyroid cancer."},
	{"id":"Medical-bcc6b060","source":"Medical","question":"Imagine you are a medical intern presenting a multidisciplinary case summary for a patient diagnosed with anaplastic thyroid cancer. Summarize the diagnostic findings, genetic considerations, staging, and recommended therapeutic approach.","answer":"The patient is a 68-year-old male who presented with a rapidly enlarging neck mass, hoarseness, and dysphagia. Diagnostic evaluation included TSH testing and neck ultrasound, which demonstrated a large, invasive thyroid mass with suspicious cervical lymphadenopathy. Fine-needle aspiration biopsy was performed, and pathology confirmed the diagnosis of anaplastic thyroid cancer, the most aggressive and rare subtype of thyroid malignancy. Molecular testing revealed a BRAF gene mutation, an actionable biomarker in this context. Cross-sectional imaging with CT scan identified regional lymph node involvement without evidence of distant metastases, consistent with locally advanced disease. Given the aggressive behavior and unresectability of the tumor, surgical intervention was not feasible. According to current guidelines, the recommended therapeutic approach includes external beam radiation therapy in combination with chemotherapy as primary treatment. In addition, targeted therapy may be considered if actionable mutations, such as BRAF, are present. Comprehensive biomarker testing for other mutations (e.g., ALK, NTRK, RET, dMMR, MSI-H, TMB-H) is also advised to guide potential targeted or immunotherapy options. Due to the poor prognosis and limited standard treatment options, referral for enrollment in a clinical trial for advanced thyroid cancer is recommended.","question_type":"Creative Generation","evidence":"The patient is a 68-year-old male.; The patient presents with a rapidly enlarging neck mass.; The patient has hoarseness and difficulty swallowing.; Initial workup included TSH testing and neck ultrasound.; The ultrasound revealed a large, invasive thyroid mass.; The ultrasound also showed suspicious cervical lymphadenopathy.; Fine-needle aspiration confirmed anaplastic thyroid cancer.; Molecular testing identified a BRAF gene mutation.; Imaging with CT scan showed regional lymph node involvement.; There are no distant metastases.; Surgery was deemed not feasible due to the aggressive nature of anaplastic thyroid cancer.; Current guidelines recommend external beam radiation therapy in combination with chemotherapy as primary treatment.; Targeted therapy may be considered if actionable mutations are present.; Biomarker testing for other actionable mutations is advised.; The patient was referred for enrollment in a clinical trial for advanced thyroid cancer.","evidence_relations":"Symptoms of large thyroid nodules include visible neck lump, neck pain, voice changes, trouble breathing, and swallowing problems.; TSH test and neck ultrasound are recommended for evaluation of thyroid nodules.; Fine-needle aspiration biopsy is used to sample suspicious thyroid nodules.; Pathology review determines cancer type and guides treatment.; Anaplastic thyroid cancer is the most aggressive and rarest subtype.; External beam radiation therapy is used for anaplastic, recurrent, or metastatic cancers not amenable to surgery or RAI.; Chemotherapy is rarely effective, mainly used for anaplastic thyroid cancer with radiation.; Biomarker testing is recommended for recurrent, advanced, or metastatic cancers not treatable with RAI.; BRAF gene mutation is an actionable biomarker in anaplastic thyroid cancer.; Clinical trials are recommended for patients with advanced or metastatic thyroid cancer."},
	{"id":"Medical-a688bd5b","source":"Medical","question":"Transform the current thyroid cancer surveillance and follow-up strategies into a concise patient discharge summary for a patient who underwent total thyroidectomy for papillary thyroid carcinoma.","answer":"Discharge Summary\n\nDiagnosis: Papillary thyroid carcinoma, status post total thyroidectomy\n\nHospital Course: The patient underwent an uncomplicated total thyroidectomy for papillary thyroid carcinoma. No evidence of lymph node involvement was detected intraoperatively. Postoperative recovery was uneventful.\n\nPlan:\n- Initiate lifelong levothyroxine therapy for thyroid hormone replacement, as the entire thyroid gland has been removed.\n- Schedule a follow-up neck ultrasound in 612 months to assess for local recurrence or residual disease.\n- Monitor with regular physical examinations and laboratory tests, including thyroid-stimulating hormone (TSH), thyroglobulin (Tg), and anti-thyroglobulin antibodies (Tg ab), as rising Tg levels may indicate recurrence.\n- If radioactive iodine (RAI) therapy was administered, consider a whole-body RAI scan as indicated to detect distant metastases or residual thyroid tissue.\n- Long-term surveillance will include periodic imaging (such as neck ultrasound) and laboratory monitoring to detect recurrence or metastasis, as recurrence can occur in the neck or at distant sites even after total thyroidectomy.\n\nPatient Education:\nThe patient was educated on the importance of adherence to thyroid hormone replacement, the need for ongoing surveillance, and the symptoms of recurrence (such as neck swelling, pain, or voice changes). The patient was instructed to promptly report any new or concerning symptoms.","question_type":"Creative Generation","evidence":"The patient has been diagnosed with papillary thyroid carcinoma.; The patient underwent total thyroidectomy.; No evidence of lymph node involvement was detected intraoperatively.; Postoperative recovery was uneventful.; Levothyroxine therapy should be initiated for thyroid hormone replacement.; Follow-up should be scheduled in 612 months for neck ultrasound to assess for recurrence.; Periodic physical exams and blood tests should be monitored.; Blood tests should include TSH, thyroglobulin (Tg), and anti-thyroglobulin antibodies (Tg ab).; If radioactive iodine (RAI) was administered, a whole-body RAI scan should be considered.; Long-term surveillance will include periodic imaging and laboratory monitoring to detect recurrence.; The patient was educated on symptoms of recurrence.; The patient was instructed to report any neck swelling, pain, or voice changes.","evidence_relations":"Total thyroidectomy is recommended for larger, invasive, or high-risk cancers.; Thyroid hormone replacement therapy is required after total thyroidectomy.; Levothyroxine is the standard thyroid hormone replacement.; Follow-up after treatment includes physical exam, blood tests (TSH, Tg, Tg ab), and neck ultrasound.; Neck ultrasound (6-12 months post-op) is recommended.; Whole-body RAI scan (if RAI given) is part of follow-up after total thyroidectomy.; Long-term: periodic physical exams, blood tests, neck ultrasound.; Rising thyroglobulin after thyroidectomy may indicate recurrence."},
	{"id":"Medical-900e7337","source":"Medical","question":"Draft a public health advisory summarizing key risk factors, warning symptoms, and early diagnostic recommendations for thyroid cancer based on the guideline.","answer":"**Public Health Advisory: Awareness and Early Detection of Thyroid Cancer**\n\nThyroid cancer incidence is rising, particularly among individuals with prior head or neck radiation exposure and those with a family history of thyroid disease or inherited syndromes (such as FAP, Carney complex, Cowden syndrome, and MEN). Early warning signs include a visible neck lump, neck pain, changes in voice, difficulty breathing, and swallowing problems. While most thyroid nodules are benign, prompt evaluation is crucial. Recommended initial diagnostics include a TSH blood test and neck ultrasound for any suspicious thyroid nodule. Fine-needle aspiration biopsy should be performed for nodules with concerning features. Early diagnosis enables timely treatment, which may include surgery and, for certain subtypes, radioactive iodine therapy. Public awareness of risk factors and symptoms is essential for early intervention.","question_type":"Creative Generation","evidence":"Thyroid cancer incidence is rising.; Individuals with prior head or neck radiation exposure are at higher risk for thyroid cancer.; Individuals with a family history of thyroid disease or inherited syndromes are at higher risk for thyroid cancer.; Early warning signs of thyroid cancer include a visible neck lump.; Other warning signs include neck pain, changes in voice, difficulty breathing, and swallowing problems.; Most thyroid nodules are benign.; Prompt evaluation of suspicious thyroid nodules is crucial.; Recommended initial diagnostics include a TSH blood test and neck ultrasound.; Fine-needle aspiration biopsy should be performed for nodules with concerning features.; Early diagnosis enables timely treatment.; Treatment may include surgery and radioactive iodine therapy for certain subtypes.; Public awareness of risk factors and symptoms is essential for early intervention.","evidence_relations":"Radiation exposure to the head or neck increases risk of thyroid cancer.; Family history and inherited syndromes (FAP, Carney complex, Cowden syndrome, MEN) increase risk.; Symptoms of large thyroid nodules include visible neck lump, neck pain, voice changes, trouble breathing, and swallowing problems.; Thyroid nodules are often benign but can be the origin of thyroid cancer.; TSH blood test and neck ultrasound are recommended for evaluation of thyroid nodules.; Fine-needle aspiration biopsy is used to sample suspicious thyroid nodules.; Surgery is the main treatment for most thyroid cancers.; RAI therapy is used after total thyroidectomy for differentiated thyroid cancers that take up iodine."},
	{"id":"Medical-350bcbcd","source":"Medical","question":"Imagine you are a sarcoma specialist preparing a multidisciplinary case summary for a tumor board meeting. Your patient is a 19-year-old with a newly diagnosed diaphyseal bone lesion. Summarize the key diagnostic steps, relevant biomarkers, genetic testing, staging, and initial treatment considerations as outlined by the clinical practice guidelines.","answer":"This 19-year-old patient presented with a newly diagnosed diaphyseal bone lesion. The diagnostic evaluation followed clinical practice guidelines and included a comprehensive medical and family history, physical examination, and laboratory studies (CBC, CMP, alkaline phosphatase, and LDH) to assess general health and tumor activity. Imaging with X-ray, MRI, CT, and PET scans confirmed a destructive lesion in the diaphysis. A core needle biopsy, performed at a specialized center, established the diagnosis of Ewing sarcoma. Molecular testing of the biopsy specimen identified the characteristic EWSR1-FLI1 gene fusion by PCR, confirming the diagnosis. Given the patient's young age and presentation, genetic cancer risk assessment was discussed to evaluate for potential germline mutations. Staging was conducted using the TNM system, with assessment for lymph node involvement and distant metastases, and histologic grading of the tumor was performed. The patient's performance status was evaluated using ECOG criteria to inform treatment planning. In accordance with guidelines, fertility preservation options were reviewed prior to initiating therapy, given the potential impact of systemic treatment on future fertility.","question_type":"Creative Generation","evidence":"The patient is a 19-year-old presenting with a newly diagnosed diaphyseal bone lesion.; Initial workup included detailed medical and family history.; Initial workup included physical examination.; Initial workup included laboratory evaluation with CBC, CMP, alkaline phosphatase, and LDH.; Imaging studies performed included X-ray, MRI, CT scan, and PET scan.; Imaging studies confirmed the presence of a destructive diaphyseal lesion.; Core needle biopsy was obtained.; The biopsy confirmed Ewing sarcoma.; Molecular testing identified an EWSR1-FLI1 fusion via PCR.; Genetic cancer risk assessment was discussed due to the patient's age and presentation.; Staging was performed using the TNM system.; Staging included evaluation for nodal and distant metastases.; Tumor grade was established histologically.; Performance status was evaluated using ECOG criteria to guide treatment planning.; The case was reviewed for consideration of fertility preservation prior to initiation of therapy.","evidence_relations":"Ewing sarcoma is characterized by EWSR1-ETS gene fusions, most commonly EWSR1-FLI1.; Diagnosis of bone cancer is confirmed by core needle or surgical biopsy.; Imaging tests for bone cancer include X-ray, bone scan, CT scan, MRI, and PET scan.; Genetic cancer risk testing identifies germline mutations associated with increased cancer risk.; Staging uses the TNM system: T (tumor size/location), N (lymph node involvement), M (metastasis).; Tumor grade (G) describes histologic differentiation.; Performance status (ECOG or KPS) is considered in treatment planning.; Some treatments for bone cancer can affect fertility; fertility preservation should be discussed before treatment.; Blood tests such as alkaline phosphatase, CBC, CMP, and LDH are used in evaluation."},
	{"id":"Medical-a5356e35","source":"Medical","question":"You are a medical oncologist tasked with drafting a referral letter to a tertiary cancer center for a patient with suspected chondrosarcoma. Transform the clinical findings into a formal referral note, including relevant diagnostics, biomarkers, and potential targeted therapies based on the provided guidelines.","answer":"Dear Colleagues,\n\nI am referring a 54-year-old patient with a cartilage-forming bone lesion, radiographically and histologically consistent with chondrosarcoma. Imaging with X-ray, CT, and MRI revealed a lobulated mass originating in cartilage-forming cells. Core needle biopsy confirmed diagnosis. Laboratory evaluation included alkaline phosphatase, CBC, CMP, and LDH. Next-generation sequencing identified an IDH1 mutation. Staging was performed using the TNM system, and tumor grade was determined histologically. Given the presence of IDH1 mutation, consideration for ivosidenib as a targeted therapy is warranted. The patients ECOG performance status is 1. Fertility preservation has been discussed given the potential impact of systemic therapy.","question_type":"Creative Generation","evidence":"The patient is a 54-year-old with a cartilage-forming bone lesion.; The lesion is radiographically and histologically consistent with chondrosarcoma.; Imaging with X-ray, CT, and MRI revealed a lobulated mass originating in cartilage-forming cells.; Core needle biopsy confirmed the diagnosis of chondrosarcoma.; Laboratory evaluation included alkaline phosphatase, CBC, CMP, and LDH.; Next-generation sequencing identified an IDH1 mutation.; Staging was performed using the TNM system.; Tumor grade was determined histologically.; The patient's ECOG performance status is 1.; Fertility preservation has been discussed due to the potential impact of systemic therapy.","evidence_relations":"Chondrosarcoma starts in cartilage-forming cells.; Diagnosis of bone cancer is confirmed by core needle or surgical biopsy.; Imaging tests for bone cancer include X-ray, bone scan, CT scan, MRI, and PET scan.; Biomarker testing includes identification of gene mutations (e.g., IDH1), protein expression, and tumor mutational burden.; IDH1 mutation in chondrosarcoma can be targeted with ivosidenib.; Staging uses the TNM system: T (tumor size/location), N (lymph node involvement), M (metastasis).; Tumor grade (G) describes histologic differentiation.; Performance status (ECOG or KPS) is considered in treatment planning.; Some treatments for bone cancer can affect fertility; fertility preservation should be discussed before treatment."},
	{"id":"Medical-25bac94b","source":"Medical","question":"Rewrite the clinical recommendations for bone cancer diagnosis and initial evaluation into a structured SOAP (Subjective, Objective, Assessment, Plan) note suitable for inclusion in an oncology clinic chart.","answer":"Subjective: Patient reports persistent, localized bone pain and swelling over several weeks. No significant personal or family history of cancer noted.\n\nObjective: Physical exam reveals tenderness and mild swelling over the metaphyseal region. X-ray and MRI demonstrate a destructive lesion. Laboratory studies show elevated alkaline phosphatase and LDH. Core needle biopsy performed.\n\nAssessment: Primary bone sarcoma (differential includes osteosarcoma, Ewing sarcoma, chondrosarcoma). Tumor grade and histologic subtype pending biopsy results. TNM staging and performance status (ECOG) assessed.\n\nPlan: Complete staging with CT chest and PET scan. Initiate genetic cancer risk and biomarker testing (including IDH1, MSI-H/dMMR, TMB-H). Discuss fertility preservation prior to therapy. Multidisciplinary review planned.","question_type":"Creative Generation","evidence":"The patient reports persistent, localized bone pain.; The patient reports swelling over several weeks.; There is no significant personal history of cancer noted.; There is no significant family history of cancer noted.; Physical exam reveals tenderness over the metaphyseal region.; Physical exam reveals mild swelling over the metaphyseal region.; X-ray demonstrates a destructive lesion.; MRI demonstrates a destructive lesion.; Laboratory studies show elevated alkaline phosphatase.; Laboratory studies show elevated LDH.; A core needle biopsy was performed.; The assessment indicates primary bone sarcoma.; Differential diagnoses include osteosarcoma, Ewing sarcoma, and chondrosarcoma.; Tumor grade and histologic subtype are pending biopsy results.; TNM staging was assessed.; Performance status (ECOG) was assessed.; The plan includes complete staging with CT chest and PET scan.; The plan includes initiating genetic cancer risk and biomarker testing.; The plan includes discussing fertility preservation prior to therapy.; A multidisciplinary review is planned.","evidence_relations":"Bone sarcomas include osteosarcoma, Ewing sarcoma, chondrosarcoma, chordoma, and giant cell tumor of bone.; Osteosarcoma commonly arises in the metaphysis near growth plates.; Diagnosis of bone cancer is confirmed by core needle or surgical biopsy.; Imaging tests for bone cancer include X-ray, bone scan, CT scan, MRI, and PET scan.; Blood tests such as alkaline phosphatase, CBC, CMP, and LDH are used in evaluation.; Biomarker testing includes identification of gene mutations (e.g., IDH1), protein expression, and tumor mutational burden.; Genetic cancer risk testing identifies germline mutations associated with increased cancer risk.; Staging uses the TNM system: T (tumor size/location), N (lymph node involvement), M (metastasis).; Tumor grade (G) describes histologic differentiation.; Performance status (ECOG or KPS) is considered in treatment planning.; Some treatments for bone cancer can affect fertility; fertility preservation should be discussed before treatment."},
	{"id":"Medical-3d413e64","source":"Medical","question":"As a public health officer, draft an advisory for primary care providers on the early recognition, diagnostic workup, and referral process for suspected primary bone cancers, integrating risk factors and the importance of multidisciplinary management.","answer":"Public Health Advisory: Early Recognition, Diagnostic Workup, and Referral for Suspected Primary Bone Cancers\n\nPrimary care providers play a critical role in the early detection of primary bone cancers. Maintain a high index of suspicion for persistent, localized bone pain, swelling, or unexplained fractures, especially in adolescents and young adults. Early recognition is essential, as delayed diagnosis can adversely affect outcomes.\n\nInitial evaluation should include a thorough medical and family history, with attention to any personal or familial cancer history or known germline mutations, as these increase risk. A focused physical examination should assess for localized tenderness, swelling, or masses. Early imaging with X-ray is recommended for any suspicious bone symptoms; MRI should be considered for further characterization of lesions. Laboratory workup should include alkaline phosphatase, complete blood count (CBC), comprehensive metabolic panel (CMP), and lactate dehydrogenase (LDH), as these may support the diagnosis and help assess disease extent.\n\nDefinitive diagnosis requires a core needle or surgical biopsy, which should be performed at a center experienced in bone sarcoma care to avoid compromising future treatment. Staging should be performed using the TNM system, and tumor grading should be obtained to guide management decisions.\n\nPrompt referral to a multidisciplinary sarcoma team is essential for optimal care, as management often requires coordination among oncology, surgery, radiology, pathology, and other specialties. Discuss fertility preservation with patients prior to initiation of therapy, as some treatments may impact reproductive potential. Early and coordinated care improves patient outcomes and quality of life.","question_type":"Creative Generation","evidence":"Primary care providers should be vigilant for persistent bone pain.; Primary care providers should be vigilant for swelling.; Primary care providers should be vigilant for unexplained fractures.; This is particularly important in adolescents and young adults.; Early imaging such as X-ray and MRI is essential for suspicious bone lesions.; Diagnostic confirmation requires core needle or surgical biopsy.; Laboratory evaluation should include alkaline phosphatase.; Laboratory evaluation should include CBC.; Laboratory evaluation should include CMP.; Laboratory evaluation should include LDH.; Family history of cancer increases risk.; Germline mutations increase risk.; Genetic risk assessment should be considered in relevant cases.; Staging via the TNM system guides management.; Prompt referral to a multidisciplinary sarcoma team is recommended.; Fertility preservation should be discussed prior to initiation of therapy.","evidence_relations":"Primary bone cancer originates in bone or cartilage.; Most primary bone cancers are sarcomas.; Diagnosis of bone cancer is confirmed by core needle or surgical biopsy.; Imaging tests for bone cancer include X-ray, bone scan, CT scan, MRI, and PET scan.; Blood tests such as alkaline phosphatase, CBC, CMP, and LDH are used in evaluation.; Family history of cancer and germline mutations increase cancer risk.; Staging uses the TNM system: T (tumor size/location), N (lymph node involvement), M (metastasis).; Tumor grade (G) describes histologic differentiation.; Some treatments for bone cancer can affect fertility; fertility preservation should be discussed before treatment.; Multidisciplinary management is essential in bone sarcoma care."},
	{"id":"Medical-fc1f08f3","source":"Medical","question":"You are a clinical intern tasked with creating a concise discharge summary for a patient treated for Stage II osteosarcoma of the distal femur. The summary should include diagnostic methods, staging, laboratory findings, performance status, and follow-up recommendations, as per the guideline.","answer":"Discharge Summary:\n\nDiagnosis: Stage II osteosarcoma of the distal femur.\n\nDiagnostic Workup: Diagnosis confirmed by core needle biopsy. Imaging studies included X-ray, MRI, CT scan, and PET scan, which localized the tumor to the metaphysis of the distal femur. Laboratory evaluation showed elevated alkaline phosphatase and LDH. Tumor grade was G2. Staging performed using the TNM system (T2N0M0). ECOG performance status was 0 at diagnosis.\n\nTreatment: Patient completed surgical resection and adjuvant therapy as per protocol. Fertility preservation was discussed prior to treatment initiation.\n\nFollow-up: Scheduled for surveillance imaging and laboratory monitoring. Monitoring for recurrence, late effects, and consideration of genetic cancer risk testing recommended.","question_type":"Creative Generation","evidence":"The diagnosis is Stage II osteosarcoma of the distal femur.; Diagnosis was confirmed by core needle biopsy.; Imaging studies included X-ray, MRI, CT scan, and PET scan.; The tumor was localized to the metaphysis of the distal femur.; Laboratory evaluation showed elevated alkaline phosphatase.; Laboratory evaluation showed elevated LDH.; The tumor grade was G2.; Staging was performed using the TNM system.; The TNM classification was T2N0M0.; ECOG performance status was 0 at diagnosis.; The patient completed surgical resection.; The patient completed adjuvant therapy as per protocol.; Fertility preservation was discussed prior to treatment initiation.; Follow-up includes scheduled surveillance imaging.; Follow-up includes laboratory monitoring.; Monitoring for recurrence and late effects is recommended.; Consideration of genetic cancer risk testing is recommended.","evidence_relations":"Osteosarcoma commonly arises in the metaphysis near growth plates.; Diagnosis of bone cancer is confirmed by core needle or surgical biopsy.; Imaging tests for bone cancer include X-ray, bone scan, CT scan, MRI, and PET scan.; Blood tests such as alkaline phosphatase, CBC, CMP, and LDH are used in evaluation.; Stage is determined by combining T, N, M, and G scores.; Tumor grade (G) describes histologic differentiation.; Performance status (ECOG or KPS) is considered in treatment planning.; Some treatments for bone cancer can affect fertility; fertility preservation should be discussed before treatment.; Genetic cancer risk testing identifies germline mutations associated with increased cancer risk."},
	{"id":"Medical-d446abb7","source":"Medical","question":"You are a head and neck oncology specialist receiving a referral for a 57-year-old patient with a suspicious ulcer on the lateral tongue. Construct a detailed diagnostic and initial staging workflow for this patient, integrating guideline-recommended assessments and justifying each step.","answer":"The diagnostic and initial staging workflow for a 57-year-old patient with a suspicious ulcer on the lateral tongue should follow guideline-recommended steps to ensure accurate diagnosis, staging, and multidisciplinary care planning:\n\n1. Clinical Assessment: Begin with a comprehensive medical history and thorough physical examination of the oral cavity, focusing on the lateral tongue lesion and palpation of regional lymph nodes in the neck to assess for lymphadenopathy. Document any symptoms, risk factors (such as tobacco or alcohol use), and relevant comorbidities.\n\n2. Imaging Studies: Order high-resolution MRI of the oral cavity and neck to evaluate the local extent of the primary tumor, including depth of invasion (DOI), which is critical for staging and treatment planning. Complement with a contrast-enhanced CT scan or PET/CT to assess for regional lymph node involvement and to rule out distant metastasis, as per staging guidelines.\n\n3. Tissue Diagnosis: Arrange for a biopsy of the tongue lesion (preferably incisional or punch biopsy) to confirm histopathology, most commonly squamous cell carcinoma. If palpable or radiologically suspicious lymph nodes are present, perform fine-needle aspiration (FNA) or core needle biopsy (CNB) to assess for metastatic involvement and extranodal extension.\n\n4. Biomarker and Molecular Testing: Conduct biomarker testing on the tumor specimen for PD-L1 expression, microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR), and tumor mutational burden (TMB), as these may inform eligibility for targeted or immunotherapy options.\n\n5. Performance Status: Evaluate the patients functional status using the ECOG (Eastern Cooperative Oncology Group) scale to guide treatment selection and anticipate tolerance to therapy.\n\n6. Multidisciplinary Supportive Assessments: Coordinate dental evaluation to address potential dental issues prior to therapy, and arrange for speech and swallowing as well as nutrition assessments, given the impact of both the disease and its treatment on these functions.\n\nEach of these steps is justified by current guidelines to ensure accurate staging (using the TNM system), optimal treatment planning, and comprehensive supportive care for patients with suspected oral cavity cancer.","question_type":"Creative Generation","evidence":"A thorough clinical examination of the oral cavity and neck is performed.; Special attention is given to the lateral tongue.; Special attention is given to regional lymph nodes.; Imaging studies including MRI are ordered for local tumor extent.; Imaging studies including CT scan or PET/CT are ordered to assess for regional lymph node involvement.; A biopsy of the lesion is arranged to confirm squamous cell carcinoma histology.; If lymphadenopathy is present, fine-needle aspiration (FNA) or core needle biopsy (CNB) of the lymph node is recommended.; Biomarker testing for PD-L1, MSI-H/dMMR, and tumor mutational burden (TMB) is conducted.; The patient's performance status (ECOG) is assessed to guide treatment selection.; Dental, speech and swallowing, and nutrition assessments are coordinated.","evidence_relations":"Mouth cancer can develop in the tongue (front two-thirds).; Imaging tests such as CT, MRI, PET/CT, and ultrasound are used for diagnosis and staging.; Depth of invasion (DOI) is used to assess tumor extension in mouth cancer.; Biopsy is required to confirm diagnosis and determine histology.; Fine-needle aspiration (FNA) or core needle biopsy (CNB) is used to assess lymph node involvement.; Biomarker testing may include PD-L1, MSI-H/dMMR, and tumor mutational burden (TMB).; Performance status (ECOG) is considered in treatment selection.; Dental health is affected by head and neck cancer and its treatment.; Speech and swallowing assessment and nutrition assessment are recommended in the diagnostic workup."},
	{"id":"Medical-fce3c59a","source":"Medical","question":"Rewrite the essential steps of initial mouth cancer evaluation and staging into a formal SOAP (Subjective, Objective, Assessment, Plan) progress note. Use the facts from the guideline to ensure clinical accuracy.","answer":"**S: (Subjective)**\nPatient reports a persistent sore and changes in the lateral tongue for 3 weeks, with mild discomfort. Denies dysphagia or weight loss. History of tobacco and alcohol use.\n\n**O: (Objective)**\nExam: Ulcerative lesion on lateral tongue (front two-thirds), enlarged ipsilateral submandibular lymph node. Performance status ECOG 1. \nImaging: MRI shows lesion 2.5 cm with depth of invasion 8 mm. CT scan negative for distant metastasis. Panoramic dental x-ray reveals dental health concerns.\nBiopsy: Squamous cell carcinoma confirmed. FNA of lymph node positive for metastasis, no extranodal extension.\nBiomarker testing: Pending.\n\n**A: (Assessment)**\nStage II oral cavity squamous cell carcinoma of the tongue with ipsilateral nodal involvement, history of tobacco and alcohol use, ECOG 1.\n\n**P: (Plan)**\n- Complete biomarker testing (PD-L1, MSI-H/dMMR, TMB)\n- Multidisciplinary tumor board discussion\n- Dental, speech and swallowing, and nutrition assessments\n- Smoking/alcohol cessation counseling\n- Discuss fertility preservation as appropriate\n- Initiate treatment planning based on final staging and patient values.","question_type":"Creative Generation","evidence":"The patient reports a persistent sore on the lateral tongue.; The patient reports changes in the lateral tongue for 3 weeks.; The patient reports mild discomfort.; The patient denies dysphagia.; The patient denies weight loss.; The patient has a history of tobacco use.; The patient has a history of alcohol use.; An ulcerative lesion is found on the lateral tongue.; An enlarged ipsilateral submandibular lymph node is noted.; The performance status is ECOG 1.; MRI shows a lesion measuring 2.5 cm with a depth of invasion of 8 mm.; CT scan is negative for distant metastasis.; A panoramic dental x-ray reveals dental health concerns.; A biopsy confirmed squamous cell carcinoma.; FNA of the lymph node is positive for metastasis.; There is no extranodal extension.; Biomarker testing is pending.; The assessment indicates Stage II oral cavity squamous cell carcinoma of the tongue with ipsilateral nodal involvement.; The patient has a history of tobacco and alcohol use.; The performance status is ECOG 1.; The plan includes completing biomarker testing.; The plan includes a multidisciplinary tumor board discussion.; The plan includes dental, speech and swallowing, and nutrition assessments.; The plan includes smoking/alcohol cessation counseling.; The plan includes discussing fertility preservation as appropriate.; The plan includes initiating treatment planning based on final staging and patient values.","evidence_relations":"Mouth cancer can develop in the tongue (front two-thirds).; Squamous cell carcinoma (SCC) is the most common subtype of mouth cancer.; Cancer staging is based on the TNM system, which includes tumor size and depth (T), lymph node involvement (N), and distant metastasis (M).; Imaging tests such as CT, MRI, PET/CT, and ultrasound are used for diagnosis and staging.; Biopsy is required to confirm diagnosis and determine histology.; Fine-needle aspiration (FNA) is used for lymph node evaluation.; Performance status (ECOG) is considered in treatment selection.; Tobacco and alcohol use are risk factors for mouth cancer.; Dental health is affected by head and neck cancer and its treatment.; Speech and swallowing assessment and nutrition assessment are part of the diagnostic process.; Biomarker testing may include PD-L1, MSI-H/dMMR, and tumor mutational burden (TMB).; Cancer and its treatment can affect fertility."},
	{"id":"Medical-4654807f","source":"Medical","question":"Imagine you are a patient navigator counseling a newly diagnosed mouth cancer patient who is concerned about treatment side effects and fertility. Write an educational summary explaining the diagnostic process, risk factors, potential treatment impacts, and available supportive services, using evidence from the guideline.","answer":"As your patient navigator, I am here to help you understand your diagnosis and the steps ahead. Mouth cancer, most commonly squamous cell carcinoma, can develop in areas such as the lips, gums, tongue, buccal mucosa, hard palate, alveolar ridge, floor of mouth, and retromolar trigone. The diagnostic process includes a thorough medical history, physical examination, and imaging tests like CT, MRI, or PET/CT to assess the size and extent of the tumor and whether it has spread to lymph nodes or other areas. A biopsy is required to confirm the diagnosis and determine the specific type of cancer. Additional tests, such as biomarker analysis, may be performed to guide treatment options.\n\nTobacco and alcohol use are significant risk factors for mouth cancer, and stopping these habits can improve your treatment outcomes and reduce side effects. Treatment planning is individualized based on the tumor's location and stage, and may include surgery, radiation, or other therapies. These treatments can impact dental health, as well as speech and swallowing function, so dental, speech, and nutrition assessments are recommended as part of your care. For patients of reproductive age, it is important to discuss fertility preservation before starting treatment, as some therapies can affect fertility. Supportive services are available to help you manage side effects, maintain nutrition, and address emotional and practical needs throughout your treatment journey.","question_type":"Creative Generation","evidence":"Mouth cancer is most often a type called squamous cell carcinoma.; Mouth cancer can occur in areas like the lips, gums, and tongue.; Diagnosis involves imaging tests such as CT, MRI, or PET/CT.; Imaging tests are used to see the tumor's size and whether it has spread.; A biopsy is performed to confirm the type of cancer.; The patient's history of tobacco and alcohol use are risk factors for mouth cancer.; Quitting tobacco and alcohol can improve treatment outcomes.; Treatments are planned based on the tumor's location and stage.; Treatments may affect dental health.; Treatments may affect speech and swallowing.; Fertility preservation options are discussed for patients of reproductive age.; Some treatments can impact fertility.; Supportive services include dental, speech, and nutrition assessments.","evidence_relations":"Squamous cell carcinoma (SCC) is the most common subtype of mouth cancer.; Mouth cancer can develop in the lips, gums, buccal mucosa, tongue, hard palate, alveolar ridge, floor of mouth, and retromolar trigone.; Imaging tests such as CT, MRI, PET/CT, and ultrasound are used for diagnosis and staging.; Biopsy is required to confirm diagnosis and determine histology.; Tobacco and alcohol use are risk factors for mouth cancer.; Smoking or vaping negatively affects treatment outcomes and increases toxicity.; Treatment planning is based on tumor location and stage.; Dental health is affected by head and neck cancer and its treatment.; Speech and swallowing assessment and nutrition assessment are recommended.; Cancer and its treatment can affect fertility.; Fertility preservation is a consideration in treatment planning."},
	{"id":"Medical-afaa48c4","source":"Medical","question":"You are a multidisciplinary tumor board coordinator tasked with drafting a template for a mouth cancer case summary to be used in board meetings. The template must prompt for all critical diagnostic, staging, and supportive care domains as outlined in the guideline.","answer":"**Mouth Cancer Tumor Board Case Summary Template**\n\n1. **Patient Demographics:** Age, sex, and relevant medical and social history, including tobacco, vaping, and alcohol use.\n2. **Anatomic Site:** Specify the precise location of the primary tumor (e.g., tongue, buccal mucosa, floor of mouth, hard palate, alveolar ridge, retromolar trigone, lips, or gums).\n3. **Symptom Description:** Document presenting symptoms and changes in the mouth, tongue, or neck, such as pain, ulceration, mass, dysphagia, or speech changes.\n4. **Diagnostic Imaging:** Summarize findings from CT, MRI, PET/CT, and/or ultrasound, including tumor size, local extension, lymph node involvement, and depth of invasion (DOI).\n5. **Histology:** Biopsy results specifying tumor type (e.g., squamous cell carcinoma), grade, and any relevant pathological features.\n6. **TNM Staging:** Detail tumor size and depth (T), regional lymph node involvement (N), and presence or absence of distant metastasis (M) according to the AJCC/UICC system.\n7. **Biomarker Results:** Include results of molecular and biomarker testing (e.g., PD-L1, MSI-H/dMMR, tumor mutational burden [TMB]) if performed.\n8. **Performance Status:** ECOG or Karnofsky performance status assessment.\n9. **Dental Assessment:** Panoramic dental x-ray and findings relevant to pre-treatment dental health and potential interventions.\n10. **Speech, Swallowing, and Nutrition Assessment:** Summarize baseline function and any identified needs for supportive care.\n11. **Fertility Considerations:** Note if fertility preservation has been discussed and addressed, particularly in younger patients.\n12. **Risk Factors:** Document history of tobacco use, vaping, alcohol consumption, and other relevant exposures.\n13. **Treatment Planning:** Outline proposed treatment approach (surgery, radiation, systemic therapy), rationale, and any anticipated challenges.\n14. **Supportive Needs:** Identify needs for smoking and alcohol cessation support, dental care, speech and swallowing therapy, nutritional support, and psychosocial resources.","question_type":"Creative Generation","evidence":"The template is for a mouth cancer tumor board case summary.; Patient demographics should include age, sex, and relevant history.; The anatomical site should specify the location within the mouth.; Symptom description should document changes in the mouth, tongue, or neck.; Diagnostic imaging should include findings from CT, MRI, PET/CT, or ultrasound.; Histology should include the biopsy result.; TNM staging should include tumor size, depth, nodal involvement, and metastasis.; Biomarker results should include PD-L1, MSI-H/dMMR, and TMB.; Performance status should include the ECOG score.; Dental assessment should include findings from a panoramic dental x-ray.; Speech, swallowing, and nutrition assessments should be summarized.; Fertility considerations should be noted and addressed if relevant.; Risk factors should include smoking, vaping, and alcohol use.; Treatment planning should include the proposed approach and rationale.; Supportive needs should include smoking/alcohol cessation and dental, speech, and nutritional support.","evidence_relations":"Mouth cancer can develop in the lips, gums, buccal mucosa, tongue, hard palate, alveolar ridge, floor of mouth, and retromolar trigone.; Symptoms may include changes in the mouth, tongue, or neck area.; Imaging tests such as CT, MRI, PET/CT, and ultrasound are used for diagnosis and staging.; Depth of invasion (DOI) is used to assess tumor extension in mouth cancer.; Biopsy is required to confirm diagnosis and determine histology.; Cancer staging is based on the TNM system, which includes tumor size and depth (T), lymph node involvement (N), and distant metastasis (M).; Biomarker testing may include PD-L1, MSI-H/dMMR, and tumor mutational burden (TMB).; Performance status (ECOG) is considered in treatment selection.; Dental health is affected by head and neck cancer and its treatment.; Speech and swallowing assessment and nutrition assessment are recommended.; Fertility preservation is a consideration in treatment planning.; Tobacco and alcohol use are risk factors for mouth cancer.; Smoking or vaping negatively affects treatment outcomes and increases toxicity.; Treatment planning is based on tumor location and stage."},
	{"id":"Medical-53e61e6b","source":"Medical","question":"Rewrite the mouth cancer practice guideline into a concise discharge summary for a patient who underwent initial evaluation and is pending definitive treatment. Include diagnostic findings, staging, risk factors, and recommendations for next steps.","answer":"**Discharge Summary**\n\nPatient: [Name], [Age/Sex]\nDiagnosis: Squamous cell carcinoma of the oral cavity (tongue, front two-thirds)\n\nSummary:\nThe patient presented with a lesion of the lateral tongue. Imaging (MRI, CT) revealed a 2.2 cm mass with a depth of invasion of 6 mm and no evidence of distant metastasis. Biopsy confirmed squamous cell carcinoma. Fine-needle aspiration of a submandibular lymph node was negative for metastasis. Performance status is ECOG 1. The patient has a history of tobacco and alcohol use. Panoramic dental x-ray identified dental issues requiring management before treatment. Biomarker testing (PD-L1, MSI-H/dMMR, TMB) is pending.\n\nStaging: Stage II (T2N0M0) per TNM classification.\n\nRecommendations:\n- Complete biomarker testing\n- Dental, speech and swallowing, and nutrition assessments\n- Smoking and alcohol cessation support\n- Discuss fertility preservation if relevant\n- Multidisciplinary tumor board review for treatment planning\n\nFollow-up: Outpatient oncology clinic in 1 week.","question_type":"Creative Generation","evidence":"The patient is diagnosed with squamous cell carcinoma of the oral cavity.; The lesion is located on the tongue, specifically the front two-thirds.; Imaging (MRI, CT) revealed a 2.2 cm mass.; The depth of invasion is 6 mm.; There is no evidence of distant metastasis.; A biopsy confirmed squamous cell carcinoma.; Fine-needle aspiration of a submandibular lymph node was negative for metastasis.; The performance status is ECOG 1.; The patient has a history of tobacco use.; The patient has a history of alcohol use.; A panoramic dental x-ray identified dental issues requiring management.; Biomarker testing (PD-L1, MSI-H/dMMR, TMB) is pending.; The staging is Stage II (T2N0M0) per TNM classification.; Recommendations include completing biomarker testing.; Recommendations include dental, speech and swallowing, and nutrition assessments.; Recommendations include smoking and alcohol cessation support.; Recommendations include discussing fertility preservation if relevant.; Recommendations include multidisciplinary tumor board review for treatment planning.; Follow-up is scheduled for the outpatient oncology clinic in 1 week.","evidence_relations":"Squamous cell carcinoma (SCC) is the most common subtype of mouth cancer.; Mouth cancer can develop in the tongue (front two-thirds).; Imaging tests such as CT, MRI, PET/CT, and ultrasound are used for diagnosis and staging.; Depth of invasion (DOI) is used to assess tumor extension in mouth cancer.; Biopsy is required to confirm diagnosis and determine histology.; Fine-needle aspiration (FNA) is used for lymph node evaluation.; Cancer staging is based on the TNM system, which includes tumor size and depth (T), lymph node involvement (N), and distant metastasis (M).; Performance status (ECOG) is considered in treatment selection.; Tobacco and alcohol use are risk factors for mouth cancer.; Dental health is affected by head and neck cancer and its treatment.; Biomarker testing may include PD-L1, MSI-H/dMMR, and tumor mutational burden (TMB).; Speech and swallowing assessment and nutrition assessment are recommended.; Fertility preservation is a consideration in treatment planning."},
	{"id":"Medical-4a6fc716","source":"Medical","question":"You are a gastroenterologist receiving a referral for a 58-year-old patient with suspected stomach cancer. Using the provided clinical practice guideline, compose a detailed diagnostic workup plan, including the rationale for each step and the relevance to staging and treatment selection.","answer":"The diagnostic workup for a 58-year-old patient with suspected stomach cancer should be comprehensive and structured to inform both staging and treatment selection, as outlined in clinical practice guidelines. The process begins with an upper endoscopy, which allows direct visualization of the gastric mucosa and enables targeted biopsies of any suspicious lesions or masses. Histopathological examination of these biopsies is essential to confirm the diagnosis, determine if the tumor is an adenocarcinoma, and distinguish between intestinal and diffuse subtypesinformation that is critical for prognosis and therapeutic decisions. \n\nFollowing tissue diagnosis, cross-sectional imaging studies such as contrast-enhanced CT or MRI of the abdomen and pelvis are performed to assess the local extent of the tumor, involvement of the stomach wall layers, and the presence of regional lymph node metastases or distant spread to organs such as the liver or peritoneum. This imaging is vital for accurate staging, which differentiates early-stage disease (confined to the mucosa) from locoregional (invasion of deeper layers or regional nodes) and metastatic disease (spread to distant organs).\n\nBiomarker testing on tumor tissue is recommended, particularly for intestinal-type adenocarcinoma, to identify actionable molecular targets that may guide the use of targeted therapies. If there is a family history of gastric cancer or other risk factors suggesting a hereditary syndrome, genetic risk testing should be offered, as this may influence both treatment planning and recommendations for family members.\n\nAdditional baseline assessments, such as general health evaluation, nutrition assessment, and blood tests, are also important to determine the patients overall fitness for therapy and to identify any comorbidities that may impact management. This systematic approach ensures precise staging and supports the selection of the most appropriate, evidence-based treatment strategy for the patient.","question_type":"Creative Generation","evidence":"The diagnostic workup begins with upper endoscopy.; Upper endoscopy is used to directly visualize the gastric mucosa.; Biopsies are obtained from any suspicious lesions or masses during endoscopy.; Histopathological examination determines if the tumor is an adenocarcinoma.; Histopathological examination helps distinguish between intestinal and diffuse subtypes.; Imaging tests such as CT or MRI assess the extent of disease.; Imaging tests assess invasion into stomach wall layers.; Imaging tests assess potential spread to regional lymph nodes.; Imaging tests assess potential spread to distant organs like the liver or peritoneum.; Biomarker testing on biopsy samples identifies molecular targets.; Biomarker testing is especially relevant in intestinal-type adenocarcinoma.; Genetic risk testing is offered if there is a family history.; Hereditary syndromes may impact treatment planning.; This comprehensive approach ensures accurate staging.; Accurate staging distinguishes early-stage from locoregional or metastatic disease.; Accurate staging guides selection of appropriate therapy.","evidence_relations":"Diagnosis involves imaging tests, endoscopy, biopsy, biomarker testing, and genetic risk testing.; Most stomach cancers are adenocarcinomas.; There are two major subtypes of stomach adenocarcinoma: intestinal and diffuse.; Intestinal type adenocarcinoma forms tube- and gland-shaped structures and is more likely to have mutations treatable with targeted therapy.; Early-stage stomach cancer is confined to the mucosa and is not present in lymph nodes.; Locoregional or locally advanced stomach cancer invades other layers of the stomach wall and/or regional lymph nodes or nearby organs.; Metastatic stomach cancer has spread to distant organs such as the liver, peritoneum, or distant lymph nodes.; Family history is a risk factor for stomach cancer."},
	{"id":"Medical-46f66098","source":"Medical","question":"Imagine you are a multidisciplinary tumor board coordinator tasked with summarizing the key factors that determine the management approach for stomach cancer patients. Provide a structured case summary template integrating anatomical, pathological, and risk factor information as per the guideline.","answer":"Case Summary Template for Stomach Cancer Management:\n\n1. Patient Demographics: Age, sex, relevant history\n2. Anatomical Location: Specify site within stomach (e.g., cardia, fundus, body, antrum, pylorus, esophagogastric junction)\n3. Tumor Histology: Adenocarcinoma (intestinal or diffuse type)\n4. Tumor Stage: Early-stage (confined to mucosa, no lymph node involvement), Locoregional (invasion of other stomach wall layers and/or regional lymph nodes), Metastatic (spread to distant organs such as liver, peritoneum, distant lymph nodes)\n5. Spread Pattern: Local extension (wall layers, lymph nodes) vs distant (liver, peritoneum, pancreas, spleen)\n6. Risk Factors: H. pylori infection, family history\n7. Diagnostic Methods Used: Imaging, endoscopy, biopsy, biomarker testing, genetic risk testing\n8. Symptoms: Presence of ulcer, mass, or other relevant findings\n\nThis structured template ensures all critical factors influencing management are systematically considered.","question_type":"Creative Generation","evidence":"The case summary template is for stomach cancer management.; Patient demographics should include age, sex, and relevant history.; Anatomical location should specify the site within the stomach.; Tumor histology should indicate if it is adenocarcinoma and its subtype.; Tumor stage should indicate if it is early-stage, locoregional, or metastatic.; Spread pattern should indicate local extension versus distant spread.; Risk factors should include H. pylori infection and family history.; Diagnostic methods used should include imaging, endoscopy, biopsy, biomarker testing, and genetic risk testing.; Symptoms should include the presence of ulcer, mass, or other relevant findings.","evidence_relations":"Anatomical Location: [Cardia, Fundus, Body, Antrum, Pylorus, Esophagogastric junction]; Most stomach cancers are adenocarcinomas.; There are two major subtypes of stomach adenocarcinoma: intestinal and diffuse.; Early-stage stomach cancer is confined to the mucosa and is not present in lymph nodes.; Locoregional or locally advanced stomach cancer invades other layers of the stomach wall and/or regional lymph nodes or nearby organs.; Metastatic stomach cancer has spread to distant organs such as the liver, peritoneum, or distant lymph nodes.; Stomach cancer spreads outward through the layers of the stomach wall.; Diagnosis involves imaging tests, endoscopy, biopsy, biomarker testing, and genetic risk testing.; H. pylori infection is a risk factor for stomach cancer.; Family history is a risk factor for stomach cancer.; Symptoms can include ulcer or mass formation in the stomach."},
	{"id":"Medical-d5faa97f","source":"Medical","question":"Rewrite the clinical guideline information into a formal discharge summary for a patient diagnosed with early-stage intestinal-type stomach adenocarcinoma, specifying the diagnostic findings, risk factors, and recommendations for follow-up.","answer":"Discharge Summary:\n\nPatient Name: [Redacted]\nDate of Discharge: [Redacted]\n\nDiagnosis:\nEarly-stage intestinal-type stomach adenocarcinoma\n\nDiagnostic Findings:\n- Upper endoscopy identified a localized mass within the gastric mucosa. Biopsy confirmed the diagnosis of intestinal-type adenocarcinoma, characterized by glandular and tubular structures.\n- Imaging studies (CT/MRI) demonstrated that the lesion is confined to the mucosa, with no evidence of regional lymph node involvement or distant metastasis, consistent with early-stage disease.\n- Biomarker testing is pending; to date, no actionable mutations have been identified.\n- Family history is significant for stomach cancer, and the patient has undergone genetic risk assessment for hereditary cancer syndromes.\n- Testing revealed Helicobacter pylori infection, which has been appropriately treated.\n\nRisk Factors:\n- Positive family history of gastric cancer, increasing hereditary risk.\n- Prior H. pylori infection, a known modifiable risk factor for gastric adenocarcinoma.\n\nRecommendations for Follow-up:\n- Schedule regular surveillance endoscopy to monitor for recurrence or development of new gastric lesions, as per current clinical guidelines.\n- Continue coordinated follow-up with oncology and gastroenterology teams for ongoing management and surveillance.\n- Provide family counseling regarding genetic risk, and consider screening for at-risk relatives.\n- Educate patient to monitor for and promptly report symptoms such as abdominal pain, gastrointestinal bleeding, ulcer formation, or new mass development.\n- Maintain communication with the primary care provider and ensure all test results and treatment updates are documented and accessible.\n\nThe patient is currently stable and is being discharged in good condition with comprehensive follow-up plans in place.","question_type":"Creative Generation","evidence":"The patient was diagnosed with early-stage intestinal-type stomach adenocarcinoma.; Endoscopy revealed a localized mass in the gastric mucosa.; A biopsy confirmed adenocarcinoma of intestinal type.; Imaging studies showed the lesion was confined to the mucosa.; There was no evidence of lymph node involvement.; There was no evidence of distant metastasis.; Biomarker testing is pending.; No actionable mutations have been identified to date.; The family history is positive for stomach cancer.; The patient was tested for relevant genetic risk factors.; H. pylori infection was detected and treated.; Regular surveillance endoscopy is recommended to monitor for recurrence or new lesions.; Continued follow-up with oncology and gastroenterology is recommended.; Family counseling regarding genetic risk and possible screening is recommended.; The patient should monitor for symptoms such as ulcer or new mass formation.; The patient is stable and discharged in good condition.","evidence_relations":"Early-stage stomach cancer is confined to the mucosa and is not present in lymph nodes.; Intestinal type adenocarcinoma forms tube- and gland-shaped structures and is more likely to have mutations treatable with targeted therapy.; Diagnosis involves imaging tests, endoscopy, biopsy, biomarker testing, and genetic risk testing.; Family history is a risk factor for stomach cancer.; H. pylori infection is a risk factor for stomach cancer.; Symptoms can include ulcer or mass formation in the stomach."},
	{"id":"Medical-d8e24b59","source":"Medical","question":"As a medical intern, draft a referral note to a genetic counselor for a patient with newly diagnosed diffuse-type stomach adenocarcinoma and a significant family history of gastric cancer. Include relevant clinical and risk factor details from the guideline.","answer":"Referral Note:\n\nTo: Genetic Counseling Service\n\nPatient: [Name], recently diagnosed with diffuse-type stomach adenocarcinoma.\n\nClinical Details:\n- Diagnosis confirmed by biopsy after endoscopy identified scattered cancerous cells consistent with diffuse-type adenocarcinoma.\n- Family history is notable for multiple first-degree relatives with stomach cancer.\n- No evidence of distant metastasis on imaging.\n- Risk factors include positive family history and absence of H. pylori infection.\n\nRationale for Referral:\nGiven the diagnosis of diffuse-type adenocarcinoma and significant familial clustering, evaluation for hereditary cancer syndromes is indicated. Genetic risk testing is recommended to guide patient management and family counseling.","question_type":"Creative Generation","evidence":"The patient is a 52-year-old male with newly diagnosed diffuse-type stomach adenocarcinoma.; The diagnosis was confirmed by biopsy.; Endoscopy identified scattered cancerous cells consistent with diffuse-type adenocarcinoma.; The family history is notable for multiple first-degree relatives with stomach cancer.; There is no evidence of distant metastasis on imaging.; Risk factors include a positive family history.; The patient does not have H. pylori infection.; Evaluation for hereditary cancer syndromes is indicated.; Genetic risk testing is recommended to guide patient management and family counseling.","evidence_relations":"Diffuse type adenocarcinoma consists of scattered cells and is less common.; Family history is a risk factor for stomach cancer.; Diagnosis involves imaging tests, endoscopy, biopsy, biomarker testing, and genetic risk testing.; Metastatic stomach cancer has spread to distant organs such as the liver, peritoneum, or distant lymph nodes.; There are two major subtypes of stomach adenocarcinoma: intestinal and diffuse."},
	{"id":"Medical-0255e97b","source":"Medical","question":"Transform the core clinical practice facts into a public health advisory warning about stomach cancer, emphasizing risk factors, early detection, and the importance of diagnostic evaluation for at-risk populations.","answer":"**Public Health Advisory: Stomach Cancer Awareness and Early Detection**\n\nStomach cancer is a serious disease arising from the lining of the stomach, with most cases being adenocarcinomas. Individuals with a family history of stomach cancer or infection with H. pylori are at increased risk. Early-stage stomach cancer may not cause symptoms or may present as an ulcer or mass. Early detection is critical, as cancer confined to the stomachs mucosa is more treatable. We urge individuals with risk factors or persistent stomach symptoms to seek medical evaluation, which may include endoscopy, imaging, and biopsy. Genetic risk testing and biomarker analysis may be recommended for those with a family history. Public health efforts should focus on awareness of risk factors, timely diagnosis, and appropriate follow-up.","question_type":"Creative Generation","evidence":"Stomach cancer arises from the lining of the stomach.; Most cases of stomach cancer are adenocarcinomas.; Individuals with a family history of stomach cancer are at increased risk.; Infection with H. pylori increases the risk of stomach cancer.; Early-stage stomach cancer may not cause symptoms.; Early-stage stomach cancer may present as an ulcer or mass.; Early detection is critical for treatability.; Cancer confined to the stomachs mucosa is more treatable.; Individuals with risk factors or persistent stomach symptoms should seek medical evaluation.; Medical evaluation may include endoscopy, imaging, and biopsy.; Genetic risk testing and biomarker analysis may be recommended for those with a family history.; Public health efforts should focus on awareness of risk factors.; Timely diagnosis and appropriate follow-up are important.","evidence_relations":"Stomach cancer is a type of cancer that arises in the stomach.; Most stomach cancers are adenocarcinomas.; H. pylori infection is a risk factor for stomach cancer.; Family history is a risk factor for stomach cancer.; Early-stage stomach cancer is confined to the mucosa and is not present in lymph nodes.; Diagnosis involves imaging tests, endoscopy, biopsy, biomarker testing, and genetic risk testing.; Symptoms can include ulcer or mass formation in the stomach."},
	{"id":"Medical-50dd4351","source":"Medical","question":"You are a neurosurgeon receiving a referral for a 45-year-old patient with new-onset seizures and an MRI revealing a left frontal lobe mass. Write a detailed diagnostic and initial management plan, referencing relevant classification, diagnostic, and treatment recommendations from the clinical practice guideline.","answer":"For a 45-year-old patient presenting with new-onset seizures and an MRI revealing a left frontal lobe mass, the diagnostic and initial management plan should be systematic and multidisciplinary, following clinical practice guidelines for suspected glioma. \n\n1. Initial Assessment: Begin with a comprehensive neurological examination to document baseline function and identify any focal deficits. Review the patient's medical and family history, as some brain tumors may have hereditary components.\n\n2. Imaging: The MRI findings are suggestive of a brain mass, likely a glioma. Ensure high-quality, contrast-enhanced MRI is performed to assess tumor characteristics, involvement of adjacent structures, and surgical planning.\n\n3. Tissue Diagnosis: Definitive diagnosis requires histopathological and molecular analysis. If the lesion is accessible and resectable, plan for maximal safe surgical resection, which both relieves mass effect and provides ample tissue for diagnosis. If resection is not feasible due to location or patient factors, a stereotactic or open biopsy should be performed to obtain tissue. Molecular testing, including IDH mutation status and other relevant biomarkers, is essential for accurate classification and prognostication.\n\n4. Classification and Staging: Classify the tumor based on histology (e.g., astrocytoma, oligodendroglioma, glioblastoma), WHO grade, and molecular features. This information guides prognosis and treatment decisions.\n\n5. Initial Management: For resectable tumors, proceed with maximal safe resection. For unresectable tumors, biopsy is performed for diagnosis. Initiate seizure management as needed, and consider corticosteroids if there is significant edema or mass effect.\n\n6. Multidisciplinary Planning: Following diagnosis, discuss the case in a neuro-oncology tumor board. For high-grade gliomas (WHO grade 3 or 4), coordinate adjuvant therapy with radiation and chemotherapy. Assess the patient's performance status to determine eligibility for aggressive therapy.\n\n7. Follow-up: Schedule regular follow-up with MRI to monitor for recurrence or progression. Provide supportive care and involve rehabilitation services as needed.\n\nThis approach ensures accurate diagnosis, appropriate classification, and timely initiation of evidence-based treatment, optimizing outcomes for the patient.","question_type":"Creative Generation","evidence":"The patient is 45 years old and has new-onset seizures.; An MRI revealed a left frontal lobe mass.; A comprehensive neurological exam will be performed to assess deficits.; A stereotactic or open biopsy is recommended to obtain tissue.; Tissue analysis will include histological and molecular analysis.; IDH mutation status is critical for glioma classification.; Further management will be determined based on histology and grade.; If the tumor is resectable, maximal safe surgical resection should be pursued.; Maximal safe surgical resection will reduce tumor burden.; Postoperatively, adjuvant therapy will be coordinated with the neuro-oncology team.; Adjuvant therapy may include radiation and chemotherapy.; The patient's performance status will be evaluated to guide treatment eligibility.; Periodic follow-up MRI will be scheduled to monitor for recurrence.","evidence_relations":"Diagnosis of glioma involves neurological exam, imaging (MRI, CT), and biopsy.; MRI is the most useful imaging test for identifying glioma.; Biopsy is required for definitive diagnosis and molecular testing.; Gliomas are classified by histology, grade, and biomarkers.; IDH mutation is a biomarker used to classify gliomas.; Surgery may involve resection or biopsy.; High-grade gliomas require additional therapy after surgery.; Performance status is assessed to determine treatment eligibility.; Follow-up with periodic imaging (MRI) is recommended to monitor for recurrence."},
	{"id":"Medical-bc869828","source":"Medical","question":"Rewrite the key clinical recommendations for glioma diagnosis and management into a concise discharge summary for a patient who underwent surgery for a grade 4 glioblastoma.","answer":"Discharge Summary:\n\nDiagnosis: Grade 4 glioblastoma (confirmed by histology and molecular testing)\n\nHospital Course: The patient presented with headache and cognitive changes. Neurological exam and MRI revealed a right temporal mass. The patient underwent maximal safe resection. Postoperative recovery was uneventful. Histopathology confirmed grade 4 glioblastoma; IDH mutation was not detected.\n\nTreatment Plan: Given high-grade status, adjuvant radiation therapy and chemotherapy will be initiated. The patients performance status is satisfactory for aggressive therapy. Enrolment in a clinical trial was discussed.\n\nFollow-up: The patient is scheduled for periodic MRI imaging to monitor for recurrence. Outpatient neuro-oncology follow-up arranged.","question_type":"Creative Generation","evidence":"The patient has a diagnosis of grade 4 glioblastoma.; The diagnosis was confirmed by histology and molecular testing.; The patient presented with headache and cognitive changes.; A neurological exam and MRI revealed a right temporal mass.; The patient underwent maximal safe resection.; Postoperative recovery was uneventful.; Histopathology confirmed grade 4 glioblastoma.; IDH mutation was not detected in the patient.; Adjuvant radiation therapy and chemotherapy will be initiated due to high-grade status.; The patients performance status is satisfactory for aggressive therapy.; Enrolment in a clinical trial was discussed.; The patient is scheduled for periodic MRI imaging to monitor for recurrence.; Outpatient neuro-oncology follow-up has been arranged.","evidence_relations":"Glioblastoma is the most aggressive subtype of glioma.; Grade 4 gliomas are most commonly glioblastomas.; Diagnosis of glioma involves neurological exam, imaging (MRI, CT), and biopsy.; Biopsy is required for definitive diagnosis and molecular testing.; High-grade gliomas require additional therapy after surgery.; Treatment options for glioma include surgery, radiation therapy, chemotherapy, and clinical trials.; Performance status is assessed to determine treatment eligibility.; Follow-up with periodic imaging (MRI) is recommended to monitor for recurrence."},
	{"id":"Medical-8feee92a","source":"Medical","question":"Imagine you are a neuro-oncology fellow preparing a referral note to a radiation oncologist for a patient with a newly diagnosed high-grade oligodendroglioma. Summarize the diagnostic findings, molecular profile, and rationale for radiation therapy.","answer":"Referral Note to Radiation Oncology:\n\nPatient: 52-year-old male presenting with new-onset seizures.\n\nDiagnostic Findings: MRI demonstrated a left frontal lobe mass. Neurological examination revealed mild expressive aphasia. Stereotactic biopsy confirmed a high-grade oligodendroglioma (WHO grade 3). Molecular testing identified a positive IDH mutation, supporting the diagnosis and providing important prognostic information.\n\nRationale for Radiation Therapy: High-grade gliomas, including grade 3 oligodendrogliomas, require adjuvant therapy following maximal safe surgical resection due to their aggressive nature and high risk of recurrence. Radiation therapy, in combination with chemotherapy, is recommended to improve disease control and survival outcomes. The patients current performance status is sufficient to tolerate combined modality treatment. Please assess for initiation of radiation therapy as per established guidelines, in conjunction with chemotherapy.\n\nThank you for your collaboration.","question_type":"Creative Generation","evidence":"The patient is a 52-year-old male with new-onset seizures.; An MRI revealed a left frontal lobe mass.; A neurological exam showed mild expressive aphasia.; A stereotactic biopsy confirmed high-grade oligodendroglioma (grade 3).; The biopsy showed a positive IDH mutation.; Molecular testing supports the diagnosis of high-grade oligodendroglioma.; Following maximal safe resection, adjuvant radiation therapy is required.; Adjuvant radiation therapy is needed to reduce recurrence risk.; The patients performance status is adequate for combined modality treatment.; The referral is for initiation of radiation therapy in conjunction with chemotherapy.","evidence_relations":"Gliomas are classified by histology, grade, and biomarkers.; Oligodendroglioma: Grade 2 and Grade 3 are recognized grades.; IDH mutation is a biomarker used to classify gliomas.; High-grade gliomas require additional therapy after surgery.; Treatment options for glioma include surgery, radiation therapy, chemotherapy, and clinical trials.; Performance status is assessed to determine treatment eligibility."},
	{"id":"Medical-bec7f927","source":"Medical","question":"Transform the clinical guidelines on glioma risk factors, diagnosis, and follow-up into a public health advisory aimed at adult patients and families.","answer":"**Public Health Advisory: Understanding Adult GliomaRisks, Diagnosis, and Lifelong Monitoring**\n\nGliomas are malignant brain tumors developing from glial cells and are more common in adults. Most gliomas are not inherited but arise from non-hereditary mutations. Early symptoms may include headache, seizures, personality or cognitive changes, and vision problems. Diagnosis involves neurological examination, MRI (the preferred imaging method), and biopsy for confirmation and molecular testing. While gliomas are rarely curable, treatments such as surgery, radiation, and chemotherapy can help manage the disease. Lifelong follow-up with periodic MRI imaging is essential to monitor for tumor recurrence. If you experience persistent neurological symptoms, consult your healthcare provider promptly.","question_type":"Creative Generation","evidence":"Gliomas are malignant brain tumors that develop from glial cells.; Gliomas are more common in adults.; Most gliomas are not inherited.; Gliomas arise from non-hereditary mutations.; Early symptoms of gliomas may include headache, seizures, personality changes, and vision problems.; Diagnosis involves a neurological examination.; MRI is the preferred imaging method for diagnosing gliomas.; A biopsy is needed for confirmation and molecular testing.; While gliomas are rarely curable, treatments can help manage the disease.; Treatments for gliomas may include surgery, radiation, and chemotherapy.; Lifelong follow-up with periodic MRI imaging is essential to monitor for tumor recurrence.; Individuals experiencing persistent neurological symptoms should consult their healthcare provider promptly.","evidence_relations":"Glioma is a type of malignant brain tumor.; Gliomas develop from glial cells in the central nervous system.; Gliomas are more common in adults than children.; Most gliomas are not hereditary.; Symptoms of glioma include headache, seizures, fatigue, cognitive changes, personality changes, and vision problems.; Diagnosis of glioma involves neurological exam, imaging (MRI, CT), and biopsy.; MRI is the most useful imaging test for identifying glioma.; Biopsy is required for definitive diagnosis and molecular testing.; Gliomas are rarely curable but are treatable.; Follow-up with periodic imaging (MRI) is recommended to monitor for recurrence."},
	{"id":"Medical-ce7d82e3","source":"Medical","question":"You are a medical intern asked to write a SOAP (Subjective, Objective, Assessment, Plan) progress note for a patient with a low-grade astrocytoma, incorporating guideline-based recommendations for diagnosis, management, and surveillance.","answer":"SOAP Note:\n\nSubjective: The patient is a 35-year-old female with a known diagnosis of low-grade (grade 2) left temporal astrocytoma. She reports intermittent headaches and mild fatigue, which are stable compared to previous visits. She denies new neurological symptoms such as seizures, visual changes, cognitive impairment, or motor deficits. No changes in daily functioning or performance status are noted.\n\nObjective: Neurological examination remains stable with no new focal deficits. Vital signs are within normal limits. Most recent MRI demonstrates a stable low-grade left temporal astrocytoma with no evidence of progression or new lesions. Histopathology and molecular testing confirm a WHO grade 2 astrocytoma with IDH mutation positivity. No evidence of increased intracranial pressure or mass effect. Laboratory studies, if performed, are unremarkable.\n\nAssessment: 35-year-old female with a stable, IDH-mutant, low-grade (grade 2) astrocytoma. She is currently asymptomatic except for mild, stable headaches and fatigue. No radiographic or clinical evidence of tumor progression. Favorable biomarker profile (IDH mutation positive) is associated with a better prognosis.\n\nPlan:\n- Continue active surveillance with periodic MRI brain imaging every 36 months as per current guidelines to monitor for tumor recurrence or progression.\n- No indication for adjuvant therapy (radiation or chemotherapy) at this time given stable disease and absence of new symptoms.\n- Monitor for symptom progression, including new neurological deficits, seizures, or changes in cognitive function.\n- Reassess performance status and quality of life at each follow-up visit.\n- Encourage patient to maintain a symptom diary and report any new or worsening symptoms promptly.\n- Provide education regarding the importance of follow-up and potential signs of progression.\n- Multidisciplinary care team involvement as needed (neuro-oncology, neurosurgery, supportive care).","question_type":"Creative Generation","evidence":"The patient has a low-grade astrocytoma.; The patient reports intermittent headaches and mild fatigue.; There are no new neurological symptoms reported.; The neurological exam is stable.; An MRI shows a stable low-grade left temporal astrocytoma.; There is no evidence of progression of the astrocytoma.; Histology and molecular testing confirm a low-grade (grade 2) astrocytoma.; The astrocytoma has a positive IDH mutation.; The patient is a 35-year-old female.; The plan is to continue observation with periodic follow-up MRI.; There is no indication for adjuvant therapy at this time.; The patient will be monitored for symptom progression.; The patient's performance status will be reassessed at each visit.","evidence_relations":"Astrocytoma is a common subtype of glioma.; Grades 1 and 2 are low-grade gliomas.; IDH mutation is a biomarker used to classify gliomas.; Diagnosis of glioma involves neurological exam, imaging (MRI, CT), and biopsy.; Follow-up with periodic imaging (MRI) is recommended to monitor for recurrence.; Performance status is assessed to determine treatment eligibility.; Low-grade gliomas have better prognosis."},
	{"id":"Medical-3fc0a01e","source":"Medical","question":"Imagine you are a hematology fellow preparing a referral letter for a patient newly diagnosed with acute myeloid leukemia (AML) to a tertiary care center for consideration of hematopoietic cell transplantation. Summarize the diagnostic work-up, relevant prognostic factors, current treatment status, and supportive care needs.","answer":"Dear Colleagues,\n\nI am referring a 45-year-old patient recently diagnosed with acute myeloid leukemia (AML), confirmed by the presence of greater than 20% myeloblasts on bone marrow aspirate and biopsy. The diagnostic work-up included a complete blood count (CBC) revealing cytopenias, a comprehensive metabolic panel (CMP), elevated lactate dehydrogenase (LDH), and flow cytometry with immunophenotyping, all consistent with AML. Molecular and cytogenetic analysis identified an FLT3-ITD mutation, which is recognized as an adverse prognostic factor. Additional testing included assessment of performance status (ECOG 1) and baseline organ function.\n\nThe patient has completed induction chemotherapy with cytarabine and daunorubicin, achieving first complete remission. Supportive care measures have included red blood cell and platelet transfusions, infection prevention with antimicrobial prophylaxis, and management of chemotherapy-related side effects. Fertility preservation counseling was provided prior to initiation of systemic therapy.\n\nGiven the high-risk genetic profile (FLT3-ITD) and favorable response to induction, hematopoietic cell transplantation is being considered as the next step in management. Please advise regarding transplant eligibility, donor search, and further management recommendations. The patient and family have been counseled regarding the multidisciplinary approach to care and the importance of ongoing supportive measures during the transplant process.","question_type":"Creative Generation","evidence":"The patient is 45 years old and has been diagnosed with acute myeloid leukemia (AML).; The diagnosis was confirmed by more than 20% myeloblasts in bone marrow aspirate and biopsy.; The diagnostic work-up included a complete blood count (CBC).; The diagnostic work-up included a comprehensive metabolic panel (CMP).; The diagnostic work-up included lactate dehydrogenase (LDH) testing.; The diagnostic work-up included flow cytometry.; Molecular and cytogenetic testing revealed a FLT3-ITD mutation.; The FLT3-ITD mutation is an adverse prognostic factor.; The patient has completed induction chemotherapy with cytarabine and daunorubicin.; The patient is currently in first remission.; The patient's performance status is ECOG 1.; Supportive care has included transfusions.; Supportive care has included infection prevention.; Supportive care has included management of chemotherapy side effects.; Hematopoietic cell transplant is being considered due to the high-risk genetic profile.; Fertility preservation counseling was performed prior to therapy.","evidence_relations":"AML is diagnosed by the presence of 20% myeloblasts in bone marrow or blood.; Diagnosis of AML involves blood tests, bone marrow aspirate and biopsy, flow cytometry, immunophenotyping, cytogenetic and molecular testing, and imaging studies.; Common genetic alterations in AML include FLT3-ITD, FLT3-TKD, inv(16), inv(3), t(8;21), del(5q), and PML::RARA.; Chemotherapy regimens may include antimetabolites (e.g., cytarabine), anthracyclines (e.g., daunorubicin, idarubicin), and hypomethylating agents (e.g., azacitidine, decitabine).; Hematopoietic cell transplant is considered for eligible patients.; Performance status and general health influence treatment selection.; Supportive care includes transfusions, infection prevention, and management of side effects.; Fertility preservation should be discussed before starting systemic therapy."},
	{"id":"Medical-0cd460d0","source":"Medical","question":"You are a clinician asked to create a discharge summary for a patient with newly diagnosed acute promyelocytic leukemia (APL), a subtype of AML, after induction therapy. Include diagnosis, genetic findings, treatment given, complications managed, and follow-up recommendations.","answer":"Discharge Summary:\n\nDiagnosis: Acute promyelocytic leukemia (APL), a subtype of AML, confirmed by bone marrow biopsy showing >20% blasts and identification of PML::RARA fusion gene. \n\nGenetic Findings: Cytogenetic and molecular testing positive for PML::RARA fusion.\n\nTreatment: Induction therapy with chemotherapy and targeted therapy initiated, as per guidelines for APL. Supportive care included transfusions and infection prophylaxis.\n\nComplications: The patient developed thrombocytopenia and neutropenic fever, managed with platelet transfusions and broad-spectrum antibiotics.\n\nFollow-Up Recommendations: Continue consolidation therapy as per protocol. Repeat bone marrow evaluation and molecular testing to assess remission status. Monitor for differentiation syndrome and provide ongoing supportive care.\n\nFertility counseling was completed prior to therapy.","question_type":"Creative Generation","evidence":"The patient has been diagnosed with acute promyelocytic leukemia (APL), a subtype of AML.; The diagnosis was confirmed by bone marrow biopsy showing more than 20% blasts.; The PML::RARA fusion gene was identified in the patient.; Cytogenetic and molecular testing was positive for the PML::RARA fusion.; Induction therapy with chemotherapy and targeted therapy was initiated.; Supportive care included transfusions.; Supportive care included infection prophylaxis.; The patient developed thrombocytopenia.; The patient developed neutropenic fever.; Thrombocytopenia was managed with platelet transfusions.; Neutropenic fever was managed with broad-spectrum antibiotics.; Consolidation therapy should continue as per protocol.; A repeat bone marrow evaluation and molecular testing are recommended to assess remission status.; Monitoring for differentiation syndrome is necessary.; Ongoing supportive care is required.; Fertility counseling was completed prior to therapy.","evidence_relations":"Acute promyelocytic leukemia (APL) is a subtype of AML characterized by the PML::RARA fusion gene.; AML is diagnosed by the presence of 20% myeloblasts in bone marrow or blood.; Diagnosis of AML involves blood tests, bone marrow aspirate and biopsy, flow cytometry, immunophenotyping, cytogenetic and molecular testing, and imaging studies.; Chemotherapy is the standard of care for AML.; Targeted therapies are used for AML with specific genetic alterations, such as ... for PML::RARA.; Supportive care includes transfusions, infection prevention, and management of side effects.; Fertility preservation should be discussed before starting systemic therapy."},
	{"id":"Medical-a2771279","source":"Medical","question":"Assume the role of a clinical pathologist and write a detailed report on the laboratory and molecular diagnostic steps necessary to establish an AML diagnosis and subtype, referencing the guidelines recommendations.","answer":"Laboratory and Molecular Diagnostic Report:\n\nThe diagnosis of acute myeloid leukemia (AML) is established by identifying 20% or more myeloblasts in the bone marrow or peripheral blood, as recommended by current guidelines. The diagnostic workup begins with a complete blood count (CBC) to assess for cytopenias, and may include a comprehensive metabolic panel (CMP) and lactate dehydrogenase (LDH) to evaluate organ function and cell turnover. If AML is suspected, a bone marrow aspirate and biopsy are performed to confirm the presence and percentage of blasts through histopathological examination.\n\nImmunophenotyping by flow cytometry is essential to characterize the immunologic profile of the blasts and distinguish AML from other hematologic malignancies. Cytogenetic analysis, including conventional karyotyping and fluorescence in situ hybridization (FISH), is performed to detect chromosomal abnormalities. Molecular testing using next-generation sequencing (NGS) or polymerase chain reaction (PCR) is conducted to identify specific gene mutations and fusion genes, such as FLT3-ITD, inv(16), t(8;21), del(5q), and PML::RARA. These genetic and biomarker findings are critical for accurate AML subtype classification, risk stratification, and guiding targeted therapy decisions, in accordance with guideline recommendations.","question_type":"Creative Generation","evidence":"A diagnosis of AML requires identification of 20% myeloblasts in bone marrow or blood.; The diagnostic process begins with a complete blood count (CBC).; A comprehensive metabolic panel (CMP) is performed during the diagnostic process.; Lactate dehydrogenase (LDH) is evaluated to assess cell turnover.; Bone marrow aspirate and biopsy are performed.; Histopathology confirms increased blasts in the bone marrow.; Flow cytometry is used to define the immunologic profile of the blasts.; Immunophenotyping is part of the diagnostic process for AML.; Cytogenetic analysis, including karyotype and FISH, is conducted.; Molecular testing, such as next-generation sequencing and PCR, is performed.; Genetic alterations such as FLT3-ITD, inv(16), t(8;21), del(5q), and PML::RARA are identified.; These findings are essential for AML subtype classification.; The findings guide therapy for AML.","evidence_relations":"AML is diagnosed by the presence of 20% myeloblasts in bone marrow or blood.; Diagnosis of AML involves blood tests, bone marrow aspirate and biopsy, flow cytometry, immunophenotyping, cytogenetic and molecular testing, and imaging studies.; Common genetic alterations in AML include FLT3-ITD, FLT3-TKD, inv(16), inv(3), t(8;21), del(5q), and PML::RARA.; Genetic and biomarker tests are used to determine AML subtype and guide treatment.; Bone Marrow Evaluation: bone marrow aspirate, bone marrow biopsy, histopathology.; Molecular and Cytogenetic Testing: karyotype, FISH, next-generation sequencing (NGS), PCR."},
	{"id":"Medical-5e1bd01f","source":"Medical","question":"Rewrite the management principles of AML into a public health advisory aimed at primary care providers, focusing on early recognition, risk factors, and referral pathways.","answer":"Public Health Advisory: Early Recognition and Referral for Acute Myeloid Leukemia (AML)\n\nPrimary care providers should maintain high suspicion for AML in patients presenting with unexplained fatigue, frequent infections, bleeding, or easy bruising. Risk factors include family history of leukemia and hereditary predisposition syndromes. Early diagnosis relies on prompt laboratory evaluation, including complete blood count and referral for bone marrow assessment if blasts are detected. Rapid referral to hematology is essential for definitive diagnosis and initiation of therapy. Fertility preservation counseling should be considered before starting systemic treatment. Supportive care, including transfusions and infection prevention, is critical during initial management.","question_type":"Creative Generation","evidence":"Primary care providers should maintain high suspicion for AML in patients with unexplained fatigue.; Frequent infections can be a symptom of AML.; Bleeding is a symptom that may indicate AML.; Easy bruising can be a symptom of AML.; Risk factors for AML include family history of leukemia.; Hereditary predisposition syndromes are risk factors for AML.; Early diagnosis of AML relies on prompt laboratory evaluation.; A complete blood count is part of the laboratory evaluation for AML.; Referral for bone marrow assessment is necessary if blasts are detected.; Rapid referral to hematology is essential for definitive diagnosis.; Initiation of therapy for AML requires rapid referral to hematology.; Fertility preservation counseling should be considered before systemic treatment.; Supportive care, including transfusions and infection prevention, is critical during initial management.","evidence_relations":"Symptoms of AML include fatigue, infections, bleeding, and bruising.; Family history of leukemia and hereditary predisposition syndromes are risk factors for AML.; AML is diagnosed by the presence of 20% myeloblasts in bone marrow or blood.; Diagnosis of AML involves blood tests, bone marrow aspirate and biopsy, flow cytometry, immunophenotyping, cytogenetic and molecular testing, and imaging studies.; Fertility preservation should be discussed before starting systemic therapy.; Supportive care includes transfusions, infection prevention, and management of side effects.; Performance status and general health influence treatment selection."},
	{"id":"Medical-ee3d898f","source":"Medical","question":"You are a medical intern tasked with drafting a SOAP progress note for a patient with AML who is undergoing induction chemotherapy. Incorporate presenting symptoms, diagnostic findings, genetic risk stratification, therapy administered, and supportive interventions.","answer":"SOAP Progress Note:\n\nSubjective: Patient reports persistent fatigue and new-onset bruising.\n\nObjective: CBC reveals pancytopenia; bone marrow biopsy shows >20% myeloblasts. Flow cytometry confirms myeloid lineage. Molecular testing identifies FLT3-ITD mutation. ECOG performance status is 1.\n\nAssessment: Newly diagnosed AML with adverse genetic risk (FLT3-ITD-positive). Currently receiving induction chemotherapy with cytarabine and daunorubicin.\n\nPlan: Continue induction chemotherapy per protocol. Monitor for infections and bleeding. Provide transfusions as needed. Initiate infection prevention measures. Discuss fertility preservation options and provide ongoing supportive care.","question_type":"Creative Generation","evidence":"The patient reports persistent fatigue.; The patient has new-onset bruising.; CBC reveals pancytopenia.; Bone marrow biopsy shows >20% myeloblasts.; Flow cytometry confirms myeloid lineage.; Molecular testing identifies FLT3-ITD mutation.; ECOG performance status is 1.; The patient is newly diagnosed with AML with adverse genetic risk.; The patient is FLT3-ITD-positive.; The patient is currently receiving induction chemotherapy with cytarabine and daunorubicin.; The plan includes monitoring for infections and bleeding.; Transfusions will be provided as needed.; Infection prevention measures will be initiated.; Fertility preservation options will be discussed.","evidence_relations":"Symptoms of AML include fatigue, infections, bleeding, and bruising.; AML is diagnosed by the presence of 20% myeloblasts in bone marrow or blood.; Diagnosis of AML involves blood tests, bone marrow aspirate and biopsy, flow cytometry, immunophenotyping, cytogenetic and molecular testing, and imaging studies.; Common genetic alterations in AML include FLT3-ITD.; Chemotherapy regimens may include antimetabolites (e.g., cytarabine), anthracyclines (e.g., daunorubicin, idarubicin).; Supportive care includes transfusions, infection prevention, and management of side effects.; Performance status and general health influence treatment selection.; Fertility preservation should be discussed before starting systemic therapy."},
	{"id":"Medical-f8205c0e","source":"Medical","question":"You are a gynecologic oncologist seeing a 54-year-old woman newly diagnosed with Stage IIIC high-grade serous ovarian carcinoma. Write a detailed initial management plan, including diagnostic confirmation, surgical approach, adjuvant therapy, genetic testing, and plans for follow-up.","answer":"For this 54-year-old woman with newly diagnosed Stage IIIC high-grade serous ovarian carcinoma, the initial management plan would include the following steps:\n\n1. Diagnostic Confirmation: Confirm the diagnosis through a combination of pelvic examination, imaging studies (CT, MRI, or PET scan to assess disease extent), and histopathologic analysis of biopsy specimens. Blood tests, including a complete blood count, chemistry profile, liver function tests, and tumor markers such as CA-125, should be obtained.\n\n2. Surgical Approach: Proceed with surgical staging and maximal cytoreductive (debulking) surgery, which typically involves total hysterectomy with bilateral salpingo-oophorectomy and removal of all visible disease. The goal is to achieve no gross residual disease, as this is associated with improved outcomes. The procedure should be performed by a gynecologic oncologist.\n\n3. Adjuvant Therapy: Following surgery, initiate adjuvant chemotherapy with a combination of paclitaxel and carboplatin, which is the standard regimen for advanced-stage ovarian cancer. The addition of bevacizumab may be considered based on the extent of disease and patient comorbidities. Maintenance therapy with a PARP inhibitor (such as olaparib) should be considered, particularly if BRCA mutation or homologous recombination deficiency (HRD) is identified.\n\n4. Genetic Testing: Order comprehensive genetic testing for germline and somatic BRCA1/2 mutations and other hereditary cancer syndromes (such as Lynch syndrome), as results may influence treatment decisions and provide important information for familial risk assessment.\n\n5. Follow-up: Establish a surveillance plan that includes regular physical and pelvic examinations, monitoring of CA-125 or other relevant tumor markers, and periodic imaging as clinically indicated. Ongoing coordination with the multidisciplinary care team and patient education regarding symptoms of recurrence are essential.\n\nThis approach aligns with current guidelines and evidence for the management of advanced high-grade serous ovarian carcinoma.","question_type":"Creative Generation","evidence":"The patient is a 54-year-old woman with Stage IIIC high-grade serous ovarian carcinoma.; The diagnosis will be confirmed with imaging review, including CT, MRI, or PET scan.; A pelvic examination is part of the diagnostic confirmation process.; Histopathologic analysis of biopsy specimens is required for diagnosis.; Surgical staging and maximal cytoreductive surgery will be performed.; The standard initial treatment includes hysterectomy with bilateral salpingo-oophorectomy and debulking of all visible disease.; Adjuvant chemotherapy will consist of paclitaxel and carboplatin.; Bevacizumab may be added based on disease burden and comorbidities.; Maintenance therapy with a PARP inhibitor, such as olaparib, will be considered.; Comprehensive genetic testing for BRCA1/2 mutations and other hereditary syndromes will be ordered.; Follow-up will include regular physical and pelvic exams.; Monitoring of CA-125 levels will be part of the follow-up plan.","evidence_relations":"High-grade serous carcinoma and high-grade endometrioid carcinoma are the most common subtypes of epithelial ovarian cancer.; Diagnosis of ovarian cancer involves imaging (ultrasound, CT, MRI, PET), abdominal and pelvic exam, biopsy, and blood tests including tumor markers.; Surgery (hysterectomy with bilateral salpingo-oophorectomy) is the standard initial treatment for most ovarian cancers.; Chemotherapy (typically paclitaxel and carboplatin) is recommended after surgery for most stages.; Bevacizumab may be added to chemotherapy in some cases.; Maintenance therapy with PARP inhibitors (olaparib, niraparib, rucaparib) is recommended for advanced or BRCA-mutated/HRD-positive cancers after initial treatment.; Genetic testing for BRCA and other hereditary syndromes is recommended for all patients with ovarian cancer.; Surveillance after treatment includes regular physical and pelvic exams, and monitoring of CA-125 or other tumor markers."},
	{"id":"Medical-42f6bec1","source":"Medical","question":"Transform the clinical facts for recurrent platinum-resistant epithelial ovarian cancer into a formal oncology referral letter, highlighting diagnostic findings, prior treatments, and rationale for advanced therapies or clinical trial consideration.","answer":"Dear Colleague,\n\nI am referring Ms. Jane Doe, a 62-year-old woman with a history of epithelial ovarian cancer, initially diagnosed as Stage IIIB high-grade serous carcinoma. She underwent primary debulking surgery (total abdominal hysterectomy and bilateral salpingo-oophorectomy) followed by adjuvant chemotherapy with paclitaxel and carboplatin. She achieved an initial remission; however, she developed symptomatic recurrence within six months of completing platinum-based therapy, meeting criteria for platinum-resistant disease. Her presenting symptoms included abdominal discomfort and bloating. Recent imaging with CT and PET scans demonstrates multifocal peritoneal disease without evidence of extra-abdominal metastases. Tumor biomarker analysis reveals folate receptor alpha (FR) positivity, while BRCA mutation testing is negative. Given her platinum-resistant status, standard platinum-based regimens are no longer effective. Current guidelines recommend non-platinum chemotherapy as the next line of treatment, with the addition of bevacizumab (Avastin) as a preferred option. Furthermore, due to FR positivity, she is a candidate for targeted therapy with mirvetuximab soravtansine-gynx (Elahere), an antibody-drug conjugate. Considering her disease characteristics and biomarker profile, I am seeking your expertise regarding optimal sequencing of non-platinum chemotherapy, the role of bevacizumab, and the appropriateness of initiating mirvetuximab soravtansine-gynx. Enrollment in a clinical trial is also under active consideration, in line with recommendations for recurrent or persistent ovarian cancer. Please advise on advanced therapeutic options and potential trial opportunities.\n\nSincerely,\nDr. Smith","question_type":"Creative Generation","evidence":"Ms. Jane Doe is a 62-year-old woman with a history of epithelial ovarian cancer.; She was initially diagnosed with Stage IIIB high-grade serous carcinoma.; The patient underwent primary debulking surgery, including hysterectomy and bilateral salpingo-oophorectomy.; Adjuvant chemotherapy with paclitaxel and carboplatin was administered after surgery.; The patient developed symptomatic recurrence within six months of completing platinum therapy.; The recurrence is consistent with platinum-resistant disease.; Recent imaging confirms multifocal peritoneal disease.; Tumor biomarker analysis reveals FR positivity.; BRCA testing for the patient is negative.; The referral seeks input regarding non-platinum chemotherapy options.; Consideration for bevacizumab is part of the referral.; The potential for targeted therapy with mirvetuximab soravtansine-gynx is being explored.; Enrollment in a clinical trial is also under consideration.","evidence_relations":"Recurrence is managed based on platinum sensitivity, biomarker status, and may include surgery, chemotherapy, targeted therapy, immunotherapy, or clinical trial enrollment.; Platinum-resistant ovarian cancer is treated with non-platinum chemotherapy, bevacizumab, or targeted therapies such as mirvetuximab soravtansine-gynx for FR-positive tumors.; Tumor biomarker testing includes BRCA mutation, HRD status, MSI, MMR, HER2 expression, TMB, BRAF V600E, FR, RET mutations, and NTRK gene fusion.; Clinical trials are recommended for recurrent or persistent ovarian cancer.; Diagnosis of ovarian cancer involves imaging (ultrasound, CT, MRI, PET), abdominal and pelvic exam, biopsy, and blood tests including tumor markers.; Chemotherapy (typically paclitaxel and carboplatin) is recommended after surgery for most stages.; Surgery (hysterectomy with bilateral salpingo-oophorectomy) is the standard initial treatment for most ovarian cancers."},
	{"id":"Medical-f581f48d","source":"Medical","question":"As a medical intern, create a concise SOAP (Subjective, Objective, Assessment, Plan) note for a patient with suspected ovarian cancer, integrating presenting symptoms, diagnostic findings, risk factors, and initial management steps.","answer":"S: Patient reports persistent bloating, pelvic pain, and trouble eating with early satiety for the past two months. She also notes increased urinary urgency. Family history is notable for a mother with breast cancer.\n\nO: Physical exam reveals abdominal distension and tenderness. Pelvic ultrasound shows a complex ovarian mass. CA-125 is elevated. CT scan demonstrates peritoneal implants. No evidence of distant metastases.\n\nA: Suspected advanced epithelial ovarian cancer, likely high-grade serous subtype, in a patient with significant family history (possible BRCA-related risk).\n\nP: Plan includes further diagnostic evaluation with biopsy and referral for genetic testing (BRCA, Lynch syndrome). Surgical staging and cytoreductive surgery are indicated. Initiate multidisciplinary discussion for adjuvant chemotherapy (paclitaxel and carboplatin) and consider maintenance therapy based on biomarker results.","question_type":"Creative Generation","evidence":"The patient reports persistent bloating.; The patient has pelvic pain.; The patient experiences trouble eating with early satiety.; The patient notes increased urinary urgency.; The family history is notable for a mother with breast cancer.; Physical exam reveals abdominal distension and tenderness.; Pelvic ultrasound shows a complex ovarian mass.; CA-125 is elevated in the patient.; CT scan demonstrates peritoneal implants.; There is no evidence of distant metastases.; The assessment is suspected advanced epithelial ovarian cancer.; The likely subtype is high-grade serous.; The patient has significant family history, indicating possible BRCA-related risk.; The plan includes further diagnostic evaluation with biopsy.; Referral for genetic testing for BRCA and Lynch syndrome is indicated.; Surgical staging and cytoreductive surgery are indicated.; A multidisciplinary discussion for adjuvant chemotherapy is planned.","evidence_relations":"Common symptoms of ovarian cancer include bloating, pelvic or abdominal pain, trouble eating or feeling full quickly, urinary urgency or frequency, and pain during sex.; Diagnosis of ovarian cancer involves imaging (ultrasound, CT, MRI, PET), abdominal and pelvic exam, biopsy, and blood tests including tumor markers.; BRCA1 and BRCA2 mutations and Lynch syndrome are major hereditary risk factors for ovarian cancer.; Surgery (hysterectomy with bilateral salpingo-oophorectomy) is the standard initial treatment for most ovarian cancers.; Chemotherapy (typically paclitaxel and carboplatin) is recommended after surgery for most stages.; Genetic testing for BRCA and other hereditary syndromes is recommended for all patients with ovarian cancer."},
	{"id":"Medical-cd76440b","source":"Medical","question":"Rewrite the guideline recommendations for post-treatment surveillance of ovarian cancer into a patient-friendly discharge summary, including rationale for each follow-up step.","answer":"Discharge Summary  Ovarian Cancer Post-Treatment Surveillance\n\nYou have completed treatment for ovarian cancer. Your ongoing follow-up care is important to monitor for any signs of recurrence and to support your recovery. Your surveillance plan will include:\n1. Regular physical and pelvic exams to check for any new symptoms or findings.\n2. Blood tests to monitor CA-125 or other tumor markers, which can help detect early signs of recurrence.\n3. Imaging tests (such as ultrasound, CT, or MRI) if there are any concerning symptoms or abnormal exam findings.\n4. Ongoing assessment for side effects of treatment, such as neuropathy or fatigue.\n5. Discussion of any new symptoms, including abdominal pain, bloating, or changes in appetite, as these can signal recurrence.\nThese steps are based on evidence that regular monitoring improves early detection and management of recurrence.","question_type":"Creative Generation","evidence":"The patient has completed treatment for ovarian cancer.; Ongoing follow-up care is important to monitor for signs of recurrence.; The surveillance plan includes regular physical and pelvic exams.; Blood tests will monitor CA-125 or other tumor markers.; Imaging tests such as ultrasound, CT, or MRI will be performed if there are concerning symptoms.; Ongoing assessment for side effects of treatment is necessary.; Discussion of new symptoms is important for detecting recurrence.; Regular monitoring improves early detection and management of recurrence.","evidence_relations":"Surveillance after treatment includes regular physical and pelvic exams, and monitoring of CA-125 or other tumor markers.; Imaging (ultrasound, CT, MRI, PET) is used as indicated for diagnosis and follow-up.; Common symptoms of ovarian cancer include bloating, pelvic or abdominal pain, trouble eating or feeling full quickly, urinary urgency or frequency, and pain during sex.; Peripheral neuropathy and fatigue are recognized side effects of treatment.; Recurrence is managed based on platinum sensitivity, biomarker status, and may include surgery, chemotherapy, targeted therapy, immunotherapy, or clinical trial enrollment.; Early detection of recurrence can improve management options."},
	{"id":"Medical-a3b9f0d4","source":"Medical","question":"Imagine you are a public health official tasked with drafting a community advisory on hereditary ovarian cancer risk. Integrate guideline facts about risk factors, genetic testing, and prevention strategies into your message.","answer":"Community Health Advisory: Understanding and Reducing Hereditary Ovarian Cancer Risk\n\nOvarian cancer can affect women of all ages, but certain inherited genetic mutationsmost notably in the BRCA1 and BRCA2 genes, as well as those associated with Lynch syndromesubstantially increase the risk of developing this disease. If you have a personal or family history of ovarian, breast, or related cancers, you may be at higher risk. Genetic testing is recommended for all women diagnosed with ovarian cancer, as it can identify these mutations and help guide both treatment decisions and preventive strategies for family members. If a hereditary risk is found, genetic counseling can help you and your relatives understand your risk and consider options such as increased surveillance, preventive surgery, or lifestyle modifications. Early recognition of symptomsincluding persistent bloating, pelvic or abdominal pain, trouble eating or feeling full quickly, urinary urgency or frequency, and pain during sexcan lead to earlier diagnosis and improved outcomes. If you are concerned about your risk or have a family history of these cancers, speak with your healthcare provider about genetic counseling, testing, and appropriate prevention strategies.","question_type":"Creative Generation","evidence":"Ovarian cancer can affect women of all ages.; Inherited genetic mutations such as BRCA1 and BRCA2 increase the risk of ovarian cancer.; Lynch syndrome is a hereditary condition that increases ovarian cancer risk.; All women diagnosed with ovarian cancer are recommended to undergo genetic testing.; Genetic testing can guide treatment and help family members understand their risk.; Family history of breast or ovarian cancer is an important risk factor.; Early recognition of symptoms can lead to earlier diagnosis.; Symptoms of ovarian cancer include persistent bloating and pelvic pain.; Women concerned about their risk should talk to their healthcare provider about genetic counseling.","evidence_relations":"BRCA1 and BRCA2 mutations and Lynch syndrome are major hereditary risk factors for ovarian cancer.; Genetic testing for BRCA and other hereditary syndromes is recommended for all patients with ovarian cancer.; Family history is a risk factor for ovarian cancer.; Common symptoms of ovarian cancer include bloating, pelvic or abdominal pain, trouble eating or feeling full quickly, urinary urgency or frequency, and pain during sex.; Early recognition of symptoms can improve diagnosis and outcomes."},
	{"id":"Medical-1f9a3a9d","source":"Medical","question":"Imagine you are a hematology fellow asked to write a detailed diagnostic summary for a patient with suspected chronic lymphocytic leukemia (CLL). Your summary should integrate the required laboratory and imaging tests, key biomarkers, risk assessment, and steps to confirm the diagnosis, as per the clinical practice guideline.","answer":"Diagnostic Summary: The patient presents with persistent lymphocytosis and clinical features suggestive of chronic lymphocytic leukemia (CLL), including swollen lymph nodes and fatigue. The initial diagnostic workup should begin with a complete blood count (CBC) with differential, which typically reveals an absolute lymphocyte count of 5,000 monoclonal B lymphocytes per microliter, a key diagnostic threshold for CLL. A peripheral blood smear should be reviewed for characteristic lymphocyte morphology. Flow cytometry is essential to confirm the diagnosis by identifying the immunophenotype of the lymphocytes, specifically assessing for surface markers such as CD20, CD200, and LEF1, which help distinguish CLL from other lymphoproliferative disorders. Biomarker testing should include fluorescence in situ hybridization (FISH) to detect chromosomal abnormalities such as 17p deletion, and DNA sequencing to assess for TP53 and IGHV gene mutations, both of which have prognostic and therapeutic implications. Karyotype analysis is recommended to evaluate for complex chromosomal abnormalities that may influence prognosis. A comprehensive metabolic panel should be performed to assess organ function, and beta-2 microglobulin levels should be measured as a marker of disease activity. Diagnostic imaging with a contrast-enhanced CT scan of the chest, abdomen, and pelvis is advised to evaluate the extent of lymph node and organ involvement. Risk assessment should incorporate the patients age, family history, and the presence of B symptoms (such as unexplained fevers, night sweats, and weight loss). While bone marrow or lymph node biopsy is not routinely required for diagnosis, these procedures may be considered if the diagnosis remains uncertain or if there are unexplained cytopenias. All findings should be integrated into a comprehensive report to guide further management and treatment planning in accordance with clinical practice guidelines.","question_type":"Creative Generation","evidence":"The patient presents with persistent lymphocytosis.; Clinical features suggest chronic lymphocytic leukemia (CLL).; The patient has swollen glands and fatigue.; Initial laboratory evaluation includes a complete blood count (CBC).; The CBC should demonstrate 5,000 monoclonal B lymphocytes per microliter.; Flow cytometry is warranted to confirm the immunophenotype of the lymphocytes.; Surface markers such as CD20, CD200, and LEF1 are assessed in flow cytometry.; Additional biomarker testing with FISH is performed to identify 17p deletion.; DNA sequencing is indicated for TP53 and IGHV mutations.; Karyotype analysis evaluates for complex chromosomal abnormalities.; Diagnostic imaging with a CT scan is recommended to assess lymph node and organ involvement.; Risk assessment includes evaluation of beta-2 microglobulin for disease activity.; The patient's age and family history are significant risk factors for CLL.; A lymph node or bone marrow biopsy may be performed to support the diagnosis if needed.","evidence_relations":"CLL/SLL is diagnosed by blood test showing 5,000 monoclonal B lymphocytes per microliter; CLL is confirmed by blood test, flow cytometry, and may require lymph node or bone marrow biopsy; Immunophenotyping identifies CLL cells by surface proteins such as CD20, CD200, and LEF1; Biomarker testing includes FISH for 17p deletion, DNA sequencing for TP53 and IGHV mutations, and karyotype analysis; Diagnostic CT scans may be used to assess lymph node involvement and disease extent"},
	{"id":"Medical-c8339278","source":"Medical","question":"You are a primary care physician referring a patient with newly diagnosed small lymphocytic lymphoma (SLL) to hematology/oncology. Write a referral note summarizing the clinical findings, diagnostic workup, relevant biomarkers, and rationale for referral, using the recommended guideline framework.","answer":"Referral Note: Patient is a 68-year-old male presenting with painless lymphadenopathy and fatigue. CBC revealed elevated lymphocyte count, and flow cytometry identified a monoclonal B cell population positive for CD20, CD200, and LEF1. Lymph node biopsy confirmed small lymphocytic lymphoma (SLL), a tissue-based equivalent of CLL. FISH analysis detected no 17p deletion, and DNA sequencing for TP53 and IGHV mutations is pending. Beta-2 microglobulin levels are elevated, suggesting increased disease activity. Diagnostic CT scan showed generalized lymphadenopathy without splenomegaly. Due to confirmed SLL diagnosis and need for further staging, prognostic assessment, and treatment planning, referral to hematology/oncology is indicated.","question_type":"Creative Generation","evidence":"The patient is a 68-year-old male presenting with painless lymphadenopathy.; The patient reports fatigue.; CBC revealed elevated lymphocyte count.; Flow cytometry identified a monoclonal B cell population positive for CD20, CD200, and LEF1.; Lymph node biopsy confirmed small lymphocytic lymphoma (SLL).; SLL is a tissue-based equivalent of chronic lymphocytic leukemia (CLL).; FISH analysis detected no 17p deletion.; DNA sequencing for TP53 and IGHV mutations is pending.; Beta-2 microglobulin levels are elevated, suggesting increased disease activity.; Diagnostic CT scan showed generalized lymphadenopathy without splenomegaly.; Referral to hematology/oncology is indicated due to confirmed SLL diagnosis.; Further staging, prognostic assessment, and treatment planning are needed.","evidence_relations":"Small lymphocytic lymphoma (SLL) is the same cancer as CLL but primarily found in lymph nodes and spleen; CLL/SLL is diagnosed by blood test showing 5,000 monoclonal B lymphocytes per microliter; Immunophenotyping identifies CLL cells by surface proteins such as CD20, CD200, and LEF1; Biomarker testing includes FISH for 17p deletion, DNA sequencing for TP53 and IGHV mutations, and karyotype analysis; Beta-2 microglobulin is a biomarker associated with CLL disease activity and prognosis"},
	{"id":"Medical-d5c778d2","source":"Medical","question":"Rewrite the clinical management recommendations for CLL/SLL into a formal discharge summary for a patient who completed initial diagnostic workup and is being managed with watchful waiting. Include key findings, risk factors, follow-up strategy, and supportive care advice.","answer":"Discharge Summary: \n\nPatient was evaluated for persistent lymphocytosis and diagnosed with chronic lymphocytic leukemia (CLL) following blood tests demonstrating 5,000 monoclonal B lymphocytes/L and flow cytometry confirming a typical CLL immunophenotype (CD20+, CD200+, LEF1+). Additional biomarker studies, including FISH, TP53 and IGHV sequencing, and karyotype analysis, did not identify high-risk cytogenetic features. The patient is currently asymptomatic, with no B-symptoms (such as fever, night sweats, or unintentional weight loss), maintains a good performance status, and has no clinical or radiographic evidence of Richter transformation. There is no significant family history or comorbidities impacting prognosis. \n\nGiven the early-stage, asymptomatic disease and absence of high-risk features, the patient will be managed with a 'watchful waiting' approach. Follow-up will include regular monitoring every 36 months with complete blood count (CBC), comprehensive metabolic panel, and physical examination to assess for disease progression or development of symptoms. Supportive care recommendations include infection prevention strategies, prompt reporting of new symptoms (such as fevers, night sweats, weight loss, or lymph node enlargement), and maintaining communication with the care team. The patient was educated on the importance of adherence to follow-up and informed that initiation of treatment will be considered if there is evidence of disease progression, development of symptoms, or new risk factors.","question_type":"Creative Generation","evidence":"The patient was evaluated for lymphocytosis.; The patient was diagnosed with chronic lymphocytic leukemia (CLL).; Blood tests showed 5,000 monoclonal B lymphocytes/L.; Flow cytometry confirmed a typical immunophenotype (CD20+, CD200+, LEF1+).; Biomarker studies did not reveal high-risk features.; The patient currently has no B-symptoms.; The patient maintains good performance status.; There is no evidence of Richter transformation.; A 'watch and wait' approach is recommended for asymptomatic early-stage disease.; Regular monitoring will be scheduled every 36 months.; Monitoring will include CBC, metabolic panel, and physical exams.; Supportive care includes infection prevention.; The patient was advised to manage new symptoms promptly.; The patient was informed about the importance of follow-up.; Treatment will be initiated if disease progression or symptoms occur.","evidence_relations":"Treatment for CLL/SLL may not be needed immediately and is based on symptoms, blood counts, and disease progression; Watch and wait, regular monitoring, and supportive care are follow-up strategies; Beta-2 microglobulin is a biomarker associated with CLL disease activity and prognosis; Performance status and comprehensive metabolic panel are used in treatment planning; Richter transformation is a complication where CLL transforms into a more aggressive lymphoma"},
	{"id":"Medical-d5b7cd3a","source":"Medical","question":"Assume the role of a medical intern tasked with drafting a SOAP (Subjective, Objective, Assessment, Plan) progress note for a patient with established CLL who now reports night sweats and unintentional weight loss. Integrate diagnostic, prognostic, and management elements from the guideline.","answer":"SOAP Note:\nSubjective: Patient reports increased night sweats and unintentional weight loss over the past month. No fever or recurrent infections.\nObjective: Physical exam reveals palpable cervical and axillary lymphadenopathy. CBC shows rising lymphocyte count. Comprehensive metabolic panel is within normal limits. Beta-2 microglobulin is elevated. No evidence of Richter transformation on CT scan.\nAssessment: CLL with new B-symptoms (night sweats, weight loss), elevated lymphocyte count, and rising beta-2 microglobulin, indicating disease progression.\nPlan: Proceed with repeat flow cytometry to assess for immunophenotype changes, FISH to evaluate for 17p deletion, and DNA sequencing for TP53 and IGHV mutations. Consider initiation of oral medications or IV infusions based on risk stratification. Continue supportive care measures and monitor for complications, including Richter transformation.","question_type":"Creative Generation","evidence":"The patient reports increased night sweats.; The patient reports unintentional weight loss over the past month.; The patient denies fever or recurrent infections.; Physical exam reveals palpable cervical and axillary lymphadenopathy.; CBC shows a rising lymphocyte count.; The comprehensive metabolic panel is within normal limits.; Beta-2 microglobulin is elevated.; There is no evidence of Richter transformation on CT scan.; The assessment indicates CLL with new B-symptoms.; The assessment indicates elevated lymphocyte count.; The assessment indicates rising beta-2 microglobulin, indicating disease progression.; The plan includes repeat flow cytometry to assess for immunophenotype changes.; The plan includes FISH to evaluate for 17p deletion.; The plan includes DNA sequencing for TP53 and IGHV mutations.; The plan considers initiation of oral medications or IV infusions based on risk stratification.; The plan includes continuing supportive care measures.; The plan includes monitoring for complications, including Richter transformation.","evidence_relations":"Symptoms of CLL include swollen glands, fatigue, night sweats, fever, recurrent infections, early satiety, and unintentional weight loss; CLL/SLL is diagnosed by blood test showing 5,000 monoclonal B lymphocytes per microliter; Beta-2 microglobulin is a biomarker associated with CLL disease activity and prognosis; Biomarker testing includes FISH for 17p deletion, DNA sequencing for TP53 and IGHV mutations, and karyotype analysis; Treatment options include oral medications, IV infusions, and combination therapies"},
	{"id":"Medical-2a322545","source":"Medical","question":"Transform the clinical facts into a patient-facing educational letter explaining CLL/SLL diagnosis, risk factors, necessary tests, and the importance of regular follow-up, using plain language but grounded in guideline evidence.","answer":"Dear Patient,\n\nYou have been diagnosed with chronic lymphocytic leukemia (CLL), a type of cancer that affects certain white blood cells called B lymphocytes, which are part of your immune system. When this cancer is mainly found in the lymph nodes, it is called small lymphocytic lymphoma (SLL). CLL and SLL are essentially the same disease, but they appear in different parts of the body.\n\nCLL/SLL is often found during routine blood tests, sometimes before any symptoms appear. Some people may notice symptoms such as swollen lymph nodes, fatigue, night sweats, unexplained weight loss, or frequent infections. However, many people feel well at the time of diagnosis. Risk factors for CLL/SLL include being older and having a family history of the diseaserelatives are several times more likely to develop CLL if there is a family history.\n\nTo confirm your diagnosis, your healthcare team performed several tests. These included a complete blood count (CBC) to measure the levels of different blood cells, and a blood smear to look at the appearance of your cells under a microscope. Special laboratory tests called flow cytometry were used to identify specific markers on your cells, such as CD20, CD200, and LEF1, which help distinguish CLL/SLL from other conditions. Additional genetic tests, such as FISH (fluorescence in situ hybridization), DNA sequencing, and karyotyping, may be done to look for changes in your chromosomes or genes. These results help your doctors understand your specific type of CLL/SLL and guide future treatment decisions.\n\nMost people with early-stage CLL/SLL do not need treatment right away. Instead, your care team will recommend regular follow-up visits, which may include physical exams, blood tests, and discussions about any new symptoms. This approach is called \"watch and wait\" or active surveillance. Regular monitoring is important to detect any changes in your condition early and to manage symptoms if they arise. Attending all scheduled appointments and keeping your care team informed about any new symptoms will help ensure you receive the best possible care.","question_type":"Creative Generation","evidence":"The patient has been diagnosed with chronic lymphocytic leukemia (CLL).; CLL affects certain white blood cells called B lymphocytes.; CLL is sometimes found mainly in the lymph nodes and is called small lymphocytic lymphoma (SLL).; CLL/SLL is often discovered during routine blood tests.; Older adults or those with a family history are at higher risk for CLL/SLL.; Blood tests, including a complete blood count, were used to confirm the diagnosis.; Flow cytometry was used to look for markers like CD20, CD200, and LEF1.; Additional genetic tests (FISH, DNA sequencing, karyotype) help understand the disease.; Most people with early CLL/SLL do not need treatment right away.; Patients with early CLL/SLL are closely monitored with regular check-ups and blood tests.; Keeping up with follow-up appointments is important to watch for any changes.","evidence_relations":"Chronic lymphocytic leukemia (CLL) is a type of blood cancer affecting B lymphocytes; Small lymphocytic lymphoma (SLL) is the same cancer as CLL but primarily found in lymph nodes and spleen; CLL may be asymptomatic and discovered incidentally on routine blood testing; Risk factors for CLL include older age and family history of CLL; Follow-up strategies include watch and wait, regular monitoring, and supportive care"},
	{"id":"Medical-fa8b9196","source":"Medical","question":"Imagine you are an ENT specialist evaluating a new patient presenting with persistent sore throat, difficulty swallowing, and recent voice changes. Using the clinical practice guidelines, synthesize a comprehensive diagnostic workup and initial staging plan for suspected oropharyngeal squamous cell carcinoma, including biomarker and imaging strategies.","answer":"As an ENT specialist, my initial diagnostic approach would begin with a thorough medical history and physical exam, focusing on the oropharynx, tonsils, base of tongue, and lateral/posterior pharyngeal walls. I would assess for risk factors including tobacco, alcohol use, and possible HPV exposure. Next, I would perform endoscopic evaluation (nasolaryngoscopy or panendoscopy) to visualize the tumor and adjacent sites. Biopsy of the suspicious lesion is essential for histopathological confirmation, utilizing endoscopic biopsy or, if lymphadenopathy is present, fine-needle aspiration (FNA) or core needle biopsy (CNB). Biomarker testing for p16 (HPV) status is recommended for all oropharyngeal cancers, as p16 overexpression serves as a surrogate for HPV-mediated disease. Imaging with contrast-enhanced CT scan or MRI of the neck, and PET/CT to evaluate both local extension and distant metastasis (lungs, liver, spine), is critical for accurate staging. Dental health assessment and panoramic dental x-ray (Panorex) should be completed prior to treatment. Staging will use the AJCC TNM system, integrating tumor size, nodal involvement, and distant metastasis.","question_type":"Creative Generation","evidence":"The initial diagnostic approach begins with a thorough medical history.; The initial diagnostic approach includes a physical exam focusing on the oropharynx.; The exam focuses on the tonsils, base of tongue, and lateral/posterior pharyngeal walls.; Risk factors assessed include tobacco and alcohol use.; Risk factors assessed include possible HPV exposure.; Endoscopic evaluation (nasolaryngoscopy or panendoscopy) is performed to visualize the tumor.; A biopsy of the suspicious lesion is essential for histopathological confirmation.; Endoscopic biopsy or fine-needle aspiration (FNA) is used if lymphadenopathy is present.; Biomarker testing for p16 (HPV) status is recommended for all oropharyngeal cancers.; Imaging with contrast-enhanced CT scan or MRI of the neck is critical for accurate staging.; PET/CT is used to evaluate local extension and distant metastasis.; A dental health assessment and panoramic dental x-ray should be completed prior to treatment.; Staging will use the AJCC TNM system.","evidence_relations":"Symptoms of throat cancer may include difficulty swallowing, sore throat, and changes in voice.; Throat cancer commonly arises in the oropharynx, including the soft palate, tonsils, side and back walls of the throat, and base of the tongue.; Biopsy is required for definitive diagnosis and biomarker testing.; p16 (HPV) testing is recommended for all patients with oropharyngeal cancer.; Imaging studies such as CT scan, MRI, PET/CT, and ultrasound are used for diagnosis and staging.; Cancer staging uses the AJCC TNM system, incorporating tumor size (T), lymph node involvement (N), and metastasis (M).; Dental health assessment is important before treatment.; Fine-needle aspiration (FNA), core needle biopsy (CNB), and endoscopic biopsies are used for tissue sampling."},
	{"id":"Medical-6adf6382","source":"Medical","question":"You are a medical oncologist asked to draft a multidisciplinary treatment plan for a patient with newly diagnosed, p16-positive, stage III oropharyngeal squamous cell carcinoma. Integrate details on performance status, biomarker-driven therapy, and required consultations.","answer":"For a patient with newly diagnosed, p16-positive, stage III oropharyngeal squamous cell carcinoma, a comprehensive multidisciplinary treatment plan should begin with confirmation of diagnosis through biopsy and p16 immunohistochemistry, as p16 overexpression is a surrogate marker for HPV-mediated disease and has prognostic significance. Assessment of the patient's performance status, typically using the ECOG scale, is critical to determine suitability for intensive therapy such as concurrent chemoradiation. Multidisciplinary evaluation should include consultations with radiation oncology, head and neck surgery, and dental services, as well as input from medical oncology. For patients with good performance status, the standard of care is concurrent chemoradiation, which is favored in p16-positive cases due to improved outcomes. Biomarker testing, including PD-L1 expression, may be considered to inform potential future use of immunotherapy, especially in the setting of recurrence or progression. Pre-treatment dental evaluation, including panoramic x-ray, is necessary to identify and manage dental issues that could be exacerbated by radiation. Additional supportive consultations, such as nutrition, speech and swallowing therapy, and audiology, may be indicated based on individual needs. Ongoing surveillance should include regular imaging and physical examinations to monitor for disease recurrence and manage late effects of therapy.","question_type":"Creative Generation","evidence":"The patient has stage III, p16-positive oropharyngeal squamous cell carcinoma.; The diagnosis is confirmed with biopsy and p16 immunohistochemistry.; Performance status is assessed using the ECOG scale.; Performance status influences eligibility for intensive therapy.; A multidisciplinary discussion with radiation oncology is essential.; A multidisciplinary discussion with head and neck surgery is essential.; A multidisciplinary discussion with dental services is essential.; The recommended approach for fit patients is concurrent chemoradiation.; Concurrent chemoradiation is recommended due to advanced stage and favorable HPV/p16 status.; Biomarker testing for PD-L1 expression may be considered for future immunotherapy options.; A dental evaluation and panoramic x-ray should be performed prior to treatment.; Ongoing surveillance will include imaging follow-up and physical exams.","evidence_relations":"Stage III is among the numbered stages in the AJCC TNM staging system.; p16 protein overexpression is a surrogate biomarker for HPV-mediated throat cancer.; Performance status (ECOG) is a prognostic factor considered in treatment planning.; Biomarker testing includes p16 (HPV), PD-L1, MSI-H/dMMR, and tumor mutational burden.; Multidisciplinary management involving surgery, radiation oncology, and dental assessment is standard.; Dental health assessment is important before treatment.; Imaging follow-up and physical exam are part of surveillance."},
	{"id":"Medical-a50184cc","source":"Medical","question":"Rewrite the key recommendations for initial evaluation and diagnosis of throat cancer into a formal referral letter from a primary care physician to an otolaryngologist. Ensure to include relevant risk factors, diagnostic steps, and rationale for specialist referral.","answer":"Dear Otolaryngology Colleague,\n\nI am referring a 56-year-old male with a history of tobacco and alcohol use who presents with a two-month history of sore throat, progressive difficulty swallowing, and recent changes in voice. On exam, there is asymmetry of the tonsillar region and palpable cervical lymphadenopathy. Given his risk factors and concerning symptoms, I am requesting your expertise for further evaluation. The clinical practice guidelines recommend direct visualization via laryngoscopy or endoscopy, biopsy for histologic confirmation, and imaging (CT/MRI and PET/CT) for staging. Biomarker testing, particularly for p16 (HPV) status, is advised for all oropharyngeal cancers. A dental evaluation is also indicated prior to any oncologic therapy. Please advise regarding further diagnostic and management steps.","question_type":"Creative Generation","evidence":"The patient is a 56-year-old male.; The patient has a history of tobacco and alcohol use.; The patient presents with a two-month history of sore throat.; The patient presents with progressive difficulty swallowing.; The patient presents with recent changes in voice.; The exam shows asymmetry of the tonsillar region.; The exam shows palpable cervical lymphadenopathy.; The referral is for further evaluation due to risk factors and concerning symptoms.; Direct visualization via laryngoscopy or endoscopy is recommended.; Biopsy for histologic confirmation is recommended.; Imaging (CT/MRI and PET/CT) is recommended for staging.; Biomarker testing for p16 (HPV) status is advised for all oropharyngeal cancers.; A dental evaluation is indicated prior to any oncologic therapy.","evidence_relations":"Tobacco and alcohol use are risk factors for head and neck cancers.; Symptoms of throat cancer may include difficulty swallowing, sore throat, and changes in voice.; Biopsy is required for definitive diagnosis and biomarker testing.; Imaging studies such as CT scan, MRI, PET/CT, and ultrasound are used for diagnosis and staging.; p16 (HPV) testing is recommended for all patients with oropharyngeal cancer.; Dental health assessment is important before treatment.; Throat cancer commonly arises in the oropharynx, including the soft palate, tonsils, side and back walls of the throat, and base of the tongue."},
	{"id":"Medical-cf2f3466","source":"Medical","question":"Transform the clinical pathway for diagnosing and staging oropharyngeal squamous cell carcinoma into a structured SOAP (Subjective, Objective, Assessment, Plan) note, incorporating key symptoms, exam findings, diagnostics, and staging elements.","answer":"**Subjective:**\nPatient reports a 3-month history of sore throat, difficulty swallowing, and recent voice changes. Denies weight loss. History of tobacco and alcohol use.\n\n**Objective:**\nPhysical exam reveals ulcerated lesion at the left tonsil extending to the base of tongue. Palpable left cervical lymphadenopathy. Dental exam pending. Imaging (CT neck, PET/CT) shows a 3.5 cm mass in the oropharynx with ipsilateral lymph node involvement. Endoscopic biopsy performed.\n\n**Assessment:**\nLikely oropharyngeal squamous cell carcinoma, risk factors include tobacco, alcohol, and possible HPV exposure. AJCC TNM staging: T2N2M0 (tumor >2 cm and 4 cm, multiple ipsilateral lymph nodes, no distant metastasis). Awaiting p16 (HPV) and PD-L1 biomarker results.\n\n**Plan:**\nComplete dental health assessment and panoramic x-ray prior to treatment. Multidisciplinary discussion for treatment planning. Initiate concurrent chemoradiation pending performance status assessment. Continue surveillance with imaging and physical exams.","question_type":"Creative Generation","evidence":"The patient reports a 3-month history of sore throat.; The patient reports difficulty swallowing.; The patient reports recent voice changes.; The patient denies weight loss.; The patient has a history of tobacco and alcohol use.; Physical exam reveals an ulcerated lesion at the left tonsil.; The lesion extends to the base of the tongue.; Palpable left cervical lymphadenopathy is noted.; A dental exam is pending.; Imaging (CT neck, PET/CT) shows a 3.5 cm mass in the oropharynx.; The imaging shows ipsilateral lymph node involvement.; An endoscopic biopsy has been performed.; The assessment indicates likely oropharyngeal squamous cell carcinoma.; Risk factors include tobacco, alcohol, and possible HPV exposure.; AJCC TNM staging is T2N2M0.; The tumor is greater than 2 cm and less than or equal to 4 cm.; There are multiple ipsilateral lymph nodes.; There is no distant metastasis.; P16 (HPV) and PD-L1 biomarker results are awaited.","evidence_relations":"Symptoms of throat cancer may include difficulty swallowing, sore throat, and changes in voice.; Throat cancer commonly arises in the oropharynx, including the soft palate, tonsils, side and back walls of the throat, and base of the tongue.; Imaging studies such as CT scan, MRI, PET/CT, and ultrasound are used for diagnosis and staging.; Cancer staging uses the AJCC TNM system, incorporating tumor size (T), lymph node involvement (N), and metastasis (M).; Biopsy is required for definitive diagnosis and biomarker testing.; p16 (HPV) testing is recommended for all patients with oropharyngeal cancer.; Dental health assessment is important before treatment.; Performance status (ECOG) is a prognostic factor considered in treatment planning."},
	{"id":"Medical-7c30e6dc","source":"Medical","question":"Imagine you are a dermatology consultant receiving a referral for a patient with multiple skin nodules and papules. Compose a detailed case summary for the hematology team, outlining the likely diagnosis, required diagnostic tests, differential considerations, and relevant clinical features based on the guidelines.","answer":"Case Summary: The patient presents with multiple skin nodules and papules, without reported systemic symptoms. The clinical presentation is highly suggestive of primary cutaneous lymphoma (PCL), with primary cutaneous B-cell lymphoma (CBCL) as the leading consideration. CBCL is a subtype of non-Hodgkin lymphoma that originates from B lymphocytes and manifests primarily in the skin. Key differential diagnoses include other forms of PCL, such as cutaneous T-cell lymphoma (CTCL), as well as non-lymphomatous dermatoses that can mimic lymphoma.\n\nRecommended diagnostic workup includes:\n- Comprehensive skin examination to document the distribution and morphology of lesions.\n- Blood tests (including complete blood count and lactate dehydrogenase) to assess for systemic involvement.\n- Imaging studies (such as CT or PET/CT) to evaluate for extracutaneous disease and lymphadenopathy.\n- Skin biopsy of representative lesions, with histopathological analysis and immunophenotyping to determine lymphocyte lineage (B-cell vs T-cell).\n- Biomarker and genetic testing to further classify the lymphoma subtype, distinguishing between primary cutaneous marginal zone lymphoma (PCMZL), primary cutaneous follicle center lymphoma (PCFCL), and primary cutaneous diffuse large B-cell lymphoma, leg type (PC-DLBCL, leg type).\n\nMost primary cutaneous B-cell lymphomas are indolent, but it is essential to rule out aggressive variants and systemic involvement to guide management and prognosis.","question_type":"Creative Generation","evidence":"The patient presents with multiple nodules and papules localized to the skin.; Primary cutaneous lymphoma (PCL) is highly suspected.; Cutaneous B-cell lymphoma (CBCL) is suspected given the presentation.; CBCL arises from B lymphocytes.; CBCL is classified as a subtype of non-Hodgkin lymphoma (NHL).; Differential diagnoses include other forms of PCL, such as cutaneous T-cell lymphoma (CTCL).; A comprehensive workup is recommended to confirm the diagnosis.; The workup includes a thorough skin exam.; Blood tests are recommended to assess for systemic involvement.; Imaging tests are recommended to rule out extracutaneous disease.; A skin biopsy with immunophenotyping is needed to characterize the lymphocyte lineage.; Assessment of biomarkers and genetic changes should be performed.; The lymphoma should be subtyped, distinguishing between PCMZL, PCFCL, and PC-DLBCL, leg type.; Most primary cutaneous B-cell lymphomas are indolent.; Aggressive variants of CBCL must be ruled out.","evidence_relations":"CBCL appears as nodules or papules under the skin; Primary cutaneous lymphoma (PCL) is a type of non-Hodgkin lymphoma found in the skin; CBCL subtypes include primary cutaneous marginal zone lymphoma (PCMZL), primary cutaneous follicle center lymphoma (PCFCL), and primary cutaneous diffuse large B-cell lymphoma, leg type (PC-DLBCL, leg type); Diagnosis of CBCL involves skin exam, blood tests, imaging tests, biopsy, and immunophenotyping; Testing for CBCL includes assessment of biomarkers and genetic changes"},
	{"id":"Medical-980656b1","source":"Medical","question":"Rewrite the clinical facts into a formal discharge summary for a patient newly diagnosed with primary cutaneous follicle center lymphoma (PCFCL), ensuring inclusion of presenting symptoms, diagnostic steps, classification, and next steps per guidelines.","answer":"Discharge Summary:\n\nDiagnosis: Primary Cutaneous Follicle Center Lymphoma (PCFCL)\n\nPresenting Symptoms: The patient presented with multiple skin nodules and papules, which are characteristic of cutaneous B-cell lymphomas. There were no systemic symptoms such as fever, night sweats, or weight loss, and no evidence of extracutaneous (systemic) involvement was identified.\n\nDiagnostic Workup: The diagnostic evaluation included a thorough skin examination to assess the extent and distribution of lesions, as well as blood tests and imaging studies to rule out systemic disease. A skin biopsy was performed, and histopathological analysis with immunophenotyping confirmed B-cell lineage. Additional testing for biomarkers and genetic changes was conducted to accurately classify the lymphoma as PCFCL.\n\nClassification: PCFCL is a subtype of cutaneous B-cell lymphoma (CBCL), which falls under the broader category of primary cutaneous lymphomas (PCL), a form of non-Hodgkin lymphoma that originates from B lymphocytes in the skin. PCFCL is generally considered an indolent (slow-growing) lymphoma.\n\nNext Steps: The patient will be referred to hematology-oncology for further management planning and surveillance. According to current guidelines, ongoing monitoring is recommended due to the indolent nature of most CBCLs, with attention to potential disease progression or transformation.","question_type":"Creative Generation","evidence":"The diagnosis is primary cutaneous follicle center lymphoma (PCFCL).; The patient presented with multiple skin nodules and papules.; The patient has no systemic symptoms.; There is no evidence of extracutaneous involvement.; The diagnostic process included a comprehensive skin exam.; Blood tests were performed to assess for systemic disease.; Imaging studies were conducted to assess for systemic disease.; Definitive diagnosis was established via skin biopsy.; The biopsy demonstrated B-cell lineage on immunophenotyping.; Additional testing included biomarker and genetic change analysis.; The analysis confirmed the PCFCL subtype.; PCFCL is a subtype of cutaneous B-cell lymphoma (CBCL).; CBCL is a manifestation of primary cutaneous lymphoma (PCL).; PCL is a form of non-Hodgkin lymphoma originating from B lymphocytes in the skin.; The patient will be referred for hematology-oncology consultation.; The consultation will discuss management options and further surveillance.; Most CBCLs are indolent.; Ongoing monitoring for disease progression is required.","evidence_relations":"CBCL appears as nodules or papules under the skin; Diagnosis of CBCL involves skin exam, blood tests, imaging tests, biopsy, and immunophenotyping; Testing for CBCL includes assessment of biomarkers and genetic changes; CBCL subtypes include primary cutaneous follicle center lymphoma (PCFCL); Most primary cutaneous B-cell lymphomas are indolent or slow-growing"},
	{"id":"Medical-3a2cfb6d","source":"Medical","question":"As a medical intern on the oncology ward, you are asked to prepare a multidisciplinary team (MDT) note summarizing the pathogenesis, diagnostic approach, and clinical classification of cutaneous B-cell lymphomas to educate new team members.","answer":"MDT Educational Note: Cutaneous B-cell lymphomas (CBCL) are a subset of primary cutaneous lymphomas (PCL), which are non-Hodgkin lymphomas that originate in the skin. CBCLs develop from abnormal B lymphocytes, a type of white blood cell involved in immune defense. The pathogenesis involves unregulated growth of these lymphocytes, resulting in disease. CBCL typically presents as nodules or papules confined to the skin. Diagnosis requires a combination of skin examination, blood tests, imaging studies, and confirmatory biopsy with immunophenotyping to determine cell lineage. Further testing for biomarkers and genetic changes aids in precise classification. Major CBCL subtypes include primary cutaneous marginal zone lymphoma (PCMZL), primary cutaneous follicle center lymphoma (PCFCL), and primary cutaneous diffuse large B-cell lymphoma, leg type (PC-DLBCL, leg type). Most CBCLs are slow-growing, but aggressive variants exist.","question_type":"Creative Generation","evidence":"Cutaneous B-cell lymphomas (CBCL) are a subset of primary cutaneous lymphomas (PCL).; PCLs are non-Hodgkin lymphomas that originate in the skin.; CBCLs develop from abnormal B lymphocytes.; B lymphocytes are a type of white blood cell involved in immune defense.; The pathogenesis involves unregulated growth of B lymphocytes.; CBCL typically presents as nodules or papules confined to the skin.; Diagnosis requires a combination of skin examination and blood tests.; Imaging studies are needed for diagnosis.; Confirmatory biopsy with immunophenotyping is required to determine cell lineage.; Further testing for biomarkers and genetic changes aids in precise classification.; Major CBCL subtypes include primary cutaneous marginal zone lymphoma (PCMZL).; Major CBCL subtypes include primary cutaneous follicle center lymphoma (PCFCL).; Major CBCL subtypes include primary cutaneous diffuse large B-cell lymphoma, leg type (PC-DLBCL, leg type).; Most CBCLs are slow-growing.; Aggressive variants of CBCL exist.","evidence_relations":"Primary cutaneous lymphoma (PCL) is a type of non-Hodgkin lymphoma found in the skin; CBCL develops from abnormal B cells; Lymphocytes are a type of white blood cell that help fight infection; Unregulated growth of lymphocytes can develop into lymphoma; CBCL appears as nodules or papules under the skin; Diagnosis of CBCL involves skin exam, blood tests, imaging tests, biopsy, and immunophenotyping; Testing for CBCL includes assessment of biomarkers and genetic changes; CBCL subtypes include primary cutaneous marginal zone lymphoma (PCMZL), primary cutaneous follicle center lymphoma (PCFCL), and primary cutaneous diffuse large B-cell lymphoma, leg type (PC-DLBCL, leg type); Most primary cutaneous B-cell lymphomas are indolent or slow-growing"},
	{"id":"Medical-917da89d","source":"Medical","question":"You are a general practitioner drafting a referral letter to dermatology for a patient with persistent skin lesions. Summarize the clinical suspicion, rationale for referral, and suggested workup in the style of a formal referral note, integrating key diagnostic criteria.","answer":"Referral Note:\n\nDear Dermatology Colleague,\n\nI am referring a patient who presents with persistent nodules and papules localized to the skin. The chronicity and morphology of these lesions raise clinical suspicion for a primary cutaneous lymphoma (PCL), with cutaneous B-cell lymphoma (CBCL) being a leading consideration. CBCL is a type of non-Hodgkin lymphoma that develops from abnormal B lymphocytes and typically manifests as indolent, slow-growing lesions, though aggressive variants can occur.\n\nRationale for referral: The persistent and unexplained nature of the skin lesions, along with their nodular and papular appearance, meet key diagnostic criteria for possible CBCL. Early specialist evaluation is warranted to confirm the diagnosis, determine the specific subtype, and guide management.\n\nSuggested workup: I recommend a comprehensive dermatologic assessment, including a thorough skin examination, relevant blood tests, and imaging studies as indicated to assess for systemic involvement. A skin biopsy is essential, with subsequent immunophenotyping to confirm B-cell lineage. Additional testing for biomarkers and genetic alterations is advised to further classify the lymphoma subtype (e.g., primary cutaneous marginal zone lymphoma [PCMZL], primary cutaneous follicle center lymphoma [PCFCL], or primary cutaneous diffuse large B-cell lymphoma, leg type [PC-DLBCL, leg type]). Early and accurate diagnosis is critical for optimal treatment planning and prognosis.\n\nThank you for your expert evaluation and management of this patient.","question_type":"Creative Generation","evidence":"The patient presents with persistent nodules and papules localized to the skin.; The clinician is concerned about a possible primary cutaneous lymphoma (PCL).; The specific concern is for cutaneous B-cell lymphoma (CBCL).; CBCL arises from abnormal B lymphocytes.; CBCL may present as indolent or aggressive disease.; A detailed skin examination is recommended to establish a diagnosis.; Blood tests are recommended as part of the workup.; Imaging studies may be appropriate for further evaluation.; A skin biopsy with immunophenotyping should be performed to confirm lymphoid lineage.; Additional testing for biomarkers and genetic changes may help classify the subtype.; Early identification of CBCL is essential for optimal management.","evidence_relations":"CBCL appears as nodules or papules under the skin; Primary cutaneous lymphoma (PCL) is a type of non-Hodgkin lymphoma found in the skin; CBCL develops from abnormal B cells; Diagnosis of CBCL involves skin exam, blood tests, imaging tests, biopsy, and immunophenotyping; Testing for CBCL includes assessment of biomarkers and genetic changes; CBCL subtypes include primary cutaneous marginal zone lymphoma (PCMZL), primary cutaneous follicle center lymphoma (PCFCL), and primary cutaneous diffuse large B-cell lymphoma, leg type (PC-DLBCL, leg type)"},
	{"id":"Medical-a2ede728","source":"Medical","question":"Transform the guideline information into a patient-friendly educational leaflet explaining what cutaneous B-cell lymphoma is, how it is diagnosed, what symptoms to look for, and the importance of follow-up.","answer":"Patient Information Leaflet: Understanding Cutaneous B-Cell Lymphoma (CBCL)\n\nWhat is CBCL? Cutaneous B-cell lymphoma is a rare cancer that starts in certain white blood cells (B lymphocytes) and affects the skin. It is a type of non-Hodgkin lymphoma that remains in the skin and does not usually spread to other parts of the body.\n\nWhat are the symptoms? CBCL often appears as lumps (nodules) or small bumps (papules) on the skin. These may be painless and grow slowly.\n\nHow is it diagnosed? Your doctor will examine your skin and may order blood tests and imaging scans. The most important step is a skin biopsy, where a small piece of skin is removed and studied. Special laboratory tests (immunophenotyping) and checks for genetic changes help confirm the diagnosis and determine the exact type of lymphoma.\n\nWhy is follow-up important? Most CBCLs grow slowly, but it is important to monitor your condition regularly to catch any changes early. Your healthcare team will guide you through treatment and follow-up visits.\n\nIf you notice new skin lumps or changes, let your doctor know promptly.","question_type":"Creative Generation","evidence":"Cutaneous B-cell lymphoma (CBCL) is a rare cancer.; CBCL starts in certain white blood cells called B lymphocytes.; CBCL affects the skin.; CBCL is a type of non-Hodgkin lymphoma.; CBCL usually does not spread to other parts of the body.; CBCL often appears as lumps (nodules) or small bumps (papules) on the skin.; The lumps or bumps may be painless and grow slowly.; Diagnosis of CBCL involves a skin examination by a doctor.; Blood tests and imaging scans may be ordered for diagnosis.; A skin biopsy is the most important step in diagnosing CBCL.; Immunophenotyping and checks for genetic changes help confirm the diagnosis.; Regular monitoring is important to catch any changes early.","evidence_relations":"Cutaneous B-cell lymphoma (CBCL) starts in B cells; CBCL appears as nodules or papules under the skin; Diagnosis of CBCL involves skin exam, blood tests, imaging tests, biopsy, and immunophenotyping; Testing for CBCL includes assessment of biomarkers and genetic changes; Most primary cutaneous B-cell lymphomas are indolent or slow-growing; Primary cutaneous lymphoma (PCL) is a type of non-Hodgkin lymphoma found in the skin"},
	{"id":"Medical-cdbc8593","source":"Medical","question":"You are a pediatric hematologist receiving a referral for a 7-year-old newly diagnosed with acute lymphoblastic leukemia (ALL). Write a detailed initial case summary, including diagnostic confirmation, subtype differentiation, risk assessment, and your preliminary treatment plan, citing evidence-based steps from the clinical guideline.","answer":"Initial Case Summary: The patient is a 7-year-old child newly diagnosed with acute lymphoblastic leukemia (ALL), the most common pediatric cancer. Diagnostic confirmation was established through blood tests and bone marrow aspiration, which demonstrated greater than 20% lymphoblasts in the marrow, meeting the diagnostic threshold for ALL. Subtype differentiation is underway to distinguish between B-cell ALL (B-ALL), which is more prevalent in this age group, and T-cell ALL (T-ALL), which may present with features such as mediastinal mass or respiratory symptoms. Comprehensive risk assessment includes evaluation of age, initial leukocyte count, and results from biomarker and pharmacogenomic testing, including BCR::ABL1 status and other relevant genetic alterations that may impact prognosis and guide therapy. Additional staging procedures include imaging studies, cardiac function assessment, and lumbar puncture to evaluate for central nervous system (CNS) involvement. The preliminary treatment plan, in accordance with evidence-based clinical guidelines, consists of initiation of induction therapy with steroids and multiagent chemotherapy, along with supportive care measures. Enrollment in a clinical trial will be considered, as recommended for pediatric ALL. The final treatment regimen will be tailored based on confirmed subtype and risk stratification results.","question_type":"Creative Generation","evidence":"The patient is a 7-year-old child with a new diagnosis of acute lymphoblastic leukemia (ALL).; ALL is the most common cancer in children.; Diagnostic workup included blood tests and bone marrow aspiration.; The bone marrow aspiration revealed more than 20% lymphoblasts in the marrow.; Subtype analysis is pending to distinguish between B-cell ALL (B-ALL) and T-cell ALL (T-ALL).; B-ALL is more common than T-ALL.; T-ALL may present with an enlarged thymus or breathing problems.; Further evaluation includes imaging tests.; Heart function assessment is part of the evaluation.; A lumbar puncture is performed to assess CNS involvement.; Biomarker and pharmacogenomic testing are ordered to assess for BCR::ABL1 status.; All patients with ALL receive steroids and multiagent chemotherapy.; Systemic therapy and supportive care are standard for ALL treatment.; Clinical trial enrollment will be considered as recommended.","evidence_relations":"ALL is the most common cancer diagnosed in children; ALL is diagnosed using blood tests, bone marrow tests, imaging tests, heart tests, and lumbar puncture; Diagnosis of ALL generally requires 20 percent or more lymphoblasts in the bone marrow; ALL has two main subtypes: B-cell ALL (B-ALL) and T-cell ALL (T-ALL); Treatment for ALL depends on subtype, age at diagnosis, and other factors; Everyone with ALL is treated with steroids and multiagent chemotherapy; Systemic therapy and supportive care are part of ALL treatment; Clinical trials are preferred for certain B-ALL and T-ALL cases; Pharmacogenomic testing and biomarker/genetic testing are used in ALL management"},
	{"id":"Medical-89ee2ffa","source":"Medical","question":"Rewrite the clinical guideline recommendations for pediatric acute lymphoblastic leukemia (ALL) into a formal discharge summary for a child who completed induction therapy. Ensure you include diagnostic findings, risk stratification, subtype, initial therapy, and follow-up recommendations.","answer":"Discharge Summary: Patient: [Name Redacted], Age: 9 years. Diagnosis: B-cell acute lymphoblastic leukemia (B-ALL), confirmed by bone marrow aspirate showing >20% lymphoblasts. Subtype: B-ALL, BCR::ABL1-negative; diagnosed via biomarker and genetic testing. Initial evaluation included blood and bone marrow tests, imaging, cardiac assessment, and lumbar puncture to assess for CNS involvement. Induction therapy consisted of steroids and multiagent chemotherapy per protocol. Supportive care measures were provided throughout therapy. The patient tolerated induction well, with no CNS or testicular involvement detected. Risk assessment was based on age, leukocyte count, and genetic markers. Follow-up: Plan includes initiation of consolidation therapy, ongoing systemic therapy, and continued supportive care. Enrollment in a clinical trial for maintenance phase is being considered. Routine monitoring with blood counts, periodic bone marrow evaluation, and surveillance for relapse or late effects is recommended.","question_type":"Creative Generation","evidence":"The patient is a 9-year-old child diagnosed with B-cell acute lymphoblastic leukemia (B-ALL).; The diagnosis was confirmed by bone marrow aspirate showing more than 20% lymphoblasts.; The subtype of leukemia is B-ALL, BCR::ABL1-negative.; The diagnosis was made via biomarker and genetic testing.; Initial evaluation included blood and bone marrow tests.; Imaging studies were performed for staging.; A cardiac assessment was part of the initial evaluation.; A lumbar puncture was performed to assess for CNS involvement.; Induction therapy consisted of steroids and multiagent chemotherapy.; Supportive care measures were provided throughout therapy.; The patient tolerated induction therapy well.; No CNS or testicular involvement was detected.; Risk assessment was based on age, leukocyte count, and genetic markers.; The follow-up plan includes initiation of consolidation therapy.","evidence_relations":"ALL is diagnosed using blood tests, bone marrow tests, imaging tests, heart tests, and lumbar puncture; Diagnosis of ALL generally requires 20 percent or more lymphoblasts in the bone marrow; B-ALL starts in B-cell lymphocytes and is more common than T-ALL; Treatment for ALL depends on subtype, age at diagnosis, and other factors; Everyone with ALL is treated with steroids and multiagent chemotherapy; Systemic therapy and supportive care are part of ALL treatment; Pharmacogenomic testing and biomarker/genetic testing are used in ALL management; Clinical trials are preferred for certain B-ALL and T-ALL cases; ALL can be found in bone marrow, blood, testicles, or central nervous system (CNS)"},
	{"id":"Medical-3f7aae87","source":"Medical","question":"Imagine you are a medical intern presenting a patient with suspected T-cell ALL (T-ALL) to your attending. Construct a problem-based SOAP note (Subjective, Objective, Assessment, Plan), integrating relevant clinical features, diagnostic steps, and guideline-based management.","answer":"SOAP Note:\nSubjective: 10-year-old male presents with shortness of breath and chest fullness. No prior medical history. Parents note rapid onset of symptoms over 2 weeks.\nObjective: Physical exam reveals tachypnea and decreased breath sounds. Chest imaging shows an enlarged mediastinum. CBC demonstrates leukocytosis with circulating lymphoblasts. Bone marrow aspirate pending. \nAssessment: High suspicion for T-cell acute lymphoblastic leukemia (T-ALL) given age, symptoms of breathing difficulty, and imaging findings of enlarged thymus. Awaiting marrow confirmation (>20% lymphoblasts required for diagnosis). \nPlan: Complete diagnostic workup including bone marrow biopsy, blood tests, imaging, heart function evaluation, and lumbar puncture. Initiate steroids and multiagent chemotherapy upon confirmation. Order biomarker/genetic testing (including BCR::ABL1). Engage supportive care team. Consider clinical trial enrollment. Monitor for respiratory compromise due to thymic enlargement.","question_type":"Creative Generation","evidence":"The patient is a 10-year-old male presenting with shortness of breath and chest fullness.; The patient has no prior medical history.; Symptoms have rapidly developed over 2 weeks.; Physical examination reveals tachypnea and decreased breath sounds.; Chest imaging shows an enlarged mediastinum.; CBC demonstrates leukocytosis with circulating lymphoblasts.; Bone marrow aspirate is pending for further confirmation.; There is a high suspicion for T-cell acute lymphoblastic leukemia (T-ALL).; The age and symptoms raise suspicion for T-ALL.; The diagnosis requires confirmation of more than 20% lymphoblasts in the bone marrow.; The plan includes a complete diagnostic workup.; The plan includes initiating steroids and multiagent chemotherapy upon confirmation.; Biomarker and genetic testing, including BCR::ABL1, will be ordered.; Supportive care team engagement is part of the plan.","evidence_relations":"T-ALL starts in T-cell lymphocytes and can cause an enlarged thymus; T-ALL can cause breathing problems due to an enlarged thymus; ALL is diagnosed using blood tests, bone marrow tests, imaging tests, heart tests, and lumbar puncture; Diagnosis of ALL generally requires 20 percent or more lymphoblasts in the bone marrow; Everyone with ALL is treated with steroids and multiagent chemotherapy; Systemic therapy and supportive care are part of ALL treatment; Pharmacogenomic testing and biomarker/genetic testing are used in ALL management; Clinical trials are preferred for certain B-ALL and T-ALL cases"},
	{"id":"Medical-deadc13d","source":"Medical","question":"You are a pediatric oncologist drafting a referral letter for a 3-month-old infant with newly diagnosed ALL to a tertiary care center. Summarize the unique considerations for this age group, diagnostic findings, and the rationale for specialized management.","answer":"Referral Letter: Dear Colleagues, I am referring a 3-month-old infant with a new diagnosis of acute lymphoblastic leukemia (ALL). The diagnosis was established based on blood and bone marrow testing, which revealed greater than 20% lymphoblasts. This case is classified as infant ALL, a distinct entity that differs biologically and clinically from ALL in older children. Unique considerations for this age group include a higher risk of adverse genetic features, differences in treatment tolerance, and a generally poorer prognosis, necessitating specialized management protocols. Subtype analysis and comprehensive biomarker/genetic testing are in progress to further guide risk stratification and therapy selection. The infant is currently stable, with no evidence of central nervous system or testicular involvement on imaging and lumbar puncture. As per current guidelines, infants with ALL require tailored, multidisciplinary care at specialized centers, and enrollment in clinical trials is strongly recommended to optimize outcomes. Please find attached the full diagnostic workup and supporting documentation.","question_type":"Creative Generation","evidence":"The patient is a 3-month-old infant diagnosed with acute lymphoblastic leukemia (ALL).; Diagnostic workup included blood and bone marrow testing.; The testing confirmed more than 20% lymphoblasts.; This case is classified as infant ALL due to the patient's age.; Infant ALL requires a distinct treatment approach compared to older children.; Subtype analysis is underway for the infant's leukemia.; Biomarker and genetic testing are being performed to guide therapy.; The infant is currently stable.; No CNS or testicular involvement was detected on imaging and lumbar puncture.; Infants with ALL are managed differently due to unique biology and treatment response.; Specialized protocols and multidisciplinary care are necessary for this age group.; Clinical trial enrollment is recommended for infants with ALL.","evidence_relations":"ALL is diagnosed using blood tests, bone marrow tests, imaging tests, heart tests, and lumbar puncture; Diagnosis of ALL generally requires 20 percent or more lymphoblasts in the bone marrow; Infant ALL (under 12 months) is treated differently than other age groups; Treatment for ALL depends on subtype, age at diagnosis, and other factors; Pharmacogenomic testing and biomarker/genetic testing are used in ALL management; Clinical trials are preferred for certain B-ALL and T-ALL cases; ALL most often affects children, adolescents, and young adults (AYAs)"},
	{"id":"Medical-f995cb67","source":"Medical","question":"Rewrite the core recommendations from the clinical guideline into a public health advisory for parents and caregivers, focusing on early detection, diagnosis, and standard treatment of childhood ALL.","answer":"Public Health Advisory: Acute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in children and young people. Early detection is crucialparents and caregivers should watch for signs such as unexplained fatigue, easy bruising, persistent infections, and pallor. In some cases, especially with T-cell ALL, children may experience breathing difficulties due to an enlarged thymus. If these symptoms are present, prompt consultation with a pediatrician is essential.\n\nDiagnosis of ALL involves a combination of blood tests, bone marrow tests, and may include imaging studies, heart tests, and lumbar puncture to assess involvement of the central nervous system and other organs. Accurate testing, including biomarker and genetic testing, is important to guide treatment decisions and tailor therapy to each childs needs.\n\nStandard treatment for childhood ALL includes steroids and multiagent chemotherapy, with supportive care to manage side effects and complications. All children should be treated at experienced pediatric leukemia centers, and participation in clinical trials is encouraged to provide access to the latest therapies. Parents and caregivers are encouraged to advocate for their child, ask questions, and work closely with the care team to ensure the best possible outcomes.","question_type":"Creative Generation","evidence":"Acute lymphoblastic leukemia (ALL) is the most common cancer in children and young people.; Early signs of ALL can include unexplained fatigue.; Early signs of ALL can include bruising.; Early signs of ALL can include persistent infections.; Diagnosis of ALL requires blood and bone marrow tests.; Further evaluation of the central nervous system and other organs may be necessary.; Most ALL cases are of the B-cell type.; T-cell types of ALL can present with breathing difficulties due to an enlarged thymus.; All children with ALL receive steroids and multiagent chemotherapy.; Supportive care is part of the standard treatment for ALL.; Genetic and biomarker testing helps tailor therapy for ALL.; Participation in clinical trials is encouraged for access to the latest treatments.; Parents should consult a pediatrician if concerning symptoms arise.","evidence_relations":"ALL is the most common cancer diagnosed in children; ALL is diagnosed using blood tests, bone marrow tests, imaging tests, heart tests, and lumbar puncture; ALL has two main subtypes: B-cell ALL (B-ALL) and T-cell ALL (T-ALL); T-ALL can cause breathing problems due to an enlarged thymus; Everyone with ALL is treated with steroids and multiagent chemotherapy; Systemic therapy and supportive care are part of ALL treatment; Pharmacogenomic testing and biomarker/genetic testing are used in ALL management; Clinical trials are preferred for certain B-ALL and T-ALL cases"},
	{"id":"Medical-4fa20ee8","source":"Medical","question":"You are a colorectal surgeon preparing a referral letter for a 52-year-old patient recently diagnosed with T1 rectal adenocarcinoma following colonoscopy. Summarize the diagnostic findings, relevant biomarkers, risk factors, and propose initial management, referencing current guideline recommendations.","answer":"Dear Colleague,\n\nI am referring a 52-year-old patient recently diagnosed with T1 rectal adenocarcinoma. The diagnosis was established after colonoscopy revealed an adenomatous polyp in the rectum, confirmed as adenocarcinoma on histology. MRI of the pelvis and endorectal ultrasound (EUS) were performed for local staging, confirming a T1 lesion without evidence of nodal involvement. Blood tests, including CEA, were obtained for baseline monitoring. Genetic testing for mismatch repair deficiency (dMMR) and microsatellite instability-high (MSI-H) is underway, as per guideline recommendations, to assess for Lynch syndrome or other hereditary risks. The patient has no known family history of colorectal cancer or polyposis syndromes. \n\nBased on current guidelines, I recommend endoscopic submucosal dissection (ESD) as a curative option for this T1 lesion, with consideration of transanal local excision if technically feasible. Ongoing surveillance will include flexible sigmoidoscopy every 6 months for 5 years and periodic imaging. Further management will be tailored based on final pathology and biomarker results.\n\nSincerely,\n[Your Name], MD","question_type":"Creative Generation","evidence":"The patient is a 52-year-old diagnosed with T1 rectal adenocarcinoma.; The diagnosis was established after colonoscopy revealed an adenomatous polyp.; Histology confirmed the adenomatous polyp as adenocarcinoma.; MRI of the pelvis and endorectal ultrasound (EUS) were performed for local staging.; The imaging confirmed a T1 lesion without evidence of nodal involvement.; Blood tests, including CEA, were obtained for baseline monitoring.; Genetic testing for mismatch repair deficiency (dMMR) is underway.; Microsatellite instability-high (MSI-H) testing is also being performed.; The patient has no known family history of colorectal cancer or polyposis syndromes.; Endoscopic submucosal dissection (ESD) is recommended as a curative option for the T1 lesion.; Transanal local excision may be considered if technically feasible.; Ongoing surveillance will include flexible sigmoidoscopy every 6 months for 5 years.; Periodic imaging will be scheduled to check for signs of cancer returning.","evidence_relations":"Adenocarcinoma is the most common subtype of rectal cancer; Most rectal cancers start in adenomatous polyps; MRI of the pelvis is recommended for staging rectal cancer; Endorectal ultrasound (EUS) can assess tumor extent and guide biopsy; All rectal tumors should be tested for dMMR or MSI-H; CEA blood test is used for monitoring rectal cancer; Endoscopic submucosal dissection (ESD) is recommended for T1 rectal tumors; Transanal local excision is an option for T1 tumors at the end of the rectum; Surveillance after local excision or ESD includes regular sigmoidoscopy and imaging"},
	{"id":"Medical-476aa094","source":"Medical","question":"Imagine you are an oncology nurse educator. Prepare a patient-facing discharge summary for a young woman with rectal cancer who has undergone low anterior resection (LAR) and is interested in fertility preservation. Include relevant surgical, surveillance, and fertility guidance from the guidelines.","answer":"Discharge Summary\n\nDiagnosis: Rectal adenocarcinoma\nProcedure: Low anterior resection (LAR)\n\nSummary: You have undergone a successful low anterior resection (LAR) for rectal cancer located in the mid-rectum. Pathology confirmed adenocarcinoma, which is the most common type of rectal cancer. The surgery involved removing the tumor and part of the rectum, with reconnection of the colon to the remaining rectum when possible. Your recovery is progressing well.\n\nFollow-up and Surveillance: After surgery, ongoing surveillance is important to monitor for cancer recurrence or new polyps. This includes regular colonoscopies, carcinoembryonic antigen (CEA) blood tests, and imaging studies such as MRI or CT scans as recommended by your care team. These tests help detect any early signs of cancer returning and ensure prompt management if needed.\n\nFertility Preservation: As a young woman interested in future fertility, it is important to be aware that some cancer treatments, especially radiation therapy, can affect ovarian function and fertility. Options for fertility preservation include egg freezing (oocyte cryopreservation), ovarian tissue banking, and ovarian transposition (oophoropexy), which moves the ovaries out of the radiation field to help protect them. Early discussion with your oncology team and referral to a fertility specialist are recommended to explore these options before starting any additional treatments that may impact fertility.\n\nSymptoms to Watch: Please promptly report any rectal bleeding, abdominal pain, changes in bowel habits, or other concerning symptoms to your care team.\n\nAdditional Guidance: You may also be offered genetic counseling and testing for inherited cancer syndromes, such as Lynch syndrome, which can impact future cancer risk and family planning.\n\nSincerely,\nThe Oncology Nursing Team","question_type":"Creative Generation","evidence":"The patient is a young woman diagnosed with rectal adenocarcinoma.; The patient underwent a low anterior resection (LAR) for rectal cancer.; Pathology confirmed adenocarcinoma, the most common type of rectal cancer.; The surgery was uneventful, and the patient is recovering well.; Post-surgery, the patient will need regular colonoscopies to monitor for recurrence.; Regular colonoscopies will also monitor for new polyps.; CEA blood tests will be part of the follow-up.; Imaging studies such as MRI or CT scans may be scheduled for monitoring.; The patient expressed interest in future fertility preservation.; Options for fertility preservation include egg freezing and ovarian tissue banking.; Ovarian transposition is also available for fertility preservation.; The patient should discuss fertility options with the oncology team.; The patient should report any rectal bleeding, abdominal pain, or changes in bowel habits.","evidence_relations":"Low anterior resection (LAR) is used for tumors in the mid to upper rectum; Adenocarcinoma is the most common subtype of rectal cancer; Colonoscopy is recommended after surgery for surveillance; CEA blood test is used for monitoring rectal cancer; Imaging (EUS or MRI) is recommended for surveillance after treatment; Fertility preservation options include egg freezing, ovarian tissue banking, and ovarian transposition; Symptoms of rectal cancer may include changes in bowel habits, rectal bleeding, and abdominal pain"},
	{"id":"Medical-3d15cf50","source":"Medical","question":"You are a multidisciplinary tumor board coordinator. Draft a concise case summary for discussion of a patient with suspected Lynch syndrome and newly diagnosed rectal cancer, integrating genetic risk, diagnostic staging, and recommended biomarker testing.","answer":"Case Summary for Tumor Board\n\nPatient: 45-year-old with newly diagnosed rectal adenocarcinoma and family history suggestive of Lynch syndrome. \n\nKey Points:\n- Diagnosis: Rectal adenocarcinoma identified in an adenomatous polyp on colonoscopy.\n- Risk Factors: Family history significant for early-onset colorectal cancer, raising suspicion for Lynch syndrome.\n- Biomarker Evaluation: Tumor tissue sent for mismatch repair deficiency (dMMR) and microsatellite instability-high (MSI-H) testing as recommended for all rectal tumors. \n- Staging: MRI pelvis and CT chest/abdomen performed for local and distant staging. Endorectal ultrasound (EUS) assessed tumor depth.\n- Management: Treatment options pending staging and molecular results. Genetic counseling advised for Lynch syndrome assessment.\n\nPrepared by: [Your Name], Tumor Board Coordinator","question_type":"Creative Generation","evidence":"The patient is a 45-year-old with newly diagnosed rectal adenocarcinoma.; The patient has a family history suggestive of Lynch syndrome.; The diagnosis was identified in an adenomatous polyp on colonoscopy.; Tumor tissue was sent for mismatch repair deficiency (dMMR) testing.; Microsatellite instability-high (MSI-H) testing is recommended for all rectal tumors.; MRI of the pelvis and CT of the chest/abdomen were performed for staging.; Endorectal ultrasound (EUS) assessed tumor depth.; Treatment options are pending staging and molecular results.; Genetic counseling is advised for Lynch syndrome assessment.","evidence_relations":"Adenocarcinoma is the most common subtype of rectal cancer; Most rectal cancers start in adenomatous polyps; Lynch syndrome is a genetic risk factor for rectal cancer; All rectal tumors should be tested for dMMR or MSI-H; MRI of the pelvis is recommended for staging rectal cancer; CT scan of chest and abdomen is used to detect metastasis; Endorectal ultrasound (EUS) can assess tumor extent and guide biopsy; Familial adenomatous polyposis (FAP) is a genetic syndrome causing multiple polyps and increased rectal cancer risk"},
	{"id":"Medical-d1daa403","source":"Medical","question":"Rewrite the clinical facts into a public health advisory about the importance of surveillance and early detection in rectal cancer, highlighting risk factors, symptoms, and preventive strategies.","answer":"**Public Health Advisory: Early Detection and Prevention of Rectal Cancer**\n\nRectal cancer is a serious health concern and represents a type of colorectal cancer that often develops slowly from adenomatous polyps over many years. Certain individuals are at higher risk, particularly those with hereditary syndromes such as Lynch syndrome and familial adenomatous polyposis (FAP), which can lead to the development of multiple polyps and significantly increase the likelihood of rectal cancer. \n\nEarly symptoms of rectal cancer may include rectal bleeding, abdominal pain, and changes in bowel habits. These symptoms can sometimes be mistaken for less serious conditions, but should not be ignored. Early detection is crucial, as it greatly improves treatment outcomes.\n\nPreventive strategies include regular screening with colonoscopy, which allows for the identification and removal (polypectomy) of precancerous polyps, thereby reducing the risk of cancer development. Individuals who have undergone local excision or endoscopic submucosal dissection (ESD) for rectal lesions require ongoing surveillance with flexible sigmoidoscopy and imaging to monitor for recurrence or new lesions.\n\nMaintaining a healthy lifestyle, including a diet rich in plant-based foods, regular physical activity, and avoiding tobacco and excessive alcohol, may also help lower the risk of rectal cancer. Early diagnosis and intervention save lives. If you have risk factors or symptoms, consult your healthcare provider about appropriate screening and preventive measures.","question_type":"Creative Generation","evidence":"Rectal cancer is a type of colorectal cancer.; Rectal cancer often develops from adenomatous polyps over several years.; Individuals with hereditary syndromes such as Lynch syndrome are at elevated risk for rectal cancer.; Individuals with familial adenomatous polyposis (FAP) are at elevated risk for rectal cancer.; Early symptoms of rectal cancer may include rectal bleeding.; Early symptoms of rectal cancer may include abdominal pain.; Early symptoms of rectal cancer may include changes in bowel habits.; Regular colonoscopy can remove precancerous polyps.; Polypectomy can significantly reduce the risk of cancer development.; Ongoing surveillance with flexible sigmoidoscopy is essential for those who have had local excision or endoscopic submucosal dissection (ESD).; Imaging is essential for ongoing surveillance after local excision or ESD.; Early diagnosis and intervention can save lives.","evidence_relations":"Rectal cancer is a type of colorectal cancer; Most rectal cancers start in adenomatous polyps; Adenomas can become invasive rectal cancer over many years; Lynch syndrome is a genetic risk factor for rectal cancer; Familial adenomatous polyposis (FAP) is a genetic syndrome causing multiple polyps and increased rectal cancer risk; Symptoms of rectal cancer may include changes in bowel habits, rectal bleeding, and abdominal pain; Polypectomy during colonoscopy can remove most polyps and prevent cancer; Surveillance after local excision or ESD includes regular sigmoidoscopy and imaging"},
	{"id":"Medical-a5e566ed","source":"Medical","question":"As a medical intern, compose a SOAP (Subjective, Objective, Assessment, Plan) note for a patient presenting with rectal bleeding and abdominal pain, found to have a rectal mass on imaging, referencing diagnostic and management guidelines.","answer":"SOAP Note\n\nSubjective: Patient reports several weeks of rectal bleeding, abdominal pain, and recent changes in bowel habits. No significant personal or family history of colorectal cancer noted.\n\nObjective: On examination, mild tenderness in the lower abdomen. Colonoscopy revealed a rectal mass. MRI of the pelvis confirmed a lesion in the lower rectum. CEA blood test elevated. Biopsy confirmed adenocarcinoma.\n\nAssessment: Newly diagnosed rectal adenocarcinoma. Staging underway with CT scan of chest and abdomen to assess for metastasis. Biomarker testing (dMMR/MSI-H) pending.\n\nPlan: Await full staging and biomarker results. Discuss surgical options, including potential for abdominoperineal resection (APR) or chemoradiation, depending on tumor stage and location. Begin genetic counseling if risk factors identified. Schedule multidisciplinary team meeting.\n","question_type":"Creative Generation","evidence":"The patient reports several weeks of rectal bleeding.; The patient reports abdominal pain.; The patient reports recent changes in bowel habits.; There is no significant personal history of colorectal cancer noted.; The physical examination shows mild tenderness in the lower abdomen.; Colonoscopy revealed a rectal mass.; MRI of the pelvis confirmed a lesion in the lower rectum.; The CEA blood test was elevated.; Biopsy confirmed adenocarcinoma.; The patient is newly diagnosed with rectal adenocarcinoma.; Staging is underway with a CT scan of the chest and abdomen.; Biomarker testing (dMMR/MSI-H) is pending.; The plan includes awaiting full staging and biomarker results.; The plan includes discussing surgical options.; The plan includes considering abdominoperineal resection (APR) or chemoradiation.; The plan includes beginning genetic counseling if risk factors are identified.; A multidisciplinary team meeting is to be scheduled.","evidence_relations":"Symptoms of rectal cancer may include changes in bowel habits, rectal bleeding, and abdominal pain; Colonoscopy is recommended after surgery for surveillance; MRI of the pelvis is recommended for staging rectal cancer; CEA blood test is used for monitoring rectal cancer; Adenocarcinoma is the most common subtype of rectal cancer; CT scan of chest and abdomen is used to detect metastasis; Abdominoperineal resection (APR) is used for tumors in the lower rectum; Chemoradiation is used for locally advanced rectal cancer; All rectal tumors should be tested for dMMR or MSI-H"},
	{"id":"Medical-fbc24d80","source":"Medical","question":"Imagine you are a urology attending preparing a referral letter for a 65-year-old male newly diagnosed with high-grade, muscle-invasive urothelial carcinoma of the bladder. Summarize the diagnostic findings, risk factors, and outline the initial multidisciplinary treatment plan you would recommend, referencing evidence from the provided clinical guidelines.","answer":"Dear Oncology Colleague,\n\nI am referring Mr. John Doe, a 65-year-old male, recently diagnosed with high-grade, muscle-invasive urothelial carcinoma of the bladder (Stage 2). Diagnostic workup included cystoscopy with biopsy confirming high-grade urothelial carcinoma, and imaging (CT and MRI) demonstrating invasion into the detrusor muscle without distant metastasis. Notably, the patient has a significant smoking history and reports intermittent painless hematuria. \n\nGiven the diagnosis, I recommend a multidisciplinary approach involving radical cystectomy as the standard surgical intervention, with consideration for perioperative cisplatin-based chemotherapy (ddMVAC regimen). Preoperative counseling regarding urinary diversion options (ileal conduit, neobladder, or continent cutaneous pouch) is essential. The patient should also be evaluated for potential enrollment in clinical trials and receive supportive care to manage anticipated side effects such as urinary incontinence and fatigue. Ongoing surveillance and follow-up will be critical due to high recurrence risk.\n\nSincerely,\nDr. Smith, Urology","question_type":"Creative Generation","evidence":"The patient is a 65-year-old male.; The patient was recently diagnosed with high-grade, muscle-invasive urothelial carcinoma of the bladder.; The cancer is classified as Stage 2.; Diagnostic workup included cystoscopy with biopsy.; The biopsy confirmed high-grade urothelial carcinoma.; Imaging tests (CT and MRI) demonstrated invasion into the detrusor muscle.; There is no evidence of distant metastasis.; The patient has a significant smoking history.; The patient reports intermittent painless hematuria.; The recommended treatment includes a multidisciplinary approach.; Radical cystectomy is the standard surgical intervention.; Perioperative cisplatin-based chemotherapy (ddMVAC regimen) is considered.; Preoperative counseling regarding urinary diversion options is essential.; The patient should be evaluated for potential enrollment in clinical trials.; Supportive care is recommended to manage anticipated side effects.","evidence_relations":"Urothelial carcinoma is the most common subtype of bladder cancer.; Cancer grade is classified as low grade (LG) or high grade (HG).; Stages 2, 3, and 4 bladder cancers are muscle-invasive.; Smoking is the greatest risk factor for bladder cancer.; Diagnosis of bladder cancer involves cystoscopy, urine cytology, biopsy, and imaging (CT, MRI, PET/CT, ultrasound, pyelogram, urogram).; Radical cystectomy is the standard surgery for muscle-invasive bladder cancer.; Chemotherapy regimens include cisplatin-based combinations such as ddMVAC.; Urinary diversion procedures include ileal conduit, neobladder, and continent cutaneous pouch.; Clinical trials are available at all stages of bladder cancer.; Follow-up and surveillance are required due to high recurrence rates."},
	{"id":"Medical-47f26425","source":"Medical","question":"As an oncology nurse educator, draft a comprehensive discharge summary for a patient who underwent radical cystectomy with formation of a neobladder for high-grade, muscle-invasive bladder cancer. Include presenting symptoms, diagnostic steps, treatment course, potential side effects, and follow-up recommendations.","answer":"Discharge Summary\n\nPatient: Jane Smith\nMRN: 123456\nDiagnosis: High-grade, muscle-invasive urothelial carcinoma of the bladder (Stage 3)\n\nPresenting Symptoms: The patient initially presented with painless hematuria, which is the most common symptom of bladder cancer, as well as increased urinary frequency. No dysuria or back pain was reported at presentation.\n\nDiagnostic Steps: The diagnostic evaluation included cystoscopy with biopsy, which confirmed high-grade urothelial carcinoma. Urine cytology supported the diagnosis, and cross-sectional imaging with CT and MRI demonstrated invasion into the bladder muscle (stage 3) without evidence of distant metastasis or lymph node involvement.\n\nTreatment Course: The patient underwent radical cystectomy with formation of a neobladder as a urinary diversion. Perioperative cisplatin-based chemotherapy (ddMVAC regimen) was administered in accordance with current guidelines for muscle-invasive disease. The postoperative course was notable for mild urinary incontinence and fatigue, both of which were managed with supportive care measures.\n\nPotential Side Effects: The patient was counseled regarding possible complications and side effects of surgery and chemotherapy, including infection, bleeding, urinary incontinence, sexual dysfunction, fatigue, kidney problems, and potential issues related to the neobladder such as urinary retention or metabolic disturbances. Nausea and diarrhea may also occur as a result of chemotherapy.\n\nFollow-up Recommendations: Due to the high risk of recurrence, the patient will require regular follow-up, including cystoscopy (if any native urothelium remains), urine cytology, and periodic imaging studies. Ongoing laboratory monitoring of renal function is recommended. The patient has been referred for supportive care services to address symptoms and side effects, and is encouraged to consider participation in clinical trials as appropriate. Education was provided regarding signs of infection, changes in urinary function, and when to seek medical attention.\n\nDischarge Date: [Insert date]\n\nPrepared by: Oncology Nurse Educator","question_type":"Creative Generation","evidence":"The patient is named Jane Smith.; The patient has a diagnosis of high-grade, muscle-invasive urothelial carcinoma of the bladder.; The cancer is classified as Stage 3.; The patient presented with painless hematuria.; The patient presented with increased urinary frequency.; Diagnostic evaluation included cystoscopy with biopsy.; The biopsy confirmed high-grade urothelial carcinoma.; Urine cytology was part of the diagnostic workup.; Imaging tests (CT and MRI) showed muscle invasion without distant spread.; The patient underwent radical cystectomy with neobladder construction.; Perioperative cisplatin-based chemotherapy (ddMVAC) was administered.; The postoperative period was complicated by mild urinary incontinence.; The postoperative period was complicated by fatigue.; The patient was counseled about possible complications.; Regular cystoscopy, urine cytology, and imaging are scheduled for follow-up.; The patient was referred for supportive care.","evidence_relations":"Blood in urine (hematuria) is the most common symptom of bladder cancer.; Other symptoms include frequent urination, urgency, painful urination, and back pain.; Diagnosis of bladder cancer involves cystoscopy, urine cytology, biopsy, and imaging (CT, MRI, PET/CT, ultrasound, pyelogram, urogram).; Radical cystectomy is the standard surgery for muscle-invasive bladder cancer.; Urinary diversion procedures include neobladder.; Chemotherapy regimens include cisplatin-based combinations such as ddMVAC.; Common side effects of treatment include bleeding, infection, sexual dysfunction, urinary incontinence, fatigue, nausea, and diarrhea.; Follow-up and surveillance are required due to high recurrence rates.; Supportive care addresses symptoms and side effects of cancer and its treatment.; Clinical trials are available at all stages of bladder cancer."},
	{"id":"Medical-9c29bee8","source":"Medical","question":"You are a medical intern tasked with writing a SOAP (Subjective, Objective, Assessment, Plan) note for a patient presenting with painless hematuria and risk factors for bladder cancer. Incorporate relevant diagnostic and management steps according to the clinical guidelines.","answer":"SOAP Note\n\nSubjective: 58-year-old male presents with several episodes of painless hematuria over the past month. He has a 30-pack-year smoking history and reports mild urinary urgency. No significant family history of cancer.\n\nObjective: Physical exam unremarkable. Urinalysis positive for blood. \n\nAssessment: High suspicion for bladder cancer given classic symptom of painless hematuria and significant smoking history. Differential includes urinary tract infection and nephrolithiasis, but malignancy is prioritized.\n\nPlan:\n- Order cystoscopy, urine cytology, and imaging (CT urogram) for diagnostic confirmation.\n- If nonmuscle-invasive disease (Stage 0 or 1) is confirmed, consider TURBT with intravesical BCG or chemotherapy.\n- If muscle-invasive disease is found, consult urology for possible radical cystectomy and discuss systemic therapy options (cisplatin-based chemotherapy, immunotherapy).\n- Counsel patient on smoking cessation and provide supportive care resources.\n- Schedule regular follow-up and surveillance due to recurrence risk.","question_type":"Creative Generation","evidence":"The patient is a 58-year-old male.; The patient presents with several episodes of painless hematuria over the past month.; The patient has a 30-pack-year smoking history.; The patient reports mild urinary urgency.; The physical exam was unremarkable.; Urinalysis was positive for blood.; There is a high suspicion for bladder cancer due to painless hematuria.; The patient's significant smoking history increases the suspicion for bladder cancer.; Differential diagnosis includes urinary tract infection and nephrolithiasis.; Cystoscopy, urine cytology, and imaging (CT urogram) are ordered for diagnostic confirmation.; If non-muscle-invasive disease is confirmed, TURBT with intravesical BCG or chemotherapy is considered.; If muscle-invasive disease is found, urology will be consulted for possible radical cystectomy.; Systemic therapy options include cisplatin-based chemotherapy and immunotherapy.; The patient is counseled on smoking cessation.; Supportive care resources are provided.; Regular follow-up and surveillance are scheduled due to recurrence risk.","evidence_relations":"Blood in urine (hematuria) is the most common symptom of bladder cancer.; Smoking is the greatest risk factor for bladder cancer.; Diagnosis of bladder cancer involves cystoscopy, urine cytology, biopsy, and imaging (CT, MRI, PET/CT, ultrasound, pyelogram, urogram).; Stage 0 and Stage 1 bladder cancers are nonmuscle-invasive.; TURBT is used for tumor removal in nonmuscle-invasive bladder cancer.; Intravesical therapy (BCG or chemotherapy) is used for nonmuscle-invasive bladder cancer.; Radical cystectomy is the standard surgery for muscle-invasive bladder cancer.; Systemic therapy includes chemotherapy, immunotherapy (checkpoint inhibitors), and targeted therapy.; Follow-up and surveillance are required due to high recurrence rates.; Supportive care addresses symptoms and side effects of cancer and its treatment."},
	{"id":"Medical-0c5272d1","source":"Medical","question":"Rewrite the core clinical recommendations for the management of nonmuscle-invasive bladder cancer (NMIBC) into a concise public health advisory aimed at primary care providers. Highlight risk factors, diagnostic approach, treatment options, and the importance of surveillance.","answer":"**Public Health Advisory: Early Detection and Management of NonMuscle-Invasive Bladder Cancer (NMIBC)**\n\nPrimary care providers should maintain a high index of suspicion for bladder cancer in patients presenting with hematuria, particularly those with established risk factors such as a history of smoking (the greatest risk factor), age over 55, family history of bladder cancer, Lynch syndrome, or occupational exposure to chemicals. The recommended diagnostic approach includes prompt referral for cystoscopy, urine cytology, and appropriate imaging studies (such as CT urogram) to confirm diagnosis and assess disease extent. Most NMIBC cases (Stages 0 and 1) are treated with transurethral resection of bladder tumor (TURBT), often followed by intravesical therapy with Bacillus Calmette-Gurin (BCG) or chemotherapy to reduce recurrence risk. Given the high rates of recurrence, ongoing surveillance with regular cystoscopy, urine cytology, and, when indicated, biomarker testing is essential for early detection of recurrence or progression. Providers should counsel all patients on the importance of smoking cessation and consider referral to clinical trials when appropriate. Early identification and adherence to surveillance protocols are critical to improving patient outcomes.","question_type":"Creative Generation","evidence":"Non-muscle-invasive bladder cancer (NMIBC) is a type of bladder cancer.; Primary care providers should be vigilant for bladder cancer in patients presenting with hematuria.; Risk factors for bladder cancer include smoking.; Risk factors for bladder cancer include age over 55.; Risk factors for bladder cancer include family history.; Risk factors for bladder cancer include Lynch syndrome.; Risk factors for bladder cancer include chemical exposure.; Early diagnosis relies on prompt referral for cystoscopy.; Early diagnosis relies on urine cytology.; Early diagnosis relies on imaging.; Most NMIBC cases (Stages 0 and 1) are managed with transurethral resection (TURBT).; Intravesical therapy options include BCG or chemotherapy.; Ongoing surveillance with regular cystoscopy is essential due to high recurrence rates.; Ongoing surveillance includes urine cytology and biomarker monitoring.; Smoking cessation should be encouraged.; Eligible patients should be considered for clinical trials.","evidence_relations":"Stage 0 and Stage 1 bladder cancers are nonmuscle-invasive.; Smoking is the greatest risk factor for bladder cancer.; Other risk factors include age, family history, Lynch syndrome, and chemical exposure.; Diagnosis of bladder cancer involves cystoscopy, urine cytology, biopsy, and imaging (CT, MRI, PET/CT, ultrasound, pyelogram, urogram).; TURBT is used for tumor removal in nonmuscle-invasive bladder cancer.; Intravesical therapy (BCG or chemotherapy) is used for nonmuscle-invasive bladder cancer.; Biomarker tests may be used for surveillance in nonmuscle-invasive bladder cancer.; Follow-up and surveillance are required due to high recurrence rates.; Clinical trials are available at all stages of bladder cancer."},
	{"id":"Medical-8ddfc9d8","source":"Medical","question":"Imagine you are a patient diagnosed with Stage 4 (metastatic) bladder cancer. Write a detailed email to a cancer support group describing your diagnosis, genetic findings, current treatments, side effects, and follow-up care, grounded in the clinical evidence from the guidelines.","answer":"Subject: My Journey with Metastatic Bladder Cancer\n\nDear Support Group,\n\nI wanted to share my experience after being diagnosed with Stage 4 (metastatic) bladder cancer. My journey began with blood in my urine and back pain. Tests including cystoscopy, biopsy, and imaging (PET/CT) confirmed the cancer had spread beyond the bladder. Genetic tests revealed an FGFR3 mutation, which my oncologist explained could influence my treatment options.\n\nCurrently, I'm receiving systemic therapy, which includes cisplatin-based chemotherapy and immunotherapy with pembrolizumab. My doctor also discussed targeted therapies such as erdafitinib because of my FGFR3 mutation. The treatments have caused fatigue, nausea, and some urinary incontinence, but supportive care services have helped manage these side effects.\n\nMy care team emphasizes the importance of regular imaging and lab tests for surveillance, as well as considering clinical trials for new therapies. I appreciate the support from this group and hope my story helps others facing similar challenges.\n\nSincerely,\nAlex","question_type":"Creative Generation","evidence":"The patient has Stage 4 (metastatic) bladder cancer.; The patient's journey began with blood in urine.; The patient experienced back pain.; Tests including cystoscopy confirmed the cancer diagnosis.; Biopsy and imaging (PET/CT) confirmed the cancer had spread beyond the bladder.; Genetic tests revealed an FGFR3 mutation.; The FGFR3 mutation may influence treatment options.; The patient is receiving systemic therapy.; The systemic therapy includes cisplatin-based chemotherapy.; The systemic therapy includes immunotherapy with pembrolizumab.; Targeted therapies such as erdafitinib are discussed due to the FGFR3 mutation.; The treatments have caused fatigue.; The treatments have caused nausea.; The treatments have caused some urinary incontinence.; Supportive care services have helped manage side effects.; Regular imaging and lab tests for surveillance are emphasized.; The care team considers clinical trials for new therapies.","evidence_relations":"Stage 4 bladder cancer is metastatic and may involve distant organs.; Diagnosis of bladder cancer involves cystoscopy, urine cytology, biopsy, and imaging (CT, MRI, PET/CT, ultrasound, pyelogram, urogram).; Genetic alterations such as mutations in FGFR3 are associated with bladder cancer.; Systemic therapy includes chemotherapy, immunotherapy (checkpoint inhibitors), and targeted therapy.; Chemotherapy regimens include cisplatin-based combinations such as ddMVAC.; Immunotherapy agents include pembrolizumab, nivolumab, avelumab, and atezolizumab.; Targeted therapies include erdafitinib (Balversa), enfortumab vedotin-ejfv (Padcev), and sacituzumab govitecan-hziy (Trodelvy).; Common side effects of treatment include urinary incontinence, fatigue, and nausea.; Supportive care addresses symptoms and side effects of cancer and its treatment.; Follow-up and surveillance are required due to high recurrence rates.; Clinical trials are available at all stages of bladder cancer."},
	{"id":"Medical-fe4d939e","source":"Medical","question":"Imagine you are a urologist writing a referral letter to a multidisciplinary tumor board for a 62-year-old patient recently diagnosed with renal cell carcinoma (RCC) displaying sarcomatoid features and suspected lung metastases. Summarize the case, including diagnostic findings, histology, staging, and key considerations for management.","answer":"Dear Multidisciplinary Tumor Board,\n\nI am referring a 62-year-old male patient who has been recently diagnosed with renal cell carcinoma (RCC). Diagnostic imaging revealed a large renal mass arising from the renal tubules. Histopathological examination of the biopsy specimen confirmed clear cell RCC (ccRCC) with sarcomatoid features, which are known to be associated with a more aggressive clinical course and poorer prognosis. Further imaging studies identified multiple pulmonary nodules, raising strong suspicion for metastatic disease to the lungs. Laboratory workup included comprehensive blood and urine tests, and biomarker as well as genetic risk testing are currently in progress to further characterize the disease and guide management.\n\nGiven the presence of sarcomatoid differentiation and evidence of distant metastases, this patient represents a high-risk case requiring multidisciplinary input. Key considerations for management include selection of optimal systemic therapy, which may involve immunotherapy and/or targeted agents, and evaluation for potential enrollment in clinical trials. Treatment planning should be individualized based on tumor histology, size, anatomical location, and extent of metastatic involvement. I look forward to the boards recommendations regarding the most appropriate therapeutic approach for this patient.","question_type":"Creative Generation","evidence":"The patient is a 62-year-old male.; The patient was recently diagnosed with renal cell carcinoma (RCC).; The RCC displays sarcomatoid features.; The patient is suspected to have lung metastases.; Imaging tests revealed a large renal mass originating in the renal tubules.; Histopathologic analysis confirmed clear cell RCC (ccRCC).; The ccRCC exhibits sarcomatoid features.; Additional imaging identified pulmonary nodules consistent with metastatic disease.; Laboratory evaluation included blood and urine tests.; A biopsy confirmed the diagnosis of RCC.; Biomarker and genetic risk testing are underway.; The presence of sarcomatoid features is associated with more aggressive disease.; The case requires input regarding optimal systemic therapy.; Consideration of clinical trial enrollment is recommended.; Treatment planning should account for tumor histology, size, location, and metastatic status.","evidence_relations":"Renal cell carcinoma (RCC) is the most common type of kidney cancer.; Clear cell RCC is the most common subtype of RCC.; Sarcomatoid features can occur in any RCC subtype and are associated with more aggressive disease.; Kidney cancer can metastasize to distant sites such as lungs, lymph nodes, bones, liver, and brain.; Diagnosis of kidney cancer involves imaging tests, blood tests, urine tests, biopsy, biomarker testing, and genetic risk testing.; Treatment for RCC is based on histology, tumor size, tumor location, and presence of metastasis."},
	{"id":"Medical-5242d398","source":"Medical","question":"You are an oncologist tasked with drafting an initial treatment plan for a patient newly diagnosed with non-clear cell RCC (papillary subtype) confined to the kidney, with no evidence of metastasis. Outline your diagnostic confirmation, staging, and treatment strategy.","answer":"For a patient newly diagnosed with non-clear cell renal cell carcinoma (papillary subtype) confined to the kidney, the initial approach involves confirming the diagnosis and accurately staging the disease. Diagnostic confirmation should include imaging studies such as contrast-enhanced CT or MRI to characterize the renal mass and assess for local extension or metastasis. Blood and urine tests are performed to evaluate renal function and detect any paraneoplastic effects. A percutaneous biopsy is recommended to establish histologic subtype, specifically confirming papillary RCC, and to rule out sarcomatoid features. Biomarker and genetic risk testing should be conducted to identify any actionable molecular alterations and to inform prognosis. Staging is critical to exclude local invasion into perirenal fat, blood vessels, lymph nodes, or distant organs. Since the tumor is localized and of non-clear cell histology, the primary treatment is surgical resection, with the choice between partial or radical nephrectomy based on tumor size, location, and preservation of renal function. The final treatment plan will be guided by surgical pathology results and risk stratification, with consideration of surveillance or adjuvant therapy as indicated by the patients risk profile.","question_type":"Creative Generation","evidence":"The patient has a new diagnosis of papillary renal cell carcinoma (PRCC).; The PRCC is confined to the kidney.; The diagnosis will be confirmed using imaging tests such as CT or MRI.; Blood and urine tests will be performed for diagnostic confirmation.; A percutaneous biopsy will be conducted for histologic subtyping.; Biomarker and genetic risk testing will identify actionable alterations.; Staging will ensure there is no local spread to surrounding fat.; Staging will ensure there is no local spread to blood vessels.; Staging will ensure there is no local spread to lymph nodes.; Staging will ensure there is no distant metastasis.; Surgical resection is the mainstay of treatment.; The surgical resection may be partial or radical nephrectomy.; The type of nephrectomy depends on tumor size and location.; Further management will be determined by final pathology and risk assessment.","evidence_relations":"Non-clear cell RCC includes papillary RCC, chromophobe RCC, collecting duct RCC, and renal medullary carcinoma.; Diagnosis of kidney cancer involves imaging tests, blood tests, urine tests, biopsy, biomarker testing, and genetic risk testing.; Treatment for RCC is based on histology, tumor size, tumor location, and presence of metastasis.; Kidney cancer can spread locally to surrounding fat, blood vessels, lymph nodes, adrenal glands, and Gerotas fascia.; Multiple tumors in one or both kidneys are treated as separate primary tumors, not metastasis."},
	{"id":"Medical-fb2edc8f","source":"Medical","question":"Rewrite the clinical facts regarding kidney cancer subtypes, spread, and diagnosis into a structured discharge summary for a patient with newly diagnosed clear cell RCC with local extension but no distant metastasis.","answer":"Discharge Summary:\n\nDiagnosis: Clear cell renal cell carcinoma (ccRCC) with local extension\n\nHospital Course: The patient presented with a renal mass confirmed by imaging tests. Biopsy of the lesion established a diagnosis of clear cell RCC, the most common RCC subtype, originating from renal tubule cells. Staging studies indicated local spread to perirenal fat and regional lymph nodes, but no evidence of distant metastasis to lungs, bones, liver, or brain. Laboratory workup included blood and urine tests, and biomarker as well as genetic risk assessments were initiated. The patient underwent partial nephrectomy, with pathology confirming ccRCC with no sarcomatoid features.\n\nPlan: Outpatient follow-up for ongoing surveillance and consideration of adjuvant therapy based on risk stratification.","question_type":"Creative Generation","evidence":"The patient has a diagnosis of clear cell renal cell carcinoma (ccRCC).; The ccRCC has local extension.; The patient presented with a renal mass confirmed by imaging tests.; A biopsy of the lesion established a diagnosis of clear cell RCC.; Clear cell RCC is the most common RCC subtype.; Clear cell RCC originates from renal tubule cells.; Staging studies indicated local spread to perirenal fat.; Staging studies indicated local spread to regional lymph nodes.; There is no evidence of distant metastasis to lungs, bones, liver, or brain.; Laboratory workup included blood and urine tests.; Biomarker and genetic risk assessments were initiated.; The patient underwent partial nephrectomy.; Pathology confirmed ccRCC with no sarcomatoid features.; Outpatient follow-up for ongoing surveillance is planned.; Consideration of adjuvant therapy will be based on risk stratification.","evidence_relations":"Clear cell RCC is the most common subtype of RCC.; RCC starts in the cells that line the renal tubules.; Kidney cancer can spread locally to surrounding fat, blood vessels, lymph nodes, adrenal glands, and Gerotas fascia.; Kidney cancer can metastasize to distant sites such as lungs, lymph nodes, bones, liver, and brain.; Diagnosis of kidney cancer involves imaging tests, blood tests, urine tests, biopsy, biomarker testing, and genetic risk testing.; Treatment for RCC is based on histology, tumor size, tumor location, and presence of metastasis."},
	{"id":"Medical-8dd14c45","source":"Medical","question":"As a public health official, prepare an advisory summarizing the key risk factors, diagnostic approaches, and importance of early detection for kidney cancer, referencing the main cancer types and common metastatic sites.","answer":"Public Health Advisory: Kidney Cancer Awareness\n\nKidney cancer includes several types, with renal cell carcinoma (RCC) being the most common in adults, originating from the renal tubules. Urothelial carcinoma arises from the lining of the renal pelvis or ureter, while Wilms tumor is the primary kidney cancer in young children. Key risk factors for kidney cancer include smoking, obesity, hypertension, family history of kidney cancer, certain genetic syndromes, and exposure to specific chemicals. Early detection is vital, as kidney cancer can locally invade surrounding fat, blood vessels, lymph nodes, adrenal glands, and Gerotas fascia, and can metastasize to distant sites such as the lungs, bones, liver, and brain. Diagnostic approaches involve imaging tests (such as CT or MRI scans), blood and urine tests to assess kidney function and detect abnormalities, biopsy for histologic confirmation, and biomarker or genetic risk testing to guide management. Recognizing risk factors and symptoms, such as hematuria (blood in urine), flank pain, or an abdominal mass, and seeking prompt medical evaluation can significantly improve patient outcomes through earlier diagnosis and treatment.","question_type":"Creative Generation","evidence":"Kidney cancer encompasses several types.; The most common type of kidney cancer is renal cell carcinoma (RCC).; Renal cell carcinoma originates in the renal tubules.; Urothelial carcinoma starts in the renal pelvis or ureter.; Wilms tumor is the predominant form of kidney cancer in young children.; Early detection of kidney cancer is crucial.; Kidney cancer can locally invade surrounding fat, blood vessels, lymph nodes, and adrenal glands.; Kidney cancer can metastasize to the lungs.; Kidney cancer can metastasize to the bones.; Kidney cancer can metastasize to the liver.; Kidney cancer can metastasize to the brain.; Diagnosis of kidney cancer often requires imaging.; Diagnosis of kidney cancer often requires blood tests.; Diagnosis of kidney cancer often requires urine tests.; Diagnosis of kidney cancer often requires biopsy.; Diagnosis of kidney cancer may include biomarker and genetic risk assessments.; Recognizing risk factors and symptoms can improve outcomes.","evidence_relations":"Renal cell carcinoma (RCC) is the most common type of kidney cancer.; Urothelial carcinoma starts in the cells lining the renal pelvis and ureter.; Wilms tumor usually occurs in young children and is a distinct kidney cancer type.; Kidney cancer can spread locally to surrounding fat, blood vessels, lymph nodes, adrenal glands, and Gerotas fascia.; Kidney cancer can metastasize to distant sites such as lungs, lymph nodes, bones, liver, and brain.; Diagnosis of kidney cancer involves imaging tests, blood tests, urine tests, biopsy, biomarker testing, and genetic risk testing."},
	{"id":"Medical-8270fb83","source":"Medical","question":"You are a nephrology fellow tasked with drafting a SOAP (Subjective, Objective, Assessment, Plan) note for a patient presenting with multiple renal masses, focusing on differential diagnosis, workup, and management per guidelines.","answer":"SOAP Note:\n\nSubjective: Patient presents with incidental discovery of multiple renal masses on imaging, with no associated symptoms such as hematuria, flank pain, or constitutional complaints.\n\nObjective: CT imaging demonstrates two distinct lesions, one in each kidney. Laboratory evaluation, including blood and urine tests, is within normal limits. Chest imaging shows no evidence of metastatic disease. Biopsy of both renal lesions is pending for definitive diagnosis.\n\nAssessment: The presence of multiple renal tumors is most consistent with synchronous primary renal cell carcinomas, as per current guidelines, which distinguish between multiple primary tumors and metastatic disease. The differential diagnosis includes clear cell RCC (the most common subtype), papillary RCC, and less commonly, chromophobe RCC or other non-clear cell subtypes. Wilms tumor is unlikely given the patient's adult age.\n\nPlan: Proceed with percutaneous biopsy of both renal lesions to determine histologic subtype. Initiate biomarker and genetic risk testing to further characterize the tumors and guide management. Discuss surgical options, including nephron-sparing approaches if feasible, based on tumor size, location, and patient comorbidities. Multidisciplinary team involvement is recommended for comprehensive care planning.","question_type":"Creative Generation","evidence":"The patient presents with incidental finding of multiple renal masses on imaging.; The patient reports no symptoms.; CT imaging reveals two lesions, one in each kidney.; Blood and urine tests are within normal limits.; There is no evidence of metastasis on chest imaging.; Biopsy of both lesions is pending.; Multiple renal tumors may represent synchronous primary renal cell carcinomas.; Differential diagnosis includes clear cell RCC.; Differential diagnosis includes papillary RCC.; Differential diagnosis includes chromophobe RCC.; Wilms tumor is less likely given the patient's adult age.","evidence_relations":"Multiple tumors in one or both kidneys are treated as separate primary tumors, not metastasis.; Diagnosis of kidney cancer involves imaging tests, blood tests, urine tests, biopsy, biomarker testing, and genetic risk testing.; Clear cell RCC is the most common subtype of RCC.; Non-clear cell RCC includes papillary RCC, chromophobe RCC, collecting duct RCC, and renal medullary carcinoma.; Treatment for RCC is based on histology, tumor size, tumor location, and presence of metastasis.; Wilms tumor usually occurs in young children and is a distinct kidney cancer type."},
	{"id":"Medical-6d57a660","source":"Medical","question":"Imagine you are a multidisciplinary tumor board coordinator. Summarize the recommended diagnostic workup and initial management strategy for a patient newly diagnosed with Stage II anal squamous cell carcinoma, integrating risk assessment, staging, and treatment planning.","answer":"For a patient newly diagnosed with Stage II anal squamous cell carcinoma, the recommended diagnostic workup begins with a thorough digital rectal exam (DRE) and high-resolution anoscopy (HRA) to assess the primary tumor and adjacent tissues. Histologic confirmation via biopsy is essential. Comprehensive imagingincluding CT, MRI, and PET scansshould be performed to determine the exact tumor size (Stage II defined as >2 cm, subdivided into IIA [>2 cm to 5 cm] and IIB [>5 cm]), evaluate for regional lymph node involvement, and exclude distant metastasis. HIV testing is advised, as HIV status can impact both risk and management strategies. Staging should be conducted using the AJCC TNM system, which incorporates tumor size, nodal status, and presence of metastases. Initial management for Stage II disease consists of definitive concurrent chemoradiation, with intensity-modulated radiation therapy (IMRT) as the preferred technique to minimize toxicity. Recommended chemotherapy regimens administered with radiation include mitomycin plus capecitabine, mitomycin plus 5-fluorouracil (5-FU), or 5-FU plus cisplatin. A multidisciplinary team approachincluding medical oncology, radiation oncology, colorectal surgery, and supportive careis essential for optimal treatment planning, risk assessment, and management of potential side effects.","question_type":"Creative Generation","evidence":"The diagnostic workup for Stage II anal squamous cell carcinoma should start with a digital rectal exam (DRE).; High-resolution anoscopy (HRA) is used to evaluate the primary lesion and surrounding tissues.; A biopsy is necessary to confirm the diagnosis histologically.; Imaging studies such as CT, MRI, and PET scans are recommended.; Imaging studies assess tumor size, which must be greater than 2 cm for Stage II.; Imaging studies evaluate for lymph node involvement.; Imaging studies rule out distant metastasis.; HIV testing should be performed for patients with anal cancer.; HIV infection increases the risk of anal cancer and may influence management.; Staging is done using the AJCC TNM system.; Concurrent chemoradiation is the standard of care for initial management.; IMRT is the preferred radiation technique.; Chemotherapy options include mitomycin plus capecitabine.; Chemotherapy options include mitomycin plus 5-FU.; Chemotherapy options include 5-FU plus cisplatin.; Multidisciplinary involvement is crucial to optimize outcomes.","evidence_relations":"Anal squamous cell carcinoma is the most common subtype of anal cancer.; Stage II: tumor >2 cm, no lymph node or distant spread.; Anal cancer is diagnosed by biopsy after abnormal findings on DRE or anoscopy.; Digital rectal exam (DRE), high-resolution anoscopy (HRA), and imaging (CT, MRI, PET) are used for diagnosis and staging.; HIV testing is recommended in patients with anal cancer.; Staging uses the AJCC TNM system.; Chemoradiation is the recommended primary treatment for most non-metastatic anal cancers (stages I-III).; IMRT is the preferred radiation technique for anal cancer.; Recommended chemotherapy regimens with radiation include mitomycin and capecitabine, mitomycin and 5-FU, or 5-FU and cisplatin."},
	{"id":"Medical-b70d577f","source":"Medical","question":"You are an oncologist writing a referral letter to a fertility specialist for a young adult patient with newly diagnosed Stage III anal cancer who is about to start chemoradiation. The letter must summarize the diagnosis, planned treatment, and the rationale for fertility preservation counseling.","answer":"Dear Fertility Specialist,\n\nI am referring a 32-year-old patient recently diagnosed with Stage III anal squamous cell carcinoma (lymph node involvement, no distant metastasis). The patient is scheduled to begin concurrent chemoradiation, utilizing IMRT and a regimen of mitomycin and capecitabine. Given the high risk of infertility associated with both chemotherapy and pelvic radiation, I am requesting an urgent fertility preservation consultation prior to initiation of treatment. Potential strategies such as sperm banking, egg freezing, ovarian tissue banking, or oophoropexy should be discussed. The patient is highly motivated to preserve future reproductive options. Thank you for your prompt assistance.\n\nSincerely,\nOncologist","question_type":"Creative Generation","evidence":"The patient is a 32-year-old with Stage III anal squamous cell carcinoma.; The patient has lymph node involvement.; The patient has no distant metastasis.; The patient is scheduled to begin concurrent chemoradiation.; The treatment regimen includes IMRT.; The chemotherapy regimen includes mitomycin and capecitabine.; There is a high risk of infertility associated with chemotherapy and pelvic radiation.; An urgent fertility preservation consultation is requested prior to treatment.; Potential fertility preservation strategies include sperm banking.; Potential fertility preservation strategies include egg freezing.; Potential fertility preservation strategies include ovarian tissue banking.; Potential fertility preservation strategies include oophoropexy.; The patient is highly motivated to preserve future reproductive options.","evidence_relations":"Stage III: lymph node involvement and/or invasion of nearby organs.; Chemoradiation is the recommended primary treatment for most non-metastatic anal cancers (stages I-III).; IMRT is the preferred radiation technique for anal cancer.; Recommended chemotherapy regimens with radiation include mitomycin and capecitabine.; Radiation and chemotherapy can cause infertility; fertility preservation options should be discussed.; Fertility Preservation: Sperm banking, egg freezing, ovarian tissue banking, oophoropexy."},
	{"id":"Medical-8dc3153c","source":"Medical","question":"Transform the following clinical facts into a formal discharge summary for a patient with Stage I perianal squamous cell carcinoma who underwent local excision. Include diagnosis, procedure, pathology, follow-up recommendations, and potential complications.","answer":"Discharge Summary:\n\nDiagnosis: Stage I perianal squamous cell carcinoma (tumor 2 cm, no lymph node or distant spread).\n\nProcedure: Local excision of perianal lesion performed without complication. Surgical margins were negative on pathology.\n\nPathology: Well-differentiated squamous cell carcinoma, tumor size 1.5 cm, negative margins, no lymphovascular invasion.\n\nFollow-up: Surveillance to include digital rectal exam (DRE) and inguinal lymph node exams every 3-6 months for 5 years, anoscopy every 6-12 months for 3 years. Imaging as clinically indicated. Patient advised on symptoms of recurrence (rectal bleeding, anal pain, lump).\n\nPotential Complications: Wound infection, local recurrence, anal pain, and rarely, bowel or urinary dysfunction.","question_type":"Creative Generation","evidence":"The diagnosis is Stage I perianal squamous cell carcinoma.; The tumor size is 2 cm or less.; There is no lymph node or distant spread.; A local excision of the perianal lesion was performed without complication.; Surgical margins were negative on pathology.; The pathology report indicates well-differentiated squamous cell carcinoma.; The tumor size is 1.5 cm.; There is no lymphovascular invasion.; Follow-up includes digital rectal exams every 3-6 months for 5 years.; Follow-up includes inguinal lymph node exams every 3-6 months for 5 years.; Follow-up includes anoscopy every 6-12 months for 3 years.; Imaging is as clinically indicated.; The patient was advised on symptoms of recurrence.; Symptoms of recurrence include rectal bleeding.; Symptoms of recurrence include anal pain.; Symptoms of recurrence include a lump.","evidence_relations":"Stage I: tumor 2 cm, no lymph node or distant spread.; Local excision is an option for some early-stage, low-grade perianal cancers.; Surgical margin: Negative margins desirable for local excision.; Surveillance after treatment includes DRE, lymph node exams, anoscopy, and imaging.; Common symptoms of anal cancer include rectal bleeding, anal itching, pain, and a lump near the anus.; Side Effect: Bowel dysfunction, urinary incontinence, anal pain."},
	{"id":"Medical-aff81dd6","source":"Medical","question":"Assume the role of a public health official. Draft a community advisory on the prevention, risk factors, and early detection of anal cancer, integrating recommendations for high-risk populations.","answer":"Community Health Advisory: Anal Cancer Prevention and Early Detection\n\nAnal cancer is a rare but increasingly diagnosed disease, with certain populations at higher risk. The most significant risk factor is persistent infection with human papillomavirus (HPV), particularly high-risk strains such as HPV16. Other important risk factors include HIV infection, use of immunosuppressant medications (such as after organ transplantation), a history of cervical, vulvar, or vaginal cancer or precancer, previous anal dysplasia (including anal intraepithelial neoplasia [AIN], low-grade squamous intraepithelial lesion [LSIL], or high-grade squamous intraepithelial lesion [HSIL]), smoking, a history of anal sex, and certain autoimmune disorders or blood cancers.\n\nPrevention strategies include receiving the HPV vaccine, which protects against several high-risk HPV strains and is most effective when administered before exposure to the virus. The vaccine is recommended for adolescents and young adults, and may be considered for adults up to age 45. Smoking cessation is also strongly advised, as smoking increases the risk of anal and other cancers. Maintaining a healthy immune system and practicing safe sexual behaviors can further reduce risk.\n\nEarly detection is critical. Common early symptoms of anal cancer include rectal bleeding, anal itching, pain, or the presence of a lump or mass near the anus. These symptoms are sometimes mistaken for benign conditions such as hemorrhoids, so prompt medical evaluation is important. High-risk individualssuch as those with HIV, immunosuppression, or a history of HPV-related cancers or precancerous lesionsshould undergo regular screening with digital rectal examination (DRE) and anoscopy as recommended by their healthcare provider. Identifying and treating precancerous lesions (anal dysplasia) can prevent progression to cancer.\n\nIf you have any of the above risk factors or symptoms, consult your healthcare provider for further evaluation and to discuss appropriate screening and prevention measures.","question_type":"Creative Generation","evidence":"Anal cancer rates are increasing.; Certain risk factors elevate the risk of anal cancer.; The strongest risk factor for anal cancer is infection with human papillomavirus (HPV).; The high-risk HPV16 strain increases the risk of anal cancer.; HIV infection elevates the risk of anal cancer.; Immunosuppressant use increases the risk of anal cancer.; A history of cervical, vulvar, or vaginal cancer or precancer increases the risk of anal cancer.; Smoking increases the risk of anal cancer.; Individuals with histories of anal dysplasia are at increased risk.; Early symptoms of anal cancer may include rectal bleeding.; Early symptoms of anal cancer may include anal itching.; Early symptoms of anal cancer may include pain.; Early symptoms of anal cancer may include a lump near the anus.; Regular screening with digital rectal exams is recommended for high-risk groups.; Anoscopy is recommended for high-risk groups.; HPV vaccination is encouraged for prevention.; Smoking cessation is encouraged for prevention.","evidence_relations":"HPV infection is the strongest risk factor for anal cancer.; HPV16 is a high-risk strain associated with anal cancer.; HIV infection increases the risk of anal cancer.; Immunosuppressant use increases the risk of anal cancer.; History of cervical, vulvar, or vaginal cancer or precancer increases anal cancer risk.; Anal dysplasia (AIN, LSIL, HSIL) is a precancerous lesion for anal cancer.; Smoking is a risk factor for anal cancer.; Common symptoms of anal cancer include rectal bleeding, anal itching, pain, and a lump near the anus.; Digital rectal exam (DRE) and high-resolution anoscopy (HRA) are used for diagnosis and staging."},
	{"id":"Medical-841e077a","source":"Medical","question":"You are a medical intern assigned to write a SOAP (Subjective, Objective, Assessment, Plan) note for a patient with metastatic anal cancer who has progressed after first-line chemotherapy and is being considered for immunotherapy. Incorporate relevant symptoms, diagnostics, prior treatments, and next steps.","answer":"SOAP Note:\n\nSubjective: The patient reports ongoing anal pain, a palpable mass, persistent fatigue, and intermittent rectal bleeding. These symptoms have not improved despite prior systemic chemotherapy with carboplatin and paclitaxel. The patient expresses concern about worsening discomfort and the impact on daily activities.\n\nObjective: Recent imaging studies, including CT and PET scans, demonstrate disease progression with new distant metastases. Physical examination reveals a tender anal mass and palpable inguinal lymphadenopathy. Laboratory results are within normal limits. No evidence of acute infection or organ dysfunction is noted.\n\nAssessment: Metastatic anal squamous cell carcinoma with documented progression following first-line chemotherapy (carboplatin and paclitaxel). The disease is now refractory to standard cytotoxic therapy.\n\nPlan: Initiate immunotherapy with an immune checkpoint inhibitor (nivolumab or pembrolizumab) as recommended for metastatic anal cancer that has progressed after chemotherapy. Continue comprehensive supportive care, including pain management and interventions for fatigue. Closely monitor for potential immune-related adverse events associated with immunotherapy. Discuss and offer enrollment in clinical trials if available, as investigational therapies may provide additional options. Schedule regular imaging and clinical assessments to monitor treatment response and disease status.","question_type":"Creative Generation","evidence":"The patient has metastatic anal cancer.; The patient has progressed after first-line chemotherapy.; The patient is being considered for immunotherapy.; The patient reports persistent anal pain.; The patient has a palpable mass.; The patient experiences fatigue.; The patient has intermittent rectal bleeding.; Symptoms have not improved with prior systemic chemotherapy.; Imaging confirms progression of disease with new distant metastases.; Physical exam reveals a tender anal mass.; Physical exam reveals palpable inguinal lymphadenopathy.; Laboratory tests are within normal limits.; The assessment is metastatic anal squamous cell carcinoma with progression after first-line chemotherapy.; The first-line chemotherapy regimen included carboplatin and paclitaxel.; Immunotherapy options include nivolumab.; Immunotherapy options include pembrolizumab.; Supportive care for pain and fatigue will continue.; Monitoring for immune-related adverse events is necessary.; Clinical trial enrollment will be recommended if available.; Regular imaging will be scheduled for response assessment.","evidence_relations":"Metastatic anal cancer is treated with systemic chemotherapy (e.g., carboplatin and paclitaxel, FOLFOX, FOLFCIS, DCF, 5-FU and cisplatin).; Immunotherapy (nivolumab, pembrolizumab) is recommended for metastatic anal cancer that progresses after chemotherapy.; Common symptoms of anal cancer include rectal bleeding, anal pain, and a lump near the anus.; Imaging (CT, MRI, PET) are used for diagnosis and staging.; Clinical trials are recommended for all patients if available.; Supportive Care: Pain management, fatigue management.; Side Effect: Immune-related adverse events with immunotherapy."},
	{"id":"Medical-6a5c7fa6","source":"Medical","question":"You are a pediatric hematologist receiving a referral for a 7-year-old newly diagnosed with B-cell acute lymphoblastic leukemia (B-ALL). Write a comprehensive initial case summary, including diagnostic confirmation, relevant subtyping, key risk factors, and the preliminary treatment approach based on current clinical guidelines.","answer":"Case Summary:\n\nA 7-year-old child has been referred with a new diagnosis of B-cell acute lymphoblastic leukemia (B-ALL). Diagnosis was confirmed by the presence of >20% lymphoblasts in the bone marrow, as established through blood tests, bone marrow aspirate, and biopsy. Flow cytometry and immunophenotyping identified a B-cell lineage. Genetic and biomarker testing, including BCR::ABL1 status, were performed to further subtype the leukemia and guide therapy.\n\nKey risk factors considered include any underlying genetic syndromes and family history of leukemia. The patient presented with anemia, frequent infections, and enlarged lymph nodes, consistent with common presenting symptoms of ALL.\n\nTreatment will be initiated with steroids and multiagent chemotherapy as per standard protocols. If a BCR::ABL1 fusion is detected, targeted therapy will be added. Fertility preservation options will be discussed prior to commencing cytotoxic therapy. Participation in a clinical trial will be considered if the patient falls into a relevant prognostic subgroup. Ongoing follow-up will include regular blood tests and surveillance for relapse.\n","question_type":"Creative Generation","evidence":"The patient is a 7-year-old child.; The child has been diagnosed with B-cell acute lymphoblastic leukemia (B-ALL).; Diagnosis was confirmed by the presence of more than 20% lymphoblasts in the bone marrow.; Blood tests were performed to confirm the diagnosis.; A bone marrow aspirate was performed to confirm the diagnosis.; A biopsy was performed to confirm the diagnosis.; Flow cytometry identified a B-cell lineage.; Genetic and biomarker testing were performed.; BCR::ABL1 status was tested to subtype the leukemia.; Key risk factors include underlying genetic syndromes.; Key risk factors include family history of leukemia.; The patient presented with anemia.; The patient presented with frequent infections.; The patient presented with enlarged lymph nodes.; Treatment will be initiated with steroids.; Treatment will include multiagent chemotherapy.; If a BCR::ABL1 fusion is detected, targeted therapy will be added.; Fertility preservation options will be discussed prior to cytotoxic therapy.; Participation in a clinical trial will be considered if the patient falls into a relevant prognostic subgroup.; Ongoing follow-up will include regular blood tests.","evidence_relations":"ALL is diagnosed when 20 percent or more lymphoblasts are present in the bone marrow.; Diagnosis of ALL involves blood tests, bone marrow aspirate and biopsy, flow cytometry, immunophenotyping, genetic and biomarker testing.; There are two main subtypes of ALL: B-cell ALL (B-ALL) and T-cell ALL (T-ALL).; Symptoms of ALL may include anemia, infections, bleeding, enlarged lymph nodes, and organ involvement.; Risk factors for ALL include certain genetic syndromes and family history.; Everyone with ALL is treated with steroids and multiagent chemotherapy.; Targeted therapy may be used based on genetic alterations.; Fertility preservation should be considered before treatment.; Follow-up includes regular blood tests and surveillance for relapse."},
	{"id":"Medical-3f2e8930","source":"Medical","question":"Transform the clinical practice guideline information into a discharge summary for an adult patient with T-cell ALL who has completed induction chemotherapy. Include the diagnosis, diagnostic work-up, treatment course, complications, and follow-up recommendations.","answer":"Discharge Summary\n\nPatient: [Adult Name], Age: 35\nDiagnosis: T-cell Acute Lymphoblastic Leukemia (T-ALL)\n\nSummary:\nThe patient was diagnosed with T-cell acute lymphoblastic leukemia following evaluation for anemia and recurrent infections. The diagnosis was established through blood tests, bone marrow aspirate and biopsy, and flow cytometry, which confirmed T-cell lymphoid lineage. Imaging studies and lumbar puncture were performed to assess for organ and CNS involvement.\n\nThe patient underwent induction chemotherapy with a multiagent regimen including steroids. No targeted therapy was indicated as no actionable genetic alterations were detected. The treatment course was complicated by transient neutropenic infections, which resolved with supportive care.\n\nAt discharge, the patient is in hematologic remission. The patient has been counseled regarding fertility preservation options for future therapy. Ongoing follow-up will consist of regular blood tests and surveillance for relapse.\n\nRecommendations:\n- Continue follow-up as an outpatient with hematology\n- Monitor for relapse with regular blood counts\n- Consider participation in clinical trials for further therapy if indicated\n","question_type":"Creative Generation","evidence":"The patient is an adult aged 35.; The diagnosis is T-cell acute lymphoblastic leukemia (T-ALL).; The diagnosis was established through blood tests.; The diagnosis was established through a bone marrow aspirate and biopsy.; Flow cytometry confirmed T-cell lymphoid lineage.; Imaging studies were performed to assess for organ involvement.; A lumbar puncture was performed to assess for CNS involvement.; The patient underwent induction chemotherapy with a multiagent regimen.; The induction chemotherapy regimen included steroids.; No targeted therapy was indicated as no actionable genetic alterations were detected.; The treatment course was complicated by transient neutropenic infections.; The neutropenic infections resolved with supportive care.; At discharge, the patient is in hematologic remission.; The patient has been counseled regarding fertility preservation options.; Ongoing follow-up will consist of regular blood tests.; Ongoing follow-up will include surveillance for relapse.","evidence_relations":"ALL is diagnosed when 20 percent or more lymphoblasts are present in the bone marrow.; Diagnosis of ALL involves blood tests, bone marrow aspirate and biopsy, flow cytometry, immunophenotyping, genetic and biomarker testing, imaging tests, and lumbar puncture.; T-ALL starts in T-cell lymphocytes and can cause an enlarged thymus.; T-ALL treatment options include chemotherapy and clinical trials.; Everyone with ALL is treated with steroids and multiagent chemotherapy.; Fertility preservation should be considered before treatment.; Follow-up includes regular blood tests and surveillance for relapse."},
	{"id":"Medical-b2b22da1","source":"Medical","question":"Imagine you are a primary care physician writing a referral letter to a hematology-oncology specialist for an adolescent with suspected ALL. Summarize key presenting features, initial investigations, risk factors, and the rationale for urgent specialist evaluation.","answer":"Referral Letter\n\nDear Hematology-Oncology Colleague,\n\nI am referring a 15-year-old adolescent who presents with progressive fatigue, pallor, recurrent fevers, generalized lymphadenopathy, and mild bleeding tendencies. Initial laboratory investigations revealed anemia and leukocytosis with the presence of circulating blasts on peripheral smear. The patient has a significant family history, with a first-degree relative previously diagnosed with leukemia.\n\nKey presenting features include symptoms suggestive of bone marrow failure (fatigue, pallor, anemia), increased susceptibility to infections (recurrent fevers), lymphadenopathy, and bleeding, all of which are consistent with acute lymphoblastic leukemia (ALL). The laboratory findings of anemia, leukocytosis, and circulating blasts further support this suspicion. Risk factors in this case include the adolescent age group and a positive family history of leukemia.\n\nGiven the rapid progression of ALL and the risk of organ and central nervous system involvement, urgent specialist evaluation is indicated. I recommend prompt confirmatory diagnostic work-up, including bone marrow aspirate and biopsy, flow cytometry, immunophenotyping, and genetic/biomarker testing, as per current guidelines. Early diagnosis and initiation of multiagent chemotherapy and steroids are critical for optimal prognosis. Please assess the patient at your earliest convenience for further management.\n\nSincerely,\n[Primary Care Physician]","question_type":"Creative Generation","evidence":"The patient is a 15-year-old adolescent.; The patient presents with progressive fatigue.; The patient presents with pallor.; The patient presents with recurrent fevers.; The patient presents with generalized lymphadenopathy.; Laboratory evaluation revealed anemia.; Laboratory evaluation revealed leukocytosis with circulating blasts.; The family history is notable for a first-degree relative with leukemia.; The patient exhibits mild bleeding tendencies.; Acute lymphoblastic leukemia (ALL) is strongly suspected.; Urgent specialist assessment is warranted for confirmatory diagnosis.; Confirmatory diagnosis requires bone marrow aspirate and biopsy.; Confirmatory diagnosis requires flow cytometry.; Confirmatory diagnosis requires genetic testing.; Early initiation of therapy is essential for optimal outcomes.","evidence_relations":"Symptoms of ALL may include anemia, infections, bleeding, enlarged lymph nodes, and organ involvement.; ALL is diagnosed when 20 percent or more lymphoblasts are present in the bone marrow.; Diagnosis of ALL involves blood tests, bone marrow aspirate and biopsy, flow cytometry, immunophenotyping, genetic and biomarker testing.; ALL most often affects B cells or T cells.; ALL is more common in children but also occurs in adolescents and young adults (AYAs) and adults.; Risk factors for ALL include certain genetic syndromes and family history.; Treatment for ALL depends on subtype, age at diagnosis, and other factors.; Everyone with ALL is treated with steroids and multiagent chemotherapy."},
	{"id":"Medical-a82e0b03","source":"Medical","question":"Rewrite the clinical guidance on ALL into a public health advisory for families with children and adolescents, emphasizing early symptoms, risk factors, and the importance of prompt diagnosis and specialized care.","answer":"Public Health Advisory: Awareness of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents\n\nAcute lymphoblastic leukemia (ALL) is the most common blood cancer in children and adolescents. Families should be alert to early warning signs, including persistent fatigue, frequent infections, unexplained bleeding or bruising, and swelling of lymph nodes. ALL may also involve the bone marrow, blood, lymph nodes, testicles, and central nervous system, leading to a variety of symptoms.\n\nCertain genetic syndromes and a family history of leukemia can increase a child's risk for developing ALL. Diagnosis requires specialized tests, including blood counts, bone marrow examination, and genetic studies. Early recognition and referral to a hematology-oncology specialist are crucial for timely treatment, which typically includes steroids and multiagent chemotherapy. Discussion of fertility preservation before treatment is recommended for affected families.\n\nIf you notice these symptoms in your child or adolescent, consult your healthcare provider promptly.\n","question_type":"Creative Generation","evidence":"Acute lymphoblastic leukemia (ALL) is the most common blood cancer in children and adolescents.; Families should be alert to early warning signs of ALL.; Early warning signs of ALL include persistent fatigue.; Early warning signs of ALL include frequent infections.; Early warning signs of ALL include unexplained bleeding or bruising.; Early warning signs of ALL include swelling of lymph nodes.; ALL may involve the bone marrow, blood, lymph nodes, testicles, and central nervous system.; Certain genetic syndromes can increase a child's risk for developing ALL.; A family history of leukemia can increase a child's risk for developing ALL.; Diagnosis of ALL requires specialized tests.; Specialized tests for diagnosing ALL include blood counts.; Specialized tests for diagnosing ALL include bone marrow examination.; Specialized tests for diagnosing ALL include genetic studies.; Early recognition of ALL is crucial for timely treatment.; Referral to a hematology-oncology specialist is important for treatment.; Treatment for ALL typically includes steroids.; Treatment for ALL typically includes multiagent chemotherapy.; Discussion of fertility preservation before treatment is recommended.","evidence_relations":"ALL is a fast-growing blood cancer that starts in lymphocytes.; ALL is more common in children but also occurs in adolescents and young adults (AYAs) and adults.; Symptoms of ALL may include anemia, infections, bleeding, enlarged lymph nodes, and organ involvement.; ALL can be found in bone marrow, blood, testicles, and central nervous system.; Risk factors for ALL include certain genetic syndromes and family history.; Diagnosis of ALL involves blood tests, bone marrow aspirate and biopsy, flow cytometry, immunophenotyping, genetic and biomarker testing.; Everyone with ALL is treated with steroids and multiagent chemotherapy.; Fertility preservation should be considered before treatment."},
	{"id":"Medical-a7cdc968","source":"Medical","question":"You are a clinical trial coordinator drafting an eligibility summary for a new trial in BCR::ABL1-negative B-ALL. List the diagnostic criteria, relevant subtyping, standard therapies, and follow-up requirements for candidate participants, referencing current guidelines.","answer":"Eligibility Summary for BCR::ABL1-negative B-ALL Clinical Trial\n\nCandidates must have a confirmed diagnosis of B-cell acute lymphoblastic leukemia (B-ALL) without the BCR::ABL1 fusion gene, established through comprehensive diagnostic workup including blood tests, bone marrow aspirate and biopsy, flow cytometry, immunophenotyping, and genetic and biomarker testing. Diagnostic criteria require at least 20% lymphoblasts in the bone marrow, unless otherwise specified by clinical context. Subtyping must confirm B-cell lineage and BCR::ABL1-negative status, as B-ALL is more common than T-ALL and has distinct management pathways. Standard therapies for eligible participants include induction with steroids and multiagent chemotherapy, with consideration of fertility preservation strategies prior to treatment initiation. Ongoing follow-up is required, involving regular blood counts and surveillance for relapse, in accordance with current ALL management guidelines.","question_type":"Creative Generation","evidence":"Eligible participants must have a confirmed diagnosis of B-cell acute lymphoblastic leukemia (B-ALL).; Eligible participants must have the absence of the BCR::ABL1 fusion gene.; The absence of the BCR::ABL1 fusion gene is determined by bone marrow aspirate/biopsy.; The absence of the BCR::ABL1 fusion gene is determined by flow cytometry.; The absence of the BCR::ABL1 fusion gene is determined by immunophenotyping.; The absence of the BCR::ABL1 fusion gene is determined by genetic testing.; Subtyping confirms B-cell lineage.; Subtyping confirms BCR::ABL1-negative status.; Standard therapy for B-ALL involves initial treatment with steroids.; Standard therapy for B-ALL involves multiagent chemotherapy.; Fertility preservation strategies should be discussed prior to therapy initiation.; Participants must agree to regular follow-up.; Regular follow-up includes periodic blood tests.; Regular follow-up includes surveillance for relapse.; Follow-up is consistent with current ALL management guidelines.","evidence_relations":"ALL is diagnosed when 20 percent or more lymphoblasts are present in the bone marrow.; Diagnosis of ALL involves blood tests, bone marrow aspirate and biopsy, flow cytometry, immunophenotyping, genetic and biomarker testing.; B-ALL starts in B-cell lymphocytes and is more common than T-ALL.; Clinical trials are preferred for certain subtypes such as BCR::ABL1-negative or BCR::ABL1-like B-ALL.; Everyone with ALL is treated with steroids and multiagent chemotherapy.; Fertility preservation should be considered before treatment.; Follow-up includes regular blood tests and surveillance for relapse."},
	{"id":"Medical-a79ca666","source":"Medical","question":"Imagine you are a medical oncologist receiving a new patient diagnosed with Stage II pancreatic ductal adenocarcinoma (PDAC). Construct an initial management plan including diagnostic confirmation, staging, treatment options, risk assessment, and multidisciplinary coordination, based strictly on the clinical practice guideline.","answer":"As a medical oncologist, my initial management plan for a patient newly diagnosed with Stage II pancreatic ductal adenocarcinoma (PDAC) would begin with diagnostic confirmation through histopathologic evaluation obtained via biopsy, supported by imaging studies such as contrast-enhanced CT or MRI to assess the local extent of the tumor and involvement of regional lymph nodes. Comprehensive staging is essential to determine resectability and to rule out distant metastases. Additional diagnostic workup may include endoscopic procedures, blood tests, and biomarker assessments as indicated. Genetic testing for hereditary cancer syndromes (such as BRCA mutations and others) is recommended, as this can impact prognosis, inform family counseling, and potentially guide targeted therapy. If the tumor is deemed resectable based on multidisciplinary review, surgical resection is the primary treatment, typically followed by adjuvant chemotherapy to reduce the risk of recurrence. For patients with borderline resectable or high-risk features, neoadjuvant therapy may be considered. Risk assessment should include evaluation of the patients overall health, comorbidities, and performance status to tailor treatment appropriately. Throughout the process, care should be coordinated by a multidisciplinary teamincluding medical, surgical, and radiation oncologists, radiologists, pathologists, gastroenterologists, dietitians, genetic counselors, palliative care providers, and mental health professionalsto ensure comprehensive, patient-centered management and to address supportive care needs.","question_type":"Creative Generation","evidence":"The initial management plan involves confirming the diagnosis of Stage II pancreatic ductal adenocarcinoma (PDAC).; Diagnosis confirmation is obtained through histopathologic evaluation via biopsy.; Imaging studies are used to assess local tumor extent.; Imaging studies are used to assess lymph node involvement.; Comprehensive staging is performed using high-resolution imaging modalities.; High-resolution imaging modalities include contrast-enhanced CT.; High-resolution imaging modalities include MRI.; Staging determines resectability of the tumor.; Staging evaluates for metastasis.; Genetic testing is recommended to assess for hereditary cancer syndromes.; Genetic testing has implications for prognosis.; Genetic testing has implications for family counseling.; Treatment options include surgical resection if the tumor is resectable.; Adjuvant drug therapy is recommended to reduce recurrence risk.; Multidisciplinary coordination is essential for optimal patient-centered care.","evidence_relations":"Stage II pancreatic cancer is a tumor larger than 4 cm or has spread to 1-3 nearby lymph nodes.; Diagnostic methods for pancreatic cancer include imaging, endoscopic tests, biopsy, blood tests, genetic tests, and biomarker tests.; Imaging is used for staging and determining surgical eligibility in pancreatic cancer.; Surgery is a treatment option for some patients with stage I, II, or III pancreatic cancer.; A multidisciplinary care team is essential for diagnosis and treatment planning in pancreatic cancer.; Genetic tests can detect inherited mutations linked to hereditary pancreatic cancer.; Supportive care is an important part of pancreatic cancer management."},
	{"id":"Medical-fd224da5","source":"Medical","question":"You are a genetic counselor seeing a patient with a family history of breast, ovarian, and pancreatic cancers. Draft a formal genetic risk assessment report, summarizing the hereditary syndromes to consider, recommended tests, and implications for pancreatic cancer risk.","answer":"Genetic Risk Assessment Report:\n\nThe patient presents with a significant family history, including relatives affected by breast, ovarian, and pancreatic cancers. This familial pattern raises suspicion for hereditary breast-ovarian cancer syndrome (HBOC), Lynch syndrome, and potentially other syndromes such as Peutz-Jeghers or familial malignant melanoma syndrome (FAMMM). I recommend comprehensive genetic testing to assess for pathogenic mutations associated with these syndromes, including BRCA1/2, mismatch repair genes, and STK11. Identification of a hereditary syndrome would inform not only the patient's risk for pancreatic cancer but also potential screening and preventive strategies for other associated malignancies. Family members may also benefit from cascade testing and personalized risk management.","question_type":"Creative Generation","evidence":"The patient has a significant family history of breast, ovarian, and pancreatic cancers.; This familial pattern raises suspicion for hereditary breast-ovarian cancer syndrome (HBOC).; This familial pattern raises suspicion for Lynch syndrome.; This familial pattern raises suspicion for other syndromes such as Peutz-Jeghers syndrome.; This familial pattern raises suspicion for familial malignant melanoma syndrome (FAMMM).; Comprehensive genetic testing is recommended to assess for pathogenic mutations.; Pathogenic mutations associated with these syndromes include BRCA1/2.; Pathogenic mutations associated with these syndromes include mismatch repair genes.; Pathogenic mutations associated with these syndromes include STK11.; Identification of a hereditary syndrome informs the patient's risk for pancreatic cancer.; Identification of a hereditary syndrome informs potential screening strategies.; Identification of a hereditary syndrome informs preventive strategies for associated malignancies.; Family members may benefit from cascade testing.; Family members may benefit from personalized risk management.","evidence_relations":"Risk factors for pancreatic cancer include family history of certain cancers.; Hereditary syndromes such as HBOC, Peutz-Jeghers syndrome, Lynch syndrome, Li-Fraumeni syndrome, FAMMM syndrome, and hereditary pancreatitis increase risk of pancreatic cancer.; Genetic tests can detect inherited mutations linked to hereditary pancreatic cancer.; Family history of breast cancer, ovarian cancer, colorectal cancer, and melanoma are specifically listed as risk factors.; A genetic counselor is part of the multidisciplinary care team in pancreatic cancer.; Screening and prevention recommendations may differ for individuals with hereditary syndromes."},
	{"id":"Medical-ba1f5276","source":"Medical","question":"Rewrite the following patient scenario as a formal discharge summary: A patient with Stage IV pancreatic cancer (metastatic to the liver) was admitted for symptom management, received supportive care interventions, and is being discharged to outpatient palliative follow-up.","answer":"Discharge Summary\n\nDiagnosis: Stage IV pancreatic cancer (metastatic to the liver)\n\nHospital Course: The patient was admitted for management of advanced pancreatic cancer symptoms, including jaundice and pain. Supportive care interventions were provided, focusing on symptom relief and quality of life. Multidisciplinary input was obtained from palliative care, dietitian, and mental health providers.\n\nProcedures/Interventions: Symptom-directed medical management, nutritional support, and psychosocial counseling.\n\nDischarge Plan: The patient is stable for discharge with arrangements for outpatient palliative care follow-up. Symptom management, nutritional optimization, and ongoing psychosocial support will continue as part of the comprehensive supportive care plan.","question_type":"Creative Generation","evidence":"The patient has Stage IV pancreatic cancer that is metastatic to the liver.; The patient was admitted for management of advanced pancreatic cancer symptoms.; Symptoms included jaundice.; Symptoms included pain.; Supportive care interventions were provided.; Supportive care interventions focused on symptom relief.; Supportive care interventions focused on quality of life.; Multidisciplinary input was obtained from palliative care providers.; Multidisciplinary input was obtained from dietitians.; Multidisciplinary input was obtained from mental health providers.; Symptom-directed medical management was provided.; Nutritional support was provided.; Psychosocial counseling was provided.; The patient is stable for discharge.; Arrangements for outpatient palliative care follow-up were made.; Symptom management will continue as part of the comprehensive supportive care plan.","evidence_relations":"Stage IV pancreatic cancer has spread to distant organs such as liver, lungs, or abdominal lining.; Stage IV pancreatic cancer is metastatic cancer.; Symptoms of pancreatic cancer may include jaundice (yellowed skin or eyes).; Supportive care is an important part of pancreatic cancer management.; Palliative care provider and mental health provider are listed as part of the care team.; Supportive care includes symptom management and palliative care.; A multidisciplinary care team is essential for diagnosis and treatment planning in pancreatic cancer."},
	{"id":"Medical-a02de386","source":"Medical","question":"You are a primary care physician writing a referral letter to a surgical oncologist for a patient with a newly detected pancreatic mass and a history of diabetes and chronic pancreatitis. Summarize the relevant history, risk factors, diagnostic steps taken, and the rationale for surgical evaluation.","answer":"Dear Surgical Oncologist,\n\nI am referring a patient who has been found to have a newly detected pancreatic mass on imaging studies. The patients relevant medical history includes long-standing diabetes mellitus and chronic pancreatitis, both of which are established risk factors for the development of pancreatic cancer. The diagnostic workup to date has comprised cross-sectional imaging and laboratory blood tests, which have confirmed the presence of a suspicious pancreatic lesion. Given the patients risk profile and the imaging findings, further evaluation is necessary to determine the nature of the mass and assess the patients eligibility for surgical intervention. I am seeking your expertise for comprehensive surgical evaluation, including consideration of biopsy, staging, and multidisciplinary management planning, to determine if resection is appropriate and to guide further treatment.","question_type":"Creative Generation","evidence":"The patient has a recently identified pancreatic mass on imaging.; The patient has a medical history of long-standing diabetes.; The patient has a medical history of chronic pancreatitis.; Long-standing diabetes and chronic pancreatitis are recognized risk factors for pancreatic cancer.; Initial workup included imaging.; Initial workup included blood tests.; Initial workup confirmed the presence of a suspicious lesion.; Further evaluation is warranted to determine surgical eligibility.; The referral is for assessment of possible resection.; The referral is for further management.","evidence_relations":"Risk factors for pancreatic cancer include diabetes and chronic pancreatitis.; Imaging is used for staging and determining surgical eligibility in pancreatic cancer.; Diagnostic methods for pancreatic cancer include imaging and blood tests.; Surgery is a treatment option for some patients with stage I, II, or III pancreatic cancer.; A multidisciplinary care team is essential for diagnosis and treatment planning in pancreatic cancer.; Referral to a surgical oncologist is appropriate for evaluation of surgical options."},
	{"id":"Medical-d5eefeeb","source":"Medical","question":"Rewrite the guidelines core facts into a public health advisory for community awareness, emphasizing risk factors, symptoms, and the importance of early diagnosis in pancreatic cancer.","answer":"**Public Health Advisory: Pancreatic Cancer Awareness**\n\nPancreatic cancer is a serious disease that often presents late due to subtle symptoms. Risk factors include smoking, heavy alcohol use, unhealthy diet, exposure to pesticides, diabetes, chronic pancreatitis, and family history of pancreatic, breast, ovarian, colorectal, or melanoma cancers. Certain hereditary syndromes, such as HBOC and Lynch syndrome, further increase risk. Early symptoms, like jaundice (yellowing of the skin or eyes), should prompt prompt medical attention. Early diagnosis and a multidisciplinary care approach improve treatment options and outcomes. If you have risk factors or family history, discuss screening and genetic counseling with your healthcare provider.","question_type":"Creative Generation","evidence":"Pancreatic cancer is a serious disease that often presents late.; Pancreatic cancer often presents due to subtle symptoms.; Risk factors for pancreatic cancer include smoking.; Risk factors for pancreatic cancer include heavy alcohol use.; Risk factors for pancreatic cancer include unhealthy diet.; Risk factors for pancreatic cancer include exposure to pesticides.; Risk factors for pancreatic cancer include diabetes.; Risk factors for pancreatic cancer include chronic pancreatitis.; Risk factors for pancreatic cancer include family history of pancreatic cancer.; Risk factors for pancreatic cancer include family history of breast cancer.; Risk factors for pancreatic cancer include family history of ovarian cancer.; Risk factors for pancreatic cancer include family history of colorectal cancer.; Risk factors for pancreatic cancer include family history of melanoma.; Certain hereditary syndromes increase the risk of pancreatic cancer.; Hereditary syndromes include HBOC.; Hereditary syndromes include Lynch syndrome.; Early symptoms of pancreatic cancer include jaundice.; Jaundice is characterized by yellowing of the skin or eyes.; Early diagnosis improves treatment options.; Early diagnosis improves outcomes.; Individuals with risk factors should discuss screening with their healthcare provider.; Individuals with family history should discuss genetic counseling with their healthcare provider.","evidence_relations":"Pancreatic cancer is a type of cancer that starts in the pancreas.; Risk factors for pancreatic cancer include smoking, heavy alcohol use, unhealthy diet, exposure to pesticides, diabetes, chronic pancreatitis, and family history of certain cancers.; Hereditary syndromes such as HBOC, Peutz-Jeghers syndrome, Lynch syndrome, Li-Fraumeni syndrome, FAMMM syndrome, and hereditary pancreatitis increase risk of pancreatic cancer.; Symptoms of pancreatic cancer may include jaundice (yellowed skin or eyes).; Early diagnosis and multidisciplinary care improve treatment options.; Genetic tests can detect inherited mutations linked to hereditary pancreatic cancer."},
	{"id":"Medical-786a5d0e","source":"Medical","question":"You are a urologist seeing a 62-year-old man with an elevated PSA and abnormal digital rectal exam. MRI shows a suspicious lesion confined to the prostate. Biopsy confirms adenocarcinoma with a Gleason score of 3+4=7 (Grade Group 2). No evidence of nodal or distant disease is found. Construct a formal treatment plan, including diagnostic confirmation, risk stratification, and initial management, referencing the clinical guideline.","answer":"As the attending urologist, I would confirm the diagnosis of prostate adenocarcinoma based on the transrectal ultrasound-guided biopsy, which demonstrates a Gleason score of 3+4=7 (Grade Group 2). MRI findings indicate the lesion is confined to the prostate, with no evidence of extracapsular extension, nodal involvement, or distant metastasis. This places the patient in the intermediate-risk category for localized prostate cancer. \n\nThe next steps include:\n\n1. Diagnostic Confirmation: Review pathology to confirm Grade Group 2 disease and ensure accurate staging with MRI and, if indicated, additional imaging to rule out occult metastases.\n\n2. Risk Stratification: Utilize clinical, pathological, and imaging findings to confirm intermediate-risk status. Consider molecular biomarker testing to further refine risk assessment and inform management decisions.\n\n3. Initial Management: Discuss treatment options with the patient, including radical prostatectomy and radiation therapy, both of which are standard curative approaches for intermediate-risk localized prostate cancer. Active surveillance may be considered in select patients with favorable intermediate-risk features and after shared decision-making. \n\n4. Multidisciplinary Care: Refer for multidisciplinary evaluation, including consultation with radiation oncology, to individualize the treatment plan and address patient preferences and comorbidities.\n\n5. Follow-up: Establish a schedule for regular PSA monitoring and follow-up imaging as appropriate to assess treatment response and detect recurrence.\n\nThis approach is consistent with clinical guidelines, emphasizing accurate diagnosis, risk-adapted management, and multidisciplinary care to optimize outcomes.","question_type":"Creative Generation","evidence":"The diagnosis of prostate adenocarcinoma was confirmed via transrectal ultrasound-guided biopsy.; The biopsy showed a Gleason score of 3+4=7.; The lesion is localized to the prostate.; There is no extracapsular extension of the lesion.; There is no nodal involvement.; The patient is classified as having localized, intermediate-risk prostate cancer.; Further workup should include molecular biomarker testing.; Molecular biomarker testing refines risk assessment.; Molecular biomarker testing guides management.; Treatment options include radical prostatectomy.; Treatment options include radiation therapy.; Both treatment options are with curative intent.; Active surveillance is a consideration due to favorable pathology.; Multidisciplinary discussion with radiation oncology is recommended.; Regular PSA monitoring will be scheduled post-treatment.; Follow-up imaging will be scheduled post-treatment.","evidence_relations":"PSA test and digital rectal exam are used for screening and diagnosis.; MRI, CT, PET, ultrasound, and bone scan are imaging methods used to assess extent of disease.; Biopsy is required to confirm prostate cancer diagnosis.; Grade Group and Gleason score are used to estimate cancer aggressiveness.; Risk groups (very low, low, intermediate, high, very high) guide prognosis and treatment.; Molecular biomarker testing helps assess risk and guide treatment decisions.; Hormone therapy, surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy, and radiopharmaceuticals are treatment options.; Active surveillance is a management option for low-risk, early-stage prostate cancer.; Follow-up includes regular PSA testing, imaging, and biopsies as needed."},
	{"id":"Medical-714cd769","source":"Medical","question":"You are an oncology nurse preparing a discharge summary for a patient recently treated for metastatic prostate cancer with androgen deprivation therapy (ADT) and chemotherapy. Summarize the key clinical findings, treatments administered, and recommended follow-up plan according to the guidelines.","answer":"Discharge Summary:\n\nDiagnosis: The patient was diagnosed with metastatic prostate cancer, confirmed by prostate biopsy and imaging studies (MRI, CT, and bone scan) that demonstrated bone metastases. Clinical presentation included bone pain and elevated prostate-specific antigen (PSA) levels, consistent with advanced disease.\n\nTreatment Course: Management included androgen deprivation therapy (ADT) using a combination of leuprolide (an LHRH agonist) and bicalutamide (an anti-androgen), in accordance with guideline-based first-line therapy for metastatic prostate cancer. The patient also received docetaxel-based chemotherapy, which is recommended for patients with high-volume or symptomatic metastatic disease. Germline genetic testing identified a BRCA2 mutation, which may inform the use of targeted therapies (such as PARP inhibitors) in future treatment lines. The patient was monitored for treatment response and adverse effects throughout the course.\n\nFollow-Up Recommendations: Ongoing follow-up will include regular PSA testing to monitor disease activity, periodic imaging (bone scan or MRI as clinically indicated) to assess for disease progression, and routine clinical assessments for symptoms such as bone pain, weight loss, and urinary changes. Repeat molecular biomarker testing will be performed as needed to guide future therapy decisions. The patient received counseling on symptom monitoring and was provided with contact information for both palliative care and oncology follow-up. Coordination with the primary care physician and maintenance of comprehensive medical records were emphasized, in line with best practice guidelines.","question_type":"Creative Generation","evidence":"The diagnosis is metastatic prostate cancer.; Metastatic prostate cancer was confirmed by biopsy.; Imaging studies included MRI, CT, and bone scan.; Imaging studies demonstrated bone metastases.; The patient presented with bone pain.; The patient presented with elevated PSA levels.; The patient received androgen deprivation therapy (ADT).; The ADT included a combination of leuprolide and bicalutamide.; The patient also received docetaxel-based chemotherapy.; Genetic testing revealed a BRCA2 mutation.; The BRCA2 mutation informs the use of targeted agents in future lines.; The patient is to undergo regular PSA monitoring.; The patient is to undergo periodic imaging as indicated.; Clinical assessment for symptoms will be conducted.; Symptoms to monitor include bone pain and urinary issues.; Molecular biomarker testing will be repeated as needed.","evidence_relations":"Metastatic prostate cancer has spread to distant organs such as bones, liver, or lungs.; Symptoms of advanced prostate cancer include blood in urine or semen, bone pain, weight loss, and urinary symptoms.; Androgen deprivation therapy (ADT) is a mainstay of advanced prostate cancer treatment.; LHRH agonist, LHRH antagonist, bicalutamide, and chemotherapy are listed as treatment options for metastatic prostate cancer.; Germline genetic testing is recommended for patients with high-risk, very-high-risk, regional, or metastatic prostate cancer.; Follow-up includes regular PSA testing, imaging, and biopsies as needed.; Molecular biomarker testing helps assess risk and guide treatment decisions."},
	{"id":"Medical-c93a242c","source":"Medical","question":"Imagine you are a primary care physician writing a referral letter to a urologist for a 55-year-old Black male with a family history of prostate cancer, elevated PSA, and lower urinary tract symptoms. Include relevant risk factors, initial findings, and the rationale for specialist evaluation, following the clinical practice guideline.","answer":"Dear Urology Colleague,\n\nI am referring a 55-year-old Black male with a significant family history of prostate cancer (father diagnosed at age 60) for further evaluation. He presents with lower urinary tract symptoms including frequent urination and weak urine stream. His recent PSA test returned elevated at 6.8 ng/mL. Digital rectal exam revealed a firm area on the right lobe. Given his age, Black race, family history, and abnormal screening results, he is at increased risk for prostate cancer. I request your assessment for possible prostate biopsy and further workup, including consideration of molecular biomarker and genetic testing as per guidelines. Thank you for your expertise.","question_type":"Creative Generation","evidence":"The patient is a 55-year-old Black male.; The patient has a significant family history of prostate cancer.; The patient's father was diagnosed with prostate cancer at age 60.; The patient presents with lower urinary tract symptoms.; Lower urinary tract symptoms include frequent urination.; Lower urinary tract symptoms include weak urine stream.; The patient's recent PSA test returned elevated at 6.8 ng/mL.; Digital rectal exam revealed a firm area on the right lobe.; The patient is at increased risk for prostate cancer.; The increased risk is due to age, race, family history, and abnormal screening results.; The referral is for possible prostate biopsy.; The referral includes consideration of molecular biomarker testing.; The referral includes consideration of genetic testing.","evidence_relations":"Age, family history, race, genetic mutations, diet, obesity, and smoking are risk factors for prostate cancer.; PSA test and digital rectal exam are used for screening and diagnosis.; Black race is a recognized risk factor for prostate cancer.; Biopsy is required to confirm prostate cancer diagnosis.; Molecular biomarker testing helps assess risk and guide treatment decisions.; Germline genetic testing is recommended for patients with high-risk, very-high-risk, regional, or metastatic prostate cancer.; Symptoms of advanced prostate cancer include frequent urination, weak urine stream, and trouble urinating."},
	{"id":"Medical-bc02cc6c","source":"Medical","question":"Rewrite the key points from the prostate cancer guideline as a public health advisory aimed at men over 50, emphasizing risk factors, early detection, and available treatments.","answer":"**Public Health Advisory: Prostate Cancer Awareness for Men Over 50**\n\nProstate cancer is one of the most common cancers affecting men, particularly those over age 50. Early prostate cancer often has no symptoms, so regular screening is important for early detection and better outcomes.\n\n**Risk Factors:**\n- **Age:** Risk increases significantly after age 50, with most cases diagnosed in men over 65.\n- **Family History:** Having a close relative (father, brother) with prostate cancer, or a family history of certain other cancers (breast, ovarian, colon, pancreatic), increases your risk.\n- **Race:** Black men are at higher risk, tend to develop prostate cancer at a younger age, and are more likely to have aggressive disease.\n- **Genetics:** Inherited mutations, such as in the BRCA1 or BRCA2 genes, can raise risk.\n- **Lifestyle:** Obesity, smoking, and diets high in animal fat may increase risk, while regular exercise and a diet rich in fruits and vegetables may help lower it.\n\n**Early Detection:**\n- **Screening:** The main screening tests are the prostate-specific antigen (PSA) blood test and the digital rectal exam (DRE). Discuss with your healthcare provider when to start screening, especially if you have risk factors.\n- **Abnormal Results:** Elevated PSA or abnormal DRE should be evaluated further. Factors such as age, race, prostate size, recent exercise, or certain supplements can affect PSA levels.\n\n**Diagnosis and Staging:**\n- **Biopsy:** A prostate biopsy is required to confirm the diagnosis.\n- **Imaging:** MRI, ultrasound, and other scans may be used to determine if the cancer is confined to the prostate or has spread.\n- **Risk Assessment:** Your care team will use PSA level, biopsy results (Gleason score/Grade Group), and imaging to classify your risk and guide treatment.\n\n**Treatment Options:**\n- **Low-Risk Disease:** May be managed with active surveillance (regular monitoring without immediate treatment).\n- **Higher-Risk or Advanced Disease:** Options include surgery (radical prostatectomy), radiation therapy, hormone therapy, chemotherapy, and other advanced treatments. The choice depends on cancer stage, risk group, and your overall health.\n\n**Follow-Up:**\n- Regular PSA testing and imaging are important after diagnosis and treatment to monitor for recurrence or progression.\n\n**What You Can Do:**\n- Know your family history and discuss it with your healthcare provider.\n- Maintain a healthy lifestyle with regular exercise and a balanced diet.\n- Talk to your doctor about the benefits and risks of prostate cancer screening, especially if you are Black or have a family history of cancer.\n\nEarly detection and informed decision-making can improve outcomes for prostate cancer. Stay proactive about your health.","question_type":"Creative Generation","evidence":"Prostate cancer is one of the most common cancers among men.; Early stages of prostate cancer are often asymptomatic.; Screening is crucial for early detection of prostate cancer.; The risk of prostate cancer increases with age.; A family history of prostate cancer increases risk.; Black race is a risk factor for prostate cancer.; Genetic mutations such as BRCA1 and BRCA2 increase the risk of prostate cancer.; Lifestyle factors such as obesity, smoking, and high-fat diets may elevate the risk of prostate cancer.; Screening methods for prostate cancer include the PSA blood test and digital rectal exam.; Abnormal screening results should be evaluated by a healthcare professional.; Diagnosis of prostate cancer is confirmed with a prostate biopsy.; Imaging such as MRI or ultrasound may be used to determine the extent of the disease.; Treatment options for prostate cancer vary by stage and risk group.; Active surveillance is an option for low-risk prostate cancer cases.; Surgery, radiation, hormone therapy, and chemotherapy are treatment options for more advanced prostate cancer.; Regular follow-up with PSA testing and imaging is important for men diagnosed with prostate cancer.","evidence_relations":"Age, family history, race, genetic mutations, diet, obesity, and smoking are risk factors for prostate cancer.; Prostate cancer is a disease where cells in the prostate gland grow out of control.; PSA test and digital rectal exam are used for screening and diagnosis.; Localized prostate cancer is early-stage and confined to the prostate.; Biopsy is required to confirm prostate cancer diagnosis.; MRI, CT, PET, ultrasound, and bone scan are imaging methods used to assess extent of disease.; Hormone therapy, surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy, and radiopharmaceuticals are treatment options.; Active surveillance is a management option for low-risk, early-stage prostate cancer.; Follow-up includes regular PSA testing, imaging, and biopsies as needed."},
	{"id":"Medical-21fe7d21","source":"Medical","question":"You are a medical intern on the oncology service. Write a SOAP (Subjective, Objective, Assessment, Plan) progress note for a patient with high-risk localized prostate cancer, integrating clinical presentation, diagnostic findings, risk stratification, and next steps based on the guideline.","answer":"SOAP Progress Note:\n\nSubjective: The patient is a 68-year-old male with no significant urinary symptoms but reports occasional blood in urine. No bone pain or weight loss.\n\nObjective: PSA is 14.2 ng/mL. Digital rectal exam reveals a firm nodule on the left prostate. MRI shows a lesion confined to the prostate, no nodal or distant spread. Biopsy confirms adenocarcinoma, Gleason score 4+4=8 (Grade Group 4). No evidence of metastasis on bone scan.\n\nAssessment: High-risk, localized prostate cancer (PSA >10, Gleason 8, organ-confined, no metastasis).\n\nPlan: Recommend molecular biomarker and genetic testing (including BRCA1/2), multidisciplinary discussion for definitive management. Treatment options include radical prostatectomy or radiation therapy plus androgen deprivation therapy. Schedule baseline labs and imaging for follow-up. Patient education and decision support provided.","question_type":"Creative Generation","evidence":"The patient is a 68-year-old male.; The patient has no significant urinary symptoms.; The patient reports occasional blood in urine.; The patient has no bone pain.; The patient has no weight loss.; The PSA level is 14.2 ng/mL.; A digital rectal exam reveals a firm nodule on the left prostate.; MRI shows a lesion confined to the prostate.; There is no nodal or distant spread of the cancer.; A biopsy confirms adenocarcinoma with a Gleason score of 4+4=8.; There is no evidence of metastasis on the bone scan.; The assessment is high-risk localized prostate cancer.; The risk factors include PSA >10, Gleason 8, organ-confined disease, and no metastasis.; The plan includes molecular biomarker and genetic testing.; A multidisciplinary discussion for definitive management is recommended.; Treatment options include radical prostatectomy or radiation therapy plus androgen deprivation therapy.; Baseline labs and imaging for follow-up are scheduled.; Patient education and decision support were provided.","evidence_relations":"Localized prostate cancer is early-stage and confined to the prostate.; PSA test and digital rectal exam are used for screening and diagnosis.; Biopsy is required to confirm prostate cancer diagnosis.; Grade Group and Gleason score are used to estimate cancer aggressiveness.; Risk groups (very low, low, intermediate, high, very high) guide prognosis and treatment.; Molecular biomarker testing helps assess risk and guide treatment decisions.; Germline genetic testing is recommended for patients with high-risk, very-high-risk, regional, or metastatic prostate cancer.; Hormone therapy, surgery, and radiation therapy are treatment options for localized high-risk disease.; Follow-up includes regular PSA testing, imaging, and biopsies as needed."},
	{"id":"Medical-ea781222","source":"Medical","question":"Imagine you are an endocrinologist receiving a referral for a 45-year-old patient with an incidentally discovered adrenal mass on CT scan. Draft a detailed diagnostic workup plan, integrating risk assessment for malignancy and hormone excess, as recommended by the guidelines.","answer":"For a 45-year-old patient with an incidentally discovered adrenal mass (adrenal incidentaloma), the diagnostic workup should be comprehensive and guideline-based. First, a detailed clinical assessment is necessary to identify symptoms of hormone excess, such as unexplained weight gain, muscle weakness, hypertension, or changes in hair distribution. Biochemical evaluation should include tests for cortisol excess (e.g., overnight dexamethasone suppression test), aldosterone excess (especially if the patient is hypertensive or hypokalemic), and catecholamine excess (plasma or 24-hour urine metanephrines and catecholamines). Imaging studies, such as MRI or PET/CT, are recommended to further characterize the mass, assess its size, and evaluate radiologic features suggestive of malignancy (e.g., irregular borders, high attenuation, rapid growth). Risk assessment for malignancy should also consider the patient's age, tumor size, and imaging characteristics. A thorough review of family history is important to identify hereditary syndromes associated with adrenal tumors, and genetic testing may be indicated if there is suspicion of a hereditary condition. If the mass is hormonally active or imaging suggests malignancy, referral for surgical evaluation is warranted. Biopsy is generally reserved for cases where metastatic disease is suspected and will impact management, as it is not routinely performed due to the risk of tumor spread. Throughout the process, results from all tests should be carefully documented and communicated with the patient and care team to guide further management.","question_type":"Creative Generation","evidence":"The patient is 45 years old.; The patient has an incidentally discovered adrenal mass on a CT scan.; A thorough clinical assessment for symptoms of hormone excess is necessary.; Symptoms of hormone excess include weight gain, muscle weakness, high blood pressure, and changes in hair distribution.; Biochemical tests are ordered to evaluate for cortisol, aldosterone, and catecholamine excess.; Blood tests and a 24-hour urine collection are part of the biochemical tests.; Imaging with MRI or PET/CT is performed to characterize the adrenal mass.; Imaging assesses for features suggestive of malignancy.; Family history is reviewed to assess risk for hereditary syndromes associated with adrenal tumors.; Genetic testing for hereditary syndromes may be considered.; A biopsy may be indicated if imaging or laboratory findings are suspicious for malignancy or functional tumor.","evidence_relations":"Adrenal tumors are often found incidentally on imaging tests such as CT or MRI.; Functional adrenal tumors may produce excess hormones.; Blood and biochemical tests are used to detect hormone secretion by adrenal tumors.; Imaging tests for adrenal tumors include CT scan, MRI scan, PET scan, FDG-PET/CT, and SSTR-PET/CT.; Certain hereditary syndromes increase the risk of adrenal tumors.; Genetic testing may be performed to identify hereditary risk factors.; Biopsy may be used for diagnosis."},
	{"id":"Medical-f5250f06","source":"Medical","question":"You are a medical intern asked to write a referral note to oncology for a pediatric patient (age 4) presenting with abdominal bloating and weight loss. The note should summarize the differential diagnosis, relevant risk factors, and initial investigations, adhering to evidence from the guidelines.","answer":"Referral Note:\n\nPatient: 4-year-old child\nReason for Referral: Evaluation of adrenal mass\n\nSummary: The patient presents with abdominal bloating and unintentional weight loss. Imaging (CT scan) reveals an adrenal mass. Differential diagnosis includes neuroblastoma, adrenocortical carcinoma, and other malignant adrenal tumors. Notably, neuroblastoma is a rare malignant adrenal tumor primarily affecting children under 5. Family history and assessment for hereditary syndromes (e.g., Beckwith-Wiedemann syndrome, Li-Fraumeni syndrome) are being conducted. Initial investigations include CT scan and blood and biochemical tests to assess for hormone excess. Further genetic testing is planned to evaluate for hereditary risk factors.","question_type":"Creative Generation","evidence":"The patient is a 4-year-old child.; The reason for referral is evaluation of an adrenal mass.; The patient presents with abdominal bloating and unintentional weight loss.; Imaging reveals an adrenal mass.; The differential diagnosis includes neuroblastoma, adrenocortical carcinoma, and other malignant adrenal tumors.; Neuroblastoma primarily affects children under 5.; Family history and assessment for hereditary syndromes are being conducted.; Initial investigations include CT scan and blood tests.; Biochemical tests are conducted to assess for hormone excess.; Further genetic testing is planned to evaluate for hereditary risk factors.","evidence_relations":"Neuroblastoma is a rare malignant adrenal tumor affecting mainly children under 5.; Adrenocortical carcinoma can occur at any age but is most likely in children under 5 and adults in their 40s and 50s.; Symptoms of adrenal cancer include abdominal bloating and loss of weight without trying.; Imaging tests for adrenal tumors include CT scan, MRI scan, PET scan, FDG-PET/CT, and SSTR-PET/CT.; Certain hereditary syndromes increase the risk of adrenal tumors.; Genetic testing may be performed to identify hereditary risk factors.; Blood and biochemical tests are used to detect hormone secretion by adrenal tumors."},
	{"id":"Medical-2faf4e34","source":"Medical","question":"Transform the guideline evidence into a structured discharge summary for a patient recently treated for adrenocortical carcinoma (ACC), including presentation, diagnostic process, risk assessment, and follow-up recommendations.","answer":"Discharge Summary:\n\nDiagnosis: Adrenocortical carcinoma (ACC)\n\nPresentation: The patient presented with muscle weakness, pink or purple stretch marks, and recent weight gain. These symptoms, along with physical examination findings, were suggestive of hormone excess, consistent with Cushing syndrome due to cortisol-producing adrenal tumor.\n\nDiagnostic Process: The diagnostic workup included initial imaging with CT and MRI scans, which identified a suspicious adrenal mass. Biochemical and blood tests confirmed hypercortisolism. Given the patient's family history of hereditary syndromes, genetic testing was performed to assess for conditions such as Li-Fraumeni syndrome. A biopsy of the adrenal mass confirmed the diagnosis of ACC.\n\nRisk Assessment: The patient's risk for ACC was elevated due to age and a family history consistent with hereditary cancer syndromes, including Li-Fraumeni syndrome, which are known to increase the risk of adrenal tumors.\n\nFollow-Up Recommendations: The patient will require regular follow-up with imaging studies (such as MRI or PET-CT) and biochemical monitoring to detect recurrence or progression. Genetic counseling is recommended for the patient and at-risk family members to assess hereditary risk and guide further management. The patient is also advised to maintain organized medical records, communicate regularly with the care team, and keep the primary care physician informed of all updates.","question_type":"Creative Generation","evidence":"The diagnosis is adrenocortical carcinoma (ACC).; The patient presented with muscle weakness, pink stretch marks, and recent weight gain.; Physical examination and laboratory findings suggested hormone excess.; Initial CT and MRI scans identified a suspicious adrenal mass.; Biochemical and blood tests confirmed hypercortisolism.; Genetic testing was performed due to a family history of hereditary syndromes.; A biopsy of the adrenal mass confirmed ACC.; The patient's risk was elevated due to age and family history.; Family history was consistent with hereditary syndromes such as Li-Fraumeni syndrome.; The patient will undergo regular imaging and biochemical monitoring.; Genetic counseling is recommended for the patient and family members.","evidence_relations":"Adrenocortical carcinoma (ACC) is a rare malignant tumor of the adrenal cortex.; Adenoma producing excess cortisol causes Cushing syndrome.; Symptoms of adrenal cancer include weight gain, muscle weakness, pink or purple stretch marks.; Imaging tests for adrenal tumors include CT scan, MRI scan, PET scan, FDG-PET/CT, and SSTR-PET/CT.; Biopsy may be used for diagnosis.; Certain hereditary syndromes increase the risk of adrenal tumors.; Genetic testing may be performed to identify hereditary risk factors."},
	{"id":"Medical-7b694381","source":"Medical","question":"Imagine you are a public health officer tasked with drafting a community advisory about the importance of recognizing symptoms and hereditary risk factors for adrenal tumors. Your advisory should integrate at least five key points from the guidelines.","answer":"**Community Health Advisory: Awareness of Adrenal Tumors**\n\nAdrenal tumors, which can be benign or malignant, are sometimes found incidentally during imaging tests. Early recognition of symptoms such as unexplained weight gain or loss, muscle weakness, abdominal bloating, and changes in blood pressure is crucial. Some adrenal tumors produce excess hormones, leading to specific syndromes like Cushing syndrome or high blood pressure. Individuals with a family history of hereditary syndromes (e.g., Li-Fraumeni, MEN 1/2, Lynch syndrome) may be at higher risk. If you or your relatives experience these symptoms or have a relevant family history, consult your healthcare provider for appropriate blood, biochemical, and genetic testing. Early detection and monitoring can improve outcomes.","question_type":"Creative Generation","evidence":"Adrenal tumors can be benign or malignant.; Adrenal tumors are sometimes found incidentally during imaging tests.; Early recognition of symptoms is crucial for adrenal tumors.; Symptoms include unexplained weight gain or loss, muscle weakness, abdominal bloating, and changes in blood pressure.; Some adrenal tumors produce excess hormones.; Excess hormones can lead to specific syndromes like Cushing syndrome or high blood pressure.; Individuals with a family history of hereditary syndromes may be at higher risk for adrenal tumors.; Hereditary syndromes include Li-Fraumeni, MEN 1/2, and Lynch syndrome.; Consulting a healthcare provider is important if symptoms or relevant family history are present.; Appropriate blood, biochemical, and genetic testing may be necessary.; Early detection and monitoring can improve outcomes.","evidence_relations":"Adrenal tumors can be benign or malignant.; Adrenal tumors are often found incidentally on imaging tests such as CT or MRI.; Functional adrenal tumors may produce excess hormones.; Symptoms of adrenal cancer include weight gain, muscle weakness, abdominal bloating, back pain, fever, loss of appetite, and loss of weight without trying.; Adenoma producing excess cortisol causes Cushing syndrome.; Certain hereditary syndromes increase the risk of adrenal tumors.; Genetic testing may be performed to identify hereditary risk factors."},
	{"id":"Medical-2e1ccbe9","source":"Medical","question":"You are a clinician asked to summarize the key differences in presentation, diagnosis, and risk factors between adrenocortical carcinoma, pheochromocytoma, and neuroblastoma, using evidence from the guidelines.","answer":"Adrenocortical carcinoma (ACC) is a rare malignant tumor originating from the adrenal cortex, most frequently affecting children under 5 years old and adults in their 40s and 50s. ACC often presents with symptoms of hormone excess, such as weight gain, muscle weakness, pink or purple stretch marks, and other hormonal changes (e.g., excess facial hair, irregular periods, or gynecomastia). Some patients may also experience symptoms related to tumor mass effect, such as abdominal bloating or back pain. Diagnosis of ACC involves a combination of imaging studies (CT, MRI, PET scans), blood and biochemical tests to assess hormone secretion, genetic evaluation, and occasionally biopsy. Hereditary syndromes, including Li-Fraumeni and multiple endocrine neoplasia (MEN) types 1 and 2, are recognized risk factors.\n\nPheochromocytoma arises from the adrenal medulla and is characterized by symptoms related to catecholamine excess, including high blood pressure, headache, rapid heartbeat (tachycardia), and sweating. Most pheochromocytomas are benign, but some can be malignant. Diagnosis relies on imaging (CT or MRI) and biochemical tests to detect elevated catecholamines or their metabolites. Genetic syndromes such as MEN2 can increase risk.\n\nNeuroblastoma is a rare malignant tumor that primarily affects children under 5 years of age. It may present with an abdominal mass and can metastasize to bones and other organs. Diagnosis is based on imaging studies and biochemical tests. Family history and hereditary syndromes are important risk factors for all three tumor types, although most cases are sporadic.","question_type":"Creative Generation","evidence":"Adrenocortical carcinoma (ACC) is a rare malignant tumor of the adrenal cortex.; ACC is most common in children under 5 and adults in their 40s and 50s.; ACC often presents with symptoms of hormone excess.; Symptoms of hormone excess include weight gain, muscle weakness, and stretch marks.; Diagnosis of ACC involves imaging such as CT, MRI, and PET.; Diagnosis also includes blood and biochemical tests.; Genetic evaluation may be part of the diagnostic process.; A biopsy may be performed to confirm the diagnosis.; Hereditary syndromes like Li-Fraumeni and MEN1/2 increase the risk of ACC.; Pheochromocytoma arises from the adrenal medulla.; Pheochromocytoma presents with high blood pressure, headache, rapid heartbeat, and sweating.; Diagnosis of pheochromocytoma relies on CT/MRI and biochemical tests.; Neuroblastoma mainly affects children under 5.; Neuroblastoma may metastasize to bones.; Diagnosis of neuroblastoma involves imaging and biochemical tests.; Family history and hereditary syndromes are important risk factors for all three tumors.","evidence_relations":"Adrenocortical carcinoma (ACC) is a rare malignant tumor of the adrenal cortex.; Adrenocortical carcinoma can occur at any age but is most likely in children under 5 and adults in their 40s and 50s.; Symptoms of adrenal cancer include weight gain, muscle weakness, pink or purple stretch marks.; Pheochromocytoma arises from the adrenal medulla and is often associated with high blood pressure, headache, rapid heartbeat, and sweating.; Neuroblastoma is a rare malignant adrenal tumor affecting mainly children under 5.; Neuroblastoma may metastasize to bones.; Imaging tests for adrenal tumors include CT scan, MRI scan, PET scan, FDG-PET/CT, and SSTR-PET/CT.; Blood and biochemical tests are used to detect hormone secretion by adrenal tumors.; Certain hereditary syndromes increase the risk of adrenal tumors."},
	{"id":"Medical-83c906e0","source":"Medical","question":"You are an oncologist preparing a referral letter for a 45-year-old woman recently diagnosed with Stage II, hormone receptor-positive, HER2-negative invasive ductal carcinoma of the breast. Summarize the diagnostic workup, relevant biomarkers, and outline the initial treatment plan for the receiving multidisciplinary team.","answer":"Dear Multidisciplinary Team,\n\nI am referring a 45-year-old female patient recently diagnosed with Stage II invasive ductal carcinoma of the breast. Diagnostic workup included mammogram and ultrasound, which revealed a suspicious lesion; MRI confirmed tumor extent. Core needle biopsy established the diagnosis and provided tissue for biomarker assessment, which demonstrated estrogen receptor (ER) and progesterone receptor (PR) positivity, and HER2 negativity. Sentinel lymph node biopsy identified limited nodal involvement, consistent with Stage II disease. Blood tests were unremarkable.\n\nGiven the hormone receptor-positive, HER2-negative profile, the initial treatment plan includes breast-conserving surgery (lumpectomy), followed by radiation therapy. Adjuvant endocrine therapy (e.g., tamoxifen or aromatase inhibitor) is planned. Chemotherapy will be considered based on tumor grade and patient risk factors. The patient will be evaluated by fertility preservation specialists prior to systemic therapy, and performance status will be closely monitored throughout treatment.\n\nSincerely,\nDr. Smith","question_type":"Creative Generation","evidence":"The patient is a 45-year-old female.; The patient was recently diagnosed with Stage II invasive ductal carcinoma of the breast.; The diagnostic workup included a mammogram and ultrasound.; The mammogram and ultrasound revealed a suspicious lesion.; An MRI confirmed the extent of the tumor.; A core needle biopsy established the diagnosis.; The biopsy provided tissue for biomarker assessment.; The biomarker assessment demonstrated estrogen receptor (ER) and progesterone receptor (PR) positivity.; The biomarker assessment also showed HER2 negativity.; A sentinel lymph node biopsy identified limited nodal involvement.; The findings are consistent with Stage II disease.; Blood tests were unremarkable.; The initial treatment plan includes breast-conserving surgery (lumpectomy).; Radiation therapy is planned following surgery.; Adjuvant endocrine therapy is planned, which may include tamoxifen or an aromatase inhibitor.; Chemotherapy will be considered based on tumor grade and patient risk factors.; The patient will be evaluated by fertility preservation specialists prior to systemic therapy.; The patient's performance status will be closely monitored throughout treatment.","evidence_relations":"Invasive ductal carcinoma is the most common type of invasive breast cancer.; Diagnosis involves imaging (mammogram, ultrasound, MRI, CT, PET), biopsy, and blood tests.; Sentinel lymph node biopsy is used to assess lymph node involvement.; Hormone receptor status (ER, PR) and HER2 status are key biomarkers for breast cancer.; Treatment options include surgery (mastectomy, lumpectomy), radiation therapy, chemotherapy, endocrine therapy, HER2-targeted therapy, immunotherapy, and targeted inhibitors.; Endocrine therapy is used for hormone receptor-positive breast cancer.; Fertility preservation should be discussed before starting treatment.; Performance status is considered in treatment planning."},
	{"id":"Medical-d168a555","source":"Medical","question":"Imagine you are a medical intern tasked with writing a discharge summary for a patient with inflammatory breast cancer (IBC) who has completed neoadjuvant systemic therapy and modified radical mastectomy. Structure the summary to include diagnosis, key findings, treatment course, and follow-up recommendations.","answer":"Discharge Summary:\n\nDiagnosis: Stage III inflammatory breast cancer (IBC), ER/PR negative, HER2 positive.\n\nKey Findings: Patient presented with breast swelling, redness, peau dorange, and skin thickening. Imaging (mammogram, ultrasound, MRI) and skin biopsy confirmed IBC. Biomarker analysis revealed HER2 positivity, ER/PR negativity. Sentinel lymph node biopsy was positive for malignancy.\n\nTreatment Course: The patient received neoadjuvant systemic therapy, including chemotherapy and HER2-targeted therapy. This was followed by a modified radical mastectomy. Postoperative recovery was uneventful.\n\nFollow-up Recommendations: Initiate adjuvant radiation therapy and continue HER2-targeted agents as indicated. Schedule regular physical exams and imaging for surveillance. Monitor for recurrence and treatment-related toxicities. Multidisciplinary follow-up is recommended.\n\nSigned,\nMedical Intern","question_type":"Creative Generation","evidence":"The diagnosis is Stage III inflammatory breast cancer (IBC).; The IBC is ER/PR negative and HER2 positive.; The patient presented with breast swelling, redness, peau dorange, and skin thickening.; Imaging including mammogram, ultrasound, and MRI confirmed IBC.; A skin biopsy confirmed the diagnosis of IBC.; Biomarker analysis revealed HER2 positivity and ER/PR negativity.; A sentinel lymph node biopsy was positive for malignancy.; The patient received neoadjuvant systemic therapy, including chemotherapy and HER2-targeted therapy.; The patient underwent a modified radical mastectomy.; Postoperative recovery was uneventful.; Adjuvant radiation therapy is recommended.; HER2-targeted agents will continue as indicated.; Regular physical exams and imaging for surveillance are recommended.; Monitoring for recurrence and treatment-related toxicities is important.; Multidisciplinary follow-up is recommended.","evidence_relations":"Inflammatory breast cancer (IBC) is a rare, aggressive subtype characterized by cancer cells blocking lymph vessels in the skin.; Common symptoms include redness, swelling, peau dorange, and skin thickening.; Diagnosis involves physical exam, medical photographs, mammogram, ultrasound, MRI, CT scan, PET scan, biopsy, skin biopsy, sentinel lymph node biopsy, and blood tests.; Biomarker analysis includes estrogen receptor (ER), progesterone receptor (PR), and HER2 status.; Treatment for IBC includes systemic therapy, chemotherapy, HER2-targeted therapy, immunotherapy, endocrine therapy, surgery (modified radical mastectomy), and radiation therapy.; Follow-up includes imaging, physical exams, and monitoring for recurrence."},
	{"id":"Medical-fe801cec","source":"Medical","question":"You are a patient advocate tasked with drafting a public health notice to educate the community about breast cancer risk factors, screening, and the importance of early detection. Your notice should reference clinical evidence and recommended practices.","answer":"Public Health Notice: Protect YourselfKnow the Facts About Breast Cancer\n\nBreast cancer is a carcinoma that begins in the cells of the breast and is one of the most common cancers affecting individuals assigned female at birth. Key risk factors include a family history of breast cancer, inherited BRCA1 or BRCA2 gene mutations, and certain hormonal or reproductive factors. Clinical evidence shows that regular screening mammograms are essential for early detection, even in people without symptoms, and can significantly improve treatment outcomes and survival rates. Common warning signs of breast cancer include a new breast lump, persistent pain, nipple discharge, or changes in the skin such as redness, swelling, or peau dorange (skin thickening and dimpling). If you notice any of these symptoms, contact your healthcare provider promptly. Early detection through recommended screenings and awareness of personal risk factors are critical steps in reducing the impact of breast cancer. We urge all eligible individuals to follow current screening guidelines and to discuss their personal and family history with their healthcare provider to determine the best screening plan.\n\nIssued by: Community Health Board","question_type":"Creative Generation","evidence":"Breast cancer is a carcinoma that starts in the cells of the breast.; Breast cancer primarily affects individuals assigned female at birth.; A family history of breast cancer increases risk.; BRCA1/2 mutations increase the risk of breast cancer.; Regular screening mammograms are crucial for early detection.; Early detection is important even in people without symptoms.; Symptoms of breast cancer include breast lumps, pain, nipple discharge, and skin changes.; Skin changes may include redness or swelling.; Consulting a healthcare provider promptly is important if symptoms are experienced.; Early-stage breast cancer is more treatable and has better outcomes.; Eligible individuals are encouraged to undergo recommended screenings.; Discussing personal risk factors with a doctor is important.","evidence_relations":"Breast cancer is a carcinoma that starts in the cells of the breast.; Risk factors include family history, BRCA mutations, and being assigned female at birth.; Screening mammograms are used for early detection in asymptomatic individuals.; Common symptoms include breast lump, pain, nipple discharge, skin changes, redness, swelling, and peau dorange.; Early detection improves breast cancer outcomes.; If you experience symptoms, consult your healthcare provider promptly."},
	{"id":"Medical-9210668e","source":"Medical","question":"Transform the clinical facts on metastatic breast cancer (MBC) into a structured SOAP (Subjective, Objective, Assessment, Plan) progress note for a follow-up visit. Include relevant symptoms, diagnostics, biomarkers, and ongoing management.","answer":"SOAP Progress Note\n\nSubjective: The patient reports ongoing bone pain and intermittent shortness of breath, which are consistent with known sites of metastatic disease. There are no new neurological symptoms (such as headache, weakness, or sensory changes) and no signs of liver dysfunction (such as jaundice or abdominal pain). The patient denies other new symptoms.\n\nObjective: Recent PET scan demonstrates confirmed metastases to the bone and lung. Blood tests, including liver and renal function, are within normal limits. Biopsy of metastatic lesions confirms the diagnosis of metastatic breast cancer. Biomarker analysis shows the tumor is estrogen receptor (ER) and progesterone receptor (PR) positive, and HER2 negative. The patients performance status remains stable, with no decline in daily functioning.\n\nAssessment: Stage IV (metastatic) breast cancer with documented bone and pulmonary involvement. The disease is hormone receptor-positive (ER/PR+) and HER2-negative, which guides systemic therapy choices. No evidence of new organ involvement or acute complications at this time.\n\nPlan: Continue current systemic therapy regimen, consisting of endocrine therapy in combination with a CDK4/6 inhibitor, appropriate for hormone receptor-positive, HER2-negative metastatic breast cancer. Continue bone-directed therapy with bisphosphonates to reduce skeletal-related events. Schedule regular imaging and physical examinations to monitor for disease progression or new metastases. Provide supportive care for symptom management, including pain control and addressing shortness of breath as needed. Discuss ongoing eligibility for targeted therapies and consider clinical trial options if appropriate. Maintain communication with the primary care physician and multidisciplinary care team.","question_type":"Creative Generation","evidence":"The patient reports persistent bone pain.; The patient reports intermittent shortness of breath.; The patient has no new neurological symptoms.; The patient has no liver dysfunction.; Imaging tests confirm metastases to bone and lung.; Blood tests are within normal limits.; A biopsy confirms metastatic breast cancer.; Biomarker analysis reveals hormone receptor positivity (ER/PR+).; Biomarker analysis reveals HER2 negativity.; The patient's performance status remains stable.; The assessment is stage IV metastatic breast cancer with bone and pulmonary involvement.; The cancer is hormone receptor-positive.; The cancer is HER2-negative.; The plan is to continue systemic therapy with endocrine therapy and CDK4/6 inhibitor.; The plan includes monitoring for disease progression with regular imaging and physical exams.; The plan includes managing bone metastases with bisphosphonates.; The plan includes providing supportive care for symptom control.; The plan includes discussing ongoing eligibility for targeted therapies.","evidence_relations":"Metastatic breast cancer (MBC) is breast cancer that has spread to distant organs.; Symptoms of MBC include bone pain, shortness of breath, liver dysfunction, and neurological symptoms.; Diagnosis involves imaging tests, biopsy, and blood tests.; Systemic therapy is used for invasive and metastatic breast cancer.; Endocrine therapy is used for hormone receptor-positive breast cancer.; CDK4/6 inhibitors are used for hormone receptor-positive, HER2-negative breast cancer.; Follow-up includes imaging, physical exams, and monitoring for recurrence."},
	{"id":"Medical-5a1e917c","source":"Medical","question":"Assume the role of a genetic counselor. Prepare a summary for a patient newly found to have a BRCA1 mutation, explaining the implications for breast cancer risk, recommended surveillance, and potential preventive strategies.","answer":"Genetic Counseling Summary:\n\nYou have tested positive for a BRCA1 mutation, which significantly increases your risk of developing breast cancer. Having a BRCA1 mutation is a strong risk factor and may also impact your family members risk. We recommend enhanced surveillance, including annual mammograms and breast MRI starting at an earlier age. Preventive strategies may include risk-reducing medications or prophylactic surgery (such as bilateral mastectomy or oophorectomy). It is important to discuss these options with your oncology and surgical teams. Family members may also wish to consider genetic testing. Ongoing follow-up and support resources are available to you.\n","question_type":"Creative Generation","evidence":"The patient has tested positive for a BRCA1 mutation.; A BRCA1 mutation significantly increases the risk of developing breast cancer.; Having a BRCA1 mutation is a strong risk factor for breast cancer.; A BRCA1 mutation may impact the risk for family members.; Enhanced surveillance is recommended for the patient.; The patient should have annual mammograms starting at an earlier age.; The patient should have breast MRI starting at an earlier age.; Preventive strategies may include risk-reducing medications.; Preventive strategies may include prophylactic surgery.; Prophylactic surgery options include bilateral mastectomy.; Prophylactic surgery options include oophorectomy.; It is important for the patient to discuss options with oncology and surgical teams.; Family members may wish to consider genetic testing.; Ongoing follow-up and support resources are available to the patient.","evidence_relations":"BRCA1 and BRCA2 mutations increase the risk of breast cancer.; Risk factors include family history, BRCA mutations, and being assigned female at birth.; Screening mammograms are used for early detection in asymptomatic individuals.; Bilateral oophorectomy is a surgical option listed under treatments.; Fertility preservation should be discussed before starting treatment.; Follow-up includes imaging, physical exams, and monitoring for recurrence."}
]
